<SEC-DOCUMENT>0001437749-26-010342.txt : 20260330
<SEC-HEADER>0001437749-26-010342.hdr.sgml : 20260330
<ACCEPTANCE-DATETIME>20260330173445
ACCESSION NUMBER:		0001437749-26-010342
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260330
DATE AS OF CHANGE:		20260330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DiaMedica Therapeutics Inc.
		CENTRAL INDEX KEY:			0001401040
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36291
		FILM NUMBER:		26813594

	BUSINESS ADDRESS:	
		STREET 1:		301 CARLSON PARKWAY
		STREET 2:		SUITE 210
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55305
		BUSINESS PHONE:		(763) 496-5454

	MAIL ADDRESS:	
		STREET 1:		301 CARLSON PARKWAY
		STREET 2:		SUITE 210
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DiaMedica Inc.
		DATE OF NAME CHANGE:	20070525
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dmtp20251231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dmac="http://www.diamedica.com/20251231" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21"><head>
	<title>dmtp20251231_10k.htm</title>


	<!-- Generated by ThunderDome Portal - 3/30/2026 4:26:31 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-11047">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-11048">2025</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:CurrentFiscalYearEndDate" id="ixv-11049">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AmendmentFlag" id="ixv-11050">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityCentralIndexKey" id="ixv-11051">0001401040</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-10-01_2025-12-31" name="ecd:NonRule10b51ArrTrmntdFlag" id="c1122" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-10-01_2025-12-31" name="ecd:Rule10b51ArrTrmntdFlag" id="c1121" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-10-01_2025-12-31" name="ecd:NonRule10b51ArrAdoptedFlag" id="c1120" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-10-01_2025-12-31" name="ecd:Rule10b51ArrAdoptedFlag" id="c1119" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonFraction id="c866" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c735" contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c734" contextRef="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c733" contextRef="i_2024-12-31_AwardTypeAxis-DeferredShareUnitPlanMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c732" contextRef="i_2025-12-31_AwardTypeAxis-DeferredShareUnitPlanMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-NonemployeeDirectorCompensationProgramMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c727" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c605" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c604" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c603" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c602" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c601" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonFraction id="c560" contextRef="i_2024-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember" unitRef="USD" name="us-gaap:ContractualObligation" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c559" contextRef="i_2025-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember" unitRef="USD" name="us-gaap:ContractualObligation" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c434" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c432" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c430" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c428" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c426" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c424" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c419" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c417" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c415" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c413" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c411" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c409" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c327" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c326" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c325" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c324" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c117" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c116" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="c111">Unlimited</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="c110">Unlimited</ix:nonNumeric>
<ix:nonFraction id="c109" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockNoParValue" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c108" contextRef="i_2025-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockNoParValue" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="c53" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="c51" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="c47" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="c40" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="c39" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="c37" format="ixt:fixed-true">true</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="dmac-20251231.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2025-01-01_2025-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2025-10-01_2025-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2025-12-31_TaxCreditCarryforwardAxis-TaxCreditsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dmac:TaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dmac:NoncapitalIncomeTaxLossesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dmac:NoncapitalIncomeTaxLossesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToPriorPeriodsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dmac:TaxPositionsRelatedToPriorPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToPriorPeriodsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dmac:TaxPositionsRelatedToPriorPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToCurrentPeriodMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dmac:TaxPositionsRelatedToCurrentPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToCurrentPeriodMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dmac:TaxPositionsRelatedToCurrentPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2025-01-01_2025-12-31_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AwardTypeAxis-DeferredShareUnitPlanMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_AwardTypeAxis-DeferredShareUnitPlanMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-01-01_2024-12-31_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="i_2024-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_PlanNameAxis-The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_PlanNameAxis-The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PlanNameAxis-The2012DSUPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2012DSUPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PlanNameAxis-StockOptionPriorPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:StockOptionPriorPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-07-31_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-12-03_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PlanNameAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-05-22_PlanNameAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:NonemployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_AwardTypeAxis-The2021EmploymentInducementIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_AwardTypeAxis-The2019OmnibusIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_AwardTypeAxis-DeferredShareUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_AwardTypeAxis-StockOptionsOutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:StockOptionsOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-25</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-25</xbrli:startDate><xbrli:endDate>2024-06-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-08-12_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-21</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-07-21_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-21</xbrli:startDate><xbrli:endDate>2025-07-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dmac:IndemnificationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dmac:IndemnificationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dmac:ResearchAndDevelopmentContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-06-30_LeaseContractualTermAxis-MinneapolisMNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dmac:MinneapolisMNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-CommonStockDeferredStockUnitsSettlementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:CommonStockDeferredStockUnitsSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-CommonStockDeferredStockUnitsSettlementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:CommonStockDeferredStockUnitsSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2026-03-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
<div>&#160;</div>

<div class="null">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentType" id="c3">10-K</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Mark One)</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentAnnualReport" id="c4" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the fiscal year ended <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentPeriodEndDate" id="c5" format="ixt:date-monthname-day-year-en">December 31, 2025</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>or</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentTransitionReport" id="c6" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">For the transition period from ________________ to ________________.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Commission file number: <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityFileNumber" id="c7">001-36291</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityRegistrantName" id="c8">DIAMEDICA THERAPEUTICS INC.</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:23.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityIncorporationStateCountryCode" id="c9" format="ixt-sec:edgarprovcountryen">British Columbia</ix:nonNumeric></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p>
			</td>
			<td style="vertical-align:top;width:23.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not Applicable</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressAddressLine1" id="c10">301 Carlson Parkway, Suite 210</ix:nonNumeric></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressCityOrTown" id="c11">Minneapolis</ix:nonNumeric>, <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressStateOrProvince" id="c12" format="ixt-sec:stateprovnameen">Minnesota</ix:nonNumeric></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices)</p>
			</td>
			<td style="vertical-align:top;width:23.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressPostalZipCode" id="c13">55305</ix:nonNumeric></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Zip Code)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Registrant&#8217;s telephone number, including area code:<b> (<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:CityAreaCode" id="c14">763</ix:nonNumeric>) <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:LocalPhoneNumber" id="c15">496-5454</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Title of each class</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:6.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Trading</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Symbol(s)</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Name of each exchange on which registered</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:Security12bTitle" id="c16">Voting Common Shares, no par value per share</ix:nonNumeric></b></p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:6.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:TradingSymbol" id="c17">DMAC</ix:nonNumeric></b></p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:19%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>The <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:SecurityExchangeName" id="c18" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Securities registered pursuant to Section 12(g) of the Act: <b>None</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityWellKnownSeasonedIssuer" id="c19">No</ix:nonNumeric> &#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityVoluntaryFilers" id="c20">No</ix:nonNumeric> &#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityCurrentReportingStatus" id="c21">Yes</ix:nonNumeric> &#9746; No &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityInteractiveDataCurrent" id="c22">Yes</ix:nonNumeric> &#9746; No &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;">Large accelerated filer &#9744;</p>
			</td>
			<td style="vertical-align:top;width:5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer &#9744;</p>
			</td>
			<td style="vertical-align:top;width:5.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityFilerCategory" id="c23" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric> &#9746;</p>
			</td>
			<td style="vertical-align:top;width:5.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Smaller reporting company <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntitySmallBusiness" id="c24" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:7.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;">Emerging growth company <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityEmergingGrowthCompany" id="c25" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:top;width:5%;">&#160;</td>
			<td style="vertical-align:top;width:5.4%;">&#160;</td>
			<td style="vertical-align:top;width:5.7%;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:IcfrAuditorAttestationFlag" id="c26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentFinStmtErrorCorrectionFlag" id="c27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityShellCompany" id="c28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> No &#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The aggregate market value of the registrant&#8217;s voting common shares held by non-affiliates, computed by reference to the closing sales price at which the voting common shares were last sold as of June 30, 2025 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), as reported by The Nasdaq Capital Market on that date, was $<ix:nonFraction id="c29" contextRef="i_2025-06-30" unitRef="USD" name="dei:EntityPublicFloat" scale="6" format="ixt:num-dot-decimal" decimals="-5">95.8</ix:nonFraction> million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">As of March 27, 2026, there were <ix:nonFraction id="c30" contextRef="i_2026-03-27" unitRef="Share" name="dei:EntityCommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">53,882,506</ix:nonFraction>&#160;voting common shares outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Part III of this Annual Report on Form 10-K incorporates by reference information (to the extent specific sections are referred to herein) from the registrant&#8217;s Proxy Statement for its 2026 Annual General Meeting of Shareholders which we intend to file with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</div>

<div>&#160;</div>

<div>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DIAMEDICA THERAPEUTICS INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ANNUAL REPORT ON FORM 10-K</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FISCAL YEAR ENDED DECEMBER 31, 2025</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 87%;">&#160;</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Page</span></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 87%;">&#160;</td>
			<td style="vertical-align: middle; width: 6%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">INDUSTRY AND MARKET DATA</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART I</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 1.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Business</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 1A.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk Factors</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">28</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 1B.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Unresolved Staff Comments</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">57</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 1C.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cybersecurity</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">57</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 2.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Properties</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">58</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 3.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Legal Proceedings</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">58</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 4.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mine Safety Disclosures</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">58</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART II</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">59</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 5.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;text-indent:-9pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p>
			</td>
			<td style="vertical-align: bottom; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">59</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 6.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">[Reserved]</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">66</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 7.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#160;</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">67</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 7A.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Quantitative and Qualitative Disclosures About Market Risk</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">74</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 8.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial Statements and Supplementary Data</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">75</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 9.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">96</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 9A.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Controls and Procedures</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">96</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 9B.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other Information</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">96</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 9C.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">96</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART III</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">97</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 10.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Directors, Executive Officers and Corporate Governance</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">97</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 11.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Executive Compensation</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">97</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 12.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">97</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 13.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain Relationships and Related Transactions, and Director Independence</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">97</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 14.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Principal Accountant Fees and Services</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">97</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART IV</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">98</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 15.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exhibits and Financial Statement Schedules</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">98</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Item 16.</p>
			</td>
			<td style="vertical-align: middle; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form 10-K Summary</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">101</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SIGNATURES</p>
			</td>
			<td style="vertical-align: middle; width: 6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">102</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">i</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</div>

<div>&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>This annual report on Form 10-K contains certain forward-looking statements that are within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. For more information, see </i>&#8220;<i>Cautionary Note Regarding Forward-Looking Statements.</i>&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>As used in this report, references to </i>&#8220;<i>DiaMedica,</i>&#8221;<i> the </i>&#8220;<i>Company,</i>&#8221;<i> </i>&#8220;<i>we,</i>&#8221;<i> </i>&#8220;<i>our</i>&#8221;<i> or </i>&#8220;<i>us,</i>&#8221;<i> unless the context otherwise requires, refer to DiaMedica Therapeutics Inc. and its subsidiaries, all of which are consolidated in DiaMedica</i>&#8217;<i>s consolidated financial statements. References in this report to </i>&#8220;<i>common shares</i>&#8221;<i> mean our voting common shares, no par value per share.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks and trade names in this report are referred to without the </i>&#174;<i> and </i>&#8482;<i> symbols, but such references should not be construed as any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies</i>&#8217;<i> trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">ii</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Statements in this annual report on Form 10-K that are not descriptions of historical facts are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that are based on management&#8217;s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, prospects and share price. We have attempted to identify forward-looking statements by terminology including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; the negative of these terms or other comparable terminology, and the use of future dates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The forward-looking statements in this report include but are not limited to, statements concerning the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our plans to develop, obtain regulatory approval for the clinical study of DM199 for preeclampsia (PE), fetal growth restriction (FGR) and ultimately to obtain regulatory approval for and commercialize our DM199 product candidate for the treatment of PE, FGR and acute ischemic stroke (AIS);</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to conduct successful clinical testing of our DM199 product candidate for PE, FGR and AIS and meet certain anticipated or target milestones and dates thereof with respect to our clinical studies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability of our physician collaborators to successfully complete the current Phase 2, proof-of-concept investigator-sponsored clinical trial of DM199 for the treatment of PE and FGR, our reliance on these physician collaborators to conduct the study, and our expectations related to the timing of Part 1b and Parts 2 and 3 of this study;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to meet anticipated site activations, enrollment and interim analysis timing with respect to our Phase 2/3 ReMEDy2 clinical trial of DM199 for the treatment of AIS, especially in the light of slower than expected site activations and enrollment which we believe are due, in part, to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the clinical hold which was lifted in June 2023; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the success of the actions we are taking to mitigate the impact of the factors adversely affecting our ReMEDy2 trial site activations and enrollment rate, including significantly expanding our internal clinical team and bringing in-house certain trial activities, such as study site identification, qualification and activation, clinical site monitoring, supporting vendor management and overall program management; globally expanding the trial; and making certain changes to the study protocol; and risks associated with these mitigation actions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">uncertainties relating to regulatory applications and related filing and approval timelines, especially in light of recent changes in funding and staffing levels for the U.S. Food and Drug Administration (FDA) and other government agencies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">pending and future government agency requests for additional studies and uncertainty and potential delays in obtaining results from the same;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the possible occurrence of future adverse events associated with or unfavorable results from the Phase 2 investigator-sponsored PE trial or our ReMEDy2 trial and their potential to adversely effect current or future trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the adaptive design of our ReMEDy2 trial, which is intended to enroll approximately 300 patients at up to 100 sites globally, and the possibility that the final sample size, which will be determined based upon the results of an interim analysis of 200 participants, may be up to 728 patients, according to a pre-determined statistical plan, other possible changes in the trial, including as a result of input from the FDA, and the results of the interim analysis as determined by our independent data safety monitoring board;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our expectations regarding the perceived benefits of our DM199 product candidate over existing treatment options for PE, FGR and AIS;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to partner with and generate revenue from biopharmaceutical or pharmaceutical partners to develop, obtain regulatory approval for, and commercialize our DM199 product candidate for PE, FGR and AIS;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the potential size of the markets for our DM199 product candidate for PE, FGR and AIS and our or any future partner&#8217;s ability to serve those markets, the rate and degree of market acceptance of and ability to obtain coverage and adequate reimbursement for, our DM199 product candidate for PE, FGR and AIS both in the United States and internationally;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the success, cost and timing of our clinical trials, as well as our reliance on our key executives, clinical personnel, advisors and third parties in connection with our trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our or any future partner&#8217;s ability to commercialize, market and manufacture DM199;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">expectations regarding U.S. federal, state and foreign regulatory requirements and developments affecting our pending and future clinical trials and regulatory approvals of our DM199 product candidate for PE, FGR and AIS and future commercialization and manufacturing of such products if required regulatory approvals are obtained;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our DM199 product candidate;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">expectations regarding competition and our ability to obtain data exclusivity for our DM199 product candidate for PE, FGR and AIS; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our estimates regarding expenses, market opportunity for our product candidates, future revenue, and capital requirements; our anticipated use of the net proceeds from our prior private placements; how long our current cash resources will last; and our need for and ability to obtain additional financing to fund our operations, including funding necessary to complete our current clinical trials and obtain regulatory approvals for our DM199 product candidate for PE, FGR and/or AIS.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under &#8220;<i>Part I. Item 1A. Risk Factors</i>&#8221; in this report. Moreover, we operate in a highly competitive and rapidly-changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, including the securities laws of the United States, we do not intend to update any forward-looking statements to conform these statements to actual results or to changes in our expectations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INDUSTRY AND MARKET DATA</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to the industry, market and competitive position data referenced in this report from our own internal estimates and research, some market data and other statistical information included in this report are based in part upon information obtained from third-party industry publications, research, surveys and studies, none of which we commissioned. Third-party industry publications, research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are responsible for all of the disclosure in this report, and while we believe that each of the publications, research, surveys and studies included in this report are prepared by reputable sources, we have not independently verified market and industry data from third-party sources. In addition, while we believe our internal company research and estimates are reliable, such research and estimates have not been verified by independent sources. Assumptions and estimates of our and our industry&#8217;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#8220;<i>Part I. Item 1A. Risk Factors</i>.&#8221; These and other factors could cause our future performance to differ materially from our assumptions and estimates. See &#8220;<i>Cautionary Note Regarding Forward-Looking Statements</i>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART I</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 1pt;"><b>Item 1. </b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Business</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS). Our lead candidate DM199 (rinvecalinase alfa), is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (rhKLK1) protein to be clinically studied in patients and has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of AIS. Kallikrein-1 (KLK1), extracted from human urine, is an established therapeutic modality in Asia for the treatment of AIS, and KLK1 produced from pig pancreas, is an established therapeutic modality for the treatment of cardio renal disease, including hypertension, in Asia. We plan to advance DM199 through required clinical trials to create shareholder value by establishing its clinical and commercial potential as a therapy for PE, FGR and AIS. Longer term, we plan to develop DM300, our patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, as a potential therapy for severe acute pancreatitis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism believed to enhance endothelial health, microcirculatory blood flow and tissue perfusion by increasing production of nitric oxide (NO), prostacyclin (PGI<sub>2</sub>) and endothelium-derived hyperpolarizing factor (EDHF). In PE and FGR, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta, potentially disease modifying results that improve both maternal and perinatal outcomes. In the case of AIS, DM199 is intended to enhance blood flow and boost neuronal survival in the ischemic penumbra by dilating arterioles surrounding the site of the vascular occlusion and inhibition of apoptosis (neuronal cell death) while also facilitating neuronal remodeling through the promotion of angiogenesis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our clinical development program in PE currently centers around an investigator-sponsored safety, tolerability and pharmacodynamic, proof-of-concept Phase 2 study in PE patients being conducted at the Tygerberg Hospital in Cape Town, South Africa. This Phase 2 study consists of three studies in PE (Part 1a, dose-escalation; Part 1b, dose-expansion; and Part 2, expectant management) and a fourth study in fetal growth restriction (FGR, Part 3, expectant management). Part 1a topline study results are intended to identify a suitable dose for Parts 1b, 2, and 3. Up to approximately 100 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject in Part 1a was enrolled in the fourth quarter of 2024 and interim results from Part 1a of the study were released in July 2025. The interim results (N=28 subjects) demonstrate that DM199 appears safe and well-tolerated with clinically-relevant pharmacodynamic activity with no evidence of placental transfer. Additionally, subjects exhibited rapid, statistically significant reductions in blood pressure with duration of effect that was sustained up to 24 hours post-infusion compared to pre-treatment baseline. An extension cohort of approximately 10 subjects is currently being enrolled at the expected therapeutic dose levels. Preparations are underway to initiate Part 1b where up to 30 subjects with PE and expected delivery within 72 hours will be treated with a dose regimen identified from Part 1a. Based in part upon these interim results, we believe DM199 has the potential to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We are preparing for an open-label, dose-ranging Phase 2 study of DM199 in participants with early onset preeclampsia to be conducted in North America (United States &amp; Canada) and the United Kingdom (UK). In March 2026, we received approval from Health Canada to initiate this Phase 2 study and we are currently finalizing plans to commence site activation in the second half of this year. In the second quarter of 2026, we anticipate filing a clinical trial application to expand this Phase 2 study to include sites in the UK. Regarding the status of this clinical program in the United States, in the fourth quarter of 2025, we participated in a productive, in-person pre-investigational new drug (IND) meeting with the FDA to discuss the planned Phase 2 study, at which the FDA requested an additional non-clinical, 10-day modified embryo-fetal development and pre- and postnatal development (ePPND) study in a rabbit model, a non-rodent species. Preliminary results of the rabbit study suggest that the animals developed an antibody response to DM199, a humanized recombinant protein, preventing us from completing the requested ePPND study in the rabbit model. In earlier pregnant rabbit studies, there was no evidence of teratogenicity (i.e., no external, visceral or skeletal malformations in developing rabbit fetuses) attributable to DM199 in the approximately 200 rabbit offspring produced. The fetal effects with pregnant rabbits that were observed, embryo/fetal lethality and decreased fetal body weights, were considered secondary to frank maternal toxicity that was observed at all doses. We are currently evaluating alternate animal models to address the FDA&#8217;s ePPND study request. Depending on the alternative species, and its gestational period, results from the ePPND study may be substantially delayed.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our clinical program in AIS centers on our ReMEDy2 clinical trial (NCT05065216) of DM199 for the treatment of AIS. Our ReMEDy2 clinical trial is a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial intended to enroll approximately 300 participants at up to 100 sites globally. The adaptive design component includes an interim analysis by our independent data safety monitoring board after the first 200 participants have completed the trial. Based on the results of the interim analysis, the study may be stopped for futility, or the final sample size will be determined, ranging between 300 and 728 patients, according to a pre-determined statistical plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We believe DM199 has the potential to treat a variety of diseases where restoring healthy function requires sufficient activity of KLK1 and the kallikrein-kinin system (KKS). Today, forms of KLK1 derived from human urine and the pancreas of pigs are approved and sold in Japan, China and South Korea to treat AIS, hypertension and other related vascular diseases. We believe millions of patients have been treated with these KLK1 therapies, including up to one million AIS patients now being treated annually with human urinary-derived KLK1 in China. Over 200 clinical studies in China have found urinary-derived KLK1 effective for increasing blood flow, decreasing ischemia in the penumbra, and reducing infarct size. Importantly, human urinary-derived KLK1 has been shown to be generally safe and well tolerated and does not increase the risk of severe intracranial hemorrhage. Similarly, in the use of KLK1 to treat PE, preliminary evidence from several Asia-based studies using KLK1 derived from pig pancreas has shown reductions in maternal blood pressure and improvements in placental perfusion. However, given the small sample size of these studies, we remain cautious in our interpretation of the reported results and believe further study is necessary. We further note that there are numerous regulatory, commercial and clinical drawbacks associated with KLK1 derived from these sources which we believe can be overcome by developing a recombinant version of KLK1 (rhKLK1) such as DM199. We believe higher regulatory standards and the potential for impurities, endotoxins and chemical byproducts due to the inherent variability in the isolation and purification process are the primary reasons why urinary- or animal-derived KLK1s are not currently available and or approved in the United States or Europe. We are not aware of any recombinant version of KLK1 with regulatory approval for clinical use in any country, nor are we aware of any recombinant version in development, other than our drug candidate, DM199.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DM199 Background</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Kallikrein-Kinin System</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation (the widening of blood vessels, which decreases vascular resistance) in the body, as well as an important role in reducing inflammation and oxidative stress (an imbalance between potentially damaging reactive oxygen species, or free radicals, and antioxidants in the body).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">KLK1 is involved in multiple biochemical processes. The most well-characterized activity of KLK1 is the enzymatic cleavage of low molecular weight kininogen (LMWK) to produce bradykinin (BK) which activates BK receptors (primarily BK2R since the BK1R is typically only activated in pathological situations). As illustrated below, activation of BK receptors by kinins sets in motion metabolic pathways which locally produce NO, prostaglandins (primarily PGI<sub>2</sub>in endothelial cells) and EDHF. Increased nitric oxide and prostacyclin work through the cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) pathways, to preferentially relax smooth muscle cells and improve blood flow (through vasodilation), potentially protecting tissues and end-organs from ischemic damage. Scientific literature, including publications in <i>Circulation Research</i>, <i>Immunopharmacology</i> and <i>Kidney International</i>, suggests that lower endogenous KLK1 levels in patients are associated with diseases related to vascular disorders, such as stroke, renal diseases and hypertension. Although individual pharmacologic activators of each pathway&#8212;such as NO donors, PGI&#8322; analogues, and EDHF stimulators&#8212;show preclinical promise; however, none have achieved regulatory approval, and no current therapy targets all three pathways simultaneously. DM199, as a protein augmentation therapy, is intended to increase KLK1 levels to more fully activate the KKS driving the local generation of all three endothelial pathways, NO, PGI<sub>2</sub> and EDHF, to promote endothelial health and protect the brain and kidney from damage. By providing additional supply of the KLK1 protein, DM199 treatment could potentially improve blood flow to the placenta and brain while reducing inflammation in damaged end-organs, such as the brain and the kidneys, supporting their structural integrity and normal functioning.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="dm199.jpg" src="dm199.jpg"/></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="edhf.jpg" src="edhf.jpg"/></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We have conducted numerous internal and third-party analyses to demonstrate that DM199 is structurally and functionally equivalent to KLK1 derived from human urine. Specifically, the amino acid structure of DM199 is nearly identical to the human urine form, and the enzymatic and pharmacokinetic profiles are substantially similar to both human urine- and porcine-derived KLK1. The physiological effects of DM199 on blood pressure, from our completed studies, are similar to that of human urine and porcine-derived forms of KLK1. We believe that the results of this work suggest that the therapeutic action of DM199 will be the same or potentially better than that of the human urinary and porcine forms of KLK1 marketed in Asia.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Supporting Data for Use of DM199 (KLK1)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Preeclampsia and Fetal Growth Restriction:</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Studies have shown that KLK1 levels are reduced in women suffering from preeclampsia. Further, the lowest levels are observed in women with preeclampsia with severe features. KLK1 plays a central physiological role in regulating vascular tone and perfusion through the generation of active kinins, including bradykinin. Bradykinin is a potent, locally acting vasodilator that promotes relaxation of blood vessels, improves endothelial function, and lowers blood pressure. By activating existing vascular signaling pathways, KLK1 enhances blood flow without introducing foreign or non-physiological mechanisms into the maternal circulation. DM199, a recombinant form of human KLK1, leverages these existing pathways to promote vasodilation and improve tissue perfusion, effects that have already been demonstrated across multiple clinical studies in non-pregnant populations with hypertension and vascular disease. These characteristics make KLK1 a strong therapeutic candidate for conditions driven by impaired blood flow and endothelial dysfunction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Preeclampsia is widely understood to originate from inadequate maternal blood flow to the placenta, resulting in placental ischemia and the subsequent release of anti-angiogenic and pro-inflammatory factors such as sFlt-1 and soluble endoglin (sEng). These circulating factors drive systemic endothelial dysfunction and the clinical manifestations of the disease, including hypertension and organ injury. By improving maternal vascular function and placental perfusion, KLK1 therapy has the potential to address this upstream pathology. Enhancing blood flow to the placenta may reduce ischemic stress and limit the release of harmful mediators, offering a disease-modifying approach rather than symptomatic management alone.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Use of Porcine-derived KLK1 for the Treatment of PE in China</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">A porcine-derived form of KLK1 has been used for decades in Asia to treat vascular conditions such as hypertension and chronic kidney disease. In preeclampsia, Chinese investigators have shown that maternal plasma concentrations of KLK1 were significantly lower in preeclampsia compared with patients with mild PE or normal pregnancies and that low levels of tissue KLK1 may be a marker of severe PE as summarized in the figure below (Yuan, et al, 2020). Thus, several small, single center, open-label case studies have been conducted in China exploring the empiric administration of porcine-derived KLK1, in combination with magnesium sulfate, to determine if augmentation of maternal plasma levels of KLK1 could have potential therapeutic benefit in severe PE. Improvements in uterine and umbilical blood flow, reduced blood pressure, improved renal function, extended gestation and increased birthweight have been observed without reported safety issues. These collective findings give support for further development of a recombinant KLK1 (DM199) in patients with PE.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="klk1lvls.jpg" src="klk1lvls.jpg"/></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Acute Ischemic Stroke:</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">KLK1, derived from human urine, was first approved as a treatment for AIS in China in 2005. KLK1 derived from the pancreas of pigs has been approved for the treatment of hypertension, certain chronic kidney and other vascular diseases in Japan, China and South Korea for several decades. There is one company selling human urine-derived KLK1 in China (Kailikang&#174;, Tech-pool BioPharma/Shanghai Pharmaceuticals), and we believe human urine-derived KLK1 is currently being used to treat up to one million AIS patients per year. We believe that approximately 20 companies are marketing porcine-derived KLK1 in Japan, China and South Korea. We have identified several hundred papers supporting the clinical use of urinary- and porcine-derived KLK1 from China, Japan and South Korea in the treatment of AIS.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As noted below, studies conducted in China have shown that lower KLK1 levels are also a predictor of stroke recurrence. The red line in the graph below represents patients in the lowest KLK1 quartile who were at the highest risk for recurrence of stroke. (2,478 stroke patients and event free survival over 5 years).</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center;">
<div><img alt="strokerecurrence.jpg" src="strokerecurrence.jpg"/></div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Source: Annals of Neurology (2011) 70:265-73</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The observations of low plasma levels of KLK1 in both stroke recurrence and PE further support the approach of KLK1 augmentation as a means to provide a therapeutic benefit.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 179pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b><i>Near-Term Goals</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our mission is to improve the lives of people suffering from serious ischemic diseases. Our near-term goals are to principally focus on supporting the Phase 2 investigator-sponsored trial (IST) of DM199 in PE, initiating a global Phase 2 trial in early-onset PE and executing our ReMEDy2 Phase 2/3 trial of DM199 in AIS. Key elements of our strategy include:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">DM199 for PE &#8211;&#160;complete Part 1a (dose-ranging in PE patients with expected delivery within 72-hours) and then Part 1b (PE patients with expected delivery within 72-hours at does selected from Part 1a) of the Phase 2 IST;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">File applications for a global Phase 2 trial (North America and United Kingdom) in early-onset preeclampsia and engage regulatory agencies in multiple countries regarding our PE development program and submit applications for Fast Track and/or Breakthrough designations, where available;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">DM199 for AIS &#8211;&#160;continue to execute our ReMEDy2 Phase 2/3 (NCT05065216) trial with the activation of up to 100 global clinical sites and continue participant enrollment;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Continue manufacturing process development to support anticipated applications for commercial approval of DM199; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Identify a strategic partner(s) to assist with future clinical development and commercialization of DM199.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Preeclampsia Background and Disease Pathology</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Preeclampsia Background</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PE is a complex disorder affecting multiple body systems, with approximately 10 million cases occurring globally each year. It typically presents after 20 weeks of gestation with new onset hypertension and organ dysfunction, such as renal or liver impairment. It is a major cause of maternal and infant morbidity and mortality, especially in cases of early onset preeclampsia occurring before 34 weeks of gestation. Globally, this condition leads to the deaths of approximately 76,000 women and 500,000 newborns each year. Both pre-eclampsia and fetal growth restriction arise from poor placental function due to reduced placental perfusion, histopathologically evident as maternal vascular malperfusion injuries. Preeclampsia is further characterized by endothelial dysfunction and maternal vascular injury. This leads to vasoconstriction of vessels and hypertension, which damages many end organs supplied by these vessels. Preeclampsia is associated with placental and systemic inflammation, oxidative stress and an anti-angiogenic state. Hence, a drug that vasodilates blood vessels to improve organ and placenta perfusion and promotes vascular health (via pro-angiogenesis and reductions in inflammation and oxidative stress) may be a treatment for both conditions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="earlydeliverymort.jpg" src="earlydeliverymort.jpg"/></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">There are currently no FDA-approved therapeutics for PE and the only cure is delivery of the fetus, often prematurely. Control of blood pressure is the mainstay treatment for preeclampsia, but it does not modify progression of the disease and first-line hypertension medications angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are contraindicated due to causing fetal harm. Magnesium sulfate is used to prevent seizures in women and steroids are given to enhance fetal lung maturation.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Fetal growth restriction is a condition of fetal undergrowth due to a poorly functioning placenta &#8211; the life support system of the unborn child. Fetal growth restriction is the leading cause of stillbirth. For those that survive the pregnancy, unhealthy fetal development in utero leaves a legacy of poor health echoing across the child&#8217;s lifespan. Currently, no approved treatment exists for this condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The pathogenesis of preeclampsia has been described in a two-stage model as illustrated below (Bisson et al, 2023).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Stage 1: Placental Disease</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The maternal spiral arteries supply blood to the intervillous space of the placenta, undergoing significant structural, cellular, molecular, and functional changes from approximately week 10 to week 22 of gestation to support the growing fetus's increasing metabolic demands. During the first trimester, placental trophoblasts invade these arteries, replacing the endothelial cells and smooth muscle cells with extravillous trophoblast cells, resulting in the loss of vasomotor control and a transformation into rigid, fixed-diameter vessels. This process enlarges the vessel diameter by at least 10-fold, creating a low-resistance, high-capacity uteroplacental interface that allows for maximal and constant blood flow to the villous. The remodeled spiral artery network is essential for efficient nutrient and waste exchange, as the uteroplacental blood flow increases from 45 mL/min to 750 mL/min at term to support the high metabolic demands of the fetus. In PE, trophoblast invasion is impaired leading to incomplete remodeling of the spiral arteries and shallow placentation. This defective placentation in preeclampsia results in high resistance uterine circulation, causing impaired placental perfusion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="placentaldisease.jpg" src="placentaldisease.jpg"/></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Stage 2: Maternal Vascular Disease and Subsequent Endothelial Dysfunction</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When deprived of adequate blood flow, the hypoxic placenta experiences oxidative stress and releases antiangiogenic factors (sFlt-1, sEng), proinflammatory cytokines (TNF-&#945;, IL-6), and other harmful substances into the maternal blood stream. These factors damage the maternal endothelium, elevate blood pressure, and contribute to organ damage. Moreover, this damage also depresses intrauterine blood flow causing reduced placental perfusion leading to a negative feedback loop. This cycle accelerates further with the increasing metabolic demands of a growing fetus, creating the perfect ischemic storm.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="stage02.jpg" src="stage02.jpg"/></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Unmet Medical Need in Preeclampsia</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">According to the Preeclampsia Foundation, one in every 12 pregnancies is affected by preeclampsia, with an annual incidence of approximately 200,000 pregnancies in the United States. Early-onset preeclampsia, which occurs before 34 weeks of gestation, affects up to 30,000 pregnancies annually and is more severe than late-onset preeclampsia (occurring after 34 weeks). Early-onset preeclampsia poses a higher risk of fetal morbidity and mortality, with infants being born significantly earlier, increasing their risk of future developmental challenges. Women with preeclampsia are twice as likely to develop heart disease or suffer a stroke and four times as likely to develop high blood pressure. Additionally, preeclampsia disproportionately affects African American women, who are 60% more likely to develop the condition than white women and are also more likely to experience severe forms of preeclampsia.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>DM199 </i></b>&#8211;<b><i> Our Novel Solution for the Treatment of Preeclampsia and Fetal Growth Restriction </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are developing DM199 as a potentially disease-modifying treatment to safely extend gestation and improve maternal and fetal outcomes in preeclampsia. In the maternal vasculature, DM199 may lower blood pressure, improve endothelial health, and enhance blood flow to key organs. It also has the potential to increase placental perfusion by dilating intrauterine arteries, which could promote fetal growth and reduce harmful placental factors such as sFlt-1 and sEng. This effect is believed to result from the inadequate remodeling of spiral arteries supplying the placenta, leaving endothelial and smooth muscle cells intact and vasoactive, making them a suitable pharmaceutical target for DM199.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">A key potential safety advantage of DM199 in preeclampsia is that it is a large protein that, in testing to-date, has been shown to not cross the placental barrier. In contrast, small molecules, including most oral medications, passively cross the placental barrier, while monoclonal antibodies are transported through active transport mechanisms. By avoiding transfer to the fetus, DM199 potentially offers a significant safety advantage over small molecules such as ACEi, angiotensin receptor blockers (ARBs) and phosphodiesterase 5 (PDE5) inhibitors (e.g., sildenafil), which are known to cross the placental barrier and cause harm to the fetus.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The mechanism of action of DM199 is believed to involve the increased production of endothelial nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor, pathways that are typically suppressed or impaired in preeclampsia. Additionally, DM199 may enhance vascular endothelial growth factor (VEGF) signaling, which is disrupted in preeclampsia due to elevated levels of circulating sFlt-1. This mechanism is thought to involve activation of the bradykinin 2 receptor, leading to either direct transactivation of the VEGF2 receptor or crosstalk between the nitric oxide and VEGF intracellular signaling pathways.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center;"><img alt="dm199profile.jpg" src="dm199profile.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">DM199 has demonstrated blood pressure reductions in multiple prior studies. Post hoc analysis of all participants with elevated blood pressure (baseline systolic blood pressure &#8805; 130 mmHg) from the DM199 Phase 2 REDUX clinical trial (NCT04123613), in three types of chronic kidney disease (CKD), demonstrated significant reductions in systolic blood pressure (SBP) at day 95:</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tbody><tr>
			<td style="vertical-align: top; width: 15.3%;">&#160;</td>
			<td colspan="3" style="border-bottom:solid 1px #000000;vertical-align:middle;width:21.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REDUX Phase 2 CKD Trial Results: Baseline SBP*</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.3%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 10.1%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SBP </b>&#8805;<b>130 mmHg</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 11.5%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SBP </b>&#8805;<b>140 mmHg</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 11%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SBP </b>&#8805;<b>150 mmHg</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.3%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Day 95 Change from Baseline</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.1%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-7.7 mmHg</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 11.5%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-12.6 mmHg</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 11%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">-22.1 mmHg</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.3%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">P-value (Student&#8217;s T-Test)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.1%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.011</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 11.5%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.004</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 11%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.003</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.3%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Number of Participants</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.1%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">47</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 11.5%; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">31</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 11%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">15</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 9pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 9pt;">*Includes participants from all cohorts</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>AIS Background and Disease Pathology</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Acute Ischemic Stroke Background</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stroke is characterized by the rapidly developing loss of brain function due to a blockage of blood flow in the brain. As a result, the affected tissues of the brain become inactive and may eventually die. Strokes can be classified into two major categories: AIS and hemorrhagic stroke. AIS is characterized by interruption of the blood supply by a blood clot (ischemia), while a hemorrhagic stroke results from rupture, or bleeding, of a blood vessel in the brain. Risk factors for stroke include, among other things, advanced age, hypertension (high blood pressure), previous stroke or transient ischemic attack (TIA), diabetes, high cholesterol, cigarette smoking, atrial fibrillation, physical inactivity and obesity.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">More specifically, with respect to an ischemic stroke, at the site of a blood flow blockage in the brain, there exist two major ischemic zones &#8211; the core ischemic zone with nearly complete loss of blood flow (blood flow reduction of 75% to 90%, or more), and the surrounding ischemic penumbra, a rim of mild to moderately ischemic tissue surrounding the core ischemic zone. Within minutes, the significant lack of blood flow in the core ischemic zone deprives these cells of glucose and oxygen which rapidly depletes energy stores and triggers the loss of ion gradients, ultimately leading to neuronal cell death, or apoptosis. The ischemic penumbra zone, however, may remain viable for several hours via collateral arteries that branch from the main occluded artery in the core ischemic zone. Unfortunately, the penumbra is at great risk of delayed tissue damage due to inflammation which may also lead to neuronal cell death. As time goes on, a lack of blood flow in the core ischemic zone (infarct) may lead to fluid buildup (edema) and swelling which creates intracranial pressure. This pressure on the brain leads to tissue compression resulting in additional ischemia. Additional events in AIS include vascular damage to the blood vessel lining or endothelium, loss of structural integrity of brain tissue and blood vessels, and inflammation. A stroke can lead to permanent damage with memory loss, speech problems, reading and comprehension difficulties, physical disabilities and emotional/behavioral problems. The long-term costs of stroke are substantial, with many patients requiring extended hospitalization, extended physical therapy or rehabilitation, and/or long-term institutional or family care. However, provided the extended window of viability in the penumbra, next generation stroke therapies are being developed to protect valuable brain tissue during the hours to a week after a stroke.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Unmet Medical Need in AIS</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">According to the World Stroke Organization, each year approximately 12.0 million people worldwide suffer a stroke, of which 7.8 million are acute ischemic strokes. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 800,000 people in the U.S. suffer a stroke each year, of which 87% are acute ischemic strokes. We believe that stroke represents an area of significant unmet medical need and a KLK1 therapy (such as DM199) could provide a significant patient benefit, in particular, given its proposed treatment window of up to 24 hours after the first sign of symptoms.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Limitations of Current Treatments for Acute Ischemic Stroke</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Tissue plasminogen activators (clot-busting enzymes or thrombolytics) are the only FDA-approved treatment of acute ischemic stroke. Alteplase (tPA, Activase&#174;, Genentech) was approved in 1996 as a 60-minute intravenous (IV) infusion and tenecteplase (TNK, TNKase&#174;, Genentech), a second-generation recombinant tissue plasminogen activator with higher fibrin affinity/specificity was recently approved in March 2025 as a single, 5-second IV bolus administration. Unfortunately, these clot busting enzymes have several drawbacks that limit their clinical usage. These include its narrow therapeutic window of 3 to 4.5 hours, potential complications with IV administration, and risk of bleeding into the brain (intracranial hemorrhage), which, due to a lack of reversibility, is the most severe complication of treatment, limiting its usefulness for the majority of stroke patients.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">A newer treatment option for patients with acute ischemic stroke is mechanical thrombectomy (MT), a minimally invasive surgical procedure that uses a mechanical device to remove an intra-arterial blood clot in patients who present with large vessel occlusion (LVO) stroke. Large vessels are the main arteries supplying blood to the brain, including the internal carotid artery, middle cerebral artery, anterior cerebral artery, or basilar artery. During an MT procedure, a computed tomography (CT) angiogram scan confirms the location and size of the clot, which is then removed mechanically using a catheter threaded through the arteries. Clinical studies show the method can significantly increase a stroke patient's return to independent life and drastically reduce mortality. While MT represents a significant advancement in AIS care, LVO stroke as described above represents only approximately 30% of all AIS, thereby leaving the majority of patients without acute treatment. Moreover, the medical infrastructure required to identify and treat a patient with an LVO is such that this therapy is limited to nations with comprehensive healthcare systems.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The limitations of both tPA/TNK and endovascular thrombectomy treatments leave up to 80% of patients without acute intervention. Therefore, there is a significant unmet need for a widely accessible, off-the-shelf drug with a broad therapeutic window that is safe, effective, and reversible in the event of unwanted bleeding.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div style="text-align: center;"><img alt="aistreatmentop.jpg" src="aistreatmentop.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">According to the CDC, stroke incidence in the United States and its related effects include:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; padding-bottom: 5px;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Every year in the United States, approximately 800,000 people experience a stroke (ischemic or hemorrhagic). Approximately 600,000 of these are first events and nearly 1 in 4, or 185,000, are recurrent stroke events.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; padding-bottom: 5px;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Approximately one of every 20 deaths in the United States is caused by stroke, which is the fifth leading cause of death. On average, someone in the United States has a stroke every 40 seconds and someone dies from a stroke every 3.2 minutes.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; padding-bottom: 5px;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Stroke is a leading cause of serious long-term disability and reduces mobility in more than half of stroke survivors aged 65 and over.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; padding-bottom: 5px;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Risk of having a first stroke is nearly twice as high for non-Hispanic black adults as for white adults, and non-Hispanic black adults and Pacific Islander adults have the highest rate of death due to stroke.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; padding-bottom: 5px;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Six in 10 people who die from stroke are women.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; padding-bottom: 5px;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Stroke-related costs in the United States came to nearly $56.2 billion between 2019 and 2020, including the cost of health care services, medications and missed days of work.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>DM199 </i></b>&#8211;<b><i> Our Novel Solution for the Treatment of AIS</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In response to an ischemic stroke, bradykinin 2 receptors (BK2) are significantly upregulated (increased) in the arteries affected by the stroke, the ischemic penumbra. This phenomenon has been observed in animal stroke models, showing a 36-fold increase on the ipsilateral side and a 10-fold increase on the contralateral side (<i>PLOS ONE (2018), 13(6), e0198553. </i>https://doi.org/10.1371/<i> journal.pone.0198553</i>). In these oxygen depleted arteries, the increased BK2 receptors signal the need for BK to bind and restore blood flow to these at-risk arteries in the ischemic penumbra. The treatment with DM199 is intended to increase the availability of BK to bind with the BK2 receptors to improve collateral circulation and increase oxygenation to the ischemic penumbra. In binding with the BK2 receptors expressed on endothelial cells (exposed to internal lumen of the artery), DM199, via production of bradykinin, activates the body&#8217;s natural physiologic processes and therefore does not need to pass through the blood brain barrier, which is a specialized structure that is difficult for many therapeutic agents to cross.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div style="text-align: center;"><img alt="bkr2.jpg" src="bkr2.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As depicted in the graphic below, we believe the mechanism of action for DM199 (rhKLK1) has the potential to preserve &#8220;at risk&#8221; penumbral brain tissue by facilitating the release of endothelial nitric oxide, prostacyclin and endothelium-derived hyper polarizing factor which may acutely increase cerebral blood flow by selectively vasodilating these penumbral arteries increasing collateral blood flow and restoring oxygen levels preserving/rescuing these cerebral tissues.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="dm199collatcirc.jpg" src="dm199collatcirc.jpg"/></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In January 2019, we published a paper titled &#8220;<span style="text-decoration: underline; ">Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke</span>&#8221; in a peer reviewed journal (<i>Therapeutic Advances in Neurological Disorders (2019), 12:1-15,.https://doi.org/10.1177/1756286418821918</i>). The paper reviews the scientific literature covering the biochemical role of KLK1 and presents the mechanistic rationale for using KLK1 as an additional pharmacological treatment for AIS. In addition to the biochemical mechanism of KLK1, the review highlights supporting results from human genetics and preclinical animal models of brain ischemia. It also reviews published clinical results for treatment of AIS by a form of KLK1 that is isolated from human urine. This form has been approved for post-stroke treatment of AIS in China and data has been published from clinical trials involving over 4,000 patients. The paper offers a series of testable therapeutic hypotheses for demonstrating the long-term beneficial effect of KLK1 treatment in AIS patients and the reasons for this action.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We are developing DM199 to treat AIS patients with a therapeutic window of up to 24 hours after the first sign of symptoms, well beyond the current window of 3 hours for tPA/TNK (on-label) and up to 4.5 hours as recommended by the American Heart Association (AHA)/American Stroke Association (ASA) practice guidelines, thereby filling a large unmet need for those patients who cannot receive tPA/TNK under the currently available treatment window. This important attribute of an extended therapeutic window could potentially make DM199 therapy available to the millions of patients worldwide who currently have limited treatment options.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Use of Urine-derived KLK1 for the Treatment of AIS in China</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In China, Kailikang&#160;is approved and marketed by Techpool Bio-Pharma Inc., a company controlled by Shanghai Pharmaceuticals Holding Co. Ltd. Kailikang has been approved for the treatment of AIS in China. We believe the initial treatment window is up to 48&#160;hours after stroke symptom onset. Based on data from IQVIA real world and health data, other publications and our own internal analysis, we estimate that over 600,000 stroke patients in China were treated in 2022 with Kailikang. More than 50 published clinical studies, covering over 4,000 stroke patients, have demonstrated a beneficial effect of Kailikang treatment in AIS, including improvements in standard stroke scores, increased blood flow, and reduced infarct size/ischemia in the brain. In a double-blinded, placebo-controlled trial of 446 participants treated with either Kailikang or a placebo with initial treatment administered up to 48 hours after symptom onset showed significantly better scores on the European Stroke Scale and Activities of Daily Living at three weeks post-treatment and after three months using the Barthel Index, (<i>China Journal of Neurology (2007),</i>&#160;<i>40:306</i>&#8211;<i>310</i>).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, a comprehensive meta-analysis covering 24 clinical studies involving 2,433 patients concluded that human urinary KLK1 appears to ameliorate neurological deficits for patients with AIS and improves long-term outcomes, though a few treated patients suffered from transient hypotension (<i>Journal of Evidence-Based Medicine (2012) 5:31-39,</i> https://doi.org/10.1111/j.1756-5391.2012.01167.x<i>)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Furthermore, in a retrospective study covering 300 consecutive AIS subjects treated with human urinary KLK1, there was an observed 6.5% absolute reduction (p=0.009) in recurrent strokes (39% relative reduction) within one year (<i>Brain and Behavior (2018), https://onlinelibrary.wiley.com/doi/pdf/10.1002/brb3.1033).</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Competition and Current Treatments for Preeclampsia and Acute Ischemic Stroke</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The biopharmaceutical industry is highly competitive and characterized by rapidly advancing technologies that focus on rapid development of proprietary drugs. We believe that our DM199 product candidate, development capabilities, experience and scientific knowledge provide us with certain competitive advantages. However, we face significant potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other research institutions. Any product candidates that we successfully develop and commercialize will compete with any then-existing therapies and new therapies that may become available in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources than we do, and greater experience in obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. Accordingly, our competitors may be more successful than us in obtaining approval for competitive products and achieving widespread market acceptance. Our competitors&#8217; treatments may be more effectively marketed and sold than any products we may commercialize, thus limiting our market share and resulting in a longer period before we can recover the expenses of developing and commercializing our DM199 product candidate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These activities may lead to consolidated efforts that allow for more rapid development of competitive product candidates.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We also compete for staff, development and clinical resources. These competitors may adversely impact our ability to: recruit or retain qualified clinical, scientific and management personnel; engage specific advisors or clinical research organizations due to conflicts of interest or their capacity constraints; and may also delay recruitment of clinical study sites and study volunteers, any of which may impede progress in our development programs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect any products that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, price and the availability of reimbursement from government or other third-party payers. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are viewed as safer, more effective or less expensive than any products that we may develop.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Preeclampsia</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There are currently no FDA-approved treatments for preeclampsia and only a limited number of therapeutics in development. Metformin, an established treatment for type 2 diabetes that improves insulin sensitivity and lowers glucose levels, is being studied in late-stage clinical trials in South Africa and Sweden but not in the United States. CBP-4888, a short interfering RNA (siRNA) targeting sFlt-1, is being developed by Comanche Biopharma. It has completed healthy volunteer studies and is expected to be studied in the treatment of pregnant patients with preeclampsia in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Acute Ischemic Stroke</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Currently, there are two approved pharmaceutical treatments for AIS in the United States. Both treatments are thrombolytic (clot-busting) agents: tissue plasminogen activator (tPA, alteplase, Activase), and tenecteplase (TNK, TNKase), and their labeled therapeutic window is limited to 3-hours after onset of AIS (up to 4.5 hours per AHA/ASA guidelines). There are, however, a number of companies that are actively pursuing a variety of approaches to develop pharmaceutical products for the treatment of AIS including, among others:</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">BB-031 (Basking Biosciences)</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">TS23 (Translational Sciences)</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Solvateltide (Pharmazz)</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Edaravone/dexborneol (Sanbexin&#174;, Simcere Pharmaceutical Group)</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">LT3001 (Lumosa Therapeutics)</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Asundexian (Bayer)</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Milvexian (Janssen/BMS)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">There is a large unmet therapeutic need for AIS treatments that can be administered beyond the 4.5-hour time window of tPA/TNK. With this large unmet therapeutic need, there is significant competition to develop new therapeutic options. Currently, the most advanced treatment for AIS uses a medical device for the mechanical removal of blood clots in the large arteries supplying blood to the brain through sophisticated catheter-based approaches, referred to as mechanical thrombectomy. According to published research, use of mechanical thrombectomy is growing and the window of time after a stroke where the procedure can be used is widening. New therapeutic options in development include tissue protection focused therapies (deliverable from hours to days after the stroke) that are intended to preserve and protect brain cells beyond the tPA/TNK therapeutic window. The goal is to provide treatment options for the vast majority of AIS patients who do not receive hospital care early enough to qualify for tPA/TNK therapy. We believe there is a very significant market opportunity for a drug that has a therapeutic window beyond that of tPA/TNK and is able to obtain regulatory approval.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DM199 Clinical Trials</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b><i>Preeclampsia Phase 2 Investigator-Sponsored Trial</i></b></p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our clinical development program in PE currently centers around an investigator-sponsored safety, tolerability and pharmacodynamic, proof-of-concept Phase 2 study in PE patients. This Phase 2 study consists of three studies in PE (Part 1a, dose-escalation; Part 1b, dose-expansion; and Part 2, expectant management) and a fourth study in fetal growth restriction (FGR, Part 3, expectant management). Part 1a topline study results are intended to identify a suitable dose for Parts 1b, 2, and 3. Up to approximately 100 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject in Part 1a was enrolled in the fourth quarter of 2024 and interim results from Part 1a of the study were released in July 2025. An extension cohort of approximately 10 subjects is currently being enrolled at the expected therapeutic dose levels.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The interim results (N=28 subjects) announced in July 2025 demonstrate that DM199 appears safe and well-tolerated with clinically-relevant pharmacodynamic activity with no evidence of placental transfer. Additionally, subjects exhibited rapid, statistically significant reductions in blood pressure with duration of effect that was sustained up to 24 hours post-infusion compared to pre-treatment baseline specifically:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Blood Pressure Reduction</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The study revealed a dose-dependent reduction in both systolic blood pressure (SBP) and diastolic blood pressure (DBP):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cohort 9 (n=3; highest dose) achieved the most substantial mean reductions at 5 minutes post-infusion:</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SBP reductions: -35 mmHg (<i>p</i>&lt;0.05)</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DBP reductions: -15 mmHg (<i>p</i>&lt;0.05)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pooled cohorts 6&#8211;9 (n=12), the potentially therapeutic dose range, exhibited statistically significant mean blood pressure reductions at 5 minutes, 30 minutes, and 24 hours post-infusion, showing a durable response over time:</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SBP reductions: -25mmHg (<i>p</i>=0.0003), -15mmHg (p=0.0018) and -20 mmHg (p=0.0031)</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DBP reductions: -13mmHg (<i>p</i>=0.0007), -13mmHg (p=0.0002) and -10 mmHg (p=0.0294)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Safety</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">DM199 demonstrated no placental transfer and no serious treatment emergent adverse events (TEAEs) were reported across all cohorts. TEAEs events were mild and limited to nausea (n=4, 14%), headache (n=3, 11%) and flushing (n=1, 4%). Additionally, there were no discontinuations of treatment and no inductions of early labor.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Dilation of Uterine Arteries</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DM199 also produced a statistically significant reduction in pulsatility index (PI) measures, with a 13.2% (p=0.0003) mean reduction in blood flow resistance at the 2-hour mark, indicating a reduction in uterine artery resistance which suggests an improvement in uterine artery blood flow and placental perfusion. Improved perfusion may reduce placental hypoxia, supporting fetal growth and potential disease modification. The uterine artery pulsatility index is a doppler ultrasound measurement that reflects blood flow resistance in the uterine arteries.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;"><i>Patient Demographics and Dosing:</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Participants were an average of 32.5 years old, had a mean gestation of 37 weeks at enrollment, and had a mean SBP of 165 mmHg and mean DBP of 102 mmHg at baseline.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Following enrollment and baseline measurements, participants received DM199 IV infusion, followed by SBP and DBP measurements at 5 and 30 minutes post-IV. For cohorts 2 through 9, at 1 hour post-IV, participants received subcutaneous injection of DM199. SBP and DBP were measured again at/through 24 hours post-IV.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Approximately 80% of deliveries occurred within 24 hours following enrollment, with a total of 9 vaginal deliveries and 16 cesarean sections.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based in part upon these interim results, we believe DM199 has the potential to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>AIS Phase 2/3 ReMEDy2 Trial</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We are currently conducting our ReMEDy2 clinical trial (NCT05065216) of DM199 for the treatment of AIS. Our ReMEDy2 clinical trial is a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial intended to enroll approximately 300 participants at up to 100 sites globally. The adaptive design component includes an interim analysis by our independent data safety monitoring board after the first 200 participants have completed the trial. Based on the results of the interim analysis, the study may be stopped for futility, or the final sample size will be determined, ranging between 300 and 728 patients, according to a pre-determined statistical plan. Patients enrolled in the trial will be treated with either DM199 or placebo within 24 hours of the onset of AIS symptoms. The trial excludes patients who received mechanical thrombectomy or participants with large vessel occlusions in the intracranial carotid artery or the M1 segment for the middle cerebral, vertebral or basilary arteries or those that are otherwise eligible for MT. In 2024, the protocol was amended to allow patients treated with tPA or TNK (thrombolytic agents), intended to dissolve blood clots, to be eligible for participation if they continue to experience a persistent neurological deficit after receiving thrombolytic treatment and meet all other trial criteria, including repeat brain imaging to assess any hemorrhagic (bleeding) transformation. The study population is representative of the approximately 80% of AIS patients who do not have treatment options today, primarily due to the limitations on treatment with tPA/TNK and/or MT. We believe that the ReMEDy2 trial has the potential to serve as a pivotal registration study of DM199 in this patient population.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The primary endpoint of the ReMEDy2 trial is physical recovery from stroke as measured by the well-established modified Rankin Scale at day 90. The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. Secondary endpoints for the trial will evaluate, among other things, mRS shift (which shows the treatment effect on participants across the full spectrum of stroke severity), participant deaths, the National Institute of Health Stroke Score (NIHSS), Barthel Index (BI) stroke scales, and stroke recurrence. Recurrent strokes represent 25% of all ischemic strokes, often occurring in the first few weeks after an initial stroke and are typically more disabling, costly and fatal than initial strokes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As previously disclosed, we have experienced and continue to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring, supporting vendor management and overall program management. We are currently conducting the trial in the United States and in the countries of Canada, Georgia and the United Kingdom. We recently received regulatory approval from the European Medicines Agency and are initiating study sites in six European countries. We continue to work closely with our contract research organizations and other supporting vendors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to enhance site activations and enrollment in our ReMEDy2 trial; however, no assurances can be provided as to the success of these actions and if or when these issues will resolve. Failure to resolve these issues may result in further delays in our ReMEDy2 trial and increase the difficulty in forecasting enrollment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In September 2021, the FDA granted Fast Track designation to DM199 for the treatment of AIS. The FDA may grant Fast Track designation to a drug that is intended to treat a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need. The FDA provides opportunities for frequent interactions with the review team for a Fast Track product, including end-of-Phase 2 meetings with the FDA to discuss study design, extent of safety data required to support approval, dose-response concerns, and use of biomarkers. A Fast Track product may also be eligible for rolling review, where the FDA reviews portions of a marketing application before the sponsor submits the complete application.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Phase 1C Open Label Safety Trial</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Concurrently with performing the requested in-use study to lift the prior clinical hold, we also conducted a Phase 1C open label, single ascending dose (SAD) study of DM199 administered with the PVC IV bags used in the ReMEDy2 trial. The purpose of the study was to confirm, with human data, the DM199 blood concentration levels achieved with the IV dose and further evaluate safety and tolerability. This study was conducted in Australia. The third cohort, which received the 0.50 &#181;g/kg dose level used in the ReMEDy2 trial, was dosed in April 2023 with no significant adverse events related to DM199. The pharmacokinetic data, including the DM199 blood concentration levels, for all cohorts was included as supplemental information in our clinical hold response to the FDA. In investigating the cause of the unexpected instances of hypotension, we noted that all three participants were receiving ACEi therapy at the time of their enrollment. Given this, we also completed an additional, fourth cohort of hypertensive patients (Part B) being treated with ACEi prior to enrolling. All ACEi patients received the full IV dose at the 0.5 &#181;g/kg level with no instances of hypotension. We believe that these results provide further assurance to investigators in our ReMEDy2 trial that ACEi patients may be safely included in the ReMEDy2 trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>AIS Phase 2 ReMEDy1 Trial</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In May 2020, we announced top-line data from our Phase 2 ReMEDy1 trial assessing the safety, tolerability and markers of therapeutic efficacy of DM199 in patients suffering from AIS. We initiated treatment in this trial in February 2018 and completed enrollment in October 2019 with 92 participants. The study drug (DM199 or placebo) was administered as an IV infusion within 24 hours of stroke symptom onset, followed by subcutaneous injections later that day and once every 3 days for 21 days. The trial was designed to measure safety and tolerability along with multiple tests designed to investigate DM199&#8217;s therapeutic potential including plasma-based biomarkers and standard functional stroke measures assessed at 90 days post-stroke. Standard functional stroke measurements include the Modified Rankin Scale, National Institutes of Health Stroke Scale and the Barthel Index. The trial met primary safety and tolerability endpoints and was generally safe and well tolerated. In addition, there was a demonstrated therapeutic effect on the rate of severe stroke recurrence inclusive of all participants and there was also a demonstrated therapeutic effect on the physical recoveries of participants that received tPA prior to enrollment but not in participants receiving mechanical thrombectomy prior to enrollment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prior to enrollment, 46 of the 91 evaluable participants received mechanical thrombectomy intervention, a catheter-based treatment intended to physically remove clots and potentially available for patients who have a large vessel occlusion and can be treated within 6 to 24 hours of the onset of stroke symptoms. While approximately 20% of AIS patients are believed to be eligible for a mechanical thrombectomy, currently only about 5% to 10% receive the treatment due to elapsed time post-stroke or unavailability of the therapy at the hospital where the patient presents. DM199 is intended to treat the approximately 80% of AIS patients who are not eligible for either mechanical thrombectomy or tPA. Treatment for these patients is limited to supportive care. Due to the large volume of participants receiving mechanical thrombectomy prior to enrollment in the ReMEDy1 trial, and a disproportionate distribution of these participants between the active treatment and placebo groups, DM199 did not produce a therapeutic effect on physical recoveries in the overall trial analysis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When participants treated with mechanical thrombectomy are excluded from the ReMEDy1 trial data set, which represents the group of participants most closely aligned with the target treatment population for DM199 in the ReMEDy2 trial, a positive therapeutic effect on participant physical recoveries was observed. As shown in the table below, when evaluating the participants treated with DM199 (n=25) vs. supportive care and/or tPA (n=21), the results showed that 36% of participants receiving DM199 progressed to a full or nearly full recovery at 90 days (NIHSS: 0-1), compared to 14% of participants in the placebo group. This represents a 22% absolute increase in the proportion of participants achieving a full or nearly full recovery. Additionally, subject deaths decreased from 24% in the placebo group to 12% in the active therapy group, a 50% relative reduction. Note that the number of subjects in these subsets were insufficient for statistical significance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DM199 vs. Supportive Care and/or tPA</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 10%; margin-right: 10%;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-top: 1px solid black; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="4" style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: 40.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>NIHSS Outcomes at 90 Days</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 9.4%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>0-1</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.4%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2-8</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.4%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8805;9</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 9.9%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Death</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt;"><b>Placebo </b>(n=21)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 9.4%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">14%</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.4%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">57%</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.4%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5%</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 9.9%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">24%</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 9pt;"><b>DM199 </b>(n=25)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 9.4%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">36%</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.4%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">36%</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.4%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">16%</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 9.9%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">12%</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, in the evaluable participants (n=91), a significant reduction in the number of participants with recurrent ischemic stroke was noted in the active treatment group: 0 (0%) participants treated with DM199 vs. 6 (13%) on placebo (p=0.012), with 4 of the 6 resulting in participant death.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe these findings from our Phase 2 ReMEDy1 trial, which are consistent with the use of Kailikang in China, provide a signal that recombinant human KLK1 appears safe and may have promise as a new treatment for physicians who have limited options for the treatment of patients following an AIS.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>CKD Phase 2 REDUX Trial </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our REDUX trial (NCT04123613) was a multi-center, open-label investigation of participants with mild or moderate chronic kidney disease (Stage II or III) and albuminuria. The trial was conducted in the United States and included three cohorts: non-diabetic, hypertensive African Americans (AA) (n=24); IgA Nephropathy (IgAN) (n=25); and Type 2 diabetics with CKD, hypertension and albuminuria (n=35). The trial evaluated two dose levels of DM199 within each cohort. Study participants received DM199 by subcutaneous (SC) injection twice weekly for 95 days. The primary study endpoints, evaluated after three months of treatment, included safety, tolerability, blood pressure, albuminuria and kidney function, which are evaluated by changes from baseline in estimated glomerular filtration rate, albuminuria, as measured by the urinary albumin to creatinine ratio, and blood pressure in hypertensive participants.&#160;</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DM199 was generally safe and well tolerated across all cohorts. Adverse events (AEs) were generally mild to moderate in severity, with the most common being local injection site irritation, and all resolved without medical intervention.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>DM199 Safety Summary</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Intravenously/subcutaneously administered DM199, in doses ranging from 0.025 &#956;g/kg to 50.0 &#956;g/kg, has been administered to over 250 subjects across 5 completed clinical studies and has been shown to be generally safe and well tolerated. The most frequently reported treatment-emergent adverse events in our Phase 2 ReMEDy1 AIS trial were constipation, oral candidiasis and nausea. These events were predominately mild to moderate in severity. A less common but important adverse event has been clinically significant, transient, hypotension (low blood pressure) during IV infusion of DM199 that was observed in a number of subjects. These hypotensive episodes were rapidly reversed upon cessation of the IV infusion with complete recovery; hypotensive episodes have not been observed with subcutaneous administration of DM199.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Potential DM199 Commercial Advantages</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Several researchers have studied the structural and functional properties of KLK1. This deep body of knowledge has revealed the potential clinical benefits of KLK1 treatments. Today, forms of KLK1 derived from human urine and the pancreas of pigs are approved and sold in Japan, China and South Korea to treat AIS, retinopathy, hypertension and related diseases. We are not aware of any recombinant version of KLK1 with regulatory approval for human use in any country, nor any recombinant version in development other than our drug candidate DM199. We believe at least five companies have attempted, unsuccessfully, to create a recombinant version of KLK1.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The growing understanding of the role of KLK1 in human health and its use in Asia as an approved therapeutic highlight two important potential commercial advantages for DM199:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>KLK1 treatment is sold in Japan, China and South Korea</b>. Research has shown that patients with low levels of KLK1 are associated with a variety of diseases related to vascular dysfunction, such as AIS, retinopathy and hypertension. In randomized, controlled clinical trials, human urine- and porcine-derived KLK1 has demonstrated statistically significant clinical benefits in treating a variety of patients with KLK1 compared to placebo. These efficacy results are further substantiated by established markets in Japan, China and South Korea for pharmaceutical sales of KLK1 derived from human urine and the pancreas of pigs. We estimate that millions of patients have been treated with these forms of KLK1 in Asia. Altogether, we believe this supports a strong market opportunity for a recombinant version of KLK1 such as DM199.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>KLK1 treatment has had limited side effects and has been well tolerated in studies to date</b>. KLK1 is naturally produced by the human body; and, therefore, the body&#8217;s own control mechanisms act to limit potential side effects. The side effect observed to limit participant tolerability in our clinical trials was orthostatic hypotension, or a sudden drop in blood pressure, which has been primarily seen at doses 10 to 20 times higher than our anticipated therapeutic dose levels. Most recently, clinically significant, transient hypotension (low blood pressure) occurring shortly after initiation of the IV dose of DM199 was experienced by three participants in our ReMEDy2 trial which were the cause of us pausing participant enrollment and the FDA placing a clinical hold on the IND for our ReMEDy2 trial. The blood pressure levels of the three participants recovered back to their baseline blood pressure within minutes after the IV infusion was stopped and the participants suffered no injuries. We believe that these events were caused by our switching away from the type of IV bag used in the prior ReMEDy1 trial, where no hypotensive episodes were reported, which resulted in an unintended, elevated dose of DM199 being delivered in the ReMEDy2 trial. We believe that by reducing the dose rate for the IV infusion to a level that matches the effective dose rate in the ReMEDy1 trial, we can manage and/or eliminate the clinically significant hypotensive events.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Moreover, we understand that routine clinical use of KLK1 treatment in Asia has been well-tolerated by patients for several decades. In 2017, we completed a clinical trial comparing the pharmacokinetic profile of DM199 to the human urinary form of KLK1 (Kailikang), which showed DM199, when administered in IV form, had a similar pharmacokinetic profile. Further, when DM199 was administered subcutaneously, DM199 demonstrated a longer acting pharmacokinetic profile, superior to the IV administered Kailikang and DM199.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, we believe that there are also significant formulation, manufacturing, regulatory, and other advantages for recombinant human KLK1 drug candidate DM199:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Potency and Impurity Considerations.</b>&#160;KLK1 produced from human urine or the pancreas of pigs presents risks related to preventing impurities, endotoxins and chemical byproducts due to the inherent variability of the isolation and purification process. We believe that this creates the risk of inconsistencies in potency and impurities from one production run to the next. However, we expect to produce a consistent formulation of KLK1 that is free of endotoxins and other impurities.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cost and Scalability.</b>&#160;Large quantities of human urine or pig pancreas must be obtained to derive a small amount of KLK1. This creates potential procurement, cost and logistical challenges to source the necessary raw material, particularly for human urine sourced KLK1. Once sourced, the raw material is processed using chemicals and costly capital equipment and produces a significant amount of byproduct waste. Our novel recombinant manufacturing process utilizes widely available raw materials and can be readily scaled for commercial production. Accordingly, we believe our manufacturing process will have significant cost and scalability advantages.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Regulatory.</b>&#160;We are not aware of any attempts by manufacturers of the urine or porcine based KLK1 products to pursue regulatory approvals in the United States. We believe that this is related to challenges presented by using inconsistent and potentially hazardous biomaterials, such as human urine and the pancreas of pigs, and their resulting ability to produce a consistent drug product. Our novel recombinant manufacturing process utilizes widely available raw materials which we believe provides a significant regulatory advantage, particularly in regions such as the United States, Europe and Canada, where safety standards are high. In addition, we believe that DM199 could qualify for 12 years of data exclusivity in the United States under the Biologics Price Competition and Innovation Act of 2009 (BPCIA).</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">From a strategic perspective, we continue to believe that strategic alternatives with respect to our DM199 product candidate, including licenses and business collaborations, with other regional and global pharmaceutical and biotechnology companies can be important in advancing the clinical development of DM199. Therefore, as a matter of course and from time to time, we engage in discussions with third parties regarding these matters.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Regulatory Approval</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securing regulatory approval for the manufacture and sale of human therapeutic products in the United States, Europe, Canada and other commercial territories is a long and costly process that is controlled by each territory&#8217;s national regulatory agency. The national regulatory agency in the United States is the FDA, in Europe it is the European Medicines Agency (EMA), and in Canada it is Health Canada. Other national regulatory agencies have similar regulatory approval requirements, but each national regulatory agency has its own approval processes. Approval in the United States, Europe or Canada does not assure approval by other national regulatory agencies, although often test results from one country may be used in applications for regulatory approval in another country.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prior to obtaining regulatory approval to market a therapeutic product, every national regulatory agency has a variety of statutes and regulations which govern the principal development activities. These laws require controlled research and testing of products, governmental review, and approval of a submission containing preclinical and clinical data establishing the safety and efficacy of the product for each use sought, as well as approval of manufacturing facilities, including adherence to good manufacturing practices (GMP) during production and storage, and control of marketing activities, including labeling and advertising.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None of our product candidates have been completely developed or tested; and, therefore, we are not yet in a position to seek regulatory approval in any territory to market any of our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and marketing, among other things, of our current or future product candidates, are subject to extensive regulation by governmental authorities in the United States and other countries. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process, approval process, or after approval may subject us to a variety of administrative or judicial proceedings, penalties or sanctions, including refusal by the applicable regulatory authority to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>U.S. Approval Process</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States, the FDA is responsible for the review and approval of therapeutic products. The FDA&#8217;s mission is to ensure that all therapeutic products on the market are safe and effective. The FDA&#8217;s approval process examines and thoroughly reviews potential new therapeutic products and only those that meet the applicable standard for approval or licensure, are approved.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">DM199 is subject to regulatory approval by FDA in the United States because it is a therapeutic product intended for use in humans. The regulatory approval process for DM199 is likely a Biological License Application (BLA) under the Public Health Service Act because DM199 is a recombinant form of the human tissue KLK1 protein. Biological products, like drugs, are used for the treatment, prevention or cure of disease in humans. In contrast to drugs, which are generally chemically-synthesized, biological products are generally derived from living material and include most protein products intended for therapeutic use. Biological products are considered a subset of drugs and, therefore, also regulated under the Food, Drug &amp; Cosmetic Act (FDCA), like drugs. However, the regulatory approval process for a drug is based on a new drug application (NDA) per the drug approval provisions of the FDCA; whereas, the regulatory approval process for a biologic is based on the biological license application (BLA) under the Public Health Service Act.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to regulatory approval, the FDCA and corresponding regulations require licensing of manufacturing facilities, carefully controlled research and testing of products, governmental review and approval of test results prior to marketing of therapeutic products, and adherence to GMP, as defined by each licensing jurisdiction, during production.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A generic description of the different stages in the biologic license application and drug approval process in the United States follows.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stage 1: Preclinical Research</i></b>. After an experimental product is discovered, research is conducted to help determine its potential for treating or curing an illness. This is called preclinical research. Animal and/or bench studies are conducted to determine if there are any harmful effects of the product and to help understand how the product works. Information from these experiments is submitted to the FDA as part of an IND. The FDA reviews the information in the IND and decides if the product is safe to study in humans.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stage 2: Clinical Research</i></b>. The experimental product is next studied in humans. The studies are known as clinical trials. Clinical trials are carefully designed and controlled experiments in which the experimental product is administered to patients to test its safety and to determine the effectiveness of an experimental product. The four general phases of clinical research are described below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Phase 1 Clinical Studies</i>. Phase 1 clinical studies are generally conducted with healthy volunteers who are not taking other medicines; patients with the illness that the product is intended to treat are not tested at this stage. Ultimately, Phase 1 studies demonstrate how an experimental product affects the body of a healthy individual. Phase 1 consists of a series of small studies consisting of tens of volunteers. Tests are done on each volunteer throughout the study to see how the person&#8217;s body processes, responds to, and is affected by the product. Low doses and high doses of the product are usually studied, resulting in the determination of the safe dosage range in volunteers by the end of Phase 1. This information will determine whether the product proceeds to Phase 2.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Phase 2 Clinical Studies</i>. Phase 2 clinical studies are conducted in order to determine how an experimental product affects people who have the disease to be treated. Phase 2 usually consists of a limited number of studies that help determine the product&#8217;s short-term safety, side effects, and general effectiveness. The studies in Phase 2 often are controlled investigations involving comparison between the experimental product and a placebo, or between the experimental product and an existing product. Information gathered in Phase 2 studies will determine whether the product proceeds to Phase 3.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Phase 3 Clinical Studies</i>. Phase 3 clinical studies are expanded controlled and uncontrolled trials that are used to more fully investigate the safety and effectiveness of the product. These trials differ from Phase 2 trials because a larger number of patients are studied (sometimes in the thousands) and because the studies are usually double blinded, placebo controlled and of longer duration. As well, Phase 3 studies can include patients who have more than one illness and are taking medications in addition to the experimental product used in the study. Therefore, the patients in Phase 3 studies more closely reflect the general population. The information from Phase 3 forms the basis for most of the product&#8217;s initial labeling, which will guide physicians on how to use the product.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Phase 4 Post-Approval Clinical Studies</i>. Phase 4 clinical studies are conducted after a product is approved. Phase 4 studies may be required by the FDA or conducted by companies to more fully understand how their product compares to other products. FDA-required Phase 4 studies often investigate the product in specific types of patients that may not have been included in the Phase 3 studies and can involve very large numbers of patients to further assess the product&#8217;s safety.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stage 3: FDA Review for Approval</i></b>. Following the completion of Phase 3 clinical studies, the company prepares an electronic common technical document reporting all clinical, nonclinical and chemistry, manufacturing and control studies conducted on the product that is transmitted to the FDA as a Biologics License Application. The FDA reviews the information in the BLA to determine if the product is safe and effective for its intended use. For novel products or those raising significant questions, the FDA may convene an advisory panel meeting regarding the product to allow the FDA to gain feedback from experts. If the FDA determines that the product is safe and effective, the product may be approved and/or subject to additional labeling revisions or post-marketing requirements as a condition of approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stage 4: Marketing</i></b>. After the FDA has approved the experimental product, the company can make the product available to physicians and their patients. A company also may continue to conduct research to discover new uses for the product. Each time a new use for a product is discovered, the product once again is subject to the applicable FDA approval process before it can be marketed for that purpose.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All FDA approved therapeutic products are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA guidance documents, and promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, promoting products for uses or in patient populations that are not described in the pharmaceutical product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities and promotional activities involving the internet or social media. Failure to comply with FDA requirements is likely to have negative consequences, including adverse publicity, warning or enforcement letters from the FDA, mandated corrective advertising or communications with doctors, product seizures or recalls and state or federal civil or criminal prosecution, injunctions and penalties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The FDA also may require post-marketing testing, known as Phase 4 testing, risk evaluation and mitigation strategies and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DM199 may qualify for 4 years of data exclusivity and 12 years of market exclusivity under the BPCIA. This means that FDA cannot accept any biosimilar applications based on data from a reference product for a period of four years from the date the reference product was first licensed. Additionally, under the BPCIA, a BLA may provide for 12 years of market exclusivity for a newly approved biologic product. This means FDA cannot approve any biosimilar applications for a period of 12 years from the date the reference product was first licensed. However, the BPCIA provides an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing reference product. The new law is complex and is only beginning to be interpreted and implemented by the FDA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>European Approval Process</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The EMA is roughly parallel to the FDA in terms of the drug approval process and the strict requirements for approval. The EMA was set up in 1995 in an attempt to harmonize, but not replace, the work of existing national medicine regulatory bodies in individual European countries. As with the FDA, the EMA drug review and approval process follows similar stages from preclinical testing through clinical testing in Phase 1, 2, and 3. There are some differences between the FDA and EMA review process, specifically the review process in individual European countries. Such differences may allow certain drug products to be tested in patients at an earlier stage of development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Other Healthcare Laws and Compliance Requirements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services and other divisions of the U.S. government, including, the Department of Health and Human Services, the Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. For example, if a drug product is reimbursed by Medicare, Medicaid, or other federal or state healthcare programs, a company, including its sales, marketing and scientific/educational grant programs, must comply with the FDCA as it relates to advertising and promotion of drugs, the federal False Claims Act, as amended, the federal Anti-Kickback Statute, as amended, the Physician Payments Sunshine Act, the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), and similar state laws. If a drug product is reimbursed by Medicare or Medicaid, pricing and rebate programs must comply with, as applicable, the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 (OBRA), and the Medicare Prescription Drug Improvement and Modernization Act of 2003. Among other things, OBRA requires drug manufacturers to pay rebates on prescription drugs to state Medicaid programs and empowers states to negotiate rebates on pharmaceutical prices, which may result in prices for our future products being lower than the prices we might otherwise obtain. Additionally, the ACA substantially changes the way healthcare is financed by both governmental and private insurers. There may continue to be additional proposals relating to the reform of the U.S. healthcare system, in the future, some of which could further limit coverage and reimbursement of drug products. If drug products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements may apply.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Pharmaceutical Coverage, Pricing and Reimbursement</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and adequate reimbursement from third-party payers, including government health administrative authorities, managed care providers, private health insurers and other organizations. In the United States, private health insurers and other third-party payers often provide reimbursement for products and services based on the level at which the government (through the Medicare and/or Medicaid programs) provides reimbursement for such treatments. Third-party payers are increasingly examining the medical necessity and cost-effectiveness of medical products and services in addition to their safety and efficacy; and, accordingly, significant uncertainty exists regarding the coverage and reimbursement status of newly approved therapeutics. In particular, in the United States, the European Union and other potentially significant markets for our product candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. As a result, coverage and adequate third-party reimbursement may not be available for our products to enable us to realize an appropriate return on our investment in research and product development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The market for our product candidates for which we may receive regulatory approval will depend significantly on access to third-party payers&#8217; drug formularies or lists of medications for which third-party payers provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payers may refuse to include a particular branded drug in their formularies or may otherwise restrict patient access to a branded drug when a less costly generic equivalent or another alternative is available. In addition, because each third-party payer individually approves coverage and reimbursement levels, obtaining coverage and adequate reimbursement is a time-consuming and costly process. We would be required to provide scientific and clinical support for the use of any product candidate to each third-party payer separately with no assurance that approval would be obtained, and we may need to conduct expensive pharmacoeconomic studies to demonstrate the cost-effectiveness of our product candidates. This process could delay the market acceptance of any of our product candidates for which we may receive approval and could have a negative effect on our future revenues and operating results. We cannot be certain that our product candidates will be considered cost-effective. If we are unable to obtain coverage and adequate payment levels for our product candidates from third-party payers, physicians may limit how much or under what circumstances they will prescribe or administer them and patients may decline to purchase them. This in turn could affect our ability to successfully commercialize our products and impact our profitability, results of operations, financial condition, and future success.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Research and Development</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have devoted substantially all of our efforts to research and development (R&amp;D), which therefore has comprised the largest component of our operating costs. Our primary focus has been our lead product candidate, DM199, which is currently in clinical development for the treatment of PE, FGR and AIS.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect our R&amp;D expenses will continue to increase in the future as we continue the development and clinical study of our initial product candidate, DM199, in PE, FGR and AIS and seek to pursue other indications or expand our product candidate portfolio. The process of conducting the necessary development and clinical research to obtain regulatory approval is costly and time-consuming; and we consider the active management and development of our clinical pipeline to be integral to our long-term success. The actual probability of success for each product candidate, clinical indication and preclinical program may be affected by a variety of factors including, among other things, the safety and efficacy data for each product candidate, amounts invested in their respective programs, competition and competitive developments, manufacturing capability and commercial viability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">R&amp;D expenses include:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">expenses incurred with third-party service providers, such as contract research organizations, clinical data management services and other study support services;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">expenses incurred under agreements with clinical trial sites that conduct research activities on our behalf;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">laboratory and vendor expenses related to the execution of clinical trials and non-clinical studies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the cost of acquiring, developing, manufacturing, and distributing clinical trial materials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">employee and consultant-related expenses, which include salaries, benefits, consulting fees, travel and share-based compensation; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance, and other supply costs.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">R&amp;D costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect that it will be at least three to four years, if ever, before we have any product candidates ready for commercialization.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Manufacturing</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We do not own or operate manufacturing facilities for the production of DM199, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We rely on Catalent Pharma Solutions, LLC (Catalent), a contract development and manufacturing organization (CDMO) with proven GMP experience in the manufacturing of recombinant proteins for clinical trials, for procuring all of our required raw materials and producing active pharmaceutical ingredient for our clinical trials. We have licensed certain gene expression technology from and we contract with Catalent for the manufacture of DM199 drug substance. We currently employ internal resources and third-party consultants to manage our manufacturing relationship with Catalent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Sales and Marketing</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have not yet defined our sales, marketing or product distribution strategy for our initial product candidate, DM199, or any future product candidates. We currently expect to partner with a large pharmaceutical company for sales execution. However, our future commercial strategy may include the use of distributors, a contract sales force or the establishment of our own commercial and specialty sales force, as well as similar strategies for regions and territories outside the United States.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Intellectual Property</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We view patents and other means of intellectual property protection, including trade secrets, as an important component of our core business. We focus on translating our innovations into intellectual property protecting our proprietary technology from infringement by competitors. To that end, patents are reviewed frequently and continue to be sought in relation to those components or concepts of our preclinical and clinical products to provide protection. Our strategy, where possible, is to file patent applications to protect our product candidates, as well as methods of manufacturing, administering and using a product candidate. Prior art searches of both patent and scientific databases are performed to evaluate novelty, inventiveness and freedom-to-operate. We require all employees, consultants and parties to a collaborative research agreement to execute confidentiality agreements upon the commencement of employment, consulting relationships or a collaboration with us. These agreements require that all confidential information developed or made known during the course of the engagement with us is to be kept confidential. We also maintain agreements with our scientific staff and all parties contracted in a scientific capacity affirming that all inventions resulting from work performed for us, using our property or relating to our business and conceived or completed during the period covered by the agreement are the exclusive property of DiaMedica.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our DM199 patent portfolio includes five granted U.S. patents, a granted European patent, a granted Canadian patent, a granted Australian patent and pending applications in Australia, Canada, China, Europe, India, Japan, South Korea, Hong Kong and the United States. Granted or pending claims offer various forms of protection for DM199, including claims to compositions of matter, pharmaceutical compositions, specific formulations and dosing levels and methods for treating a variety of diseases, including stroke, chronic kidney disease and related disorders. These U.S. patents and applications, and their foreign equivalents, are described in more detail below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Issued patents held by us cover the DM199 composition of matter based on an optimized combination of closely related isoforms that differ in the extent of glycosylation (process by which sugars are chemically attached to proteins). Issued claims in this patent family cover the most pharmacologically active variants of DM199 and methods of using the same for treating ischemic conditions. These patents are due to expire in 2033. A second patent family includes an issued U.S. patent with claims directed to methods of treating subjects by administering a SC formulation of DM199 or related recombinant kallikrein-1 (KLK1) polypeptides and is predicted to expire in 2033. An additional patent application family is directed to a range of dose levels and dosing regimens of DM199 that are potentially useful for treating a wide range of diseases including, among others, pulmonary arterial hypertension, cardiac ischemia, chronic kidney disease, diabetes, stroke and vascular dementia, which if granted, are predicted to expire in 2038. This family has an issued U.S. patent directed to a range of dose levels for treating ischemic conditions and is predicted to expire in 2039 because of patent term adjustment. This patent family has another issued U.S. patent directed to a range of dose levels for treating vascular dementia and is predicted to expire in 2038. An additional patent family is pending in the US only and is directed to treating chronic kidney disease based on a selection of biomarkers. This application is predicted to expire in 2043. A further patent family includes pending PCT and US applications directed to treating pregnancy disorders such as preeclampsia and is predicted to expire in 2045. Another patent family includes pending PCT and US applications directed to KLK1 formulations suitable for use with polyolefin-containing intravenous bags and is predicted to expire in 2045.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our DM300 (recombinant human ulinastatin) patent portfolio includes one issued patent in each of the United States, Taiwan and Japan and pending applications in Brazil, Canada, China, Europe, Hong Kong, India, Japan, South Korea, Taiwan and the United States. Granted or pending claims held by us offer various forms of protection for DM300. For instance, granted or pending claims in a first patent family cover the DM300 composition of matter based on mutants and optimized glycosylation patterns of human ulinastatin and methods of using the same for treating various conditions such as acute pancreatitis. This family is predicted to expire in 2041. Pending claims in a second patent family relate to methods of using DM300 and other ulinastatin polypeptides for treating diseases associated with neutrophil elastase (NE) including inflammatory lung diseases such as A1AT-deficiency. This family is predicted to expire in 2042.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As previously discussed, we do not own or operate manufacturing facilities for the production of clinical or commercial quantities of DM199. We are contracting with Catalent for the manufacture of DM199. We also license from Catalent certain gene expression technology. Under the terms of this license, certain milestone and royalty payments may become due by us and are dependent upon, among other factors, us performing clinical trials, obtaining regulatory approvals and ultimately the successful commercialization of a new drug, the outcome and timing of which is uncertain. The royalty term is indefinite, but the license agreement may be canceled by us on 90 days&#8217; prior written notice. The license may not be terminated by Catalent unless we fail to make required milestone and royalty payments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Methods and reagents required for commercial scale manufacture of DM199 are subject to a series of patents issued to Catalent. We license these patents from Catalent, and such license is exclusive as it relates to the production of DM199 or any human KLK1 protein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that our proprietary technology, along with trade secrets and specialized knowledge of the manufacturing process, will provide substantial protection from third-party competitors. We also believe that DM199 cannot be easily reverse engineered for the production of a copycat version.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that the most relevant granted patents and applications with composition of matter or method of use claims covering DM199 are listed below, along with their projected expiration dates exclusive of any patent term extension:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Patent/Application </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.4%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.4%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Geography</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:0.4%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Predicted </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="7" style="border-bottom:solid 1px #000000;vertical-align:top;width:46.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>DM199 Patent Family</i></b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Issued patents</i></b></p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">&#160;</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 9,364,521</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Human Tissue Kallikrein 1 Glycosylation Isoforms</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2033</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 9,839,678</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Human Tissue Kallikrein 1 Glycosylation Isoforms</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2033</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">CA 2880085</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Human Tissue Kallikrein 1 Glycosylation Isoforms</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2033</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">EP 2 854 841</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Human Tissue Kallikrein 1 Glycosylation Isoforms</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Europe</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2033</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 9,616,015</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Formulations for Human Tissue Kallikrein-1 for Parenteral Delivery and Related Methods</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2033</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 11,857,608</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2039</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 12,329,805</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">AU 2018230478</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Australia</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Pending applications</i></b></p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">&#160;</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">&#160;</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">AU 2025202779</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Australia</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">CA 3054962</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">CN 201880016380.4</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">China</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">EP 18763243.5</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Europe</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">IN 201917037712</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">India</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">JP 2019-548655</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Japan</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">JP 2024-225007</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Japan</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 9.2%; padding-left: 9pt;">KR 10-2024-7038300</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SK</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">HK 62020009783.5</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Hong Kong</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">HK 62020007146.7</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Hong Kong</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 19/211,792</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2038</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 9.2%; padding-left: 9pt;">US 19/577,830</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">Dosage Forms of Tissue Kallikrein 1</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align: top; width: 7%; text-align: center;">U.S.</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align: top; width: 4.6%; text-align: center;">2038</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 18/295,991</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tissue Kallikrein 1 for Treating Chronic Kidney Disease</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2043</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 19/041,742</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tissue Kallikrein-1 for Treating Pregnancy Disorders</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2045</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">PCT/US2025/013869</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tissue Kallikrein-1 for Treating Pregnancy Disorders</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">PCT</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2045</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 19/178,631</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Intravenous Compositions of Tissue Kallikrein-1 and Related Methods</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2045</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">PCT/US2025/024594</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Intravenous Compositions of Tissue Kallikrein-1 and Related Methods</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">PCT</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2045</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 69/980,517</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tissue Kallikrein-1 for Treating Resistant Hypertension</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&#160;</td>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2046</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td colspan="7" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 46.3%; border-top: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>DM300 Patent Family</i></b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Issued patents</i></b></p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">&#160;</td>
			<td style="vertical-align:top;width:8.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 11,725,043</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">TW I888497</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Taiwan</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">JP 7778077</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Japan</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Pending applications</i></b></p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">&#160;</td>
			<td style="vertical-align:top;width:8.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 18/338,970</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">BR 1120220177186</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Brazil</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">CA 3174478</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">CN 202180032829.8</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">China</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">EP 21764369.1</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Europe</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">HK 62023075807.5</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Hong Kong</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">IN 202217056697</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">India</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">JP 2022-553090</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Japan</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">JP 2025-197322</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Japan</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2041</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">US 17/586,238</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides for Treating Diseases</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2042</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">CA 3206854</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides for Treating Diseases</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Canada</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2042</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">CN 202280021674.2</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides for Treating Diseases</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">China</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2042</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">EP22746605.9</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides for Treating Diseases</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Europe</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2042</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">HK 62024091076.5</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides for Treating Diseases</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Hong Kong</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2042</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:9.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">JP 2023-546004</p>
			</td>
			<td style="vertical-align:top;width:0.9%;">&#160;</td>
			<td style="vertical-align:top;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ulinastatin Polypeptides for Treating Diseases</p>
			</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Japan</p>
			</td>
			<td style="vertical-align:top;width:0.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:3.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2042</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The base term of a U.S. patent is 20 years from the filing date of the earliest-filed non-provisional patent application from which the patent claims priority. The term of a U.S. patent can be lengthened by patent term adjustment, which compensates the owner of the patent for administrative delays at the U.S. Patent and Trademark Office. In some cases, the term of a U.S. patent is shortened by terminal disclaimer that reduces its term to that of an earlier-expiring patent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of a U.S. patent may also be eligible for patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act, to account for at least some of the time the drug is under development and regulatory review after the patent is granted. With regard to a drug for which FDA approval is the first permitted marketing of the active ingredient, the Hatch-Waxman Act allows for extension of the term of one U.S. patent that includes at least one claim covering the composition of matter of an FDA-approved drug, an FDA-approved method of treatment using the drug, and/or a method of manufacturing the FDA-approved drug. The extended patent term cannot exceed the shorter of five years beyond the non-extended expiration of the patent or 14 years from the date of the FDA approval of the drug. Some foreign jurisdictions, including Europe and Japan, also have patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency. In the future, if and when our pharmaceutical products receive FDA approval, we expect to apply for patent term extension on patents covering those products, their methods of use, and/or methods of manufacture.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. Companies typically rely on trade secrets to protect aspects of their business that are not amenable to, or that they do not consider appropriate for, patent protection. We protect trade secrets, if any, and know-how by establishing confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and partners. These agreements provide that all confidential information developed or made known during the course of an individual or entity&#8217;s relationship with us must be kept confidential during and after the relationship. These agreements also generally provide that all relevant inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employees</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2025, we had 35 employees, all of whom were full-time employees. We have never had a work stoppage and none of our employees are covered by collective bargaining agreements. We believe our employee relations are good.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Information About Our Executive Officers</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth information as of the date of this filing regarding each of our current executive officers:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name</b></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Age</b></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:23.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Positions</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rick Pauls</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">54</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:23.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer, Director</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Julie Krop, M.D.</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">60</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:23.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Medical Officer</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:19.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Scott Kellen</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">60</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:23.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer and Secretary</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The present principal occupations and recent employment history of each of our executive officers are set forth below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Rick Pauls</i> was appointed our President and Chief Executive Officer in 2010. Mr. Pauls has served as a member of our Board of Directors since 2005 and served as Chairman of the Board from 2008 to 2014. Prior to joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund, from 2002 until 2010. Mr.&#160;Pauls was an analyst for Centara Corporation, another early stage venture capital fund, from 2000 until 2002. From 1997 until 1999, Mr. Pauls worked for General Motors Acceptation Corporation specializing in asset-backed securitization and structured finance. Mr. Pauls previously served as an independent member of the board of directors of LED Medical Diagnostics, Inc. from 2006 to 2017. Mr.&#160;Pauls received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Julie Krop, M.D.</i> joined DiaMedica as our Chief Medical Officer in August 2025. Prior to joining DiaMedica, Dr. Krop provided independent consulting services as President of JSK Consulting, a clinical development consulting firm, from April 2024 until August 2025. From August 2021 to August 2025, Dr. Krop served as the Chief Medical Officer and Head of Development of PureTech Health, a clinical-stage pharmaceutical company focused on the development of drugs for the treatment of multiple rare diseases. Prior to PureTech Health, Dr. Krop served as Chief Medical Officer at Freeline Therapeutics, a clinical-stage pharmaceutical company focused on gene therapy programs from 2020 to 2021. From 2020 to 2021, Dr. Krop also served as Chief Medical Officer and Executive Vice President at AMAG Pharmaceuticals. Previously, she held various roles of increasing responsibility at Vertex Pharmaceuticals, Stryker Regenerative Medicine, Peptimmune, Millennium Pharmaceuticals, and Pfizer. Dr. Krop received her medical degree from Brown University School of Medicine and completed her internal medicine residency at Georgetown University Hospital. She completed fellowships in epidemiology, clinical trial design and endocrinology at Johns Hopkins School of Medicine. Dr. Krop is board-certified in Endocrinology.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Scott Kellen</i> joined DiaMedica as our Vice President of Finance in January 2018 and was appointed our Chief Financial Officer and Secretary in April 2018. Prior to joining DiaMedica, Mr. Kellen served as Vice President and Chief Financial Officer of Panbela Therapeutics, Inc., formerly known as Sun BioPharma, Inc., a publicly traded clinical stage drug development company, from 2015 until 2018. From 2010 to 2015, Mr. Kellen served as Chief Financial Officer and Secretary of Kips Bay Medical, Inc., a publicly traded medical device company, and became Chief Operating Officer of Kips Bay in 2012. From 2007 to 2009, Mr. Kellen served as Finance Director of Transoma Medical, Inc. From 2005 to 2007, Mr. Kellen served as Corporate Controller of ev3 Inc. From 2003 to 2005, Mr. Kellen served as Senior Manager, Audit and Advisory Services of Deloitte &amp; Touche, LLP. Altogether, Mr. Kellen has spent more than 30 years in the life sciences industry, focusing on publicly traded early stage and growth companies. Mr. Kellen has a Bachelor of Science degree in Business Administration from the University of South Dakota and is a Certified Public Accountant (inactive).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Available Information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a corporation governed by British Columbia&#8217;s Business Corporations Act (BCBCA). Our company was initially incorporated pursuant to The Corporations Act (Manitoba) by articles of incorporation dated January 21, 2000. Our articles were subsequently amended several times, including on April 11, 2016 to continue the Company from The Corporations Act (Manitoba) to the Canada Business Corporations Act (CBCA) and on May 31, 2019, to continue our existence from a corporation incorporated under the CBCA into British Columbia under the BCBCA. Our registered office is located at 301-1665 Ellis Street, Kelowna, British Columbia, Canada V1Y 2B3 and our principal executive office is hosted by our wholly owned subsidiary, DiaMedica USA Inc., and located at 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota, USA 55305. Our telephone number is 763-496-5454. Our internet website address is http://www.diamedica.com. Information contained on our website does not constitute part of this report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We make available, free of charge and through our Internet web site, our annual reports on Form 10-K, quarterly reports on Form&#160;10-Q, current reports on Form 8-K, and any amendments to any such reports filed or furnished pursuant to Section 13(a) or 15(d) of the United States Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the United States Securities and Exchange Commission (SEC). Reports filed with the SEC may be viewed at <span style="text-decoration: underline; ">www.sec.gov</span>.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">27</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 1pt;"><b>Item 1A. </b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Risk Factors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Below are material factors known to us that could materially adversely affect our business, operating results, financial condition, prospects or share price. The summary of risk factors is not complete and should be read in conjunction with the more complete and detailed descriptions of risk factors that follow. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, operating results, financial condition, prospects or share price.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risk Factors Summary</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risks Related to Our Business Model</i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our business model assumes we will generate revenue by, among other activities, marketing or out-licensing the product candidates we develop. Since our product candidates are in various stages of development and we have no products approved for commercialization, there is a limited amount of information about us upon which you can base an evaluation of our business and prospects.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may need to establish relationships with strategic partners to fully develop, and if approved, market any product candidate.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risks Related to Our Current and Future Clinical Trials and DM199 Product Candidate</i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have had and may continue to have difficulty enrolling patients in our ReMEDy2 trial or we may experience other clinical testing delays or setbacks.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The adaptive design of our ReMEDy2 trial could result in a requirement to enroll more patients than anticipated in the trial and an increase in time and costs to complete the trial.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The expansion of our DM199 clinical development program into PE and our investigator-sponsored PE trial involves risks.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DM199 and any other product candidates we choose to develop may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if granted.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We face the risk of product liability claims and may be unable to maintain product liability insurance sufficient to cover such claims or as required under our contractual agreements.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The initial investigator-sponsored PE trial is being conducted in South Africa, we are commencing a PE trial in Canada and the global expansion of our ReMEDy2 trial involves risks.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Data from the PE trials could adversely affect our ReMEDy2 trial and any interim, &#8220;top-line&#8221;&#160;or preliminary trial results could differ from the full final results of the trial.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our ReMEDy2 trial fails to adequately demonstrate the safety and efficacy of DM199 to treat AIS, we will not be able to obtain the regulatory approvals required to market and commercialize DM199 to treat AIS.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may be required to suspend, repeat or terminate our ReMEDy2 trial or future clinical trials if they are deemed not to have been conducted in accordance with regulatory requirements, the results are negative or inconclusive, or the trial is not well designed.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our prospects depend on the clinical and commercial success of our DM199 product candidate, which in turn depends upon many factors outside of our control.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risks Related to Our Financial Position and Need for Additional Capital</i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Since we have no revenue from product sales and do not expect any revenue from product sales for at least two to three, we will likely need additional funding to continue our clinical development activities and other operations, which may not be available to us on acceptable terms, or at all.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have incurred substantial losses since our inception and expect to continue to incur substantial losses for at least two to three years and may never become profitable, or if achieved, be able to sustain profitability.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risks Related to Governmental and Regulatory Compliance and Approvals</i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The regulatory approval process is expensive, time-consuming and uncertain and may prevent us or any future partner or collaborator from obtaining approvals for the commercialization of DM199 or any future product candidate.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any product candidate for which we or any future partner or collaborator obtains marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with the product candidate.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risks Related to Our Reliance on Third Parties</i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely on third parties to support the planning, execution and/or monitoring of our preclinical and clinical trials, and their failure to perform as required could cause delays in completing our product development and substantially harm to our business.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely extensively on contract development and manufacturing organizations (CDMOs) for the manufacture and testing of DM199 under current good manufacturing procedures (cGMP).</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Future development collaborations are expected to be important to us.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risks Related to Intellectual Property</i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We could lose important intellectual property rights that we currently license from a third party if we fail to comply with our obligations under the license agreement under which we license intellectual property rights from this third party or otherwise experience disruptions to our business relationships with our licensor.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may be unable to adequately protect our technology and enforce our intellectual property rights.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We or a future partner may require additional third-party licenses to effectively develop, manufacture and commercialize DM199, or any future product candidate, and such licenses might not be available on commercially acceptable terms, or at all.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Changes in patent law and its interpretation could diminish the value of our patents.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Intellectual property litigation may be expensive, time consuming and may cause delays in the development, manufacturing and commercialization of DM199 or any future product candidate.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risks Related to Human Capital Management</i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely heavily on the capabilities and experience of our key executives, clinical personnel and advisors and the loss of any of them could affect our ability to develop DM199 or any future product candidate.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We will likely need to expand our operations and increase the size of our Company and we may experience difficulties in managing our growth.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risks Related to the Future Commercialization of DM199 or Any Future Product Candidate</i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The successful commercialization of DM199 or any future product candidate, if approved, will depend on achieving market acceptance and we may not be able to gain sufficient acceptance to generate significant revenue.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we fail to obtain coverage and adequate reimbursement for DM199 or any future product candidate, its revenue-generating ability will be diminished and there is no assurance that the anticipated market for the product will develop or be sustained.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We or any future partner will likely face competition from other biotechnology and pharmaceutical companies, many of which have substantially greater resources than us.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our DM199 product candidate may face competition sooner than expected.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our estimates of the market opportunity for our DM199 product candidate are based on a number of assumptions and may prove to be inaccurate.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risks Related to Our Common Shares</i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our common share price has been volatile and may continue to be volatile.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We do not have a history of a very active trading market for our common shares.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may issue additional common shares resulting in share ownership dilution, and if there are substantial sales of our shares or the perception that such sales may occur, the market price of our shares could decline.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">A limited number of shareholders possess substantial voting power.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Risks Related to Our Jurisdiction of Organization</i></b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are governed by the corporate laws of British Columbia, which in some cases have a different effect on shareholders than the corporate laws in effect in the United States.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We were classified as a &#8220;passive foreign investment company&#8221;&#160;(PFIC) for our taxable years 2025, 2024 and 2023 and certain other prior years and may continue to be so classified in the current and/or future taxable years, which may have adverse U.S. federal income tax consequences for U.S. shareholders and adversely affect the level of interest in our common shares by U.S. investors. Any common shareholder who held our shares in years when we were classified as a PFIC will be subject to special reporting rules in order to avoid adverse PFIC tax consequences. Even if we subsequently no longer qualify as a PFIC in a future taxable year, shareholders will still be subject to the PFIC rules for shares acquired in years when we were a PFIC unless a so-called &#8220;purging election&#8221;&#160;is made, as described below.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Business Model</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business model assumes we will generate revenue by, among other activities, marketing or out-licensing the product candidates we develop. Since our product candidates are in various stages of development and we have no products approved for commercialization, there is a limited amount of information about us upon which you can base an evaluation of our business and prospects.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None of our product candidates have completed clinical development, and therefore, we have no product candidates approved for commercialization and thus have not begun to market or generate revenues from the commercialization of any product candidates. Because no product candidate has completed clinical development and been approved for commercialization, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in the biopharmaceutical industry. For example, to execute our business plan, we will need to successfully:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Demonstrate safety and efficacy of our product candidates in human clinical studies;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Complete manufacturing development activities relating to our DM199 product candidate for the treatment of AIS or PE or any other indications we decide to pursue and any other product candidates we choose to develop;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Receive FDA approval and/or approval from similar foreign regulatory bodies;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Gain market acceptance for the commercialization of any products we develop and have not out-licensed such rights;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Obtain reimbursement by commercial and/or government payors at a rate that permits commercial viability;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Develop and maintain successful strategic relationships with suppliers, distributors and commercial licensing partners;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Build, maintain, and protect an adequate intellectual property portfolio; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Manage our spending and cash requirements as our expenses are anticipated to increase in the near term as we ramp up enrollment in our clinical trials and if we add new indications for DM199 and other product candidates and conduct additional preclinical and clinical trials.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are unsuccessful in accomplishing these objectives or in making sufficient progress toward these objectives, we may not be able to develop and maintain successful strategic relationships, raise capital, and continue our operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may need to establish relationships with strategic partners to fully develop our product candidates and, if approved, market any product candidates that are approved.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our business strategy includes securing license agreements and collaborations with other pharmaceutical and biotech companies to support the development of DM199 for various indications. We do not possess all of the financial resources necessary to complete the development and commercialization of our product candidates, if and when they are approved. Unless we expand our own internal sales and marketing capability, we will likely need to make arrangements with other strategic partners to commercialize any product candidates that may be approved. We may not be able to attract such partners, and even if we are able to enter into such partnerships, the terms may be less favorable than anticipated. Further, entering into partnership agreements may limit our commercialization options and would require us to share revenues and profits with our partners. If we do not find appropriate partners, or if such future agreements are not successful, our ability to commercialize products could be adversely affected. Even if we are able to find collaborative partners, the overall success of the commercialization of product candidates in those programs will depend largely on the efforts of those other parties and may be beyond our control and our licensees may elect to assume greater control over these programs. In addition, in the event we pursue our commercialization strategy through collaboration or licenses to third parties, there are a variety of technical, business and legal risks, including, among others:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may be unable to control the amount and timing of resources that our collaborators may be willing or able to devote to the commercialization of our product candidates including to their marketing and distribution efforts; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disputes may arise between us and our collaborators that result in the delay or termination of the commercialization of our product candidates or that result in costly litigation or arbitration that diverts our management&#8217;s resources.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The occurrence of any of the above events or other related events could impair our ability to generate revenues and harm our business, prospects, operating results and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Current and Future Clinical Trials and DM199 Product Candidate</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have had and may continue to have difficulty enrolling patients in our ReMEDy2 trial or we may experience other clinical testing delays or setbacks, which would delay our ability or the ability of a future partner to obtain regulatory approval for DM199 to treat AIS and commercialize it, which would substantially harm our business and prospects.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our ReMEDy2 trial is a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial that is intended to enroll approximately 300 patients at up to 100 sites globally. We have had and may continue to have difficulty enrolling patients in our ReMEDy2 trial, which could delay further completion of the trial or even jeopardize the viability of the trial. We believe these enrollment difficulties may be due, in part, to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the clinical hold which was lifted in June 2023; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, it is possible that we may experience other clinical testing delays or setbacks, which would further delay completion of the ReMEDy2 trial. Product development costs typically increase with delays in clinical testing. Significant clinical trial delays could not only extend the time period for obtaining regulatory approval of DM199 to treat AIS and increase our costs, but also shorten any periods during which we or a future partner may have the exclusive right to commercialize DM199 to treat AIS or allow our competitors to bring competitive products to market before us, which would adversely affect the ability to successfully commercialize DM199 and may harm our business, prospects, operating results and financial condition. The ReMEDy2 trial may be delayed for a number of reasons, including without limitation those described above as well as the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">sites waiting for internal approvals of the most recently revised protocol for the trial;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">patients choosing to participate in competing clinical trials or not at all;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">scheduling conflicts with participating clinicians and clinical sites;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">complexities in setting up and coordinating with sites that are located outside the United States and additional risks involved in a trial that is being conducted, in part, outside the United States;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">suspension or termination of the ReMEDy2 trial by regulators for any reason, including concerns about patient safety or failure of our contract manufacturers to comply with current Good Manufacturing Practices (cGMP) requirements;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">any changes to our manufacturing process that may be necessary or desired which affect our ability to produce adequate or timely clinical drug supply;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">delays or failure to obtain clinical drug supply of DM199 from contract manufacturers necessary to conduct clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our DM199 product candidate demonstrating a lack of safety or efficacy at the planned interim analysis of the ReMEDy2 trial;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">patients failing to enroll or complete the ReMEDy2 trial at the rates and within the timelines we expect due to dissatisfaction with the treatment, side effects or other reasons;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">clinical investigators not performing the ReMEDy2 trial on their anticipated schedule, dropping out of a trial or employing methods not consistent with the clinical trial protocol and regulatory requirements or other third parties not performing data collection and analysis in a timely or accurate manner;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">inspections of our clinical trial sites by regulatory authorities, Institutional Review Boards (IRBs) or ethics committees finding regulatory violations that require us to undertake corrective action, resulting in suspension or termination of one or more sites or the imposition of another clinical hold on the IND for our ReMEDy2 trial; or</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">public health crises, epidemics or pandemics, such as COVID-19, which may adversely impact our ability to continue to engage and activate clinical trial sites, recruit or enroll subjects for our ReMEDy2 trial or any future trial and obtain the requisite staffing for our ReMEDy2 trial or any future trial.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our product development costs may increase if we need to perform a larger or more clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend trial protocols or alter our manufacturing processes to reflect these changes. Amendments typically require us to resubmit our trial protocols to the FDA and other regulatory authorities and IRBs or ethics committees, for re-examination, which may impact the cost, timing or successful completion of our ReMEDy2 trial. Delays or increased product development costs or any of these events would likely have a material adverse effect on our business, prospects, operating results and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The adaptive design of our ReMEDy2 trial could result in the trial being required to enroll more patients than anticipated, which would increase the time and costs to complete the trial.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our ReMEDy2 trial is an adaptive design trial intended to enroll approximately 300 patients. The adaptive design component includes an interim analysis by our independent data safety monitoring board after the first 200 participants have completed the trial. Based on the results of the interim analysis, the study may be stopped for futility or a new total sample size may be determined, ranging between 300 and 728 participants, according to a pre-determined statistical analysis plan. Because of the ReMEDy2 trial&#8217;s adaptive design, it is possible that the number of participants required to complete the trial may increase significantly from the 300 patients we are currently targeting. If we are required to enroll more participants than currently anticipated, it will increase the time and costs to complete the trial, which may result in a need for additional funding that may not be available to us on acceptable terms, or at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The expansion of our DM199 clinical development program into PE involves certain risks related to timing, regulatory approvals, costs and enrollment, and the fact that the initial PE trial is investigator-sponsored, raises additional risks.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We are currently financially supporting the conduct of a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored trial of DM199 for the treatment of PE at the Tygerberg Hospital, Cape Town, South Africa. This study may enroll up to approximately 100 women with PE and potentially an additional 30 women with fetal growth restriction may be evaluated. Part 1a top line study results were released in July 2025 which we believe demonstrated the potential for DM199 to lower maternal blood pressure and improve uterine artery dilation. We have received approval to commence an additional Phase 2 study of PE in early-onset preeclampsia in Canada which we anticipate initiating in the second half of 2026.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The expansion of our DM199 clinical development program into PE and the progress of that program may not occur on the anticipated timeline or at all. In addition, these Phase 2 PE trials may cost us more than we anticipate. Additionally, the first trial is investigator-sponsored and the conduct of the second trial is expected to rely on a contract research organization (CRO), we have less control over the timing and costs of these studies and the ability to recruit trial participants than if we conducted the study with our own personnel. There is no guarantee that our physician collaborators or CRO will devote adequate time and resources to perform these studies and/or maintain adequate clinical trial information regarding our product candidate. If these third parties fail to meet expected deadlines, fail to transfer to us any regulatory information in a timely manner, fail to adhere to the study protocol, or fail to act in accordance with regulatory requirements or our agreement with them, or if they otherwise perform in a substandard manner or in a way that compromises the quality or accuracy of their activities or the data they obtain, then the current PE trial or future clinical trials may be extended or delayed with additional costs incurred, or our data may be rejected by applicable regulatory agencies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Data collected from the current on-going investigator-sponsored PE program in South Africa will serve as the basis for the design of Phase 2 clinical studies to be conducted in North America and other parts of the world. There is risk that the safety and pharmacodynamic results, differing standards of care, dose and dosing regimens used in a South African population may not translate or generalize to a typical PE population in North America or other parts of the world and could affect the safety/efficacy profile of DM199, the need for additional clinical studies, leading to additional development delays and expenses.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Any of these risks could adversely impact our business, prospects, operating results and financial position, including our ability to raise additional financing, if and when needed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>DM199 and any other product candidates we choose to develop may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if granted.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As with most pharmaceutical products, DM199 and any future product candidates could be associated with side effects or adverse events, which can vary in severity and frequency. Although the most common DM199 related adverse events that have occurred to date in our clinical trials have been constipation, injection site reaction, nausea, headache and flushing. A less common but important adverse event has been clinically significant, transient, hypotension (low blood pressure) during IV infusion of DM199 that was observed in a number of subjects. These hypotensive episodes were rapidly reversed upon cessation of the IV infusion with complete recovery; hypotensive episodes have not been observed with subcutaneous administration of DM199. Side effects or adverse events associated with the use of DM199, or any future product candidates, may be observed at any time during clinical development. If unacceptable side effects arise in the development of our product candidates, we, the FDA or comparable foreign regulatory authorities, the Institutional Review Boards, or independent ethics committees at the institutions in which our studies are conducted, or the data safety monitoring board, could suspend or terminate our clinical trials, similar to when the FDA imposed a clinical hold on our current ReMEDY2 trial in 2022, or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may be required to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. The safety profile of DM199 observed in one disease indication could affect the labeling, dosing, route of administration, and/or commercial value of DM199 in another disease indication. Any of these occurrences may prevent us, or any future partner from achieving or maintaining market acceptance of the affected product candidate and may harm our business, prospects, operating results and financial condition.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Results of our trials could reveal a high and unacceptable severity and prevalence of side effects, toxicity or other safety issues, and could require us to perform additional studies, including preclinical studies, or halt development of DM199 or any future product candidates, or expose us to product liability lawsuits that would likely harm our business. There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any other regulatory authority in a timely manner, if ever, which could harm our business, prospects, operating results and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are required by the FDA and other comparable foreign regulatory authorities to report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA other comparable foreign regulatory authorities could take action including but not limited to criminal prosecution, the imposition of civil monetary penalties, seizure of our products, halting our clinical trials or delay in approval or clearance of future product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We face the risk of product liability claims, which could exceed our insurance coverage, deplete our cash resources and lead to clinical trial delays.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A risk of product liability claims, and related negative publicity, is inherent in the development of human therapeutics. We are exposed to the risk of product liability claims alleging that use of DM199, or any future product candidate, caused an injury or harm. These claims can arise at any point in the development, testing, manufacture, marketing or, if approved, commercial sale of a product candidate. Such claims may be made directly by patients involved in clinical trials of our product candidate, by consumers, healthcare providers or by individuals, organizations or companies selling our products, if approved. Product liability claims can be expensive to defend, even if the product or product candidate did not actually cause the alleged injury or harm, and could lead to clinical trial delays and could negatively impact existing or future trial enrollment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Insurance covering product liability claims is expensive. To protect against potential product liability risks, we carry product liability insurance coverage at a level we deem appropriate based upon the current safety profile of DM199 and our stage of development. We may choose or find it necessary to increase our insurance coverage in the future; however, there can be no assurance that such insurance coverage is or will continue to be adequate or available to us at a cost acceptable to us or at all. Any liability for damages resulting from a product liability claim could exceed the amount of our coverage, require us to pay a substantial monetary award from our own cash resources and otherwise have a material adverse effect on our business, operating results and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to maintain product liability insurance required by third parties, certain agreements, such as those with clinical trial sites, contract research organizations and other supporting vendors, would be subject to termination, which could have a material adverse impact on our operations.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Some of our agreements with third parties, including most agreements with study sites, require, and in the future will likely require, us to maintain product liability insurance in at least certain specified minimum amounts. If we cannot maintain acceptable amounts of coverage on commercially reasonable terms in accordance with the terms set forth in these agreements, the corresponding agreements would be subject to termination, which could have a material adverse impact on our operations.&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The initial investigator-sponsored PE trial is being conducted in South Africa, we are commencing a PE trial in Canada and we are in the process of globally expanding our ReMEDy2 trial to countries outside the United States, raising additional international risks, which could materially adversely affect our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The initial investigator-sponsored PE trial is currently being conducted in South Africa, we are commencing a PE trial in Canada and we are currently expanding our ReMEDy2 trial to certain non-U.S. countries, including Canada, Australia, Georgia, United Kingdom and certain countries in the European Union. In addition, we plan to seek regulatory approval of DM199, or any future product candidates, outside of the United States. Accordingly, we are subject to risks related to operating in foreign countries including, among others:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">different standards of care or ethnic composition of patient populations in various countries that could complicate the design of our clinical trials and/or the evaluation of our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">compliance with differing regulatory requirements for drug approvals;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">availability of different competitive drugs or therapies indicated to treat the indications for which our product candidates are or will be developed;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">compliance with different United States and foreign drug import and export rules;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the imposition of U.S. or international sanctions against a country, company, person or entity where or with whom we are conducting clinical studies that would restrict or prohibit continued development in that country or with that company, person or entity;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">compliance with the Foreign Corrupt Practices Act and other anti-corruption and anti-bribery laws;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">foreign taxes, including withholding of payroll taxes;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">foreign currency exchange rate fluctuations, which could result in increased operating expenses and other obligations incident to performing clinical trials in another country;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">difficulties in managing and staffing international operations and increases in infrastructure costs, including legal, tax, accounting, and information technology;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">potential liability resulting from development work conducted by foreign partners or collaborators;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">delays and interruptions in delivering study drug and related supplies to clinical trial sites;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">interruptions in our development resulting from natural disasters or geopolitical actions, including war, such as the current war between Russia and Ukraine and the conflict between Israel and Hamas and in the Middle East, and terrorism or systems failure, including cybersecurity breaches; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">compliance with evolving and expansive international data privacy laws, such as the European Union General Data Protection Regulation.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>It is possible that the FDA and comparable foreign regulatory authorities may not accept trial data from countries located outside the United States.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The initial investigator-sponsored PE trial is being conducted in South Africa, we are commencing a PE trial in Canada and we are currently globally expanding our ReMEDy2 trial to countries outside the United States. The acceptance by the FDA or comparable foreign regulatory authority of study data from clinical trials conducted outside the United States or another jurisdiction may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to good clinical practice (GCP) regulations; and (iii) the FDA, or comparable foreign regulatory authority, is able to validate the data through an on-site inspection or other appropriate means. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional participants or trials, which would be costly and time-consuming and delay regulatory approval and commercialization of our DM199 product candidate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Data from the investigator-sponsored PE trial, which we expect earlier than data from our ReMEDy2 trial, may adversely affect our ReMEDy2 trial, which could adversely impact our business, prospects, operating results and financial position and harm our ability to raise additional financing, if and when needed.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our drug candidate, DM199, is currently in clinical development in two areas, PE/FGR and AIS. We announced interim data from Part 1a of the investigator-sponsored Phase 2 PE clinical trial in July of 2025. Part 1a topline study results demonstrated improvements in blood pressure and the pulsatility index. However, future data from the Phase 2 PE trial may materially change from the reported Part 1a topline study results. Should this occur, we may be required to repeat clinical or non-clinical studies, our clinical development plans may be significantly delayed, and we may incur additional costs, which could adversely impact our business, prospects, operating results and financial position. Adverse results from any future Phase 2 PE trial could adversely affect our ability to raise additional financing, if and when needed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Interim, </i></b>&#8220;<b><i>topline</i></b>&#8221;<b><i> and preliminary results from our clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">From time to time, we may publish interim, topline or preliminary results from our clinical trials. We announced Part 1a topline study results for the Phase 2 PE clinical trial in July 2025. Interim results from clinical trials are subject to the risk that one or more of the reported clinical outcomes may materially change as participant enrollment continues and more participant data become available. Preliminary or topline results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary, topline or interim data and final data could significantly harm our business and prospects and may cause the trading price of our common shares to fluctuate significantly. We also make estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">34</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Further, others, including regulatory authorities, may not accept or agree with our estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular development program, the approvability or commercialization of the particular product candidate or our Company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed meaningful by others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If our ReMEDy2 trial fails to adequately demonstrate the safety and efficacy of DM199 to treat AIS or if the PE trials fail to adequately demonstrate the safety and initial signs of efficacy of DM199 to treat PE, we will not be able to obtain required regulatory approvals, which would substantially harm our business, prospects and financial condition.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Before obtaining marketing approval from the FDA and other comparable foreign regulatory authorities for the sale of DM199 to treat AIS or the approval to continue testing DM199 as a treatment for PE, we must demonstrate the safety and efficacy of DM199 to treat AIS or PE to a level acceptable to the FDA or similar regulatory bodies in other jurisdictions. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and has uncertain outcomes. The outcome of early clinical trials may not predict the success of later clinical trials, and the interim results of ReMEDy2 and the interim topline results from Part 1a of the investigator-sponsored PE trial may not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety profiles, including the emergence of undesirable side effects, notwithstanding promising results in earlier trials. We do not know whether our ReMEDy2 trial by itself will demonstrate adequate efficacy and safety to support regulatory approvals to market DM199 to treat AIS in the United States, or in any other jurisdiction, or that a second confirmatory trial will be required. A product candidate may fail for safety or efficacy reasons at any stage of the testing process. In addition, the patient population in our ReMEDy2 trial often have co-morbidities that may cause severe illness or death, which may be attributed to DM199 in a manner that negatively affects the safety profile of our DM199 product candidate. If the results of our ReMEDy2 trial are inconclusive with respect to efficacy, if we do not meet our clinical endpoints with statistical significance or if there are unanticipated safety concerns or adverse events that emerge during the ReMEDy2 trial, the PE trial or other clinical trials, such as the events that caused the FDA to place the prior clinical hold on the IND for our ReMEDy2 trial, we may be prevented from or delayed in obtaining marketing approval, and even if we obtain marketing approval, any sales of DM199 for the treatment of AIS may be limited.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be required to suspend, repeat or terminate our clinical trials if they are deemed not conducted in accordance with regulatory requirements, the results are negative or inconclusive, or the trial is not well designed.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clinical trials must be conducted in accordance with the FDA&#8217;s current Good Clinical Practice (cGCP) requirements, or comparable requirements of applicable foreign regulatory authorities, and provide statistically significant evidence predictive of patient benefit. Clinical trials are subject to oversight by the FDA and other foreign governmental agencies, and IRBs or ethics committees at the trial sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates produced in accordance with applicable cGMP requirements. Clinical trials may be suspended by us or by the FDA, other foreign regulatory authorities, or by an IRB or ethics committee with respect to a particular clinical trial site, for various reasons, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or trial protocols;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">deficiencies in the clinical trial operations or trial sites;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">unforeseen adverse side effects or the emergence of undue risks to trial subjects;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">deficiencies in the trial design necessary to demonstrate efficacy;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">in the case of interim analyses, the product candidate may not appear to offer benefits over current therapies; or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the quality or stability of the product candidate may fall below acceptable standards.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">35</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The design and implementation of clinical trials is a complex process. As a Company, we have limited experience designing and implementing clinical trials. We may not successfully or cost-effectively design and implement clinical trials that achieve our desired clinical endpoints. A clinical trial that is not well designed or that yields unforeseen adverse side effects or undue risks to trial subjects may delay or even prevent initiation of the trial, can lead to increased difficulty in site activations and enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the trial results or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third-party payers. Additionally, a trial that is not well designed or that yields unforeseen adverse side effects or undue risks to trial subjects could be delayed and more expensive than it otherwise would have been, or we may incorrectly estimate the costs to complete the clinical trial, which could lead to a shortfall in funding. We can provide no assurance that our ReMEDy2 trial, the PE trials or any other clinical trial conducted or sponsored by us has been or will be designed and implemented successfully or achieve its desired clinical endpoints.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our prospects depend on the clinical and commercial success of our DM199 product candidate.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We are highly dependent on the success of DM199 and we, or a future partner, may not be able to successfully obtain regulatory or marketing approval for, or successfully commercialize, this product candidate. To date, we have expended significant time, resources, and effort on the development of DM199, including conducting preclinical and clinical trials, for the treatment of AIS and cardio renal disease. DM199 requires significant additional clinical testing and investment prior to seeking marketing approval. A commitment of substantial resources by us and any potential partner or collaborator to continue to conduct the clinical trials for DM199 will be required to obtain required regulatory approvals and successfully commercialize this product candidate. Although we intend to study the use of DM199 to treat multiple diseases, we have no other product candidates in our current clinical development pipeline, with the exception of our new second candidate, DM300, which is in the early, preclinical stage of development and is intended to treat other inflammatory diseases, such as acute pancreatitis. The ability of us or a future partner to generate revenue from product sales and to achieve commercial success with DM199 will depend almost entirely on our ability to demonstrate sufficient safety and efficacy to obtain regulatory approval for DM199. We may fail to complete required clinical trials successfully and not be able to obtain regulatory approvals or commercialize DM199. Competitors may develop alternative products and methodologies to treat the diseases or indications that we are pursuing, thus reducing or eliminating the anticipated competitive advantages of DM199. We do not know whether any of our product development efforts will prove to be effective, meet applicable regulatory standards required to obtain marketing approval, be capable of being manufactured at a reasonable cost, or be successfully marketed. DM199 is not expected to be commercially viable for at least two to three years. In addition, although the most common DM199 related adverse events that have occurred to date in our clinical trials have been constipation, injection site reaction, nausea and headache, it is possible that DM199 may be observed to cause undesirable side effects. If regulatory authorities do not approve DM199 for the treatment of AIS, PE or any other indications, or if we fail to maintain regulatory compliance, we, or a future partner, would be unable to commercialize DM199 and our business, prospects, operating results and financial condition would be harmed. If we do succeed in developing viable products from DM199, we will face many potential future obstacles, such as the need to develop or obtain manufacturing, sales and marketing, and distribution capabilities, if we do not partner with a third party to provide these functions.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Financial Position and Need for Additional Capital</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Since we currently have no revenue from product sales and do not expect any revenue from product sales for at least two to three years, we will need additional funding to continue our clinical development activities and other operations, which may not be available to us on acceptable terms, or at all.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect we will need substantial additional capital to further our R&amp;D activities, planned clinical trials and regulatory activities and to otherwise develop our DM199 product candidate to a point where it may be commercially sold. We expect our current cash resources of $59.9 million in cash, cash equivalents and marketable securities as of December 31, 2025 to be sufficient to allow us to continue our Phase 2/3 trial in patients with AIS, the PE trial and to otherwise fund our planned operations for at least the next 12 months from the date of issuance of the consolidated financial statements included in this report. However, the amount and timing of our future funding requirements will depend on many factors, including, among others:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the rate of progress in the development of and the conduct of clinical trials with respect to DM199 or any future product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the timing and results of our ongoing development efforts, including in particular our Phase 2/3 ReMEDy2 trial and the PE trial;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">36</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs of our development efforts, including the conduct of clinical trials with respect to DM199 or any future product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs associated with identifying additional product candidates and the potential expansion of our current development programs or potential new development programs;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs necessary to obtain regulatory approvals for DM199 or any future product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs of developing and validating manufacturing processes for DM199 or any future product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs associated with being a U.S. public reporting company with shares listed on The Nasdaq Capital Market;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs we incur in the filing, prosecution, maintenance and defense of our intellectual property; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs related to general and administrative support.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may require significant additional funds earlier than we currently expect, and there is no assurance that we will not need or seek additional funding prior to such time. We may elect to raise additional funds even before we need them if circumstances or market conditions for raising additional capital are favorable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Since our inception, we have financed our operations primarily from public and private sales of equity securities, the exercise of warrants and stock options, interest income on funds available for investment and government grants and tax incentives. We expect to continue this practice for the foreseeable future. We do not have any existing credit facilities under which we could borrow funds. We may seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if we experience additional adverse events, if our clinical data is not positive, or economic and market conditions deteriorate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Although we previously have been successful in obtaining financing through our equity securities offerings, there can be no assurance that we will be able to do so in the future. To the extent we raise additional capital through the sale of equity or debt securities, the ownership interests of our shareholders will be diluted. Debt financing, if available, may involve agreements that include conversion discounts or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. It is possible that financing will not be available or, if available, may not be on favorable terms. The availability of financing could be affected by many factors, including, among others:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the results of our clinical trials and other scientific and clinical research;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to obtain regulatory approvals;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">market acceptance of DM199 or any future product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the state of the capital markets generally with particular reference to pharmaceutical, biotechnology and medical companies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">various events outside our control, including without limitation geopolitical events and current wars;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the status of strategic alliance agreements; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">other relevant commercial considerations.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If adequate funding is not available, we may be required to implement cost reduction strategies; delay, reduce or eliminate one or more of our product development programs; relinquish significant rights to DM199 or future product candidates; obtain funds on less favorable terms than we would otherwise accept; and/or divest assets or cease operations through a merger, sale or liquidation of our Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">37</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have incurred substantial losses since our inception and expect to continue to incur substantial losses for at least two to three years and may never achieve or sustain profitability.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a clinical stage biopharmaceutical company focused on the development of our DM199 product candidate. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront financial expenditures and significant risk that a product candidate will fail to prove effective, gain regulatory approval or become commercially viable. We do not have any products approved by regulatory authorities and have not generated any revenues from product sales to date, and do not expect to generate any revenue from the sale of products for at least two to three years. We have incurred significant R&amp;D and G&amp;A expenses related to our ongoing operations and expect to continue to incur such expenses. As a result, we have incurred significant operating losses in every reporting period since our inception and we may never achieve or sustain profitability. For the years ended December 31, 2025 and 2024, we incurred a net loss of $32.8 million and $24.4 million, respectively. As of December 31, 2025, we had an accumulated deficit of $172.8 million. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our shareholders&#8217; equity and working capital. We expect to continue to incur substantial operating losses as we continue our R&amp;D activities, planned clinical trials, including our Phase 2/3 ReMEDy2 trial and the PE trial, regulatory activities and other administrative expenses and to support the development of DM199 or any future product candidate to a point where it can be out-licensed or receives required regulatory approvals and may be commercially sold and we begin to recognize future product sales, or receive royalty payments, licensing fees and/or milestone payments sufficient to generate revenues to fund our continuing operations. We expect our operating losses to increase in the near term as we continue development of DM199 and the clinical trials required to seek regulatory approval for DM199, or any future product candidate. We are unable to predict the extent of any future losses or when we will become profitable, if ever. Our failure to achieve and sustain profitability may depress the market price of our common shares and could impair our ability to raise capital, continue to develop DM199, or any future product candidate, expand our business and product offerings or continue our operations. Even if we do achieve profitability, we may not be able to sustain or increase profitability on an ongoing basis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Governmental and Regulatory Compliance and Approvals</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The regulatory approval process is expensive, time-consuming and uncertain and may prevent us or any future partner or collaborator from obtaining approvals for the commercialization of DM199 or any future product candidate. </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidate involved. Our DM199 or any future product candidate, and the activities associated with their development and commercialization, including design, research, testing, manufacture, quality control, recordkeeping, labeling, packaging, storage, advertising, promotion, sale, distribution, import, export and reporting of safety and other post-market information, are subject to comprehensive regulation by the FDA, the EMA and other similar foreign regulatory agencies. Failure to obtain marketing approval for DM199 or any future product candidate will prevent us or any future partner or collaborator from commercializing the product candidate. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on a future partner, collaborator or third-parties to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA, EMA or other regulatory authorities may determine that DM199 or any future product candidate may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit its commercial use. One issue of which we are aware is that because the plastic bags we use in the IV administration of DM199 are made of PVC, certain countries have banned or limited the use of PVC in a manner that may limit our ability to conduct the trials in such countries, or in the future in the event we are able to obtain required regulatory approvals, may limit the salability of DM199 in certain countries, thereby decreasing our worldwide market opportunity. Additionally, the regulatory approval process and requirements can change substantially based on amendments to federal regulations, new or amended FDA guidance documents governing the regulatory approval process, and/or changes in FDA approval priorities based on governmental priorities. As a result, any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Our or any future partner&#8217;s inability to obtain regulatory approval for DM199 or any future product candidate, or if such approval is limited, could substantially harm our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Any product candidate for which we or any future partner or collaborator obtains marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with the product candidate.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The FDA and other federal and state agencies, including the U.S. Department of Justice (DOJ), closely regulate compliance with all requirements governing prescription drug products, including requirements pertaining to marketing and promotion of drugs in accordance with the provisions of the approved labeling and manufacturing of products. The FDA and DOJ impose restrictions on manufacturers&#8217; communications regarding off-label use, sales and marketing activities, transparency laws, and reimbursement obligations, which restrictions can change substantially based on new and/or amended government interpretations of regulatory priorities, new and/or amended federal regulations, and other external forces. If we do not market our products for approved indications, we may be subject to enforcement action for off-label marketing. Violations of such requirements may lead to investigations alleging violations of the FDCA and other statutes, including the federal False Claims Act, the federal Anti-Kickback Statute, the Sunshine Act and other federal and state health care fraud and abuse laws, as well as state consumer protection laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">38</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our or any future partner&#8217;s failure to comply with all regulatory requirements, or the later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, may yield various results, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">litigation involving patients using our products;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions on such products, manufacturers or manufacturing processes;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions on the labeling or marketing of a product;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">restrictions on product distribution or use;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">requirements to conduct post-marketing studies or clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">warning or untitled letters;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">withdrawal of the products from the market;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">refusal to approve pending applications or supplements to approved applications that we submit;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">recall of products;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">fines, restitution or disgorgement of profits or revenues;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">suspension or withdrawal of marketing approvals;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">damage to relationships with any then current or potential partners;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">unfavorable press coverage and damage to our or any future partner&#8217;s reputation;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">refusal to permit the import or export of our products;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">product seizure; or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">injunctions or the imposition of civil or criminal penalties.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-compliance by us or any future partner or collaborator with regulatory requirements regarding ongoing safety monitoring, or pharmacovigilance, and with requirements related to the development of products, can also result in significant financial penalties. Similarly, failure to comply with regulatory requirements regarding the protection of personal information can also lead to penalties and sanctions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be unable to obtain regulatory acceptances necessary to conduct clinical trials in the jurisdictions or on the timelines we expect.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We must obtain appropriate regulatory clearances before commencing new clinical trials for DM199 or any future product candidate. Delays in obtaining the requisite clearances may occur for a variety of reasons beyond our control, including supplemental data requests from regulators, clinical holds, government shutdowns, and agency funding or staffing reductions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">For example, prior to commencing additional clinical trials in the United States for DM199 or any future product candidate, we must have an accepted IND for each product candidate and for each targeted indication. In April 2021, we filed, and in May 2021, the FDA accepted, an IND for the Phase 2/3 ReMEDy2 trial in patients with AIS. However, in July 2022, the FDA imposed a clinical hold on the IND under which we are conducting our Phase 2/3 ReMEDy2 trial, which clinical hold was subsequently lifted in June 2023. We plan to file an IND to enable us to commence additional clinical trials studying DM199 for the treatment of PE in the United States, and comparable filings to conduct additional clinical trials studying PE in Canada and the United Kingdom. In the fourth quarter of 2025, we participated in a productive, in-person pre-IND meeting with the FDA to discuss the planned Phase 2 study, at which the FDA requested an additional non-clinical, 10-day modified embryo-fetal development and pre- and postnatal development (ePPND) study in a rabbit model, a non-rodent species. Preliminary results of the rabbit study suggest that the rabbits developed an antibody response to DM199, a humanized recombinant protein, preventing us from completing the requested&#160; ePPND study in the rabbit model. We are currently evaluating alternate animal models to address the FDA&#8217;s ePPND study request. Depending on the alternative species, and its gestational period, results from the ePPND study may be substantially delayed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In March 2026, we received a &#8220;No Objection Letter&#8221; from Health Canada allowing us to perform the trial in Canada. However, there is no assurance that the U.S. IND will be filed on a timely basis or accepted by the FDA on a timely basis or at all. A submission of an IND may not necessarily result in the FDA allowing further clinical trials to begin and, once begun, issues, such as clinical holds, may arise that will require us to suspend or terminate such clinical trials. Additionally, even if relevant regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, these regulatory authorities may change their requirements in the future. Failure to obtain required regulatory acceptances may cause the development of DM199 or any future product candidate to be delayed or terminated, which could materially and adversely affect our business and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">39</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have received Fast Track designation for DM199 for the treatment of AIS, and we may seek such designation for other uses of DM199 or future product candidates. Fast Track designation may not lead to faster development or a faster FDA review or approval process, and it does not increase the likelihood that DM199 will receive marketing approval in the United States. Further, there is no guarantee we will be able to maintain such designation.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In September 2021, we received Fast Track designation from the FDA for DM199 for the treatment of AIS where tPA/TNK and/or mechanical thrombectomy are not indicated or medically appropriate. The FDA may grant Fast Track designation to a drug that is intended to treat a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need. The FDA provides opportunities for more frequent interactions with the review team for a Fast Track product, including pre-IND meetings, end-of-phase 1 meetings and end-of-phase 2 meetings with the FDA to discuss study design, extent of safety data required to support approval, dose-response concerns and use of biomarkers. A Fast Track product may also be eligible for rolling review, where the FDA reviews portions of a marketing application before the sponsor submits the complete application.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">However, Fast Track designation for DM199 may not result in a faster development process or a faster review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. Any delay in the review process or in the approval of DM199 will delay revenue from potential sales and will increase the capital necessary to fund our development programs and operations. In addition, the FDA may rescind the Fast Track designation for DM199 if the FDA later determines that DM199 no longer meets the qualifying criteria for Fast Track designation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Current and future legislation may increase the difficulty and cost for us and any future partner or collaborator to obtain marketing approval of and commercialize DM199 or any future product candidate and affect the prices we may obtain.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States and many foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system and data privacy that could prevent or delay marketing approval of DM199 or any future product candidate, restrict or regulate post-approval activities and affect our ability to profitably sell DM199 or any future product candidate for which we obtain marketing approval. Further, changes in government administrations may result in changed administrative or legislative priorities and could also prevent or delay marketing approval of DM199 or any future product candidate, restrict or regulate post-approval activities and affect our ability to profitably sell DM199 or any future product candidate for which we obtain marketing approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Among policy makers and payers in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. For example, the Affordable Care Act (ACA) enacted in the United States in 2010, and principally taking effect in 2014, included measures to change health care delivery, decrease the number of individuals without insurance, ensure access to certain basic health care services and contain the rising cost of care. This healthcare reform movement, including the enactment of the ACA, has significantly changed health care financing by both governmental and private insurers in the United States. With respect to pharmaceutical manufacturers, the ACA increased the number of individuals with access to health care coverage, including prescription drug coverage, but it simultaneously imposed, among other things, increased liability for rebates and discounts owed to certain entities and government health care programs, fees for the manufacture or importation of certain branded drugs and transparency reporting requirements under the Physician Payments Sunshine Act. In addition to the ACA, other federal health reform measures have been proposed and adopted in the United States. We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we may receive for any product, if approved. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The U.S. federal government has recently prioritized and may continue to prioritize policies targeting reducing drug prices and healthcare spending and may remain committed to lowering spending in federal government programs. The Inflation Reduction Act of 2022, which was signed into law on August 16, 2022, includes provisions aimed at lowering prescription drug costs for Medicare patients and reducing the federal government&#8217;s spending on prescription drugs by requiring certain prescription drug prices to be negotiated directly with the government, certain rebates to be paid by prescription drug companies, and certain spending caps to be implemented, among other measures. The implementation of cost containment measures or other healthcare reforms may prevent us or a future partner or collaborator from being able to generate sufficient revenue, attain profitability or even commercialize at all DM199 or any future product candidate. Policies implemented by the U.S. federal government may also introduce new, unexpected challenges such as supply chain disruptions based on international tariffs or taxation, other inflation-related measures and other measures that may affect the revenue, profitability and/or commercialization of DM199.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">40</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in funding or disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, authorized or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could adversely impact our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The ability of the FDA to review and provide marketing authorization for new products or changes to existing products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, federal government shutdowns, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent&#160;years as a result. In addition, government funding of other government agencies that fund R&amp;D activities is subject to the political process, which is inherently fluid and unpredictable. Decreases in government funding of research and development, including any reductions in funding to the U.S. National Institutes of Health may impact our business, as could changes in government programs that provide funding to research institutions and companies, including changes in the amount of funds allocated to different areas of research or changes that have the effect of increasing the length of time of the funding process. Disruptions at the FDA and such other agencies may also slow the time necessary for new products, or modifications to authorized products, to be reviewed and/or authorized by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, during the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates, and any resurgence of COVID-19 or emergence of new variants may lead to further inspectional delays. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could adversely affect our business.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Future legislation in the United States, Europe or other countries, and/or regulations and policies adopted by the FDA, the EMA or comparable regulatory authorities, may increase the time and cost required for us or any future partners or collaborators to conduct and complete clinical trials of our current or any future product candidates.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The FDA and the EMA have each established regulations to govern the therapeutic product development and approval process, as have other foreign regulatory authorities. The policies of the FDA, the EMA and other regulatory authorities may change. For example, in December 2016, the 21<sup style="vertical-align:top;line-height:120%;">st</sup> Century Cures Act (Cures Act) was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation. Additionally, the EMA issued Annex 1: the Manufacture of Sterile Medicinal Products which was effective August 15, 2023, intended to update standards to reflect change in regulatory and manufacturing environments and to remove ambiguity and inconsistencies in regulations governing the manufacture of sterile medicinal products. We cannot predict what if any effect the Cures Act, Annex 1 or any existing or future guidance from the FDA, EMA or other regulatory authorities will have on the development of DM199 or any future product candidate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Reliance on Third Parties</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely and will continue to rely on third parties to support the planning, execution and/or monitoring of</i></b> <b><i>our preclinical and clinical trials, and their failure to perform as required could cause delays in completing our product development and substantial harm to our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely and will continue to rely on third parties to conduct a significant portion of our preclinical and clinical development activities. Preclinical activities include in vitro and in vivo studies in specific disease models, pharmacology and toxicology studies and assay development. Clinical development activities include trial design, regulatory submissions, clinical site and patient recruitment, clinical trial monitoring, clinical data management and analysis, safety monitoring and project management. If there is any dispute or disruption in our relationship with third parties, or if they are unable to provide quality services in a timely manner and at a feasible cost, including as a result of staffing disruptions, our development programs may face delays. Further, if any of these third parties fail to perform as we expect or if their work fails to meet regulatory requirements, our clinical testing could be delayed, cancelled or rendered ineffective. For example, our prior contract research organization that we engaged to assist with our ReMEDy2 trial did not perform as we anticipated, thereby adversely affecting the conduct of the trial and resulting in delays in site activation and enrollment. No assurance can be provided that will not have similar issues with CROs that we have engaged to assist with the trial in non-U.S. jurisdictions. In addition, in connection with a prior clinical trial, we commenced litigation against Pharmaceutical Research Associates Group B.V., which was acquired by ICON plc (PRA Netherlands), as a result of its handling of a double-blinded, placebo-controlled, single-dose and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and proof of concept of DM199 in healthy subjects and in patients with Type 2 diabetes mellitus, as described later in this report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">41</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely extensively on contract development and manufacturing organizations (CDMOs) for the manufacture and testing of DM199 under current good manufacturing procedures (cGMP), and we are subject to many manufacturing risks, any of which could substantially increase our costs and/or limit supply of DM199. </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We require the services of third-party CDMOs to provide process development, analytical method development, formulation development, and manufacturing. We do not have, and do not currently plan to acquire or develop, the facilities or capabilities to manufacture and test bulk drug substance or filled drug product for use in clinical trials or commercialization. As a result, we rely completely on CDMOs, which entails risks to which we would not be subject if we manufactured DM199 or any potential future product candidates or products ourselves, including risks related to reliance on third parties for availability of drug product to use in our clinical trials and for regulatory compliance and quality assurance with respect to such drug product, the possibility of breach of the manufacturing agreement by third parties because of factors beyond our control (including a failure to manufacture DM199 and any potential future product candidates) and the possibility of termination or nonrenewal of agreements by third parties, based on their own business priorities, at a time that is costly or damaging to us.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DM199 is a biologic, and the manufacture and testing of biologic products is complex, highly regulated and requires significant expertise and capital investment, including the development of advanced manufacturing techniques, process controls, and advanced analytical testing capability. As a result, the manufacture and testing of our product candidate is subject to many risks, including the following, some of which we may experience:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">product loss or other negative consequences due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, shortages of qualified personnel or improper delivery or storage conditions&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">difficulties with product yields, quality control release testing, including challenges related to analytical method development and the qualification and implementation of those methods for release testing, which can delay availability of clinical trial materials&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">challenges with long-term stability of our product candidate and products at reasonable and expected storage conditions&#894;&#160;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">challenges with comparability of product made following changes in the manufacturing process such as a change in the manufacturing facility, scale-up, changes in the storage container used for drug product, or other changes&#894;&#160;control release testing, including challenges related to analytical method development and the qualification and implementation of those methods for release testing, which can delay availability of clinical trial materials&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">challenges with comparability of product made following changes in the manufacturing process such as a change in the manufacturing facility, scale-up, changes in the storage container used for drug product, or other changes&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the negative consequences of failure to comply with strictly enforced federal, state and foreign regulations&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">major deviations from normal manufacturing processes, which may result in reduced production yields, product defects and other supply disruptions&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the presence of microbial, viral or other contaminants discovered in our product candidate or in the manufacturing facilities in which it is made, which can necessitate closure of facilities for an extended period of time to investigate and eliminate the contamination&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the negative consequences of our CDMOs&#8217;&#160;failure to be approved for commercial production following an audit by regulatory authorities, by us or by our partners&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">42</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our CDMOs&#8217;&#160;changing strategies and/or competing business priorities, which can affect the availability of facilities where we intend to manufacture our product candidate;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the possible termination or nonrenewal of agreements by our CDMOs at a time that is costly or inconvenient for us&#894;&#160;and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our CDMOs&#8217;&#160;manufacturing facilities being adversely affected by labor, raw material and component shortages, turnover of qualified staff or financial difficulties of their owners or operators, including as a result of natural disasters, cyber attacks, power failures, local political unrest or other factors.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We cannot ensure that issues relating to the manufacture or testing of our product candidates, such as those described above, will not occur now or in the future. If we or our CDMOs experience any such issues there could be a shortage of drug substance or drug product for use in our clinical trials, which could delay clinical and regulatory timelines significantly and have an adverse effect on our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, to date, DM199 has been manufactured and tested by our drug substance and drug product CDMOs solely for clinical trials. We intend to continue to use CDMOs for these purposes, and also for the supply of larger quantities that may be required to conduct larger, later clinical trials and for commercialization if we advance our product candidates through regulatory approval and to commercialization. These manufacturers may not have sufficient manufacturing capacity and may not be able to scale up the production of drug substance or drug product in the quantities we need and at the level of quality required in a timely or effective manner, or at all. In particular, there is increased competition in the biotechnology industry for CDMO manufacturing slots and other capabilities generally, which may have a negative impact on the availability of manufacturing capacity and therefore our ability to supply clinical trial materials for planned, ongoing or expanded clinical trials or commercialization.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The scale up and validation of the manufacturing processes in the CDMOs&#8217; facilities to manufacture larger quantities or different formats, such as a pre-filled syringe, involve complex activities and coordination. Scale up and process validation activities entail risks such as process reproducibility and robustness, stability of in-process intermediates, product quality consistency and other technical challenges. We may be unable to scale up or validate our manufacturing processes, which can be expensive and time-consuming and could delay the initiation or completion of our clinical trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Similarly, we or our CDMOs may make changes to our manufacturing processes at various points in product development for many reasons, including changing manufacturing facilities, scaling up, facility fit, raw material or component availability, improving process robustness and reproducibility, decreasing processing times, changing the storage container, or others. In some circumstances, we may fail to demonstrate that the product from the new process is comparable to product from the prior process and we may be required to perform additional bridging studies, animal or human studies to demonstrate that the product used in earlier clinical trials are comparable to the product we intend to use in later trials or later stages of an ongoing trial. These efforts are expensive and, if required, there is no assurance that they will be successful, which could impact our ability to continue or initiate clinical trials in a timely manner, or at all, and could require the conduct of additional clinical trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We currently have a single source of supply for our drug substance and for our drug product. Single sourcing minimizes our leverage with our CDMOs, who may take advantage of our reliance on them to increase the pricing of their manufacturing services or require us to change our intended manufacturing plans based on their strategies and priorities. Single sourcing also imposes a risk of interruption or delays in supply in the event of manufacturing, quality or compliance difficulties and/or other difficulties in timely supplying us with materials. We do not currently have arrangements in place for redundant supply for drug substance or drug product. If one of our suppliers fails or refuses to supply us for any reason or we otherwise choose to engage a new supplier for DM199 or any of our future product candidates, including a second-source supplier to mitigate the risks of single-source supply, it would take a significant amount of time and cost to implement and execute the necessary technology transfer to, and qualification of, a new supplier. If there are any delays in qualifying new suppliers or facilities or a new supplier is unable to meet the requirements of the FDA or comparable foreign health, there could be a shortage of drug substance or drug product which could impact our ability to continue or initiate clinical trials in a timely manner.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our CDMOs are unable to source certain raw materials and components from their supplier and if they must obtain such materials from a different supplier, additional testing, and regulatory approvals, may be required, which may negatively impact manufacturing timelines. Any significant delay in the acquisition or decrease in the availability of these materials, components or other items, or failure to successfully qualify alternative materials or components, could considerably delay the manufacture of our current or future product candidates, which could adversely impact the timing or completion of any ongoing and planned trials or the timing of regulatory approvals, if any, for our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">43</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, our CDMOs&#8217; facilities and operations may be adversely affected by labor, raw material and component shortages, high turnover of staff and difficulties in hiring trained and qualified replacement staff and the operations of our CDMOs may be requisitioned, diverted or allocated by U.S. or foreign government orders such as under emergency, disaster and civil defense declarations. Changes in economic conditions, supply chain constraints, labor, raw material and component shortages and steps taken by governments and central banks could also lead to higher inflation than previously experienced or expected, which could, in turn, lead to an increase in costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If any CDMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CDMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CDMO and we may have difficulty, or there may be contractual restrictions prohibiting us from transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CDMOs for any reason, we will be required to verify that the new CDMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We would also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CDMO may possess technology related to the manufacture of our product candidate that such CDMO owns independently. This would increase our reliance on such CDMO or require us to obtain a license from such CDMO in order to have another CDMO manufacture our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Future development collaborations are expected to be important to us. If we are unable to enter into or maintain these collaborations, or if these collaborations are not successful, our business could be adversely affected.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We intend to collaborate with pharmaceutical, biotechnology and other companies and organizations for the future development, funding and/or commercialization of DM199. We face significant competition in seeking appropriate collaborators or partners. Our ability to reach a definitive agreement for any collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s or partner&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s or partner&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators or partners on a timely basis, on acceptable terms, or at all, we may have to curtail the development of and/or seek alternative means to commercialize our DM199 product candidate resulting in, among other things, reducing or delaying our development program, delaying our potential development schedule, or reducing the scope of research activities. If we fail to enter into one or more collaborations and do not have sufficient funds or expertise to undertake the necessary development or commercialization activities, we may not be able to continue or further develop DM199 and our business may be materially and adversely affected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Future collaborations we may enter into may involve significant risks, including, among others:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborators may have significant discretion in determining the efforts and resources that they will apply to the collaboration;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborators may not perform their obligations as expected;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes in the collaborators&#8217;&#160;strategic focus or available funding, or external factors, such as an acquisition, may divert resources or create competing priorities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborators may insist upon our relinquishment of certain rights with respect to our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborators may delay nonclinical or clinical development, provide insufficient funding for product development of targets selected by us, stop or abandon nonclinical or clinical development for a product candidate, or repeat or conduct new nonclinical and clinical development for a product candidate;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed than our products;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">product candidates discovered in collaboration with us may be viewed by our future collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the development of our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">44</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the preclinical or clinical development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborators may not properly maintain or defend our intellectual property rights or intellectual property rights licensed to us or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If a collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and the way we are perceived in the business and financial communities could be adversely affected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our collaborations do not result in the successful development of DM199, or any future product candidate, development could be delayed, and we may need additional resources to develop DM199 or any future product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this report also apply to the activities of our future collaborators.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our inability to maintain contractual relationships with physicians could have a negative impact on our research and development.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We maintain contractual relationships with respected physicians in hospitals and universities who assist us in the design and conduct of our clinical trials and interpretation of trial results. If we are unable to enter into and maintain these relationships, our ability to develop, obtain required regulatory approvals for, and market our DM199 or any future product candidate could be adversely affected. In addition, it is possible that U.S. federal and state and international laws requiring us to disclose payments or other transfers of value, such as gifts or meals, to surgeons and other healthcare providers could have a chilling effect on the relationships with individuals or entities that may, among other things, want to avoid public scrutiny of their financial relationships with us.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Intellectual Property</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We could lose important intellectual property rights that we currently license from a third party if we fail to comply with our obligations under the license agreements under which we license intellectual property rights from this third party or otherwise experience disruptions to our business relationships with our licensor.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a party to a license agreement relating to an expression system and cell line for use in the production of DM199 and DM300. We may need to obtain additional licenses from others to advance our R&amp;D activities or allow the commercialization of DM199 or any other product candidates we may identify and pursue. Future license agreements may impose various development, diligence, commercialization and other obligations on us. If any of our current or future in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain access to technologies that are material to our business, and we may be required to cease our development and commercialization of DM199 or other product candidates that we may identify or to seek alternative manufacturing methods. However, suitable alternatives may not be available or the development of suitable alternatives may result in a significant delay in our commercialization of DM199. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including, among others:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the extent to which, our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the sublicensing of patent and other rights under our collaborative development relationships;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the priority of invention of patented technology.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">45</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, the agreements under which we currently license intellectual property or technology from a third party are complex and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have in-licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be unable to adequately protect our technology and enforce our intellectual property rights and our competitors may take advantage of our development efforts or acquired technology and compromise our prospects for marketing and selling DM199 or any future product candidate.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that patents and other proprietary rights are key to our business. Our policy is to file patent applications to protect technology, inventions and improvements that may be important to the development of DM199 or any future product candidate. We also rely upon trade secrets, know-how and continuing technological innovations to develop and maintain our competitive position. We plan to enforce our issued patents and our rights to proprietary information and technology. We review third-party patents and patent applications, both to refine our own patent strategy and to monitor the landscape related to our technology.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our success depends, in part, on our ability to secure and protect our intellectual property rights and to operate without infringing on the proprietary rights of others or having third parties circumvent the rights owned or licensed by us. We have a number of patents, patent applications and rights to patents related to our compounds, product candidates and technology, but we cannot be certain that they will be enforceable or provide adequate protection or that pending patent applications will result in issued patents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the extent that development, manufacturing and testing of our product candidates is performed by third-party contractors, such work is performed pursuant to fee for service contracts. Under the contracts, all intellectual property, technology know-how and trade secrets related to our product candidate arising under such agreements are our exclusive property and must be kept confidential by the contractors. It is not possible for us to be certain that we have obtained from the contractors all necessary rights to such technologies. Disputes may arise as to the scope of the contract or possible breach of contract. No assurance can be given that our contracts will be enforceable or would be upheld by a court.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The patent positions of pharmaceutical and biotechnology firms, us included, are uncertain and involve complex questions of law and fact for which important legal issues remain unresolved. Therefore, it is not clear whether our pending patent applications will result in the issuance of patents with commercially meaningful protections or at all, or whether we will develop additional proprietary products which are patentable. Part of our strategy is based on our ability to secure a patent position to protect our technology. There is no assurance that we will be successful in this approach and failure to secure adequate patent protection may have a material adverse effect upon us and our financial condition. Also, we may fail in our attempt to commercialize products using currently patented or licensed technology without having to license additional patents. Moreover, it is not clear whether the patents issued or to be issued will provide us with any competitive advantages or if any such patents will be the target of challenges by third parties, whether the patents of others will interfere with our ability to market our products, or whether third parties will circumvent our patents by means of alternate processes. Furthermore, it is possible for others to develop products that have the same effect as our product candidates or technologies on an independent basis or to design around technologies patented by us. Patent applications relating to or affecting our business may have been filed by pharmaceutical or biotechnology companies or academic institutions. Such applications may conflict with our technologies or patent applications and such conflict could reduce the scope of patent protection that we could otherwise obtain or even lead to the rejection of our patent applications. There is no assurance that we can enter into licensing arrangements on commercially reasonable terms or develop or obtain alternative technology in respect of patents issued to third parties that incidentally cover our products or production technologies. Any inability to secure licenses or alternative technology could result in delays in the introduction of some of our product candidates or even lead to us being prevented from pursuing the development, manufacture or sale of certain products. Moreover, we could potentially incur substantial legal costs in defending legal actions that allege patent infringement, or by initiating patent infringement suits against others. It is not possible for us to be certain that we are the creator of inventions covered by pending patent applications or that we were the first to invent or file patent applications for any such inventions. While we have used commercially reasonable efforts to obtain assignments of intellectual property from all individuals who may have created materials on our behalf (including with respect to inventions covered by our patents and pending patent applications), it is not possible for us to be certain that we have obtained all necessary rights to such materials. No assurance can be given that our patents, or patent applications if issued, would be upheld by a court, or that a competitor&#8217;s technology or product would be found to infringe on our patents. Moreover, much of our technology know-how that is not patentable may constitute trade secrets. Therefore, we require our employees, consultants, advisors and collaborators to enter into confidentiality agreements either as stand-alone agreements or as part of their employment or consulting contracts. However, no assurance can be given that such agreements will provide meaningful protection of our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure of confidential information. Also, while we have used commercially reasonable efforts to obtain executed copies of such agreements from all employees, consultants, advisors and collaborators, no assurance can be given that executed copies of all such agreements have been obtained.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">46</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We or a future partner may require additional third-party licenses to effectively develop, manufacture and commercialize DM199, or any future product candidate, and such licenses might not be available on commercially acceptable terms, or at all.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A substantial number of patents have already been issued to other biotechnology and pharmaceutical companies. To the extent that valid third-party patent rights cover our product candidates, we or any future collaborator, would be required to seek licenses from the holders of these patents in order to manufacture, use or sell our product candidates, and payments under them would reduce profits from our product candidates. We are currently unable to predict the extent to which we may wish or be required to acquire rights under such patents, the availability and cost of acquiring such rights, and whether a license to such patents will be available on acceptable terms, or at all. There may be patents in the United States or in foreign countries or patents issued in the future that are unavailable to license on acceptable terms. Our inability to obtain such licenses may hinder or eliminate our ability to develop, manufacture and market our product candidates and have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in patent law and its interpretation could diminish the value of our patents in general, thereby impairing our ability to protect DM199 or any future product candidate.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property rights, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is costly, time consuming, and inherently uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our or any licensors&#8217; or collaborators&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on decisions by the U.S. Congress, the federal courts, the U.S. Patent and Trademark Office (USPTO) and the European Patent Office (EPO), the laws and regulations governing patents could change in unpredictable ways that would weaken our or any licensors&#8217; or collaborators&#8217; ability to obtain new patents or to enforce existing patents and patents we or any licensors or collaborators may obtain in the future. Changes in either the patent laws or interpretation of the patent laws in the United States or other countries could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act (the America Invents Act), enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could, therefore, be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or any licensor were the first to either (i) file any patent application related to our product candidates or (ii)&#160;invent any of the inventions claimed in our or any licensor&#8217;s patents or patent applications.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent in USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">47</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Intellectual property litigation may be expensive, time consuming and may cause delays in the development, manufacturing and commercialization of DM199 or any future product candidate.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Third parties may claim that we are using their proprietary information without authorization. Third parties may also have or obtain patents and may claim that technologies licensed to or used by us infringe their patents. If we are required to defend patent infringement actions brought by third parties, or if we sue to protect our own patent rights or otherwise to protect our proprietary information and to prevent its disclosure, we may be required to pay substantial litigation costs and managerial attention may be diverted from business operations even if the outcome is in our favor. In addition, any legal action that seeks damages or an injunction to stop us from carrying on our commercial activities relating to the affected technologies could subject us to monetary liability (including treble damages and attorneys&#8217; fees if we are found to have willfully infringed) and require us or any third-party licensors to obtain a license to continue to use the affected technologies. We cannot predict whether we would prevail in any of these types of actions or that any required license would be available on commercially acceptable terms or at all. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Competitors may infringe on our patents or other intellectual property. If we were to initiate legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Moreover, similar challenges may be made by third parties outside the context of litigation, e.g., via administrative proceedings such as post grant or inter partes review in the United States or via oppositions or other similar proceedings in other countries/regions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation, validity or enforceability, interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation or such other proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the market price of our common shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Because we rely on third parties to develop and manufacture our DM199 product candidate, we may share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, employment or consulting agreements or other similar agreements with our collaborators, advisors, employees, and consultants prior to beginning research or disclosing proprietary information. These agreements typically restrict the ability of our collaborators, advisors, employees, and consultants to publish data potentially relating to our trade secrets. In the future, we may also conduct joint R&amp;D programs which may require us to share trade secrets under the terms of R&amp;D collaboration or similar agreements. We cannot be certain that our current or any future agreements have been or will be entered into with all relevant parties. Moreover, despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. Trade secrets can be difficult to protect. If the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secrets. A competitor&#8217;s discovery of our trade secrets may impair our competitive position and could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">48</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Patent terms may be inadequate to protect the competitive position of DM199 or any future product candidate for an adequate amount of time.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Certain extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not be able to protect our intellectual property rights throughout the world.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">49</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Human Capital Management</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely heavily on the capabilities and experience of our key executives and clinical personnel and advisors; and the loss of any of them could affect our ability to develop DM199 or any future product candidate.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We depend heavily on members of our management team and certain other key personnel, including in particular our clinical personnel. We also depend on our clinical collaborators and advisors, all of whom have outside commitments that may limit their availability to us. In addition, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled scientific, managerial, medical, clinical and regulatory personnel, particularly as we continue to expand our activities and seek regulatory approvals for clinical trials and eventually our DM199 product candidate. We enter into agreements with scientific and clinical collaborators and advisors, key opinion leaders, and academic partners in the ordinary course of our business. We also enter into agreements with physicians and institutions that will recruit patients into our clinical trials on our behalf in the ordinary course of our business. Notwithstanding these arrangements, we face significant competition for these types of personnel from other companies, research and academic institutions and other organizations. We cannot predict our success in hiring or retaining the personnel we require for our continued growth. The loss of the services of any of our key executive officers and clinical personnel and advisors could potentially harm our business, operating results or financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will likely need to expand our operations and increase the size of our Company and we may experience difficulties in managing our growth.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As we advance our DM199 product candidate through clinical trials and develop future product candidates, we have expanded our product development, scientific, clinical, regulatory and compliance, and administrative headcount. As of December 31, 2025, we had 35 full time employees, compared to 28 full time employees, as of December 31, 2024. In addition, to continue to meet our obligations as a U.S. public reporting company, we will likely need to increase our general and administrative capabilities. Our management, personnel and systems currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and various projects requires that we:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">successfully attract and recruit new employees with the expertise and experience we require;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">manage our clinical programs effectively, which have been and will continue to be conducted at numerous clinical sites;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">develop a marketing, distribution and sales infrastructure if we seek to market our products directly; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">continue to improve our operational, manufacturing, quality assurance, financial and management controls, reporting systems and procedures.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are unable to successfully manage this growth and increased complexity of operations, our business may be adversely affected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to the Future Commercialization of DM199 or Any Future Product Candidate</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The successful commercialization of DM199 or any future product candidate, if approved, will depend on achieving market acceptance and we may not be able to gain sufficient acceptance to generate significant revenue.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Even if DM199 or any future product candidate is successfully developed and receives regulatory approval, it may not gain market acceptance among physicians, patients, third-party payers, such as private insurers or governments and other funding parties. The degree of market acceptance for DM199 or any product candidate we develop will depend on a number of factors including, among others:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">demonstration of sufficient clinical efficacy and safety;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">50</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the prevalence and severity of any adverse side effects;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">limitations or warnings contained in the product&#8217;s approved labeling;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">cost-effectiveness and availability of acceptable pricing;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the availability of alternative treatment methods and the superiority of alternative treatment methods;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the effectiveness of marketing and distribution methods and support for the product; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">coverage and reimbursement policies of government and third-party payers to the extent that the product could receive regulatory approval but not be approved for coverage by or receive adequate reimbursement from government and quasi-government agencies or other third-party payers.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we fail to obtain coverage and adequate reimbursement for DM199 or any future product candidate, its revenue-generating ability will be diminished and there is no assurance that the anticipated market for the product will develop or be sustained.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our or any future partner&#8217;s ability to successfully commercialize DM199 or any future product candidate will depend, in part, on the extent to which coverage of and adequate reimbursement for such product and related treatments will be available from governmental health payer programs at the federal and state levels, including Medicare and Medicaid, private health insurers, managed care plans and other organizations. No assurance can be given that third-party coverage or adequate reimbursement will be available that will allow us or any future partner to obtain or maintain price levels sufficient for the realization of an appropriate return on our investment in product development. Coverage and adequate reimbursement are critical to new product acceptance by healthcare providers. There is no uniform coverage and reimbursement policy among third-party payers in the United States; however, private third-party payers may follow Medicare coverage and reimbursement policy in setting their own coverage policy and reimbursement rates. Additionally, coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are or subsequently become available. Even if coverage is obtained for DM199 or any future product candidate, the related reimbursement rates might not be adequate to make the product attractive to providers, or may require patient cost sharing (e.g., copayments and/or deductibles) that patients find unacceptably high. In addition, healthcare reform and controls on healthcare spending may limit coverage of the product and the price we charge and get paid for the product and the volumes thereof that we can sell. Patients are unlikely to use DM199 or any future product candidate unless coverage is provided and reimbursement is adequate to cover a significant portion of its cost.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outside of the United States, the successful commercialization of DM199 or any future product candidate will depend largely on obtaining and maintaining government coverage, because in many countries, patients are unlikely to use prescription drugs that are not covered by their government healthcare programs. Negotiating coverage and reimbursement with governmental authorities can delay commercialization by 12 months or more. Coverage and reimbursement policies may adversely affect our or a future partner&#8217;s ability to sell DM199 or any future product candidate on a profitable basis. In many international markets, governments control the prices of prescription pharmaceuticals, including through the implementation of reference pricing, price cuts, rebates, revenue-related taxes and profit control, and we expect prices of prescription pharmaceuticals to decline over the life of the product or as volumes increase.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We or any future partner will likely face competition from other biotechnology and pharmaceutical companies, many of which have substantially greater resources, and our DM199 product candidate may face competition sooner than expected and our financial condition and operations will suffer if we fail to compete effectively.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Technological competition is intense in the industry in which we operate. Development of new, potentially competitive therapies comes from pharmaceutical companies, biotechnology companies and universities, as well as companies that offer non-pharmaceutical solutions. Many of our competitors have substantially greater financial and technical resources; more extensive R&amp;D capabilities; and greater marketing, distribution, production and human resources than we do. Moreover, competitors may develop products more quickly than us and may obtain regulatory approval for such products more rapidly than we do. Products and processes which are more effective than those that we intend to develop may be developed by our competitors. R&amp;D by others may render our product candidates non-competitive or obsolete.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">51</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our DM199 product candidate may face competition sooner than expected.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that DM199 could qualify for 12 years of data exclusivity in the United States under the Biologics Price Competition and Innovation Act of 2009. Under the BPCIA, an application for a biosimilar product, or abbreviated BLA, cannot be submitted to the FDA until four years, or if approved by the FDA, until 12 years, after the original reference product is approved under a BLA. The BPCIA provides an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing reference product. Any such approvals could have a material adverse effect on the future commercial prospects for DM199 or any future product candidate that is a biologic. There is also a risk that the U.S. Congress could repeal or amend the BPCIA to shorten this exclusivity period, potentially creating the opportunity for biosimilar competition sooner than anticipated after the expiration of our patent protection.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Even if, as we expect, our DM199 product candidate is considered to be a reference product eligible for 12 years of exclusivity under the BPCIA, another company could market competing products if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the products. Moreover, an amendment or repeal of the BPCIA could result in a shorter exclusivity period for our DM199 product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our estimates of the market opportunity for our DM199 product candidate for the treatment of AIS, PE and any other indications we choose to pursue or any other product candidates we develop are based on a number of assumptions and may prove to be inaccurate. The actual market may be smaller than we believe, which would adversely affect our business, prospects, operating results and financial condition. </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our ReMEDy2 trial excludes patients who are eligible to receive mechanical thrombectomy, specifically participants with large vessel occlusions in the intracranial carotid artery or the M1 segment of the middle cerebral, vertebral or basilary arteries or those that are otherwise eligible for MT. As a result of our recent protocol amendment for the ReMEDy2 trial, participants treated with tPA or TNK, (thrombolytic agents) intended to dissolve blood clots, are now eligible for participation if they continue to experience a persistent neurological deficit after receiving thrombolytic treatment and meet all other trial criteria, including repeat brain imaging to assess any hemorrhagic (bleeding) transformation. We believe the ReMEDy2 trial population is representative of the approximately 80% of AIS patients who do not have treatment options today, primarily due to the limitations on treatment with tPA/TNK and/or MT.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We estimate total addressable markets for our DM199 product candidate for the treatment of AIS, PE and any other indications we choose to pursue or any other product candidates we develop. Our estimates and forecasts are based on a number of complex assumptions, internal and third-party estimates in published literature, and other business data, including assumptions and estimates relating to our ability to manage operating expenses of, invest in, and develop and generate revenue from DM199 or any other product candidates we develop in the future. While we believe our assumptions and the data underlying our estimates and key performance indicators are reasonable, there are inherent challenges in measuring or forecasting such information. As a result, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors and metrics. Consequently, our estimates of the total addressable markets and our forecasts of market growth may prove to be incorrect. For example, if the annual total addressable markets or the potential market growth is smaller than we have estimated or if the key business metrics we utilize to forecast commercial opportunities are inaccurate, it may have an adverse effect on our business, prospects, operating results and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Common Shares</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our common share price has been volatile and may continue to be volatile.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our common shares trade on The Nasdaq Capital Market under the trading symbol &#8220;DMAC.&#8221; During 2025, the sale price of our common shares ranged from $3.19 to $10.42 per share. A number of factors could influence the volatility in the trading price of our common shares, including changes in the economy and in the financial markets, industry related developments in the overall biotech and pharmaceutical sectors, and the impact of material events and changes in our operations, such as our progress in our clinical trials, results thereof, operating results and financial condition. Each of these factors could lead to increased volatility in the market price of our common shares. In addition, the market prices of the securities of our competitors may also lead to fluctuations in the trading price of our common shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We do not have a history of a very active trading market for our common shares.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During 2025, the daily trading volume of our common shares ranged from approximately 24,100 shares to 3,185,200 shares. Although we anticipate a more active trading market for our common shares in the future, we can give no assurance that a more active trading market will develop or be sustained. If we do not have an active trading market for our common shares, it may be difficult for you to sell our common shares at a favorable price or at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">52</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may issue additional common shares resulting in share ownership dilution.</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Future dilution will likely occur due to anticipated future equity issuances by us. To the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted. As of December 31, 2025, we had the ability to sell $86.2 million of our common shares under our At-the-Market sales agreement with TD Cowen. In addition we had outstanding options to purchase 6,502,444 common shares, deferred stock units representing 164,770 common shares and 1,601,791 common shares reserved for future issuance in connection with future grants under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan and the DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan and options to purchase 362,410 common shares and deferred stock units representing 9,745 common shares under our prior equity compensation plans. If these or any future outstanding options or deferred stock units are exercised or otherwise converted into our common shares, our shareholders will experience additional dilution.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If there are substantial sales of our common shares or the perception that such sales may occur, the market price of our common shares could decline.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sales of substantial numbers of our common shares, or the perception that such sales may occur, could cause a decline in the market price of our common shares. Any sales by existing shareholders or holders who exercise their warrants or stock options may have an adverse effect on our ability to raise capital and may adversely affect the market price of our common shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are a </i></b>&#8220;<b><i>smaller reporting company,</i></b>&#8221;<b><i> and because we have opted to use the reduced disclosure requirements available to us, certain investors may find investing in our common shares less attractive.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are currently a &#8220;smaller reporting company&#8221; under the U.S. federal securities laws and, as such, are subject to scaled disclosure requirements afforded to such companies. For example, as a smaller reporting company, we are subject to reduced executive compensation disclosure requirements. Our shareholders and investors may find our common shares less attractive as a result of our status as a &#8220;smaller reporting company&#8221; and our reliance on the reduced disclosure requirements afforded to these companies. If some of our shareholders or investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and the market price of our common shares may be more volatile.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>A limited number of shareholders possess substantial voting power and could limit other shareholders</i></b>&#8217;<b><i> ability to influence the outcome of key transactions, including changes of control.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As of December&#160;31, 2025, four holders of greater than five percent of our common stock collectively beneficially owned shares constituting approximately 47.6% and individually or collectively could be able to influence significantly all matters requiring approval by our shareholders, including elections of directors and the approval of mergers or other significant corporate transactions. These shareholders may have interests that differ from those of other shareholders, and they may vote in ways with which other shareholders disagree, potentially adverse to their interests. The concentration of ownership of our common stock may have the effect of delaying, preventing, or deterring a change of control of our company, could deprive our shareholders of an opportunity to receive a premium for their common stock as part of a sale of our Company, and may affect the market price of our common stock. This concentration of ownership of our common stock may also influence the completion of a change in control that may not be in the best interests of all of our shareholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Jurisdiction of Organization</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are governed by the corporate laws of British Columbia, which in some cases have a different effect on shareholders than the corporate laws in effect in the United States.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a British Columbia corporation. Our corporate affairs and the rights of holders of our common shares are governed by the BCBCA and applicable securities laws, which laws may differ from those governing a company formed under the laws of a United States jurisdiction. The provisions under the BCBCA and other relevant laws may affect the rights of shareholders differently than those of a company governed by the laws of a United States jurisdiction and may, together with our Notice of Articles and Articles, have the effect of delaying, deferring or discouraging another party from acquiring control of our Company by means of a tender offer, proxy contest or otherwise, or may affect the price an acquiring party would be willing to offer in such an instance. The material differences between the BCBCA and the Delaware General Corporation Law (DGCL), by way of example, that may be of most interest to shareholders include the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">for material corporate transactions (such as mergers and amalgamations, other extraordinary corporate transactions or amendments to our Notice of Articles), the BCBCA, subject to the provisions of our Articles, generally requires two-thirds majority vote by shareholders; whereas, the DGCL generally only requires a majority vote of shareholders;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">under the BCBCA, a holder of 5% or more of our common shares can requisition a special meeting at which any matters that can be voted on at our annual meeting can be considered; whereas, the DGCL does not give this right;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Articles require two-thirds majority vote by shareholders to pass a resolution for one or more directors to be removed; whereas the DGCL only requires the affirmative vote of a majority of the shareholders; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Articles may be amended by resolution of our directors to alter our authorized share structure, including to (a) subdivide or consolidate any of our shares and (b) create additional classes or series of shares; whereas, under the DGCL, a majority vote by shareholders is generally required to amend a corporation&#8217;s certificate of incorporation and a separate class vote may be required to authorize alternations to a corporation&#8217;s authorized share structure.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">53</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We cannot predict if investors find our common shares less attractive because of these material differences. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and our share price may be more volatile.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We were classified as a </i></b>&#8220;<b><i>passive foreign investment company</i></b>&#8221;<b><i> in 2025, 2024 and 2023 and certain other prior years and may be so classified in the current and/or future taxable years, which may have adverse U.S. federal income tax consequences for U.S. shareholders and adversely affect the level of interest in our common shares by U.S. investors.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>General Rule</i>. For any taxable year in which 75% or more of our gross income, including our pro rata share of the gross income of any corporation in which we are considered to own at least 25% of the shares by value, is passive income, or at least 50% of the value of our assets, including our pro rata share of the assets of any corporation in which we are considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income, we would be characterized as a &#8220;passive foreign investment company&#8221; (PFIC) for U.S. federal income tax purposes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The tests for determining PFIC status for any taxable year are dependent upon a number of factors, some of which are beyond our control, including the value of our assets, the market price of our common shares, and the amount and type of our gross income. Based on these tests, we believe that we were a PFIC for the taxable year ended December 31, 2016 and again for each of the taxable years ended December 31, 2022, 2023, 2024[, and December 31, 2025]. Our status as a PFIC is a fact-intensive determination made for each taxable year, and we cannot provide any assurance regarding our PFIC status for the taxable year ending December 31, 2026 or for future taxable years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are or were classified as a PFIC for any taxable year during which a U.S.&#160;Holder (as defined in &#8220;&#8212; <i>Certain U.S. Federal Income Tax Considerations </i>&#8208;&#8211;<i> U.S. Holders</i>&#8221;) holds our common shares, such U.S.&#160;Holder could be subject to adverse U.S.&#160;federal income tax consequences (regardless of whether we continue to be a PFIC), including increased tax liability on disposition gains and certain &#8220;excess distributions&#8221; and additional reporting requirements. Please see the section entitled&#160;&#8220;&#8212;&#160;<i>Certain U.S. Federal Income Tax Considerations</i>&#160;&#8212;&#160;<i>U.S. Holders </i>&#8211;<i> Passive Foreign Investment Company Considerations</i>&#8221; for a more detailed discussion with respect to our potential PFIC status. U.S.&#160;Holders are urged to consult their tax advisors regarding our PFIC status for any taxable year and the possible application of the PFIC rules to an investment in our common shares, including the availability and the advisability of making certain elections under the PFIC rules.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>It may be difficult for non-Canadian shareholders or investors to obtain and enforce judgments against us because of our organization as a British Columbia corporation.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a corporation governed by the BCBCA. Two of our directors are residents of Canada, and all or a substantial portion of their assets, and a small portion of our assets, are located outside the United States. Consequently, it may be difficult for holders of our securities who reside in the United States to effect service within the United States upon those directors who are not residents of the United States. It may also be difficult for holders of our securities who reside in the United States to realize in the United States upon judgments of courts of the United States predicated upon our civil liability and the civil liability of our directors, and officers under the United States federal securities laws. Our shareholders and other investors should not assume that British Columbian or Canadian courts (i)&#160;would enforce judgments of United States courts obtained in actions against us or such directors, or officers predicated upon the civil liability provisions of the United States federal securities laws or the securities or &#8220;blue sky&#8221; laws of any state or jurisdiction of the United States, or (ii) would enforce, in original actions, liabilities against us or such directors, or officers predicated upon the United States federal securities laws or any securities or &#8220;blue sky&#8221; laws of any state or jurisdiction of the United States. In addition, the protections afforded by the securities laws of British Columbia or Canada may not be available to our shareholders or other investors in the United States.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>General Risk Factors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not achieve our publicly announced milestones according to schedule, or at all.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">From time to time, we may announce the timing of certain events we expect to occur, such as the anticipated number of clinical sites and pace of enrollment and the timing of the interim analysis for our ReMEDy2 trial and the timing of completion of the PE trial. These statements are forward-looking and are based on the best estimates of management at the time relating to the occurrence of such events. However, the actual timing of such events may differ significantly from what has been publicly disclosed. The projected timing of events such as the anticipated number of clinical sites and pace of enrollment for our ReMEDy2 trial or the filing of an application to obtain regulatory approval or an announcement of additional clinical trials for a product candidate may ultimately vary from what is publicly disclosed. These variations in timing or events that we anticipate may occur as a result of different factors, including regulatory actions, the nature of the results obtained during a clinical trial or during a research phase, problems with a CDMO or CRO, health crises, epidemics or pandemics, full or partial clinical holds that may be imposed by the FDA or any other event having the effect of delaying the publicly announced timeline or leading to results that are different from what we expect. We undertake no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as otherwise required by law. Any variation in the timing of previously announced milestones or changes in other events of which we anticipate could have a material adverse effect on our business plan, financial condition or operating results, and the trading price of our common shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">54</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If securities or industry analysts do not continue to publish research or reports about our business, or publish negative reports about our business, the market price of our common shares and trading volume could decline.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The market price and trading volume for our common shares will depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will continue to cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our common shares or negatively change their opinion of our common shares, the market price of our common shares would likely decline. If one or more of these analysts cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause the market price of our common shares or trading volume to decline.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We, or our third-party contract research organizations or consultants, may be subject to information technology (IT) systems failures, network disruptions, breaches in data security and computer crime and cyber-attacks, which could result in a material disruption of our product candidates' development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are dependent upon IT systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party consultants who have access to our confidential information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IT system failures, network disruptions, breaches of data security and sophisticated and targeted computer crime and cyber-attacks could disrupt our operations by impeding our development programs, including delays in our clinical trials, the manufacture or shipment of our drug product candidate or other clinical supplies, the processing of transactions or reporting of financial results, or by causing an unintentional disclosure of confidential information. Despite our security measures, our IT and infrastructure may be attacked by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. In the ordinary course of our business, we collect and store sensitive data on our network, including intellectual property, proprietary business information, and personal information of our business partners and employees. Despite our efforts to protect sensitive, confidential or personal data or information, our facilities and systems and those of our third-party service providers may experience security breaches, theft, misplaced or lost data, programming and/or human errors that could potentially lead to the compromising of sensitive, confidential or personal data or information, improper use of our systems, software solutions or networks, unauthorized access, use, disclosure, modification or destruction of information, defective products, production downtimes and operational disruptions, which in turn could adversely affect our reputation, clinical trials and results of operations. If our systems are damaged or cease to function properly due to any number of causes, ranging from catastrophic events to power outages to security breaches, and our business continuity plans do not effectively compensate for these events on a timely basis, we may suffer interruptions in our ability to manage our clinical trials and other operations. In addition, we and the third parties on which we rely may be more susceptible to security breaches and other security incidents due to many of our and their employees working remotely for some portion of time. While management has taken steps to address these concerns by conducting employee training, implementing certain data and system redundancy, hardening and fail-over along with other network security, comprehensive monitoring of our networks and systems, maintenance of backup and protective systems and other internal control measures, there can be no assurance that the measures we have implemented to date would be sufficient in the event of a system failure, loss of data or security breach. Because the techniques used to obtain unauthorized access change frequently and can be difficult to detect, anticipating, identifying or preventing these intrusions or mitigating them if and when they occur may be challenging. Although we have been the target of cyber attacks and expect them to continue as cybersecurity threats have been rapidly evolving in sophistication, the aggregate impact of these attacks on our operations and financial condition has not been material. However, in light of the fact that cybersecurity threats have been rapidly evolving in sophistication and prevalence, no assurance can be provided that we will not become subject to future attacks, especially when our cybersecurity protection is dependent at least to some extent on the lack of human error. SEC rules related to cybersecurity risk management may further increase our regulatory burden and the cost of compliance in such events. As a result, in the event of such a failure, loss of data or security breach, our financial condition and operating results could be adversely affected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">55</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We currently use limited traditional and generative artificial intelligence (AI) solutions for certain administrative and other functions. We may incorporate additional AI solutions into our information systems in the future and these solutions may become important in our operations over time. The ever-increasing use and evolution of technology, including cloud-based computing and AI, creates opportunities for the potential loss or misuse of personal data that we use to run our business, and unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices, which may result in significantly increased business and security costs, a damaged reputation, administrative penalties, or costs related to defending legal claims.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We could be subject to securities class action litigation, which is expensive and could divert management attention.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the past, securities class action litigation has often been brought against a company following a significant decline or increase in the market price of its securities or certain significant business transactions. We may become involved in this type of litigation in the future, especially if our clinical trial results are not successful or we enter into an agreement for a significant business transaction. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and our resources, which could harm our business. This is particularly true in light of our limited securities litigation insurance coverage.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our insurance policies are expensive and protect us only from certain business risks, which could leave us exposed to significant uninsured liabilities. Additionally, future fluctuations in insurance cost and availability could adversely affect our operating results or risk management profile.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We hold a number of insurance policies, including, but not limited to, product and general liability insurance, directors&#8217; and officers&#8217; liability insurance, property insurance, and workers&#8217; compensation insurance. The costs of maintaining adequate insurance coverage, most notably directors&#8217; and officers&#8217; liability insurance, have increased significantly in the past and could do so again in the future, thereby adversely affecting our operating results. If such costs increase, we may be forced to accept lower coverage levels and higher deductibles, which, in the event of a claim, could require significant, unplanned expenditures of cash, which could adversely affect our business. Future potential directors and officers could view our directors&#8217; and officers&#8217; liability insurance coverage as limited or even inadequate. Limited directors&#8217; and officers&#8217; liability insurance coverage, or the perception that our directors&#8217; and officers&#8217; liability insurance coverage is inadequate, may make it difficult to attract and retain directors and officers, and we may lose potential independent board members and management candidates to other companies that have more extensive directors&#8217; and officers&#8217; liability insurance coverage. In addition, if any of our current insurance coverages should become unavailable to us or become economically impractical, we would be required to operate our business without indemnity from commercial insurance providers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The widespread outbreak of communicable diseases could delay our clinical trials and otherwise materially and adversely affect our business, operating results and financial condition.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We face risks related to health epidemics or outbreaks of communicable diseases, for example, the outbreak around the world of the highly transmissible and pathogenic coronavirus COVID-19. The outbreak of such communicable diseases could result in a widespread health crisis that could adversely affect general commercial activity and the economies and financial markets of many countries. Many countries around the world may impose quarantines and restrictions on travel and mass gatherings to slow the spread of communicable diseases and close non-essential businesses. Such events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could delay our clinical trials and materially affect our business, operating results and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A pandemic or outbreak could result in difficulty securing additional clinical trial site locations, and adversely affect the ability of investigators and other study staff enrolling participants and may also adversely impact the ability of activities of CROs, trial monitors, laboratories and other critical vendors and consultants supporting our clinical trials. The potential negative impacts also include the inability to have study visits at trial sites, incomplete collection of safety and efficacy data, and higher rates of drop-out of subjects from ongoing trials, delays in site entry of study data into the data base, delays in monitoring of trial data because of restricted physical access to sites, delays in site responses to queries, delays in data-base lock, delays in data analyses, delays in time to top-line data, and delays in completing study reports. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the willingness of participants to enroll in our current or future clinical trials. These situations could cause delays in our clinical trial plans and increase expected costs, all of which could have a material adverse effect on our business, prospects, operating results and financial condition. Additionally, the manufacturing of DM199 and other product candidates, as well as other clinical supplies required to conduct our studies may be delayed by related supply chain issues, specifically supply of raw materials, compounded by international shipping delays.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">56</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Further, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital and negatively affect our liquidity. In addition, it could materially affect the value of our common shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business or the value of our common shares could be negatively affected as a result of actions by activist shareholders.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We value constructive input from our shareholders, and our Board of Directors and management team are committed to acting in the best interests of our shareholders. However, shareholders may from time to time engage in proxy solicitations, advance shareholder proposals or otherwise attempt to effect changes or acquire control over the Company. Responding to proxy contests and other actions by activist shareholders can be costly and time-consuming, disrupting our operations and diverting the attention of our Board of Directors and senior management from the pursuit of business strategies. In addition, perceived uncertainties as to our future direction, strategy or leadership created as a consequence of activist shareholder initiatives may result in the loss of potential business opportunities, harm our ability to attract new investors, customers, employees, and joint venture partners, and cause our share price to experience periods of volatility or stagnation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 1pt;"><b>Item 1B.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Unresolved Staff Comments</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This Item 1B is inapplicable to us as a smaller reporting company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 1pt;"><b>Item 1C.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Cybersecurity</b></p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="c34" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize the importance of identifying, assessing, and managing material risks associated with cybersecurity threats, which risks include, among other things, operational risks, intellectual property theft, fraud, extortion, harm to employees or participants in our clinical trials, and violation of data privacy or security laws. In the ordinary course of our business, we collect and store certain confidential information such as information about our employees, contractors, vendors, suppliers, and clinical data. We augment the capabilities of our people, processes, and technologies in order to address our cybersecurity risks. Our cybersecurity risks, and the controls designed to mitigate those risks, are integrated into our overall risk management governance and are reviewed regularly by our Audit Committee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Risk Management and Strategy</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="-sec-ix-hidden:c37"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="c38">Identifying, assessing, and managing cybersecurity risk is integrated into our overall enterprise risk management systems and processes. Our cybersecurity risk management program has been developed based upon prevailing security standards and the National Institute of Standards and Technology (NIST) framework for evaluating and responding to potential cybersecurity risks, and addressing cybersecurity threats and incidents to the extent they arise. We have designed our business applications to minimize the impact that cybersecurity incidents could have on our business and have identified back-up systems where appropriate. Security events and data incidents are evaluated, ranked by severity, and prioritized for response and remediation when or if they occur. Incidents are evaluated to determine materiality, as well as operational, business and privacy impact. An important component of this program is employee awareness of and vigilance regarding cybersecurity risks. Our employees receive ongoing cybersecurity awareness trainings, including specific topics related to social engineering, phishing and email fraud</ix:nonNumeric>.</span></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recognizing the complexity and evolving nature of cybersecurity threats, incidents and risks, we <span style="-sec-ix-hidden:c39">engage third-party experts</span>, including managed information technology (IT) service providers and cybersecurity consultants, to evaluate and support our risk management systems, <span style="-sec-ix-hidden:c40">monitor potential vulnerabilities</span>, periodically test our cybersecurity controls and procedures, and respond to cybersecurity incidents affecting us, including prompt escalation and communication of major security incidents to legal counsel, senior management and the Audit Committee of our Board of Directors. We utilize advanced technologies for continuous cybersecurity monitoring across our IT environment which are designed to prevent, detect and minimize cybersecurity attacks, as well as alert management of such attacks.</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="c41" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Governance</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="c44"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="c45"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="c46">The Audit Committee of our Board of Directors is responsible for overseeing our cyber security risk management and strategy, including overseeing management&#8217;s responsibility to assess, manage and mitigate risks associated with our business and operational activities, to administer our various compliance programs, in each case including cybersecurity concerns, and to oversee our IT systems, processes and data. Our Chief Financial Officer and cybersecurity consultants regularly meet with and provides periodic briefings to our Audit Committee regarding our cybersecurity risks and activities, including any recent cybersecurity incidents, if any, and related responses, and cybersecurity systems testing.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">57</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="c48"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="c49"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="c50">Management has implemented risk management policies and procedures, and management is responsible for the day-to-day cybersecurity risk management. Our Chief Financial Officer is responsible for the day-to-day assessment and management of our cybersecurity risks.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Cybersecurity Threat Disclosure</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="c52">As of the date of this annual report on Form 10-K, risks from cybersecurity threats including as a result of any previous cybersecurity incidents, have not materially affected, and we do not believe they are reasonably likely to materially affect, us, our business strategy, results of operations, or financial condition. However, cybersecurity threats are constantly evolving, becoming more frequent and more sophisticated and are being made by groups of individuals with a wide range of expertise and motives, which increases the difficulty of detecting and successfully defending against them. While we have implemented measures to safeguard our operational and technology systems, the evolving nature of cybersecurity attacks and vulnerabilities means that these protections may not always be effective.</ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For further discussion of cybersecurity risks, please see Item 1A, "Risk Factors".</p>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 2.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Properties</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our principal executive offices, together with our research and development operations, are at the office of our wholly owned subsidiary, DiaMedica USA Inc., located at 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota, USA 55305. We lease these premises, which consist of approximately 6,000&#160;square feet, pursuant to a lease that expires in January 2028. We believe that our facilities are adequate for our current needs and that suitable additional space will be available if and when needed on acceptable terms.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 1pt;"><b>Item 3.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Legal Proceedings</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Resolution of Litigation with Pharmaceutical Research Associates Group B.V.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Beginning in 2018, we initiated legal proceedings against Pharmaceutical Research Associates Group B.V., acquired by ICON plc as of July&#160;1,&#160;2021, (ICON/PRA Netherlands). As previously disclosed, in October 2025, we entered into a Settlement Agreement, pursuant to which the parties agreed to settle any and all disputes, claims, and liabilities that had arisen, or will arise, out of their relationship, past and present, including, but not limited to, the pending legal proceedings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">From time to time, we may be subject to other various ongoing or threatened legal actions and proceedings, including those that arise in the ordinary course of business, which may include employment matters and breach of contract disputes. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. We are not currently engaged in or aware of any threatened legal actions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 1pt;"><b>Item 4.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Mine Safety Disclosures</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">58</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 1pt;"><b>Item 5.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Market for Registrant</b>&#8217;<b>s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Market Information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our common shares are listed on The Nasdaq Stock Market LLC under the trading symbol &#8220;DMAC&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Number of Record Holders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of March 16, 2026, we had 43 holders of record of our common shares. This does not include persons whose common shares are in nominee or &#8220;street name&#8221; accounts through brokers or other nominees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dividends</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have never declared or paid cash dividends on our common shares and currently do not have any plans to do so in the foreseeable future. We expect to retain our future earnings, if any, for use in the operation and expansion of our business. Additionally, we may in the future become subject to contractual restrictions on, or prohibitions against, the payment of dividends. Subject to the foregoing, the payment of cash dividends in the future, if any, will be at the discretion of our Board of Directors and will depend upon such factors as earnings levels, capital requirements, our overall financial condition and any other factors deemed relevant by our Board of Directors. As a result, our shareholders will likely need to sell their common shares to realize a return on their investment and may not be able to sell their shares at or above the price paid for them.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Purchases of Equity Securities by the Company</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We did not purchase any common shares or other equity securities of our Company during the fourth quarter ended December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Sales of Unregistered Equity Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We did not sell any unregistered equity securities of our Company during the fourth quarter ended December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exchange Controls</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There are no governmental laws, decrees or regulations in Canada that restrict the export or import of capital, including foreign exchange controls, or that affect the remittance of dividends, interest or other payments to non-resident holders of the securities of DiaMedica, other than Canadian withholding tax.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Certain Canadian Federal Income Tax Considerations for U.S. Holders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following is, as of March 1, 2026, a summary of the principal Canadian federal income tax considerations under the <i>Income Tax Act</i> (Canada) (Tax Act) generally applicable to a holder of our common shares who, for purposes of the Tax Act and at all relevant times, is neither resident in Canada nor deemed to be resident in Canada for purposes of the Tax Act and any applicable income tax treaty or convention, and who does not use or hold (and is not deemed to use or hold) common shares in the course of carrying on a business in Canada, deals at arm&#8217;s length with us, is not affiliated with us, is not a &#8220;specified shareholder&#8221; of us (within the meaning of subsection 18(5) of the Tax Act) and holds our common shares as capital property (Holder). A &#8220;specified shareholder&#8221; for these purposes generally includes a person who (either alone or together with persons with whom that person is not dealing at arm&#8217;s length for the purposes of the Tax Act) owns or has the right to acquire or control 25% or more of the common shares determined on a votes or fair market value basis. Generally, common shares will be considered to be capital property to a Holder thereof provided that the Holder does not hold common shares in the course of carrying on a business and such Holder has not acquired them in one or more transactions considered to be an adventure or concern in the nature of trade.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This summary does not apply to a Holder, (i) that is a &#8220;financial institution&#8221; for purposes of the mark-to-market rules contained in the Tax Act; (ii) that is a &#8220;specified financial institution&#8221; as defined in the Tax Act; (iii) that holds an interest which is a &#8220;tax shelter investment&#8221; as defined in the Tax Act; or (iv) that has elected to report its tax results in a functional currency other than Canadian currency. Special rules, which are not discussed in this summary, may apply to a Holder that is an &#8220;authorized foreign bank&#8221; within the meaning of the Tax Act, a partnership or an insurer carrying on business in Canada and elsewhere. Such Holders should consult their own tax advisors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">59</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This summary is based upon the provisions of the Tax Act (including the regulations (Regulations) thereunder) in force as of March 1, 2026 and our understanding of the current administrative policies and assessing practices of the Canada Revenue Agency (CRA) published in writing by the CRA prior to March 1, 2026. This summary takes into account all specific proposals to amend the Tax Act (and the Regulations) publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (Tax Proposals) and assumes that the Tax Proposals will be enacted in the form proposed, although no assurance can be given that the Tax Proposals will be enacted in their current form or at all. This summary does not otherwise take into account any changes in law or in the administrative policies or assessing practices of the CRA, whether by legislative, governmental or judicial decision or action. This summary is not exhaustive of all possible Canadian federal income tax considerations and does not take into account other federal or any provincial, territorial or foreign income tax legislation or considerations, which may differ materially from those described in this summary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This summary is of a general nature only and is not, and is not intended to be, and should not be construed to be, legal or tax advice to any particular Holder, and no representations concerning the tax consequences to any particular Holder are made. Holders should consult their own tax advisors regarding the income tax considerations applicable to them having regard to their particular circumstances.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Dividends</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dividends paid or credited (or deemed to be paid or credited) to a Holder by us are subject to Canadian withholding tax at the rate of 25% unless reduced by the terms of an applicable tax treaty or convention. For example, under the Canada-United States Tax Convention (1980), as amended (US Treaty), the dividend withholding tax rate is generally reduced to 15% (or 5% in the case of a Holder that is a company that beneficially owns at least 10% of our voting shares) in respect of a dividend paid or credited to a Holder beneficially entitled to the dividend who is resident in the United States for purposes of the US Treaty and whose entitlement to the benefits of the US Treaty is not limited by the limitation of benefits provisions of the US Treaty. Holders are urged to consult their own tax advisors to determine their entitlement to relief under the US Treaty or any other applicable tax treaty as well as their ability to claim foreign tax credits with respect to any Canadian withholding tax, based on their particular circumstances.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Disposition of Common Shares</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A Holder generally will not be subject to tax under the Tax Act in respect of a capital gain realized on the disposition or deemed disposition of a common share, unless the common share constitutes or is deemed to constitute &#8220;taxable Canadian property&#8221; to the Holder thereof for purposes of the Tax Act, and the gain is not exempt from tax pursuant to the terms of an applicable tax treaty or convention.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In general, provided the common shares are listed on a &#8220;designated stock exchange&#8221; (which currently includes The Nasdaq Capital Market) at the date of the disposition, the common shares will only constitute &#8220;taxable Canadian property&#8221; of a Holder if, at any time within the 60-month period preceding the disposition: (i) such Holder, persons with whom the Holder did not deal at arm&#8217;s length, partnerships in which the Holder or a person with whom the Holder did not deal at arm&#8217;s length holds a membership interest directly or indirectly through one or more partnerships, or any combination thereof, owned 25% or more of the issued shares of any class or series of the Company&#8217;s share capital; and (ii) more than 50% of the fair market value of the common shares was derived directly or indirectly from one or any combination of (A) real or immovable property situated in Canada, (B) Canadian resource properties, (C) timber resource properties, and (D) options in respect of, or interests in, or for civil law rights in, property described in any of subparagraphs (ii)(A) to (C), whether or not the property exists. However, and despite the foregoing, in certain circumstances the common shares may be deemed to be &#8220;taxable Canadian property&#8221; under the Tax Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Holders whose common shares may be &#8220;taxable Canadian property&#8221; should consult their own tax advisers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Certain U.S. Federal Income Tax Considerations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following discussion is a summary of certain material U.S. federal income tax considerations relating to the purchase, ownership and disposition of our common shares by U.S. Holders (as defined below). Although this discussion is generally limited to the U.S. federal income tax considerations to U.S. Holders, the U.S. federal income tax treatment of dividends on and gain on sale, exchange or other taxable dispositions of our common shares by certain Non-U.S. Holders (as defined below) is included below at &#8220;&#8212; Non-U.S. Holders.&#8221; This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations, or of any other potential tax considerations, that may apply to a U.S. Holder or a Non-U.S. Holder arising from or relating to the acquisition, ownership, and disposition of our common shares. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder or Non-U.S. Holder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">60</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (Code), U.S. Treasury regulations promulgated thereunder and administrative and judicial interpretations thereof, and the income tax treaty between the United States and Canada (Convention), all as in effect on the date hereof and all of which are subject to change and differing interpretation, possibly with retroactive effect. This summary is applicable to U.S. Holders who are residents of the United States for purposes of the Convention and who qualify for the full benefits of the Convention. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation. Each prospective investor is responsible for monitoring developments with their own tax advisors, and we do not undertake to update any of the information in this summary based on any change in law after the effective date hereof, including any change that may have retroactive effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (IRS) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of common shares. This summary is not binding on the IRS or the courts, and none of the IRS or the courts are precluded from taking a position that is different from, or contrary to, the positions presented in this summary. In addition, because the guidance on which this summary is based is subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the positions described in this summary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This discussion is limited to U.S. Holders and Non-U.S. Holders that hold our common shares as &#8220;capital assets&#8221; within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all of the U.S. federal income tax considerations that may be relevant to any particular U.S. Holder or Non-U.S. Holder, or to U.S. Holders or Non-U.S. Holders subject to special treatment under U.S. federal income tax law (including, without limitation, banks, certain financial institutions, insurance companies, brokers or dealers in securities, traders in securities or other persons that generally mark their securities to market for U.S. federal income tax purposes, tax-exempt entities, governmental organizations, retirement plans, regulated investment companies, real estate investment trusts, U.S. expatriates and former citizens or long-term residents of the United States, persons who hold common shares as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion transaction,&#8221; &#8220;synthetic security&#8221; or integrated investment, persons that have a &#8220;functional currency&#8221; other than the U.S. dollar, persons that own (or are deemed to own) 10% or more (by voting power or value) of our common shares, &#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; persons that acquire their common shares as part of a compensation arrangement, persons deemed to sell our common shares under the constructive sale provisions of the Code, persons subject to special tax accounting rules as a result of any item of gross income with respect to our common shares being taken into account in an applicable financial statement, corporations that accumulate earnings to avoid U.S. federal income tax, persons subject to the anti-inversion, base erosion or anti-abuse rules, and S corporations, partnerships and other pass-through entities, and investors in such pass-through entities). This discussion does not address all U.S. federal income tax consequences relevant to a U.S. Holder&#8217;s or Non-U.S. Holder&#8217;s particular circumstances, including the impact of the Medicare contribution tax on net investment income or the alternative minimum tax, and does not address any U.S. state or local or non-U.S. tax considerations or any other U.S. federal tax considerations, such as under the estate and gift tax laws. In addition, except as specifically set forth below, this summary does not discuss applicable tax reporting requirements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an entity or arrangement treated as a partnership or other pass-through entity for U.S. federal income tax purposes holds the common shares, the U.S. federal income tax considerations relating to an investment in the common shares will depend in part upon the status and activities of such entity and arrangement and the particular partner or owner thereof. Any such entity or arrangement (and the partners and owners thereof) should consult its own tax advisor regarding the U.S. federal income tax considerations applicable to it and its partners and owners of the purchase, ownership and disposition of the common shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>This discussion is for informational purposes only and is not tax advice. Investors should consult their own tax advisors as to the particular tax considerations applicable to them relating to the purchase, ownership and disposition of common shares, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws, and of any applicable income tax treaty.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>U.S. Holders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As used in this discussion, the term &#8220;U.S. Holder&#8221; means a beneficial owner of common shares that is, for U.S. federal income tax purposes, (1) an individual who is a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate the income of which is subject to U.S. federal income tax regardless of its source, or (4) a trust (x) with respect to which a court within the United States is able to exercise primary supervision over its administration and one or more persons that is a &#8220;United States person&#8221; (within the meaning of Section 7701(a)(30) of the Code) have the authority to control all of its substantial decisions, or (y) that has a valid election in effect under applicable U.S. Treasury regulations to be treated as a domestic trust for U.S. federal income tax purposes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">61</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Distributions</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Subject to the discussion below under &#8220;<i>Passive Foreign Investment Company Considerations</i>,&#8221; a U.S. Holder that receives a distribution with respect to the common shares generally will be required to include the gross amount of such distribution (before reduction for any Canadian withholding taxes) in gross income as a dividend when actually or constructively received to the extent of the U.S. Holder&#8217;s pro rata share of our current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder&#8217;s pro rata share of our current and accumulated earnings and profits, it will generally be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&#8217;s common shares. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&#8217;s common shares, the remainder will generally be taxed as capital gain. However, we cannot provide any assurance that we will maintain or provide earnings and profits determinations in accordance with U.S. federal income tax principles. Therefore, U.S. Holders should expect that a distribution will generally be treated as a dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The U.S. dollar value of any distribution on the common shares made in Canadian dollars generally should be calculated by reference to the exchange rate between the U.S. dollar and the Canadian dollar in effect on the date of receipt (or deemed receipt) of such distribution by the U.S. Holder regardless of whether the Canadian dollars so received are in fact converted into U.S. dollars at that time. If the Canadian dollars received are converted into U.S. dollars on the date of receipt (or deemed receipt), a U.S. Holder generally should not recognize currency gain or loss on such conversion. If the Canadian dollars received are not converted into U.S. dollars on the date of receipt (or deemed receipt), a U.S. Holder generally will have a basis in such Canadian dollars equal to the U.S. dollar value of such Canadian dollars on the date of receipt (or deemed receipt). Any gain or loss on a subsequent conversion or other disposition of such Canadian dollars by such U.S. Holder generally will be treated as ordinary income or loss and generally will be income or loss from sources within the United States for U.S. foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method of tax accounting. Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Distributions on the common shares that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes and generally will constitute &#8220;passive category income.&#8221; Because we are not a U.S. corporation, such dividends will not be eligible for the &#8220;dividends received&#8221; deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations. Dividends paid by a &#8220;qualified foreign corporation&#8221; to a U.S. Holder who is an individual, trust or estate will generally be treated as &#8220;qualified dividend income&#8221; and eligible for taxation at the lower applicable long-term capital gain rate, provided that a holding period requirement and certain other requirements are met, subject to certain exceptions. However, if we are treated as a &#8220;passive foreign investment company&#8221; (a PFIC) for the taxable year in which the dividend is paid or the preceding taxable year (see discussion below under &#8220;<i>Passive Foreign Investment Company Considerations</i>&#8221;), we will not be treated as a qualified foreign corporation, and therefore the reduced capital gains tax rate described above will not apply. Each U.S. Holder is advised to consult its own tax advisors regarding the availability of the reduced tax rate on dividends.&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If a U.S. Holder is subject to Canadian withholding tax on dividends paid on the U.S. Holder&#8217;s common shares (see discussion below under &#8220;<i>Certain Canadian Federal Income Tax Considerations for U.S. Holders </i>&#8211; <i>Dividends</i>&#8221;), the U.S. Holder may be eligible, subject to a number of complex limitations, to claim a credit against its U.S. federal income tax for the Canadian withholding tax imposed on the dividends. However, if U.S. persons collectively own, directly or indirectly, 50% or more of the voting power or value of our common shares, it is possible that a portion of any dividends we pay will be considered U.S.-source income in proportion to our U.S.-source earnings and profits, which could limit the ability of a U.S. Holder to claim a foreign tax credit for the Canadian withholding taxes imposed in respect of such a dividend, although certain elections may be available under the Code and the Convention to mitigate these effects. A U.S. Holder may claim a deduction for the Canadian withholding tax in lieu of a credit, but only for a year in which the U.S. Holder elects to do so for all creditable foreign income taxes. The rules governing the foreign tax credit are complex. Each U.S. Holder is advised to consult its tax advisor regarding the availability of the foreign tax credit under its particular circumstances.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">62</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Sale, Exchange or Other Taxable Disposition of Common Shares</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Subject to the discussion below under &#8220;<i>Passive Foreign Investment Company Considerations</i>,&#8221; a U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition of common shares. The amount of gain recognized will generally equal the excess of the amount realized (generally, the amount of cash plus the fair market value of any property received) over the U.S. Holder&#8217;s adjusted tax basis in the common shares sold, exchanged or otherwise disposed of. The amount of loss recognized will equal the excess of the U.S. Holder&#8217;s adjusted tax basis in the common shares sold, exchanged or otherwise disposed of over the amount realized. Such capital gain or loss generally will be long-term capital gain or loss if, on the date of sale, exchange or other taxable disposition, the common shares were held by the U.S. Holder for more than one year. Net long-term capital gain derived by a non-corporate U.S. Holder with respect to capital assets is currently subject to tax at reduced rates. The deductibility of a capital loss is subject to significant limitations. Any gain or loss recognized from the sale, exchange or other disposition of common shares will generally be gain or loss from sources within the United States for U.S. foreign tax credit purposes, except as otherwise provided in an applicable income tax treaty and if an election is properly made under the Code.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If common shares are sold, exchanged or otherwise disposed of in a taxable transaction for Canadian dollars or other non-U.S. currency, the amount realized with respect to such Canadian dollars or other non-U.S. currency generally will be the U.S. dollar value of the Canadian dollars or other non-U.S. currency received based on the spot rate in effect on the date of sale, exchange or other taxable disposition. If a U.S. Holder is a cash method taxpayer and the common shares are traded on an established securities market, Canadian dollars or other non-U.S. currency paid or received by such U.S. Holder will be translated into U.S. dollars at the spot rate on the settlement date of the sale. An accrual method taxpayer may elect the same treatment with respect to the sale of common shares traded on an established securities market, provided that the election is applied consistently from year to year. Such election cannot be changed without the consent of the IRS. Canadian dollars or other non-U.S. currency received on the sale, exchange or other taxable disposition of common shares generally will have a tax basis equal to its U.S. dollar value as determined pursuant to the rules above. Any gain or loss recognized by a U.S. Holder on a sale, exchange or other taxable disposition of the Canadian dollars or other non-U.S. currency will be ordinary income or loss and generally will be U.S.-source gain or loss.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Passive Foreign Investment Company Considerations</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>General Rule.</i>&#160;The U.S. federal income tax considerations relating to the purchase, ownership and disposition of our common shares by U.S. Holders will differ depending on whether or not we are considered a PFIC during such U.S. Holder&#8217;s holding period. In general, for any taxable year in which 75% or more of our gross income, including our pro rata share of the gross income of any corporation in which we are considered to own at least 25% of the shares by value, is passive income, or at least 50% of the value of our assets, including our pro rata share of the assets of any corporation in which we are considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income, we would be characterized as a PFIC for U.S. federal income tax purposes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The percentage of a corporation&#8217;s assets that produce or are held for the production of passive income generally is determined based upon the average ratio of passive assets to total assets calculated at the end of each measuring period. Calculation of the value of assets is generally made at the end of each of the four quarters that make up the company&#8217;s taxable year, unless an election is made to use an alternative measuring period (such as a week or month). The &#8220;weighted average&#8221; of those periodic values is then used to determine the value of assets for the passive asset test for the taxable year.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Assets that produce or are held for the production of passive income generally include cash, even if held as working capital or raised in a public offering, marketable securities and other assets that may produce passive income. However, proposed regulations section 1.1297-1(d)(2) provides a limited exception to the passive asset test valuation rules for working capital required to meet the short-term cash needs of operating companies. This proposed regulation provides that an amount of cash held in a non-interest bearing account that is held for the present needs of an active trade or business and is no greater than the amount reasonably expected to cover 90 days of operating expenses incurred in the ordinary course of the trade or business of the foreign corporation (for example, accounts payable for ordinary operating expenses or employee compensation) is not treated as a passive asset. Taxpayers are permitted to rely on the proposed rule provided they consistently follow the rule for each subsequent taxable year beginning before the date of filing of the Treasury decision adopting the rule as a final regulation. The Treasury Department and the IRS indicated that they continue to study the appropriate treatment of working capital for purposes of the passive asset test.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>PFIC Status Determination.</i>&#160;The tests for determining PFIC status for any taxable year are dependent upon a number of factors, some of which are beyond our control, including the value of our assets, the market price of our common shares, and the amount and type of our gross income. Based on these tests (i) we believe that we&#160;<i>were</i>&#160;a PFIC for the taxable year ended December 31, 2016, (ii) we do&#160;<i>not</i>&#160;believe that we were a PFIC for any of the taxable years ended December 31, 2017, 2018, 2019, 2020, or 2021, and (iii) we believe that we&#160;<i>were</i>&#160;a PFIC for each of the taxable years ended December 31, 2022, 2023, 2024 [and 2025]. Our status as a PFIC is a fact-intensive determination made for each taxable year, and we cannot provide any assurance regarding our PFIC status for the taxable year ending December 31, 2026 or for future taxable years. U.S. Holders who own our common shares for any period during which we are a PFIC will be required to file IRS Form 8621 for each tax year during which they hold our common shares, unless, after we are no longer a PFIC, any such U.S. Holder makes the &#8220;purging election&#8221; discussed below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">63</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Certain PFIC Consequences</i>. If we are a PFIC for any year during a U.S. Holder&#8217;s holding period of our common shares, and such U.S. Holder does not make a &#8220;qualified electing fund&#8221; election (QEF Election) or a &#8220;mark-to-market&#8221; election, both as described below, then such U.S. Holder generally will be required to treat any gain recognized upon a disposition of our common shares, or any so-called &#8220;excess distribution&#8221; received on our common shares (generally, any distributions on our common shares in a taxable year that are greater than 125% of the average annual distributions received by such U.S. Holder in the three preceding taxable years or, if shorter, the U.S. Holder&#8217;s holding period), as ordinary income, rather than as capital gain, and the preferential tax rate applicable to dividends received on our common shares would not be available. This income generally would be allocated over a U.S. Holder&#8217;s holding period with respect to our common shares and the amount allocated to prior years will be subject to tax at the highest tax rate in effect for that year for individuals or corporations, as applicable, without regard to the U.S. Holder&#8217;s other items of income and loss for such year, and an interest charge would be imposed on the amount of deferred tax on any such income allocated to prior taxable years. Any such interest charge will be non-deductible interest expense for individual U.S. Holders. Pursuant to the specific provisions of the PFIC rules, a taxpayer may realize gain on the disposition of common shares if the securities are disposed of by a holder whose securities are attributed to the U.S. Holder, if the securities are pledged as security for a loan, transferred by gift or death, or are subject to certain corporate distributions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>QEF Election</i>. In general, if we are determined to be a PFIC, a U.S. Holder may be able to avoid certain of the adverse tax consequences described above by making a timely and effective QEF election. A U.S. Holder who makes a QEF election generally must report, on a current basis, its share of our ordinary earnings and net capital gains, whether or not we distribute any amounts to our shareholders, and would be required to comply with specified information reporting requirements. A U.S. Holder generally may make a separate election to defer the payment of taxes on undistributed income inclusions under the QEF rules, but if deferred, any such taxes will be subject to an interest charge. Any gain subsequently recognized upon the sale by that U.S. Holder of the common shares generally would be taxed as capital gain. The QEF election is available only if we provide certain information regarding our earnings and capital gains, as required under applicable U.S. Treasury regulations. We intend to reasonably endeavor to, upon a U.S. Holder&#8217;s request, provide all information and documentation that such U.S. Holder making a QEF election is required to obtain for U.S. federal income tax purposes (e.g., the U.S. Holder&#8217;s pro rata share of ordinary income and net capital gain, and a &#8220;PFIC Annual Information Statement&#8221; as described in applicable U.S. Treasury regulations). However, there can be no assurance that we will have timely knowledge of our status as a PFIC in the future or that we will be able to provide such required information to a U.S. Holder on a timely basis or at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Mark-to-Market Election</i>. As an alternative to a QEF Election, a U.S. Holder that owns shares in a PFIC that are treated as marketable stock may also make a timely &#8220;mark-to-market&#8221; election. A U.S. Holder who makes the mark-to-market election for the first taxable year of such U.S. Holder in which it holds (or is deemed to hold) our common shares and for which we are determined to be a PFIC generally must include as ordinary income each year the increase in the fair market value of the common shares and deduct from gross income the decrease in the value of such shares during each of its taxable years. Losses would be allowed only to the extent of the net mark-to-market gain previously included in income under the election. The U.S. Holder&#8217;s adjusted tax basis in the common shares with respect to which the mark-to-market election applies would be adjusted to reflect amounts included in gross income or allowed as a deduction as a result of such election. If a U.S. Holder makes an effective mark-to-market election, any gain recognized upon the sale or other disposition of our common shares in a year that we are a PFIC will be treated as ordinary income and any loss will be treated first as ordinary loss (to the extent of any net mark-to-market gains for prior years) and thereafter as capital loss. A mark-to-market election may be made and maintained only if our common shares are regularly traded on a qualified exchange, including The Nasdaq Capital Market. Whether our common shares are regularly traded on a qualified exchange is an annual determination based on facts that, in part, are beyond our control. Accordingly, a U.S. Holder might not be eligible to make a mark-to-market election if we are characterized as a PFIC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Certain Election Tax Risks</i>. Certain economic risks are inherent in making either a QEF Election or a mark-to-market election. If a QEF Election is made, it is possible that earned income will be reported to a U.S. Holder as taxable income and income taxes will generally be due and payable on such an amount even if no cash is distributed with respect to such income. There is no assurance that any distribution or profitable sale will ever be made regarding our common shares, so any such tax liability may result in a net economic loss. A mark-to-market election may result in significant share price gains in one year causing a significant income tax liability. This gain may be offset in another year by significant losses. If a mark-to-market election is made, this highly variable tax gain or loss may result in substantial and unpredictable changes in taxable income for an electing shareholder. The amount included in income under a mark-to-market election may be substantially greater than the amount included under a QEF election. Both the QEF and mark-to-market elections are binding on the U.S. Holder for all subsequent years that the U.S. Holder owns our shares unless permission to revoke the election is granted by the IRS. U.S. Holders should consult their own tax advisors regarding the availability and tax consequences of a&#160;QEF Election and a mark-to-market election in respect to our common shares under their particular circumstances.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">64</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Purging Election</i>. Although we generally will continue to be treated as a PFIC as to any U.S. Holder if we are a PFIC for any year during a U.S. Holder&#8217;s holding period, if we cease to satisfy the requirements for PFIC classification, the U.S. Holder may avoid PFIC classification for subsequent years if the U.S. Holder makes a so-called &#8220;purging election,&#8221; by recognizing income, based on the excess distribution regime described above, on the unrealized appreciation in the common shares through the close of the tax year in which we cease to be a PFIC. When a foreign corporation no longer qualifies as a PFIC (due to a change in facts or law), the foreign corporation nonetheless retains its PFIC status with respect to a shareholder unless and until the shareholder makes such an election under Code section 1298(b)(1) and Treasury regulations section 1.1298-3 on IRS Form 8621 attached to the shareholder&#8217;s tax return (including an amended return), or requests the consent of the IRS Commissioner to make a late election under Code section 1298(b)(1) and Treasury regulations section 1.1298-3(e) (late purging election) on Form 8621-A.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>The U.S. federal income tax rules relating to PFICs are very complex. U.S. Holders are urged to consult their own tax advisors with respect to the purchase, ownership and disposition of common shares, the consequences to them of an investment in a PFIC, any elections available with respect to the common shares, and the IRS information reporting obligations with respect to the purchase, ownership and disposition of common shares in the event we are considered a PFIC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>U.S. Information Reporting with Respect to Foreign Financial Assets and Transfers to Foreign Corporations</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain U.S. Holders may be required to file an IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) to report a transfer of property (including cash) to us. Substantial penalties may be imposed on a U.S. Holder that fails to comply with this reporting requirement and the period of limitations on assessment and collection of U.S. federal income taxes will be extended in the event of a failure to comply. Furthermore, certain U.S. Holders who are individuals and certain entities will be required to report information with respect to such U.S. Holder&#8217;s investment in &#8220;specified foreign financial assets&#8221; on IRS Form 8938 (Statement of Specified Foreign Financial Assets), subject to certain exceptions. An interest in the Company constitutes a specified foreign financial asset for these purposes. U.S. Holders who are required to report specified foreign financial assets and fail to do so may be subject to substantial penalties and the period of limitations on assessment and collection of U.S. federal income taxes will be extended in the event of a failure to comply. Potential investors are urged to consult with their own tax advisors regarding the foreign financial asset and other reporting obligations and their application to an investment in our common shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Non-U.S. Holders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A beneficial owner of our common shares, other than an entity or arrangement treated as a partnership or other pass-through entity for U.S. federal income tax purposes, that is not a U.S. Holder is referred to herein as a &#8220;Non-U.S. Holder&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-U.S. Holders generally will not be subject to U.S. federal income or withholding tax on dividends received from us with respect to our common shares, unless that income is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such Non-U.S. Holder maintains in the United States).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, Non-U.S. Holders generally will not be subject to U.S. federal income or withholding tax on any gain realized upon the sale, exchange or other taxable disposition of our common shares, unless:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the gain is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such Non-U.S. Holder maintains in the United States); or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Non-U.S. Holder is an individual who is present in the United States for 183 days or more during the taxable year of disposition and other conditions are met (in which case, such gain from United States sources generally is subject to tax at a 30% rate or a lower applicable tax treaty rate, which may be offset by U.S. source capital losses of such Non-U.S. Holder (even though the individual is not considered a resident of the United States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses).&#160;&#160;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">65</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If the Non-U.S. Holder is engaged in a U.S. trade or business for U.S. federal income tax purposes, the income from the common shares, including dividends and the gain from the sale, exchange or other taxable disposition of the stock, that is effectively connected with the conduct of that U.S. trade or business (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base in the United States) will generally be subject to regular U.S. federal income tax in the same manner as discussed above relating to the general taxation of U.S. Holders. In addition, if such Non-U.S. Holder is a corporation, its earnings and profits that are attributable to the effectively connected income, which are subject to certain adjustments, may be subject to an additional branch profits tax at a rate of 30%, or at a lower rate as may be specified by an applicable U.S. income tax treaty.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Information Reporting and Backup Withholding</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For U.S. Holders, dividends on and proceeds from the sale or other taxable disposition of common shares may be reported to the IRS unless the U.S. Holder establishes a basis for exemption. Backup withholding may apply to amounts subject to reporting if (1) the U.S. Holder fails to provide an accurate taxpayer identification number or otherwise establish a basis for exemption, or (2) the U.S. Holder is notified by the IRS that backup withholding applies. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a U.S. Holder&#8217;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to the IRS.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For Non-U.S. Holders, information returns may be filed with the IRS in connection with, and Non-U.S. Holders may be subject to U.S. tax withholding on amounts received in respect of, a Non-U.S. Holder&#8217;s common shares, unless the Non-U.S. Holder furnishes to the applicable withholding agent the required certification as to its non-U.S. status, such as by providing a valid IRS Form W-8BEN, IRS Form W-8BEN-E or IRS Form W-8ECI, as applicable, or the Non-U.S. Holder otherwise establishes an exemption. Distributions paid with respect to common shares and proceeds from the sale or other disposition of common shares received in the United States by a Non-U.S. Holder through certain U.S.-related financial intermediaries may be subject to information reporting and U.S. tax withholding unless such Non-U.S. Holder provides proof of an applicable exemption or complies with certain certification procedures described above. If a Non-U.S. Holder sells its common shares through a U.S. office of a broker, the payment of the proceeds is subject to both U.S. backup withholding and information reporting unless such Non-U.S. Holder certifies that it is a non-U.S. person, under penalties of perjury, or it otherwise establishes an exemption. If a Non-U.S. Holder sells common shares through a non-U.S. office of a non-U.S. broker and the sales proceeds are paid to such Non-U.S. Holder outside the United States, then information reporting and backup withholding generally will not apply to that payment. However, U.S. information reporting requirements, but not backup withholding, will apply to a payment of sales proceeds, even if that payment is made to a Non-U.S. Holder outside the United States, if such Non-U.S. Holder sells common shares through a non-U.S. office of a broker that is a U.S. person or has certain other contacts with the United States, unless such Non-U.S. Holder certifies that it is a non-U.S. person under penalty of perjury, or otherwise establishes an exemption.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder or Non-U.S. Holder. A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. U.S. Holders and Non-U.S. Holders should consult with their own tax advisors regarding their reporting obligations, if any, as a result of their acquisition, ownership, or disposition of our common shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A U.S. HOLDER OR NON-U.S. HOLDER. EACH U.S. HOLDER AND NON-U.S. HOLDER IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN COMMON SHARES IN LIGHT OF THE INVESTOR</b>&#8217;<b>S OWN CIRCUMSTANCES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 1pt;"><b>Item 6.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>[Reserved]</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">66</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 1pt;"><b>Item 7.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Management</b>&#8217;<b>s Discussion and Analysis of Financial Condition and Results of Operations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based upon accounting principles generally accepted in the United States of America and discusses the financial condition and results of operations for DiaMedica Therapeutics Inc. and our subsidiaries for the years ended December 31, 2025 and 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This discussion should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this report. The following discussion contains forward-looking statements that involve numerous risks and uncertainties. Our actual results could differ materially from the forward-looking statements as a result of these risks and uncertainties. See &#8220;<i>Cautionary Note Regarding Forward-Looking Statements</i>&#8221; in this report for additional cautionary information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">Business Overview</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a clinical stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with a focus on PE, FGR and AIS. Our lead candidate DM199 (rinvecalinase alfa; rhKLK1) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein (serine protease enzyme) to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1 for the treatment of AIS and porcine KLK1 for the treatment of cardio renal disease, including hypertension. We plan to advance DM199 through required clinical trials to create shareholder value by establishing its clinical and commercial potential as a therapy for PE, FGR and AIS. Longer term, we plan to develop DM300, our patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, as a potential therapy for severe acute pancreatitis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DM199 is a recombinant form of the naturally occurring protease enzyme KLK1 (rhKLK1)and the first rhKLK1 undergoing global clinical development studies in PE, FGR and AIS. DM199 has been granted Fast Track designation from the FDA for the treatment of AIS. Naturally occurring KLK1 (extracted from human urine or porcine pancreas) has been an approved therapeutic agent in Asia for decades in the treatment of AIS and hypertension associated with cardiorenal disease. DM199 is produced using recombinant DNA technology without the need for extracted human or animal tissue sources and thereby eliminates risk of pathogen transmission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism believed to enhance endothelial health, microcirculatory blood flow and tissue perfusion by increasing&#160;production of NO, PGI<sub>2</sub> and EDHF. In PE and FGR, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta, potentially disease modifying results that improve both maternal and perinatal outcomes. In the case of AIS, DM199 is intended to enhance blood flow and boost neuronal survival in the ischemic penumbra by dilating arterioles surrounding the site of the vascular occlusion and inhibiting apoptosis (neuronal cell death) while also facilitating neuronal remodeling through the promotion of angiogenesis.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our product development pipeline is as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="develpmentpipe.jpg" src="develpmentpipe.jpg"/></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">67</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are developing DM199 to address two major critical unmet needs. In PE and FGR, there are currently no approved agents in any global market to safely lower maternal blood pressure and/or reduce the risk of fetal growth restriction. Historically, the major issue is that traditional vasodilators that are commonly used to reduce essential hypertension (e.g., beta-blockers, angiotensin converting enzyme inhibitors (ACEi)) can readily cross the placental barrier and enter into the fetal circulation and cause harm to the developing fetus. We believe that DM199 is uniquely suited to treat PE since its inherent molecular size, approximately 26 kilodaltons (KD) is typically too large to cross the placental barrier, as was demonstrated in the interim result noted below, and therefore may reduce blood pressure and enhance microcirculatory perfusion to the maternal organs and placenta without entering fetal circulation, a potentially significant safety advantage. Additionally, we believe DM199 has the potential to not only address hypertension of PE, but also to confer disease modifying outcomes for both maternal and perinatal outcomes, including fetal growth restriction. In AIS, up to 80% of AIS patients are not eligible for treatment with currently approved clot-busting (thrombolytic) drugs or catheter-based clot removal procedures (mechanical thrombectomy). DM199 is intended to enhance collateral blood flow and boost neuronal survival in the ischemic penumbra by inhibiting neuronal cell death (apoptosis) and promoting neuronal remodeling and neoangiogenesis, and accordingly, offer a potential treatment option for AIS patients who otherwise have no therapeutic options.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Preeclampsia &amp; Fetal Growth Restriction Program</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our clinical development program in PE currently centers around an investigator-sponsored safety, tolerability and pharmacodynamic, proof-of-concept Phase 2 study in PE patients. This Phase 2 study is being conducted at the Tygerberg Hospital, Cape Town, South Africa and consists of three studies in PE (Part 1a, dose-escalation; Part 1b, dose-expansion; and Part 2, expectant management) and a fourth study in fetal growth restriction (FGR, Part 3, expectant management). Part 1a topline study results are intended to identify a suitable dose for Parts 1b, 2, and 3. Up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject in Part 1a was enrolled in the fourth quarter of 2024 and interim results from Part 1a of the study were released in July 2025. The interim results (N=28 subjects) demonstrate that DM199 appears safe and well-tolerated with clinically-relevant pharmacodynamic activity with no evidence of placental transfer. Additionally, subjects exhibited rapid, statistically significant reductions in blood pressure with duration of effect that was sustained up to 24 hours post-infusion compared to pre-treatment baseline, a durable effect extending up to 24 hours post-infusion. Preparations are underway to initiate Part 1b where up to 30 subjects with PE and expected delivery within 72 hours will be treated with a dose regimen identified from Part 1a.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PE is a serious pregnancy disorder that typically develops after the 20th week of gestation, characterized by high blood pressure and damage to organ systems, often the kidneys and liver. Affecting up to 8% of pregnancies worldwide, preeclampsia can pose significant risks to both the mother and baby, including risk of stroke, placental abruption, progression to eclampsia, premature delivery, and death. Symptoms may include severe headaches, vision changes, upper abdominal pain and swelling in the hands and face. Delivery of the baby, often very prematurely, is the only available option for stopping the progression of preeclampsia. Women who have had preeclampsia have three to four times the risk of high blood pressure and double the risk for heart disease and stroke and there are currently no approved therapeutics for PE in the United States or Europe. Fetal growth restriction is a closely related condition of fetal undergrowth due to a poorly functioning placenta &#8211; the life support system of the unborn child. Fetal growth restriction is the leading cause of stillbirth. For those that survive the pregnancy, unhealthy fetal development in utero leaves a legacy of poor health echoing across the child&#8217;s lifespan. Currently, no approved treatment exists for this condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We are preparing for an open-label, dose-ranging Phase 2 study of DM199 in participants with early onset preeclampsia to be conducted in North America (United States &amp; Canada) and the United Kingdom (UK). In March 2026, we received approval from Health Canada to initiate this Phase 2 study and we are currently finalizing plans to commence site activation in the second half of this year. In the second quarter of 2026, we anticipate filing a clinical trial application to expand this Phase 2 study to include sites in the UK. Regarding the status of this clinical program in the United States, in the fourth quarter of 2025, we participated in a productive, in-person pre-investigational new drug (IND) meeting with the US Food and Drug Administration (FDA) to discuss the planned Phase 2 study, at which the FDA requested an additional non-clinical, 10-day modified embryo-fetal development and pre- and postnatal development (ePPND) study in a rabbit model, a non-rodent species. Preliminary results of the rabbit study suggest that the animals developed an antibody response to DM199, a humanized recombinant protein, preventing us from completing the requested ePPND study in the rabbit model. In earlier pregnant rabbit studies, there was no evidence of teratogenicity (i.e., no external, visceral or skeletal malformations in developing rabbit fetuses) attributable to DM199 in the approximately 200 rabbit offspring produced. The fetal effects with pregnant rabbits that were observed, embryo/fetal lethality and decreased fetal body weights were considered secondary to frank maternal toxicity that was observed at all doses. We are currently evaluating alternate animal models to address the FDA&#8217;s ePPND study request. Depending on the alternative species, and its gestational period, results from the ePPND study may be substantially delayed.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">68</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>AIS Program and Phase 2/3 ReMEDy2 Trial</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our clinical program in AIS centers on our ReMEDy2 clinical trial (NCT05065216) of DM199 for the treatment of AIS. Our ReMEDy2 clinical trial is a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial intended to enroll approximately 300 participants at up to 100 sites globally. The adaptive design component includes an interim analysis by our independent data safety monitoring board to be conducted after the first 200 participants have completed the trial. Based on the results of the interim analysis, the study may be stopped for futility or the final sample size will be determined, ranging between 300 and 728 patients, according to a pre-determined statistical plan. As previously disclosed, we have experienced and continue to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring, supporting vendor management and overall program management. We are currently conducting the trial in the United States and in the countries of Canada, Georgia and the United Kingdom. We recently received regulatory approval from the European Medicines Agency and are initiating study sites in six European countries. We continue to work closely with our contract research organizations and other supporting vendors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to enhance site activations and enrollment in our ReMEDy2 trial; however, no assurances can be provided as to the success of these actions and if or when these issues will resolve. Failure to resolve these issues may result in further delays in our ReMEDy2 trial and increase the difficulty in forecasting enrollment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Financial Overview</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We do not have commercial approval to market any product, nor have we ever had such approval. We have financed our operations principally by the public and private sales of equity securities. We have received additional capital from the exercise of warrants and stock options, interest income on funds available for investment and government grants. During 2025 we received combined gross proceeds of approximately $43.9 million from the sale of common shares under a private placement offering and the sale of common shares under our at-the-market offering. We have incurred a net loss in each year since our inception. Our net losses were $32.8 million and $24.4 million for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, we had cash, cash equivalents and marketable securities of $59.9 million and an accumulated deficit of $172.8 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development (R&amp;D) activities and general and administrative (G&amp;A) support costs associated with our operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect to continue to incur significant expenses and operating losses for at least the next few years. We anticipate that our quarterly expenses will increase moderately relative to recent prior periods as we continue to advance our DM199 clinical development program into PE and we continue our ReMEDy2 trial, including the activation of additional study sites in the U.S. and Europe and the enrollment of additional participants in the trial. Our efforts to expand our team to provide support for our clinical programs and administrative operations will also likely contribute to such increases.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While we expect our rate of future negative cash flows per quarter will generally increase moderately relative to recent prior periods as we continue our clinical development programs in PE and AIS, we expect our current cash resources will be sufficient to allow us to fund our planned operations for at least the next 12 months from the date of issuance of the consolidated financial statements included in this report. However, the amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including the current Phase 2 PE trial, our current ReMEDy2 trial and in particular the rate of site activation and participant enrollment in the study, the potential further expansion of our current development programs and other factors. We may require or otherwise seek significant additional funds earlier than we currently expect. We may elect to raise additional funds even before we need them if market conditions for raising additional capital are favorable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Components of Our Results of Operations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Research and Development Expenses</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We incurred R&amp;D expenses of $24.6 million and $19.1 million for the years ended December 31, 2025 and 2024, respectively. R&amp;D expenses consist primarily of fees paid to external service providers such as contract research organizations; clinical support services; clinical development including clinical site costs; outside nursing services; and laboratory testing. R&amp;D costs also include non-clinical testing; fees paid to our contract manufacturing and development organizations and outside laboratories for development of DM199 and related manufacturing processes; costs for production runs of DM199; consulting resources with specialized expertise related to the execution of our development plan for DM199; and personnel costs, including salaries, benefits, non-cash share-based compensation expense; and other personnel costs. Our R&amp;D efforts have been primarily focused on developing DM199. At this time, due to the risks inherent in the clinical development process and the clinical stage of our product development programs, we are unable to estimate with any certainty the costs we will incur in completing the development of DM199 through marketing approval. The process of conducting clinical studies necessary to obtain regulatory approval and manufacturing scale-up to support expanded development and potential future commercialization is costly and time consuming. Any failure by us or delay in completing clinical studies, manufacturing scale-up, or in obtaining regulatory approvals could lead to increased R&amp;D expenses and, in turn, have a material adverse effect on our results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">69</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>General and Administrative Expenses</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We incurred G&amp;A expenses of $9.8 million and $7.6 million for the years ended December 31, 2025 and 2024, respectively. G&amp;A expenses consist primarily of salaries and benefits, including non-cash share-based compensation related to our executive, finance, business development and support functions. G&amp;A expenses also include insurance, including directors&#8217; and officers&#8217; liability coverage, rent and utilities, travel expenses, patent costs, and professional fees, including for auditing, tax and legal services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Other Income, Net</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other income, net consists primarily of interest income earned on marketable securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Critical Accounting Estimates</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While our significant accounting policies are more fully described in Note 3 to our consolidated financial statements included elsewhere in this report, we believe the following discussion addresses our most critical accounting estimates, which are those that are most important to the portrayal of our financial condition and results of operations and require our most difficult, subjective and complex judgments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Research and Development Costs</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We charge R&amp;D costs to expense when incurred. Our human clinical trials are performed at experienced clinical trial sites and are generally administered by us with assistance from contract research organizations (CROs) although, during 2024 and 2025 in an effort to mitigate the impact delays in our ReMEDy2 trial, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring, supporting vendor management and overall program management. Trial costs also include outside service providers, such as outside nursing services, testing laboratories and data coordination and collection. Upfront costs of setting up clinical trial sites are accrued upon execution of individual trial agreements. Expenses related to the performance of clinical trials are accrued based on contracted amounts and the achievement of agreed upon milestones, such as participant enrollment, participant follow-up, etc. While we utilize electronic data capture systems to facilitate the transmission and capture of clinical trial activity, such information is often incomplete or delayed. Therefore, we are required to estimate levels of performance under each significant contract, including, among other things, the extent of participant enrollment, the extent of supporting services performed and other activities through communications with the clinical trial sites, CROs and supporting vendors and adjust the estimates, if required, on a quarterly basis so that clinical expenses materially reflect the actual work performed at each clinical trial site and by each CRO or supporting vendor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Share-based Compensation</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for all share-based compensation awards using a fair value method. The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">70</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fair value of option awards are estimated using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our common share price, as well as assumptions regarding a number of complex and subjective variables. Risk-free interest rates are based upon United States Government securities rates appropriate for the expected term of each award. Expected volatility rates are based on the historical volatility experienced over a period equal to the expected term of the option. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by us during the years ended December 31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common share fair value</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">$4.07</p>
			</td>
			<td colspan="2" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 2%;">-</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;">$8.67</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">$2.40</p>
			</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 2%;">-</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;">$5.38</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3.7%</td>
			<td colspan="2" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.4%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.8%</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="4" rowspan="1" style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">0%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="3" rowspan="1" style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected option life (in years)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">5.0</td>
			<td colspan="2" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected stock price volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">75.7%</td>
			<td colspan="2" style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83.3%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83.0%</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124.1%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Comparison of the Years Ended December 31, 2025 and 2024</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes our results of operations for the years ended December 31, 2025 and 2024 (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,614</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,057</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,783</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,624</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,659</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,267</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Research and Development Expenses</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">R&amp;D expenses were $24.6 million and $19.1 million for the years ended December 31, 2025 and 2024, respectively. The $5.5 million increase is primarily due to cost increases driven by the continuation of our ReMEDy2 clinical trial, including its global expansion, the expansion of our clinical team in the prior and current year periods, including increased non-cash share-based compensation costs. These increases were partially offset by cost reductions related to manufacturing process development work performed and completed in the prior year period. We expect that our R&amp;D expenses will moderately increase in future periods relative to recent prior periods as we continue our clinical development program in PE and as we continue our ReMEDy2 trial, including our global expansion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>General and Administrative Expenses</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">G&amp;A expenses were $9.8 million and $7.6 million for the year ended December 31, 2025 and 2024, respectively. G&amp;A expenses increased $2.2 million due to a series of factors including increased non-cash share-based compensation expense, increased personnel costs, increased investor relations expenses and increased patent prosecution costs. We expect G&amp;A expenses to remain steady to slightly increase in future periods as compared to recent prior periods.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Other Income, Net</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other income, net, was $1.7 million for the year ended December 31, 2025 compared to $2.3 million for 2024. The decreases resulted from reduced interest income recognized during the current year related to lower average marketable securities balances as compared to the prior year.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">71</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following tables summarize our liquidity and capital resources as of December 31, 2025 and 2024 and cash flows for each of the years ended December 31, 2025 and 2024, and are intended to supplement the more detailed discussion that follows (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liquidity and Capital Resources</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Cash, cash equivalents and marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59,890</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,147</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">61,371</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,345</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,132</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,390</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total shareholders&#8217; equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56,111</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,718</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Working capital</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,497</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,220</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash Flow Data</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash flow provided by (used in):</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(29,062</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22,076</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Investing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,192</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,564</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Financing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">43,876</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,994</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net increase (decrease) in cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,622</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,518</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Liquidity and Capital Resources</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We had cash, cash equivalents and marketable securities of $59.9 million, current liabilities of $5.1 million, and working capital of $55.5 million as of December 31, 2025, compared to $44.1 million in cash, cash equivalents and marketable securities, $5.4 million in current liabilities, and $39.2 million in working capital as of December 31, 2024. The increases in our combined cash, cash equivalents and marketable securities and in our working capital are due to the net proceeds received from the sale of common shares in our July private placement and under our at-the-market offering program, partially offset by the net cash used in operating activities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cash Flows</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Operating Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net cash used in operating activities for the year ended December 31, 2025 was $29.1 million compared to $22.1 million for the year ended December 31, 2024. The increase in cash used in operating activities resulted primarily from the increased net loss, partially offset by changes in operating assets and liabilities during the current year period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Investing Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Investing activities consist primarily of purchases and maturities of marketable securities. Net cash used in investing activities was $2.2 million for the year ended December 31, 2025 compared to net cash provided by investing activities of $8.6 million for the year ended December 31, 2024. This change resulted primarily from the investment of proceeds from our July 2025 private placement, partially offset by maturities of our marketable securities during the current year quarter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Financing Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net cash provided by financing activities was $43.9 million for the year ended December 31, 2025, consisting primarily of net proceeds from the sale of common shares in our July private placement and under our at-the-market offering program. For the year ended December 31, 2024, net cash provided by financing activities was $12.0 million, consisting primarily of net proceeds from the sale of common shares in our June 2024 private placement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">72</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Capital Requirements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Since our inception, we have incurred losses while advancing the development of our DM199 product candidate. We have not generated any revenues from product sales and do not expect to do so for at least two to three years. We do not know when or if we will generate any revenues from product sales or out-licensing of our DM199 product candidate or any future product candidate. We will not generate any revenue from product sales unless and until we obtain required regulatory approvals. We expect to continue to incur substantial operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments are sufficient to generate revenues to fund our continuing operations. We expect our operating losses to moderately increase as compared to recent prior periods as we continue the research, development and clinical studies of, and seek regulatory approval for, our DM199 product candidate, including, in particular, the expansion of our clinical development program into PE and the continuation and global expansion of our ReMEDy2 trial. In the long-term, subject to obtaining regulatory approval of our DM199 product candidate, or any other product candidate, and if we are unable to secure the assistance of, or out-license to, a strategic partner, we expect to incur significant commercialization expenses for product marketing, sales, manufacturing and distribution.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accordingly, and not withstanding the sale of common shares during 2025, in which we received net proceeds of approximately $43.3 million, we expect we will need substantial additional capital to complete our R&amp;D activities, including current and anticipated future clinical studies, regulatory activities, and otherwise develop our product candidate, DM199, or any future product candidate, to a point where the product candidate may be out-licensed or commercially sold. Although we are striving to achieve these plans, there is no assurance that these and other strategies will be achieved or that additional funding will be obtained on favorable terms or at all. We expect our rate of future negative quarterly cash flows will vary depending on our clinical activities and the timing of expenses incurred and will increase moderately relative to recent prior periods as we expand our PE clinical development program and continue and globally expand our ReMEDy2 trial. We expect our current cash resources to be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of the consolidated financial statements included in this report. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the Phase 2 PE trial, the potential further expansion of our current development programs and other factors on our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising additional capital are favorable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Historically, we have financed our operations primarily from the public and private sale of equity securities. We have received additional capital from the exercise of warrants and stock options, interest income on funds available for investment and government grants. Our most recent equity financing was our July 2025 private placement in which we issued and sold an aggregate of 8,606,425 common shares pursuant to a securities purchase agreement at a purchase price of $3.50 per share to accredited investors. As a result of the offering, we received net proceeds of $30.0 million, after deducting offering expenses. Additionally we sold 1,724,472 common shares under our at-the-market offering for net proceeds of $13.3 million. We do not have any existing credit facilities under which we could borrow funds. We may seek to raise additional funds through various sources, such as equity or debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if our clinical data is not positive or economic and market conditions deteriorate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted. Debt financing, if available, may involve agreements that include conversion discounts, pledging our intellectual property as collateral or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. The availability of financing will be affected by the status of our clinical trials; our clinical data and other results of scientific and clinical research; the ability to obtain regulatory approvals and other regulatory actions; market acceptance of our product candidates; the state of the capital markets generally with particular reference to pharmaceutical, biotechnology and medical companies; the status of strategic alliance agreements; and other relevant commercial considerations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">If adequate funding is not available when needed, we may be required to scale back our operations by taking actions that may include, among other things, implementing cost reduction strategies, such as reducing use of outside professional service providers, reducing the number of our employees or employee compensation, modifying or delaying the development of our DM199 product candidate; licensing to third parties the rights to commercialize our DM199 product candidate for PE, FGR, AIS or other indications that we would otherwise seek to pursue, or otherwise relinquishing significant rights to our technologies, future revenue streams, research programs or product candidates or granting licenses on terms that may not be favorable to us; and/or divesting assets or ceasing operations through a merger, sale, or liquidation of our Company.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">73</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Commitments and Contingencies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the normal course of business, we incur obligations to make future payments as we execute our business plan. These obligations may relate to preclinical or clinical studies, manufacturing or manufacturing process development and other related or supporting activities. Currently, these obligations include costs to be incurred with contract research organizations, central laboratory and pharmacy services, clinical study sites, home nursing services, various other vendors supporting the performance of our clinical trials and contract manufacturing and development organizations. The contracts we enter into with these vendors and the commitments within these contracts are subject to significant variability based upon the actual activities/services performed by each vendor. As a result, the ultimate amounts due may be materially different as these obligations are affected by, among other factors, the number and pace of clinical study sites activated, the number of countries in which clinical sites are activated, the number of participants enrolled, the amount of time to complete trial enrollment and the time required to finalize, analyze and report our clinical trial results. Clinical research agreements, including supporting vendors, are generally cancelable upon 60-90 days&#8217; notice, with our obligation limited to costs incurred up to that date, including any non-cancelable costs. Cancelation terms for product manufacturing and process development contracts vary and are generally dependent upon timelines for sourcing research materials and reserving laboratory time. As of December 31, 2025, we estimate that our outstanding commitments, including such cancellable contracts, are approximately $24.7 million, of which $19.3 million become due over the next 12 months and approximately $5.4 million become due in the next 12 months thereafter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2025, we had future operating lease obligation totaling approximately $225,000 over the remainder of the lease, of which approximately $101,000 is due over the next 12 months.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have entered into a license agreement with Catalent Pharma Solutions, LLC (Catalent) whereby we have licensed certain gene expression technology and we contract with Catalent for the manufacture of DM199. Under the terms of this license, certain milestone and royalty payments may become due under this agreement and are dependent upon, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain As of December 31, 2025, one milestone payment obligation remains which is due upon our first regulatory approval of DM199 for commercial sale. Following the launch of our first product, we will also incur a royalty obligation of less than 1% of net sales. The royalty term is indefinite but the license agreement may be canceled by us on 90 days&#8217; prior written notice. The license may not be terminated by Catalent unless we fail to make required milestone and royalty payments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 7A.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Quantitative and Qualitative Disclosures About Market Risk</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a smaller reporting company, we are not required to provide disclosure pursuant to this item.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">74</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<div>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Financial Statements and Supplementary Data</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:44%;">&#160;</td>
			<td style="vertical-align:middle;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="text-decoration: underline; ">Page</span></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Report of Independent Registered Public Accounting Firm (PCAOB Firm ID <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AuditorFirmId" id="c57">23</ix:nonNumeric>)</p>
			</td>
			<td style="vertical-align:middle;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">76</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Balance Sheets as of December 31, 2025 and 2024</p>
			</td>
			<td style="vertical-align:middle;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">77</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025 and 2024</p>
			</td>
			<td style="vertical-align:middle;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">78</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Shareholders&#8217;&#160;Equity for the years ended December 31, 2025 and 2024</p>
			</td>
			<td style="vertical-align:middle;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">79</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:middle;width:44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024</p>
			</td>
			<td style="vertical-align:middle;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">80</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:middle;width:44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes to Consolidated Financial Statements</p>
			</td>
			<td style="vertical-align:middle;width:2.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">81-95</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">75</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the Shareholders and Board of Directors of DiaMedica Therapeutics Inc.:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Opinion on the Financial Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have audited the accompanying consolidated balance sheets of DiaMedica Therapeutics Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Basis for Opinion</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Critical Audit Matters</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AuditorName" id="c58">Baker Tilly US, LLP</ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AuditorLocation" id="c59">Minneapolis, Minnesota</ix:nonNumeric></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have served as the Company&#8217;s auditor since 2018.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">76</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</div>

<div>&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Balance Sheets</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except share amounts)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>ASSETS</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current assets:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c64" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,647</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c65" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,025</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c66" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:MarketableSecuritiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,243</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c67" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:MarketableSecuritiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,122</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c68" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">481</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c69" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">227</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Amounts receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c70" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">258</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c71" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">236</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c72" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">60,629</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">44,610</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-current assets:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred offering costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c75" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredCosts" scale="3" format="ixt:num-dot-decimal" decimals="-5">400</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c76" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredCosts" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease right-of-use asset</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c77" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">197</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c78" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">279</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">145</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c80" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">148</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deposits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DepositsAssetsNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DepositsAssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,308</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total non-current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">742</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c84" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,735</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c85" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">61,371</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c86" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,345</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>LIABILITIES AND EQUITY</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Current liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c88" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,475</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c89" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">940</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c90" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,545</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c91" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,347</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c92" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">101</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c93" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">90</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Finance lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c94" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">11</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c95" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">13</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c96" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,132</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c97" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">5,390</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-current liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease obligation, non-current</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c99" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">124</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c100" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">225</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Finance lease obligation, non-current</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c101" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c102" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total non-current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c103" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">128</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c104" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">237</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commitments and contingencies (Note 11)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<ix:nonFraction id="c105" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<ix:nonFraction id="c106" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Shareholders&#8217; equity:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Common shares, <span style="-sec-ix-hidden:c108"><span style="-sec-ix-hidden:c109">no</span></span> par value; <span style="-sec-ix-hidden:c110"><span style="-sec-ix-hidden:c111">unlimited</span></span> authorized; <ix:nonFraction id="c112" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c113" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">53,742,370</ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="c114" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c115" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,818,660</ix:nonFraction></ix:nonFraction> shares issued and outstanding, as of December 31, 2025 and 2024, respectively</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c116">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c117">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Paid-in capital</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c118" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">228,829</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c119" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">180,697</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accumulated other comprehensive income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c120" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-4">50</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c121" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accumulated deficit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c122" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">172,768</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c123" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">140,002</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;">Total shareholders&#8217; equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c124" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">56,111</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,718</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total liabilities and shareholders&#8217; equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c126" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">61,371</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c127" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">46,345</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;">See accompanying notes to consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">77</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Statements of Operations and Comprehensive Loss</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except share and per share amounts)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c132" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,614</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c133" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">19,057</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,783</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c135" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,624</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total operating expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c136" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">34,397</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c137" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">26,681</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c138" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">34,397</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c139" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,681</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other income, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c140" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,659</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c141" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,267</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total other income, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c142" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,659</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c143" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,267</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c144" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,738</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c145" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,414</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c146" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">28</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c147" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-4">30</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c148" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,766</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c149" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,444</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other comprehensive income</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Unrealized gain on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c151" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">27</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c152" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Comprehensive loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c153" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,739</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c154" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,427</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted net loss per share</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c155" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.70</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c156" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.60</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Weighted average shares outstanding &#8211; basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c157" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">46,980,777</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c158" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,404,681</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">78</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Statements of Shareholders</b>&#8217;<b> Equity</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands, except share amounts)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Paid-In </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Capital</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Comprehensive </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Income</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Deficit</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shareholders&#8217; </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Equity</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balances at December 31, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c162" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">37,958,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c163" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">166,609</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c164" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">6</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c165" contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">115,558</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c166" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">51,057</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares under Private Placement, net of offering costs of $<ix:nonFraction id="c167" contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c168" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,720,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c169" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,747</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c170" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c171" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c172" contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,747</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares upon the exercise of stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c173" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">117,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c174" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">256</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c175" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c176" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c177" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">256</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares upon the vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c178" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">23,660</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c179" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c180" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c181" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c182" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Share-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c184" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,085</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c185" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c186" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c187" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,085</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Unrealized gain on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c189" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c190" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c191" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c192" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c194" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c195" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c196" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,444</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c197" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,444</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balances at December 31, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c198" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,818,660</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c199" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">180,697</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c200" contextRef="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">23</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c201" contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">140,002</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c202" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,718</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares under Private Placement, net of offering costs of $<ix:nonFraction id="c203" contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c204" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,606,425</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c205" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">29,967</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c206" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c207" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c208" contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">29,967</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Sale of common shares, net of offering costs of $<ix:nonFraction id="c209" contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c210" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,724,472</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c211" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,315</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c212" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c213" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c214" contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">13,315</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares upon the exercise of stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c215" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">415,253</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c216" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,004</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c217" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c218" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c219" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,004</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares in settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c220" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" scale="0" format="ixt:num-dot-decimal" decimals="INF">142,345</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Issuance of common shares upon the vesting and settlement of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c225" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">35,215</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c226" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c227" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c228" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c229" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Share-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c231" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,846</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c232" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c233" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c234" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,846</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Unrealized gain on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c236" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c237" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">27</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c238" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c239" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:num-dot-decimal" decimals="-3">27</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c241" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c242" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c243" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,766</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c244" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,766</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balances at December 31, 2025</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c245" contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">53,742,370</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c246" contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">228,829</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c247" contextRef="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">50</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c248" contextRef="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">172,768</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c249" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">56,111</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">79</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Statements of Cash Flows</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from operating activities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c254" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,766</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c255" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,444</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c257" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,846</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c258" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,085</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Amortization of discounts on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c259" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" format="ixt:num-dot-decimal" decimals="-3">942</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c260" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,343</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Non-cash lease expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c261" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="dmac:NoncashLeaseExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">82</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c262" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="dmac:NoncashLeaseExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">75</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Depreciation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c263" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">43</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c264" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">39</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Changes in operating assets and liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Prepaid expenses and other assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c266" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">254</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c267" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">184</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Amounts receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c268" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:num-dot-decimal" decimals="-3">22</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c269" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">133</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Deposits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c270" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,308</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c271" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,308</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Accounts payable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c272" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">535</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c273" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">14</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Accrued liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c274" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">892</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c275" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,489</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash used in operating activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c276" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">29,062</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c277" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">22,076</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from investing activities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Purchase of marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c279" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">59,278</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c280" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">50,411</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Maturities and sales of marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c281" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">57,126</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c282" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-6">59,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Purchase of property and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c283" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-4">40</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c284" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">25</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash provided by (used in) investing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c285" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,192</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c286" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,564</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from financing activities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceeds from issuance of common shares, net of offering costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c288" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">43,282</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c289" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,747</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceeds from the exercise of stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c290" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,004</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c291" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">256</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Principal payments on finance lease obligations</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c292" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" format="ixt:num-dot-decimal" decimals="-4">10</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c293" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" format="ixt:num-dot-decimal" decimals="-3">9</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred financing costs, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c294" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-5">400</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c295" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Net cash provided by financing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c296" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">43,876</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c297" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,994</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net increase (decrease) in cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c298" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,622</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c299" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,518</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at beginning of period</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c300" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,025</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c301" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,543</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at end of period</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c302" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">15,647</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c303" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,025</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Supplemental disclosure of cash flow information:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Cash paid for income taxes</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c305" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxesPaid" scale="3" format="ixt:num-dot-decimal" decimals="-3">28</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c306" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxesPaid" scale="3" format="ixt:num-dot-decimal" decimals="-3">26</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Assets acquired under financing lease</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c307" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c308" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-4">30</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">80</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Notes to Consolidated Financial Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="c309" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>1.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Business</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica Therapeutics Inc. and its wholly owned subsidiaries, DiaMedica USA Inc. and DiaMedica Australia Pty Ltd. (collectively, we, us, our, DiaMedica and the Company), is a clinical stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS). DiaMedica&#8217;s lead product candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein, an established therapeutic modality in Asia for the treatment of preeclampsia, acute ischemic stroke and other vascular diseases. Our common shares are publicly traded on The Nasdaq Capital Market under the symbol &#8220;DMAC.&#8221;</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dmac:RisksAndUncertaintiesTextBlock" id="c312" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Risks and Uncertainties</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the United States Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union, and comparable agencies in other countries. We are in the clinical stage of development of our lead product candidate, DM199, for the treatment of PE and AIS. We have not completed the development of any product candidate and do not generate any revenues from the commercial sale of any product candidate. Our lead product candidate, DM199, requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for at least three to four years, if at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">With respect to our PE clinical program, a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE is currently being conducted at the Tygerberg Hospital in Cape Town, South Africa. This Phase 2 study consists of three studies in PE (Part 1a, dose-escalation; Part 1b, dose-expansion; and Part 2, expectant management) and a fourth study in fetal growth restriction (FGR, Part 3, expectant management). Part 1a topline study results are intended to identify a suitable dose for Parts 1b, 2, and 3. Up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject in Part 1a was enrolled in the fourth quarter of 2024 and interim results from Part 1a of the study were released in July 2025. The interim results (N=28 subjects) demonstrated that DM199 appears safe and well-tolerated with clinically-relevant pharmacodynamic activity with no evidence of placental transfer. Additionally, subjects exhibited rapid, statistically significant reductions in blood pressure with duration of effect that was sustained up to 24 hours post-infusion compared to pre-treatment baseline. Preparations are underway to initiate Part 1b where up to 30 subjects with PE and expected delivery within 72 hours will be treated with a dose regimen identified from Part 1a.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">With respect to our AIS clinical program, we are currently conducting a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial of DM199 for the treatment of AIS, (the ReMEDy2 trial). Our ReMEDy2 trial is intended to enroll approximately 300 participants at up to 100 sites globally. The adaptive design component includes an interim analysis by our independent data safety monitoring board to be conducted after the first 200 participants have completed the trial. Based on the results of the interim analysis, the study may then be stopped for futility or the final sample size will be determined, ranging between 300 and 728 patients, according to a pre-determined statistical plan. We have experienced and continue to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring, supporting vendor management and overall program management. We are currently conducting our ReMEDy2 trial in the United States and in the countries of Canada and Georgia. We are in the process of preparing regulatory filings and identifying and engaging study sites in an additional seven European countries and, on August 28, 2025, received approval for the conduct of this study in the United Kingdom. We continue to work closely with our contract research organizations and other advisors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to enhance site activations and enrollment in our ReMEDy2 trial; however, no assurances can be provided as to the success of these actions and if or when these issues will resolve. Failure to resolve these issues may result in further delays in our ReMEDy2 trial and increase the difficulty in forecasting enrollment. We currently estimate that the interim analysis will be completed in the second half of 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">81</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our future success is dependent upon the success of our development efforts, our ability to demonstrate clinical progress for our DM199 product candidate in the United States or other markets, our ability, or the ability of any future partner, to obtain required governmental approvals of our product candidate, our ability to license or market and sell our DM199 product candidate and our ability to obtain additional financing to fund these efforts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2025, we have incurred losses of $<ix:nonFraction id="c315" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">172.8</ix:nonFraction> million since our inception in 2000. For the year ended December 31, 2025, we incurred a net loss of $<ix:nonFraction id="c316" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">32.8</ix:nonFraction> million and negative cash flows from operating activities of $<ix:nonFraction id="c317" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">29.1</ix:nonFraction> million. We expect to continue to incur substantial operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical study of, and to seek regulatory approval for, our DM199 product candidate. As of December 31, 2025, we had combined cash, cash equivalents and marketable securities of $<ix:nonFraction id="c318" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" format="ixt:num-dot-decimal" decimals="-5">59.9</ix:nonFraction> million, working capital of $<ix:nonFraction id="c319" contextRef="i_2025-12-31" unitRef="USD" name="dmac:WorkingCapital" scale="6" format="ixt:num-dot-decimal" decimals="-5">55.5</ix:nonFraction> million, and shareholders&#8217; equity of $<ix:nonFraction id="c320" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">56.1</ix:nonFraction> million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our principal source of cash has been net proceeds from the issuance of equity securities. Although we have previously been successful in obtaining financing through equity securities offerings, there is no assurance that we will be able to do so in the future. This is particularly true if our clinical data are not positive or if economic and market conditions deteriorate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect that we will need substantial additional capital to further our research and development activities and complete the required clinical studies, regulatory activities and manufacturing development for our product candidate, DM199, or any future product candidates, to a point where they may be licensed or commercially sold. We expect our current cash, cash equivalents and marketable securities to be sufficient to fund our planned operations for at least the next 12 months from the date of issuance of these consolidated financial statements. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the rate of site activation and participant enrollment in the study; the Phase 2 PE trial; the potential expansion of our current development programs; the effects of ongoing site staffing shortages; and other factors on our clinical trials and our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c321" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>3.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Summary of Significant Accounting Policies</b>&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ConsolidationPolicyTextBlock" id="c840724690807573" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Basis of consolidation</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements include the assets, liabilities and expenses of DiaMedica Therapeutics Inc., and our wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dmac:FunctionalCurrencyPolicyTextBlock" id="c1422491984920406" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Functional currency</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The United States dollar is our functional currency as it represents the economic effects of the underlying transactions, events and conditions and various other factors, including the currency of historical and future expenditures and the currency in which funds from financing activities are mostly generated by the Company. A change in the functional currency occurs only when there is a material change in the underlying transactions, events and condition. A change in functional currency could result in material differences in the amounts recorded in the consolidated statements of operations and comprehensive loss for foreign exchange gains and losses. All amounts in the accompanying consolidated financial statements are in U.S. dollars unless otherwise indicated.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c8868404978462" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Segments</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company operates in a <span style="-sec-ix-hidden:c324">single</span> segment focusing on developing potentially transformative treatments for severe ischemic diseases. Consistent with the Company&#8217;s operational structure, its chief operating decision maker manages and allocates resources for the Company at a consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting. Substantially all assets of the Company are held in the United States.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">82</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:UseOfEstimates" id="c280241568477491" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Use of estimates</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c1115645225243019" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Cash and cash equivalents</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of the Company&#8217;s cash equivalents approximates fair value due to the short maturity of the investments.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:MarketableSecuritiesPolicy" id="c1571481191849694" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Marketable securities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third-party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the consolidated statements of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive income or loss, which is a separate component of shareholders&#8217; equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no material other-than-temporary unrealized losses as of December 31, 2025 or 2024.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ConcentrationRiskCreditRisk" id="c1550197030631463" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Concentration of credit risk</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with two financial institutions. These balances generally exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c940050838047353" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Fair value measurements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The hierarchy is broken down into three levels defined as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"><i>Level 1 Inputs</i> &#8212; quoted prices in active markets for identical assets and liabilities</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"><i>Level 2 Inputs</i> &#8212; observable inputs other than quoted prices in active markets for identical assets and liabilities</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"><i>Level 3 Inputs</i> &#8212; unobservable inputs</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">83</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2025, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled &#8220;<i>Marketable Securities</i>&#8221; for additional information.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="c629656696643157" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Long-lived assets</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at purchased cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:c325">three</span> to <span style="-sec-ix-hidden:c326">ten</span> years for office equipment and <span style="-sec-ix-hidden:c327">four</span> years for computer equipment. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss. Repairs and maintenance are expensed as incurred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets may not be recoverable. If the expected future undiscounted cash flows are less than the carrying amount of the asset, an impairment loss is recognized at that time. Measurement of impairment may be based upon appraisal, market value of similar assets or discounted cash flows.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c1255766035085671" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Leases</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We determine if an arrangement is a lease at inception. We have made a policy election to not separate lease and non-lease components for our real estate leases to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. Our facility lease includes variable non-lease components, such as common-area maintenance costs. Our operating lease is included in operating lease right-of-use (&#8220;ROU&#8221;) asset and operating lease obligations on our consolidated balance sheets. Our operating lease ROU asset represents our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. The operating lease ROU asset and operating lease obligation are recognized based on the present value of lease payments over the lease term. The lease does not provide an implicit rate and, due to the lack of a commercially salable product, we are generally considered unable to obtain commercial credit. Therefore, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases, we estimated our incremental borrowing rate. The operating lease ROU asset excludes lease incentives. Our lease includes an option to extend or terminate the lease; lease terms are only adjusted for these options when it is reasonably certain that we will exercise such options to extend or terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Assumptions made by us at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c583541001068176" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Research and development costs</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development expenses consist primarily of fees paid to external service providers such as contract research organizations; clinical support services; clinical development including clinical site costs; outside nursing services; and laboratory testing. R&amp;D costs also include non-clinical testing; fees paid to our contract manufacturing and development organizations and outside laboratories for development of DM199 and related manufacturing processes; costs for production runs of DM199; consulting resources with specialized expertise related to the execution of our development plan for DM199; and personnel costs, including salaries, benefits, non-cash share-based compensation expense; and other personnel costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We charge research and development costs to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from various contract research organizations. Upfront costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials are recorded or accrued based on actual invoices received and estimates of work completed to date by clinical trial sites, contract research organizations and outside vendors that assist with management and performance of the trials, and those that manufacture the investigational product. While we utilize electronic data capture systems to facilitate the transmission and capture of clinical trial activity, such information is often incomplete or delayed. Therefore, we are required to estimate the levels of performance under each significant contract, including, among other things, the extent of participant enrollment, the extent of supporting services performed and other activities through communications with the clinical trial sites, CROs and supporting vendors and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual work performed at each clinical trial site and by each CRO or supporting vendor. Additionally, actual costs may be charged to us and are recognized as the tasks are completed by the clinical trial site. Accrued R&amp;D costs may be subject to revisions as clinical trials, non-clinical research and DM199 development programs progress and any revisions are recorded in the period in which the facts that give rise to the revisions become known.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">84</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dmac:PatentCostsPolicyTextBlock" id="c1271729201649828" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Patent costs</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Costs associated with applying for, prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, the resulting probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in general and administrative costs and were $<ix:nonFraction id="c328" contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="dmac:PatentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">377,000</ix:nonFraction> and $<ix:nonFraction id="c329" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="dmac:PatentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">251,000</ix:nonFraction> for the years ended December 31, 2025 and 2024, respectively.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="c365378272781826" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Share-based compensation</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fair value of option awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our share price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon United States Government bond rates appropriate for the expected term of each award. Expected volatility rates are based on the historical volatility over a period equal to the expected term of the option. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c1589218084476396" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Income taxes</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted rates for each of the jurisdictions in which the Company operates, and expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of December 31, 2025 and 2024. See Note 16, titled &#8220;<i>Income Taxes</i>&#8221; for additional information. The Company&#8217;s policy is to classify interest and penalties related to income taxes as income tax expense.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c1151118916321710" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Net loss per share</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to the exclusion of common share equivalents as their effect would be anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="c358" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c361" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,766</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c362" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,444</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding&#8212;basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c363" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">46,980,777</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c364" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,404,681</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted net loss per share</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c365" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.70</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c366" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.60</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">85</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c367" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c370" contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,864,854</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c371" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,692,438</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c372" contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-CommonStockDeferredStockUnitsSettlementMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">174,515</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c373" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-CommonStockDeferredStockUnitsSettlementMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">284,886</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c374" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,039,369</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c375" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,977,324</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c872651020400267" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Recently adopted accounting pronouncements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). ASU 2023-09 is intended to improve income tax disclosures primarily through enhanced disclosure of income tax rate reconciliation items, and disaggregation of income (loss) from continuing operations, income tax expense (benefit) and income taxes paid, net disclosures by federal, state and foreign jurisdictions, among others. ASU 2023-09 is effective for annual reporting periods beginning after December&#160;15, 2024, and early adoption is permitted. Adoption of ASU 2023-09 did not have a material effect on the Company's consolidated financial statements and disclosures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Recently issued accounting pronouncements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03), which is intended to improve disclosures about a public business entity&#8217;s expenses by requiring disaggregated disclosure, in the notes to the consolidated financial statements, of certain categories of expenses included in the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 on its consolidated financial statement disclosures.</p>
</ix:nonNumeric></ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="c376" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>4.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Marketable Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" id="A69AF074-EB91-46DA-A17A-3836E16F290C" escape="true" continuedAt="c98BD0764-9841-42C1-AEA6-FAF353436B7A">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025 </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Using Inputs Considered as</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper and corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c408" contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,822</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c409">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c410" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,822</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c411">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Government securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c412" contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">39,421</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c413">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c414" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">39,421</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c415">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c416" contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,243</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c417">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c418" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">44,243</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c419">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:continuation id="c98BD0764-9841-42C1-AEA6-FAF353436B7A">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Using Inputs Considered as</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper and corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c423" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">28,291</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c424">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c425" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">28,291</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c426">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Government securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c427" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,831</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c428">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c429" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,831</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c430">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c431" contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,122</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c432">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c433" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,122</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c434">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:continuation>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued interest receivable on available-for-sale securities was $<ix:nonFraction id="c403" contextRef="i_2025-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" unitRef="USD" name="us-gaap:InterestReceivable" scale="0" format="ixt:num-dot-decimal" decimals="0">250,000</ix:nonFraction> and $<ix:nonFraction id="c404" contextRef="i_2024-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" unitRef="USD" name="us-gaap:InterestReceivable" scale="0" format="ixt:num-dot-decimal" decimals="0">235,000</ix:nonFraction> for the years ended December 31, 2025 and 2024, respectively, and is included in amounts receivable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the year ended December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">86</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the Company&#8217;s investment policy, purchases of marketable securities are limited to investment grade governmental and corporate obligations and bank certificates of deposit with a primary objective of principal preservation. Maturities of individual securities are less than one year, and the amortized cost of all securities approximated fair value as of December 31, 2025 and 2024.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="c435" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>5.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Amounts Receivable</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amounts receivable consisted of the following (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="c444" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued interest receivable on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c447" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">250</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c448" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">235</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c449" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OtherReceivablesNetCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c450" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherReceivablesNetCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total amounts receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c451" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">258</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c452" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">236</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:OtherAssetsDisclosureTextBlock" id="c453" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>6.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Prepaid Expenses and Other Assets</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prepaid expenses and other assets consist primarily of insurance premiums, yearly subscriptions for services and deposits expected to be recovered during the next twelve months.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dmac:DepositAssetsTextBlock" id="c456" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>7.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Deposits</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We periodically advance funds to vendors engaged to support the performance of our clinical trials and related supporting activities. The funds advanced are held, interest free, for varying periods of time and may be recovered by the Company through partial reductions of ongoing invoices, application against final study/project invoices or refunded upon completion of services to be provided. Deposits are classified as current or non-current based upon their expected recovery time.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c459" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>8.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Property and Equipment</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment consisted of the following (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c478" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c481" contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">151</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c482" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">118</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c483" contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">128</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c484" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">128</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c485" contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">16</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c486" contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">16</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c487" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">295</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c488" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">262</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less accumulated depreciation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c489" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-4">150</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c490" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">114</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c491" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">145</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c492" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">148</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation expense was $<ix:nonFraction id="c474" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="0">43,000</ix:nonFraction> and $<ix:nonFraction id="c475" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="0">39,000</ix:nonFraction> for the years ended December 31, 2025 and 2024, respectively. During 2025 and 2024, we disposed of $<ix:nonFraction id="c476" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" format="ixt:num-dot-decimal" decimals="0">7,000</ix:nonFraction> and $<ix:nonFraction id="c477" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" format="ixt:num-dot-decimal" decimals="0">25,000</ix:nonFraction> of equipment, respectively, all of which was fully depreciated.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="c493" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9.&#160; &#160; &#160; &#160; &#160; &#160;<b>Accrued Liabilities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued liabilities consisted of the following (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c508" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c511" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,380</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c512" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,060</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical trial costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c513" contextRef="i_2025-12-31" unitRef="USD" name="dmac:AccruedClinicalStudyCostsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,291</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c514" contextRef="i_2024-12-31" unitRef="USD" name="dmac:AccruedClinicalStudyCostsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,277</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development services</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c515" contextRef="i_2025-12-31" unitRef="USD" name="dmac:AccruedResearchAndProfessionalFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">749</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c516" contextRef="i_2024-12-31" unitRef="USD" name="dmac:AccruedResearchAndProfessionalFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">888</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional services fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c517" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">120</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c518" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">112</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c519" contextRef="i_2025-12-31" unitRef="USD" name="dmac:AccruedTaxesAndOtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">5</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c520" contextRef="i_2024-12-31" unitRef="USD" name="dmac:AccruedTaxesAndOtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">10</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total accrued liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c521" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,545</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c522" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,347</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">87</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></ix:exclude>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:LesseeOperatingLeasesTextBlock" id="c523" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>10.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Operating Lease</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In June 2022, we entered into an agreement to lease approximately <ix:nonFraction id="c526" contextRef="i_2022-06-30_LeaseContractualTermAxis-MinneapolisMNMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,000</ix:nonFraction> square feet of office space in Minneapolis, Minnesota. The lease commencement date was September 1, 2022, has a term of <ix:nonNumeric contextRef="i_2022-06-30_LeaseContractualTermAxis-MinneapolisMNMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c527" format="ixt-sec:durmonth">65</ix:nonNumeric> months expiring on January 31, 2028, and included an incentive of five months of full rent abatement. This incentive is subject to repayment if we default in performance of any material obligations under the lease prior to the 48<sup style="vertical-align:top;line-height:120%;">th</sup> month of the lease and the landlord terminates the lease. Upon lease commencement, the Company recognized an operating lease right-of-use asset and a corresponding operating lease obligation of $<ix:nonFraction id="c528" contextRef="i_2022-06-30_LeaseContractualTermAxis-MinneapolisMNMember" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:num-dot-decimal" decimals="0"><ix:nonFraction id="c529" contextRef="i_2022-06-30_LeaseContractualTermAxis-MinneapolisMNMember" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="0" format="ixt:num-dot-decimal" decimals="0">446,000</ix:nonFraction></ix:nonFraction>, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating lease costs were $<ix:nonFraction id="c530" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="0"><ix:nonFraction id="c531" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="0">104,000</ix:nonFraction></ix:nonFraction> for each of the years ended December 31, 2025 and 2024, respectively. Our variable lease costs were $<ix:nonFraction id="c532" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:VariableLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="0">91,000</ix:nonFraction> and $<ix:nonFraction id="c533" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:VariableLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="0">89,000</ix:nonFraction> for the years ended December 31, 2025 and 2024, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Maturities of our operating lease obligation are as follows as of December 31, 2025 (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="c542" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c545" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" format="ixt:num-dot-decimal" decimals="-3">116</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c546" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">119</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c547" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" format="ixt:num-dot-decimal" decimals="-4">10</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c548" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" format="ixt:num-dot-decimal" decimals="-3">245</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Less interest portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c549" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" format="ixt:num-dot-decimal" decimals="-4">20</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Present value of lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c550" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:num-dot-decimal" decimals="-3">225</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Less current portion of operating lease</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c551" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">101</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Operating lease obligation, non-current</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c552" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">124</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c553" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Commitments and Contingencies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Clinical trials and product development</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the normal course of business, we incur obligations to make future payments as we execute our business plan. These obligations may relate to preclinical or clinical studies, manufacturing or manufacturing process development and other related or supporting activities. Currently, these obligations include costs to be incurred with contract research organizations, central laboratory and pharmacy services, clinical study sites, home nursing services, various other vendors supporting the performance of our clinical trials and contract manufacturing and development organizations. The contracts we enter into with these vendors and the commitments within these contracts are subject to significant variability based upon the actual activities/services performed by each vendor. As a result, the ultimate amounts due may be materially different as these obligations are affected by, among other factors, the number and pace of clinical study sites activated, the number of countries in which clinical sites are activated, the number of participants enrolled, the amount of time to complete trial enrollment and the time required to finalize, analyze and report our clinical trial results. Clinical research agreements, including supporting vendors, are generally cancelable upon 60-90 days&#8217; notice, with our obligation limited to costs incurred up to that date, including any non-cancelable costs. Cancelation terms for product manufacturing and process development contracts vary and are generally dependent upon timelines for sourcing research materials and reserving laboratory time. As of December 31, 2025, we estimate that our outstanding commitments, including such cancellable contracts, are approximately $<ix:nonFraction id="c556" contextRef="i_2025-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember" unitRef="USD" name="us-gaap:ContractualObligation" scale="6" format="ixt:num-dot-decimal" decimals="-5">24.7</ix:nonFraction> million of which $<ix:nonFraction id="c557" contextRef="i_2025-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember" unitRef="USD" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="6" format="ixt:num-dot-decimal" decimals="-5">19.3</ix:nonFraction> million become due over the next 12 months and approximately $<ix:nonFraction id="c558" contextRef="i_2025-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember" unitRef="USD" name="us-gaap:ContractualObligationDueInSecondYear" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.4</ix:nonFraction> million become due in the next 12 months thereafter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Technology license</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have entered into an exclusive license agreement with Catalent Pharma Solutions, LLC (Catalent) whereby we have licensed certain gene expression technology and we contract with Catalent for the manufacture of DM199. Under the terms of this license, certain milestone and royalty payments may become due under this agreement and are dependent upon, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain. As of December 31, 2025, one milestone payment obligation remains which is due upon our first regulatory approval of DM199 for commercial sale. Following the launch of our first product, we will also incur a royalty obligation of less than 1% of net sales. The royalty term is indefinite, but the license agreement may be canceled by us on 90 days&#8217; prior written notice. The license may not be terminated by Catalent unless we fail to make required milestone and royalty payments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">88</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Indemnification of directors and officers</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company, as permitted under laws of the BCBCA and in accordance with the Company&#8217;s Articles and indemnification agreements, will indemnify and advance expenses to its directors and officers to the fullest extent permitted by law and may choose to indemnify other employees or agents from time to time. The Company has secured insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to the Company. As of December 31, 2025, there was no pending litigation or proceeding involving any director or officer of the Company as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. Insofar as indemnification for liabilities arising under the United States Securities Act of 1933, as amended (Securities Act) may be permitted to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the United States Securities and Exchange Commission (SEC), such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company had <span style="-sec-ix-hidden:c559"><span style="-sec-ix-hidden:c560">not</span></span> recorded any liabilities for these obligations as of December 31, 2025 or 2024.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c561" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>12.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Shareholders&#8217; Equity</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Authorized capital stock</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica has authorized share capital of an unlimited number of common voting shares, and the shares do not have a stated par value. Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company&#8217;s annual general meeting and any extraordinary or special general meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Equity issued during the year ended December 31, 2025</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 21, 2025, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate <ix:nonFraction id="c564" contextRef="d_2025-07-21_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,606,425</ix:nonFraction> common shares at a purchase price of $<ix:nonFraction id="c565" contextRef="i_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.50</ix:nonFraction> per share in a private placement. As a result of the offering, which closed on July 23, 2025, we received gross proceeds of $<ix:nonFraction id="c566" contextRef="d_2025-07-21_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">30.1</ix:nonFraction> million, which resulted in net proceeds to us of approximately $<ix:nonFraction id="c567" contextRef="d_2025-07-21_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="dmac:ProceedsFromIssuanceOfCommonStockNet" scale="6" format="ixt:num-dot-decimal" decimals="-7">30.0</ix:nonFraction> million, after deducting the offering expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the July 2025 private placement, we entered into a registration rights agreement (2025 Registration Rights Agreement) with the investors pursuant to which we agreed to file with the SEC a registration statement registering the resale of the shares sold in the July 2025 private placement (2025 Resale Registration Statement). The 2025 Resale Registration Statement was filed with the SEC on August 1, 2025 and declared effective by the SEC on August 8, 2025. Under the terms of the 2025 Registration Rights Agreement, we agreed to keep the 2025 Resale Registration Statement effective at all times until the shares are no longer considered &#8220;Registrable Securities&#8221; under the 2025 Registration Rights Agreement and if we fail to keep the 2025 Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to <ix:nonFraction id="c568" contextRef="i_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Pure" name="dmac:LiquidatedDamagePercentageOfInvestedCapitalMaximum" scale="-2" format="ixt:num-dot-decimal" decimals="1">10</ix:nonFraction>% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the 2025 Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the 2025 Registration Rights Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On August 12, 2025, we entered into a Sales Agreement (the 2025 Sales Agreement) with TD Securities (USA) LLC (TD Cowen) under which the Company may, from time to time, sell common shares having an aggregate offering price of up to $<ix:nonFraction id="c569" contextRef="i_2025-08-12_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="dmac:EquityIssuanceMaximumAggregateOfferingPrice" scale="6" format="ixt:num-dot-decimal" decimals="-8">100</ix:nonFraction>&#160;million, through an &#8220;at-the-market&#8221; offering program (ATM Offering). TD Cowen receives a customary commission from the Company for any common shares sold under the 2025 Sales Agreement. Any shares offered and sold in the ATM Offering are to be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 424(b)(2), the prospectus contained therein, and one or more prospectus supplements. As of December 31, 2025, the remaining availability under this ATM was $<ix:nonFraction id="c570" contextRef="i_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="dmac:EquityIssuanceRemainingAvailableOfferingPrice" scale="6" format="ixt:num-dot-decimal" decimals="-5">86.2</ix:nonFraction> million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended December 31, 2025, <ix:nonFraction id="c571" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" scale="0" format="ixt:num-dot-decimal" decimals="INF">142,345</ix:nonFraction> common shares were issued upon settlement of deferred share units, <ix:nonFraction id="c572" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">35,215</ix:nonFraction> common shares were issued upon the vesting and settlement of restricted stock units, <ix:nonFraction id="c573" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">415,253</ix:nonFraction> common shares were issued upon the exercise of stock options for gross proceeds of $<ix:nonFraction id="c574" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million and <ix:nonFraction id="c575" contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,724,472</ix:nonFraction> common shares were issued and sold under our ATM Offering program for aggregate gross proceeds of $<ix:nonFraction id="c576" contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">13.8</ix:nonFraction> million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Equity issued during the year ended December 31, 2024</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On June 25, 2024, we entered into securities purchase agreements with accredited investors, pursuant to which we issued and sold an aggregate <ix:nonFraction id="c577" contextRef="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,720,000</ix:nonFraction> common shares at a purchase price of $<ix:nonFraction id="c578" contextRef="i_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.50</ix:nonFraction> per share in a private placement. As a result of the offering, which closed on June 28, 2024, we received gross proceeds of $<ix:nonFraction id="c579" contextRef="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">11.8</ix:nonFraction> million, which resulted in net proceeds to us of approximately $<ix:nonFraction id="c580" contextRef="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="dmac:ProceedsFromIssuanceOfCommonStockNet" scale="6" format="ixt:num-dot-decimal" decimals="-5">11.7</ix:nonFraction> million, after deducting the offering expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">89</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the June 2024 private placement, we entered into a registration rights agreement (2024 Registration Rights Agreement) with the investors pursuant to which we agreed to file with the SEC a registration statement registering the resale of the shares sold in the June 2024 private placement. This registration statement was filed with the SEC on July 10, 2024 and declared effective by the SEC on July 18, 2024. Under the terms of the 2024 Registration Rights Agreement, we agreed to keep the registration statement effective at all times until the shares are no longer considered &#8220;Registrable Securities&#8221; under the 2024 Registration Rights Agreement and if we fail to keep the registration statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to <ix:nonFraction id="c581" contextRef="i_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Pure" name="dmac:LiquidatedDamagePercentageOfInvestedCapitalMaximum" scale="-2" format="ixt:num-dot-decimal" decimals="1">10</ix:nonFraction>% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the registration statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the 2024 Registration Rights Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended December 31, 2024, <ix:nonFraction id="c582" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:num-dot-decimal" decimals="INF">23,660</ix:nonFraction> common shares were issued upon the vesting and settlement of restricted stock units and <ix:nonFraction id="c583" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">117,000</ix:nonFraction> common shares were issued upon the exercise of stock options for gross proceeds of $<ix:nonFraction id="c584" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="0">256,000</ix:nonFraction>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Shares reserved</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common shares reserved for future issuance are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dmac:CommonStockReservedForFutureIssuanceTableTextBlock" id="c590" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c593" contextRef="i_2025-12-31_AwardTypeAxis-StockOptionsOutstandingMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,864,854</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c594" contextRef="i_2025-12-31_AwardTypeAxis-DeferredShareUnitsMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">174,515</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c595" contextRef="i_2025-12-31_AwardTypeAxis-The2019OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">948,666</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Shares available for grant under the 2021 Employment Inducement Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c596" contextRef="i_2025-12-31_AwardTypeAxis-The2021EmploymentInducementIncentivePlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">653,125</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c597" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,641,160</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c598" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>13.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Share-Based Compensation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Amended and Restated 2019 Omnibus Incentive Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan (as amended from time to time, the 2019 Plan) was adopted by the Board of Directors (Board) on March 14, 2019 and approved by our shareholders at our 2019 Annual General Meeting of Shareholders held on May 22, 2019. Subsequent amendments to the plan, comprised principally of increasing the authorized shares under the plan, were approved by our shareholders at our 2022 and 2024 Annual General Meetings of Shareholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The 2019 Plan permits the Board, or a committee or subcommittee thereof, to grant to the Company&#8217;s eligible employees, non-employee directors and certain consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units (RSUs), deferred stock units (DSUs), performance awards, non-employee director awards and other share-based awards. We grant options to purchase common shares under the 2019 Plan at no less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of <span style="-sec-ix-hidden:c601">ten</span> years and generally vest over <span style="-sec-ix-hidden:c602">one</span> to <span style="-sec-ix-hidden:c603">four</span> years. Options granted to non-employees have a maximum term of <span style="-sec-ix-hidden:c604">five</span> years and generally vest over <span style="-sec-ix-hidden:c605">one</span> year. Subject to adjustment as provided in the 2019 Plan, the maximum number of the Company&#8217;s common shares authorized for issuance under the 2019 Plan is <ix:nonFraction id="c606" contextRef="i_2024-05-22_PlanNameAxis-The2019OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,000,000</ix:nonFraction> shares. As of December 31, 2025, options to purchase an aggregate of <ix:nonFraction id="c607" contextRef="i_2025-12-31_PlanNameAxis-The2019OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,402,444</ix:nonFraction> common shares were outstanding and <ix:nonFraction id="c608" contextRef="i_2025-12-31_PlanNameAxis-The2019OmnibusIncentivePlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">164,770</ix:nonFraction> common shares were reserved for issuance upon settlement of DSUs under the 2019 Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>2021 Employment Inducement Incentive Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On December 3, 2021, the Board adopted the DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan (Inducement Plan) to facilitate the granting of equity awards as an inducement material to new employees joining the Company. The Inducement Plan was adopted without shareholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and is administered by the Compensation Committee of the Board of Directors. The Board reserved <ix:nonFraction id="c609" contextRef="i_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,000,000</ix:nonFraction> common shares of the Company for issuance under the Inducement Plan, which permits the grant of non-statutory options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other share-based awards, to eligible recipients. The only persons eligible to receive awards under the Inducement Plan are individuals who are new employees and satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4) or 5635(c)(3), as applicable. Also, on December 3, 2021, the Compensation Committee adopted a form of notice of option grant and option award agreement for use under the Inducement Plan, which contains terms substantially identical to the form of notice of option grant and option award agreement for use under the shareholder-approved 2019 Plan. The Inducement Plan has a term of <ix:nonNumeric contextRef="d_2021-12-03_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c610" format="ixt-sec:duryear">10</ix:nonNumeric> years. The share reserve under the Inducement Plan may be increased at the discretion of and approval by the Board and, on July 31, 2025, the Board increased the number of common shares reserved for issuance under the plan to <ix:nonFraction id="c611" contextRef="i_2025-07-31_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,000,000</ix:nonFraction>. As of December 31, 2025, options to purchase an aggregate of <ix:nonFraction id="c612" contextRef="i_2025-12-31_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,100,000</ix:nonFraction> common shares were outstanding under the Inducement Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">90</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Prior stock option plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Board of Directors ceased granting awards under the DiaMedica Therapeutics Inc. Stock Option Plan, Amended and Restated November 6, 2018 (Prior Plan) upon receipt of the shareholder approval of the 2019 Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the 2019 Plan. As of December 31, 2025, options to purchase an aggregate of <ix:nonFraction id="c613" contextRef="i_2025-12-31_PlanNameAxis-StockOptionPriorPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">362,410</ix:nonFraction> common shares were outstanding under the Prior Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Prior deferred stock unit plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Board of Directors ended participation in the DiaMedica Therapeutics Inc. Amended and Restated Deferred Stock Unit Plan (Prior DSU Plan) upon receipt of the shareholder approval of the 2019 Plan. Awards outstanding under the Prior DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of December 31, 2025, there were <ix:nonFraction id="c614" contextRef="i_2025-12-31_PlanNameAxis-The2012DSUPlanMember" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,745</ix:nonFraction> common shares reserved for issuance upon settlement of DSUs outstanding under the Prior DSU Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Stock options</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Share-based compensation expense for each of the periods presented is as follows (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c736" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c739" contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,526</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c740" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,464</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c741" contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,320</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c742" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">621</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c743" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,846</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c744" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,085</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize share-based compensation for options awards based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those options that actually vest.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A summary of option activity is as follows (in thousands except share and per share amounts):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2C30E968-81B0-4781-A879-0209D2007EEF" escape="true" continuedAt="c19392D94-2B76-4B98-A212-3AB2EC258D3D">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Underlying</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances as of December 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c748" contextRef="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,871,013</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c749" contextRef="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.61</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c750" contextRef="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">832</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c751" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,864,775</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c752" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.03</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c753" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">531,350</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c754" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.96</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Expired/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c755" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">395,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c756" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.08</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c757" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">117,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c758" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.19</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances as of December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c759" contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,692,438</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c760" contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.33</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c761" contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,243</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c762" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,433,416</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c763" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.88</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c764" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">830,747</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c765" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.80</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c766" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">415,253</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c767" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.43</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Expired/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c768" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">15,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c769" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.02</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances as of December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c770" contextRef="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,864,854</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c771" contextRef="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.11</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c772" contextRef="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">26,479</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">91</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A summary of the status of our unvested shares underlying options during the year ended and as of December 31, 2025 is as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:continuation id="c19392D94-2B76-4B98-A212-3AB2EC258D3D">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Underlying</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grant Date Fair </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested as of December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c776" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,371,983</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c777" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c778" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,433,416</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c779" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.30</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Vested</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c780" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,143,530</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c781" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.28</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c782" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">801,372</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c783" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.57</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested as of December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c784" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,860,497</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c785" contextRef="i_2025-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.06</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:continuation>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information about stock options outstanding, vested and expected to vest as of December 31, 2025, is as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="c786" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding, Vested and Expected to Vest</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options Vested and Exercisable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (Years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual Life </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c789" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.00</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c790" contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.99</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c791" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">51,443</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c792" format="ixt-sec:duryear">7.1</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c793" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.64</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c794" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,989</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c795" format="ixt-sec:duryear">1.66</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c796" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.00</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c797" contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.99</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c798" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,278,895</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c799" format="ixt-sec:duryear">6.7</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c800" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.73</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c801" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,515,350</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c802" format="ixt-sec:duryear">2.70</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c803" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.00</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c804" contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.99</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c805" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">311,893</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c806" format="ixt-sec:duryear">4.7</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c807" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.56</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c808" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">247,519</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c809" format="ixt-sec:duryear">3.66</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c810" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.00</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c811" contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.99</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c812" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,917,069</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c813" format="ixt-sec:duryear">7.7</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c814" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.32</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c815" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">808,626</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c816" format="ixt-sec:duryear">4.51</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c817" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.00</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c818" contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.99</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c819" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">549,287</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c820" format="ixt-sec:duryear">7.6</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c821" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.16</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c822" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">256,787</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c823" format="ixt-sec:duryear">5.03</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c824" contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">6.00</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c825" contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">16.00</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c826" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">756,267</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c827" format="ixt-sec:duryear">8.5</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c828" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.14</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c829" contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">133,086</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c830" format="ixt-sec:duryear">7.97</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c831" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,864,854</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c832" format="ixt-sec:duryear">7.3</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c833" contextRef="i_2025-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.11</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c834" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,004,357</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="c835" format="ixt-sec:duryear">3.68</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The cumulative grant date fair value of employee options vested during the years ended December 31, 2025 and 2024 was $<ix:nonFraction id="c703" contextRef="d_2025-01-01_2025-12-31_PlanNameAxis-The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.6</ix:nonFraction> million and $<ix:nonFraction id="c704" contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.5</ix:nonFraction> million, respectively. A total of <ix:nonFraction id="c705" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">415,253</ix:nonFraction> and <ix:nonFraction id="c706" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">117,000</ix:nonFraction> options were exercised during the years ended December 31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2025, total compensation expense related to unvested employee stock options not yet recognized was $<ix:nonFraction id="c707" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" format="ixt:num-dot-decimal" decimals="-5">10.6</ix:nonFraction> million, which is expected to be allocated to expenses over a weighted-average period of <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c708" format="ixt-sec:duryear">3.1</ix:nonNumeric> years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended December 31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c836" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024 </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common share fair value</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c839" contextRef="i_2025-12-31_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.07</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c840" contextRef="i_2025-12-31_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.67</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c841" contextRef="i_2024-12-31_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.40</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c842" contextRef="i_2024-12-31_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.38</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c843" contextRef="d_2025-01-01_2025-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">3.7</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c844" contextRef="d_2025-01-01_2025-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.4</ix:nonFraction>%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c845" contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">3.8</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c846" contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.5</ix:nonFraction>%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><ix:nonFraction id="c847" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonFraction id="c848" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>%</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected option life (years)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c849" format="ixt-sec:duryear">5.0</ix:nonNumeric></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c850" format="ixt-sec:duryear">5.6</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c851" format="ixt-sec:duryear">5.5</ix:nonNumeric></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c852" format="ixt-sec:duryear">5.7</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected stock price volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c853" contextRef="d_2025-01-01_2025-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">75.7</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c854" contextRef="d_2025-01-01_2025-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">83.3</ix:nonFraction>%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c855" contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">83.0</ix:nonFraction></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c856" contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">124.1</ix:nonFraction>%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Deferred stock units and restricted stock units</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under our non-employee director compensation program, non-employee directors may elect to receive RSUs or DSUs in lieu of all or a portion of the annual cash retainers payable to such director. Each RSU or DSU represents the right to receive one common share. These recipients receive a number of RSUs or DSUs equal to the amount of the elected portion of the annual cash retainers divided by the 10-trading day average closing sale price of our common shares as determined on the third business day prior to the anticipated grant date of the award. These annual RSU and DSU grants vest quarterly over <span style="-sec-ix-hidden:c727">one</span> year, conditioned on continuous service. The cost of the RSUs and DSUs is measured and recognized based on the fair market value of our common shares on the date of grant. RSUs will be settled immediately upon vesting and DSU awards will be settled following a separation from service by such director.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were <ix:nonFraction id="c728" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">174,515</ix:nonFraction> and <ix:nonFraction id="c729" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">284,886</ix:nonFraction> vested DSUs outstanding under our share-based compensation plans as of December 31, 2025 and 2024, respectively. During 2025, <ix:nonFraction id="c730" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="INF">35,215</ix:nonFraction> common shares were issued upon the vesting and settlement of RSUs. During 2024, <ix:nonFraction id="c731" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="INF">23,660</ix:nonFraction> common shares were issued upon the vesting and settlement of RSUs. There were <span style="-sec-ix-hidden:c732"><span style="-sec-ix-hidden:c733"><span style="-sec-ix-hidden:c734"><span style="-sec-ix-hidden:c735">no</span></span></span></span> unvested DSUs or RSUs as of December 31, 2025 and 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">92</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></ix:exclude>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="c857" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>14. </b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Employee Benefit Plan</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We maintain an employee 401(k) retirement savings plan (401(k) Plan). The 401(k) Plan provides eligible employees with an opportunity to make tax-deferred contributions into a long-term investment and savings program. All employees over the age of 21 may elect to participate in the 401(k) Plan beginning on their hire date. The 401(k) Plan allows eligible employees to contribute a portion of their annual compensation, subject only to maximum limits required by law. We contribute an amount up to <ix:nonFraction id="c860" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" format="ixt:num-dot-decimal" decimals="2">4</ix:nonFraction>% of each employees&#8217; compensation under the safe harbor provisions provided by the Internal Revenue Service rules governing 401(k) plans. Employee and employer safe harbor contributions vest immediately.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have recorded contribution expenses of $<ix:nonFraction id="c861" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" format="ixt:num-dot-decimal" decimals="0">234,000</ix:nonFraction> and $<ix:nonFraction id="c862" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" format="ixt:num-dot-decimal" decimals="0">166,000</ix:nonFraction> under the 401(k) Plan for the years ended December&#160;31, 2025 and 2024, respectively.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SegmentReportingDisclosureTextBlock" id="c863" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>15.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Segment Information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An operating segment is identified as a component of an enterprise that engages in business activities about which separate discrete financial information and operating results is regularly reviewed by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. The Company's CODM is the Chief Executive Officer. The Company operates in a <span style="-sec-ix-hidden:c866">single</span> operating segment focused on the development of its drug product candidate DM199 for the treatment of severe ischemic disease. The CODM manages and allocates resources to the operations of the Company on a total company basis. Further, the CODM reviews and utilizes functional expenses (i.e., research, development and general and administrative) at the consolidated level to manage the Company's operations. Other segment items included in consolidated net loss are revenues, share-based compensation, interest income, other expense, net, and income tax expense, which are reflected in the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table presents financial information, including significant segment expenses, which are regularly provided to the CODM and included within segment and consolidated net loss:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="c889" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses, excluding share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c892" contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">23,294</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c893" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">18,436</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c894" contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,257</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c895" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-4">6,160</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Total operating expenses, excluding share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c896" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">30,551</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c897" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="dmac:OperatingExpensesExcludingSharebasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,596</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c898" contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,320</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c899" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">621</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c900" contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,526</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c901" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,464</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Total share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c902" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,846</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c903" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,085</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c904" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">34,397</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c905" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">26,681</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Interest income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c906" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,669</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c907" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,301</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Other expense, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c908" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">10</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c909" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">34</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c910" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">28</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c911" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-4">30</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Segment and consolidated net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c912" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,766</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c913" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,444</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c914" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>16.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Income Taxes</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The domestic and foreign components of gain (loss) from continuing operations before provision for income taxes are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="c1008" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Domestic (Canada)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1011" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">33,119</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1012" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,452</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1013" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" format="ixt:num-dot-decimal" decimals="-3">381</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1014" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" format="ixt:num-dot-decimal" decimals="-3">38</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c1015" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,738</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c1016" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,414</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">93</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has computed its provision for income taxes based on the actual effective tax rate for the year as the Company believes this is the best estimate for the annual effective tax rate. The Company is subject to income taxes in Canada, the United States and Australia.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant judgment is required in evaluating the Company&#8217;s uncertain tax positions and determining the provision for income taxes. The Company recognizes benefits from uncertain tax positions based on the cumulative probability method whereby the largest benefit with a cumulative probability of greater than 50% is recorded. An uncertain tax position is not recognized if it has less than a 50% likelihood of being sustained.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The provision for income taxes consists of:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="c1017" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Federal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1020" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">24</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1021" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">28</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">State</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1022" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1023" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1024" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1025" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1026" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">28</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1027" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-4">30</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Federal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1028" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1029" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">State</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1030" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1031" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1032" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1033" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1034" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c1035" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1036" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">28</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1037" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-4">30</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table reconciles the expected Canadian statutory federal income tax to the actual income tax expense:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c1038" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1041" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,738</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1042" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">24,414</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Canadian federal statutory rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1043" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">4,911</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1044" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">15.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1045" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,662</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1046" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">15.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Canadian provincial and local income tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1047" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">3,640</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1048" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="3">11.1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1049" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,719</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1050" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="3">11.1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign tax effects</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1051" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">74</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1052" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1053" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" format="ixt:num-dot-decimal" decimals="-3">13</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1054" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nontaxable or nondeductible items</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1055" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">515</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1056" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">1.6</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1057" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">273</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1058" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">1.1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Share issuance costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1059" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="dmac:IncomeTaxRateReconciliationShareIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">149</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1060" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="dmac:EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.5</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1061" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="dmac:IncomeTaxRateReconciliationShareIssuanceCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">8</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1062" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="dmac:EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1063" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">4</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1064" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c1065" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1066" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1067" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,291</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1068" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">25.3</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1069" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,133</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c1070" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">25.1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Actual income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1071" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-3">28</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c1072" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1073" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:num-dot-decimal" decimals="-4">30</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c1074" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As the operations of the Company are predominantly conducted through its Canadian parent company, the Company has prepared the tax rate table using the Canadian federal tax rate of <ix:nonFraction id="c975" contextRef="d_2025-01-01_2025-12-31_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">15</ix:nonFraction>%.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">94</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The principal component of deferred taxes are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c1075" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets (liabilities):</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Non-capital losses carried forward</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1078" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,316</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1079" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:num-dot-decimal" decimals="-4">32,240</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Research and development expenditures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1080" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" format="ixt:num-dot-decimal" decimals="-3">817</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1081" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" format="ixt:num-dot-decimal" decimals="-3">817</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Patents and other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1082" contextRef="i_2025-12-31" unitRef="USD" name="dmac:DeferredTaxAssetsPropertyPatentsAndOther" scale="3" format="ixt:num-dot-decimal" decimals="-4">460</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1083" contextRef="i_2024-12-31" unitRef="USD" name="dmac:DeferredTaxAssetsPropertyPatentsAndOther" scale="3" format="ixt:num-dot-decimal" decimals="-5">400</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1084" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">419</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1085" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">284</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Share issue costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1086" contextRef="i_2025-12-31" unitRef="USD" name="dmac:DeferredTaxAssetsPropertyShareIssueCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">379</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1087" contextRef="i_2024-12-31" unitRef="USD" name="dmac:DeferredTaxAssetsPropertyShareIssueCosts" scale="3" format="ixt:num-dot-decimal" decimals="-3">275</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Accruals</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1088" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" format="ixt:num-dot-decimal" decimals="-3">92</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1089" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="3" format="ixt:num-dot-decimal" decimals="-3">256</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Property and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c1090" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">71</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c1091" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">89</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax asset, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1092" contextRef="i_2025-12-31" unitRef="USD" name="dmac:DeferredTaxAssetsLiabilitiesGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">42,412</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1093" contextRef="i_2024-12-31" unitRef="USD" name="dmac:DeferredTaxAssetsLiabilitiesGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">34,183</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c1094" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">42,412</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c1095" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">34,183</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c1096" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c1097" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table presents a reconciliation of the valuation allowance:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="c1098" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at beginning of the year</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1101" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">34,183</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1102" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">28,039</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Increase based on tax positions related to current period</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1103" contextRef="d_2025-01-01_2025-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToCurrentPeriodMember" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,229</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1104" contextRef="d_2024-01-01_2024-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToCurrentPeriodMember" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,144</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Increase based on tax positions related to prior periods</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c1105" contextRef="d_2025-01-01_2025-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToPriorPeriodsMember" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c1106" contextRef="d_2024-01-01_2024-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToPriorPeriodsMember" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at end of the year</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1107" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">42,412</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c1108" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">34,183</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company assesses available positive and negative evidence to estimate if it is more likely than not to use certain jurisdiction-based deferred tax assets including net operating loss carryovers. On the basis of this assessment, the Company continues to maintain a valuation allowance on its net deferred tax assets for the year ended December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company&#8217;s net operating loss (&#8220;NOL&#8221;) and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company&#8217;s NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period). Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net operating losses and tax credit carryforwards as of December 31, 2025, are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="c1109" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(In thousands)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 19.2%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiration Years</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 65.8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital income tax losses, net &#8211; domestic</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1112" contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">145,679</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Beginning 2027</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital income tax losses, net &#8211; foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c1113" contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expense carry forwards</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1114" contextRef="i_2025-12-31_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,027</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Indefinitely</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c1115" contextRef="i_2025-12-31_TaxCreditCarryforwardAxis-TaxCreditsMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">473</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Beginning 2026</p>
			</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">95</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div></ix:exclude>

<ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p></ix:exclude>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9.</b>&#160;&#160;<b>Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9A.</b>&#160; &#160; &#160; &#160; &#160; &#160; &#160;<b>Controls and Procedures</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Evaluation of Disclosure Controls and Procedures</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the United States Securities Exchange Act of 1934, as amended (Exchange Act)) that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of such period to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Management</i>&#8217;<i>s Report on Internal Control over Financial Reporting</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#8220;Internal Control-Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management concluded that, as of December 31, 2025, our internal control over financial reporting was effective.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This annual report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s independent registered public accounting firm pursuant to the rules of the SEC that exempt smaller reporting companies from the auditor attestation requirement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Changes in Internal Control over Financial Reporting</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There was no change in our internal control over financial reporting that occurred during the fourth quarter ended December 31, 2025 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:MtrlTermsOfTrdArrTextBlock" id="c1116" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9B.</b>&#160; &#160; &#160; &#160; &#160; &#160; &#160;<b>Other Information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and </i><i>Modifications</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the three months ended December 31, 2025, <span style="-sec-ix-hidden:c1119"><span style="-sec-ix-hidden:c1120"><span style="-sec-ix-hidden:c1121"><span style="-sec-ix-hidden:c1122">none</span></span></span></span> of our directors or &#8220;officers&#8221; (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) and 408(c) respectively of SEC Regulation S-K.</p>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9C.</b>&#160; &#160; &#160; &#160; &#160; &#160; &#160;<b>Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 50pt;text-indent:-50pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">96</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART III</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<div>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 10.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Directors, Executive Officers and Corporate Governance</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Executive Officers</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information concerning our executive officers is included in this annual report on Form 10-K under Item 1 of Part I under the heading &#8220;<i>Information About Our Executive Officers</i>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Code of Ethics</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have adopted a code of business conduct and ethics applicable to all of our directors, officers and employees, in accordance with Section 406 of the Sarbanes-Oxley Act, the rules of the SEC promulgated thereunder, and the Nasdaq Listing Rules. The code of business conduct and ethics is posted on our website at www.diamedica.com. We intend to disclose on our website any amendment to or waiver from any provision of the code of business conduct and ethics that applies to our principal executive, financial or accounting officers, and that relates to any element of the code identified in Item&#160;406(b) of Regulation S-K, as promulgated by the SEC. Such disclosure will be provided promptly following the date of the amendment or waiver.&#160;We are&#160;not&#160;including the information contained on our website as part of, or incorporating it by reference into, this report or any other filing or document submitted to the SEC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Additional Information</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The additional information required by this Item is <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="c1126" format="ixt:fixed-true">incorporated</ix:nonNumeric> herein by reference to the information under the headings &#8220;Voting Proposal One &#8211; Election of Directors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Stock Ownership &#8211; Insider Trading Policy,&#8221; and, if any, under &#8220;Delinquent Section16(a) Reports&#8221; appearing in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual General Meeting of Shareholders (Annual Proxy Statement).</p>
</div>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:AwardTmgMnpiDiscTextBlock" id="c1127" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 11.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Executive Compensation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:AwardTmgMnpiCnsdrdFlag" id="c1130" format="ixt:fixed-false">required</ix:nonNumeric> by this Item is incorporated herein by reference to the information under the headings &#8220;Director Compensation,&#8221; &#8220;Executive Compensation,&#8221; &#8220;Corporate Governance &#8211; Compensation Committee&#8221; appearing in the Annual Proxy Statement.</p>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 12.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information required by this Item is incorporated herein by reference to the information under the headings &#8220;Stock Ownership&#8221; and &#8220;Equity Compensation Plan Information,&#8221; appearing in the Annual Proxy Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 13.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Certain Relationships and Related Transactions, and Director Independence</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information required by this Item is incorporated herein by reference to the information under the headings &#8220;Related Person Relationships and Transactions,&#8221; &#8220;Corporate Governance&#8212;Director Independence,&#8221; &#8220;Corporate Governance&#8212;Audit Committee&#8221; and &#8220;Corporate Governance&#8212;Compensation Committee&#8221; appearing in the Annual Proxy Statement</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 14.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Principal Accountant Fees and Services</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information required by this Item is incorporated herein by reference to the information under the headings &#8220;Audit Fees&#8221; and &#8220;Audit Committee Pre-Approval Policies and Procedures&#8221; under &#8220;Voting Proposal Two&#8212;Appointment of Baker Tilly US, LLP as our Independent Registered Public Accounting Firm and Authorization to Fix Remuneration&#8221; appearing in the Annual Proxy Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">97</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART IV</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 15.</b>&#160;&#160;<b>Exhibits and Financial Statement Schedules</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Financial Statements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our consolidated financial statements are included in &#8220;<i>Part II, Item 8. Financial Statements and Supplementary Data.</i>&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Financial Statement Schedules</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All financial statement schedules are omitted because they are inapplicable since we are a smaller reporting company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Exhibits</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The exhibits being filed or furnished with this report are listed below, along with an indication as to each management contract or compensatory plan or arrangement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A copy of any of the exhibits listed or referred to herein will be furnished at a reasonable cost to any person who is a shareholder upon receipt from any such person of a written request for any such exhibit. Such request should be sent to: Mr. Scott Kellen, Chief Financial Officer and Corporate Secretary, DiaMedica Therapeutics Inc., 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305, Attn: Shareholder Information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item No.</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Item</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Method of Filing</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774925026207/ex_849527.htm" style="-sec-extract:exhibit;">Notice of Articles of DiaMedica Therapeutics Inc. dated May 20, 2025</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 3.1 to DiaMedica&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774923015120/ex_523059.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Articles of DiaMedica Therapeutics Inc. Effective May 17, 2023</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 3.1 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on May 18, 2023</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774924008522/ex_640349.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 4.1 to DiaMedica&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.2</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774919011313/ex_146353.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Specimen Certificate representing Voting Common Shares of DiaMedica Therapeutics Inc.</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 4.2 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange&#160;Commission on June 4, 2019</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.3</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774921023302/ex_288747.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Registration Rights Agreement dated as of September 28, 2021 among DiaMedica Therapeutics Inc. and the Purchasers Party Thereto</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 4.5 to DiaMedica&#8217;s Registration Statement on Form S-3 as filed with the Securities and Exchange Commission on October 5, 2021</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 333-260066)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.4</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774923019036/ex_539608.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Registration Rights Agreement dated as of June 23, 2023 among DiaMedica Therapeutics Inc. and the Purchasers Party Thereto</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 4.6 to DiaMedica&#8217;s Registration Statement on Form S-3 as filed with the Securities and Exchange Commission on June 30, 2023</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 333-273068)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.5</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774924021220/ex_692149.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Registration Rights Agreement by and among DiaMedica Therapeutics Inc. and the Purchasers Party Thereto</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.2 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 26, 2024</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.6</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774925023048/ex_840934.htm" style="-sec-extract:exhibit;">Form of Registration Rights Agreement by and among DiaMedica Therapeutics Inc. and the Purchasers party thereto dated as of July 23, 2025</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.2 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on July 21, 2025</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">98</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;"><b>Item No.</b></td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; text-align: center;"><b>Item</b></td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; text-align: center;"><b>Method of Filing</b></td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.1#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774924018140/ex_678897.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan (Effective May 22, 2024)</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.1 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on May 23, 2024</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.2#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774922006163/ex_344771.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Option Award Agreement under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.2 to DiaMedica&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.3#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774920017514/ex_198797.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Deferred Stock Unit Award Agreement under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.1 to DiaMedica&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.4#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774925034469/ex_886862.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">DiaMedica Therapeutics Inc. Amended and Restated 2021 Employment Inducement Incentive Plan</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.3 to DiaMedica&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.5#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774922006163/ex_343868.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Inducement Option Award Agreement under the DiaMedica Therapeutics Inc. 2021 Employment Incentive Plan</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.6 to DiaMedica&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.6#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128111.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated November 6, 2018</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.1 to DiaMedica&#8217;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.7#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128690.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Option Agreement under the DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated November 6, 2018</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.3 to DiaMedica&#8217;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.8#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128109.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Option Agreement under the DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated December 21, 2017</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.2 to DiaMedica&#8217;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.9#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128110.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.4 to DiaMedica&#8217;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.10#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774919012427/ex_148184.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">DiaMedica Therapeutics Inc. Short-Term Incentive Plan</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.1 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 21, 2019</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.11#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774925004891/ex_781126.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Indemnification Agreement between DiaMedica Therapeutics Inc. and Each Director and Officer</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.1 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on<br/>
			February 24, 2025<br/>
			(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.12#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128113.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement effective as of September 12, 2018 between DiaMedica USA, Inc. and Rick Pauls</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.6 to DiaMedica&#8217;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 333-228313)</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">99</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;"><b>Item No.</b></td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; text-align: center;"><b>Item</b></td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; text-align: center;"><b>Method of Filing</b></td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.13#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774919005272/ex_137868.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement effective as of September 12, 2018 between DiaMedica USA, Inc. and Scott Kellen</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.7 to DiaMedica&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.14#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774925034469/ex_884117.htm" style="-sec-extract:exhibit;">Employment Agreement effective as of August 11, 2025, between DiaMedica USA, Inc. and Julie Krop, M.D.</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.5 to DiaMedica&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.15</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774922016176/ex_389816.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">301 Carlson Parkway Office Lease dated June 22, 2022 between Medica Services Company, LLC and DiaMedica USA Inc.</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.1 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 29, 2022</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.16</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774922016176/ex_389817.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Lease Guaranty Agreement dated June 22, 2022 by DiaMedica Therapeutics Inc.</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.2 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 29, 2022</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.17<sup style="vertical-align:top;line-height:120%;">(1)</sup></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128119.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">GPEx&#174;</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">- Derived Cell Line Sale Agreement dated February 2, 2012 between DiaMedica Therapeutics Inc. and Catalent Pharma Solutions, LLC</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.12 to DiaMedica&#8217;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.18</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128120.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">First Amendment to GPEx&#174;</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Development and Manufacturing Agreement dated April 10, 2017 between DiaMedica Therapeutics Inc. and Catalent Pharma Solutions, LLC</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.13 to DiaMedica&#8217;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.19</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774920005906/ex_178135.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Second Amendment to GPEx&#174;</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Development and Manufacturing Agreement dated as of October 22, 2018 between DiaMedica Therapeutics Inc. and Catalent Pharma Solutions, LLC</span><span style="text-decoration: underline; ">&#160;</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.19 to DiaMedica&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.20</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774924008522/ex_640350.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Third Amendment to GPEx&#174;</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">Development and Manufacturing Agreement dated as of April 11, 2022 between DiaMedica Therapeutics Inc. and Catalent Pharma Solutions, LLC</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.23 to DiaMedica&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.21</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774921022654/ex_286562.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Securities Purchase Agreement dated as of September 26, 2021 among DiaMedica Therapeutics Inc. and the Purchasers Party Thereto</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.1 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on September 27, 2021</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.22#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774923017922/ex_535788.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Securities Purchase Agreement dated as of June 21, 2023 among DiaMedica Therapeutics Inc. and the Purchasers Party Thereto</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.1 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 21, 2023</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.23#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774924021220/ex_692148.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Securities Purchase Agreement, dated as of June 25, 2024, by and among DiaMedica Therapeutics Inc. and the Purchasers Party Thereto</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.1 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 26, 2024</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.24*</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774925023048/ex_840933.htm" style="-sec-extract:exhibit;">Form of Securities Purchase Agreement, dated as of July 21, 2025, by and among DiaMedica Therapeutics Inc. and the Purchasers party thereto</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 10.1 to DiaMedica&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on July 21, 2025</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.25</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774925026273/ex_851711.htm" style="-sec-extract:exhibit;">Sales Agreement between DiaMedica Therapeutics Inc. and TD Securities (USA) LLC, dated August 12, 2025</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 1.2 to DiaMedica&#8217;s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on August 12, 2025</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">100</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;"><b>Item No.</b></td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; text-align: center;"><b>Item</b></td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; text-align: center;"><b>Method of Filing</b></td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">19.1</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774925008018/ex_788436.htm" style="-sec-extract:exhibit;">DiaMedica Therapeutics Inc. Insider Trading Policy</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; text-align: center;">
			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Incorporated by reference to Exhibit 19.1 to DiaMedica&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024</p>

			<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">21.1</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774920005906/ex_178136.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Subsidiaries of DiaMedica Therapeutics Inc.</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 21.1 to DiaMedica&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.1</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_931768.htm" style="-sec-extract:exhibit;">Consent of Baker Tilly US, LLP</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">24.1</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#poa" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Powers</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">of Attorney</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Included on Signature Page</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.1</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_931769.htm" style="-sec-extract:exhibit;">Certification of President and Chief Executive Officer Pursuant to SEC Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.2</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_931770.htm" style="-sec-extract:exhibit;">Certification of Chief Financial Officer Pursuant to SEC Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">32.1</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_931771.htm" style="-sec-extract:exhibit;">Certification of President and Chief Executive Officer Pursuant to Rule 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Furnished herewith</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">32.2</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_931772.htm" style="-sec-extract:exhibit;">Certification of Chief Financial Officer Pursuant to Rule 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Furnished herewith</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">97.1#</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774924008522/ex_640351.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">DiaMedica Therapeutics Inc. Clawback Policy</span></a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporated by reference to Exhibit 97.1 to DiaMedica&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following materials from DiaMedica Therapeutics Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2025, formatted in Inline XBRL (Extensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income (Loss), (iv) the Consolidated Statements of Equity, (v) the Consolidated Statements of Cash Flows, (vi)&#160;Notes to Consolidated Financial Statements, and (vii) the information under Part II, Item 9B of this Annual Report on Form 10-K.</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Embedded within the Inline XBRL document</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;;">#</p>
			</td>
			<td style="width: auto;">
			<p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; font-variant-emoji: normal; margin: 0pt; font-family: &quot;Times New Roman&quot;;">Indicates a management contract or compensatory plan or arrangement.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Portions of this exhibit have been redacted and are subject to an order granting confidential treatment under Rule 406 of the United States Securities Act of 1933, as amended (File No. 333-228313, CF #36833). The redacted material was filed separately with the Securities and Exchange Commission.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">*</sup></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Certain exhibits and schedules have been omitted pursuant to Item 601 of Regulation S-K.&#160;A copy of any omitted exhibit can be furnished to the Commission upon its request</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 16.</b>&#160;&#160;<b>Form 10-K Summary</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 51pt;text-indent:-51pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">101</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 51%;">&#160;</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DIAMEDICA THERAPEUTICS INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 51%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 46%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 51%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">&#160;</td>
			<td style="vertical-align: bottom; width: 46%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 51%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 30, 2026</p>
			</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Rick Pauls</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 51%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rick Pauls</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 51%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">&#160;</td>
			<td style="vertical-align: top; width: 46%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="poa" href="#"></a>POWER OF ATTORNEY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Each person whose signature appears below constitutes and appoints Rick Pauls and Scott Kellen, or either of them, as such person&#8217;s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for such person and in such person&#8217;s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and any documents related to this report and filed pursuant to the Securities Exchange Act of 1934, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Minnesota and applicable U.S. federal securities laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name</b></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:7.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Rick Pauls</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President, Chief Executive Officer and Director</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rick Pauls</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(principal executive officer)</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Scott Kellen</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer and Secretary</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Scott Kellen</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(principal financial and accounting officer)</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ James Parsons</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman of the Board, Director</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">James Parsons</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Michael Giuffre, M.D.</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael Giuffre, M.D.</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Richard Kuntz, M.D., M.Sc.</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Richard Kuntz, M.D., M.Sc.</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Tanya N. Lewis</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tanya N. Lewis</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Daniel J. O&#8217;Connor</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Daniel J. O&#8217;Connor</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Charles Semba, M.D.</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Charles Semba, M.D.</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.9%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:7.9%;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">102</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>[page intentionally left blank]</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#160;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">103</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex_931768.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title></title>


</head>
<body>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-260066, 333-273068, 333-280744, 333-289159, 333-278146 and 333-289542) and Form S-8 (File Nos. 333-228821, 333-231717, 333-263543, 333-266789, 333-279710 and 333-291508) of DiaMedica Therapeutics Inc. of our report dated March 30, 2026, relating to the consolidated financial statements, which appears in this Form 10-K for the year ended December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Baker Tilly US, LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Minneapolis, Minnesota</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex_931769.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title></title>


</head>
<body style="cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION PURSUANT TO SECTION 302(A) OF THE</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Rick Pauls, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">I have reviewed this annual report on Form 10-K of DiaMedica Therapeutics Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(c)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(d)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:23.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 30, 2026</p>
			</td>
			<td style="vertical-align:middle;width:17.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Rick Pauls</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rick Pauls</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(principal executive officer)</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex_931770.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title></title>


</head>
<body style="cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION PURSUANT TO SECTION 302(A) OF THE</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Scott Kellen, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">I have reviewed this annual report on Form 10-K of DiaMedica Therapeutics Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(c)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(d)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:23.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March 30, 2026</p>
			</td>
			<td style="vertical-align:middle;width:17.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Scott Kellen</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Scott Kellen</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer and Corporate Secretary</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(principal financial officer)</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex_931771.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title></title>


</head>
<body>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION PURSUANT TO </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Annual Report on Form 10-K for the year ended December 31, 2025 of DiaMedica Therapeutics Inc. (the Company) as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Rick Pauls, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Rick Pauls</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Rick Pauls</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:23.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:17.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(principal executive officer)</p>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Minneapolis, Minnesota</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex_931772.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title></title>


</head>
<body>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>CERTIFICATION PURSUANT TO </b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Annual Report on Form 10-K for the year ended December 31, 2025 of DiaMedica Therapeutics Inc. (the Company) as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Scott Kellen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:middle;width:25.2%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:23.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Scott Kellen</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:25.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:23.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Scott Kellen</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:25.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:23.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer and Corporate Secretary</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:25.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:23.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(principal financial officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Minneapolis, Minnesota</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 30, 2026</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>dmac-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 04:26PM UTC 2026-03-30--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dmac="http://www.diamedica.com/20251231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.diamedica.com/20251231">
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.diamedica.com/20251231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-and-comprehensive-loss" roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-shareholders-equity" roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-shareholders-equity-parentheticals" roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-business" roleURI="http://www.diamedica.com/20251231/role/statement-note-1-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995550 - Disclosure - Note 1 - Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-risks-and-uncertainties" roleURI="http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995551 - Disclosure - Note 2 - Risks and Uncertainties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-" roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995552 - Disclosure - Note 3 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-marketable-securities" roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995553 - Disclosure - Note 4 - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-amounts-receivable" roleURI="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995554 - Disclosure - Note 5 - Amounts Receivable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-prepaid-expenses-and-other-assets" roleURI="http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995555 - Disclosure - Note 6 - Prepaid Expenses and Other Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-deposits" roleURI="http://www.diamedica.com/20251231/role/statement-note-7-deposits">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995556 - Disclosure - Note 7 - Deposits</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-property-and-equipment" roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995557 - Disclosure - Note 8 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-accrued-liabilities-" roleURI="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995558 - Disclosure - Note 9 - Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-operating-lease" roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995559 - Disclosure - Note 10 - Operating Lease</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-commitments-and-contingencies" roleURI="http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995560 - Disclosure - Note 11 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-shareholders-equity" roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995561 - Disclosure - Note 12 - Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-sharebased-compensation" roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995562 - Disclosure - Note 13 - Share-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-employee-benefit-plan" roleURI="http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995563 - Disclosure - Note 14 - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-segment-information" roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995564 - Disclosure - Note 15 - Segment Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-income-taxes" roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995565 - Disclosure - Note 16 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995566 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-tables" roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995567 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-marketable-securities-tables" roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995568 - Disclosure - Note 4 - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-amounts-receivable-tables" roleURI="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995569 - Disclosure - Note 5 - Amounts Receivable (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-property-and-equipment-tables" roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995570 - Disclosure - Note 8 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-accrued-liabilities-tables" roleURI="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995571 - Disclosure - Note 9 - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-operating-lease-tables" roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995572 - Disclosure - Note 10 - Operating Lease (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-shareholders-equity-tables" roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995573 - Disclosure - Note 12 - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-sharebased-compensation-tables" roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995574 - Disclosure - Note 13 - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-segment-information-tables" roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995575 - Disclosure - Note 15 - Segment Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-income-taxes-tables" roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995576 - Disclosure - Note 16 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-risks-and-uncertainties-details-textual" roleURI="http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995577 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995578 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995579 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995580 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-marketable-securities-details-textual" roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995581 - Disclosure - Note 4 - Marketable Securities (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995582 - Disclosure - Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-amounts-receivable-amounts-receivable-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995583 - Disclosure - Note 5 - Amounts Receivable - Amounts Receivable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-property-and-equipment-details-textual" roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995584 - Disclosure - Note 8 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-property-and-equipment-property-and-equipment-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995585 - Disclosure - Note 8 - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-accrued-liabilities-accrued-liabilities-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995586 - Disclosure - Note 9 - Accrued Liabilities - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-operating-lease-details-textual" roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995587 - Disclosure - Note 10 - Operating Lease (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995588 - Disclosure - Note 10 - Operating Lease - Maturity of Operating Lease Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-commitments-and-contingencies-details-textual" roleURI="http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995589 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-shareholders-equity-details-textual" roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995590 - Disclosure - Note 12 - Shareholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-shareholders-equity-shares-reserved-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995591 - Disclosure - Note 12 - Shareholders' Equity - Shares Reserved (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-sharebased-compensation-details-textual" roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995592 - Disclosure - Note 13 - Share-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995593 - Disclosure - Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-sharebased-compensation-stock-option-activity-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995594 - Disclosure - Note 13 - Share-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-sharebased-compensation-stock-options-outstanding-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995595 - Disclosure - Note 13 - Share-based Compensation - Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-sharebased-compensation-stock-option-assumptions-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995596 - Disclosure - Note 13 - Share-based Compensation - Stock Option Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-employee-benefit-plan-details-textual" roleURI="http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995597 - Disclosure - Note 14 - Employee Benefit Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-segment-information-details-textual" roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995598 - Disclosure - Note 15 - Segment Information (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-segment-information-segment-information-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995599 - Disclosure - Note 15 - Segment Information - Segment Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-income-taxes-details-textual" roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995600 - Disclosure - Note 16 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995601 - Disclosure - Note 16 - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995602 - Disclosure - Note 16 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995603 - Disclosure - Note 16 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995604 - Disclosure - Note 16 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-income-taxes-summary-of-valuation-allowance-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995605 - Disclosure - Note 16 - Income Taxes - Summary of Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995606 - Disclosure - Note 16 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dmac_ATMOfferingMember" name="ATMOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_AccruedClinicalStudyCostsCurrent" name="AccruedClinicalStudyCostsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" name="AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_AccruedResearchAndProfessionalFeesCurrent" name="AccruedResearchAndProfessionalFeesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" name="AccruedTaxesAndOtherLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_CommercialPaperAndCorporateBondsMember" name="CommercialPaperAndCorporateBondsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_CommonStockDeferredStockUnitsSettlementMember" name="CommonStockDeferredStockUnitsSettlementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" name="CommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_DeferredShareUnitPlanMember" name="DeferredShareUnitPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_DeferredShareUnitsMember" name="DeferredShareUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_DeferredTaxAssetsLiabilitiesGross" name="DeferredTaxAssetsLiabilitiesGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_DeferredTaxAssetsPropertyPatentsAndOther" name="DeferredTaxAssetsPropertyPatentsAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_DeferredTaxAssetsPropertyShareIssueCosts" name="DeferredTaxAssetsPropertyShareIssueCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_DepositAssetsTextBlock" name="DepositAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" name="EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_EmployeeAndNonemployeeStockOptionsMember" name="EmployeeAndNonemployeeStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_EquityIssuanceMaximumAggregateOfferingPrice" name="EquityIssuanceMaximumAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_EquityIssuanceRemainingAvailableOfferingPrice" name="EquityIssuanceRemainingAvailableOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange1Member" name="ExercisePriceRange1Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange2Member" name="ExercisePriceRange2Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange3Member" name="ExercisePriceRange3Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange4Member" name="ExercisePriceRange4Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange5Member" name="ExercisePriceRange5Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ExercisePriceRange6Member" name="ExercisePriceRange6Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" name="FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_FunctionalCurrencyPolicyTextBlock" name="FunctionalCurrencyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_IncomeTaxRateReconciliationShareIssuanceCosts" name="IncomeTaxRateReconciliationShareIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_IndemnificationAgreementsMember" name="IndemnificationAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum" name="LiquidatedDamagePercentageOfInvestedCapitalMaximum" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_MinneapolisMNMember" name="MinneapolisMNMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NoncapitalIncomeTaxLossesNetMember" name="NoncapitalIncomeTaxLossesNetMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NonemployeeDirectorCompensationProgramMember" name="NonemployeeDirectorCompensationProgramMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NonemployeeStockOptionsMember" name="NonemployeeStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_OperatingExpensesExcludingSharebasedCompensation" name="OperatingExpensesExcludingSharebasedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_PatentExpense" name="PatentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_PolicyTable" name="PolicyTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ResearchAndDevelopmentContractsMember" name="ResearchAndDevelopmentContractsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_RisksAndUncertaintiesTextBlock" name="RisksAndUncertaintiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" name="StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_StockOptionPriorPlanMember" name="StockOptionPriorPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_StockOptionsOutstandingMember" name="StockOptionsOutstandingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_TaxCreditsMember" name="TaxCreditsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_TaxPositionsRelatedToCurrentPeriodMember" name="TaxPositionsRelatedToCurrentPeriodMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_TaxPositionsRelatedToPriorPeriodsMember" name="TaxPositionsRelatedToPriorPeriodsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_The2012DSUPlanMember" name="The2012DSUPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_The2019OmnibusIncentivePlanMember" name="The2019OmnibusIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" name="The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_The2021EmploymentInducementIncentivePlanMember" name="The2021EmploymentInducementIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_WorkingCapital" name="WorkingCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_statement-statement-insidertradingpoliciesproc" name="statement-statement-insidertradingpoliciesproc" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" name="statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-10-operating-lease-tables" name="statement-statement-note-10-operating-lease-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-shareholders-equity-shares-reserved-details" name="statement-statement-note-12-shareholders-equity-shares-reserved-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-shareholders-equity-tables" name="statement-statement-note-12-shareholders-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" name="statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-13-sharebased-compensation-stock-option-activity-details" name="statement-statement-note-13-sharebased-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-13-sharebased-compensation-stock-option-activity-detailsD9E7AFC8-358E-40B8-A210-68476F132CF8" name="statement-statement-note-13-sharebased-compensation-stock-option-activity-detailsD9E7AFC8-358E-40B8-A210-68476F132CF8" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details" name="statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details" name="statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-13-sharebased-compensation-tables" name="statement-statement-note-13-sharebased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-15-segment-information-segment-information-details" name="statement-statement-note-15-segment-information-segment-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-15-segment-information-tables" name="statement-statement-note-15-segment-information-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" name="statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" name="statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" name="statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" name="statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details" name="statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-16-income-taxes-tables" name="statement-statement-note-16-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" name="statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" name="statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" name="statement-statement-note-3-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" name="statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-detailsCED8302B-7F27-471E-81DC-FA9DDB73E1A8" name="statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-detailsCED8302B-7F27-471E-81DC-FA9DDB73E1A8" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-4-marketable-securities-tables" name="statement-statement-note-4-marketable-securities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-5-amounts-receivable-amounts-receivable-details" name="statement-statement-note-5-amounts-receivable-amounts-receivable-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-5-amounts-receivable-tables" name="statement-statement-note-5-amounts-receivable-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-8-property-and-equipment-property-and-equipment-details" name="statement-statement-note-8-property-and-equipment-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-8-property-and-equipment-tables" name="statement-statement-note-8-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-9-accrued-liabilities-accrued-liabilities-details" name="statement-statement-note-9-accrued-liabilities-accrued-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-9-accrued-liabilities-tables" name="statement-statement-note-9-accrued-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>dmac-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 04:26PM UTC 2026-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-7-deposits" xlink:href="dmac-20251231.xsd#statement-note-7-deposits" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-7-deposits" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DepositAssetsTextBlock" xlink:label="dmac_DepositAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OffsettingAssetsTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_DepositAssetsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets" xlink:href="dmac-20251231.xsd#statement-note-6-prepaid-expenses-and-other-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OffsettingAssetsTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-1-business" xlink:href="dmac-20251231.xsd#statement-note-1-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-1-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-document-and-entity-information" xlink:href="dmac-20251231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets" xlink:href="dmac-20251231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredCosts" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dmac-20251231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="dmac-20251231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity" xlink:href="dmac-20251231.xsd#statement-consolidated-statements-of-shareholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ATMOfferingMember" xlink:label="dmac_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dmac_ATMOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:href="dmac-20251231.xsd#statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ATMOfferingMember" xlink:label="dmac_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dmac_ATMOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dmac-20251231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoncashLeaseExpense" xlink:label="dmac_NoncashLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dmac_NoncashLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties" xlink:href="dmac-20251231.xsd#statement-note-2-risks-and-uncertainties" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_RisksAndUncertaintiesTextBlock" xlink:label="dmac_RisksAndUncertaintiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_RisksAndUncertaintiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-" xlink:href="dmac-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:label="dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities" xlink:href="dmac-20251231.xsd#statement-note-4-marketable-securities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommercialPaperAndCorporateBondsMember" xlink:label="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable" xlink:href="dmac-20251231.xsd#statement-note-5-amounts-receivable" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:label="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment" xlink:href="dmac-20251231.xsd#statement-note-8-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-" xlink:href="dmac-20251231.xsd#statement-note-9-accrued-liabilities-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingLiabilitiesTable" xlink:label="us-gaap_OffsettingLiabilitiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OffsettingLiabilitiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OffsettingLiabilitiesTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease" xlink:href="dmac-20251231.xsd#statement-note-10-operating-lease" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_MinneapolisMNMember" xlink:label="dmac_MinneapolisMNMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="dmac_MinneapolisMNMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies" xlink:href="dmac-20251231.xsd#statement-note-11-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_IndemnificationAgreementsMember" xlink:label="dmac_IndemnificationAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ResearchAndDevelopmentContractsMember" xlink:label="dmac_ResearchAndDevelopmentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="dmac_ResearchAndDevelopmentContractsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="dmac_IndemnificationAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherCommitmentsTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity" xlink:href="dmac-20251231.xsd#statement-note-12-shareholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ATMOfferingMember" xlink:label="dmac_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dmac_ATMOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_StockOptionsOutstandingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitPlanMember" xlink:label="dmac_DeferredShareUnitPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange6Member" xlink:label="dmac_ExercisePriceRange6Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NonemployeeDirectorCompensationProgramMember" xlink:label="dmac_NonemployeeDirectorCompensationProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockOptionPriorPlanMember" xlink:label="dmac_StockOptionPriorPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_StockOptionPriorPlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange6Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_NonemployeeDirectorCompensationProgramMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_DeferredShareUnitPlanMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan" xlink:href="dmac-20251231.xsd#statement-note-14-employee-benefit-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information" xlink:href="dmac-20251231.xsd#statement-note-15-segment-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-15-segment-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoncapitalIncomeTaxLossesNetMember" xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxCreditsMember" xlink:label="dmac_TaxCreditsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:label="dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:label="dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="us-gaap_CanadaRevenueAgencyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CanadaRevenueAgencyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="dmac_TaxCreditsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies" xlink:href="dmac-20251231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_FunctionalCurrencyPolicyTextBlock" xlink:label="dmac_FunctionalCurrencyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_PatentCostsPolicyTextBlock" xlink:label="dmac_PatentCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_PolicyTable" xlink:label="dmac_PolicyTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dmac_PolicyTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_PolicyTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dmac_FunctionalCurrencyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dmac_PatentCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:href="dmac-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables" xlink:href="dmac-20251231.xsd#statement-note-4-marketable-securities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:label="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables" xlink:href="dmac-20251231.xsd#statement-note-5-amounts-receivable-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:label="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables" xlink:href="dmac-20251231.xsd#statement-note-8-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables" xlink:href="dmac-20251231.xsd#statement-note-9-accrued-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingLiabilitiesTable" xlink:label="us-gaap_OffsettingLiabilitiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OffsettingLiabilitiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OffsettingLiabilitiesTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables" xlink:href="dmac-20251231.xsd#statement-note-10-operating-lease-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables" xlink:href="dmac-20251231.xsd#statement-note-12-shareholders-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables" xlink:href="dmac-20251231.xsd#statement-note-15-segment-information-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:href="dmac-20251231.xsd#statement-note-2-risks-and-uncertainties-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_WorkingCapital" xlink:label="dmac_WorkingCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WorkingCapital" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="dmac-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_PatentExpense" xlink:label="dmac_PatentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_PatentExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:href="dmac-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:href="dmac-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:label="dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual" xlink:href="dmac-20251231.xsd#statement-note-4-marketable-securities-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivable" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:href="dmac-20251231.xsd#statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommercialPaperAndCorporateBondsMember" xlink:label="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details" xlink:href="dmac-20251231.xsd#statement-note-5-amounts-receivable-amounts-receivable-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:label="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual" xlink:href="dmac-20251231.xsd#statement-note-8-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:href="dmac-20251231.xsd#statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:href="dmac-20251231.xsd#statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingLiabilitiesTable" xlink:label="us-gaap_OffsettingLiabilitiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OffsettingLiabilitiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OffsettingLiabilitiesTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual" xlink:href="dmac-20251231.xsd#statement-note-10-operating-lease-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_MinneapolisMNMember" xlink:label="dmac_MinneapolisMNMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="dmac_MinneapolisMNMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableLeaseCost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:href="dmac-20251231.xsd#statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual" xlink:href="dmac-20251231.xsd#statement-note-11-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_IndemnificationAgreementsMember" xlink:label="dmac_IndemnificationAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ResearchAndDevelopmentContractsMember" xlink:label="dmac_ResearchAndDevelopmentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="dmac_ResearchAndDevelopmentContractsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="dmac_IndemnificationAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherCommitmentsTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual" xlink:href="dmac-20251231.xsd#statement-note-12-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ATMOfferingMember" xlink:label="dmac_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EquityIssuanceMaximumAggregateOfferingPrice" xlink:label="dmac_EquityIssuanceMaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EquityIssuanceRemainingAvailableOfferingPrice" xlink:label="dmac_EquityIssuanceRemainingAvailableOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum" xlink:label="dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dmac_ATMOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EquityIssuanceMaximumAggregateOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EquityIssuanceRemainingAvailableOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details" xlink:href="dmac-20251231.xsd#statement-note-12-shareholders-equity-shares-reserved-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_StockOptionsOutstandingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitPlanMember" xlink:label="dmac_DeferredShareUnitPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NonemployeeDirectorCompensationProgramMember" xlink:label="dmac_NonemployeeDirectorCompensationProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockOptionPriorPlanMember" xlink:label="dmac_StockOptionPriorPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_StockOptionPriorPlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_NonemployeeDirectorCompensationProgramMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_DeferredShareUnitPlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange6Member" xlink:label="dmac_ExercisePriceRange6Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange6Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual" xlink:href="dmac-20251231.xsd#statement-note-14-employee-benefit-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual" xlink:href="dmac-20251231.xsd#statement-note-15-segment-information-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details" xlink:href="dmac-20251231.xsd#statement-note-15-segment-information-segment-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="us-gaap_CanadaRevenueAgencyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CanadaRevenueAgencyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:label="dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsLiabilitiesGross" xlink:label="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:label="dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:label="dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceTable" xlink:label="us-gaap_ValuationAllowanceTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoncapitalIncomeTaxLossesNetMember" xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxCreditsMember" xlink:label="dmac_TaxCreditsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="dmac_TaxCreditsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>dmac-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 04:26PM UTC 2026-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DocumentAndEntityInformation" xlink:label="dmac_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="dmac_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DocumentAndEntityInformation" xlink:to="dmac_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common share fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="dmac_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="dmac_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canadian federal statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-significant-accounting-policies-policies" xlink:label="dmac_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-significant-accounting-policies-policies" xlink:to="dmac_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:to="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_AccruedTaxesAndOtherLiabilitiesCurrent</link:label>
    <link:label xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of accrued taxes and other liabilities classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-4-marketable-securities-tables" xlink:label="dmac_statement-statement-note-4-marketable-securities-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-4-marketable-securities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Marketable Securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-4-marketable-securities-tables" xlink:to="dmac_statement-statement-note-4-marketable-securities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="dmac_AccruedClinicalStudyCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label xlink:label="dmac_AccruedClinicalStudyCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of accrued clinical study costs classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AccruedClinicalStudyCostsCurrent" xlink:to="dmac_AccruedClinicalStudyCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-5-amounts-receivable-tables" xlink:label="dmac_statement-statement-note-5-amounts-receivable-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-5-amounts-receivable-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Amounts Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-5-amounts-receivable-tables" xlink:to="dmac_statement-statement-note-5-amounts-receivable-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-8-property-and-equipment-tables" xlink:label="dmac_statement-statement-note-8-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-8-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-8-property-and-equipment-tables" xlink:to="dmac_statement-statement-note-8-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-9-accrued-liabilities-tables" xlink:label="dmac_statement-statement-note-9-accrued-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-9-accrued-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Accrued Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-9-accrued-liabilities-tables" xlink:to="dmac_statement-statement-note-9-accrued-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-10-operating-lease-tables" xlink:label="dmac_statement-statement-note-10-operating-lease-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-10-operating-lease-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Operating Lease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-10-operating-lease-tables" xlink:to="dmac_statement-statement-note-10-operating-lease-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoncashLeaseExpense" xlink:label="dmac_NoncashLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="dmac_NoncashLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label xlink:label="dmac_NoncashLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expense recognized over the period for lease expense, non-cash.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NoncashLeaseExpense" xlink:to="dmac_NoncashLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-12-shareholders-equity-tables" xlink:label="dmac_statement-statement-note-12-shareholders-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-shareholders-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Shareholders' Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-shareholders-equity-tables" xlink:to="dmac_statement-statement-note-12-shareholders-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-13-sharebased-compensation-tables" xlink:label="dmac_statement-statement-note-13-sharebased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-13-sharebased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Share-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-13-sharebased-compensation-tables" xlink:to="dmac_statement-statement-note-13-sharebased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-15-segment-information-tables" xlink:label="dmac_statement-statement-note-15-segment-information-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-15-segment-information-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Segment Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-15-segment-information-tables" xlink:to="dmac_statement-statement-note-15-segment-information-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-tables" xlink:label="dmac_statement-statement-note-16-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-16-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-16-income-taxes-tables" xlink:to="dmac_statement-statement-note-16-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:to="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:to="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:label="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:to="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-5-amounts-receivable-amounts-receivable-details" xlink:label="dmac_statement-statement-note-5-amounts-receivable-amounts-receivable-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-5-amounts-receivable-amounts-receivable-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Amounts Receivable - Amounts Receivable (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-5-amounts-receivable-amounts-receivable-details" xlink:to="dmac_statement-statement-note-5-amounts-receivable-amounts-receivable-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected option life (years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:label="dmac_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-8-property-and-equipment-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Property and Equipment - Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:to="dmac_statement-statement-note-8-property-and-equipment-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:label="dmac_statement-statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-9-accrued-liabilities-accrued-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Accrued Liabilities - Accrued Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:to="dmac_statement-statement-note-9-accrued-liabilities-accrued-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommercialPaperAndCorporateBondsMember" xlink:label="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_CommercialPaperAndCorporateBondsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper and Corporate Bonds [Member]</link:label>
    <link:label xlink:label="dmac_CommercialPaperAndCorporateBondsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Papers are unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents and commercial bonds are debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CommercialPaperAndCorporateBondsMember" xlink:to="dmac_CommercialPaperAndCorporateBondsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:label="dmac_statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Operating Lease - Maturity of Operating Lease Liability (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:to="dmac_statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-12-shareholders-equity-shares-reserved-details" xlink:label="dmac_statement-statement-note-12-shareholders-equity-shares-reserved-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-shareholders-equity-shares-reserved-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Shareholders' Equity - Shares Reserved (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-shareholders-equity-shares-reserved-details" xlink:to="dmac_statement-statement-note-12-shareholders-equity-shares-reserved-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:label="dmac_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:to="dmac_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:label="dmac_statement-statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-13-sharebased-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Share-based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:to="dmac_statement-statement-note-13-sharebased-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:label="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block]</link:label>
    <link:label xlink:label="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of marketable securities measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:to="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:label="dmac_statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Share-based Compensation - Stock Options Outstanding (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:to="dmac_statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:label="dmac_statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Share-based Compensation - Stock Option Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:to="dmac_statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-15-segment-information-segment-information-details" xlink:label="dmac_statement-statement-note-15-segment-information-segment-information-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-15-segment-information-segment-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Segment Information - Segment Information (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-15-segment-information-segment-information-details" xlink:to="dmac_statement-statement-note-15-segment-information-segment-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:label="dmac_statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:to="dmac_statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:label="dmac_statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:to="dmac_statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:label="dmac_statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:to="dmac_statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="dmac_statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="dmac_statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:label="dmac_statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Income Taxes - Summary of Valuation Allowance (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:to="dmac_statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:label="dmac_statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:to="dmac_statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatements" xlink:label="dmac_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="dmac_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NotesToFinancialStatements" xlink:to="dmac_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="dmac_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="dmac_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturities and sales of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitPlanMember" xlink:label="dmac_DeferredShareUnitPlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_DeferredShareUnitPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Share Unit Plan [Member]</link:label>
    <link:label xlink:label="dmac_DeferredShareUnitPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common shares issued under deferred share unit plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DeferredShareUnitPlanMember" xlink:to="dmac_DeferredShareUnitPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average grant-date fair value of options (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested, weighted average grant-date fair value of options (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited, weighted average grant-date fair value of options (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, weighted average grant-date fair value of options (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, weighted average grant-date fair value of options (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireMarketableSecurities</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired / cancelled, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired/cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EquityIssuanceMaximumAggregateOfferingPrice" xlink:label="dmac_EquityIssuanceMaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="dmac_EquityIssuanceMaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_EquityIssuanceMaximumAggregateOfferingPrice</link:label>
    <link:label xlink:label="dmac_EquityIssuanceMaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Issuance, Maximum Aggregate Offering Price</link:label>
    <link:label xlink:label="dmac_EquityIssuanceMaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum aggregate offering price for equity issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_EquityIssuanceMaximumAggregateOfferingPrice" xlink:to="dmac_EquityIssuanceMaximumAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ATMOfferingMember" xlink:label="dmac_ATMOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_ATMOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A T M Offering [Member]</link:label>
    <link:label xlink:label="dmac_ATMOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents ATM offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ATMOfferingMember" xlink:to="dmac_ATMOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum" xlink:label="dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum" xlink:type="locator"/>
    <link:label xlink:label="dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum</link:label>
    <link:label xlink:label="dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidated Damage, Percentage of Invested Capital, Maximum</link:label>
    <link:label xlink:label="dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of liquidated damage as percentage of invested capital, maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum" xlink:to="dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional services fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="us-gaap_CanadaRevenueAgencyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CanadaRevenueAgencyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada Revenue Agency [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CanadaRevenueAgencyMember" xlink:to="us-gaap_CanadaRevenueAgencyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses, excluding share-based compensation</link:label>
    <link:label xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_OperatingExpensesExcludingSharebasedCompensation</link:label>
    <link:label xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Generally recurring costs associated with normal operations, excluding share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:to="dmac_OperatingExpensesExcludingSharebasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanCostRecognized</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_CityAreaCode</link:label>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balances (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_VariableLeaseCost</link:label>
    <link:label xlink:label="us-gaap_VariableLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestReceivable</link:label>
    <link:label xlink:label="us-gaap_InterestReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDepositOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseCost</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets acquired under financing lease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentPeriodEndDate</link:label>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidExpense</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityFileNumber</link:label>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentType</link:label>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityShellCompany</link:label>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityPublicFloat</link:label>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCurrentReportingStatus</link:label>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityVoluntaryFilers</link:label>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityWellKnownSeasonedIssuer</link:label>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="ecd_AwardTmgDiscLineItems" xlink:type="locator"/>
    <link:label xlink:label="ecd_AwardTmgDiscLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgDiscLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_AwardTmgMnpiDiscTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_AwardTmgMnpiCnsdrdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_AwardTmgMnpiCnsdrdFlag</link:label>
    <link:label xlink:label="ecd_AwardTmgMnpiCnsdrdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" xlink:type="locator"/>
    <link:label xlink:label="ecd_InsiderTradingPoliciesProcLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityRegistrantName</link:label>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:label xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCommonStockSharesOutstanding</link:label>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:label xlink:label="ecd_TradingArrByIndTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfProductInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_LocalPhoneNumber</link:label>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon the exercise of stock options (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon the exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon the vesting and settlement of restricted stock units</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</link:label>
    <link:label xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares under Private Placement (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares under Private Placement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease obligation, non-current</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease obligation, non-current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Present value of lease obligation</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease obligation</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less current portion of operating lease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseLiabilityNoncurrent</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligation, non-current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositsAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeasePrincipalPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeasePrincipalPayments</link:label>
    <link:label xlink:label="us-gaap_FinanceLeasePrincipalPayments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments on finance lease obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less interest portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_WorkingCapital" xlink:label="dmac_WorkingCapital" xlink:type="locator"/>
    <link:label xlink:label="dmac_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_WorkingCapital</link:label>
    <link:label xlink:label="dmac_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:label xlink:label="dmac_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of working capital.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_WorkingCapital" xlink:to="dmac_WorkingCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_RisksAndUncertaintiesTextBlock" xlink:label="dmac_RisksAndUncertaintiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_RisksAndUncertaintiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Text Block]</link:label>
    <link:label xlink:label="dmac_RisksAndUncertaintiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A complete disclosure of the risks and uncertainties the company may face.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_RisksAndUncertaintiesTextBlock" xlink:to="dmac_RisksAndUncertaintiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_MinneapolisMNMember" xlink:label="dmac_MinneapolisMNMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_MinneapolisMNMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minneapolis, MN [Member]</link:label>
    <link:label xlink:label="dmac_MinneapolisMNMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Minneapolis, MN,</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_MinneapolisMNMember" xlink:to="dmac_MinneapolisMNMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_PatentCostsPolicyTextBlock" xlink:label="dmac_PatentCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_PatentCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent Costs [Policy Text Block]</link:label>
    <link:label xlink:label="dmac_PatentCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for patent costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_PatentCostsPolicyTextBlock" xlink:to="dmac_PatentCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_FunctionalCurrencyPolicyTextBlock" xlink:label="dmac_FunctionalCurrencyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_FunctionalCurrencyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Functional Currency [Policy Text Block]</link:label>
    <link:label xlink:label="dmac_FunctionalCurrencyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for functional currency in use by the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_FunctionalCurrencyPolicyTextBlock" xlink:to="dmac_FunctionalCurrencyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee and Non-employee Stock Options [Member]</link:label>
    <link:label xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to employee and non-employee stock option awards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_PatentExpense" xlink:label="dmac_PatentExpense" xlink:type="locator"/>
    <link:label xlink:label="dmac_PatentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_PatentExpense</link:label>
    <link:label xlink:label="dmac_PatentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Expense</link:label>
    <link:label xlink:label="dmac_PatentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of expense associated with gaining and maintaining certain patents.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_PatentExpense" xlink:to="dmac_PatentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DepositAssetsTextBlock" xlink:label="dmac_DepositAssetsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_DepositAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposit Assets [Text Block]</link:label>
    <link:label xlink:label="dmac_DepositAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of the companies deposits labeled as assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DepositAssetsTextBlock" xlink:to="dmac_DepositAssetsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_DeferredShareUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Share Units [Member]</link:label>
    <link:label xlink:label="dmac_DeferredShareUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The deferred share units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DeferredShareUnitsMember" xlink:to="dmac_DeferredShareUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and accrued research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_IndemnificationAgreementsMember" xlink:label="dmac_IndemnificationAgreementsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_IndemnificationAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indemnification Agreements [Member]</link:label>
    <link:label xlink:label="dmac_IndemnificationAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to certain indemnification agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_IndemnificationAgreementsMember" xlink:to="dmac_IndemnificationAgreementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ResearchAndDevelopmentContractsMember" xlink:label="dmac_ResearchAndDevelopmentContractsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_ResearchAndDevelopmentContractsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Contracts [Member]</link:label>
    <link:label xlink:label="dmac_ResearchAndDevelopmentContractsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ResearchAndDevelopmentContractsMember" xlink:to="dmac_ResearchAndDevelopmentContractsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockOptionsOutstandingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Outstanding [Member]</link:label>
    <link:label xlink:label="dmac_StockOptionsOutstandingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to stock options outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockOptionsOutstandingMember" xlink:to="dmac_StockOptionsOutstandingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Reserved for Future Issuance [Table Text Block]</link:label>
    <link:label xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A tabular disclosure of common stock reserved for future issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="dmac_CommonStockReservedForFutureIssuanceTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator"/>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_ProceedsFromIssuanceOfCommonStockNet</link:label>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock, Net</link:label>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the issuance of common stock, net of offering costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_The2012DSUPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2012 DSU Plan [Member]</link:label>
    <link:label xlink:label="dmac_The2012DSUPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the 2012 DSU plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_The2012DSUPlanMember" xlink:to="dmac_The2012DSUPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 1 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange1Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the first exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange1Member" xlink:to="dmac_ExercisePriceRange1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_NonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonemployee Stock Options [Member]</link:label>
    <link:label xlink:label="dmac_NonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the nonemployee stock options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NonemployeeStockOptionsMember" xlink:to="dmac_NonemployeeStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange5Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 5 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange5Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the fifth exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange5Member" xlink:to="dmac_ExercisePriceRange5Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange4Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 4 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange4Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the fourth exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange4Member" xlink:to="dmac_ExercisePriceRange4Member-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 3 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange3Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the third exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange3Member" xlink:to="dmac_ExercisePriceRange3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 2 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange2Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the second exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange2Member" xlink:to="dmac_ExercisePriceRange2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="locator"/>
    <link:label xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents and other</link:label>
    <link:label xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from patents and other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:to="dmac_DeferredTaxAssetsPropertyPatentsAndOther-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="locator"/>
    <link:label xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issue costs</link:label>
    <link:label xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share issue costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:to="dmac_DeferredTaxAssetsPropertyShareIssueCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoncapitalIncomeTaxLossesNetMember" xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-capital Income Tax Losses, Net [Member]</link:label>
    <link:label xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to non-capital income tax losses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:to="dmac_NoncapitalIncomeTaxLossesNetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxCreditsMember" xlink:label="dmac_TaxCreditsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_TaxCreditsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credits [Member]</link:label>
    <link:label xlink:label="dmac_TaxCreditsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to tax credits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_TaxCreditsMember" xlink:to="dmac_TaxCreditsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares, no par value; unlimited authorized; 53,742,370 and 42,818,660 shares issued and outstanding, as of December 31, 2025 and 2024, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized, Unlimited [Fixed List]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockNoParValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, No Par Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetDomain" xlink:to="us-gaap_DeferredTaxAssetDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares reserved for future issuance (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of the year</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of the year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeaseDescriptionTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceTable" xlink:label="us-gaap_ValuationAllowanceTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_ValuationAllowanceTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expenditures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsLiabilitiesGross" xlink:label="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:type="locator"/>
    <link:label xlink:label="dmac_DeferredTaxAssetsLiabilitiesGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_DeferredTaxAssetsLiabilitiesGross</link:label>
    <link:label xlink:label="dmac_DeferredTaxAssetsLiabilitiesGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax asset, net</link:label>
    <link:label xlink:label="dmac_DeferredTaxAssetsLiabilitiesGross-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total deferred tax assets (liabilities), gross.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:to="dmac_DeferredTaxAssetsLiabilitiesGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_PolicyTable" xlink:label="dmac_PolicyTable" xlink:type="locator"/>
    <link:label xlink:label="dmac_PolicyTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_PolicyTable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_PolicyTable" xlink:to="dmac_PolicyTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentDisposals</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts receivable</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total amounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsAndShortTermInvestments</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label xlink:label="us-gaap_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_MarketableSecuritiesCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherNonoperatingExpense</link:label>
    <link:label xlink:label="us-gaap_OtherNonoperatingExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-capital losses carried forward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</link:label>
    <link:label xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of discounts on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_The2019OmnibusIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2019 Omnibus Incentive Plan [Member]</link:label>
    <link:label xlink:label="dmac_The2019OmnibusIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to the 2019 Omnibus Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_The2019OmnibusIncentivePlanMember" xlink:to="dmac_The2019OmnibusIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockOptionPriorPlanMember" xlink:label="dmac_StockOptionPriorPlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockOptionPriorPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Prior Plan [Member]</link:label>
    <link:label xlink:label="dmac_StockOptionPriorPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the company's stock option plan known as the Prior Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockOptionPriorPlanMember" xlink:to="dmac_StockOptionPriorPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2019 Omnibus Incentive Plan, Stock Option Prior Plan, and the 2012 DSU Plan [Member]</link:label>
    <link:label xlink:label="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the following plans: the 2019 Omnibus Incentive Plan, Stock Option Prior Plan, and the 2012 DSU Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:to="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest Receivable On Available For Sale Securities [Member]</link:label>
    <link:label xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to accrued interest receivable on available for sale securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:to="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceed from the exercise of common stock options</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of common shares, net of offering costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockByClassTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CurrentIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic (Canada)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued interest receivable on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:label="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Noncurrent, Credit Quality Indicator [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:to="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_IcfrAuditorAttestationFlag</link:label>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OfficeEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:label="dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_CommonStockDeferredStockUnitsSettlementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Deferred Stock Units Settlement [Member]</link:label>
    <link:label xlink:label="dmac_CommonStockDeferredStockUnitsSettlementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents common stock shares issued as settlement of deferred stock units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:to="dmac_CommonStockDeferredStockUnitsSettlementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares in settlement of deferred stock units (in shares)</link:label>
    <link:label xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares Settlement of Deferred Stock Units (in shares)</link:label>
    <link:label xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares issued during the period due to the settlement of deferred stock units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:to="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2021 Employment Inducement Incentive Plan [Member]</link:label>
    <link:label xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the company's 2021 Employment Inducement Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentFinStmtErrorCorrectionFlag</link:label>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityInteractiveDataCurrent</link:label>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NonemployeeDirectorCompensationProgramMember" xlink:label="dmac_NonemployeeDirectorCompensationProgramMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_NonemployeeDirectorCompensationProgramMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Director Compensation Program [Member]</link:label>
    <link:label xlink:label="dmac_NonemployeeDirectorCompensationProgramMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to non-employee director compensation program.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NonemployeeDirectorCompensationProgramMember" xlink:to="dmac_NonemployeeDirectorCompensationProgramMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivableTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EquityIssuanceRemainingAvailableOfferingPrice" xlink:label="dmac_EquityIssuanceRemainingAvailableOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="dmac_EquityIssuanceRemainingAvailableOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_EquityIssuanceRemainingAvailableOfferingPrice</link:label>
    <link:label xlink:label="dmac_EquityIssuanceRemainingAvailableOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Issuance, Remaining Available Offering Price</link:label>
    <link:label xlink:label="dmac_EquityIssuanceRemainingAvailableOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remaining available offering price for equity issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_EquityIssuanceRemainingAvailableOfferingPrice" xlink:to="dmac_EquityIssuanceRemainingAvailableOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_AuditorName</link:label>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_AuditorLocation</link:label>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligation</link:label>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligationDueInNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligationDueInSecondYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligationDueInSecondYear</link:label>
    <link:label xlink:label="us-gaap_ContractualObligationDueInSecondYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, to be Paid, Year Two</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issuance costs, percent</link:label>
    <link:label xlink:label="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for stock issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:label="dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="dmac_IncomeTaxRateReconciliationShareIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issuance costs</link:label>
    <link:label xlink:label="dmac_IncomeTaxRateReconciliationShareIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to share issuance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:to="dmac_IncomeTaxRateReconciliationShareIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding&#8212;basic and diluted (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding &#8211; basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Actual income tax expense, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange6Member" xlink:label="dmac_ExercisePriceRange6Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange6Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 6 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange6Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Exercise Price Range 6.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange6Member" xlink:to="dmac_ExercisePriceRange6Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:label="dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_TaxPositionsRelatedToCurrentPeriodMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Positions Related To Current Period [Member]</link:label>
    <link:label xlink:label="dmac_TaxPositionsRelatedToCurrentPeriodMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Tax Positions Related To Current Period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:to="dmac_TaxPositionsRelatedToCurrentPeriodMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:label="dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_TaxPositionsRelatedToPriorPeriodsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Positions Related To Prior Periods [Member]</link:label>
    <link:label xlink:label="dmac_TaxPositionsRelatedToPriorPeriodsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Tax Positions Related To Prior Periods.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:to="dmac_TaxPositionsRelatedToPriorPeriodsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based compensation, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingLiabilitiesTable" xlink:label="us-gaap_OffsettingLiabilitiesTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OffsettingLiabilitiesTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Liabilities [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingLiabilitiesTable" xlink:to="us-gaap_OffsettingLiabilitiesTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canadian provincial and local income tax rate, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign tax effects, percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canadian federal statutory rate, percent</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OffsettingAssetsTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting Assets [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balances</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Per share exercise price, upper range (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_OtherReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherReceivablesNetCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canadian provincial and local income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign tax effects</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Per share exercise price, lower range (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>dmac-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 04:26PM UTC 2026-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-7-deposits" xlink:href="dmac-20251231.xsd#statement-note-7-deposits" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-7-deposits" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DepositAssetsTextBlock" xlink:label="dmac_DepositAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_OffsettingAssetsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_DepositAssetsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets" xlink:href="dmac-20251231.xsd#statement-note-6-prepaid-expenses-and-other-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_OffsettingAssetsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-1-business" xlink:href="dmac-20251231.xsd#statement-note-1-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-1-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-document-and-entity-information" xlink:href="dmac-20251231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets" xlink:href="dmac-20251231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredCosts" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dmac-20251231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="dmac-20251231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity" xlink:href="dmac-20251231.xsd#statement-consolidated-statements-of-shareholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ATMOfferingMember" xlink:label="dmac_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dmac_ATMOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:href="dmac-20251231.xsd#statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ATMOfferingMember" xlink:label="dmac_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dmac_ATMOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dmac-20251231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoncashLeaseExpense" xlink:label="dmac_NoncashLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dmac_NoncashLeaseExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties" xlink:href="dmac-20251231.xsd#statement-note-2-risks-and-uncertainties" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_RisksAndUncertaintiesTextBlock" xlink:label="dmac_RisksAndUncertaintiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_RisksAndUncertaintiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-" xlink:href="dmac-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:label="dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities" xlink:href="dmac-20251231.xsd#statement-note-4-marketable-securities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommercialPaperAndCorporateBondsMember" xlink:label="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable" xlink:href="dmac-20251231.xsd#statement-note-5-amounts-receivable" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:label="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment" xlink:href="dmac-20251231.xsd#statement-note-8-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-" xlink:href="dmac-20251231.xsd#statement-note-9-accrued-liabilities-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingLiabilitiesTable" xlink:label="us-gaap_OffsettingLiabilitiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_OffsettingLiabilitiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OffsettingLiabilitiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OffsettingLiabilitiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease" xlink:href="dmac-20251231.xsd#statement-note-10-operating-lease" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_MinneapolisMNMember" xlink:label="dmac_MinneapolisMNMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="dmac_MinneapolisMNMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies" xlink:href="dmac-20251231.xsd#statement-note-11-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_IndemnificationAgreementsMember" xlink:label="dmac_IndemnificationAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ResearchAndDevelopmentContractsMember" xlink:label="dmac_ResearchAndDevelopmentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_OtherCommitmentsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="dmac_ResearchAndDevelopmentContractsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="dmac_IndemnificationAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity" xlink:href="dmac-20251231.xsd#statement-note-12-shareholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ATMOfferingMember" xlink:label="dmac_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dmac_ATMOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_StockOptionsOutstandingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitPlanMember" xlink:label="dmac_DeferredShareUnitPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange6Member" xlink:label="dmac_ExercisePriceRange6Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NonemployeeDirectorCompensationProgramMember" xlink:label="dmac_NonemployeeDirectorCompensationProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockOptionPriorPlanMember" xlink:label="dmac_StockOptionPriorPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_StockOptionPriorPlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange6Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_NonemployeeDirectorCompensationProgramMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_DeferredShareUnitPlanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan" xlink:href="dmac-20251231.xsd#statement-note-14-employee-benefit-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information" xlink:href="dmac-20251231.xsd#statement-note-15-segment-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-15-segment-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoncapitalIncomeTaxLossesNetMember" xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxCreditsMember" xlink:label="dmac_TaxCreditsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:label="dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:label="dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="us-gaap_CanadaRevenueAgencyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_CanadaRevenueAgencyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="dmac_TaxCreditsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_TradingArrByIndTable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="ecd_AwardTmgDiscLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies" xlink:href="dmac-20251231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_FunctionalCurrencyPolicyTextBlock" xlink:label="dmac_FunctionalCurrencyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_PatentCostsPolicyTextBlock" xlink:label="dmac_PatentCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_PolicyTable" xlink:label="dmac_PolicyTable" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-significant-accounting-policies-policies" xlink:label="dmac_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-significant-accounting-policies-policies" xlink:to="dmac_PolicyTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_PolicyTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_PolicyTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dmac_FunctionalCurrencyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dmac_PatentCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:href="dmac-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables" xlink:href="dmac-20251231.xsd#statement-note-4-marketable-securities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:label="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-4-marketable-securities-tables" xlink:label="dmac_statement-statement-note-4-marketable-securities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-4-marketable-securities-tables" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables" xlink:href="dmac-20251231.xsd#statement-note-5-amounts-receivable-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-5-amounts-receivable-tables" xlink:label="dmac_statement-statement-note-5-amounts-receivable-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:label="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-5-amounts-receivable-tables" xlink:to="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables" xlink:href="dmac-20251231.xsd#statement-note-8-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-8-property-and-equipment-tables" xlink:label="dmac_statement-statement-note-8-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-8-property-and-equipment-tables" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables" xlink:href="dmac-20251231.xsd#statement-note-9-accrued-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-9-accrued-liabilities-tables" xlink:label="dmac_statement-statement-note-9-accrued-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingLiabilitiesTable" xlink:label="us-gaap_OffsettingLiabilitiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-9-accrued-liabilities-tables" xlink:to="us-gaap_OffsettingLiabilitiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OffsettingLiabilitiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OffsettingLiabilitiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables" xlink:href="dmac-20251231.xsd#statement-note-10-operating-lease-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-10-operating-lease-tables" xlink:label="dmac_statement-statement-note-10-operating-lease-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-10-operating-lease-tables" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables" xlink:href="dmac-20251231.xsd#statement-note-12-shareholders-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-12-shareholders-equity-tables" xlink:label="dmac_statement-statement-note-12-shareholders-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-shareholders-equity-tables" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-13-sharebased-compensation-tables" xlink:label="dmac_statement-statement-note-13-sharebased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-13-sharebased-compensation-tables" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables" xlink:href="dmac-20251231.xsd#statement-note-15-segment-information-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-15-segment-information-tables" xlink:label="dmac_statement-statement-note-15-segment-information-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-15-segment-information-tables" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-tables" xlink:label="dmac_statement-statement-note-16-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-16-income-taxes-tables" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:href="dmac-20251231.xsd#statement-note-2-risks-and-uncertainties-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_WorkingCapital" xlink:label="dmac_WorkingCapital-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-n2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WorkingCapital-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="dmac-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_PatentExpense" xlink:label="dmac_PatentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_PatentExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:href="dmac-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:href="dmac-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:label="dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dmac_CommonStockDeferredStockUnitsSettlementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual" xlink:href="dmac-20251231.xsd#statement-note-4-marketable-securities-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:label="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivable-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:href="dmac-20251231.xsd#statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_CommercialPaperAndCorporateBondsMember" xlink:label="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:label="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="dmac_CommercialPaperAndCorporateBondsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details" xlink:href="dmac-20251231.xsd#statement-note-5-amounts-receivable-amounts-receivable-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-5-amounts-receivable-amounts-receivable-details" xlink:label="dmac_statement-statement-note-5-amounts-receivable-amounts-receivable-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:label="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-5-amounts-receivable-amounts-receivable-details" xlink:to="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual" xlink:href="dmac-20251231.xsd#statement-note-8-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:href="dmac-20251231.xsd#statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:label="dmac_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-8-property-and-equipment-property-and-equipment-details" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:href="dmac-20251231.xsd#statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:label="dmac_statement-statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffsettingLiabilitiesTable" xlink:label="us-gaap_OffsettingLiabilitiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:to="us-gaap_OffsettingLiabilitiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OffsettingLiabilitiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OffsettingLiabilitiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual" xlink:href="dmac-20251231.xsd#statement-note-10-operating-lease-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_MinneapolisMNMember" xlink:label="dmac_MinneapolisMNMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="dmac_MinneapolisMNMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_VariableLeaseCost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:href="dmac-20251231.xsd#statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:label="dmac_statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual" xlink:href="dmac-20251231.xsd#statement-note-11-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_IndemnificationAgreementsMember" xlink:label="dmac_IndemnificationAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ResearchAndDevelopmentContractsMember" xlink:label="dmac_ResearchAndDevelopmentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_OtherCommitmentsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="dmac_ResearchAndDevelopmentContractsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="dmac_IndemnificationAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual" xlink:href="dmac-20251231.xsd#statement-note-12-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ATMOfferingMember" xlink:label="dmac_ATMOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EquityIssuanceMaximumAggregateOfferingPrice" xlink:label="dmac_EquityIssuanceMaximumAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EquityIssuanceRemainingAvailableOfferingPrice" xlink:label="dmac_EquityIssuanceRemainingAvailableOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum" xlink:label="dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits" xlink:label="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dmac_ATMOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockNet-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EquityIssuanceMaximumAggregateOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EquityIssuanceRemainingAvailableOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details" xlink:href="dmac-20251231.xsd#statement-note-12-shareholders-equity-shares-reserved-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-12-shareholders-equity-shares-reserved-details" xlink:label="dmac_statement-statement-note-12-shareholders-equity-shares-reserved-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-shareholders-equity-shares-reserved-details" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_StockOptionsOutstandingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitPlanMember" xlink:label="dmac_DeferredShareUnitPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NonemployeeDirectorCompensationProgramMember" xlink:label="dmac_NonemployeeDirectorCompensationProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_StockOptionPriorPlanMember" xlink:label="dmac_StockOptionPriorPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:label="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_The2021EmploymentInducementIncentivePlanMember" xlink:label="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2019OmnibusIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2021EmploymentInducementIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_StockOptionPriorPlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_NonemployeeDirectorCompensationProgramMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_DeferredShareUnitPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:label="dmac_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:label="dmac_statement-statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-13-sharebased-compensation-stock-option-activity-details" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares-n8" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-5" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_ExercisePriceRange6Member" xlink:label="dmac_ExercisePriceRange6Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:label="dmac_statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange6Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:href="dmac-20251231.xsd#statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:label="dmac_statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual" xlink:href="dmac-20251231.xsd#statement-note-14-employee-benefit-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual" xlink:href="dmac-20251231.xsd#statement-note-15-segment-information-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details" xlink:href="dmac-20251231.xsd#statement-note-15-segment-information-segment-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-15-segment-information-segment-information-details" xlink:label="dmac_statement-statement-note-15-segment-information-segment-information-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-15-segment-information-segment-information-details" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_OperatingExpensesExcludingSharebasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="us-gaap_CanadaRevenueAgencyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_CanadaRevenueAgencyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:label="dmac_statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:label="dmac_statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:label="dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:label="dmac_statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsLiabilitiesGross" xlink:label="dmac_DeferredTaxAssetsLiabilitiesGross-3" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="dmac_statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n9" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_DeferredTaxAssetsLiabilitiesGross-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:label="dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:label="dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:label="dmac_statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceTable" xlink:label="us-gaap_ValuationAllowanceTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details" xlink:to="us-gaap_ValuationAllowanceTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="us-gaap_DeferredTaxAssetDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="dmac_TaxPositionsRelatedToCurrentPeriodMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="dmac_TaxPositionsRelatedToPriorPeriodsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoncapitalIncomeTaxLossesNetMember" xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_TaxCreditsMember" xlink:label="dmac_TaxCreditsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:label="dmac_statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="dmac_TaxCreditsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>dmac-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 04:26PM UTC 2026-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets" xlink:href="dmac-20251231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DeferredCosts" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="dmac-20251231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dmac-20251231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="dmac-20251231.xsd#dmac_NoncashLeaseExpense" xlink:label="dmac_NoncashLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dmac_NoncashLeaseExpense" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details" xlink:href="dmac-20251231.xsd#statement-note-5-amounts-receivable-amounts-receivable-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:href="dmac-20251231.xsd#statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:href="dmac-20251231.xsd#statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:href="dmac-20251231.xsd#statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details" xlink:href="dmac-20251231.xsd#statement-note-15-segment-information-segment-information-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details" xlink:type="extended">
    <link:loc xlink:href="dmac-20251231.xsd#dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:label="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="dmac_OperatingExpensesExcludingSharebasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="dmac-20251231.xsd#dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:label="dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="dmac_IncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dmac-20251231.xsd#statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsLiabilitiesGross" xlink:label="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20251231.xsd#dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:to="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:to="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="dmac_DeferredTaxAssetsLiabilitiesGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>aistreatmentop.jpg
<TEXT>
begin 644 aistreatmentop.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M^Z//O_\ GA%_WW7BWV']IK_H+_ G_P %&K?_ "31]A_::_Z"_P "/_!3JO\
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M'?AN^T;6M/LM6TC5('M;RRO(5GM[J)QAHW1@592#@@BG%VDF]@>UCXI\(?\
M!6/Q)X<TNS/BOP?;:TVG6'B:^\32Z9#+H]YH;:/;6MR;26PNV9Q<,EU'G;*\
M9#QLCL"=O5_%[_@JI'X(T?Q+9V_@;6]-U[2M&N#!-J4EO+90:TNC2:Q#ITPA
MF,AS:*&:5 8PQV;\\U[19_L/_"/3_!UCX?A^'7A*+1M,:[:VM5L%V1F[B,-R
M2>K>;&=CY)W* #T&-/Q%^R?\-_%OBV[U[4_ _AB^UJ_TI]#N;V:P1II[)XS$
MT#-CE3$3&>^PE<XXKLE6PS=^1_U\SG5.K:W,>$^&O^"NOA373X(CA\+>*M1_
MX3/?-#-8VRR;+-+V/3VO/)W&4(;MV'ED>8L<;.P' *>,?VYO%_P,_:I\>:7X
MWE\+/\,/"3:-NN]/TZ:*_L(]5:Z6":YEDN#'Y436NQV2/+&X0@*%->YR?LB_
M#237+/4_^$'\-B_T_47U:WG6S57BNG\O?*,=V,4;$="R*Q&X9K/_ &A?V-O!
MG[2?A#Q+HVN6LME#XT2RMO$%SIXCBNM9M+24R1VDTC(Q\K+.#MPP#MM92<T*
MIA^;2+L_\^GR*Y*EM6>*WW_!8GPKX8T^\U#Q#X$\:Z%I-C;RF6ZF^RR$7::1
M!JPL_*64R!S;3@;BH0.I!;H:]_\ V:/V@;?]I/X9#Q%!HNL>'Y(KV?3[BQU&
M+;)'+"^UBC#Y98FX*R+PP/U%8&A?L)?#/2?BGXS\977AK3];U[QT[B_GU.WC
MN!# ]I!:/:P@K\D+10("ISG+<X.!Z%\./ACH/PA\(V^@^&=*L]&TBU+-%;6Z
ME44L2S'G)))))).365:5%JU).^G_  1TU4O[[-^D?H:6BN<V.,\#?!BR\"_%
M3QQXL@N[J>[\=S64UU!(%\JV-K;+;J$P,_,JY.2>>E=ELQWK+U_QA:>'+B.*
MX6X9I%W#RXBXQG':J'_"TM,_N7W_ (#M6GLYRUM<S=2$7:YT97'<U\8?LE?\
M%2+GXE:[=_\ "Q+70M$TC6]+LM?\/RZ+;7EW)9V]U?7]HEI?!1)B9?L)=I0$
MCPY!"[<GZK/Q2TQ@1LO@<?\ /NW%<A\-/"?PX^#&J:_>^%/">G^';SQ/=F^U
M>;3]+$#ZA/R=\A4#)R7/IEF/4G.U.G:$E*%V[6\C*51<R:E8\=_8V_X*6P?M
M:ZU\99;/_A%8M*\%+;WOAJ&'45:\O;"2VDD6:\RVV)VDC;Y!CRU90YW!L=5_
MP3S_ &I/%O[17AOQ%8_$&TT_2/'7AM[&74-+L].^S164%Y:K<0%9!=7*3JPW
MX=77A>47OV>J>!_AEK/B*;5[OP?IL^IW%Y!J$US)I2F26XAADMXI6..62&22
M,9Z*["I/@WX0^&_[/.A7.E^!O"=CX4TZ[G-U<0:9I@MTED(V[FVCG &T#HH4
M 8 Q6E6$6FH0:O:WZ_U8F%2UN:1ZIM)[FC;[FN<_X6EIHZQWPQU_T=N/\X/Y
M4#XI::3_ *N^X_Z=V]_\#7*J%1_9-O;4]VSH]ON:-ON:X"Y_:3\/VMS)$UKK
MQ:-BI*Z;(0<''!QR*9_PTUX>S_QZ>(/_  62_P"%:_4J_P#(_N,_K=#^9'+_
M +>_[7EI^QC^SY?>*"-+GUV^D_LWP_;:E<_9;*YOWC=XQ/+_ ,LX56-W<]=J
M$+\S*#YA\5?VX_'5U^QM\)_'_P .=/\ #7B'6O'%E!J.KK"B7D5E;C39;JZ>
MWMVN[=I2DD>S:)2RKN)!Q7L'CO\ :6\!CPW>0^)8KF'298"MT-3LO+@,3_(=
M_F8 1MVW)X.<=Z\=\0>)?V3?&.B6&C:EH?P_U"QUH6::?:RVUJPOOLB&UMA
M-V9/+3="OEYX+)SDBNNE@ZBBN:DV[]OP,)XRDV[5$97[1W_!3O4-#^#WA[Q#
M\*[2T\2K-9OJ&MZC?^']2:VLXUTS[="BP1[9"MQPGGJSQ6^<R$\ _5OP@\?C
MXL_"?POXI6UDL%\2Z1::J+5VW-;">%)?+)XR5WXSCM7@/Q-^/?[-'QL\(PZ9
MXK'@CQ#H?A&>-E@O4M9;;19!F)%(W[8<X,>PX#8*X/2NWL/V]?A2EWIMA;^)
MM.,^IQ(VFVL4T.^]C.0A@0/F13M(!0$':0.E35P55P2A2:>O0J.,HIMRJ+[S
MVK;[FC;[FO$D_P""B?PADTRXOE\9:.UE:2K#<7 O8##!(V=J._F;59MK8!()
MVG'0TS5O^"BOPHT>XM;=_$<$UY>QK-;6D#QR7-Q&R%UD2,/N9"BE@P!!49SB
MLEEN*;LJ;^XMX_#)7<U]Y[CCGO2;1FOG%?\ @J]\$FT9M2'BN Z:DPMVNP\7
MV=92I81F3?MWE06VYS@$XQ5D_P#!4/X/C5FT_P#MZ7^T%@^U&U\M?/$/E^9Y
MNS=NV>7\^[&-OS9QS6O]CX[_ )\R^YD?VGA/^?B^\Y/_ (*&?MV>-OV/O&^B
M?V)X6LM5\,1Z:-4U2ZGM+FY>\;[;!;?8HWA(6T?RY7E6>X!C9D$8&XFMS7OV
MU]<UG]J#X:>&_!^F:'J7@3QH=;L+C4+];RSU+^TK"UDF\E(I(D"0@HH,IW[]
M_P H 7)Y3XD?MK_LM?%G4_#WBWQ0/#6N3^'KIET?5[ZUMYEM)UVR%(Y6;:6!
M$;[,G!"-@$ U#\4?VG/V6_B_\3[36O%EAI>M>+O"%I(89KRV5KW1[?!:1B-X
M:)-LA+,0!M;DX-=4<KK\J3H2O9W=G\M/(Q>84+MJJNG4]*_87_:$\=?'NV\9
MCQC:>$KBU\/:I'8:=KOAD7 TK6&\D-=10&<EIEMIRT!G7"2LC852K >^8P>]
M?&GP-_:W_95_9?\ #FSP"FA>#]&UJ584&GQ1PVMV\(VB./\ >;24$@&U.FX9
M'->B2?\ !4CX.PWFHV[^('CN-'5GU")D026"JP5FF7?F(!B 2^,$@=36%7*<
M8YMPHRMZ&D,RPR5G45_4^A]ON:-ON:^=3_P52^# AL)/^$E'EZJQ6Q;]WB^(
M;81$=_[PA_E^7/S<=>*Y;QE_P6M^ _@?6M1L+S6M7EFT=%>_:WL/-2PW/L F
M8-B,[_EP^/F('7BIADF/D[1HR?R83S7!Q5Y5$OF?6>WW->)?\%!/C]XR_9@_
M9JU3QKX+TCP_K%WH]Q;M>KK%Q+'#!:M,B2.B1C=+)\P"J609.2V!M/D\?_!=
M7X S3Z=$FI^)7EU@!M/1=(8M?@L4!A&[,H+@K\F?F!'48KC?C5_P5H_9)_:0
M^'M[HOCBVO/%7ABPNHI+VVOM&,MI;S@LL?F_-M5L[@H?&2#@9%=%+(<P4TY8
M>37^%F$\[P%FE6C?U/7/%?[8WBSX8_M?ZOX<U^V\*7?PYTC2;C5=2GT:"^O=
M5\,0*L(M9KTHK(SW4KS*EM'&9 D/F;F7=CF?B+_P44\0?!;XR>*I-?MO!VJ_
M#?1M#?5@^E-<QZAHC2R6T6F17\TP$*3W\DTFV#:K0)%YCL5)->7> /\ @H#^
MQC\.OB[:^)O#7ABZTOQKK$0EMKRST&07NI(T/DJZ -F8&*/8& ;*IP>*;X4_
MX*4?L6>#OB)K/Q)T;1OL/B'4KMSJNO0:*09[FX7YO.DW[#*ZQ_Q?,0G' XZ%
MD>+O9X>;T_EZ_IZ_AWR_MG!O_E_'?N?5/_!/;]IR]_:]_94\/>-]5?PU_;E[
M->6FJ0Z!<M<:?;7$%U+"4C=B68;41LG[P8' ! KVO;[FOB/P#_P6._9I^&EA
M:>&/#D>M:/ 4>^M=*LM :(E)BUP\R1 Y*ON>4L!@@ELXYJ^/^"]/[._]CC4/
M[=UPZ>9?L_VO^S3]G\W;N\OS-VW?MYVYSCGI7-4R#,'-N&'DD_)FL<[P*BE*
MM&_J?9NWW-&WW-?'S?\ !</X(R7DUK:Q^/=1O[94DFL[+PU/<W42. 5=HDRZ
MH05(8C!#+ZBE_P"'VWPD)_Y%OXQ?^$)?_P#Q-<\\FQT':5*2^1M#-L%)7C5C
M]Y]?O\BDY)Q7R3\7_P!OWQ-^SO\ 'SQE;>*+3P9J7P_\-:1-J$S:1+<?VAH3
MM);PZ;%?7$F+=9K^664+"%!B2(2,Q0DU6;_@MI\)67 \.?&+GT\"W_\ \37F
MWAC]OC]ECP9\6]2\>:5\*/B)8>,-:FEN;_58?A[?K<7LLJJLDDAVX9F55&2,
MX 'I5T<LQ"OST9/Y?U853,L,_AJ)?,]&^!/_  43O/C_ /L@V7B%?%/P[\+_
M !"AL=0U?6ICIU]JWAS3+2QO)H;@B>-XP2(HU8 S!CN#;-I J+X8_MA_&_4?
M%/P1LO$&A?#V:X^(]O'>:IHFGPWL>LV-C)Y\CZBZL[1VD,$8M%992YEEG>-6
M5E /+R_\%-?V<)/A?<>"6^&OQ'_X1"[=WFT8?#N\%G,7F,[[H]F#NE8N<\$D
MYK(\1_M^?LM>+/C+;?$+4OA5\1KKQO:"!8M;;X?7XO%6 DPKO"C*H6) / )/
M'-;+ 5KR2H2L[VT_X8AYAA[+]ZOO/T&4[QUI=OU-?'J?\%L_A)&#_P 4Y\8C
M_P!R+??_ !-./_!;;X2#_F6_C%_X0E__ /$UQK*<9_SZ?W&O]JX/_GXOO/HW
MP3\&;+P1\8/&_B^"\NYKSQQ]@^U02!?*M_LD+0ILP,_,&R<D\]*S?VH?^2;0
M_P#82MO_ $.H_P!E_P#:G\._M;>!+KQ%X9L?$MA86EZ]@Z:WI,NFW#2*JL2L
M<H#%,.,-T)SZ5)^U#_R3:'_L)6W_ *'7'4C.,G&>Z.VG.,XJ4'=,Z[P+_P B
MW;_[@HH\"_\ (MV_^X**@L=XEUW^SHQ%'@RN.O\ =KEY)6F<L[%F/4FI]8N3
M=ZC*Y.><#Z56KOI044>?4J<S#O1116QF%%%1WEW%I]G+<7$B0P0(9))'.%11
MU)I %W=Q:?:23W$J001*6>1VVJ@'<FO$/BU^TQ)-%-;Z+-_9]A&"LM\_RR2?
M[F?NC]3[5S/QY^//_"3>8!));:);MB*$'#W;#HS#^0Z <U\_Z_KE]XWU..,*
M[[WVP6T:EN3TP!]YC6$ZK?H=-*BVTDKLVO%7Q;EN99$TX$;R=US*-TC'U /\
MS6)X/\*W?Q-\61VKWC!B#)-/*=_EH.I [GT KO\ P)^SOJND2?VEXCT:=+6,
M I"S+R>Y<9R![5ZO;^-=/TJU@M5TO1;6.3*0Q^3$A<^BY&2:\+%9I"+<*>_<
M^PROAJI44:U=:?R]?F<5H'[-_@@:RUNMWXJ\1W=JB27%K:VZ1I$6&5#OPJEA
MR!NSCFO9O ^D1>#K6.&PT"#0[0  0VYCEF?'0R/G]!GZUX]I?C:[7XL:E%H.
MEZI/)86XM=0CLH2Z7$CJLD2N>$3RU;[S'=^\( Q6_/J&N1MYFJ2ZC8LY^6&W
MA8(GL7VDL?R'M7D/&U*BO)MGUCR6E0?+225[>O\ 75'1?%CPY9>(=3MKZ33$
M74+!Q/ 9H@5EQG*YZ$']#@U2TO6-!O[J*"XG>$75O]H@2".-6<!MK*<@],KV
M[GTKGKSQH3>PVRS7>H7:\I V0R \;CP/S/%8UIJ#^ -:U"^U6P5[&]N W]I6
M\BR_V?$<!8Y%P&2-6R=RY'S9.*YY5G>YW4LOO!I[]//^O^&/04\ _#^:Y>:3
MPK:W5Q)R\D[,[.?4C('Y"J7AOP1X:\*>,M7O=*LY](-Q;0FW^RS%&MSE@Y0G
M(Y(Z'(XQ4LEOX:U25!>-+J( #"U:0"+\0OS,/J<5QN@ZK:W'C"QG\.0V&EVG
MB2<VL5JS^;%9+'$TC3-$K865BN/+!'8MSD5M]9E:USDIY;3ES2Y7?O\ UY&[
MXB\(Q_'GQ/-X=U:/1EN;&WAN?[9M[7[/<,CLZA'7.-Y\LG(XYX KC?BG^S-X
MI^"-B^JZ%J$NL:-"-TZ*I9[<>K)W7U*]*[KQI%;?":XL;Z&>\O\ 6M=NA;3[
M8PTFHL%)C1(UP%V@,% P -Q8]372:/\ $3QEH5N)+GPCJ,T&,ND%Y:W,@'?*
M"0$\=AG\:Z</CI4Y:ML\_,<DI8B*G!)77DF^]CYZ\&_&Y8KR.69Y-,NT/R7,
M#D+GUR.1^HKZ$^''[3SHD4.O@75NX^2^@ + >K*.&'N.?:O/O&GP:\#_ !KU
M>8^';P>$O%<N7;2;Z)K9+AN^(W 93U^Z"/:O']0M/$?P,\1R:?J=J\)1OF@<
M[HI1_>1AQ^(KZ##8ZG42Y7J?"X_**^&;]I'3O;^OOV/T&T_4;?5[&.ZM9HKB
MVF&Y)(V#*P]C_2IJ^3O@K\=9M D%UIDIFM'8?:["4]_IV;T8=:^G?"'C"P\<
M:)'?Z?+OB?AU/#PMW5AV/\Z]*$T]]SQ)PML:E%%%6016_/BC2EQP;@']#3?V
MM/CU%^S#^SAXP\>2VJWI\.:>]Q!;EB%GF)"1(3V!=E!]LTZU_P"1MTC_ *[_
M /LK5Y'_ ,%E/D_X)N?$D_\ 3"T_]+(*K X>&(S"A0J?#*44_1M(SQ]>=#+Z
MU:G\48R:]4F?G#^P1^TAXY_:)_X*@?#K6_&7B?5=9O+W4KEVB:X=;6 &TG(C
MBA!V(B]@!]<GFOV]7.XYK\!O^"3+@_\ !1GX6C)YO[C_ -(YZ_?L=37UOB51
MITLPI4Z45%*FM$K+=GR'AI5J5,!5J59.4G-W;UZ(****_.S]'"BBB@ HHHH
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M/0/^"9WPDT_6/$>IWWA#3M:U3Q@[2:W<ZLTFH-J691-L<3,X\L2 ,J !5(&
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M<'<.XH]I84LNY]826NVO6UVM.VVMCT+X5SOX9U'6?"<[F=-&:.YT]Y.3+8S
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MG IOFC.,9K\]/T =161XX\<:=\.O!NK:_J\QM=*T2TEO;N8J3Y<4:%V.!R>
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M",=R<]S6OXSXU-,?\\Q^')K(7YB>X/;_ #_G^OH4O@1Y];XV(.G  Q_G_/\
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MP7*D1_ #P7#X_P#VJ/#NM?V'I-S]@GN+A=7N_"$>K('B1DDBBU6.X#V%TC,
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M7_)'XO\ L*VG_HRO2-#YMCSG+>M>;_ME?\D?B_["MI_Z,J(_Q$4_A.V^%O\
MR(]A_P!<_P"IHH^%O_(CV'_7/^IHI2W".R,"BBBO2/-$9UC0LS*JJ"68G 4#
MJ37SA\:OB>WQ"\0^5;,PTJP8K;KG_6MT,A^O0>U>D?M)^-W\/>%8M-MGV7&J
MDK(P."L0QNQ]3@?3->!]*PJ2Z&].-E<*:8E/:G45D:C#"#W(IK0=L\>]2T4
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M4B\ZSOK.42P7"9(RK#T(((Z@@@C/74!R>>W7W_S_ )]_YR?^"3/_  6/UO\
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M(3_SS&>/?_/^3@Y (SU[_G_G/Z]\\^A2^!'GU?C9G^+1_P 49K//']FW./\
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M9P^/FB^+?AG;ZYHOB_27N/(,MNT,%VD$3375K,)-J2)Y4;%XB=V!D ,%-?T
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M *B-U_Z07-?TP=Z]WC=WQL'_ '?U9Y?"T;8:2\_T0M%%%?&'TX4444 %%%%
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MIK%N4M7OU]7MY)6_X<++XRRZ;\(Y==OH[;5M3LL'4+/2YT?["S'/EN2W!12
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MX(>YV!"S1C:<J!(AYP3D@ D$4YX[.HMWK5-/[\K?F$H8I;M_>>1?\,U> /\
MA"_^$;_X1'2/[ %Y_:/V#:_D_:/+\KS<;L[O+^7KTK6G^$GABZ\87OB&30[%
MM<U*R;3+J^PWFSVS0BW:$\XVF$!.F< 5ZKK_ ,$K[2M?U*QMK_3+X6-U+:6[
M;VC?4)8XO-D2-2/O*A&<D D@ DG%-B^!^JW"1;;_ $/S97AB6'[6?,$LT/G0
MQD;<;G3..< @Y(SR_KF=WLJM3_P.7^?];[ HXJ]M?O9XQ+^S?X!N/"=EH,GA
M/26T73;N6^M;+:_E6\\JHLDB_-G<RQH#R?NC\=*]^#_A;4_$NOZU<:'8S:MX
MJMI+/6;IE;S-1ADV[XY.<;6V)G&/NC\>]U7P!J&CVBS2"W*2S6]O!MDW?:&G
MB$J%..1M(R>Q8#G//5-\!A?Z?>-I^I>==:=K$NGW$<L815MH5C\ZZ!_NH[G<
M/[N#SSDI8S.IR<56J773GE_F$(XJ3LF[^K/"I/V>_ \^BZ+IS>%]+:P\.3R7
M6EP%6V6,LCK)(Z?-U9T1CG/*C\;-S\%?"-YJ'B:[E\/:=)<^,U9-=D96SJJM
M*LS"7GD&55?C'(_ ^U>*/AKX:\*P:^9;[7YFT/6(]+WI%"$F617=9<'D85.1
MZG\^,\5:#)X7\3ZAIKL)'L+AX"_3S I.&_$8/X_G&(S'-Z.L\1/Y3D_U[IBJ
M^WIZRD_O?]=#A8O@5X.MW\-E/#>FJ?!S;M#^5O\ B5GSO/S%SQ^]^?G//Y%G
M_"A/!0M/$$'_  C.E^1XKD276$VMC4G67SE:3YN<2DOQCDFNN//0G\J!R>E<
MO]N9E_T$5/\ P.7^9A]8J_S/[V<S9_!KPGINN>&]3AT#3XM0\&Q1P:'< -OT
MN.-VD18N> KNS#.>6-5+']GGP)I^A:EI<7A/1!INKW45[?6LD'F0W<\1<QR.
MK$@E3(^/]]O7CL2?FX[4=?P/^?\ /\NQ_;F9=<1/_P #E_F'UBK_ #/[V='X
M2^+?B?X?Z-;Z?H.MWFB6%K;QVL-M8!+:.*&,;8X@$4811P!T SC%:7_#2/Q!
M[>-/$?\ X%G_ #_GMVXLDC_/^?\ /IV!PV>V?\_Y_EVQ>:8UN[K3_P# I?YE
M+%UUM-_>SZ8_8;^+WBOQY\:)[+6O$6KZM9C2YI1!<W!= X9 &QCJ,G\^_2OK
M=>0?3_/^?\\_$W_!/ ?\7^N?7^Q[@?\ C\?^?\XK[: R>/\ /^?\^_[=P!6J
M5<J4ZLG)\TM6[OIW/ON')RGA.:;N[O<1CQQ^'^?\_P"(WU_/_/\ G^8.!Z$_
MI_G_ #[KG:?\\5]P>\(1NQTQ0& ]<4I.0!QS29YZ@4 '11UX_"@87/7G_/\
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M?QI"0%]?\_Y_ST"N<\=OR_S_ $]N)B I)/X=/\_Y_P $ X_S_G_/Y'7.>/\
M]?\ G_(X4#D?3_/^?\BGL!JZ"3]D/3[U>:?MESJGPJLX21ON=7M40>I#%OY*
M:]+T,XM"3C[QZ5X]^T;=-X\^+/A7PM;L3%IQ.JWQ'(3/R1 ^_P!\_EZUG'XB
MGL>J?#BW-MX,L$)R?*!].O-%:6D0"VT^) ,*J@ >@ P!14MW=QQ5E8L21+*A
M5AD'M6)J7@U9"6MVV?[)Z5NT4XSE'8F4%+<Y)_"5XK8"JP]<@4G_  BE[_SS
M'_?0KKJ*U^L3,OJ\3D?^$4O?^>8_[Z%'_"*7O_/,?]]"NNHH^L3#ZO$Y'_A%
M+W_GF/\ OH4?\(I>_P#/,?\ ?0KKJ*/K$P^KQ.1_X12]_P">8_[Z%'_"*7O_
M #S'_?0KKJ*/K,P^K1.1/A*[<%6B4JPP06&"#UKYW\0?LI>+;?7KU++34FLQ
M,WD/YZ#<F<C@GBOK8C(H Q4RK2EN7&E&.Q\??\,L^-_^@2G_ ($)_C2']EGQ
MOC_D$K_X$)_C7V%2,"14^T97(C\K_B3_ ,$\OC!I'_!0WPE\0O#_ (2-YH-[
MIL=CKL\=] GE8$D1)4L"W[LQMP#]ROH__AEKQOG_ )!*?^!"?XU]@%"2.:55
MQ7-0HJE*3C]IW_0]O-\[K9C2PU*NE^XI^S35[N*DVKZ[J[2M;0^#?VA/V#O&
MOQA^"'B?PW_8\33:G8N+;=<1\3K\\1Z\?.H'XU\[?\$T/^">'QY^ OBWQA8>
M*O!$FEZ%KEK!=P2MJ%O(JW<3%"N%<G+1OUZ?)7Z]L,BF[#GM657!PGB88MZ2
MBK>OJ>E@.+\9A<BQ'#T8QE1K24G=.\9*VL7?K97O<^0?^&6O&_\ T"4_\"$_
MQKYQ_:S_ .">/Q?U#]I;X5_$3P?X4.J7'A^Z6WU9(KZ"-OLWF<D[F&1Y<DPP
M,U^IXZ4UDR:UQ=".(AR3[I_-'F9!G5;*<2\302ES0G!J6SC.+BT[-='IYI'R
M"_[+'C978+I2%0< _:$Y_6D_X99\;_\ 0)3_ ,"$_P :^P%&!2UT^T9XJIH^
M/E_9<\<(05TI593D$7* @CH<YKV_X9Z%XIN-!6#Q!8>1?6V%\X2*RW*]F.#P
MWKZUZE13C5:=T2Z46K'%)X8O(/$>FS-&!'#-N8[AP,$>OO5?]I?X67'QK^!'
MB?PQ:2QP7NJV;):N_P!Q9E(>/=[%E )]#7:W%JTMS&XQ\AY'Y5,T>\Y]JPQ4
M(XBG*G55U)-/T>XG0BX.F]GH_F?DW^Q9<ZSX*_;X\&>&_$6GW>CZQ;W\\4UI
M=(4<,+:7)&>&7C(9<@CFOUE4\^]4KKPY8WNHV]Y-9VDUY:_ZF>2%6EAR,':Q
M&1P3TJZ!BO%R')(992E1IRNG*YQY9ERP=.5-2NF[G(_'GX+:3^T+\(]<\':W
M)>P:=KD*QO-9R^5<6SHZR131M@@.DB(ZY!&5&01Q7C,G_!.M9]9'BB3XD>+C
M\1YM3?4+OQ4MI8">>-[);%K=;<PFWC06Z@*53<KEGR<D5]*T5[IZ1\Z?\.][
M"V^UV]MXX\50:1'XHA\7:1IQ@M'ATF_6_%_,^XQ>9,)9=PQ(Q"JY"\@$<B?^
M"3&@_P#"!ZKH)\<^)Y8KQ+*VLKF6RLVN-&M[1[UH5MW$09)5%](!.#Y@*J=Q
M!93]<T4 ?+VH?\$NO#6H^)GU(^+/%*B_U*6\U>)A!(=7@>]MK\6[NR%DQ<VL
M3F1"KL"X)Y!';? 7]BO0_@'KMY?66K:KJ#WN@CP_(DZ1JOE?;[Z],GRJ#O+W
MTB^F$7OG/M=% '@WA;]C^^MM*M[?4/$?DV=WX5MO"6LZ=;V<<T-_;VJ7$<$J
M2N!)$^V?<<9&Y1Z9+;/]AJVTGPC'H^G^-/$EG!J6B1Z#XGE\JWDG\2PJTSO,
M[%/W5P[7%QNDCQD2G@%5(][HH XKX.?#:7X>3^)Y9C; Z[K#7L,4&=EM;I!#
M;01\_P 7E0(3VRQ'.,UVIZ44&@#X2_X*;3+'\=M(#.JYT1.I _Y;2_Y__7@_
M.OVN(_\ +2/_ +['^3_GUY_6?4_"FEZW<"6]TVPO)57:'GMTD8#TR0>*K_\
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M*\T#_H!Z/_X!1_X4+PRJ?\_U_P" O_,/]4I_\_?P_P""?D^+J/)_>I_WT/\
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M %1G_P _%]W_  3\H#=Q_P#/6,?\"% NH@/];&/^!"OU@_X5YX?_ .@'H_\
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M(DOO!?[1]QI]W-#XM\%07;3R_9K<6H:)(G+;<N822\8VE.,'D/GK6-X9\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>bkr2.jpg
<TEXT>
begin 644 bkr2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M>9&+BTEFA+IN7>@?<N1D#(K\<?\ @K:GA>3Q/^Q<GC3P-J_Q+\*M\9=7&N>
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M'FV!;>"K8NLO:U(RHQGAL5&C^K-%?S_^+O\ @I/\>9/&?Q1\9^"M8T&;P_\
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M2PZ6\40GFBU.6.=X[":"(AYX[EHVA7+.%7FDA\4^&+C3;?6(/$>@SZ1=^?\
M9=5AU?3Y--N?LT,]S<_9[Y+AK6;[/;VUQ//Y<K>5#;SRR;4BD9=*?'?%]+$U
M,5'-9NO4Q&(Q51U<#E]:+Q6*S"CFU7$>QK8.I1CB%F.&HXRA5C353"U::>%E
M1BY)Y5.".%:N'AAI99%4:=##X:"IXW'TIK#87 5<JI4/:TL7"K*@\OKU<)6I
MRFZ>)I3:Q,:K46OA/QS^P9-KWB[X&^/O ?QW\:_"CQE\'?@Q8_ >\U[P[X:\
M,:O/XO\  =K8K93QM;>(8[ZRT+5KKS+R5-1CM]4>R>>WDM(X[JPMKH<W8?\
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MQ9]U^WW\#QX4\,^+=!T?XK^.+?XA>-_&_@OX3:-X!^&^M>+_ !'\7X?AT/\
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M6K83^TJ.+5&=:<Z<?WDN;\3?V+M%_:7\+>/_ ('^ O#T?QOOOA3J'@BZTO\
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MI8C"XO$8W#^PA4Q$H8:A3QN+Q.)CA,/&EA'7KU:DJ#G.3?QQ^T]^QYK?Q_\
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M<?'+?&7_ ()[_!99/$GB[X=?LLZ)X@^)GC#XL:CI2Z9I^L:QX:TVS\,?#?0
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M ()4?&WX277P5^,6K_%#XC>/_P!KS0O '@WP1\%?B!XV\016_BK]I;X@^*=
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M:5\1?C^^H_L^ZMXB^$GQ._;0^$.NOXIUSX!>//B_IW@CP1X<_9.\)V>C^/\
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M;Q/KVH>&]2\/VCWNA>'T\&"[7][_ .T]-_Z"-C_X%V__ ,<H_M/3?^@C8_\
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MK-AX?T?2]/\ "=SI\WBW1851+G^BK^T]-_Z"-C_X%V__ ,<H_M/3?^@C8_\
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MPD^)OCGXS_L^:UXZ\2_#[3/V>/V%M/T'Q=\/O&7CF#6OA/\ #/QA9>)/C/\
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M1O#]G::WX\UK1M;7PQXWCG?3?$LR/X@TG7KNWMWU"+%^+_P*F^(/P[^.MO\
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M36M0T/X7VGC"5Y[;2OB0=!;3?#-WJ6G:FGB*PMIKR6ROX8YI99/WR_M/3?\
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M_P"A?Y(N'$6?N]\[S;2UO^%#%_\ RWR7W'T<_P"V'^T6.1\1KWTQ_9^E^_\
MTZ5&?VQ?VC,$CXCWHP#_ ,P_2OZV=?-3]!]?Z&H6Z'Z'^5<\O!3P=6WA7X>?
M9_YH[A_KR_\ 4OT^1V4\_P \=KYSFC]U/_?\5Y?]/3Z3?]LG]H\8Q\1[WO\
M\P[2O;_ISJ%OVROVD0"?^%DWN/3^S=)_G]CKYGD[?C_2H7^Z?P_F*PEX*^#W
M+_R:SP\^%O\ Y([A_>[_ .I?Y+[CKAGN=V7_  KYG\\=B7L_.KY+[CZ7;]LW
M]I-1D?$J\ZXYTS2C_P"VE;5I^U)^V#J.DW?B#3=>\::CX>L/-_M#7].\%/>Z
M%8&%0TPOM8M=&FTZS,*$/+]HNHC$A#/M4@U\BOT'U_H:_I&_X)A^--&\/_LA
M^ (+[Q)8:/I]E\=OVA!XZOM1^,/@GP3X5\%^&/%'PHL- LO%_P 3?AKXFN;:
M^^,'ARUNIYY] \)6%YI\CZ[9I+$]Y-+#;U\?QAX<^$W#.4PS&AX0>'>83EBZ
M>'^KRX7X?PJY98?$U^95?[,J>_)X>-&G!0E*=2K"-.%6JZ=&I]EPA2S/B7-9
M9;7XBS/ 0CA)XA5XUL3B&I1Q&%H6=-8BF^2*KNM4GS*-.G1G*I*G24ZM/\3'
M_;3_ &E@2!\2[T?]PS2>/;FSYXJ9OVQ/VJ5T\:O_ ,)YKG]D&].F_P!K'P]9
M?V7_ &D(%NCIPU'^SOL7]H"U871L?/\ M0MBMP8O)(<_HWX8^''P&U76OV=/
M"7A/PM^S'*OA7]BW4/C5XQU[Q#X8T?Q+XJ^+OQ%M]=O_  L-!70_$'Q$\%^!
M]1\9)H\UMXITCPMXTU#2]*CCL-0U?7[;69K>SM*]M/PO_9(TKXH6_@*+3OA1
MJ'PK'_!1/5Y)/".H^)-'N?"LG@2[_9#LM<:U>VB\07%M!X33QG)):6UW::A+
M9V.HJNEZ?K#2V\&/GL3PWX,4)RIKP:X.E.GAL7C)TUP;P]S^PP=>I1:2^HI1
MJXCDIU,-%R:<93C6]C.DXOZ+"<,\05J<*DN)W&$\3A,)"?U[%.'M\70HUHN_
M.W*EAW*5/$R44U*$)TE5A4C)?C,/VU_VG&<(GQ*OW=F"(B:5I+.[L0JHB+8E
MF9F(55 +,2  215C4_VR/VKM&O)]-UCQWKNCZG:LB76FZMX<LM,U"U:2-9D6
MYL;[38+JW:2&2.5%FB0O%)'*N4=6;[RTSX=?L[^._P!J'_@G]XR&E?"#X5>"
M-0^#2_&_]HG2_"-]!IG@VRE^#?CCXBZG?1OHEYK>I2P>(]=\.>$/#-K-X?\
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M1F2)_P#5RH'L1OB?!V2+E'P=K'!JL?VX?VGP2/\ A9UYQ_U"M&_^0:_9]O\
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MV,/P MO"E_XY^*FD>./"WAP:6\&JZ7H'@?PKXZ'Q)O+G7;#7;X7EC:0I]J^
M7_8Q^&G[06FZ_HOPY_98\')\&OVEOV%?#?AOQE9+I(;4_#OQR_9J_M'XOZ[K
MTUSXDN='OX= \<I9"/4K2QLM(\&:Q+?7M_"FKW^J7EQ6-X:\)<,L7&EX-<*5
MJ^$>.IRI+A7AI*5;!XC!X.,)-82I4C&OBL;1=*:I3<\'*.,IPJ1E[-5A.&L?
M7>%E/B&C2HXGZE.,W4Q4W[+%T,1BG-*2A!NCA\+5C5C*K!1Q498:I*$ESO\
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MJ8?_ )]X[IT?E_TZZ_\ MWH/^V\=_+1?_<.7E_?_ *OZ6_5'_A:GA+_GM?\
M_@#+_C1_PM3PE_SVO_\ P!E_QK\KQ^W/^Q.>G[8'[+Q^GQ]^%1_]VNG?\-R?
ML5?]'>_LPGZ?'KX6'^7BJE_JKA_^?>-^[T_Z=>OW^@?VWCOY:/\ X+E_\G_5
MWY6_4[_A:GA+_GM?_P#@#+_C1_PM3PE_SVO_ /P!E_QK\LQ^W#^Q:>G[77[,
MASTQ\=_A<<_EXII3^W#^Q<.O[7/[,@^OQW^%P_GXIH_U4P^_L\;;O9^7_3KU
M^_R#^W,;VH_^"Y>7]_\ J_I;]2_^%J>$O^>U_P#^ ,O^-'_"U/"7_/:__P#
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MHM:IIJZ:?9K5'SW\9K^0ZCI>F!B(X[$WA 8@,UQ<31'<H.UL?9$*EE)0@[2
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M/WKHK'^VFJM>I#"4J2Q&$IX6<*$YX=7IV?.Y45"<X56KUZ4Y2]K>TJBLK:/
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MGF1O#NI2[510[2XETJZD"AO(N6:(D[8YB ,^!_%+4?EG(<,I&5((PP(8@@Y
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MCE_Z4SWZ?\.G_@C_ .DH****@L**** "BBB@ K\<?VG?^"Q_PK_8[_:FUCX
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MOFP\JDU!T*N%K034T^6H[1/Z+XM"TCQ%I5[ =MMJL2RQW-A*5\F[V ET6-@
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MW/8?&;]NS]I73[&R_9\^#FG?LH_#*XLK:W'QT_:>T\:O\2]3M%M[=1J7P_\
MV?M'O!]D$\9\_3]1^(FO6=I<P2AQI\%U"T(_N/PFH5L3P%DF(<?84)P=JV)?
MLH.-.AA:+<.9<U5QE3DG"A"I-.,O=;3/\)/I?JEA_I'^*T*4E553BG,,9%4[
M2DHYA4CCX*27P>YB8N\W'1ZL_0?XA_$OX>?"3PQ?>-?BCXX\*_#WPGIL337O
MB'QAKFG:!I4**0N!=:E/!'+(7942*$R2O(RHB,[*#\#2?MR?%7X]33:/^PA^
MSQKOQ0TIY'M6_:*^-R:O\(?V>+"1)S!-=:"-2L5^(/Q.%N5<^5X6T&UM6;R9
M?MLUG,LS=M\//^"=WP:TKQ/9_$SX[ZUXR_:V^,5I,UW;^/?V@=2B\4:7H5V[
MK)_Q1/PWBBM_A_X/MH&!BM5T_0Y;P6PCAN;ZZ:)9*^]XXXX8HH88XX88(TA@
MAB18H888U"QPPQ(%CBBC4!8XXU5$4!54  5^C<V$H/W8RQE1?:J\U+#I_P!V
MG&2K55UC*=2BNDZ+1_-=JL]VJ2[1M*?3>37*M+I\JE;I+J? WPE_X)XZC\??
MB/\ VC^WS\</%?[2ICT"[U=?@WX9^V_"C]F_3)[;6=(:WT^7P#X;U"/4_'%G
M!Y\9?_A.M:U:"YN;6&\%A Q,2_LE/\"?@^_PBUGX"V/P]\,>'_A!K_AC5O!V
MH^ ?">F0>$_#[>'-<LI=/U73[:T\.+I@L1>VL\J33V;07+L[2F8RDN?(_@U_
MR4N\_P"Q/U/_ -/'A^OK:O@>),=BZF8*$J]14Z,:52C1IOV5&C4M?GI4::A3
MISNE><8J;:3E)O4^QR.A1C@N;V<'.<JD:DY14ISC>W+*<KRE&WV6VM7IJSGO
M"7A3P]X$\+>'/!/A+2K30O"WA'0M*\->'-%L4\NSTK0]$L8--TO3[9,DK#:6
M5M#!'N+,50%F9B2>AHHKYIMR;E)N4I-N4FVVVW=MMZMMZMO5L]M)))))))))
M*R26B22T22V05BWWB3P]I>IZ3HFIZ]HVGZSKSSQZ'I-]J=E::GK+VT9EN4TN
MQGGCNM0:"(&29;2*4Q(-SA1S7E?[2/A+XJ>._@5\3_"/P0^("?"SXL:[X6O+
M/P-X_>S-^OAO6A)#,EU]G6.:16N+:*XL$NH89I[![M;Z"&::VCC;^)'X7>(_
MVAM/_P""COP2\0_M>_%+Q)\5?B7\.=&L_'/PGU+7];NYM*U2_P!$5]=LO"CM
M<6MC)I4<[6>MZ;K-M%917BZW L%P9W55?Y+BOC?AK@K!8C'<19C'!T\/D^=9
M]*E&G5K8FIE'#M+#8C/<;0H4HRG6AE6%Q='%XN%.]6GA?:XA0E2H5I0]3+,G
MS#-ZU.C@,.ZTJF*PF"4G*,*<<5CY5*>"HSG)I0EB:E.=*DY6C*KRTW)2G!2_
MO<KYS_:[^!UY^TM^S)\;_@+IVLV?A[4?BI\/==\(Z=KFHVTUW8Z5J&H0 V-[
M=V]NRSRV\%U'"\HA/FA 61690I]R\.>(-+\5^']#\3Z)/]JT?Q%I.GZWI=Q@
M*9;#4[2*]M7= 6V2&&9/,C))C?<C?,IJ]-J%A;>>)[VUA-K US<K)/$KP6Z+
MN:>5"P:.(+R78!<=Z^J4X.*FI1<)).,E).,DU=.,D[236J:;36JT/-Y97:L[
MK1JSNG>UFMUKIZZ'S)^Q+\ M?_9=_95^"GP"\4^(].\6>(/AEX/@\/ZIKVD6
M]S:Z7>W0O;R]8:=#>$W0L[9;M;6![@)++' )'BB+>6OU/7 :A\4? >FZ;::M
M/XCL9=/OKQ["VN+,R7@>XB"F8,ELDDD:0*Z/-(ZJD:.K,V&4FI/\6_ MMJ^H
MZ+)JS&[TRRFOKF2.VGDM6C@@6YEC@N45DFG6)UQ$GWG)C4EU91A+&82+M+$T
M$[P5O:PO[Z<H?:^TDW'NDVC98;$2VH57\7_+N7V6HRZ?9E))]F[,]*KY\_:H
M_9V\,_M8? 3XA_L_>,/$'B?POX<^(VG6.G:GK?@^]CL-=M(M/UC3]:B%O+/%
M/;36]Q/IL5M?V5U#+:WUC+<6LZ-'*U=*/CC\/O[(M=9?4+R.WNK^73T@:PF-
MY'-"BR2/- F[9 (W5Q*&8-DJH+JRCI[?XC^"[K69] AUZT.HVUD=0E5O,2W%
MLMLMX["[=%MF>*T87,L:REXX<NP 5L$<;A)VY<30ES<EK587;J)N"M?>23:6
M[L]- EAL1&_-0JJW->].6B@TI-Z;1;2;VU.8^ OP2\"?LX_!_P  ?!+X;6#:
M?X-^'?AZST#25F,;7EY]G4O>:KJ4T:1K<:GJM[)<:AJ%QL4275Q(554"JOK,
M,\-S&LUO-%/"^=DL,B2QOM8JVV1"RMA@5."<,"#R#7SY\>OBKIGA[X$^//%O
MAC7=/GO;C3F\,>'+VWFCFC_X2GQ)<P>']&A WJ?,34-2@E<#YXX4>?&Q"P_-
M#X4_$GQ;::-^SC\$/A1XTU2RFO/'6J:]XX;29O.N]);7O'%Q/IG@[6#-#+*;
M30O"^G^(]<\5:7&8A(EYH]U(1 Y#?F'%WC#PQP;Q7E7"681K8K,,URG+\QH4
M\#6PD\5.OGO&G#O W#67X;!5ZU">+J9SFV>8NM[>E55+ 8+(\PQ&)7(Z;7T&
M5\*9CFN68K,Z/+2HX7%5\/4=:G5C3C#!91C\YS"M4K0A-4EA,+@Z4.24>:M6
MQM"%/7F/VWHHHK]8/F HHHH *_-'PO\ \FK^*_\ L5_BI_Z<O%-?I=7YH^%_
M^35_%?\ V*_Q4_\ 3EXIKZ3(/AK?]AV5_GC#YW/?BH_]@>8_EA3]!_!/_(F>
M$?\ L6- _P#35:5T]<QX)_Y$SPC_ -BQH'_IJM*Z>OGJG\2I_CE_Z4SWZ?\
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MY=R>)[73O[5T_2/&5KX3N'_M>TTJ1[8:C;VNNJ+FTL9'A%TBQPOL#D#^1_\
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MXQ_Z^5/S7W_TN@457N[NVL;6XO;R9+>UM89+BXGE.V.*&)2\DCGT502< D]
M"2!7SYXL^.9@;1I/ MA%XBLKNXGAU*[DCNE%M)$\2K;*BB,PR21R&X6YN/\
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MJ^W&/.ESPO%][-'BXC"5L,_?C>&EJD;N-FY*-W]B3Y6^65I+JKF_7YH^%_\
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MN#+<116\LEH+>ZVA07:-524FE,Q=;N>$Z%J&H&=#IBJL$,MKI;0RV\L0?%H
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MY9XL<4<%<09KQ;Q7PA6X1SG*<?CJ'"^.CE^!XJP.0YYE?%.59%Q+3G3J3QN
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M_8_^$/\ THNZ^PZ^//VX?^2+VG_8_P#A#_THNZ^MP'^^X7_K_3_]*1\_C/\
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MPB9H(HVE$*LRQ"0MY:L53:I(KUT):-<26:S6[7<4,5Q+:B2$W$=O.\T<$\D
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M4_\ !D__ )(^>?\ AGB/_HOO[77_ (E+\8__ )IZ@C_97^$U[J5IJWCD^/\
MXQ7NG30W.FK\;OBAX^^+6FZ==6[B2*[L=#\:Z_JNB07*,%(F&G,Y"JI)50*^
MC:*:G*+O%J$MN:"4)*^]G%)J_KMILV)RE)6E*<D]U*4I)^J;:?W#41(HXXHD
M2***-(HHHD6.***-0D<44:!4CBC152.-%5$0!54* *=114B"BBB@#N?@U_R4
MN\_[$_5.W_48\/\ ^??BOK>ODCX-9_X67>?]B?JG_IX\/X_S_+-?6]?!<0?\
MC*?_ %ZI?^DGV62_[A#_ *^5/_2@K\Z?VB/@)\4O'7[2_@/XA^$]!U"_\/Z3
M8?"A&U2/5/AO:>'+"]\&_%:3Q/XA7Q?%KUI)\3?LH\*75\^A)\--0TXW_B V
M%MXC-WHZ75LWZ+5\J_&;]IE_A)XCU;0$\ :KXGCTS2/A]<I?Z=J5I&USK?Q*
M\7ZCX1\/Z0+!XVN(X(9=*O-1O]3=Q L2P6%M'/?W<$3>(>L?$O@W]FOXZ?#'
MX'6/PVU+X)Z!\7_&.IS>'?\ BXMQKWP\O]9\ :'>^"Y/#.NZ;;Z#XSU;1?#N
MO:U\/;6.ZT+X<^1,GAV6TUY=;U>";4K'78_%?LGP>_9;\=> _CKH7Q3FLY4\
M*IXL\;0VGA;5;_PG-KG@_P -:S\'OAWX:T'Q#?>*-&MW\0^+]7.J>#;_ ,,>
M(-#UOQ)XCTD3ZC9^)-&M[46!O;C7B_;M-UXBLM&C^%U]8)8:%X=USQU%J?B*
MP;4/"UOXEO?#6EV,HETR"_T"ZLO[2\1/$;HZY'-Y&D7UQ-9V\4ML[Z-[^V<+
M?Q/XT6VTC2KG0]$M4T?P]I,NII'J6O\ BC2O''Q*T+Q!<6FIV:7\5Q9_V!X
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ME+O/^Q/U/_T\>'\_Y_.OK:ODGX-?\E+O/^Q/U/\ ]/'A_P#S^%?6U?!<0?\
M(QG_ ->J7_I)]EDO^XQ_Z^5/_2@KQCQ9XH^"=SXJUSX<>-U\%7'B37O">GR:
MCX>\466B2S^,_#4LGB"YM='MK/55:3Q7%9MI&MWLFC0PWJV*>9=-!&)V<^SU
M\P?%+]FRW^)_C^#QA=>+9-)T^6'P%#JVDP>'M-NM2G'P]\0:]XDTK^RO$EQ(
M+[1EO[[6S!JL<$,BSV=MY2[6GD8>(>L<QX>\ ?LG>,=>TSQU93>#YYM?^'FF
M>/X/ &JZKH=MIEKX$\0>!K/P_;>(-2^'UVRRZ?X>E\#M;Z-<65];KX3MK993
M_9\=[YMRW4:]>?LCZ;X:\'SWVG? S4_#OBF^T70/ -GINE^ M9M?$4FH^,=)
MTZRA\(V-I%/%JUGI_BO5["^OY-'CN(-+N6?4[GRI(VEKQ<_L$Z5<>&[?PE?_
M !)U"?2;30!9PW$7A;1X]6?7T^%'ACX1Q7]W>R3RBZ\.?V+X3T[4KGP>\0T^
M^U&XOHKFY>SDBBCWS^Q;%)XKOO&$OQ"SJ?B;Q3X6\4^,;?\ X0W1Y-.GG\(?
M%/0/BGI5IX5MY;DMX76?4- @TS4;F.6^GN8YGU,;-1CCD ![S?VW[-]CJ&N:
M5JD/P2M-5T3P\ESXDTV_3P+;ZAI'A31=);PQ'<:W9W 2YT_P]I.AZB_AY);^
M.'3;'2KYM*#16ER8'\^\9>#/V6O$WBF\\>:]XL\!Z?J/@^V\.ZQXN>R\;^'-
M'TR&T;7W\6>%M7\8QQWD8T\7FO7#ZI9:R\^EW&OM*L%Y>ZI9QP6\?G_B_P#8
M]N_B?XE^(NH>,/%%II&A:_XC\<ZCX>T_1= TRZU*2+QIX-T+P?<W7B#5[D+/
MJ%I!96%\\7AZ:)K5KM].NIKAQI5G&)=5_8=\+7^L_$?68O$3-=>//$7B;Q/!
M=ZE:Z]>ZEX?U#Q9X\\.?$'4$T>[M_%UA;:,FG:SX:L#HEWH&GZ1J-L8;*>[N
M[UK'R[@ ^@=6MOV=O$=[JGA[7(?@QKNHW&I:5XPUK1-53P1J5[-K'B33;+P[
MH?BC5--NQ-/)J.OZ.-.T+2M:NX3<ZKIOV+3+2YGMO(@K.URT_9A@MO&-MXD@
M^!$-GK<%AKWQ M];3P!%;:K:Z5J$^CZ9K/B^*^"Q7MOIVJZ;<Z79:AK"R16F
MH6%Q9031W-M)$GBT_P"QI/)>RZFOQ6U@:F]CX'DGNVT"Q\K7?%'@2X\$SZ3X
MI\2Z8EXNDSZDT?@R.QN9=!L?#\E[8:BL.I27TFDV$PCO?V)-(U&PO#J7CS4]
M0UR[U7P#KLNI+IC:)!<:GX&\7_%SQ<JW,?A[5M+U1--U6Y^+VKV\ME9:S:/9
MG2]/N(;AV>XB< ^B]0\+_ >;5+S4M5\/?"676?$OANSM-0OK_2_![ZGK_A'5
MY+#PW86]W<W$!NM4\.ZI+)I>@V<4SSZ;>R/I^EP"5FMH*YRSU[]F#PQ:Z_XR
MT?4_@=I47AWQ%]L\1:_HMWX"M9-+\9:K:ZI#$=2U&QEC:U\5ZO;:SK-M:I<S
MQZOJ*:OJ,$0F74+E9?.=5_9(LYU^&5OH/C63PW8> ? /PW^'-Y86GAZWN[35
MO#_PU^(?@_XC::FG+?:E/<:))>ZEX1CTR;?=ZH;;2[Z01.]U;0SG D_8HTFT
M3PC/H'CB;3M3\'6/V.SDO/"ND:EI6H/<:;\6]%U"]U71WE@@N[V73?BYJGV:
M=I!);W.DV;;WAN[V%P#V%M;_ &9O'^GOXAUL?!_4FU[P[X$^)FLQ^+[?P:-;
MCT2>SMKGP#XG\56.M!M0L19P:A##H&HZNB?899S:V$\;.4/5ZF/@;/J5KX3U
MC_A5,VK^.;#5Y;'PUJ1\(OJ7C#2_&<HU/7I+31[DFZU^P\5S>'!J&K/#;7=O
MKDNA?:[LW3Z9YD'RUH7[ W@[165&\67^IQ)H?AO2DN=2LKVZO4?18?AK!?1P
M6<VOR>&+/1]63X;61ETRU\.QR1&_5/MTJZ7:>9['\6_V9/#WQ;\2:KXCU+7]
M0TBXU6R^#.G2?V;8V)O+2R^$'C'XC>+HHK'4I0;FV;Q$?B+>:?=NG%E'IMM<
M6Z/)+*M '1W%_P#LR:KHGA1[N^^!6I>'/"VIWNB^"&N+OP#>:)X>UGP]:?:-
M1TGPNTDDECI6IZ'8V(N+VPTHP76FVMD)IXH8K8,C/[3_ &8?%]I>:;_:7P(\
M3V-EI-WJ.H6 O?A_K-K9Z'X5UIM2O[Z\MA+<Q6^E>'/$3/?W=U,B6FD:RS7,
MTEO>DN?"V_8>TB^.I76L^/)[C4[_ ,*:_P"#5ETWPIHVDZ?::5JGP6U#X*V-
MU!IL4LT8UFUT?4[O5+[41*K:G*;727CATNQMXQL^(?V,=#U/4+S5]#\9WGA?
M4KG6=5U<3Z;X>T8?)JWPF^%OPEN],D(6.0VD^D?#*.Z:>)XKZ"77KS[#<6EQ
M8V%W$ ?1_@?QI\.]7D3PA\/KW1+K2_#GA7PSJ6EQ^%EL7\*0^%=56_L/#B^'
MKO22VCRZ;'#HES;6T&FM]FM8+>**,+'L4>C5\T? ']G.W^!$FIM9>+;WQ%%K
M%KK27L5]8F)DO-7^)GC_ .(XG@NIK_4+YX;1_']YHRI>W5Y<W,.GVM]<7;7,
MTX/TO0 5^:/A?_DU?Q7_ -BO\5/_ $Y>*:_2ZOS1\+_\FK^*_P#L5_BI_P"G
M+Q5_7C\:^DR#X:W_ &'97^>,/G<]^*C_ -@>9?EA#]!_!/\ R)GA'_L6- _]
M-5I5GQ/HGAGQ+H.I:!XQTO1=;\-:Q"FGZMI'B&TL[[1]1AN9HHXK2]L[])+2
MX6:Y:%88I48M<&'RQYNRJW@G_D3/"/\ V+&@?^FJTKE/C-X O_B=\/-6\(Z3
MJMIHFKR:KX/\0Z/J6H64NHZ=#K'@CQGX?\;Z5#J5E;W-G<3Z;>ZAX=MK+45M
MKJWNA97,[VTJ3K&P^>J?Q*G^.7_I3/?I_P .G_@C_P"DHRH?A5^S]::KX=:#
MP%\*+?6M"T'4/"'A;RM \+QZEIGATQZA9ZIX?T4+;BYM]-$4NK6U[8V@6)$F
MU.*9 )KM6BUWX7_L\>-Q9P>(_ WPD\5>6&URPBU71/"NL%4L=.M]"DU6U6Y@
MG/E6FF65II4EW$/*AM;.UM7=4MH5C^3;']CCQU<^,X+C7?$G@M]+B\0GQOJ?
MBVS\*M'XKN=9N?C!\5/BW_PC_A*X?59KGPUHL=UX]MM UUKJ2_.MZ*E_%"+6
M6_G\OC/%W_!/S5+#PCJ,'@W6/#^M:I9_L]Z;\--$TJ[M=5T)+;Q;X=^#&O\
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ML-#CTRXU6_\ $GQ5\0?$:VU;4;R*=FO9]-MM>DT=6N4EF=EFN4EB2<P#Z@H
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MV'AS3_!HUF/5=<\(0?"OQ#X@2Q\&9M;#4/"VL7/A5O#\:63<]X3^+/[:^O\
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M9Z=KD46F^=?127:7K7#Z7K>C6T/:G]MCX-I%J6HS6OCV+P_9^'/!VO6'B!O
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M>[\2Z=JNGZG>JWPJAO5_M;5?"FO3:C8WD?PL6XT[6+/7/!'AC6-+U>TDBO\
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M4 <\/^1F3_L%7G_I5I_X^G]>U=#7/#_D9H_?2;S_ -*M/_S_ )%=#0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%,>2.)=\CI&N0-SLJ+D]!EB!D]N:5'210R.KJ>C(P93]""0?SH =111
M0 4444 %%%% !1110 4444 %?''Q6_:"\>?#CXH:_P"%8M*\ 7/AR71_A+:>
M%+O6M8U31KNR\3?$KQOJ7A&?6?&5[]GN;*T\%Z2]G&/-L(7O[G4I[+3$<7&H
MQ>5]CUFWVBZ/J9E.I:3INH&>T:PG-]86MV9K!Y%F>RE,\4ADM'F196MGS"TB
MK(4+ $ 'Y]?%#]JGXH1?#OPQXV\"Z9X-T*R\2_ /X_\ Q N1K5U=ZCJT/B_X
M5ZQX)T/0X_"DB0KI.LZ+JL_B&^U6)[N(27_A]%U*%8A;%)]2']L?QO#X_P##
MGPWOOA/83ZV/%7B70_&>J67C'1M/\/VUAHOCS3O UO=>%[SQ5>^'KC6M2WZK
M9:IJ6E06UW=V\<MI8P0S7&KZ<[_>4^CZ1=16L%SI6FW,%BC1V4,]C:S16:/;
MM:,EK')$R6Z-:.]JRPA ;=VA(,;%2V71=&GGMKF;2=,FN;*[EO[.XEL+62>T
MOIP%GO+:5XC)!=S* LMQ$R32  .Y % 'PEX__;4U;P+XA\?:4G@/2?$D'AO7
MO%W@_1M/T'Q1;S^*!KOA@>$9(M7\7Z7=I8V?AOPEJ">+[."/4;C4%:.\CM(G
M=8]7M)(Z3?MG^.+>>Q^W_"G2K:&#3M!M]=M8/&%EK&I'Q)XBB^/,=A'HLGAS
M^W-"NM)^U?!'S9@=;EU*"W\4VUG-!'JFEWUM7V[I'@#P;H5SXDO--\.Z9%=^
M+]1O]4\27,MM'<SZM=:F(1>I=S7*RR/:3?9XB;#=]C5@62!69B=Z#1M'M4@C
MMM)TVWCM4M8[9(+&UA2WCLEF2S2!8XE6%+1+FX2U6,*MNL\RQ!!*X8 _/[Q?
M^W'JEA:^)+[P-X*\,>,+3PCX0\1>.M8N%\9[+>?1_!_PS\&?$K7=(T^YT_3M
M0@_MZYM/%9TS35N&2UBG@M[J^*P7!5<F?]L3XB:3\5=7\/Z[H7@FVTSPE)IW
MA;Q1X:3Q%)'J&K:[=?%RP\"+JWP[GNM.AO\ Q!>2Z;XI\.S/H-Y!:J+FSNK:
M&4SZA925^A]MX;\.V<!M;/0=%M;5H[B)K:VTNQ@@:*[4)=1F&*!8S'<H MPA
M7;,H"R!@,5)+H&A3W<-_-HNDS7UO<&[M[V73K.2[@NF!#7,-P\)FBN""09D=
M9""06Y- 'PUX(_;/OO$'C/X6>'?$'AGPOHNG^/O[5_MZ[@\3R&;P2C>'OB+X
MO\.W.IRZK:Z7:W4-UX<^'D]WJ@T_[7'8#5H9Y[FVALIA/]Z6MU:WUK;7ME<P
M7EE>00W5I=VLT=Q;75K<1K-;W-O/$SQ3P3Q.DL,T;M')&RNC,K G/;P_H+3Q
MW+:)I#7,-L]E#<-IMD9XK.3S=]I'*8?,2V?SYM\"L(F\Z7*'S'S?#VMLL5NK
M6]NJ(D<, :.)4C0!$2*(%0J*H"HJ*%4     4 6**** "BBB@ HHHH ****
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MW'GP]"MB5IC</CJ>N"QDG*NZTH4:DJGM5]7_ *.Z***_F _H\**** "BBB@
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M]F'X*^ _"O[+OQ8_8,\=> ]%\-VVIV?P4\<:SIGPF\1:#>:XS:]J^@Z'\0?
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M4(9H;B&*XMY8Y[>>-)H)X9%EAFAE4/%+%*A9)(Y$9721&*NI#*2"#7S[X/\
M@Y^SMXT\)^&O%VG_  -^%\&G^*-!TGQ!907?P]\)+<Q6FL6,%_;Q7"QZ8\8F
M2*X190CN@<,%9A@GZ M[>"T@AM;6&*WMK:*."WMX(UBA@@A01Q0PQ(%2.**-
M52-$4*BJ%4  "OSF,HSC&<6G&45*+6SC)737DT[GM5J53#U:M"M!TZU&I.E5
MIR^*%2G)PG"6^L91<7YHFHHHJC,**** "BBB@ HHHH **** "N>\1^+O"G@Z
MTAU#Q=XG\/>%;"XG%K!>^(]:TW0[2>Y9&D6WAN=3N;6&2<HCN(4=I"BLP7"D
MCH:YCQ5X)\&^.;*#3?&OA3PYXMT^VN!=VUCXET73M;M+>Z"-&+F&WU*VN8HI
MQ&[H)419 C,N[!(H _)W_@L?^U#X!\(?\$U?VJY_ 7Q0\!ZOXK\1^!K#P%I]
MAH7C3P[J6I3V7C[Q1H7A+Q$L-I8:I+>/CPOJVMEC#$Y0#>X6)9'7^+W_ ((\
M_#WX=_%'_@H'^SIHGQ,UCPYIG@7PYXBU/XB:])XDU+3+#1[L_#WP_J?BO0],
MO9-4G@LI+?4O$FFZ+9W-K,^+FTFN(PCD[3_H >,]!_9<\'>/_#7PTU7]G[X?
M7>O>,#HO]@BW^&G@R:QODU'4-2M=0<23:>H'_".6.DWNN:PI0O%I<0FB$CNB
M'RW2/''[&FLZ7X.UW0?V=?!%[I'C#XDZW\-(=9@^%O@*UTC1]0TC4],T^VU#
M5M;FM8=,LK/Q';ZWI.K>&89[R*ZUK3KF9;6)K^W-C)YF*\/<VSC.LNXAA'$R
MPV&PN'ITL+'#PE1JQ]KC,5[;V[KQY5B(T*]/6G9_5)P3<XN,?W_P]^E%@_##
MPGXV\*L'D."K9CQ9F.;XNMQ2\XJX7'9=/&Y-E>1T*$,NAEE=5WE4VL;1E]=I
M-SS)MQITVJD_LG_A>OP1_P"BQ_"O_P .%X1_^6]? /[3/_!9/]AS]EKQO??#
M?QIXX\0>+?&MEHVE:TVE_#3PU<>,["2/7(!=:59IXBL;A-!^W75J\-SY OV$
M,4\1E9';RQV][XW_ &4X6U&"P_9B\-:I>MK'A_2O"%K%\.?A];#QW'X@^)P^
M$$=_HT]RB16%O9>.!)974>M_V=<?8O(U&&.2WN%*KX9TK]B/7OB9X+^)^B?L
MX>!(?B-<:1\,M%\/^,6^''A>SUC1K+XF:KX]T'2=.)6$+:W&B7O@+7K/4)X8
MGGMH);>.QN9;>9@/K9\.YU3I2K3RZNJ4)<DY?NWR2:IOEFHS<H/][&+4DK5%
M4IO]Y1JQA_-,,_R>I4C2ACZ+J3CS0C[Z<XWFN:#<$I+]W*5XMW@Z=1>Y5I2G
M\@^'?^"Q'Q-^-EV+#]GC]BGQ/!;2Q>=%XR_:8^+_ ,/?@#X3BMGVF&]:#4I]
M:UZ[@F1A+ EG9$W:AE@E)P:^2O\ @HUXT>W\-_#+X_?M,S?LA?$_QS;ZG/X$
MT#P'\$=<NM430],OK>7Q"?\ A-?&OC#Q)K=EXDT^VO+1[6.RL_A59R0S7ETU
MAXCL8[MR_P"ROC/QS^S-/>_%V>W^ OA3XB:_\)/%GA#PSXLCA\(^!);V]G\:
M:F^@6NI6%YJZKY]KI_BRVU7PUJB7#P7-OJ6D7SK"]J(IY<C4O%?[(MCKEQH%
MQ^SCX-N9]'\4:MX=\4W$?PR\"3VGAFWTKQOH/PY;7KMI;97O-/N?%WB32K&"
M+3([J_6R:[U*6V2VM),^]PM1SO(,ZR_-XY5C\33H3E[;!X7,\1D^(Q5"O@J5
M9X:>+P-:GC<+#$8;&X:?*E%XB-6%!1FZC@>'Q)6R;/<GQV52S/ X>=>,72Q>
M)RZAFF'PU:AC*E)8B&%QM*>#Q,J&(PF(@VVU0E2G5<H*FIK\;O\ @GC\9?@U
M^V5X1_:P_90_: TSX _#SX$^/?AMH93PGX*A\)?#FTAOKC5+FQ.JV6KS7K:G
MJ/B?1YX-*UO2-3O;R\ETK4=-M;FV@A@18*^&/ _[$G_!6_\ X)_?$+Q=X"_X
M)M_M0?#KXR_"GQ?J5UJ.CZ7X:^(OP=UB\OP58K?ZU\(_B'<ZI9Z5XNL],MHO
M[:USPC!<VEU!;&5[U;5/LL']3_P@D_9%^,7B3Q/X5\*_ 3X>6&M>$7UR+7[7
M4OAAX,LI+5]$\7ZMX24E8M.=Y;?57THZOI5TH-O=:=<IAUNH+NW@^G_#_P &
MOA'X2U:VU[PM\+_A]X<URR$ZV>L:'X/\/Z5J=JMS!);7 M[ZQT^"YA$]O++!
M,(Y5$D,CQOE'8'Y7Q6RK \9<5SSNOE&-X-S.E0PM.C'*LQJPQU"G'"T:53FQ
MLJ,9XBGC'36)DZU.3E.I*HJDG4G.?[;]'GQCXL\&>#<PX1P&)X6\3>#<]Q<L
M7F_#?'G#>'SOA?'8^AB*D\+C:>4SQ$7@<PP$)+"0KX/$T5*C2I4J]*:PV'C1
M_F._88_X(K_M5?$W]J32?VWO^"JGQ!C\<>-?"VLZ;XB\+_#*X\0V?C'4=:U_
M095NO#$_BZ_TI$\*:#X,\,7?EWVD^!/#:36MW>6\<-_%I^FI<6.I_P!75%%?
M+Y)D. R##5</@E6G/$5I8G%XO%598C&8S$223K8FO.TJD[)))*,(J_+%.4F_
M2\4?%KB[Q<SG YMQ34RW#8?)\MI9-P]P_D&74<FX;X;RB@W*GEN293AVZ6$P
M_.W4J3G.MB*TN55:TX4J,:91117M'YF%?''BJ^;XC_'>VTRR9IM&^'UK_9KN
MK%H)-:O)([K560;=C& 1V5DTD<AQ-:7$3JKQUZE\;?BRO@'28]#\/F*^\?\
MB.)[?P_IX E_L^.0^3)KVH1*<K:618M;1/M^W7:I I\I9Y(\GX#?#=O">A+>
M:@7GU6_=KV^NYR7N;F[N6,UQ<3ROEI)9IG>221B6DD9F8DDF@#Z$M8A!;PQ
M8V1JN.G0 =.U3T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MSX!_X26,XX_LJ\Y_[>M/_P #U_#OGH*YKQ!IU_=0R2Z5<M9WQ@>&.X7=NC$C
M(Q*[64$[HT.'W(<$D9 (\)N/!WQF>9VA^(6K)&6.U$CM\*,\#YHF/YDGCG%
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M2>\U#1];;Q+IMS%<VD\$^GM:>(I)=>C339+.(ZQ-/J3H]Y/-,]J]^!?PBO\
M3H-)F\!:#%I]K!X3M;2VL89M,%I!X%N]5OO",=K)IL]I+;#0;S7-8N;$P21L
MLNI7;R&0S/GS7_A#/C7_ -%$UC_OW:__ !BC_A#/C7_T436/^_=K_P#&*O\
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<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>develpmentpipe.jpg
<TEXT>
begin 644 develpmentpipe.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M<$O==I2/RF\3?\%8OVTVO?$FJ>$OV</#*?#TV?[#.N2^,M5M=5DL_@S%\?\
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M *M\_:/_ /"*\)__ #?4?\-1_P#5OG[1_P#X17A/_P";ZOG?]7<X_P"@2/\
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M2_=TIJ27-"5+-<->#>:R7*K3BL)BVI?N803NZ-U+VD?:M[>_.+3T:_.K3_\
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MDZ;:(24MK#3['QS!:6ENA9BL,$4<:DG"C)K7_P"&H_\ JWS]H_\ \(KPG_\
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MSC_H$C_X58/_ .:/-?>']O95_P!!4O\ PFQ7_P H\_S[,^IZ***\0]@****
M"BBB@ HHHH **** "OR&_8J_Y+1_P40_[/%\5?\ IBTNOUYK\AOV*O\ DM'_
M  40_P"SQ?%7_IBTNON^%/\ D0<;_P#8NR3_ -:'+SXGBC_D=<'_ /8=F_\
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M;F:$-U?_  ]K_8$_M237/^$"\;C6YM$3PS-K0^#_ (,&KS>&HT$<?AR74_\
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M!.+O5;.V7Q((+74[L75T+K4((X[NX%U<B:9_M$N^#4/^"M7[ >KZ#:^%-6\
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MP5F_X)_C6=)\1CX>>,O^$BT"PBTK0?$/_"F_!/\ ;VA:5 KK!I>BZS_PD/\
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MO/VE/C5J-Q=75]\7O%-S<WUA9:;>32:S'YEU::>;XVBSLJJ9)XSJ>HE[QO\
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M-HR>C^%[)6Z6U\E=+U;/>=,_X)U?M+:,GA<:;\=-.NY](\:?#_QEJ(U7Q_\
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MZ=%Y2QC[/86<:6\&X-)Y:C?([<UC_:+?_GO#_P!_4_\ BJ_N_P#^&9?V</\
MH@?P>_\ #>>&/_E=1_PS+^SA_P!$#^#W_AO/#'_RNKOA]([)*<8PAPKF,(12
M480QV#C&*5M(QC0226MDDEIYG#+P"S:<G*?$N!G*3O*4L'BI2DW:[E)UFVWK
M=MM^O7^$#[1;_P#/>'_OZG_Q5'VBW_Y[P_\ ?U/_ (JO[O\ _AF7]G#_ *('
M\'O_  WGAC_Y74?\,R_LX?\ 1 _@]_X;SPQ_\KJK_B9')_\ HE\S_P##AA/+
M_ISYO[O,7_$ ,T_Z*/+_ /PAQ/E_T]]?ZW_A ^T6_P#SWA_[^I_\51]HM_\
MGO#_ -_4_P#BJ_N__P"&9?V</^B!_![_ ,-YX8_^5U'_  S+^SA_T0/X/?\
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M;QO^VY_P6%^)GA3XJZ/X0^%GB+X+SV?[*WA3XD^$-1E_9Q\1?\+2OO$:>%_
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MRCE[C)Q4DY)-\JEKL?V]?\+M^"W_ $6'X5_^'"\)?_+>C_A=OP6_Z+#\*_\
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M0X_CYI?[27C#P7.=1UQDM=)^('Q1TM-<UK4;)H-8TVXF:30[JRCBBME[B?\
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M_N?E\^?3(=/E59' M6+C+(J5_01_PYL_8E_Z!7Q6_P##D-_\H*/^'-G[$O\
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M.'CL0N)TOJ?]FX&5-M9;%+'NAA?;0HK WJ2E&?UQXZI7:HRKNDL#2I8>/O\
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M9.RS#A_7:^+Q^NW;+7Y_=]V$O&GA:.^"SW_PEP7=+?\ M'S^\_M2HK^+N/\
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M;_@JS^W6@R_QBM4& V7\#>$4&TC(;+:6/E(Y#=".02*#_P %6?VZP"3\8[0
M<DGP/X0P!ZG_ (E='_$O'&O_ $,>&_\ PLS'R_ZE?]6]+G_$=^$/^@#B#_PD
MP'_SR]?Z>G]B]%?QT?\ #UG]NS /_"X;4!@&4GP-X1 93T92=*^93V89![$T
M?\/6?VZ_^BQ6G_A#^$/_ )5T_P#B7CC7_H8\-_\ A9F/_P Z_P"K/RN?\1WX
M0_Z .(/_  DP'_SR]?Z>G]B]%?QT?\/6?VZ_^BQ6G_A#^$/_ )5T?\/6?VZ_
M^BQ6G_A#^$/_ )5T?\2\<:_]#'AO_P +,Q_^=?\ 5GY7/^([\(?] '$'_A)@
M/_GEZ_T]/[%Z*_CH_P"'K/[=?_18K3_PA_"'_P JZ/\ AZS^W7_T6*T_\(?P
MA_\ *NC_ (EXXU_Z&/#?_A9F/_SK_JS\KG_$=^$/^@#B#_PDP'_SR]?Z>G]B
M]%?QT?\ #UG]NO\ Z+%:?^$/X0_^5=?6'[,7_!9;XL:-XRTK0?VEXM%\9^ ]
M7O;>QO?&&C:-9^'_ !+X3%S*D0U66VTU(=-UK2K7=YE_:R6T-\MNK36UV3&8
M)>',? /CG 8.OBZ4\GS&5"$JCP> Q>)EBZL8KFDJ$,3@L-3J32O:G[53FURT
MXSFXQ?;@/&S@S&XJCA:D<UR]5IQIK%8W"X>.%IRDTDZT\/C,14IPN[.I[)P@
MO>FXP4I1_IGHJM97MIJ5E9ZCI]S#>6&H6MO?6-Y;N)(+JSNX4N+:YA<</%/#
M(DB,.JL#5FOQ1IIM----IIJS36C33U33T:>Q^NIII----733333V::T:?1K1
MA1112&%%%% !1110 4444 %%%% !1110!\Q?\%5/B;\0/A+^PK\9O%?PQ\2Z
MOX(\7WE[\+_!-KX[T"Z:PUCP-IGQ(^+G@7P!XA\7Z=J"JQTZ\T'P_P")-3O;
M741M.GW$<5X'4P C\1OVH?\ @HY^WK\*]1\:?$/0+CPOJGA[X.?M(_\ !1+X
M,_"GP;8>"/BG;G7/#G[+OP4GU;P+XE^,5WIWQ%&F?%.7Q9K5W8S6L;Z!I6G0
M7-A-?Z1--JFH+)I_[T_\%'O'/A/X<_L3?'SQ5XZ^'?A+XK^$(O#V@Z%X@\ ^
M/-0U/2O!NO:=XQ\;>&/!TQ\2:EHMEJ.LV.E:4=>76[JYTBRN-5B73=VG(+P0
MNOQA\,_^"N7[.NG^$_!NE_&S2/#7AW6M<^*GCWX7:#J?PVU*+Q?\.->\.^!O
M'7@OX23?%/0]0\=1>"_&U[X6N_&WC33/!&IV(\,:GXPM-8T3Q+>W6EW7AS3E
MUR?Y<^H/@R\_X*F?\%,O"/Q.TCX+:UX%^$'CWQ%\1?VH-6_9!^'?C[P?\&_B
M%H7ABU^)-KJ?[.WQ&E\5^)-#O/'WB.?3_!^E? CXC_%5A/<:\+>_\0^!M/NF
MU&)VOM.E\K\$_P#!:W]O[Q9X%\3:SXV\.? GX':5J'[0?PP^'NO?%/Q)\,_&
M?C&U_9%\->,=2^.-OXBTWXQ?#?PO\0[C5M=N=+E^&/@O0-(\1ZSK/@2[FU;Q
MU<7.J>%+.R/A][W]V;#_ (**_!75_!^B^/?#GP>^/7B#3?''C.ST'X)C3/A;
M9"\^/,E_HWC+63XP^%$]WKMK9:CH,'A;P#XDUZ\U#7[[PYJ<6@1:9<G3V76=
M.AG\\N?^"J_[+]W-I]EX/^$OQY^).E>.+;1KW3-6\$_"#3K_ $'Q/XCUKX17
M?QYC\,22:IX@TJ9_%.E_"W1->\4:['JMG!:Z6/#.J:;)J#ZO#9V-T ?CA^UC
M_P %=/VO=8\6?$SX%_!_5+74-+UC]DCXQW$GC'X<_!CXB_#OQKX;^*_A']D$
M?M :+\3_ (4ZOXB\;7?CZYT+Q%KKK8>'K?6_AGIEC!93R:+IVO:UXJT349QB
MZG_P55_;P\&7'Q<NO@MJ/@SQ=X1\,:U^T9\46UCXJ^!_BM\2KGQ?X+^"OP]_
M8>N=#\)>"KW_ (3[0K?P>WC&\^,GCV1[FPL+G1+6^@N;_3O"S7T&I"X_6FW_
M ."M7PDN],^*7B.7X7:YHT&E7?C>T^#'Q)U?PU=/\._BE9>#?A'H'QB&BW.O
M64$WB71O%K_#G7-6UJY\.#09[2&QT'6K*WU2>^MIK(^UZ;_P4B_9SO1\0H(/
MAG\5+=/ >A>.=9MKF^\ >'-$T3XA6'PZ^*/AGX,_$>;P+J^L^)=/TRXT[POX
M\\2^%]-U?4/$]QX9L6L+ZWU*.6>SM97B /QI^+G_  6C_;/L_C-^UGX$^$.F
M_"%/#?P^\/>);GP#J'Q6^%^O^#)/ ^M> ?C-\//AOXATF_OI?BA=0^+-2U_1
M/$OB'4/"-YX[M?A-X=U[4[31=4M+NV\*W$UQ+[!^S5_P5R_;#^.'[9/[*7PA
MNOAYX)T?X0_%KX5?!#Q#XH_X33X=ZW\+_B#XU_X6/\,/'7BSQM\2O ^FZG\2
M/$E_I-IX'\8>%=/\-MX.M]'\7:$+"YU"\O\ Q_'+>^&_MOZ!I_P5:_92UVTT
M&_\ "?PZ^*?C.U\?^!O!'BFVUO3/AWH;^&GU+XI:=\3Y_A[X"\2:_+KIBC\4
M^*]0^#/C'1(HH(-5T2UO-/L9;S5X[*[M+A\3XE?\%.+#P3\./V%OB%I?P"OK
M;QC^W-X2U?3/@YX!\9:II6@>(-(^).J>'O#&I?#?P)K&OV$.J:'HOACQ+<:\
M;S6/$LVH6]OI_AO3UNK+3=0UV]L?#\P!^2O[37_!6;]JKQ3\7OVI_A+X)UK5
M/!WPK^#_ ,6?A9?:9X\\,_"[Q1X"\>?#[P]\+?VZO@Y\(_BQI_B6[M/''BS5
M?%7@GQ+X!U;Q-J>N:IJWA?P(-;\*BYU/0+"X\+7AO6X#X3_\%/?VXOV?])^
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MX4>+O^""/[-/B*#Q4^D?$7QKX3U;QMXGU?Q[XPOK'PKX*U33_&OCZ7X[:_\
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M'Z!#7-4+VT8\#^-"UTS+%_HF@C"+=K:F=P?$6Y(-I-V)"I)LT>0+YJ^28O\
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MR&T\/!K>(?:29;DGQ+MA0+;*QRQ8"[M/ES)*(6#Q#J1C\W_A!O&NULB(?9-
M+SR"."3R8$'B,EY-TYA).V(303H9=JQO+^8&I?\ !27XM1Z3IWC#0OAM\$?%
M/PZO_P!B[XH_M>7NMZ%\1O&^HWNK3?">/4])UWP;I,UWX4T4F&?QG:VUD7U?
M3],U+2M.35;?5K*#7=/-N_1^)/\ @HQ\5)_&-AX ^&OPD^&^K>,M;\<?"_P9
MH]WXP\<ZWH?A:UM/'/[+NO\ [2&J&XU+2M)U2:PN]/@T&?PSI\D=I<12&YAU
M"[51YH-K+<QOKA:-E"I.;>(A%05*:IU?:-UOW?LYR2FG[T4GHVVHS[7#V3]K
M4U<4DH7OS)2C;W5?F5^5Z1DW?2"YI?H^VNZFK2*? _C/]RZ+.WV;P_LAWW+V
MVZ1_^$CV@*$%RRH7D^S2(5C:?? B+KVJ,R*/ OC8/+$9H4-IX?#RJ+8W& O_
M  DA*$D&V!EV1_:!@N(,SC\]/@!_P47\;_'[XP? SX7:%^SY/HNE?&OX;6GQ
M[T?Q#?:_)?Z5HOP:TW3=3\/>.M6UF[M(HH;OQCHGQGM-,\!Z+IZK#I^L:!K5
MKXI_<6P:%_U:)4B9GF+1,^V]O5_UMW)P18V((!$0X4L %*@._P HCC/'BJ>(
MP=2-+$4*<)S@IJ*J*HTN:5.S]E4FE)5(33@WS*2<->64UK3C3K)RIU)M*25W
M%16T9;RC&Z<9*TDK)/G=FXPEY>?$&HA#)_PA'C0QBX:V+BUT J76YCM]Z?\
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MR(7NK6FO7&C27>J^++J]UOPV^N:=8ZJ="\0W&JZ)'>65M=1V"O#$HT4\$_\
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MQ)^&.O7^DW6FWD#ZUHD%U-%HWBK11(IU'0M:L4;[-<V]_:^;"DSQ-/:3,EQ
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MI*+;3;A%N;J33MU_/=WLWOIJDG>R324I)4U"$@D8F=YC@_)?7J=22.-/L!D
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M3M[D$:+>UER[\EEJDOC;AI9I7O:S5.[52<O1J***\8]H**** "BBB@ HHHH
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MM).,>92C=--6E&5HK]YHHCX,\9)*W&M"R7+94\:X\K2O%ISLXRMLTXN-Y/\
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MW]H7#V<)#NIT_51<:C.;=+P2W'^A;X[80.LP&. X09G+;?!OVD_^3JOV"O\
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M,E/^$Q\-"(.+IS#!)(MO9O8:E_K4:VC>\U!OL8#;7N[<!#P?,"KB-)#7RO\
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M[:.YRG+8'WLLS[U]LHH^N1Z4I+;_ )>KH[]*:V6SW4G*=W-IH6#E_P _8_\
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M,?\ HHL#_P"$.(_^7?U9^5S_ (CCEW_0@QW_ (68?_Y5_5GY7_TZ:*_S%O\
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MBM/;WWASQ-H7BQ)9_#NGZAX=G\)S:EJ\=U_0=10!^%5S_P $6]6\5_#SX<^
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M*) FG#PW>7E_(&O1(K'^O8?\$ ?^"7(QCX"ZN,=/^+G?$/\ ^:&IE_X($_\
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M'_X58S_YW_U9^5_X!**_O[_X<9?\$V?^B):K_P"'&\>?_+ZC_AQE_P $V?\
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M1@*. C3(/EF<$^KQ_P"?O_DC_P#DA?6)?\^U_P"!^G]S^K'OE%>!?V"O[O\
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MPDFI[ 3.MQA5\W"J'0( .!!F'_5L03ZO'_G[_P"2/_Y(/K$O^?:_\#_#X?\
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MK_VE46S7_4$][_+S/F\1XI5Z,N59-1EK:[QLU_[K,_JR_P"$^\!_]#QX-_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:^E9(RH_M*RRPPYRH\_YAB.0\9XCD/1'(#K.C %CK&E!5R"3J5D -NS=DF?
MV^;%G/3S8\_ZQ-WR='_Q\Z=_U[1?^D7BVHKC_D'ZA_W$/_0_!]+ZG&\5SO5)
M[+J_4?UIVOR+9/=]5%]O[WX'UO\ VSH^<?VOI6?3^TK+)Y=>!Y^3\T<B\?Q(
MZ]58!O\ ;6BX+'6=("KRS'4[$*HV+)EB9\*/+99,G'[ME?[K GY4B_X_K/\
M[:?^G?Q)6=+_ ,@S5/\ KA_[I^C41P<7?WY:)/9=91C^K8?67_(MF]WTBI=O
M.Q]?_P!KZ1N"?VMI>]CM5/[1L][,7\L*%\[<6,@,>T#._P"3&[BF_P!M:,06
M&LZ05 !+#4[': 4,@.?/Q@QJTF<X\M6?.T$CY>B_Y#FG_P#85A_]2=ZP(?\
MD'7'_7G'_P"HEJM"P<;2?._=47LM;M>?2[!XIJWN+5=WT47V_O?@?8/]L:1P
M/[6TO)S@?VC9Y;#*AVCS\D!W1,C(WNB?>=04_MK1L$_VQI.!C)_M.QP,AR,_
MO^,B.0C/41R$9V-CY9F_X^[#_=?_ -27P_65_P L+SZV/_HKQ;2C@XR2?.U?
M^ZN\?/S#ZT[_  +:^[[7['UW_;.C\?\ $WTKG./^)E9<X"$X_?\ .!)&3CH)
M(ST=<@UG1CD#5]*."5.-2LN&#,A4_O\ A@Z.A!Y#HZ$;D8#Y+;K8_P"[<?\
MI-X1I8OOWO\ U^W/_J2^(JKZE'3]X]4OLKO%=_-B^MN[]Q:6ZOJD^WF?6?\
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BM6_["3?^D5E4_5(_SRZO9='%?^W,:Q+;2Y%JK[OM?L?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>dm199.jpg
<TEXT>
begin 644 dm199.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M"V$$]QU?\0YXN5:-"674(2<)N=2IFN4T\/0K4Z^#PL\#BL3/'1P^%S..)S#
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M(;N[U#5(K.1+VZN-:%BMBD3337:16]K'+/.D1]C,N N+,HCF,L?E%:DLKS+
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MU^-?%WP(\.>$-:U_4/@MI7PC^'7C1]*O]&U6T\/^%K6%='U37O&UGX=TK6=
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MNK_V58&QMI+N[@AMQ:1SP+'%2\7_  W^*/QQ_83_ &H/VC-)\'>(K3QA\?\
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M?#7@Z#PYH[_L-7=IK4^B>'UTC3&U%3JC16VIO8VEO:?;E*1XCNC]I!$08<1
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M6TO-0F@L.UA_;N\5:M^TAX,^$.G_  X\(>$_!_B_1OA-KNA7WQ=\;>(/AO\
M$3X@:1\3O#C:_J-]\*]"U3P+-X'\4:C\.Y);?2O$_@BZ\?:;XXN+V#55L]$1
MK6QCU3U+5?V(?#LO_"(:CX3^.W[1OP[\:>'/A/>_!77OB7X8\:>$M5^(?Q'\
M":AJAUV=/&_B'Q]X!\:@>);;7IM1UC1/&/A&S\)^)?#-WJ^I1^&M2TFRDM[2
MVU?'7[&OACXB^+_#FO>*?B_\=M4\(>&_&'PK^(-M\)=4\6^&_$/@2?QK\'9M
M.O/!_B"/5/%/@S7?B=H4TVI:1IFK^*+#PG\1/#^D^+-5M9+[7;"[FU/6CJ<*
MKD7)&/U=*3HXB,ZCEB[JK*I!TYPHWDERQ4_80=>2<).%>K3J*-5/DS"[?M;K
MVE)QC:E\"B^:,IV3?O->TDJ:?,KTXRBW YC]LW]J_P 5_LRZ<-4\-:-\(-9@
MTSP#XS^(6LV'Q$^)VL^%?$VM6OA&&*X3P]X'\)>$? _CSQ#J=WJD8NUN/%6K
M6.E>#] N$L;;4=0DFU )!\4>./VH/B?XDO\ XZ^+?"'C?Q?X=\.7?QN_X)0S
M^"-%.HJDGA?P=\?=?^$EYX]\-PK#OAAA\5Z7XCOK#Q+%"S17HNKI0VUP:_0+
MXX_L:>"_CCXXUOQ_=?$?XL?#O6?%WP<U+X">.8_AQJ?@BS@\8?##4]4U'5YM
M#O+GQ;X"\8:QX=NTN]7U1%USP)JOA/6Y;6]DM[F_G$%FUKPNK?\ !._X2:CI
M_B32[+Q]\8?#UEXG\,?LZZ+=1:)KG@L&P\1_LM7WAB]^$/Q)TM]6\ ZM)!XW
MTI/"6DV&JI<-=^#M:L5F2[\(^>T=Q%6!Q.3T*-#VM-2Q'[KV\Y4JDTU'&X*O
M.,H2YX75*C7A"5._/":C-0YY12Q%+'5*E3DE:DG)TXJ<8N_U>M334E:5G.<)
M-2^&46TG92=S]HGXM?M!^"_VL/V*_AO\,D^'TGPR^+NM?%NR^)=GXFU74+#7
M-7A\'?#W4/$ZQZ=):^!O$AL%T6WMTUC29++5]-DUS6D70]8%GH\CZ@OR=^RI
M^V/^T'I_A/X#6_Q7\&Z#XM\#?&?XB_M)?#[PQ\2K[XF:EJ/Q2E\1?#.]^+7B
M[1KKQ)X/7P;_ ,(_9>$+_1_ EYX9TU[3QM?:]IT4&EW=[H\:32VEO^E'Q+^
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MM&TCQGX%\6>#[SPU<>$_#UO$=+\3^&?$-W;:C=WFI6.I6ETMDUGS6F_\$^O
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MJDHN<J4HKF5-I2O33Y4N>,%!12J7E*+IM)>:^._VZ/CG\./%?P=\&^-/@_\
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MG\(_#-K6+09?[32*\\2K<2>)1$_ES6#.YBCT$3F(R6]RLFHF$2!;@.5(ZKX
M?$OQ3\3/"FNW?C;1])T7Q3X7\8ZMX2U>#0#?MHEQ)966E:I;7FFOJ<DEZ\,E
MEK%M',9FXNX;A4'EA<JI@*M.C.NJN'JPIN'M/8U5.45.4H*3C9>ZI**;Z>TI
M[W=B&+A.K"DZ5>G*IS\CJT^6,G",9M)J3U<9-Q[^SGV5_5OL_B'_ )_--_\
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M(!80@E))41@#G@E2<'L>:\HMYDN;>WN8PPCN;>"YC# !A'<1),@8 D!@K@,
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M+V>STJ-H4:S@\F(2/%;6\<7Q1X<MOB)XGFTI+#Q/KL5OJUU?VL5Y=>*=46*
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MEK]7_P#"S?"W_/Q+_P!]6?\ \F4?\+-\+?\ /Q+_ -]6?_R97RA11_JYE_\
M-B?_  9#_P"5_P!7?E8_MS'?]./_  6__D_7^EK]7_\ "S?"W_/Q+_WU9_\
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M  4,DDA_;;_:$EADDAEB\<6<D4L3M%+%(GAO0&CDBD0J\<B, R2(RNC ,I!
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M/VQ0+G))\W)-?V+?\.Q/^"9G_1&+?_P[7QC_ /GBT?\ #L3_ ()F?]$8M_\
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MH5(C@@CCAB5(T51_;)_PZ'_X)Z_]$"?_ ,.I\9__ )X=*/\ @D1_P3U4AO\
MA0+'!!PWQ2^,K*<'.&5OB$58'NI!!'!!%*/TDN (7Y,GXI@W=OER[)HW;U=[
M9YU:5V.7T?>.)VY\UX:DE9+FQ^;2LEHK7R;HMD?ST_\ !)'1OBEH?[0VI_'3
MP/\ !_Q?\7/"WPH\*:O8^--.\&WN@V.N6\?B^U:QMVT&'Q+J&D:=XEUJS@M[
MC4&\*V6I0ZS?62,]@D]P;:UNOZR/@_\ M(?!_P".+ZCI_@7Q4H\6Z"A/BGX<
M>)K"_P#"'Q-\(NDB02KXF\ ^([?3O$NF0I<N+9-2?3Y-(NILK8ZA=+ACUWPL
M^$7PS^"7A&R\"?"?P5H/@3PG8,\L.CZ!9K;0R7,@59KV]G8R7FI:A<!%^TZC
MJ-Q=7UP5!FN)" :Y;XO?LY?!WXXC3KKX@>$(9_$N@RBY\*_$#P[J.J>#?B9X
M-ODP8M0\'_$7PG>Z/XQ\-W<9 R=+UFWAN(]UO=PW%K+-!)_-/B+QOA./^)J^
M<3P-?+L-##T,#@+3C6Q,,+AW4FI8RDYJA4J5:U:M4Y:%6E[&,XTW4Q/LU.7]
M%>'_  =6X'X<HY1]<I8W$SQ%;&XZ2A*GAY8JNJ<)1PTVG5C2ITJ-*FI582=6
M4)5?9T?:>SA[1/:VUR8#<6\%P;:=;FV,\,<IM[E%94N(#(K&*=%=U66/;(JN
MP# ,<RNI9'4<%E903TR01S7Y0?M*?$O]L+]B3X6:YJ?AK7Y/VN=(U&UO=!^%
MUGJ?@'5[C]I#3/%HTK4;[0M.U:+X<>''^'WQ9TIS8!=0UG5=-^$&IVUJ"+C4
M/$6K3+<S?I7\.O$FM>+?AYX*\6>)?#&J>"_$/B'PCH&NZ_X/UJ*.#5O#&LZC
MI-K>ZIH&H0Q7%U''=Z5>RSV,RK<S@/"?WC=:^#KX*I0H4L3[6C6P]:I4ITIT
MIN\I4U%SO2J1A6@DY<MYTXIRB[-KEE+[:G7C4J3I<E2%2$8SG&<59*3:C[\7
M*$F[7LI-V:O9W2_"3QK_ ,$YO%WA749Y_%GQV^!/A<ZK=7M]9V_B#7]9TNYG
M@GNY7WQ0W>CQ23)&7$<DD2O&LGRE\D9YYOV.=7>YO[QOVM_V>S=ZHULVHW(\
M=ZLL]ZUG)'+:/<RKIHDE>VDABD@9FW1O&C*054CX_P#B]X^\2?%'XC^+O&?B
M[4)M4U;5-=U-@;B1Y(;"TBNY8+/3;"*0LMK86-M%#;6UO"%CCCB4 $Y)\V\N
M/_GFG_?*_P"%?Q1B\UX8ABL1'!<-5GA56FJ,ZV>8Z-6I"+<8U*D*<>2$IP<F
MX)S4%-PYYIRE+^6,5F?#L,37C@^'ZKPZJS5.=7.,9&I4C%N*J3C3ARQE.+F^
M5.7(IN'-)7;_ $AN?V6/&5X-0%U^V5\!YQJK6KZCYGQ U<_:VLBAM#)C3!M$
M!1"@B\L':-X;FK1_9F\?&:"X/[:?P,,UM<&[@E_X6%J^Z.Y9;Q#*/^)9AFVZ
MC?JH<,J"\N0@7S6S^:GEQ_\ /-/^^5_PKT3X8^'O#OB'Q%=6/B*:UM+&'PYX
MDU""6YCO)(#J6GZ3<W6FQ26^FS6VH7BRW<<2?8[*>.XN"?+C;)P70SC*J]>G
M2AD%2-2M.$%*?$F:0CS2GS)SF](I3E.?,]%)N3U;8Z&;9=7K4Z4,EJ*=6<8*
M4\_S&$>:4TTY2MHN>4Y-O9R<MVV?<;_LO^,C)ILL/[8?[/=G+I.D7>AV<EAX
MUU"R==.U"_NM5U&.=K?24-U-J&IWMU?WMW<>9=7%Y+]H>7S4C9:D_P"REXNN
M5MTN/VR/@/.MIY1MA+\0M9?R3#:SV,3(6TXD.EG=7-MO)+M%<3*S-YCD^ ^&
M?AO\/=5FT6WUN.QT[2[W3;^]U'Q-!KO]F-9ZO!XTOM'L-(&CZM=7=T]MJ>E0
M6L:VGEIJNGFY&M75Y)96\L$E>_\  'P>TGPO?ZM;>,=*UFZAT[59;:YNM/\
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MPD$MO_91M-1A/AY=X'VA/#W]EI>+^[O%GC^6OSM_X57XN_Z*=\2O_"\\6?\
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MQ7\9=%O?ACIEQKO@;]DWXA:EX4\=7:^(M$^&'A/QU\'?B7XL^(>N^ _ %O\
M$OX<^*_'=G?^*/#=E%-9>&_%^N^*(-)M;F^T3PSXYU'3IM.)+&4H\EU*\X*:
M22;4>5R?-:32:5KZV]Y--I2<6L-4?-9Q]V7(W=I-\RCI=)M7;MI?1JUW%/\
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M$<=ZYFFWSGS9-W3T5JH02:48I/=**2>VZ2\E]R,W*3WE)^K;_K=_><E)X \
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MVOM>O;2 7%]?7M]<9MM"\+Z%;LEYXE\2WP-GI5J\4<<=YJ5YI^G7GSU^Q?\
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MVO=9NTM];\/SV/Q$\83P:9 ;/5+OQ/XG_L'7)K;^T-,\$>%1=-ID7\-OQ/\
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ME3"*$JM"M.%Z=90]M2]C6IS;<9U*=2/-24Y_1U%%%>X?F@5\6>*/^1F\1?\
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MQ-?XA?MT?&C9-OL/ T^@_#/35#$F*/PAHUNFKQ$\@?\ %47VOR!0!L61%(W
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MI>*M0FA49)VPM=^6">3MRP#$BOP.\'^%9/B9\=/A)\/DC,__  F/Q,\&Z%)
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M"VU+26JZ3_P4(^)NI:K^TMX6UCP6OA[Q!\//"/A7XN:=!#K>@V;^!? 'B/\
M9Y_9>\86/ACP?J6N>!=2M?B]XOE^(_Q=U[4_%%QJ/AN*R\ >%-4TQ]?:%K_P
M/HFLS]=P]D^:7O-I>Y)-V4M;-72?*TKV;:>B49-/ZM5NU9:)-OFBTKN*M=-Z
MKGC?M==6D_V)HK\G_$O[?WQ%MK;Q%%>?"W2?">A3>)_&WA[X?^-/#7Q/MO$?
MC'6'^#_[;/@O]E'QE)XJ\&>)_@K'X3\*6_B:/6[WQ%IITS7/&]PFG&?38_[
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MO(JNOASX(>+9XF*Y,=UJGBCP9IT;!B3M8VK7B>I5V&>N?A_XD7>$N<$9"M@
M@C'3H#C@\X'4@>]?H+_P0@ NOVE_CO=$@M:_"/2H <#(%WXNMW(!'0-]D!(Z
MY4#H!75PVO:\5Y+!W=L4ZGDG3HU*J_&'WO[ODO'^<\O^C=XKXJ+Y7/AFGA+[
M>YF&:Y9E\XV_O0Q4XI=V_E^RA_Y.!_:2_P"RA?#G_P!4?\,:Y7]FF>"V_9_\
M$7-TZQVUM;>);BYD8X6.W@\3:W+.[$\!4B1V)/  )/ KJC_R<#^TE_V4+X<_
M^J/^&-?-]KXE/@[_ ()_^-_%*R^3)H?P?^,=[!-N*&*Y'_"6PVLBL.0R7,L+
M(1SN QS7]><0551X<P5:7PTJ.757Z4\JJR?X(_P#X8P%3->*X971;5;,LP67
MTFE=JKC<TH8:G9=7SU8V1_ W^TKXWN_B#\7OBEXXOYFGOO%_Q"\:>)KF9FW-
M--K/B'4;UG)ZY)DR!G&/:OE^ ;YF/)R<]^V<_3I^@ ZG'>^+[IY9/,D;=))%
MYDC$@DR2@R.QSSDNY;..IY[$\-9 [L_3]3DGJ>,?7KGUK^-<%*4L/.M-MU*T
MI5)-[RE4DYMOYM/?>Y_T+\7T:-'/L+E>&C&&&RRC1P="G%)0IT<%1HX2C3@D
MK*,:5))*UDHVZ(ZBQ4<8/?OG/3GMCMQ]/S[JP4A1W^[G'/<]/RYKCK!>G'0#
MZ9QG^9/M7J?ACPOX@UXJ-&T74=1& 6EM;662%59A&6,V!#@,0&(<[3G.,$UY
M./FHM7:45JY2:2CHM&WHM_+TU/T?A+#JU*ZO\.V^B7I>WSL[670T+!.GJ<D#
M&, #./49Z<=1Z5[9X"M2TR-TRP/ [YP.W3Z8/MBKWAO]G'XMZLP6+PQ<0@H)
M%DD\R56#<J ;2*Y88 SEPJD$8)YQ[9X;^!OC_P .LHO]&D)A($@AANFP1RW+
MVT:_CGH!T[?/.K3E534N:/NV<5*44[KK%-+?]3]PHYIEF%RZ=">.PD*[C']U
M*O2C-))-OEYKI7ZZZZ:,]D\ VN! ,<C:<X/<#^>._P#+(/V=X(MAB+(Z;!^
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M.A+>C0O&7_"%>&)_$^CA[ZX\P:5XD;39-7L 2JJPM+Z(#8J$ (H'E%Q^R/\
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MI';^%/V0/BUX<^&W@KPEJ?PZ^%GB+7?A?\0/A=XG\7^)!XQD_MK]K;2_ GQ
M\<>*M0L_&1U'1Q:Z&D]KXHM-;TI/&6H7QF\9RZ]9:G;0^'DT_4;U1FG%RCA4
MU>:Y4G9.G:44U[-I.4IU))I)*S3O4?*$HM/E==W2B[WWY[1D[N2=E&,$[W=K
M.R@G)??M[\!?@5?K;Z??_"SX?W2Q7FOZE:V5SH>GR%+[Q;\0+;XO^);V&!QN
M,_B#XF:7:?$/4Y54F]\46$>M2%IX"XP+ ?LY?"OQO8:!H^E^"/!_CK2/",VE
M65MHVCF#4M(\$^+_ !Y>:U>V#3V-O)'IVA:K\0Y;S6=3BN)(;>/6IY-1O3#Y
MHD;\\O!/_!/GXK>''\/ZQJ=_X(N_%GAO0OV0-*\.:U9ZOJ<MQX+TWX0?'/XY
M?$GXE>$/#&HZA#_:,.@6?@_XC^$_!_AYV,)\26WA\6]]##;P1(,[X8?L"_&;
MPSJOPT;6-&^&>E?\()X0^!G@+QOXMTGQ/=ZAKGQINOA=\0O%OB+QA\1?$MN^
MEP3"3QQ8Z^-;CTK5KN]U1];UCQ!9:HL4,5G/>/VE7W&L(HM]7KRI.R6D(V>E
MUJDE:UVTA<E.TKXAM)JRM:[DDV[.6N_+IJWO9)GWOX?^'O['OQ&?X<>,?#G@
MGX1^*8/AUIB?%7X6^+;+1;671O#6F?$3Q!?>,U\6>'M;:*+2?+\0>*;Z_P#%
M;++/.UOKUY)K1MK34)TN&](G^ ?P,GL9/#=S\*_ $EA+X;\;>"Y=$ET*P,4G
MA3XA>(HO&GQ!\-O9,-S:1XN\41P>)?$EB4\K4-46._N5+[6K\R/"?["OQL\)
M:7\!TGT;P/XAT/X&^"_@)X2U[X3KXIBLO#7Q>?X1?#KXQ?#?5+_S9[9-'TU+
MW5?'OA;XIZ);>(K<HVI^'/L.I"+5[33KN/;^&W[ 7Q0\&2Z-JNO:EX+\2>+=
M$U_]E!['Q+_;6M0W=EX-^$>F:W8?$'P5IVL/ =?L?#Z:7XAO_!^AB$I=:OH"
M&XF@AFF^SJHU*FB>$2YM)-+E5DE;3D=T[<J3=TXJZ2<;N487=L0[)+EOJVVW
M=7YE:U^9O;WG:[4K?<WQ ^'W[-FG:QH.N>,/A+X8\0:I\0OB)/X07Q#9>"HO
M$@7QM\1?$/A"\U.X\4ZG9K*NCQ>(?%OPV\ ?VSJM^RQ?\)#X6\*I>>7<6=N4
MX'XK?L+?";XH^.-*\;PZUXM^'4T%SJ%[XET7X?6W@2QT[QK>ZS\4;#XQZ_J.
MJZEK_@KQ#XJ\/:SXE\>V/]K>)M=\ >(O!^L^(1</%JU]=?9[!K3A/V<_V/\
M4O"WA#6/"/Q7BU:P\/:+\6_!7Q-^&6G>&_B1=Z/XSL-3\$>&]%L+%/'7C[X-
M6/PJ3XI>&M(UW33_ ,(-:_$72M<\3S>%;#04^)5WX@\1V0N8/T/))))QDDDX
M 49)SPJ@*!Z   #@ "MHTU5BW5HPBI6M&UI*S::DTHZ.R:U=T[,S<W!I0J2D
MUU^SJE;EUEJMGV:T9Y+XK^ WP5\=>.M-^)WC'X6>"/$OQ!T?1[_P_IGB_5]#
MMKS6[/1-2M=0LKS3$NI!^\MY+/5]5M(C.DTUI;ZIJ,5G+;I?70EX?QS^QW^R
MM\3(]+C\?_ #X9>*UT2/PU%H[:GX?03Z9%X-T74?#?A2.QNK2:UNK9/#OA[5
M]4T325BF46>F:C>6<>(KB16^D:*U=*G*_-3@^9WE>$7S.R5W=:NR2N^B1FIS
MC:TY+E5HVDURKLK/1>2/GSX?_LS_  R\!ZCX\UR:Q?QGXB^(7Q9T[XQ:MKWB
MS3O#9O['Q-X9T:V\,_#^VT>/P[H/A^PM;#X;^%;2#PYX2NI[.[U]; 2W.N:W
MK6JW5UJ$VOJ'[-O[/^J^'K_PEJ7P<^'UYX:U/PV/!]]HLOAVS%E/X87Q=JWC
M^/1 L:I)!9P>.=>UGQ?:_9I(9K3Q'J=WJ]K+#>2>:/;**2I4TK>SA;5:Q3^*
M_-=M-OFN^:^]W>X<\[WYFFK6LVK65E:UK66BMMT/-D^#?PFC\&^#_AVOPX\&
MCP'\/]6\+:]X'\('0K)M \*:YX'U:WU[P?K&B:>T9ALM4\-ZW:6VKZ5?(/M-
MOJ,*W?F-.6=N<G_9L_9]N= ?PK-\&/AP_AJ3P_XY\*-H0\,:?'I@\-_$WQ'I
MOC#XAZ*EK%&B1V/C/Q9HVD>)O$,<>QM0UW3;+4Y7^UV\<B^V457)![PB].7X
M5\*M:.VRLM-M%V#FEOS2WO\ $]WUWWU>N^K[L\AD_9_^!\M@NER_"?P++IRW
MOBG4A9RZ#:RP_P!H>.)X+KQE?$2!F>[\475K;7&N3NS2:A/!%+.S.H-=#H7P
ML^&WAC5K'7O#O@7PQHFM::GC2+3]4TW2K>UO;*/XC^+KSQ]X_2VGC4/&OC+Q
MOJ-_XK\1 '_B9Z[>7.H7&Z:5B>]HH4(+:$5MM%+:UNG2RMVLK;"YI;.4FO-M
M_F_ZN^[/$O#O[-?[/_@]];E\)_!WP!X:G\1^,[?XBZS<:+H%K93WGCNR-\UA
MXK$D8W6VKZ?)J>HS:?+:?9X;&>]NIK:"*6:1F^>/AO\ \$Z?V?O!-OK.G^+H
MM9^-FBW\'A6TT30?BIIW@231O!]MX,U3QIJVA2Z%9^!?!G@@7FO+<>/_ !/;
MZGXR\3/K_C+7=-OCIFLZ_?6(:!_O2BH=&BW%NG#W>:RY5;WE:5XK1W\T_(I5
M:BO:<M>6[N[^[\-GNK:;-;(\CM?@#\#[*VALK3X2^ +>RM]4TW6X+*/PUIWV
M2+5]&\"I\+])U%;9HF@^U:=\.(H_ ]HY0B'PPBZ2J_90$JCH?[.'P#\-?#'7
MO@MH/PA\":7\)O%+WLOB3X?6VB1?\(UKDNH&U^URZG92M(UU*XL+".&5Y3):
M0V%A!9-;P6-I'#[515>SIWOR0O9J_+&]I6YEMM*RNNME<7-+^:6Z>[WC\+WW
M71].AX?HW[,_[/7A[39='T/X,?#S3-+N+"]TJYLK7P[:+#<Z=J7C+2OB'J-I
M=%P\ES%?^/-"T;QA>F>222Z\1:99ZI.\EU$'.CX5_9^^!_@?Q_XE^*O@[X4^
M"/#7Q)\8R:I-XH\;Z/HD%GXAUN37+F&]UMKR^3D?VS?01:AJP@2%=2U%3J%Z
ML][)+._K]%"ITTTU""::::C&Z:5DUIHTM$^BT#GGK[TM='[SU3M=/779;]D?
M/&C_ +)'[,'A^T\76&B? 3X7Z59>/;[1=2\8VUEX8LXH=?U#PYXC7QCH%W=J
M,^5-H_BY1XIL&L_LP@\0YUD Z@S7!O#]EO\ 9P&D_$C0E^"'PW31_C!?PZI\
M3].3PW:1VWC74;:]DU.TO-75 K">RU6:;5K%K%K,6.KSSZK9B#49I;E_>:*/
M94O^?=/9KX([.]UML^:5^]WW8>TG_//=/XGNK6>^ZY8V[679'@&I_LI_LT:U
M/\/[G5?@5\,[^?X5:3::#\.))_#-F3X-T;3]0&K:?INBJ@5(K73]6#:M8).M
MP;'5);G4;1H;V[NIYOH!F+,68DLQ+,3R22<DD^I/)I**:C&-^6,8WM>R2O96
M5[+6RT79";;W;=KVNV[7U=K[7>KMUUW"BBBJ$%%%% 'AOPPOFTOX!_M.ZFAV
MOIWQ=_;"OT;^[):>(/$\\;9'3#QJ<]L?A7^<'XVO6O(9[N1BTEY>274A&#EK
MN62=SQS@O*3VZ\FO]&3PCG_AF3]K@KG</B1^V@1C@@_VOXKY![<5_G*WVFW^
MO_V1H^E6TEYJ.IW.GV=G;1C+2W$P6-0<9"HO,CN1A(U=V( -?RYXPSY>(\O<
MFHPA7S6;;=E_'PU[O9))-MO16NVK'^LOT (/_B'/B]*E%RQ%?_4O#PC&+E.I
M;!<02C",8KFDW*HU&*O>5DENC#\'^&=;\5ZI;:+H%A+J&HW+96*( )%$I_>7
M-S,Q$=M;1*09)I655&>2< _J]\"_V*;>WAL=;\9^5>W;B*XC>ZAWV,.TJ=VG
M:;* 9]CJP74]4"J3MDM;-"I$GL_[)O[+NE>!/#":]JL,$]T8H;O4+^>)=VHW
M87*,JLNX:;;.#'IMH1MDPU].&9@3]N6JZ9!'-=7D3SR[/]'M4+ !%7*RW+@A
M]HX( 96( 4,.:_$<3B9X^4N5SIX2]H1C>-7$?#RSG)6E3I36L(0<9RC9SE'F
M43^_<OI0X=PT*,(TJ^:)+ZS5FXSH8"7*I2HT(-3IU\3!^[4JU(RI4ZGNT:<W
M#VKX[1/AO\/O#%K;1Z?9KJ.IQ(5CD9$=8<C:VTNOV>./J2EI!!%G/(SENT73
MDBMUGDU"QA14VQ6)::9HP#D*B+M4,<[2/DQQ\O&XMMY[&%)+BYL7O9=N(E#/
M#;0>@X*S2N&(SM(#CC)RM.@BL)R99[B:&Z/R6UK9VKRERQ&$4R %V+'"@AV&
M,[0>3E"G&E'W$J:5UI"-KK5WM?I9MM-I.]WHS+$8JMBI2J8JO+$-.-13JUI-
M1IR7*I2DY.ZBN>T5-1L[6BTYJ7^TK[[-]G:WMA9<JMP=/0(7QC&/*'SC ;)D
M+9SSG($,VG>9:B9;ZQNX9 1+81M+%N&1]^*7<C.IXV_.O7[I7<-AM.\6I9@S
M:?KZZ8#@,=/GW =V9#&$$87D$QA<YYZDXT\>GP%)K6X>\)YN+>ZMFB*E/O(K
MQ$[6P-C*I3YL<*2S40J4ZG-[.=.2V?LVII/325M8MW[KJDD<M.M1K)2IU(U.
M6;<G&K%2IVLTUR2DG9I>[--R3LY5&E&7'WWP[\':MNU"SFG\.>(XF$J76GRO
MIMVTRE2"LT),<Q.Q=BS0L">AQC+9?B'\0?#"2P^.)9?&?A] D;>*((MNO:<B
MHL:2ZQ;(2+V!43+7(+3;09&N96 @7LKF?30T=S:6DEJI0-<6TQ+P2A1EO*D4
MF49'RY8JV /F]&7T6FN([BQ,HAEC$-S:S<M;B0 -A6 62!F.&5D*E<EPPR:(
MPE2?M,-.>'J2:NXQ7)-K[-:DFH5$[I7:Y]?<G%WOZE',9-TZ>,ITLPI05HTZ
M\TZ]"C*2<IX3$-2K8>5H1DXQDJ$U&]6E./L[>!^/]:L[^S-]97*7-K<(9(IX
M6W(Z$$@@X&&'1@P#*<@@8K]+_P#@@%<K/^T-^T>,@LGPN\)GW /BN]'0\\X!
M/I]",_EU\5? %[X3BGU'2(F;0=0'FSV<7-O9RRX$=Q:CK';3NRQM$!B&0B,
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M/E5@<8X. .3]*_K?C:3AP15FG9QRJBT^S61XFVVM[[6ZG^%_@;AX8OQP\/\
M#5$I4ZWB'PO3G%ZJ47Q=E?-%I[IK1^3/X7_%DI-U(HQA2J#..@1>Y&.@_H/2
MI/!'A/7_ !GJ]MH?AO39M3U&X*$11+MCBB+!//NIV_=VT&65?,D(!;"J&; J
M\OAO6/&GB^R\,:'!]IU+5;Q8H%^;RH8]J/-=7# '9;6T(:69QT4!5#,ZJ?W)
M_9X^!WA/X'^%+7[/8KJWC2_MHY[O49H%$MO,T>#=2*P8)=88I:1$_9]*MR$C
M\Z]>XN&_CFKB_JV%H4*24\15IJ:C+6%*G:*=6K:SY;IJ,;Q]I)22<8QG./\
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M3*1"YW >'^)_#E]HEM?R:6DS6L3RG5]*&YA QR3J=F@R8U"@_;H5^0!6F&T
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M[:I6J^VPLXX?#485*U2I.G]3BI4YU:L:7)S1C.I5I1E\$%'^2O%+Z'F3^&?
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MAKQ'H_AMV0J\9UN^L4E4AHV8'-?4^G_M(?#/PA966E^,K?XF>"X+>SNKV_\
M$WC#X)?&7PQX"TFW^U7$@;6OB)K7@2R\#:*S*RA(M5\06<C,RJJ%F4'H8?CG
M\ /!_P +/%'C/P_XJ\*0_#/X3^$-4\0ZS'X)M$N['P[X3\,V$UY>OI?A_P /
M6CS/:65G;2?9[/2+"0/M6*VB9F13\E?$?_@J-\#O#/ACX6>)/A_I6L_$S_A:
M_AZ#QGHUDLK>$GTWPA=7=U8VFJ:Q_:>GWM[9W]]<6<S66C2Z<EPUO&]Q=S62
MF%9_@\ZXFP%3 4<;C*;H99*O6CA\5#$<\:]?#JA&M2IU(8:I"K4HQQF&E6I4
MH2G35>C*349)R_1N'N!.(,9F.(R_*\!B\7F=".%IXS#3PWU=X2./ACL1@I8I
M8BM16$CBZ>49D\+5Q-2G3K_4<4J?-*E**_1S0]?T/Q/I5GKOAS6-,U[1=0B$
M]CJNCWUMJ6G7<3=)+>\M))H)5SD'9(=K JV&! UJ_._X>ZYX<\>:==_&O]EN
MSB\%_$..-]8\<_!>:>"P\%?%BSRD^IZ=>V$"PZ5HWC2<JY\.?$C2;.PO[779
M1%XLM]7\/:IJ=K/]P> /'.A?$GP=H/C?PV]R=)U^S^TQ07\'V34M.NH9I;34
MM'U:S+N;+6-&U*WN]*U:R9W:TU&SN;<N_E[CY=.IAL5AJ>-P-=8G"5M(U$K2
MA)IM4ZBN[-I-Q>G,HRO&$XSIPK'8''Y5C:^6YIA*F"QV&=JM"JM=D^:#VE%W
M3YHN46G%QE*,HREV%%%%!S!7Q9XH_P"1F\1?]AW5_P#TX7%?:=?%GBC_ )&;
MQ%_V'=7_ /3A<5]-PS_O&)_Z\Q_]+1\_Q!_"P_\ U\G_ .DHPJ***^R/EQ22
M3DDD^I.3Z?RKYP^,W[27AWX'^.?AKX8\6^'O$#^&_'.A?%GQ/K_C^Q@$WA[X
M?>'_ (1>![OQWKVJ>(E16N'MY-*L;EE6V4RQQP23*D[!86^CJ\5^+_P$\"_&
MZ;PL_C5M:-OX9A\<:9-I^EWEG;6/BCPK\2O!&L_#WQUX,\31W>G7\TV@>(?#
M>MW,4LVC3Z+XBTV_@LM1T77M,N[?S'BIS\C]E93O&W-\-E)<R?DXW6FNNC3L
MRH<O,N=-QM*]M'=Q:37H[/JM-4UH<)I?[8'PDU'X??%/XB7%G\0-!LO@WI/A
MCQ!XY\->(? VL:7XWM?#WCG3(-8\#ZYIGAB17O-8T[Q;I\TC:-)9,\DM[8:M
MI<\<-_IEU G@?Q=_X*0?LY^'=$^,W@X0CQ%\3? 7PJ\?>*=2^#7CFUL]"EUS
M5O"GPHTWXKZU\+_$EC=_VS>Z9J[>"O$.CSZS;WWA^]TV-+V\T\27M[I]]9Q^
MZ^'?V0?AUHG@/XG>!M4\3?$3QI+\7+#P;HGC/QIXLUK0I?&=SX9^'5I;Z?\
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M]U-J\H-VES<R2BIJ*2L^:/-K!2/J<@@D'J"0?J.*2CKUHKM.8**** "BBB@
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M_P#!)[]MFXE2SN/B?\%!9!MAN6'BJ7;'G D^RB!6/&2(U=<9(#9.:]#\,?\
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MVKJIM[I2N3^C5M;06<$5M:PPVUM!&L4%O;Q)#!#&@PL<4486.-%'"HBJJ@
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M.F^(Q=^'->6/YBL)U&T>?3[AE& KR1AG(^<J#@?LQ+I'[3,QR_[1WA0\ ?\
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MR_M??&GP'X(\)>--63X9Z1+>_##]I/XAW.C?#;Q=_P )7!J^F^#/V8K?XP^
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M3XT:/\*M3D\':M- +3]G;XK^,;CXY6NNWKW<]EILWBSX1KX*OOAA;%[32?\
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M\0A_%GAS4=5TX7DMYXE@M[F*/Q%=W#6]V[KY4NI&&XA\O\0_MZ?M*67A;Q+
MT'A3POXM\-? #P+^U;JVNZI\/-8U#PII?PM^+7A'X:Z)X/T%['^U+2\U/5]
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MS^+Y-9?PU/XGU#5;_5M*L]/U'3"+=5N]1\!L/VR_C]\+]-N/!7A2ZUCXF_\
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M /H$R_\ ?^Q_^3*/^%:^+_\ H$R_]_['_P"3*^LZ*/\ 67&_\^<+_P" 5?\
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MCXKM]6L/"/B*;1[C2I3_ %EQO_/G"_\ @%7_ .6_U=^5C^P<)_S]Q'_@5/\
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M#A/^?N(_\"I__*_ZN_*WN?\ PK7Q?_T"9?\ O_8__)E'_"M?%_\ T"9?^_\
M8_\ R97DFK_MK?$'PWHVJZSJ?[.'BB73+/5[/0-/UJ_\31^&M,U+6]8L/#NK
M:8[W&N^%[&RTOP@L'B"339/%M_?*HU/2)X)M,A:=Q9W+S]L_XEQ^/[[P-I/[
M)WQ*UNQTTZ.S>/H->TD>#-6L[KP+;^-=4U'0;S2;'Q#->V@:6;1?"UQ*L&G>
M+-1M+B&WU.PN(+BUA/\ 67&_\^<+_P" 5?\ Y;_5WY6/[!PG_/W$?^!4_P#Y
M7_5WY6]/_P"%:^+_ /H$R_\ ?^Q_^3*/^%:^+_\ H$R_]_['_P"3*\9M?V[/
M&FJ7EQH^A_LT^*M:UZXTK6_%/A_3[/Q-J$<6H>"]&UGQ#X?.MZY)>> +;4?"
M>J7>JZ=X;2+PIJFD/K<5IXTTNXFB673-<MM/])^$?[5/CWXC?%RW^%7B/]F3
MXF?#NV'AG6==U'XAZO?V-UX'@OM.U*2VL]#TRYN+'1M8UJ6^L/LMW<:A!I$%
MEIU[=+I;O<.HN9#_ %EQO_/G"_\ @%7_ .6_U=^5C^P<)_S]Q'_@5/\ ^5_U
M=^5MW_A6OB__ *!,O_?^Q_\ DRC_ (5KXO\ ^@3+_P!_['_Y,JG^T%\>_B#X
M#U35?!7@/X=ZY>Z@/#?AG73X]&@>)O%%EH^C:KXZT;P]XW\0:-X6\.>'=2B\
M5W/PS\%7>N>.KS0+OQ#HFK:W>:5IOA[1M'UJ;6(<_)4_[2W[<\PUVX\)_"NV
M\1>"-+\3_##2[3QYX@\"ZUX;U^^T._\ $,-CXMUC3_ HNC?:U%XJM->T=O#E
M_9P6MCX7TOPUXPUSQ$B)=>&H-0/]9<;_ ,^<+_X!5_\ EO\ 5WY6/[!PG_/W
M$?\ @5/_ .5_U=^5OL'_ (5KXO\ ^@3+_P!_['_Y,H_X5KXO_P"@3+_W_L?_
M ),K(^#?Q'_:DB\%_ V/XM?!Q?%_B7XB-=7WQ!\6>#==\,^&M'^$^A7B:=>^
M'Y/%7AOQ+>:5KNJ:R]I?W$&K:9X5TZ_.GW>FSP.9&>.23QO2/VOOBCX.TPW_
M ([^'OC;Q]XP\5ZXWAVP^%GASX;Z_P"#Y_A]XZBL_B+KI^'\/C'5[*?2/B'%
M>Z+X.BAM/$.D-+'!?7'AZZN&DTWQYH$\)_K+C?\ GSA?_ *O_P M_J[\K']@
MX3_G[B/_  *G_P#*_P"KORM[W_PK7Q?_ - F7_O_ &/_ ,F4?\*U\7_] F7_
M +_V/_R97BDG[9/Q2LM=OM2G^"'B6_\ "%UX:\&:CI<=CH_CJ/3M$OM2O?B;
M8^([G7_%#_#N36+[3+2;PCH4*MH?@B^F@O-7L%M8M5TO6M,U>?L?$G[:LWAW
MXK^+?ATOPE\0:W8^%[=K1=1\/W]QKGB'4/$<OASP9XBTZRE\$:3H5[XET71=
M2/BZ31K?Q'J]C;Z7%JNB:G'?SV30M"I_K+C?^?.%_P# *O\ \M_J[\K']@X3
M_G[B/_ J?_RO^KORMW7_  K7Q?\ ] F7_O\ V/\ \F4?\*U\7_\ 0)E_[_V/
M_P F5Y5IG[;?Q UC3M6UNR_9.^*T>CZ1)XQ662_;5;;5KZ'0?#WBK7O#]WI.
MA1>#+J_O8_$DGANWTF[M"(=6\.:IK5KIMUIM[J]O/I=1R_MJ?$2?5+'3M/\
MV8_B/,SZ/<Z\ES:_VQ=:1K,=OX3^(>IC3H]1G\%6EQHEM=ZWX6T&ST76-9TZ
MR?Q%!XCM+C1--O4MM1BMS_67&_\ /G"_^ 5?_EO]7?E8_L'"?\_<1_X%3_\
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M?@.Y\1>'KO0O#'C&QT9],M?C=HUMXNUFYTGQ/H.I3:MXJ2Q\)>(O'7PX\'Z
MVG> -6UO2$\36>N*]B?ZRXW_ )\X7_P"K_\ +?ZN_*Q_8.$_Y^XC_P "I_\
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MXC_P*G_\K_J[\K=I_P *U\7_ /0)E_[_ -C_ /)E'_"M?%__ $"9?^_]C_\
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M\^<+_P" 5?\ Y;_5WY6/[!PG_/W$?^!4_P#Y7_5WY6]W_P"%:^+_ /H$R_\
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M?_T"9?\ O_8__)E'_"M?%_\ T"9?^_\ 8_\ R97UG11_K+C?^?.%_P# *O\
M\M_J[\K']@X3_G[B/_ J?_RO^KORM\F?\*U\7_\ 0)E_[_V/_P F4?\ "M?%
M_P#T"9?^_P#8_P#R97UG11_K+C?^?.%_\ J__+?ZN_*Q_8.$_P"?N(_\"I__
M "O^KORM\F?\*U\7_P#0)E_[_P!C_P#)E'_"M?%__0)E_P"_]C_\F5]9T4?Z
MRXW_ )\X7_P"K_\ +?ZN_*Q_8.$_Y^XC_P "I_\ RO\ J[\K?)G_  K7Q?\
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M $"9?^_]C_\ )E?6=%'^LN-_Y\X7_P  J_\ RW^KORL?V#A/^?N(_P# J?\
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M]$M8M0:XUC29I-5L= FM L<,/E4]O\#_ (L>-[:6;QE\2#X'^.W@_P 9?'A
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MQG\3/ 7P^T-_$GC'Q3I.AZ'%J&GZ5+J5S.98(]1U5E73[23[*L[I+=ET,(9
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M2_GN/VF]0O!!-<^(]9U.R\=>#8M;UAV\4Z?J*PZN+70XY-5TC_A*?!@N-?\
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MB+X:\,:7/)%IJ+?7MA!I<DLMNTT#T-+_ &$_AI::]H_B^]U:^N?$VG_$F_\
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M&YOM7-WXMFGM-1OKJXNK:30_#;I)OT^X:^ /9;']EK]GK3+VTT^#P:KWEO\
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MP06ME"R6\"(?+C4NY;IJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>dm199collatcirc.jpg
<TEXT>
begin 644 dm199collatcirc.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M)KGIU8T_V7HK^>SXA?&CXR?#3]A7P/XE_9H_:>D_:&\+W/QSTO28_BKKPO\
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M.E1QU"-?"\F88:CA,1?!T')4:&03X9BJ<N5.$GE$Y4)2?,U4;KPY:LIRDJG
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M5-.U%[-+G5YXY+&1+:-$O+>ZU?@)^P_\5?!'[0O@[XT^.)/@#X7\/^'OV?\
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M<:/:>*_!=UX<D:*?48]+N9A'9:S#]CCO&#RI=0L%@_3)F55+,0JJ"S,Q 55
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M"XD**74%5<J"ZJQ!90V,@,0"0#@D#/04U88E\O;%&OE B+:BCRPPPPCP!L#
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M_A=%K_P5WUS2O$?P['C#6Y_'&G_!6[U?QIJ&B6?B318KR74]+^%.I:1?: =
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M/!'C;P?\5(M#T&UN%TS3)I?%FK:AXON8=6_H=$,2A (HP(F+1@(H$;,&5F0
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MJL:+]YG<[44?[3'./10SG"([* 22S1PJ6D=5  )+,J@ D %F8A5!) !8@%B
M.36:UY?2C-E9,ZG&);@BVB(('S*)/W[#G.?)VG'REN,V8+/E9KHK-< $@8S%
M"3@D1@CEN &E;+L% &U0JB]0!AF/7FYW6$9X^437# <<@G[,O(.>F?KQRGDZ
M]_SVL/\ OY<?_&*W:* ,+R=>_P">UA_W\N/_ (Q1Y.O?\]K#_OY<?_&*W:*
M,+R=>_Y[6'_?RX_^,4>3KW_/:P_[^7'_ ,8K=HH PO)U[_GM8?\ ?RX_^,4>
M3KW_ #VL/^_EQ_\ &*W:* ,+R=>_Y[6'_?RX_P#C%'DZ]_SVL/\ OY<?_&*W
M:* ,+R=>_P">UA_W\N/_ (Q1Y.O?\]K#_OY<?_&*W:* ,+R=>_Y[6'_?RX_^
M,4>3KW_/:P_[^7'_ ,8K=HH PO)U[_GM8?\ ?RX_^,4>3KW_ #VL/^_EQ_\
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M95*D9N%.,Z=YTW4E%5()R@Y*+:^E/)U[_GM8?]_+C_XQ1Y.O?\]K#_OY<?\
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MA_W\N/\ XQ7QW<_MT> ;3XE?$SX4W'AC78/%?PW^*OPK^&[0SW5E#;>)=/\
MBCX@\/\ AB/QGHD[X232O"VLZ_!:>(K)S]MM&^R,<+J5J3[GX)_:)^$?Q*D\
M86O@#Q;:>)M0\%:;-K&J6-O;WUG)<Z4EQJEC#K&D2ZA:6T.LZ'=:GHNJ:7!K
M>E/>:8]]8W$ N"Z -[6)X<SS!T5B,1E>+IT'3P];VRI^TI1I8NCAJ^&J5*E-
MSA2A7I8S#.G*I*"E*I[-/VD*D8>1AL_R7%UGA\/F6%J5U4Q%+V+J<E657"U<
M10Q-.G3J*$ZLZ-3"UU4C34G&,.=^Y.$I>H^3KW_/:P_[^7'_ ,8H\G7O^>UA
M_P!_+C_XQ7P!:_\ !0W3K?X>:CXZ\4_!+QQX9DO?@UJWQS^&FDGQ!X4UB/XH
M>#M#U31M)U:ST;4M,OI1H_B;3I_$6B3W>AZ[96DJ6>I6\\4TV)5CZ'PW_P %
M"_A7XTUSQ-I?@KPA\0?&5GX6^">@?&"]O/#&B'5;VZO]=N=+AD^'%EHR-'<M
MXN\/0ZWI$_BHW$MOIWAYKY8-3N;=[>[,'?/@GBF$:L_[(K3I4*DZ56M2K86O
M0A4IU*-&<77HUZE%N-:O3H/EFU[=5J-_:X?$0I<$.,>&IRI06:T85*].%6E2
MJTL31K3IU(5:L)>QK4(54I4J,ZR4H)^QE2K6]E7H3J?;WDZ]_P ]K#_OY<?_
M !BCR=>_Y[6'_?RX_P#C%?#VN?\ !0KX9Z!IGPMUV_\ !WB^+1/B!\,/ ?Q?
MU[4)KWPC9M\/_!/Q$U[3O#.AW>I6%]XAMM0\4WUIK&I1C6M-\$VVO7>F:;!<
MZDZ21+&DO<?"#]M+X??&#QKXC\&Z;X=\2:&VG:#XW\5>&=1U*X\.7K>,?#?P
MY\83>!?%^H6^AZ)K6I>(?#=WI_B*.*.VT?Q7IFCZGJ-C>V=]:V[)(\<>-;A'
MB.AA:N-JY5B(86C[15*KE0:C*E-PJ0Y8U7-U8).M*E&+J+"KZWR_5?WQM2XJ
MX?KXFGA*6:4)8BK[/V=+EK)R56*E3GS2I*"IS<E2C5E)4WB7]5YOK/[H^J?)
MU[_GM8?]_+C_ .,4>3KW_/:P_P"_EQ_\8KYG\#?ML_ /QKX8\'^)I?$.I^$5
M\:>$_$WCG3M)\7:)J&GZE8^$_"&IW^E>(-?UAK6*_P!.T[2K"ZTZ8/?3WXMG
M$ENL<C2SI&>H;]K'X$+X,;Q^/&4K^&8-;N_#^IW</A_Q'-<:#J.GZ9%KE^/$
M=A%I3WOA^TM-"N+76YK_ %>"TLQI=W:7:S/'<P[^6KP[GU&K*C4R;,XU85I8
M>4?J6(E^_C5JT73C*--QG+VM&K37)*2<Z<XIMQ9TT\_R2K3C6AF^7.G*C'$*
M7URA&U&5.E5522E-2A%TJ]&I[RBU"I"35I(]P\G7O^>UA_W\N/\ XQ1Y.O?\
M]K#_ +^7'_QBOF.Q_;;^!$T?C:?5M6U_P[;>"_BA>_";[1JOAK5I4\3^)K+P
MHOC,OX4CTF#4KC5+*XT);FZA+0V]X$M3+/9PP75A-=]!IG[8?[.FM:#JWB31
M_B/9:EI>CS^#[:1K72M=-YJ,WC^*ZE\&+H6G2Z9'?Z\OB+[!J,>F2Z5;W<,\
MFG7ZB0?992KGPWQ!3UGDN:*-Z*YU@<1*G?$.FJ$?:1IRAS595J481YKN<U"W
M-="AQ#D51VCG&6\UJLN26,H0GRT/:.M+V<YQGRTU2J2F^6RA!SORZGOGDZ]_
MSVL/^_EQ_P#&*/)U[_GM8?\ ?RX_^,5X+/\ M@_LZPZKX7T5/B1I]W?>,]+\
M*:SX;%AI^LWUKJ.G^.I]2M/"$OVZVT^2SM9/$.H:3?:7IUO>SV]Q+JD/]GM&
METRQGN?@5\:?"W[07PST/XI^#;+7].T#7KC5[:UL_$NF_P!E:O%+HNK7FCW7
MGVRS7,)CDN+*22"6WN9XGB=076998H\,1DN;X3#/&8O+<;A<+&K1HNOB<-5H
M0=7$1KSHPBZL8.3J1PM=KE32]E*[3M??#YOE>+Q"PF%S'!XG$RIUJRHX?$4J
MT_9T)4(5IM4Y225.6)H)W:?[R-DU>WH/DZ]_SVL/^_EQ_P#&*/)U[_GM8?\
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MQ-DY.6<&!", )$V!F1B;EVVV!^V[">GWCC_/7Z&F:<ACL+-"2Q%O$68\EF9
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MGR;T>&,VQ')'#?4Z]2=.M5=.E7K2G3IT*:J3E/\ V;E2MS))-MN#5DYT^?\
M0^BOGC]D75-4US]E+]FC6M;U+4=9UG5O@%\(-2U;5]7OKG5-5U34K[X?^'[F
M]U'4]2O9;B\U"_O;F22XO+V[GFN;JXDDGGEDED9S[SJCO%IFHR1LR21V-V\;
MJ2&1TMY&1E(Y#*P!!'((!%?05:?LZU2DW?V=2=/FM:_))QO:^E[7M?YGSL)*
M<(3M92C&5GT4DG9ORN?&?C;]A?X9>._%]KXXU;7/$4/B&Q^/VG_'BUO;(V4#
M":WTWPYI^I> KHB'=>>#]:D\*:%JMU#,?MMOJ^FV-]:7$+V^V3IO@U^R3X<^
M#VIZYJ,'C?Q7XK$WP]C^$G@VUURWT&UB\#?#6#7]?\3P>';-]'TRPFUV[75_
M$$[2:YKKW>H26ECIUH"@BN)+KYB^"G@#PEXL^#_P_P#$_B"7XHZ[XCU70!K/
MB+5%^,'Q:_TZ_NKR].7DM_'<%K')=3LA-O;VZ>3&HMXH$#1[/7]"_9[\%W%O
M'-J<WQ#1XF>.2W7XR?& /YD;2#$SKX[&0 P)",3(53)C52LG3B?$/%RC5R*I
MFN;8G#T$\+*FL#@Y4*4,'548PIU9XJ,Z<>?G35*49SC[>%2+52I&<4/#[!PE
M3SF& RVAB*DOK$:GUK%1K59XFE=SJ4X4G"K+D4&G54HP_<3IM.-.4,G1_P#@
MGWX;A\'3>$/%7Q=\?^-(-+^%E[\&OAY/J.F>#=+@^''@?5-;T/7=8AT:ST30
MK$ZIK6K3^&]%L[[7-?N]1O9-.L(K52F7=O:=2_9=\+P>(_$'BOX?ZP_PQUK7
M_ACXD^',LGACPWX::QAG\6^+;#Q?XB\92:7>Z?)8W_B35KRSDAO9[Z&:*<74
MES(K74<4B^::3\!OAM=SZC"UUX_F?2KG^SY(Q\:/C S;S%'<+/<;/':XE>*5
M$"#"(T<V5+$[+4_P%^&\JE+$?$26=6)5E^,7QC^SET!_=RRR>/0AC8_*QB+L
MI'."I4NIXC8O%VK5<SS&:=3$35!9?EL</.I5E!8E?5*>(6%FZM2CSU8.DX5*
MSK59IU*]>52:7AY@\+^YIX# PE[/#P55XW,'7C3IQD\,_K=2D\1'V=*M:E-5
M5*%)4J<'R4:,8<O>?\$_?#FN^#/A%\/O%OQ3\4>)_"7PKT'1/")T^^\(?#J*
M\\0^$O#6M:3K.C:*NN1^&CKGA>1AHUII&NZIX;U"QO\ 7]%:>UO)5GF:['K'
MPQ_9,\+?#GXP>,?C//XGU7Q1XD\2:5XB\/Z7%>Z!X/T,:#H7BOQ'%XHURWNM
M0\,Z%I.I>+-3N;^TTZTBUWQ-<7VI0Z5I=E9F2643W4_GVB? /P>NF6_]LVWC
M^2^4SQSS6OQJ^+\JNT4\D08Q_P#">QA#M0%@N4!Z&OSE^/6GZC\$?VU?V9H-
M3\3?%!OV?_C9IFI>"M0\*-\7/B:;*V\>:1=C2&U%;]O%PU*WDD/B/PYK$T9U
M,6TD-C=*D:CS<<N-\4L3+ VQ..S?ZIC>>%>E'*<LP[I1S/%T:F*J5%#$4G25
M:M.FL5.E+GG1@J#<L/35./TW!_@C_K+GM3+,GIY'#-L#EF:9I@?K6:9I668S
MX6R7&YA3R[ R6'Q,:V-JX/ XE971Q"IT'C'&I.I1KU76/TPT3]AOP)IWA^_\
M)ZGXQ\7:]X?O/@K\0O@-#;W2:+9WMGX%\?>-?^$S(2]LM.B6?5-!F"Z9I][<
M6T@NK1%EU&*YN-SMQ&N_\$\?"GB'X<6'PZO/B=XBM+2/4_%5_K-QHG@OX<Z#
MI_B!?$W@_3O!4+ZEX;TGPY::/=ZWX?TS2;2XT/Q/J<6IZY9WTM_(MUY$]K;V
M.+X%^%W@2ZEU_P *ZVOQ*E\2^%?$&JZ;>W=_\8?C';VTVGW-R-1\.W-S/!XY
M\A)[O2+ZS6WMH_WDD,8D;<[,3W>H_ ;X>6:27%]??$"VL["SDU*^-K\7_C(C
M-%%G$*R/X]FD9"RMYCI'&X_=ID"3Y?5Q'B/F.78S$J.<YA4J8?%2Q$J]/+\L
ME1=6I"4UBZ;K8B*A"O1Q'MVU"//"5.<X<].ER?%8'@#+,VP&$JK*<)2I8K"Q
MP\<-5Q>81KQC3J0ISP=54:<N:KAL1A_JSC[22A5A4ITY\E6HY]9:?L<>&+'7
MVU>#QOXJ-D/BF?B_;:-+;Z.\%EXKO?A&_P (=<6"^6SCOWTW5])CL-7^R7$T
MYT_4[(K9R+;74\1X?4O^"??P^U'PYI>AOXS\1FZ\/^$O@/X8\/ZE>Z5X=U6&
MSF^ :^*8O#^I7^C:E87&F:Q'KMMXMU*WUW2[N);5ECMGLGM98R[:EC\!/AZ\
M.F7,S_$%AJ,;R2+_ ,+G^,0BA-Q']I@6/_BNT8B-$$,88;B&+.6?)-?6?@3\
M.[#4=$D-]XYM;!YYX=0BG^,?QB E-Q&L-B3,?'X\D&[9(D.?FED1><X')'Q+
MQU&G#$0S7-HJ*P5+3 9<FJ5&K3JT)3YL4HRA2E4=:OSN4JB57VJJN34^^7AO
M@*TYT)Y?ELI2>-J6>*S"7-4JTITZZIN-!RC.JJ?L:*ARJ$O9>S]DDI1W;7]B
M;P5:W>CW:>+-<1]*@^ R&&QT;PKHEC<S? ?QEK/C?3)UTK0-(TK2-.7Q'JVN
MWBZK:Z9I]I;6L.PV,23F263WKX(_"6Q^"'P^L?AOI&O:MX@T+1M6\1WF@S:W
M%IZ:AINEZ_KVH:_'HDD^G6MI'?Q:7<:E<V]M?7,/VV>W\L74DLB;S\_+^SY\
M.;B>7][\0HXK>01B./XR_&$&5MB2,TC'QXS;,2*%5"AR#O8@A:KZE\"?ASID
M;WAMOB1=VZ1JKPVOQC^,<EP'\P 2)$/'N74AP'QG8J%L8(KGQ_'$\=A:M#'X
M_,Z^$=:EB9PG@,#R^UPU&6'IUTJ>+4H^SH2E23A:\'*\6G=[X'@BE@L53JX+
M"8"CBO95,-"4<5C.9TL36A7J4G[2@XR]K6C&K[R;YU&S4M#[CHKX;?X"_#W[
M7;M"OC^6VN;(.D1^,_QBC;S5<NSHS>/,%O)=-T18%@I9,>6Y.8WP%\!37IU"
M&7XFP6*0&W6SD^+GQ?EL9V20M)>R3Q>/WO(7)!AB,2R0^6GF.F6)3Q)Y[E<;
M6_M&5Y):8/#)*-DW4YI9@HN"4E>S<M4E&[5_9CD./E=NI@8KD<KRKXC5K14[
M1P;DIRDG%72C=/FDDG;[WHKX,U+X$>"3:3/IUO\ $)9S97.R1_C3\76M892B
MO#=K*?'[>>L05OW00"3<,D=:P];^%OPL\*Z7I4NKGXH3S^?:P7DD?Q6^,ZFX
MC2!C>7@9/'K6BC(,RVXN%E< I$A/%8UN)<EPZJ3KU,?1HTJ:J3Q%7"8>%))R
M45%.6/4I2=V[1BTDM^9J+UH<,YMB72IT/J5:O6J.G3P].O7G5;2YFVHX-Q4;
M=7+773E3:_0^BOE_]CJ[FO/@58F34=9U6&R^)_[0FCZ;=>(-9U3Q!JJ:'H7[
M0GQ1T;P_87&KZS?:GJ=Y%I6AV&GZ79?:[^Z>WL;.VM4E\J"-1]05[LU&,Y1A
M+GBI-1G:W-%-I2M>5KK6RDTMDWN_!M):27+):2CJ[26C5VDW9W6J3\EL?&_Q
M8_8]T[XK_$/QKXPN_BGXX\,>'/BCX0\%^!/BAX%\.V/A5;/QIX7\#ZCKFI:=
MI,OB'5-%U'Q!H=MJ#^(=3M-8;0;JPN;ZPN'MC<(-C([7?V*?A;K_ (9^(NA7
M3.FJ^/O'>N>-(/%ZZ/HLGB;PC;>(?$/A7Q%J?A3PYJ$MHTUMX?NKGPAI4-Q;
ML^ZXB3=-O=(R/ / /@W1?'H^)VO^(Y?B9KVN)\:_BSI37-M\5/B=I-DD%GXG
MGTW0]*LK33?&=AI=E9V%KL6"ST^PBBB$<*B-5\QCZQI?[._@B>P2:^N_B$MQ
M);; L7QD^, 6*;:J&5S_ ,)V0SJR;@@RFYI"Q8.BQ=D_$#&X3$4\NIYEFD9Y
M5*G3A+#8# TJ4)X'V%"GS5EB*4\3*G'"4,.IUU4J2H8:E0J+V,(07.N ,%B:
M%3'U<#ELHYE&<ZD<1B\75JRCC?;5ZBC1=*K'#QF\56Q#C1]G3C7Q%2M3M6J3
MF=#X@_9&O/$7C?XZ^,KSXS^*E7XYZ'X9T'5-!_X0[X>7FE:'8^![O4+CP=;0
M1:IX>OUUFRTR'5M4L-1LM:CNH]?L[QAJ;//#;SP^:W__  3B^'6I>$?#G@F[
M\<^(9-"@UOQ1K_CVV'A+X<(?'%_XR\36'B;7VTV1?"@E^&RW)TVT\.1+X"DT
MA8/"<:Z4%>Z5=2'7:-\#/AGJ%@=1-QX]DC:2:-MGQG^,!AA^RR/ Z[E\>@!P
MR,TY9CM<LHPJJ*IZY\!?!+V$\F@I\03=1HA#7/QD^,=O;-&)4>5E:7Q[YF]8
MU9=WE[=K,5!8*:JEXG8W#8>E6PV99C"%*&'KT887*,I55K!X&. PDXJG63J3
MH8*-.E0<I.5.4*52+C7ITYQ53PTP.(Q%2CB<%@I3JU*]&M+%9EFCI1>*QWUW
M%QDZD7&G&KC)SJUE%14XRJ4VG0J3@_1_C)^RCX<^,.O>)]:O/&'B/P[#XQ^&
M&D_"[Q!I&F6VD75C<Z9X>\;6/CCP_JMO)?V<M[9ZEIM_;WMDZ0W/V.]LM1?[
M3;M/;6\J\YJW[%?@[4/BM\2?BE8>,-?T&^^)MIX@FU2'2]$\'-KFB^)_$7P_
M7X;W'B7POXYOM!O/%WA^2UT!$GM-/TK4K2W_ +35IKB2>REGT^3)N_@-X!CM
M"PM/B(MPOEN GQI^,#1/M=<H9?\ A/@RB3[GW"0&SD'I^1O_  45T3Q-^S=\
M9/V6/B%X5\>?&.U^%_B6XU7PKX]\'VWQJ^+J:!K/B7PUJNF^+87NXY/'#%6\
M0>&9M7T1422(O;Z9(_$B%QYU?Q,K9/@FX8[-_JF'PSPTX1R[ -1PN*J8*G44
MU6Q-ZG+'!823E-RJTJ6$A&G**48R^VX(\#I^)/%V7\,X+^P<)G.<U\57R^KC
M\;F5.CB,RRW+\RS##X:G/"X6I[*KBW5Q>&PZ48T*N*QEZVDI3C^LG@;]@SPM
MX$FT34=,^)'BI]:TGQKK'B^:]31/"=E9:E#XE^%5C\)/$FASZ3::2EM%;:KH
M6GP:@-3AD768-8>>[-].9B%U]!_8=\#Z%9Z?9)XQ\47D%@G[-D6VXATQ?M$7
M[--[KUYX<CE\J!"J^(SK]S%K7EE6@2&(Z>T#[B?(]-^&WPVD\76%S'J'Q&_X
M0SXBZ9IL_A*]U;XQ?&>-;37[>!V_LF&U/CN(VD/BC1WM-7T0W$^W4;VSUB*"
M0SM:6\_H$/P*^'3:E8V#WOQ#DO-16YU-HE^,GQAC2WTVR8Q".%!XY=/W]RT,
M<C/*92AF*,"JY]?'>(F/C'#8BIG.8UZ&98;!5:&)I8'+8TJU.&*C6HTH26)I
MR;PF92G2Y8Q48UX57&])\TO@,OX!R^K/'86.4X/"XK*,;C\-C,%7Q6/>(PU;
MZNZ52K5@Z4U%8S+(TL1&4Y<\J%2E&:C63A&;P3^P-X"\#646EZ;XOU>73M,\
M9> ?%'A['A;P)I^KZ=8_#_QI=^-]-T+5/$NE>'K+Q!XGCN]0N8[.[O=9U"8I
M9V=M);6L6H-=7MSZ1\(OV5-!^#7B[P_XL\.>-/$MV^D^$/''@W5-*U*UT>2Q
MU[3_ !C\3]>^*MO<S2)9K>Z?>Z!KOB/4K2UDL;E(K^P>)+Z&26,2'D+3X ?#
M=X&,C?$ O;R3PRNWQE^,7+6TLD;.W_%>JH#!!(<A0%8'@<UAZ+\"O $VEB*X
MO/'-YJEO=M8W<R_&'XPQ^6\I:ZMI);=?B!E"^G2VTRHVTL9!N"C=CEQ?B+BL
M9&K1Q>9YG6IYC&=6O&> RU0K3C06':G%8J+=>5&M.490BWSQJ5Y3C6C&H^S"
M^'F"PGLZ^%P674IY>Z=*@XXO,.>C3E6^L7A)T&HT(5J-.,E*7+RSI4%!T92@
MOO:BOBAOV=_AVD#K%)\0Y9L$H\WQF^,0)?C ;9XZ554D8(1  "2!66/@=\.[
MNWU(06WQ(M+G3Y1&5N?C!\9!YFW;(TD.WQZ?.@9 ZB1,[B#CGIX,LZRN#2E+
M'J4E)QBL)AVY.,7)Q3^OVYE%7LVEV;U/<AD>834G%X-J+BI-UZR4>:48Q;_V
M2_*Y2M=)VZI7/NNBO@W4O@%X#NDCL[;_ (6;83EHKF:ZL?C'\6;MH[='#!(Q
M/X_$<HNRK0GY0RQ"5UPX3-D_ GP"\1\NV^(<TL<L?,/QD^,<:R%65FAGCF\?
M"2T+H=K,1(JA@Z,T9#&'GN5J<H_\*5HQ34OJ5"TI._-",?K_ +3F@K.3<%'W
MDE)R32O^P<PY8/GP%Y-IQ>)K)P7NI2D_JG)RR<GRVES6@Y.*BXM_=-%?GM-\
M&? &BZ'K6HZT?B2\T4^HSVHMOBU\99XH$CD:&TTX36WCJ125DB"R75Q'%$OF
MNTD@"Y%JS^#7P[\2>'FU70(OB-&LEI=F)Y_C+\8$N#?6T<L:VJP#Q_( ?MJ"
M-Y'91L4[1\X:L8\2Y+*:I*>8?67AWB5A?J>&>(=%24.9TXYA*RYG%7;2O))N
M[L;RX8S:,'6_V)X98A85XI5\0L/[9Q4^3VDL'&]HN3T5[0DTFM3[_KYY_:8_
MY$#2_P#L=O#/_HVZKQW]CF\F'B?X_:)#/XFCT;1O$7@0Z=HOB3Q3XH\5?V->
M7OA(_P!MIIUWXLU35M1M;6[U"V::2U6XCB696)A63>S>Q?M,?\B!I?\ V.WA
MG_T;=5[%*K1Q%'#XG#SE4P^*PN%Q="<Z;I3=+%X>GB*?/3<I.$U"JE*/,[23
MU/%Q&'K83$8C"8B,8U\+B*^%K1A-5(*KAZLZ-11FDE.//!\LDDFK,]<\&?\
M(O:;_P!>L/\ Z":ZJN5\&?\ (O:;_P!>L/\ Z":ZJK,0HHHH HZB<6K$=1)&
M1_WV!_6K%O\ \>\'_7&+_P! 6JVI?\>C?[\7_H:U9M_^/>#_ *XQ?^@+0!Y!
M\2_C_P#"OX1:MIFA^/-<UC3]4U71=5\2P6VC>!O'OC%;3PWH4UM!K/B+6[CP
M9X8\06OAS0=+DO+?[?K/B";3--M8W::6Y6&*9X\VY_:=^ %G)\28[CXJ^$U_
MX5#\/O#_ ,5_B)(EY+-;^'?AOXKTG4=<\-^-&NH8)+;5/#^M:7I6H7-A?Z++
MJ4<YMF@7_27BAD\]^,/@/XV/\;?!WQ0^$_AGX<^*;2T^%7C?X<:Q;^.O'6N>
M#VT:]\2:UH6JZ;KEO9:1X#\7CQ+86W]ERI?Z2VH^&[B965(-10R&6+Y<\,?\
M$V;*QMM:M?%.N0:U-H7PS^$?@?P1J&F:I?:-!XR?X=?"Y/#]QI'Q,T>/39XF
M\$1?$G2_#/CKP]X?M[W5DL)_#]G&Q%I-JFFZH ??5G^T'\%+_6'\/VWQ+\*-
MK</PSA^,E[IDNHK;7FE_#"X33Y(/&>M17*0MH>DS1:KI\T9U?[%<O#<K,MN8
MDE=.4/[6O[/2^'?^$H;XB0+IPUF;0'LF\.>,%\3Q:C;^'4\8W#3^"F\/CQC;
MZ;!X,DC\9SZW/H4>BQ>#98_%DFH+X>D34F^;+C]G+XQWGB7P%H&I^ OA'K7P
MYTG]CG7/V>/&.LWWQ)\3VFK:WXHUS1_A[,]RWA;3?AO;SW7AVWU3P NA#4%\
M=:=K!TS58]:M[6VFTS^Q[OR2']B[X]P2>(/B/NT^\^*.N:WI>G:/;WG[0/B@
M:MX,\':9\+KGX?2./B9!\'H[7Q.FN7-V\^M^&;SX:6#-HEGHT5GXFAUZPEU:
MZ /U(U_XB>"/"_@NY^(FN>)M+L_!-KH;>)9/$:S&\L)="2R_M+^TK,V*W,VH
M0/8?Z5"+"*YDGA(>%) 1GH[;5M,O%S;7]K*1:07SH)XQ-%9W,0F@N9X&99H(
MI8F#HTR1@K]#C\P_C'^Q%X\USX3_  B^&WABU^'?Q.B^'_[-GC7X$%/BCJU_
MH]EX?\6^(H/A^=(^,?AXP^$O&4L_B#1X_!NK:"L4::)JZ:7XIN9;;7TC6^T_
M4,;Q#^PY\7-<N_B/;6FI> ] N]?MOCI<-\3]/UC4SXU^*UA\6KO2;WPU\,?B
M+:KX4BFTWP=\.K"P'@S3KT^(/%L!\/Z?I<VE^&M+)N;"@#]5UU33'6S==1L&
M34&*6#K=V[+?.H)*V;"0BY8!6)6$N0%)(P#2MJ6G)>)I[ZA9)J$N?*L6NH%O
M)-L?G-LMC()GVQ?O3M0XC^<_+S7Y=:=^QE\0-*NO@UK.A>#_ (>Z/K/@_P")
M<GBN^CUSQ_\ \)GHO@;P]?>-_!>O>(-,\-Z#)\'-"T.^NM6TWPUJ&H:/=>#M
M/^%.H>&/%VIF\.J:WI]SJD%WY/\ M!_L0?%OX@?M7^+?COX7\&:?'?S?&_\
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MBF93(D4KQAPA*UZC^TKS^SQ\<QUS\)/B%QZ_\4KJM><^"O\ DY&X_P"R-/\
M^IC!7H_[2G_)O/QR_P"R2_$'_P!175*ZLPN\RPC=VW2P%WNW[E-*_5Z))>22
M.?+$E@L0DK)5\59+1*[N[+97;;?=MO=GGG@V2^BL/#=[?6\EO86O@?0+2SM(
M8#=-;O)8VLES<2/:&63$Z6L($8MSL5%#R9!SH>&/&>GZ\-0L-'AGFN=,N9H\
MRQ^1;M:O<SQVMUODVR;9_*E!B\KSXWB=9%3*,UKP/*;C1=,E!W0)H'ANWBXP
M,Q:-:M(03]\&1V(8=/ND#;FM2UT^RT_7M0N(;:.&;6X8;F:544&6>P7[-*2P
M4$%X9;=PH.9&6XD.3O-?C+IXF->C.A6A]7>+Q:Q7M:;E7G";E&E*C54_9P2J
MTJ48P]DX>SFE'E<%%_L4:N&E1KPKT)?6(X7"2PGLIJ-&$X>SE4A6I.'M*CE1
MJ5I3J>V4O:1;ES<TI+D]-UB6SUO5O"E]9-!::7-8:G9WR(RPW6FWC6[71= @
M54CU*>=$,;%52*175#!N;TOY77@AD8=0<AE(['N"#U!YKG=67SKJW%L TRLL
M-PP_YYO)%<06X?H))I[= RD_)"S.2"R _+/C3X]>*?AM^TW\.?A?XET72=-^
M$_QI\/W.G_#CQQ;M=O/#\6M&-U>ZQX-\3V<KB"SAU+2#:SZ&]H+=Y9$O$E(G
MB1)HI57@54A7J2K4UB%3I3Y%%TX5ZK5"DVK1=.A[2EAO:R<;-)S=^9GJ8#)L
M9Q/B*E'*</1CC*&48[-*V&EB(QJ8NGE&!^MYE4PL:C4ZV+GA,-BLQ6"I*56K
M2HUEAX5)*$)?5T5DUC?2M]JN)K._00I:RL7ALGCC)"P;BS%9E$A93PFP ';M
M _'C_@H[>W'P*^.W[)'[6^G6U]*/#NN>(OA/XX.FLEK+J>D&VN?$VF6:78*@
M:CJV@KX\TZ%IB8TQ&JMB/!_5CQ-XMAL88].U!;S3-8-]ITD1M8);E)K%;Z);
M^]L[F.)T:%+$W*2QS*EQ#(X0Q,=DC_G[_P %1=)N/&/[&?Q!\2:5':RZ-X"\
M4?"_QQH=Q('>YN+W3?B!H/AW6YTAEB95LQX>\0^)('>4I+<&9RZ^5_K/+S:O
MAZN#Q^&PLU+$8>F\7"$;SJT:M*I]:O.E*TZ4:=3#_O.=1C35>E3BOWD('Z-X
M)U)Y=XF<$U<UI<^3Y_FBX1S:G.3I8?'Y-Q5AGPSCZ/MJ=HU57P6;U'"5.4IR
MGA:E634J$IGTK\.O'7AWQ3X7_P"%I_ ?4K+XE?"KQ8ZZYJWA6QU"TBU_PYKD
MJ1OJL^GQZA.B17UU(5GU?P]J=]I\T6J ZAI>H&"X\MO6[#QS\/M8U"QTU=2D
MTSQ/--;C^P?$O]H^'?%<,*;W+1Z;K7V.^N+6)E93>Z<+W3IG7]U>7*%7/Y:^
M$/V.=+U*V\ _$7]EGXJ^)_V6_B5XG^#7@OX@ZY8Z7$FN?!SQ=JTHCT[5!J'@
MN:ZM3ICQZC;?;KNUTF:/3#)K,4EM80%)4DZF_P#B9_P4%\"V\UI\;_V6_!/[
M4?@+0KV:UN=?^%,UI-K.IV\8*KJB^ =;MX-:FN>5<C2?#/B*>&:,E)@A:1OH
M)YO2E3P<.(\DQ'M\1A<).AF^46Q$:^%C&*ABL3@91KSJ2I4(\JC"G@ZLJD)Q
MKXVO6O,^=QGA9EE?-,ZI>%'B+D4J67YQFN"Q7 ?B+B*?"^=Y;F5+$U(5LJP/
M$&*G@N&\9">,4E3Q4<VK.M3J4ZF&X<RRBXX=?IAKWAK6&\3>&]8M?$&H+8+<
M?8;NS=Q&B6LX\]TC>U6W>>.]F@@BD\[?)"4BEA<$.#M^)_#%CJ4&CW6YK.7P
MYJMKJ]M)#M"A4GC:]20$8\N6#S&DD&' #,6(9\_$_P #OCW\-OC9X1\5>(_@
MIXKUSX?>(/ $F?'WP@^+,UY'9>'+RWE"R6VH0ZU++JOAFV:ZC-E'JVF7,$.F
M3>7!J&@V9<6<GU5X0^*WAKXE6YCT"66XGM;&RGU_3PJNFDZG>7%_9MX>U/4H
M?-TR.]M;S2K^.\MHKF666"&*:&*>UO('DUED>"K9=CLURRI/-<GQ5:B\17G"
MO&>"Q-Z5*%+%49U*ZPK56G2G!4,17I*LXTE.%=0HQ^ S#,,\X=XDP_"'%V7R
MX4XNRRC*%+*JU3#R>/P=2E+%?6LOQ%.G0>84*V#KRJPJU<-0>(P36-I1K8.I
M];GZ'ID\R64<BQO<6H,JHJA5NH8XYI$C#(Y02KY:HRC='(B, 0Y7G12>UU&&
M6.*1900T4L9#*\;XP8YHV"R1/R,HZJ^TA@,$&JMO;7-@D'E_Z0@A@CN(U(WM
M)'%'$;B$R,J[G"#S$9\%0&5@P(;D?&<^ZSFN=)35+/Q!:6S7$5Y:6Y@,-I$V
M^Y74)K@)926IA67RXYGDD,@W6J%U-<E6M+"89U)QY_94KSI/XZO+!-JC+6,I
MR5^6E*Z<FH<U-:FE"A#&8J%*$U3]M42A6?\ #I.4DN:O%V<:<6TYU(ZQA>?)
M-OE+XU>WDM[+5=09;/3HS+:*UPR)+?7MO),"2-S#R?/LV-K%N,L\CY*(F4?I
M+R??;BW$8:XO(WC2%CG9E0))'(XV0*VYF!QOV*I+,H/SWX4\2?9)8WUNUO-7
M\/VDC6UA)Y0OX[#5KB62Y#E7B"FXNX)C)ON'C:VW21P,SLZ-[HMYY]_']BC#
M/=:9;31/,"(K>#SYO-9T4[M[,]NHB7:7=/G=5B->=E694\PP[FIVE-48SIN+
M]LG)<DY](NE4<7'#<EXI/FJ-2<XP]'-\KGEU>,.1N,74E3JQE>DXQ<94Z;WE
M&M3C-2Q*DU+FM&DE!0G.>^E/VG2;&,EG6ZMKF4CKY-NLGWA@\R,I8@D$JDC
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M,3/;LKK$C*77$B&YGCO")K*ZEMV,DL>QK6[,;0W%M<0GY4-S;([Q2X2/SSG
M)B>N"\<Z5J?B5M*\+^'M822X\RZN]5TN>Z3['!9V1,,&I"Y$=S=VKR7DENEC
M "\3R/YPA40-(?)QV(J8;"8F6%I3K8B-=3PE&,N:?UJIB(N-/D<XN>'JU)N5
M2E2FI1HNHX1YXWCZV P]+%XW#4\75A1P\L/[/%UYQY8+"TL*E[3G4)^SQ%*$
M5"G5J0M*NJ?M&Z<[2Z&RU?2]4.FZA+=K=7NIZCJ5]X7L;8O++:6'F7$8U%X(
M@&>>:!_,(O-D$+S10@KL=FZJPTK[+K$-]<966YL9;2&W\PRQ6XCE%P69S\LM
MY.-[7-P /,8I$G[J(%O-/ACH&OZ)9RZU#::)=VFM;9;BRC=X=8M&M";9HH[^
M2(6ESNDB:2>UE-K")VD>.8.6W>MQWHOY(@+=X#:3B6Z6>2%);<JCXB>)7=\R
M!@P<?NBJ[ED88HR>53$8/#XG&T)4<34=&M&FZ4_>]RFE7]KJJLJE->T4?<^K
M4I4Z$Z:>'C-F<1IX7%U\-@:ZK8:FJE&5158/D7.W*@J22E2C2JVI2D^=8FK&
MI7A5MB91,;]C/_DT+]EK_LW?X,?^JZ\.5]!ZO_R"=4_[!U[_ .DTM?/?[&7_
M ":#^RSCI_PSM\%\?^&Z\.5]":O_ ,@G5/\ L'7O_I-+7[)BO]\Q'_836_\
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M?PW\1[1/LUM%O%M%KZQQQK&A12RJ/$/VIM%_X*/? []GS7/$OQ@_:$^&VL>
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MMM<PW6WQ#\,(IY+=MT*W2^!BUQ$C<[A%(Y0')R #GFI_VX?^2+VG_8_^$/\
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M[>:7_P )2^FZKKUKJ6C6V\_K[10!^;?[8W@WXH:OXN\"^)_ 7AGXT7NNV'P
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M32M\T[3+*AD);SB"=OH-J^'NKJ13!%=/"84DP)'V0*A<H-WSOM"JBLQ*(C
MMBL/PG/'<^"O#GFH&)\.Z-:7$() \XZ7:0R19X*[RXQR&"..0U3:/9+8:0;>
MV^]9?:+2TWLSB"))72!5:1FD(C4J6W-OD*Y=BS$C\@C"5"5.C"4JE"G2J2A*
M:C[2'L^6$(-0A!3BX3DH_#)."4W-RYE^NSFL1&K6G&-.O4JPC4A!2=.?M/?G
M-.=24H2]I%-J*E%J;<5!147+_;-HVHW%E)(&NIH$CMK %I+F:* SF>3RP-L4
M.^1HR7=,-'*S<CBQ8P&8,E^3+-;[8U@8YB2+&8)<# FE=.))7'$JRI$%C&7K
MV%A;07,]WI]G:/=LJVUSJ<V[S;CR0JO#',JR2&*)U/R K"K@JJ[E8FU/-/;7
M5O/+;J$D)MII;<O*I63YX\IM$OR.GWMC'#-@#)HASI*=?D=JD[*$9."ISDK<
M\GI*<9/F;2C3BKJ*E**FU/V;]R@I+]W!R<Y0YW5C'7DC%WA!KW4FY5)2]Z7*
MI.$?FC]L_P#:!TW]F'X"^*OB9%':7'C*3R?"GPST28 IK_C_ ,1K+;:'97,*
M,DDND:>4N->UYXV5X-'TF\>*1+EK</\ F+_P3QTK5/#_ , _VM]%\3:;K&F?
M'33M6UW4/B%>:I'+)XHUZ37/#2>+K34KH I/#?WXUNYUZ"*V\MXK^_FB\MS;
M20I]6_M(?!/QW^T)^VC^SR/$6BRWO[-/P?\ #NK>-M2NQ/83Z9JGQ(FOB/[(
MU#26F;5)KS[+8Z19M%_9\UK-I%QJL+,DKL#RWQ.\2I\!OVO],^/\]E+:_!?]
MH)=)^!_QANIX72Q\->.=)$[?#KQ9J48'^AIJ=I'?:3>2R@86*<S.9IM/@D\2
M6/CA.(LLS:JN;#95F6'C2PTE98J,*<:V-Q3DTXPI0;PU!5FG3C2AB934XIQ?
M]$9/E&58SP<S[PRR>M0Q/&GBEPICN(<7F6%Q,:D\LQ&2YQ[/A7@>4*4W*>89
ME@<NXCS>>63BL17S7'\+8>G&-54ZD?T"T]M'\7OHM]>6VE7?AW^Q9HO">A11
M^9()1%9V]Q<A)%6.=8K<I:V,L<:PV]O#-,/F<LOE^@?L^2ZC\;-"^*GC*ZT:
M?3_AK\.[OP)\-O"FF0W,<VAZUXFOQ>^-_&6K7Y,276IZOI]EH&DZ2;<,+73[
M)Y)?+OB9).U^%UK%X9\077PYU(PR7_A/39+WP=<.B*]UX#U::VEM([=\LKW&
M@WC7.@7Q@8'[);Z;-(OEW4,DOJ>JZPVDZ[HL2Z=>WEIJQ:QO9[*/S%LW$L/V
M*:8G9$JGSKI3NE0LOS L8@M>EC<IH8'%5*^/FL6U7I2AC72<I8ZAC(X.>'Q-
M:"52I>52-"4:$I2C@X1=&HE4I3Y/P?(.*LPG@JD,E3RN>*RS'Y7B<&IP<LL4
M88W!YOE^%JSY(P=;"3QV!KXNE"$\QP^)JNE)X?%QE4_,/2=2M?B1_P %8M3T
MPW\,]I^SE\"O["TR&]OI;J>]\3>+88/$OB&2 RL^)=-L/%?A6&YCAVRJVBS-
M.=ZL5_3;5HM:O9572;NVM'MID6XU.Y1'6V4H'G^R6SQRQ22B-TC7SEVJQ;?,
M"E?@-\ _AG\5OB-!\3OV^O@HUQJ'QLL/VC/BMXCTSP9>7,R6'Q*^%\]S:'7_
M   5>06\&IW5K=>1X:E==YGT!-*1TCNCC]D/V=/VBO!7[2OA^/Q/X0AN;6UM
M;7_B>:!JB&#7/#'BM+N2'6/#WB"PD59+:\TJXW0Q^8@$[+)*%1T:./QLLQ5*
MI&K0K>UH2S+'U\1@Y1G.'UBA:,:*IU8ZPG1I4(1G:7/&*IRBU*K=?N7C#PQ4
MP$.'L1D]:CFF X!X1X>X+XIH>SI^TX=XGA&OFN90Q>%E*3JY?G.:9QF%7+L9
M)>PQ&+IYG@914\ H5?H)A;0!+BWF2>:'][<L)EEEF@Q^_9]C,244>9&@&U3'
MY<:H&K1GN[>U@-S<S1P0*%)ED8*@W8"C<>,L2 HZDD"FW$%N\3>;''M4%N0H
MP5!^8'@J0,X8$%<DY'6N>AL'U*RMQ<2A]/$-NZ6]] LZRO&@:*8_-#(8H\*8
MQ))([N/,9L;:^EDYT^:-*$93G!NG%/ECSQY8N4[ZJ+O'F:DVVM%S2;?\\QC3
MJ6G4G*,(3BJCM>3C)M\M-I-.:M*RDDDG=VC%D.I6*ZC/IT3W,EC=WUZ;Q&B*
MB9K2P@)$4B-\LD>Y[<3H00/-!P"I(YRQTZ];Q;'JEK-'%!KMA<_VJJQ>4T'V
M,Q6]F+&0#!%REJH=F!E0122AB7B*0:UI_P#Q46D:U=ZDR6(M)[6V2^N!;M/>
MM)';VR6T4(A2"VN6OU:5&WM/#;,UP?)(8=1=%K4PZC91"6UTZ>V@# !5EMEM
MS#/) W"!/.D$1;(0HLI1CE2?(DHUZ]656DZ3PN+HU4XU6ZM2%.G3E[=QC\$)
M0EBX/E^.%9Q;3C&9[/,\/AZ,*56-58O!5J<XSII4Z=6I4G%X>,Y:SE"<,)5C
M=_NYT8NUG4@;&GVUIH\QTVUBAM;2=9;NU@B4(B3;U-ZD:CKYCN+LXRS/)<R-
M@ 8KQV-L-?>_$*)->6K02$9!N4LVW0S3#[K^5\T<(QA4<,<L1MIZSHL/B.?2
M;V+4;ZQET:]%PL=I/):RN77R[BWN0K"6,2P.55H]C[22'DAE*MI0J[2PM&69
M=.M41MV69Y9R#*F[C+)#$&(;)S)'C!;CT+-R]FZ$%1HU:<\)*+@U*/)%SY(1
MBO8^R4JU-);PLHVC+E/.<DHJHJ\Y5ZU&<,93E&<'&7/[BE-R?ME5<:-23:]V
M=W*[C<Q_V,O^30?V6<=/^&=O@OC_ ,-UX<KZ%U?C2=3/II][_P"DTM?/7[&)
MS^R#^RP?7]G;X+G_ ,QSX<KZ$U?_ )!.J?\ 8.O?_2:6OU+$Z8S$>6*J_P#I
MV7J?F%'6A2_Z\T__ $A'Y[?L@V6J>&_@%\.FOM$M[F"^\/F^76-*E-SJ$L,V
MH7KPP:C:SJERS6\1"1FV>6!(UP(XR,'ZD@N%O+B*\CCD2VCM9D\^91&',TD#
M@("<E5$+;W.T*Q"C)+8\0_97F;_AGOX4V\S9EM_"%JQ; 4O!)=7CPR!?9<QL
M>FZ,@9(./7M*T^"VO=4$8D6&YN4U,P/*\J)/=HZ2L [, 9/LZS*@Q%&9"(U4
MY+?G&*I?5<;7H4)2G0ECL;I5=-5*4HUZM2UZ=-*<>=24G*]1RU]K-7M^CTZ_
MUK#1Q%>*A76#PFM)3=.K&5*E3ORSJ2=.7)*,ERVIQCHJ=-J*=J^U>QMKRR6Y
MNH[>+S&,9D8@7-Q<1F""&%%!:1W!D92!C$9 R",D$4DEQ+!<!X+61WN;:W9B
MLDQD<&X6<H<@"9C*L&X9$I,F5C""G'IUK<7EO?2VD-[J<#27$,DS%HM.6X(5
M?+!W(DIBC1$D5#.Z1_?"#;6C?27,42W#VX<VKB??;MYC+&O$ZF-U1V#0[\[#
MDL%X. #SQ<W*I4J6Y%-2C&"FVX*$5-5&URIKENJ<;I.*YY2;<8Z25.*ITZ2E
M[1P<*DIR@DJGM'*#I13YM;J]2:4FIM0A%)2GS?Q%\7^#_A?X \6_$+QE>P:+
MX3\">']5\5:UJ112UG8:-:2W<S0(%+3W4HC%M:6B*\E[=3Q6D<<DDZH_X5?\
M$^_''B/XI_MG?$GXS?&#P[)H?CSXW^ ;SQO\'YM116BT_P $V.KOX73P]I,1
M987L]'L;:T\/WMPF!<WZ:[<VCPBYEDK[S_X**_#OXL?'GP)\)O@S\,K!KOPE
MXS^+.AW'QHU2&[L[630/!F@^5J&DW&IVU_=6<MQHC:^T6JW]M!'<7$TV@V$<
M<1$F3Y[^USX83X0GX*?'+X.>'+AV_8^TV'3O$>BV=JZR:[\!=4@CTWQS:3M.
MB37*>'[*6+Q"+MHI&>.X\3ZG&9M0CMBWSN=5D\90J-\F&RZMA*L8*#G'&XFK
M-RJ1@HOWU@\'"K-.%I*O4A%24X)']'>%E'(\!P9F.3O$X6KQ=XO8;B+A6CB8
MXVE2J<(Y-EM"A+*H9A/G3P,N->,9Y9E^(EBTJ,<@P&*KU(RP^)DY?7WPTNHO
M$?P^\.:-J4=C#I&EZUJ=MXT@NFE:YO==C\0ZG.MD@=$$D<NJA9[A7DEN);6*
M.+E9&WX/Q _9XC^)_BOX>6.I#1=(^&7A#XE2?%/Q!X9-EYVK^-+O1M/MD\":
M09C&UO8:#H_B*2\UO6+%VCN#);>'3:NFVZ5]3P9K'AF76_#.OZ/=6>I?#GXY
M3V'COP5J"PQB%?&4-E;27UG*X0!)==TA+C6;2.9V9-5TW7+/*/'9QR_07BK5
MCH=C;ZLEG<W[VMY;B6WLHWFN&M)W$-Y($C#.RPPMYV6_=AXHV<@ ,/H<\P6%
MKXW%9WC'3Q6'QTO[8P^)Y(RG+ XJI5F\-)1C*2A@I>UP]6G2:IU\51Q%6*E1
MKQ<_Y[X0SC..':>#R7+8U\KSOAYXCAG%X2K%PJ8/-L)A88&6.A"MR^RQU>G4
MIXW!8FK!8K+H5<''FIXS!-TOR\_;OU"Q\3?M)?L,?L]2ZB_V#6OBO-\6-=AO
M;V::&&S\*B/1_#^GW'GNP$.J:QJ=U/IZRL?WNDW4:,8U"1_J/K9U*>-[73T@
MEOF1IX8'8QV=N5DQ";A\$N$D^<)MPZP%8XL%C7XD?$[X0ZQ^V#^W!^TX^C^)
M=0\(^*/@%X"^#^B_!GQ&SS01^&O'6E6^F>/[4:K;V[S";3;S6O%GBBRUF+$I
M^SK%,JR&Q1&^^/V:/VI;WXN7EU\+?B/X:N/ ?Q_\!SC0?B[X+N]T4D%Y8VQD
MM?$?AU]S?VCX7\3K(FH65[;O);_9;F-HII[:XAE;P<+BZ*Q68JIST:.-QD,)
M@JT6[3=!K!NA"7*U3FJ_/5I*:E%4JE2<8_N9J/[OQQPM67 /AU2RBK#'XS@W
MA19_QIE+26)R[_7FO2XHR[B#V7M%/%9;7RC&91DV/Q%+E^H8_ 8&AB94UFN"
ME6^P[2UD%G M]J$-]K448W7(,:*MTIW,L%M$(_*AR3$RHBRS0Y\TEF.-J"X2
M6W2<_NUV;I/,('ELN1(KL<+F-U97.< J><4K6UL8O*:&'R@  AC38!P  I7:
M.P'%<^EJ]S]KL[29TLC<7$=TLB>="%=4\R"U=F23<Y9Q*PE=(59EC5),;?I+
M2HJ,8Q<[PY$N>\Y3BERN<ZFLG9/VE24N:6DI+0_GIM5W.4Y*'O\ .Y<BC"$9
M2U48TU:*NUR4XQ4(M.,;7(M86#5+&YD6=8XIT33-/O(W )N;Z=(/.AD4C<DD
MK0PIAMK&,D95C7'ZOI5ZFKZ'>V4MO)?Z)J=IHJ&:(K'?6]Y%:W,][*4R4N8&
M6!60DH2@ =3+@S^*]%DGLM.@MK]K/3-(U*U%YY;I96%M:@M$[Q ;IFN[4S"X
M2>2[$<+1'8HF92O0M"MQIRBQ7SY5ADU+<LN\">6YM+NVC>X_>.9)8D+G<S2%
M4_>'#J7\:O!XNKB*-6BZ<Z4,+5C4A5;=6I3J2JMTH)/^%54/9SDG*2I\KC92
MB>S0J+"4</5HUU4A5J8JG*E.DE&C3J0IT?WTY)-2K4I2]I!-1BZG-&2DX3>O
M%8VNDWQNX@%?59(H=0G<@27=TB".SGE. #(J@VRJ@55B,48_=P1J(-5M8)]2
MTF]:/][8W!@%P#(KA+P;);9-I"XD_=,Y8,P  3;N<FGJMI'XOT(V*7EUI<TR
M0W(EA)CNH9(W$D$B!9%#Q>:JMYB%AA=H*2@[+L=LZ+9V EFN)HIXKE[BX;S9
M?]%MH0KRN K2>;-(%=OO')RW(KO:4N:E"A'ZK+V%>C5C*$E*LZKJ3C[+XXRC
M4C"LZC^*I4E*ZE&3/.B^3EJSKS6)7MJ%6FU-2C0C2C3A+VM^6<9TI5:*IJZ5
M.G&/+:449'[(RJGP;N44 *OQK_:A4 #  '[3?Q>' KZ:KYD_9$9G^#5RS*48
M_&O]J$E3U4_\--_%[(]\>O0]1P:^FZ_3ZSO6J?XY?F?FRT23W6_4_/W]G>YN
M-,TGXK2S:&%LKCX_?&29=4TTQW$]R1XON4+:E:A4N8Y(<%1*IFA$2@Y4_+7T
M?;3"6:>\*/#;R06\<3380R>4T[M(JY/R,)T5&SE]IP, $^&_L[W$1\-?$Q3U
MM_CU\:%E4]1GQA=.IQZ.C!ESV()Q7K>CV45A:7L$*.$M+NZ>WBED>X$#W(6[
M*9E9G.V2X(.XY"_(F$557X;-%*EFV,BI<]*6+QM2\N12IU/:2;@E3IQ4H/FJ
M_%:I&<4ISJ<TI0^WR^4*F68>3CR58X7!T[)S<:E-0@N=RJ5).$TXTM%>DXSE
MRQI*$(SLMJMG_:4UI+(HGN((X;:T&6N;L1^<\[)"!DQJ'"AW9 ")@<%& FLK
M=KA2FH'S9;;$7D,08XT&&AD*K\LDLD9!>4C"N)(HE 1F:O9:=;17CWMM:03Z
MCY0M;O4IV)8["6>VA<!V15D9FD2(*GFEO-W3%S5N:XFM;N&6:!EBE5H)98MT
MT9.&DA)55\Q2'#KN9#A78G:#D^=3=1+GK\NM25E!3<%3J-<OM)M*,IQE9MI*
MG%72<II3?=-0NH4.>[IPYI2<%-U(1]Y4XQ;E&G*.B5W.<DFU!/V:^9?VT_C]
MI_[+W[/7CKXMQPVEUXI@M(/"GP]T.XCW0^)?B#XH,NG^%-*FCC*2M:6UX9=;
MU62)A+#HNDZG*I+J@/X-_P#!,WQ/XI^"/[4ZZ/\ $ZWN4OOBU\-KSQ9I7B'6
MR!J'C:Z\3WLGBG4?$S73;GDN-=U;0?$<!C<$S3WFFK$N)K;'ZM_M[_LP_$']
MK+Q1^S_I^@:]H&F_##X<>+-=U[QY%<WTQU6ZEU:PLM-CU+1=-M8;DZQ?Z/IJ
M:G!:6I6/R;R^$JRJHG \'_X*-?":ZE^%/PT_:I^$FC2Z)XC_ &5-4C@U*+3X
M%BD?X.?;M-(-E'&6W_\ "N;VTTGQ*8?+VP:2OB7<9GB@A?X_/'B<1F#Q&'E*
MFLKI?6,'34&WBYTY1>/JT^RH4G",).T*CYW!N[;_ *_\&<SX(RG@2CP)CL3@
MJ^<^-N)SKA[BC-*E7E_U+P]+#U,%P!@\7I;DS/B63S/'6;G1PD:/M8Q2I37Z
M#^"M!M_$>C>.=)U"QL;[Q1I'B'5+#18B<2VFC7MXWB;1=0E>15DMX-6BU0W7
MGNJ&\B=(0A12B])XH_9S^'/COXI?#/XT:E%J,6O_  MTK78O"6BV=S!:^&;7
M6==-DTOB&[TR.T+W&OZ>MA%9V5Y]I188%">4V,GQ7X-?M >"/%WAGP5^T+:W
M^E:;HOQ \+VOASXA:5#<6PFT#7/#XFM]"OEM05N);6#5OMG@XW(#K<#6_"@9
MXXK28CZTTKQ.NH:G<:7#I>K0VU]::=J^GW4MHT,7V;4[>TFN([DNRB&X@N;H
M130Q&5HI&:%E1XF+?:YA@,'5AA.(ZF'A4PO$WLZ]/$N@W&IF<:E?%8BFJKC*
M4*M/%RQ%2G&51.G@ZV 3A"-2"E_).5YCQ'PEF^><#+%XG*.(N 7FO#N98".(
MC#%83*:^&CD=6G*FI).AB,LE'+\16ITU[?%TLUY*D^2I*'X??M0?$CPYXZ_X
M*>_LT>!_%EX-)T'X,6OAZW\02277VNW@\=_$?67\1FW,L[*LHCT#PKX!N+>?
M#^0FN-!&I7>6_9'2M<\02_&3Q'X;U:_CL_#D_@30O$VCZ<ZVB75U>'6=6TS6
M[B6_\M;L1)YNC0-;&X9%>,O''$EW*K?A_P##7]G?0_VUOVF/^"C,WBB[N--U
MG2_'NLZ1\-O&-LAEU#P3XG\%>);;PKX"UFT5'C::WMM%\!MI5_9!T6[TJYO(
M,B5T>OJS]F+]HKXB:[XIM/AW\8?#]X/VF?V?+6^T+QCHUJ(YKGXN_!S4EAMC
MXM\'&9H8]9U#2+K3+#Q"D-N4&MQ6^H#%OK-O?Z=;>3PA*C6S3'8#,948RS]9
MA0RC&5W3II9EEDJ4,+0K56H4\//&5L#1PD*B=&C../Q,*U2%%RC+]_\ 'WAV
M=+@+@*7"=7%5\?X-<)\*X_Q!X:HQG5KK(./:,>)\RXFRO#PYZ^9X+*I\5UWG
M6'Y*^-P$LJR7'4</5C*6(PWZXVIC@FDMXMI@D!N+<QXV)DXFB4K\N Y$JA>0
M9')SG@O)8KACIJ-'+-,$^T0[E9HK5CF1Y4R2@E0-%$6 W2.I&55B.1T7Q1X<
M\7Z?9:_X7NIIA+?WNG21_9+C3=2M=0LE:'4M,U;2]1MX;FQOK*985N[>_M4E
MA4I+&3%+%))ISZ7*GVF4W175-3@%O)<6,*07+"-"(TCGF>Y2WMX-Y+2&$O\
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M(SDKYD0$E<[X=O;B&V%K>VK)?(;DFWMY$FW6:7EPT-Z)F,<0CFCE0\M\KYA
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M[H^M7HTZ]MWPDUKJ&GPWEI@1O$T\EO;R$M(BUZFI736\N1@MF^#',^U5BE)
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M[L?VE*&U!;RP-M<::0]M/O0PZE$OER-/;*I+QQK,4BFA?YXV\MC\C1FOP?\
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MMZ9C!<[K*.&9=T#!?IUVW07US-M-S'#L:*1 $MTP7 V,S[T?/FNQ)#@;5P%
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MXGTP_P#ZD43XW*/^1CA_^XW_ *8JGO%%%%?GQ]L4-2_X]&_WXO\ T-:LV_\
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M_P#$NC^(M=\-Z9<0O?1ZK-/K.G>%M7>*ZLM-NM,LKC^SK/4[ZRN=5L(YO/\
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M<4TZF"H8+@.AF%:"H5,-F-?&0Q.!XDQ%%U:&11KU<5@ZN8X1RQ?W[^S'X_\
MVQ_B]XIN/'OQ:\'>"_@M\&;OPY,GA/X:3076M?$N_N;F:!]+\2:YK]VEN8!'
M:I,EQ:BQT>TN//@>WTF>,1ZC+]0S>"M/D\67.II?W'VY+,:JNT0,T>ILTMH)
M_P#5 ;%@B7;:G WMYO'RFNLL9[_5E66ZMSID[PA+FV:5?M%M'(YWQJR,97FD
M"A?/80)&K Q(T@WUSGC'4KW1;[PGI6@Z-<WEQXBU&[TNYNK,QJFCV!MTFGU6
M_P L)S#&88X5G3>\1>1E#MMC;W:>#HU<-1^LNMC?9588B%;%<T*CJZ*#A1C&
MFJ/)>T*:A'DT33GSV_ ,^XA6/SC$XG*LGRCA7"5,+'+Z649$JL\+0PE*]E7Q
MN,K8O&9EBJL;RQ6/Q6(JU,3-WC[/#QHT8?#_ (?>]^.W_!0?4?%-H?*\+?LG
M_"<^$K7480);._\ B?\ %'?=ZVD2GY0MAX>QI>H1(QEBNM(LV5PDR8XG]KG]
MD[PI\1/C9\'M?\&:E%\'O''C[5O%VC>)-?T72+"\\/\ BWQUX3T)?'7@$>.O
M"]UY.C^+(KF?2=6$L5X(KS58Y;6X>Z-YIUK<)[I^S396OP_^.O[6_@F\A%O=
MZO\ $S1/'UC=O@?:=#\1^'+*RTYY"0,*9=-ES+N:-9[A(Y2CS1>9[Y\4/ %K
M\1[J3PQX@N$L?#-UINGZAINL:2;BQ\6^$O'^EZE)-X;\5Z/K$<@BL)[11)%;
ML4;[1+#]AN@]I<,C9?48U\)7C7BJM2OC:E:K%MQ7/3K*G34)1M*F_J]"G1=6
M.O*Y3=]4_OI\<8WA3C'AJMDV.Q&59=D? N3Y!@Z^&A3Q36$SS(99MF6,Q&"K
M<^&S2"XDXAS+/EEV*A*A4K0HX9>SY(3C^>.G_&CXB^$OV@O@CX?_ &M?#>A_
M#RZT76?'!T/XP^%Y[L_#'XM>)-2\,'P-I%AI;36G_%%>(U@O-3N-7\/ZW/IT
MBR0VL.G6KV\EI=77NG@G5]+^-G[97BOXFZ7>P7'PZ_9Y\"77P0T7Q#+=QS:7
MKOQ-\?ZE8ZWX_M-/D<K#=VOAK3]*T+1+JZMY"]MKO]I63%"B%_#OCM\1KWQU
M\#=>_9P\7_\ ",ZM\</%OQ+TCX)>)XM<TR*>TADUG6+^>7XS^'=/*1JA?PAI
M,7B?0[[3_+AL=<CO+:*XM[NU?')_"GQI\2/V&W\5_!34/AO=_'O]F[P%-I&L
MZ?XO\':7I+?%'PC9>.[O7KA#XC\+))&WC:.#4M"UI+[6K!(KZ&W@L[B06J3V
M^F#S8.5&K"FY5*N ]M3Q56M*C*I6HXF-.;CA\2J/ORA"5!UZ]:-.4Z;@HXF5
M1U9US[RIE=+-LBQF.PF&R7(>.UDF:\*Y5D=#,J>7</YSP[B\SP<\UXJX9K9I
M[/#8?$9O1XGK9-E61XG'TL'F6'S3&8GAZ.&67X/)'[;_ ,$VO%MG_P *!U.)
MYBGB7QG\=_C!XBOY9XI/LD%_K_B,WMP\URQ9'=)5E6&W,QDEGD1'*(Y>OT@G
M%M;I#%','NHIEG(9D>1Y2NR62X /[M7CD8,[;5B0AU(\M<_C+_P3Y\0Z)X[E
M^/\ X*\%W]A<>&_#WQA\7^./!%K#'J,:3>&/'=W%XOM-!9IULGL7TCST\*W)
MGLDN['6-(U*V$>(69?UST!?#EW8+K>BP):-?0)/<6UZ78O\ 9R8F@D1W?$L$
MP>(F(MB53OC<$(=,BQ&*J82,)QP\J5/FIT*L:K7-2HR=.I*G#EG&=2-51G*<
MJE-VJ1<8-12E^=^-664\!XA\1.M2QN$Q.+Q.&S.I@L1AI4ZF'AG. P6:8"AB
M8U'2J8?DP&+A2E0]E4=*K2J49R4N9PZ2],US:M.JQI:0NMR-PS+<1VLJSY7A
M5ABD,."29'>,9 C)4B#09C>112/M M83!"O!:>WG998;HY&#'-%%&(ASMV2[
MFW$JCM1_XF\4FD1?+;S1!-3FW&,0PR@ 6<; X-S,"0RJP\F-"6P9(@;JZ;%;
MP6T>GD0O8PK;V^YF='@7 \B<@EF7@E6R6BD^=><@^ZE.6(=2-Y4H0Y9.^M2I
MSW<81M91I6O=2;YTZ;7,IR/R5NG'#\DKPJU*G-&+CI3IN*]Z<KW<JG6/)?DY
M9IJ+A%Q1M9Q7LVC221'S[<W=K9N1N^S%]ERB)U\F*4JR8^X)MJ8$7&9%%'//
M-:3M*/)OKB2UN=P$R^7;QP13+(!S/ ]K+'EMQD509"WG.HEE=+C5K>7RX[34
M;2TD\H72X,PGFA22!)@")8"JD&2)F*R2(X0L"M9L%[:W>LWVC@S6^I6\+7!M
MYHV25([N[MW2X1L".XA,CW<2R0R,CQ*X)0D$8U*D;QC+DY?;.G1B_=]K>"J*
MBU)IJ<4JK4$DXPC!I6YK[TZ<FI3@JCDJ$:E65N;V34G!UERWO3G>DG-MQ<I-
M2:?(5OV.?._X4C)]H<23_P#"Z?VHO-<*$#/_ ,-._&#<0@)"@GHH. .!Q7U'
M7S'^R$''P8N!(%$G_"ZOVH=X1BR[O^&F_B]G:Q52P)Y!*J2#R >*^G*_3JJM
M4FDV[3EK*]WJ]7?6_>^I^:M\S;LE=MVC:RN[V5K*W:R2ML?D/KO[.W@?]I3X
M-?$'PUXNOO&5A/X5_:,^-7B+0+WP-XFG\.:O8ZTGB;4K)))2BRVFH1?9KF1D
ML]0MYX/-$<BIN4JWRAXD^$/[>G[&T$GC#X#_ !5\0?M3?"'2@MSK_P ,O&%H
MU_\ $/2M+M0TUT;:QCD.G>+U@BC;SE\)W7ASQ+:0[5L-#U8AY5_2_P"!Z!/"
MOQ#NHO\ 6K\?OC##*J\_:('\=SK) X##)4.7B;(,4@4\H71O9I)TTV:ROTN8
MXK.YO)Y+Y9G$,"3O'*BW2R ,8CYTD?GJ/E?:DGRR*WF?FW$V7X>MG>8UY3JX
M:O[9Q>)PU3V5:G%5IPC5YTX^TBN90JTZRJ4U3C=1ZO\ H'P]\3^)>&.'\NR%
M0RWB3A:]2M6X0XGR^AG.18F5>E2J8FG0H8B$\1E6)JRC*K2S#)Z^ QL:]3G=
M=M-'R/\ LE_MP?#+]JW08[7P_,WAKQVC/_;?@J]G,E_9>5*XU.?2IWB@FO+"
MVG22%VGM[;4-*D)L-6L[6YB@DO.R_:M_:S^&/[*OAC1KGQ+#>^)O'7B2<VGP
M\^&7A@PR>+/%E] T<<AM]X:/2-$MV>.'5-=OT-I:I*L<,&H:@]MI]Q^:7_!1
M7X">(/V=?'.F?MZ_ .TM?!^I:'XFTZ?XPV/A^7.GZC%J<D-C;_$:315MX(UU
M&&ZE.F^.([<&T\0^';U+N]"ZAI@FNE_8*T#Q3^TQ\<_BO^VO\7]"/C'7=)UZ
MV\'?#72C/!=:%X*M;4F:QATR*=4R=#T:2TU5WMK%/M.N:_<:GNA>.V2/Y;^V
M<PHUY9/5ASY@ZG)3QJPM3V*P,8<\L6\+!.I*K&T[PIPC1<N3EFHJR_:WX5^'
M.:9*_&C+,5B<)X7X/"3J9YP1_:]"7$>!XW>(PF&PG V&S>M&4991FL\;0QF%
MSVNJV/PN2TL>\10J8^C"=?[L_9IE_;-^)^N:M\3OVC+[PE\-/AUX@\/76F^&
M?@+X;TA9=8TG[3+$\&L^(O$FHH^KQZHEGYL,\%W(DMP\S.=&T*)(K>3V.Y\-
MVND^)_AUHEE.;N"\\2:QXGU=)?*$,]EX+MFL?#UH40*QNUUW6M(N[*7_ )>+
MO369D;JOO=I";L&6X*O$\CSE-ZGS)F"H6E6-F1$B1%6.$R2N#EY7WG:?*"AF
M^/%K%/&T&FIX%NTTN4$>5+JNF:Y:76JFW5<1K):6^KZ3+C_6*Z1,,;,+]CE&
M$ITL33Q4G4Q./P^ S:6#KXB4I5Y8BKE]:]:GR<E/#K#4U5Q48TXQIP5%J*]Y
MRE_,''?$4L]E5]AE64<.Y1BLRX?P]7)\AP<,+EF%R["9EA_8X6M*O.OC<SKX
MVHZ6"Q&/S'%8K'XRKB83Q%><80A2_*_X*$_M'?\ !4;XY?&!87F^'W[.FG_\
M*S\/B7$MKY^CVFH^%O.M5;*QPW_B75?&VOF(,'@FT;*(2Z ZO[87[)?AOQO^
MV;\,+[1O%.I?"#Q-\8/A[XED\&_$+PU!:K;I\;/AMJ.G7]E<>)=/9K:+7KKQ
M%X2U2UT]HHKFSUF^CT)KZTOA?6<MP[_^"7MP/"GQN_;F^#>O[(_%^D_&#Q5K
M]P\J&.>[M+KQIXHNIF*-B3[/9VWB;0)U8$KMU90C'&6_1CXS_!S1?CU\+?\
MA$/$]W-H_B;1]5LM<\%^-=!EDL=>\">-M+:<>'/%F@7@#30/$)!%=Q;6AU/2
M[F^T^=&2=POR6'PE+'9975:E&K7Q./QN,G":2C&MA,8J$L*YQ=X.>%A"E2:3
M]G[]57Y4G_47%?&F-\/O%7A[#Y=F.+RC(,B\+^$.#LLS# QCBJO]B<2<%8?-
MUGWU.JEALVI4^)<ZQ.=XS UDZ>8JG_9M=7E*4?S4\,?'#XQ_#7]IOX&>!_V\
M5TWPM;^%-,^(.D_#;XR:%!<-X&^*NM^+;'3=#TN]N-: @M=#GT[38M1_M*RO
M[*SUNVN=2LGU>RBL5CUF[]5^$OBV3XO?M'?M&?M:Z9J,5]\+_AMX4'[/_P +
M]1CB24>*1X=AU/5/$_BW2#;!OMFG7?B34)K>VN81(-2T5=#OHL;Y8T\*^.OQ
M:O/VF_@%\)OV2O'UAHP_:%\7?'+1O@C\7=+U33K>?5?!4_A5+_6]8^)&CV;H
M&LU\5>'-)AN/#VN::PMLZW<6D-U+"TA?C=!\:_&3]B?4/'_P0\2^ [_XV?LY
M?!7Q)INF2_%?P3X8MX/$/@S1_&^CGQ386_B30])NVF_L[['JD]KJ5S>1KIT&
MIZ?>-INJZ;;F'3#YN(Q-:C=T(U\9A:=:AC(U*CE+$PQGU6]'"XQ0ESSA@UAI
M5ISY+Q=.-.O57/*JOL9\,0SG),=4C@>'^&O$3%Y+F'"]+(,)BL/E?#6=<%1X
MNPM7-N+^#5C</0P&$QG%F9YU#*<KRV68QP>98',<PQ?#N%C".!RN/J'[#%[X
MP\-_LF_L87GA/PA'XNM+_P"+VN-K%ZNK/I\?AL:EH.MZ)<WFJQK87ADLWT^9
M]5DN?,A:,:.EBL/F:A'-'^TMM-)L%K:JDFQI/+>52J16P(\DRH 78N=RQH1&
MTB)YC,H(+_CI_P $C_$O@S7/@]XU^&0,NI6WPY^(VJR^$/$#FYMSK/A"]F*^
M&=0-JTA^S&6PTVSU'#JPW:@\4SEHSG]AUO(["&6,+'--YL<-MY 4-?3RA=@9
M@VS>I91/+N$,2G>?+C7 ^URS.Z>8\.<-8..#P>%62Y?BL%5Q^'Q6+Q&*S"=3
M'5L4_K5*N_889T'4E3H1PE-*I3;E.<YN$G_,7C1PGC>'_'+Q@QN+QN9UZG%/
M%\>(,/E&/P.#P6'R?"8W+<%/!PPLZ4(XRO+$X.KAJ^,_M&JZN'JQ]BJ=&$*D
M%EVTCI?S:8Q1U9X4N;@J0%F#RW$:XY59;JW9%@!;=&D+LQ:0Q+)MWLUOI\]O
M?331V\=S-%93L[!8Y9)CLM#U \P3;8T)R3'(R\[4VUM/T6VMX[UY6\R\U29;
MJ_E29B#<(0(V@R3Y8@*JL9 # H,\\57U3;);Q66IQ@QM>6H2[V!H7Q.C1R%B
M"(+D$ @,%7S 3&S+E01C5IT).<8QJ7<Z5Y.4:?+.3I4ZDK1DKP:<Y;.4ZE/F
MLHN7P3=*I7A&,I2I^Y&LTE&52\(*M.G%N2LI1:@DK\L*<W%-R467D$45_) R
M!K.XME1XF/R1R7%TLLR*N/E2=+5I&4$*DB$H 9F*PVUPZW.IZ-'>6[WKK-)I
MBWDA\\P0PPQ"1PBLTB6=RR9.U9)48,S[@S4V]U*&WU'3[+4BBRZDJPVTP60V
M]\]N)G*03+O19GMYIY9(6?S%\O=&73#'+U#4IM)U:RLEMH;K6=3LVBT^9C&J
M>2LJ+=7US.0'AM[59(GND (F=8UB!:3:O/5JTZ<IU%-14*\:=7E4I5(>VC%0
MP_)"\E4J*K!T-U[24>5.,DGU4:-2JH4^1RE4H2JTKN,8R]C)N5?GFN5TJ;HS
MC7=T^2$[OFBW'!_9S:];XQ_M1_VC#:PW:^(?A<D@LYFF@DV^ UVS*9(HI$,@
M.3%(K-'P/,D4ABO[</\ R1>T_P"Q_P#"'_I1=TS]G"TCL_C!^U#$DHG=_$'P
MOFN+CS#*UQ<R^!<SS.Y9LL[C(4':B!(UPB**?^W#_P D7M/^Q_\ "'_I1=U^
ML96I*IE"E=R^K95?FDI._P!3PU[RC&,6^[44F[VTU/RS-N5O-'&RC[?'6M%Q
M5OK%7:,I3E%=HN3:5DV>5>#_ /D V/\ U[P_^@"OJ#X)?\S-_P!P7_W+5\O^
M#_\ D V/_7O#_P"@"OJ#X)?\S-_W!?\ W+5]SG?_ "*<3Z8?_P!2*)\7E'_(
MQP__ '&_],53WBBBBOSX^V*&I?\ 'HW^_%_Z&M6;?_CW@_ZXQ?\ H"U6U+_C
MT;_?B_\ 0UJS;_\ 'O!_UQB_] 6@#PW7OV<_ASX@^)=[\5;A-=L?$VL:=IFF
M^(HM*U9K+3/$D6AZ9KNCZ')K,"P/=2OI5AXCU.*&"TO;.PO)/L%QJMGJ$^E:
M9):<B_['WP?C@T0:2?&'AW4_#5IX$L?#_B'0?%5]9:]I%I\/?AYK?PJT>WM;
MYTG0Q7W@/Q'K.AZXEQ!.NI?:TU%EBU2RL+VU_/[XE_&+XA?\/3]5^$]U\7O$
MWA[X=:#\,/@#XA\/^!+/X^_#OX6Z->>(_$VL_$Y-8+_#GQ3X?U+Q1\8#KQT+
M1K"\T3PCJ>F7<,<<4)F62YBW?GQX*_;+^/5A^SIJ_B#X>?M8^,?CAXM\2?L%
M?'7XR_&6PU#Q!X*\4ZC^S=\7O!6OZ/I_PXU33/$'A_0;6^\#S^+DO]7T9OA_
MXMNM1N93I8U^RMK=+.\>< _H$\-?L;?!;PG>>'9='MO%<>D^'H_"<O\ PB]U
MXKU.\\-ZYK?@7PO/X-\(^*?$EE<M)<:OXCT/P]-':P7TUXD-S=V&DZQ?VEWK
M6DZ=J%MJZ+^R?\(]$TRQTB&W\27UIIEI\)M-L?[5\17E]-!I?P1\:^+?'OPY
MTTS2!6FL]%UOQIK4,JS^;+J.E&ST^^EGCM48_BI\8_VG/VTM7\1_'_PI?MXK
M^$GB>VUW_@FEX<\&^ O OQ:\,7EY%:_&GXD>,M \<7&A?$*7PQ/H_AK4OB)9
M6=I8W]WJ.CZE#I0M8+AHID!W_I5XU^(?QI^!&@_LA:=<:OK).II\58/BMX6\
M?:GHOQ.\>^-M2\)_!'QY\1?#_A&/XD:38^&-.N-?NM:\+FQMM4T7P_ VIRO:
M[-/FM[2YL;X ]OT#]CSX0>&=+LM$T<^+K72-$\0^&O$/A?3X_$L\5OX4E\)W
M>N7>DZ=HJV]O"SZ>P\1:G9:B=7;5=2U73?[/T_4-1N+72-+CL^6;]@G]GJ19
MK6XTWQ9=://X:O?"TN@S>+-1_LQ[#4_@_IOP)U&<O$(M4^V77PVT?3=)&-2%
MG9W]N^OZ=9V>MWE]?W/FVA_M>>.S\'?V@?'5X?A9XMU;X4?!SP!\7M$UOPA?
M:D/ YNOB#X<\2:Y)\/\ Q+,U]J5U;ZQX+/AVWN]8O[>[BEO?#GB?P[JDFE:7
M/</:5RJ_MF_%R'6M7T&PTGX:^/T\%W/Q*U?6O$?@E=;O-/\ '&A>"?@%X(^-
M5MX6\#6\&IZA"GC0ZEXP_P"$/U%KC4;^QCBBT[5%MX[Z_DTFW /K#XA?LG?!
MGXKS://\2-&U3QBVD?!GQY\!G36-8NGAUCX?_$JS\/6?C"#6X;<6\5[K.HKX
M8TJXBUI4@O+"]CDN[%K>9U9/"KK_ ()C?LL7&D^%O#UO8?$?2/#.A?#OP1\)
MO$GAG0?B?XLT70/BS\._AS>S7_@WPO\ %_3=/O8(O'=EH\MS=PI+?^3>76GW
MEUI5[<W&F3O:'Y_UG]K#X[Z_+\-?$45YHL>A>&I?B'\0==\/^ DL9M1^+>G>
M#_@-_P +3TGP0;?2O%WB:_\ #D;:K.VGV?VC4)#XNLKC1=8FTFWA,VFUZ;X2
M_;!^-&OW_A#3E\/_  \U*"_T_P"(GBW5]4TV4W5YKGAGP)\._ /CYM(\.:!H
M/BSQ,-)U_4KKQ?-H&FSZ]K!CO],^P>)ET^%I3I4@!]+ZS^ROX6\=_"3XG?!?
MXM>)_%7Q#\%_$WX@:IXTN+2ZU74M.F\-Z3-XFTGQ/H'@;PY=/J.IW=AX9\,W
M.BV5O86<=REJ;8W,$-G96<R6<5OX[_LF?";]H,^#+SQ3_P )AX3\0?#^U\5:
M7X2\7?"WQ=JWP\\4:5X>\=Z=;:5XV\*C4]!DA%SX9\5V%E8Q:QH]W!/;22V-
ME>6XMKVUAN4^--!_;7^.WBK0?"!T?1?A5;ZGXJ3Q!K::W>R7%_9PZ)I/[/;?
M&XZ:_AKP]XNU>^T_48=47_A&;2]UC5[)M:T"6W\5)I&GRS+I37/#'[6?Q$FU
M3QQXL\;^)_#L/A*P^)'PNO-!\+6.GW6GWG@KP5XM_8T\.?''44UFZTJ>[U7Q
MAH1\6:GJMI#<7&EQ7%Q<Z=J+6TJI;VVE:: =?\4O^"?/@VQ^'VJ^%?V<?#?A
MWPMJ'B>R^ O@O6$\4>//'FB:1H/P^^ =OXCLO"$WA >'[#7Y%\:Z38^)]6_L
MK4-<L]0T\ZS<VWB+4XKZ^TFTBE]M^)7[$GP/^+OQ2\*?&;QQ:>+)_'?A73_A
MW8P2Z;XRU>STF_'PN\4W_C3P<^JZ?'LAOY-,\0ZKJ5S-*$M?[5BNO*U2*Y6"
MT%M\&^-?VSOBCXHT3Q6^G>*;7PU=^"5^+^B1:SX:CM=&M?$D\'[-?PS^-7AZ
M\GTF;7/%:Z?J_AB;QIJUNEJNM7,LMCHJ:Q>6FGS3WFFV/W/\#/V@_&7Q*^*?
MBOX4ZIH>BI/\+K+7+CQYK^F7$]S;20^(=4TC6?@7-IS-,T;_ /"<_"K68_$V
MKW ,UM#KVE:UIEDP2U;8 <J?^"<7[-$>A^%M%T[3_'>B2>!O#?PR\,^"]?T/
MQ]KVF>)O"T'PB\4^(?%W@C5-&UFWE%Q;:Y8:GXK\06]UJ3"1[_3-2FL;E'C6
M-D^G/@E\&O!'[/OPN\*?!_X<6^J6W@OP;#J<&BPZWK%]K^K!=7UO4O$%_)?:
MSJ<DU_J,\VIZM>S-<7<LL["0*\CE=Q]5HH **** "OE[]HS_ )#WP+_[*3<_
M^HKK5?4-?+W[1G_(>^!?_92;G_U%=:KTLH_Y&.'_ .XW_IBJ<&9_[C6]:/\
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M(IO$/B*PO+?3M&FMTCU=UB1MU]&K(PC@L& G>[20Q1F,A9"ZE1Y;\.=+O9]
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MO^'-0\3OI(_;4T?XAZ;J&ISR^);XWVO?\*S6XUIEFU6[OSI\4EI<//K:_8Y
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M#HZK]DT6YMK>[CWN%EN9C%)NF!1XQ]2Z+,NH6]W->012PWBOI]Q:3*LL$EM
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M^/5N-#LM!OUUXS*FH3BPT^_NIY7-L]M--+Y)\N1O+B^R7 \_(VM<222F5P9
M$FOM8MM,TC6=3U29+61IIG$-X##*?[.D6"VL[9CFVGD?[,#Y-L\B&YN)MC@M
MFF:QJEGXE\.2ZAI,#ZC:M;-<I)+#)%&;S37-W#!'%.L<LER+NV-JV(_*1B\4
MC^8PC/)RX6$*J<Z%3&0I_P!H4**A&G.,_>I/$PH4^:<'/EINM-<TH*JZ<YV?
MO=?/BISHR4:]+ SJ++JU=SG4BZ=Z=586>)J<M.I&"E+V-/2-3V:J0@I+W>4_
M9ANQ>?%G]J.81740_P"$I^'* WB/'+.$\&.!<JCQQLL<^=ZKL4(2R8RI)O\
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MOH;5^=)U0>NG7O\ Z32U^LXK_?,1IK]9JZ+;^++1'Y31M["EKI[*&OER+4^
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MQT?51:WDOQ;^*'CBY;Q;>^*=4M-.^'&J:?#=QV]K=?9K.E_M^?MSPWEE+/\
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M(--\122^++2[N)O(EUCS-2FWW\TMR?=OA_\ LC_LN^"+#PN_@CX!_"CP=?\
MA+4M=U_0Y_"G@O1_#%]H7B'Q7I>GZ3XHO+2?2+6QNK6?6-*TS2])O8_,\F32
M=+TFP2,6.G:?%!Z O[/_ ,<D*E/VG$CV^< (_@7\/$7$YE,@VI=!2,SRE,C*
M%V(())-E/@7\>XV9U_:B 9E1&;_A1GP]RRQY" G[7R%#-M],GVQA@.#9X.G*
MB\?E]6E5AR5J5268UJ<W91<_W^#JSM*$:=)TI3E24*47",)2J>TWS#C".-JP
MK+"XJE6HS<J-:E'"4:E./-SQA_L]6E!.-252JJL*<*LIU7&HYQA3<.GT:TOK
MJT:/5KAHWM'EL[N*SNK@Q32PMG>TTA%R%>U:WDVQR(',C$DH?+IHGTF#4=/1
MFMXY[B65K%=IED%G;P2?.TAW/NF<I*CLP)C2(*2JKCD9/@!\=I99I&_:CE N
M1&MQ$OP1\ +#,L:LH#H+O^-6 D*E3(J(K$J"IE7X"_'9&A9/VG8D,"2)$$^!
M/P[55679O 47( XC4#&.,@YS74N&,1&%.$<?EK=.5-.I56/J3J1A4CK)+ PL
MW23T34?:._([<SY9<2864ZDWAL:E5C.].D\/2A"4Z;346Z\^:/M+)W7,Z45'
MFNVEU#6MH^N7.J6V9-0:,V[,)#CRH$AGAC*8!420>;%)G^,QE=K@-6OIDT12
MZOVD 29%N)9& 4HH:XD"L>N(;=HEP>44!<< 5YZWP"^.[7BWW_#43K<+ UN&
M7X'?#Y5,3$LRE1=<Y?8^<\-%&1C#!JD/[.WQSBLWL#^U+<36TDWG/'<?!'X>
MR!QO5S W^D*#;%E ,0 ^7*[L4X\.8JG4<H8O++2E6J:2QT%[62CRS:67MJ4V
MY^TDN9I)-;V4SXAPU6FHSI8YN,:%-76'FXTHM\\(MXF*Y::C!4HOECOHK7??
M:1<2Q&:*UM&DBNYKK5+<LXMT07<YEN$C+J[2!9IEDWA4B<7!,)=$W-DQZ!<W
M$6JZ;J[6]S'X@UV?5I#:*]L]HMJ;4011S*RS>>D%A9E+M6CF64S[2,HR\S??
ML]_'F^N+&Y/[5E[:RZ?))) ;/X)_#N%7\V,Q2).AFD$T;(2-C8 .&'S*I&A_
MPHOX^;XY/^&HR7C5D5C\#?A]T90I)_TL9) 'U^E9_P"JU6K:G7QN E3I7A37
M-C52G3JTX0K1E26 T2C*M2C";FE!IQ:;]W1<34:7[RC0Q4*M6TZLE&BJE.M2
MJ2G1<*KQ-W[T:564X*G)S34E**7-T/[& Q^Q_P#LKCT_9U^"PY.3Q\.?#@Y)
MR2?4DDD\DDU]"ZO_ ,@G5/\ L'7O_I-+7'?"3X>V?PD^%7PT^%>G:E>:S8?#
M7P#X0\!66L:A%;P7^JVOA#P_I^@6^I7L-HD=K#=WT6GK<W$5LB6\<LKI"JQJ
MH'=W,"W5M<6SDJEQ!+ Y7&X+-&T;%<Y&0&)&01FOLZ\XSQ-:I%WA.O4G%V:O
M&524D[/5:/;<^,I1<:5.,OBC3A&6SU44GW3U]4S\V_@4=)@_9Z^&VHP:M;Z#
MXGTWX=Q7-A/81&6[6%;V])-];K"R:C!=31HKVTT4ODD)+%LFQ-6AX!\0^(;K
M5[$V[)KYT[3]9O88M0O([>#2XKJXA>]U.*:&W)FFN&E:T%KY<LMO#(R(T2A\
M^B>$OV8?B]X&\.Z3X2\,?M,W%MH&@6KZ;HT%_P#!?X?ZC?6^EBYGGMK2ZU&2
M>*6]>W2;RFN)(T:?9YCH'9LL;]F'XRFRTRQB_:?GMHM)GDGLY+7X)?#R&X!G
M:5KF&659_P![;W8E9;J$J%F 4G#*&'YWG?!6/Q^<_P!IX/.<OP])8G$8AT81
MS&E*M*>,HUZ3J1GA:^&=7V<??J/#M\V'HQ2LJ,\/^E9+QKEN!RF>6XS*L7B*
MDZ-&A&O4GA:JH0CA*]&HJ?)/#XF-+VE1I4HXI+DQ%>5VW5IXGOHM4UC37LYK
MOPU<W<-S'YMQ?V=]9NFFPR'?)YD,Y@D8_-YUPR$[R&);"(M=+)J\14I:Q7-Q
M=,JF.!;:=0-XS&TLLB) D9P3N\TA@K&/=BO/I_@3\>+FWEM9_P!I]9+>>)X)
M8C\#?A^%>&12CQG%X"%93@X(..AS4%C\ ?CKIMK%96G[4!C@A54C4_ [X?,R
MHBA(UW&[R1'&JQIGI&BKSC)]:EPYC:4W%9I@:E&459U%BO:4Y)*+C!4LMIIJ
M7QN=651J7-%1<7&WBU>(<!5A&;R_$4ZT96<:3@J56#?-S5)5<;5E&4/@4*4*
M<91?,Y1DFWT,MC?:QJ5M87JVYT".7[7?0.JO<:G?VX601W9W,GV6*9X9#;*9
M$S''"[%$*C^1?]L#0;?X5_\ !1S]J;2-!1M+L-7U#P-\7=,AM1]F6PO]8T+3
MKBXEM!&$\G?J.C7-TIC"A99G88YK^LN+X#?'F'84_:C;*1M&"?@=\/26WOO=
MV_TH9DD<EG;NQ)Q7P5\5?^",NA_&;XP>+OCEXX_:<^(=QX\\:Z3H^AZS+IG@
M+P#I^D)INA6CV6GP:?IBVTPL]D,CF5A<2&61V<@9VCY_/N!<9F.#5/"XW+)8
MEXA57.O5QR4::ARJE&:RV4E3BVY*"23DW4:YY-O^A_HV>._#'A7Q]B,\XLPV
M>?ZO8GAS'91B,)D^"P>,JXBMB<3A*L)U,-5S/"TI.5.C4C.M.K*2CRTE%T[)
M?H1X+OI/%OACPUK]E>7EA#KOA?PUXA::"3S6_P"*CT*QUF.WMTO1<V\2P)>J
M3((F8G$9^ZU5_#GAC4=&GUS3+7Q!=^8FI6EW:W=W##>3?V;-!;S3V@24[(B]
MRUUYH@$<(,J3+#$9N<+PW^SA\;?"NA:/X=TC]J"5--T+1](T+3UG^"/P^FG7
M3]#TVUTG3TFF-RIEDCLK.!))"JF1PTA +$5;;]G[X[/<?:6_:EN/,W2,0OP3
M\ QH?-V[@PCNT9E^2(*&=@HAB Z$M[$^$IU'AJL\7@'7HN:O"OF=*,85:;IS
MC#V>"5E;DE>,8R<Z47LV?@=7BO"PK9A3P>'Q<,#B*MZ$:M# UJG)2KJIAW55
M6O*[4.>$H.<XJ-22]ZR1\P>.?V*/V=?'_P 6?BKX^\4?#+X5^)_'WB_P?9V'
MC/Q%K?P]\+7?B+Q9HUY%%97/AGQ%JWV'[==:5<:5X=T73II3(]^UDFE6SSO!
M9VJ+Z7X+_9(_96MDU74M._9R^$OA?6=:\=:=\2=2_LWP/X?TK68/'6@_VI%I
M'BHZEIEI#<_VY87&L^(;BWU>VN1*]UKVMS2R/=:GJ1G]3'[/?QO4LR?M-1QL
M[([NGP+^'H>1TX#2/]J+2,PPKM(6+@#<21FK*? ?X\HRN/VH<NCW#JQ^!OP^
MR#<RO+*.+L94NYPIR ,=P#66$X-J8:M6J/,,!..(E6=>G4JYG7C452O.=)7Q
M&#J2C[&C4=-QBXTZB2<J::@Z;QG&%/%4</36$Q-.6&5#V,Z=+ T)TY4Z%*G4
MDOJ]6E&7M:U*-7FFI5:;;4*K3FI]+I6GW=G=W>B1.]CIUGY$VG^3=RW4KZ=(
M@7RV-XLQB>*Z62-0CNB0A% #'(75(M'M8V%W)$MM'-% LUV[3N^H71P9%>4R
M,K6Z$RL5V*LAWM@QHR\O+\!OCU+*L_\ PU+)',D4D(DB^!_P]4F.3!*L#<E7
M"N!(@8$*XW#N*B'[/WQP$8B'[346T31SDGX$_#QW>6.99U=Y)+IG=O,7<2S$
M\G!%=2X7KQI2I0QN6.,>=4O:K'2C"#LZ=*-*& C&,*=^6T91TA#62;MR_P"L
MU"56-6IA\==^S=54WATYS5E5JRJ3Q,Y3J3LYN4XR]^<VN5J-^PU6TT[4M2TV
MX$Z//IRQO:&&=%"&:?[/.Q"9?<@>UD3:P#M&J XS6C9L]S?+/* )K<O!QG@1
M6Y%SM'\+/<70#A>&6&+.=HK@;GX!_'>ZDMY)?VHFW6LGFP[/@;\/5 DRI!/^
MDG.&56QP"5&<C(,4?[/_ ,>8KF\N4_:IN0]Z,.O_  I'X>^7$=NTO;J+@&)R
MNT;MS?ZN/(.T5:X;Q$*TJD<9EKYZL:E1IX^+FXTTE*2>!EK'EC22NURI2OHD
M0^(L/*E&G*CC?W=%TZ<6L/*-/FJ)RC!K$1]V7-.K)\J]]N.O,Y'<1W*KK%_<
M00//'=M!83>4%6-KJR4^3+)-(50N6DGM66,22$06Y;$8C)J2V-^-;U'5;J&R
M>VO-'L]#BLF7S946:YG9Y+F<J(YXFED1)+=$VB$DY+$D\9<_L[_'2YT^+35_
M:FN+2"!X'ADLO@C\/8+B)[9Q)&RRFX<AMXW.=N7W,#PS9T#\"?CXR1(_[4KR
M>4\<@=O@=\/2[O%DJ9"+H!N220%5<\@ UG_JQB)OEJ8[ I0J?68.$\:H>VJ>
MU52#B\!S.$'4<DYMQG*3DX)I%KB3#TUS4\/BG*<?J\^>-!S^KTW1=*2E]9<8
MSFJ:@U%)TX148U))Z:?[&MC%IGP-73H6E>&Q^,7[3=I$TTAEE:.#]ICXN1(9
M)&)+N549)[^@XKZFKRKX+?#.7X1?#ZQ\$W/B:[\8WT?B'Q[XIU3Q)>Z9I^BS
M:IK'Q"\?>)OB#K$BZ5I0%AI]K!JGBB[M+&VM]PCLK>W#O)+O=O5:^NJ*G&<X
MTN7V<9.--Q347!.T7%249*+23BI1BTK)Q3T7R3G*;<YN3G-\\W*SDY2UDY--
MIRNW>S:O>S:U/S$^&\VG6/A+XQZM8:XFD^)[#XU?&,.;.'S99;.7QG>[+34+
M8PRQ78N5,OE7,R;[%A&Z2Q(KB3M/ASKGB*:XNY((H]:6TT?3-,^U7]_'!)I=
ME/<W0M[.T$-N1>'4)%%Q+.$++)!&LLK!$4=W;_LQ_$K0;OQE%X+_ &AKGP[X
M<\6^+O%7BU=#O/A+X&\03Z7/XNOI=0U&PCUJ]EAO;VVAN)YOLKW2&6.-EC9G
M" FL/V9_C0DNCS0_M/RP-HELEE:"'X(_#V-)K2(Q-%;WJ+< 7,44L*3Q*=GE
MS%W3'F.&^"SK@W'X_B!YQA,XP.&P\JM>J\+"./I2G*O6D_:5%/#8O#.NJ52+
MJSC1_>.AR0E!NC5H_H.3\99=@LA>48O*\3B*[IT::Q51X6JH1HT::]E3=.>%
MQ*HNK2DJ,'B.6DJ\ISC4BJU+$>@VNJZCI]^+*_\ #US#;R*@.M0W5K<6LDI4
M>5 ( T=RH!W0QHL3$$95&#,QV;C4A<JT-G'<R+EA<SB&2WCACC)$T?G7*P 2
M'!C+1ES""SG#( ?.M0_9_P#CGJEO]EOOVGA-")H+A5/P.^'ZE9K:59H9%9;P
M$-'(BL.W&""*F/P'^/)@%M_PU"5A"JNQ?@;\/@-BD'8<W9RC;<,IX920>":]
M.'#F-@ZE/^U,!.BUS4YS^MJLFV^:E^[RRE",(I1Y:DE4J2YI<SNDSQZG$&!G
M[.I]0Q,*JM&I"G[-T7RJ-JS=7&U)RG)N7-2C[*E%0ARW4G%7I](FU.SUV_UF
MVM+B6*PGM/#]I'#OBL$9&FMS"KIYGV^:7[)YDH1'51'$@7#*?Y&[O4M8_9Z_
MX* ?'II;>6TO/!7[2EI\8;&WA:6$W.E^-]1L/'.H0Q<I*MO>G7=6TYT.&*"2
M)N20/ZUC\!_CT4E3_AJ-@)9!*Q'P.^'P8.!&%9#]JPNWRD*\'!R>Y%?!GQ1_
MX(T:%\7_ (O^+_CAXP_:8\??\)UXWT_1=,UY]'^'_@#3-&DM] M?LFGO:Z6M
MM,+>X\G'VB;[1(9W56*C&VOG,\X"QV-I4)8+,<M^LTJT*LIUYXZ+J2A4E4C4
MG4CETI2E!-1A&RA&+48I1C%+^C/HZ^/'"?AOQ)Q#+C;+\YQ'"_$7#&89#C,-
ME6#PF,K6Q<</25*.&K9G@Z:I5:7UI5YNI*4I34VG*4F?H'K_ (?N/$OAU;JR
MUS4K*-XX=9TN&&5!$4$7VFQ$\^/MSLT;H^X7:^7*P&R18PI@\4:-=WOA#6&;
MQ')8Z6VC17,$*65H/(^R6AEEAFG*GS$NYT"S%55E)8(P)P<NQ_9Z^.FGZ-I^
MA0?M2SM8Z9IEAI-N9O@C\/9;A[33K6&S@,\QN1YLS0P(9I-J^9(6?:N<!1^S
MU\<3"8)OVGVN8V9V*W/P0\ 3)EV+\1/>&%=C',>V(>60"N",U[%?@UU?K#^N
M8%RQ6$6'K2>)S:";C"K"/NT\(KTTJ\[TX\D7[K7*X1:_ :7%U*A.@J='$NEA
M,;*OAE+"Y?*:INI1G=NI5FHU9?5Z?OOVDHWFN:49R4O!)_V3_@!KGQ \+_$[
MQ[\&_AC\2?&Z>%[+2]*^)7B7P)X:UGQ!X2T-H]0@OM M=2O;.ZNET34[;Q!K
M$=H-TC6Z7FM1 0V]_>,^Q??L0_LCZ&NJ:UX>_9J^#%G<:UI7@SPYXDE@\&Z/
M9IJ7A+P/<:!)X9L)O*M&24>%V\+^%[C0]Z?Z&_AG06251H^GFW]JC^ ?QVB+
M%/VGPNYT? ^!OP^V@Q[BH53=D*N7=BHPNYW( SQ)_P *(^/'D?9?^&GU^SF,
MQ>5_PHSX?;?+(*E,&[/RE25(]"1TIX3@^>$PKPM+'X&-.$8_5_>QTGAY0;G%
M4Y3P$IN'M93JIS<IP<Y0C)P4%&,7Q=3QF+6,JX7%2J3E?$76'BL3%J,9>TA3
MQ$(*7LH0I2]FHQJ*"G)*HYRGU.L>'=+U?3'L/$5K:^(+>^\F%],U>WM[[2'*
M2QW">=IT\9M+J*U>WBNU-U'*QDMT==D@CV\5%X"^$MQIFIPVWA#P,D4EU?6L
M\D?AS08YVCO$O[+5Y-YL0QEOK76_$$%T^";N/6-320RQZE=+-*OP ^.H,32?
MM0M<&"-8H3<_ [X?3>4J@ E0UUC>V%W2,&<[1\PYS(OP$^.R02VZ?M/JL4QE
M,BK\"_AVN3.29#Q<@9.3R02>^3G/4^&\3)_[[ED8N%2,XR_M"I*?/%1UE]2@
MM;RYF^?FBH;6:.5<189)7P^.E*-2G*+C]6IPBHSYGRP]M/56BX:QM)SO>ZD9
M5M\(OA58>'/^$*M_AGX!'AJ]L[6VN]#'@[PZ-)O].T*[O+^QL[S3QIOV&\MM
M/UNX&IVEM-"]O:7>H3W$$:33R._;OH&A:#>_;- \/:7IU[)?+KFLS:-I=A83
MZK<1Z5%H*W&HRVT=O]KNVTN&"QAN;QY98['3(;=&\NUMXUY(_L\_'3;8(O[4
MUQ&NG,6@V?!'X>C=N*EDFS<'S(R5R4^49/H !='P(^/0%P!^U$<W)/FL?@9\
M/2Q!3RP!FZP J?*HP0.2023DCPYB>25-X[+TK4.1J6.DX>RC"24;X#>%6/NM
MZ62FE>T12XAPRG&I'#XJ3_?<Z<:"YO:RG!\UL1]NC*\[-^\W&]O>.LU&TU+4
M+_P]=PP6T%IIE]-?F.<B>>Y#Z?/#&(BJA+5L3,P<ECN"K@*S4NCZ0^EW=[<6
MH9/[3N%O[VRE<,D$EY/<2RBU'*VX0N&EB0>7/+YTY ED)/%Z=\ ?CWIMK#:1
M_M575S' NR*2]^"7P]GG5 250R_:$+A =JLP+A0 6-6C\#/CX9?._P"&I&#F
M/RSCX&_#X KNWC(^U=0<X/H2.]3#A>;G'$3QN!]M*:JR3EC9>RJ.A3H/DDLO
MBK*%.,;**C-*\HW;O53B6GR2P\*&(=",?91:C1C[2G&O.O'VD7B9-MSG*5W*
M4H.T8M)#O@)_R6O]J/\ [#OPL_\ 4%->&?MH^*D\3?$?X8_"?39!.V@M/XW\
M1QQR%A!-=HVG:%;SQKCRYOL_]H7<98Y:&X7& 3GT_.E_L?>'/B5\1?B/\2;[
MXH^./B7JVE7&GV3>']!\*7FM:GH>B)H^BZ!H>B:$&@BMHHPUSJVK3F46T#O-
M,2RP0S_)/PMT/Q)XK\1Z]\4/',@N?%/B[4'U2];:P@M8WVK::;9(^3#8:=:K
M%:6L7\,408DR.['](R3 RJ5Z%1M3IX7#86ESQ4U"I6I8:E1GR<\(2<8RC/5Q
MB_A=M[?G>>8V,85Z<;J>)K5JG*[<T*4ZTZD7+E<HJ4DTK<STYOG]&:/;?9=/
MMHNFV)!CTPH&/PP17T7\$O\ F9O^X+_[EJ\&50JA1T4 #Z"O>?@E_P S-_W!
M?_<M7T>>:95BEV]A_P"I%$\'*/\ D8X?_N-_Z8JGO%%%%?GI]L4=1&;9@2 -
M\99B<!5# EC[ #GT'/:N4O?B)X(T/R[76/$^DZ=<1QQH\-W<B)U944$%6'8U
MV[J'5D895@01[&O/=7^&?AC69C/>:=;RR,2Q9HXR222><K_G\* (O^%P_"__
M *'GP]_X')_A1_PN'X7_ /0\^'O_  .3_"LS_A3/@O\ Z!-K_P!^8O\ "C_A
M3/@O_H$VO_?F+_"@#3_X7#\+_P#H>?#W_@<G^%'_  N'X7_]#SX>_P# Y/\
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M -^8O\*/^%,^"_\ H$VO_?F+_"@#3_X7#\+_ /H>?#W_ (')_A1_PN'X7_\
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M<'P]GN);C1?[)GLX_&VE6LDA,6EZSH-U+!+J%S;(1&-2TAKJWNHD$\Z6D[/
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M &S2/^34?C&/^Y2D/Z"6L_\ B W!?_1>T-TO^1ADO=?WF^O;JOGK'QRXS>_
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M[*-O=L_B\_ZTO:\8>*'_ ,T?5^>#S3R_N_U\M?[V_P#AZ[_P35_Z/C_9G_\
M#K^%O_DZD_X>O_\ !-/_ */E_9F_\.QX5_\ D^OX(O\ AV1^V_\ ]&B?&S_P
MCI?_ (]3#_P3'_;A_P"C1/C6?IX0G_\ CXJ'X)\)+_FM:/I]>RE_R_WO-_=<
MT7B_Q._^:0J_^$>9KMTLW_5MS^]__A[!_P $T_\ H^3]F?\ \.OX6_\ DZ@_
M\%8?^":0Z_MR_LS#_NJ_A;_Y.K^!MO\ @F/^W#DY_9$^-8_[DZ8_KY_-,/\
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M*35KN4I.*BFWI7MZ=Y+5J-^9VT5I1B^M]'*[=K))MG[+45^/GPT_:\_:.O\
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MX1FN/%4?E>))Y-#L#+K2":"Y OY/)#RL+JVM[Q9 5D6^ACOE87:B:KL?P[\
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MW\!>%]-O?"\.@W^Q/$^M20PZ;/8ZYJ.J26EIK&IKH$EMIT@D^BG^'/@"33=
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M7EQ;0%(9I4>Q+\,/AQ/HI\.3^!O"\^@FZL+TZ1-I%I+8_:]+L;?3-.N?)=&
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M?_7O_ K3_P#Y5UZU11_:V8_]!=;[U_EY?GW8?V;@?^@:E]S_ ,_+\^[/)?\
MA37AC_G_ ->_\"M/_P#E71_PIKPQ_P _^O?^!6G_ /RKKUJBC^ULQ_Z"ZWWK
M_+R_/NP_LW _] U+[G_GY?GW9Y+_ ,*:\,?\_P#KW_@5I_\ \JZ/^%->&/\
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M_M;,?^@NM]Z_R\OS[L/[-P/_ $#4ON?^?E^?=GDO_"FO#'_/_KW_ (%:?_\
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3DO--W:?FM0HHHKC.H**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>dm199profile.jpg
<TEXT>
begin 644 dm199profile.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
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M^(WBSX:P_P#!8[Q)\.=4?3_B%H>O^%M0TF2PF4:WI.GWNEVNE:KXCLH5;[1
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M-A82ZE=7>JPZ=\VGZ?%:PR.UY,1$I5BQ"([KR/[-G[9?P@_:LEUA?A59^/\
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M*^,;+7[6ZT?1Y_\ A%)=.N91^O'_  V1^R__ -%J\%_^!=U_\B4?\-D?LO\
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M?4]*O;NS+_JI_P -K?LJ#_FN/@C_ ,"[S_Y#I/\ AMC]E(=?CEX''_;W=_\
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MS_\ (O\ \;H^J8O_ *!L1_X)J?\ R(?6L+_T$X?_ ,'4_P#Y+S7WG545RO\
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MF+_Z!L1_X)J?_(A]:PO_ $$X?_P=3_\ DO-?>=517*_\)OX4_P"@Y9_^1?\
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M..JP2<O9QQ-6G&4DGRRDK+F:/>H/VF_B1:E1;+X1A@BU#0M0LK(:"9;+3/\
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M\.?M%V4FO>);30M!/A'Q4TC:KK$6FZ0;M[6V$9D^UW$-D;EP@6,M^^?:%3)
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M3P^OA^"UU?[2\\:O>$^5!MA$WS,S, 2&8$ *#N.0HX"@YR% XVCC'&,5#N;
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M:SG.%MFN9+TQV*7_ +E%_JYP]_T(LF_\->!_^4'RO_PP_P#LB?\ 1O'PM_\
M"8L_\*:?V'/V0CU_9V^%9[?\BO9_X5]545?]NYVMLYS5?]U#%_\ RX3X<X>>
M^0Y*_7*\#_\ *#Y2_P"&&?V/SU_9T^%1_P"Y7L_\*3_AA?\ 8]_Z-R^%/_A+
M67^%?5U%4N(,_6V>9NO3,L:O_<X?ZM\._P#0@R7_ ,->!_\ E!\GG]A3]CL\
MG]G#X4<_]2M9?X4W_AA+]CD]?V;_ (3G_N5;+_"OK*BJ7$?$*VS[.5Z9ICE_
M[G#_ %:X<V_L#);=O[*P/_R@^3#^PA^QP>O[-WPG_P#"5LO\*3_A@[]C8]?V
M;OA.?^Y5LO\ "OK2BJ7$W$BVX@SM>F;8]?\ NP+_ %9X<_Z)_)/_  U8#_YG
M/DH_L&_L:GK^S9\)3]?"EE_A2']@S]C0]?V:_A(?KX3L?_B:^MJ*I<4<2K;B
M+/5Z9OF"_P#=@7^K'#?_ $3V1_\ AIP'_P SGR.?V"?V,CU_9J^$O_A*67^%
M)_PP1^QC_P!&U?"3_P )2R_PKZYHI_ZU<3_]%'GW_AXS#_YH#_5CAK_HGLC_
M /#3@/\ YG/D;_A@G]C'O^S3\(S]?"5@?YK7JGPY_9X^!WPAAU.W^&'PM\&^
M!(M:D@EU9?#.CV^EMJ+VH9;?[7);A9)EA#MY:.Q12=P7=@U[+16.(XBX@Q=*
M6'Q6>YQB:$W%SHXC,\;6I2<&I1<J=2O*$G&48RC>+LTFK-(UH9!D6%JQKX7)
M,HPU>'-R5J&6X.C5CS1<9<M2G1C./-%N,K-7BVGH8G_".:'_ - Z#\Y/_BZ/
M^$<T/_H'0?G)_P#%UMT5YWUG$_\ 017_ /!M3_Y+R7W'H?5L-_T#T/\ P53_
M /D?)?<8G_".:'_T#H/SD_\ BZ/^$<T/_H'0?G)_\76W11]9Q/\ T$5__!M3
M_P"2\E]P?5L-_P! ]#_P53_^1\E]QB?\(YH?_0.@_.3_ .+H_P"$<T/_ *!T
M'YR?_%UMT4?6<3_T$5__  ;4_P#DO)?<'U;#?] ]#_P53_\ D?)?<8G_  CF
MA_\ 0.@_.3_XNC_A'-#_ .@=!^<G_P 76W11]9Q/_017_P#!M3_Y+R7W!]6P
MW_0/0_\ !5/_ .1\E]QB?\(YH?\ T#H/SD_^+K&\1#P/X1T+5?$WB:32]"\/
M:%8SZEK.LZE.;73],T^U0R7-]?7,D@CM[6WC#23SR%8XHU:21E121VE0W-M;
MWEO/:7<$-U:W4,EO<VUS$D]O<03(8Y8)X95:.6&6-F22.161T8JRE213CB:_
M,N:OB'&ZYE&M-2<;JZ3;:3LM&TTG;1VL#PV'L[8>A>VEZ4+7Z7M%::+KT/YY
M_P#@LS^WG\&O#G_!/GXLZU^R5^UC\/\ 3?C=!XA^%R>&+[X0?%3P_<^.TL;C
MXA^'H?$ TE-(U.ZOVMI=!?4$U(PPM&+ S-,50;A_$G_P]"_X*,?]'K_M%?\
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M'UG$_P#017_\&U/_ )+R7W!]6PW_ $#T/_!5/_Y'R7W&)_PCFA_] Z#\Y/\
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MSQ=^P1^VWXFTCX*6_P 3OV=/B9\8?B/8_L\_\$O]#\&^/9/BUX*33OV?-;^
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MJ:^K3O.K&$:E/GG&E&,W&=92BN?^B3XK?%;X>? _X<>,?B[\5O%.G^"_AOX
MT2Z\1^,?%FII=RZ=H6B6947.H726%O>7CQ1%T#+;6T\I+ +&QKX;TOXR?\$P
M_P!J'QO\'/C]:ZI\"_BK\2M%^*3_  1^$'CS5O!\UQX]\/\ Q4UCPW>>*8?
M]O%KGA^V\1^']6NO#=C>>(-'&O65C:1P0R:EI%S'.PF;\WM,_8K_ &A+G_@D
MI_P4#^ WA/X4_%S2/'/QOTC6H?A#\"/B._P<\('3M5F\&>"=(U>V\!>'? WQ
M)\:^"? ?ACQ)XCTG5-5^PZKX^\[5-=_M?Q9<VVER>(FMCXK^S_\ L6?MM>%/
M''AOXNZU\ ?BU<>$M'_X*!_LK_'";1?C+\1O@AXK_:GUGP[X8_9V\3? SXK^
M,_$FN>#?%5C\/+[X?^!]3U;PQ<?#[PE#K5OXJL_!^F>(S::7?W\]M!?=.#X>
MR.GA<RJ/B.$,9A<5B,+AIT<?@L''%T'A<"Z<5AYRJ5I*O5QF(HU)PQ$J"CA*
ML'S)RG#&MF683JX2*RR3H5J-*M44\/7KNC45:NI/VL5""=.%&E.$7251NM"2
MM91E_5@"#G!!QP<'H?0^E,>6..-YG=5B1&=W)RH1 69LC.0 "3C/2OY,?!7[
M!'_!0JT^$W[0OA;P7X ^(?PD^,>J_LE_$OX;_&CXBZS\:-&N[?\ ;,_:"U;]
MHNP\;Z1XX\"Z]I_CC6]3TR;5_@O9>+/"EAXY\8Z9X"UC0HO'EAX,EM[;2]&E
MNK3O$_8I_:0.G>%M5B_9/^*\/['$'[=>I_$W2?V U^*OA"T\>>%?A?=?LRQ?
M#_0_$ERL/Q6'@BQT:P_:1CN/BK#X1T_XG3S>'4O!XIL;!;Y'L1SRX2RN,ZD5
MQ3ETU3J58KD^IN514Z=.<%"^:*G[3&.;^I)U/82A3F\9B,#64</+:.<8MQ@W
ME&*CS0A)W]O:#G.49*5L)S<M!)>W]WVBE.*H4J\+U%^X_BW_ (*&_L9>!OA-
M\*_CGXG^._ANP^%7QON]2L?A/XN@T?Q=JMOXYN]'CU";5(-$TW1_#M_K<CV,
M.E:C-<&?38%CALYYBWE(6KZ7^&WQ+\ ?&+P'X5^*'PM\7:%X\^'OC?2;?7/"
M?B_PU?Q:EHFO:5<EUBN["\A)611)'+!-$P2>VN89K:YBBN(98D_G)\"?\$_/
MVQ9?V4?^"*OPFM-.\6_ KXB?LT_$+XJZG\</&>A7WPO\7^(/@?IFO^!?BOI6
MFZJ+77]7UGPUXN?6;G7],T(G28/$LT$>N-J$UK#+;/)!ZJ__  2S\;_"_P",
M>O:!\#+/Q=-X8^&G_!,_QE\,?V>/C7XM\=06D]E^UYXQ^)WQ0UZ_\6:GIF@Z
MEIGV;Q9+9>.;S4K;7_\ A$$T/P]9ZQ/;:)<6UTDJ4\5D'#$(SI4.(.3$QQ.9
M<LYU,-BL//!X7,\=@<-*?LUAH4ZE>E1P6*C.GBL1.M0K5Z]/"0I4Z#KS1S'-
MI.,ZN6WI2IX52C&-6C4C7K83#8BJH\[J2E&G4J8BBU*E2C"I3ITY5G-U%3_H
M8W+@G<,#()R, @X()Z<'@^]&1D#(R02!D9('4@>@R,GWK^2W1?\ @GM^T3-^
MQI\0/"&K?"+]J[3-8F^)W[./BNW^#<*_LW3>$M9\?_#/X9>)]"\?>++[X.#X
MVW_A?XG_  M\;^+M3T4?$L>)?BAX3\9?$'6M)TKXK:=I.FZWI,D-]Z_8_L>?
MMB2_M'_LK?$Z3]GC7[+QE>_ #X1?#CXRCQ#\0-+\4_ KX&66D?"#QOX:\1GX
M+?$$_&+_ (77X1\0Z%XDU;3['Q5\/-<\/_%WP%\5WOHO$&HZI=7VE)=V<5.%
M,KA]8Y>*<OG[#ZRHODPT55=#"T,134;YE?\ ?2J5:%XJHJ=6CJY*K N.<8M^
MSOE.)CS^QNKU7R*I5G3F],+K[-1C4:?*Y1GTY9'].>1ZCGD<]CT/XT;E. ""
M2,@9'(]1ZCWZ5_)'IW[%_P"WI\0?@Q'\/_$O[-?Q-\$W7@_]@3]BW]E.;^T_
MBM\.%O/'/COX*?M>>&_%'Q3U_P -ZCX3^),]]H^FW?PXLM1\2Z3KU]?:1K=Y
MIB^1;F#65M;.;ZX\!_L-?'SX?_\ !3H>.K;PC\5-+^#OACXE^"=4^"OQ"\":
MA\.G^'/A;]FSPW^SY8^ )_@5XSUSQ/\ $1OBE:>'K?QI9ZA/+\+M!^'.I:/K
MVO:AIGQ&E\5IJ5O>&&*W"V648XM2XHRZ57#4,=6IPIK#588AX2&!E2I0JT<P
MJKVF*EC)JG&,:C2PF(<54G"=.#IYOBZCHM93B8PJU,/3DY.K"5/VTJZG.49X
M:/N451BY2<HINK33<(RC*7]$M%%%?%'NA1110 4444 %%%% !115>XG6%?5V
M(6-!R[N>%5%XW,>3C*@ %G945F4 EDD2-2SLJA022Q "@=V)X &1DGI68^J9
MR+:UNKL@_>AA?R\=.)7"1MST*.P(&>!@U,+>-0UQ>LK8_>%9&'V> *#SACL>
M0!B&F<9)/[M8T"H,.\\7V$!*6T4MVPR-P(BAXXX=@S-]1'M(QACFM*=*I5;5
M.#E;>VR]6[)?-F=2K3I*]2:BGM?=^B5V_DB\=4U+/&BW9'^];@_K<"D_M34_
M^@)=_P#?5M_\DUSY\:R9XT],>]PV?TBI/^$UE_Z!\?\ X$-_\:K;ZEB?^??_
M )-#R_O>?X/L8K&X9_\ +S[XS\O[OG^#.A_M34_^@)=_]]6W_P DT?VIJ?\
MT!+O_OJV_P#DFN>_X367_H'Q_P#@0W_QJC_A-9?^@?'_ .!#?_&J/J6)_P"?
M?_DT/+^]Y_@^P?7<-_S\_P#)9^7]WS_!]CH?[4U/_H"7?_?5M_\ )-']J:G_
M - 2[_[ZMO\ Y)KGO^$UE_Z!\?\ X$-_\:H_X367_H'Q_P#@0W_QJCZEB?\
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M/J6)_P"??_DT/+^]Y_@^P?7<-_S\_P#)9^7]WS_!]CH?[4U/_H"7?_?5M_\
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MU;?_ "31_:FI_P#0$N_^^K;_ .2:Y[_A-9?^@?'_ .!#?_&J/^$UE_Z!\?\
MX$-_\:H^I8G_ )]_^30\O[WG^#[!]=PW_/S_ ,EGY?W?/\'V.A_M34_^@)=_
M]]6W_P DT?VIJ?\ T!+O_OJV_P#DFN>_X367_H'Q_P#@0W_QJC_A-9?^@?'_
M .!#?_&J/J6)_P"??_DT/+^]Y_@^P?7<-_S\_P#)9^7]WS_!]CH?[4U/_H"7
M?_?5M_\ )-']J:G_ - 2[_[ZMO\ Y)KGO^$UE_Z!\?\ X$-_\:H_X367_H'Q
M_P#@0W_QJCZEB?\ GW_Y-#R_O>?X/L'UW#?\_/\ R6?E_=\_P?8Z'^U-3_Z
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M4K.UU#3X;2]L+ZWBN[.\M;T3VUU;3H)(9X)HXVCEBD1@R.C$$'K5G_A-9?\
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M'[KH0012_P#":R_] ^/_ ,"&_P#C5>A]2Q+_ .7?_DT/+^]Y_@^QT_7<,_\
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M:Q??#WX(>%]/7S3X/T?Q!8S&0'*FXDTAD^51A<B%L\ ''KT^KOAIX+B?X*^
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M7V[L#U.U?RK*MO$?A2&SA:W\0Z#]B74_^$>AF75]/,!UM9#"=%247'EMJJS
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M2J4^2]1/FDHZ492W_P +>O9/>[M>VGTG_P -B^&O^B"?MD_^(E_&O_YEJ/\
MAL3P\01%\ /VRII""(X1^RA\8;<RO_!&)[[P]:64)=L*);R[M;6,G?<7$,0:
M1?KNBN;VF$_Z!:G_ (4__<4:<M7_ )^1_P#!?_VW]7?E;X;\.:;\9A>?'/\
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M?Q*G^!?^E(ZOX4?\B=I7_7O'_P"BTKT4N0C,,$J&)!XY'3([<>GX5YU\*/\
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MG";H8K!XF4.2MRODG.,E.3BI6<E3G3E:_+*+=S\??^"./B7]J+4/A/XY\/\
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M_P"P+\/O_0/%]=Q7#Z-_R4#Q]_V!?A]_Z!XOKN*X\#_ G_V&9C_ZL,488?\
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M3GKWHK]L/Y!V"G_&_P#Y(7XA_P"P5X;_ /3UHE,I_P ;_P#DA?B'_L%>&_\
MT]:)7FYE\%+_ !2_)'HY=_$J?X%_Z4CJ_A1_R)VE?]>\?_HM*])^4YY'OR,_
MC7FWPH_Y$[2O^O>/_P!%I7I 7!/0Y)(Z]^3D=.OM[UY)ZX;U )R,#/?GY>HY
MYR,<]Z RD<$= =HQD9&>G7D<TC*3DJ<$AASDCYL=@0#C QGISSR<H$((YX!S
MCOG&.O'&>><]!0 X,"2.G (R1SGVHW*._P"A_P .]&T\DGDXZ#C@]1G/4>I.
M*:%90 "" , DMD_7!QF@"2BBB@"*?_4R_P"XW\JYV_\ ^1?U;_KKJ/\ Z72U
MT4_^IE_W&_E7.W__ "+^K?\ 774?_2Z6M*/\6E_U\A_Z4C*O_!J_X)?D>744
M45](?.!1110 4444 %<GX^LK[4_ 7CO3=+A:YU/4O!/B[3]-ME(5KC4;WP]J
M5K8P*Q("M-=2Q1 D@ MDD=:ZRG*Q5E88)5@P!Y!(.>1W''- )M--:-.Z?9H_
MSZ_!X\/Z3XO^+FF_\)MJ_A&74?B=XE@M=.M[?R[K=;7TT3W\\%Y:W!TUHKAQ
M]H\P00/(L;70?8E?5WP$^&/B[XG?$&?1-!\=Z5K-Y&C7]W?'5K+PS<P6UG):
M02Z;X:UXWQEL/&&J3-%'9QVI73[.22&\2V26TVW7Z[?'7_@F[\/?']SXJ\$:
M=J<G@GQ3%X[\4^*+[4-3TA_$T7B_PWXJET*XT?5X[>+6=#O'EM++P_HEI/?V
MMZEO9>);+Q)!+IXBU!7FM_!']@O2/#VMW/P?\,1:7XH\)W_A[2G^(_Q#U+0=
M*BU30=3T[4(5@TW2;B&XN;NRO4L89GTG3;JYU*:VE>"YU-[FX1]0E\O"Y-+G
MI3Q%2O+#481=26(J83$U:L*<J/LZ5&LUA,1[3EITZ-=/EJUHTI-5I^UG2C_I
M/F?C+P]6X)J9M3>'P=3,L/&O*4,(\/A*'UFE.KBKX>,<;0K8B5>OB*> H0YG
M0QE2+DJ57#0KS]^_81^&E]\1?B+K/[3?B2"%?#GA+2M9^''P4L(+_P 6ZEIY
MNM=O(+_XF>-[:7QG.-6>>^FM]-\+6TQTK2+:.'3]0&EP/I]PCG]9:YWPCX4\
M/>!/"^@>#/">F6VC>&O#&EVNCZ)I=HBQV]E86B;(HU50 SNQ>:>4C?/<2RSR
M$R2,3T5>U7JNM4<M5"-X48-4X^SHJ4G"'+2A3III-N;A"*G-RFUS29_GGQ'G
MF(XCSG&YOB8\D\54CR4O:5:JHT:4(TJ--5*]2K5DXTX1YI2F^:;E)6321111
M6)X@45^87C3_ (*&W7@C]I3XP_"&X^'AU_P9X*TKPKX;\ :SIT.L:7J'CCXR
M3ZY\/;/QKX4'BS50?!+6&A:7\4-+E-G8QG5]'N_!'C1M7GF2ZTFUMV?#K_@H
M9K/CSQWI.DW7PCU/1?#.KGPE=:?I>APZE\1?B?J=AXC^&6J>,KU;;PEX;^S2
M[])\0Z3?:'#J&DV_B6UU6VLYW6VL9M\EOZ']E8[V?M?8_N_90K*7M*=W"I",
MXVBY<[=I*Z479J2>L96Y_K5#FY.?WN=PMRR^)-IZI62NMVTK6?57_4"OD?X\
M>&/BOX]^,7P5\.> K6X\/>&= T/XB>)_%OQ6N$WVW@K4-<MM*\':,?!UH\3V
M^K_$R3PY=>/-.T9+PC2_#=CXDD\3:DMXUG8:-J_SCXX_X*@^"_"OB'XH>'M%
M^$_B[QA<?##5?$=GJ$UEK&FZ.+NT\%^#?'_B_P 7-)#K=I:2:?K.CK\-O$>C
MKHC_ &DW.I-81M?6WG3BVRM>_P""FB:;JFN:C;_"35HO OA?Q9\0?"=W<7%_
M9WGB/Q)>^!?"7C;7;IK>-+[3-+\%6B7OA:T>[U;5)/%%A'HVHFXN!I\D5S)8
M[4,MS&E-5%A$VZ<^5594[6JTN5/D=1.3Y:EXQDG%N_/%QC-*9XG#R3C[5V4H
MW<5+[,T_B2LE>.K3T6SNXGZ:>#?!OASP!X:TSPEX3TU-+T/28G6W@\R2XN;F
MXGD:XOM3U2^G9[K5-9U2[DEOM6U6]DEO-0O9I;BXE9WXZ>ORGOO^"HVAPC6+
MJP^"/B[4=,\(>!_$7C+Q?>6GB'2;T@:+--I=FG@_[!:7%OXK\.ZSK9MELO%T
M-Q:0G1H=4U==(E@M$\VSXB_X*6+;Z&EWI7P8\5Z'=7_AK3=0L]2\43:=?6FG
M>(=2\%WWQ AT;4/#=EJNB:Q?6,OAW0];\G5K;4[")KEM&)C)O;JVLH>59C*5
MY4'>3;E*56DW>Z<G)^T<KZJ3WDTTTG=7:Q6'2LIJR222C):;)*\4K=%T7D?I
M_J]QJ5II.JW>C:=%K&L6NFW]SI&D3Z@FDP:KJD%I-+I^F3:K)!=)ID-_>)#:
M2ZB]M<)9),URT$RQ&-OY8=/\+^,_B9\4O%VF:9X:OI/V[/BOXJUF+QK\*-52
MZ\(^'/A+#;7+:E=1:VL,6K'PW\#?"%E<P:A:^*]$DU.'XFZI?0:KI%QJNKZ[
M&+/^B#]F_P#:)TW]HWP_XB\2:5X9E\,6.C:W_9MK:7GB;P[KFLO;/]H$2^)-
M'T6ZFO\ P5XCA:UD_M+PKK\,5]9I+:313W<4[-%[TFA:''K<_B:/1=(C\276
MF0:)=>(DTVR37;G1;6YDO+71[C5UA&H3Z5;7DLMW;Z?+</:0W,DD\<*RNS'Y
M7B+A?*>(*$,LS_!NO0P^*IUZM",U2EB(T[5'@<1B*2^LQP5:K&A5Q-+"8C#S
MK3P])3J<U.G*E4YXVI"DL%F>+P6'E5IU<30H2M1QL:7-[)5Z4TX3E2<INC.<
M)^R=2I*"4I*2_FY^ _B+QG\.?VB_!;_!GP=XC?\ :F_MVU^&?[0OP(UF5'%W
M\.].U*V?Q7J'Q!\1+&=+\->&O!,-Z?&7PP^*4)GL_$\%Y::7HMEKJ^(WTZV]
M7^+W_!:3XBWVO>-K?]D?]EX_%3P)X$UF[T*Y^*7CW7[G1M&\5WVGMJHO!X,\
M.:;/INH:M"8]$U.XLUMM7O=5FLK;[;=:-8))'$_[WV^A:'::QJ7B&UT72+;7
M]9M-/T_6-=M]-LH=9U:PTHSG2['4]4C@6^O[/3C=7)L;:ZGEAM#<3&!$,C9_
MG<_X*4?\$V?@K\%O@]\8_P!J7P-\7OC1\)O"?@R2\\>ZC\'?!,%GXJ\+:AXT
M\::M!X2MH?!VEWNI:'/X6;Q)KGB^/3]1GEU'4=-TG3M2OIK:QALH&M'_ #_B
MOASC3+LAR?(?"R=6G2I8S%4ZN%6(RR.;*CBY45EV RW&9O0E@H8+"5764_K+
MEF%3FI1IXN-)NG2_K[Z&>-^BOD?%'%=;Z5M/&9Q@ZN%P%;@W'9UA>,,TX-RN
MK3Q&+JY]'/\ *?#W'8#BO&8S$858"AD;H3Q&3864LTKYA@*M7Z@E]1_L2?\
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MS_#SX:7%_%Y]E8>*?$-M::I=0$E1<Q:1!]IU0VS,"J7)LQ;R,&5)&*.%]S!
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MQ$(8JK4PM64)T\-*W)3G&$8RF[?%.332:4;1LGS-)I22>I)^I)KP?P__ ,G
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MLUK>G0M,O9O%*3VMJSP[FTR>0PO+$\4C2.C?8GA7_@AC^TIX]TNUT?\ :/\
MVR0_A^/5O[>G\,^#H/%7C4/JLEE!I\D]OJOBNZ\,Z?:R)9V\<2EO#5["67S%
MC60EV_INHKV\)X=9#A[.O4S+&M)IQK8R5&EKNE2P4<*E"^O*W)-[W6AY>8_2
MMXV=.C1X4X,\*. H864W@\3P[P!E.,S2@YM-U/[4XG_U@Q'UG3_>:2HU;MRB
MXRLU^/?PC_X(=_L+_#:2RU#Q7X>\9?&C6K8B2>Z^(WB:;^R;V<G>\ESX<\.Q
M:/I;@OE@&5B>LC2,69OU"^'7PE^%OPATI-#^%GPZ\%_#S2DB$)M?"'AW3-$,
M\0(8+>75G;QWNH$, =]]<W+Y"_-\HQZ%17U6 R7*<K267Y=@\(TK<]&A3C5>
MEO>K-.K-M;N4VWUW/QOB_P 4?$;C^;EQGQOQ-Q)3YN>.%S/-\97R^E)-M/#Y
M8JL<OPRBW[L</A:48*T8I122****],^#"BBB@ HHHH ***DBBEGD6*&-Y9&.
M%2-2['/LH)Q[GCWH;25VTDMV]$OF"3;LE=O1);M]AUO!)<SQ6\2EI)I%C0#U
M8XR?0#JQZ  D\"JG[1-]!IWPMFT8#=-KVK>'-"LXP5WL8M1MM2F8*<96.STN
M=F('!*@?,R@^GZ!H0TQ6O[\QK<"-B S#9:Q@$N[N3MWE0=[9VQKD9ZFOE77=
M<;XX?%?3[31"USX'\"2RQ6U\J@VVL:Y,RK?ZA;L=V^UMHXTLK*==@E4WLJB2
M"XA<^)C:\:LU&#O"%_>Z2D[7:[I)63ZN_2S?MX*A*E"4IJTYVTZQBMD^S;;N
MNEDGK='T[\.K1K+PMI<+##+:P@@]02@Q^&.E=W5.PMEM+2"W10JQ1JH Z< #
M^F.IZ=<5<KB.T**** "BBB@ HHHH CF!,4@')*D >YZ5\O?&K]KK]F#]FY=*
MTS]H'XR>"_AE)XKFUV70[;Q5=7=J=8@TZ\A-^]IY%I.)$M?[0L?-.Y<?:8L9
MR<?4O6OY;?\ @X[\,V=U/^RG?R6JLCP_&*W>0H"#(DGPXE12V.&V,3CN,D>H
M^W\..%L-QIQED_#.+Q=;!4<S>.3Q.']G[:$\)EN,QU-0]K&<+SGAHP=XM\LI
M<MI6:^'\2.*L1P3P;F_$V%PM'&5LM> 2P^(]I[&I'&9G@\!/G]E*$_<ABI35
MI+WHJ]XW3_6G_AZ3_P $QO\ H['X-?\ @VU3_P"5](?^"I?_  3%ZG]K/X,_
M4ZOJG_ROK^!4^%]*(XMHO^^%(_'*U$WA73,$_9H<_P"Z/7_=Q7]3R^BWE,4O
M^,FSO=?:P?E_U"]-;>GI?^6%]*/-6TO]6<DUM_T&=X_]1/KO;;7JC^^[_AZ7
M_P $P_\ H[/X,?\ @WU/_P"5](?^"IO_  3#'7]K3X,>W_$WU3_Y7U_ 6_A?
M3,<V\77LJ^_JE5W\+Z5G_CVBZ?W%X_\ '>?RK-_1=RKIQ-G7_@6$[+_J&[W^
MY&T?I/YJVD^&LD\],9_=_P"HFW??Y]3^_O\ X>G?\$P?^CM/@Q_X-]4_^5]'
M_#U#_@F#T_X:U^"_';^V-4_E_9]?Y_Y\+Z9VMXOQ5?Z)4+^%M,R?]'BSQ_ O
MH.^W^E9_\2P94O\ FI<ZVOOA/[O_ %#V_'HK7MKK'Z3>:2_YIO)>G3%_W>^)
M]?N=[:G^@&?^"J/_  2_'!_:V^"__@WU3_Y7T?\ #U+_ ()?8_Y.V^"^.O\
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M6_\ !OJO_P KJ3_AZO\ \$NAU_:Y^"H_[C&J?_*ZO\]]O#.F-T@AXSD;5_\
MB:@?PSIG3[/#[_*N.W0[>>O.1Z5#^C1E25_]8\Z7SPGEVP_E\K(UC](_,FTO
M]7<G5[=,5_=OOB/7\?._^A-_P]8_X)<CK^UU\%!_W&=4_P#E?1_P]9_X)<_]
M'=?!3_P<ZG_\KZ_STSX9TP$#R(.?]A3_ $%1-X<TW)'D0^G"+W_X"3Z?C6?_
M !+5E?\ T4><??A/+_IQ_5O0TC](O,G9?ZO9/?3IBO+_ *B=O^#W9_H8?\/6
M?^"7'_1W7P5_\'&J?_*ZD_X>M_\ !+?_ *.\^"G_ (.-4_\ E=7^>2_AS30<
MF"+!Z91?ZK4!\-Z;C_CW@Z=E&?P^7\JS?T;<L6W$6<=/M87M%_\ 0.O/IT7;
M7:/TA\QE_P T]E"VZ8KK;_J(_P ]GW9_H>?\/7?^"6O_ $=[\$__  <ZI_\
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M/C)C'_S)<LW72O\ W7_S^Z;/_AT_])$_\%</^"4P.#^V/\#O_!UJO_RNIO\
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M5VT2QR?W46,]=B__ !/_ .NLWX+8)?\ ,ZS/IUH=;?\ 3KII]U^AK'Q,KO\
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M\(_%7C;Q'X=U2_\ AS\._!7PDGU+Q-X?\16%_P"%6NM6M1K<>H7ES!'8KL?
MGP?^R9=^$M!^-$W@GX;>(/AEX ^)GQD_X)IV37-AX?OV\0VWQQ_:8LHOA/\
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M[G5SX?ATJ^UNX@TNXUXZX-+UW^R)O#^GW=YK5G?_ -A:[]GO;&V8Z+JP_P!
MN.:M@\-B*E*O5I1^L4.;ZOBH.5'%X?FMS?5\71E#$4'*RYG1JP<K:W/,S/)L
MISFDJ&;9;@LQI*_+'%X>E7Y;[\CG%RA?KRM'YO?\.4_V1/[GB;_P'\)__,Y2
M'_@BE^R&>J>)O^_'A/\ ^9RO5M(T#]KG2XO#OB+Q=?\ CQO$\FN?LSVOC#0O
M!WB2U\1^#M0U#2)/$FC_ !XO-*LM7M()]+\":I+#I'B&&2PL/#NI7MG-8!K"
M"1[_ $Q.?^+S?\%)-9\<^/['X;>"_ FA:!XRM/"OACP!JJ_&F^&@_#_5O B'
MQKK_ (^U[S?A$VL#0_B%<7-O\-[6PTO2]9U/49+"];5=$\.:5+!X@DTY,3_T
M-N(O_$FXA\O^IGY(^<7AOP&MN%,F_P#"2/EY^2.'_P"'*'[()ZQ^)3_V[^%/
M_F<I/^')W[('_/'Q)_X#^$__ )G*^V?&>K?M:7EGXQUGP7X;^%-EX?U/X'SW
M'@'PEJ]_XEA^*VD?'G5=/MAINE^+-<M?MW@2+P+HU[=31:KJ.DVM]JL;69N[
M6&]@'D2_,9^*'[>?PE^'&G1^/?#?PUU"?PY9:'X)O/%D^B>,/B'J&I:Y:>(/
MA]I<OCF]O?#&O^$]0\6Z?XA\.:OXREC@M?AUX+O8_$?AZ'4KN)+/45T5U[/$
M?]#;B+_Q)N(?_GGY?GW8_P#B'' J_P":6R?_ ,)8^7GY(X+_ (<G?L?_ //'
MQ)_X#>$__F<I/^')G['W_/#Q'_X"^$O_ )FZ]:'Q"_X*$S:=I*Z+\./ +1P6
M/@G5KB[U31+FXN]:AO=6\'MK%H=1G^).EFW?5M-U/QI]LLW\):9JO@2'PI92
M3?V_/XFTZ.TNP_$G_@HVO@%/$%[\)O@:?%YTN^BD\+:9I?C2ZMQJL5G?ZC8:
MK#>ZA\1-(U"2SO)+6R\-/X9GTBTN+;5=5369O%B:+I]PLQ[.O_T-N(?_ !)N
M(>EO^IGY(?\ Q#G@;_HELH_\)8^7GY?U=GBW_#DK]CT_\N_B/_P&\)C^7ARC
M_AR5^QY_S[^(_P#P&\)__,Y7TU:ZO^VIJVC>,;35?#/A30H+H^.K/PN-,C*>
M,[&:'6)-1\'ZU/XBD\;ZMH$MC>Z6PT.30HO#<=Q:RK'J!\0-#&;.7S.\O?VN
M_AEX0^%/Q-U#3M;\=>-= ^ GAOPUXU^'VJ^*KO\ L/Q?\9O$'CGPWX>BBDL=
M$U!--@U^.TUJ\U&3Q-+97FC0:9IMY%>)#)+;:EIZ]E6_Z&G$'_B2\0>7_4S\
MD'_$.N!E_P TOE'_ (3+R\_)'F'_  Y)_8[_ .?;Q%_X"^$__F<I/^')'['1
MZVOB$_\ ;KX2_P#F;KZ!\(?%K]N7Q#XO\-02_"7X8I\/Y?C'XD\*>+O$6IZ7
MXI\,:K;_  ]\/>*[_0&U?PWIJ>-_%LMW?7NDZ=<>(M.\1ZW;:1HE_(;;1$T6
M![VUU23-\;^&?VK_ !1X&U?0_ _B'QOIOB"T_:8^*%];:]XHU&'P[?W?PA7X
M5?$:X\$16T_AA]#$F@Q_$J;P;9:+9QQ1-,EK82^(;2\T\ZF]P>QK?]#3B#_Q
M)>(/+_J9^2&O#O@=;<,92O\ N67EY^7]79X?_P .1OV.3UM/$!_[=/"7_P S
M='_#D;]CC_GS\0?^ GA'_P"9NO;/#WQ4_P""A\UG?2>(/@9\+K&X$GCT>&["
MVFU75[R]&FZ3X;E\!:9XWU@^,?#.E^'+O4;BZ\2W_B#Q1X4TCQIH>H2:5!X;
MT;0](O[JSOKS'TOXO?\ !0K7)KFP/PJ^&>G:EX93P2WB$V/A+Q ='U?4=1T/
MX9Z[K&G:%J_B3XJ:3>BVO6\3>,]/NT?PX]QX+7PU UWJVO7DX@F/8U?^AGG_
M /XDF?\ _P \A_\ $/."%_S3.5?^$_I_>\E_39Y4?^"(G[&Y.39^(/\ P$\)
M?_,W2?\ #D/]C;_GR\0?^ GA+_YG*]U\2:Y_P4 \=?"7QCI.B>$/AUX/^(>M
MZ?X:TGP-K37>K?#]-)U>]\<^-UUWQAK]TFO?&&ZT70]$\%Z%X*=?#5IH/B76
M=5O?$UW<O?6:/+H6C<+X8_:1_;C\9S^,E\,_!GP@FI^&KK7-*/@W7_"WB2";
M3=;TV[\7Z?H^BZQXXN?'OAW0[Z/58=%LM;N_&7A?3O$6F&[0>$F\,Z"FM:5X
MRE/8U7OF>?\ _B29_P#_ #R\E]P?\0]X)_Z)G*O_  G]/[WDC@O^'('[&G_/
MAKW_ (!^$?\ YFZ#_P $0/V-#Q]@U[_P#\(__,W7MOC#QE_P45L%\56OA7P%
M\*]5U2;S]'\/:Q_8NHQZ5<32>'O%,NE>(--T"^^*?E:*NGZ[+X:&OP>)/$UW
M::G8Z;J0TUX=1U/3-+30\2>*/VY= ^*MOXWT3X?Z%XT^%-UX!^&OAJZ\+P:P
M=*\0+XL?6O"6K?$+Q=!\/;V6.#1S#HFL^.=.TZX?XI:W<_:=!T'2+CP[>K"V
MKZFO85?^AGGW_B1Y_P#_ #R\E]P_^(?<%?\ 1-97_P""/3^]Y?U=G@'_  X^
M_8R_Z!^O?^ ?A+_YG*/^''W[&7_0/U[_ , _"7_S-U[=I7Q+_P""AUC'J(US
MX3?#S5KM]+\5ZE9067AN2UM+2_/A;6;_ ,.::-2B^,\GVFVT?Q5'X7T2[LCI
M\VI>+=/UO5;W3]8T.3P[=^9JIXS_ ."@E_:>"[[4/ ?PLT./4-9GA\8:)HN@
M:GJ&IZ7IED;_ $R$0:S>_%9(FC\4WE[H^MVNH0:,9_!NGZ1J5OJ=AXF.I))I
MA["I_P!#+/O_ !(\_P#_ )Y#_P"(?\%_]$WEG_@A^7][R_J[/GO_ (<>?L8?
M] [7?_ +PC_\S=)_PX[_ &+S_P PW7/_  "\(C^7ANO4O!GQ!_X*.:!X1\.:
M5J/P@\%^,-<L;;5;>]O_ !,PTK4M>UFUTO1KG3M!U76+'XE7=CHFFW5U=ZY*
M?BM'HFJ6MR^EVOAMOAAILURGB6;TK]FKX@?M5ZA\0]2\#?&[PQI4>E76G^*O
MB,_B6/P]J&BS:+I]_P"-_$&B^&/! M?^$W\6V>FSWNG)I.M>'K.74=7NX-"T
MCQ'#K,]M?R:6M+ZO/_H99]_XD>?_ /SR#_B'_!?_ $3F6?\ @E^7][R1\Q_\
M.._V,/\ H&ZY_P" 7A'_ .9ND/\ P0Z_8O/73=<_\ O"/_S-U]0_$5?V@=2N
M?A[<^&CXT:T6Y^/]GJO]DSZI9>7K:^(]7M/A3/K,.F:GI2-I,5G!;?9)]:BU
M'0EM?+EO+.3S$<^&:/X:_P""@<UG/-X8\2:EX>\)(GPPDLM#^)]HOC#XE:C#
M#\1? TGQ-M[7Q+;_ !!T:+PM-=Z'#XUN=+N_$NG>.)_^$>N$TR/3++.F11GU
M:?\ T,<]_P#$BS[_ .>0?Z@<&?\ 1.99_P""7_\ )>7Y]V<A_P ../V+?^@9
MKG_@%X1_^9ND_P"'&_[%G_0+UO\ \ O"/_S-U]K?#GP]^U?X:\$_L_Z<^K?#
M/5KUQ87W[1US\2=3^(6M^,/(O++19;^V^'-]9:G?Z5'K]M<_VVEQ#J\@\+QW
M'V-=(L[2Q\Q*\&^'VN?MV>$_!VB06'@G3?&7B&/7?B!=_$./XI7/B.75-1GF
M^(WAO3/!ECX+UV?X@V^CZ-H]I\/]8USQ-/-I^@ZGHU_+X7BT&ULM$U#49]3H
M^K3_ .ACGO\ XD6??_/(?^H/!B_YIW+?_!+\O[WDCR+_ (<;_L6?] O6_P#P
M"\(__,W1_P .-_V+#UTK6S_VX^$?_F;KTWPWXT_X*.1:5/8WO@?P>LVHZWXL
MUV77=7\)/>W]CH%YXR\3WVGVNFZ5;_&E(M*N+31D\.>%]$\$7,_B.[M--U(^
M,[GQMJ+:5=^$S1_M_P#X*8PZ#X1\#W'@GX=7]M;1:"_BCXE65_JFC>/-3LK-
MOA9KNJ1:;I\FO^(_#MIKEG;7_P 1?#>ISZI=QVGC:?0TGT.T\+2W5M97I]6E
M_P!#'/?_ !(L^_\ GEY+[@7 /!JVX=RU?]PI>7]_R1Y__P .-OV*_P#H%:U_
MX ^$?_F;H_X<;?L5_P#0*UK_ , ?"/\ \S=?0C_$?]OY["ST71?@]\/;#5M/
ML-#FOO$WBRWNM<TO4O,\!^%]7OK.VL](^*'AZ]DU5_&+^+?#5S=R306NEK!I
M6H?9-3B#C4+'Q,\6?M[2^&/!.G>%OAQ\/?\ A(3XZL?^$FUGP[J>H6RZ]HOA
M+XT:,GERZ?J^NF/X6^'O'OPQTV_U:^NQK/QFU"*SU:[\.?8M.U06NHNOJLO^
MAAGG_B19]_\ /(?^H7!W_1/9=_X*EY?W_)'SE_PXU_8J_P"@3K/_ ( >$/\
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MU:'2H9O$7A;4]5MGM+FX:P\,SRV$J7)]1A_T&9S_ .'_ #S_ .>(?ZD\*?\
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M];_Y:?.'_#A[]A?_ *%K4/\ P5^#O_F:IO\ PX;_ &%3_P RUJ'_ (+/!_\
M\S=?5EOXK_;:\7?"_P"/$?CGX>^&?AMK=OI7B6#X5W/PKU^[OOB1'<+H,\WA
MN)-,\0:/XH\&ZYJ5_J_]GI?:K9>(-+L-*M;^[M;>&XU+1Y;J3Z5&H>-?M_P&
M22/5H$U*WU$^/[=X,F.XC^'U]<Q1:RRATMWC\1)"JL)0CWP1$=PPRO[/I?\
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M6XURU-SI-N9[BX33+:*6X%]_:$5U;SV,+VTB@ POV>?$W[8NL:^MO^T=X/\
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MGR:A BWWA7PMJ7C;3S+=1K<^$)+36-R+,T,0!YWH'BO_ (*(W6A7GCZ3P?\
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M_9DN--UK3;;X9Q:,FOZ5#HNI7OA[Q1XST'5)=/M-%7PYI\":GI?B&VO$33-
MCBT734\TQ6>DQ1Z7#&NGK]F-S3OV-_V=-.TKPOH__"!7&HVW@O4K_7/"\VM>
M,O'.L7VB>(-6MI;+5_$.F7FH>)9Y].UW5;.>:RO]3L&MKF;3W_LT.NG1Q6L?
MT]10!\P6'[&'[,6EQ>'8-,^$NBZ=#X0U.#6_"4-AJGB6SB\+:S:Z:^C6VK^'
M([?6XTT/5+;1Y)-*@U#2Q:W<.FN]C',MJS1&O:?L2_LKV%I%86/P;\.V5C;Z
M%K7A:"RM+WQ#;6D'ACQ)<W]YXB\.0VT.LI#%H.OW>JZI=:UH\:+IVJW.I:A/
M?VUQ+>W+2_4]% 'SMI?[)W[/^AV%KI6B?#^/1]+L;&[TRRTS2O$WC'3M/L]-
MO]6T[7K_ $ZULK/Q##;6]C?:[I&DZU>6D,26]UJ^EZ=J4\<E[8VL\5R^_9@^
M!^IV6MZ9J7@VYU#3?$MI-8>(]/OO&'CB[L?$%A<:K>:[<66N6EQXEDM]6M)]
M<U"_UF:VOX[B&75KZ\U*1&O+J>9_?:* /G2P_9,_9\TJVL[+2_AY#IMGIUVE
M_I]II_B3QA96MA?QOHLD=[96]MXABBM;R.3PUX<=+F!(YT?P_HC*X;2; V].
MQ_8[_9MTRRU+3=-^%VG:=IVLR"76-/L=;\56ECJTHU6'71+J=I;Z[';W\@UR
MW@UD27<<KC58(=1!^V1),OTO10!\K#]B/]E5="E\++\&?#8\,33V]U-X<%YX
M@&@RW-I?7>J6MQ+HXUC^SI)[;4[^^U&WF:V,D-_>W=Y&RW%S-(_2R?LJ_ 6;
M4;+6)? C2ZOIB^)$TW59/%7C234M/3QE"MMXP6QOW\1FZM%\5VZ);^)5MY8Q
MKT")%JHNXU51]"44 ?/,'[*GP$M;;2K*U\!FVL]"TG4= T.T@\4^-(;;1M"U
M>SNM/U;1-)@C\1+%IND:I87U[8ZCIMFD-E>V=Y=6MS!+!<31OSTW[$W[+%S;
M75E<?!SP]<6=[X=LO!]Y:3WWB&6VN_".FW_]JZ=X5NK>366BG\-V&J?\3*RT
M*5'TNUO_ /3(+6.Y_>5]3T4 ?.^J_LH? '7=-FT;7/ "ZSI%Q+J4]QI6K>)_
M&6HZ;/-K$=G#J\TUC>>(IK66758M/L(M2DDB9[^.QLTNFE6V@"8-]^Q-^RSJ
MDM_/J?P<\/:C/JM_HVJZI-?7_B*[EU+5/#MF-/\ #VI:A)<:S(][?Z#8*MCH
MMY<M+<:59J+6PDMX $KZFHH ^;O!O[(/[-?P]U'PAJO@GX1^&_#5[X OKS4_
M!!TN75X;;PI?ZC9#3=1NM!L#J36&F2:CIRKI^H?9;:-;ZQ5;2[$UNJQCZ1HH
8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>earlydeliverymort.jpg
<TEXT>
begin 644 earlydeliverymort.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M%^S#X5^-N@?$[QE<^&T;QA9MIT":M:ZO;:1)$D7BV,P7^HZLEC;?V:JV]S-
MX@\MFUS+@+.LOI8VK#V6.C@)VQ/U7VB4*,<EP&>5J\95X4E4C0PF84E5I0YJ
M\73JU%3=&/M#++N-\GQ]7!TI>UP<L="^'^L^S;E5EF^-R:C0<:,ZKA*OBL#4
M]E4GRTI*=.FYJM+V9]]45^;=C_P4J^'>K?"30?BAHGPT^(.OWWQ%^,&M_!KX
M+^ M%.C7?B;XKZWHES!:W&NZ/)+>VVFZ9X92>;RKK4=0N2UG.A@>&25XU;7A
M_P""A_@JU^$?Q_\ 'OBKX8^//!GC[]F>?0K?XJ_!?79]!/BS3O\ A)M0L;'0
MK[2]6L;^[T/5='U-;U[BTU**>-9H[29DA:&6RGNN67 O%D6XRR:NIK'0RYT_
M;83VJQ53&T<MBG2^L>T]@LQQ%'+ZF,Y/J=+'5%A*M>&(O373'C7A>24HYO0<
M'@IY@JGLL3[)X6&#JYBVJOL/9^V>7T:N.IX3F^MU<'!XJG0G0M-_H;17YRZ+
M_P %$]"OE^">LZ_\"_BWX$\!_'OXCZ#\-? ?C;QG:Z5H]I>ZEXDT?3M1T76_
M[,>Y>^/AW5[N^FL='U ^6^IP6%SJ4$ MMBGZ(^&'[26B_%7XX?'CX+Z!X5UZ
M#_A05QX6TSQ)XVNI]/;P_JVO>)]/DU%-%TF&":2^%SIL4%U%?/<QQ*D]M(@7
M#1L_)C.$^(,OI5ZV+RZ=*CAL+4QF(JJOA*M.E0I9A1RJJYSI5ZD55IYAB*.$
MJ8>[Q$*M1*5))-KJPG%&18ZI0HX7,(U:N)Q,,)0I.ABJ=2K6JX&KF=)0A5H0
MDZ53 4*N*IXBWU>=.#<:K;2?TE17XX>"OVV=)^&_[?O[8_P]_:#^.^F>$?A?
MX7L?AW#\+O#_ (QU*UT_1[#4;[P[HNHZY'HI%LLKS.;MKBY62:0@7!;!&-NY
M^QG^UEK7Q)^*7_!07Q;J'CWQ!\6?A%\+?%&DZM\+=.\+V1\2NGA1E\>7KV/@
MC3-+M$O]7N=6M],L+73[-6FENY8+2-"KO)(_MXOPZS_"8+&YC."E@\)DO#F=
M4\0J&,C0QT>))Y53PN"P>(GAXT*N,PT\VI1Q4/:*$70KJ$Y\L>;QL-Q]DF*Q
MF#P$)..*Q6<9]D\\/*OA'7P<N'XYE/$XS%T(8B=:GA,1'+:DL-/V;G)5J#J0
MAS2Y?USHKX,^$W[<@\<?%OP7\'OB/\!?BE\"/$/Q2\(:MXX^%TOCZ;PY<#Q/
MHFBQRW-];ZI8:1J-QJ7A37H[&":\.C:K;/-$D?E7,L$\UM'/@?"__@H3IWQ=
M\7Z?!X*_9Y^.&M_"+5OB+>?"VQ^-NC:3HNNZ!:^)K.40O>^(_"^C:I>>*_"_
MA-G>&1O$NL6,%M;6]Q%->06Y6XC@\NIP5Q-2^LN>6VAA<+2QE6O'&Y?/#2H5
MYXNG1^KXJ&+EAL76JU<!C:4,-A:M;$RJX/%4U1<\/5C#TJ?&/#E18?DS&\\3
MB:N$I47@\?#$1KT886I6]OAIX6.(PM*G3QV"J3Q&)I4</&GB\-4=50KTI2_1
M*BOS)_X*J_%?XF_"+X"^ =:^%7CW6/ASKVO?'#P7X2U#Q#HIM!=+H>L:1XH-
M[ _VR*2+R1-;6MVPW0YDM(]THCWAO#OAI\?/B;^SM^V;>_ 3XB_M-)^T=\'+
M[X'^)?BWXD\6:UINAKKWPGD\*:=JNJW<NJ7WAR2ZVV=Q9Z*^;*YGG^T+KND&
MWMK:X"&\]++> LPS7AY9]A,=@G4G1SG$T,I=/,'C<3A\A^J/,)TZM+!5,#&I
M&.-HRH4*^+I5,2^:G14ZO+!^?F/'. RS/_[#Q6"QBA"ME&'KYFJF!6#P]?//
MK2P$*E*IBZ>-E3E+"557K4<-5IX=6J5G&G>:_:>BOS9^&7_!2?P;X\\8?"S2
MO$'P6^+WPR\ ?'G6;[P_\$?BOXRL=$7POXYUBUN?LMI97%MIVIW5_P"'Y-<F
M*1Z&URMW'?M-%)NBM?-N8IOBI_P4@\(?#[QM\5- \-?!;XN?%7P=\ [G3[/X
MY_$SP59Z(?#'@"[O9'2XM(HM3U.TO-?N=&6*=M:6V%I%8"VNG:=X+::=.-\!
M<7+&_P!GO)JJQ7L/K%GB,%[%06,67.#Q?UGZHL2LQ:R]X-UUBUCFL&Z/UEJD
M=?\ KOPM]3^O_P!KTOJWMUA[_5\9[9S>$^OJ:POU?ZT\.\ GC_K:HO"_4D\7
M[;ZNG47Z045\#_%G]O\ \ _#GQ'\$/#WA?X??$+XQS?M"?#_ %#Q]\,C\-M/
MM]3O-;MHK"&_TBP&F7$D%U"VJ0SQRW-]/Y5KHMJEQ=ZCM2VE5>:^('_!1/2O
M"'B/QWH?AOX _%[XDV?P3\/^'=>_:%U_PG_PC"Z9\(GUW2SJ\^AW!U/5[.3Q
M1KN@6D5V==M-'"P69L+X_:F2RO6M<\/P1Q3B8X:=+*:BCC*-7$4'6Q&#PW-1
MHXY99.=18C$TG0OF4HX"E&NJ<J^,E##48U*TXP>M?C+AK#2Q$*N:4^;"UJ5"
MLJ5#%XBU6M@O[1A"G[##U56MEZ>.J2H^TC1PD98BM*G2C*:_1VBOSU^)_P#P
M43^'O@;Q1\$_"_@_X<_$?XRW/[0'PWG^(WPU_P"%<6%GJ%[K%JT-U-IVEMI5
MU/;W<$]PML\FH7<NRUT2U2ZNKX[+.=1[5^TY\?[_ . ?[+/C_P"/3>'##XA\
M.^"=.U33?"NLR!Q9^*_$<VF:1I&DZR]I(HEATS7-9MDU<6DJ--;VETMM*KO&
MPYGPGG\:^2X>KE\Z%;B'%1PF4TZU6A"KB:\L:\OLZ+J.M0C'&1G0G.O3IQC4
MA-7O%VW7$^1RHYO7I8^%:ED6&EB\TJ4:=:=/#T8X../YE55/V-:4L)*%>,:-
M2I*5.<))6DCZ@HK\&?&%K^WA\(/V7=!_;CO/VL=9\7>+8-%\(_%+QK\$=:\+
M:-#\,9?!OC"YL9Y/"]A#:I'-:7>DZ=KM@+FYLK/3YV-K=I8W=K/%!=3?HAX*
M_;8\'^-/BW\ OA!9>$]=75/CY\ =-^/NBZ^+FP.CZ/H^H:?J=]_8E] [KJ$N
MH1G2KB+SH8?(S)"2?]9L];,^!,?A,-+&Y9C\OXAP="KF^'QV(RMXNG' 8G(L
M/2Q>94ZT,RPN!J5*=/"UHXBAB,/&K2Q-.-1TGSP<#R\NXUP&*KQPF8X+'9#B
MZ]+*L1@L/F2PM26-P^=UZF%RZI2GE^)QM.%2IBJ4L/6H5Y4JN'J.'M%R34S[
M6HK\5_VE/^"F'C9/V7?B=\5_V??A[XBT+6_A]\=+OX,ZOXI\0P>%]<T3P]<Z
M!JOAZ.YU;4-+GNG>YL/%::NVC:.L-O)<VE_F6Z-N@AD?ZN\<_MRCX<>#O@A!
MKWP.^)=]\>?CO/J]GX+_ &?M/G\-2^,W_P"$>GDCU/6=9U.#4IM"TG17LA;:
MO#=":XD2SO5-Q;6Z6.J26$U?#WBFC0P566"H.KCLPS'+:>"CCL']<H5LKP=#
M,,96Q=-UE3PV$I8.O]8J8JI55'#T:<JN+EAZ57"SQ%4^/.&JM?&4HXRLJ6"P
M&7YC/&/!8OZI6HYGC*V PE+"U(T74Q&*J8NBJ$,-3I.K7JU(TL*J]6GB84/O
MJBO@^S_;_P#AI8_L_P#Q#^._Q$\#?$WX7O\ "WQ++X(\6_#CQ;X=%MXS?QF;
MB"TTW1/#1-Q%I'B.'6;BXC33]5M;^*Q1([N6_:Q2TG*R?!K]N?1OB1\0=5^$
M?C[X0?$KX%?%"'X>R?%3PUX4^(,>D2?\)GX&196?4-#U'2[R:%=2M_)E^VZ1
M=Q0S6OD7B^;++IVH16OGRX-XFA0Q^*EE-;V&65:M'%S57#2Y98>&'J8B5",:
M[GC*.'I8K"UL1B,''$8>A0Q%"O6JPI5:<Y=\>+>'9U\#AHYI1=?,:5*MA8.G
MB(\T:\Z].A&M*5%0PE;$5<-B:-##XN5"O7K8>M1I4YU:4X1^[**_(73/^"OG
MP\N_ G@WXKZA^SW\>=)^$WB+QF_@36_B-)I&BWGAWPYXA>ZO(K:RM7M=3:[\
M3S?9+*34+Y=(M]EHI.GV\M_K$<NG)]*?!S]N?PQ\3_C3XJ^!?BGX5_$[X*>,
M=$\#?\+.T2'XHV&EZ6_B/P"D\,,^N/;6.H7KZ%- +B*>73M1D:6*%;J.XE@O
M;*ZLXNK&\ \7Y=1Q6(QF2UJ5+!PQ,\2UB,%5G2C@Z]/#XQ>RHXFI5G/"5*M%
MXFG"$JE"E6HXBK&%"K3J2Y<'QQPKCZV&H83.*-6KBYX>&'3H8NG&I+%T9U\(
M_:5</3IQABJ=.JL-4G.,*]6E5H4I2KTJE./W-17YG^&_^"F?@37]4\':]<_!
MWXL:%^S_ /$;XA-\+O ?[1>J6NA+X)UWQ:;^^TNV:XT:'5)/$>D>'K_4=-O;
M6SUZ\M#$98)DN+:WDM+^.SZ/QA_P4#T_2?BQ\1_AI\/_ -GWXU?&:R^"^J:-
MHWQ<\3_#JPT#4IO"]]K<ABB31O!DVKQ>+O%\5G(LT>HSZ1IJQVS6UR^Z2V1+
MB27P)Q9&O+#SRBI"I##U,14=3%8&G1HQI8FC@JM&OB)XJ.'P^,IXS$4,)4R^
MM5IXZ&*K4L/+#JM4A"5QXUX8G1C7AFL)TYUX8>FJ>&QLZM657#U<93JT</##
M2KUL)4PE&MBH8ZE3G@IX:C5KQQ#I4YS7Z&T5RWB+Q;9>&_!FL^.+G3M?U#3]
M%\.7OB672=&T6^U'Q/?6UEI\FHG3M,\/11C4+S7+E$^S6FDK$MU-?/':E4D)
MQ\9_"3]N4^.OBYX%^#OQ&^ 7Q5^!/B'XL^$M8\:_"F;Q])X>N!XIT?0[>6^U
M"UU6PTC4)]1\)Z_%IT$U\^C:M TT"(L-U+;W%Q:Q7'D8+(LUS'"XW&8+".O0
MRZG5JXMJMAX584Z%&IB<1.GAZE:&(Q*P^'I5,1B?JU*M]7H0E5K<E-<QZF,S
MK+,OQ&#PN,Q2HUL?4I4L*G1KSI3J5ZT,/AXU*].E.AAWB,15IT,/]8JTO;UI
MQI4>>H^4^]:*_)?4/^"L_@73O#7B+QU)^S]\<+KX>> _B5>?#GXC^/['3M$F
M\+>$+F/5[?1["].H2:C!_:\^H3W$<K:991J]A'-917=VEWJ5A;W'O_Q:_;G\
M.> /C!I7P3\$?"CXG?&[Q>? <?Q0\8I\-K+2KA/!/@&X$;VVKW2:I?V4FIZE
M<030W=OH5IY5W<0W5A%;237NH6EI+[%7@+BVC6IT*V35:=2K3QM1.>)P2I4H
M9='#SQKQ-?ZS['".C#&8.?+B:E*=2.+PLJ49K$4>?R:7&_"U:E4KTLWI5(4Y
MX.FU'#XQU*D\PE7AA%AZ/U?VV)5:>%Q4>;#TZL:<L+B55E!X>LH?=-%?G1_P
M2Y^+GQ!^-O[+-OXZ^)?BO5_&7B.?XC>/-,36-;6%+_\ LG3KZUBTVTD2&WME
M1;>)VPC1!D9V4X 55\+^!_[<GA7P1^U!^VYX)_:2_: T7PUX>\*?%+3]'^$V
M@^-M5M-/MM-T>"?Q(NJVVA!;5)'@A']E17'FRR%56V/WFE=]ZO ><QS'BW*\
M/R8_&\(-+%T,%1Q>(K8YO-,-E<OJ-&GAW5G[.IB57G[6%+EH4ZDG[RY3&GQM
ME+P/"V8XCGP6$XJ3>%K8RMA:%+!_\)N(S*/UVK.NJ4>>&'=&'LIU.:O4IQ6C
MNOV+HK\"/A_^UWXW\2_LM_\ !0+XJZY\:?B'J6@> _V@9-&^&7C7P"WAV[\0
MZ%X&U+Q9H\.A6WA)M7@L],DTJZL]1MX9'N)8KLZ1-,]M=1WWERG[T\2_MMV'
M@F[^&?PP\%_#3XF?'OXHZU\"]%^-.OZ5HESX1TC4=&\!?V79F3Q#XFU+5M1T
MO29?$.K7)D\G1=%@E6[O69(6MHIK8/OF7AUQ!E]>>&A&CC*U+&8C"5E3E+#4
MJ#PF4Y3F^(K8C$X^.%P^'I4:&;T*51UZM-PKQ<6K5*+J8Y?Q]D6.H0Q,Y5L+
M1J83#XNESQCB*U98K-,SRNA2HX; RQ6(KU:M;*ZU6FJ-.HI49*2?N55#] Z*
M_"+XG?MZ?%SQ'X>_8<^..@M?>&_ ?Q@_:-\2Z?)\/_A4U[XM\5>,/ACX?U;P
MUI4'A#Q1I]]IUJ+GQ_<:M;^(-(N](T&7^R1)=0)::I)O^U1?<'PR_P""@_PY
M\6:+^T3??$CP1XX^".N_LQ6MKJGQ-\)^-(M-O]7M]&U.UN;G1;G3&T2[N;>^
MO]5>U^Q6^F(X=[V[T^.VN;N&\CN!&8>'7%&7X*AC'@XXOGJ8BABL/@ZL,1B<
M%BL/G<^'Y8>K1C+VE>;S.-/#N>#CB*-.IB,/3JU(5*U.,JP''_#>/QE;!K%R
MPKC3P]?#5\73G1P^-PV(R:&>QKTJTER48K+I3KJ&*E0K5*="O4I4YTZ4Y1^_
M:*^ _@W^WKH_Q)^(?P\^'GCCX*_%#X'W7QK\-WWB[X'ZQ\0#X<ETWXD:+I]C
M%JL\<(T35KZYT'6FTF>+4XM'U.(R-:R1%IT>ZL$N]3]FS]N#3/VG/&.L^&O!
MWP9^*.E:+X8UGQAH'BGX@ZQ9Z>O@;1]8\,W$$-CI":Q#<,-2UC7(Y&NUT^RB
M=M+M3;27LI^UQA?+Q/!W$F#IXVMB,LE3H9?AZ6+Q>(6*P4\-3P]>IBZ%*I#$
M4\3.C7YL1@<9A>3#U*M2.+P]3"2BL2E2?I8;BWA[%U,'1P^8QJ5\?B*N%PM#
MZMC(8B=>A3PE:K"=">'C6H*-#'83$\]>%*$L+B*>*C)X=^U7W117Y1_'WXF_
M';XY_MG6'[&7P5^*-]\#O"G@KX;1_$WXM?$7PYIEEJ?C*^EU!K9=(\.Z-)?,
MB:; J:GHTCR6\D$DS7U[+<RS165O93^I_ *']J3]GK7_ (XZ5^T[\0K;XH?L
M\>"O#4OCGP#\>->DT6P\6P6.F6<.H>(]#\3:-IT\NI3)9V<E]+%>744Y2;0Y
MC;7D\&KV=I9]=?@ZMALKP^,K9QE%/,\7EN#SC"\/2J8N.:8C+L?B(8?!SH3>
M$67UL97C4ABZ>6TL9+&RP4O;QI-J5-<M'BVE7S*OA*64YK/+L+F&*RG$9]&&
M%EEM#,,%0E7Q4*\%BGCJ.$H2A/"U,PJ82.$CC(NBZBBXU'^A-%?FO\,_^"E7
M@KQYXP^%FE^(/@S\6_AE\/\ X\ZU>^'?@A\6/&5IH:>%_'>LVUT+.TLIK:PU
M2YO]!DUNX:.'1&N%NTOI)H3NBMVDN(M74O\ @H5IDWQ0^(?@;P!^SY\;?BQX
M6^#_ (\MOAO\4_'_ ,/]-T36O^$7\3RW\FF78L_ T6J-XSU_2=+NX+N/4-4L
M-,2.-;*YEABGB-L]S%3@3BREB*N&J914IU*.&>+J2GBL#&A"DL6\O<'BGBEA
M7BECT\#+!*L\8L9&6%=!5XN"N'&W"]6A3Q-/-83IUL0L-34<-C95I5'A5CE-
M898;ZRL,\"UC%C'26$>$:Q*K^Q:F_P!$Z*_*&^_;*^/=K_P4</[.%K\*/$^I
M?"H^ ;6\32K:V\(Q:J1<^);339/C(VLW-]%>+X&L[2=XIM$>:/5Q)'(PTZ2X
M*0CTC1/^"ANE^,/B)XG\.> /V>_C?\0/ASX(^)W_  J'QA\6O"&DZ-K5AH?B
M])UMKJYF\$V6IS>-'\*64I=[KQ,VF16R6\3RQP2.]O#/I7X"XDHPPU6&&PN)
MIXG)L'GGM,/F&"<*&#Q\IPPM+$3JUZ488VM.$H4<'%SK8B:E##1K2A44(H\;
M\/59XFG/$8G#SPV;8O)N2O@,8IUL7@HPGB:E"-*C5E/!T83C*MBY*%&A%QEB
M)48SIN?Z+4445\:?6A1110 5^//C+]B72OCI_P %'?BAX[^.7P;N/&'P0NO@
MUX6M?"WB'4KZ^L-$F\:Z7%X9M9(+>71-:T[4GNH;4ZM"8YT-L?)G++D0,_[#
M45[_  _Q)F7#53,Z^5U)8?$YEE5?*7BJ5;$8?$X2E7Q.$Q,J^$K8:K1J4L0I
M82$(R<I1]G4J)Q;::\//>'\OXBIY?0S.G&OALOS.CFBPM6E0KX?%5*%#%8>-
M#%4<12JTZE"4<5*<HJ*ESP@U))-/\O\ ]N#]FF_N/@G^SY\,OV<_A7#%H/P_
M_:'^'7B>7PKX,L;&PLM!\,Z4=<N-8UF6&2:V$@%S=++?7;O/>W5W=&YN7EDD
MFF'DO[<'[,OB75?VM_ '[24OP?\ B5\>/A?-\);CX8>,/!_P>\67/A;XA^'M
M:T_5M9UK0M>LS9^(_"]WJ>D7;:HMI=VL6IBVB,,\]W'YHLUN/V:HKW,J\0,X
MRJ.7QA"GB'@J?$%*K6JU\=#%XV'$CPTL;*MC*&*I8FGB*57"TJ^&Q-"I3JQK
M)RK.M%RA+QLSX%RG,WCG*=3#K%U,AJTJ5*A@YX7!SX>]O'!QHX2MAJF'J4*E
M/$U*.(P]>G4I2I/EI*E)*2_ 3XB_L2>.?&/[(7P]O/ O[,][\*_$?@O]IV'X
M]ZY^SY;_ !:U?Q+XP\:>&!IEEX>UJ63QMJ=Y:W&A>/-:TW2]/FBL;'4A-86U
MNUS;70U^X^R+W7@#]D^7XK^#/VJ]/\'_ +*_CG]FV[^(7P=N/AUX,\=?&[XJ
M>(/%7CWQCJD]QIFM)I&M>%;S6?$MKH/AJWU?0[&!]8CUF[G-HT!M89-]W;VW
M[@T5Z,O%+/WAIX>-.$)QS*MF.#K?VCGM1X5UL?A,Q="M3K9K4I9K3IU\'%4I
MYQ''U53K5E.=27L)T//CX:9&L3"O*I.<)9?2R_%4?[/R2FL0J6!Q67JM1J4L
MLIU,KG4H8J3JPRF6"IRG2I.,81=>-;\M_P!E#Q_^V-86G[/7P'U;]EY_AIX,
M^&'@V+PG\:OB3X_UG3KFRU&'PIHUMI/A]_A1;^'-<8ZA=:U<6:R7<FH6M]9V
MD=V=K>19-=W?RWX:^$W[;GPF^!G[=/P?^&'PZ\5>&/B#XB^+VO\ Q5^&/Q/T
M'7]%BM_&'A;Q)XG\/P:KHO@V[AO8[_2_%[^%K6_OK=YFL[J(/<6=M)9ZNEF\
MO[V45RTO$">'Q>-Q&'X9X>I4<?BLLQ^*P,H9GB,-7Q^5YO6S>GB:RQ.8UJE:
M->IB*^#K8:K.6&^HRITH4H5::K/IJ<"QKX7"4*_$6?5*V!PV8X'#8R,\OH8B
MC@<QRNCE53#T7A\!2A1E1AAZ.+I8BG&.(^NJ=2=25.HZ*_"C]GKX ?$:U_;'
M^'7Q;TWX _'#X=_#ZW_9U\7>$O$/B/XV^-T\9^,]:\?7EM?_ &J]UG[1XL\3
M7.C#4[R9+;3K19[5+U8_[4.F:8MZ8(^*NOV6?VA'_P""77A[X,+\*_$K?%&T
M_: /BRX\%#^SO[7A\/\ _";:KJW]HL#??9/(^QSQ2_+<D_O <;,N/Z#**[I^
M*>;RQ6!Q2R[+[X#&</XRC&K5S'$.<N'*V=UL'"M6KXVI6J1K//<1'$OVD7:C
M05#V$8RC+BCX992L+C,*\?C^7&X3/<)5E3IY?048\04LDI8N=&E0P=.C3=%9
M'0EAX\C2=:LZWMI.,E^;'B;X3?$>;_@I)H'QC3PEJ;_#'3OV2-8\$WGC+-J=
M*A\5S>)-9OET5O\ 2/M7VO[))%.?]&\HI/'MD8^8$_&K]G[P]\??V@_^";_@
M_P#9-^'/P(\0:KHWQ ^+UQ>I\<!JVAOX$\/:%I7CF+6]=DU^WDNXM8TC6-+U
M.U\E;=[62#4M(8SZ=-<W\GV"OZN)8HYXI(95WQ31O%(A) :.12CJ2""-RDC(
M((SP0:\O^#?P4^&7[/\ X&L_AO\ "/PS'X1\%V%]J.I6NC1ZEJ^JK%>ZK<&Z
MOY_MFN7^I:@YGG)<I)=M'']V)40!:VR?Q+>695"E4RK"XK-,MK\)SR2=58CZ
ME0_U97$E2GC<5[+'4*L\9'$YU0E2H\E7!5Z5.M"O3@U!RRS?P[699G*I3S/$
M8;+<?1XHCG$:;PSQE;_6)\.TYX/#>UP-:E#"2P^35HU:W/3QE&I4I2HU)IS4
M?R6_;O\ @7KWBOQGKTOAO]DSXN:Y\2-*^'.@Z7\"?VGO@#X[LM.\02^*]/TV
M&VMM-^+&ES:KX=?1=)T35(PJZL'UJ^GT:./^S[JRD:(:;WB_ _\ :7O?VD_^
M";WCSXDZ)J'B[5_A=\)O%>D_'+QY8SV-WIVD^+M5\+7]N!JEXLMN;V\GNY(;
M2YOK&VFAO;]WNHBT$K2K^P-%>73\1<RIY9@<L67X&<,#EV;Y;#$8BKF.*Q"I
M9QDM;)<3[">)QM7ZE25*O/&?4L&J. >/M56&C2C&BO2J< 9?4S'&9B\=C82Q
MF895F$J%"E@,-0]KE&;T,XP_MH8?!TOKE5U</3PGUO%^UQJP7-2>(E4DZS_F
M4^-G[/7[7GQ4^'WQS\._$?X(_M!?%'X\S_&R/6_#?CZ;XB0CX*Z;\*K/7=+;
M2M-^'7@Y_&%MI5[=2B.](TV/PLO]FZ7=1:G=:G:7MA-95^TG[:'@#QE\0OV+
MOBY\//!?AZ^\0^-->^'FG:3I'AVQ\C[=?:A'?:+)+:Q>=-% 9(X[>=WW2@%8
MGVEFVJWV/11F?B)F&98GAS$?V9EF$7#6;O.<%A\-]<6&E7DLHOA_8U<54CAL
M#%Y/1]EA<%]7ITE6K<JYY.;,MX!P&78?/Z"S',<5+B'*EE&,Q&(^J/$1H1>:
M<N(]M3PM.>(QCCFM55,3C'B)U'2H\UHQY#\B?V)D\2>!KKX,> =:_P""=5]\
M*/$6C^#K7PGXG_:"DT[X=V]Q!>Z7X2F34=8U&\TK2(/$<\?BC4+!+&9#J4L\
MDNIQ&[DN%65F^ _B/^SO^U[\3_AYXGT?XG_ []H#XB_M#VGQ^LO$&H_$C5/B
M)#<?"&V^'-EJ8&FV/PS\(R>,UTNZ@;$KFUM/"EK%I.GR173ZE#)G3H/Z<J*[
M\%XH8K+LWQ6<X/(,KI8K%U,#7FZF,SW$RC6P6*QF*?L\1B<UJXJ&$Q;QCAB\
MNA6C@*WU;"3>'O2DJG%B_#?#8_*L-E&+SS,ZF&PM/&T8<F$R3#QE1QF&P>&7
MM,/A\KIX6>)POU-3PV/E1ECJ7UG%05>U2+I_F[\*OA'\2M$_X*2_M"_%W5?"
M&J6/PU\5_ KX?^&?#WBZ8VO]EZKKNDVG@%;_ $VVV7+W)GMGT[4$?S+=$#64
MYW;3"TOS=\%?V:?B-I/PD_X*#?LR?&/X>W?A;PK\3/'_ ,7?BAX"^+]]K&B2
M>"]73Q3%I2^#VBVW+75E?:3J&BZ;X@N?MJP>7&L]C<QVL]NK7/[9UYQ\6/A)
M\/OCCX%U?X:?%'P^OBCP3KTFGR:MHCZCJVE)>-I6HVVJV.Z]T2^TW4HUBOK.
MWF98+R)90ABF$D+O&WFX3CS&*K3IXBC1PV'EA.$<!+%X2C6K8W QX1GAU@,R
MP5*>/PM&OCE3I5)5*&(K0PE:=1I?5[0J0[\3P1A/93J8>K6Q%>.+XIQ\<+BJ
MM&E@\;+BF-9X[+L95C@<35HX)SJ0C"O0HSQ5&%--^WO.$_RC_P""/-AXL^(O
MA?XJ?M/_ !#S<^)?&R_#KX-^'KQIOM$9\)?!#P3I/AJYO+&4-M$>O:Z9;K4$
M4,@U'3I%CFD5,UM?'_1?C]\-O^"B^B?M(_#_ /9S\<_&WP59?L\P^ )#X4U/
M1M)C&NW^MZW<RQ->:DT[ V,!MWGC-FH9;R%HY6V2(/U8^'_P^\%_"OP?H7@#
MX>>'--\)>#?#5H;+1- TF)HK*Q@::6XEVF1Y)YY[FYFGNKR[N9IKN\NYYKJZ
MGFN)I)&[&ML;QY"IQ;G^?X?)\+6RW-\#B<DHY/C9XFE2H9'+#8? 8;#<^7XG
M#U:56E@L+1C)T,0HJJZDE*5^9Y8/@B5/A;(\BQ&:XFEF&58W#9S5S;!PP]6K
M6SJ&)K8[$8CEQ^&KTJM*IC,35DE6H.3IJ$7&-N5?C=\,OV3_ (]?'?7_ -LK
MX^?'_P /Z=\'?&7[2_P3UGX$?#OX<Q:O!KUYX(\(WN@VFFQZEXDU&P\VV-W/
M=Z/HDK0V^V=Y!K5S/8VL-S96]?.W[,O[+.OZ!KO[.GP^\;_L-?$^7QU\*O&>
MF:EXX^,7C;XW:[9_"#P])X-US^T-%\=_#K2-,\1:SIGB'4IX;6"6W\.PZ)H]
MJ;DQ6ID:QNKJ>U_H:HK6/BAG<:.8X587"4<'C*6"HX/"8+$YOE]+*J67954R
M;!T,-4P694<3B</2P<XNI1S"OBXXC$T:=:LYWK0JYR\-\G=7 8EXK%5<7A:F
M+JXO%8S#93CZN9U<?F=/-\56Q$,9EU;#X>O/%TY*G6P%#"NAAZM2C14&J,Z7
MX-W?[/W[1?AWP]_P5"^#_P#PICQ'K%E^T!XA\:?%7X5>/=(U'1+G0?$AUGQ)
M:/IWA)+4WR7]OX@GT[5GOGCGBBBMSI&JV\Q!%B]WL_M!_L[?M%:7^SA^PY\1
M/@Q\/M9U']H#X&_#&Y^%WB;PG:S6L&M6'A_XB_""?PCXF6[*W0MY9?#FI0*L
M)BN9OL][?>=;DJTDJ_N7151\3\UCB<%B7E>4S>&Q:Q>*HSCC94,RY^'*'"^*
MH8NF\8VL/C,MH+VU.A*DE6G.=+V<>6"F7AOEDJ&,PZS+-(*OA/JF&JQE@XU\
MN4.(*W$F&K86I'"I.OA,QK/V,ZT:MZ48QJ*<KR?X8?'G]@[Q?I/[.G[!]EX5
M\ ZS\1W_ &7[Q;OXJ?#'P?XA_P"$3\7>)M/\?IH.K?$2[\)ZM;:AI\BZ_8^(
M].NC!'9ZI:W,\=_)/#*R6[)6+>?LU>*/$O[+?[:*?#/]C[QW\'/$/Q/TOP!X
M=\&6'COXGZOXX^+7Q0M?#WBW2M2GO?$6@:WJVJV7A5-&M3*;4+X@OI[R%;B&
M-GAL8&G_ 'IHHP_BGG]*AA*=:E0Q57!YQ_:].K/%YM1IU9RXAAQ/5H8K!87,
M*& Q<*N:*H_:XG#5:U.C6E"G.-2EAJM K>&F1U*^)JT:M;#T\5E7]E3I1PF5
M5ITXQR%\.4J^&QF)P%;'86=/+?9Q]GA\32I5*M*,IQ=.IB*5;\JOVO/A=>W'
M_!,O0+37C;>%?'_P,^%GPC^(VC_VS<V=I<:+XZ^$_A[1;N_TQ+B25HUU66SM
MM=T.&.TG::XNKH6]M(6D5J[/_@EWX9UZ3]GC5_CAXTMHX/'G[47Q-\<?'7Q&
M45PJ6WB759+30+:V$J+)'IBZ78)J&F0[I(EMM3\Z)O\ 2')^O?C7^S[\'_VB
MM T?PM\9_!EMXX\/:#K\'B?3-*O-3US3;:+6K:SO+"&[F_L/4],EO$2UO[N)
MK2[DGLY!*3+;N54CU31]'TKP]I.F:#H6G6>D:+HNGV>E:1I6G6\=I8:;IFGV
M\=I8V%E:PJD5O:VEM%%!;PQ*L<44:HH"@"O.Q7%\*W!M;AV$*SQN/XCQ><XR
MM*C3IX?#8.M"E+^S<)66)JUZ]'$8RCA\=7C5HX>-"MA::INNZDYQ[\-PK.EQ
M=2S^4J*P>"X?PV482E&K4J5\3BJ4JD?[0Q5)X>E1H5</A*U?!T94JU>5:EB:
MCFJ"A"$ORD^%'[*$VN_\% OVS_B5\:/@AH'B?X9>---^')^&OB'QYX7\-^)]
M&U&^TWP_HUCK3Z'%JT.H/:SQO;/;W,BV]N\BV^UF*A ?(O!'[.W[2WPI3_@J
M--\"_ %Q\,]<^(7B#P[=_L[3Z/#HGA[3]5TC3-9\5G5H_!$5I-%9Z3?+X;O)
MHM =HM.CM-3U#3)(9+>5&>W_ ')HK:/B-G"E557"X'$X:KEG"N5O 8I8FO@%
M1X4KY/7PLWA9XATI2Q[R:C3S",DZ=6GB,3&G&ES0<,9>'^4N-)T\5C</B*68
M\2YDL;AGAJ&.]MQ-1S2CB(+$PP_M(QP2S6K/ 23]I2J4,/*I*IRR4_P(_9\^
M 'Q=7]J[]D;XJ2_ 7X]>$M(\'_#KQAI'Q>\??&WQV?%^NZ[\0[[PCJ5KJ6K3
M6M]XP\37VB:#>ZW<"#1I$ATUM3BO!*VB6:6A+9J_ ;XTP_M&_#GQ7\ _V6OB
MS^RK\3(?CG'?_&SQ%H'C_2]3_9A\7?">/5)I=>U"&(:G#)JFH>(+-$>/PW9^
M&M/M8Q++'%"EZ;&;3_Z":*]"IXJ9I4Q53$O*\ ^?)Y9*J%3%YQ6PT\*\5FN+
M2QF'JYE*AF,%4S:I:ACJ=:C2^K87ZK##J%2-7AI^&>64\-3PZS+'+DS:.<2K
M4\-E-+$1Q4<+E>$;PE>GE\:V7SE3RJGS5L'4I5JOUG$_6)UY3A.G^9G_  51
M^"?Q ^/7P(^'_@OX>^"=4\>7MO\ '+P5K>OZ/I30)+#X7L](\46VK7T[3W5I
MMMD^VP6[M#+YJO<QD!5W.GI.O_L!_ 'P[\$?CG\-?@1\-_"WPQ\1?%WX:^)O
M \GB>W&HZAJ8.IZ;<Q:?:7.M:S=ZOJ\&BC4&MY;RPM;@6L@03O:S3118^ZJ*
M^9H<9YYA,GRG),%BJN#P>4YABLS5/#U\3"GC\3B*^!Q-+^T<,JWU7%0P=; T
MY893H^XZE6[;DFOHJW".2XK-LUSG&8:EB\7FF PV7.=>AAYU,%A\/0QF'J?4
M,0Z7UG#3Q=+&SCB7"K[_ +.E9+E=_P !?!_P8_:<^+>A?L+?LW^,/V>?%WPK
MT?\ 9+^(OASQ?\1OBMKVN>'9?"NNZ?\ #QY+72+?P1)I5[<W>KW7B.S=V8I
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M'F@W5G>Z!9VMW'96NDVVCV+W%O;_ .C>39PK%%;AU$ K?'KPU\0[[]I;X/\
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MG+%+ 0:^M*DTU36-E%T^>I)\WMX.%*--\^<(XZK5F^:M!1K6DY14(JC]9?\
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MPK\6_!_PK\2?APWCGPY'X$U+6/&WPP^*OQ D^)?B;P;XDT_Q5X1U[0HI=/\
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M)_T#M4_\%M]_\CT?\)$G_0.U3_P6WW_R/7244 <W_P )$G_0.U3_ ,%M]_\
M(]'_  D2?] [5/\ P6WW_P CUTE% '-_\)$G_0.U3_P6WW_R/1_PD2?] [5/
M_!;??_(]=)10!S?_  D2?] [5/\ P6WW_P CT?\ "1)_T#M4_P#!;??_ "/7
M244 <W_PD2?] [5/_!;??_(]'_"1)_T#M4_\%M]_\CUTE% '-_\ "1)_T#M4
M_P#!;??_ "/1_P )$G_0.U3_ ,%M]_\ (]=)10!S?_"1)_T#M4_\%M]_\CT?
M\)$G_0.U3_P6WW_R/7244 <W_P )$G_0.U3_ ,%M]_\ (]'_  D2?] [5/\
MP6WW_P CUTE% '-_\)$G_0.U3_P6WW_R/1_PD2?] [5/_!;??_(]=)10!S?_
M  D2?] [5/\ P6WW_P CT?\ "1)_T#M4_P#!;??_ "/7244 <W_PD2?] [5/
M_!;??_(]'_"1)_T#M4_\%M]_\CUTE% '-_\ "1)_T#M4_P#!;??_ "/1_P )
M$G_0.U3_ ,%M]_\ (]=)10!S?_"1)_T#M4_\%M]_\CT?\)$G_0.U3_P6WW_R
M/7244 <W_P )$G_0.U3_ ,%M]_\ (]'_  D2?] [5/\ P6WW_P CUTE% '-_
M\)$G_0.U3_P6WW_R/1_PD2?] [5/_!;??_(]=)10!S?_  D2?] [5/\ P6WW
M_P CT?\ "1)_T#M4_P#!;??_ "/7244 <W_PD2?] [5/_!;??_(]'_"1)_T#
MM4_\%M]_\CUTE% '-_\ "1)_T#M4_P#!;??_ "/1_P )$G_0.U3_ ,%M]_\
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MV@7>FWLFGZ?H^NB7;/:RZ[>1_8]/OF=+3[;-:VCGSKB,'COA!_P4!^!OQ/\
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MKCE&4).,DXR3LT]U_73NM4=D91G%2BU*+U33NOZ[K==0HHHJ2@HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_D%7G_7%_P#T%J^@- _Y 6B_]@G3O_2.&OG_ %S_ )!5Y_UQ?_T%J^@- _Y
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M_P @J\_ZXO\ ^@M7T!H'_("T7_L$Z=_Z1PU\_P"N?\@J\_ZXO_Z"U?0&@?\
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M\,]>U)+O4/&?P^U*6"TN[[6O %_=IX5\<^$M31O$?AVVM=&U<I-H&IVD]O\
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M10E*,HW492IU:52,Z&)H5*N&Q-.KAZU6G/@_AE\3/!7QA\#Z!\1?A[K<&O\
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M^'_&/BCX(ZS8V7Q/U?XT^*=#U"#PQXC_ &+O^%7^'/V?+_X>QN[>&_$'AO\
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M&+:&%S=QAA\%B^T:>8PC2RZN[_[W3RWDAS8C$U#[PHHHKYH^B"BBB@ HHHH
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MZ7K7@_QWHVFZIKVI:=X>\2:DGA:WTK7= \/>-=<^'OBKQ?#"?$IU33].\/\
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M\H[ HHHH **** "BBB@ KPS]HGX-1?'#X9ZCX6M-3;PWXST>_P!.\9_##QI
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MY*M*K3IU(M>]"-T%%%%>>=X4444 %%%% !1110 4444 %%%% !1110 4444
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M%?0'SX4444 %%%% &3KG_(*O/^N+_P#H+5] :!_R M%_[!.G?^D<-?/^N?\
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M ,:?"[X@Z):>)/ _Q!\,:WX/\6:%?1K+:ZIH/B#3Y],U*TD#*VQI+6XD\F9
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M 5\:?MD_\@3X7?\ 90X?_3-J-?9=?&G[9/\ R!/A=_V4.'_TS:C6V'_C4_\
M%^C,<1_!J?X?U1UOAK_D#V7_ %Q3^5;U8/AK_D#V7_7%/Y5O5]#'9>B_(^?G
M\3^7Y(****9(4444 %>B^"ON77_7*W_]'WE>=5Z+X*^Y=?\ 7*W_ /1]Y7+C
M?]VJ_P#;G_IR!U8+_>*?S_)G=T445X)[P4444 %%%% !7(^,?^0=!_U\-_Z3
MSUUU<CXQ_P"0=!_U\-_Z3SUT83_>*7^+]&<^+_W>K_A_5'EM%%%?0'SX4444
M %%%% &3KG_(*O/^N+_^@M7T!H'_ " M%_[!.G?^D<-?/^N?\@J\_P"N+_\
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M3-\UPK-'<>;&[HWP5)^P[_P4J_9T_:PU+]H[X ?MA:[^T[\&-(^'NF>%[/\
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M_KB__H+5] :!_P @+1?^P3IW_I'#7S_KG_(*O/\ KB__ *"U?0&@?\@+1?\
ML$Z=_P"D<->9F6U'UG^43U,M_P"7O_;OZFM1117E'J'\SW[.'Q"\'?'#]O\
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M,_\ PM']HS_HUEO_  ]W@/\ ^0:/^%H_M&?]&LM_X>[P'_\ (-'U2K_/AO\
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M\?\ X.>*_A+;6'[:'A*W\2'27276_P!O_4_BEX31](U:SU*WBUKX?>.]6O\
M0/$-FBVSQ6T-T]O-9W#P7]O=+<6L>?:M!_8D^/GA71M'T7PSX^_X*,:-!H>E
MV&DV#'_@H1X(UZ&.WTZUAM("=.\5^!->TW'EPJ?(6U6WC_U4,<<*JBZO*LM]
MC"<,YI^VE4J1G2J4L/!0IQC3=.HYT\?53YY2J1Y8IN*IW?Q*\K&8KGDI8&?(
MH0<9QG4;E)N7-#EEAX-<J47=V3O9;.W[BTUE5P5=593U5@&!QR,@@C@\U^*G
M_#-O[?MB?^)#^TI^V[:1KCRX==^+'[#WBQ$ '1IM3_9NBO9\GDFXNI6[;@,
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MV'ZA?\(3^WG)A9/CW^SM '^^]M\!?&#O$#U, N/BXZ,5/W/.# @#?DYS\/\
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MP=^RCX$\*?"+6=,UGX$/\-/#7BG3/BMXI\-^)[K0OC+?VWC74=4\1ZXGQ?\
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MA?Q##86<2+'%')I.D76U$4!5+7%A(Y(4 99B3W)ZD ^AJ*^1,?M(?]#I:?\
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M+3_PG/#_ /\ *R@#Z[HKY$Q^TA_T.EI_X3GA_P#^5E&/VD/^ATM/_"<\/_\
MRLH ^NZ*^1,?M(?]#I:?^$YX?_\ E91C]I#_ *'2T_\ "<\/_P#RLH ^NZ*^
M1,?M(?\ 0Z6G_A.>'_\ Y648_:0_Z'2T_P#"<\/_ /RLH ^NZ*^1,?M(?]#I
M:?\ A.>'_P#Y648_:0_Z'2T_\)SP_P#_ "LH ^NZ*^1,?M(?]#I:?^$YX?\
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M:.UA2&)0JHH4 # X&/:GQ0QP*$C4*  !@ <#H.!VJ6@ HHHH **** "BBB@
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MPOCNWN[^P,?_  G/AMA#>Z8\<5_9W4J:BT-G=6TTT4$D%W)#+Y\L<"JTKJA
M/8=B?W5_[Y'^%&Q/[J_]\C_"O*&^//P4$2SI\5_AY/ 5M)7FMO&&@7,<-O?W
M4]A97=P\%^ZP65W?V\UC;7<I6WGO$-M%(\WR5JQ?%SX7W&B7'B6S^(/@^_\
M#UGJD6BWVN:?XBTF^TBPU.:!+I+2_P!1M;N6TLY?LLL=RPN)8]MO(DQQ&ZL0
M#T+8G]U?^^1_A1L3^ZO_ 'R/\*\@TG]H3X$Z[ EUI/QB^&E[;2ZQ/X?BGB\:
M>'Q%-K5O<7]K)IL#R7Z":[:?3-06&.(N;E+.>6W,L2%ZIW'[2O[/5J+ S?&_
MX4[=4U";2K!XO'OAFX2XU"VM+J_N;57M]2E1)+:SLKJZN3(42"&"229D4 D
M]KV)_=7_ +Y'^%&Q/[J_]\C_  KRQ?CA\(Y+.ZO8?B'X3N5L[T:;<VUKK>GW
M.HQ:BU^=,%@=.@GDO3>_;08#:K 9U=6W1C:V*LO[0'P0BN;>V;XK_#]A<#5Q
M]LC\5Z)+IEM+H<%C=ZG;7^J1WK:?I]W!::A;78M;VX@GEM3)<11O%#*Z 'KN
MQ/[J_P#?(_PHV)_=7_OD?X5Y'!^T%\"+JXM[2V^,WPMN+J[2WDM;>'Q[X7EF
MN8[N)9[:2W1-49IDG@83QO&&5H=TH/EJS"O!^T5\!KBY%M%\8?AN2\5O+;W+
M^,M CL+T7-[<Z<D=AJ$E^ME?SQ7]I-:7,%I/--:S^7%<)&\B!@#V38G]U?\
MOD?X4;$_NK_WR/\ "O)H_CY\$9K.XU"'XL_#R6SM-5M-#NIH_%NB.+;5KX2-
M9V-PBWADAGNHHIKF 2HJR6<,MZK&TBDG6KJ7[1'P*TB\L;+4/BY\/8)K[4;S
M2@Q\6Z&UO97]CI<NL7%OJURM\;?2&%C$'B_M*2U$\L]K;P^9/=01R 'L>Q/[
MJ_\ ?(_PHV)_=7_OD?X5XS%^T#\*GU=?#[^(I;;6Y/&9\!0Z5=Z1J]O?W'B-
MKW3K*WB@MI+(2O87AU6RN[/5=HTZ?396U);D644DR]!JOQB^%.BZF^AZG\1O
M!5IKR:C/I#:#)XFT8:Y_:EI#875[IZZ1]L_M!KNQL]3T^^OK=;<RVEE>6]W<
M)';RI(P!Z-L3^ZO_ 'R/\*-B?W5_[Y'^%>5R?';X)11VLLOQ>^&<,=[91ZE9
MR2^.?#,27.GRZC;Z1%?PM)J:B2SDU6[M=-CN5S"]_<0VBN9Y4C-BY^-'PFLU
M\,3W/Q$\'Q:?XTM-;O?"VLMX@TS^P=<A\.W>F6.KC3]<%R=*N)K6ZU>RA\A+
MLRRL9O*1_LT_E@'IFQ/[J_\ ?(_PHV)_=7_OD?X5Y9:?'7X*7Z[[+XN?#6[3
M?<Q;[;QOX;F3S;-MEU%NCU)E\R!\I)'G>K*RD;E8!Z_&[X0MHT/B$_$GP4FA
MS:B-(;5)?$FDQ6-KJAM9;PV%_<R7:PV%W'##()8+MX9(I@()%68A* /4-B?W
M5_[Y'^%&Q/[J_P#?(_PKR ?M!_ \7M[83?%CX?VDUC/IEK(]_P"*]$L;6XN-
M8'_$OAT^[N[V&VU*2>3]P$L9;@I<@V[A9E*"UI'QV^"_B#4$TO0OBI\/]8OI
M);.VC@TSQ=H5\9+N_DOH[.RC-M?2![VX;3;\Q6JYG9+6=PFV-B #U78G]U?^
M^1_A1L3^ZO\ WR/\*\JM/CQ\$;]%DL?C!\,KR-S&$DM/'7AFXC8RPO<1[9(=
M3=#NMXWN.#@0*9FQ'\U9\/[1?P&N;NVL[7XQ?#:[>[L[^_AGM/&?A^YL?L^F
M103WADU"#4'LHI8K>X6Y$,LZ2R6\5S,B-':SM& >R[$_NK_WR/\ "C8G]U?^
M^1_A7D&F_M!? _5IK6UL_BS\/C>7\VJPZ?8S>+-#MK[45T6_DTW4+K3[.XO8
M[F]L8[F-3'?6T<MI-!<6=S%,\%Y:R2PZ-^T7\"/$.J3:/HOQ<^'^H7T2PLBP
M>*-(\B]\^.655TN[>Z6UU9DAB\V;^S9KH0I)"9"OG(" >R[$_NK_ -\C_"C8
MG]U?^^1_A7G.L_&/X2>'-4N]#\0?$_X?:%K5A<0VE[I&L>,?#^FZG:W5Q8S:
ME;VUQ8WFH0W,5Q/I]M/>PPO$))+:)YD5D4M6/=?M!?!"TO\ 3-)?XK^ IM5U
MF^&G:7I=GXGTB]U"]O=@D:"&SM+J:?='&RO*715B#QAV5I8U< ]>V)_=7_OD
M?X4;$_NK_P!\C_"O)K?X]?!6Z9X[?XJ> IY0L,D<$/BG1IKFZAN;FUL[6XL;
M:*[>XOK>[O+RUL[6:TBFCN;J:."!GE8*:MU^T5\ [)8WN?C1\+DBENY;$3KX
MY\-RV\5U!#=W$T5S<1:B\%IY,-C=-+)=20QQF+8[J[QJX!['L3^ZO_?(_P *
M-B?W5_[Y'^%>8)\</@Q*T"1_%GX;R-<EQ;"/QMX;?[08FE67R"NI$2^4;><R
MF,L(EAE>3:D;L.>N/VEO@/:W=Q9W7Q3\'6[6\]K;M=3:S:1Z;(UW;6UVLL.J
M-(-.EMH(+N%KRZ6Y\BU<2Q32)-!-&@![AL3^ZO\ WR/\*-B?W5_[Y'^%06=Y
M::A:6M_87,%[8WUM!>65Y:RQW%K=VES$LUM<VT\3-%-!/"Z2PRQLT<D;JZ,5
M8$V: &[$_NK_ -\C_"C8G]U?^^1_A3J* $  Z #Z#%+110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?&WQ
MH^(MW'XEU/0M8_9?\1?%+0]#M;S1[76H8(K\:K%XB@\-W<]KX?MGTFZMD-R8
M;A-0>\U'3GMI= MF2?-]:AOFWP[XE\(^+M%\:>(OAA^R;?ZO%I5U:W6B3ZEJ
M+ZQX;U;4]$\8K8WEC%I%E+;ZNNIZ?J;W'B>X6[MKVVM]9TVUU&"5I+72M1;T
M'XNBT\.?%/X@ZA8_M,^*OAM>Z]/#!=^'-#^%WC/Q0VEZII_@>SN;&_\ [3M-
M2EM=0$=GKMF^GV2P+X7FO-0GT^+3&\86MOJ>FW]?M]76R@@E_;.OM)UWQ'IV
MCZX;VU\*ZRXT739])L?&QO$\/Q^+C;^&-"U;PIX/UPS7/B=)[G3SJ5HMMJ-M
M>:K>67B@ &BE\4_$*+2/B#^S%I5KX!\0ZOKFHZGXK;0O$5QJ5K%XBBO[Z-M4
M6T##^T-=O+^/3/$\$:-93IJ>IV=VLNG37*/R]Q_8.H^']6O?$7[#6L:C?Z_?
MG0O$=MI[W20Z[+K46I'5X+&*XLDO%\.W;S75GJ]K=I9Z+=:I?:G%=O=V<ZZM
MJ?KMW=Z=H_P<\%W7BGX^V<X\=>+?AKXQ\%>.?$>@^.8KG5])D\<:'XJT+3+W
MPY-XZCO;);_3K[1_#E]>M)H>G67VM+OQ!H\I(TQ?+_B'I/AJ[\1ZS\7=#_:C
M\7>'-6UR]F0P^&O#/CGQ5X'M+JS^&_@RVUJV\,^&-%UY#%K.IP> OMUJG]I7
MSR7]V?#,.GW6LSZR=? ,_3-:C\-+XCU:T_8K\4/:7/CVY@U[2[B[NK_5M-U3
M3[O3OAMIOB71U.@-:/\ #T>'+&;Q+;?V3)?7T/A:]DUE=+AU&]FT5L./Q5X(
M\0:+]IT;]B'QK>2>$_$.H^%O#MJT.KR6L&F> M;\4B]M=.N[2!8=%CT'Q!X<
MMK/0-,A,NFZ)KVM>'K_20W]BS&P[77=2O_#NKZ,;C]K_ ,4_V-X@N/!'BZ#2
M[OX9^,]575-.\3>&M8.G6\'B+0-<L+O2?#'B;4;&^UJ:WLI+671=6_X1GPTE
MU86VH6^F:QS6@>$/"OB^Q\)Z'HW[5/B+4O&^C26'@NT\6OX*U^VUC59],\5Z
M1\0_"FE7UE<:S%I\=AH.I3^%?#^NHT40U71X+GP]J5W:ZKJFJ7@ -*ZL=!L+
M%]%L_P!A_P 6:9<WNB>(7E?PYK$MN;>SO=&N!K*Z=K5OIR*NHWUEIL>GS?+;
M7\WB#7+%+07,NK:UJUF:3K7P_.HZAI _8G\0Z+*;/Q/K.CQ3K;P77B3_ (0Z
M;1K[4)X;*&%KM;?4IW\-WTTTR3-JFNR:C'J5M<:Y'C5^G\1:'H+^/O%/CX_M
M3:7X1U_Q!_8%CX@T:"'4(_"UEJ>AZ=<^&ETS1)H_%FCZMI\5[<:7XC_M(6^I
MIK<;ZCI?]F:CI+W<4NN<#X^\'>&-:G\/>%_'O[5OQ1O/%>O^5K7A+5]!\'>-
M+'1?$GA7QGXRT/Q#H5E<KH-Q<:9KFB:9)I^F69N+#5]+_LR_OK![@V&C3#P[
M. 4[/Q=\/K>SL9K[]BW4Y+RQNO[$OI+!KJ[TV'QM?'3/[3\/VT+:?=77V>6'
M6[+[)-J%O%%%JMNWA^_ATS5-#VVVAIM[H>OWVFRZ_P#L6^/;>^GT/0/[3ED3
M5HO#^C:IJD5[XI\5KH>C(YO-.UC3M4UGQ%HUYK%HP?\ T[[+#?3:=K=Q;W_/
MPZ/X'UCP#IEWX/\ VK/%/_"->%_C=X2\9Z1XUUGPKX_\6^)TU_7OA^UO!X>\
M3+/JNE^9I6F"TM?$TEQ/96ND:%#8ZS8^*[$2+>WU;]Q)H_@;4_AGXI\;?M7^
M+=1OM7?P[XYT>/\ X5K\2[./Q=I^BZ?K5I%HFHVND^)9M3CAU+3X-5U&[\/Z
MW<3ZQJ5AX9U2^U.#4K'2=2>, ^M? /PG^%7C'P'X/UO4O@K:^!;I[0:C;>%M
M5A:WUWPA?&*]TXPV]]87$<MI/!:3W,-A=Z?-;E-/N8Q:BWB98DTKK]E[X#3V
M4EE:?#;P]HP_X12[\%65SHEM_9MSH_AV]\+7?@J6QT4PL8-+*>%;ZXT.":U@
M2:#3VC@C<)!"(_ O!VGZGXA\(:7\+/!/[1E^R:KJFN^(M"\?:5X#\:Q:KJNG
M?#[Q0GA3Q]H,GB2^\22:-<Q+K%K<G3KG3M5L9I[673+^/3=>\/2RRZWD_"7Q
M3X:U77M)\96/[6=AXK\.:%9^'O"%IX6\4>'?%6E7,366D6/@[7M1NY_$WC9M
M6NM;\3ZF]KJEOK5[:2VEO<SI<W,.K2//J$H!]%^+?V6?@?XUU#0-2UGP7;1W
M7ANSL-/TU]*NKK1R+#3-?\/^([.RN)=.EM[B:TBO_#=E']F\Y8&M;B^A:,M.
MDD6X/V=/@>EN;2+X9>%H+8ZO)KODVMD]K&-6E>>1[Q%MY8MC%[F=EC3; GFL
M$B4$ ?&Z> _#>B_"2^U#P7^V7XMM_AU\/M.A_P"$TUC36U?Q%<+-=6FJ?:[N
M"3PMX@TS5;*35O$.K&_@M=-CO)A9Q)IEO)+J%K8ZQ8^GZ1\(_'2:+J,NL_M:
M?$#7+CX>RZDOBO5['2-2T:UDDFT#0/%]@TEC9^(;A;Z.RT+5(]1D6TN-1@O1
MK/V*,6PTZWL;< ]]NOV>O@I>&$W'PW\-L;6QTK3K,QVTL#6-KH4UI<:)]@,$
M\1L+C2+C3["XTR]LS!>V,]C9S6UQ%):P-'IV7P3^%6FP-9V'@C1;2P>/28VT
MR&.9-+)T)84TBX_LP3?8?MNGQ6\$%M??9_MD=O$MN)_)+(WQS=WD?B/4;7Q)
MHG[;>H:!H/B&+6-1BT#7-&N[*T>?QE>-J/AVV6\F\3Z!J.B)I>BFQAL]#M9M
M/O4MK*+5;5M(BU/65U0TSX<^//'6L^'+_P +_MI>+M3TW7['Q+=>'-.N/!GB
M>V34]=\ :Q:^%/'>KW=WI'C?PQ;-I$.M,$M/#C6.GV,5U<&ZT>:[TX;* /JJ
M7]FWX$SV+Z7-\,/"TNFR:GJ&L/ITEI(UBVIZIYIO[LVAF,'F7$D\]P1Y>R.\
MFFO8DCNY9)FF'[.OP.$5M GPP\*116>N3^)+2.'3_)6UUNYMM1LKB_M_*D3R
M9)K'5]4L)(X]L#V&H7=BT1M9Y(6^2;6[TO6-,GTC3OVQ_$ND^)/ WB[Q#X:\
M0:K:^&-:TN34O%NG-I=EJRWNC:KJTUIKL>DZH]I=L5?4M(^Q>?%=+/:2:Q/<
M\YI'A*&]\2:GX@M_V^!JE]X@?3-#L=.075Y::7_9OBFTU'0=#TC3+WX@WT<C
MOJ&IC2H]0U""]\6:G<SI!:Z]YEG<6K 'VU<?L\?!6[E$L_P\T-BNJZKKB1*;
MZ*VCUC6[F2^U;48;.*\2TANK_49I]4GEBA0MJUQ<ZJ-NHW,]S)+!^S[\%;?1
MM1\/I\-O"[:+J\NK3ZKIT]B;JWU*;7;;1K/6);X7,DK74FHVOAW0X+MYF=I8
M]+LE8_N5KXL\ >"]9\/^+?B)I?A[]K?5+P^$-*\:0_%*V\0Z=XQM-.\%:E%9
M:E+H>LP6/B+Q;>I>6NGZOK"7L^L6NO6=UK>F:'<Z?<^(=0N8+2XT3IM(T6?6
M$\$7$/[9^K^)/.U:+3G6'1=4:W\5>(=#NM$\.Q76BVMIXG4VYT_5KI/M<,IU
MS0[\ZM/JNK6]]>Z;8ZSIP!]47'[._P $;L:3]H^&GAB1M"!729?LDBW%BDEM
M>V5Q'%<I,LYBOK'4]2L=2BDD>/4['4M0LM06YM;VZBE@U_\ 9O\ @;XGTFPT
M/6OAKX:NM-TF6XGTJW%J\(TVXNHM6AFGLVAE1HI'CUS5@V2R-]NG#HP; ^0]
M1TZ/3=5U+1]5_;;\;Z=IOA/QO-IWB?1[_2_$=OK]U';QZ-::AX4TW78_$,6H
MSZ?--XF\*K=^(+"UU"\T^\6U31M3TI]3\2_VIQNJ>'V@T_Q!XC'[=5K<ZWX4
MTS0M4T^.1/$FC1Z1)X8BU.:RMM?F_P"%@:UK4VD:I>:G'%XHM;V*^MKB06UK
MJ&GW G%E. ?7VG_L@?!#3-(\):-::)K"P^$?$MGXJBNY/$6JRZEX@U2RL;[3
M8T\5WKS&77M/EL=0N;:ZT^YVVURA4S([@L>LN/V:?@1=7MWJ%Q\,O#<M[?:O
M/X@O+AHKO?<ZY/#):MJ\N+H*^HQ6DT]G:7A7S[&RN;JRLW@M;JXBD^4;6#Q#
M'>:UXF\%?MA:/K&GR:-=:KXITZ^GVV%GJ8\%-X3L=0(:_P!1.GW&K_$:?PQJ
MC6NDV7AU8[:"XTRTTV\OM9>\''^$VU'6---IKG[=$ZZC'#97,L%]IWBG2K"&
M>QUQ/#$2Z5X@E\8^&)?$>GMXQ\&:O;7EW:S3I?:-]M"7,D-[>^*=8 /O6X^
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M[C1]:N-1COIC_P )DB2S0VMT]M%-J9U&YU!K.P379]3LTEMF /+[KP]X>NO
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>edhf.jpg
<TEXT>
begin 644 edhf.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MUZ>%C5P$O[1=;%UJ\,-1PF'IX)5ZF(Q57$5*=&&'HQG5=2:7*M6OMJBOA_\
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M #&21>.=8_8\_92FD\+ZS\/-+_90_:F\1>$/B[>>$OA@=>?0$L9&N-%^+[^
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M>^$WU.YU'5KYM1@E-KIEKI>H:IQGP7_:E_:"UKP?\!-<^/\ -X?OM3\;?\%
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M\0T#_@HL_BW1)Y?#WPUA/BGQ;\1_V5O#GP8\-ZKK]Q9R>-? /[57ACPYXO\
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M7A.7P59>&5\+ZS>^ GTK4;"Y\8PZYI\VII?0VUS9VK>=]*ZC^R)X7;XFZ_\
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M$_XL?'WXHW&L_"OQ1\&O#NJ^-_%O@Z^U_P  >!O%GC;PQ\0=1M="\1:?\/\
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M_P"?VV_\!KG_ .3Z ->BLC['J7_/[;?^ US_ /)]'V/4O^?VV_\  :Y_^3Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "/L3_A9_AG^_/\ ]_-/_P#DZC_A9_AG^_/_ -_-/_\ DZOCO^WM,_Y^HO\
MOM?\:/[>TS_GZB_[[7_&C_5_+?YJ_P#X-7E_<_J[[:']N8[M0_\ !<O+_IYY
M/[_(^Q/^%G^&?[\__?S3_P#Y.H_X6?X9_OS_ /?S3_\ Y.KX[_M[3/\ GZB_
M[[7_ !H_M[3/^?J+_OM?\:/]7\M_FK_^#5Y?W/ZN^VA_;F.[4/\ P7+R_P"G
MGD_O\C[$_P"%G^&?[\__ '\T_P#^3J/^%G^&?[\__?S3_P#Y.KX[_M[3/^?J
M+_OM?\:/[>TS_GZB_P"^U_QH_P!7\M_FK_\ @U>7]S^KOMH?VYCNU#_P7+R_
MZ>>3^_R/L3_A9_AG^_/_ -_-/_\ DZC_ (6?X9_OS_\ ?S3_ /Y.KX[_ +>T
MS_GZB_[[7_&C^WM,_P"?J+_OM?\ &C_5_+?YJ_\ X-7E_<_J[[:']N8[M0_\
M%R\O^GGD_O\ (^Q/^%G^&?[\_P#W\T__ .3J/^%G^&?[\_\ W\T__P"3J^._
M[>TS_GZB_P"^U_QH_M[3/^?J+_OM?\:/]7\M_FK_ /@U>7]S^KOMH?VYCNU#
M_P %R\O^GGD_O\C[$_X6?X9_OS_]_-/_ /DZC_A9_AG^_/\ ]_-/_P#DZOCO
M^WM,_P"?J+_OM?\ &C^WM,_Y^HO^^U_QH_U?RW^:O_X-7E_<_J[[:']N8[M0
M_P#!<O+_ *>>3^_R/L3_ (6?X9_OS_\ ?S3_ /Y.H_X6?X9_OS_]_-/_ /DZ
MOCO^WM,_Y^HO^^U_QH_M[3/^?J+_ +[7_&C_ %?RW^:O_P"#5Y?W/ZN^VA_;
MF.[4/_!<O+_IYY/[_(^Q/^%G^&?[\_\ W\T__P"3J/\ A9_AG^_/_P!_-/\
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MW.?L-S=:GT]/[-M+O/T&<]J_ENA\9P,!N:(\ GYL>^.GIZ^G:M:+Q+9R8#%
M>,X<'T_Q_P ]^2IXT9XU^[R?*HOO.>+J+IT5:E^?_!TCX2Y9%_O,QS*2ZJ$<
M-%OT;I5/R9_2Q+^V]^R[$,_\+4LI.O$7A[Q<YX]O[ !Y[9X/K65-^WE^R_$I
M*_$"XG(S\L/A7Q46/T\S1XEY[98<U_.;%J]E(<"51]2/ZX_S]:N+=6[_ '9H
MS_P(5Q2\9N*7>V R./IA<<[?-YBT;+PKR!?%B\X?K7PB[=L"OZ9^_=__ ,%%
MOV<K,D0W'C;4\9P;#PO@''I]OU&Q(SVW 5B2_P#!2GX JI,.D?$>5NRMX>TJ
M+)^O_"0.!]?TK\)0RM]UE/T(/\C67KFN:7X<TV;5M8NDM+.*2"!6(+RW-W=S
M);6-A9P+F6[U"_NI(K6QLX%>>ZN)$BB1F:N2?B_Q?)MQ_LRFGLHX*32]'4KS
M?WMG1'PRX9BDFLPF^\L6E?\ \ HQ7X'[I77_  4V^#\:L;3P9X]N2 2!-!H]
MH" ,Y+#4KC ZY.#@#->;6_\ P5L^'.N:U>^&_ _PG\7>/?$6G[%OM'\.>(?#
MTLNGSS;A:6>KZI.(O#N@7NH.K1:;:^(-:TJ34)4>.S$SHZK^4?A?X*>._$VL
MPZ]\2KW1-)\"O!=6VG?#;2KJ\N-:GU#R&+R^/]62;0X_M\$/G2:=X;\/:C=:
M+#<0P7>H:MK$:FW/TW;>&O!?@V!HM.T3P7X-T>YL7:\DT>.'PAIAO;7=:ZEG
M1]*D*KJ%[;OI]W/-%$]]<(Q+7,=P8XF\K$^,/&7M(4:6,H*M4JT:<*-#*J57
M$577E&%)X:A+#U?K"G4DH1;J48S?,Z4ZBCKZ5'PPX5A%U,1AJT:4%SSE5QV(
MARP6LI2<:M&,%&*<FV]/=O92O'['T[_@I+\3O$%O?RZ?^R7>^$;BU8+;:?\
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M97?]'WGP?\]HO^_B?XT>?!_SVB_[^)_C7QU\)?BWX'^-O@?3?'_P_P!3DO\
M1;Z6YL;RSO;>33]>\-Z]ITAM]:\+>*=&GQ=Z'XET*\5[+5=+NU$D$R;XGGM9
M8+B7TJOZ.H82AB:-+$8?%0KT*].%6C6I*,Z=6E4BI0J4YQFXRA.+4HR3::::
M/PFMC*V'JU*%?"SHUJ,Y4JM*I*4*E.I"7+.$XRIIQE&2:::NGOMK[WY\'_/:
M+_OXG^-'GP?\]HO^_B?XUX)16O\ 9J_Y_/\ \ 7_ ,D9?VD_^?*_\&?_ &GK
M_2U][\^#_GM%_P!_$_QH\^#_ )[1?]_$_P :\$HH_LU?\_G_ . +_P"2#^TG
M_P ^5_X,_P#M/7^EK[WY\'_/:+_OXG^-'GP?\]HO^_B?XUX)11_9J_Y_/_P!
M?_)!_:3_ .?*_P#!G_VGK_2U][\^#_GM%_W\3_&CSX/^>T7_ '\3_&O!**/[
M-7_/Y_\ @"_^2#^TG_SY7_@S_P"T]?Z6OO?GP?\ /:+_ +^)_C1Y\'_/:+_O
MXG^->"44?V:O^?S_ / %_P#)!_:3_P"?*_\ !G_VGK_2U][\^#_GM%_W\3_&
MCSX/^>T7_?Q/\:\$HH_LU?\ /Y_^ +_Y(/[2?_/E?^#/_M/7^EK[WY\'_/:+
M_OXG^-'GP?\ /:+_ +^)_C7@E%']FK_G\_\ P!?_ "0?VD_^?*_\&?\ VGK_
M $M?>_/@_P">T7_?Q/\ &CSX/^>T7_?Q/\:\$HH_LU?\_G_X O\ Y(/[2?\
MSY7_ (,_^T]?Z6OORNCC*,K#U5@P_,$TZO#=/U"YTZX2>WD9-K R("=DJ9^9
M'7(# C(&>0>001FO;XW$D:2 8$B*X!Z@,H8 _G7'B<,\.X^]S1E>SM9W5KIJ
M[[KKJ=F&Q*Q"E[KC*-KJ]U9WLT[+L[JVGF/HHHKF.D_*OQ;_ ,G8?%3_ *^/
M"_\ ZBVCUYK^Q#_R;-X*_P"QT^/_ /ZTA\7J]*\6_P#)V'Q4_P"OCPO_ .HM
MH]>:_L0_\FS>"O\ L=/C_P#^M(?%ZOT[*/\ D40_[D/_ %'Q!^?8[_D85_\
M'7_]+IGU=36;:K-Z G\J=7\[?_!6G_@L/XQ_9:\?3_LW?LU6.@2_%#2=-T[4
MOB+\0?$>G+KNG>#GU>U2_P!.\+Z#H<S1V6H:])ILMO?:MJ-^TUKID=Y;V5M
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MY?-+^:7WO^NB^X[^6/\ +'[E_71?<9O]C:/_ - K3?\ P!M?_C5']C:/_P!
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MK>D/SD3T445Y1ZI^5?BW_D[#XJ?]?'A?_P!1;1Z\U_8A_P"39O!7_8Z?'_\
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MX:DQ:***\<] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFL%B<IR?'XF"E:$,PACLRP&'Q,E*481K8W T94:DT^>O2RJA"3Y:$4?T\?\
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M?^/:W_ZX0_\ HM:\S,MJ/K/\HGIY;O6](?G(GHHHKRCU3\J_%O\ R=A\5/\
MKX\+_P#J+:/7FO[$/_)LW@K_ +'3X_\ _K2'Q>KTKQ;_ ,G8?%3_ *^/"_\
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M+P[\<M6\._##5O!_@[X3>'/@%K-WXDOO%%IX<^)AU?XV6/P_UZP\,#P;XB\
M^*+#0]0T*+Q1>:?XFDURTNE^S6Q@L(H=2N!-I_>_\-F>*+OQ%'>+\/\ 3;#X
M+>)_C5\2?V9O!GQ C\3/<^-F^+/PZM_&EC>Z[J_@R31(]+M/ FI^*? /BKP]
MH]Y#KMYK/GZ;::IJ&C0:;JL'E^W:Q^R5\*-=T3XL:!J,OC&XL?C-_P *N_X3
M2:Y\4WFH:G,WPAT[P_IGA*6UU?58[_4S=/;^&=-?6[W4KK4KW5[DW5S<7 EN
M&89UA^QU\*;#XF'XB#4/'%WIT/CKQ-\5=*^%=[XAMYOA3H7Q5\9Z7<Z3XJ^(
MND^'5TJ/58O$6MP:CK5W/!=>(+OP]:ZQXAU_7-,T*QUC5[R]D /B[PI_P4(\
M=:%\,/@+#=>!=3^+_C1/V4O@1\=_C?J&G:7XG;Q5X@;XF:!:O)9_#OPWX!\!
MZYH5]XPNI;+7/$4NEZS<>#M"D@2#2M)G^TW"I;_5GPT_:F\0>.OVDO'OP.UC
MP=X:\%6OA6Z\1VNDZ?XE\5:EHOQ8U_3O#RZ6UMX^T;P1K'AJPT?QA\./$W]H
MR1V/B'P%XI\2GP[/;):>+8M*OKR.TB31_P!ACX9>&;/P38>$?'WQM\&V_@WP
M=H7PTGD\*_$%-%U'QA\+?">LRZOX-^'/BO6[711KIT/PC#-+H.A:SX:U+PUX
MXC\.RS:9?>+;Y9YI9/1],_9G\)6/QBL/C+J/C+XG^*M4\/WGC#4_ _A'Q;XM
MCUSP9\/M6\?6-IIGBW4?",%QI2^)H%U33K5[*WT;5_%&L>&]"M[V]C\.:)I
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M/?B-^S[X7\!_LZ^/OVB/B;^SK/\ %.W^*DNMZOH.O> K_P")>G6'B;5/"_\
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MX$\0^(/AMXXBMX?&'PV\4:E90W,FL>#/$ M()+NP=8KVUF\^?2]1T^6[O'N
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MZ+XTLO\ A#_'NJWO@G6]1LO"VAZ_IEM<6/B30+.7Q3XBT_3A-?66F7D_DO\
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MX5UF_BD):%M>T+4X$!*>08R5K]T?^$*TG_GM?_\ ?Z#_ .1:/^$*TG_GM?\
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MQOM.O5M&;[<T6BF>SM;,I-,EJOV'7M-6Z:%S'X=EG9&D_6GX??\ !%G]M?\
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MQ-/,<34]I5Q-#%5</4NK*,(NBX<E.G&,84Z<;0A",8I62/Y+OCE_P:Y?LO\
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MTR/4HI6B=D,T6JQ3,IVM(0:_3O\ X0K2>!YU^  % $MN %4 *H M<!5  4
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MI876E^+/#U[XN\*^.](\6^(M#\16%Y-;:MI7B36]6L;M!"9(2]M;M'VOB?\
M9(_9_P#%OA[X&>%]1\!G3])_9JUOP_X@^!R^%?$OBSP9?_#W4?#&DG0=+72=
M8\):[HVK3Z>VCL=.U72-3O;[2M=M28];L]0ZT ?"_P"R_P#\%&OBA\</BO\
M RR\7_"3P)X8^"_[6<7[0<_P!UGP]XSUW5_B1X?3]GG7[G1=5B^+6B7OAZT\
M/"7QK;6=SJVBMX3U2XAT%433=8DN+F19:\)\2_MO_M)? ;]JW]L+4+[3_#OQ
M(_9O\&_M>_LH_!G5-.\4>,]>M_&G@#1_C9\+?A[IS_\ "I?#=EH5QH L=.\4
M:^_BWQ&FMZTD^KO-/8Z9IZ3S/J5K^GGPM_8>_9C^#'Q*?XM?#KX<RZ)XRA7Q
MTF@FY\8^.M>\,^!X_B;KZ^)_B#%\-? WB#Q+JG@KX:0^+]<47NN0^ ] \/17
MN7MG06CO V1XD_8!_92\7?%W5OCCXA^'&HZE\0?$'Q$\"?%CQ%/)\1?B;%X6
M\1_$+X7Z5I^C?#KQ+XA^'UOXPB\ ZU=^"[/2[*3P[#J7AJYLM-U&)M6@MEU2
M::[D /SA^#'[:G[3,'AOPY\*O %EX8^+WQP^,7[6O[>>C>&?$?QV\7^(M'\%
M^"OA=^SUX^UFX@TBXE\,:)JVO7[_ -ERZ7X6\*:;8QQ0Z8/],OVEL[=T:;4/
M^"N_Q0\<?"CPS\6?@5\"? MWI7AG]CG6?VU?COI?Q,\?ZYI5YIW@KPMXJ\0>
M$]=^'/PSN/#_ (7OHM7\77%SX1\2:CI'B378;3P^;.#3X+ZP@NKTK#^@6L?\
M$Z/V1=9@U6*3X=:_I4NJ?%;QQ\:TU'PO\6/B]X1UK0?B-\3=*OM$^(^K^#M;
M\,^.M)U?P3IWCW3-2O;?QAX7\)7NC>%O$)F$^J:-<W$4,L;O&?\ P3F_8Y\=
MZ#X"\,:U\(5L-!^&_P -'^#/AS3/"'C;XA^ [:Z^$LVI:=K-S\-_%R^"O%>@
M'Q]X,O=9TNUUB_\ #_C=O$&GWVJM>:C=PS7>I:A-= 'Y:?ME_P#!0S]HKX@>
M /BEJ'[.VEZ-\,OA)\+/'G[!VF>)OB6?&NO:3\;9]5_:&\<?"?Q?/I_A[P]8
M>'KOPU)X2;POXHA\!>*+?4=<L[R_BUK4-5TZ^EALWT>?^BBOB3XF?\$ZOV0/
MB[XMU3QIXV^%=S/J^N'X7RZW:>'OB#\2O!?AC6;OX*W,=S\*M2U7P9X-\7Z#
MX2U#5? R1G3]"U2ZT66_MM&EN-$:XDTFXFLW^VZ "BBB@#Y1^"'_ "/'Q._[
M*!XQ_P#3_J%?5U?*/P0_Y'CXG?\ 90/&/_I_U"OJZ@#$OO\ D+:-_P!?-Q_Z
M;+^MNL2^_P"0MHW_ %\W'_ILOZVZ .:\8^)K7P;X8UKQ3>V\]W:Z)9/?3V]L
M4$\L<;*I2(RE8P_S9&Y@..M?.%K^V+\-;C[^G^(+4X!_TBV@ SW4-'-+R#W(
M"]\UZW\=O^20?$#_ +%ZY_\ 1D5?C17P'%W$&9Y1C,+1P-6G3A5PSJS4Z-.H
MW/VLX73FG9<L4K?,^4SSB+$Y'C\-&GA<'C*%3#^TG1Q:Q*3DJDXWC/"XG#5(
MW25TY26BLEK?]7K;]IWP/>?\>EEJ-R0H8K!+82.JGH71+@N@[?,HYXZU;_X:
M.\*_] ;6_P#OFU_^/5^2X)!R"0?4'!K7M=?UJSQ]GU.[0*-JJ\IF15 P%6.<
M2(H Z;5&.V*^-EQKQ-]C%X3TE@Z:_%-_D>UE?B1P;+ECG7".94K?%7RO.I5[
MZ_9PN+IX;ELK;XV?-=OW=$?JC_PT=X5_Z VM_P#?-K_\>H_X:.\*_P#0&UO_
M +YM?_CU?FA:_$#68<"XBM+M0,?-&T+D_P!YGC;#'U 10>O%=%:_$2P? O+"
MY@./F>!XYUS_ +,;&)@/JY/M6,N..+%M5PDO\.%I/\'9_@?HN5\1^"F9<L9X
M_,,LJRLO99HL=0LW;XL11CB,)%;WE+$))7NUHC]#?^&CO"O_ $!M;_[YM?\
MX]1_PT=X5_Z VM_]\VO_ ,>KX4M?%GA^[(":C%"Y7=LNE>VVCCAI)56'=S]U
M96)P<9'-;T4T,Z+)!+',CC*/$ZR*P]59201]#6$O$#BB/Q5,/'UP5-?FC]$R
M[A+P]S>"J95CL/F4+7O@<ZIXJR]V_,J%6;BTY14E))Q<DFD[(^S?^&CO"O\
MT!M;_P"^;7_X]1_PT=X5_P"@-K?_ 'S:_P#QZOC:BI_XB'Q+_P _\+_X24CU
M/^(;\+?] ^+_ /"RK_7_  [\K?9/_#1WA7_H#:W_ -\VO_QZC_AH[PK_ - ;
M6_\ OFU_^/5\;44?\1#XE_Y_X7_PDI!_Q#?A;_H'Q?\ X65?Z_X=^5OK6;XY
M?#NXGDNKCP?//=2KMEN9M-TJ6>1<@[9)GW2.N54X9B,@>@J]!^T-X.M8UAMM
M U6WA7[L4$%E%&N>NU(Y%49]A7QY12_XB%Q(FVJV$3>[^ITKOU8/PXX8:2=#
M%M+9/&UK+;S_ *OZ6^R?^&CO"O\ T!M;_P"^;7_X]1_PT=X5_P"@-K?_ 'S:
M_P#QZOC:BG_Q$/B7_G_A?_"2D'_$-^%O^@?%_P#A95_K_AWY6^R?^&CO"O\
MT!M;_P"^;7_X]1_PT=X5_P"@-K?_ 'S:_P#QZOC:BC_B(?$O_/\ PO\ X24@
M_P"(;\+?] ^+_P#"RK_7_#ORM]D_\-'>%?\ H#:W_P!\VO\ \>H_X:.\*_\
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MO_QZC_AH[PK_ - ;6_\ OFU_^/5\;44?\1#XE_Y_X7_PDI!_Q#?A;_H'Q?\
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M.WQT\/7IP]I4HU84^=T^>=.<8<\6U*',TES)IIQO=-/31GH%%%%8&(5+%--
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MX*CB*>)@Z?LV_:4U-1NJD*D''WW=.-[V::L?SCK^QO\ M?\ C&^^(W[.5_\
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M!;:SJOCWP?I_B3P3X9\+^'[NXAU.YU+5[_4%TJ_O+Y[32-#@A;5+Z],4L4)
M/<]4_9*O=<M/#VJ:Y^T7\<]7^*G@[Q_/X_\ !OQ@O&^%H\1>$Y[WP6OP_P!5
M\+:)X0M_AG!\++?P=KGAIKM-<TE_ DMSJ>KZA?:]/J']JR1W$7GNK?\ !._X
M?W'AFP\,^&OBW\9?! N?A5\4/A!\0M<T*]^'U]X@^*_AGXQ^*=2\=_$"_P#%
M]]XF^'VO1:;XEUOQOK6M>)/[;\#VWA*>RFU:\TW3X[72!:6%K\KR_P#!9OP)
M%\'O'/CW_A5:7GBKX>?%OX:_"?Q5:Z)\4_"7B/X0: WQ9\,7'BKPAXYU[XXZ
M';7WAW2/!0ALK_P]KM_<:4;C1/%]G)HEU!M>.\/?>(_^"AU_X3\8^+/&M[X3
M\>>)/"/AK]@G3/VI)?@WX 3X=>/A?7UU\3G\,RW/ASX@>%-0U*?Q'>KIH\R2
M;3[R?P9'X<BGU_>MW!-&@!]96'[&?PYT[3]=TZ#Q%XU:'7_B-^SA\3+IY+S0
MVEAUK]F2\^'U[X)LK<C054:7K,OPXT9?%$<J2W=S'>:F-*O-(:2U>T[SP%^S
MUH/P^\)?%KP)I_BWQ?JGA+XJ^*/B!XH&DZN?#1_X0>7XF/>WGBO2_"=]IOAS
M3K^?3+C6M4U/6[,>*[GQ+?V5W>R6T=^=-BM[*'\T=3_X*:_&GQ?8?L8^)/@U
M\&?ACXA\/_M#?M#ZG\(/%CV/QF\)^/=+N=.L?!]UXGA3P9XK\-ZCIL6B:T]L
MAO;T>,= COM,;3+G1[OPVL^I:??U[!J'_!3SPWH7QX\>?!37?ASI_F^'/!OQ
MX\6>'+_PO\8?AOXX\0:@?V?](76_$5CXW\'^%M1U'4/AH_BG3F:X\()X@NI;
M^4VMY!K.G:5=1"!@#V?Q'^P?X(UC1-$\/:%\4?BSX%TI/@+X&_9K\?P>%KKP
M*TGQ7^%'P]BO8/#>F>++CQ!X%UR?1];M[?6?$MI)XD\!R>$M7>S\2ZG;"=4@
MT@Z9[]\.O@3X-^&2?%BW\/3ZR=/^+OBP>+-:T^>\AAAT21?A_P"$/AO#I'AJ
M?3K:QOK'3+;P_P""]+>V:XNKS4H;Z6ZG34 AMXK?\X-(_P""NFAV?@?QUXV^
M)O[._C[X=IH_[/7PE_:-^'FA_P#"6^#O$^J?$CPG\9O%]O\ #KP=HR2:5<I9
M>%O$-YXYO+'3#;ZQ.UO%IU[#J<\\7ES6R^B?%G_@HQXD^ 7PS\,:]\=OV<=5
M^$7Q/\=_&FR^"G@7P=XU^+7PYL/A_P"(KR[\)R^,9?'LOQ@CO)M#T'P!INFV
M>HZ?J6H:YI%EJ\&NV7]GQ:1<17-M>2@'-_$O_@FU#HWP8\4^'OA3XY\=>+O&
MB?"G3?@MX&T_Q'-\,O"MCH_@J;XN_##X@ZC=?VEX4\!^%)-0\6::G@+[3!XK
M\1W6JZQJL\DHU2;4+EK-[?M_BC^Q)XSO3X3USPK\5OB/XO\ BAX@_:4^#'Q'
M^(WQ?\1W7PQTGQ=X9\#_  I\(^,?#WA^V\):)I'@+1/A]+:^%I?$$US!HMUX
M-U277[SQ#K]QK?\ :<-RT,-B3]O34?B/^QO\-_VJO@/X"BU*?QS\4?"'P_O/
M"/B[5=.']DRS_%L?"[QC;Q:OINI1:7JC1:C:7T'A[6K"]FTZ[CN=/UHV]Q9>
M;:MZ7%^V=%_PG4.CW7PK\0VGPZ/QZ@_9FN/B:?$&@S6\/Q<;1X[J[M8_#,;C
M5[GPK8>)3/X&G\21N"_B&UN)4T[^RD%\P!T?@#]C?P'X&\1^#_&=UXN\=>-/
M&7A[7OC9XK\1>)/%$_AA;KXB>)OCS9^&],\7ZMXKLO#_ (9T+2+8:=H_A/0-
M$\-:=X6T_P .Z9I>DZ=;VLMI>,GFGS?3_P#@GCX M]+T[PWJOQ<^-'B'PCX7
M\"WGPD^'OAC4M4\$VMG\/?@YKOBGPUK_ (S^&>A:CHG@;2==U#2?&NB>$?#_
M ,.]:UWQ-JNN>+[;P#IZ:5H?B#2=2FNM8GYOXM_M??$CX)_';]H^*_\  6J?
M$+X)?!/X)?"?XJ>(VT74?"VB7_@G2M7U'QROCG6[9=1CCU7Q;>0Z+H4>MG1!
M=Q10V&BW264R7U[%;W.[HG[5WC/3?&_Q!\ OX=G^)_C77OVJ/&WPA^$'A>PN
MM#\)V>G>#_!?P?\ "_Q*U_5=?\17%L+=-+T*"[O2UW<1:AK&I:CK>D:9:QR1
MOYEJ ;>K_P#!/OX2ZMH^J^&_^$J^(>G^&KGX:?%[X1>']"L;_P -K8^"O /Q
MB^(?P^^)6J:!X8-QX9N+B&R\+:W\.M,T_P &0:C-J,6DZ#J&H:9<)?I'I<FG
M>G>*_P!E#P'XOO/B_>ZAKOBZWE^-'B;X/>*?$BV=UHRIIU_\%8- M_#4&B"?
M1+@PVFHIX>LSKB7YU"6=I;G[#-8*T2Q>(V_[?MOXBT8W?@'X*^+O%>O^&?AE
MXQ^*OQ:\+R^)/#&AWGPXT3P/XV\1_#_5M%2_O;A]/\5>);[Q!X*\9_V+9Z3+
M%97NG:!]MEU"V_M*QADY#XE?MR^*?$FF7&H? ;P/JT_@;0_BU^SIX$\0?%^_
MU'PPMJDOQ<A^'/C'4=)LO!.JK/J]W;6G@[XA:#I6K:S'Y4VG:SJMPNGPSC2+
MF\0 ]3T;]@7X:Z5XYC\73^.?B%J^EVGBGXZ>*].\&WT7P_@TNWO?VAM-\5:;
MX_M]0\2:9X$L/B%XE@BA\7ZDOAR;Q1XQUF^T2W@L+*.ZGM+<Q24(/V O"UG!
MX'>P^-/Q<LM<\(_#3P_\'-2\61Z?\')O$GC'X:^#]:GU7P?H>J7MU\*9[?P_
MJ?AJTN[W0;'Q7X#L_"?B:?3+ZZN-0U.\UHP:M!YU^V!^T1\=_AW\3OB1X;^'
M]PWAGPI\-OV+/BW\>[?6+:/P;J9USQWI6IV.A>'&URP\0Z/J^I#0/#CFZE33
M-&?2[C5=4N[>YU"^N-)LI=-NO5M?_;1B\+:_XALI?AMX@U_P+\,?%/P3^'7Q
M<^*%KK.A6%KX9\;?&JV\(2:-'I_A:Y=-5U_2M$_X3_P1/XHO[ P_V?%XBW6-
MI?II6HF$ \Q_:,_8=F^(=J? /A"?Q1?^$?B]^U#HOQT^)FK:IXE\-:7I_P *
MM#A\+6WA3XLZ%X1BL]'M?&&O0_'#P2-:\#3Z-J%WK]II4_BO6=5EO]*TJ&WT
MV?Z#_:2_9%\,?M%>(/A!XZB^(OQ+^#?Q-^!>H>,+KX<?$3X4WOA6WUK2['X@
M>'!X4\9:%>Z7XU\*>,_"^J:/KFC1V\4D5WH37=G+:PR6-W;J]S'<>'2_\%+O
MAI8RVB:Q\/\ QMID,?P3^,_Q5\37;SZ)<V_A3Q3\$_$.N>&M>^#>HM!>%[GQ
M]KE]X6\42^&ELTDT_4[;1998Y@+B -Z%^T!^UC%\!-4L-:\2>'/'%PFE_LN?
M&?X]ZW\/-';P9);W;_#?4_A5;76A76M7^S48O%-G-XTDTW2&T[4H/#%TDNJW
M&K^9)!I,L8!\W>(/^",_[-FJ>%O!'@[0OB-\?O ^B:'\+;GX+?$B'POXWT".
M;]H#X;:AXX;XBZOH'Q@DU3P?J:ZDVK^*[C4[N^OO#$?A>Y>RUC4-*C:.P^R0
M6OVA\5/V1_AA\8)[:/Q;<^(QX?T;X->+/@SX/\)Z9>6%IH/@FQ\:0V%AK7C7
MP[')IEQ?)X[70M)TSPWIFK:A>W]CIF@Q:AI]KI:QZ_KYU/:^"?QVU7XI>*_B
MIX#\5?#75OACXQ^%EWX/;4-+U#Q!HGB>UU71/'7AX>(?#^JV6J:$YMXK@1QW
MEAJNF3H);&^LW$4]Y:RPW+_15 'B'[/GP+T3]GKX?2>!-'\2^*/&EQJ/B_QK
MX]\3>,?&;:#_ ,))XH\7_$#Q-J/BKQ)K&I0^%M"\,^'+0S:CJ4D-K9Z-H.F6
M5K906\*0,Z22R>WT44 ?*/P0_P"1X^)W_90/&/\ Z?\ 4*^KJ^4?@A_R/'Q.
M_P"R@>,?_3_J%?5U &)??\A;1O\ KYN/_39?UMUB7W_(6T;_ *^;C_TV7];=
M 'DWQV_Y)!\0/^Q>N?\ T9%7XT5^SGQO@FN?A+X]@MXI)YI= N5CBB1I))&W
MQ85$4%F8XX !)["OQ^_X1KQ%_P! +5__  77?_QJORWCS"XK$9A@I4,-7K1C
M@VI.E1J5$G[>IHW",DGJM'KJC\UXVC*6.P?+&3_V1[)O_E]/MZHQ**V_^$:\
M1?\ 0"U?_P %UW_\:H_X1KQ%_P! +5__  77?_QJOA?[.S#_ * ,;_X2U_\
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M/9S_ ))_^ O_ "\U]YB45M_\(UXB_P"@%J__ (+KO_XU1_PC7B+_ * 6K_\
M@NN__C5']G9A_P! &-_\):__ ,K\U]X>SG_)/_P%_P"7FOO,2BMO_A&O$7_0
M"U?_ ,%UW_\ &J/^$:\1?] +5_\ P77?_P :H_L[,/\ H QO_A+7_P#E?FOO
M#V<_Y)_^ O\ R\U]YB45M_\ "->(O^@%J_\ X+KO_P"-4?\ "->(O^@%J_\
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MGC(\R$R$]>NP#@^F:\K_ .$:\1?] +5__!==_P#QJC_A&O$7_0"U?_P77?\
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MJV*^'O%>H:7H>AQ^%/B#X?>RL)=<\+L-5A6WUBTGL]6N/*NHX0"EX[_X)R_
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M31>P1.'2;7OV-/ VJ>,-;\?:-X\^*'@SQ?J'Q3?XQZ'K7AG5?"OF^"_&FH^
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M_P!@W2^)VUE"-[^UV][F;Z14W]G0_L7"?S8O:^T>S?\ SZO=\MO5I;M'FO\
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M3OI );W4+BYNI/WDS5YM<ZC'XE_:4^,^L63"2R@\3Q:''*/F5I/#VD:=HUZ
M1Q\FHV-Y$!G&(QFO=UX51_LC^5?IN73?]G82GR1IJ-&DY)7O.?LHI2FY-MM)
MM12M&-Y6BI2G?\_QJ3QF)DFVW5J)/LN9Z):63LKO5NRNVDDG5_$5^WM$6_;.
M_:E?'7XS>,SV[WH[Y!YK^W6OXF_V\[>1?VR_VH"Z,N_XQ>,)%#+C<DEVK(XS
MC*LI!5AD,,$'%?T-X 1YN(<]5O\ F2)_^7^$U\_0_G?Z0DW#A_('T_MQIO\
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M1E10C_9O_P""7GC'P?X>\%1^#_@5XB\&_&_X)^"/V3?">BKXEGO]/^(7P7^
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M\*_#+X0^&H-9\97/C'2-'MM*-A-I]Q:?1FJ_\%N_VBM/^!7PI^-%S^S;X/\
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M=V?.5*V=TI<LHUFUUA352+M;:4%)/;OU?<\+_P"&K?VBO^B<?#S_ +^>)?\
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MXON>&?\ #5O[17_1./AY_P!_/$O_ ,L:/^&K?VBO^B<?#S_OYXE_^6->Y_\
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M )8T?\-6_M%?]$X^'G_?SQ+_ /+&O<_^%5>(O^@3)_Y)_P#R;1_PJKQ%_P!
MF3_R3_\ DVCZGD/_ #]PG_A0O_EOE^?=A]:SG^3$_P#A//R_N>7XON>&?\-6
M_M%?]$X^'G_?SQ+_ /+&C_AJW]HK_HG'P\_[^>)?_EC7N?\ PJKQ%_T"9/\
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M /BW_P":>O=?^%6^)/\ H$R?E9?_ ";1_P *M\2?] F3\K+_ .3:Y_JF0_\
M/S!_^#X__+/+\^[-OK.<_P N*_\ !$__ ) \*_X:<_:<_P"A(^%G_@#XM_\
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M>07T=LMW9V5I874_]A^$KZQOKF&^M[)/%%M;7.G:@RW+6F;XB\5_M6:]X3^
M-YX3T+QE::A#\9/$%E\9;BUL/ MD^K_#,>&OB/\ V!J<%OK9EN8]+37U\#07
M3:?8:5K<M[&9!#)H<EQ=S^3^'9/^"BTZ1MITOB"VM!X&\=-K ^+MC\)'UAOB
M)'_9"Z5%X67X>>59)X=D@VR>!Y-::5VOSXJ'B\-:CP^J)5J2_P"8:#]92[[6
MV?:[N_,'3J/_ )?2^21Z]X2^._QUT#3=3MO&_@7Q1XLU&QT33KVRU#2O VL-
M)X@U6ZT^P35=/L[.PT?1;+1CH>KR7[P6NHW-V_B#3HH9+?4--D69!VS_ +17
MQ"ETO3[N/X3^*;'4&\&Z'J>JZ=-X,\8WSQ^*KS4H+#Q)I%A+:V*12)X;M6FU
M;3[>:0/XIM0D5M?::R/(W(?#ZZ_;3\-?"_PG=^+M+M_'7Q+USQGKK:S::IJ?
MA:SL_"OA*ZS;:*VNV^A:5H=K<3Z>'>]>P\/W]\[M#;;]5N%DGMQ-XL\8_MM?
MVGX5U/PS\//#PMX/A1HGB[Q#X6+:0=/O?B3!HOB6?Q3\.Y?$=QXD:_A6^U6+
MPUIWAJZM--BL[-[BYU'4]=N;>)[(DJU*3O\ 5H)W3TDTM$OLVLKV;=EU=K*U
MDJ=1*WMI6M;6*;^]N]_/KI>^M]"3]H+XY&[TQ$^$:+:7ZZ3;7>-*\;?:-*N]
M2T("YO)YY-#^RG3M(\4R+'J!$<D\>AQM=11W-PWE)1G^//QRTY=&M(/AMK>M
M7%AJ.H>&=1U2[T'6;>TUV**YO+?3O'E]8Z=X96>QLK\:/9RSVFE36RZ1;>*9
M[QM-U8Z?:V*4->^)G[;,G@K3/%.E_ RUL?&6F_$+Q/ITWP[MM<\+7]EXC\*P
M>&K\^';C5M<N=?@&F:3?>*/L-I_PD&EW)U.UL7;5KOPM(L+Z5/7USXN?MPKJ
M4-EI/[-MC<1V>CRZI)J</B[PS::->ZY_PBWBB_M-!9+K7;K5;C3SKG_"-Z+J
M#I;Z7/'>^;>VFH2:<9!1[>C_ - T/_ I=FK]^O>S=KK0?LZG_/Z7_@*\G;\/
M75J]F3ZC^TM\9)+'Q)/J?PLUKP5::-=V]SHE]!HVMZCJ7C!(UM!:^%[&UO?#
MM[:Z?J_B;6KW3]"@N);>Y2"RDUN\@:*\TNT^V:)_:4^-<5C#;1? S7[S5Y[J
M*"VN[G1/%%GI0MDO/#MO?W&L2KI1FL9K..?Q-)9O!;21>(8=.TV_L[?38M0D
MLK70\7^+?VOO^$!TK6_#?P_M)?B-I'Q)2'5O!MNWARU\,:[X-M/#GBN".YAU
MO4O$%]?S:1K&LIX9U2Z,*Z)XATF[F;2H%NK*"XOIO,AXZ_;YT'QYK'C'5OA;
M)XM\(&UNM"L/AEX7NO D%A%-96?PYE7Q?::GJVO:=KT\^IW,GQ"6QL+W7([>
M)HK2TN[.-!:7[OV]'3_98;I_'.VB7SULVTY-:Z)"]E4O_'EM_+'O]WDM/6YW
M.M_M$_'2TTB2TM?A#JEYKNHI?BRU'0_#'BF;3=%0^'+R]LSJ":K9Q2/?0ZI+
MI-LC1P7=G<Z@NJZ:T"V]K#J5U>LOCU\8)TU21OAWXI$?A'5WM;:"^\):QIUY
M\3+"ZN['2-*GMI3HTL6E1VL-U/XC\1W\%G8Q6[6%W9V-FUC':S:CS]C\8?V[
M[V[NC/\ LP>$]+M;3Q&(4@N_'.ESS:GX>CN=5B2>RO+36I(K2>_L(]"OY)+R
MV9M)O;O5],:UU&&QM+Z[Z70/BU^U_?2J-1_9WL;.-?A/XH\2&2^U[1=.2;XJ
MV%AK$^B_#\);>*]:FMM-O=5M]%TVS\0M]H@U+3M1NM5NUT*>R^P3+V]*UOJU
M/>]^:5WM=>EKK2UKW7O)-/V=3_G]+_P%?Y_\/HGIOC>&_C%\<=5TG7[+Q3HG
MB[1]0TK7/%.J6&K^'_ ]Q97>OZ6VL:Y9>$/".E0^(?">M:;!;FUN/#U_J/B2
M\LFN+;3K6\>;[1.9B9+7XI_&'0-6\'6M]+\3/&8@M?&']KR0?#.QLO#^M7&D
MZ*^G:+_PDNH0^#]+O]%D\0^+=3_M7P__ &*NG0V?A?PS NN"[N]5G:6O8^/_
M -M6VT?QYXXN_A-'JU\+KP9IW@CX5_:?"NF3W6EVM]XWC\4:ZU[_ ,)-/'IN
MM:Q;V_@R6>RU/Q-J&FZ/!=77]G+?3AD'0^#/C/\ M4?V_92?$_\ 9QFT+P6T
MWB*'5[SPKK&E>)?$MA/;ZC)8>%8;#2;37I%UC3]:5FN[S5XS9R:39VEG-=:4
M#K4ZZ >WIW?^ST[.^FFEXM:-P<E9OF5FM?167LIV7[Z=U;5WULT]5S)-M*S;
M75]6SQW6_B;^U7;:C8Z+INH>-KFWL_$_B#1QXG@^%NE-!XBTS3);5[+Q!JD+
M>#[J'0-(UQ_%+6VA)%!#+!I_PVN[C5;Z:Y\0"63O/B+\8?C%<>*_$C>!;7XN
M:)I.AI9VT%A_PJBQUS0O$]ZTVCS;O"&IW7AAM96P*6NI6&KZ[K4S):?VV]W8
M>'I(-#^TR]-X@^*?[8UIXK_L;1?V?/#U]X<A\6>*=%;Q8?%.G/#>Z#I4?A>Z
MT'Q5'I+:W:ZA:V.OVVL>([.VLG$NI1:UX2CCO;>STS6H;R'C#\:_VZ+G^QK>
MV_98L;=M5;P0NI7U_P"+_"]O%X9CU;P[J4_BMKF"#Q7?R:G/H?B:#3[.5K%6
M@@TW4%N+1-:FM+E'KZS3O%_5J7NIK102;;BVY+DY6[1:2M:/,[)"5&:NO;3U
M:W;;22:23YKK>[[M*]SHOB%\6/C-'K]NOA:S\:V6EVWA;P_=7D>A> O^$BLI
MYYK_ %B'Q>5N]5\)0WMYXTMK)=#D\*Z7:KI^@QR27UUJUKK$12RM_*]2^*O[
M5:R6Z67_  L!HX;.VCU#9\--*62>:?PQH-SHD&GWG_"!7T0U6Y\23>(+'Q_X
M@FT]O#WA^*WLIM%\-"*)A?\ I5[\1?VP?#^F_"K3HO@SK7C0R_#KPQKGQ$\0
M6NJ> -.UZR\:VMOXCD\4>'KO3Y_$%GHNH75Z]CH,-C::''8::USJ<Q;Q%8VZ
MAH.T^#WQ:_:2U?7+K3OC-\";KPEILNCZ!'H6JZ%=:5J U'Q)<>$]-UK7(]0A
MM?$NL#0=,L];;7?#XGOI3&ES9:2T%S>QZE+- 1Q-.*2^K4I65O>2;>VK;BVW
MO]^X.C-_\OJBUOHVNO;FM;I_3(/$G[07Q0^WZU;^#/A5J<]C#;Z=-X=U#Q3X
M?\::>=2GDTUY-2M-4@L-%N'TOR-8GTW3XKA5GWV!UO51:G^RK>SU'UGX)>*_
M'?C.Q\7:SXZT^YT.:/Q3<:5H>A2:/=:9:0:+IMK;Q6VLV$VHV5IJEW#XC+G4
MIHKYIVTRZ,VG0R&* ,_S;I7QC_;CO_#\^M7_ .S1HVBW,5]HED/#MQXET.\\
M2-8:Q917VL>((4L_%CZ%<-X,)N--_L%M7MIO$^HPVXMM2TZUNGN[?%\7^-?V
MY[/1?AO8>&?AI?:MJ2>%/$_B?QKJ<5WX#L+O5/$C>$OC-'HG@:_EO-5N-/\
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M.GN;SPQI=GKX6YO8>8\2:]^W9X?U;18O"G@!O%>D66M^-/$<KZKK7@"2YO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>klk1lvls.jpg
<TEXT>
begin 644 klk1lvls.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M,3$//(J"0IZ"?'/@D>)1X+/C'PL/&+1>>OA,^(=)'B4P>69?.&A?:_[4,7E
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M'?M3ZUI_A7PW:22C2= T]K2YB^R:5:O(Z6ML%M88@D0 V6T49)$*A?E/X5_
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M94Z>#I5L'B*-;#T:-/'0HU:<9NG6H4YT7!4ZG*OQ0\:_LT_"5/\ @H?^R#\
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MQ:3J-U;B[M['47T+Q:+.]GLRR"[@M)]EQ-;%T$T4;H70,6%;XK?LD>,OAO\
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M)',NZ.1&;S/QC^V5^S)X%TSX5:YKWQD\$?\ "/\ QI\=/\./A[XBTS7+#5M
MU?Q5!I^IZC=V<^L:?//8:;;V$6E7-OJ-[J$]O;6%_+9V-U)%=7EO&_Y7?&3]
MGSXQ_&Z^_:;^)7PK^"/Q"^"7@O4#^Q+I$?PQET3X=^'O''Q=N?V=OB9X_P#&
MOQ2\1>'O".MQ^*/ UU-;^$O%WAKP?X1'C+3+W1_',GA%K>:TDTVWTF23I_\
MA0/B*SM_"/QBT'X._M'>,+73/VZ_ ?QF\:^&OB[X:^!6G^/]:\-6'P/U/X5:
MWXY\#?"OX7>%_A]X;\-:>E]>^'4UW2;ZQB\3>(Y?#=UXL=9FD@-P0RG+DN>I
MC'*[M["-;#QJQJ2PF'JPHSJ6G2YG6K3A[2+:?L)P=.,G4E04L9BGI&AI_P _
M'"JX.*KU(2FHJT[<D%+EW_>1?,THJI^QME\3/AUJ3^%H[#QUX2O)/'%WKMAX
M,CMO$&E32>*K[PN;I?$EGX>C2Z+ZO=: UE>+K-O8+/+IC6MPMXD)AD"\_?\
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MQ5#=>,O#]O-X;TFRO+73[K4==AEOTETFSAO[VTL6N+Y((S>7,-LK&:14)?\
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M;<2?^8K.%V_ZE_GZG]2M%?RQM_P<H0KC_C%O.<_\U);M_P!RI4#?\'*\*_\
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M8_,__F,_K$HK^35O^#GF($C_ (9./_ASSZ?]BE3&_P"#GR(?\VFG_P .>?\
MYDC_ $J'X.>(JWR#_P R>4JWWX[Y&B\5>!);9W>__4!F2_/">9_6;17\EK?\
M'0,*YS^R8QQC_FIY[_\ <I5$?^#H2+M^R6?Q^*!_^9*I?@_XA+?(+>?]I95^
MF-+7BCP.[6SK?_J S'_YD/ZUZ1E5U9'4,KJ596 *LK##*P/!!!((/!'!K^21
MO^#HF)?^;2CUQ_R5 ^__ %*50G_@Z.A!Q_PR22?^RHG_ .9&H?A%X@+?(O\
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MP31AU+P)^UYXF^'OQ-N_$?B7]EKXT6WPLM?!E]I-A!J'Q*TW0=#FUGXF^(-
M:VNO--[X3L].UG6[71;>WN9+CP_IES/<3+-"[-Y1\3?^"='Q5T#XO?&3X??#
M37? /BWPW\)/&)\(3>(O&_Q7^$/PKUG5+I/#VC^();B+POXW\<:'JDL AU>.
M*.ZL+:ZLII(WACN&N(Y88^Y\<_M]3_#SXO?$+6_V?19ZIX9U+]LV/]K;POXH
MU6#5].NM0MK[PKX@\.ZO\,O$/AS4;>W\_0M3TSQ?K&B:^TV\7212?9&N+6:*
MX/D?Q4_X*(?M"^-?B_\ &'XH^!/%$GP@T[XQ^-;KQQK7@;PU;:#K.CV&J7>D
MZ;H\R6M]XAT"]U%XOL>F6\:J'AC1 %2)2"S>=@UQS*JINK@I8:M@HUJ3S."I
MRI8B<,IBZ&(H82$,1&25/'UZ;:3A5Q->E7C&-/#'IXE\'JGR*EBXXBGBY4JG
M]G3=2-2A&>8R5:C6Q,I4)0?M,%2FDWS4J-&K0E*53$'TM8_\$AO&?BSP!X,N
M_ ?Q)O-<^*^N>$?V=?B)XA\.ZG\.M3TCX4:?X/\ VE_%>G^$/"8\+_&"+6-0
MM?%?B/P=J&KZ;/X\TF+P[9Q6MM/<?V5=7LMA*DW)_$'_ ()EZ-X6^,ND_!7P
M_P#%#XD:OXK\6?#;X]:UX,M?&WP(\2?"B;Q)\0O@=H&K^(H;+0[C7[[5?#WB
M;X<_$6R\-ZXGA;Q+HGB$Z[8S#3QK^A:<ES&\^+X-_P""I'CWX4?";PEX#^$7
MP[TKP1XOT2;X5KK_ (PE\?\ Q \3^&-=L_A)XTL?'VE'2/A/KVL7/@OP5JOB
MWQ)I6F7GQ U7P_#$_B!;9K>WM]-@GEC/J.A?\%0O#.N?$KP)XJU7X<V/PK\)
M_!+2OVLOBUX,\-1>)O'GQ3U#QQ^T;^T-X!U?PS]FN/$'B26]U#PUX+;6]5M+
MS3=%\V#1?#>F:9<Q?;IKJ>W\SR*DO$"E4Q,ZE3VV&@LS>$4(94JLI1P+>#E7
MIT55J.C/,(P6%HT&ZRP]2J\?7A&G!3]BBN"JE/#PIQ]E7G]06(<YYBZ:B\9%
M8M4JE1TH*K'!2E+$U:T52=6%-8.C)U)2A^)SL'"N.C#</HV".O/0]ZIMT/T/
M\JM-A51=P8J,%LC+$  L?<]351B,'D=#W%??56GS6:Z=?0^5H]-+?#_PQ2FZ
M'Z#^=5'^Z?P_F*M3$'(!!X'?WS51R ""0.G?\:XJC7=?$G\O<U]#TJ2>FGVD
M_EIJ49NI^H_E55^@^O\ 0U9E()."#S_(8-579<#D=?4?Y[UPU&M-?Z=K'I44
M[K1[OIY(J-U/U/\ .JDO?_>/]:M%AD\CJ>_O525EYY'WO4>]>?/I\_T/5HIV
MCH]U^A_H/?\ !M'\7_%GQ+_X)XWOA7Q3J%SJ<'P7^-/C#X=>$[F[GEN)[;PG
M<:%X4\:V.D^9,[O]FTG4/%>JVNGQ*5BM-.%I90(D%K&H_H5K^9#_ (-8Y(T_
M8>^-P9U4_P##47B X+#H?A?\+\?R-?TU>?#_ ,]$_P"^A7\>\;TZ=+BS/H4X
MQA#Z_4GRQ22YJD85)M):>].<I/S;/Z(X;G*>197*<G*7U6$;MW=HN48J_E%)
M+R2):*B\^'_GHG_?0H\^'_GHG_?0KY4]LEHJ+SX?^>B?]]"CSX?^>B?]]"@"
M6BHO/A_YZ)_WT*//A_YZ)_WT* ):*B\^'_GHG_?0IPEC/21#_P "'^- #Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD) &20!
MZDX'ZT +13/,C_YZ)_WTO^-'F1_\]$_[Z7_&G9]G]S%==U]Z'TA95&6( ]S_
M "]3[#FFF6,<F1 /4NO^-9ISJ,K*L@^Q1G$C12!C._>$.A*K&!C[1M)<[A#E
M?WP(TUNFO4+I[-/YCWN9[CY+)5(/#7#G]S'W.&&6F<8&4C  + /*K*R"(Z29
M<_:KVZFW=5B*VR#'0*8P9U'J//.>_'%:RJJJ%4!54 *H   '   X  Z"EI#,
M?^P[$YRUZ<G/.HWW'L,7  'TZ\9S@8/["L/^GS_P8W__ ,DUL44 8_\ 85A_
MT^?^#&__ /DFC^PK#_I\_P#!C?\ _P DUL44 8_]A6'_ $^?^#&__P#DFJFH
M>%-%U2PO]+OX;JXL-3LKO3KZW?4M0"7%G?6\EK=0.5N@P2:WEDC;:0=K'!!Y
MKHZ*:;BU*+:DFFFFTTT[IIK5-/5-:IB:4DXR2<6FFFDTTU9IIZ--:-/1H_-)
MO^"/_P#P3J<DM^S=H!)))/\ PDOC?J3D_P#,R^M1G_@CS_P3F/7]FSP__P"%
M+XX_^:6OTQHKZG_7OC;_ *+#B?YY]FG2W_45Y(^67 O!*VX/X87_ '0<K\O^
MH7R7]7/S+/\ P1V_X)QGK^S5X>/?_D9?''_S2TP_\$<O^"<!SG]FCP]SU_XJ
M;QSW_P"YFK]-Z*7^O'&G_17<3?//<S\O^HKR12X'X+6W"7#2],CRSR_ZA?+^
MKL_,4_\ !&[_ ()NGK^S/X>_\*;QU_\ -/33_P $:O\ @FV>O[,WAW_PI_'?
MZ_\ %3\U^GE%3_KMQD]^+.)'ZYYF;VM_U$^2_ILI<%<'+;A3AQ?]T3+?+_J&
M\D?F!_PYG_X)LGK^S+X=/U\3>.N/I_Q4]1G_ ((Q_P#!-8]?V9/#Q^OB?QW_
M /-/7ZAT4O\ 73C#_HJ^(_\ P]YEY?\ 43Y+U*7!O"*VX6X=7IDN7?\ S-Y'
MY<G_ ((O_P#!-,\_\,Q>'?\ PI_'?_S3TP_\$6_^":!Z_LP>'#V_Y&CQY_\
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M_L*P_P"GS_P8W_\ \DUL45D68_\ 85A_T^?^#&__ /DFC^PK#_I\_P#!C?\
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M_2_X(!112,0JECP%!)//0#)Z9/3T!-+\NOX?U^J%?\&E^7GY_P##BT5XQ/\
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M^&]=5WO_ $@O_7W=O7^EJ%%%%/\ K^OZ_P""7W]?/RW^_P"[T849YZ'Z]O\
M&BBE_7;\]O3</U^7_#O^O4HHHIA?[M.N]_ZT[O[PHHHI:VZ=/3I_2^07U^7X
MMI+;^NVS"BBBC^GZ_?\ Y^H-V_KT_P ]%U84444=?O\ T_X/]7&%%%%%_P!/
MTZ.UM_/YO0/Z_(****8K[>?FO+5=UKZ^6H5\C?MMDCX%W9'!'C#P7_Z>X:^N
M:^1?VW/^2%7?_8X>"_\ T]PUTX/_ 'O#?]?Z7_I<3#%_[KB/^O-3_P!(9Y!X
M)FD'AZPPQ&+>(=!TV#VKKO/E_OG]/\*XWP3_ ,B]8?\ 7"+_ - %=;7Z732<
M(MI-VW:/S\GCNKB)UEBFDBD7E9(V,<BD="KIAE([$$$'I7HOAKXF:WH[I#J$
MTNJV0PICNI#)<*HQ_JKIR95?'0S-+%P%V1[C*OF=%17PN'Q,'"O1A4BU;6*Y
MEYQDO>B_.+3-J->M0DIT:DX--/W6[.W24?ADK:6DFK'V_I.JV.MV$&HZ?-YU
MM.N5)&V2-QP\,R<F.6-OE=#T/(+*58Z-?-OPEU^2TU@Z-+)_HVI(XB1FX6[A
MC>6-D&WJT,<L3DN<@6ZJOR9KZ2K\]S+!/ 8J="[E!I5*4GO*G*Z5[:7C)2BV
MK)N-TDG8^UP&+6,P\:MDIIN%2*V4XI-V\I)J2[)VUL%%%%<!VA1110 4444
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M HHHH?IV7ENO\];VOMJMCK_7E_P=->CTZE%%%']?E_2?0/ZT_KH%%%%&UO\
MAEV]/E]UV%T[/;;\;:?/2_\ P HHHH?GZ>6MOZ^=@Z^G7[KW?3TZ]T%%%%'7
M^O+^MGZH/U_X&OG^&VS"BBBC_@>7;M^7E;8/Z[W7]?\ #A1111U_K7;_ "MY
M7"]_P\^W6S[_ /#;HHHHHZ_?^FW_  WW+<]._3Y.^W;_ "5W8****/PV^_\
MK37ML'Z=M?TWW7DK[7"BBBG;^ON_R#[K?EM;3I_3ZA1112MMV[?E]W^0:/\
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MJRZ%H^HZRUCJ6III=G<7K:;HUG+J.K7XMX7<6>F6$'[V]OKA@([6V3YIIF1
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M^-+G]I@>./"MY81:CI9&L^'X/A!X&2&PN[[_ (E4WBBYDUIC%<6"H6_K[O\
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M'A%%%%?H1\2%%%% '5?"O_DJ&F_]@?6?_14-?8U?'/PK_P"2H:;_ -@?6?\
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MX;\/:AXA^-EU?>']#OKJ7]HKXWB6ZO-(L+NXD">-[Y4$D\]M),VQ5")N<A$
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M6'_7"+_T 5UM?IE/X(^A^?A1115@=1X+_P"1IT/_ +"5E_Z4Q5]D5\;^"_\
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M+>-)$)7X5$95@1D'&1D$@U?_ .$YE./^+8_M&]3_ ,VJ_M*]A[?"K^5?O/\
M:N6:_P#"EE^Z_P"8W#=;?]/?._IZ.W\VK)LWLU_969=/^8#%OM_T[[[VM=VW
M6AZQ\ R/^&U_@%QU^&'[16WC@?NOA,3CTSS[9)'7K^V5?B'^S#+KGB?]L;X/
MZQ:?#SXQZ/HGAOX9_'6+7-?\;?!+XN_#KP_87&N'X81:-9-KGC[P7X;TJ>_U
M-]/U V=A:W<UW,EC=2K 8X9'7]O*_*.*ZU&OG5>K0JTZU-T\.E4I5(U(-JE!
M-*4'*+::L[.Z=UHS]IX,H5\-D.&I8BC5P]6-7$MTZU.=*HE*M)Q;A44913BU
M:ZU[A1117SG_  --++;RZ;K_ (:WU/\ 5_N]-_+3OV/YW?\ @NP<>*OV/^F?
M,^.'![_\27P3T]QUQWQ^(_#8]2.W0GC SU[Y&3Z^G /;]\?^"W7@+XB^+M:_
M95U3P-\,/BA\1;/0+KXOP:Y)\-?AMXW^(\FB/K&C>%$TPZO:>"-!UZ[TV*_:
MRNH[6XO((8)I()(TE+@K7X@_\*I^.G_1MG[4WT/[+W[0'7'_ &3GD8P,G.>0
M.XK^O?!S/LAR[@C"X;'YUE&!Q,<PS"4L/B\RP6&K*,ZJ<).C6K0J14E\,FK2
M35FS^1/&3(,^S'CC%8G+\DS?'89Y=EL%B,%EF-Q5"4X4&IP5:A0G3<H2:4DI
M7BW:5K:<8#SQQR,<@#.?PSCD#C!QU/&/Z>/^"(W_ "8EI?\ V7/]HW_U<?BO
M\OISBOYNA\*OCIQG]FO]J;\?V7OV@">Q_P"B==>/\*_II_X(W^#/&O@7]B/0
MM&\>^"_&'@'7KGXN_'?7$\.^._"^N^#?$D>D:[\5/$NIZ-?7?AWQ)8:9K5A#
MJ6G7$%[9B^L;>2:VFBF52CJQ\+QUSK)\SX?R:EEN;99F%6GG#J5*>!S#"8R=
M.G]2Q$>><*%:I*,.:2CSR25VHI\S2/=\"LDSG+,_SFMF649IEU*IDRITZN/R
M_%X.G4J?7L++V<*F(HTXRGRISY(MRY8MVLFS]3Z***_E_M\O/:W?\]_G8_I[
MRZJU_/S^?Y^@4444GMNMM[)WO;IUO:UK_?H'9?KKI;[]]=?O"BBBG;[_ /AM
M-O+^M 7W_<^VNEO7KO?R"BBBC73T\O+SMWV^3VN/R_K^M=.NUPHHHI=G=?YI
MV_X;YWOT#7^MNGS_  ^[0****=MO^&_X/R;]>EC^OR^3]>GWA1111;3L]%>R
M\EZ?IMN';3Y:=U^7E^.@4444/RMY+RNOP76UK^MF&O\ 6O\ 7=76VFG0HHHH
MZ?-;:;6>S^^V]@Z^7_#?=_P^W4HHHHU[_-;/;_@K=]^P?UKTV]?SW_ KY%_;
M<_Y(5=_]CAX+_P#3W#7UU7R+^VY_R0J[_P"QP\%_^GN&NK!_[WAO^O\ 2_\
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M%K_M6_\ 1I&B_P#B1?A3_P"8NOK"B@7_  _])_TCY/\ ^%K_ +5O_1I&B_\
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M]?D7^Y2_Z_U/_2:84445X1[(4444 %%%%39]==NWE>ZV^Y^FNZ[=O7TZ[O\
M"_5.X4444[_*_P!_3M?YMZ?>"6_JOR7]=?T"BBBC[GJO/33M_2O>_0-?GIM^
M/ZL****'^7Z.[Z/RTZ]+;A^7GOTM^M[ZA1110_Z_X&GE?RWZ!W_X/E_P?38*
M***&]'VTW\[=+7^3Z^0?U\_\OZUN%%%%#_#KZW5N^V_]7#7^NW2]^O??8***
M*.UMONM\K?Y _P#+\U^@C$ <D#(/4X^O_P!?TK\^M<_9X_:4U?QWXKNY_CH+
MOX9ZCJUM=^&O"-SJFKK<65O9>+M+UBR6]N$LRLHET/4/%FG7=JDLD/VBP\'-
M;R+]CFD@]7_:/\$Q_&B70?AQX8^(]AX,\<^%-0TWQS+YMM=7\ECIUP]UIFG7
M\MH2VCSSF]61K"QU*-+VY:&232-0T2ZC35(O$=$_9/UC0+ZWTO4?VA+V'5/$
M/CN_OIA%<J=3\6^$X436/$>C3V?VBQA3Q#J5[9>')=6U:W@N[JSTB#4K;[7(
M=7CEMCS_ *UMJT[;#/1?V:OV>OB%\&;[09=;\6R7VGIX?\3:7XHT6#QEXEU_
M2+[4B? -KX,UBQL=:AA@BO+2ST/Q:^J7GD6][+)XA@MWDOTB,L7VP"#R#D>H
MK\PM,_86\1VGA_5+#4_C=<ZAK@L].MM&NY96,"7,.M^%[K6);^TGCDTQ!\1K
M#0+_ $KQEY6B7%Q<IXDUA3-JLMQ<SWOWY\*_"\W@?X?>$_!EWKQ\27WAG1K;
M2+S5WGEGEN[BU!$A=IYIYPL180QK*X*11QJ(X5"Q(P/0:***73[O+MMU7H_1
MZ"^6^_6VWX=[>MMPHHHHOT6GRMHK7W7F'_#:>JUN_+?KKIK8****%_P^M[;>
M5_O[_<*ZZ?Y]-]7MWN]%T"BBBG_78/3\;WZ=_*_]704444O+MWZ[:JVFGIOV
MZE_ZUO\ /MZ=.X4444+H_+MWMZV_JXM5OMY-MZV77MU?SLM0HHHH_'OMOIKY
M6WTMZ#_R?:^ZTU^[>R^ZQ1111;7;1:?DU;I_PP=?2_X]^W_#6:6@4444?K;R
M[?U;KL"O?R:OUT^__@>FX4444>7;_@>GX:+\ U_SO\NVG?3J]NH5\B?MNLH^
M!EPI.&D\9^#$0?WF&L1N0/\ @",WT!KZ[KX&_;L\21OI/PP^'=M)&U_XC\9+
MX@NH5?,T>E^'+.>)7>(<B&XOM3C"2-A3):LHR0<=N7P<\;AHI-_OH2T[1?,_
MP3.;&R4,)B')V7LI1^<ERK\6CF_!7_(OV'_7"+_T 5UM8/ANW-MI%I$1C;"@
M[CHH['IU_'K6]7Z5%6BDNR/@0HHHJ@.H\%Y/BG0\ G_B96?3T%S$2?H!R?85
M]D5\P_"K19+_ ,01:BRM]GTQ7N"W1&D9)(84.<;B9&\Q-I.&MV)' -?3U?$<
M25(SQE.$6FZ5!*=GM*<I22?9\K3UULUIW^LR&G*.%J3::52J^7S48J+:\N:Z
M]4PHHHKYX]P**** "BBB@ HHHH **** "BBB@ ILB)*CQ2*KQR(R2(P#*Z."
MK*RG@JRD@@\$$@TZBC;8-]SYM\;?#:\TZ674-#MY+O3R2[6\*F2XM%QG:8E!
MDFC4\))&'8)M$R+L>>3R3RY,D;&RIPP"D[3Z' X/L>:^[:RKO0M%OW,E[I6G
MW,C'+2S6D#RD^ID*;ST[M7TN#XCJ4J<:>*I.ORJRJQDHU&E9+G334G;[5XM]
M4VVSP,5D<*DW/#U%2YG=TY)R@F]^5IWBNO*TTMDTK)?$_ER?\\W_ .^6_P *
M/+D_YYO_ -\M_A7V7_PB/AC_ * .E_\ @'#_ /$T?\(CX8_Z .E_^ </_P 3
M7=_K-AO^@:O_ .!4_P#/U_IZ<O\ 8%?_ *"*7_@,_P#(^7?A8CK\4--+*P']
MCZSR5('^JB[D5]B5P\>@Z'IOBC3+BPTC3[.Y^S7R_:;> 1S;&A4,F5(7:W?Y
M<G'7K7<5\[F>-AC\3[>$)4X^SA#EDTW>+EKII9W/;R_"2P=!T9SC-NI*=XII
M6DHJVNM_="BBBO..X**** "BBB@ HHHH#]0HHHH **** _K^N@4444 %%%%%
MOZ] _K^OZN%%%% !1110!\9?'C]CW1OC5XMN/&2^*/\ A&]4O+'3-*ODCT..
M[BOK"QLM6LEEO+BUO]+U*;4=-_M5[[P[=QW\$NBWRS36DD<MR9XO.+7]@Z\M
M->U#Q4GQ2MY?$,_B76?$EA>S> ]*1+.\U"&80730V>H6B/J!FATF/5;V#[-<
M:O86EW:WDLDMZUS'^BE% 'YTWW[ -IJ2WNH:A\2'O?$VI^+=.\2:EJT_A>);
M>YM;;PW?Z#+I M8-7BNXK:RNM3N]=T QZDHTG4I)GC4RW4MROT=^S]\!C\"K
M;QO91^)_^$@M/%GBB3Q#:6XTB+3AI2O:6]K)'+=R76H:MK%Y>20?:KN^U?4K
MV=9&$%L\-I'%!']$44 %%%%']?U< HHHH **** M_G]P4444 %%%%%OZ_K\>
M_4 HHHH **** "BBB@ HHHI6_3\/4/Z_K[@HHKG?$WBSPWX.TV;5_$^LV.C:
M?",F:\F5&E8\+#;0+NGNKB1L)%;VT4LTKD)&C,0*8&MJ.HV&D:?>ZKJEW;V&
MFZ;:7%]?WUW*L-M9V=K$T]S<W$SD)'##$CR2.Q 55)/2OQ^N/$NH?M!_&O6?
MB8;>[3PGIBKX?\"VUQ%*I70+&9V_M%HG4>3-K5TTM_(AP4CDMXGP\9KZ?\5>
M(O$?[2-]_P (QIFEWFD?"I;B,WL5\DD-_P"+?*D61&U*&-U-MI:NBR1::9&:
M8A9;TY46T?T[X.^$W@?PMI%K86?AC18O*C5"R62Y;  Y\POZ#&,8Y]:]/+<7
MA\%5=:K2J59VY8<KBE&+^)ZO64MNEHWL]7;S\PPM?%TU2IU(4X7YI<RDW)K;
M9:):Z=7KND?+T%N\44<8C?"J!]UNP]Q4OER?\\W_ .^6_P *^R_^$1\,?] '
M2_\ P#A_^)H_X1'PQ_T =+_\ X?_ (FO?_UFPW_0-6_\"I^7GZ_AWT\;^P*_
M_012_P# 9_Y'QIY<G]Q^.3\K=!U/3M73>'?".L^)+A8[*V=;<,HFO959+2)2
M3N+3%=KL "1%%YDQ)7$80EU^J(_"OAJ)@Z:%I08=";&W?'0\!T89X'.,UNHB
M1HL<:+&B *B(H1%4= JJ % [  "L*_$UX-8;#N,VK*=62:CYJ$?B:Z7DELVF
MM#6CD%IIUZZE!?9IQ:<O)RELN]HM]FMS"\-^'K+PUIL=A:#<Q(DNK@J ]S.0
M 7;KM10 D4>2$0 9+%F;?HHKY>I4G5G.I4DYSG)RE*6[D]6_\DM$M$DD?10A
M"G"-.$5&$$HQBMDELO\ @O5O5ZA1114%!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <MXDMM4*+>Z+)'%J,$4R0O-")XAYB[3NC+H&Z#'S9'I@U
MX'>7_P"T0LSBVU;P\(LG8&\.Q,<>Y^T\]N>YS[8^I:;L3^ZO_?(_PH ^4O[1
M_:0_Z"WAS_PFXO\ Y*H_M']I#_H+>'/_  FXO_DJOJW8G]U?^^1_A1L3^ZO_
M 'R/\* /E+^T?VD/^@MX<_\ ";B_^2J/[1_:0_Z"WAS_ ,)N+_Y*KZMV)_=7
M_OD?X4;$_NK_ -\C_"@#Y2_M']I#_H+>'/\ PFXO_DJC^T?VD/\ H+>'/_";
MB_\ DJOJW8G]U?\ OD?X4;$_NK_WR/\ "@#Y2_M']I#_ *"WAS_PFXO_ )*H
M_M']I#_H+>'/_";B_P#DJOJW8G]U?^^1_A1L3^ZO_?(_PH ^4O[1_:0_Z"WA
MS_PFXO\ Y*H_M']I#_H+>'/_  FXO_DJOJW8G]U?^^1_A1L3^ZO_ 'R/\* /
ME+^T?VD/^@MX<_\ ";B_^2J/[1_:0_Z"WAS_ ,)N+_Y*KZMV)_=7_OD?X4;$
M_NK_ -\C_"@#Y2_M']I#_H+>'/\ PFXO_DJC^T?VD/\ H+>'/_";B_\ DJOJ
MW8G]U?\ OD?X4;$_NK_WR/\ "@#Y2_M']I#_ *"WAS_PFXO_ )*H_M']I#_H
M+>'/_";B_P#DJOJW8G]U?^^1_A1L3^ZO_?(_PH ^4O[1_:0_Z"WAS_PFXO\
MY*H_M']I#_H+>'/_  FXO_DJOJW8G]U?^^1_A1L3^ZO_ 'R/\* /E+^T?VD/
M^@MX<_\ ";B_^2J/[1_:0_Z"WAS_ ,)N+_Y*KZMV)_=7_OD?X4;$_NK_ -\C
M_"@#Y2_M']I#_H+>'/\ PFXO_DJC^T?VD/\ H+>'/_";B_\ DJOJW8G]U?\
MOD?X4;$_NK_WR/\ "@#Y2_M']I#_ *"WAS_PFXO_ )*H_M']I#_H+>'/_";B
M_P#DJOJW8G]U?^^1_A1L3^ZO_?(_PH ^4O[1_:0_Z"WAS_PFXO\ Y*H_M']I
M#_H+>'/_  FXO_DJOJW8G]U?^^1_A1L3^ZO_ 'R/\* /E+^T?VD/^@MX<_\
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M'/\ PFXO_DJC^T?VD/\ H+>'/_";B_\ DJOJW8G]U?\ OD?X4;$_NK_WR/\
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>placentaldisease.jpg
<TEXT>
begin 644 placentaldisease.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MRJPGEV/I2IX98R:J82M&5'").3Q4^:$4J+UBY25E9.Z<9I\=//LHK*E*CF.
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M<DH1M4?[Q*$FD]9=C8+$$C:,]LM@'\<?X]QVII=AQM'_ 'U_]C6;_:5J+I;
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M:J*:O+E]W7>U1113-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"G<*HAEWIN0(=RG RIZKG*J0P^5MV%(R&^7-?RV
M6_Q:T+X3_%.Q3]DGQ)\5-.\4>+?VHQHWQ$_8 ^,_@"/Q9;VM]JOBN1/%7Q"\
M%ZDMM>GP?IR>6=0L]9LM:DGBMVA5KL6=J(I?ZE96(C<DXPI.3M &.^6!11ZL
MPVJ,LV ,C"-AI37,NHI8V+WA1HAJBV\1O6B0>4(3>(/M4JPN?+<I*)  D.&N
M$)/T?#F>0R9XY5<)/&T\32I4YT8XB,,//EC44/;TJN%KPJ)2FIQJ4I4\1#V;
M]E6AS29\AQ1P]+/*>$]E7CAI82HJE.L\-.M4A%N+G&G5A.+I1FE:2FI4K:S@
MTK/^="&/X1_L[?$C_@K!=7'PEUG5O'6G:+;ZUX'\#Z+J'C'PKX@\2_"7QEI.
M@KX]U#P_XNTY)+JRT"X\6:O!J_B'5M-GEU>TMA<K8,L>Y$^;=,UB#2O _P"W
MOI7PY\2>&_"O@>[_ &6?@/KRQ? *T^(%I\.8M<?QK::3J;077B;4$U_5;Z^T
M]9?#GQ#\:65['J-QITVLWK03ZI;36*_UF36-E)(9IK*":1H6A9IH(F=[=V<-
M;!RA9D?[C0,=DT;+',K Y7Q?XW?L_P#PU^/_ ,,/$'PD\>:=>0>'/$::67D\
M,7IT36M,N/#VIVNM:1J.C7UG&TL,FEZI:VMQ:+-;W5H'Q;7=HT4TL3_48'CW
M".M3ECL#C*SK2RFG6G];>)HNAEO]G)^SP]3#^SBYK!>TC+VKY98BK=R32/E<
MP\/L:Z<E@,=1BZ;S.=-0P;PT_:8[ZS4BIUU57M%SUU3:7+S>RBKJ[/YH-<AT
M"[^!G[1WB[X-ZW\,-%TOQC\5OV9O^%F?!SX0I\1-4M/AI\$=!AGT?Q-JGB67
M4O#?@?X@WW@[QOXE33=5\8Z=X;TZVMC96L2)?27FHR3G]6/^":6B:9_PC_[4
M=I\.?BCX1\:> =:\4Z9+X6T3X9>#?B)X5^%'P\\3WOA:YM?$EC\/M1\>75^-
M:TS5)(=(U6_CT34+VQT?5$N(Q(@U")I_LSX(_LB^ /@YXW\9?%";Q5\0OBK\
M3/'OA_2?">O^/?BEX@LM=U?_ (1+0)&GTWPW91:;I.BZ1::.MQ,+NX8Z=-J%
M[,5DGNI(HUB7ZCMK:SM(EM[.&"VMXV<K'96\4,>YI&# "- D;[\F8JT;"3=F
M0!6 SX@XVPV,P^+P.%P^)]G4Q.&Q,:]:TX)4Z>7<WM$\-"OB?82P?L:>)E4H
M3J4JE1U82J.7,^'>!\7@:V%QV+QF'BX8>O06'A)SG*51XQ\\)JL\/2G5CB.=
MQE3DU*,4Y:'\M'[.=Q%XBU7_ ()Y_LW:'X=UR#X]_LZ_M3?&+Q;\;](ET#5-
M/O/!/AJPUC7+[5=<U?4+FSBM'M/%=K>V$=G(U],+VYMUM)$D@>PD;ZN\$?$;
M]ECX;?\ !5G2-/\ AO?>%/"7A-O@MKGPEU"'PWX<U/3M.N?CSXC^+EQ=WOA^
M\:WT>-;G7]3>5Y[G5IWDM9V>WB.H^1"B']YTL+*.5[LVUDMW=1K'+=+;0-<S
MI&H9(YYD0R7&U%12 Y V9CC1 "D8TG2GE:X.E6!F\XN9A9VOV@3<LSB7R3()
M=QD\R5W65#U,<F2F&(XXP^+EBJE; 8R%'$Y9C\)4I4L:X)UL=B<1B'BJBJ8:
M?/3P]3%<N%H27M534FZC<Y,ZZ' M?"+!JEF&']IA,?A,72G6P*JR5+#T8T94
MX*&(@U*NJ4ZDZR:3E)7C:*/PQ_X*&#X<2?M>:+'^U4-8'[/+_LI_$ ?"TRKX
MB_X19OCL=?:.[%N_AY#"GC[^P9+-= BO7CE:2>R%H'NG6)?%O@/\)9O%GQT_
MX)8:G\>?!U]K'Q"UK]GCXDZUXPO?%<>JC6M1G^'TL6K_  =O/$K33QW#:OH.
ME3:;?6<>H"*ZF:>?^T([@((X/Z.[BSM+X"*]L[:]\H^:L=Q;Q3(LD1C"3)'-
M!_K%*L(9HU5655QM9 T4SP6N]+N6"W:2!9C%<3PQLUNLP'V@K-@B*-R$,Y20
M QAEVA(P4RH<<U<)E-#+J."K4ZE# U<'.M#$2A'EK8/,<+3JX>,81EA^=X_Z
MQC5*<O:8C"4)WBXHZ,3P+&MF>(S"KBZ?/B<92QE.,\-&;A&GC*&*G2KSE6DJ
MK2I.A1?+^[C-IIZH_%G]JCPC\7_%_P#P4S^$NA?!CQ]H_P ,O%M[^R-XU@D\
M7^(/!G_"<6%OHLGC^5M2M;/2)+NQLWU66:2VN+6\GN!!"]N(9+.XB>05Y(W[
M%?P^^&O[5O[!O[+/B:YU?XC^"?#/P=_:"\5Z]=7LNHZ!;>)_&$OBB#QG/J&J
M67A^]@M[?2WUZX:XLO#TM\UB]O96\%U#J$44C-^_QM+*66.[%K#+-$LL:3&&
M'SDBSM,(DEC$H23>S((I LI=/G,+!RKP6KW$=S)#"US"FV&<I$\\8)02B%WB
M9RA8P@A&VO*N&B658]^%#C7'8?#8/!X>G"%"AEM?!<U)4XU:N(JQS&%/$NI&
M*JN>$CCINFN=\LVYKWG=;U>!\%7KXO$5*TZM;&8ZABHN52I)0PT*E"I4PZ@Y
M^S4:LJ,5:R37NN\;W_EI^ ^G:[>_M1>&+KQW\3= \#_M.:9^V=XGF\0:5/X(
M^,&N_&[QIX7.L2Q3^$]8U;1M1?P59_!75O \[1^']5O-'M/#^C6T"71F9HGI
MW@#3=8O_ -JJ[D\=_$GP[\/?VE=/_;DU.^M(K[P)\7/%/QT\3>!X]?,.D^%K
M?4=(OY/!D7P*\1>"V^SVTUSH_P#8VE,L][J%Y;!%D7^H]M/L1=O?BPMVO1"8
MVO3;Q"Y:+*N(/..V4PG)7R9IG3 *,%B*F8_L[3OM0U$65O)?B-D%^MI ;PPG
MCRA=!#*X+(?W*N4)50Z':@D].KXATJTL5/\ LU4HU<%0P=2//1?)5HNK55"D
MG@G&IETY8F,IX6:J3<J<8^U2@DO(7AS-*G2GF<IR6-GC:E6%.K3A)U%&-.?*
ML7SPQ%H2INK2<86^*#L?SO?LYO\  1?CUJ;?'RR^+MW^W7-^VWXZCT0>%G\:
M#Q5!X/FO9SX4GUUH);?P\W[/%OX;+C4(V$VC_9MV(IHW8CS*T^)W@_PA^S[\
M5?@WXZ\%:;KFKZC_ ,%'O','C6R^(6L>./!_P^^'>D^*_%.LZ]X/\<_%$^&O
ML6I^)/ VK)I%ZT&D"\;2M>EBMX[RXS#:N_\ 3DFG64=S]J6UM5NGB,?VKR4:
MX= RM'$+DQF=X4;9\I?9'LCVI$ H:*73M.F%T9[.UN5NEB-T)H(9'N3:L%@6
M82*PE^SN7(:9O*@G&^,JPED'+/CC"O$5:E; 8ET9SP5?ZM_:$U3PE;!^WY88
M5QPUJ&"BL34E0P\HRE3G&E>;3DCI? F(^JTH4LPHK%6QL)XAX"#G*EBU3A)U
M>;$<]7%U/94XU:O.H>S3Y8IML_E<\):;;>,?@I\,_!%W-<W7@2Y_X*X1>&M-
MM?"3>,_"OAVW\#:UX;EEFT[P1;ZA>Q^*O#/@N^6^NYM*LVOX+NWM+N&9I[6Z
MG$DE/Q]\&O!O@GP#^VIK_A/3?$6C:S^S_P#MP?#OPY\$'M/$?BYH_AWHVJ^)
M_!4^LVWA+3IM6>TB34SJ-^NJW?V>>:]A2V@GO2EG$P_JP%EIZR*JV5J)5FDO
M%'V2 $708 71CP'>5-S*UQ&V6P\8*[H%9S:;I\HN8WL+-UOF6:XC:WA99IHM
MK)--$T+1R[=D3I-*CS1YCXR5KHCXARIU9.G@:_L'4IUY4/K#G&I.IF&'Q=2I
M.^&C&52=*E.C.HX-N%5W23<7S?\ $.+QM/,8.JE[&-1473E!1P,Z,+)8AMVJ
MRC/1\SLM>J_E/_:DF^$4GQ-_X*1VWB&YU_\ X:#7XI?!\_LQVVCR>+FU%/&L
MOA[PM)<'P=!I .BV_B!91$-9DGCBOY-";=;.X59H_5/VJI-*\#_M5V_Q#\47
MNB_&CXEWEU^S7IWB/X!>);+XK^"_C%X4UV+3M MSKG[,/C_PM-:Z5K>EW%]/
M=:IXMM["*YLUO_M-MK3EDD>7][?AS^SK\/OAA\0OC-\3=!.KWGB3XX>)O#WC
M+Q:FO7EIJ&E:?KGA[P^WAW3KGPQ9"RB?2;=].W1WK2S75Q.T:,UPL"[*]O;3
M].N+BVO7L[66\ME9K.Z>WMGN8T.Y-MO,R;X49"0/(>%)5D8"3!9QN^/\'AJV
M$]A@<95H4<$J%:=7$*%2JZV!P%"K2HU%A93PF!]M@W+EC-UY5*E6:JP57E,:
M7A]C,13Q;QN8X>AB,3BW7I4Z-%RIT/98C$2A4E'ZUR5L14HXE1BI)Q3A'GB^
M33^;7QCXVTGPIX1_;@T_QIX+B\9>'?&W_!2O2O!=])XO\3>-?#/PZ\&6=_HV
MF:R/%7Q)N/!SIK.H?#K3;C3@FJ^'(S;Z1K%W/%;7\S92*36_9COOV>+CX1?%
M;2?VA;S4YOA-I/\ P4+\-1_!BV^%^F_$;2/"%EXWU+2[&^\+)X0T:SFN_$FD
M_#.]EDOKQ+#59SH:V[)*H\^2%Q_1I)I6GR++;O967DW+&:XA%K"8;B0^6PGG
M1E E/FP1N[LLDX80-YJJ,&-=/T\F4I86N3,L\A:TMD/VV!T2UN&S;LWVF K'
MY-PZL?+5)+<R)M->54XPH5,!6P/U.K3K5JV&E[6GC'S)82C@X4W24J7+3K.%
M&5.3A))QGK&ZN>EA^!\10Q]'&_7\/5HX:E6A[&OA%34E5JXFK5DXTZRC+FE4
MC/6,GHK6V/R2_P""E6G>--=^.?\ P3QTWX;:]IWA;QM<?&[QG%X>\3:SX>NO
M$NC:+J+^"45KS4M$C>V-];20F6$VUU=V2"XDMI?M<8@?/SM\?OV<)?V0O GP
M2^('Q%\>7WQ'UGQ7_P %#?AO\>_C_P#%*+PD=)T31IIM-UNPNM2B\.:,VJMH
MOAW2K<".-BUPTQN'@9!&]O9C]_6L[2=H7DMX99;9O,MY'BC:2 E-GF0R2EGA
M=E=XUD1XYFVRJ9<J-J2VT%W');W"1W$,Z1JT<HBFB=<9176576<LPW;F#912
M44AGSS8/C.IA,+E&7TZ%)8+"T\1#%W]C#$XNG4Q&)Q,5[=4W.*H5,3&=*DW*
MBZE)5)1D]#KS#@FGCL1F&,KUU+'8VI&>&=-U7A\(Z>'HTU'V-2HJ<E55#ED[
M<RBVE);G\N7QV^(_AKQ3^T[>>,?#'AG0?AU\0M _;L^$/A=KVZUGXE>(/C]X
M@\+:?JFCZ7/XRMK^XO(_!O@'X+^*M&O(X],\+6-DUIJ]O+")MFH(/.]B\$?\
M*!MOVG_C#)^TU9?&&?\ :[;]MYW^#<?@5/&T?C-OASG3_P#A6\VAO;R6>B-\
M'ETB2Z;Q2'D&GOIH0:A#Y$;QC^B0Z9I9>246E@;F=;;S)3;VIDE%L ;)_,*,
M\@@:-GL&>28PDL5VE0$E-G:_:UNGMK?[:L30I=>2/M"QEPR6ZS[9)!'\I\Q2
MS1%U+JCHCQ1^G7XVPTL)3PE++\3AH4<'+!1JTLQYL9%R6$:I3K_5;SPM1T)^
MTH<K<H5&HR5CS</P)B*6+EBIYE#$2KXYXRIAY82,<$XM8B%XPA748UZ2J*4)
M12?-%-W>I_+6FF^(=1_:R\=-X]^*/AWX;?M%Z=^V]9W?@R6^\"?&'Q9\:=:^
M'\6IV*^#?#7A!M O9?"4'P(\2^$9+G3KM9-'?2K9VFO=4NK>-;1P[QKX!TJV
ML/CS\=+>#Q!;?%/PC_P5@T;PWX5\2PZUXA230?#^H^,O#[ZI9:5I0O'T>*VU
M#^T)QJUS#8E]0MHK:WO+IDM A_J.%EIKW<5ZUI92:C;0F."\$,#7<4#G'DK,
M=TZ0O,SJB^8C2#S(Y%WK(SO-AILF^);.S,9GBN)/]&B\M[D!9A<G*;6F1]CB
M=MP#KM61I5=(]9>(%GAI++Y4U2PV%I3M6A[M.-:E*5"/^S*HL)75/DA0JRJ*
MG*=3HVGE_P 0ZJ\E5O,Y5)U,5BJK?LJB]I*K3<:<[*K:#H.6B@HI\JNGN?SM
MF#X4?L]?'?\ X*IZG?\ PFU/6?'EOX'TWQ)\-_!>B7/BSPUX@\5_#;Q9X3MI
M_BI>^%O$VF+<M9Z;/XEU:VU3Q#JFC.=;T^V:9M,$"PR*ORMH<,>I^#_VZO#/
MPMLO"-UX0UO]A#P1X@C\+?!"R\>77@)O$VGZZ3-+;/XKN=0U'Q;XQT?1[BZL
MO$_BFQ0/?SQWD=];VVH0W=DO]9AM]/DG:>2&WDNC:R0JS+;R7#VUPSS)&DDY
M=EA=8R8X3*D#8E:2(B-?+2UTS3;-%^R:?;V96+R(S:V<<#Q0Y\Q($6.$ 0&1
MC*+=PRJY7?"6WE9P_'_LX>UK995Q&,Q-+*E-U\9.=+DRN&"Y4J<J#4*<W@E)
M22<^;%5>9RBXQ6F(\/9U:L(4<QAA\)3J9A)>SP;]HI8NI6E*<I*?/5=L0DE.
M4K>S5EW_ !8_;B\8>&O'/_!)[P=XL\*ZC_;>A3Q?L]A;NRM;U"TNA>+_  QI
MVL12V@A@O8Y+"\L-1AN8V@#K-;[E! 0MP_C'XF>$/VK_ -L'X??$W]GVQUSQ
M-X%_9_\ V;/CQ9_%7XLIX;US0M#O;OQAX*U"Q\->";34]7T[29M:U*#4KF75
M9(8&GM[5I+B[M"5BN9C^[YT_3Q:M9?8[<V)*K]F:VC%FGEDR$B%T:V3YL/*Z
M1*@)9E<2@;EBL["SMY(HK>VM;=L@HD$,,:M/@%5A6((LCNQ5%'F2SLZ[XY\*
M3PX+BS#8+#5:%/ U98J-;-9X:K/$*-"E2SBA2PU>%2"P_P#M%>C2H-4I*I"$
M92C.=*=DCLQG!N(QN)A7GCH1HSPN7T*D5AY.<YY96Q%6E*C4]I>%/$3G#VT4
MU=)QV9_)KXPTGPM)^RG^Q-XU\8>.O"NHZUX5_9D\>S6OP-^-N@?$O_A77Q-L
MV\5ZH=0N/"'COPM)9MX?^.16WM]*\.QW$_\ :T[3Z=-!)'"))9/0OVHKP^-/
MB%\-KWXR2:)\'?A/XD_85\%2?".V^-FF?%OQU!X#\37Z1CQ1:^#[GPGJ6FZO
M?_'30P^E3:?J.OQ:AK.H:?:V8^Q">Z-FW]0LNE:7/#%#+IEI-%:2)-:Q2V-O
M)%;S1+(L,T$0C=(IP3D31" J-L8E!BD59+K3M/NXU6_L[6\6VF6YMS<VL%PT
M<Z91)8A(C#[2262-H A56,<:JC(S^A2\0Z498:O4P,ZD:57-*E.K2Q485:$,
M?7E7E'"-87V<:D)2G&I5KQJU9TY2IJ2BTEYM?PUKU*.)H1S1P52GED)TE1J6
MJ5<#%P3YO;)QC4<HWC"48MJ[ON?R^?M?^+K#4_#F@?#WXB6.B^(O'W@7]A+P
M[K&@?&[XI6_QAL]>^(&KZU:37%K'\'?A;9WMI%X?^*%M)8KJ&N^+O%,+Z_IM
MPIBU.T33K&]D%#]I^X\/:=-\%_B]XN\4:5\7/'$?[*7[.K7O[//Q5M/BMX>\
M3>(FO+72+W_A*OV;/BGX.:PM?^%F:GJ\UR/$2Z=-<7T$D-\+HM%=_94_J/DL
M-.NC%/<6=I=2*DBP3FTMKIX89D"2V]O-Y3,(IPC"=(F!=4^81*T,*MDTG29)
M+"66PLF>Q5GTYC;V\OV#<D:AM/+1>7;96!&5HA%\J%PJJ9=BPW'F'PT<#RY;
M5C"@\4ZWL\7!+$?7)4)58THO".6"ISK4TZ_L7&7+5DJ,J.B>M?P^Q6(GBIO,
MU.>(^KJE'ZO_ +LJ$FX/3$-56H0T53F4K>\G=L_E]_:WMM2\1?M.?M #XO\
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MX1L(?$W@3PM#H"6UGXY^%/QUT.W\=Z%<^&M0U6;Q?XC\,:AXFM%^@;7]LO\
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M!*T8MN$;>ZURII+5E3P<Y3@Z>(FH1@N:.EYSC%QBYR:O*RD[7D[:-:Q1_/\
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MC_\ A,-,'5;K'^X_]4 _6D_X3'2ST6[S_N'^@)_2CZOB/^?3^_\ X ?6:/\
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M+X76IJ7^%SBG^!CB).-"M);QIS:^46?D%^W_ *-JOB#]E_7M(TC1CXEU._\
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M>%;R\N]*T*S\7>/;_6_#\NF^(M<U&'57N ?V,0X(!/4@=.O!_ #-><Z=\1_
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MH2W5W%>V>D7-C;:@9I<?VC'=KLB7]POL*QC)3<1GJ,G&U5"A=A)15(!#+&J
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M7S=>$M1T#Q!\0[>_OM+W7A-WI \!_$"YLM @9[6XTOQ#I=L.=-FEBM^1T_\
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MX/\ ^$2OK5;S3M%O='N+6*4SV"7FDW?ZYI$B  ,HY/\  6V@XRJ[B0J#D*@
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M*D-G8?YZ]/\ ^"EO_!+#3!-)\/?B;\>?@82_F2W/P@\(?'#P1X5$K',4ESX
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M0"<_*#7Z-2FITZ=9+W*D?=B[WBWRK]YV;;]RSUNKW/\ ++.<MJ95FF.P'QK
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MCZOH6IV-Q8ZMINJV=XLUE<Z9?Z?<3VU_!<1M;W5O++!,'@D:(?EKX"^,VO\
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MP/#JPN4QP-+'U:]7^UGAZ%"GBL1AYPC"%"I54/:JE24;RIPE&,DY*:DG)/\
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MO$/QJ_82^*4\ WO9:U:1-XAU3PKI]^V_]U*GBV&QMYHY9K*!(#)#^K/[-/\
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M%TK7]-U"UDTW._9P^%G@W]KS]E7XK?\ !/7]I".$?$?]F+Q9K>@?#CQJ8O\
MBJ/ EM?7M[/X#\<^%[Q6AN9=+T_4TFTW4-,63^S]9\,W.FV6H.WVBPNK+Z3"
M\4Y5G]>&#S3 0HTL12A"&<0<*6-PV(IR3J3JJ"C2K4K7;4H-M7Y>[_$<3X*\
M8\&Y5F>:83-Z>-QF%QM?%?V9&G/ZIB,!5J8EPE*%64JD*[E",%43:AS*3M=(
M_IM\%^.M>^'NLIJ6E2,H=E@U;2KDA+:^BMR5DAN;=V#17< 8>5<I'(]O(I0(
M(EFAD_2+P1XUT;QSH\.M:--N4@1W=K*R_:;"Z"[I[.Y4 %)(2?O-E60JR,=U
M?RE_\$H/VFOB)\6/A=\1?V=?V@KR2X_:5_8V\:M\)/B#>7MR9]2\8>%;62[L
M_ OC2>5F#ZE+);Z5=:)J.K,C-J8T_1]8N7:YUIY)/V9^'WC[5/A_K\.JV3,]
MG+Y46LZ8I(BOK/<1E4.\"XME8M;,0SD9A=V#AX_/S#"5<JS"M@*SNJ+@HU$K
MK$1J14Z=6.GPSIOGTTZ'X_Q;P=@^.LFCQ%E%-87.:=.NL13G%T_;5<.U"IA*
MT='.I=2C0J-/2SNTS]3O,;CY003@G=@Y^F"3QGOVIZEB3D8';_/?\/ZUS?AS
MQ!IWB?2-/UK29Q/8WUN)XG4 ,NXY,,J;F:*:%@T,B-DHZ.&Q\F[HPV3WY[>F
M!U'U],?_ %\E9WU_K_AM?^'/Y?J4JM&K6I583A4I3E3JTIKEE1G"RDG%^]JT
M]]N][H?11100%(W0_0_RI:1NA^A_E0!\]_M%?\@3P#_V4O0O_37KM>Z:3_R#
MK/\ Z]HOY&O"_P!HK_D"> ?^REZ%_P"FO7:]TTG_ )!UG_U[1?R- &C1110
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MR\U:\U'459LF[64+*KD7RHXDC:20(D2+)*OF3.8T$2F68VZQ,$<%92F0A,3
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M8.I4;E&$ES.--7TA.FY2]U.W+T:L?J[\.]?%Y8MILKEF10]J7/W?,&)(P.K
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M;T :7X/\(Z9 P?6/%.LR@16T,4;F"W-SJ]_+:Z987UW']E?L[_#[7/A?\%_
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MXI6W\MM/^"/G[3^K? SX"^"9]+^%?@WQE\!+'XH:Y?S0^(?!%[!\4O'5]=?
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M.M#*H3PM3-*&'DH-Q>"Y_:SG%14*OLHU%%IM*#/:_P!O;4OVS=9\%:?\*&^
M7AOX<?!NTU@W3K\"H([[PYKNN7\\<"OK":+I>@RZ':3W[VTM\)=$@>\ECAAU
M"^O+6"WM8_U8\#75OX$\!?#;X4ZIIWA[0=7LOA'X6T6U^'FJ6^C#X=_$'QE<
MZ;?Q^.?@7JWB34]+.AVGC_Q;X+;1=9\!^'&O[:^UAM1O-3OO#OB;2/M6GS<E
M\+O^"U?[+7Q?-MH'[87P0\1_ /QI<+'9W7Q,^&ZW7BWP/-<SD(TUY9PQV_C;
M2+57QF'4=+\:1AG"M?/;EV7[/;X.^!_CWHMWX_\ V6/C;\,_CIX7U*VD/BGP
MC;#2/B5X#\9V0T<:%#;_ !?^"-YJ%EJ-OJ]AHVS3+#Q;X6N_"/C?3K.VM1J.
MFZY'I.GPV^U7(L?E5;$9S.&)QM',*5.E'&8:MAZU&FJ5I4)8;$8=RH*2NIR<
MJ[E-*TTFG;X7'^*>"S;*,LX%S?(JGAGF.65ZOML)C,%B:&%QM>:Y:^&Q:2A)
M*M#FE!N$H<UDGN?%OBK2I?#MK?\ CWP3XQ^*GAKPJ/ACX1\>2ZK;:V/$'Q,^
M'_P>ED-CX4^(<0BO-2L_C=X'^"U\FGP^/O@C\7+37_BG\/\ P?<&Z^#7QEU1
M=*A\*5\8^#_C/%I?QX\6_!R\^$OB_4[WXE_&'Q/<_%3X6_L\7[^.]+\9_#RR
M\-^&M:T_X??"^SSI^J>'_#GB?XA>$)_$?B?6M+EM;+7O@[\198K[5Y'>WNX?
M8O$_CGQ+^Q-%=7WB:'5SXYTV/Q]X&\-?LW>)KG7?$OPEU/X.>+?&-SXWT'6/
MV=_'S>'XO%&B0?"W6M)T>#XN?#GXFVIO)?#Z7D,>G:!#K=CJUS\-_LHZ)H^K
M>+=?\0Q^/_V5M%N/A[ G@#PWX%^+_B+XG^%;#XP0Z[J%UXBN/&^A?$/P?JFB
M>)/@L=(L#H'@KP-XFU%;FPM[2,Z,=,GM;74B>98>EQ;5HT\AGA\/B_J4ZF=4
M*GM,/AG)2E"GA_9T[MXRO-OVT;.E.E*4IRBDFNS+,-#P_P DSK/.-*./Q^1U
M,TI83A#%X5TL57H1G&5268QKTZM*;RR@K.BXSA*&*5.*C[LX/]B]"M/&7BB3
M2O$-K\)?$G@WXE:GIUMJ6L>.?&?P8M/AM\*?@MIL<6J6.F_#7PU'XO\ "DNH
M>*_#G@71-6U2ZBT[P!H)\4?%SXI:U;>)+WQ7X"\$^&M+L],\'^+7[6OP._9\
MO=?U;Q5\0/%7Q0^+E]X0\1^'D\,:=X$OO".G>+KG7?L9GU3QY=ZMJ_BW5_'6
MJV\FG)_8=SX@\97.G>&+1KM-'T6#[7:V[6K+2O%>A?$RWN-9U+XO> [_ %J*
M2;Q/\"=>\>_%[X@>*?!>E6%LD>D?$/\ 9L\<^%?BM;G]IOX2201Q:I\1=-\)
MR:A\3_!POW\0S_#>70[064WJ'BOX?>'?VA_!?CKP/XOO?!?Q?\)VW@36-7T#
MQ=IWCCP%XZ^(OA_QK93V4.D)H$OAK2_!OQ#U/1;RSEU"]O9_B1\*_"GB+P??
M:59:3>^*O%2:J]O9_(5Z./H9EB:&8X&6#S"KB91H5J:;P3=&GRTW1PU.T8TI
M62=6HYI2>L6?I7!>*X)K5LGKX7'XK-LEK^QGBL13E.&8QG.LJBCB*N(C7K^V
M52<HJ,9T%*.BD]&O&O\ @BW\26\5^%?'WP\OI$2ZT76KW6M/L4+,MK:W=[_:
M200 ($$,<6MS6J!64+#IRQK$/)!7^A"R@,$$:X'(W'!S@8X[=SV[9K^27_@C
MEX@U+P)^U[J?@;5HKK3;K4[.ZT34=-U%);.[M]5L#J>DO'=6,PC>.Z5[NV,J
M;7VD*7,9EC(_KBRP!3C@D#'8# *@]\,<=L8XYR!\KBY3JQR_$34HU98:=.NY
MI1A[6E5K49)65^9VBU?TO8_;N.*-&CG]>G@ZE.>$J<F,H2YG:5+$4^:Z;;O:
M4VWVG=/1)%VQF^SZAI\P^]%?V4R$'!5X[J)T(/8[@.>W6OUVM3N@B;CF-",=
M@RKQ^&/;Z"OR"MHS->6J+R6O+15'J3<1@#/UXK]>[(,L$2GG$48_$+]3G/\
M2IPOVC^.O'B,?K7#[35U1QO7>\\)=?AMTT5E=END;H?H?Y4M(W0_0_RKL/Y_
M/GO]HK_D"> ?^REZ%_Z:]=KW32?^0=9_]>T7\C7A?[17_($\ _\ 92]"_P#3
M7KM>Z:3_ ,@ZS_Z]HOY&@#1HHHH *1NA^A_E2T$9!'J,4I;/T?Y ><>-?]?:
M?[DW_H<5<.H+,%& 2< D,0">F[:KMMS]XA&(7)VG&#VWC1LW%HN/^64ASG^\
MZ\=.VW]?;GB, X! ;)&%894G(P" 02"<9P5/HRG!'OX/6A%7M?KVT6I\]B)1
MC5<I?"E%R]$E<^6O&'[3MYX6UO5/#EO^SO\ '36M5TZ]N;:&ZND^&/A/PWJE
MK!.\-OK.F:_KWQ&2:?1]3V+<6$RZ.UY):N1<:?:W<<EHGF6I_M&?M&ZSB/PY
M\,/A!\/(I Q6_P#''CCQ5\3M<MHR"/-3P[X/T/P7H;>6/X#XP>!CDRS>2K[O
MI+XTZ'+JOA>#5+:%Y+W0[E)/-0DRK87JM'<ERH8+%!((I)'@AW!4GE,<LDTB
MO\4^%-/^+/QK;4O^%/:9X:\/>!+#6-0T"7XS_$=KN[\/:EJVB7;:9KUK\._A
M]HLUEK/CN/1-4BN]+O?$>K:[X.\*3:Y97-CIVHZXEM<(?,Q<L9'%>RA)RC):
M6C%:Z):I.W9N^FOF?T9P7DOAE+ABCG^<>QHU:$O9X]8O'NT:]DXTZ5"DX.:D
MM>62=[\KNM^4\?:=/XEL&\4_M+?%R;QSX;T)XKXZ%XC?0OAM\!-#GCDS;WEQ
MX"L)X=&UZ[$P'V"7XF:OX^N(]D<EG;V\GDHW;>#])^+'QJ>WN?AGHJ^ _A_<
MHLQ^,WQ/T/4K6WUFQD!\AOAK\+99M%\4>+49,&/Q)XKN/!G@Y!*LFE#Q<L\,
M;?2?@3]E'X9>&-7TOQCXU&K_ !F^(VE>7<:?XR^*)L=3M?#MZFT/<^!OA]:V
MT/@#P-.SA9+:^TG1+K78HXT,_B.[GW2-]-/)(Y9G=G=RK.[L[L2N>-[,9/+;
M.7C9V#')))V[;H95-VJXRIS.3_AO5N]M&]6K]]T^J.'B#QAP.78:64\%9;1R
MRA3E+DQDJ-.E*I!JW/0PRBXM-.\:DUH]XO5KP'X7?LX?#_X7ZS_PF;W&O_$'
MXGFQN-,?XH?$.[M=8\1Z?;76XW6E^$-+LK:U\)?#O1KQ6DEN='\$Z/I1NXP(
MM9O-5D:25_?2<C')QT+$L>-W.3]YCN(9WW.55%5E'F>8W&#QG S@<  $Y(VH
M$3KT;9O ^4L1FEKUJ=*G2BH4X*$5T7ZO=GX7F>;8_.<5/&9CB:N+KU-ZE9\T
MK7;5KZ16K:44EM9:(****T/."BBB@""Y)6WN&#8(A<C(#+E5)7*L"K#(Y5PR
M,"5=60E3Z;\-M)TW2/ GA33M+M$L["VT2Q2WM4>:41J4,A'FW$DL\A,DC-F6
M5R"3M(4X'F-W_P >MQ_UQD_] ->O>!O^1.\-=_\ B3V/_HE:\K,VVJ:>W-;[
MN7^ODCNRW6I5^9T;0DD'>0NT@J 1U4J6#!@RL 3MVD!=[D@L5*'D#USW)(R2
MQ)+.#G*L21M*X";4"@*@6IZ*\S^OZ_3L>RU>R[-/33:UMNFFQ$(S@#?C XVH
M@VD@@[,@[5P<J#N((&689!8;<9!#L"N,'DMD*5#;G9B6P6!8Y9AA&)0RK+8H
MI)*-K=+6^2LOP&0B$!556*[1@%>HQC&-VX8XR0P8L0N3\O((5 /0L26).XC<
MQ!8@%R0&P!M#!54*J@ <S4R0$H0.IQT^HI->ZTKK=Z.S[[K6VFQ+2L]+Z;/5
M/Y/3\#YF_:?LVF\"Z;=8^6Q\06,C$<;!<075LQSG !9E4\$'=T%?E[\;K.2\
M^#GQ2M8 RR2^"/$+D)MRPBLI)B%*A&'RQL2-PW %<KNW#]@/C9HYU?X9>)X%
M0RRVMH-25 "S9TV=;YE7N&,,3J#ST^Z>E?F#JNFQ:QH^JZ-<X,&KZ7>Z9.3A
MD-O?VDUC,3_>7]^3MXWJ,[E)R(YG3Q.'M)V<X74F[-\T=7=VZV[/?J?U5X(X
MFA6X>Q6%<*<IX+-)RY.6/P584:D'>WPRE"HM][KH?R3?\$\_B-\7M=^+VC?
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ML\>#C@)9GBYX6"484JE5S4(QBXJ,92O*,>5N/*I*+6C6BM6BM4B 5#@#H H
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M\4_#S3] TG^QM0\16>I75Y<+>:H(K^*'4(S):-?Z7%-I]N7CNK1/Z&/VDO\
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MU]#_ -]-_C1Y:^A_[Z;_ !I@?-6S]HS_ *#'A'_PG5_^3*-G[1G_ $&/"/\
MX3J__)E?2OEKZ'_OIO\ &CRU]#_WTW^- 'S5L_:,_P"@QX1_\)U?_DRC9^T9
M_P!!CPC_ .$ZO_R97TKY:^A_[Z;_ !H\M?0_]]-_C0!\U;/VC/\ H,>$?_"=
M7_Y,HV?M&?\ 08\(_P#A.K_\F5]*^6OH?^^F_P :/+7T/_?3?XT ?-6S]HS_
M *#'A'_PG5_^3*-G[1G_ $&/"/\ X3J__)E?2OEKZ'_OIO\ &CRU]#_WTW^-
M 'S5L_:,_P"@QX1_\)U?_DRC9^T9_P!!CPC_ .$ZO_R97TKY:^A_[Z;_ !H\
MM?0_]]-_C0!\U;/VC/\ H,>$?_"=7_Y,HV?M&?\ 08\(_P#A.K_\F5]*^6OH
M?^^F_P :/+7T/_?3?XT ?-6S]HS_ *#'A'_PG5_^3*-G[1G_ $&/"/\ X3J_
M_)E?2OEKZ'_OIO\ &CRU]#_WTW^- 'S5L_:,_P"@QX1_\)U?_DRC9^T9_P!!
MCPC_ .$ZO_R97TKY:^A_[Z;_ !H\M?0_]]-_C0!\U;/VC/\ H,>$?_"=7_Y,
MHV?M&?\ 08\(_P#A.K_\F5]*^6OH?^^F_P :/+7T/_?3?XT ?-6S]HS_ *#'
MA'_PG5_^3*-G[1G_ $&/"/\ X3J__)E?2OEKZ'_OIO\ &CRU]#_WTW^- 'S5
ML_:,_P"@QX1_\)U?_DRC9^T9_P!!CPC_ .$Z/Z7@.?3GKZ]*^E?+7T/_ 'TW
M^-'EKZ'_ +Z;_&@#YJ,?[19 !U?PD0/^H XZ<C/^G=B 11L_:,X_XG'A'CG_
M )%]NIXR/]. 'XY[]SFOI7RU]#_WTW^-'EKZ'_OIO\:5DTT_>3ES-2]Y7225
MKWM:VB6B#HXV5G)R>BNVVGJ[7:NEI>UM-M#YJV?M&<8UCPD#W)T!R>_3-_@=
M>X/M3MO[1N<_VQX1/N?#Q)'T)ON/RKZ3\M?0_P#?3?XT>6OH?^^F_P :2A%7
MM%:_=]VR^0VV]];=7OTM=[NUM.W0^;?^,CO^@SX2_P#">/\ \FTF/VC?^@QX
M1_\ ">_^[:^D_+7T/_?3?XT>6OH?^^F_QJMORV)LO/[W_F?-O_&1W_09\)?^
M$^?_ )-H/_#1QX.L^$O_  GS_P#)M?27EKZ'_OIO\:/+7T/_ 'TW^- SYL*_
MM&D8_MCPC_X3W^-[BF[/VC/^@QX1_P#"=7_Y,KZ5\M?0_P#?3?XT>6OH?^^F
M_P : /FK9^T9_P!!CPC_ .$ZO_R91L_:,_Z#'A'_ ,)U?_DROI7RU]#_ -]-
M_C1Y:^A_[Z;_ !H ^:MG[1G_ $&/"/\ X3J__)E'E_M&?]!GPC_X3J__ "77
MTKY:^A_[Z;_&CRU]#_WTW^- ;GS3Y?[1O_0:\)?^$ZG_ ,E4"+]HS.?[9\)'
MZ^'5Q^7VNOI;RU]#_P!]-_C1Y:^A_P"^F_QH%;S?WOR\_)'S0T?[1Q4A=;\)
M(QZ.OAT97GJ,7H^G7'J",@Y\W@'XV>)\1>(OB9J5C:,&26S\-VEEH$;QL#E&
MN+*!+LYZ;A=*^.-Q&0?J@(H.1G_OIO\ &G8YSS^9Q^70_C0,\&\$? +P=X1=
MKS[(+[4I7$L]]>NUU<SRG)>2YGF+S7,C$G+32MG/S!ERI]R@MHK=0D2A%4
M* H"@$!55=J(@SPB(JC P,\U/10 8Z^_6BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>stage02.jpg
<TEXT>
begin 644 stage02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MW\8^,;6_TGQ--:/\8?B/J>N3_#A-/M-330=7^%U_H6D6Y"/%I&E)*SRA.K\
M? 32+CX!_P#!+/2;KP]X^=_C1\5XM5^-<LNM?$*WUK6UB^&WBFR2S\17Z:A#
MJGAS0?L$,.F-IB3:58_9&DMQ$9;R<S\^)X,P>%J<M3/*%5+_ )]TU)QMA<PK
MN\?:Q7(_J-14WSMR=>BY1BI)/LPO'6/Q%)5(9'5IMNT:=1S3E:M@Z"M[N_\
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M7+;FDFVWI/S9_0,84# @+D 8&U=P!#[$58P,H JHFP E(@?-E )&;JVN^'=
M&FR>(-9T?1DU;5[#P_HAU34;/3O[4U[5I7BTS1=-:\N($O\ 6-5=9%TS3[-6
MN[EP\5O%*0,_EM>>"_VDO%W@_P#X)N>'O$/C3XXZKJ5E;>+]9^.OBJQ7Q5\&
M[[Q5J/ASX):_JWP]A^.>DZ'KE[J>B:;KWCZS\-VVO^&]9U^:;5-:+:7JTUP+
M_4M,N?@SX->%?VL=6\/?#;Q1\9W^/'C?4?!7QR_8P\;_ !M\%Z_\,?CE>CP=
M\5= ^)?C%/BYXW\,:K\2?$&OVNOV^G6.L:0_BK0_V=?#,7P<T?P3I7AOQ;HP
MLW%]9+G# J=/VBQE.,H:2HWDG)*4X6ANM5!RTMI4BGO=:.K24Y..%TJP]K)R
M4;\]J=11?N[\\K7_ )J4O(_I.:((=X&5)9@?*8CE3,IV89W8%G4QPLJ,TKA(
M@S.%5B-Q<J"JR*[-SD -A6<-N? V_.Y$>PJ$9Q"CR1_S?^ +S]M/0_!GQMO_
M (FR_M)^+?%FK:1:>'OC/X*TK1_VD?#>G^%O%VM_M*6%B_Q,\*_$:SOO$K7W
MAKP9\*#JMU?^"?V,O"D$?B?X0G3I(M3\/>(;2"^MK9NOVM=/\!_LZZSK2_M;
M>(-9\'?%?X[:/H7PJT_0OVC/!LGC?P6/VEK&+X8ZI>?$FPU3Q!XE\)>+_#7P
MEMS)X.T3]K*T\5^ /%WPBNM>@\6>)=.UVUN-5CT>52=W+%8:;YY4I+5NI#EY
MZ4MU[JFTKO1;O<2Q=./PTJJYH*H[-7A4A-7C#3>I3]U6W5U==/Z-]D+':T9.
MTL1A#&Q!<.<AP"RJS#,GW6^^7+RJK9FK:GI'A[3-3U_7]3TW1-"T73[S5M5U
M?6+NUTO2-)TS3[>6ZU'4]5U&^EM[:QL-/M8Y;B]NY[F&V@MHS).8HDED?\??
MV'+3]JG_ (:=\>W_ ,;?%GQ0ANP/V@+;XF>#=?\  GQF_P"%;WMVWQJM3\"=
M:\-^-_''B6Z^#=DFG_#430>#=*^ >BBVUOP?J=VGQ$F@\2Z%82W_ ,3?%CX:
M?M0?%OX0?'GX?>)-$_:R\3^.O$GP7_:?B_:C\-ZW=?%2/X=:W\2;+X^>!IOV
M8+#X#PFXB\*7UA<_#VV\5BVTSX,.?#6K?#6-+3XC17/B%[2"*(X!O$*C+'T8
MT_W4N>F^:.O,Y^\_YK+9:OE6G.V$JE+E]HL/>I[^B2YG\'LKIK7DM&VS7(['
M](VG>,?!>JR^'(-)\5>&;^Y\8Z)+XH\*PZ?K.F7<OB?PQ:-I9N?$&@PP733:
MQHUN=>T62;5=/DGM(I=8T]VN)%N[19^F4KF-Q&HR<Y)4 ,VQ&7" J[*"6#G[
MV%AB\Q)01^1/[<W[/_C+Q-X[^%W_  K5/CII5K\(_P!B7]LBT\%^)OA1XN\>
MZ-X@M?B/9Z=\#C\*/#^K^,_#U_%XBUO4=5OO#LNI:9X9U/7)X?&.K:"9M7MM
M8AL+VWG^4?'?BG]M+Q!\7=3U?0/"O[37AGQ+!\._B=X6\4"V_P"%X:AHFNZ<
M?V%]>UCP7XNT>&!=+^ '@FVUG]H.'3(/"&@^%;'7?BW%\2;/4[GQ!X@T*"[@
M\+HZ67NO&,Z>,IJ4M9JH[<OOM):-[TU;LK*]^:Q3KJ-U/#NT;<C@XI/W:>RM
M_P _%"?2[@S^B:2%&R#$2H Y&YG4#.2KJ"^\98J0QD(9G1D; ?FM9\7>$/#6
MK^'-&USQ/X>T+6/&FJW&C>$=*UG5]-TO4?%.L6EC-J%UIGAFQO;FWO==U*VT
MVVGO;FVTR.9[:TMIKN6-5@F,GX0?%#X+?M/Z?X>E/A+QW^VN=:\#?LV?L.ZE
MX/OM.^*?Q/O=3U?XN>.?V@?$UI^TAJOB!;B[N].\9>,[+X<ZE)!XGTCQ#9:C
MHOA+PN]M<1>'=.@LM.O;6EJO[-_QXN_BS?ZEIFG_ +1^MZ[\%M#_ ."G7A']
MG#QKXF\??$C5;S0[?Q%X'^"%U\"HT\4ZYK9AU]]7\1>)?'UOX'UOQ9/J=]?1
M^'[?3WU>]M/!MFEH++Z=TY8ZFXVJODM4UY*"DHM<W_+V3BHZVYI33MRW>?MX
MVLL+[[=*\VHK>M%OHW^ZBG)[O2-EII^_6I:YH&D3Z-!K.KZ3I5WXCU,:'X>M
MM3O[6RN=;UO[!?ZFFCZ/!<3PW&I:I_9FEZAJ/]EVBM>FRT^\N6B2&TNGBI1>
M+?!]UXLOO EOXH\.3>-M+T:S\2:GX.AUK39/$VGZ!?7$MG8^(+_P]%=KK%KH
M=_=6\^GVFH7=I'87%S;36T<TC6[HOX6^#-?^.OQ2^+'P-\?^)/A[^T[=?#KX
M<?%/]AA;D?$?X6_$+2)M(\3?\*!_:<^'GQ>\8Z9X:\1:=#K;:;I_Q!\6^!M)
M^(WBRUTLVGVR>VUJ^N9_#ME;ZA+K_&GX7^.? 'Q\_;6\>Z!X!^/=U8?''X[_
M +(WA74_&GAGQ5^T'#I5E\-].^#-SJ?B?Q);Z?\ ")M2^(VN^!=+\<6$'@'4
MO#7PJO/#%Y9ZCXDL-.U+Q+X>\(+KT<TPP$7)0>*2J.FIPO?V<*KJT_W;O*R4
M54<FF]H\FB=BW6C&#:P]Z?M>6>D?:5$H:5;M:I5'S<VC>^Y^[QCC4+\A(4!=
MX!81[TC!D&]I%R%=MKN"5C\U-Y#X:I;365U!'+:2Q7$,@P);8QRPRB"62&1$
ME1IPR^?')$RI([[HI#&2AE>OP1_9MN?VA=7U?X W/[5Z?MVP>*W^&?[/FE_"
M-?AW;?$71]*'B&+XF_$?2?CC-^T)$LLOA6SOD\.P^ KSX@W_ ,9KM]7E^&4<
M5YX U+4/'TU]>WOA.@?#CX[?"3X$^'/AI8:%^VGX9M?"7@+]LC3/ 6D?#2Z^
M-]WKB_MP-\94U+X(W/B75-/GN7U?X:ZS\/[RRUKP1J/B6]N?V>]2EU'QI>^*
MY%UR[NRERRR<95:?UJ,Y>TITY3C+2:G[3FJ4WSK2DTE)V5F[6]V[%7I6IR^J
MWBJ527*U'1Q]G^ZLHW;J_O&N_-YM']-NQ-SAO+,6%5HRA"^:@;S2S,Y7:HVN
M%V*5=<O/-N$<*M# H4.J! X^5E(/S_,2> 0(2 $<@>5&KJ0BJ6'\_P#\5O _
M[2J^!?C?XZ\7>-OVI]-\:W'[6-Q96/A?P_+^T1K_ ,+=;^'/A;X':--I_A'0
M;#X&ZS9_$;X5_#CQ+\4]6US4O#?Q)^'.A^(+)_B'I'AJR\;:3K?@L7MA'^@-
MK\:_'_Q-_96^//@?X0:#\0O#'[5WPB_9VT73'\,^.%@U+Q'X>^.OC;]GZQ\?
M>$M 'C:\L;/POXW\8:)J6M:99Z_J\$%O8GQ,DS:M:V5O.57GK81TU1G3Q2J)
MUO9U;<S]GI#]Y%MVE>4TO:6=XQEW+IRH5)5(RP^]%2U4;?Q&O8[:NT85&MK-
M=3[LM/$'AR]UC6?#6GZUI%_K_A^WTNXU_0K/4;*?6M#MM;2YFTBXUK3()GO-
M.76(+&[ETMKZWA35(K&Z^Q+-#;7+QRZ-XE\/>)-.&L^&M<TGQ!I#76H62:MH
M>HV>JZ8]WI%]<Z5J]LE_ITUS:M<:5JEE?:;J< D\ZPU"RN[2ZCBF@D1?YT?A
M=\*OB5KWQ+UU_AI;?MU^&_AG\1_C)^P!I/C3QQ\0]0^-/A'XH>(O!OAWX7_M
M 2_&?39_&WB]K;Q[!X LO%E]X>L?&KQ:G#I%AX@UO5(?"UY:Z=>:#,OJO@7P
MS^V?9>)?@]\/POQTL_!/[17Q"\<6?Q*\0376NV2_ 31?V<?VM_BU\4H]0FO'
MEBN/"L'[2/P/O_#?P\TF]A4R^,#9:?<WLE\)/.&M3+J,934<53522IWG.FM>
M>FJM2^K_ (<VU%=96NT-8IP<4Z$N6GS<D(*WP34(6UL[PU7X^?[M:#XET#Q3
MH^G^(?#6M:9XC\/:Q9IJ&D:_H.I66KZ'JMC*I>"[TW5[&XGT^_MKA SQ7%K<
M2PE%):125!V/,Z_?'( R",\'Z@ 88'<1PN[[K(S?SR_#?P+^UO-X7\!>/?$-
M[^U3H/B_X9_#'_@F'+H?A.WU[QOH'A*;Q!KWQL\8Z;^U=)XI\"6PM]$\77UG
M\.+F*W^)RZ_INH6GAWPY+I^LSVEG+:IJ%;'_  3;\>:]\1/BWX\\<>//'?Q0
MN/B-XK_9Z\:77P\LO%E[\2?%5_\ %3P[I'QJ\3MX@_:"^$P\:00_!SPSHM[I
M^M_"7PCI_@/X9WVM^&)X['P[>OJ;:"+)KISRI0I5ZL,32G"BTHN-.[?PN]F]
MN[5^NB28X8URJ<KIM:WVT^SII\_+4_H#$B-@@N"<JNX%26!P5).-OS84%MJL
MS*%9LU!=7]K:QRSW4\=I;VZE[BXN98[>"!%&YY)Y971(HT0-(9)"J,B.49\
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MBOKU2]FXWTTMZ?UY7\CUB7Q7HR[$6[5YIY!#;QHC%I)68HB*"!DNP 3W;)(
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M2M+IFD>'/!EI]G\;^-KY/#?BBXT/PL][K+V5A;V]D^I_<GC:^\6:9X8UO4O
M_AVR\6^*[*SW:)X<U'7U\+6.K7@DMQ]CN=?;3]4CTR'8S3_:C97!+0"'9L=G
M7Y _:.^.'[5'PM\>V]G\(/V=)OC+X"M_#'@O7M=U#3KVZLM=_MB\\1^.[3Q)
MX:T&W^QR6.KW]SIFC>%O+NFGL5\+?VQ'K6I6VLVU];6$>L&X1BXJ4(SJU:LY
M1J2C44W22C>*5EJE:RW6KZKG=*E.I*,X>T<*5*45.G%TGRM7I*;3?-W5TE>Y
M\^O_ ,%%-7_MGQ!X6L/V3_&_BWQ?H7]NWMTOA\7NEZ&;'2?$OB6VTZW/B#7O
M", GU*7P5X=\/^(-*NM.BN+#Q#?WUM86<^E&TAB-"+_@J.?)UFQTG]F/XD)J
M>A^+8_!6J6UK>1:X/#_BZ^T#6M6FL]>TS1M&CU$W-SKMK;QZ38V.^_U_PWJ4
MWCS5IO#FA6M[+71VO[9_[9K:;#K.H_L,ZG::7>:!'<LEEK/Q&U;5K+6)M#2Y
MFU&\T5/A3#J5WX;M=2,T\UGIEK=^,)M.2#2=.T&_U^=+$SQ_M2?ME1W-AK>F
M_L2R:%X>;7;76_%WAZ2X\7WWCS7] GL_&UOJC:1]@\&VFE6WC*TF\*^'[NT;
M4&U6'4K/Q1X>T74KCP_?2/<VQ*=2=HR?-!25HSG)V5H^]N_?Z)]+:6Z;1I4(
MM2A3C1J<BCSPA%)P37[O96_X'W?77[,W[1D7[2'AKQOXBM_ 7BOP)#X*^(>L
M_#M(_%5E>6(\0KI.E:)JB>(]+AO]-T>\BL+AM9&ESVUS:J]AJUCJ-K'+<0P+
M<R_3@GC) 4EMP)!569<8)!9@"J*P&4=RJ2#!C9A7XJV/_!2K]H[7?']Q\/M-
M_9'U[3_%7A[PC>>-=9\(:E#XY7QGJVC7.M>*M*T?6K#P])X.BU'2_#MK8Z3I
M6N:]&UKJ7B%VU73=!\,V&LWVLVA;WGXF?M8_M5^'/&VB:!X"_96N?&NAR>$/
MA[XCU'Q(++XJQ6-_JOC/PCXHNM1\/V]S)\.K2[\*W_ASQC8^&-/NO[>TN_O8
MO#EWJ=[XDTSPSJ4ECIMM!H?IBTR*P4GDG'5>"%9RO+ [@JEMH!8KEE#*KE7"
M13T.><9&",GH-V=H))  8@DD<<U^0'B7]N3]M/0_$6N1:;^P;XUUWP_9Z-J\
M.GWENOC.TLH_%FF>-;#18[&]U+_A$)M3N+,^'M6N]2O+W2_">I>'[NX\'ZI>
M>#?$7BI=?\/6DWZTZ1<7E[I6G7NH6;:9>W5A:W=[IKSFYETVYN+1)[BQ>X$4
M0G>RG<1"?R59BK8C4=0#9HHHH *^?OVC?^10\-?]E#\)?^C;VOH&OG[]HW_D
M4/#7_90_"7_HV]H ]OT?_D&67_7O%_Z M%&C_P#(,LO^O>+_ - 6B@"74 #8
M78/3R)2<=<8)]NU>%J<@$U[GJ##[%=CG_CVE.1C'W2.N?4_H:\/MXF?8F",
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M!=6-S;W[?J7#&1PG#^V,PJPCEN&A4FE7O.I75.,93M1:4)<J>OO73M9-VM_
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M>%? _@WP[XB\46NCV/B;6?#_ (7T?1-3\16OAFV&G^&8=7OM,M;.YU&+0=*
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MTZZ^(_@"WU"PUV/PM?6$_C+PY%?67BB5'EC\-W5I)J2W%OK[Q12R#2)8UO\
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M-9A!*.8X/"SNERXBJJ:UMUDM>WI?Y_F^8YM_9NLLOQ6(AT="G*IVZ13[:_\
M#GZBY VG( <,5)90I Y!#$A2&&""I.U3NDV*&*J002K#:0=I#$*5._8-P)!0
M'*ME@,*Z,V RY_FV^.'[1'_!37P/X3\7Q:YI/Q1M?"$GA_68?$NJZU\'--GL
M+#0+S3Y[;5M0N-?L?#L<FC06EA-<?\3E[ZVCMD+7.56-&;]#?^"3GQG_ &C_
M (R?LPVVH?M#>#-5TR#PQJ5MX>^$WQ2U^XAM];^-OP\M[-TT_P 2:GH]QY=^
MEQX?=3H5MXQDMEM?'5G'#J6E1WMS::EJ%SWYYP9C\CRJ.;5\QRC,,+/'K"JE
M@\53JU;\O/;EA=V7+IRN3:;D^57/)R7C'#YOFT\IHX#,L%B8T?K,ZV+PTZ=*
M-^5)N4TEUV^2U/J?]JW]JCX<_L?_  KD^*/Q'@U_4X[WQ!IO@[PAX0\+V:7G
MBGQSXWUT3S:/X6T.&XFM+6WN-3%I>WMWJ%[<PVMA9V<K2W"2/;Q3?E5+_P %
MB/CWH_B;2K;Q7_P3\\3:7X/UC4H+!+K3?BYX6O/&5C+<Z;=ZU;6VL:+>:/I^
MDZ?JD^DV<DZ:?JMYI=NLTEMI\EVFHWEM:2?K+^T]^S'\*?VN/A1??"#XO:9?
M7.@2ZC:>(-%U?1+TZ9XE\(^*M-$XTSQ+X8U)H[E;+4K-;FXA<74-]87UG<7&
MGW]C<6<PCC_%;6/^"%OP[\%W>J_$'XA?MO\ QWM_AYX>O'\9:O-(;'3O$:26
MRQVIU"\\427>I1KK!MO+TBVU"RT)=2G\R"SL!/+-;0C^=N.:W'.&QL,3D+P\
M,HI*E6J5)8BC0CAVHJ6-J8MUTU5I0BJ;M!KE4:EUJFO]#?H[TOHKXOA;'83Q
M9>8RXN6*Q,*>&>7YMC8YAAZU/#4L!#)Y995A"ABG66*IU5BHR?-4IJ#5.,E+
M]SO@'\<_AY^TI\(O!?QN^%6I76J>!/'>GS7>DW%[:26%_8WEE=W.G:OHVJV9
M,ALM6T35+*[TW5+?S)8H;FW9HIY[9H;B3Y2_:9_X*@_LF_LL^-[CX7^.O$OB
MCQ?\3[*Q34=6\ _#'PK>>,-:T:TDMA?(?$4L4MGI.B7/V$I>OIU[J<.I6]I+
M!<7-I!%<0/)Y_P#!3]KC]D7]GWP-X,^!_P *O OQ-\-?"_P5I[:;X<U >'SJ
M$ MFGN;^]UZZBEU;_A)=3NM4O9+_ %S4]0F@>_O+F[NI9;5DS#!\A_'_ /X)
MG?&[Q]\3?B#^T?\ L)_M _#W3]#_ &C=7TSXDZ_HWCW3'G>+6YEF6\NO"7CB
MVT/7;JUT/699[HWOAF_TFQN;:9KK2YY[F%[:"S\^IXBU,YR:G2X/Q669SGF"
MC0I9G1PL7.5-TJ*>(K4<-5=&6)57%?NZ<E+^$V][H\W@/PB\+5XD9Y'Q2GG'
M!W .,GB:W!D\TK1P="O4EC<++"8;.<RPF'Q?U*I3P$JV(JJ%%\]6BJ2E&-1M
M_H1^RU_P4J_9*_;)U^[\!?##Q?K.G^.VL;FZC\!^/] E\+>(-1L[+R9;\Z'+
M<O>:-X@;3[=VEOH=,U"ZO;6VS>2VRV2O<+]_K&!OVJ(]\CSLH #F38/.9HQ'
MYD4S%47S60,D?[H))P]?SG?"[]B#Q?\ L1WTG[>/[=7Q>\*^)++]FRZ\8?$;
MPYX,^"WAM0;KQEXYL=+\(3I>^(+K3-!.K?;KB>QM-+\.6=O;0W&KW=M?ZUK1
MTV.>%^2\1_\ !<C]IZVEMO$NA_L$:G;_  WO]7L],TV?Q/X@\60:W?2W&L+I
M5@DLEEX42PT^_O=0*V&U-.O[2:\9;>"\G8\]F7\=RR?"8:7'=*.#S><E5P\:
M.#J/$2RUSC%5L10I.M##1YGR\SFKN-[7/H>*?HGX?Q%XOQM3Z,E>/$_">74<
M/1S#-,RSG#4LNAGKFJE;*,HS/,5@9YM*.!6%Q+C2P\>65=PNXQC*7],&.0.C
M$$JI!#MCLJ$;^>Q*@>XI!SC!X)P"V4)/IMD"MG_@./>OBW]AW]MCP+^V]\--
M?\:^&?#.O>!O$?@;Q*W@KXE^ /$?D37WA?Q5!;BZCMXM3M$CM=9T?4H/--C=
M""SO/-M[FVOK*PO(VM1X3\7?^"OG[)GPQ\6>(_!7ARQ^+GQTU[P;JCZ)XRF^
M"'P\OO%WAOPYJ-O.+6]L[OQ=/>Z;HD]Y876^TOAIUY?);W<$]JTAGB9*^[GQ
M9P]#+\/FU7,<-1PF*<OJTY5+QK<B7/[.*7//EM[]H^[M)IJQ_-]+P/\ %+&<
M99YP3A>%,VQW$_#];ZAFF5X;#PE]0DTG&>(Q7.L-#VB]^D_:-5H^_2<X+F/U
M)QR!ZC(/8GT&._M25\<_LJ_MX?LY?MAVU[!\(?$NLP>*-+TB'7M2\">-] OO
M"?C&+1KB\ETZ+7].TR]#V^O^'QJ4,NG3ZWX=O=6TNSOT:TOKJVGCDC3[&KU<
MOS'!9I0IXK!8FCB</4^"K2FI0?PZ7>TO>2Y79JZ5M&?"<3\*<0\%YSB,BXHR
MG&Y+FN$E&.(P.8470K4W*48KW7=24FU9Q<HM.][,****[7HTGNY<EO[W\OD_
M4\"SMS=+-ZM)V5V]&[[1?36VAU7PU_UWB?\ ["5A_P"D5=+XV\*2^-/#6K^&
MT\1^)O"#:O%!%_PD?@O4XM&\4Z9Y%W;W1DTG5)K6_CLY)O(,$A-I,/)GN!@F
M<E.9^&QQ-XG_ .PC8G\K(?XUU7C3QUX5^'?AG5O&/C76;7P[X8T**"?5]:U#
MS196$-S=P65O).\$<Q"RW5U;Q+M#,IE5G"(&8?/XE26+J-+WG:R6K;:6R5_)
M'MX9)X6E%O2-KO;LOZ_2Q^6O[;OP/\(^-/CSH'Q(C_;3T+]F/XM6/P@M/"O@
MW2;_ %_0]'U&;P_)K/Q!M?$GB"UN)]<T?Q+:+XAN_&FA>&[>^T2[M].MY=.N
M[VXTW6_$-IH$_A;PZ3P/?>'_ (@:_/:_\%6_!^AZY\0+^'POJ;ZUXNO[GQ;<
MV?@/4M4L5CCL=0^)5KX>T;Q3H6O32^$KN+3_  _HNC/X<@O]<O-+G\3:IJFL
M3?8G[3WAO]C;Q)\8C/\ '7X7>)O%GB#1/A7X>O/B!\0='3Q%'X.\"_#6;Q9X
MIUOX:GXCWOA[Q#I=Y+_:OC?PKXOE\$_V'HWB#5(];L;F&]^RP76FR77SW<V'
M_!(_PSI6M>&Y?$5C:7_CF '4KF[U;XRZSXJF?XB6/B)(]7O&UI-1O$^P07>O
MPZQ?ZO;FT\,7UE<:/XLCL=2M6TX<YV'(^'_ !^)/C_P9IVG?\%)-%\5Z?J7C
MGX&ZQHOPKM?&WCV^\)ZU#X*BM/%,WA;P-JFH_$5M:\?7QE\':IJ$8UKQ-XR7
M68=<N1\4=#U:XTKPS(,C3/A!!9>//'EOX>_X*2:!X,U>R^-/C/X=/X;GU3Q3
MI&L>#O$5]XZ\3?$*7PUI5OXL^(D,UYK<,EU>:U;^$+2UG^$VL:GX2T2UA\,7
MGA2_U[0]1[O0=#_X)<>!]3C%CXP\4Z/\0?AY%-X*L?BL=;^+6L_$/6=<FT*T
MLGUW3==MK;63K'C;4KR[72] G&C6^LZYXL\%R6?@G3+E?!%K!8:OQ7\:_P#!
M*O4?&MGJ_BM9_%/B_4=7_P"$@N]:\#Z7\9M6NM)_X6?=Z?=7>LZK>^'D TO3
M/$%W\5(/$&+*42)>V]R=.LO[4\'W%O9 '#>"_@G:?&/QQ??#B]_X*#Z?\:M8
M\2?L[?%I-/\ "F@^)_B!J^J^'O"7Q&M/#^@77C#3[K3_ (DW$(L;]?$OASQ)
M?76N3S>+])O_ !"_AWPAJFC?#6"VT"R\OA\*PZ7X4\,VG@C_ (*W_P#"MM N
M)O#_ (>\ G3+3Q*VEMI\?A[5=;TS1=3\.:UXY.FZ+#X433- NM?O["+1TT_3
M#XMT+XBWS:EJEA=Z;^E'[./P8_8[O;'P[XE_99U.]MM/^&VLSV$VK^!/&WC>
M.'4+C5;/P;JVK>%/&+:O>7"^)+#6K;PUX/U+6=,NH9)8IK*VFF:![^^^U:5C
M_P $W_V-]&M=,T[1?A'_ &-I.EK-;VFB:5XX\?Z?HRZ;,L]R- DTNW\4I9W/
MAV#5KFX\3VWA]XSI%MXGN;SQ#%9C4;J9Y@#X3\9^!O!FN?$KXB_&/P7_ ,%!
M?"'@35UM[/7+:?PK\0M6\:>*+[X03V&B:OIVK7?A[2/&%C-?^(].OK>QM-/\
M.0:/K>F>*YM"T63Q3:ZPFKQZ3:?L=\(]%'A_X7_#O0O^$KU#QR=,\$^%K-_&
MVJZAJ&J:CXNFAT:U,_BB[U#5;J]U*YE\0RB753+=WUU,HNROG@*H/RCKG_!-
MW]E_4M2;5M$\(W_@R^F\6WGCR^N_#>K3O<ZAXPN?!7C?P3!KDTGB :Z()[&'
MQW?^(C;VB0V.K>)](\-ZAK5K?6VB6EB/MOP[X=TSPIX?T/PSHD+6VD>&]%TO
M0-)MWD,I@TO1K.&PL+<LPRYBM((XO,;YB 3WH V2S#^[T![]"<?G7!>)[^:2
M>+3HG("A9)4#A#*['=Y18L,(J'S'+;0J8SEB%/<$YW\'E0H]RO7^5?#_ .TQ
MXBN+S2]*^'>GZA<:->_%S7M1T'5]<MIVMK_P[\+O#^FW'B+XJZY8741:2SOE
M\)V#Z'8WT:%K*\\2:?=QL)[=472C-4HU\1*#DZ348Q:O><N515FTM7=:=K7[
MWAL'/,L9@\#%N*K5YO$22?N8>C#GK5)6L^6$%=O?31/9^#>+/B7\4?B;\8?#
M<GP(E\-6/@32/"WQ \)-X_U32G\0^*_%>M7>M^'1?ZQ\-/#-[J6E>&I/ ^@W
MWAUM(U#XC>-;V+0[[5&U"U\-Z/KP@AEF[&Z^ 'Q#OTAN?$'Q<^(/B;5)HY4>
MQ?XP>(O"5K/YT<JK;6">!?!V@^%K%XY0BQ!-!N+'R8E@\R\C#2CU/X0Z#9>#
M_!-IK$6G6^F7OB6STV_CT^>Z6VM_#O@^WC2'P5X5LYY&9[&Q\,^'FM+>"VAB
M\IM7N[V]*DW$LB<A\?\ XQ0^$O#MMINBR*OBC7EF&F:G:ZC83SZ!80N]KJ.N
M'[#/<O',L,ILM(>Y,:--/<R1PD6K..EX?^TJ>&KXN4U75#E<:+J4::E[6,E%
MI2MMK;:RW;/H*>95<@QM;+N&Z:E1EBDJN*Q=*E7Q$ZOLZ47"@ZL9>RH*:E#F
MB[W3:232/SV^->B>)?!EQ"/AUX^\::KXM\&^-= \5ZS\,OB,/!WB'3)]3\%:
MIIVO64.@?$SPW9:-))-<36-G%):W=E<7LSM?KJ\VEWCO)<\!\9OVGH;CXZS?
M%?PI8:EIOCMOA7H&B^#-'_M31]7TZS\4:]JEI;1V&J+:Q7*74>FZE87.J:DL
MC6T\!T_2S-;K-<326_6>(YU@\-ZMJ$%M+*VF6MY?&]:1-JS6]I)>W31[V^T2
M22^86D?S3,9%%Q))._[JO@'X5?"G1_'^A:AXFUO6]1LI%UB1%33'LU=62.&]
MO+V>XN(YRDSR7$<EC<HQ2%461C.LX+?G7$^._L?,*& R^4JD<9"C7Q,K\W-.
MBU94F[.BVGK:U]&];'];>$_#F&XOX;Q&?<30]GB<J]ME^%BH4ZO/[?V"?MU3
MA'VM)2A%*=1<T5&:O:3O^UWPS?P[\38-(T3XB_%_XVZ9\69HX8KC7-)^(6H>
M$_#.M:J%$K6WAC1=&,'A_3+=[IE@T[1[ZU:>\C98Y)M2GS%7<:MH7QA^! ?6
M;:6V^/\ X2$T=NR^+ITTCXE64E]*MO!:/XR*7=OJB7D[?9[&Q\46MU8WEUY-
MHFL:+<W=E!=?#V@SZA>^']%U&W$>H6%]I]I-IMZMR\&HSQ"".YM-1G<1A)+N
M6*V2XW%K2:.\;S;:5) T:_HC\$/C%8_$KP\=!\5W":AXCCB.DW]CJ%K$MCK6
M@/;R02:G)*[1QWMU>P.]MJ\$3"Y6XCMKX*+21[BOT%X;"XC!X2O2E6P]>M!3
MISFZJK35D[VBW3JJ_DFNA_,F:U<YRK-<?AL=3P&<Y31Q%5XFC2A3Y(6GRU84
MG"$*U"LM%"FW))Z)VL>U^ _&EM\0?#FG>)]+L8HM(U"-S;S)J=I?217MO,UK
M?Z5=V]O9V5_IFHZ3>I/8:OI.J6]GJ>EW]O-:7MG#/&4KW;PQJ4MS%-9SOYDE
MLH,<A.7>$N4^;U8$ GV=3NR2!^?]O=3? OXI3-<7<D_@'QM?:7:^)YKJ7SX$
M76[R#PWX)^)0N#(8AK>D:R^G?#+XG7RAI-;L-0\ ^--0:;4+'4Y;O[<T"7[+
MJ]NK;D$IGM)5; P3&=B,,_>62*,OUQNQDL"HTI59XC"5:=3E=:@[:_$FK:-6
MO=VVVM^'PN=9=3R[&T*V$4O[+QZ=?"W>M-5>1K#S_P"GM)25[]6MMET/C;P]
M?>*O"VM^'].\5^(O!%[JUK]EM_%GA,Z2/$6A2?:(G^U:3)K6F:UIAO2D9M]M
M]IFH0[7=?*Y&?D']HC]G'XH?$WXKZ'X[^'_Q \+>&M0L/AMJ7A?P_?\ B1_&
MI\2?#+Q'97GB*>7QW\--/\-Z_I&D7^I^-K?Q-I'AKQ[-XFLKN&QT?PKX=N-,
MAU%Y9=/G^O?&_A6T\<>&-;\*7^J>(]$MM=LS:2ZKX3U_4/"_B>QA,L$OFZ+X
MATJ:#4])N1)!$OVNVGB<"60'C[WPI^TU^SAX4^+7Q_\ A?XEUW]J74?A-XSB
M\%:E\-_ 7PMTO5M!T?4/&G@S6]8CUSXS6FDQR:YHGCK4=4\;V>D> =+?5/"&
MJ6"^%+7P9#/>P:^+Z<6?(K.'-U[+=7MUT\T<ZUJ::_\ #?KT[GF%_P#L9?M<
MBQT_6[K]LK73XRMM.UNRGU+4]<\=2>&=%@>P\,1>&]-T;2KC5%TV:^LIK37M
M#U#XBZA:Q>.+N#51XDM[X:]=WM@MO4_V1_VKO$>M_%F7Q3^TWI5SIWB_X6>)
M/AW\//"-MKWQ+W> ]6UO1/",J:W'XC?6(O$D]^]UX/C2^UF#9J#I)>^+M+.E
M:QJ&HV-U0TS_ ()TS_#_ $F==5_:^^(MAX5T>'P;%X8L-7U#6+'PGX/D\):;
M'X9\.-_9FK?$6XT&_@L[J[%U'%JD,O\ :6O:S=R71N'GT<6#F_X)YZ_HOPT\
M6^#=?_:]\51>(O''B;2+T>/[G3M0T+5K36GT3XI^#M"\-Z?>Q_$:+7#H[S?%
MC2SHVB0Z_!-)?^'K#1#/>6.NS:7;R:$6@_L5?MA:3<ZM>1_MHWVF>(M0N)==
MM[O3K?Q#>I)K%U>1D2Z]8:QJ<P\4:)HEIJ.JZ#IUC>)#8:I+;:+XFOK*RUEY
M&CAT3]B[]L[P[HV@1V'[;.OZ'-#XKT_4?$>DKJOBGQ'IUSI4OC*V\0WNA:3X
MA\:KKNIRZE>ZCJ6N2:GK%[IL][XOCN-/\'ZM%9:4AEBV_$__  3?\3>))=1U
M>?\ :P^)&A^.I-,\8Z/I_P 1/#]IX@TKQ2VC>.KJQO/$,6NF7XBW.E7L=Q%:
MVWA](M%TSP[I=AX=M-*LM&T_2?$EG+X@N)Y/^";7B%[Q-:A_:]^.-GK+0:5!
M>ZJ=:\5:S*4T:WN[>S>UM/$?Q UC2K&ZL;N/P[?6VI?V8=4@NO"=E=74UQ?7
M5Y=, >V_LS_ W]IWX7>/]:UWXR?M -\5?!VH>#+S0-*\-W-YXBO[G3]<3Q[J
MNO:3KADO_L.G?;H/!MW%X?U[4!8L=3NK?3(-*LO#VE:4]EJOW)]JA\Q(2X6:
M2.65(F*K*\5N\<<\J(Q#/%#)- KR(&0>? P8I*C-^7_Q$_80U?QNGPLT34?V
ME-5\-7/@WX::1X/M]$TJ+QG_ &9X@\3^#_B#!\1-+\:Z9I&N_&/5-8M;K2%M
MY[!II-8U?7)X8;&?7_$6H:9I&F:/;\AXB_X)I^*9=7OO$5C^VA\9/"4.FZ3X
M]TC20)M9N!IOA_QAX;L=(NKK6-;UCQW/J$^L>'_['TZXTW4M/O?#VB36?A[P
M\^K^']0U33Y_$&I 'ZY><F0.<DA>5(QN!()ST!("Y/ =EC.')42UY)\&=)T_
MPO\ "WP1X2L?'3_$2/P;X<TOP?=^,I]7DUF[UW4_#MI'I-_=:GJ%SJVM:A-J
M8N+*7[7#?:O>:G#-FWU"[N;M)95](O=:TC37L8]1U33]/DU/4(M*TU+Z]MK1
M]0U2:&YN(=-L5N)8VNK^6"SNYH[.$/<O%:W,BQE+>5D -.OG[]HW_D4/#7_9
M0_"7_HV]KW"YU;3;-8FN[ZTM5N+N*PMVN+F"!;F^FE%O#:0-+(JRW,MR?LL<
M*L9&N080N\8KPO\ :*ECD\'^&6C975OB'X0(960KAGO'!W!MI#(RLF"3(&'E
MA\T >YZ/_P @RR_Z]XO_ $!:*-'_ .099?\ 7O%_Z M% $FH+BQNL=K>7K],
M_P!#7X9_\%8M/\"ZW\,O@EH7Q(T[P3KOA;6OB=XOTQ?#_B_X4^(?BOJ7B+Q'
M<_"GQ59^%-'^']MX7^(?PFU?PMX]U+4IWTG0-9MOB3X;,UO>WEO?OJFA1ZS/
M9_N=J'_'C=_]>\O_ * :\* BD"&6""X"E75+J%;F+<% #B.9G$;(K2QYC(F>
M.69#<+%-Y,?LY-/V-5U5%N5._+9O5-)??KI=/9OM;Q\TBJBI1YDDW>^S2NMW
M?KZ(^!_@SK=AXC^*G['&M:7K&I^(K'4?V /B'JEKKFM6>JV&JZMIU]XX_9B%
MAJ>JZ?K>M^(-6@N+J*.50=5\2^(&GN%GB&M:T[R7MS]F>/O!FD?$;P/XN\ :
M[+?6^C>,]!U'P[J5SIDT,.IVUIJENT4UWI\UW;WEK!J$#E9H));.XM3*B.]H
M(HQ;MR?P[^"W@OX:Z[XM\7Z9/XK\3>.?'(M;;Q+X\^('BB_\8>*KG0M+N[^^
M\/\ @S3;J]6&Q\-^!?#=SJFH2:1X0\,:?HV@K/<R:E=V-SJ[RZA+ZS7I^UDJ
ML:M+W)4G[CEYU(5M+[-3Z^5VKGE.E%PG2E=PJ_'VL[77?;3=O3JCX^N/V)OA
M;=SI?W/BKXG2ZS-X@TOQ7K.O?VYH$&L^(/$5AXE\6^*[K5[N_M?#$$NCWVKZ
MKXUUH7UQX5_L!H;'R=.TU;"TDO8[O'L/V#/A%IZ:'Y?BCXER7'A;0]7\+^&+
MC^UO#=O!I'AGQ%#X@M_$NASZ%;^%D\,^(K;Q)%XBF&NW7BG1-:OK_P#LO1T6
M>VA@NHKO[9HKTUG^<*"A]>J**LDD]$ERK1<MEI?;IH[Z'D_ZO9-S<_U"E>^N
M^M[7>^UW?R?H?._P:_9I\%? W7=7U_PEX@\::K=:WX8T'PM?Q>*[[1=6WV_A
MJUM;'3+V+48-#L=;MRMI:I#'HT6J#0--@"6^F:=;I#;O![SJFE:5K=HVG:UI
M>GZOI[R0RR6.IVD%]9O+#D1SBUNHY;=+B$,TL3I&$^T%G,:B1@+]%>?B,55Q
M=:6(Q=2I7JU$E*=2*J/112O&UK^?1(];!T*.74Z=+!1A0]G5=:CRQ<?93T_Y
M>)\RW>UNO2]N*;X9_#5RQ?X>>"&+*Z.Q\+:+YC(WRA"_V/F/RAY7E.LD0623
MY3P#\:?MU> ?A]HG[/7C>^A\.:)HVCZEX>\=>&/%EG8V:66CZMX?U/X5^/K^
M!=6T:U:#2+VYTOQ%H_A[5-+U&6T34](NK!I=,O+=)FM6_0"OS?\ ^"MEYJ6G
M?L#_ !NO])0RZA;:<WV>-25+?VEX>\2Z4\;-GY-POMHW8PK%FV@''EXYJEA<
M6TI1BJ"?N.R6D=7;SO\ \%7M]WP/C,37XOX<I5L?BW"IF^#H32J5ING"M6H<
MRI<TKRZ[O30_DQ^#7@:]UGPEX9OO$FH:QX?C\-^%_">@:!HO@[QCKUE'9./"
MNA7^O>)]4OH);>VN]2\6W%]#?VVD7>FS6'A'26MM#@=I(+J27T;X&> +K4_B
MK#HWB#XC^#1!J7BVTOM+\8^.[C4IK2?['<VUXL6MW.CZ9=&*XNIH8O#>G&6*
MT$>KBV\G4K5!9R5XGX'O=!U/P/X7T_7?'>K6V@7.F31S>&8--UG2KN]U5()8
M9=.U#7+*\L=M^EC87%OINCM(-/AC9)Y7EGBB@;[Q_89^&7@^_P#'-GJ.G>)?
M&%G8^$-)O/'_ (>N_#NB:/XGU32;>)DT73M7UO6]:\5:-::?I&A#Q(-??39]
M'EU&[MM-:RM+J\^R2F[\&=2KB'1YZL'4K?5OW'L;IJ5G5?MU=IQZWMY6/](,
MW^IY1PI6CAY8FEA:>%KQH5DE7K3>)HI0IXJC5?NPC*ZO%IJ^R9^F?[+'@+PA
MXN_;A^#>G:=H_@K1)/@I\.?B%^TEJ&@_#W-KX;M?%7Q!%_\ "+0/$$MC:W-W
M&+J2T/B.*Q@O+Q9HX]0O1!IL-Y'<2#]\*_-S_@FSX)>\\!?$3]IG6+".'6_V
MDO%WVOPQJ4L)BN]3^"GP[-QX4^%^JJ+R:XOK>T\9V=I?^/[>QN9)/L8UN"6&
M*&[$KR_I'7TN'@Z5-0M:W33R_P OZU1_F[QYF]/-^(<74IM.&'HX?!TI07NM
M45&<ZJ\ISG-/?5.]^J@GN6('0!V'Y[M_]?SH/)R>2.A(48_ +BDH].V20."3
MN 0LI !8%2X5B0%R&P2 "=7%2?,X\TM/CG*=_AVM\_N]3XM64>5.I%?].YJ'
M56Z/I<S=<T;2?$VBZKX;\0Z=::UX>URSN-.UK1-1ACN=+U?3[I1#=6&HV;J8
MKJRN[=?(N[64-#/;R26Q0*!(;\4:0(L4$44$,42PPP6Z?9H(XHT2&""*WA*P
M06]K## MO#'&8XU18XUC$22%^#GHW;)*L, NB*3D9&XNI4$!BI&!DJ"I! &5
M89( RK8+$$E0P!4D$%2%)^8<9!4FE-J/*I5(--U%3E94[RLW4M%NZ;2;>C=E
M?96CV48.,XPCS5*7L:DYWE64%;5N6OSNW^(E>=_%CX<V/Q:\ >(? .H7TVEI
MK26%S::K%!'>G3M6T74;/6-'O);"9XH-1@BU+3[-[^SGD2&\M5G@40O,LT'H
MAR,9!&[IE6'7&TG(XW97;G&=R]-RY3DG *\@D$,I  &7R02,Q]649<C!16R,
M\.8X"AFF!KY?CJ%.OA<=0JX;$TE/D]M0KT5&LN=?#-M>ZUK?:VYZ.6X[$Y-F
M.!S'!UY0Q.$KT<31K049>QKT*BJT:CC)VE:5U.+5O7K^8UQ^S3^V%<ZG-IDG
MC_X)0>&KEVMWU6W\.S1M]D^RMI_GV?A_^S#<V,D=KY+R:9::O;Z>LUK#N;#7
M#2_8/A>P^'O[*_P=\$>"M6\0W4FF:);OX?T19-/N-4\7^/O$VH7,^JWFG^%O
M">CQ7VK^)-:U:[NIKBVT+0=/O&LM.VSS7-M:1SZC#9O?BEK7C2^NM ^!&FZ1
MXO>UNI=-UWXK:V\[?!WPE>1,RW=E97&ER)JGQ8\56D@,,GA7P3=)I%E<*;7Q
M9X\\.W&(CTG@SX5Z1X3U&_\ %.H:QKGC3XEZMI\NEZQ\3_%'V63Q1!:3L[R:
M5X5L+*VMM!\!>%;.1!*GA7P=IVEZ;=QQ03>(;GQ!=B77)?@>%O#3A_@G%9AF
MN34,3BL;7PLJ</K6(5:486]JL-0E)1Y+XC:33?)IL]/O.*?$[B'CG"Y?E&9_
M4,%E=#$0KU(X.BZ#G74E2=?$*[<W&G=J"?*EM%(\-^-?QL_9(\5>$_$'P;^/
M6O:!=:/X]\.#1O&WPZURUN=6U#3;34+:*XE\/^)4\)IJD>@^(-(?RFD:TUDW
MGA[4+-;FUF6Z@^T5^?6H?\$G_@M\28KCXC>#/VW/VGK[X77[:1J$6E:3XT\'
M^,M/CM/#%[]KT?2M/UK5/#L]_%_8]X5CBAUJVNM3EE=%U)K_ #N&SK/P3^-/
MPPN$\)P_LJ^&_BS##<:FK>/K(+XEB\=7-[<)*GB36UDC&IZ3K),,5S/;7,EO
M8-//>PDS12B2ON+]DCX->,OA]H7Q+U/X@Z%IG@^3XI^)=/UR#X7:;=PWNF>$
M;&VT7^S)OM<MNEO8C6]=)1K]+$E+46=N[L%EDM4_*<EXAXDXWXOQ.4\3<(45
ME^7QQ,/K4\/C,+_9J@E.C2JXRIR4,9AISNE3@Y7;>FB;_H[!YQC?!?@V&/\
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M#MB:^UB]UGPI=/=^(;>WDN[G1/%($>N>'O$4R>*=+NH=7B5Z_6&B@#\L8O\
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M[J=Q:""WPR%9$659 Z^6'PV,!Y? M]=V]YJ'Q1T/3=6"R0M%H5PDME'8ELK
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MSY6P_P VP;6QMR\G[N-20TK?-$'C^>OQZ^-'_!;O]C;X>7%UX;^$1\=_M/\
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M;7VB>(KF/?>6?AKP\UY:V7C;5[*Z._\ X2":X@T8_P"LL/$^KK_HM?H#X/\
MA3X;\*Z[)XMNY+OQ1XQN+^/4[GQ#JRPV=NE]%86NEPS:1X4TL0>%M"N;?3+.
M*P@U:UTV?7VMVE&H:MJ)?Y?A<RS_ #C-XUXJ3P6&DOX-#2K5L_\ E^]%*Z=G
M:VG>US],R#(^$^&?84LHH8C'YE-QI5.(<PA3E2P+E*/M:V7X)W49-:TZU5SD
MMXQ2=CXUU#XF?LL_ ^PTCP!\3?%7AOX8^%O#<4*:-^SSX>L[W7=2MHBMM=6N
MH?&:+PO8ZK/<ZQJ$C0:A+X*U&_:QMX_)N/&ESXBNOW%G]R_L\?&KX/\ Q_\
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M2- >1=1AO[>RYN?_ (*8_")]0U+3M.\(>-KN:+P=9^/]!>>'2M(_X2;P?>_
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M;Y91A+E5[2E;E6E[WTVNNXY.%-7=H04'+FE))<L8IR=[]%K?3R#K@$  #L
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M^89UFM57GC,=B*V(K5)>SIKFG5K2FY/G51J.R4K*R6G4_#;_ %_B;_L(V/\
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M=)TZ"C"[UYFXJUNKZVTUT.')\-/&9G@\/&#G*6+P\)15G:FXJ=679J*5WO\
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M$:XBHUJGRV:]#V\)%K#TDU9I:KM[MA:***Q.H**** "BBB@ HP,D^O7\***
M$ _PSU/X\=?SI3T/&?:BB@5EV7W?UV7W'CVH((-4NXR"5CO9#C_9)\T?3Y>!
M_M#'O7G.DQF#5O!L."/L(\=VI&21FWO+&&/.<#;Y/3H2.H]?5O$L7EZK*P
MGBMYCSU.QTD]BV8S[<C)Z@>: ^5K^BIQA]9\9Q J?G*SZ5::B< X& (I"Q!Z
MJV,@9KV'+FI8:=]5&[7:ZH[]%K%^3=['+EW[NMBH13T;YO\ MV$:DK^D+RLM
M$M3+^&&1X5GC; :W\9?$.V*CILC\;^(0H/?C>".!D=J]5GC/]AZ?(,8^WWO!
MZDMCH/3]TV>>ZXZG'EWPZ .CZ\. J_$'XB@C/13XKU-LX&>%<.&QR-ZD9R<>
MN7$6/#FG-DDB^E93STE^T;=W3TYQG'O50M"E@IKX9NA9]U&U[=?=[OJ99I>>
M:8VZTE9+SLH]]NSVZGB/Q0(:+X=0X!:;XO>!,=.5MI;^]. .X:(%1_>'4#FM
M?7(@NI^)DSSJGPYO 1S@2:=>ZQ 2<# (CU<;,%C@KG%8_P 21_I_PFQRO_"W
M?#6>N.-&\1RQ[OHT:GOR1[D=)KL;'4X<<K-X2\6VAC')=EET.1$!&<D&)R0>
M &[G(K*24\5B>KYL-'3K*]+3:U[5)[^:OT/5C/EP&4TDW:>%Q4JCUTK4JD*L
M(O3XG.E%+?5^M_2O"D).H6XR#Y%EDY))+^0(2>!Z\]B1SUXKU$@'K7GO@^-S
M<W4NTC9;PQACC&Z4.ZX([ (0W?)7 (S7H.>,GCZ\5R8U_P"T.*U44D_+3;YZ
M?CIN<&%NZ:GWU5GOU?XA@XP2?J.#2DX!/I137^Z<=?\ Z]<IU$?GQD@9SNWX
MP4;.WG@*Q+;DRZ[0<*"&VN50N\T8SA@.G.,]-V N=Q)3YPH&[:<$!@5'RSJ<
MG[3B^(==_L#4_AIJ&C1^(=9O-+LKF]D6^TS3)[6*RT70-=8:="6:T"PZ^S6[
M-=7<^LO;3:A';6ME)>0+)^UQ<6L]V$^%]G->V]P8=-GCN)KG2@D-X+)8[FWN
M9[6>]FG9;D7%U<7NFJ(K".6WC#:MD ^K1*C?=R<$ @8R&R05*DA@P +$8R%&
M?3+3/&.Y.,Y P6!R0H9<[@792B C)<>6</\ +7S/Y?[1D%Q>1Z5X@^'.L"2\
ML8#%JD;^;I#1^'+)-1MW.F);2S_\36&XODL)8X[F22Z1O.&F;[:+0U>Q_:.G
M\/Z9%IFK>";/Q-9:S+/J<\4$EOI6MZ$]HUG_ &?;Q2V^K7&FW<3WYU..Z$=P
M3<>'K*WR+;5YHX #Z*$JD9Y Z988 ()##)XRI!R,\X.W=2&9%.#D$AB 2N3M
M*AL#=DA2V&891,$NRC!/RY;W7[441Q?3_"6T?4(U:W$\NH2VNEWUO9O&-$LX
MX'M+O4GU75'MH)+J6XBEL2;GR8I@L7FES_PTD-=L-3LO$OPLN-/N-"\/V=_H
M=P;A+.+64TL7VK:C8%)'O/\ B8ZJ\MA9M+J5ZMMI<?VQ;:\E AH ^I!*ASMR
MV"1A02>"H8X'( + \@$CYE# @E1(#V8#&<E2.?0 X9C_ +H/US7RW#/^U)%=
M )<?!:6UN-6M(I8[@^(&FL8'$SZA8VLD<T9OM1LXTAM[.*<0)=0113O-'*UQ
M'%[WX.D\3OX9T4^,AI7_  E!LE.M)HN\Z4FH<[TLC)\Y6,_(WS!@^X!6&& !
MU>?K],9Q['&1G\:^7OB]>_\ "2?$[X;>!+4O)_9+7GC+6T0@B"-S)I>E+-AB
MP,A_M&2-60;HT$BDAE%>W>.?'&A> ?#>H>)=>N#%:6**D4*9^T7^H3$BTTRQ
MCRIN;^]<8MH%;#+F:5XK?,P\2^"'AK7-7U'7/BCXOA\KQ#XLNTNDMF&Z/2].
MA1X-*TRW+@-Y.FVICBC4+B5Q)*QW.<@'TU;1>3!%$.D<:(/JHP3T''3'MV%%
M3T4 (1D8R0,8X[_6F;<8[Y]O_LA_D5)2'/&,>^:A*VW,MO\ VW_@?<^R$TGN
MD]5T\U_DK^2&[![?D?\ XJC8/;\C_P#%4OS_ .S^M'S_ .S^M7K_ #2^_P!/
M\E^(*.VE-;=%_=\O7[GYW38/;\C_ /%4;![?D?\ XJE^?_9_6CY_]G]:6O>7
M3KVM_P#(K\04=M*?3HO[OEZ_<_.Z;![?D?\ XJC8/;\C_P#%4OS_ .S^M'S_
M .S^M&O>73KVM_\ (K\04=M*?3HO[OEZ_<_.Z;![?D?_ (JC8/;\C_\ %4OS
M_P"S^M'S_P"S^M&O>73KVM_\BOQ!1VTI].B_N^7K]S\[PET'7_9['.7Z+M+[
M@W3Y2 6)"IN?*AV5.<8. ">#@9&[!)? .,$Y(P"I/#+GYS_:FT#2O%'P4U[0
M=;^*&F?!ZPU'Q!\.8W\<:MJ,FD:9!/;_ !$\*7EGX:OKL:IH@AM_',T2>";I
M3?0&2V\0-&UI=(1;/^=U]^S3X>OM U;P]J'_  4<O]&L[J_6#4O#G@KQ[:KI
MTQT_6-:EUSS+'7/B)XN\22^*]<=-0_M&#2]1L-.CU^WOHX/#.H6%NFDPO_MZ
M73KVY?/R_J^@H^4.G1?W?+U^[UO^S8=#C +9"GY59AA\[3E6(*G&-P)4<Y;"
MN57<G?CG R#G[P7IOR,;E)R 0& .&RH_-WXL^&? GC:QTV]\+?MM6OA_3]+^
M(WA/QAI<4GC/PGK.C^#["+PIXC^#NAZ7X?'AN]T2^@TZY\>:M:^(;:\\67WB
M+3)OB#X?M[-6MO*6"V\:/P<\5:S9ZB(?^"H\\\'B?['H-G?GQ'I^F:M)#HB0
M:7::,7TWXD:6;/6VU+Q3HVC^(5TJ#2/$%[-K%M>:DP\9ZC8:DAV]Z73KVY?7
MM_70Y?*'3HO[OEZ_=ZW_ &'W)WXY(R00,[]@YW\!C]S/W^BY;Y:3?'SP<C'&
MQ\Y)QC&<C&5+EL+&K*TA0'-?DQHGP$^)-[XC\$Z3X6_X*1^)?%&H7NE7?B/X
M7:5<6=CXKMM1\.^ +>#0O$LBW^E>*]OBZUM=<U[P_:>)/$&K:CJU^\.HSZ>5
MM=5M[+4[70\0^#O$7@WP?K&J>)O^"C7B2"7XQ^%M$L_"37FGVK)/?^(?$N@Z
M=I&M>!= T?5&\8Z7I&K3:C%X9:]\(W-G>V4WB"RU.+Q!!?00F0_[>ETZ_P"'
M_P"1^?D"CY0Z=%_=\O7[M>M_U8W1X8[EPI*MST8?PDAR-W^SG/J >*1I(T!9
MN%'5\'8 0S;RV_&P!<LP)5 <N5"N5_&'X<^%KWQ5#X7T?PC_ ,%4/%/BS6X]
M(U'6;#Q-I6AZ/J>FOX%EL+G6+R>^DN+Z?PII5^?"DK7.C7VOW5U?6,V@?;X+
M?4K;1=:T^"]-X&U71K'QIH/B'_@IAJUU\1_">G_"[Q78^);S4I?#Z644?P_^
M)-UH5A<21:Y>^%=>TGQU%XD'BN6PT71]4U35=#\,Z+J^N:=XEOH;#4U/G+IU
M_P /_P C\_(%';2GTZ+^[Y>OW/SO^QWG0X!WK@@E2<J'P,C:6==P(^8./W>W
M#;P""7!T)P 3C=EMIV*5)#!GW;58' VDY;(90R!F'XM67A'XJ66H:KIOC?\
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M_A27W_Q5'_"EM>_Z*9X\_P#"DOO_ (J@#Z&HKYY_X4MKW_13/'G_ (4E]_\
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>strokerecurrence.jpg
<TEXT>
begin 644 strokerecurrence.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***_!S_@JO8^(!^W/_P1XTC0OBU^
MT3X T#XU?M/^-_A7\6/"WPD_:<_:'^#7A#Q_X&\+_!_QQ\2-%TCQ-X0^%'Q/
M\&^&=1NH/%UA97EUK\ND_P#"1:KI=M%X8U;5K[PNHT:@#]XZ*_.#]K;_ (*&
MZ)\!_&'PC^"?P;\&^'OCG^T?\:/VG+']E;P[X \4>/\ 7/@_X \(^/5^"6E?
MM&^(+_XF_$_3OA?\6M3T#2-'^#OB/PEXALT\*?#CQWJ6M:GXR\.Z/#96D:^(
M=2\/_F2?^#@#X@>*/ G['WQ+^$_[#^A>+O"G[;'[/'[1/Q!^#,/BO]J+5?!7
MB?5OVD?V4;S4M#^-'[)2:/I/[,OCO3?^$DNO$^CZEIGPF^)5_P"(-*\)?$#2
M[2Z\2ZQ9^!=*TW6VTD _I5HK\^?^"=_[9OBC]OSX%:9\?[OX8^!/AO\ #7QQ
MX&^#6O\ @@^#OC7XH^)GBFXUOXA?!GP;\2?B;X3\76]]\$OA)IGA.]^%'B7Q
MK%\.K'6/"OBCQR?%FIZ#X@U6]@\!7>GPZ'<?RR?LN_M8ZOX0_:M_;'_8N^/?
MQN_;;\*_!'XS?\%8?CI^QA\.OVQ?B9^V=^UIXU\&?!;P7\&+WPAXV^&'[)WP
MX\;R_M5:;\0/A!\<_BNT.KV.@_';Q')&VI:0S^&]7D^-VC7'CGP]X! /[H:*
M_GJU#X=W'PW_ ."[_P"RO\#_  O\9_VN7^#K?\$]?BC\9[_X8>*?VW?VQ?'W
M@77_ (F?#;XJ> _AQX2\4^+/#/CWXY^)=)\83VWA/5+^UUC3O%-KK&C^+-6N
MI/%/BW3M<\5!=:7YY_X+;?'G7]%_:"_X)>?$S]G7Q5^U]\2])\;?M)_M'? O
MXJ_ ;]D_]J3X[_ R3X]M^S;#XUL=>^%</A+PS\8?A3X(E\7:%\8/#?BOP_JG
MBJWM8_&/B2TT1?#EEJ7C/2+3PQX9NP#^INBOPG_9%U#X2_MI_L$_&/\ ;D\,
M_M"?'[Q?XM_:>^&?Q#\5>,M&\!?M8?MC?#?PS^S5XKT:SM/$7_"B?AU\,8/V
ME-?@^ _CSX0ZQX9TC1/'WBKP!>^&;_XA:_<>-M=\)Q^%O@+\2O#?PIT/W_\
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MN?V?/A1XD^"-C\-_B;X.U[XA:W>_ 74M8^&O[1'C_P >_#'QYI4&H?%_X5>
MM!\2>&KK4P#];:*_ '2O^"V'C7Q'X1_9[T+PI^S+\)O$_P"TM^TO\9_VD_AC
M\/?A3I_[5GC#3_AKHFC?LE? .#XZ?'74?BS\1?$?[).A_&?X,?%3P5+++\,=
M1_9_^*/[+'A7XAV?CNV>XU(:?X-NM-\4W_0?#C_@M1K?[3_B3]FCPG^Q'^R%
MJ_[0/B3XO?LE_#_]M'XM^%_&7QO\-_ CQ%\*?@]X[^._AOX"S:5X"E\2^"?$
M?@OXP_$?PAJZ_%3Q?XC\/:YXV^#?AJY\(_#"(>%O&WB/Q1XXT'PU" ?N]17\
MT7@+_@J)\1_@9\/O^"AOCW3O@KXR^+_C#P#_ ,%:_C-^SQ>>$/C7^W-%K_@[
MP^OA_P""'@SQ:]A^SZZ?LV_\+DMO USIOA62?X<_LD?!#X!_M!_$I/&6O>.?
M$L6J7/A>37M9\/=QX0_X+.?%GXS_ !?_ ."8LGP^^!O@?P1\ ?VL_P!C3XH?
MMK_'+5?&WQ3UBZ\:^$O#_P +O#]E;?$;P#X+MM ^#_B*+Q3!\-K[73KWA[4+
MFT\#:I\:=5TS3M.FNO@YH>FZE'XY /Z):*_G%^'O_!P)?^./V8_%/[25Y^PM
M\8?">D>(_$'[-GA[]EN3Q/+\8/"'PS^.^J_M2_$O5OAKX&\/:W\:/B1^S+X
M\*^&_$_@>:QTSQ5\7)O@M8_M-_#?1/"_B71)OAY\3?BEJW]J:3IOJW_!$WQ]
M\:_'/B;_ (*L>$_CEXB^)%UJ?PO_ ."BOC[X=Z#X)\9?M!_$K]HG2_A1HT'P
MJ^&.I:CX'^$_Q2^(U[#XNO/A;!XBU36M8\ W$^A?#[4Y-#U2QU#5/AY\/=>G
MO_".B '[R45_"/\ M*:7^U!\++3_ (+)_L#>#?VM/V\K[]JO]GKQGX2_;?\
MV#?B;J'[>O[7$7BGQ#^R1K?PIOOBMX_^$LI;XLWEYXV\)?"SP[\,/'?PK@NM
M4THZCKOQ?\:^'/MOB^WU"32]6@_1C]I']L7P[KG_  20^)G_  5,^%>M?M/7
M?@+QUX,_8:\!V>G_  F_;X^/7PL\0>'="'C[X%:%X\UCX7^)/&ND?M#> =,^
M*>B?'7Q?J'P ^.FK+\,=-\6>.O#OPV^)VF>)_B-<>*]9UK^U0#^J"BOY#_\
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ML_?#WX->%_'/BF<#QGX$\(_"KXX_'^XE\+Z9XLL/B%>_#?QQX6O/!]Q^ O\
MP4D^-.J?!+]NC_@J]X-\1_&#_@H[X6^'-O\ !K]D^+X*_&'X:?MY_M9>"OV;
M_P!A3]H?]K&/Q]H>E_&KXY:%X7_:*&L^$?@#?_$JX\*K/I7@?X$_&7P-X,M-
M'3P?X?\ AUX:F\1>%='UX _M_HK\#/BO_P %3OB?^Q#JO[&O[&GB7X1^.O\
M@H%^U9>_L8_#_P#: _:4\=?L_P#A3XT>*)O$OA'0O$WP_P#@WXQ^)WPE\'?
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M^'UTC0Y]*ETKP[X>M-+_ $UHH ^2?@1^PO\ LN?LS>._'7Q%^"'PWO? ^O\
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MG:YU'7O&?Q(^)?B+Q=\1/'?B.^D*K=^)/&GBG7M=N((+6UEU![6SM88?2:*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  @'J,_6O'_C1
MI/BW6?ASXMTOP7I.C:YXDU/2+S3],L?$-W-9Z6\]U;RP(UU-;0SN$B=UD4>7
MC<JLS$KL?V"HIHEE50RJVUU==RJVUESAANZ,,\$<\D=": /Q>^&G[)W[3MS^
MQWXB_9<^)>E?#G0(/'C^-4U_Q+X9\47\[:3#KVL'5;!88YM(MXI%>1I89PP
MA6*U5(V)F+^M_ C]F+XSR_'KP/\ '#XY#POH4_P=^%$/P:\$:/X/O[S48?$^
ME6TC^5XGUPW6G:?-8:@T1C62*-KFS6.)66>1IC';_I^;8GD,$. I.U264,7
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MH.E<<D _9!@XQR./3D#UKK]5\-:;K-I)!J5C9WD$Q*3V]Q;[XI$9@"'C9'#
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M<^-OA/X4>/\ Q!>Z_P"%]3T/X(2>$=/L+#6OAUJ>N>"_$?PZ\4>(_#VE^/\
M2 #^MVH) 6;;D%0$8J&PZE69@V.ZDJ%QGGYO3!GJM+@2J2.6,2 C&[DR\<XP
MH&6)R<A2 N<9 &R9V, H<D;0K' 8M\H4D?=R2!NYV]<'%?FO_P %#?A[XS\6
M:'\)O$VC>%M0\=>$_AS\1/[=\>_#_37A>[U[09KBPCM;@65P#;7\,"070D@G
M(1HY=K,H+$?I>T8((!(SWX/&>>W7'0]0>00:H/9[B4PHAQM"H6S)'P?+F)+&
M2/!9=C?)AS\N=K  _$[X$>#-=\3>*?VE[34_A_\ $OX9_!/]J:\BL_AYX<TV
M+2=-7X>'0; Z7XA\4S6UK<P0>'1K.NPW-W86]HM['/;BWEF++,F%_P""?_[*
M7Q9\-?M">+_CA\1M6O[?P;X#\*7'P5^#VFWNE:;H.J>*?#UKJ,]T_BSQK;Z9
M(RW>MW-Y/=Q1W3M*+BQ@L7)C9?F_;&#3XHD\M5 10HC3:H2(+PHB0($0!51"
M%7#!%+AGW.TOV,#(&/+9@[H<ME@SL3E@2,LY. 0!@;0!P0"6%G2*)9#O=8T#
M-T!;:,D#GC/0DDD8)))KPK]I8Y^!7Q5/KX7G/_DQ9U[N(MH501A551G.<* !
MGKV%>#_M+<? GXJCT\+S_P#I19T =9\&?^29^"_^Q?TO_P!(UKU*O+?@S_R3
M/P7_ -B_I?\ Z1K7J5 !367<0<XP".GKCW]J=10!2-JP?<&!'!Y&.A)QU/K3
M9()"!LVLPSE2VWT[X/\ *K]-*@_7U_SQ5J?1VVLG:_WZF<HMMM?UM_7R]##:
MWVQR,7D#M\K9$;JH_B5<1H64L3U)) '.237YK_M^?\$X?@S^W/X(N;'Q-I%E
MHGCG2H+BY\)>.K&V$&HZ9J(A<V_VQ(/)DO[<7'EN4>=?+VY5';@_J"8E((RP
MSDY!&<G\/\X%021*, $]0,\ \CN5 /ISUKDK87#8N$X8FA"HY*45.5FXWLE)
M76ZU:\UNCV^'\\S'AS,Z6;9=7JX?,*3IN.(C5G[+]W*+C&6&OR2C[MFK6ELT
MTS^)#X>:Q_P5F_X)[:GXO_9CTGX/W?[2'PXCN+@^%KC6);R?3(K!I6:VFCU&
M2"<AHXU5X[8>6(G1?G? 4V=0T'_@L[\9M0LK[2/@-H_PTL)).+6,VTEOY+9
MBG>2,R;07!WB$.-AP1T/]I\^E64K[YK.WN'5BRR7$,<[J2"#AG4M@CIG( P1
M@X(M110P@A+:*-0/E$$*Q$?0H%X )P!Q[>GSU/AO%4JEXYIB*5&F[QI0E+EE
MY/567K?6W8_6\S\7<IS7#REB^ N'\7G.(@XYAFU54[Y@VTWS453O"[7-\2:>
MEWU_EC^%O[)/_!6,_8F\;:?\#8=.95,9O==URWO%N@?E6?[%HLL<9/=22&8
M!AC)\"\?_MN_%/\ 97^.EC\'?VF_ >I_#5;S4X[*V^(NERWNJ>$-0AE?[.NH
M6<MU%8KY'F13;D+'"JK;\OM']B3*6 52XVY^9_+D.&/*_O5<<XYPH88&&'?X
MC_;5_8=^$?[9GPMU?P#\0="LYM1>VN/["\2&TBEU70+R='VWMD\<0D=('56D
MB! 4-D$9->FGFV!I2EAZ[KNG'FM4J6NHV[^FF^_2Q^<X+%<"Y]F]#"\2\-Y?
MEN#Q=>-.I4RZE4C*A&5DJBFI?#%M7BDG)Z>3^;/"_@CX]^+/"VC^,OAOX]\
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M^"-_P;_X)Z_LZ:-\5/A1\4/B7KVNZEXI@T&*RUN[CMM.@L+H*9H8WBNRS2!
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_(?\ M2_M$?\
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M?%;_ +%BX_\ 2BSH ZOX,_\ ),_!?_8OZ7_Z1K7J5>6_!G_DF?@O_L7]+_\
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M<6 X&XX(Z^&?L7?$#P<G@$^$9];BL==BU*61]/U"YCBN;AMJ1N(EDPS*)&'
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MG?;\_0M*P8!AG!SUZ\'%+443<*O7J,^P)QQ4M:@%%%% !1110 4444 %%%%
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M-[9\A6$;$,,#!/3/3Q\SRI9A@(THN*KT9>UHS;UA--2BHO2R;Z*U[=[H^VX
MXSQO!>:U\4HPQ.7XR#HXW!3:E3Q-":M4C.#M&4_9N482:;BW9:ZK\L/V(_\
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MA.KF^?6_^)?,J.P$B,KN5:/&05D8)C@C::_2*VMH94#L4"N%89C"G:1D!L'
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M8=_9 \.0_M;?$#53X!^'&G?L0^!=0^%_Q&^*'P-^%_Q ^(<<WB[4?#OP?O\
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MDEED<JD<<:*SN[L%1068@ F@#\?_ /@G/X=^%_P[^,WC/P)^S7!I:_ /Q/\
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MQ%H_AK3-,U#QG#X7\;2^&[*2]UF"2ZU6+PEX@DMH(Y&33+EB%K\0?B9\!OV
M?A+\</VQ?VK[#]DW3?V@/VU_@_\ %_X*_$SXT:G^U%X=\9Z]\.O 7_"[M?\
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MITGC;P=\.OAU)\']=BF\3>%= TOXJ6GPS\*?\)Q>^*?C5\0_AY:^&H=&\!^
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MK$%SXQ3Q_P"$[;Q7X1XO^)/Q#^%/[!/_  4/_P"":7B7]G7]L;XH>./ _P
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M'AN^\=^/OAH 7/\ @E'9^*[;_@F)^R3X1U#PU\0?A1\0O!W[/_AGX>:WX?\
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M &S_  C\>/A+>7WBCX"_#KX=?"'P!^W=\*-._:>^"7C.XF_:T\1:%^UG\?O
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MK?QS\/YO%-KJ7[<?B+XB0:+#;:1H4VN:S>^*]5\ O:Z1?VD&GSZII^/[=TX
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MX8?VW/VG?@KHW_!1GXN_"FP_9]_X(4>+/BQ=_M?_  U\+12?$7X)?M(^._\
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M\&?^29^"_P#L7]+_ /2-:]2KRWX,_P#),_!?_8OZ7_Z1K7J5 !1110 4444
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M5+6QYBO97T=M?7K^(4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO?J\"_:7_P"2%?%;_L6+C_THLZ .K^#/_),_!?\ V+^E_P#I&M>I5Y;\&?\
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MB#KJMCM.0K?:+<#Y6922#/GJ#UYZ9[4P:[H9*J-7L0[J[#-Y9D;5!8DXG!'
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MGQ!X9OO&7A;X2:]\7_"7@#7/A%X;^.GC3PK9VNO^!/@+X@\<Z9\9O'6F>)?
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M_%OPZ\6:W\7S^S9JMS\-@/AQ\9-"^,&B>&/"/P'T+X_^$M5\->%M/D\+>'/
M^AP:G\:_%>N67A'3&DUW7_%/B>\N/$1^0O%G[!7[6'@3Q-J7Q_3]H3X3?%7_
M (5A\7OVPOVJ-&^"O@']CC7]'\>?$;6?CE\"]>^&UE\(O#GBGQS^V;XI\$0:
MW:V=[=PZ)K?B?P1J/A_7_$5]I2ZYH&FZ';:A:WX!]<^"?^"BOP'^/?AOXF6_
M[.FH?$C6/B!X0\+_  _OM#M?BW^S!^U-\$O"-]K?QSU2+PI\ [LZ[\9?A-\+
MM-\2^%?B!XKO],EM=0\(ZY??:O"OV[Q+:W<>BV[:I'M?L8_$W]I/XL>%?VA+
MCXV^,_@=K7B'P'^T-\9?@O\ #V^^%GP4\>_#?1K'2_A=KUYX7M-:\9Z+XM_:
M'^+M]XJO]7OHH=5N;?1/$'@BWMK59=*B,LTB:M%^??\ P2S^ OB71]0U&&?7
M?$_BOX=^$-2^&?BB_P#%GQ3_ &*_^"A_[)OQ$\1>)_!O@;Q[X*\&?"N:P_X*
M-?M/?'_QGXJ^%_PW@\26'Q$\$^'OA!H?@#X$?!GQO9*OP]T6ZU[Q;K[^$/J[
MX*_LN_MT?!+6?%\MW^UO^S[XK^&GB_X\^.?VA/&?@SX=_L1>+/!7Q@\13>,/
M&/\ PGNN?#+P?\3OB+^W5\2/AOX:TGQ+/;IX,N]7U_X2ZKJL/A?5=7.C^(/!
M_BB71_''AD ^N?V<OC+JWQ=\-^-=.\9:5H>@?%?X-?$K7O@U\8=!\,ZE<ZMX
M;LO'&@Z3X>\4Z?JOAV\OH+;45\/^.?AYXS\"?$?0]-U6'^U]"TGQC9Z%JT][
MJ.F75]<_0E?*W[*GP@\2?#C2OC'X^\?:/I'ASXH?M,_&[6_C]\1O#&@ZJ=>T
MOPKJ=UX%^'GPC\&>%AKHMK2'6M7\._"/X1_#C2/%FK6%O'I&H>,+/Q!=:$T^
MBRZ?<S?5- !1110 4A )!]*6B@ HH) Y--WKZ_H?\* '44W>OK^A_P *4$'D
M4 +7@7[2_P#R0KXK?]BQ<?\ I19U[[7@7[2__)"OBM_V+%Q_Z46= '5_!G_D
MF?@O_L7]+_\ 2-:]2KRWX,_\DS\%_P#8OZ7_ .D:UZE0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M4<BD@X)]>O QW_S]:DHI62=UOWZAL97V=]Y9F=@3G9D^7GCG .0QQS\WL.*D
M2UB R068G)+$DDY[YY_'.<8&< 5?9=QSG'&.G_UZ;Y?O^G_UZTYYVMS.PW)R
M4DW=27++^\NS[_KU,YK6(N[-$C%L@[D+9'3C)(''<#\Z5K"-@ L42CU*G)![
MD\$GITZY/K6AY?O^G_UZDJ-_^&)IKV3O3]Q[>XW'3MH90TN' 5XXG0#[I13G
MV^92"/K\W^UQ65J'AO1]1M[BTO=.M;BWN(S%-#/"'AEC/6-XR0K)ZH01755&
MZ]P<'/7('\_Z5A4PU"JG&5.'O:-N*ZM=U;6UOR.B.*Q-)\U/$5J<DTU*-2:D
MI7T::=[IV:MU/S@_:"_X)@?L?_M#6%V/&WP?\,C4G20V^I:)8VNE7<4LK R3
M.;=(Y+A\X;+NQR!R.0?QV\3?\&[-SX<UN\U?]GO]I?X@_"W1II;ACH&FWLMC
M;LQ.8A,]K,DDPBS@.R!B ,EL5_5&8P#E@"3D L%/U[>_\O2J\B*" $  '& O
M'N,C.>Q_/K7#4R/+JRM.GKHU*D^6:2MVM=.ZOYVV2/N\C\6N-LAH*A2SK%5Z
M:C[.,,PB\QHJFU%.,:=?G<79*S5K-N^MS^4MO^""7[49^8_MS?$4*V#MB\1Z
MV$R0"<9N0<9SD<<\XSFHY/\ @@Q^U((Y!#^W%\3A+)A69O$&L, !\H\MOM'R
M @ G )(SGK@_U8BV3@!R@'\(*G!)YXSD DDXR>>G4"I57GD#@X!'!..,GIU_
M#WXQCS)<+8;VL)TZ^)C&$N90K5'R/X>5)7:TUNON70]]^-_&LJ$J/UC*72JI
MQJQ>54,.VI)? U%.3[V::TLSYW_9;^%/B#X)?!/P+\+_ !)XIOO&NN>%=*@T
M_4/$NHSRW%UJ4D2JK32RSEI'9CD%R02.O6OINJOE$$,, \\_*"<].@ )/_ZJ
MM5]+3BZ=.%.]U3BHQ]$OS/R7%XR6/Q>)QE2/+4Q%1U*FB2<GNXI;1OLNA^<O
MC+P[J?[7'[2/[07P3U[XK_'3X7?"W]GSP;\$-,MM'^!'Q+\6? SQ/XK^(?Q4
M3Q%XX\9>*=<^)G@&[T;QY?:';_#BQ\+_  Y\):)X?\1Z'IOA^[\2_%/Q=<)J
M7Q)LO@_XP^$'Y'>(/A9KWPI_8B_:"_:A\$?'G_@H#XF^)WPM_;C^,GP7\,>#
M[C]O_P#:J\=6'BCP5X%_X*S^&OA7X \,6VC?&S]H.[\*)XDTOX5^!C\)-.O]
M4\3>%?#GC#P]XX\71_&:]\4-J4&OZ'_0G/\ !)[+]H:W_:!\(^,+WP[>>(O
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MW\5/$&E>&=+\/Q^/O&&OG4M.\,2:Y:RPZGXC\8^-_%?B;Z8H **** "BBB@
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M4 ?85%?'O_#3GB'_ *-]^*W_ (!:7_\ +:C_ (:<\0_]&^_%;_P"TO\ ^6U
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MX!:7_P#+:C_AISQ#_P!&^_%;_P  M+_^6U 'V%17Q[_PTYXA_P"C??BM_P"
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M!.=^X%>H*E"I^OI0!;\H_P!X_P#?1_PH\H_WC^9_PJ2/[O///]!3Z (/*/\
M>/YG_"D*8."Y_,__ !-6*J/*@=P^4P0%XW;A@<@#D<\8/UZ4 2>43_$?S/\
MA32H'5SUQU/7\JJ)=[V(V,@#2 B4%)=B<)((B"S+*<[2.BC<1@@4QM0@>4QJ
M59DD592)H&$4C']W'*$E=XY)LY@5T7S1TP< @&AY1/\ $?S/^%'E'^\?S/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 27, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DIAMEDICA THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">301 Carlson Parkway, Suite 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">496-5454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Voting Common Shares, no par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DMAC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,882,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Baker Tilly US, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Minneapolis, Minnesota<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001401040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,647<span></span>
</td>
<td class="nump">$ 3,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">44,243<span></span>
</td>
<td class="nump">41,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts receivable</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">60,629<span></span>
</td>
<td class="nump">44,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">742<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">61,371<span></span>
</td>
<td class="nump">46,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,545<span></span>
</td>
<td class="nump">4,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligation</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,132<span></span>
</td>
<td class="nump">5,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Liabilities, Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation, non-current</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligation, non-current</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value; unlimited authorized; 53,742,370 and 42,818,660 shares issued and outstanding, as of December 31, 2025 and 2024, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Paid-in capital</a></td>
<td class="nump">228,829<span></span>
</td>
<td class="nump">180,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(172,768)<span></span>
</td>
<td class="num">(140,002)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">56,111<span></span>
</td>
<td class="nump">40,718<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 61,371<span></span>
</td>
<td class="nump">$ 46,345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br> $ / shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common Stock, No Par Value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common Stock, Shares Authorized, Unlimited [Fixed List]</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="nump">53,742,370<span></span>
</td>
<td class="nump">42,818,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding (in shares)</a></td>
<td class="nump">53,742,370<span></span>
</td>
<td class="nump">42,818,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 24,614<span></span>
</td>
<td class="nump">$ 19,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,783<span></span>
</td>
<td class="nump">7,624<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">34,397<span></span>
</td>
<td class="nump">26,681<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(34,397)<span></span>
</td>
<td class="num">(26,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">2,267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">2,267<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(32,738)<span></span>
</td>
<td class="num">(24,414)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(32,766)<span></span>
</td>
<td class="num">(24,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (32,739)<span></span>
</td>
<td class="num">$ (24,427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.7)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding &#8211; basic and diluted (in shares)</a></td>
<td class="nump">46,980,777<span></span>
</td>
<td class="nump">40,404,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Private Placement [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>A T M Offering [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>AOCI Attributable to Parent [Member] </div>
<div>Private Placement [Member]</div>
</th>
<th class="th">
<div>AOCI Attributable to Parent [Member] </div>
<div>A T M Offering [Member]</div>
</th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th">
<div>Retained Earnings [Member] </div>
<div>Private Placement [Member]</div>
</th>
<th class="th">
<div>Retained Earnings [Member] </div>
<div>A T M Offering [Member]</div>
</th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Private Placement [Member]</div></th>
<th class="th"><div>A T M Offering [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (115,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares under Private Placement (in shares)</a></td>
<td class="nump">4,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares under Private Placement</a></td>
<td class="nump">$ 11,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,444)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,444)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,818,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares under Private Placement (in shares)</a></td>
<td class="nump">8,606,425<span></span>
</td>
<td class="nump">1,724,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,724,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares under Private Placement</a></td>
<td class="nump">$ 29,967<span></span>
</td>
<td class="nump">$ 13,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,967<span></span>
</td>
<td class="nump">$ 13,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares upon the exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon the vesting and settlement of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32,766)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits', window );">Issuance of common shares in settlement of deferred stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,345<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,742,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 228,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (172,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period due to the settlement of deferred stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parentheticals) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dmac_ATMOfferingMember', window );">A T M Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dmac_ATMOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dmac_ATMOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,766,000)<span></span>
</td>
<td class="num">$ (24,444,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,846,000<span></span>
</td>
<td class="nump">2,085,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of discounts on marketable securities</a></td>
<td class="num">(942,000)<span></span>
</td>
<td class="num">(1,343,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">82,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other assets</a></td>
<td class="num">(254,000)<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Amounts receivable</a></td>
<td class="num">(22,000)<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits</a></td>
<td class="nump">1,308,000<span></span>
</td>
<td class="num">(1,308,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">535,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(892,000)<span></span>
</td>
<td class="nump">2,489,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(29,062,000)<span></span>
</td>
<td class="num">(22,076,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(59,278,000)<span></span>
</td>
<td class="num">(50,411,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities and sales of marketable securities</a></td>
<td class="nump">57,126,000<span></span>
</td>
<td class="nump">59,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(2,192,000)<span></span>
</td>
<td class="nump">8,564,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares, net of offering costs</a></td>
<td class="nump">43,282,000<span></span>
</td>
<td class="nump">11,747,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceed from the exercise of common stock options</a></td>
<td class="nump">1,004,000<span></span>
</td>
<td class="nump">256,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance lease obligations</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Deferred financing costs, net</a></td>
<td class="num">(400,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">43,876,000<span></span>
</td>
<td class="nump">11,994,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">12,622,000<span></span>
</td>
<td class="num">(1,518,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">3,025,000<span></span>
</td>
<td class="nump">4,543,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">15,647,000<span></span>
</td>
<td class="nump">3,025,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Assets acquired under financing lease</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized over the period for lease expense, non-cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTable', window );"><strong>Effective Income Tax Rate Reconciliation [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 11.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Executive Compensation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information required by this Item is incorporated herein by reference to the information under the headings &#8220;Director Compensation,&#8221; &#8220;Executive Compensation,&#8221; &#8220;Corporate Governance &#8211; Compensation Committee&#8221; appearing in the Annual Proxy Statement.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement [Text Block]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9B.</b>&#160; &#160; &#160; &#160; &#160; &#160; &#160;<b>Other Information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and </i><i>Modifications</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the three months ended December 31, 2025, <span style="-sec-ix-hidden:c1119"><span style="-sec-ix-hidden:c1120"><span style="-sec-ix-hidden:c1121"><span style="-sec-ix-hidden:c1122">none</span></span></span></span> of our directors or &#8220;officers&#8221; (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) and 408(c) respectively of SEC Regulation S-K.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize the importance of identifying, assessing, and managing material risks associated with cybersecurity threats, which risks include, among other things, operational risks, intellectual property theft, fraud, extortion, harm to employees or participants in our clinical trials, and violation of data privacy or security laws. In the ordinary course of our business, we collect and store certain confidential information such as information about our employees, contractors, vendors, suppliers, and clinical data. We augment the capabilities of our people, processes, and technologies in order to address our cybersecurity risks. Our cybersecurity risks, and the controls designed to mitigate those risks, are integrated into our overall risk management governance and are reviewed regularly by our Audit Committee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Risk Management and Strategy</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="-sec-ix-hidden:c37">Identifying, assessing, and managing cybersecurity risk is integrated into our overall enterprise risk management systems and processes. Our cybersecurity risk management program has been developed based upon prevailing security standards and the National Institute of Standards and Technology (NIST) framework for evaluating and responding to potential cybersecurity risks, and addressing cybersecurity threats and incidents to the extent they arise. We have designed our business applications to minimize the impact that cybersecurity incidents could have on our business and have identified back-up systems where appropriate. Security events and data incidents are evaluated, ranked by severity, and prioritized for response and remediation when or if they occur. Incidents are evaluated to determine materiality, as well as operational, business and privacy impact. An important component of this program is employee awareness of and vigilance regarding cybersecurity risks. Our employees receive ongoing cybersecurity awareness trainings, including specific topics related to social engineering, phishing and email fraud.</span></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recognizing the complexity and evolving nature of cybersecurity threats, incidents and risks, we <span style="-sec-ix-hidden:c39">engage third-party experts</span>, including managed information technology (IT) service providers and cybersecurity consultants, to evaluate and support our risk management systems, <span style="-sec-ix-hidden:c40">monitor potential vulnerabilities</span>, periodically test our cybersecurity controls and procedures, and respond to cybersecurity incidents affecting us, including prompt escalation and communication of major security incidents to legal counsel, senior management and the Audit Committee of our Board of Directors. We utilize advanced technologies for continuous cybersecurity monitoring across our IT environment which are designed to prevent, detect and minimize cybersecurity attacks, as well as alert management of such attacks.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Identifying, assessing, and managing cybersecurity risk is integrated into our overall enterprise risk management systems and processes. Our cybersecurity risk management program has been developed based upon prevailing security standards and the National Institute of Standards and Technology (NIST) framework for evaluating and responding to potential cybersecurity risks, and addressing cybersecurity threats and incidents to the extent they arise. We have designed our business applications to minimize the impact that cybersecurity incidents could have on our business and have identified back-up systems where appropriate. Security events and data incidents are evaluated, ranked by severity, and prioritized for response and remediation when or if they occur. Incidents are evaluated to determine materiality, as well as operational, business and privacy impact. An important component of this program is employee awareness of and vigilance regarding cybersecurity risks. Our employees receive ongoing cybersecurity awareness trainings, including specific topics related to social engineering, phishing and email fraud<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">As of the date of this annual report on Form 10-K, risks from cybersecurity threats including as a result of any previous cybersecurity incidents, have not materially affected, and we do not believe they are reasonably likely to materially affect, us, our business strategy, results of operations, or financial condition. However, cybersecurity threats are constantly evolving, becoming more frequent and more sophisticated and are being made by groups of individuals with a wide range of expertise and motives, which increases the difficulty of detecting and successfully defending against them. While we have implemented measures to safeguard our operational and technology systems, the evolving nature of cybersecurity attacks and vulnerabilities means that these protections may not always be effective.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Governance</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Audit Committee of our Board of Directors is responsible for overseeing our cyber security risk management and strategy, including overseeing management&#8217;s responsibility to assess, manage and mitigate risks associated with our business and operational activities, to administer our various compliance programs, in each case including cybersecurity concerns, and to oversee our IT systems, processes and data. Our Chief Financial Officer and cybersecurity consultants regularly meet with and provides periodic briefings to our Audit Committee regarding our cybersecurity risks and activities, including any recent cybersecurity incidents, if any, and related responses, and cybersecurity systems testing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management has implemented risk management policies and procedures, and management is responsible for the day-to-day cybersecurity risk management. Our Chief Financial Officer is responsible for the day-to-day assessment and management of our cybersecurity risks.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><b><i>Cybersecurity Threat Disclosure</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of the date of this annual report on Form 10-K, risks from cybersecurity threats including as a result of any previous cybersecurity incidents, have not materially affected, and we do not believe they are reasonably likely to materially affect, us, our business strategy, results of operations, or financial condition. However, cybersecurity threats are constantly evolving, becoming more frequent and more sophisticated and are being made by groups of individuals with a wide range of expertise and motives, which increases the difficulty of detecting and successfully defending against them. While we have implemented measures to safeguard our operational and technology systems, the evolving nature of cybersecurity attacks and vulnerabilities means that these protections may not always be effective.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For further discussion of cybersecurity risks, please see Item 1A, "Risk Factors".</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Audit Committee of our Board of Directors is responsible for overseeing our cyber security risk management and strategy, including overseeing management&#8217;s responsibility to assess, manage and mitigate risks associated with our business and operational activities, to administer our various compliance programs, in each case including cybersecurity concerns, and to oversee our IT systems, processes and data. Our Chief Financial Officer and cybersecurity consultants regularly meet with and provides periodic briefings to our Audit Committee regarding our cybersecurity risks and activities, including any recent cybersecurity incidents, if any, and related responses, and cybersecurity systems testing.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Audit Committee of our Board of Directors is responsible for overseeing our cyber security risk management and strategy, including overseeing management&#8217;s responsibility to assess, manage and mitigate risks associated with our business and operational activities, to administer our various compliance programs, in each case including cybersecurity concerns, and to oversee our IT systems, processes and data. Our Chief Financial Officer and cybersecurity consultants regularly meet with and provides periodic briefings to our Audit Committee regarding our cybersecurity risks and activities, including any recent cybersecurity incidents, if any, and related responses, and cybersecurity systems testing.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Management has implemented risk management policies and procedures, and management is responsible for the day-to-day cybersecurity risk management. Our Chief Financial Officer is responsible for the day-to-day assessment and management of our cybersecurity risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Management has implemented risk management policies and procedures, and management is responsible for the day-to-day cybersecurity risk management. Our Chief Financial Officer is responsible for the day-to-day assessment and management of our cybersecurity risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Management has implemented risk management policies and procedures, and management is responsible for the day-to-day cybersecurity risk management. Our Chief Financial Officer is responsible for the day-to-day assessment and management of our cybersecurity risks.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The Audit Committee of our Board of Directors is responsible for overseeing our cyber security risk management and strategy, including overseeing management&#8217;s responsibility to assess, manage and mitigate risks associated with our business and operational activities, to administer our various compliance programs, in each case including cybersecurity concerns, and to oversee our IT systems, processes and data. Our Chief Financial Officer and cybersecurity consultants regularly meet with and provides periodic briefings to our Audit Committee regarding our cybersecurity risks and activities, including any recent cybersecurity incidents, if any, and related responses, and cybersecurity systems testing.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>1.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Business</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica Therapeutics Inc. and its wholly owned subsidiaries, DiaMedica USA Inc. and DiaMedica Australia Pty Ltd. (collectively, we, us, our, DiaMedica and the Company), is a clinical stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS). DiaMedica&#8217;s lead product candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein, an established therapeutic modality in Asia for the treatment of preeclampsia, acute ischemic stroke and other vascular diseases. Our common shares are publicly traded on The Nasdaq Capital Market under the symbol &#8220;DMAC.&#8221;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_RisksAndUncertaintiesTextBlock', window );">Risks and Uncertainties [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Risks and Uncertainties</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the United States Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union, and comparable agencies in other countries. We are in the clinical stage of development of our lead product candidate, DM199, for the treatment of PE and AIS. We have not completed the development of any product candidate and do not generate any revenues from the commercial sale of any product candidate. Our lead product candidate, DM199, requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for at least three to four years, if at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">With respect to our PE clinical program, a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE is currently being conducted at the Tygerberg Hospital in Cape Town, South Africa. This Phase 2 study consists of three studies in PE (Part 1a, dose-escalation; Part 1b, dose-expansion; and Part 2, expectant management) and a fourth study in fetal growth restriction (FGR, Part 3, expectant management). Part 1a topline study results are intended to identify a suitable dose for Parts 1b, 2, and 3. Up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject in Part 1a was enrolled in the fourth quarter of 2024 and interim results from Part 1a of the study were released in July 2025. The interim results (N=28 subjects) demonstrated that DM199 appears safe and well-tolerated with clinically-relevant pharmacodynamic activity with no evidence of placental transfer. Additionally, subjects exhibited rapid, statistically significant reductions in blood pressure with duration of effect that was sustained up to 24 hours post-infusion compared to pre-treatment baseline. Preparations are underway to initiate Part 1b where up to 30 subjects with PE and expected delivery within 72 hours will be treated with a dose regimen identified from Part 1a.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">With respect to our AIS clinical program, we are currently conducting a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial of DM199 for the treatment of AIS, (the ReMEDy2 trial). Our ReMEDy2 trial is intended to enroll approximately 300 participants at up to 100 sites globally. The adaptive design component includes an interim analysis by our independent data safety monitoring board to be conducted after the first 200 participants have completed the trial. Based on the results of the interim analysis, the study may then be stopped for futility or the final sample size will be determined, ranging between 300 and 728 patients, according to a pre-determined statistical plan. We have experienced and continue to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring, supporting vendor management and overall program management. We are currently conducting our ReMEDy2 trial in the United States and in the countries of Canada and Georgia. We are in the process of preparing regulatory filings and identifying and engaging study sites in an additional seven European countries and, on August 28, 2025, received approval for the conduct of this study in the United Kingdom. We continue to work closely with our contract research organizations and other advisors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to enhance site activations and enrollment in our ReMEDy2 trial; however, no assurances can be provided as to the success of these actions and if or when these issues will resolve. Failure to resolve these issues may result in further delays in our ReMEDy2 trial and increase the difficulty in forecasting enrollment. We currently estimate that the interim analysis will be completed in the second half of 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our future success is dependent upon the success of our development efforts, our ability to demonstrate clinical progress for our DM199 product candidate in the United States or other markets, our ability, or the ability of any future partner, to obtain required governmental approvals of our product candidate, our ability to license or market and sell our DM199 product candidate and our ability to obtain additional financing to fund these efforts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2025, we have incurred losses of $172.8 million since our inception in 2000. For the year ended December 31, 2025, we incurred a net loss of $32.8 million and negative cash flows from operating activities of $29.1 million. We expect to continue to incur substantial operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical study of, and to seek regulatory approval for, our DM199 product candidate. As of December 31, 2025, we had combined cash, cash equivalents and marketable securities of $59.9 million, working capital of $55.5 million, and shareholders&#8217; equity of $56.1 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our principal source of cash has been net proceeds from the issuance of equity securities. Although we have previously been successful in obtaining financing through equity securities offerings, there is no assurance that we will be able to do so in the future. This is particularly true if our clinical data are not positive or if economic and market conditions deteriorate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect that we will need substantial additional capital to further our research and development activities and complete the required clinical studies, regulatory activities and manufacturing development for our product candidate, DM199, or any future product candidates, to a point where they may be licensed or commercially sold. We expect our current cash, cash equivalents and marketable securities to be sufficient to fund our planned operations for at least the next 12 months from the date of issuance of these consolidated financial statements. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the rate of site activation and participant enrollment in the study; the Phase 2 PE trial; the potential expansion of our current development programs; the effects of ongoing site staffing shortages; and other factors on our clinical trials and our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_RisksAndUncertaintiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A complete disclosure of the risks and uncertainties the company may face.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_RisksAndUncertaintiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>3.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Summary of Significant Accounting Policies</b>&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Basis of consolidation</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements include the assets, liabilities and expenses of DiaMedica Therapeutics Inc., and our wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Functional currency</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The United States dollar is our functional currency as it represents the economic effects of the underlying transactions, events and conditions and various other factors, including the currency of historical and future expenditures and the currency in which funds from financing activities are mostly generated by the Company. A change in the functional currency occurs only when there is a material change in the underlying transactions, events and condition. A change in functional currency could result in material differences in the amounts recorded in the consolidated statements of operations and comprehensive loss for foreign exchange gains and losses. All amounts in the accompanying consolidated financial statements are in U.S. dollars unless otherwise indicated.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Segments</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company operates in a <span style="-sec-ix-hidden:c324">single</span> segment focusing on developing potentially transformative treatments for severe ischemic diseases. Consistent with the Company&#8217;s operational structure, its chief operating decision maker manages and allocates resources for the Company at a consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting. Substantially all assets of the Company are held in the United States.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Use of estimates</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Cash and cash equivalents</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of the Company&#8217;s cash equivalents approximates fair value due to the short maturity of the investments.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Marketable securities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third-party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the consolidated statements of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive income or loss, which is a separate component of shareholders&#8217; equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no material other-than-temporary unrealized losses as of December 31, 2025 or 2024.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Concentration of credit risk</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with two financial institutions. These balances generally exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Fair value measurements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The hierarchy is broken down into three levels defined as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"><i>Level 1 Inputs</i> &#8212; quoted prices in active markets for identical assets and liabilities</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"><i>Level 2 Inputs</i> &#8212; observable inputs other than quoted prices in active markets for identical assets and liabilities</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"><i>Level 3 Inputs</i> &#8212; unobservable inputs</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2025, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled &#8220;<i>Marketable Securities</i>&#8221; for additional information.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Long-lived assets</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at purchased cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:c325">three</span> to <span style="-sec-ix-hidden:c326">ten</span> years for office equipment and <span style="-sec-ix-hidden:c327">four</span> years for computer equipment. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss. Repairs and maintenance are expensed as incurred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets may not be recoverable. If the expected future undiscounted cash flows are less than the carrying amount of the asset, an impairment loss is recognized at that time. Measurement of impairment may be based upon appraisal, market value of similar assets or discounted cash flows.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Leases</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We determine if an arrangement is a lease at inception. We have made a policy election to not separate lease and non-lease components for our real estate leases to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. Our facility lease includes variable non-lease components, such as common-area maintenance costs. Our operating lease is included in operating lease right-of-use (&#8220;ROU&#8221;) asset and operating lease obligations on our consolidated balance sheets. Our operating lease ROU asset represents our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. The operating lease ROU asset and operating lease obligation are recognized based on the present value of lease payments over the lease term. The lease does not provide an implicit rate and, due to the lack of a commercially salable product, we are generally considered unable to obtain commercial credit. Therefore, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases, we estimated our incremental borrowing rate. The operating lease ROU asset excludes lease incentives. Our lease includes an option to extend or terminate the lease; lease terms are only adjusted for these options when it is reasonably certain that we will exercise such options to extend or terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Assumptions made by us at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Research and development costs</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development expenses consist primarily of fees paid to external service providers such as contract research organizations; clinical support services; clinical development including clinical site costs; outside nursing services; and laboratory testing. R&amp;D costs also include non-clinical testing; fees paid to our contract manufacturing and development organizations and outside laboratories for development of DM199 and related manufacturing processes; costs for production runs of DM199; consulting resources with specialized expertise related to the execution of our development plan for DM199; and personnel costs, including salaries, benefits, non-cash share-based compensation expense; and other personnel costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We charge research and development costs to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from various contract research organizations. Upfront costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials are recorded or accrued based on actual invoices received and estimates of work completed to date by clinical trial sites, contract research organizations and outside vendors that assist with management and performance of the trials, and those that manufacture the investigational product. While we utilize electronic data capture systems to facilitate the transmission and capture of clinical trial activity, such information is often incomplete or delayed. Therefore, we are required to estimate the levels of performance under each significant contract, including, among other things, the extent of participant enrollment, the extent of supporting services performed and other activities through communications with the clinical trial sites, CROs and supporting vendors and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual work performed at each clinical trial site and by each CRO or supporting vendor. Additionally, actual costs may be charged to us and are recognized as the tasks are completed by the clinical trial site. Accrued R&amp;D costs may be subject to revisions as clinical trials, non-clinical research and DM199 development programs progress and any revisions are recorded in the period in which the facts that give rise to the revisions become known.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Patent costs</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Costs associated with applying for, prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, the resulting probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in general and administrative costs and were $377,000 and $251,000 for the years ended December 31, 2025 and 2024, respectively.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Share-based compensation</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fair value of option awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our share price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon United States Government bond rates appropriate for the expected term of each award. Expected volatility rates are based on the historical volatility over a period equal to the expected term of the option. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Income taxes</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted rates for each of the jurisdictions in which the Company operates, and expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of December 31, 2025 and 2024. See Note 16, titled &#8220;<i>Income Taxes</i>&#8221; for additional information. The Company&#8217;s policy is to classify interest and penalties related to income taxes as income tax expense.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Net loss per share</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to the exclusion of common share equivalents as their effect would be anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(32,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,444</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding&#8212;basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,980,777</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,404,681</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted net loss per share</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.70</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.60</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,864,854</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,692,438</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">174,515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">284,886</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,039,369</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,977,324</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>



<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Recently adopted accounting pronouncements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). ASU 2023-09 is intended to improve income tax disclosures primarily through enhanced disclosure of income tax rate reconciliation items, and disaggregation of income (loss) from continuing operations, income tax expense (benefit) and income taxes paid, net disclosures by federal, state and foreign jurisdictions, among others. ASU 2023-09 is effective for annual reporting periods beginning after December&#160;15, 2024, and early adoption is permitted. Adoption of ASU 2023-09 did not have a material effect on the Company's consolidated financial statements and disclosures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Recently issued accounting pronouncements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03), which is intended to improve disclosures about a public business entity&#8217;s expenses by requiring disaggregated disclosure, in the notes to the consolidated financial statements, of certain categories of expenses included in the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 on its consolidated financial statement disclosures.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>4.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Marketable Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025 </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Using Inputs Considered as</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper and corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,822</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c409">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,822</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c411">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Government securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,421</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c413">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,421</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c415">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,243</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c417">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,243</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c419">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Using Inputs Considered as</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper and corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c424">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c426">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Government securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,831</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c428">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,831</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c430">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,122</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c432">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,122</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c434">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued interest receivable on available-for-sale securities was $250,000 and $235,000 for the years ended December 31, 2025 and 2024, respectively, and is included in amounts receivable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the year ended December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the Company&#8217;s investment policy, purchases of marketable securities are limited to investment grade governmental and corporate obligations and bank certificates of deposit with a primary objective of principal preservation. Maturities of individual securities are less than one year, and the amortized cost of all securities approximated fair value as of December 31, 2025 and 2024.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Amounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>5.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Amounts Receivable</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Amounts receivable consisted of the following (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued interest receivable on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">235</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total amounts receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">258</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">236</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Prepaid Expenses and Other Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Other Assets Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>6.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Prepaid Expenses and Other Assets</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prepaid expenses and other assets consist primarily of insurance premiums, yearly subscriptions for services and deposits expected to be recovered during the next twelve months.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Deposits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_DepositAssetsTextBlock', window );">Deposit Assets [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>7.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Deposits</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We periodically advance funds to vendors engaged to support the performance of our clinical trials and related supporting activities. The funds advanced are held, interest free, for varying periods of time and may be recovered by the Company through partial reductions of ongoing invoices, application against final study/project invoices or refunded upon completion of services to be provided. Deposits are classified as current or non-current based upon their expected recovery time.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_DepositAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the companies deposits labeled as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_DepositAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>8.</b>&#160; &#160; &#160; &#160; &#160; &#160;<b>Property and Equipment</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment consisted of the following (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">151</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">118</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">128</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">128</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">295</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">262</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less accumulated depreciation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(150</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(114</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">145</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">148</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation expense was $43,000 and $39,000 for the years ended December 31, 2025 and 2024, respectively. During 2025 and 2024, we disposed of $7,000 and $25,000 of equipment, respectively, all of which was fully depreciated.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9.&#160; &#160; &#160; &#160; &#160; &#160;<b>Accrued Liabilities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued liabilities consisted of the following (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,380</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,060</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical trial costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,277</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development services</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">749</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">888</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional services fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">120</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">112</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total accrued liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,545</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,347</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Operating Lease<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>10.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Operating Lease</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In June 2022, we entered into an agreement to lease approximately 6,000 square feet of office space in Minneapolis, Minnesota. The lease commencement date was September 1, 2022, has a term of 65 months expiring on January 31, 2028, and included an incentive of five months of full rent abatement. This incentive is subject to repayment if we default in performance of any material obligations under the lease prior to the 48<sup style="vertical-align:top;line-height:120%;">th</sup> month of the lease and the landlord terminates the lease. Upon lease commencement, the Company recognized an operating lease right-of-use asset and a corresponding operating lease obligation of $446,000, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating lease costs were $104,000 for each of the years ended December 31, 2025 and 2024, respectively. Our variable lease costs were $91,000 and $89,000 for the years ended December 31, 2025 and 2024, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Maturities of our operating lease obligation are as follows as of December 31, 2025 (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">245</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Less interest portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(20</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Present value of lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">225</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Less current portion of operating lease</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(101</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Operating lease obligation, non-current</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">124</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Commitments and Contingencies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Clinical trials and product development</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the normal course of business, we incur obligations to make future payments as we execute our business plan. These obligations may relate to preclinical or clinical studies, manufacturing or manufacturing process development and other related or supporting activities. Currently, these obligations include costs to be incurred with contract research organizations, central laboratory and pharmacy services, clinical study sites, home nursing services, various other vendors supporting the performance of our clinical trials and contract manufacturing and development organizations. The contracts we enter into with these vendors and the commitments within these contracts are subject to significant variability based upon the actual activities/services performed by each vendor. As a result, the ultimate amounts due may be materially different as these obligations are affected by, among other factors, the number and pace of clinical study sites activated, the number of countries in which clinical sites are activated, the number of participants enrolled, the amount of time to complete trial enrollment and the time required to finalize, analyze and report our clinical trial results. Clinical research agreements, including supporting vendors, are generally cancelable upon 60-90 days&#8217; notice, with our obligation limited to costs incurred up to that date, including any non-cancelable costs. Cancelation terms for product manufacturing and process development contracts vary and are generally dependent upon timelines for sourcing research materials and reserving laboratory time. As of December 31, 2025, we estimate that our outstanding commitments, including such cancellable contracts, are approximately $24.7 million of which $19.3 million become due over the next 12 months and approximately $5.4 million become due in the next 12 months thereafter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Technology license</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have entered into an exclusive license agreement with Catalent Pharma Solutions, LLC (Catalent) whereby we have licensed certain gene expression technology and we contract with Catalent for the manufacture of DM199. Under the terms of this license, certain milestone and royalty payments may become due under this agreement and are dependent upon, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain. As of December 31, 2025, one milestone payment obligation remains which is due upon our first regulatory approval of DM199 for commercial sale. Following the launch of our first product, we will also incur a royalty obligation of less than 1% of net sales. The royalty term is indefinite, but the license agreement may be canceled by us on 90 days&#8217; prior written notice. The license may not be terminated by Catalent unless we fail to make required milestone and royalty payments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Indemnification of directors and officers</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company, as permitted under laws of the BCBCA and in accordance with the Company&#8217;s Articles and indemnification agreements, will indemnify and advance expenses to its directors and officers to the fullest extent permitted by law and may choose to indemnify other employees or agents from time to time. The Company has secured insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to the Company. As of December 31, 2025, there was no pending litigation or proceeding involving any director or officer of the Company as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. Insofar as indemnification for liabilities arising under the United States Securities Act of 1933, as amended (Securities Act) may be permitted to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the United States Securities and Exchange Commission (SEC), such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company had <span style="-sec-ix-hidden:c559"><span style="-sec-ix-hidden:c560">not</span></span> recorded any liabilities for these obligations as of December 31, 2025 or 2024.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>12.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Shareholders&#8217; Equity</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Authorized capital stock</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica has authorized share capital of an unlimited number of common voting shares, and the shares do not have a stated par value. Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company&#8217;s annual general meeting and any extraordinary or special general meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Equity issued during the year ended December 31, 2025</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 21, 2025, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 8,606,425 common shares at a purchase price of $3.50 per share in a private placement. As a result of the offering, which closed on July 23, 2025, we received gross proceeds of $30.1 million, which resulted in net proceeds to us of approximately $30.0 million, after deducting the offering expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the July 2025 private placement, we entered into a registration rights agreement (2025 Registration Rights Agreement) with the investors pursuant to which we agreed to file with the SEC a registration statement registering the resale of the shares sold in the July 2025 private placement (2025 Resale Registration Statement). The 2025 Resale Registration Statement was filed with the SEC on August 1, 2025 and declared effective by the SEC on August 8, 2025. Under the terms of the 2025 Registration Rights Agreement, we agreed to keep the 2025 Resale Registration Statement effective at all times until the shares are no longer considered &#8220;Registrable Securities&#8221; under the 2025 Registration Rights Agreement and if we fail to keep the 2025 Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the 2025 Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the 2025 Registration Rights Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On August 12, 2025, we entered into a Sales Agreement (the 2025 Sales Agreement) with TD Securities (USA) LLC (TD Cowen) under which the Company may, from time to time, sell common shares having an aggregate offering price of up to $100&#160;million, through an &#8220;at-the-market&#8221; offering program (ATM Offering). TD Cowen receives a customary commission from the Company for any common shares sold under the 2025 Sales Agreement. Any shares offered and sold in the ATM Offering are to be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 424(b)(2), the prospectus contained therein, and one or more prospectus supplements. As of December 31, 2025, the remaining availability under this ATM was $86.2 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended December 31, 2025, 142,345 common shares were issued upon settlement of deferred share units, 35,215 common shares were issued upon the vesting and settlement of restricted stock units, 415,253 common shares were issued upon the exercise of stock options for gross proceeds of $1.0 million and 1,724,472 common shares were issued and sold under our ATM Offering program for aggregate gross proceeds of $13.8 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Equity issued during the year ended December 31, 2024</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On June 25, 2024, we entered into securities purchase agreements with accredited investors, pursuant to which we issued and sold an aggregate 4,720,000 common shares at a purchase price of $2.50 per share in a private placement. As a result of the offering, which closed on June 28, 2024, we received gross proceeds of $11.8 million, which resulted in net proceeds to us of approximately $11.7 million, after deducting the offering expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the June 2024 private placement, we entered into a registration rights agreement (2024 Registration Rights Agreement) with the investors pursuant to which we agreed to file with the SEC a registration statement registering the resale of the shares sold in the June 2024 private placement. This registration statement was filed with the SEC on July 10, 2024 and declared effective by the SEC on July 18, 2024. Under the terms of the 2024 Registration Rights Agreement, we agreed to keep the registration statement effective at all times until the shares are no longer considered &#8220;Registrable Securities&#8221; under the 2024 Registration Rights Agreement and if we fail to keep the registration statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the registration statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the 2024 Registration Rights Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended December 31, 2024, 23,660 common shares were issued upon the vesting and settlement of restricted stock units and 117,000 common shares were issued upon the exercise of stock options for gross proceeds of $256,000.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Shares reserved</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common shares reserved for future issuance are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,864,854</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">174,515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">948,666</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Shares available for grant under the 2021 Employment Inducement Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">653,125</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,641,160</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>13.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Share-Based Compensation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Amended and Restated 2019 Omnibus Incentive Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan (as amended from time to time, the 2019 Plan) was adopted by the Board of Directors (Board) on March 14, 2019 and approved by our shareholders at our 2019 Annual General Meeting of Shareholders held on May 22, 2019. Subsequent amendments to the plan, comprised principally of increasing the authorized shares under the plan, were approved by our shareholders at our 2022 and 2024 Annual General Meetings of Shareholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The 2019 Plan permits the Board, or a committee or subcommittee thereof, to grant to the Company&#8217;s eligible employees, non-employee directors and certain consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units (RSUs), deferred stock units (DSUs), performance awards, non-employee director awards and other share-based awards. We grant options to purchase common shares under the 2019 Plan at no less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of <span style="-sec-ix-hidden:c601">ten</span> years and generally vest over <span style="-sec-ix-hidden:c602">one</span> to <span style="-sec-ix-hidden:c603">four</span> years. Options granted to non-employees have a maximum term of <span style="-sec-ix-hidden:c604">five</span> years and generally vest over <span style="-sec-ix-hidden:c605">one</span> year. Subject to adjustment as provided in the 2019 Plan, the maximum number of the Company&#8217;s common shares authorized for issuance under the 2019 Plan is 7,000,000 shares. As of December 31, 2025, options to purchase an aggregate of 5,402,444 common shares were outstanding and 164,770 common shares were reserved for issuance upon settlement of DSUs under the 2019 Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>2021 Employment Inducement Incentive Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On December 3, 2021, the Board adopted the DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan (Inducement Plan) to facilitate the granting of equity awards as an inducement material to new employees joining the Company. The Inducement Plan was adopted without shareholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and is administered by the Compensation Committee of the Board of Directors. The Board reserved 1,000,000 common shares of the Company for issuance under the Inducement Plan, which permits the grant of non-statutory options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other share-based awards, to eligible recipients. The only persons eligible to receive awards under the Inducement Plan are individuals who are new employees and satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4) or 5635(c)(3), as applicable. Also, on December 3, 2021, the Compensation Committee adopted a form of notice of option grant and option award agreement for use under the Inducement Plan, which contains terms substantially identical to the form of notice of option grant and option award agreement for use under the shareholder-approved 2019 Plan. The Inducement Plan has a term of 10 years. The share reserve under the Inducement Plan may be increased at the discretion of and approval by the Board and, on July 31, 2025, the Board increased the number of common shares reserved for issuance under the plan to 2,000,000. As of December 31, 2025, options to purchase an aggregate of 1,100,000 common shares were outstanding under the Inducement Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Prior stock option plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Board of Directors ceased granting awards under the DiaMedica Therapeutics Inc. Stock Option Plan, Amended and Restated November 6, 2018 (Prior Plan) upon receipt of the shareholder approval of the 2019 Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the 2019 Plan. As of December 31, 2025, options to purchase an aggregate of 362,410 common shares were outstanding under the Prior Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Prior deferred stock unit plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Board of Directors ended participation in the DiaMedica Therapeutics Inc. Amended and Restated Deferred Stock Unit Plan (Prior DSU Plan) upon receipt of the shareholder approval of the 2019 Plan. Awards outstanding under the Prior DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of December 31, 2025, there were 9,745 common shares reserved for issuance upon settlement of DSUs outstanding under the Prior DSU Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Stock options</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Share-based compensation expense for each of the periods presented is as follows (in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,526</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,464</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,320</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">621</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,846</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,085</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize share-based compensation for options awards based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those options that actually vest.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A summary of option activity is as follows (in thousands except share and per share amounts):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Underlying</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances as of December 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,871,013</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.61</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">832</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,864,775</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.03</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(531,350</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.96</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Expired/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(395,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.08</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(117,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.19</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances as of December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,692,438</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.33</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,243</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,433,416</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.88</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(830,747</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.80</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(415,253</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.43</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Expired/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5.02</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances as of December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,864,854</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.11</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,479</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A summary of the status of our unvested shares underlying options during the year ended and as of December 31, 2025 is as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Underlying</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grant Date Fair </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested as of December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,371,983</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,433,416</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Vested</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,143,530</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(801,372</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.57</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested as of December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,860,497</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.06</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information about stock options outstanding, vested and expected to vest as of December 31, 2025, is as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding, Vested and Expected to Vest</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options Vested and Exercisable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (Years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual Life </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$1.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$1.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51,443</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.64</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,989</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.66</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$2.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$2.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,278,895</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.73</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,515,350</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.70</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$3.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$3.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">311,893</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.56</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">247,519</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.66</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$4.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$4.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,917,069</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.32</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">808,626</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.51</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$5.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$5.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">549,287</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">256,787</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.03</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$6.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$16.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">756,267</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8.5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7.14</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">133,086</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7.97</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,864,854</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7.3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.11</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,004,357</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.68</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The cumulative grant date fair value of employee options vested during the years ended December 31, 2025 and 2024 was $2.6 million and $1.5 million, respectively. A total of 415,253 and 117,000 options were exercised during the years ended December 31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2025, total compensation expense related to unvested employee stock options not yet recognized was $10.6 million, which is expected to be allocated to expenses over a weighted-average period of 3.1 years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended December 31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024 </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common share fair value</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$4.07</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$8.67</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$2.40</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$5.38</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.7</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.4%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.8</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">0%</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected option life (years)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.0</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected stock price volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75.7</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83.3%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83.0</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124.1%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Deferred stock units and restricted stock units</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under our non-employee director compensation program, non-employee directors may elect to receive RSUs or DSUs in lieu of all or a portion of the annual cash retainers payable to such director. Each RSU or DSU represents the right to receive one common share. These recipients receive a number of RSUs or DSUs equal to the amount of the elected portion of the annual cash retainers divided by the 10-trading day average closing sale price of our common shares as determined on the third business day prior to the anticipated grant date of the award. These annual RSU and DSU grants vest quarterly over <span style="-sec-ix-hidden:c727">one</span> year, conditioned on continuous service. The cost of the RSUs and DSUs is measured and recognized based on the fair market value of our common shares on the date of grant. RSUs will be settled immediately upon vesting and DSU awards will be settled following a separation from service by such director.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were 174,515 and 284,886 vested DSUs outstanding under our share-based compensation plans as of December 31, 2025 and 2024, respectively. During 2025, 35,215 common shares were issued upon the vesting and settlement of RSUs. During 2024, 23,660 common shares were issued upon the vesting and settlement of RSUs. There were <span style="-sec-ix-hidden:c732"><span style="-sec-ix-hidden:c733"><span style="-sec-ix-hidden:c734"><span style="-sec-ix-hidden:c735">no</span></span></span></span> unvested DSUs or RSUs as of December 31, 2025 and 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Compensation and Employee Benefit Plans [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>14. </b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Employee Benefit Plan</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We maintain an employee 401(k) retirement savings plan (401(k) Plan). The 401(k) Plan provides eligible employees with an opportunity to make tax-deferred contributions into a long-term investment and savings program. All employees over the age of 21 may elect to participate in the 401(k) Plan beginning on their hire date. The 401(k) Plan allows eligible employees to contribute a portion of their annual compensation, subject only to maximum limits required by law. We contribute an amount up to 4% of each employees&#8217; compensation under the safe harbor provisions provided by the Internal Revenue Service rules governing 401(k) plans. Employee and employer safe harbor contributions vest immediately.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have recorded contribution expenses of $234,000 and $166,000 under the 401(k) Plan for the years ended December&#160;31, 2025 and 2024, respectively.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>15.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Segment Information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An operating segment is identified as a component of an enterprise that engages in business activities about which separate discrete financial information and operating results is regularly reviewed by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. The Company's CODM is the Chief Executive Officer. The Company operates in a <span style="-sec-ix-hidden:c866">single</span> operating segment focused on the development of its drug product candidate DM199 for the treatment of severe ischemic disease. The CODM manages and allocates resources to the operations of the Company on a total company basis. Further, the CODM reviews and utilizes functional expenses (i.e., research, development and general and administrative) at the consolidated level to manage the Company's operations. Other segment items included in consolidated net loss are revenues, share-based compensation, interest income, other expense, net, and income tax expense, which are reflected in the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table presents financial information, including significant segment expenses, which are regularly provided to the CODM and included within segment and consolidated net loss:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses, excluding share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23,294</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,436</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,257</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,160</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Total operating expenses, excluding share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,551</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,596</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,320</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">621</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,526</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,464</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Total share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,846</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,085</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(34,397</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(26,681</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Interest income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,669</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,301</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Other expense, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(34</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Segment and consolidated net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(32,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(24,444</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>16.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Income Taxes</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The domestic and foreign components of gain (loss) from continuing operations before provision for income taxes are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Domestic (Canada)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(33,119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,452</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">381</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(32,738</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(24,414</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has computed its provision for income taxes based on the actual effective tax rate for the year as the Company believes this is the best estimate for the annual effective tax rate. The Company is subject to income taxes in Canada, the United States and Australia.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant judgment is required in evaluating the Company&#8217;s uncertain tax positions and determining the provision for income taxes. The Company recognizes benefits from uncertain tax positions based on the cumulative probability method whereby the largest benefit with a cumulative probability of greater than 50% is recorded. An uncertain tax position is not recognized if it has less than a 50% likelihood of being sustained.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The provision for income taxes consists of:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Federal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">State</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Federal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">State</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table reconciles the expected Canadian statutory federal income tax to the actual income tax expense:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(32,738</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,414</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Canadian federal statutory rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,911</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,662</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Canadian provincial and local income tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,640</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,719</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign tax effects</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(74</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nontaxable or nondeductible items</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">273</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Share issuance costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(149</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25.3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,133</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Actual income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As the operations of the Company are predominantly conducted through its Canadian parent company, the Company has prepared the tax rate table using the Canadian federal tax rate of 15%.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The principal component of deferred taxes are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets (liabilities):</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Non-capital losses carried forward</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,316</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32,240</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Research and development expenditures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">817</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">817</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Patents and other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">460</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">400</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">419</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">284</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Share issue costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">379</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">275</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Accruals</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">256</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Property and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(71</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(89</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax asset, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,412</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,183</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(42,412</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(34,183</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table presents a reconciliation of the valuation allowance:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at beginning of the year</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,183</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,039</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Increase based on tax positions related to current period</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,229</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,144</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Increase based on tax positions related to prior periods</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at end of the year</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">42,412</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,183</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company assesses available positive and negative evidence to estimate if it is more likely than not to use certain jurisdiction-based deferred tax assets including net operating loss carryovers. On the basis of this assessment, the Company continues to maintain a valuation allowance on its net deferred tax assets for the year ended December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, annual use of the Company&#8217;s net operating loss (&#8220;NOL&#8221;) and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company&#8217;s NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period). Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net operating losses and tax credit carryforwards as of December 31, 2025, are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(In thousands)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 19.2%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiration Years</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 65.8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital income tax losses, net &#8211; domestic</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">145,679</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Beginning 2027</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital income tax losses, net &#8211; foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expense carry forwards</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,027</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Indefinitely</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">473</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Beginning 2026</p>
			</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Basis of consolidation</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements include the assets, liabilities and expenses of DiaMedica Therapeutics Inc., and our wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_FunctionalCurrencyPolicyTextBlock', window );">Functional Currency [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Functional currency</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The United States dollar is our functional currency as it represents the economic effects of the underlying transactions, events and conditions and various other factors, including the currency of historical and future expenditures and the currency in which funds from financing activities are mostly generated by the Company. A change in the functional currency occurs only when there is a material change in the underlying transactions, events and condition. A change in functional currency could result in material differences in the amounts recorded in the consolidated statements of operations and comprehensive loss for foreign exchange gains and losses. All amounts in the accompanying consolidated financial statements are in U.S. dollars unless otherwise indicated.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Segments</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company operates in a <span style="-sec-ix-hidden:c324">single</span> segment focusing on developing potentially transformative treatments for severe ischemic diseases. Consistent with the Company&#8217;s operational structure, its chief operating decision maker manages and allocates resources for the Company at a consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting. Substantially all assets of the Company are held in the United States.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Use of estimates</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Cash and cash equivalents</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of the Company&#8217;s cash equivalents approximates fair value due to the short maturity of the investments.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Marketable securities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third-party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the consolidated statements of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive income or loss, which is a separate component of shareholders&#8217; equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no material other-than-temporary unrealized losses as of December 31, 2025 or 2024.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Concentration of credit risk</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with two financial institutions. These balances generally exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Fair value measurements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The hierarchy is broken down into three levels defined as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"><i>Level 1 Inputs</i> &#8212; quoted prices in active markets for identical assets and liabilities</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"><i>Level 2 Inputs</i> &#8212; observable inputs other than quoted prices in active markets for identical assets and liabilities</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"><i>Level 3 Inputs</i> &#8212; unobservable inputs</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2025, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled &#8220;<i>Marketable Securities</i>&#8221; for additional information.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Long-lived assets</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at purchased cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of <span style="-sec-ix-hidden:c325">three</span> to <span style="-sec-ix-hidden:c326">ten</span> years for office equipment and <span style="-sec-ix-hidden:c327">four</span> years for computer equipment. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss. Repairs and maintenance are expensed as incurred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets may not be recoverable. If the expected future undiscounted cash flows are less than the carrying amount of the asset, an impairment loss is recognized at that time. Measurement of impairment may be based upon appraisal, market value of similar assets or discounted cash flows.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Leases</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We determine if an arrangement is a lease at inception. We have made a policy election to not separate lease and non-lease components for our real estate leases to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. Our facility lease includes variable non-lease components, such as common-area maintenance costs. Our operating lease is included in operating lease right-of-use (&#8220;ROU&#8221;) asset and operating lease obligations on our consolidated balance sheets. Our operating lease ROU asset represents our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. The operating lease ROU asset and operating lease obligation are recognized based on the present value of lease payments over the lease term. The lease does not provide an implicit rate and, due to the lack of a commercially salable product, we are generally considered unable to obtain commercial credit. Therefore, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases, we estimated our incremental borrowing rate. The operating lease ROU asset excludes lease incentives. Our lease includes an option to extend or terminate the lease; lease terms are only adjusted for these options when it is reasonably certain that we will exercise such options to extend or terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Assumptions made by us at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Research and development costs</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development expenses consist primarily of fees paid to external service providers such as contract research organizations; clinical support services; clinical development including clinical site costs; outside nursing services; and laboratory testing. R&amp;D costs also include non-clinical testing; fees paid to our contract manufacturing and development organizations and outside laboratories for development of DM199 and related manufacturing processes; costs for production runs of DM199; consulting resources with specialized expertise related to the execution of our development plan for DM199; and personnel costs, including salaries, benefits, non-cash share-based compensation expense; and other personnel costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We charge research and development costs to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from various contract research organizations. Upfront costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials are recorded or accrued based on actual invoices received and estimates of work completed to date by clinical trial sites, contract research organizations and outside vendors that assist with management and performance of the trials, and those that manufacture the investigational product. While we utilize electronic data capture systems to facilitate the transmission and capture of clinical trial activity, such information is often incomplete or delayed. Therefore, we are required to estimate the levels of performance under each significant contract, including, among other things, the extent of participant enrollment, the extent of supporting services performed and other activities through communications with the clinical trial sites, CROs and supporting vendors and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual work performed at each clinical trial site and by each CRO or supporting vendor. Additionally, actual costs may be charged to us and are recognized as the tasks are completed by the clinical trial site. Accrued R&amp;D costs may be subject to revisions as clinical trials, non-clinical research and DM199 development programs progress and any revisions are recorded in the period in which the facts that give rise to the revisions become known.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_PatentCostsPolicyTextBlock', window );">Patent Costs [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Patent costs</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Costs associated with applying for, prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, the resulting probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in general and administrative costs and were $377,000 and $251,000 for the years ended December 31, 2025 and 2024, respectively.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Compensation Related Costs, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Share-based compensation</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fair value of option awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our share price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon United States Government bond rates appropriate for the expected term of each award. Expected volatility rates are based on the historical volatility over a period equal to the expected term of the option. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Income taxes</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted rates for each of the jurisdictions in which the Company operates, and expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of December 31, 2025 and 2024. See Note 16, titled &#8220;<i>Income Taxes</i>&#8221; for additional information. The Company&#8217;s policy is to classify interest and penalties related to income taxes as income tax expense.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Net loss per share</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to the exclusion of common share equivalents as their effect would be anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(32,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,444</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding&#8212;basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,980,777</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,404,681</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted net loss per share</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.70</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.60</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,864,854</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,692,438</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">174,515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">284,886</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,039,369</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,977,324</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Recently adopted accounting pronouncements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (&#8220;ASU 2023-09&#8221;). ASU 2023-09 is intended to improve income tax disclosures primarily through enhanced disclosure of income tax rate reconciliation items, and disaggregation of income (loss) from continuing operations, income tax expense (benefit) and income taxes paid, net disclosures by federal, state and foreign jurisdictions, among others. ASU 2023-09 is effective for annual reporting periods beginning after December&#160;15, 2024, and early adoption is permitted. Adoption of ASU 2023-09 did not have a material effect on the Company's consolidated financial statements and disclosures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"><i>Recently issued accounting pronouncements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03), which is intended to improve disclosures about a public business entity&#8217;s expenses by requiring disaggregated disclosure, in the notes to the consolidated financial statements, of certain categories of expenses included in the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 on its consolidated financial statement disclosures.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_FunctionalCurrencyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for functional currency in use by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_FunctionalCurrencyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(32,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,444</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding&#8212;basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,980,777</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,404,681</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Basic and diluted net loss per share</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.70</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.60</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,864,854</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,692,438</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">174,515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">284,886</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,039,369</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,977,324</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock', window );">Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025 </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Using Inputs Considered as</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper and corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,822</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c409">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,822</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c411">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Government securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,421</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c413">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,421</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c415">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,243</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c417">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,243</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c419">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value Measurements as of </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Using Inputs Considered as</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 1</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 2</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Level 3</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper and corporate bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c424">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c426">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Government securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,831</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c428">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,831</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c430">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,122</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c432">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,122</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><span style="-sec-ix-hidden:c434">&#8212;</span></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Amounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued interest receivable on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">250</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">235</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total amounts receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">258</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">236</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">151</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">118</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">128</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">128</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">295</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">262</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less accumulated depreciation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(150</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(114</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">145</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">148</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,380</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,060</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical trial costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,277</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development services</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">749</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">888</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional services fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">120</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">112</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total accrued liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,545</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,347</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Operating Lease (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">116</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">245</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Less interest portion</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(20</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Present value of lease obligation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">225</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Less current portion of operating lease</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(101</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Operating lease obligation, non-current</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">124</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_CommonStockReservedForFutureIssuanceTableTextBlock', window );">Common Stock Reserved for Future Issuance [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee and non-employee stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,864,854</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common shares issuable upon settlement of deferred stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">174,515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">948,666</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Shares available for grant under the 2021 Employment Inducement Incentive Plan</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">653,125</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,641,160</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_CommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A tabular disclosure of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_CommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,526</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,464</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,320</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">621</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,846</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,085</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Underlying</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances as of December 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,871,013</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.61</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">832</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,864,775</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.03</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(531,350</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.96</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Expired/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(395,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.08</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(117,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.19</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances as of December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,692,438</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.33</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,243</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,433,416</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.88</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(830,747</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.80</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(415,253</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.43</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Expired/cancelled</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5.02</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances as of December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,864,854</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.11</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,479</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Underlying</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grant Date Fair </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value Per Share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested as of December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,371,983</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,433,416</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Vested</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,143,530</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(801,372</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.57</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested as of December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,860,497</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.06</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding, Vested and Expected to Vest</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options Vested and Exercisable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Life (Years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual Life </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$1.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$1.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51,443</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.64</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,989</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.66</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$2.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$2.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,278,895</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.73</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,515,350</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.70</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$3.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$3.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">311,893</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.56</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">247,519</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.66</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$4.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$4.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,917,069</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.32</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">808,626</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.51</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$5.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$5.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">549,287</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">256,787</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.03</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$6.00</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$16.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">756,267</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8.5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7.14</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">133,086</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7.97</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 2%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,864,854</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7.3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.11</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,004,357</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.68</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024 </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common share fair value</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$4.07</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$8.67</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$2.40</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$5.38</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.7</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.4%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.8</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">0%</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected option life (years)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.0</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.7</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 72%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected stock price volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">75.7</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83.3%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83.0</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8211;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">124.1%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses, excluding share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23,294</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,436</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,257</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,160</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Total operating expenses, excluding share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,551</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,596</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,320</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">621</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,526</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,464</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Total share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,846</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,085</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(34,397</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(26,681</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Interest income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,669</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,301</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Other expense, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(34</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Segment and consolidated net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(32,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(24,444</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Domestic (Canada)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(33,119</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,452</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">381</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">38</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(32,738</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(24,414</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Federal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">State</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total current</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Federal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">State</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss before income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(32,738</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(24,414</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Canadian federal statutory rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,911</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,662</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Canadian provincial and local income tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,640</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,719</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign tax effects</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(74</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(0.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nontaxable or nondeductible items</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">515</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">273</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Share issuance costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(149</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25.3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,133</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Actual income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets (liabilities):</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Non-capital losses carried forward</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,316</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32,240</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Research and development expenditures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">817</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">817</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Patents and other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">460</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">400</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">419</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">284</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Share issue costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">379</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">275</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Accruals</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">256</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Property and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(71</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(89</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax asset, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">42,412</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,183</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(42,412</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(34,183</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at beginning of the year</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,183</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,039</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Increase based on tax positions related to current period</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,229</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,144</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Increase based on tax positions related to prior periods</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at end of the year</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">42,412</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,183</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Operating Loss Carryforwards [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(In thousands)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 19.2%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiration Years</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 65.8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital income tax losses, net &#8211; domestic</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">145,679</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Beginning 2027</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital income tax losses, net &#8211; foreign</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expense carry forwards</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,027</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Indefinitely</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">473</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Beginning 2026</p>
			</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Risks and Uncertainties (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Total</a></td>
<td class="num">$ (172,768)<span></span>
</td>
<td class="num">$ (140,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent, Total</a></td>
<td class="num">(32,766)<span></span>
</td>
<td class="num">(24,444)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities, Total</a></td>
<td class="num">(29,062)<span></span>
</td>
<td class="num">(22,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-Term Investments, Total</a></td>
<td class="nump">59,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_WorkingCapital', window );">Working Capital</a></td>
<td class="nump">55,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity Attributable to Parent, Ending Balance</a></td>
<td class="nump">$ 56,111<span></span>
</td>
<td class="nump">$ 40,718<span></span>
</td>
<td class="nump">$ 51,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_PatentExpense', window );">Patent Expense</a></td>
<td class="nump">$ 377,000<span></span>
</td>
<td class="nump">$ 251,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_PatentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense associated with gaining and maintaining certain patents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_PatentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,766)<span></span>
</td>
<td class="num">$ (24,444)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding&#8212;basic and diluted (in shares)</a></td>
<td class="nump">46,980,777<span></span>
</td>
<td class="nump">40,404,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.7)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">7,039,369<span></span>
</td>
<td class="nump">4,977,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_EmployeeAndNonemployeeStockOptionsMember', window );">Employee and Non-employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">6,864,854<span></span>
</td>
<td class="nump">4,692,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_CommonStockDeferredStockUnitsSettlementMember', window );">Common Stock, Deferred Stock Units Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">174,515<span></span>
</td>
<td class="nump">284,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_CommonStockDeferredStockUnitsSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dmac_CommonStockDeferredStockUnitsSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Marketable Securities (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember', window );">Accrued Interest Receivable On Available For Sale Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest Receivable</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 44,243<span></span>
</td>
<td class="nump">$ 41,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">44,243<span></span>
</td>
<td class="nump">41,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper and Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">4,822<span></span>
</td>
<td class="nump">28,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">4,822<span></span>
</td>
<td class="nump">28,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper and Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">39,421<span></span>
</td>
<td class="nump">12,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">39,421<span></span>
</td>
<td class="nump">12,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=dmac_CommercialPaperAndCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=dmac_CommercialPaperAndCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Amounts Receivable - Amounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent', window );">Accrued interest receivable on marketable securities</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total amounts receivable</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, Plant and Equipment, Disposals</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Property and Equipment - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">$ 1,380<span></span>
</td>
<td class="nump">$ 1,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_AccruedClinicalStudyCostsCurrent', window );">Clinical trial costs</a></td>
<td class="nump">1,291<span></span>
</td>
<td class="nump">2,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_AccruedResearchAndProfessionalFeesCurrent', window );">Research and development services</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services fees</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_AccruedTaxesAndOtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 3,545<span></span>
</td>
<td class="nump">$ 4,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_AccruedClinicalStudyCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued clinical study costs classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_AccruedClinicalStudyCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_AccruedResearchAndProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and accrued research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_AccruedResearchAndProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_AccruedTaxesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued taxes and other liabilities classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_AccruedTaxesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Operating Lease (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 197,000<span></span>
</td>
<td class="nump">$ 279,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">104,000<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable Lease, Cost</a></td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=dmac_MinneapolisMNMember', window );">Minneapolis, MN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">65 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 446,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 446,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=dmac_MinneapolisMNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=dmac_MinneapolisMNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Operating Lease - Maturity of Operating Lease Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less interest portion</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease obligation</a></td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of operating lease</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">$ (90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation, non-current</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dmac_ResearchAndDevelopmentContractsMember', window );">Research and Development Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation</a></td>
<td class="nump">$ 24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Contractual Obligation, to be Paid, Year One</a></td>
<td class="nump">19,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">Contractual Obligation, to be Paid, Year Two</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dmac_IndemnificationAgreementsMember', window );">Indemnification Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dmac_ResearchAndDevelopmentContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dmac_ResearchAndDevelopmentContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dmac_IndemnificationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dmac_IndemnificationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Shareholders' Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 21, 2025</div></th>
<th class="th"><div>Jun. 25, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,282,000<span></span>
</td>
<td class="nump">$ 11,747,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits', window );">Stock Issued During Period, Shares Settlement of Deferred Stock Units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,215<span></span>
</td>
<td class="nump">23,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,004,000<span></span>
</td>
<td class="nump">$ 256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,253<span></span>
</td>
<td class="nump">117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">8,606,425<span></span>
</td>
<td class="nump">4,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 30,100,000<span></span>
</td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds from Issuance of Common Stock, Net</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum', window );">Liquidated Damage, Percentage of Invested Capital, Maximum</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dmac_ATMOfferingMember', window );">A T M Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,724,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_EquityIssuanceMaximumAggregateOfferingPrice', window );">Equity Issuance, Maximum Aggregate Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_EquityIssuanceRemainingAvailableOfferingPrice', window );">Equity Issuance, Remaining Available Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_EquityIssuanceMaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate offering price for equity issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_EquityIssuanceMaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_EquityIssuanceRemainingAvailableOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining available offering price for equity issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_EquityIssuanceRemainingAvailableOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liquidated damage as percentage of invested capital, maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period due to the settlement of deferred stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dmac_ATMOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dmac_ATMOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Shareholders' Equity - Shares Reserved (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">8,641,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_StockOptionsOutstandingMember', window );">Stock Options Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">6,864,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember', window );">Deferred Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">174,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">948,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_The2021EmploymentInducementIncentivePlanMember', window );">The 2021 Employment Inducement Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">653,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_StockOptionsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_StockOptionsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_The2019OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_The2019OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_The2021EmploymentInducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_The2021EmploymentInducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Share-based Compensation (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 18, 2022</div></th>
<th class="th"><div>Dec. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>May 22, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,641,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,864,854<span></span>
</td>
<td class="nump">4,692,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,871,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,253<span></span>
</td>
<td class="nump">117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember', window );">Deferred Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,402,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member] | Employee and Non-employee Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember', window );">The 2019 Omnibus Incentive Plan [Member] | Nonemployee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2021EmploymentInducementIncentivePlanMember', window );">The 2021 Employment Inducement Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_StockOptionPriorPlanMember', window );">Stock Option Prior Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2012DSUPlanMember', window );">The 2012 DSU Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember', window );">The 2019 Omnibus Incentive Plan, Stock Option Prior Plan, and the 2012 DSU Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_NonemployeeDirectorCompensationProgramMember', window );">Non-employee Director Compensation Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_NonemployeeDirectorCompensationProgramMember', window );">Non-employee Director Compensation Program [Member] | Deferred Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,515<span></span>
</td>
<td class="nump">284,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_NonemployeeDirectorCompensationProgramMember', window );">Non-employee Director Compensation Program [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,215<span></span>
</td>
<td class="nump">23,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_NonemployeeDirectorCompensationProgramMember', window );">Non-employee Director Compensation Program [Member] | Deferred Share Unit Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_NonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_NonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_The2021EmploymentInducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_The2021EmploymentInducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_StockOptionPriorPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_StockOptionPriorPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_The2012DSUPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_The2012DSUPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_NonemployeeDirectorCompensationProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_NonemployeeDirectorCompensationProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_DeferredShareUnitPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_DeferredShareUnitPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 3,846<span></span>
</td>
<td class="nump">$ 2,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 1,320<span></span>
</td>
<td class="nump">$ 621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Share-based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested (in shares)</a></td>
<td class="nump">2,371,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant-date fair value of options (in dollars per share)</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,433,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant-date fair value of options (in dollars per share)</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="num">(1,143,530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant-date fair value of options (in dollars per share)</a></td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited (in shares)</a></td>
<td class="num">(801,372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited, weighted average grant-date fair value of options (in dollars per share)</a></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested (in shares)</a></td>
<td class="nump">3,860,497<span></span>
</td>
<td class="nump">2,371,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant-date fair value of options (in dollars per share)</a></td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance (in shares)</a></td>
<td class="nump">4,692,438<span></span>
</td>
<td class="nump">3,871,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance, aggregate intrinsic value</a></td>
<td class="nump">$ 26,479<span></span>
</td>
<td class="nump">$ 10,243<span></span>
</td>
<td class="nump">$ 832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,433,416<span></span>
</td>
<td class="nump">1,864,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.88<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(830,747)<span></span>
</td>
<td class="num">(531,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired/cancelled (in shares)</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(395,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired / cancelled, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(415,253)<span></span>
</td>
<td class="num">(117,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance (in shares)</a></td>
<td class="nump">6,864,854<span></span>
</td>
<td class="nump">4,692,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.11<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Share-based Compensation - Stock Options Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">6,864,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares)</a></td>
<td class="nump">3,004,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">3 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange1Member', window );">Exercise Price Range 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Per share exercise price, lower range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Per share exercise price, upper range (in dollars per share)</a></td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">51,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares)</a></td>
<td class="nump">42,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">1 year 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange2Member', window );">Exercise Price Range 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Per share exercise price, lower range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Per share exercise price, upper range (in dollars per share)</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">2,278,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares)</a></td>
<td class="nump">1,515,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange3Member', window );">Exercise Price Range 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Per share exercise price, lower range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Per share exercise price, upper range (in dollars per share)</a></td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">311,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares)</a></td>
<td class="nump">247,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">3 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange4Member', window );">Exercise Price Range 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Per share exercise price, lower range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Per share exercise price, upper range (in dollars per share)</a></td>
<td class="nump">$ 4.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">2,917,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares)</a></td>
<td class="nump">808,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">4 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange5Member', window );">Exercise Price Range 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Per share exercise price, lower range (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Per share exercise price, upper range (in dollars per share)</a></td>
<td class="nump">$ 5.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">549,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares)</a></td>
<td class="nump">256,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">5 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange6Member', window );">Exercise Price Range 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Per share exercise price, lower range (in dollars per share)</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Per share exercise price, upper range (in dollars per share)</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">756,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares)</a></td>
<td class="nump">133,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">7 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Share-based Compensation - Stock Option Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Common share fair value (in dollars per share)</a></td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years) (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">75.70%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Common share fair value (in dollars per share)</a></td>
<td class="nump">$ 8.67<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years) (Year)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">83.30%<span></span>
</td>
<td class="nump">124.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Employee Benefit Plan (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="nump">$ 234,000<span></span>
</td>
<td class="nump">$ 166,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Segment Information (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Segment Information - Segment Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_OperatingExpensesExcludingSharebasedCompensation', window );">Total operating expenses, excluding share-based compensation</a></td>
<td class="nump">$ 30,551<span></span>
</td>
<td class="nump">$ 24,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">3,846<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(34,397)<span></span>
</td>
<td class="num">(26,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">2,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense, net</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(32,766)<span></span>
</td>
<td class="num">(24,444)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_OperatingExpensesExcludingSharebasedCompensation', window );">Total operating expenses, excluding share-based compensation</a></td>
<td class="nump">23,294<span></span>
</td>
<td class="nump">18,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">1,320<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_OperatingExpensesExcludingSharebasedCompensation', window );">Total operating expenses, excluding share-based compensation</a></td>
<td class="nump">7,257<span></span>
</td>
<td class="nump">6,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 2,526<span></span>
</td>
<td class="nump">$ 1,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_OperatingExpensesExcludingSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations, excluding share-based compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_OperatingExpensesExcludingSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Income Taxes (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember', window );">Canada Revenue Agency [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic (Canada)</a></td>
<td class="num">$ (33,119)<span></span>
</td>
<td class="num">$ (24,452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">$ (32,738)<span></span>
</td>
<td class="num">$ (24,414)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">$ (32,738)<span></span>
</td>
<td class="num">$ (24,414)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Canadian federal statutory rate</a></td>
<td class="num">$ (4,911)<span></span>
</td>
<td class="num">$ (3,662)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Canadian federal statutory rate, percent</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">Canadian provincial and local income tax rate</a></td>
<td class="num">$ (3,640)<span></span>
</td>
<td class="num">$ (2,719)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Canadian provincial and local income tax rate, percent</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="nump">11.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects</a></td>
<td class="num">$ (74)<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects, percent</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">$ 515<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation, percent</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_IncomeTaxRateReconciliationShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">$ (149)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts', window );">Share issuance costs, percent</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other, percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">$ 8,291<span></span>
</td>
<td class="nump">$ 6,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance, percent</a></td>
<td class="num">(25.30%)<span></span>
</td>
<td class="num">(25.10%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Actual income tax expense, percent</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for stock issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_IncomeTaxRateReconciliationShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to share issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_IncomeTaxRateReconciliationShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 16 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Non-capital losses carried forward</a></td>
<td class="nump">$ 40,316<span></span>
</td>
<td class="nump">$ 32,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenditures</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_DeferredTaxAssetsPropertyPatentsAndOther', window );">Patents and other</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_DeferredTaxAssetsPropertyShareIssueCosts', window );">Share issue costs</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dmac_DeferredTaxAssetsLiabilitiesGross', window );">Total deferred tax asset, net</a></td>
<td class="nump">42,412<span></span>
</td>
<td class="nump">34,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(42,412)<span></span>
</td>
<td class="num">(34,183)<span></span>
</td>
<td class="num">$ (28,039)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total deferred tax assets (liabilities), gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_DeferredTaxAssetsPropertyPatentsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from patents and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_DeferredTaxAssetsPropertyPatentsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_DeferredTaxAssetsPropertyShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_DeferredTaxAssetsPropertyShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Income Taxes - Summary of Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 34,183<span></span>
</td>
<td class="nump">$ 28,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at end of the year</a></td>
<td class="nump">42,412<span></span>
</td>
<td class="nump">34,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dmac_TaxPositionsRelatedToCurrentPeriodMember', window );">Tax Positions Related To Current Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">8,229<span></span>
</td>
<td class="nump">6,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dmac_TaxPositionsRelatedToPriorPeriodsMember', window );">Tax Positions Related To Prior Periods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dmac_TaxPositionsRelatedToCurrentPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dmac_TaxPositionsRelatedToCurrentPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dmac_TaxPositionsRelatedToPriorPeriodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=dmac_TaxPositionsRelatedToPriorPeriodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 16 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=dmac_NoncapitalIncomeTaxLossesNetMember', window );">Non-capital Income Tax Losses, Net [Member] | Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 145,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=dmac_NoncapitalIncomeTaxLossesNetMember', window );">Non-capital Income Tax Losses, Net [Member] | Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">3,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=dmac_TaxCreditsMember', window );">Tax Credits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=dmac_NoncapitalIncomeTaxLossesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=dmac_NoncapitalIncomeTaxLossesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=dmac_TaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=dmac_TaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>153</ContextCount>
  <ElementCount>305</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Note 1 - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-1-business</Role>
      <ShortName>Note 1 - Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995551 - Disclosure - Note 2 - Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties</Role>
      <ShortName>Note 2 - Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995552 - Disclosure - Note 3 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995553 - Disclosure - Note 4 - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities</Role>
      <ShortName>Note 4 - Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995554 - Disclosure - Note 5 - Amounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable</Role>
      <ShortName>Note 5 - Amounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Note 6 - Prepaid Expenses and Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets</Role>
      <ShortName>Note 6 - Prepaid Expenses and Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995556 - Disclosure - Note 7 - Deposits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-7-deposits</Role>
      <ShortName>Note 7 - Deposits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Note 8 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment</Role>
      <ShortName>Note 8 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995558 - Disclosure - Note 9 - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-</Role>
      <ShortName>Note 9 - Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995559 - Disclosure - Note 10 - Operating Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-10-operating-lease</Role>
      <ShortName>Note 10 - Operating Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995560 - Disclosure - Note 11 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies</Role>
      <ShortName>Note 11 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995561 - Disclosure - Note 12 - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity</Role>
      <ShortName>Note 12 - Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995562 - Disclosure - Note 13 - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation</Role>
      <ShortName>Note 13 - Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995563 - Disclosure - Note 14 - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan</Role>
      <ShortName>Note 14 - Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995564 - Disclosure - Note 15 - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-15-segment-information</Role>
      <ShortName>Note 15 - Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Note 16 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-16-income-taxes</Role>
      <ShortName>Note 16 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995566 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995568 - Disclosure - Note 4 - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables</Role>
      <ShortName>Note 4 - Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995569 - Disclosure - Note 5 - Amounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables</Role>
      <ShortName>Note 5 - Amounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995570 - Disclosure - Note 8 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables</Role>
      <ShortName>Note 8 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995571 - Disclosure - Note 9 - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables</Role>
      <ShortName>Note 9 - Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995572 - Disclosure - Note 10 - Operating Lease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables</Role>
      <ShortName>Note 10 - Operating Lease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-10-operating-lease</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995573 - Disclosure - Note 12 - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables</Role>
      <ShortName>Note 12 - Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995574 - Disclosure - Note 13 - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables</Role>
      <ShortName>Note 13 - Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Note 15 - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables</Role>
      <ShortName>Note 15 - Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-15-segment-information</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995576 - Disclosure - Note 16 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables</Role>
      <ShortName>Note 16 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-16-income-taxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual</Role>
      <ShortName>Note 2 - Risks and Uncertainties (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995578 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995579 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995580 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995581 - Disclosure - Note 4 - Marketable Securities (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual</Role>
      <ShortName>Note 4 - Marketable Securities (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995582 - Disclosure - Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details</Role>
      <ShortName>Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995583 - Disclosure - Note 5 - Amounts Receivable - Amounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details</Role>
      <ShortName>Note 5 - Amounts Receivable - Amounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995584 - Disclosure - Note 8 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual</Role>
      <ShortName>Note 8 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Note 8 - Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details</Role>
      <ShortName>Note 8 - Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995586 - Disclosure - Note 9 - Accrued Liabilities - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details</Role>
      <ShortName>Note 9 - Accrued Liabilities - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Note 10 - Operating Lease (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual</Role>
      <ShortName>Note 10 - Operating Lease (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995588 - Disclosure - Note 10 - Operating Lease - Maturity of Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details</Role>
      <ShortName>Note 10 - Operating Lease - Maturity of Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995589 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 11 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995590 - Disclosure - Note 12 - Shareholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual</Role>
      <ShortName>Note 12 - Shareholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995591 - Disclosure - Note 12 - Shareholders' Equity - Shares Reserved (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details</Role>
      <ShortName>Note 12 - Shareholders' Equity - Shares Reserved (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995592 - Disclosure - Note 13 - Share-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual</Role>
      <ShortName>Note 13 - Share-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995593 - Disclosure - Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details</Role>
      <ShortName>Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995594 - Disclosure - Note 13 - Share-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details</Role>
      <ShortName>Note 13 - Share-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Note 13 - Share-based Compensation - Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details</Role>
      <ShortName>Note 13 - Share-based Compensation - Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995596 - Disclosure - Note 13 - Share-based Compensation - Stock Option Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details</Role>
      <ShortName>Note 13 - Share-based Compensation - Stock Option Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Note 14 - Employee Benefit Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual</Role>
      <ShortName>Note 14 - Employee Benefit Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995598 - Disclosure - Note 15 - Segment Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual</Role>
      <ShortName>Note 15 - Segment Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995599 - Disclosure - Note 15 - Segment Information - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details</Role>
      <ShortName>Note 15 - Segment Information - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995600 - Disclosure - Note 16 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual</Role>
      <ShortName>Note 16 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995601 - Disclosure - Note 16 - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details</Role>
      <ShortName>Note 16 - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995602 - Disclosure - Note 16 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details</Role>
      <ShortName>Note 16 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>995603 - Disclosure - Note 16 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details</Role>
      <ShortName>Note 16 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>995604 - Disclosure - Note 16 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 16 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Note 16 - Income Taxes - Summary of Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details</Role>
      <ShortName>Note 16 - Income Taxes - Summary of Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="dmtp20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>995606 - Disclosure - Note 16 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details</Role>
      <ShortName>Note 16 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dmac-20251231.xsd</File>
    <File>dmac-20251231_cal.xml</File>
    <File>dmac-20251231_def.xml</File>
    <File>dmac-20251231_lab.xml</File>
    <File>dmac-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="dmtp20251231_10k.htm">dmtp20251231_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>aistreatmentop.jpg</File>
    <File>bkr2.jpg</File>
    <File>develpmentpipe.jpg</File>
    <File>dm199.jpg</File>
    <File>dm199collatcirc.jpg</File>
    <File>dm199profile.jpg</File>
    <File>earlydeliverymort.jpg</File>
    <File>edhf.jpg</File>
    <File>klk1lvls.jpg</File>
    <File>placentaldisease.jpg</File>
    <File>stage02.jpg</File>
    <File>strokerecurrence.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="607">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dmtp20251231_10k.htm": {
   "nsprefix": "dmac",
   "nsuri": "http://www.diamedica.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "dmac-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "dmac-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dmac-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "dmac-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dmac-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "dmtp20251231_10k.htm"
     ]
    }
   },
   "keyStandard": 282,
   "keyCustom": 23,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 28,
   "hidden": {
    "total": 50,
    "http://fasb.org/us-gaap/2025": 35,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://xbrl.sec.gov/ecd/2025": 4,
    "http://xbrl.sec.gov/cyd/2025": 6
   },
   "contextCount": 153,
   "entityCount": 1,
   "segmentCount": 54,
   "elementCount": 477,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 607,
    "http://xbrl.sec.gov/dei/2025": 36,
    "http://xbrl.sec.gov/cyd/2025": 16,
    "http://xbrl.sec.gov/ecd/2025": 8
   },
   "report": {
    "R1": {
     "role": "http://www.diamedica.com/20251231/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
     "longName": "004 - Statement - Consolidated Statements of Shareholders' Equity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals",
     "longName": "005 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-1-business",
     "longName": "995550 - Disclosure - Note 1 - Business",
     "shortName": "Note 1 - Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties",
     "longName": "995551 - Disclosure - Note 2 - Risks and Uncertainties",
     "shortName": "Note 2 - Risks and Uncertainties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dmac:RisksAndUncertaintiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dmac:RisksAndUncertaintiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
     "longName": "995552 - Disclosure - Note 3 - Summary of Significant Accounting Policies",
     "shortName": "Note 3 - Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
     "longName": "995553 - Disclosure - Note 4 - Marketable Securities",
     "shortName": "Note 4 - Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable",
     "longName": "995554 - Disclosure - Note 5 - Amounts Receivable",
     "shortName": "Note 5 - Amounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets",
     "longName": "995555 - Disclosure - Note 6 - Prepaid Expenses and Other Assets",
     "shortName": "Note 6 - Prepaid Expenses and Other Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-7-deposits",
     "longName": "995556 - Disclosure - Note 7 - Deposits",
     "shortName": "Note 7 - Deposits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dmac:DepositAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dmac:DepositAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment",
     "longName": "995557 - Disclosure - Note 8 - Property and Equipment",
     "shortName": "Note 8 - Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-",
     "longName": "995558 - Disclosure - Note 9 - Accrued Liabilities",
     "shortName": "Note 9 - Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease",
     "longName": "995559 - Disclosure - Note 10 - Operating Lease",
     "shortName": "Note 10 - Operating Lease",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies",
     "longName": "995560 - Disclosure - Note 11 - Commitments and Contingencies",
     "shortName": "Note 11 - Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
     "longName": "995561 - Disclosure - Note 12 - Shareholders' Equity",
     "shortName": "Note 12 - Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
     "longName": "995562 - Disclosure - Note 13 - Share-based Compensation",
     "shortName": "Note 13 - Share-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan",
     "longName": "995563 - Disclosure - Note 14 - Employee Benefit Plan",
     "shortName": "Note 14 - Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-15-segment-information",
     "longName": "995564 - Disclosure - Note 15 - Segment Information",
     "shortName": "Note 15 - Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
     "longName": "995565 - Disclosure - Note 16 - Income Taxes",
     "shortName": "Note 16 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies",
     "longName": "995566 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
     "longName": "995567 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables",
     "longName": "995568 - Disclosure - Note 4 - Marketable Securities (Tables)",
     "shortName": "Note 4 - Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables",
     "longName": "995569 - Disclosure - Note 5 - Amounts Receivable (Tables)",
     "shortName": "Note 5 - Amounts Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables",
     "longName": "995570 - Disclosure - Note 8 - Property and Equipment (Tables)",
     "shortName": "Note 8 - Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables",
     "longName": "995571 - Disclosure - Note 9 - Accrued Liabilities (Tables)",
     "shortName": "Note 9 - Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables",
     "longName": "995572 - Disclosure - Note 10 - Operating Lease (Tables)",
     "shortName": "Note 10 - Operating Lease (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables",
     "longName": "995573 - Disclosure - Note 12 - Shareholders' Equity (Tables)",
     "shortName": "Note 12 - Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dmac:CommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dmac:CommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables",
     "longName": "995574 - Disclosure - Note 13 - Share-based Compensation (Tables)",
     "shortName": "Note 13 - Share-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables",
     "longName": "995575 - Disclosure - Note 15 - Segment Information (Tables)",
     "shortName": "Note 15 - Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables",
     "longName": "995576 - Disclosure - Note 16 - Income Taxes (Tables)",
     "shortName": "Note 16 - Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual",
     "longName": "995577 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual)",
     "shortName": "Note 2 - Risks and Uncertainties (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "dmac:RisksAndUncertaintiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
     "longName": "995578 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember",
      "name": "dmac:PatentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "dmac:PatentCostsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember",
      "name": "dmac:PatentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "dmac:PatentCostsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
     "longName": "995579 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details",
     "longName": "995580 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual",
     "longName": "995581 - Disclosure - Note 4 - Marketable Securities (Details Textual)",
     "shortName": "Note 4 - Marketable Securities (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "i_2025-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
     "longName": "995582 - Disclosure - Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)",
     "shortName": "Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details",
     "longName": "995583 - Disclosure - Note 5 - Amounts Receivable - Amounts Receivable (Details)",
     "shortName": "Note 5 - Amounts Receivable - Amounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual",
     "longName": "995584 - Disclosure - Note 8 - Property and Equipment (Details Textual)",
     "shortName": "Note 8 - Property and Equipment (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details",
     "longName": "995585 - Disclosure - Note 8 - Property and Equipment - Property and Equipment (Details)",
     "shortName": "Note 8 - Property and Equipment - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details",
     "longName": "995586 - Disclosure - Note 9 - Accrued Liabilities - Accrued Liabilities (Details)",
     "shortName": "Note 9 - Accrued Liabilities - Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual",
     "longName": "995587 - Disclosure - Note 10 - Operating Lease (Details Textual)",
     "shortName": "Note 10 - Operating Lease (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details",
     "longName": "995588 - Disclosure - Note 10 - Operating Lease - Maturity of Operating Lease Liability (Details)",
     "shortName": "Note 10 - Operating Lease - Maturity of Operating Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual",
     "longName": "995589 - Disclosure - Note 11 - Commitments and Contingencies (Details Textual)",
     "shortName": "Note 11 - Commitments and Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "i_2025-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual",
     "longName": "995590 - Disclosure - Note 12 - Shareholders' Equity (Details Textual)",
     "shortName": "Note 12 - Shareholders' Equity (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-07-21_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details",
     "longName": "995591 - Disclosure - Note 12 - Shareholders' Equity - Shares Reserved (Details)",
     "shortName": "Note 12 - Shareholders' Equity - Shares Reserved (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dmac:CommonStockReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31_AwardTypeAxis-StockOptionsOutstandingMember",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dmac:CommonStockReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
     "longName": "995592 - Disclosure - Note 13 - Share-based Compensation (Details Textual)",
     "shortName": "Note 13 - Share-based Compensation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "dmac:CommonStockReservedForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
     "longName": "995593 - Disclosure - Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)",
     "shortName": "Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details",
     "longName": "995594 - Disclosure - Note 13 - Share-based Compensation - Stock Option Activity (Details)",
     "shortName": "Note 13 - Share-based Compensation - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details",
     "longName": "995595 - Disclosure - Note 13 - Share-based Compensation - Stock Options Outstanding (Details)",
     "shortName": "Note 13 - Share-based Compensation - Stock Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details",
     "longName": "995596 - Disclosure - Note 13 - Share-based Compensation - Stock Option Assumptions (Details)",
     "shortName": "Note 13 - Share-based Compensation - Stock Option Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual",
     "longName": "995597 - Disclosure - Note 14 - Employee Benefit Plan (Details Textual)",
     "shortName": "Note 14 - Employee Benefit Plan (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual",
     "longName": "995598 - Disclosure - Note 15 - Segment Information (Details Textual)",
     "shortName": "Note 15 - Segment Information (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details",
     "longName": "995599 - Disclosure - Note 15 - Segment Information - Segment Information (Details)",
     "shortName": "Note 15 - Segment Information - Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dmac:OperatingExpensesExcludingSharebasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dmac:OperatingExpensesExcludingSharebasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual",
     "longName": "995600 - Disclosure - Note 16 - Income Taxes (Details Textual)",
     "shortName": "Note 16 - Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
     "longName": "995601 - Disclosure - Note 16 - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)",
     "shortName": "Note 16 - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
     "longName": "995602 - Disclosure - Note 16 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "Note 16 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
     "longName": "995603 - Disclosure - Note 16 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Note 16 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details",
     "longName": "995604 - Disclosure - Note 16 - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Note 16 - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details",
     "longName": "995605 - Disclosure - Note 16 - Income Taxes - Summary of Valuation Allowance (Details)",
     "shortName": "Note 16 - Income Taxes - Summary of Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToCurrentPeriodMember",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details",
     "longName": "995606 - Disclosure - Note 16 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details)",
     "shortName": "Note 16 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dmtp20251231_10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dmac_ATMOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "ATMOfferingMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A T M Offering [Member]",
        "documentation": "Represents ATM offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r62"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r51",
      "r923"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r771"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts receivable",
        "totalLabel": "Total amounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_AccountsReceivableNoncurrentCreditQualityIndicatorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNoncurrentCreditQualityIndicatorTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Noncurrent, Credit Quality Indicator [Table]",
        "documentation": "Disclosure of information about credit quality indicator for accounts receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "dmac_AccruedClinicalStudyCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "AccruedClinicalStudyCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical trial costs",
        "documentation": "The amount of accrued clinical study costs classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_AccruedInterestReceivableOnAvailableForSaleSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "AccruedInterestReceivableOnAvailableForSaleSecuritiesMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Interest Receivable On Available For Sale Securities [Member]",
        "documentation": "Represents information related to accrued interest receivable on available for sale securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "dmac_AccruedResearchAndProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "AccruedResearchAndProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and accrued research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_AccruedTaxesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "AccruedTaxesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "dmac_AccruedTaxesAndOtherLiabilitiesCurrent",
        "documentation": "The amount of accrued taxes and other liabilities classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Less accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r127",
      "r600"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r63",
      "r132",
      "r597",
      "r621",
      "r625",
      "r941"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r15",
      "r472",
      "r475",
      "r551",
      "r616",
      "r617",
      "r849",
      "r850",
      "r851",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r771",
      "r970"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
        "terseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r83"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total share-based compensation",
        "label": "Total share-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r401",
      "r402"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AreaOfRealEstateProperty",
        "terseLabel": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r101",
      "r128",
      "r157",
      "r158",
      "r159",
      "r192",
      "r203",
      "r216",
      "r219",
      "r264",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r459",
      "r461",
      "r519",
      "r588",
      "r589",
      "r594",
      "r661",
      "r730",
      "r731",
      "r740",
      "r771",
      "r774",
      "r775",
      "r786",
      "r887",
      "r888",
      "r956"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r133",
      "r157",
      "r158",
      "r159",
      "r264",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r459",
      "r461",
      "r519",
      "r771",
      "r887",
      "r888",
      "r956"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsNoncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r264",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r459",
      "r461",
      "r519",
      "r887",
      "r888",
      "r956"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r804"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_AuditorLocation",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r804"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_AuditorName",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r804"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r274",
      "r496",
      "r512",
      "r513",
      "r514",
      "r515",
      "r585",
      "r706",
      "r759",
      "r762",
      "r769",
      "r876",
      "r946",
      "r947",
      "r948"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_AwardTmgMnpiCnsdrdFlag",
        "terseLabel": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-1-business"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r854"
     ]
    },
    "us-gaap_CanadaRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CanadaRevenueAgencyMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada Revenue Agency [Member]",
        "documentation": "Designated tax department of the government of Canada."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r125",
      "r707"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
        "terseLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r71",
      "r154"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r71"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_CityAreaCode",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_CommercialPaperAndCorporateBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "CommercialPaperAndCorporateBondsMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper and Corporate Bonds [Member]",
        "documentation": "Commercial Papers are unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents and commercial bonds are debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r95",
      "r595",
      "r648"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r285",
      "r286",
      "r702",
      "r884",
      "r886"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares reserved for future issuance (in shares)",
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "dmac_CommonStockDeferredStockUnitsSettlementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "CommonStockDeferredStockUnitsSettlementMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Deferred Stock Units Settlement [Member]",
        "documentation": "Represents common stock shares issued as settlement of deferred stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r777",
      "r778",
      "r780",
      "r781",
      "r782",
      "r783",
      "r863",
      "r864",
      "r866",
      "r942",
      "r969",
      "r972"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, No Par Value (in dollars per share)",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "dmac_CommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "CommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Reserved for Future Issuance [Table Text Block]",
        "documentation": "A tabular disclosure of common stock reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "xbrltype": "authorizedUnlimitedItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]",
        "documentation": "Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is \"Unlimited\"."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r55",
      "r649",
      "r667",
      "r972",
      "r973"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, no par value; unlimited authorized; 53,742,370 and 42,818,660 shares issued and outstanding, as of December 31, 2025 and 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r307",
      "r312",
      "r596",
      "r771"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r892",
      "r893"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r89"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r137",
      "r139",
      "r144",
      "r586",
      "r606",
      "r607"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r719"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ContractualObligation",
        "terseLabel": "Contractual Obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r862",
      "r966"
     ]
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ContractualObligationDueInNextTwelveMonths",
        "terseLabel": "Contractual Obligation, to be Paid, Year One",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r862",
      "r966"
     ]
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ContractualObligationDueInSecondYear",
        "terseLabel": "Contractual Obligation, to be Paid, Year Two",
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r856",
      "r862",
      "r966"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r855",
      "r860",
      "r934"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r855",
      "r860"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CurrentIncomeTaxExpenseBenefit",
        "totalLabel": "Total current",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r855",
      "r860"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r855",
      "r860",
      "r934"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r818"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r818"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r820"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r820"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r822"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r820"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r813"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r814"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r814"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r812"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r812"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r812"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r815"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r817"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r817"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r818"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r821"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r819"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r816"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest receivable on marketable securities",
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r274",
      "r275"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r836"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r855",
      "r860",
      "r933",
      "r934"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit",
        "terseLabel": "Foreign",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r855",
      "r860",
      "r933"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredIncomeTaxExpenseBenefit",
        "totalLabel": "Total deferred",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r108",
      "r855",
      "r860"
     ]
    },
    "dmac_DeferredShareUnitPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "DeferredShareUnitPlanMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Share Unit Plan [Member]",
        "documentation": "Common shares issued under deferred share unit plan."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_DeferredShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "DeferredShareUnitsMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Share Units [Member]",
        "documentation": "The deferred share units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r855",
      "r860",
      "r933",
      "r934"
     ]
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset [Domain]",
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "dmac_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenditures",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "dmac_DeferredTaxAssetsLiabilitiesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "DeferredTaxAssetsLiabilitiesGross",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dmac_DeferredTaxAssetsLiabilitiesGross",
        "totalLabel": "Total deferred tax asset, net",
        "documentation": "The total deferred tax assets (liabilities), gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Net deferred tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "dmac_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-capital losses carried forward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "dmac_DeferredTaxAssetsPropertyPatentsAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "DeferredTaxAssetsPropertyPatentsAndOther",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "dmac_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents and other",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from patents and other."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_DeferredTaxAssetsPropertyShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "DeferredTaxAssetsPropertyShareIssueCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "dmac_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issue costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share issue costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "dmac_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "dmac_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
        "terseLabel": "Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Valuation allowance",
        "periodStartLabel": "Balance at beginning of the year",
        "periodEndLabel": "Balance at end of the year",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "dmac_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment",
        "negatedTerseLabel": "Property and equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanCostRecognized",
        "terseLabel": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
        "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_DepositAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "DepositAssetsTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-7-deposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit Assets [Text Block]",
        "documentation": "Description of the companies deposits labeled as assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r28",
      "r146",
      "r712",
      "r713",
      "r715",
      "r717"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r364",
      "r393",
      "r394",
      "r396",
      "r748"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-1-business",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable",
      "http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets",
      "http://www.diamedica.com/20251231/role/statement-note-7-deposits",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r804"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentFinStmtErrorCorrectionFlag",
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r804",
      "r806"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentPeriodEndDate",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentType",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r145",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r182",
      "r183",
      "r186",
      "r187",
      "r188",
      "r191",
      "r305",
      "r399",
      "r449",
      "r458",
      "r493",
      "r494",
      "r587",
      "r608",
      "r722"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r190"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Actual income tax expense, percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r751"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canadian federal statutory rate, percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r161",
      "r411",
      "r436",
      "r751"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in valuation allowance, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r751",
      "r855",
      "r861",
      "r924"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign tax effects, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r415",
      "r751",
      "r855",
      "r861",
      "r924"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r855",
      "r861",
      "r924",
      "r925"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation, percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r855",
      "r861",
      "r924",
      "r925"
     ]
    },
    "dmac_EffectiveIncomeTaxRateReconciliationShareIssuanceCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationShareIssuanceCosts",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs, percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for stock issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canadian provincial and local income tax rate, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r751",
      "r855",
      "r861",
      "r924"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r751"
     ]
    },
    "dmac_EmployeeAndNonemployeeStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "EmployeeAndNonemployeeStockOptionsMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee and Non-employee Stock Options [Member]",
        "documentation": "Related to employee and non-employee stock option awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityCommonStockSharesOutstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityCurrentReportingStatus",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information",
      "http://www.diamedica.com/20251231/role/statement-note-1-business",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables",
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan",
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables",
      "http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets",
      "http://www.diamedica.com/20251231/role/statement-note-7-deposits",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables",
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityFileNumber",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityInteractiveDataCurrent",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityPublicFloat",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityRegistrantName",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityShellCompany",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityVoluntaryFilers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityWellKnownSeasonedIssuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r113",
      "r120",
      "r121",
      "r141",
      "r142",
      "r143",
      "r163",
      "r164",
      "r165",
      "r168",
      "r176",
      "r178",
      "r180",
      "r193",
      "r265",
      "r268",
      "r280",
      "r304",
      "r330",
      "r399",
      "r431",
      "r432",
      "r445",
      "r446",
      "r447",
      "r450",
      "r457",
      "r458",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r492",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r533",
      "r551",
      "r604",
      "r616",
      "r617",
      "r618",
      "r637",
      "r686"
     ]
    },
    "dmac_EquityIssuanceMaximumAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "EquityIssuanceMaximumAggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dmac_EquityIssuanceMaximumAggregateOfferingPrice",
        "terseLabel": "Equity Issuance, Maximum Aggregate Offering Price",
        "documentation": "Maximum aggregate offering price for equity issuance."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_EquityIssuanceRemainingAvailableOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "EquityIssuanceRemainingAvailableOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dmac_EquityIssuanceRemainingAvailableOfferingPrice",
        "terseLabel": "Equity Issuance, Remaining Available Offering Price",
        "documentation": "Remaining available offering price for equity issuance."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_ExercisePriceRange1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "ExercisePriceRange1Member",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 1 [Member]",
        "documentation": "Related to the first exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_ExercisePriceRange2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "ExercisePriceRange2Member",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 2 [Member]",
        "documentation": "Related to the second exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_ExercisePriceRange3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "ExercisePriceRange3Member",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 3 [Member]",
        "documentation": "Related to the third exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_ExercisePriceRange4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "ExercisePriceRange4Member",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 4 [Member]",
        "documentation": "Related to the fourth exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_ExercisePriceRange5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "ExercisePriceRange5Member",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 5 [Member]",
        "documentation": "Related to the fifth exercise price range."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_ExercisePriceRange6Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "ExercisePriceRange6Member",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 6 [Member]",
        "documentation": "Represents Exercise Price Range 6."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r341",
      "r342",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r504",
      "r506",
      "r513",
      "r555",
      "r556",
      "r557",
      "r706",
      "r738",
      "r739",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r759",
      "r762",
      "r769"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r497",
      "r498",
      "r500",
      "r759",
      "r947",
      "r950"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r332",
      "r337",
      "r341",
      "r497",
      "r504",
      "r513",
      "r555",
      "r706",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r759",
      "r769"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r332",
      "r337",
      "r341",
      "r343",
      "r497",
      "r498",
      "r504",
      "r513",
      "r556",
      "r706",
      "r738",
      "r739",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r759",
      "r769"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r341",
      "r342",
      "r497",
      "r498",
      "r499",
      "r500",
      "r504",
      "r513",
      "r557",
      "r706",
      "r738",
      "r739",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r759",
      "r762",
      "r769"
     ]
    },
    "dmac_FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r497",
      "r498",
      "r500",
      "r759",
      "r947",
      "r950"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r341",
      "r342",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r504",
      "r506",
      "r513",
      "r555",
      "r556",
      "r557",
      "r706",
      "r738",
      "r739",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r759",
      "r762",
      "r769"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r950"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FinanceLeaseLiabilityNoncurrent",
        "terseLabel": "Finance lease obligation, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FinanceLeasePrincipalPayments",
        "negatedLabel": "Principal payments on finance lease obligations",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r541"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r301",
      "r327",
      "r467",
      "r482",
      "r507",
      "r518",
      "r521",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r593",
      "r605",
      "r737",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r772",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r878",
      "r879",
      "r880",
      "r881",
      "r943",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412"
     ]
    },
    "dmac_FunctionalCurrencyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "FunctionalCurrencyPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional Currency [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for functional currency in use by the company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r670"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_IcfrAuditorAttestationFlag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r804"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r78"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic (Canada)",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r160",
      "r410"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss before income tax expense",
        "totalLabel": "Loss before income tax expense",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r97",
      "r100",
      "r588",
      "r590",
      "r602",
      "r714",
      "r716",
      "r718",
      "r724",
      "r730",
      "r868",
      "r870",
      "r871",
      "r872",
      "r873"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r160",
      "r410"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r284",
      "r463",
      "r464",
      "r465",
      "r466",
      "r501",
      "r502",
      "r505",
      "r520",
      "r521",
      "r522",
      "r611",
      "r613",
      "r671",
      "r705",
      "r706",
      "r752",
      "r753",
      "r757",
      "r758",
      "r761",
      "r769",
      "r935",
      "r936",
      "r968"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r284",
      "r463",
      "r464",
      "r465",
      "r466",
      "r501",
      "r502",
      "r505",
      "r520",
      "r521",
      "r522",
      "r611",
      "r613",
      "r671",
      "r705",
      "r706",
      "r752",
      "r753",
      "r757",
      "r758",
      "r761",
      "r769",
      "r935",
      "r936",
      "r968"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r411",
      "r412",
      "r420",
      "r427",
      "r751",
      "r930"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r411",
      "r412",
      "r420",
      "r427",
      "r751",
      "r930"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r930"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r930"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r161",
      "r406",
      "r411",
      "r417",
      "r418",
      "r419",
      "r421",
      "r426",
      "r437",
      "r439",
      "r440",
      "r441",
      "r592",
      "r627",
      "r636",
      "r751"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Total income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r109",
      "r157",
      "r179",
      "r180",
      "r192",
      "r205",
      "r219",
      "r409",
      "r411",
      "r438",
      "r609",
      "r714",
      "r716",
      "r718",
      "r751"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r407",
      "r408",
      "r421",
      "r422",
      "r425",
      "r429",
      "r630"
     ]
    },
    "dmac_IncomeTaxRateReconciliationShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "IncomeTaxRateReconciliationShareIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to share issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r751",
      "r924"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign tax effects",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r415",
      "r751",
      "r924"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canadian federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r751"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r924",
      "r925"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r924",
      "r925"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canadian provincial and local income tax rate",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r751",
      "r924"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r73",
      "r853",
      "r928",
      "r929"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
        "negatedLabel": "Amounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
        "terseLabel": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInDepositOtherAssets",
        "negatedLabel": "Deposits",
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidExpense",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dmac_IndemnificationAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "IndemnificationAgreementsMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indemnification Agreements [Member]",
        "documentation": "Related to certain indemnification agreements."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r811"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r811"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InterestReceivable",
        "terseLabel": "Interest Receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r974"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r204",
      "r219",
      "r730",
      "r852"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium",
        "negatedLabel": "Amortization of discounts on marketable securities",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r110",
      "r230",
      "r231",
      "r508",
      "r509",
      "r965"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r826"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r826"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r544"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information",
      "http://www.diamedica.com/20251231/role/statement-note-1-business",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables",
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan",
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables",
      "http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets",
      "http://www.diamedica.com/20251231/role/statement-note-7-deposits",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables",
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r545"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r856",
      "r862",
      "r966"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r856",
      "r862",
      "r966"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r856",
      "r862",
      "r966"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r856",
      "r862",
      "r966"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "negatedLabel": "Less interest portion",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseTermOfContract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r96",
      "r599",
      "r771",
      "r774",
      "r775",
      "r855",
      "r859",
      "r882",
      "r953"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r124",
      "r157",
      "r158",
      "r159",
      "r264",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r460",
      "r461",
      "r462",
      "r519",
      "r771",
      "r887",
      "r956",
      "r957"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesNoncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r50",
      "r51",
      "r52",
      "r53",
      "r157",
      "r158",
      "r159",
      "r264",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r460",
      "r461",
      "r462",
      "r519",
      "r887",
      "r956",
      "r957"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "LiquidatedDamagePercentageOfInvestedCapitalMaximum",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dmac_LiquidatedDamagePercentageOfInvestedCapitalMaximum",
        "terseLabel": "Liquidated Damage, Percentage of Invested Capital, Maximum",
        "documentation": "Amount of liquidated damage as percentage of invested capital, maximum."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r874"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_LocalPhoneNumber",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities",
        "label": "us-gaap_MarketableSecuritiesCurrent",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r287",
      "r288",
      "r289",
      "r290",
      "r360",
      "r388",
      "r389",
      "r390",
      "r403",
      "r500",
      "r583",
      "r610",
      "r612",
      "r626",
      "r640",
      "r641",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r704",
      "r736",
      "r741",
      "r747",
      "r752",
      "r754",
      "r755",
      "r762",
      "r763",
      "r767",
      "r768",
      "r773",
      "r889",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r287",
      "r288",
      "r289",
      "r290",
      "r360",
      "r388",
      "r389",
      "r390",
      "r403",
      "r500",
      "r583",
      "r610",
      "r612",
      "r626",
      "r640",
      "r641",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r704",
      "r736",
      "r741",
      "r747",
      "r752",
      "r754",
      "r755",
      "r762",
      "r763",
      "r767",
      "r773",
      "r889",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "dmac_MinneapolisMNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "MinneapolisMNMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minneapolis, MN [Member]",
        "documentation": "Represents Minneapolis, MN,"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities, Total",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r74"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      },
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "terseLabel": "Net Income (Loss) Attributable to Parent, Total",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r74",
      "r98",
      "r121",
      "r122",
      "r136",
      "r138",
      "r143",
      "r157",
      "r158",
      "r159",
      "r162",
      "r167",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r179",
      "r180",
      "r185",
      "r264",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r305",
      "r308",
      "r310",
      "r313",
      "r399",
      "r449",
      "r458",
      "r494",
      "r519",
      "r603",
      "r668",
      "r684",
      "r685",
      "r714",
      "r716",
      "r718",
      "r784",
      "r887"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r147",
      "r148",
      "r149",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r174",
      "r181",
      "r191",
      "r227",
      "r228",
      "r265",
      "r266",
      "r267",
      "r268",
      "r279",
      "r280",
      "r283",
      "r302",
      "r303",
      "r304",
      "r305",
      "r397",
      "r398",
      "r399",
      "r400",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r510",
      "r511",
      "r530",
      "r531",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r628"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dmac_NoncapitalIncomeTaxLossesNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "NoncapitalIncomeTaxLossesNetMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-capital Income Tax Losses, Net [Member]",
        "documentation": "Related to non-capital income tax losses."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Amount of expense recognized over the period for lease expense, non-cash."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_NonemployeeDirectorCompensationProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "NonemployeeDirectorCompensationProgramMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-employee Director Compensation Program [Member]",
        "documentation": "Represents information related to non-employee director compensation program."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_NonemployeeStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "NonemployeeStockOptionsMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonemployee Stock Options [Member]",
        "documentation": "Related to the nonemployee stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NonoperatingIncomeExpense",
        "totalLabel": "Total other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "dmac_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r869"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets",
      "http://www.diamedica.com/20251231/role/statement-note-7-deposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r709",
      "r710",
      "r711",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r937",
      "r938",
      "r939",
      "r940"
     ]
    },
    "us-gaap_OffsettingLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OffsettingLiabilitiesTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Liabilities [Table]",
        "documentation": "Disclosure of information about derivative and financial liabilities that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r709",
      "r710",
      "r711",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r937",
      "r938",
      "r939",
      "r940"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_OperatingExpensesExcludingSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "OperatingExpensesExcludingSharebasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total operating expenses, excluding share-based compensation",
        "label": "dmac_OperatingExpensesExcludingSharebasedCompensation",
        "documentation": "Generally recurring costs associated with normal operations, excluding share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r714",
      "r718",
      "r724",
      "r868",
      "r870",
      "r871",
      "r872",
      "r873"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseCost",
        "terseLabel": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r770"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of lease obligation",
        "terseLabel": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligation",
        "negatedLabel": "Less current portion of operating lease",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligation, non-current",
        "terseLabel": "Operating lease obligation, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain (loss) on marketable securities",
        "terseLabel": "Unrealized gain on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r263"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherNonoperatingExpense",
        "negatedLabel": "Other expense, net",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r756"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "us-gaap_OtherReceivablesNetCurrent",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Costs [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for patent costs."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_PatentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "PatentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dmac_PatentExpense",
        "terseLabel": "Patent Expense",
        "documentation": "The amount of expense associated with gaining and maintaining certain patents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "negatedLabel": "Deferred financing costs, net",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquireMarketableSecurities",
        "negatedLabel": "Purchase of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920"
     ]
    },
    "dmac_PolicyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "PolicyTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dmac_PolicyTable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common shares, net of offering costs",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dmac_ProceedsFromIssuanceOfCommonStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dmac_ProceedsFromIssuanceOfCommonStockNet",
        "terseLabel": "Proceeds from Issuance of Common Stock, Net",
        "documentation": "The cash inflow from the issuance of common stock, net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities and sales of marketable securities",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r877"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceed from the exercise of common stock options",
        "terseLabel": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r544"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r105",
      "r106",
      "r107"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisposals",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentDisposals",
        "terseLabel": "Property, Plant and Equipment, Disposals",
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r126",
      "r601"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r544",
      "r591",
      "r601",
      "r771"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r544"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r287",
      "r288",
      "r289",
      "r290",
      "r331",
      "r360",
      "r388",
      "r389",
      "r390",
      "r396",
      "r403",
      "r500",
      "r558",
      "r567",
      "r583",
      "r610",
      "r612",
      "r626",
      "r640",
      "r641",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r704",
      "r736",
      "r741",
      "r747",
      "r752",
      "r754",
      "r755",
      "r762",
      "r763",
      "r767",
      "r768",
      "r773",
      "r778",
      "r885",
      "r889",
      "r947",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r287",
      "r288",
      "r289",
      "r290",
      "r331",
      "r360",
      "r388",
      "r389",
      "r390",
      "r396",
      "r403",
      "r500",
      "r558",
      "r567",
      "r583",
      "r610",
      "r612",
      "r626",
      "r640",
      "r641",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r698",
      "r699",
      "r700",
      "r701",
      "r703",
      "r704",
      "r736",
      "r741",
      "r747",
      "r752",
      "r754",
      "r755",
      "r762",
      "r763",
      "r767",
      "r768",
      "r773",
      "r778",
      "r885",
      "r889",
      "r947",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r62"
     ]
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27"
     ]
    },
    "dmac_ResearchAndDevelopmentContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "ResearchAndDevelopmentContractsMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Contracts [Member]",
        "documentation": "Related to research and development contracts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r705",
      "r714",
      "r715",
      "r730",
      "r964"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r83",
      "r598",
      "r620",
      "r625",
      "r635",
      "r650",
      "r771"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r120",
      "r121",
      "r163",
      "r164",
      "r165",
      "r168",
      "r176",
      "r178",
      "r180",
      "r265",
      "r268",
      "r280",
      "r304",
      "r399",
      "r431",
      "r432",
      "r445",
      "r446",
      "r447",
      "r450",
      "r457",
      "r458",
      "r470",
      "r473",
      "r474",
      "r477",
      "r492",
      "r530",
      "r533",
      "r616",
      "r618",
      "r637",
      "r972"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets acquired under financing lease",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r770"
     ]
    },
    "dmac_RisksAndUncertaintiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "RisksAndUncertaintiesTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Text Block]",
        "documentation": "A complete disclosure of the risks and uncertainties the company may face."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan",
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36",
      "r37",
      "r38",
      "r39",
      "r338",
      "r339",
      "r340",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r186",
      "r188"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r751",
      "r924"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r855",
      "r860"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-1-business",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r544"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r396"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r85"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r81",
      "r82",
      "r83",
      "r129",
      "r130",
      "r131",
      "r194",
      "r315",
      "r316",
      "r317",
      "r319",
      "r322",
      "r327",
      "r329",
      "r467",
      "r631",
      "r632",
      "r633",
      "r634",
      "r741",
      "r825",
      "r855",
      "r857"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r192",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r208",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r226",
      "r725",
      "r728",
      "r729",
      "r730",
      "r732",
      "r734",
      "r735"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r222",
      "r225",
      "r726",
      "r727",
      "r733"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common share fair value (in dollars per share)",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected stock price volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
        "negatedLabel": "Expired/cancelled (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average grant-date fair value of options (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Balance, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Balance, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired / cancelled, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share exercise price, lower range (in dollars per share)",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, shares (in shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, shares (in shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share exercise price, upper range (in dollars per share)",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected option life (years) (Year)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
        "periodStartLabel": "Unvested (in shares)",
        "periodEndLabel": "Unvested (in shares)",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited, weighted average grant-date fair value of options (in dollars per share)",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodStartLabel": "Unvested, weighted average grant-date fair value of options (in dollars per share)",
        "periodEndLabel": "Unvested, weighted average grant-date fair value of options (in dollars per share)",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
        "negatedLabel": "Vested (in shares)",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested, weighted average grant-date fair value of options (in dollars per share)",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, weighted average remaining contractual life (Year)",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, weighted average exercise price (in dollars per share)",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, weighted average remaining contractual life (Year)",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balances (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r55",
      "r59",
      "r60",
      "r113",
      "r120",
      "r121",
      "r141",
      "r142",
      "r143",
      "r163",
      "r164",
      "r165",
      "r168",
      "r176",
      "r178",
      "r180",
      "r193",
      "r265",
      "r268",
      "r280",
      "r304",
      "r330",
      "r399",
      "r431",
      "r432",
      "r445",
      "r446",
      "r447",
      "r450",
      "r457",
      "r458",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r492",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r533",
      "r551",
      "r604",
      "r616",
      "r617",
      "r618",
      "r637",
      "r686"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals",
      "http://www.diamedica.com/20251231/role/statement-note-1-business",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-maturity-of-operating-lease-liability-details",
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies",
      "http://www.diamedica.com/20251231/role/statement-note-11-commitments-and-contingencies-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-assumptions-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-options-outstanding-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables",
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan",
      "http://www.diamedica.com/20251231/role/statement-note-14-employee-benefit-plan-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-segment-information-details",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-amounts-receivable-details",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables",
      "http://www.diamedica.com/20251231/role/statement-note-6-prepaid-expenses-and-other-assets",
      "http://www.diamedica.com/20251231/role/statement-note-7-deposits",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-property-and-equipment-details",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-accrued-liabilities-details",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables",
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r193",
      "r306",
      "r307",
      "r309",
      "r311",
      "r533",
      "r584",
      "r629",
      "r638",
      "r639",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r649",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r686",
      "r716",
      "r718",
      "r779",
      "r971"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r193",
      "r229",
      "r306",
      "r307",
      "r309",
      "r311",
      "r533",
      "r584",
      "r629",
      "r638",
      "r639",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r649",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r686",
      "r716",
      "r718",
      "r779",
      "r971"
     ]
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares under Private Placement (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r55",
      "r83",
      "r631",
      "r686",
      "r696"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon the vesting and settlement of restricted stock units (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r55",
      "r83"
     ]
    },
    "dmac_StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares in settlement of deferred stock units (in shares)",
        "terseLabel": "Stock Issued During Period, Shares Settlement of Deferred Stock Units (in shares)",
        "documentation": "The number of shares issued during the period due to the settlement of deferred stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation",
        "terseLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r55",
      "r83"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon the exercise of stock options (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r55",
      "r83",
      "r373"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares under Private Placement",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r55",
      "r83",
      "r637",
      "r686",
      "r696",
      "r785"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon the vesting and settlement of restricted stock units",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r83"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon the exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r55",
      "r59",
      "r60",
      "r83"
     ]
    },
    "dmac_StockOptionPriorPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "StockOptionPriorPlanMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Prior Plan [Member]",
        "documentation": "Information related to the company's stock option plan known as the Prior Plan."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_StockOptionsOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "StockOptionsOutstandingMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Outstanding [Member]",
        "documentation": "Related to stock options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total shareholders\u2019 equity",
        "terseLabel": "Stockholders' Equity Attributable to Parent, Ending Balance",
        "periodStartLabel": "Balances",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r59",
      "r60",
      "r75",
      "r651",
      "r667",
      "r687",
      "r688",
      "r771",
      "r786",
      "r855",
      "r858",
      "r859",
      "r882",
      "r953",
      "r972"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r314",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r330",
      "r467",
      "r483",
      "r689",
      "r690",
      "r697"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TableTextBlock",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-tables",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-tables",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-tables",
      "http://www.diamedica.com/20251231/role/statement-note-15-segment-information-tables",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-tables",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-tables",
      "http://www.diamedica.com/20251231/role/statement-note-5-amounts-receivable-tables",
      "http://www.diamedica.com/20251231/role/statement-note-8-property-and-equipment-tables",
      "http://www.diamedica.com/20251231/role/statement-note-9-accrued-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credits",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "dmac_TaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "TaxCreditsMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credits [Member]",
        "documentation": "Related to tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_TaxPositionsRelatedToCurrentPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "TaxPositionsRelatedToCurrentPeriodMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Positions Related To Current Period [Member]",
        "documentation": "Represents Tax Positions Related To Current Period."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_TaxPositionsRelatedToPriorPeriodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "TaxPositionsRelatedToPriorPeriodsMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Positions Related To Prior Periods [Member]",
        "documentation": "Represents Tax Positions Related To Prior Periods."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_The2012DSUPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "The2012DSUPlanMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2012 DSU Plan [Member]",
        "documentation": "Related to the 2012 DSU plan."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_The2019OmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "The2019OmnibusIncentivePlanMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2019 Omnibus Incentive Plan [Member]",
        "documentation": "Represents information related to the 2019 Omnibus Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2019 Omnibus Incentive Plan, Stock Option Prior Plan, and the 2012 DSU Plan [Member]",
        "documentation": "Information related to the following plans: the 2019 Omnibus Incentive Plan, Stock Option Prior Plan, and the 2012 DSU Plan."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_The2021EmploymentInducementIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "The2021EmploymentInducementIncentivePlanMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity",
      "http://www.diamedica.com/20251231/role/statement-note-12-shareholders-equity-shares-reserved-details",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation",
      "http://www.diamedica.com/20251231/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2021 Employment Inducement Incentive Plan [Member]",
        "documentation": "Represents the company's 2021 Employment Inducement Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r301",
      "r327",
      "r467",
      "r482",
      "r507",
      "r518",
      "r521",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r593",
      "r605",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r772",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r878",
      "r879",
      "r880",
      "r881",
      "r943",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities",
      "http://www.diamedica.com/20251231/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721",
      "r742",
      "r744",
      "r967"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r195",
      "r196",
      "r197",
      "r198",
      "r588",
      "r590",
      "r723"
     ]
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes",
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ValuationAllowanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceTable",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-16-income-taxes-summary-of-valuation-allowance-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, Valuation Allowance [Table]",
        "documentation": "Disclosure of information about valuation allowance representing portion of deferred tax asset for which it is more likely than not that tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-10-operating-lease-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_VariableLeaseCost",
        "terseLabel": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r770"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diamedica.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average shares outstanding\u2014basic and diluted (in shares)",
        "label": "Weighted average shares outstanding \u2013 basic and diluted (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r188"
     ]
    },
    "dmac_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.diamedica.com/20251231/role/statement-note-2-risks-and-uncertainties-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dmac_WorkingCapital",
        "terseLabel": "Working Capital",
        "documentation": "The amount of working capital."
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-10-operating-lease-maturity-of-operating-lease-liability-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Operating Lease - Maturity of Operating Lease Liability (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-10-operating-lease-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-10-operating-lease-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Operating Lease"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-12-shareholders-equity-shares-reserved-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-12-shareholders-equity-shares-reserved-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Shareholders' Equity - Shares Reserved (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-12-shareholders-equity-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-12-shareholders-equity-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Shareholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-13-sharebased-compensation-stock-option-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-13-sharebased-compensation-stock-option-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Share-based Compensation - Stock Option Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-13-sharebased-compensation-stock-option-assumptions-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Share-based Compensation - Stock Option Assumptions (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-13-sharebased-compensation-stock-options-outstanding-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Share-based Compensation - Stock Options Outstanding (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-13-sharebased-compensation-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-13-sharebased-compensation-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Share-based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-15-segment-information-segment-information-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-15-segment-information-segment-information-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Segment Information - Segment Information (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-15-segment-information-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-15-segment-information-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Segment Information"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-16-income-taxes-deferred-tax-assets-and-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 16 - Income Taxes - Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-16-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 16 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-16-income-taxes-schedule-of-components-of-income-tax-expense-benefit-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 16 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-16-income-taxes-schedule-of-effective-income-tax-rate-reconciliation-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 16 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-16-income-taxes-schedule-of-income-before-income-tax-domestic-and-foreign-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 16 - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-16-income-taxes-summary-of-valuation-allowance-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 16 - Income Taxes - Summary of Valuation Allowance (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-16-income-taxes-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-16-income-taxes-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 16 - Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-4-marketable-securities-fair-value-of-marketable-securities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-4-marketable-securities-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-4-marketable-securities-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-5-amounts-receivable-amounts-receivable-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-5-amounts-receivable-amounts-receivable-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Amounts Receivable - Amounts Receivable (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-5-amounts-receivable-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-5-amounts-receivable-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Amounts Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-8-property-and-equipment-property-and-equipment-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-8-property-and-equipment-property-and-equipment-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Property and Equipment - Property and Equipment (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-8-property-and-equipment-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-8-property-and-equipment-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-9-accrued-liabilities-accrued-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-9-accrued-liabilities-accrued-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Accrued Liabilities - Accrued Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-note-9-accrued-liabilities-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-note-9-accrued-liabilities-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dmac_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diamedica.com/20251231",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001437749-26-010342-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-26-010342-xbrl.zip
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M!%L2^ZRVP!6YW[[N>2F=&<Y:I@7.\E1Q5P#?NK0\Q(I*T,CE:1 \54>I.,*
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M[W0HUX(GCZX ]1\/G\B^>IZYGEW8 :ST"55F_JW^T\RQSG.I-!3/D:VS<'Z
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M!&X7:[V&'[\",(L$.L/!$1>B#3 EW^^A.A%^-CJ8584(I2^YW@EKMO+S_$8
M@**[!:3'+<;  5PK +'/"WS1H%/"$^!, )D.!DMFG;F^ >KF/I)Y6YI?138&
M<2B SZ_2O7M./N>0[I4$U;NCJC2.5E(I,*.*'[X0 W64AZ_;?BV26NYQ4ZL
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M7K[JO_5>FCAE!O3T])QP(?K7OE17@"%F5$.O'B9K[OCB&7AUSXTH&[3V&+,
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MKR7]@@WEE;[1B=4JGV?HL_J11G6BK1%&8D1""#!<42- C: !]QW]K:U7BYT
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M7U?)^GC\5Z3SA">M<;"6&"&1#$U-5T9952>L]56-IHL6/DFP%/.CB;>2]T?
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MIVL'7= _"UQ:*"!MTC,H_H.>F^!#\*D$&C!RV150$Q,0P'T12X+IU#1;.M$
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MOMP"'V7)(Q\FMYP,0I:?U^\^ONKLV(5+ A$O^2';*6A <R@0]LD$XU5!-""
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M.,Y#=3&KK6W,S6>FY\D(?1<X=$4^ BEHR^-LLEMMGX2I&5VL-)F?+'5]OA-
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MC7[J=NL &H %V0+N1J$!VVO7+2N9G^_L/HA=D@.O/%6O$82,*+2B =Z03#1
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M8-G\%I:FVKN3*M.W"70;C#W_!C,:T#GV5V7@R7_K1.BM$T&.&!TRXC,1=+?
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MJ#%Z>ZWS1S8ZY)ONI';'KXZ0RM]-JY%ZX<"43"KC];:4U2XLHEF1A?&9-MT
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MS+?Z80%)LW=2Z%X\B)Y-*^,YJ((Q%-F1!8Z7K!&+)JG=Z[/+7^YA_?9VHR>
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M.8_NC*2K$I3(166(4==F2.3# ?XX*\?RQ\G!=4\!5^X"HH/^*J.BT9[#\]=
MK=H)BXB^N*[8I3O2V^-UR[-^K2 )A!/LK'+Y_MXY,^O4W<7./@]'J_C^/IER
MXF,E5V\/K.=%W;0VO8"97'7<1#2@'6O=Z8K!@W\(TAZ+>"KC@ ;(JN9>0A&Z
M/]_X$@@\N0OP 2-9F,70@*Q\3>3,[=CI!^SNY5.17=-4-"#4MQOW>P[VZ/^_
MI'R45;K\B2D,JM=Z2O5&'3?6"$DTC7SA4H2(U&N,6A>LZL!!?J0>]Q9>$8M=
M?9HG;<$C.2R5>F3S':_$?KTBUOX=%4'2IW\?U_H[ML5S4XJB@;1O(9ZXK5[
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M8'PD>)4[DU:%'?KQC&WR3=J.<V5AR$:VHWG-W=^<&"@><*V]2GS*!/J*!N#
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M*4?ID']VHW9^%;V#I9 .LP%5@]4B_4N49QWD;3= [.S>.#W(+6FKNR+X5C*
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M<LGHLRIR;2Y+PMRQ@GGHW'EZ,O&^Y]R>05!<E@0?793^'<*H2%<!X@;#$ J
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M9GMT57^J32)XW40R6ORZX+2.[K5>I!(Y=\]15@X?DTOBZYJ=P9QUL<,3"#A
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M;6_X)+YD(7767*ON8_X)EU)0*'/%1&6?% L(7#KN#'5.KN9YDB3!AG^3>4U
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M/W7CBZQ7Y729H>: M9C<[.\M^VW"M<3/:J)WBUF=.RVU;='";4$PZ 3:[NM
MZ"_K^'[B37BMIH^%P-EE<M=WM@FWI>+DG8;KF\DV*!,)QW"5I_T;.C$7:[W[
M"%M6M=\5C$SO8[1C%UV#CAU.9D\R,M'HY>5-VW)=5!%J%S<Z5ZA>[2D3LDO(
M66O*O<LXI9>0\?VV[X4P.PCDZV9NA' 2*C(0_=6E?_K["L3=,- ?>OY2Y[R
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M@".$\+'?]^AY#NYWK>]@3F;-FEES7=>OS9KYSV!K+J6PSBN\8E*G55<ME'B
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M]SQMXH.J3>9=7 HUR^ON7UEWC.&'X]YR).3#@(]5R72'[AO ,]\4^OOZ"U[
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M,CQD;(<"_COX..I;'?/ZZS%^8(F(P9AW6$=+X/.G[&MJIPMKC"FE;N[H2?>
M29_.L;6L34/_M96;K]M_]!\B]!]]6ILC%V(F^L!2X.5T./]TH%O*ZQ;\=_I7
MQ\4^Z=-ABR:BL=WCQ8GD9P[=5A)DLWJ9L #;<*V.?>76W<P>*R%3MK?)$VD[
M]C&IBJH^:#:S7%VMFY'Y[69(9LWU[(-2?WN5'QGEB=8=22KT24U%)P54J.JU
MU8BIOK_#[]\IW(7,%F).(GUEG<91^PF?C2_M0F*#?_8Y&>OQYDD5H#6P:C64
M,'&X:FIFZ9*G,B^^9+(A61/9JN']AEE.S7!XW<YD=[[.0YT?[$VOQGEO0H%6
MDD!*,($Y&HP/K5[<BECQY6(2")?&*(?7#:4T$>)$[M^W73@CLY(9IM4%OZW,
M=C6^;@O4+0QT^7GV; XL> &]&5>?W%02B+9YJ:XI,P@NH%,+7ZC7,[,I[9<R
MK#<#XTXWB]W)C+!%C[[J".F5^F)ZQT899JE7:^HNCK>.E/:T?UR74)?#\4KI
M=J*CA![2!BGNQO(%!IF+CO<*2JI:%J(>Q<P.RG1[+7B]!&721:X4:J4>T?FA
MSI2VC%,GR.&N^:@>[^4&,E)5UY7U',C69I(9N9;D+H(32-H,X?7C??;B;Q1?
MPA5AP5DC81H'$SG0Q,+SX*O*!:L*_RW&*W;=I2$:3&0=(I_+&=$(QY:XKH;]
M73__),PLL+?G;?<NQ*&RI.,#UZAW_GH_.RE5;P_D;)Y#!ED<BG63?>X=ZGY;
MLTR^U$8\D!,R)JDH95]JDZJJ7<5,BF.59O[SVKW0Y9=7N1W&LR&^>LQ"/^J(
M'J+]0+;7^>8Y997W!:<O'8$6ULX[E:.SJFWNA7XL25+K-7I8DG0.\N_6,)_1
M(T.D4Q,P+XV+MO?[L2"[$#\--2XT6:")Z[_&4T[D^P)N?8(#H ?0W]-*I) 3
MC=6L>$H_.9B4, ^A'O1W?\%1-P]?FDQ$3'AT!'J,LEV@-#(^H]'J?(GZ<5K\
MVVPHM,K,PC;55=U)3-K,+K^DBG/>ZGCE^Q"+;4OBRHE[Y $A9:DH?L=PSB4%
MD97)GU_$RM&Q(TG!#C5M-@$:U/M.94^SRGV4RY<G.%\+M@]@\'?!H>WKN*9>
M@Z+4KI/H "2%41S$<:U;-Z=0=DJIMT4"9UN70;PKT+:U^BMH@/6X \6%'7A7
MT<_14++XI_$Q7.;;_13%L0:9J0_&YT WAISP7N\<\$&@13C@S)5HX)EP=-/W
M(M* \%LY$<"\&Y,@=XFWWTF@NE/>]3M(_N-U>Q-0%!_NWZ'&;C@.WO: VX]0
M"F[XY\I5>2G&3$[;I-\Y]?-]TG):=.)76I2+:N9+"J"7Y)#Y1M_G$5G/#,%_
MFI'J?'8Q-%1'JOIN2&I=3/]"N6./>T:=3:=!1F#N8@=7Z=>#IS9'-,S&K5M5
M5"Q_\FUWRN"K:X3?P1@NK*=3;/,+&%V#Q^WD=1BQ _\6G!9\:)M/U>@Z;_UB
MT5BO$1BBK4G@B+TSOW7RH,L+/&6:%N[QSP&>.=T0NQ\,_ME3^'M\Q)@,]VI6
M7==5'FIY@!?*1KZER@D^",1:=FH12!Z2"UOF 43V+B0)#P=^LC5RZ V/,5)=
M\GU D0D8&L[!"1 -<914V&P)3FF0P:0A3TST%BH S\>U64?0(*D'P-37[+/>
MT1IV-D%6D>(,[M*N7(\IFZQ1#5?4C<_2]SHYIRJ9?ZXZ0 .5:_F3-B3\SM0N
M]WE8P/M[64[EBF??.)245%?4W"NWGPX_G=?QP)F_D^KI_T800!B&-4WPU:$)
M+, &>0C7SQY%GN0?!J9Z9_0PB1:5. +F!$ZU]P[2%W,2C+HZBO? AF(O/9NT
MWH4DHD?&>V0)RB^[1LE-CU:^OK[P.WAP@HU*:<;&(H\0#H+]FWX3T$=A'LZ"
M(X<*#X\W$&\WG.1'C?+/*)&WK?"7F<90O";0\' @;CY&<!I'9%"%=:*1UP$J
M'2;[Z1/.B=G=@@[.*P%C+H_,Z0IMJ90TTN;#O]F5FC+MXR3F]E?;7*J<\8+[
M2VU_M,.>?YHU.UIL*>H_W;@XM[YH63;ZQ<?N7:LX/%Q=]7KPHHW:8E7# QV5
M=^0*ZL Z\1 "^P(D;IKQ5HL!$\X:'3NI9K[SG.J%.8++8#?T4C^SZ#.&@'."
M3OK!F6^HZFF<.7<P[G3;_'(W+X(=OC/>Q($ER*2GA;,.?\OM'2RHZ&JHP!5.
M![L:]^ZT]/50_EU;\]:"X")>D0=E$']#"P:1E/R?,\>!GSU$43PV6XW!@RWO
M0K#>-8M($81&*9CA.K$.%K+7*\MB:)'_H,THM7Y;O;U=12+)@9/(I;E[SH7[
M 4(Q-TB(8[1&:EXJDL5YTV;. &02'Z7^YV(;BH1PC=H;T[/#*TI?Q-4IR6O"
M(.'KIE;*K1R+YAO]+^.'Y],JY LB1\DP7Q.8191,1P;&G?8^UML&7V4?I\1,
MR0\8L[2SL2?+:%?UC>K[6^:KFOYPH*%^_F67OJK**+V7RM(F!VKG*X3EVN;E
MSX'"LT./(W\^[E  -+&319MWP"R>%;L9\ZJHMX'T[_?ULO >Z E^Q&C7";SY
M7@50QW&E/84G>$*Q"/TRW/NEMYX71HV/LOB&0' !M\ZNWV)D71*X3V8/F/0:
MG$GDM(]^W(7<1J5Z2H]NZ%%@<5NUQ.8B.AP\^_-QUTG0A&M$?K2JTU^GMOD0
MN,62X?)0I+VKU%B/8.L0I[AY1;^!.=UR4LT3'58<#T7\]6RG7.OXABJBSU0W
M;%W9U.%ULJBR[;84/%!E\*ZC\G+]DF6'@DU&6YRNOIO8P;F-+/$/;#C.2KWB
MC7-SUHN2DE_>0V4*-G:9@M%1[^TJURB)=3O/!?ZP\G)?U1+RMZYS"YY"@')?
MW94UNC%DYPE"C-M 0FW+PSZ3W_Z,),7O47[Z_J5(T$.+AOJ(M^7I<C Q>!W)
M9%(B0>&;C-,K=A[V(*NC@=O?7NQ[5*Z)MPO9M&*&$:4)(U8O!/U5U?B3P/P*
M<EL(CQGFB\_N\6D5!P5=S#WVJ+1 F5N40)#C&W_D&Q(*E<8D+9,&)_JR/8\-
M8S?J;LY,OZ VCVI*E^1L[2^IV;G5JYJ_*&.0OVH\W-O>#\>BKY<?"WMYY'@N
M&==36_+KC7WH3I9YEK*&PP-[VS8P1-C__;TF'$G?/'?PNA-EG:\)IK*A4OX8
M40*RJW3;>'%&'K3@&6Y^!$WJJ4GA0P\]$2"5C%/HECN]D]&A[%L*[D)HK/T=
MNJ5? @2ZWQ'^%?!'-W+7:)-#\7QH?4<.X<S(S4ZF1MG+TNT3^$M@%3#%F5BF
MU.TQ#ZG72*SG4@L5N,Z*SW6?V(4(4Z)_@^[[#&YSAVB81)CP[SS)N&8UPP$U
MMG,,PIJ-% 8?S_=PO+W8LI<6]1!&V!#?\ @O'_CJCGCRD++Z15H'0D/5,G-N
M13&B_U'-H]0_\]U2=@K<!D<V[VW>I>B]&RVP=L*(.T]6IRWBW]VK@R>0$T*&
MR[@#PFKU/D-J[ZVR+_"5P95M)"X61Q,<B:K@(T'1>G,N/"6[Z#\=X>RUXR"2
MG37XC"K1)>H7:=ZSC4R''=.&)1G<3@XL\\!1>YE^G@J-5) 8SC'$BN*>;G&W
M;QI=VI3(LTU>@GUJZ)%P@LE2 W8A<G@UT)Z#?%S4%)&J7?00'4%C"07N0@[S
M30$MI@.8QT9"P1EHDD#[H^ $2*9UB8ROGQ*>ACN!@>S E9M8$?_[ N4Q/"PJ
MQ$>'+Q%8Z4[(&'9U&E0=[T$=5HVT23VB&5R6.U=ZM.OTEU37@=J6=(5[%&1@
MHE-.<WI3Y0TOFXY %?S%*F-/!TK^JV-?)CY'!Y"U*%^Y%M/WC(E?R;-]RV,\
MJ/E'2CM<R@\F&XSTZQ1F(U<*RO%76X>1/E%88="[3TZ>UQ?3$4Y&4].(_F_N
M-/\B(/WE],8ILL*>H#\9#'3B#;9J4N72E:K*P/LBFLN?O^'-=O["6[/ACR9D
M)'O2/[,\/X9C3NU"NN4WBO;A31H![$.=4T:^O2R9$IYOSZD!7=K,A3S4*P\W
M.DQLY##"6Z<D\.(,KN9OP=3WN>_9_\#74TWO=RGU&@S7+!?[V.DH6EMEGP@(
M#SAW;R1.[_N5\%L+H56CCVV_5ME9/6?O9)@_H16B>WLMZOW/<@^U/GAC[&]V
MV"J+H;DV;64"]'%8;Y?VH%9X::>B5B!*Z+]D0.Z!)B /[T*\K27I!/%AXY-@
M#AT&#3_5#D_N4G@)9G'WCB?!H"LK%&*R0 V,FOV\'+YV N=F:8VB%ZJ\;'G5
MS#LMPTB9N*]K; ]0-_UY\&2"(GCJ,@_5C9$*I/Z&XI\D>8(9!Y]PAAXY4X]T
MB")IR;N03Q$<FT1X<H.Q6$N1-QEG_W9KC=XRLEYPA>8YHOU:9R=R\Q3TY+?O
MTTOV+M.[D#\SG:YSCOZIXD!JM*FS]'SO.(U.BW!!2[F,6<]8-GN;6MA<M/BA
M][K+Y9U[XZ1=/L:H6/I'-?X)I;.Y^K5QVHE[_KV]DQ/6'F3^+QQFUK&5-N#-
M=B@ZO:?8IT'NIC,8Q<L1'!$M^X0_.VQ\"%?**4R<W0GL$^@!CKN0MT09-[PX
M,$3"6U0M>AYN SSS>/8]74?'U],/NW\SAG;Q4@M&(]#6\2^Q*R%(/^+GK1^]
MGA<^8BGPV%W(Z:[3^./CQ)M%D'_1-0L3%O2_V[Z&VX7\ZR-V(:?PEZD\["/U
MK]G$DY<!.">.D56'AX^MPT\OH7<A\>OFZ;00?YG6E+!Q0-UI:>>DK:.</-VL
M-C *'JU:-5ESUW.DT]T<H3(:9QE2O^B8&>"4J:PR\E.^6,4F%*5>,<O^4(?3
M63V[,WFWO%_%S#:#W&^MUVVI>O%GWM,4!=A[.'A.\C'>(GH6]2D^[.7."THT
MG-VW @5^>H)Q>U1>>))GGD*X 'K_P>R2 B?,.WD.6[ZTZ%.,R#:,+'J+,>'6
M-KR^@OZL/*KL4I8MZ9H^7T'95N"[@9]GAZ!\>6#FT;8I*#D[GT0-;D@T/@<@
M&? $.5'>P>3M*Y=GUQ(P3;J));P^.BNEI6V DI-0^G&M"QY@D!.K'81BC!.D
M)SI,9P-KD,>LC^7<#M.OV?)Y>I5C]_WO)R\6OVN5I-=<@!"4JHG^"]1UT5=[
M36HG"O1=O7#Q]4?B#*Z3K1W*5]Q5;0*SM6H,,E*OCH2T4LBJ32D^*I9Y%7-"
MEM_G9?$'5"F*^J-S]O]TA-D]?1SK?OI7QMVGCX/.E@_X#OF\)US!-6R2P2F
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M1@_1=R%"N!QS7O!SK@><EDV0Y2'C$8J^D@F:&TN!LC>_H_:RZ(NMZ8JG<+O
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M"'#_'#G%WBABI$-P_0S,<827=S1/J/>^IS)S(V&5  .Q?T3#Z($ZNY!)3.O
M:F(]3E)P>+X*;P'D)!F?_88FK5@!#78\<FPI^* >@R/3_Z)V#R5&M%5[\E73
M&$A1CZ$#;Z/M/0%YOY_HVA:GR+3X,!&G>V&!U''4_Y@4M:<\9%R7'&YDNT<F
M)ZEY99\[%8 FLGE%,<$-7^,M\(:<9]J=]J8D=Z;+M2[']4@G2O6GVA19?/+"
MA+_Z(8EH2_O^.;M4O1VS++1M@<RK5%?[0NGK<><LWS'+;<J73&;RN784?_T!
M ]N*:&O3FR=#CF!<\I78=H-'+*NK5-Z%&C]X;_Q/L^W=.+U*!C-S%R(B@ D^
M#'!W(0FP_2)KRRR.M>ZFUR@16S1ISB$][I( Y]F$!G;GOF[,H0WDY\4^\^$-
ME 3^_,3Z  (4[C'6 0?*P=)>8QD E8(P+.D]G;N9_]/@J*[N1S=37=K0XQGU
M)MY:M[6PQ5Y+AD0$8P2AG5=4/V("M1F^\I]0H(C>AB0A?(%]]/O$TZGY0MPX
M1E*A.!CW@O\',)\H$,4Y]\!$FK%B2Y.D^ TX=-)H-8Z]#MQHQ\SL0OXK_JK=
M+>SV#.[II)2J*\8S-JNHD_DUNN7!.,Y4@T1)S5CYE5I6^SO%TP<.?=YV^1%U
M=1"5G0LZ0N]+"&#JE?#;S.!\93WS<$7P\#9"0"/(/"1V7S)/W87X]$.H0#DQ
M0!:^F8XYB;]HD7-]7.<<'EJ-@UJ"7]KJ\^27FBK>!$95@J>L>+.C\B,4MTN=
MP#0E:RY%J_MOG.XLHXJ-(;%^(ZVH;>O@46#-K!ORDR2#)220Q<DA]]@.;(\&
MYKDE?#N>R/*6#RLVK &*B[$%?3A0*=PQ['_\">(@J?83CF@^LKX7E[XL_,"U
MFL;9:A)+&OX?U4!YEI4MWGMG>:^H/;%*YJ_YNO2Z !VWC+)=R-1.1J9]<);4
MY05EG]/M4*ERF2?69A?&M;_<*D6)H%B/&_=TTG?>HE/9SLY-X=<6LDF9086R
MP,E)+IM0NPMIGJ W@&?)-$Q<UREPHAR4CW:ZOU.,/UHD_>_[WE%H\#/9W_X3
M:-[71HU%F,QBH"Z!QDH\XY09E?A^FU>OQK 9IO&&Q$KB;"'RD#;U$.X'H^OW
MX3!6\J3$DRJ\)!C.AHKC,+VPQOLYVZIX3>P)?^>V_*I@;>$:V7VN8#)/X7+C
MZ]&PU @&^GY,+<XNZ,C6X##"N_J+3F<'IK;HOVN8=P+GR+-\H\@3J5([-[5+
ME0^;9*D2!LPNI+#U&?G>EGEDFX*KJN&R%C.VE<7"Y8^*+>L,DNJF]6ULVYM^
MKDX%:UF\>V.5:Y>27]Q_LH0S!Y_?4Q5D$R$5J.7+3'0I"OHC"\F D.E.-7&V
M!$VE#Y&,)78**4BYPSIP*3Z&A\<T.=.+CN-E 4PLI3."01!_":A'MB3.I@9#
M#P6V&(N/(*R*IUV-BTJ_7 [%VK/WSNY&W;\+Z7D^_F^$_IS'B>A-?Z@"^&YF
M FL]J%B%V8G$+KW%(B'-#O_M/W QO7O8[I#DH$@$V9$.MTH0UFN0\S:9=1@'
MO\R[1/;U\9Y-T/;GBU:!I;0EWQ;L-_A_)_ ZS(G1@E\CP:&5<^=ND@]7#KJ\
M(YO=SRA'@PL]CCD7"\[9DOM/5BQ>Z?]FGI-=:_2IV]3RY#]YCVE]+&=W@.B<
MDJG=/*^O;S5M*WBP"PE"_@:N]44ZT[$BH,FF&V\B%F'%QCS<A305I"__BB@C
M# DTP'Z>KF.,N15<;)$@C4T3$!,1,& /"Q=KDNLTMZ:N\'2*TL,[/0>Y;LQ5
MOE=(Y;>[UEMJVT9\M3R/EATJX0C?#G!.TNZ4Y#BO"/$PKMLV%':='9-F? '$
M\G)Z)GWJG]?@S.D33MY_\!0T.BNJ FLF%W0GT*1XBMZ9&->6ET^74($-'Y'_
M%5=OEGSKZT\42IPG6]O/9:JJ#MJG.FX@HRV=\ZS9#W[YZE/L.K[<+I:R1]MW
MC\3Y.X5GYN>H)5^W#:$$R23;4M?>!)=DI,CGN^?OS651JO!;5K-C7P\JL4L?
M'-HV#O0TX,%I*Q<W<3MQS3M"O2QHAP_WF4[#7H(\RO?RX:!2]L#G] 28Z.E&
MH'C./9Z*/,VZ%XL&][,JW&9,.%/(N!:Q 7* @4M[T@^A:^!_%"<>&2N:<*'[
M\5B %=?<,-6* 7, NTWHIVHN R,R=65B+WC XPRBQ]MY0IM_,IL-=WP(TC@J
MO1'L&NSE&\ZR&\# OHQ%=$."%X!-UM3Y)V9+\;_:9[7B$/4<PU15[9VRT3K+
M:MM8![\KHVP[<6^),:7R4K(..J!<A>4^@[&H)"=\G4MM,';Z9TUW3>^]2,,#
M]( EXLE<[BL^;Y$JLA%DTG/?H&]%:%L*U^[0Q(O@B\U;@VZ &-OYD;$P;IYS
M/P>(X.RDM7(#HUB'OXW[EX-D1U"D 5<Q^'//U33#Q< )6^!O("@M3RZQ&AP9
MW /1TUIW5!_U8=%Q27;1BOTL*YW8Q**O3>[;+.0-+;=O7P*)L^F]L,-\>9YN
MKY0"#_:8(/)M4H@^)2O$*4PM]_!C'=/<8^"D;$\UGG-B<ZH574ZZ"XPC+UTQ
MNFC)2YEL](L@CN3\SZ25^3]SF#,J<=ZFS%?&88PL/:F7^V0N;(F]Q$R5UE49
MB9T^9'[R3;FZ7?Z<"B-8*Z5?H_2<G@$OPD8W4Z6]RK[*QB9@P<;"(;/*4-&B
MLESR))/O CX"ACBWGV^;@S4<$_Q%,+$2-#?;A3PN$ QAQ.IU1/9U&\OS#O3.
MT_ZF>LNBV)?*N=:GK(?7MSNM/("9&&[1B85)5$*XD=SXEJSXF='5-7Q[M.9&
M,< Z@C_+F^^%I5,/;ZR8;P:-=@A5@TG;F^/ 7G]W(4>F! /&OP/D1^NO.T*!
M^;Y-3S%FU^_X<%YY9@RW0\Z()[LGVW]O"&O8TS'08R_#JNJ(+^N=:9N2R(]#
M_[4X+K0$]S/OJVSG7:[.LFT=(^W3)'"WYH3"50@;8QWN9ZNO/$TI/6 G'NQR
M1"MKFA@^OCF2/!>1TQ+GIN+A&I4DX4^6MEGH,H?.QYB"0CSL]9VBO=F&'L*+
M@3K<HG@Y/8"T+++MS3\W4<=B,UJ!$LPQ?O@XXB)09.YFV#YM;@;L%%2T<@<"
MS<8G:'*Z:1%,O)46,D&[(')U9GKCT"L"G'\DCP.E4=-:]B@+N=RY%W?)-&N3
MS3] (X#61_@-N;_#%PC>*Q%5IGD7DLZ"AD^YK*_M7T1+QF\4R>)BWB*A>_NE
MIT 2QRG&JV:AA.D4?PHEN>@E[+8+,4?^=]D*E%.NDNXI(5NN+[WO$*-;,^P*
M=;AG:S2,FE+*2J]8]PX'C;J/9#_]OGA,\UAC<Q4C+^!\VW4:XW'8!F%P4;<R
M:W2LM"2->D#P 7G@CN H80Q#V2$_)DBB\1= 4P[V".%#;DZ<1H<.6P^O,FL=
MV!M)C!><\2_4[?K(9M;6-KL-W#M4"DRW)FG>R5KS8#R;+.T8$"X:PCZD-EXJ
MY4(E\$K-X,(V@H7+Z1&<WLE%!@WH-[,2,=!Z"DIDH>LBC[22R!DZ#EX97[*:
M:/X5%L,QPG9/)D[@X9LUKCI*PPTV-27-=[_D)2*)Q/\I0*7_2Y_^(1>.5RP-
M:I&:&U"';1RCF\=,-ZZ)7#N2F_LTQ\C%*30/RQGV&RB/H?5_)NM]9Q;XGT,?
M@W71[>EZWY=+I>UMDSQ.17WB^X-/ )->SXM[4+E&&!2([.$H"@/&[4V)#&;Y
M.:=!E&\XP3\0RDV'?7+EZX Q@&"MK\7)4WA4>\4*,XHW]0=6^^A;B"W9U#A&
M:XU_A R)Q*&T>YBY&:;#P95M37/N<^KLBUW(2;S^-B*@C92\VN&\+16(:8(E
MN+'O-U2 -,L1Q!E@>[9O,Z7HB'K#>J!15$\H>&\)-;K.$D/[73(P*_72S+B4
MR-$[Z3?\V57PX[\_S2D_=J;FBGWF24ECU1;E+*?,&UEXSWV2!I8J_&,N4O8L
M=/CM?#?_)PB1(T]2?!R-T0X+ET9/%S65)I1*7UJK>W7,:7PD%AUH#V!IL*:?
M*=R=EWS;.KY)"\CTX:GL0H*-0CGD&+[M;/KG""O>@3U[<^^?!P*A(._-SK&@
MNO4Z!;91.FV> DBF&$OK)D_0T>&,O)!B?T^A49FHJ.3!]LWWKT 3XG8XCL'D
M"KW%2.()3!THJ,QH*L.%TN1.@/H<5&K$73#''FRH1"\ FG'L ACF-3!.KATX
M>U\&GKIQ2M;0 MB965A#V++!?G?J2NO_NOV_R7$$V3[NFRYEI3SV!F^G+^XF
M@)A1.]&]TZ <>V,,XY[\1V"ZH9!-NO.3C0.DVZ;]DM.#JFSZX8FXR%>M3=T(
M#3WV8D^R77!6ONH5T2R#^X\;">,A]P)S+9TL9JNJ[Y&/-+.,<&,95=OT$;L1
MV\PYZ?Z9L>TG]]%*];N0@@8Y03_KU"J,EFN^H@AE%'A[=NZ0D#Y#\3-'>- >
MZN>VJ<UL7D4J+[1[4J[<FX>Q!M+I-97UZPV/J&)U?&SH"UP%DZ/4R4$= */<
MBE"M//&)9 5!3PBL'<?==)O (IRW;?'.L'WAJ1C.%R)@NPOY1-U3;F.%@5G7
M8'[H'ATOT8S5=IX%(:(Y#?N6GGQZ]\"+K>;Q6W]?(M>0>G3H8)QB7$,"HYXY
M-?7EV2XDXO\!L%;Z1E[%Z#F3)U<T3\[)A'U1<!-RNFX;ZVUL67/81L?;KMQ1
M6?_=O8H73_M?+EA$W?Y5/UHV6I%'=CIB_=XZ]/)X1DR*UZT22D0&7QF8><23
M8=*+#G<=IG:C4EG $QQ4<(3,+4H5J/(,\2J\."I-5I>-3-"!)[6UDO@A@3RM
MM6LMP&UJ^>)'L-WBH0D[&N,VJAWXY%[AV:9A[T3%G'V;A!U2A[YL$5_LRCQC
M%]*XDQ'P'Z1_)=7O5X<]\&DH)-R_&O2E;S7$- ^E"CDQ_PFR-\WH=6H[,!&K
M#9<1[I3ILV\=(9&6-=#".ND_6?_=^U;BS6VOA)1+V88[FMM=I]M\KW*&II6J
MU.A]-G/YY5@N^T#1,FM.)=3&X>5)_5*5L91?^@X.I<+G&!5R(6B6F]?HK?6V
M_-JGC9A!# T98Q#Q:)5X*YDZ&;II#5)XNNP(&NNSY&8]&!K*#L0^--8%._UG
M=XA..R4=TB$ MZ<MYZ&VD;#[Z(TB5T SQXCTV'5=N-T#BI*8I'WY)J.8V;:2
M7HP7WRGLTL)I8>+E$&#&-F*1*$Y0P1_?([7K4_Z$?<-\+V^C;S'<[!R.=>#U
MCP+)25R/<^&4)?A7F 03?S&BRG\R%Y?4,QGX[DX#.\W?)^-G__\JB&W50ME#
M'>$3%F]_6_W-8GW?AW_&1CD!62<GFBHZ:ZOUR0F5W'Z[%OF:.+TJTQ%[E^J_
MZKEJXTGE@)ZN?KS'E6/(+M23R^;3Y0.XGDRQC C[N<WS6=K<55UDHG8IR-R%
M[,4:,*H!]-TLXBDGKF/C"0H@$1A"[SSIDO:;> =='N)@/^>]/<ZW&L8'5?57
MXIRM]OQ'LKKVVDE<C2M0_X0P3@0R<6VG!F[_0&4F&X6ZM4KFB!*&1WX[M/_X
M9<CC8Y>%_KI\^KCY[VG-E*_>O,8^CO&K<^>0/I8%;S+S'%X42UM:GK?+2'(.
M4-']N$*[[A))&+!ZKF\90<GZNCKBG)6UV4ZH/5>2Q#'X+>G<B_]?&Q6Z-TO%
M1, 9>T0P*)-6"K3.\AIY*'J4#TXG^O9%;)1/L7N\W\PX0P4QI:_Y(EPMI))E
M'NI[-.DCVG\KLT9M*KI@%W) <:?B[$X6]=8:C'^9J>R"]ZB+SGD[<TC.-^<<
M[__CZSVCFMJB?]%8:2(B55I44#JH@'1RU ,("$A'6E1 FG20("%1>D>I4J,4
MD1KI2@LE@(""]%X2$*0GE+ A[>;\[WAOC/O>&/?#_I"U,V;VFFO.7\E.U@;'
MFN*5FB(B_<1& YH]#4P2^^^(30P'HZ3]*:R;KQ?*\890D\GZYNE#85O+YFP2
MC;2JD^*V(^ZW\W/P9X?.JYZL:Y>DY$%6VPOLL+L4XQY'A0N;7 GM/@ACFWPP
M'Q5E:?T2$?QA,->CI9P],7K7A__178%B@>E\^8OKR[F^,)LKH7#-)Y/=SS#9
M+:^)(<(=!FQ=&JJFBK4_$7R;'W[ZZYL.^%B(JYE;\+?RRG-*!3I?:28+^"2,
M>!49U]#$&-96&^*.C+6I.\FH)'*91O3O#+#9V;G?5WHA4X:9,;6S[;2ZZEE=
M7Q/N:O&0T\("'DD'>6!FKB!7"Z BOK^2<G;I(*/Z_0'J+H-I-^D@FV+Q*W10
M",6#S,:VI!O.KW^KD(,- %_ZF$(Z3K[XYWO#W4++(^*5*)<'?$G=YJ^LRF.Q
M%J7R]7>1O!/X!?'NB0Q13NR5;IMQIV)3[UO8DIO;0:YC"59%I@8%6DET4%0K
M]1,=]+=@$;ET/HL.^I'.AF!8I[J'\\DQDW,NX+\"4&]R #K7O9D.XJ.PG8PS
MQ* 0'51H@5L8H+DNB-AST4&?D"ER0MJHYD7U7W7U&-P#/CIH )XY%\IX7P-X
MFU<5S(D.O4U%%9/IH-%B'>1+Z(S"V>28HT(0'?03HD]K"-PW.P!#_[KS_D5$
M'UMIM' 3 CUQT&B4"\UU![PY0 >94K5TG37H((U7;?[9D$#($<4JDZJIE8J<
M%2<E\_=B0Q;HH/V+(ZV8]<%/WK/2I/<@%/!$^=L![=<($C6UN1JLCH",?$(V
M(3E6I5E@TDM'\I3L(0XM7CIH)0E'W:&#-J K;<M55W:"G!FT<XP:$HX-@:BU
M&>QH97K/*I-23=X3I?:K5$<5"QDS2J]W(YLBIM224H/P[,H.Q,^%N$T.9?(#
MZ&@+]U$3S]O(!X_DZ^/M!3S5?G9&:&!<FV*P$0K;INSP."K3Y(D [3UFZ0-"
M<;@%0KX&G&;;O6SM>A*:V>L]<PFV038!NI909P&K#@0_4;<SGOWT0#<=Q(40
M +)79\C+3-&R7B7YH6<Z+?FRX<E5TT75FBLC7=Y0<(^($&#8I?I(04#D$BSH
M@Y%U$PQ9/A )(%F_.T=C)U<MD+52(7LPV'#).1;]0*E.19QE>8E.R;1/I,Q0
MK/\3YWH@7J']OHH>G@<V@<4+I/GRV_ &3%S/68FKVC1'W4E4"W"12BG1,ZJ$
M8'NI#*GO]O0A^/*N+K5+,5_S>^U:7!;FI?%,<0"QG&%%@ZN03H*C#(WO >9X
M@F3DTXV9]^]ZEPEMD,Q'>E/_+. EG ZJ9WO>>%Y>+!I2B. '? F"%A,8%V,6
MF''G8JU0.0XZU?@8&%\6#L%J\0]3#/#H> RGYR$#N=G8SP5 +L'_)4#?'H*O
MW$Q6:HP+2&:#C3X>.?BR_'5,*10Q^R1[87"DM8XB3TU11,?QTD['&P$F7^#2
M8(*)IH.>AN@7(%7W.Z$B_VPS]=U6?4]]B&O+/5]/IHC1'C\]-\\@MR\&+HY?
MRM9?([Z.S'8DYV,)B^'<XE(>'547T]9QU;"^43O!KCE:%Y-#,6_*29Q)><Q*
MB1D[W\U<9Y4)DD(1GA;/TJ5QSR97RB!V[IF&$1<+"S6$&[=-#)"8B,>H^Q5'
M^Z5K/$HS,XT0U[.(?-B'4."8A9)R79A1E]'STV'7;Z87U397LWZ):;B1E15C
M\9CM]E60'H^C&;4&XKXML!>J;$U<:"[<>%41&_AY8T&H9E2)S3)%*8MWM8=L
M&+8Q7Q3U\(]VMI@\]_O^[[J6WBUU0]'06@RCR=W!@/A10E0Z(1QG%:;$$6Y
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M&&%ZF2'.#_9NY5PP;NWP/E=Q>W;V 4\+I\3#CV&*4?SO=7A$DY3,M1^#6,M
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M?/"%@R)X3/;,;Y,'&(HEDB\&>7P/.DU%BB#K%BD\!J0):O5__W^^!+]"#=>
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M"M,,S""Q3(HH@-Y^%9=Y$$6\MAO7[TD'/6]"4K[6'X02UCVC?F52QZ60>[5
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M&'7RZ/+'-P__:Z!S;U3.)KQYR'1V\DA:&TP4IOP3@O<;HMP=I8-6&&B]Y-P
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M=)E[!2:D A]\ 9A''&U/HA2A0&Q>:+,OH1K@ADLH-&B\+.Q)I^],DOI: LJ
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MEXY +-H:]!<4=._]#JD:[VS(U;$0>R9O-!DB1OJ9U_W7R^44S2]Q.0QVUB*
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M'-YMLR62DU<4]'?^*"WK)TYH,'A]-ZN[S*:_O<BOU+?6J!C)&4\Q[ ^V]NS
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MT0[)D^D?).$FA3\?G\IW!XSI3C.UBZ"?V3.%[T":T5IFPJ$+B<PO!%^%P*T
M0%RL!V$><WP9#)5#= B_X.6VP5#,2NS9<R/@VQ)B/SX)@YF*C7L.QLO*SW.<
M?C6IN=.D=/:V3A*R.Q[F5?9G>L_]('[MU5*(6IF.DR%TJ4Q2?A,FYXI2N=4Y
M2Y;"TPQE6^=$QHN&NV3,!Q$H"8R1XH2??JTR]_AL_FAC;2\I_2>L?1!U!;&
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M_2$:PN$]5Y]&E$N2@P?223N%I'X<7<D2[Q@9"LXF'H&F#PPZQ![S]",/H>9
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M_N)6_C>L7;.UA09Z8ORW?2C2"^^!JJV2#2+;KU?PZ9X',\=7W\*<1#<)$(]
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M.C,6'^K!,(;D]C3')@AZ""W\.)90!0M\G] UTN20\"#0@XB=05[%, EL_;N
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MSPC&6=7+ .DOQ6HXMBM#XSH\L2UG=F&D=NH S2P95&K@4G"I_NG%?-F"&GO
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MI1PJ=!]EB;F3^KE"_P,>%=G&FP<+6TLMV)662=[]K<+0!JDB(GIV@K^I?EV
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M+ [_EH7&_+]67#DC0G^@R(MCG6?_?OES2X:L 2$%@LC%/RY%8OBX* "R-Y)
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MOC3*;P>7S,J>O@HL>KD"::+RWWFLHMG3?$M&ME^H]=86KTE^>?J:$VJ_='0
M8R_8-,\SN=&C5[OU&]R-+][@Z&X#$.@C2!Q81=!# @\/<Q8\AR=0UV;1+A:G
M2/9T36.CO><]F<(K[\$6GRA%W?B/]HM$KI+P/,M2XMDE(UP9;TMZ:#C02446
MA"GT+(L2E)-7%U#1K!V5I3NS" M49(C@7Y,TA3KC>$ T-4FB_^;".ALUYZP]
M>18L#H'\$G9;BQUQR9@@!]3,JD!4?KWJ[@8]_#MQSI=@\J!)@W02Q\-Y2\W2
MD!G;F_5>4*I_4#L->]2A;"3>HO\L0TKMT\C2#?61(RV1>BS'*C;7%*MYD,9S
M_JO\?_:N*>X\:KZXIH" @R]SX??6_V=*],XUA<UG<NK5<)= CN5G@^%20^,7
MS&[_;1OVS+1NA N)W!<PVB),ELW6EMYJ7K^F"&+]XDY+>D2X(3LBFQOC(\(U
M"FEI;@B,[MMLCN 6#+(RD6"QI3-=G GB%DB0W#G01<8]&QY"GJQ\XF!59H0'
MXY4S")RK1PF2HAPP"6/*-S.G"BA)S-)30Z]BUW/Q"HN(Z(KYNCM']<$6L^/Z
M]<D;.4OB1>W*G2ID47(O,V&LE'!YKD'X<854<8D]9[+A:IJ27#F@#<ME699[
M/6I'R,46BM[*+E]<8DS5C//5+X%530(L'(*\+?2VNJXI%MYS/-[)I5"!A-ZD
MG<\]CVV_&HC<1UMKV9+8B>,;U5&[*Y0AW+II%TZUOT$G'+<AM':X/4:/9Q7N
MUEQTP4;5$Z4LQMV F4^FDMN#HA43,4M#8I-HV;UWT_7 Y7+=^,E0YC)9-&NT
M>J/+(/QAL-!*#R^I]C2N,"2+Q*I"\#Y24L'>GY&]@+#_%29*G3U[[_[PKLZ&
M8AV70W]EEY[]N*9([XPD_$G0_+;N96MINKFH>DW!^5>BS)797@#._XA>?E+9
MVP!=\?UI7:-!Q!V<M08["4/M\0Z_XI7W ">;9AMI+E4FFX+9RDKE(74?:^L7
M_KIE!Z>H6Y_<_[0+%TK'-$A7[TSM^/R8DQ[UW(/*I=ZS4O?Q\I)5@X2Z,0B/
MC)4ELG71URT*RLS;,KNMM^'[:ON^",FW9VWWR&G&:1M'*'Q4/=V'21TO#43Z
M"6L?Z==-0]<:\.=TI\V^O]$R7]7YI3_;82PCC:*7W!_^^<__4E_XCGHTY.0U
M)BQ!W)U]-F1J9>;D>,P+M)0,^C6EFV70$-VJQ.IU6=%2"X.5RJJE'N\PL+OT
M%1VI2QWPK,D$873G6N8RLU*Z:#;;[V>SM,XX)(C66ZX(5-:'VP AP^\W<6+"
M/R(V^40F"E^LZ!XO]C5+/Y]N26->#W1. WY01GB4++J\J!]T=#5^+OC8M!N<
MFH?.84;E&YDSVX0<JG'96U^-8!X=:U0+N7XNE)Y=>]!;!V0H!%"K@+.? ]R9
M[_3@3/U,N)X:WZ-4(:KGD@-#UTI(@B.I]UJ^#0!;P8?EPZ;0P$R#NBUW\8;J
MCO(&*?#V^H*_]E[ 89?%U4.PU%!*_DJK@ME)J:@H/*4!K74@;!^?_^$_/9#?
M/:V1$[=IKK #ERF%.N ZX"8TJ9RU].EZ>U;M ^OL'\R4@_:WO_+RLB\)0G!C
M9;GW.ICA+XD97@56D&H85;?\5BSW!)3[4FFV#"D<UUC<O>SCX;,^ZK?Q!_"T
MH8G/TC/"X%^.2+3'0KG.A(=N="@>TJL/22+*:!/<L[F0:QBBLQ[D*%*,I#HC
M63SG09( !Q2#L(73<*DBU_&R[0:?%E@,C6[_V*:PBGYCXVXWG@Q)[S9^\2MP
M[A-;;,ADG)P5 R]7@8&G_R=7U4:&889RL(:NG,FHIZPYG_&WTB$ 0,1\.#-C
MD&?1CFLQRQ'2VM#2@#H7_66[G%C=V0[O*PF9(^S)MZ>%%Y'XTJ :6]W(A%H#
MC\?F&@AD7T0BX8:%,7XN%;NS09#IN8P-C91OTR=IUR:PT2J?=YEJ^C'1,"F@
M0A:ER6P-G0TSRG=@U;!($'XN@J0FU9Y3$!R,!;/U7MS^X+<@++#2AX>][@DH
ML^1-J,"U3[F=#IX9)?3C#I_(NVQ^N$_ "AT:&LW2-#?U6\72A7MOI$P_PIS/
MZ7O[;_I;2D\F/=O*\$Z40+DL+RZ/H3/U-[U \WM<Z(8+!=?@T'.FWP7[HD<V
M+.4A,^R/\+\CI:Q]+/%%.&M84"]K1%C5]CN;;U)*)M._X%13RM+JH>"2!H1S
MV9)J!<U_1)G_/D)%QD[T9O/N?RZLE?IDZ,*!Y@A'KT1VTI%\_J*S?[ES,'X*
M:Q--$#3!NV%2JPF4(W-(IV_DY_AUSU&PAU(S/C1:,EBMA[4?+868-X&QGE5^
MU3]WB,5FS:L:P>2S$HQ6B\:UQXR=[_E.PB].M,&V;Y')KK3IG0=Q-Q"B#59#
MXLDFJ=-V3/S2S;[UAB=0R:I3I7JS'W>>?E;]P?F1]AOGY^ ]D[$CPUK!]:%$
M]$CT>28DJ#@^PU\E6;C70 >Z63+(WY#&Z$>5MA@U?%R1BQ[-3FLN!;,B>I8D
M,;"@[\B .)(:3O@&CJ8S&BY&C8R,.X0_]CU@ZTVS88I4G8'N%Z.3]5H[6J=]
M@YH.)M^R C,AT8:[MA%D_I]D'IVU'Y*.#>9ME(0;O>2;'3%/-.;TDK9A(62@
M@A*<NWH)6D+\R(R\!)JKW85^<-G,-FK7@8=)=/4LF.09I$A>K;L:(K5MQL:1
M*1MO%]?:47XKFB#)+E,$%T\)K]\@WZ"2:# OY?S.^B5KPY'+3^X*;VN7>Z+Y
M'6E!)LC314E7?2;7=*[H2AF%7^LM)=DRR$.R.2M3XS^59S(ST*?UU;F&<=\O
M@%S)2W^FT*/=BHD^/-/(.U\P@9QJ38$",2J^\HG_$R0$8' E1;:VII_E:W#O
MKB>].O4;0#5%@_]&2E+MPU.."YV:.5^5655)ZRJV" I:#&H+# UGD!3CYYM]
M)$PMD@-,=R -F("$TMUS &2TX+?;&TGQ/B_A_5:N*6&AC]RUU -<[\)3! 6M
M,!4=4%2FL] []VR&X0')EVKB3V;KY/;@=VECW*5"J79"F&;H>[RN*5Q 0:'%
MPJ.3ZCZL+4O:O^_UZY=I(5T##0944A\%%<13.-LWR^0\F:Z,/R_Z^FK*%1/_
M"WFX3)Q7RM<XD1K.E&R;OT'GJ6KG:Z.%DPWC#$3I$9T+1YD2?,L'"]1A%55?
M>ITTXIV309^74@)9EGH1WB#>],/]RRXAC44_K(L.#JQ>]MF@7$=;WUNGWSC_
MZ%[9Y&\[7?X^BZ$A=\L!:G6S"L7U+*X9.2D6/C1LRI9!QL^9OQ6PDK$\"!4M
MA_Q_CU2:J_V?Z?RD827BM[_WV!W_V-'^#+UY3?$C \MQR2A)>R5E8:+9VR[:
M)]\9+K)/>O:WRLEU,RCP-0Z[OPS42D>/T"UIL&JQJV/4JN[>,_2DAMC^;\?=
M)G0E;O;,\M_>C.B T.N8&.\ A@0*2F_S ?H! #1LT!6Y0]:<L"O>N;Q;Q+BV
MOYZ2E&)IX@_>GO,-";+..$3+KD_;LT:@@DNJLI4;Z5__-FW,QP#E/@L":B'#
MV=) W^H.OF)"TL-=^)]Y,91=X\?9,1IW0Z[!$"%LSLV(WZ,)HMS6AQ/IB<(5
MA9:6L6SOW?^K>=ZFS:BNE#J&P+$959-[&^HR<&VWMI>NLK75'G<'A1(O_/2I
M=9T<N#O<UT0&.7Y\E_B*KY>WMUK8*5><T/'9^H.,,YD3YD T/[\4KZ>T4]"U
M\&3$XF,.HJ9-MPY3UI<*N X7B_A:;;3%=:2<+>##R]_6BUA<%UNN8DIO(MHJ
M/?SYE^:5K4W*LJP<"X6YN?/U+0-Y/JS&W^@R>7>>F;?S$Z:L<.6]O#$:?EA:
M,1[(GDLY6IE=('6("E7JR"U\^2Q2&QU>Z2:49/(1,RFI\\7-RO7FHHW5O'FA
MX0H#D\32G:/_ME&/XW2R>\4M.4%" ,G+WGEW^C=C00WXMKB1D?",]#HQ:J#$
M0_-HSO^10'@,&"P&8",2Y+C$'G(F .[<\_[/9>SE6BG5AT-77DTZ U/XH0XJ
M!(0L".)9,-'A'^1E8')T#NYF<.GB?IMT*695;;K1$>N[:'^U)>QGTKS1>#?0
M=V1JE/-H(859Z[TZ%2N76'B$[-K+A[)KZEH_*=6-*8P]JE4Z-VR9=VP;&Q)]
M2DB\TWZV'Y>%IE:)K<XXA4K6(!T#RP6=AU#Z7GF32+L26$S0.,V.N+DU9.>;
ME=5.(YVJ<H9P7Y8_XT7X@FV7_"GK[8,BATJ..UV\W:65*$55G)+$JVF:Q@0W
MT=,?:[.''0SF.ROXR%T@EG@[ :X*YNU;NF]+#[.97 &VX@]0D7 /+ZF926)@
MQ]0NZ)//CX:MCTGNACIM&@Q[NG[/#&VA*&%MX^>8]HU'B('[[F9;S0Z-PGYE
M80##BOHL\!#;I$F;@.H?P>4AD173X/"K[4NJR[EA<?*O\0+;[7<J,>2[Q*0>
MT[E#4B#4%2Y7804K?UF3^%V%CA2 '[L(]N@5(]J^1D\DE%; 5690DK"C_#B;
M7TMF%:+<4Z/4UKR?0B$T5+WLM),DG0KB<]O[*Z[O9+II'VABS^<P06>3RL)P
MP)3RDP'?&M=W]\-+M13Y,(7RL_4] "WV1>$V>DHD6^,87##KE>)D-S!U.IR;
MSZ1G6M?GVW:?>G=%,Z(^;G6+K4NV=5 8F."'&)PWF5$?+;E7XRI E]F2*N4\
MR"UB"I8\[XC\:6L7^D[Y._F: G%-8='F@&4Z4%L]BC7%!(=WAONA:*S^?E0?
MU+M[W"+#;@8MJ!*!W/S@\,8W^_GN6/=O?8\GQ(!>$_87^%_1#+D K]2,QU:)
M*K57M<_:/6Y6J%!55F7V76CVCM,-27I$F9"?L]Z/Q1]UDV\2].IG+37P1=T[
M(2(S%:3@$@L0MMUEY\'V[P93L>$*Z^A]TGJ3K:R?@,%%UHPVH+G?V$7]6Y^)
M=])6*0-7&FM'32?^FJ+SOO,5^KU^W%7M1FKSVP+]I48 =R&;[EGID4?LX,(>
MFV-[O1^,QP_#XO_"_-E;=W:YIZDV+ Y>/0//Q64(_'UNEBM?O*!^@2[LNY-R
M=NC6.OZW4 .07$&2@@*LH%%\?M3S-V,QI_L-_.4/D\>V/:#H949B'@YJV\,J
M,%\YF[$*BEA6_.B"SGRB=JG;@WN2T^YY?NYI^0_G7T<JY9<'*'%%:+W]M+0X
MP&(9^*!_>>6OC*F[IA@7)?E>4X1[S@S7P"QRANIY=<&&N5R57"EKNH7<4 ?\
MD+!469WNJ&1C@@2MA2(>/@&?V(QU/7=_:%H+Y?6#&DZ4%V=NNB5Y2K9"I,.L
ME@)\*$<NHM-F(6:B%C>3J!R#^G)DJ^Q/6,%YYE:#Z3_AF_PA<.)4R2A."ZY4
ML@"#F!-0$55H6SH;UQ9)>;> &[TAPM)?%F"&.C/3@^L6.RK.TU*"1-:-CE%(
MF<7"LF*UM<5\-+G<EEH[KBK*>"),D._-T)!W12'UQSLWZ7YP/J\ 8&%2M^NM
MU7FBA=U9'8.5V2!VS_SCLZSR7WY\7>L.[G>_PQWPYMYDN'Q*V:N0[FQ=ZR<"
MI2T&;9R4_H>3,5"TJ$MVEJ].@4!MN)DN^V3A(_169'_[H7^K,O1Y<R#4=VDI
M8S7T5@@#>.7N*4$DDU5][9IB/S,3"AF0:<EIK'!EQ"04<"Y;;;]3SJM865DV
M<T$JTBAEZ;"5J3(T=Z3=;/<5O7#$SP[_G4_:R:\$C4(I'?U98"(Z\-A:KK[)
M1RK+VVJHG.OPLWP89_RO9P!N']NGEML75S/9%WMI#9Z+.M[JS767"H%I(U,@
MW\<6K?W/T[;V)_\[L3_TX+O[0\N>X;=-4HY-:K'FU:CRH,I1ILO *4HMO':1
MW1*T^XOZ"74C963A6N3W-_CI:F9YNDKCZ2SPJN?/DLBB(Q'(U"?W]>7&J3"Y
M7J/*80&T8U2YW'+1.S1W5+F,+EV,!YW^4&%JX4SA:>,HZ>32X"]5)Z]V7@K9
M4H>>/4MHJ@22@8G?/2XN"5OD?.\YR/];P>Z? %*LDEVV**FZY J\4//G_/]Y
M>*9-9<VX)"X^(K4<YF$CKYQ9M'A[9E*A5)@KM<JYL;'>>R+.6N-M\@_IVMIN
M"[UC.RKQRW#/SH<'-+\_^K7JB3NRAG(<NC:(^V\1)?K@[M*YZ&[3\"VF_0U)
MK,Q='\/_B[4OCV:S:_M-1VU54]1<M$6UQ@Y":TB>5A554M0L\J@J$:&*"D):
M:J9:BI:BYC%4B3&DQ/"HJ@JB8DR4FB7&NT0<[S>\YSOO^WYG?>NL\T?6RDKN
MM?>]]_Y=U_6[]GWOZV?/MN^E=;==5*G ^&=:A656MO8FY<@MR@@7"%U8Z5[I
M&DV.RQVV&AK*Y#=RKS%WJ]ZP["Q V"/P*%W_?;617TJN&F*>"!O:T_712I5Z
MA?0)O?U?!HU74 RK#+9(!$F+B67V:M_XLSYNE/O6V4ZM-GDO,?%7AK[%$./4
MM\966E9H;&AO@1L=L5Y%N^!X5/O*9T3CN?D_!E4@1]RYW3P<F4U+8^&\)PEV
MA+DN66>5W(AN[R<IQRUE#M[[4)DVK7'@RMWU!]*\C81<8<OBN^J]W>)P+Z'*
ML4\]:HEWQ*?."=R.I5[Y?:]>KS(NMS(9*.PM+L#>OO<XU2O-!+KF(M9^GTG
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M54AERB,[712P-$>?E:W(0_F=>WGH8/&V&^EJ^LU\#7E?.=DYBY9V2"%SY<L
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M*3A<W*/$A=--B6< -/['4ZO?D^#TGF %V ;/6ZZU^9K,/[QX_FM<FB//5)7
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M^XZ9^JCWYRI&[;?;6/!(U^$49V\,"]EFE=I>XX)A>O*YQC#)1UI]\1&#W,-
MPV0CK"UQ[M'BPEI)T=IR2,;5JA2*AA[1#EV9)\:K&RP;>^!K&8=GVUWGA:U>
M2C3.RZ5@&&<PL-Z)@ZL7Y,YE0 8(R]K0!-?'""R.8T2MDKQ*J5>-DE&GAZ?D
M 1EX'C1_M^1(\,$*:O*\"?X!D,7JFSR8>4K;BDGF=9,6.+]G-S%J\)  _4@,
M1W7RMYJ+YPFLDRGP(O@L':MA5$M;]-D%'<,VK2#LFC7&AVWO!P1G%<ZJ;RVF
MOZP0ZM+6@%:PNC;"/P'QDSOXSST,/F2+DPEK/3YJ31+>*K+!W\E<E)KU@62:
M]5;-^+WSF=?J#O[28E=;KN(@4?UR_%Y-WZ_ZJG#\@7Z\>[GDC&8&,9" D])G
MI83C7-B9E*V15/T8GQB"!4Z15=Z1JO]"HH,_IDZ):;D-X=2D9 A9%_0O/3*5
M#/OVO<GU$%Z0H[U3N(X\AK7TAV3RH\8N21^J4@5C$ZU9&T4Y1F5@(3TVC_'
MLA)$;&W\)/8VJB"SA3;=T9JZ&;J^J, NBYNB/?=Z7%KMY^O!E0JF2JE])^DY
M3AK!(S4]HXBC@I\KABEY. /6Z!ZQ;CQ&,:D#[(H1/_0/MO#=7F8>?DVPQBY9
ML8,S\U#LN8_9Z3?MNNSBA*GCA6SIQ?C"<8[T3KYVX$1\1/UTBA_+<X\3M68*
M827V+#X1 :#;-QT.-K ?A71O*!HU*G#/:.LR4*WUNDB[47@!G%=B6S$B61&O
MW$MV7X[AFX3MYUP:7(.=<&V282-;P2(<G0%M(R:2URU#K(KE3UV7WM?-B,.W
M0R5JV/%1,M^72!8%0,+>/6>(L]:@%_LG!G$N18 *#8/7C["L#P'QE7A&D*N-
M,V-\_@+'X:R;A%@C4N?[< H4TX_L0],5!5U,F$2D1 >]*6\R[JPGA#>3UW!B
MQF?4^SZK(V8=H?EGC:;U1YKRNF'9Y7(N;S#MH^LNZ-%>SR\YMSW+3%X7HS+.
M \\=2ZP-&=WP#?_O$#Z'J0>DQP7F,1OQE63C*VO7&ZA5-F5J.TK#6)/)A0AO
M)L_B1?9>@$MIDJOJDV'!H]9JFV0X,!8TG1F_'W>-C8R3H4+&!=!2U^""V ,F
MWY$=4E)I3/U(DC*C4:1%,[RH=-:V( *C!$G'F_>>I^;64>_ *EREJ[@$, 4Y
M]*M=ZB++UJ&;'4[KX0H$X2GTV*<9QUE*":.HI_M7+>OZH0-^CU0]U@T>A,+K
MSTE(_*5:U;7CIE6H;,SB<63!]("L/&QB^RI''ZJ5O+0+,J7E;EN6,./!<V2P
M/#&F3;,8>Q<K2-F(5Z]@$..;.XP0-_=7"U<:[!M87,;=K-'HF+7EL",VV.&B
MI6>0X1GGV*<VFDY0<5;,(".30!T%7CF:3^>ZA.B#OJFZ@7.5X?XGTG/SQ@H(
MS4<&EB>K)/H[U)*T];>=@8VM94H].*3I](U<@&+*'BU_1C+<0]0I)"KU#52T
MH:_IJBYKLI4>JTE[5_9C"%U,?]"X]-K%(_E#9]#Q31%CY3?UB,\\,]U";)'G
M9'=!)OX8 IO%.>JO_IS1$U;/$\LQ9P['^5$R3G]""F,CFN]A^XQ8OA'AR[X8
M?1N_?O<ES*+3@/)TO_N?3;5V%@G+7Y(M*#4[]1C5\*0-U1=0!=Q</4\$QP[R
MK?&#C3Z#SZ^-+.+!/0HX]$Z0$L:V[4)V0>U1?PXF_J#KG4_)&8>L=Y/?N>@0
M04&K>L$^@-'&)*WO=FCK+D@0*@Y]GC_7),AZ6N*T%\<MJ]B'OJ4Q88)8<%NP
MVJ?OY9"KD,:FK%W0T:M8A\G;K)_5U:]$B3$Q?%=81MZ%=L3@B&%#M6K:RHA=
MFE'4G]&&B[8&TVA4!@2%H;M&19OS)L=VBEVN0_QUYY7K@5_@?]]VQP\] !S_
MZZX[?G \7H<\;9Y"_)_K$-=PC\_O@NZA,J_'[8)>[Y$U*?.])C]!N\J?0W4X
MI]DUL5QY+-F,M?S,I* 82&P9/Z:6&9$IF+P+NK5'+L,03/AQH._^P#I<6"*F
M9#OH:1^7?S@P!N'L[H.V>T>ZS2I[_?-KXE?!Y7H@9>/5SH=@&8YF'5L]D[5Z
ME[HTW0N)'QJF\!,[PCVUK4J-"3A7H-%QHM&X:G2_M!!PDP^YK=$R^&#^3F60
MMY$@^M.AAD8[ ]OK4.NMJQU0:>Y?9'Z<XB3R.5=U -)H9<8:#X->Q;FR\XM8
M(^-_5&<<KP3R)LKI)RAM 6L!K0$Y<&8\8 3!"^ @H7J]XA<B0I*7[;G=#VO(
M_>+C/;[XH1PF-XNU^5D<_$+[4! #87[C(U#"X#O?A_0\#H3>85F41P4K8V'M
M&1)L]439#+6^9<YEYA&U(!5&-OMIIG3,^>@N.)FUN/1,%<*GLA9 ;HD?YF$B
M6\F1P0< 1_77$\LGT%*RK/M-9P<@W4ACFK+/#,>(L3?UDJCZ<4J#EAYMZ6"P
M%@T>4;7HQL>W+O'6!WS"E0MMBC=EJ]4KYWIOBO<LQO@RR&#<&;9'#D.W:'87
M=+()C.UJ\[,]$7]ZL724<Z.7*\OA SP9.Q*&#:C\ZLKO1$ESYJ-*N='N14+_
MQ^'F?'O_KI\CND_W_42>P+N,TV4^LW%6=:S%MNDPO,AGO#"6IZ7^1=P'5+ "
MF]S:L L2'D,'B['+(WVWP0)H6I,"^T24:\H"]QJM:OSH3A$.(?0>>CK$2-))
MLG&9(DT/;7D%1'#YR8*<V^R@ZAQO)AP\3)__FVD,^!8 <%//B)HMC_)\^TYO
M5"%?H&'_$E=6IW%$/"XB<JFJ4(FCXUDV^[0H:\3:9RME<?##3#V",K<7R:%G
M4&/R51^IOC%DGA$^[;GJ+:F&O*$;N>@5[2?7Q)4W6\66F\3;GCH*\ 7>S9@E
MM+VG;:]ZD#'&WH9XP7G-FA;XR1L?9FS!%*-%?</:Y''C 9(@+-(7'Y?J$@>)
M%W/KZ_)RU5;.C0]+[IO53"I+VJ^3M^JF65JM;OZ[^H]3P0?!=*EAYD;8!"S2
M08[MD)4+H#_7.$#9R(TPNGW;X7*5"J;J04"^.36\DF^IG&^$7A[&[,.A"X=4
M*DH[=_(>;FYE%/D5?MD4P?V*\,$/F]\=6%<]Z1;@%Z/JT[ L.$]_SG+#_KK9
MF-$.Y\==9X?%-6:D%\^-R22,_:)D2+.[L(C%H7.L;YD'--U2D>$$Y3.-3ALN
M;9DQPF0^M?ACZ%F>C?271*:RT5U2])=K*GG)@W< OTGR:>-3@FG;!A@/62E^
M8?;(QT8+_UNJJ$].>U29*[A#6)<60=<C7[@W\0$A@VVKH_"@LIF:ILLLG/"8
M-$O;UC,4$LEQV!I)B<IW,S?.!R;OO 6>?$,N7I +6>&-DFFK2CDC+0$<GMQ(
M N+8GFU-QV@X.!MO2*;B;DR,@N\W5+!UQE[GDY^1KD]F1GAQC)J("8I_*7'.
MEG;EV(_/TB6GD_ZL[VCENP[I?MIG'AAW+6RMVXCALEB)VL/VK*UGJZH$R8_&
MY1L@>1?V,'FE!8 R:?XAP)NYE!:$9L1E*+/.#<T>0%8!%XO1F@\=SE1^7S\]
M[R>2;)M'6(Y24FU,@^\0U^:7!6?$]W/DV-F44CADNJ14-R@'80MXMPAP[K#A
M+8LB[>+DUV<-%E37RWG0]*3U]S4G$:ZI0I\0([\'K\2<&3_!'0YPB5118B##
MI>0JB/!(FL-!ME2#;PEJGE'.9S,/%6&!8[6O,P.[[8?/IIBP3\2P172#KC7F
MY475A6\=];W/ T^\!UJ%G^(([^3C#/.QA6BH,I"&JU\JF0P<6NN69J)8DVU.
M69Q EGYDL%@;XZ\J8[,OTF"X'ZL7YR2<A2D8EQ6Y!VF**H$_KJZ_]1C-<010
MV_J&;*M)<'0P.%YTU@JJR(*FY0-VUC7L_"0GQG4)$T"?+7(G06+TV+RIQF6@
M'2PU!DBN23Y9-4ERK[8?;<-C4%+9*GX+> ]199_A(",K ,U4UK]5P0J.8X+Y
M@7)CTG<?@$#TY >0[="+WWT457E'W38#2JGCPUA5T\J,655G8M_2^2K__(3K
MTE\&!L@8- S,$9<67<\,IY,LO>>XU]6EQ*MIA#3K?HX$:_-V+8VC-RDI5Z:V
MC5U'W_KXL:D^1-$UH;]5F19T9__RN6?^RY$DOFU["I,LT,SHUNT(;8[C"5?3
MRD]D\A&7B 2LN<D@5W@4B#=CY1?AR_6E(TB>!"  &5UMN:D.E:9")!0C2]^1
M3+V]-"(FJ=I>7,E@:LV6? P4Y"H2?*%RCT,R(MKBHP8MF\X/3@SD4'$63+P8
M#KZ7/E#PH'G;@;COU')WCFD^4-S!U(A,[K/(6)%$MU@:*@X?E3**+X,@Z95M
M5X=1]>6A7+"]6Y/D0!/$&B=']26X=$B)4Z5M:HCL\<A@28",J.E-L$NW,L$(
MM@:+]S_H(T!$A2 QR/-3*LKTA\^F9O'5^:]H<.? B47;7VV7K>?%24\7H6E9
MLUOYK]%>AU.RW83-NH)*KFDN1_LB>)J%A4V)4QSNF?YC%,R9:",?$&.88;5X
MHY22HU\XGW&U%Z(XJ]S'/$S,QFYTF/3[(G2- "OVTIA-%<;(!*NBA),OQ)D/
M-(F,SXCKE5I::3Z*V^!%MUE2B2A$?0$%3O\R]VWX7L6@MF[N?/68!%L^TB54
MCQV<EF>#A@FD+F\\X38CGHX-48?-^VS[;@-=IVDB![;/,NM2)6HE(;R'="PS
MMQ_-I9)?$PQ9<Y.4X",)XPSEGHV!Z0+GTOG;RQW2@B0CUF9K@!)7JKJVKZ"*
M^R6EA1Y+$R=G7G][(:FJ")%3Y:J*]R!6]2W^P FQ[W//U(5R!8ZL'62[O !)
M[4]A>!#8 7UM"6Z[(#3Z8&TM*SFB*)PU++UH +GVH?H);?/IYLM]F^M";(W6
MY6%A51X*<YK506FT:WW*/<T*3\-!YKN1AM0U@./%)$?8]K1Z'@0LY^\D>Y=V
M.Q;.:F)J-FHBE2;1RBIV[:&"G2@L;8\8X=0'M W+<%"6"7%2(E "+N3&%?I.
MA)VDST87%0RC1;8PQ &.\)T:>FJ,=9E<PK7+A0X'Q(M$KOSR!RVB_R>G&<I(
M/-M+(EQRW]X%K[OB_OTTP[M=T*S2__49)ISK1_X9:/4/AQHN?<&/7 C8^VKT
M>E7_'[1](8'(=@S4M B5^M;L00)E(2PD08BP].C5TI^7ZK9M#QT,:4W_P(AD
MW]G6SKYCX\%?0(1:_9R\J%?>**WZKN!TL!P$W0U[DR6<V7TI.UJ1>FU_](4/
M_^IS8O[OC\1@.]I8/.S7:CFAY&?FW]]\W07]NY0A8$4;8-G_K?21V'^6/K)1
MW8[%_UOI(\5V;1MF?(@?5&$0>AH[BA/R8AH'M@3@4N,C2*;.V4:P6 Y$*>-,
M';%WL73= J5M)92&$A]=2%6[-$:(]D\Q/OC@J??"^BI/F^K0IW$F/GZ"'388
M\Y#J\]N1=4JS.I$GHFJ8<,=K#XOBFU%JY0OE O8&JE7.Y";:5_'2Q[KG>EPP
M4RJTC-M29^=/=T20]FW+8SL<^K1]G35"?Z4A ?]\+!<,<JLOB\#DVP*"K5*'
M*UD[-9$0U8A!]T^S7*F4SXN>.?8V2+OR%XN$9/.=3,GEM">CMQO]MV5FF\19
MN$VZW^=N.*7I8E.O#Q@T-%N/?$9,0_(;%@(=AGVE6:RXN%SSMA*;6:[BP()J
M^<_>R=I0HSJ7_B5<D0P*W=:S()AGC_48;[':!0GX'EU+,P;94+Q$PJJPZRZ#
M?0S]<"A_&]XO4'8EIOP$_@$ -^DOPTFQ^:#;IK5-T=-3"S^C+VSV+-B=RE!L
M8K\@GZPL M+:H,)L>"QF#Y)\O3_["C);I$^M@:,#+ K",%-UR@S?S'O?S_1!
M)-Y.-65,7\\TEX"(3KX"!7;OU"R,.Q6B4RV+P,V*QE:W6"OV0*(Q&;Y_>$Y<
M/TP-(4>Z+-E>X_)8X!><M9&8-:?*^)G,O>8S+*GPN^I#KZW]6^D>DO-$SQ"Z
M=>PBB3W=R.S9-[L5'[I(TBK%UBV0/!G=TG?#>XF;;)<P(EZT0_*G$UPD=9TR
MEVS;U9,W@EY4:/8/++;I.$0*QC-W03\VEIGXJ.!S<U*7V'KYK[/07!GVMQS&
M(DSONUH7X8X!"34QRMN\J>%P9F#I9D^A[0UG1QP;&^":.E V;E*?RFA/<A%-
ML=B)P"GC2SGZM =L0<A@O+8>TU.PV:_(=GZP/B5B'2R,7:5DGO0]V+NTR$$X
M8G+.IY<";I]G4@(.9^:ZJ;=+7%Q:6K;MZ*H%;?%85N^DD_0#B[&!]A$3[0V%
M(VZV5K$0@J %_*";5>4>V^]S)VEE 3GW^SQ:^SH+Y[>N]54I*]HVO!B9J_?\
M4=5E]&Z1%*FH95^U\_;/:G9<3=09@)\OH^90>"-[_[@='*2'*:;/VK[8@KXK
M!9H4)RH<AF?I96G>>4-NXBV=0OE9CE[.!WM'A@T%L'\KG)J[XM!55-Z&^=/-
MTVG"7[X!L[_CRR#.=,(H_F!/+E#06O_ 0241FML+7-&2>.<C(0WN#'0L+-5\
MDT)%J0L>6<8_,)8Q_4C23(F'Z.C:-PS@#I1U%:F\I<N*B&<^)R'9WFU?:BX#
M@9;4]5M]OG:9,?1&4K6E;7?.4+HJO#:<,;1T[C$X>QW,R^%)NT_J)R+!.+D4
M&[9J^,(BA'=^1[5YN6B>RS_P\R-K-*QQM+OU\/Q]UE*14JI#J,NI'FA:H,SL
MEOU^2[2KXOO*0?(C\'';>>Z5WG78<_I]!TFVR+"V7OE,3?!^8J(1.[D$7:S+
MWT^4$'-"(X7F-NC?*C%N*5<[2N8NELQ=NG4><7/*>37=:L.@,CU8S&X&"DFD
M/)7:QP)3\!$:R<(94C4-50,D&&N0*1W*E4$5%2AOY.FT1\DMY3%$USIK1N?"
MAXV:7MU:]L4<_[4?_B/'L I^I.<#EHG1,F?YQO]8^$G:2VF+4+:A(RBR\!KB
MYJ9%[YCUF8;&%&.@KC@H]>DK0T_OW*'JS?"E#1'0AO!>B'GD*3V[S)1TQTGW
MISFPEI]#SZ,O TWCS3EV\;<ROM%_?8;*LRU>5DG<JQ!^[':2\L%-LU[^A_-[
M^@^XQ'7=@3FG"?>MI/(7Z_& Q54W[O6/ U,5+%HN[MQ62JP:6>P+1"? R%CJ
M9QHAF-+FC7WL)EY)P?AYEAEE!94MC$+?3=]8H85M'\!JZ3G?9CMS"P1<@R6H
M";_,/C76-^KW.@+H0VN/;;K+.QDQ.M*6\'#:;<2504I%)S_Y_K9/21[=/Z.#
M[;GQD+791A9P:Y+I)^[H&M0.N#<=GZ7B'_WXD=9EI/I"ZC(0QYS)KNC/.SP]
M1+H5?&X,M>GQWD8_?]C>+J=3J>0/2<FV7=!"9_%,QJG AN7GMBD1VLI%8S--
M1] Q9-"8:X84#:>#VHC3-V0U&,HF:UH69/WX$1,SS'>AV3>?/G2T(%J4$"H#
MV\/X(VD1N@.*3$?NUX8[.>>.SFF&/6L$\*7TH9E@(5J:&;F)5"TPTN:9A_5N
MO;NYZ6=^SA8EW@7Y2K4;2_C5,KPA155]F>=;"JP$QIGL@EI2=T&AE@B-EE3U
MQ (ZRK:@&:,[08CK%W<WZQ:E87R"3);O-_7?*J:_SQ\TQ#*H"YA)">C9G5@?
M'?@]TL :3&P,BS2KH_DB[.'Y0.!MZ?,$5AK#L\6N\<I-X>M\N5OZE M+J=@,
MQ1FYP7(HQ0OEY>3H=Y*GE\O#+J T.MQB15#F1P7FC5B_PG!7BU!>@(T[<B^#
MMK*PVP:?4(TH6TN@:]>[/YY)4:=]1Q$VT-;*S.A+%0NF,P.K^I^EA[Z-3]Q*
M3;/!5F^VFJ*%ZZD.;4$/'CPD#7#/8W=!S&L9O$7EZ[R_PGLY>/\<!8=1!_L1
M2@%]W!Y!_-H7NM8($OI7U9>H<YQ>%IF32H[>6R\KH&@75* JA'> B6_=#640
M=D&.0\A?L5"__TM=)HM,P9D,,;9*:)&KU&7J&L*38MMZL6".KA^)45JN"KHM
M\2[[I:+1L-9: I7QJ,[54C3OMO)CQY6.M$\E6'GNK9XC>PU7?,#/%E/KX+%C
M(#*0SEJU9+U,+*:[II)2RT,YNCESMF%OZE^FGZB8B!<#\.U;]S63DAJ[TUNW
M,$M9C&&TLAZFC+ 4EO1U&:-@4O'QGU_SW@7EYBA(AR$KU_-+&+30S\ACRNL$
MWAO]VF<9GHI_L$@!R>\8?5)9+L58O!ZOAPIFK?=4/9&X&/?!^O7Y?N8[4.JB
MK;(? [_ GO1RX8GD\+$2VQRL,4]:E/?"8]E'"R6?^:!CQI8#'G^^_VV9ZIR4
MGR0WHOLEG/:--C!J1A>*_SDL_6.RPPIZ-602P98/&3>*:95OW\J,<><H] )E
MOVSJ@&:V.7.<(\,5J VR1&?RN5:,8C>&_QBTG3-:)<P4X4^=H]G]YC1=;1MG
MP;O-*"V:L5)\-&T8P2T97SF6QNJ[12U;]$4<52;9,<9#Q?=@KH4F\\7HN*F>
MF-F"14ZPA7/*YEAS6R9%CR&6((0"7.[K29O-.[/2H/*PGCB"#SE<O 1 J/R9
MV:J)R8SPM4N_\ /(AXG!'ZDJF3&Q96?896G2D6:=$CU(03IAS12/*MN:5MNY
MNF'-JGGAH>WBG,4YRZH)@]@]!%X7SNGKLI9"3[T"AF^E4,BL-W/55!OZZ(WS
MC1^ U,D;J2M;1Z9J/]+*JCKA2?YJJBOC8>2'X"C-MF?BWQJR =6[ R1#!N^X
MP&Q*O;WM8 RQ03I"6HQ8'FTKW B9CBJA,# \K0Z*< &WZF 9JD^)W0[8*+7+
M,$W?\30]KL&H,+@E^.H@S(_ ,6;E?55'@A.;Z6:4"2>!+AWR<Y(BPTB0T Z!
M:):E80(G&D7,'?T@[7FR9L8NDB/\UJAS/P[,I^LRI!<VO0K=-%O'^ 'O@KD-
MVX@P",';JF^QRECFO@U'R\^Q$&M!;+S3M3"8_6ULV82ZI+2X+&]G5U!1\2#Q
MR%EZMWC/1A#;.)+]Z!V#?' ,M0L2\NG6;:T)6!@3K*DFLBTS ^J-,W+^%V5O
M&M5$&KT/QG9!18B $ $A;HB*@ M+"S%1$1#3$ 79EZ@T0A(AC1")$(C*#D):
M$&BA 1$!D24*"1$(B1"65II]DR"$)"H[5)2EA! F_3MSYLS_/Q]FYL/]4N<]
MM^K6>^_SW*>JWK=>$>IBQY[M@AYY49-M<L;HK4F8!6W8$!5VEN68?QJS!L7;
MMOB<D#SU,0"8WUBETO-9(H?'I%%HLT5#QK?"<LI%%DBK)-NV\$/']+S--B"-
M+ME_'RL"[PG0;]\,&#+6#(]$U \'W<D-LBRE_GXF#*@6&O,L%U0GLS2HRI1#
MPOR=TW8;D.UU2C ?5C=GOQ0I8?X;/$F+T&O(RXD@CC]CQ/05$5X5T*ZE?&K7
MJ;<ZJM! YW$?NJQBDKTI<*!5"2H"WU5)RI-?DH,,C46_#J;-*Y;9WV\V((AN
MOB[Z^AVSM<][O;:RLKV<CFAA8QO#Y8TI]14>NTT*>RXUP,S.8!(\HBJ$R= M
MGSY-FO%OQU=,F>7OUEH6V>LJ::^=DMH2B_F"T?:[@:1SOI>'][#,M:QR@@Q$
M\;,$D;&6=!]-J!_/V1_@H_LVDKJ<VA]T)+\1^#PRXB:]*W%-I=@7&#W>7_=H
M W)9SA(;D!W>S)2ZJ:&:>QYLEW1-T:-3_KLT\_368\1#AR27:F0G^TX0F<EE
MN1X?*A:U<XY^[3^T_GP.B7#'\4<'<TKY>%<MY0*]&%UUR2X7<Y<LELL9KS%/
M+^N32?LW+>K0>-1A[/BL!S>9T;6-H@E&[KL&3[#H9)5,CFGT8#_VS1-)</"W
M(/^:1\=T H.6#-8:*Z0M1L9!?C#=W^<]*^L XON&VVV\/\?((<+,PA+R;EL1
M5]$JI 0,$O4U79L^75R@RRVR.A&HFZ(TVVHPP(V]D23R2Q+_>U_5')LQR[UU
M]LXB;0]XT[3K%VZ\U'_<OX>IF"S8_'DF2@_@)G"%6_HIRG^289Y#INUKN8<:
M^VQ+[5\+W+S/?:L@F?!S'W"3VMWKW7X8<6^.WE[QEJ 2YQ'>0G=2AS=#L!OW
MO>L%F#GCH'LHW@U UI:2/=UZBB6G>HD<=2\O$&9?Q0(6[UV;_E <F3GF?2WG
MMYHPR$P)Z+ZVWYL\P_MOT6Q=-W_"4TOV3(B%(O,+T44$#,"[T&\R%X$!.I]2
MS(V3B2:CBNAN(E.3?:@ ']_$JHMEK"Y&Z; 'F-K)(X(BVWBD8EL(J8*3#"SS
M5SN_&^_&PU;,M-2+9/FOINO^CCJ0?+W?Y]NOE8RUM;F;A0/-*X\4GY%469=R
MGKRCB,NC_N'G%0(3PJ[H"LHU823*";!O:Q4&A^&$&C4]J?D25A,'!8P5$85S
MIY6L]7JT+Q*U+H3<2 XQ;.BW(/ _V[SX^GO\,XG"K%/9M%R-[5X(W8#L 2\.
MPM7D;(C74H^1:?9_=@>K,7E-$5TPP32ZO*:46#K+2!O3,;Y2F]P4GI5--.U2
M&O-F]U[>M+B^T"@8GO^&,S:%QLG3L>1==..0[B^9WQ9X2/4T-XH"\2:<SSYV
MN(JO@5$:P65=_5GG=/(-Z^V[Y% [XO&@0&XT<A/9BC=T9LI'";Q_\_EDC99Y
MXN],8"(NM*QG:VJT""8AQC,C @TNOJVKK_5&M;C014I:HMY>G)K/PR7M@T0Q
MSO;CJIS:K43YN[VFE[/DL3 ^A"JVH]<FV;2==B\)YC+]?HH^@.8-Y?.["O&#
MX<[<6.($:'AG954W_F8)HLXVB91R4/NO@S75?X:[)*^9@8_:A9A4))0]MKG7
M)%^-<K8!&*4G+MH;>.:[)S=''1YB7Z.3H[L""2[]I&/28S=#*MO,4DJ\9IP^
M,Z6KS"^T(*-F_*;)(2Y$MIF<.F-;U4LQ%QH>!5$M2%6)\_R3\1&4,BX_D M@
M$TE033*2U]SSR>W<SUX3HO;GSV 5SSXI$GG6]!\_7':$9<J5CPN35WY2A?JS
M8H6FKH1P&LV0%&CD/X@P%XUJN]:\Z1;W&9EZRB4UQ5FBT$P(]+S&3KI'&%X<
M"0RWU_'XJO=L^':MW2V[?S=/[X3\+%DNVH \T6_$+KMQ]E*GK72"/?*E6? '
M@J45<=?ZI:^50__G .I_ S8@_S,BZ_\:09<FW5V:^^G:_U7PW6 #PCI#7S]?
MLAZZ-$GY]G_?RXIS&RSS7S/#DM.]JL &TOAZD-BG+TH+]&SV49!XA=]CO>C,
MXEAD8N/X'+JPO0Q=Q*K3-:[]+B_+L?OWENVWJ*)-Z]Q;$-3?AC[F:Z!N+X#N
M@MT5;&>S N'3[A(V>$I.+0X5PJ(!DM)%:K1\MI^#T8$!62DA.M53=1U_YJ.S
M^<N]7_@^>A6+OTE>9G9\;^O)RR$ ?>//^Q8%BI-YZB"UF*>15>A-OMMVOE=J
MZ1]2[$8.1W^@G"DGW]7VI S3H-[X+%:X<I'O;GNS[\NB"'=5=.)O&49(+<HN
M[ YR&"]O/[ !>6!*5R:CFX9T]_8(6ES&X .J?;SPYI/NTYD=I%<V/<G8W371
M:M,CE'>FG@TGT!9VAFE_19% JS48/):K3CDKV8E1QXWMK^E.^S8_-B;B>3*Y
M/0M#O#Q]("B_F'S;(/*^B39463^>C3Y06\/I)2DR&^(N567R^>18.I2TIB6U
M[4VW8?91K(&)EII5^Z%'BSK*(RU12N_J>Q:YN\CFU]>?DT:\?5NT_%I9^M+#
M%AW-&Q#-$[,>2GJ,5X%%/9FKP]>]KCQY$/G,7(YG#\T&B46?0;0P5.,D^0I/
M^#E3;0JIF3H&WS(Z6EQ4!)I=/AQSD!S^[6?ZU;Y%EVM^IB.&HPRE4ZK[%+DQ
M&Y!JC;+[A/%D 42JT6^JHV_=%SJ"W?$Y *E<QWT+R&AA8689O]>=R%P(T<CP
MC2B;AA(V>R:[30P8WZN<&7EHW*[5)56;__BCZ8\ ,YEQWY(VB, 6$<S-LY>?
ME+8I)# ,J,,S353(?"A7K5VX3KP\:*J=8B2X-,!V$CZJ>^GB09HO4H^IZ=KY
M^;-]]#AJV%6LD2Z!^@S>VH#$1/!XMF".B @GNS9G_["N_/2!>%^":?.0PW:N
M^>7N)6T=AQF; ;:!.+DCS+5?:A^LP2HD?^SMLNV+&A;6U.[:M!P?%]KU4'6$
M3./56;-BC0U/< X3S/D=E:_^]/+@-F-T LHJID-P"Z]+F?6<0?8YL7="Z+W,
M'28=MR*V?Z_R:O8D"HG#;:+#X1K5T'B.*EB[7V+];YXV-_T*T%ER.,H(N![-
M"\.\M#-11:^_%0YVW^HM,GN6UV&2$Y#ZJ<)PF?( =4.@-4+6YN5!JD#Z<R5]
MNU[*(=S]^ZA'GZ?OXL=T0"PP\=[<HB:'7%=0V]?,$BB%-KA\[!S[MB=5QV;:
MX">QY&U?<7)QW7I<<8,D+(XY0M<(2,=Y*"0@K(*WY>JF5^*^XU9--R"M]D3Q
M;=JKR9XIY/XW;Y-;,_/V#_GUT)=T+HZMV=7V+G8<F3]W*DCX+G5\\XC4J32J
MW>..UD*2:9<R&>I"?=#K:3KZ+7\\ 8%^!5HLM(99.28-74Q&]RPI?J S*ZRN
MKGD->FAY?38KNMO[^5+6XPZ?".&Z__+>Q^00^VZ*-M!G7Y>.94J0#Y_3FUB]
MIA'&,+-:?5XK)U!9S#.KBWLF"C1V!)PF5]M&# .92E ,P [+IG]:3#FN_>Y^
MRN9E8XE&/! B6N"Y23W'20.(R)?24STFWF@'(*JD$'=M1*Y %@.AZ'ZV)Z%D
M1H(/KV&)+ ,UM+DJV*FZS)S]#77O L\56"?L$BC(>%$' 6(*6T_B>05,+O2D
M7 #L\Q-LX^;4>'6Y7=$F+9(2&L);E \#'<^AK@X%,0FT[8+)**.Z;I.9Y H;
MK-H4ZYZ$H()OHRR??D#2U0,KUK0(G%V#B+-&N<$:ST01$2BE]>@F.4<B2 11
M68H%9B>Y<^V\!!;/&+5LY(ZD3YK)8+WL$))P00,W:&X!'RXWG4$3:B\W5$=Q
MWW,W4_WLS=]KZ<=0WR!TQ-RMY$?:7<E:>H(4RBEASH*R/4ZD!+\(C'8RBY*Q
MNR;'MG??&C!Q[0V\W<=HL+3+<8'!LG/G<I>6QNA4\[]:UF!@>UOOA6#)2EN>
MCL2AS/@QDZHV(],#(XAB[B8PNEDC/)Y'UP(WH[O3EKM:;Q.A 7DJ+(DU8VQ?
M=RBN[]*G[)'IY?#B I&2PZJX6VJW=GP:>:H/J3H,9K4@X9P<X<I#]E;AN?#M
M4OU]'L:)1FRX>"$^S[R67=,C^Q1HTJZ]#)P9'L$5&1UZ2P"+7)\84DHAEK2]
M4]RJK$=]S5'[)?[Q'!7<#W+;%6J"[$ ]41F,FG&21#T;UYPE]8AJ"ZO?YFU
MFE% RFAE?IFGH"DK9,2[HF&N7G/@=YV.K@?(K3.9/1ZC9(PPM0(GLE?%;O?D
MF64)R_XA<:'#,TY@$E&97V9]4#!5DW?@_A*K[_F/FZR!?[,?)AHU/J5,B5&?
MOD\TYRLO;D @;N1TGDNFA&RY_!#0&>W8@,3:?W89TP:[RJ:U:K((+SQXD4$U
M*N!5C%\1,]UR:H7OY>39N/7/DPD2P3*\AB9:SVI.QJH$5!1:2500-V$Q1;VD
M"!U+7J96V&,&7'=*!708L1HR:4".>"+W]SP.3QDLQ-TOM@\\ 5.9RL<_NA:Z
M:<'G:!_W=GY,W77D_B&$)=#'<^'LC&_RT7JK@=3I$5SM%M5+8F!C.[I#Y\Z@
MJW*NUM@AB*76KR8U- 8_/IG)NHO7*-VW8++D*8Q+7#,&TWEOO2FG@*RF16"^
MNH+,]_R5P=T9P#^A-59\HT&>_$N6BIJA:\=(OQ)#P06&#OHZZQ&!L'[8+L _
M"W.CI(VT ?FTXB.Q;8DDB)1KQ17;UM#UDL!,;O'DW/@:N5(-70V6R8O1KX;V
M&DT,WII7:/0W4A-?IY-9&DPPG7T+TN98:>UZ[.[/(;2UK2/HU^0@5TGL"]PR
M<AMU^[2C!VZU(ZZPR/N_UW;,7'UW@&)QK\'_I:=]F'YSV3^FDZ8C.AX&&7V^
M$23LG.(_[Q7Z7?G0V8ERL,VZMM^$%L,O2=4'D-R7 >8L#>3>AJ'#8,1+^K)^
MHDD'<NE%VCA(Q"3[1)YQK$HBOAUI?.WMB5;E!=]-&<%S=R,V";4QBBV1(AVM
MIK[F[-1T8=>.1G^3L&.EH].G*U*S",47;APQQO_N_,"K]=''X8L_^R[]9?K=
MZ.V:SDS48: H+K:4'"_\%DNAJ(GD*3,#B]H.[)'IQ 4><LL1CBYG4 ,D!$P4
M?Z!EA6=_'*H^ZN-]N2XOI9*@Y9<VO)YEGWMJ$?XI^5KW$G<3OF9L/W#B9 #G
M,-"5S+:3B^OME:Q2+[<974TP5DQ/V :-]ZBL%7FCKP)SM(0%"K746N3"S;F:
M_3W2_#<V2Z.P@P6!%PQ()N;DK'[8IT_6)O= G;(>C8S'ZD9]1GVWGD/-4H%X
MV5/O(9_-ZRN*&Q#LU 9DZO*W5FK=+=1,_P;D4-5Z-O>+8[ZL%B=8B\!>'NJB
M5L<^?0/J!(WNK/A0DWKZ\G'1]CS'CQ<04.:6&W]\G!Q/W1JYP_/;'/ITBTF?
M5[='6,KQX+0E>Q-I3YPK;-\V'5-"RP<LXR6?:M+G8VLIHD$]P2R[',S3UU?.
M&+[\MS[&?&?Y:T\PYJZ!R=W9 TVG?C\P8$]Y4C89GIE(,BPN(!Q6;;8[JYWQ
MY[X=UX:^IFG\,W)<&K]?A_X46X-/D3TKF7ZRW53[5R.QRZYDDYM))_?'I8#D
M3[N5O_@%*2!<?OH0G8P;CK4,\#YZ=>[@AWZ9_?OY6(H),[HJT/O7>L$)WHDX
MLX$#>@YLY]IL]NVZ8R/7A^P,'0--#0V!.?6E&.XNR@&3E$-NG^-\TV!7V3O/
M=$'^_>/,B&EZ.1DF;(MGE*V'>#\Q28%?86:N./8OZ=R.0&MK7][#'C)W/=/Y
MQ&H7?H?_/4CXEZ05@>I7B8-CZI%C1[Y\/E:T)V,D<-#N<.5(I)I_RGIT2M#'
MZ[HU+G\OS?G-TNF!&Q!%:;MUI!8'!CJLYCUY45Q:\J&,L/H[?S"^N$UT;J6.
M\^27YN_3X8%UH\^(=Z[I)\H&@JHN]KPEW4WX&K8!$;J0+6642BYP\_X&I UG
M=*2]*,I-!#>XXA*K_Y'_N'S.??C[ARM=GB;+^(EE95./[\_IS GD\@8D/W*^
MP<GV8ZCK0#Y0AM#9@"!=L>!)]@9$S* VE0-ATI_>U/&F'QN0U %J^5_0+RW4
M\3JJM'ZU^GN=K*EU V(&WX!LSM^ &,C*I?3ON>I+_M+C70K4KHPAV2YC%#@'
M_W]X_5^]U*['ILCNH&0**)GKNOM/[%<+@^DNT#E/67YI!G3I7A^JA(_Z7Z,+
MV("XGX1_2-J -,H5[,^P_U8+KREJ2S]1I<I4*5WNE/O_)9X>6=4-5+KZ!N21
MO!2^+TQW?9Q8UC#_^68# NZ3N\7*W5*?3M++_I]GCW4?7_CYO4Y^_MB)#8A.
MX?KO[ZE'Y,IH:]\&Y*O@O\7LLR>(/VYN0("S<L]<N6>9-D"07?F?)9;Y_RVQ
M%$@G 'I%60<#M16,X.49KP5E$$*4^OE*2^4TPR]]K3<)<T8NU_85/;@%M(8%
M'=ZZ_\8I]2G3'YJ51IGFL..+U_OW'=A3_-2/7'9NS\N*$:?)N[.FOQW1,L&_
MJRWMM&]D:=N-XON]UR;5O[NV8#2E 3T< [LB\D5!<U5 MQ05B7Z?K9$%?,>H
MD-$B>&IV6VL57@M%D^U/-H\6-J2FD$K(AB93Q8,F-@/;ZL,/VE]^W]0WXV'0
M84EK3[$2H>9R[@M1*CYD)%5+8"OLVDFQD83%+RVH4* L8"4)$2*B[J2@@&_<
M(HHY%_ I>SGU8RK<I4A,R'7B:?E4^!:[3W/V/QCE%0I&O7!88EIN)VL- Z:+
M.%Q2,+29J<$Y )3$=_Z)A$_SH8_8>L6V:VB]QS".YA"RQ:^(/-X.I)VS;.'7
ML/GQ"8'EJO/S0]?R%",(*0='EAR2(-+7/92;:\[D$.%$C-^[.K#H_FO[EV3+
M*Y*5U 6.ZAA!=I8YP-B ;*.XUM4GC;S_,^ ,7V#[2BZJY%V+MY-''_NLB09?
MF4.J:8@;O#3$D/7*)QQ5<_W>2G;+T,BBS< B:B_.WZH&=),=[)-"RP+&E(&\
MAD)R]L"BX1EWB5DMLH3^F1S/>SNL&!C5\C23T;.DW7"RHFU*:<\F,74+@B""
MP^1M?72K!SQYD:C9*$0IXZ/TD$>!T;$$%JRN;?GO\YZC9K'".;/I=8<,O<&2
M8@^<A_=RLM+R7Z:1,)MLF>*IV:?7SF_=\[]9E!]X5[07Y4?3/-%[PCY0N)"4
M.:1X8'MWIREFS[$D9^*SP[L^FIU42MMVEMYWY>>:^_I?,M49SN$&B<YR5GGL
M .GZD&G^+CZ8[L$ ;K/*$E5QQDM8Q0OWLIT_LYQ:T\<*F_8W/*.TORJ^?7>L
MTRF5-S[JG+C\^G19'%WABDI.",^"6Y^6<87R^L7K]<6O'T5TC;P\&\)#>O+U
M/)W>;RD(:\WCU4]5XPXXK8N"8VWU[7M]OF:=3F>DVZ$\ (PT,4]E _+6]_P&
MI,^YZ'[7G)JX(D3(:@HDMHSMJX_CN3"&.+I3UWRZ"C^##PT-$=<DVDU1&@-&
M3M:,@Q..[^*O#-)_9]0\,*&%OLE(M>=X1G@<M$G>AW^5\#HAH>":RGEG9V?(
M\5>0XP\@$,A)@T=@CABZ!51KPHB,$VP."#,D^@]#;<[@TF9VK#>(NO:!(4U1
MRO";<8I91A3?BLF#EER#VSD'[&W<]Z?V?*/]D_[M:1$AQ*Z>2*C_M'2KUG?O
M0OL>^F1YU&U0(.;.?2 (:6K38[N[;V:/V.BJ =^RRF?@2J0*_37T90F\50 #
MC_P0GQME<J)%%2[_XN#*)L;*Y*H)GH8N=&#N!";QB\2LJ)@>9^C"5W9JP6IM
M0.Y@811S\.W-BHY*LF>K&7=S[%",5 \0C\>W:-H^-OX"^.4G5"*/D/U%#A4%
MY(CK *="MWHY116U;69U6_[];_&]![M]!P^S:N%WO64C L@)ME,)V3'2MR4J
M<@.29$K;YD5X2U9H^4&VO2@Q>B)>V$<QLC_3/':,9A<(XWV?B4*!]T5813!P
MR;*>O#3G8&AA>.Z;-]:>D/?+B&RG^]J1+O78?V6&DMM9."HP(#-8+W,%@\61
M2&WH]@_CD5114/J1U_H]E^INEXDP\3Y[!]D$8<7![T?I3#K4H^CKWPY#+F_M
M]> H/!<F#W7=3$:@*4^&S[5%+RZH@K_P)RZRP; RO <KB=&5G,]8:%F(E>EQ
MHIO3_LF.2R8 74(_VD/9X4^V)2.BWJTU[P;W35K\F50^"6? YE OR)@65^2!
M&DDN+8%B#I3Q,O.TP&#8>Z(&6:X?KK/KP;#Q<[<Q24-4U</?%Q/HAFPL'8RV
M'311PLS59 (!85J. 4.ZAWN78+6K1,PZ6[9E6J8F<4TLKT1<PZ%B%]B6A>T%
MA#'- 4:*0R2A-5\%807D-]91>I()O!)JD/0\T%GZ I%5MB_[DDI;&?Z-QU1?
M(^)OVV3J^$OL5K;B>+*QBAPEL*H+"%<2D-R4#SL$P&+8FN5@SM7^68I=(6CL
M50NLQ)F^*I]E$'?/\)4SQ"EGKO>7"_/XV-EV[RM3!P6^(<3="D^D^F##FMN,
MCS8X)X;O^31M :<%<OWA,1_&]22P1Y1PBE*$&*M$N;/^FGU,1%?_1 [!  &#
MO@.DKNT7 'HS<C\:ONWV(.\J4/,V1.@"2'&_?UZ)D9V0\5?E"8*P)&<+4AC)
M6-U/LDX?30N%1-FN@!4MUS@-HC;E#X#;VI68[5-0_,FMZ/OH,.C_WF(LWZP
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MVEL,A/X3ZODLB#2<SENQ63N?3=!Q^JVFMB_HV\/6HIOJS;K[ULLX"E[347L
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MTK%8,,0I<>S; 1W&,:7/Y89!@5^SVA<V((&TN&Q4;&B'KY.<HE,K$7:O*,<
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M1[O7)+;/5'NFF=4O9R4%L)C?N<-1YRRC[]3HOZ/2K>N5Q7U+]62I[ZL4JZL
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MQ[^C*+;,2^!'-+F3L\QC;BKK01IOX+:607*48G]+LHM,?J'1H^3T]"KO]XB
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M'S*UTTT>Y"0-JR)\>:M?ZI@@P-^[1U:T LC]WLK/,R&)>F V/8PL<1PJ5XH
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MH,?!Y(?\^X)\HF'B56-*4A-J%!MXI7J/J-'8?%.F25Z"@FVICUO"USPW7?&
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M]A -H(3EY7S) ZCMVT6P<=KB9TR]PU-'J+?IFS_]S^LIX6P=K9_=F>H:2IU
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MJ@GF1.9$7DX-@]!Z\>&]S(;[R*_\<B_A'2S_"CB+Y/^#4 QBL64^ISXB=X4
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MT#G$#:.!@]M_<&U [RHWG,'0,;8ZIS=FDCB=+_83J3X0FU.TF'F]-SBRTN)
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M?_^LY=#.=HVG;G&0'6D6YR$'ON=!R(I@R/85[FZPA:4C!UYANG2B8ND'35P
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M-Y^V;<D[GS-24A\6,@BV&#.%?7=QA3[H"Q";(2\]F+Q.1-1[IFH0)S:VD:*
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MH:ZZQL;3'=Z%/:;XT!G$5DL+,J--\=)8LYB?3@_WM<4T'4,9$0U:.BVY)=5
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MS=PTD76(EM08$PNYJO/+Q=;T/O!A)\!;O)]CJE\U7[YGD 4*FJ>U1G$AAMT
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M'@:A%1GPKUW*KT'<T '$N8OT^,H#-89:ZR3#D=9E&1-UL=E/EWE=TH;\94X
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M^$K3!N[^S"B%JF[9-G]6MN"\MIOU\7IGUV2*I'U(M-?[5\Y2/1QMVIC52]2
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M%2!&Z7&4]7C2YHXNBU<]4Y_C7)D53[C0<HNB*MX51D4=-;VK415;@\G73;9
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MH*T@Q!]8N396KRSE>\BS37;4MUZLY?*4NO^L"X./Y@O).Y#W8=Q>N(8C!;>
MX$Y_#&K;!?+.P]175@Z1F[,KPFZ \ Y<#(G?6T]G5NT+73X,*+NB64LW].;;
M[,<)X3INX'R+DDVMAM=OMIB+R[ZX_X^G-;NYVZ :BXAC:HCN&>*6%H,#]E46
MRKXBBOHA'W1ON)YWN%'Z(']N/7<DJI0(J%9SH/.]-=>$I'Q'32:W9,U13%Z<
M.-]1*9]I7SA"^7/0H/1]%NPR[UA8=1K7:.%FIV:25E/D7M%<QL4#GV 0W=F$
MPZ)3BP?$3^E]^?N#P,>>PON.\;;N;?*V^:TTCY<#G!%A2Z1&K1[&X[V/3 E@
MZ.-03%9FPDG('-F#CVOR3=*[1:MZ-N63/2_&E#$$]JY4 Q6-71OLD*^3K_#W
M"VWCOUK!@8QXRG-O]#WNBN_O5H1%8JN@IWNX'I9OW'9A$%GGU'?HT)%>1AQB
MZD%#\ZK1+;HXZM/B*:PE&)%.Q1W#6+9_F5MI5"AYX[026A5_^_W$0OS=NA'U
M,HG^K6"S1V=W,[2R7@M+)>8XO\L3[:Z3547;YQ=86?!5#/"$-'?U9YQ+;,(^
M3S>;T^"Z$&;QNCHQ#9NL:.S?-S!J/J7JXE8Q]>N%)ZEN'T:1'K.J"S[U<5;S
MV\DS)=O6\+^Y-QN=Z.]88%H+5IJ[)^6BPU6D,/AN[?4 H[$DGO@$DNNVF/A8
M-R+AS=9K)\(WO?!92EI;]NZ>F:E=VNKBC[>OE;BAOV :D^N"7&>XZF50+LH
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M?T_[HH%_Q\B6;)S/ XJ^2)= F6J% P[NJ.&D"T^U>9IE#/K0,G'^;OGQ-.)
MRK\^BZ0.'VNA+I ZT #+DJ90(P?E;_-;2:U2IPT>-;OO3E/02J5"_L 0ZS 9
MU:*)X(V9$PA7;^L'&7KFMR;BIJW59XX*EF/FTUCM&!>]T^E0+10JJ8CSB><W
M,I3OMQVCOA[6YC:C B?]0BWX9RCOIHYLZ?Y63M(BR+@2"HKXK55IR+U:)*4E
M5KUY3R(#[#!XKR#+7LO/55Y72^?;.M',A1Z)U3FB^LTN@IV)KPD?8X;$* :L
M[J7&7 I@B8@4_SA8J-YJ6Z%37]&CXM[63!*+>3<,#@8>[CO_8$QO-_\FQ[PM
M9F7HP]>!7[PM%P#U560<DA)TC0].**QR?_ V$@_]PL'\VW>G"-C:\E^)9J,B
M,JE /V^T6GRI*7"Z:D&3V>5TX@5.4<D>PF.#[8>P'M3,K!AC4?%E/1G:E"?]
MR#A)-E\KV85=?6<3?2L7-,_28<G&'#[ZS2\I,GN$?]VTE_M!S3W)7LIZ8J*2
MPG*U'M_[_?O0=VA#<^-BK\H=\]B%FD:6"P6%1);$/;)#(?\0(B?;BX'74_N-
M9K :VX;V)O_DY;<J/PGTJV='RC1[0\<?6OY]I]5U-3P0AL!DAPR)!4YRTDMT
MS &NQP;)2E8F28K6U<@I1M7Y&I,3O!1]HV5ZKP"/06Y/X<&!C92\KD&6RGD:
M GN'0+-+1?6[B#'!9KY>AT$=CKM=7++#L*Q<-V6'J/]O32$1)GR1Q[O3:W]N
MPM!*'(L+U<- J/;,X:W3J"]2Q-$,1X3P*2[1<?>$'[E:(%\;07#"HO[T*3=T
M7UOO5%9DWQ@]V+$7E2><ZE$;JIZN(Q^ "XN8:$P43*7<_6[I(A\PTG'Z7CJ7
M!];_O>4#S\_C!@@?\\!^,"Y6;?POS--*H3O(^%U68>/4VABJB"E8,MZKW0:&
MYP-]GVI?:/YH;;,7SC%E/ VTQG#',)DVIZ.W9!L;.>;RUXTSH!8K-B[LK)>3
M'1W9J(%>:?/EXG*W#'D=3#?EYD]C* Q.Y#SM[6>V;G"KLEY4>>N?:WSH\ECS
M,Q6H.X7&LY"@W8\0>KFN(V#+(Q4'U9>HXKF<VB0SR"I[ E-5;9[)/.+7(4?=
M!\+1J\P"+Y+E,[)P%2%/TK2*D"9ZZ>6UC),FOAO^F1Y,W1!3=O;6_\E4QK,O
M)R6I'H:/G%M]B\0.6^.5OZ'[UU:H%G?R9'J*'UHW5:W9D*@[^56.L9?8KP'5
M-$4:&]XA3-YE;9S16"YI _O[8)OJ&"H"37S[+0?L7-D^=OE.'2X8UYF+F<$7
M<RYR,"3?MB$KBZL]Z<.Y[M6S0,A!,K% (>YI%E#3K[=AG,LS0$5)'4+MWA6@
M?@4E0H%WL\*%PS! :>7[X/"11@68UJP-]N38YO?O5I*FMB^J;B'<Z,,/:?B2
MYVDG5M)R!UQ6:L!C0:&$HEL;SZ\ BM<N&NER2?=[M?W&H$]:H?L=#L=/Y:BO
MR>:?-&Q=45)?.[[J9PD9;%;0&0U:5?3K-+H8%D![$W"S3[N''N(*6*)Z1KVW
M/XA)^?A#GWA:MO]*ME2T_+QYNR8C"4K:E) $:=$A&>#X7O:!\!R#I 4[K7%T
ML9%88M5[,[ YO>C.Q'6.^W.:):'2'B#0#%5$J+*35P5/5DU$@!6?3L?;"]FT
M,KAFD0<T'03B:&387VFEYV#OO%^ZJ=%T[74IB?DZ[]/?VI^N<;>XT\M1='\?
M$#(4P<K]KZMZ&/P ,L:(/$)#HEU$2JP-]$?+Z!T;7,S_=&'>[I^X'C:--*&-
M=4):U?1!M_Y^&-&OQU0W6B_8^U@Q-US2[_ Y=1"W@\T&B!2*P'40*7X=)!\;
M1=#[#.Y5U^P)7F:=J9;*@(!!E,&\Q3[*\Q@*3:,,SV<]]&$_Y=--X=63_&D&
M'@>[5$OH@21RE@=E;IKO&P0.;Z"94K$2%T\O?Q73(!U!<>=\?<4Q\B>7&0'?
MEI^=S\3?FAIW7GXR_C(A@(W<O$[M0FJD@UB;?^\53O(T0]SRV3"WO?+22F2H
MB>WZRBV\( JM>,/_"L" MU'!&;\OJUO,GI$_S/6H5 D./X@8?=QBD'.QH")Z
M]R9BS9H/;!^/_4,;F?>3*W<SM\!M@#(QBRZF5JN38UZKB8-:U;"*O#7@L7ZA
MZ5AZ9;*ZK,I<I1\1TEM+[4T(BD6IF?+E.)H%U8&3)-WD_[KJU6PS&V%/P@H%
M+/(*,/J97T9TFGV'/*LKU2LYWM&9 KS)3><0B]%B&6'A X Z#EFJ;C;OB-N>
M]@)<DBE8Q4\M!4X'S#"4VB,$1[!'9@09(V.OZ**1(7%YD/''$4DS@PP)Y[IA
M\YW$D/#JIMU%^@%0;LQ:.3=Q^Y.N?<J6[*7C%2#'@WGA6U_WXYI/WCXY][TE
M!(20V3:>0PO+.U5/O8+\T>_*>(!O"\W4Q(@\(N/^^]F#QQUTK;P921XZ6OHJ
M6\&QG]9;DF]O<^ .2A;\[S632DW>IS*A\%8&:QHGM]D9Q>?1A\UD>UPVG;\)
M;FO?YGS@:TB_$&'D3?+#@*R>QW3IJ].2BS-DUF9L^13[7^L+VJ@;1NLA6=P<
M<GF^-QZ+'$W>"8)&1Q7=BY#.MKQ-PBVD)4..,'(3]*C?J3DH_;J@TZS:TIJA
MNP1YNK2_?.Z:'E2OPR/ H_."AHPQ=]G^_;&-=9F^QCKH.Q,@*12: ZC1[-.2
MX5]F%^5ZF4L; *N"E$]^>901$&AJ6\9%0[E:@/GD-)S$RZKX1BU>_+&;F[%R
M\^07E,X21I%IC#+G5N3C3S<V!W2(\ZG5J9['3G)>\-VSYZU!;QM-%(FK=ZPF
MFHP$P\W-@KFKJXMRC!,;-%'"DIEE7!9582-7@&AB56.53E-+S51IH>8+:H/-
M3U> S=+L(SZ^-+]JJ]N_J5:T#</]%D@4H.Z"\=['-'NLOR,]/0VIN'0CL-=N
M+=Q CLEFJ6#[\?V@P>?"[*]:N:^;A9]= =0GWSP%>@!DW:)NO!(0"C9R/_HH
M]5SIA1 3:7;==[_A@M#9V?UGC(^\C$)ORMZRN^,S:=414HYL?/M7$_&U?BNK
M@E]-M:@86)/78-S:YCJZ.]B4[PJ<\BLP,E%Z4<UDF?V]+M3QA1HE\9\B7==B
M99^ ]>VY'*'H'/?JB;:7(TV'N."\<^N9P(CU!RDDU)&IA3&_XEYG+4A(5H]+
M1+>UVYR<-=@G"BIK@&]\NBE*THRFD7CT1R8R;JU9XS@.="Z<ZAZ\O(&==9<;
M$&(\]!@=>OB'\,YE6!CQ3D'KP$IFC'MKIT<0-.B,,.?[&MB@-<B;89)D'E6A
M5]Q.X\V9@N%4,G\;5JS1M)K+4=?Z1H6JXY%]1NL+.K,/8JB;BME'O&\BWI\F
MZZ\KCOD,.B#N?.9.>DM1YPB8W_QLNI&^K"E!2IGF5[E(<MD9KFGQUCUK7WV(
M7$&A*EXNMRC@/H/'R?&-IKO_%FS?W+GUXQ]C&<EG3M'^XF&=I]85@MR'>>_,
MK);@+55R6CQ'M2&>&2"GL/1YUZ6O:QDN>GI)/;J.CKDJT>0A[]X+>+&+-M$_
M\K9,_;@OR_7H060\X/$7HVAC5:M38Y%48;32M\M_*3=\;[AK_F:*Z:)+DGYS
MW?@,6NV>SP(L09E?$@H$/J86W!EXUN=Q+_K#MP&AXZ?MZ79K/L5P5P3'GQZ*
MY&%W%A)9E-P;RTI!D.KQ_M] <QZW!=/?I[IBH94!C(TKLV&=]&>:50J:2S+A
M9IIR\OX3Z=&LN6RKP6**^"N QK3G\Q]1%!NP^B;Q=S?^B KKD2#!/';6DBTI
MRLM*=^;_)OJ*<B;=9]Z,'&!Z,W#O572NS@09V1)KD!B*9/ *((Q^VB3*E<HJ
M->GD1=KL]]U1S=$XVO)E%;GDJX7J_;DUBT'?(&OK\Y>B&G?(X73Z#"'U>\?F
M;5*55OO5$YV5HP(RPVH"&L=_S%T+#SO,I]M<-TKW"RH'FX4?5C_YWJ!VU#HZ
MTI)]K/N\HUWN1Z+<(^_J&T8]L>]<3*T*H?!B@_R@HYHW3J:DGYAB'B08#M <
MO'[V.AC]17HRGO35F-PC F)V\ S*%_W].^O-4EO3VJ$N3P6[&Z8NI!;Z%J<3
M749B9B^X(4]HQ&.,+6DE"D=XKP %&[01+\IKH2T92)!+V-I*5\LR84PUI$)W
M>8/ZZ_*,9=NQF6LZ?B$FV\7ZM,'P<%IS>+S\:P(NU9G_:P+@?V__#U[/9CE7
M /RB'^F%_0@)>=[G4Y\E;K4HVD7.G/J1=I TO?RN\@BD]PC/>80Z(G45P!EH
MX0?71.Z%&N/&#@QPY*;XG#L1[4%>V+V>;&1#>!V.8?VH;XQRY_LUL,%K*<"]
M:Z#XVE"K]2O 3=?EQ[&HUDM$L,<WEQQVILE-Q 2P%-Y\F2%Y"700OT'7H$7O
MI'*9 7YV2^@+Z\?<?Z6VQQ%=G?M/"CF6R>Z<PZ]E9&GA/+,R>!C']=12;FQ$
MX!]8\(5X^<+O@S#)AD2W2O/&,!9=S;:1'L'6S$5;=BOAK,-\I&YK9Y.))M1A
M^.X0Z!\$:T.@3;V\-P;%.ZUZYJZ)H(-08Y#5HR1V'IQZ7[ZV36J.Q CI&9JC
M1YN-8RWE?;6UJE_;<QVW'AN: .VQ:/0P."+WDM/2VOQW$TC0S*7P$S$"LEK"
M[)BV6DMK6A9-,,&E=LT6L_V=;[=:KT4CUP;B<]:R6W!>F#M)A%O**!U:G:R_
MB;51V0;6NZT/!5=M .#$%^W$'VW!_IGC!YO-E^DQO:RN7$%1ZD W]_D+M3)O
M<:7I@&Y!SVI-H]%[&P+*"A/I?A+P=>\;(D>SAY]1MZ*C(FYKL 0]!D2F<#*Y
MAV4WM=? ELQ@TM,$*SKBD8^?SNCK231R,[GP"#K3CC"9!"\?E.:Y^NJ5,:)L
M?O)%(%<_%6/U@;H@"DV<V_I8B@>\EG(W6QXTURYP81*J-QZ=VKN 3/SO+4^I
M5'(%L%/?3)E)NTWLI11>&9/OUK:P!-*+&GO6/ Z3LG7[!L]14L#FG_Y7EK(!
M/WDM$LP*$T$-/X!9>0!VZF6&]+(9]/VYG H7G%3O]Z)Q7J&X KQMBPO@N(F'
M6%JLD.]<4D\2;#%4B0CT;/(7JYM[:X;A CBJF!HI&*?;V=0!!+8HZYQE]S*-
MKFATY,=Q]9JL8V>'(Z.+UN4?MQ0RBF<L#^"98FQC0M>A>B:#VW)W]@9R>H"@
MAZY"K&H(44"-5-6DC3/AFL"@<6[$K.%,RI@14XB4W."%F>>4U<G\%2"@XW0G
MI&PX0"#D\('-3P_D/LGU@+-M:,8F[X?+8WFR#@;ZE=^O/" 8U>)MUF?[YJ0T
M3I1)P)#3\%^A.@[4L^T&WI="V*V*4KS@FG6&/'A(F=5M-BBO3],CP WJABZ\
MUC](/&/[Y] @ZP]&35& Q8XT-,[T$=EQ?GJS08,0X_ZKSFWJC$>!=CAU']8W
M(&5"VX[TW!/@ >ZLQI0MU[+9\0G9Q[:8B'L]\>1TCBOV=GU>+>%GLYL@ZE5Z
M(V[*SY5I[&<RC.7+2R$+]6$>]'G3^WEG4%>M)P8"<E+^\''NO+9.HG7RF2?P
M&'5BX7WIAUQ=?Z;>!9HG/(GS&.M;"OX<CUQ?>^;/\F8VAW%,@KKQ1I<1BSWI
MS8%_8#P(EX-:N0OMS.G.D0^ MV8WKA;Z[AQ5VW<N!:]RT'2O%=(\K=>H=-^:
M\LA>,8)[C^_*^R/H]0\T<ZLNX,1: MFJ<CR$XSHB0<A"U;%EL800C YHC:K?
M3*J0J]^<MW"-[8Y1<SW>Q<_/S=,_V7AYJ\?'15Z=!Y[>=6G9(V=_SUCQXA$Q
M3MD^.FV ()ZZOT<W7'9>>QWF;A[[#[L#')K]OGB&))=Y&Q30;VK7HY2#,5>
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ME/;Z(Y7!ARXGD7V?"ZYJ5P@F3XF4!;P8+TR+48XB;8T>< M1O>QE>6R PI8
M#CVUH.^H<;7O@\N>%##$5SQ)\\D/\-;/2-I3:]#:@1>Z^F\>H@^S%)2T'IR&
MBG0? O62;/OQSFK,_6K90!Y^_5.Q#!,3UX*M_"RTT1/IS*I!$'ZXGEBK!&Q"
M""/\.Q],<7>,Q\:>*)!?WSGN<\>RKQRT^/?]#3N(TQX<NX;P"8AV=]#;/D]
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M%)C"=J=;B=O%%HD+S9MBYHA?3[D.5_4>H&Z323S$*&:L[]TS9#TR1"'#;E;
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MR-.VU%[UNK7WGQ_\C%\P:< 5]F$M=M'^YLOQ:SJ\V[WOHINR@K^Y9L\*E ^
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M_[Z':#EA(E8?;LF0+$_7V.P>OSZ;$L3O?<^QTV^_O?J(C+J9N.X?K#N$KRA
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M+X9<)*V0:5Y,"M>#%Z(ER)OV(F,"/>MN_G[EG2$:8_*)EU/UQ:%G:CF0)_N
M8^CQCT3I.E8.QAR9"WA0$)*!* $^'J96=Z,LXWA;AB0P1QN/=54<(HK/(XYK
M$ 1":V:HGW Q?2/C:'_*L$BL@"-3MV!>2C*SQ=_;J3$(T1THN >P]0==DO-
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M15E*3&"7,+_"J<<,K:(7+Y_HM?WUMNW!2($2_G6^W[\Q+'00RMQ% -!).MB
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MXZ=8KACAZV474#KFG-(W]3Y/M\3&8JMI;!C)CN)G7@&0VCN94<0]*?IZ)#'
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M3%WOIF5WV?JH7"RI/O&:&'0T>W%R)+MJU,4 I:XS\M#/DC@%ZH-BX'@L!4%
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MS]*F74P%^VPLAUJJF#G3/@8A3N3W+D) %#(=GUF,A(T^GOV1=P+72RSK;'&
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M@"JL8+YVS]!+\F?JTCSK%#M;CUP,JC-\LR=1\N=9C@AT0PVUT($4Z++OE8]
MY^TI3)X8E,4EH7)-K7'P:N>4%2!8H)WP3H&62=Z^Q85PY,R#PWWY_<W08'=
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MT?GF0#D:P16(5M-6LDJ<^>,\_11K,J@E-;ADZ3<TY&U3_9L0;C1V2WU&I>6
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M\1.WG$K:2VHJH3:6 IT=R0I],"_WS7%K_J:4YM!FAVN^-;3@#_1^:M>/N98
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ML-I8^K6.":1NX;7XH>M=),OC& W_,AHD93 TJ[H*D1PV*G4.,,X:LIYZ=0Z
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M_[V]I/0E*M 9P'&@ZK, TJ:S9,R^1-K+%ZP") ED4$D<V(JFX#K0(>G,(FU
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M]E+)*K=X_@5LRR6P/%W&Q+-L<<$Z]#YB78:3M1P\1\FT.C\IQ$;Q--E]U*Y
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MZ-V&B?5/IH/!RM:3NTJRCB_*_(Q9KA+<$7UXA(T7[? 1>G+#GK*9.]"!0)K
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M*,*:\HJR(% T.;N7BZ5#0<%6^P#3.4V&)@N:!;V;<<5M_ ](%%M366C* _?
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M%#U<Y?RD;[_"!GULHC J!>Q.C"JNAR*'14*?,'>05343K2"3$%/VH#%U]A2
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MD17U&W>DO9UGW2?[%W*]8BK^['%?OP9>V%;,)Y;MM\OA=.CR+W^FS]M5Q':
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MZL\:I_2EZC>/7E>R5BYDN)O;.+D\R<DH:*\H*UI8T5V-N:WRQJE6U\)]H9\
M/5X#RS][/_W>: C,\Y"9AF@H+F_;YS]O:+;LC5.CU'][SY^G,?\#=B?_)_6)
MBR=W_'_]#-)OVU44!"R>63__^)1(6QC0-E[;*1>5%F?I/VF2 KD0$<$*M4 9
MXG-HK;.:X^B+>%0!?&3Y:VOFY.+ V\(K:9W7M3J>."#E/C/P$_36=I1^K_]A
M(&E.#-J'VNPQ&UWT/\C+?XQ'X:CMN5O1A H';.E2]/5%BX#EPGO-@820R=W?
M^MF'1 -57@S_2X>UZ)TNNR\VO=Y@72K1=JM\O1%H$;GT@!*HESL:\23_,\\E
M_86/R]?LO#;O>R%$,Q>W7/9BSYG<JIF(5P.L D,A\7M%4WO(IJ,2^3_N>+Z<
M_WB;3#X/#+#!R<> .(ZZ TL,>KR>X2)P^! YL]OR/!)9NUSG/6-ZX9X($9OV
M'(G<I\WYYXE7*%$>?E3^4J+'X%,V?*4X/* LQ!G]@&?2HBH&)?XA=+P3(?<F
M9U?FFDO6-57'4>TB\M2-A/G6CNS)F\_L[MPO4!H;4G+/^JE'-O@B!GG3;W'-
M/9!_C_4,]GJ]@)P>P9^OJL9,'JA*SK"Q=XV.)ZC8>V9P-.YBPEUIRU7L<)/3
M#\.",Q-5G<Z2+JE$.86[?.$_<R4=JGZ0_RR7H[3>Z1H,_4[XSU@011J1M433
M[7$K7].$<)[C\J3H6C3!EA>3M)$[@=1I^T#<E5]H\DN[Y.'M(IK% ]_^#_BN
MQG^J3E4'_/G.^AHP(O#V:Y[BDU84JE$A)YL1LK_WSKOPCH5X>,^V5DW+##BH
M:PAZ&)[)IWZPS@WO:PRY'37*$C@VQ!&_/,L^CS&X6:XES?T1Z^38+/C(TK4Y
M/[OH6I4<?VP]KZVBC8C_]0Q,^WSB7BDDR8*@S=A>OM^4'=XUCG?IO*-<WFKL
M.[F)1#&WK/ZS\U%>: /U B1M*MQ7"..MX <;WAU)7(*/',E$^,06-'>-VZQG
MMD=:V.2.O&]5'1S\;'$5@?@XN5%1WWE5']7*,5LIGQN).U?#B^@=_>@5@OUD
M],H+P0CX;/QY&[_L$8L(XHA&BAP+G%-#SS$]E*ROM8W?S.^?_>&3>\9M@/Y^
MWRV+;-;0D73=BD5[M_L+%RT[AC8*].S/(@LG[<P"3LXXT(2';^EE_V/\3X_F
M8;S]$V?OEJ^/9A?MSDV/Z$M>7\->9?X/7SSXOP4JSS7]<LR(&-3,[ZKV#6(@
MZ<,:Q;9#APR-;E$F(P<U]%7NH-B!Y,Y)I9[^?TS&K'=>6F0KE;"#0EGRCJ?"
M6\N#*0I81)<3QV%LBI\U'FI:Q,,/8"O@2]X9M63UILEU\\XK^)FE1VD 0B!_
MOG+D3M+U-YE]KN22WEG^^ S]<.(WRX K],^4_3GE?P5&N. :TRD?RP^YM?OW
MRY=HGREVCYXY;V:JTA^F=R"W[!50_IB$#,B^]].EX(3?ZV?IU7Y&@=(.!Q0M
M4E?:P\-"SN2V/;S-$*58_6>23CGQ/%=(48A*6)7P$4\JZ8?I#7J%11B^*L3,
M.P._7C@XFQ(:7,WX7J(^ ;^&**K1#;Q1]Z\G:LJM'6]0[/;6LVA!G,!'-'ZN
M\N<L+&/6X@:Q\)LTI,METN;&32.UY7S+P$P;N:2[SQIM.7+I_1?U#[#Y?O$9
MYNP'^Q;C0R2:;U51,7H]IQ/3.*@\8#):F(8(1=XYP,[<(:,:0;O[O$O1W1\'
M'1\+&<FOW^HS\2,H!Y]L);9 7SUW]7NB&YB]ZA3$ROAZ_TC[SMH0O]>8D>^R
M;EQ<J@':^69!2YWZH0.MAF?6]%KK8I\-AR^D]G,3-KX1N#4]6\7;M(*8K23J
MBOP6_\=M5431 $G.^[/O9_NWH+N%P1I7CH!NI+PEG=HNNOL0<C3,+TU3U^*%
M)(AO32VY5>LU54W8X3U>Z)W8M ]WL9MVJ-BHWPK52R5:1+D$N\7_WYZVRBU+
MU;_4\__FZZG7.2);>4OL/9@8A#\7U>%E)P8=EQ:#7M\5@[9< _^E82.X.CL[
M+3S3_KI^HK8IGR?7P5J5\ROZJ#0O@%V;:%9A343Z!-VU.X8H]H3Y%,%G#;O#
M-G?^%0Z'BL8H+9K=8M!'SSE12AU0/>H80;?8:/P$R+!FLTR4VBDI=<LL:\B:
MG]WA^B"&[&-4@<ND]I.Y2Z/T743BRGC:KK@= IL3*W..Y[OE\D[#5 ''>8NB
M8YWG.,[483PRRJ"F_*#2/X\_TZ94+OUV_-<I,>A).HKD LR(0;OVCJ.EV6J"
M[YWF+,H!]#D 6F:-.'EVP5MKW5\SQ[O]=29+NSE1M.H^U:Q/.3W=Z?)WK0W-
M=<]]9AW@WOVWH>E0T,TUNR%S*\^$]Q&UH\72)SWISE2W;M8"R_VJEL=>HOWX
MKZ^#*\<O*7;%5XV_"-0<Z+S&_ARXY^Y&_<,_;IV:.MM[\T%Z2U39_!59CZY3
M-L'L *?0T2*\4['3U>9W>F-E2[85QT]2KO!:A<I2_(&IC;2BX3T^:$/N[LPA
MF\H,)&L'VS-Q__OC:QOJ#WY]*XEV)$?T'=[_?(?*RY0]-APH:QW;VKHMAY/#
M<J>"L,)G[AO(CQ%S^'9 4C(]@1P.Z:EJ=)[B=DF6%'VLS-]WH3T_@><A!G7+
M+\YJM8]T&KV$/63AU(-4_296__S2^,'$(8]WBE_H3N]M)-2/>^<QEVVXA1?"
M^)9&\NB@-Q],AAEJ=)QT'6FUT[+TH_?,=PL8U9-'26"_YLEF%A"GC9+1UM7)
MD LU0.::==)%+FW3)8<U>"OR4Y@AA? ]8%;.M:+*.KZAY55/65@K&'*YJ-0I
M?1Y<YU[NK5)8P^A5SM1N+(8UGQS'6U &-^I%^N-5*SKT0X5YP:[!+L/D.J(W
M_NHEK!O>(_?U.K,QHNGUNMLM;)1]L9?KA!B4-"*:9:Y;H,W%(*I?J1@DZ1_<
M+>CTM"@)E@0%$$U0T=5:6"KN-8%*V@58T@IQ21@MA.>6Z#&') V$?IL,'.&,
M[  ZV+9I<U>%JOG16UK%0P2VGXSCU$V>4RE[QM);]<)B<#LYG7Q@]&OC&TKK
M5_0%P?[O5J?>\)XPA%?2J*-^#NSS5H<6O(LK2;$05U0L)XK0C<<>GOV$"D$$
MAT;5B$$M P3L+8B94H,:HLLQM/99^9L%? 'J@N>^^G#6'XGGL;5QGB5HLYT3
M8=<NN!6;QN<YW;A.4EU$9VH,*:J%^-;C+OAB4\?K-=W1=L7M(NH2I)Y]:/I3
MA$<ETY*NA^XG*MM1BXI*(I=?G/BJ:?/_Z$3J8'3LZ^$D$[A4L36544"#'D)5
MK\W= O !P:SO3<4PQS&(>R!W<VXSU5"XH\;K$_#(\=ZJ^SB)? SA_:T@-.2/
M@*=OMZ(SC!A1<?9QMSFPCD#!?K2EE2&@P_+)B&!_JV4J0Q244^J,.H]6H")\
MGU(UCB ?8_8 >6+0'J<W#3<^?0Z:^HDHT>GJ*G IG')6LI(3O6U(<I@TC;,5
M>(T%W(1HY&EY0PS^.F]QOGW!4)-J+C@E"ZZ]?8^U_+"LW,GX2X0SO^[%A&'D
M6!X$F<JK6L;3GB]FUR2430^'[]6K/-M0FI0%;?V:DV=WT2%OX%,5??SK9EL,
M7"1C)XBM-@:KHLW_\3@N,HA.&O\=.\^FU,(_9?7Y'P-*!1>$:D *^Q?1L-.9
M TV:5>,I=84'!*HG5# J"01Z>(Q6<ZY->7,"/EIW[QFOWH,*J2)9\DE@[T"W
M-ZQG^]*PP/X0.H([J:FPN(4A-OD%MV]34CH=6(,NC(/[?=YIE*R440V:8@X4
M)=\SNS]P_)?]%3Y.< 'MQ4WJAG]$\I$\;.9P\NV1(A:)NGT$VV/.TCR(&G85
MA(J2[[5(V7!+<FH7>S[VA>IF<S^E>8'S&Z\E>CT5P3A3LO>'_*A"LQ16;9+!
M .*.<>T]I8J?R^1$U>:H2PGV8>G;\<?UGF6$/ CW# ^-T)\Q7A>#=D:(CKV/
M^"P&R>+F;V3>@<GDLL(/LK+Z/&FCY7H356X95_7&<F_I.K_*+<[-#C-R&]F,
MEGHI3%#1>/I3D:<IA.CPD6)0"5-9#.)ID"5 6Z-40>\@IP.[F<U;:/AH)%P&
M2.LI,0+4.(US\,,?0U0]D\>HK2[,BX8$UHR/! Y30G-6;/%%TPN*M]LFFF1A
M-B.=[BSUR^_P0))-$[AR=A'^WG4@?/W[!,VMQY-@F]7(;]9SS3VH>./DQ>83
M16DORG>/AIQ]<5S[13EV80^;.U:U]S[)*:)J\)W*.SNRUYII>8BP-=OG395I
MA1^YB(?+7(:<3 E[9L"O@=R[2MRQZ^H=<YD+T^D-QT_WV):_S]U]I"QC@V.,
MOL&[FVU\>2MRCYV^_,>*QU=NM5\)/+^A_695/D0AI)!/C+-4>DBJ.RU]XD3X
M/W<2M=Y)[H\=V\>MUM_'E5[?32Z0RKL5[)S4A-\[$:#2_^!5;H&QW4\Z-,K6
MZ/)*3,>C3^A)_;.TB1IHH(=;E:WC)1.F?K"EKKW]:)A/<ZQ!]NJ")K>Y\Y88
M!#VG"1@E"8/$H 0B!_SKUVN)<*.A''C!K-IV@ZE=4ZP8= !%HK:[X^N>UZ!P
MU["R0?DQ@;3VC-9$R=O ^XLQLQP/W@G5N,R4.BKK^Q\F^HE)+FNK1-/X+H1B
MD"PA($;@O_ HCH^7'7XLM#'ZB/ET<,M-/NA B.I=AAR.<P%&B_!;S 8RU@>=
M]H2B#SV:/./E,_W/\*D#OPK\$5V4J8FY:SUY=JX/G50?/(FYCXI1XIRH*-<]
M7W6RQMX5WN'@A D^2<DC]/Z]]Z\,F\+;QRK9V063YMG9G3[I;H7?,(M9/#78
MYZ^.I ]B$. ]>UJ2\(O 0F6JR 3;,\E+$@H_8N?(FCS2L"5S6JUG0&LPOV!N
M!;/I$AKCR!4]4QS"EWI[S\(18$Y0Y/<HW5ODKO8/S=(_T#)5O28.2T8KX4JE
M97YJSJ&O:NO;8=,*U)1;K^ Z5*;:@ :N#AY4=Z/)\OP/VYP*H-QK@F0P*P:Y
MMH3S99#23),6XS[9-0-^MHO\E*M6"W31Z8X8=,D>$:JU<;7Y??G)%KSS#9.Q
MCK&98I'T-'R#^MO8^5>;TTNA5AYCC6Z,Z! &'"4&0<PIER@L!(HJPOP!Y<+!
MP$2-9JJ&00E_2-KPU+4(/Q_Z$:7]3USLG%5VE$B[W(_50/0;?',HBHW]F[KG
M1^A<6_KIW^)C#ISX1^7W?]VLVP&Z*ON7].%B1Z-BF-,.TC01NEYF\>O7W.EP
M5[C[RQ=N!=S2R-'U[U/S,R5?SKPAG,0V306_$8,&/GVJG"H9U+P_]PC\C_/C
M[]"C_OJ\+/YC((*K;; ;F0QF?X').\3)%4BTF$1=/8Q:25L8F7X7P1_GWGM<
M9U58&G;[)_RZTKL'],F9BJ O,FO?ZB5A2A:0WIU3-5AJP[,5@WR28)T%5^LG
MK'8*4:--TS-.E@\U>L>N3QP% JH<*S_Y^NTI;:>D.5&RAZ1BXQO:@VA&O/'7
M*@Q>AOUY7QO[B.B,JZ-%3YO:X.0"@]RF,+XW\UY</._\HP?A5=XO3C2'Y[(K
MZG*\S>)</<9\:L+BIO_7'F <S906AN+[=O^<4$51J;1^A$FM#;ZVF-6S?VVH
M;7MN7XK"K4/%FV62*2SC!;X E-^U76(@LD2I6?\?M+UW4%-MVST:>T%$I0D(
M6.A5I2.01Q$0$)!> N111 @Q1#I(((H"TI42I$:DA([20H]TZ4(H$GJ0WA)*
M""0D)\\Y,V>^[WU_<^;YYV0FD\F5R=[W==_7NM9:>T_ND,7#GN[0]><VH/?)
M<FD!+EH)\QSG!L32B&R:TJ:U55559*VWIS%<[_3(6BE7OX^L4PQ^C3N6+&:X
MM'?=ZMZ2B7;4%\S4<T*Y>-I^1INU)3CF.22I?&AK%30P15W)SM;02#.RBD)T
MN\M;LKW,A2AG3'H'.SI]5O?.UY#!VWR@Z5@I(^N')K%6#65%;F3](LE[9;KP
MR&EY&8,!3+YX*#]"[P1>-$)QYG]A06E[OQ,L[#;#QN#RQW:^OJ9N<5CZ7O%4
MA9$[6U2)),B&;!S^Q4ASHZJTX*N)AV!)=9'24$MJQ^=RPPL0V8T&7?TS?8<J
M&Q79(*JVT2C=84ZZ?9C3$(\9$__EOEL?)&=DQC+VL6B?IUF0P\SO'D7V/3#A
MD#VVSD=+P]ZDA&;!TOH"$&SX!2V:XRQ1X9I Y]^>O5HW(]L;.$TM+$W<"X:*
MW UB5:)B[""JU0<9);7DS_V266_:CTSX/H]EV<Y9R6W[9 "?K5KD!KMZV1E8
MY!$@(DE;!8<L/+&!.H1W=E@M+H2*[(C[WQD?X."TYY MHLDE.\/9*?W=LU4Q
M"LT,WD#]W96]G@$!-WYTA#=45M@Q3-/17_$=D5VO-?FRZVCRD_$9VPZG(-LG
M4P^*S%O1U99-F!Q7WK'I*_4UPW Y#<.OJ^K*R=PEZ?NO-Y/F<>&.%_"+>)'1
MAOML*Z^5>A#W*VIC88[3\[1G9\6;OM>75V,C9?5R27+/XI'C7$I)$B*9?+2]
M_/Z&9S-*"=&0FN%%R /W(8C*K12/S&/U,J--D<5HVD"K097ZW?A]N,B"V=UP
M*7>/^DCW+@9+ZOS/=I;-X,%& Y<66UE8(C$!,<$!*[@JRKN @G&"\%G_R$"8
MU>JO%I)<#$PN%-,#)Q4*I"B]J"&?;+5*U00141G78#D3/XQ*2EK2K"_);LS\
M7L^U39R7:C=6?W[MFC>QH=?O8@/V]Y&?7+;>VN7$ D<NY_ZLGWDE/(17GI'Q
M\=:-\WU\DD"]4VB]VQ2<1:^T%>5*M!O!)[M[,6=V2R0Q,1%D+$OH,Q@REA[=
M!7X(%AM5@FK>/0P4KZR'9&>8=4A,?ITPNGY^U3/<4_+G$I_@ZM;ZEL<2!,=Y
MB_$;9K*.X]Z;\' =W3C[*YQR)A3#Z-*_^FP%U,\8WL%+")BY*C3QGNAO$&89
M2KD$)L#!A0D8NI>Z S_+& 6?:V)W8W$976!^;8!'OYCC@SJJ",8;TG0%H4].
MJBI-06:[2L-/?R^A:K>H5Z,.!VNP]:F&$+AS(Q:?BT?,?M(XBU.+;9Y9XWKE
M#^V:RS<<_Y63GO%=7\VS(YW@.]BE[DY0JYF^<JAQ6K1FL""B3 PE5\RU.IQ4
MLF>8/S4<"4VI3LRV!%N>DK8(7\X-6&I'1PI=ILJ2)CJ0W @_Y%':'/#XLDH=
MH\+SB\;6J9R R/[^*]WN2NP/%KY\PY=8;-4UUF*QCQM"FCBI+!]RZB%5D-0Z
MEQS9=,/?KW7F"OVISRQ-U6?#\*^18&Z$ TG$.E@ OR6[2'X\ZB@VQA!$<Q"@
MREI"#@:TAU5C6XH.G)8C)<6[C29M6L*5#<G6%3LF5,GD=F$.NB,++7;4"B(V
M! 0*;\%=KF0"WFF)#G(Z#E;)LT/1OPG[;?#3#O=/EV6Y_0*YJ3O/)%T'I4G7
MF XVTY8MQU]ML8_U[C"NL;24QU5['B^T\[B1W61ZTJUK5M(<QMB;J0TO\D<]
M,9)Z25WWO#R-Q-OX)N\VA&OU?O/*!G,G_1D/<S9(0) 22;_M1B"2VU7^ZHG$
MO&Q149[JQ2ADO# W<+867.42@3#-GT)(#6F<(N%;CB]:#+(L1.MW_U9[Z*E/
M37UR%05NO'<(U=DB(/9N".6;;<?!(^VWB\#/+'^R H0C#P6#!9%S_\B!@YLX
MR:(]9#.:9#(3KJ5 XOA1QH6-0UC.@>(B'"_C?>*XU]0IV5DJH;M&VFW"['M;
M_)"ZT&*3.=F[BZWW\4J"IX. 9E@CIW8LKY7,SHS;-&>&K/43QDHO5:^EE*?E
M[]&G+0$BKB8$TURK/'.3V\6,L@>62U(CA2U-4I4+_+YFB87#!6:FD28I$]0*
M>2*:4S69.])?2+Q?W%&HO\3 8D=_5E(>[LCU+'\(HZ[J9AI=Z-!Q!V/,-2^I
M\M58F!HDOK'%!&B7M9;1E0Z%_[DYPP1PY!PU,@'+/E0?)B ,I_W/1=H>DLFZ
M$0G?YC6!OKR"JQ1_\Q),C(NE"\."YGE)CE%Y_@GZ)-WP>0>0.1;OTT;*S'7^
M8N_ZG0K51[=IJ8W=2&N-\"F9I'H])BT,'YJMI8:WSE2>:>T[,0=NG^&A"K2D
MHG*+J4Z/P1?=A(1&JFR+W3?W!(7;IKE^-9@[>:=FID P*ZE34:TEIX;HVGF_
M;6S\PXT,C=R&.OK9=JL^]*CZM31,"%O+-I."[\L879,A>RW^)&EU_L:W:;/+
MV9$QZN;Q1:*\5PVLW') 2QB[2PH7]ML:*DZ9W&XG6P5<T[1_>/O70O_WIC%"
M_[LVO=3H0MV<FRLZ76HZ#JKZXN<3EX $].]DQODRFBL=3#W*HG*V!_.%S_NF
M%;IJB:9R !#*)%SKS"EJ&,VL D]?8W\PW\:0)YN$5<H*/QA:.+UF5X<VB_]C
M=QRE[IOK.VBG3WLR??RH0NOV<58/"99D,;XK*>/71\-9^)O;PA^$+]L-F0K)
M[IG$S%Q2E)4W+*^?6.04?]?$ U'A48CY"*V+?O@8B8JCBJI$(DQG9R:$6U*W
MWC7Q^:.)F[5GWB'\+FB=(X5A9^4YUI(_VKNN";:O\R>WH7FHXBU=%]'"6YLW
M:L9FZU.T0-*!*9[O#C&L]8T]^@I<$0:S_+4@\O<8$_#U&2ZUX567YV1X]"NJ
ML7"WITP1ATS<*<<G.>7TFQ1\NU.6>A2;7:6$EX'B2AE\S\5R&V(U6,Z()(%5
M>KU*KY1%]E?(X!7:]-0[3&,>ZSRV$G-+O%USKB6M39>SJ(?/(LVB$7MS$=8Z
M[6>#^QL^'K$+Y(34+;W=TH 0.?A6^G+],427.(1."76,6%WDI)&V)PV""_O'
M[CP9TU!Q+NX8 KD=NKP7(S&2@J#2$XT?HG4YUVB!TB"!LXH;6@0V0^E[JL7%
MQ1O9CV E,-B<C6S)EXCCG5R7'D9PF7ZQB%6R?,)U#(Q"5\EO?*=9($2H^H'S
M9>>#VX1Y-(!$6?DV+9YW^G@-Z#QN'-ZF#H]SKQ)TQYN P_E]T;-H@H(E.=X_
MJD/Z%<$E?(_CPK*0^'#EE-&7)BW^T9+K=>4)NZW-=8M%1.!9?Y>VU_NA>\ 3
M:^JC;W/=#G'OJHI*E/>M2=5904[L(YMO"Z9=Q_P(EB.4!(UX6_L!S-2D78^,
M#.GGD^A@R>C<6 H7E/C]4IEQKMVOO.R8[$B/@K.F/IH$2S=/\7-F^F4^$OGU
MBI]HI\[-'>4:6$#4O:)O2#J^7\;PJ>6OJ>JE3!GJE6)'[J'[PPI8AGG_J#AG
MV$<ZEPI[?IVE+#"1>N2E5FJKGN;D4)N'>,1PP7/G>S:G^9H!(=)U0TR ,WP"
MJUN19HRGB^>V.WGDN:H_KHZ;!X>9_8 U*&DD\VM\B/?/>&_MNR43(3H)$JMY
MVQ Q/G\^>\F$P$'Y2,T@QQ%5(I3Z3-KM*.BO$VZ$I.0PNDKNZAC!-^GK,F7,
MY%1)@^^H.:A3$]]^TM-QNC].L[U'_X8S^S?OIIM4;6+/O1KO@8MTB[$MG[=B
M23"OW+7#*DJ2EX]':74RY&M/=HQXF]:- )DJ69!%E&$LS$V6?3:)?]$;I%B3
M.4/MTPX;E1:423[1;A.MQ5^40[X]4#[);3!8M.'$)\4FFG[@UL*]<4H]WF)S
M56+'0/J@\,[<WH>.'HEF#\'7JJ\SNXBWTF=O)TEUE%5%VWW=3ND>N7&^3SO3
MDP+9R?5-KD*VRC"FH@*<\[5G^RX2*"W3]_SE9.E@4H<*7&[K01/MX2PU8PA:
M*X=0R=%7[*U)7M_,/=YW77$#^!P^8=="W(8"PX(OA+ 510DL*[:1S[1\SUGA
M1Z6< $'JJJ-8"O.<5H^@<3>?R*/2'F.\^VFRNYW$!<=C&+HL]5/0PI1\6Q?P
MNW/M((_FLQD'<E6+"6;U\,N0\\C3[\I/9O3@>?81[;WJ[Y5Y581=D-_TO(64
M/>?GP&W+WK3&@.!;Q@@%YP(W93^[]<.EF(VYZHK*!/-8O$5J[^^N(!G^!(BU
M/GLU^M311N7;4^L\9/UK _I_@V5-UDME7JNS"JBXU@D1(6%<#OYM5&B/-2N!
MOUC)[^IJEI1B IXAJH2LV_J[+6_)[[V3A^G(Z8^ 27%(EYY@-Q3%_9RQV8)]
MSPKWT6>@._UD6O/K4Y-B0T'*-O(:MJ0FHG3,S>7P^L%2;?]TC4.'R3X?+P^W
MS<?)=K'9:A_U VY9FEP)[D9CK:,4NQ2#H,V$AZ/R!<IY$?!Y9#A/"4P2EV8)
M@LI+MX?<,Y2H,HR*T968C1 W+,@16\B2/D_O8OGF",JH-7_N?ES>]Z%;5;RH
MPQR&./DY"DLR% N'0$13;0E3CG<=W#)OXA5SXPUMAJ;W2D/G0?>= A0UY2I(
M:9T4K8 *:E(^]E-0_HJ'7L%:TZV*--/A8E@5=*3\NZ&DCVJ\/LQ;4R=Z;)_'
M]P.Y+6]IOZ>RZ7R.U -;,*_!Q3LQ=E[$E[5J+=D+D:\R'^:J>RVDQL9R+E2Z
M[PJ2?&Z8<<@2_7BO=KQ*OC0;M&S1\*S6.0$CY?4G/BP]?J$2[C6B"/R=3>G]
MI23=9S;Q0UTYRZ, I)E9P%,_CP[G'\DK.*'/-:<D$+C%_5.NU_K2?0].@UXK
MFR<97;4"F#B*[5']C6^@LPU\66TQUVX[VNO,<X29.JRB4*^=1V/R;-WBVXGO
M8[?''N'E72J&LEU-BV>WGUW1L!HEMY/UPF6;;OIGPB1E-$Q*V^%%#F!">X /
M,</TV1N(G4-'5:&)QTF5BIFS+RN+#-,ZMDM$XSTNAPS=BTI^!!K3N$/"= K=
MJ!S< LX]I[Z96!-2)PV$;916;FB#ZZK36ODIF.P5%:$[6,,-;</AIH&G@640
MU[J@Z0P7$4:@2#(/7D=$.NQ\@*5K_FQYD]3"/N$)4:,N?E1QR<S4Z^??Q?-F
M*O&#-)NBZ6RSUG,:Y3D6KU)<KN33A@S4**=31\S3_Z27NZY VFME-7?+7I<
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M>?M',G&5P13<=Q.JKSB=4X'QH1W'$"R+1M+)K#&&/T,V*P"7HUE(GR-0.YF
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M<W6,<VZ8><])M%A*ZK_^_%HQW[+U:8$AP1A=W6:5A$M-S4FK%+^JIM9N_J[
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ME&7R!F5,96AB==\_A5YB:!U),\5J@4!3;8,/S1HQZPLDJV[9XP+(8RLT#85
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M#ZT*17'Y.FE^T!7>F@S::5CGW4#$F.L',K,WB8UO%'CJ-E)8MTGD_0,+)8U
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M=>A;P!F5<Z&DX.\SK%$.FN'_UTWW;5<4JMVQW.<M<U$U_$9:[5Q%32@I.M;
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M]%_9-KK<L5O+J*M3U]^;&W>-!T57[MN _9'0<6>4T=:QYA7T17-K>CXI^>'
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MQL7^(G S>D^DTU9KGP6Q7*IGNH.]KT16@:2D.55@T@M:+'/'=@F'63A$-7X
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M7K'JR]7CB//@V^)1 <0C.-(9J(YT\957LU;CG[WK,@=\EB\LF]%:?[(#>6/
MKM[.W%B4V8$4R5F7<2;X@H7<?7Q1VFA9>RW<YW4)56Z7\95?E72:*MV<2KN9
MU,;@0@[;C2M8MP7\[WOHM&CS7: QG$_@^H@#?PD80P,SA0SK9N7A";O4?\RZ
M+SW\:;_ 1-(((?*7CTZWU\=H%PD'PJ'-,AMBYB9.1W(:K;Y^ZEZU(D?UGALN
MV+#.2P\PGAS_?"Z;V^-3:_Q(KU<--RWPTCN;O']+</UPM5OO)6C("=<_E[<;
MBQT2!QQU]""9G$(EPI6URPWGS7W]#UW,_22M_(-HW>$=:\N6N-QY/GKK/%J'
MXJA3,4<DO\"D:NJUL95&_;RUZHB8N\'XC(# ZB+]11CBP?E+'8BLS<!I.G=]
ML?B.:*3\DB(_+U.L0_I2>]!Q.CP[/4N$^$  /AGX8/J2?/ %Q_Q7T"2RX4]<
MK]*JLKPBE>:4\@<LW**[[T!,U'5F-8>G5UT//4R9=<_G@)I&F\LYJY?EFOM>
MI/5Q,B5DE@Z?TEMO#R0HR6Z9L;8+X GWE1^A]-#6\9G;ST5,_YYJ7-]:2OF<
MU&![8A_=76\^7F0Z^XO$^O)+]8O8=JV^587/O,@=2+'M&5%U2E6YX]-5S%(P
M-9 4T"8A 8>[DP%Z=,"R,]TK)H"Y#4-4 3#R9CRD\;[8(H,NW:-%PN]CS"^>
M/52)U?BY;ZL.$U,UGW#Q-XMSV^=-ZS,-U'N9)<QOY'[[ER?U5B&!P3^%_^7P
MTC?MOR;3NXX]_]0>K=4O<?&@=SOJ^WG]I#YYVQ\/)=XS[/)=\XO9JXXT5N]O
M@A)A5,($#=Z]OS#!]/9-G%DO4@ZV&BW\3;A4(R@^3?N.@^_I>=%!X%0CP+^]
MC8K'D>(T-\U0M##\[1F4]*XKVX3J&_Z/T!7,ECM=Z__@XAMC3Z47>?)*IDL_
M[EY:+X,ZIL1[DRPSN7.!TS0BJKUV&3R3$(F*14Z^(Q[\YPW^*UQ_7)O[='KY
M +\-</GR]-?37QHPU1A1\BNH)^+1N;[W:]\9ZDT4'-L;-+5V&)>X()YK,('R
M5Z^NRA(FG.@YW4R5XVZ(67EF/8U\!6; 6CK7,6(AWSZG %7>%;'9_V1=:F>.
MD7.1[^W>1XLD$"N=ZX_GW;[.F8CXU"*.^7PJ&AE".BIZJ=_X2-1+E0\SD'WY
M/J2*J^J 5)-P:UHR+M5=^H_3/?R]$GA\1YV!Z/>@1',_ ;Z%P'KB#J0\')C>
M@=PAMLA.T5R\_IX@[-^!E#J=W($,%MTK6_@^Y7"RRV9\R9;L!9H75J<]YC_[
M,SSN_:_.*)8CYV4S,<SRGP@8Y'OOQGRV9HRZ1@.@/%F2-7-^5E\YBG\&DZK"
M*QDO>P;78M6]AO"W2Q)>BYX?D;%J%$EF_"%_T-FB'OKZ,/NJLC)I90<R7/:#
M!JIUM#+ \"U?O-N(SI;(/M0[GA;]SH4S9WDG<QT*RH[#0W8@$H;KM!.W#[:]
M$8]K3 )'3ZYH9"9>>G#HU[K\2B-\,ZDGT(66Z(.___GG]:Q'R[@.&6LADQT(
MO5XV0E0#@1I96?<T+QJKV!X"YB-M#^%.LI2%MF"F%$^9QND?,_=4$A3:)%2\
M=<[ GI;.6;[(@FMA=:7[8A7^>JXO'/-N?W980.G9,Y0BYT_I*.IZ4X<>U$GD
MUN,9%.=^:O8[+'0I)).O4/MG3W> ;*#O[""GZMF+WK]\OY5+&[DH!F%)9X+.
M%['>Z#G>LE6Y/79Y,&-H;GA34QU&^#A][P'-1^$P3Z!L]G_(;XHQK"^ZX]<N
MT+D]!,O-?:/(!%BCG?)/F041,CRAB_>[P;6IBN_,KM[O?.>)[XELG]$/<)]&
M'L*S8<I*L&?3OMM]>@31$(#,^W.$T"%@54*5-2\1JTA366RHGN_?0'P&#KS;
M;A=XSZ&'T,LLWS#*% X$ETQB[A^Z)'\6OO'K&")4;S(PR/77#@3"C+W>U+O4
M-!N+K^G81R7>FLX/SIT,<E:\\D"/J2^L]?)"A\ KXJV ,M=]@M^\\LN&5G<@
MH2O^HU[?<77'7]P=*G&F!2-L_%>&-DGW<+<%48?SKB][V&<[G%@YD*QR8?1$
MY\S5^11EYA>:],_P^%OK0E^>R+N>>"S_)C-8ZZ<M-I^D>8O^4/JP4''B2\C6
MAI1(HG?V%4.9CE- ;PJ..1-5\'7:O1=.>LJ!DJ"1J'<?_KJWH0VER[2+,S">
M)76+98^Y^/(TA'[EKS38_;NF<6L5A=^$T'>-Q-FK@>IJHP@X^)X@JII3]V_(
MJ0-.9N<%]AA9W'O=V*'TYJ4Y\084L"#NF2,>)3J/B36F_WQECFZ9.$[0NEKX
MX.'C^EHPGUURS>W.DZQ/E(G4P[\6NR"M_Y$',?P)^)9+9RFW_(KMW8$<3FCM
M/3AC=>5=33ISQ:EBZ\YI(Y,5=2MG3Y&CF$TB:";^3"0F%6C_?-5KRYC0MP[<
M"#TL?A[OP+USOCVT/,_M8^ZGO;0'@+)@=QS[:=/$V/M7372&64_Q_/ :84HJ
MJ.Z<@1<9Z%A49:,>M_!%GSGJRK$OC&R(<QX-^(DVLS[5&-G1^]O%4K4N6=E4
M9IWUP1Q*HVK,VK?G3SK,]PJ-WA\'2<WZ91'\DSB/YF\#!F.V=H! E/:R1,>[
MD6^J2B9^["#UBULMQTQ4\RRIY4IO4B2B_GJM4T$SKD/'9A9Y40!0;6&@Q0DR
M>-1G@!2C_0U_#EX;4>T)RS) 1;/E%B69>FOG5MM?2YJ,]PAV5$GIVNCZ5]$>
M-VU1OY0= LO::!55E(\3N("6S;($Q%$<Z5X=@V<V:2Z [8A%*. B[S4$E1T#
MZUA+:3[P\[B8EO3NM>_\$US7EXMGJH?I=]+L&#R%@]7%<\]!U[O;H;%?'J6)
M354"BSTP@.)L'Y/'D>E*AY?'WJ?'YD.CCZ6II*?<R%]4T-Z!=).$<#L0*&LI
M2(TN8";DE'TFM)G]X?%)*UQ@<I:IG[SK MDB'^%JH3IZS;RI'=Z?HJM-1!+%
M8&62>-GA-1&A79= 1Z_2Q'Y02KIFF7&E[U5GS>3>^H*K&-R_ZC\OMNRW7>?^
M,'TT.&T<P<H)N8(>)(V$\@]SD+OI_A 8Q*YNG1"?(\@".Y#8!S'V=)X!ZVNI
M;\*Q^6SY04*WBCE;</@-HENGT%6<^#C5S4MS=4M+).67UG%T$1,:2W0A,O]I
M%[+O66:YMK;DCE_%JJ=%59:(;K5FBPW;B#<X0IV CNCBQUSD*Y[YHS3!T].1
M:XNJQHS5FJP<ZB?*%]NK<[(3L0@H_G*?)PQZ'$=JXA\&>F(>;038UK97Y.("
M;@Q4_KCJKN&2_8?=T][9>4(FW=:-=371S@?]OP>@H$AH^Z!=F[6$25#E,S\W
MBSB[[F^PQ>0G64:IF1\OQ([61=N\WN('<]:]TW_]L+\'D_GU@L)@5#S5T9%.
MAYW=A<2(@RFFR 7L8'3ZQX\6OBRWPLZ/?E._J"+;;V@N$WLIQ=E0$,F"ZG3*
MV:G]'E[TA-\]_6]YHAXVO\)+_/X\]'%-O%UNLJ-]E*=@3M+)QE;D@=.*NF H
MMXQC7C_0O1LI13T(LJ#EY+F0V!]SU"/@Q?$S#F6B=I56)O+KF[VM$_*\6]5T
MBK3CXEJ"T"Q"?@B;%Q3TY9H/,RT6[K!E?%TSG"IE#R8UD03\3B>.MM'D*%B#
MVT!/&7M;^%9;P'N\<#_%3HTRRV*<7"GY!385_G ?EZ/T3T?:@BYXK$:^:]D,
MTAPDMFQJAFNKGVI!R-.QE<$"5^C%JW%0LXKK"B4160_W.MC;-^=5/(V0[M<U
M@,=??:'PR^7QAO:GY(M,B;-6[Z^+6-7&*AO%Z?L.J=S.]"#\T68G8TSS3B0K
MD"TNI!>*SQE-A'-\X!V76J^+_<OAUH3-KIA>BO54H:KD35_Z4WWDW]>#29&J
M 8GX"D]UG7=/+0TEWKRT;<L^N\O8&:WH=86A'<@JRQOMSOA_]YFW()>E29LK
MT&UU*+(5VMRR V%\VX',GFW.B;[][*KTUQ.QL?%ZOQ0/K5_&+"2D[3VD=/[$
MAH >SZ?[-&ZYN:ZNR]&:C0R5G./<ZX-+L7]3^F!_IX-2;Z[57:(L&C=M2&EI
MF0<$3=9MS6J/:%3?(CU);Q_XKY%."4S0 ?6&YJ7)]&$'+'#9R)?IJ)=EOEER
M1F!1,%>PF7^!ZT][/SKOI @^]DQ7S)!,X :TF:J74F! 64O6=2O^Z%")VB.,
M^C5+9R^V3FA+J'7M*^XGNW/F%O>YT;F7.B]4I,!OG!O,53ZX _'_J=)L'98?
MB$J_&!"CU32(^WKM=H)2WERS95)MG*E8EOYG*U-Z=);>!PN5H5-=9XM,H+F^
MMK\UXW8@[LBX<:'MK!V()Q+JOOF%&QF] W$E,5%--$&"_(0=:-ML>7_>2;KA
MTW:J,XUN&*J1Q7(T=N3N2HT8STU[?M'H-W.@A^- 'S#8,E!0Z0QZ,H"XS.^C
MG@6-MU3Q+GV$TWA$L"I':E&=11/B60&.M!:]-2%,,T*:FUU4.GL<?W@ UK6U
M Q%QQ&%:28*>OJY]5*7Y\8N #ID3Y]5>9=]/EVJLU2OO6\3Q*:BW[?3:5QE.
M2V_6XS.(DE6)0ZIU,$R#<-EC5<?.PSYGG?X05LBRK]WEYF64,LSNT"FEA*Q^
M]!%"/ZURHU4S%"GF5R8(BK'^JXV(Z4*%T83QC[&LTT.EE5N''-K0XG@_EF-0
MZZO>)J(@00EO,^P"3$?R5,\4%LYF2PS@[\KT+^8/]H:O8H246ZD:U=U@S98Y
MWO)SU7;*&BTLD-B\Z-6,5*@7XSJT.:DS1MO2APLE$P3""'LQ$^*5HQ.1NF:3
MSE7<\/P4?I*W-P89A87+PZ]C'WHY%[J/*R98-9!NUCPZ9YR]9!L:G6B9QDQ_
M54%)_^VQ'JCN^$8EEAEC8F]2.6JS\;!GN811FU6:PG1W^KZU'LWS["-.YA'E
MM%$0'K*O'KUEX([0!5?8HYHAQV8"T2UE\KB--B<H-ZNL37,DJ956"=N(@=V$
M*VS!YQ35@-1J2=(D5.+'3U"KA22"1[]SKPT?3^2TGP>#80K7S3:6=P=(U70"
M5<X-*K@V<7#W8<'-E&.)K@E0?O_XQ3X>D6ML!6*+0,T6I#",%J:/H+&R]"^K
MLKQ:;W"A,4^2V.]U=&K_!>(SG_2E&RP:M95]+8]BSYB*IF=,15LX_5J6HXBG
M6P8$8 R#%=8'R9$?\Z6_%'7RRK(E_>\S:+#$JH^+:.PJ\L9,62=)80?29 1W
M!Y99&ZWJ0:W0_3P1/ZX(2RJNWH&,VV+1(A#JX.YS]1G#ZP!IS?\U8I6DB$1E
M"PQ6>HV,.UI;1W2TT*3P6OE@.-R=182 9BV$?TQ*RN#>")*/^X=Z4<+$#N18
M)?$X2#:E(R1F$9> Y;!Z+/L%SY4-E>#=K@8(-;LJO$]ST9+5.U)M0@%0D7A5
MX+$-'>_XP;T"EZ@I:D@&,QR!L>_I?K&UGKD<<P?++^8F C$M9%?= ?ZOU;IR
M\^?C&P/#M5LVT*'Y>XB[+@LDN-HRYM[*O?&YL:42GS7_:-X\.+1EB[\+PK:N
M@_1KU4!"&!X+V#8C%+;__<5]8IM] 2'*[0TK)<!YCW9O\;I4%/QT'A,4:RWB
M'K0L\F#>'1L/98M(@+(#JNH7YR:NT ;7,J;*4;HH<%<38Q8JD6%4=0;B,&C
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MQ)R0XLOR=+G.ZQEL1Y]VJ!A,?1^;,IRTBY.HY@0Q/B/[[/9;O,![_(6^7/
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MQ*<-93Q]0"0&=EFKE:H""+RJMRS!>=_S11_')34K0AE^1)&\MQJU%A5%[HR
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ML=*B&3<26BS=%@O!X/V;3YR$^OV@0J"5@5R128EG25(+57%HS5S,Q*[ TK7
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M51YQG)Y!5D.N5\:+P8)@EE7-KV2#*1XRIGERA>Q%K0=>HBRKA0%XJL&/DJV
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MO[&(?:FD+!,I%AIKP@L/'H-ZQ@&R&6302>R;^2G0I2..I\[N9#PH"D$'1II
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MBS-79N0;Z2IA)909K?B>UIGS\0BN<4<D05)=<Z?++: HJ[WZKC3#-;ZHN.9
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MJ]*S>G5@P4+T8*@9T_"1P4<ZY(BF0$DS_#3E!$"'>)_QT_7J-S;8+;A@!I7
MBFUB3$VZMS#UBOV!S&XUP-X\\MX>U'R8+5Z-=MG_@-<H/.B>:Q3^#,,+NS'"
M2!'7@0^JGX?B]:\C>;WS^6K9!O B]G$&F&3!!Q-KCD'K4MMF0M=MF7S='7&M
MI;7% (:<)SX> #NK+S^A,6/TB.'ZB#QH[&]IV:&R"=.2?TY1?=MSOR7;5V$
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M7V9Y-!=VM[IPI,2"57O[D..5/5IYN 9TWC^$64;+J_*C(J6 E)[0V2+!GI@
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MML<!F?,_X8%.%JL=%QIC;$97"]VOW^--HEU#(@H:7IRF8R<F+"\J*ES;!%^
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M_*VY@G5N%K2+YN/;_OJHP#S 7>1QKA)HP7+B]_-?42 ]XXD">9/X)/FF_%=
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M0;3(<U\<L#UH7A#>SRFCBQ]R5$62T_>-YPW%2D!5VN0!C;.^FOI'FM4[^8+
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MIB_L:0&ZGR&#!26 /4TKFLZ6^F\Y3R:%BJWM@L]Q U$@#4]&_2''0DEW1QF
M=(_.?OR?"^K"I/5D\;A<WLB,ZK]CRFNL6;*?BQQ)E;)K<0QM!5C/PU.B7!7P
MC/6DB%- WT)/$LC>>Z5<ZQ5(EQKU;3[&H+EY1'E]"^%IFWK( ;$97U]#&Q3]
M";6-:E@^MRS,U.?OQGBM W(_\_2SNRB_NR2"NOJ@(]L6W!98!_1MIGY1B=?D
M(X"?ZEK!:/O<2L@-*00X>\X32JA5B(<KP13)9BK"XC[39?4N97G!"'?32.O;
MW(6.I_\+Q!Y!RQQR"*)M:>VFW;,7 60!P/N[6U((P4V,*_<6,TI$\S.%+ 3E
MHFL:]>#$PL6%'OT3(X%JU'U3LW&0M'^):1AUP(VX6Y,4K%?U">_$>NM]WN\G
M"R%3)%,2<G5.LSZEK? (CB/L>!Y/2N.S4C-U$"T&GXJSZI/HBNU.BZ,E(Q7S
MT.G@^7S2$EJ:C_A>_Q*P82'0*3N^@-+M%(N)0X $/:5(>M94AS$0HGR)WV6)
M8OA!-:G1Q6I0PG!V>7?$17(0>:&ZX[LW4O$% \P6T*7:QZ*/43'BJ-K.? '0
MN=W!=%J*("KS(>:TM^2E&&K/"Y NTY,$Y<0>7$9MVHU\@_PA"(RS+:CM]YUF
M>\7[> C9-/$/ES1=)<9\)S\R5%?!C&EJ7AUUP/]SA![02S6[9]K1T<:T_J.O
M.J(> !2XA3,E#SEHGX]@*CDZFPHWBB2R"%KC&J;E6X<<QSI>#LS%X'0/.?Y9
M;O"6/-&21@S,U%KE9D28ZKI<415@6S4PIB'_"VR69K27Q:+UA%(6,%$'LL"'
M:K1K]OQZ@@-@L.TTQ &+ #'EXC4DKB"TK$?P@;S9M/ P8F:>)H&QO;<4#Z[9
MP^K BL?2,Q6#HK*"%^N][<>]*,84)3NB"SMHT2RX_GEKJ&SPVJ?U^C;7#4UQ
MUA_@6IXLHRQ*W!SX(%F[D"\![%!W(@FC\\IWNT;)8I-$"3B1(,&L/I#$CZDH
M_SNQNC4 )XLA<HM#X<[>K?U!>9<[AK?ZIOEXX/::^7:H,-<4DAW_7$\Q$&/H
MH!&.--*,N#I<$Z!LZ*BN#-E\D&;YZNOZ3H,7I6BJJ> _;_A>$M2PI7Z,WN$7
M*('N/9*\H]3:1+S:D1,Y!07^%Q(5I0X51I5UBR6_=,.B(ES 9"V"*C.I-AFG
M&.ZN@>%:'EGR=UQA^>5RDUW/9':!SZDKJRS8##<.B3@MA<XVP#%;DS$!Q@'<
MBFW:N$..\ZA4TW9_DLZ"M[Y<1XSEV.,C8(N$$":BWR) 0AF6Y$*O)SM[TL0)
M?5/]_$+'[U/&?H$R/'Y7Q_:;U5@Y^*8$<_" >W]>S9+NU%(XMA"IO:>K8EKA
M,J,5KO(7$N14Y0*OJ5AQ+]-+2AICV=O;V05K07SJATI__(!TZG7GJS-PC9L.
M0TI(Y9P&IS:G =FV[HW; _P-AB;9-I9.HE'V>2,C?Z:SJYS@13!_B5\%+<WQ
M_O"0TX'Q:]^_)B/6"AUE'-:N3-U42E7X9/^OC^7MDZ)Z:CTE H].AF6;FG9R
MS4*<7+#M_5H9*X%(GJ[.$.2GZ9FN!NG8FG]5NL5CN_K.>]QH3?4F"SPZ9O#_
M_S@Y]VX<<GS)93H=#(:Q$@\YQI,JQO(E]051;@M0(D8(K<[TT=U*N;!$]VV^
M]K(FH-WDRM61[02U=XK!I5 E>TLZJO^EY(7E^AL24JL%U)9M* ?;YE.S7,A^
M68<7.\6L@U_#ZV7GE\Z-Z9%V.(1A6'\BZO)<S_$3%Q/#I XZL!&>^=^*XKL7
MO_L8W)HHB,7&%T'>C5.MTNUOF5]P<;ME7/9S:.037*W_IN//D&[;!.R+_HV6
M7W^3H<E$LU'2XQN?M$=(C_T$/'!)$(V*+K_0DFO+6:W@=V;6]YG0+@O^E?SC
M$8J.XI@+7L]!64(-=00R+4G<3TAL[2THOL*?9Z"U+%_LK?I-1:.;LB1^0X03
MQ2@$KD,.>./:%:Q1)7A^L$-1J6DUXM&/I\_*_K/Z+0]MZVB<7$W_+^*;OK"+
M^%%'#.;6+/$H#T6!8,6%I>U4[&WJZXP-B5?+71[<K)F;GN=^*$0;-><8Z42(
ML*T 4V8""S$&Z5G@?+VNH7KF;Z]0+M.4V!1\Y%'&KLQ>X*]2MQ155W[PJG)X
M5HE;)O'$$T]1Y*+*5:H2DL>NPNHZ-KXW^SG1;4'8DFKM/:8FD+[TE6LX6<7T
MNYUEPKL*V[3(0XZGZ/.[MY_U)(;X\JN2GUP7%8X=^].5#"<&+O=P6H"J3LN"
M^E[_UNJ++XF#C=>^'<ED);MHVR>).> OPIX\.*&U,QQ>J'Q'IJ6!4G5Q31H?
M]^@5P2;1UD'R+H<XZ-ESQ2=]Y+S+(UNYACQ:)#4#]3>#XO?&Z(_;1I"S7K,W
M,^U&[^E5#YOEIBIEK(M';C+@:=$+Q-U</"0OJGIZ^=F7>+$S5ZV5P@C_MD5>
MJ&[Y:5I7E]-]RLS%8V3QM?KYN9[RJX*L]V6Q;Q.O^5RB6/2K?4IDR06B [U%
MT.ZJ[J[I2F;"GGU6Z3IOVG EL HCH\9W+KFKZP$1](3.;Z2RJ/YG*+0!&,X'
M>]UC;;LT%I %^QI]!93#A"VIV!765+]SETH/P$2VKK54N?;18.HI9U"A.]:9
MCSJ&\=HGY,-HHHMYCL4(D]VOI_]KK//XUVYP3%>)3^:\P=.[[>$A*@7E1F5+
MLY(C&E5QZGV*MQKWP:9U\;H2TA9-44*WL/\U)UF)+"3=YCC!&^*VF>I=O*-3
M_49)Z]F01"%]6NZ[F[&(_\[[C=.#QV^D!0<.:9Q(*BF^JRC;D?J'O:F^H8Q7
MS/FWGH,4^>H8[RU.49!-]55)WISV).VO&8W+YC>J%#!GPZ<&E8GWB]9,=,)J
M#4,=\W1*D2!Q\DC7:-E+UIO/CXJBHR4SN)A)VB )C2$-JT>EA2N.XP%%(I6I
M92)D8W6=J$*)&[Z/9YX_ZA5LD%:4U(=_:/ZH^,KAE4WB@D)(J2O%@)OLM>/W
MX^9K+1XI358E2>+-//5'LKC7#W!4-I>Y1U4X=8C/0>^@CL:-<D^[R>WUZSO^
MY G?V886*=+;ZF+/6\=EPC"KO_=DT.'[->OT$H;0RV#& M6,-)QDOZ":X*.B
MC/ <W2 \!X2-,GO;F(*;)-*=<&[9F _-X?N?K&7"OWN+Y/A>$0&=Y/K>[V+8
MGB?%Q^M=#UCG&A5[C21O8%T?E?#\5F]T/16<^Q1_X]T35&2\VL..F(V+5YK4
MU ?\S#,$GQM\5;_>2+>J>9R$]87<.DM(]PD,V_A6("<PJ$K%=$F)14SD"ZE;
MO)3B5EZL'Y4^]P-MQ$S]O &;Y61D9M4M!S<WD*RN3FB<?IV1Y9'SU-'7M\3)
M_6GB@%[S]A*CC5K[^H"/K<]((8*/+U64H)PZ0V4SHHHH/%BY*;HTUXZ6E<)_
M62R6O_(O>O<WS]8\V .7::.LB &I!LZNCBE[ZJ]:XB%'M,Z=*/>WJGA3&N)^
MCQ\-*@(/^V>@&K[[JKL49M&?T?3V]&KCWO-+C5%JTKU;9A&'')UH6<F+1!O2
MDU]<4P3-<PY9;_ 5C\O)F_=.QJ09?SV?YH^U&PY<IIA=LRX1.>1( S^8DUP&
MB+F/;_8GYRD>^^RL#<%O/+PJK^#0/RT%44B6B_6'7'^W-$*R+SD9T\<P"11R
M>KE81I>+)[M5CK.9__?N1N4]-4SO/PRY_>=,OH,2R #"BY);T\',9,4Q>?,<
MMU9J$RC(&%IZ]/%ER>- V'S*B94_^+/8IK9"Z+1GSOL4[2\B'0U:[#>J_V F
M5<\=<BS;5D_2'2EPZ;["47-%I02+P&N_QI^,;IJI8R[_0H"F)2<J]A%E,R!G
M,7@OUG*3C\[<TYEAPX%P=QJ&\SLYD*E%S<EL[8A!-)6GD4*5^_]W7\;YNB_'
MP^7N:>FV4=L4]FOL98.3)1P' I!EOI#B_S X'NV2O!L7F5^:(>Y;/#]G*+.W
M/QN?_)7S9=CDM5+Y']#8DC3&KK7VWO8AAQB[:K\*\]1T &XWH:^(%JYOD+PV
MEO #-4W].9@!,4I^:O#;87CQ5HP1,_ZJ13Y.&>?!X5P_:&K*IO?@I6.[;3+"
MWEFF^YB\MG-[59J/(W4GVL!HC#J33;)E:;K..]M?KHGRE2:V, 7;0X[AVL*8
M$3E%JH\RF!O8D[ X]G:<-%G1A39*2'50RB+H5U4D?FF(ZRW_UNOWO3+]QGM0
MP ]Y=]0NT($=+WK5W2>:<>#UY^ *8[&"&N[4%:$ZHA38SD<20U/LZHJ7,^A7
M,VN64C/ 'I\LXZP,,F\N[7SS6+'X=./'_64FQQRW-^;(J\01>)?S+C,]/[M(
MZ"NB^)R%)G52(FLDKQTH ?HC7V9Z-7.]*[\-T/2NW0M^EE3EI319[S0]_0-*
MN0<ZJT)H?L4:G+9K'\:%@Q^-^FY-ET7:,UAU/@'T8*-<<]EXVM?EFY8<__:I
MPV7.G@[$7+$)7:X)T.4.C+%CS-8G^"'W?B8;G\2.<=V6N>0HH-US=F+OZ?S-
M&(YXMNKYUTG&8]CH:L9X::Y._*/ :W8_T94B628!96*-6<]8;Y[5FG^]&2A/
MML8LF8OOW5,F6??75WYW3ZXZ*_OP(?RN0V*S^G]%YC;PR0+S:FF7L:+U?_V5
MKFIQ:@F+^6(A-S)$V%1&30=CQY%I(Q:4*96X-6!O]FX%\ONE_F68W:3=KMYV
MI?JD6.(%;[<]JXFP6_=,3]13*#@VG&6:;7UBVN)D$3!)=6TK VA#W:WU4]YI
M:!.DX+)80(&R,LC2TZV$X@![1%;W"\]"KO;]&JO!-/RT<2AKW7OJO6AU>=]I
M''2G!)7U54^+)IDD^<DN\&W@F53-L;5TFX+Z;/OH6SC%!&TW69FF,!SOR^=1
M8[?F/8%@QI7%[;*10PY/OJCG;6TWN6MYYP93Y'43VMN6JTYDOU][*C1XNE>W
M5[NSYWJBM"@UO-+;\E=1HNM7GEM?U7[7BLFWJ%/B$WXU).34?-@:7CAM]0BK
M(E:F-#YI>X._KPYEDOK:ZV[ 4H5M]Z-.#ZN,JWE7BBJXWGM:GRTX42?83DG8
MY*9Y]ABSP^&E:!W D9J0#7?H"Q&"\+3/UF*7,PVEY&N"IBC5F[$TSSV]]I*L
M'E^)7WGP:(>?%F' C3U!MD%[8P/3DWZ^8B6/BZ'QR1A+D'*:JW8%,:UNR?KX
MXC,?4WDD_YQ31=;D+-?"I+%1.<]U9N_L'B_(M?^<\62N\X"'$4-<$7C3]PNE
MVI5E$7UYT^.$=EB"GKJK5I9(G!"\%]1E_FOU!DX/[C2)/ %)K(=&R18_$-=^
MFSR>?*]>X^30+!=6.EDD2D;8@CNY,D?.*IHK;:*(.,[Z7D%VA#F.%EB<I31"
ME14:)K:61W/+),\.Q6^NCKR^/O9LZU/8,<M6<Q$=X$<$W';"U_H5>9QH5?2R
M0N-JG<:2D0;)NFQ@6V%+UCQQ 5NZA*"=;*ZO:ZIC3$:"M-V1)7\@0ME<4W\H
M0G%>;8\_UKVZ7MQ]&Y:;RYYN^;!64^*F)3HA1,FKI;7S$PG<PZH@"YJ+OT,3
M8^<56\U3.#L<NQ*<6DD\ERS3Y43&7>WX=".VFFY%<W2Q%(W.C\+K,?EHX'CU
M]6@I'KQ&-=#3'5K40 %,;R?V*5<_K>RK@.^46/41*2X?%7P#><R*DM4O7_'(
M>."6MFNT__*08SY/1VJUP[OC0H3T#]C!36 '"Z,C]<NX/FRIQK0BYOG\J1V<
MXE&;DB%WSL/U+P<DKU@I3+!HXO^L^+,NJA%%\+OX9^_%,'9]?TS4F;>^=^Z=
ME95%PKB>IQ?$]@RX?DO(7LS&QOFE] #@A(CKC)B7/T"5"S-G@\*AW#HY6EW/
M:A;>>Z1/(_GB>ZQ^YRFJ4)<=/I@3Y"3B<A729T0?U_]*Z![#VF5^FZM#KH["
M]E38YX;QYP/5Q3*3<7T5[,=,7=)Y#DP3'EE=;%;^_FGWXFCC>[?FX8!BCV<9
MFC>N/QG1!BNP+S#Y8MAW]36<41B78=QWI4,.V#I%\^L&0MRF;OQ*8[N4$,@X
MR&>MN"XOH+E-*#,H$^KYOGC.H[4IWS,=]'"N:AS [8$/AN;^P2N6HAT[&$BB
MZK$EBGURA]=02IZV:9+T_7JAT#&Q6A+V>9_1Q)7'HO;Q"\16UQ2DSY-I+@KD
M\]LKA2^AW]'G7W7^ KR_*X'D#*/Y>5X3J04B%>2[%[(B1LPM?1$&O;TS8]DY
MQ>M!AQS$H?.W$F[1^M<E2"UK\@O^Z!VU[L60C*L1"Q6QI#Z*L65Q6I*"P-]T
M!8%+"Z9\=P7*K1)A73=<DYB''*XCU6B^,I2IY>16TC_0A%EMAE;GM/:VV?/1
MN_ J3*R^S,=AO+%GZ<R/&4CO?I7?_ [SA!CR>['6VV4UQUY?T+?T#2FV /]"
M:0$-F1+JN=I'_9"<QFB>9Z53O^!2^);VL#X:*1=^+&4$4\)SZ?BP)Y]&V+I%
MSK W2Q.H/1WGWF<#DG_2D)\.AL'_1)SQCA!CJ";A+1A5GRDSM9TIB1@N@HH<
M*SG)ZRU,DR#$S'NG@44/OI(^X7IQN&8=9.$O_>6R0X"T3"7M>@P53!DBAD;'
M[6'04*=/+I>8RD>&G&U=])#>CFS\W\J,6T[E3@512'H@M\'QM6R[1Z@!]&3"
M]HIE[T9K@)RM->G)\@B)8"NBT2NZ(2?:2W$=3,M*-1E*]Y?OE2H.%_]XZR)4
MR".=&?!GC.3^U^RAZS]JC3F*^VX\,:SAQ")/'9LZP?W<VFM?S2L;RH3:&TA"
MS:V9JSO,/:.1&N6"@\']G(CKR[LLWX)7BW,F,9\I2?@@QE1;<?/P,MA;<T,6
M;Z6<<]NEWXU;:'VH+9\/\%:=FF9Y,8.2A./_8R9'@SP90Z1O*SJVY)BH;2C7
MG_QSN 157E0D,8L\7>F=ZE5C&!>.*#$"G4WK'C&&ZU67KJ_GQTGQ-:[43JTO
M9,;C]L1=[K+ZYN>2HY/@<NGZ.?^+"G\&JV',W*Z? C(?,E\3Q"<"DJ 6+;'B
M\+!]?2\9'O&.WQEE"QV"D(,OX ;,ZZM1JUM@*0=,%[1F^5%-7Y(A-^)Y.,;@
MF]O8(^6!]N3\6F](3&R-SW_I%WX_RC=O_71VXID8.U*CO[+C[(:2D.3KZQ]B
MV/>/VHC'%;5],4BLQA&4'^7/A5H]\>Q3HK*WH-]WYUK1#,-;!(ORA8KQ;F./
M6Q:>T=C]RT2;.BA3$*"50-V=CJM(, 9O2579Y?$VU'(1%(D21M<#/P+QJ$]4
MN?=*MB*/2XMBBY24SX!XKZ;[W-UWVX_[/Y2]=U037?LV&ANH@ C26Y#>>92F
MM(@^@( 0 :47&R5$0'J4D*A(;X]4I46!4*2)$)  "9U'$1!"$1!"$E$ZB4 8
M(22']UO?6>N<W_O]<<ZL=<],]EI[<L_>=[FNW#,[2*N04B"OY^+,\%+F2/ Y
MD!6_U"$Q&L7';BF\_]S528LSN>6\4M'#XXJ49Q!INT_7 VD)/4_:O?E1EY8&
M11S4->]3_1EY+UC!V-G.D^DJ=<;F="PKY+%<);PC;""_;SQ]4_XX*Y4#>HY>
MVIU794#B[S2Y;LB3\HUF!\MO_JW/'/[0GG51[4TW7W(OWV_= !OC6$B]*5=[
M02^D"3H0$S2I%\C=31  #.AE7ES'!VDF8JQK0 :UP*530:\C+X&@RH) =67T
M3NFI6_8V!U4SVX^L>T%?;7E/*XORS'__W"QN-8"=NNB\5-@^"E2D#_++J ^6
M<O/7:( WOP<.+TP$/W@7M/;'3Z' .3+2R7E/)%FEO@8B?AIH[ /_UD&DL'OP
M1':AEOJZX?]L6?[H=T [=Q@8[G- V-)?0"S@@M[[ SE0%+ME;Q[S\C?EEIZM
MW8@YJ3XBT,*JI(%4.[^R<5UC,^+4V$FZYW\^;VQN%/HE!FI6%!V.C7[UMF.&
M6O;CK!#\3_N BR'$]E)E<97FNNS"!UF',^U:%19*<,JN^>.1E7VKMC3$(243
MZI1=,C-J%11"$#P,3W'MH=H%/0;Y.=](-XYN[5OVF*K1?_:$*OSUYUKOC%)Z
MT.[)PM9&T:-21PQR/8\A^??MV=/HLT0_[U2VVM<@7<CI(;H?]* P GJNCR8Y
M&]U3A3"BU56%4%W8HEW4UA/;^E%@?N.02G_5A89%;,X<)F5'FFMD?7CFH,9J
M[[;7-0;_@G(W?XJ(]]EP<B+[Q!C2LX)U"T"03R/1/M562"9!GGX*WTJPY:**
M!5%M[(-CHO1VBK$5*;9>G[?-HF!HOK[:II<6:FJEZ%O,[/OA"]6WTURK+8;L
ML(:Z]Q555[$JE_JP42I;C;R+)\ U^ BL;_FR8XY8VR?7[G/5;O8A:;O5"C]P
M3>[)K*U1XD*IERX))^V*&WGQ%3'0C1(&8(P!JF6&L64I$&M'SZU]0^S2?DX^
M2E">!\*ZV1+M[&EOH1ZJ)#$%<[=Y8H</^G?QIY_-:6M>9&M\:]O.G [S&R/B
M5X8>,7XOJI,LB*BGQHWOZ5>_92DU,)QCPXTZN+LF.:"3QMP,G;Z9HMV,^B"_
MK^W7*K^AN_OH,7%UV;F&MQI7O>1L)7AR&\:"=@9V>3:_33$?C@<JO6\%X((S
M'GVT:/B_-2PHS>12@ A$T!2,\*,$I^L.W5AFR^$,R[.HX&. =O<3V\F<RH(B
M0YYZ?IC;8@ZNKB, 7^3%J%A[N6\*L#?V'1C:S[3 3N,X$^W;[9--VN*(S6Z)
M'U,2EL_6"!)=\ ,<1?N<?WZ)_V[Q"5(X!W0&[G;:4RNEWNW;]'>XONA,'+;V
MAS%A1*1^?XGX1%/35,;=VB"\H.U)'TZA;M9NU*8"PQ^QWXK4-*CO"Z>NKPOB
MZK]DI4PKU2O]&<D@XWSR.MN(_+ 0EBX#DKY3=(V"[M5.8RN/Z1[ K])W1IZS
M!5EJ>+H,AC9R=FZPJJ#-,[A7PJN4 >Z)=(MZ$?YI,L9GRBE7VFE>VD1FM4^/
M P)4HIY3&,K)2 B,DG'./Y)\BBW+4AHSU5AM8>Y9U,(K$.[4WP&F*D!46/FW
M:Y5NGM];>K5?S#SD@ 3/M^'@*?7<KAWES]XM3STY(,VZQW@R(,Q'P 5&)OCT
M+.LJ/9C9[L5#BI#FZ>& IN?/,Z!QBPD]$E^>:#SY%8OCR3B]^D2SOW6A]C'2
M@#(YU0ZN':Q$1+GDF8U6C.O.)FW/6MWKAGR KBW-]+HQ /<2#BA J26,:I04
M][/I_$1$ 4;8BF;>-E5C4<'DB]$P-C,9GU$L;@R,]GD#:YE)2-BVB8'T[.[F
M>TQ=NE?X@^9PFC_W4^WM4K\FK7K-X"\;65:6^8Q7GY^G/J88:#[.GZ7:!JM#
M(E<FG0)-'&"LVX<8(J,7KYQF?+L<^+40MY%P!D>IGVZT!S07%!E>KR.H?$^\
MTR2\!Z#G5F;(R4B?,MA,_VOL\OM#D\K-4&Q^*9K@1QS;B1]O6MZ(.%EWAQB[
MG"&#&L/_*!8_P+#,Z+2K6389-.<>3!)$S+<%B'L;8(AJ?(. =$).:K(0QB;O
M@">N3?L'\GTM$K^2C=7]*MWFT_;"W7P[[NKAOP\*3>XVD;]!F=ZCVW/7[$C&
MW%0>@W$E^@V:!S0%+/J#$9^-DNRB1D..7:-@)$=HGY#>%!MMOF6V#L,B[WX%
M(MAM;)M)TDNIYBEP3PD1M%PV50.X*6 !&_ICC?*VK]O$6&:Q(GVRJ+1+82^N
MKI6^V6_*A3X*9'7BB^;?ANF7:P:O!1J;(/!?"5FNR32S*T$/X*NO ^[S.J1F
MKUC8XH*<-]7';><]_L'?Q(]J)2G"\=GOUP=R!:V4AU#-Y9D??A9O.4]TN <V
MK8,'I<^Q3P<SDM$GD+HDO<T3 (\UL%B-E /"N'NU3P_*5(,3=#-2."!Q@B:2
M'[A/KZ>*8$*83"+T.4%NE'UQ&FFV+Y6B5<Z [;7$W9D88F;H_2#;0O=MD$&
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M+=.1?0>$ ^USF!3!LI/_]-#B=<,!Y1Q:\^\?TJ/TGH]5_=A]=RD:LX"^W*E
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M:?[ND1YJB0]BW:\*>,)ZXFXE9_XX1L7Y]_V6=%7,0D7W*:1/#$,0&N]U,FO
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M-=AV8BXK_7?4%/KE:^[NS=E5:US+5-W.2.*\[.1.QC&60#,0'ZZ=>$AUMC/
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MQ0&]2 ]\0K),JEEHPF6DTJ?6J_>M@;P>+Y&$7H(R7?FIKK<4(L6N>9*MY@E
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M;:V]\0ZQ>1=3%FVCJQ1F4D9=.S0C9S_\]*.-] ;/2-(J8EF!%(PH@I\V43$
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MO#->8FGM;KL$H!TD]WR#*BR1_A.'3>NM\A9%7F0Y;D/E G'PC!B37SQ&^DZ
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M*G9KK$8HX7%L,@A<:]6N%M BH*>-M7%"<NU5R79L/SW>P@NQ8['X+.B&(ZL
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MKNW%@MP+X3."V(1P,<3>C!F'%ZC%K*<4#\\TMA[,^!"JH1G(2^\R+AB&$O?
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MN'5@W])(I,N_BA5PE0-"$<=&?\U7&P!95;AN)S?+\\0C >>E$[2?0SY5(Q9
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MW4K0HTDE"XEX?U!.26- ,5P1=D%Z8T,E.C0*>16'9:.PFX"V'PYLJ/$:)9;
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M- (-3P(I22$CEE:'7&7&+;*UN"O]H9 D\TNA^@OQ3#UI>S8H'57&X-,U4;]
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M_X/V_R#[WP/VZ/\(V?\$]O_CHH"XV4Z=;!X;/P@*.CI2JL8_YYL;71XBV>:
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M&DKE:$7>QAEIL8IYOWT>.7#=.)S&$[EK/GYT!B$Q@4B,/G &^(8@\A.Z2'X
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M_EGWRH:O3D _"22]&O]]]712 D-SMQWHHAV#*%8D<#MF</MQ,A@(:%E J$U
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M85?,<:NM248B53X2C;M4I#S8&&.D'&7+1TA9'4M3$8@>=IV&T5O!'BA?E:&
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MB.,H6^1%4'_;%$)BIMB%'WA$=,-F><NL$Q+++<GA.09;ZI,&VI\]R>H-.NS
MZ- B+Y 07!,JHSNSB3,)I(&%@;"W^^KDO?)V>V9PCMX-75ONU:@$;<NE.]-Z
MGJ5JS?$IV1^?(.8";K[^Y2L3?;,FLQIME\,LS9K-L*QP3T%Y<K=>&NYO31_^
MK62^WFVYH32\-LIS3:6RG= 899]KN8XY Y=-*V3L).5=M"=\JKD6U5#JO^Y
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M55PM5N&BOW#8\%E]3O  K=.$%OV87((I/KM=54>XN##UKF,/T/)M),8JB8!
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MY&\RKA>J/NH4?X:R<N!U,SY:8P3PZ]^!Y2C_ZG6S5;\BTR'0XHM,9^KJY"9
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MPC]-OH0_36.>R?"0[=;I%&#LX<'QG^.PRL_K\[@*=5"NYE@^=RU"GE534]?
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MCX\*UU"3R_,")Y^2M.>8CB:T9#->2<(JY-F6?T[K(\3LS#L61O4ETD-ZR6?
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M@\M7[O9(1!UATX>IS;K4T+G-H?1&_+'=/;E\>%X6[H!P1C$G@B Z>8)4$3,
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MWI'@6#E6MK<LF8U;1[W>.Q^.#0#&GO$LO]GLL"+XVC(:SS?-[P+X+H3AMM,
MR(4*K&?[&4$#6@-7GODM03%T?HB8J,YBAT8V05D)VW;7[NW:OT8=@ZXM<J6(
M S80P;PM^,7(@*)H\VSVZO/8Q:Z'53M9RPJY+C?.(?828;/TVN6V<)9I*)/K
MS!_:>#H;>ZOGE3A;'00AW*K[RRGVI;EF:Z=IV[/7)A//?!&IS\^S>NPN2X"_
MGN"D2*/Z4Z3/'?-OK+1RD]EJV / H2:F'G*S.[,Z9<WZ@LU*LIIP&O\_H*6A
MVB3=9KG9HSR(_+Q"HE1,ED('])"OBNJ.\;0\,/*[?KFV]V?6VJUZO,> *P"O
MW:(LU!H=_#G>Q8174PS%^5#,KN1"]_0" /?C\L.E8UBX>_&Z>\W;JG>OR-)3
MVZ[(&N2NR,YSOMJE7.B&CW01?:]']/ 45V1&ML8=C51=8W=65_R_L(2T'IGH
M7MK%"?Q*4SX9S**B2VLPPYOK/:L].FBQ@+2NMOQU+80IZ.U4 Q1#0J$"W5%U
M[WY3Z3U^_E)1W_O$<GG$SX=OF<UI<-?S#GV"7[V1QL@'O^O&Q+9[CIL3EX.Y
MYFV_:,\#C/&D>B_4^0$"6ZU_K0@N$2O4$D9/L; ")]-163 .4(;5G!6@\*?\
M!/->DWPDRYSD,4,'6B?7=F#UORBE::_1LU4= RTV4\5"2J(AWJS>+IE&:EDA
MMR_D2K\8JL&<6U]_VM*RCKMG<&J?V '+62Q182K^$Y0P5&W17+9I]SH_PUTW
MR0SH>JMR!L$ZL*04HHS@MKC-<G'? XW0ZA+[GKW %]6O1WE05J+%&-.8^=R\
M%'THJFQ4 3:I.,SH+K7.5I0K;7^B:)DU93W?)1+J]!WL[F?I$1CT+?'+JGMK
MDO>BYO<'9L__B&P_DZXW>UYJ8?K(&ZKWSQ;V,#7&T)?M^4%(!*UA<&V0N;W*
MWD]KLEDQ<45JX';^"-,@,_J<4K!P]:8(D%]\\KGX6V(C%I1B)T* 7.@3E0GV
M&%L6G=DP1J([[G*R"(<=9CX,/!W >VHI6G0,1\)!KF*QXNBYIDA/U>BSB-7-
M5"D&8Z$X!C>$V8;9<XL*T;F%AR8(54T6 Z:]9O5TCVG_G1!=2ZBG$(?<Q]5_
MN7LO9;Q<&3&B1J.O?SLF%F<X-NK^<'?@8\_I"-:BV _.?"'N(:_RHQW]Z$?U
MT,L*$;,JW23GF"@=875["TVG!<69UN5:P<9>M;O@T2%T PS++\Z1(&V5\=P*
M1/F%+/#P)AY+NOLXQ <GAFT]2+VPWEU8G$FYMU_(2P!A(\L:P&,5N^3+VX/+
MSGFV$9\\5%HB>@"SQ>YQ2=+L50X GOD41E@+!ZOC;//MKEGYR%"D#GUSA'5&
MWA#TL_7%RN,<C+^;\>#/TOKQ"A_J9+K!8:>4?Q=79+<U9[P!CA=L1#6\8"97
M=8?BVRXC7.\P.]?@N[4MS%]]PKM/A"#K@H=9@F:-W-QXVK@'01FEK>2NDCT6
MYU-2"G4Q59'#Z"^-QH.O=KML'G),UK W589ZG"+$##+<YP9(IP5:<O-O3#&]
MP7=X2F!"QL%!<1\9+>014^G;_SZC.9<__MI]A?^GR/2JB!J[<^$1F&1F?SM_
M[G6FLJYO(3/"2EZ4(?=WW4 =%RQH2)7EVOR1.![C!D(FKFHHN6.K!FW-I3XC
M$3Z0]ZN"8Z]Q%[_'^%DS-."AU9]P6H^@9?BTQ]L]=KM/+]M.5A8. 'ZX"\LY
M<?_YN=)9 $AN 7M!,=B[K,J%MWE4]E>".[\F-/D<LR!H;A*"I%I5<;5?M;,I
MM@!F]=!=)OMWZZ[T >G#G8OB>X0NLT@"L**-Q0C2@_TL%1N=6C@G/K!&.,5@
MGKQXH[VVQB 'OZ>P[MW9/..2\D+&4UH'\NJ&CK'!-5YA7(GW6?I:3L%PZ&46
MD?'"B$"EWIVWL&U/,)$O79Y$0EE%.SX3**Q;(\%YVYF^<D74A'B82V)&SD-W
MCAVA_)E, *=2"O]@"%R+A5*%K<?(ZYDGVI&UW*%>B4VK:T\W\\Y)>7_AO>I*
M=9^ZI#KPJ6H0&]K%REYNL@)FA)'4%+4*\\G;J+>AP$CR%E%M!WL[ZS$:,S54
MT](Y("/074Y"B<:F>*.)*I6Y/9.*:/1X0T(R5UB.YQK[ L?@&L>"!%RM7"+B
M9VCTT<1/K3A/I=-5OA"SUF!L=]X=WO3)=7X!WBR66TJ/PX1P0\D(\I2 ]NI-
MW%:59]6*SKWOQ<:PY3_\MQS'LFBE2S^\ZJ,>BG6=&KPBN]GSA*A 6$+S,,%2
M-I#Q?Z9BUA[@;N7B__;3)LC::3NCQ\:"U4<@Y1HU>I)5Z'R7CL0E[2KW[$<:
M9?J;7\O=%)R'/A:9P30PK=$] M8YORF=VPH74*.AX:"[M7D&R&"?<)<U[KD_
MPO!5F<<KUA.BI,=C;K7.698/X]T<"A=.*-*MG&"B2X&/Y<=$0?(C>+/R+LW@
M_B[7B,&U3&'C(:,"W?V[\V!_Y&T->KNT:JR. =.<\/"&+/4  +W&/X"+87$^
M01M(C@F/WF^HG']T B-RZ1H/A7I*#9H@U;;NB[W<'ZT6G1\PA"4R6BX;U416
M_&D_Y\X%C#AS)G#\!$>*?BXWZXA6VDKEHTXVU.T!EPBO<L8FWKAG47"_<-$H
MVA*3ZGQ+SABE(88B?$UV^R&>"N03WJMKBKYYB[T*"O%[^2$X?/?.PXC'L7-)
MA_P^VO1M[[^-=GY\<$I?=/NI\\N^Z%]P5]5]Y5K_C'EQHIJ[UR*]'=@ZAUHA
M5>$B<TZPC=)9H"+*^02;^^O#-T5P<8#\B'G3EQQ78Y_M,],Z%1"V:NS6<HF$
MH\B(?59&[<>\&'GY"L1=.I1#L2ZCZ67SLV*K*[)[Z1EI6W4LKNP^$.6YY/JH
M[1&%?WI8B]:TM3&S.3:OWSOC+?&+U'$2?PZ[TO][_G-@Y/3@Q_)0VQ@@)2TV
M5WM72FC=6V+P5:T4'VR&67DI\S\=SF2%IS7M.9S0'Y5Z,I&GZU$ G3,=QU#O
MA5,+W&5I$N254(84]LM\K4#:+V6+6)&VS@A'P8N8I)I6'4[JR<FDHX3@[?7A
M,^&!)PNY$#G0(UXQ&.!?UX*_26>([$IY7&"V_[]5<SZ[0+-<D_%'1QZ!&?.L
MD_D)9R,CO@:AO+NF/CX#OG8BJAY).I./?OO!:X,#8 .I;4-SF2KUF;M*0RC3
MW>Y-]CFLO+ANNO%6D[O ;<K)D%W0LG\^ZXBK=95G[O/]7RO51;"7IWPB#I2W
M*I_W$:.3O">7W0Z.M^+L;-G/)'171\EA7<UI8M$:$6.D!+GQK\&A\5V_3%6T
M"F@0D\A0@8FAB?D_^R)I1[9C["N?AWXM#8;IP5[$\4<+1U-QMNAN57NH=#=7
M*.Q%'^UF\RX &+XF#VG[LIF5.C#1D:=&6PIE-:B<IV29>HQV),D;@[7T]35-
M6NM#0F:[F+Q-2[&*;JVCN9M(X04$]>./JTI5HR*S?@'&9V/VT=S$\E.%C,^U
M<\%YCZ[('!EH#]Y=B-/YTAX<XFPB]V@'BNZ]7/R>UTN," !=4%P#X:Y<\^GB
MP4OI"Q[2*);#YT*%R,P1WGE%QKP]\-%U!1%*51W^3<CTBNQ+P#$I7<\>Z="[
M[B-5MU 5OKO$DS=-HN$Y_P.J^\MB]J]D0VJI?+VU;^K=EV#JO(">MZU_&W*H
MC\-P(-A9-&M)>)/F6?"O>(MQ&3$YHYROAI872<@D?QV 3CGL#:6DM]3Z:)XP
MMB73T3.JA<>SF59TL%X/2BUMJ^LJ744Y6M(5NP-H/7/,'B<(X3SXE2T!M^HD
M9^Z<"O;^]\AGM$&;HUXHVHJ,0K@OQ)F4_3)O*[ON237YGG"M7%F;='% \I_/
M::L)$'%;28D%UO7HY,<5<URU_;VR$R(.KW*P>Z\\9YO\*I-[6\NV)V*V33WZ
M$TN4*NTF#$P2,O@_8I4-CGQ]+\4DJZ*SJ&A +%J(-1,OV8')1YN#GN#$?2W#
MC,K*9/KW[:[,%;KTR#%6->V<SODC?R##<-E8&8:'R7+U9_Z8X?"W>?&7)]BH
M'UK,[F"4TIKY:!N,^.T[JB9%H]DM;XV/TH0GJU/A\N?+UX_(6'=,;S3AW\TT
M_.F_W9&A&9(SID^W3/E\_J[-N.4I:_+JKX?O;A<Y.3XF_ .=Y1&V,5-+*R\(
M$/S=]8$%E=[^7H*^_Q7973AT@<^SI ZFJ+WX'AP8B;EX\H2MIO;WCS]Q#U/,
M@AUDJUF81S@H!1/O:2J^S9(,J-2MN3.V,B3JKD>KBVP,X(-UFNHB6P;G(%I&
M2,D/974'FU9:8O$^2P;Z&=\_-]J$*]#2Z)8)RI7D.+JK-WUI$NDXU%+ZZ,2G
M(=DW;1(.'E:1>WBQO#T?9.Z[LO:U?"!8SKP^V[H;0'_FGC0@VCPM),$Q4"3]
MEE?F5M+; QWBPK7N5A&!V7:7.=X]#]P#:X1B2?_!G^)2AKA$3U;^!@62N/,-
MK\T%BIKFR!S\8+7L!KZ<BO5N:7$*IUU62<(+ C7DH4Q6ENYI!3:QZ#EQP5!9
MPT8=2?$ :?EZF..[#SK\+";\L=,:DHZ9E@#9D5/18(JA)!K51W!:0@+N?/Y3
M;R,^I?^8&09%*?XUP(UX"K:C/1/<'>(?,I+W)MDY<CK(Q\]Y.7]0^KHY+OI*
M^CX^&.XZ8<VHCMA!3MG)BVJ:Z,HY_<1"5Q=L*HR-D"I[-K4G?V%4<N-*)@EM
MH(3[-B). (U,K)"YT:]B"\HHE$E5?(EQDT.QTN) E_G=9N61A:(%9K;AW'(-
M5*]K>+(J^^7G+A$D49^@C:&B*HH+7'Z2'(-/0$>W5VC07.?*R^3"$+D$_[/T
ME=7\ ?1EZ(,B4,^LI+WV_']ZKA0_2$E ^B[Z)Z7FA2*VVE_?S%)$3&GB$TW<
M\!.P\=0N%?*F&9U/^^,_ 89NYPO%<D:Q8\O@;YV,>*$SU6N$N8F?.G.Z+"()
M$_P&PV0);!=/]^P>X(4B4X;"HX-2ET)K?B?Q62T^@'+L,.IP1;>E#R.3.-?[
M%_*:QOQN=Z].S/'?(36VSX5OE $IHZ:BFJ$41+'+!CB5H^OM(12RN+LN F ?
MBE3C3WU2,)F >5PCI3U79_5P30(2L K665/FTU?5>D5= 'NQ!1(9O2);H,XJ
MDRGDDT)RDKMFFJ8L>!@W1HE:?A3?70QX&/515.AV5(&G"=* =5G)\M6N\3GI
M,2X_JAR6,*QL$;7&ZPQX$O^-T"G_=:N+!B.D8!$]@"EW6*ZP>(A)0#> V[SZ
M,[[\*3<?;TPL]$?'I@TZ*Q'[+7^&B?U.1RU+-H9\_AJ"/J9;75$H\($$<QKE
MV(D\TW2T,M^E&PT;9FS"* :_^J@UIJ!VRQ^\& 4).+ZWNK/(P)1UMG938"\K
M3:NS54R.L?6CY0C[9'%7'&WVIBRJ\FT$4#7L!FDZG#I,BC!F3#!#P%PQB@<(
M_+[^EY"+E/=KDK.2OR]YC.M-3_D5"N_/UU0W)8P)Q>K+EA64[C#^7#[NF&VF
MT7%PYSM?[.ME\T^ASP?=6;-?LH$M+WM>B,WAED)=7W35S[QD2&':77Q$^9Z=
MN9&9KS'=T%_A38?]3C;#6 "RJ_&-Z8E-IW1)KDOP$X]_+?]9.NO)#RR4V"7!
M;ZL85B)-Z",S;33%G[#-Y$?I9GC6N52H6^99NAKG5Q&V@NWC"$)*HTKVR3*5
M (F"403 6R,6D=B'/3DX*I3T=XZNR-AF?6Z"S/LZCYB*J6 U'\"XBG[O<\#W
M6@QJQ52XT?K0M*8S/L%8:SI2E[D,#:9P9="-"0==S/S[T#'%F<AJ4$M5!67Z
MKA8*?7U\MV<LMD_&6I?:[Q. W"V'7-A _5OQ9SA#\MB$Z_+2!(1G66+6,3LS
MJ4H)\OW;Z(K5@$PHHBAT[#E;:EF6INM+%!A1.^+HY]H":Q:&OA-!CCF[!EV6
MT.R+2.?K/(R;?N=D(NS./H$UE@1ER2BA1= [FJT<0[;JI1\=Y?X81>EX4GJ.
M9LPUZ\C?\XS79?VH,6->P?]Q=SC/\(V0\FQR6LJR]ST1P>6,]F#=4]OHB]!R
M0:I0=OP:Z<3<<H;*2F*B7]O[%WHK32RB8?0K7X3"ZY6<#:A&.3CA?F="OAW#
M[-C#I/ZC$S0=9!*.^:^_-[A-(O$C?+T,EF*>8MR>8G7A4H-L_M:!=_Y<+>MD
MK94E(3$8N .O"M%+A7!FH9.ZUZ8*QE6=8E8AS;:J1[.:G3,/>)S2MBPA$'AI
M$\=0S>@G-T*R<.K;T#ZZ3]6QK(<4XZ.G;Y2VS0W#1@V]55%-$%O-1=/=R4=)
M<Q7J'W?[X8T9:[RR*9U,]Z#V"B-[&URL$R%NDX^*6DHD/>X9Q#154.KJRB:!
MTZ-TOBJAZ =&,VJW]H37>H+%?[N^?]NJJ,-/KX7D59;4<V:<?VCQ@.F6L!D_
MY%8"N#834NWV%VSVRP.W"OXG7EO<_XV.%;&L08,;K>#]H.2,C= T3C%(LX5>
M:)T=;H98LSI&3]L@WDOYR(W/B@L)U)+%&0D%2C1MW.ZK\9Q07Q@R0Z:J!2['
MWLWVO<'_]KF9)EEVFM;S$INFY$I9NVI'2O6&NMOLDE2T(\9&:9G"%9KM"!C2
M:-1P<[Z9:?X'_B."\OL98WH-6[4V@$^XS3S]/>832;"B'&5S13:^ N9?9[K@
M&MDB,@3?E7,FR8;-CD]_&="Z(L/-VK.TH@;JM48Y?5*'F?XPP;]>\(QM$YGR
M(-41]DG YIM1+S6$H<M0#)XLXGYD8L#-)Z'[N^>7O%7=.IVGJNXA(^#S8TCF
MA<1CMS#8WS>^>[^[#VL7WW1" L/@Q-MII]_PZ0 H<[8K?A$[?MQ"7G#D?46&
MELI;9DL_.#A!?1@*$A;%*;DZP,QNA;C$8+F$3.8"0GGT3H^EQ&N1'VA%GW_*
M$H(--E2?BE9JWOZ9!O[V/KBX9)43Q$9CIW^ATJGOBN>R4#6K0_4F"6_4<7N1
ME-L=(]_>H2*S*ZV*N>5?YV,K@YH=3/.H@/QGZ[$@O30&S"A>ME5&Y#VIBX"/
MU!RY,*2VCNL)1S)+)\+)?:AU)WTRA<W*RL<4!\6-JR@-JLHVRH716V7%5&9(
M'>$.8_TU8V]=7?O0+-#=DZXG $WVY":92AXS?U?VUV?QR!;?0;6ODTAYMCGX
M:"EX1D1@=/=D@;T3[-G1&B5Y$-7<G%N_4'.$,6Y95&@]]EY^)VRF7@JN/KWE
M)/"H@2]V7$,U2F H!U;CG'=#X(=_!"7_T[\/+63$C>II'IDJOW[W5B/KG[Z#
M)U4/YH=UN>PU-+\N>1VAP]>63$;H[QY<F*XL?I"Q+CA3J1_F'/[5H(NJ9D?U
M/T+PA2U1:?'/$UK4%5DC*-Z_<[LY_@1Z$*KQ=4UVL<F6UC(:JR\C[G T9IFN
MF2Y<O#TK,"^W1-;:E@K*5&GV/5"5@?=:)W.--CD>36>\CB\IWU5;-BK'-?&C
MJ<K;.SP8TS+R[=W[X< (K($(FL1=DZL=@RQ:C#:+&1?]7OB8EO.4*>:\QQC_
M.@DL[_:JT69]+T/:,D>E[K8>DPG+7=8HM5=[806:SA)-BRTGZR" XLZ)E?C@
MXR6YYQ6;SX8E>"7-#2?UO'FD'8)X)M8)8A0#QP3]*S*'*S)V6-:4@=8\B1Z6
M\K6(]>7'1G$C#72-]Q.AH<,[ZK=JKLCNJ'9C*KBU7\AHLM=+:DW5=TGAPS7Q
MZ^]([(1.EC?4A9+375*8_'PV3%#6E#:>_+V\"&BY)&DC[9N.#U.CK59?1#*;
M@_]+I>-E3P,H:]C8>E-/4;DVE"*J.>4=\+Z$W A\ZU2PH0.G5<.S(O0>Q1<M
MH$GK01VU %P#N#DM*^^;?W5AA9O?2YQWFQM82-@,6S"=]S"HS-24=)].%!#B
MF-#.,HZZG]U1LMYOYM=#C9UDGO2<*:3E^>!C9P)^G7?FOC#F!W]"K<5]+S]1
MK*,>(1K Q 8JS*LP:Q?\=47&?47FG$(0GDQ  ZD)01OAAX[HP\#]OFR%-/<B
MVK"'>V\ IX((=+>,D2>$J[1,*7OP#'Q[7.&,QWM:\JBYF^W0G*J3I:VY1>+\
M#^[O(#MMPKOYL!MP#]QVRF\_5\X8W<5F$.&YMQ=S\#=/MH 0=T>\:M'K*H:,
M1KQ"46CYX"_Y\5]*4]M31,:Q@3!R0OT%+?PQKFCHBNPFS 0C%?$'&L].2E>-
MP=+P<H'%I"M@U\X%5DF.=^)Q_[)H81X],[-N..O2TMW<6KCUV*HDSQ!;@A<B
M,K"@NP\2L#Q+5V28X2'HTK'MP*K;&XDA8H_L=[EV/9:6NQV(B;H$_U@^#I-O
M,T1]KGX44U)?1K-S&J8M06*T 0G:"YZ\^:A_F(N:_(E)IH=NNB6X,0K\O4Z]
MP,##HT %?]XCC_[WH I%4QXVA.76W^!A)" Q@E9YD@*X]'A"2+S?B^1>^M<]
M[,%3_X>M]XR&JWWC?R?)@^B]MT3OHI<HCX@>Q.@]B#"C18O!(-&[1QM!$&&,
M/GHOT1.]BU'&C"!:,H,P^O%;Y\TY_W/N-WOOM>\7U[KO:UW7Y[O6=]^;=#L1
MDK#YMBW9PCAZR#5X\7[@+\L4SW?T)):RWS93 O<U15.T-]6G.4D&.^X@':J)
MU,&_&3"?:?)H=^IL64P9#SF+<BG<"W:R_BMN:12YUO3P=&7$YQ9 WRTQI97\
MT,;KN?UHCUO%]R\KNS=\G7C*E$V7P?] N2ED!E[\"R6V*R/^K"3TST]%F<R\
MR2+U>/X++NM]?$-^Y76-B'!U1+GU]3:@#T.Q*;Q8[N@>/O<S81P:ZZF]]WO.
MK#5O5W;B%@!>> D^G7*I_HX W0CB?K?[5ANZ,#7"':WWSEJ6VKE+N<FZ5/%J
M8T-LB^G8I_8/7A#\BZL;(&J<9$?8[?7SYFKV*@]RCQ.VU(0O[K.VJV,(D(_X
M_#M-RS2CQGFWN9-R'N.@>['?&Y,;V2UB1((%W#*<;QI5.KD_FE<I'PT:PY8]
M?>7PD(OF"AVV+\5_/[FR?03/#>E;B;#8=*&GH,$#5Z:85MK7+'8.;G&;/8R;
MU86*J=R;7&QC[=)71@_(@68(4]FL)TH6S/\4QX_B&>J;I*S?6:9\W5:TL0Z!
MYRZ.OVVF+C'$M:):QTZ]AEX:^7G9_\#XRP.BZQ^;"Y+"'INOI8K4(@):@ICH
MQ"3?GDW)%S'X,G*]'B;UQARSQIM]X&UN=\O,^)#P<O"#A<IBS OF>I5O#.4%
MCSSBMY*C;GH49[53OIV_7BTTW?3[CU0+Y\@*;D49U;A?R&W#O> E[!-L[!\'
MWPZ%N!2.'A[P=#DV3;DG* \1=0X_$L!JN%L#1'>V<]-.PSDM\K(V#X4%/I<<
M[DJ"B)04]<HGQ1W(0K2, K#S)6JN UE;&>/U:L/Y*4JARAE)^45U5?Q&=G7F
M/' A0SV1C"B@]R?P*"Y@WO4P1&Z0;&XY@3?O=#D2;,PN;,5OI\/ \CW@>8IN
M##=%/4_CO6UQA]@ \>!R#G%D#ALO1?BY5S)\A[/N4#A1 @Z34[HW3\7<G[>8
M$XAP0(4E&BHX1$Z@'168^I4*_](S Z<"1OERER=QR(SX/B>*>,H 2XN,O5.4
MIY^!7':FW?(HK.6(I:SP(?T$K8-NV_5X^7O5!@JO5WQ!CQ8_V@%K8N' -'ZW
M[\+]3[SX%00-GY4BW%A-M\$=6<'7\'.+5 '%3Y+U0^9PV\+(+A>E>;N)(2VS
MP,<L\G RF%%4,ISZ=:;?@HREKD6.T9HBY6F%CT# *[*/M;5OLK0UN*59?I)I
M4IEM),9IM+3,R1Z7];%I$&>+M92_?U_AC9AJ$41PO\F3/HC8^OP?G7ZFC;^=
MK?5*+CP@\>&\G[+O5]T%/_N$<Q,:)I<8<[X/=IO??<.7SN1'Q3VW+AD;#7A$
MQY0B02K8I'&A>$':WH^NU,V;7K49/ %CL*QRU(+HLZS=@^Z2LDU6?=M:W5$X
M6Y!7>4MU_CL=6;N]X8:@&+9L)Y.]!74/UK8A:\F0EP@'>$92!K"SR=8GX;K@
M65HRNEDI^4FB,=V5#.S1*+.PPH>NQ< '!0VCLZ.=[YWYON\!UJZ1@66X6T#_
MFHRIE4O;45<81M;]]3K=\XS0NE$;>9U_?<^6_"5?)D-J?4X]/1"$[LN7S5M-
ML,8B6JCT&D=CS4"VXX-L/8J$F,'XRM%$1C,N!C<!GY6X&]UNQ'7:#<TM8#:I
MXUI0(EE4I5(Z*6#/2;I92%\Z:@M&30EIZ['66%X>T>',K@X/RFV?+7P]GZ.J
MHBT_EUPB-\&AY1ALI)#\UW+;$H@VFPHDF&*[>0=OF.LRC=-+VB)G5^U_C)M-
M>8]W/7'MGWA0]-=?D#U*YY$>+:Q;N5>]AW6?.82Q++U\>=09QO+J^S^'D-$4
M_&C)]6MI"8OGC[;TA%NT=!P[3\*,*-T,F^9K<+SM:?X"6_X,E?J&M*_%2H=$
M.NBHJ%;/D,8*HS?%BF:EJW5_ U+^9BNA?M.%F5J^A1T*%-9W=74U2ET<\),E
M:'?+?LI E<K:[08TOLM8EL^;60:9:#%N<E5H F\!:7=(&RYY30F>Z+T*[;L%
MV-WAPC13%=@1_PO]YZY/%==8M][-@JCO)SM>W)\F&71LCC@4Q#_=R.J1;<(9
M1W;)5?^ 1)RZ$*;P%5"=JGU+6@?0#3\AT)4C3R!+10661%P#WV.V9,*OPQ9.
MELW?K&9^Z1^3H$[J]6$W?D \TZ6'2W-LQA\6)5R%E>P5DK?BC:+*#:_3<<>:
M../X9H-#<HOZV%#[T$&VYKA!;LKE7UPLJ>R*O_\V5E@[>'2$I92RU?R9CV#L
MH;T2)*2[R)T-<3(;=<\=0,6QMP *-!J]%V2C6DG0' XQ!3F(S\H9=(:."97.
M-(M2EFV++K,]%(@D_Y:L0%-:E;1I_)[[GRL=U<E&+))ZQ69M3TT@Q[ISL7CI
M;P35^MJ^FF#C=)=P&.)[Y6Y'68'?HH-HTVR7>O$>&YD=.:>?@:$TJ9=@1^J/
M]]2/"&F7)H1,S-(PIX^6&DD$'51@6HT2RD'(Q=J'HVZFM)>@O#YX9JSCH#H1
M6!D^G%_1UKF4,3LPT*$-9_K@Z@4*8NPIP@K"".B>3#B8HS5*W?/:P>M!WQD7
M/R',OUK9G8L,+SB4QN >4I@+!ZD]G%43@EKCS_J+[MF#\KA*5%"(A$)#4\QI
M>S!6U,.ZAEMOULNYJ\G+XO2"4BB,&6O\OI=(31#2J$W(J2&\&QFT.<UT^?SK
M74AS66L%I_*Q 4X]0<X^XOE,H('X4Q-#7MNZZ2OKL(B*)$HCU)'07\C+*=:,
M&1-AP8-FG("XF\:2,XXQRW*=?=[6=,XE\19@D=I79LP 5I.?._Q+*249$UN%
M<%>37)1SI(/X&,S7_&ZZ!5#O763_74_W<C\SC0/@/'Q6>@V[XIY?*O07T7;O
M#(ZIDIL3J,$WO-,9Z@DAZO'ACY:AB@W=B][W6Z\>T6M4[J'DD6%N$50->$BH
M14M;:\:^1=3+&<\CDL-TI Z.'8A772\J7H&^:R5D;U(RS6&4IT!R5SV,N#L*
MJ(0^H-$)O(8S)?A6IMP??JJS0-5,G"T8;[4GL7CAY)JV[GJ=T^M&'K!TDJ#"
M7F+S?=-VS$HEJF9/_FR16=D"(9E2?1?]/PJG>?80PX!#L-Z5K0\"\F*W?@7]
M="\24)Y<T!0!4*,=P=5N;GPA*$]?277.__F;5$3>O5V&,ZX %RJT$5+*'?1"
MSA"FH-]=H$#?VC'A[G7O+<\G:0\!:D'<+:7X_<+'N.:[8B=ZK3"H=G^V1P"L
M3@>[8SS!2%DT-43?,:[>W=3:=@!K[[QCT+#X&!\)Z>V;*G4X5PX("?%@=K%)
M'0Z3_-:]67S=\[@+-FRO@%E'5(--]Y6YW\-QL9E(]PR;5<C.(#?'E2C.8=1+
M<M@F#_3$_M?]_2'4FP9)R8 4"<NYH7X]-Z*#9\P7-BNGY@1:KV)P.!<746OA
MF,U,X 2Y55OW@ES^FJUY"YZKUP5;8'/\<K&VF330H.9-!,UNB$,-5:OX"A@6
M9/.FT//W9P/1URD7C@?U.%$=V.3VU-?%PV!7Y*Z#<.K-L=EB,_EYETX)9.DY
M(<FEQL$!#69F5LB+)"P-=.C$ORG<UF/#7BS)^"3J.;^EEL#''3[%EN"XOZHS
M7M%NN#K2$W(V$0/&T2CD![D48']0Y(X]8:T,*HQ_5P#"/OS9/,>Z\'I><.;O
MDH9WO5S-SXO@__1>2:EC.E14*4<&0KTTOQZ!SKC$\9X._^##<P13H$KJ\5WT
MV(0>?L<KH:/J*W5P YJ T&S!.^0&\R_%XS_O-H >"LP6F2_R]$P?]"0OW3RX
MXE_JNA_.L:_&W.I#I(7M].$2R.<JJ; *RQR"<8D[<J(\3B]2:@Z[_\(/BQ)G
MY-KX$_?D$G>9W6EK1S'5ZJYIR]U_3C3+($]?9%QBKL*9YA;))6GVZ?08IV+^
MKNE@F:,%\/9-RHT1GOML%IW8-8^A$/,_\9M=\T0CB<VJ&OR0OV[! !6JE=/]
MA;^W *I?RMTY?1.A _+K? 0?3&\B;@\5EP@5K;K3/02#(6YZV3]Q:MRV*1*C
M3OSK5;7K]@80V,L7]/IS#%,5=BM[]V27)88N(W;92CNZ>V-NZ F9@\=ZV#69
M_IZ'H=PT[J<M:H(Y9H0/0;CM=4,?\]Y(M"'.]:JCIL&C!26^ME@1ZHMAS0>.
MVW3#?W\@F?6]F;J3-N+B3;UD@M$G[BY-.*Z4C0)1'>68V=6T^P29(7D'X=D3
M@CCJ[%#&RGU=**/__/?[=ZE[H1!O06'EYT>H\(E>XH- @S4'=/]3MRZ\84[R
M[**AFWV^_IR*E@MR%5+[])!<.Q^8:3"]&$&_MK9_!NLPA\-KMBL"50=Q/=>?
M'TS<*(3/7J#[)#GYRY ;H8:VF)XTG"A6<)B;93\DO#.-:=F>P+5I%+DR@"*.
M\W6CRJU20ZI>R4O9.>RA7@C[!S(<V]FNV$YLA_3V<R>>.=+%I004A/9;<A'C
M6P>0]((Q5_:87+E\==KE%;NU7Q<^\;*=UZ*#3#0VMGLAX26E>RVSHGJN3D%>
M08QK3:<>'&_MUKP(^QCJ@;2$H'=!A4JXYKAX>,/TE0GF?4[9YL%9.!N^[&-
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M-&+\CG7>.EZ/6:[LI -'J^2;HXJ%SA5L/DETAC9FG'@2Q@N-E&(86CZ!AQU
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M5+,'CVH&9S*.A]@S1$N^) )$M_Z@9&XTT?=O 0>EJ[> /=$:RWFYH[-#UEO
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MO;XJ0#1QX=$JG_:P':9_.75#)HK[@QT9*;H/%2#(X$;[:J_X-]63E#E'AE.
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M/[^XOXY;&PAR(&JYC3745WUY3-;7=:VEN8#VET#+#ZT2_XR+Y.G&R;L@7.I
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M:&M&L,WZ*I, 5$G*5K7TQ05VH19']J$3H$*!D%YEBYRUQ;-Y?$+HE0K4?X1
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M?7B2F=PWPT8^)(,T/3CI^7ADVA^E?$JW$8NM;G"'=YG/!%=&]!N&U]8!Z?.
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MW#P[E-9-]>3ASBO)3%[]-Q6@8?8Q ^'"D'RYHY_$!#9$+PFP1 (,0.ZJ<I(
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MANR/.7R[(@#"Z*/+3#6Z=(]K?MCS3X,Y(73S[T#?KX6=YDMVC\]$RG,?F/S
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M%TW#?CQ@DAT5=RAC06.]:6%%J6?4(KWZF;+KZA>K/8SNT-SPB GFQ_%/AJF
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M&N?=-^$;X&FJA&WD'R#R$W:Q:QO^$3(>]$19G'A7\Q?7XQQG]> -XZF##++
M@"^N&8K0DT[@*LWTDVG'U8.9&#<)@:><#;"R_5?GSE<\$]@YI<H&\^A_5S:X
MEM0EG#A+O(<-Z9W,,[A98SEH5T6H-(Q=/+^D2^#R2YC[EB.Z;V>RN%NR;?*R
M^+C_WU/<>4_W71)@/5/MWGZP$/QN<W/F.O>08F."?/_J[=;.]@)MK$>2^,EY
MM?E\CTGF(W7[YA^'OW5.D\C6;AYP/T^\9]$O,>F!IV@]F[R\58CM-HGKRQ>[
M^ KW+UZ&:Q+V<5%F[7.-:NPNF7(%+DB4I$.* +L/ U/VH"QM0_U/_G!1-RCZ
MDXR5W/<W^QD81962/#MKG@ ]GJ398TIA+6-T5*5U@LH])3TO1&0AA5*CDTGZ
M2+P@A5YVKK&9[K1+V39L[98"+=]WEK@9[Q?Z]#!(7"2SBNQ'X[&W"TYTCG"+
M^ &3,L-P6.H]':T,LR@T 5TQ-]'P@C'@F).]OZ/<IHXM!:;62@(X5B(6,ZVQ
M5PA ?'JN)_^^0[Y\USRA>C*B@W+=XA:]/KGSKG/?[HNYT\#*N'^R'*.9S@?D
M]1"(/N4$>Z#5T!"M-HHH60)SUW4:8'?_BB<!%N0#V2VR#"PX@OC]=$/N_>&@
M&'B>R6(">CO-ERSCBMQ\8!WA2@9QS_A5F+!BCEGF?#3*.N Y3O_?CO(,'N84
M<'*.3^(3XQIY2XM]NP'SJ/ W)_-6/$'D5B[FX8YJ]9US"W;U*/MH[69YBG0N
M9K=)UA3PR^A2_<)$^K3"B/)71@/@_M9S:BT>/>-_.P*=7W[_CN?PVWP9;\-E
MA&9B?8K8(CIZ&#X:?_3"F)K++!DM55=D0I?V"\G,(MQG\[ BGIF;%L1@06?=
M6#ZT3(C7$F2+K03[2LGNF@S8\DO&7"$/A\5A[-K=;A>/Q=) 5EO4I2C\25(/
MU\W:E@3^IEE53J((,K/_E<[;E*&1R4J7&R=L'0TTXQW,-;COY/6\L)#8$ <:
MBWY(HW:\BM6Y%.P_XQ&U"@B-("<8;K!\Z.*$1:GK&J(%$/(Q$D1=-&TT[MYU
MONP0*I?#H$+3$15-=*5?RS0+! 8>"M1JB CNN0BUC]*^R#^AO6ZY5))1O>Y!
M!^OO>Y=+CBZ>.4GPVE3.2 >6@\J-JONU_@6\AM7<[?!H\2M@5N6 Q0UL@7'R
M$8W/?3QB@\E33><NZ7;];LY]]W?S=Z*8Z%ZG9:CTB#+_H?**CVYQ1PF.GKZU
M.FE<&VA1R0=3Y+K!5,L*@=XRKF1'L+WJ;?,MBJG8,:G:UI-@*)-5_#X=ZR*=
M*]2G^[25NV)VXXV?#D:2V>:(&$1=*3S@T.)^LP\U.%7VR4$6%LA?DF'?RCY>
M3]04TV-YV ON^?W)V=&WXE4E.)**.QN#1>Z 7_7/$#;6!8=!RFH):W0GB,15
M3OW_MJ SE?6IW80%ZF&Y*BM9?C1>B/:W=2=U6&$@T5SL.#M-KIQJ O#0$&<3
MJ%!U*GJ>)S$]$G 8IY5*9:V.OR!:G3\,7N-&.LP4 >LO"CND-CX%LYFZ/)\[
M2UCK6XNZI,A!KT7Z(D&=F4U'L-AQ7VYZJM=&A2W>3:X!'S,OIYA5[URT;A&H
ML)+ P,?T:Q:UN*B! DY"LL^H*((#+J9*46\E1+@S9LT@D53NJBHXFZHS]Z:F
MP:-\NXLM>P)6;$&0*-QL5$OLDL<V]ZAQ$V]<E*LR+^UPD;5.J0H0*;%;^RS8
M<\W0W=XS+YB7K@EZ&+]V-5Z7# =4PVX\%H"]GA67%76%B@L@8Q?PBBPL6^/I
M.H:;16 X0>35P"1MO%%.?!T3%I<D[J]M_K9(FTFH#PGMIQ4V!EI/&%DZG3&)
ME>;+L:JLB8\*_UZVRK53L+LU8$E_++.+)KA&-?Q3@_;?'2_>W52H.E1"B[!6
MM,I:CG(,L%JJFAF4,FW^5#E@.B(!KI#9G@1@^;-8T-/]0?7F]%9;?:H>X?%Z
MC"Q'SA_V[S5C7-PHFW;DM+T7;VOR@;6.4^N'+)M&AZ,/Z3_[3[:[4?28U2 Y
MS*KSYU"0<D&]M*6Z^,8RMJ=4NF=%?&(@DE&<MRKE@/N^Z#^'<ZJ=[QM)"PAT
MV8"X]=R245R/N6]F5(=.X2#-<)9X:=R]H?!Y3ZO'"XF@:@9=*XF=YU]B;TI\
MAEJKI_"T7V;_,3>)0K**4T86AG((.YDH!1[XA:_:_.ILEL[(H$B\W_!M*:%]
M20LHK8/L+DNU=<4\5( :)RBL)K#<*/'?"WC +G'7),YR*M?A\-A:7($/$RR*
MZ0)%?F_9BGM88=IJ*^PI$*C!=,LPO#PHP%$ANV70D$Y8O:I$Q!<[6WNX,Y+4
M4,U<<=SWUMQ\U'+81=(]?W5F/Q#V^6F;9LJQO=\N7]63E'7+DGKA2)EG*T*&
M]Q>W''O$EQG&/=G=.[R:Y0;LU:=XEI!WR@@_M.3EKBU[M7"XYLQ45<$M9+N7
M5NQ^(-M_M39]7.[,S3S+*\4T:/5NV$&AK>D6RNZLW]8#;%A/Z9_](0%<ZQ<>
M?.35O?N6I\784BRY5AG\NNPW/"U=??@!@'=X1XL>/RM"-,J.U5D9,= 9,A9W
M]?JZ2!<?S+>Y[TLA.>YR)"(#[?9K\^6<%Q03UFSS*@,59#7+0_6*4C;+^&\"
M37PMH18@5_][!_E_K[LF"+Q.E6YQC8-_;FE(_Q0*-B037K[!_BS=\WT/1D1F
MT5#^$_XL/?]3,M_W]QI?=!G_Z6\TM=(P#MZY:1)KO"!=S@X>DNN<<1</C2MW
M,'6OLJ<B/^[+:+HT>[FD,4D'-1>P_38U-F)F/#4OK]D19AJ[;OXH"*'?E3)R
M)ER4L?HL6UQU0G%_*_8E7[Q.A+-5F,1Z2J&]RM%,FH.(SV^AMI2S<1'/R,0J
M._Z]1?B$7C6KUB,H*$L7Z!?[UG%F0T@D-=RQ?-"F8OR[0*%BK_>0]4XXU+A<
M6--;D$5W2#YU4Y<$J(LB9I$ >XBK<8IZ&VNALE5 ,.'BG!1<[8J84_O%4!'R
M4^DO":!3@LCOMKN6]),$P)MP%30@>FU^GA"\T;U+2:.Q9RS_(Z;&>#"DRU9M
M3Z#Y,B_YGQO+>;;^99YAR#\>-4$> G6(<\@"[WI-C U.'^/?E^?4EWU]=]&O
M$CMOUCPMB3AXH910#SV;+3EA6-AY9]D>GBPV4LBIK"&2Q3<YTM8Y3V3TQBO4
MD0#A7Y8&P"1 X]]>7=6% Z)&Z??B%<&![IO;-V2A:T98HH'U3B:=F?J!_2R1
MOW)G@IT-(=DA[%;6M]FMT^WTB&E^#X6M.!HR>M2[_JW(C+>7VJZCTVQ?@"Q#
MR\'!>6E3Y_KS=BL-DWHKA:97E>:ZO]QGQ"/V_@]?YQD-5Q?%?4^D$$3T3A*]
M1X^2D400!-&[":*,P408!H,G>A<]49-HT:*.T851HC-:C#HC.C&C93#&ZUGK
M7>M=ZVT?[K>S[K[KWG/.__];=Y^]-<.T'U<*4BV13DWFYX58C3X0*IZ?OS<N
MR-CX)6(Q0B!^LZB.KJRP6.]Q$&OQ>F6V+3+0_2?#F49D-,]RE+&T7%?_.3E^
MQ9!1SI[W)Y[[<=+@E6(V.>5DPQ5Z.0!L/-$).UJY!''*3UJ)$CN"/3,95E.%
MB8,R1-TC;];T4RP'GWS(B'IC:-<E!<:D:P\'I'0?<JV<G\?0,Q#EC#.59H[T
M3I\K/K1[\L!,W^E9]HJF.]1&9,IF^*NDUJQ!Z[EFI5W!'O_Y2Y+01:8:#7TL
M0!!H9[\=N'MH"=/X<<8MXYZO0%AOJ:V,-AR7'Q!\K]MCS1]<L:P/*G+#M[U;
MLD>U4/TFU5YTAKI< $^@!,_2O;5S>>M?,+ !^EA<7V,U-,J74A0MY3#]_>M_
M3O^3\U<4A"Z7]6! C37TKH3G2S],5=Y4X($VI'Q.7V'1\%?4;(\ZHG^/@W#K
MI)XX_[4Z 4%_JP[FA%6*, ZR*:"'2:$,'!3S,U_9QP=9N2 1X&"?5RUQTH#S
MGFS<LIJQIK,S2^=8J*?3VZ;DW;:7]]6@%@;Y],S?S&#N#:ZB*DW]6FQE2H,9
M-4>K(BVUV68.6CH:)WS$B Z^]5-!0[8Z^-C#+]@0N^AJF]A'UB5.D7"[=&]]
ME8]B[%*47SZ:AWTQH?LXVZ?!]![W4I/-/$J3\_C*S3<G,0RQ_=W?[5^]I)CG
MP_V-\U(+(H"[EFB(DGB7?52:< 294__&#((@15Y?=^/3(P@U5R\6-_^K[9XF
MV/NM=F)/2HW(NZR3+\-;*#TE!Q,W3.O-4LD&+@0W2_25MSZGG=CV0&.H+RFF
M_ZE]'>N'R:7;6R<<9.](N'9.9SBW(%7>[%/IY;ADA$QX<B?Y]U4F. <4W68;
M<[BF54G[ DUW/ KK-VZ?@+0)%[NI*(RL]<<@N-JEUK>'^\H*?W'Y9@=?K10)
MX8=]#DDL>4IMFK^=[\P[0?SR[R3:*O!5MOQ:=C9GCS'O]7E66/$U/)*]+[MP
M(.A9=D2 O+[RX3R>]CS&7/U1#^Y=98$(UE;PI<2[,RNMY^5C-!K4NB=FA*;!
M7VTNSG$57$,LR;V.8E,](TN ,7I.>8<KTQV]]'<526+F,R+H?SEHDSP7)@D#
M&!%3#M=L5"\IK@PGL__B#HBQ(%TR.KJV>)N!G\.Q!2TQ9RLPD"1\TGR1UB9*
M8%IU[=H+[<I.!]YJ\U[=L^G%*,4J7+"]J&F[NGT\'(I]3 V'KC"L5M,L!JBH
MQS]H+M"9CJBUIZI6L%Q#- 45!I1:+PBWA(PHFG?2DU7(,V3JM@B;Q>U+"B9Y
M0S[+Q8Y;&%]U!N*[P2&# &K*V\Z3SL.MV0KY6/[TPA&V3_L%S&K_@ F\VX:T
ML#"L!%P.6K)U%I53"1+"]?=V,!+(664Z2E$DB\(=AI\/:O(GGJ?8U&J=/Z^Y
MB-I\7(SB=SYFG^VV2(25(\17W<TK6!<L'JL,YBE0:Z%+R-7/\MC,50Z:]9=-
MR6=P[T2L@0RV?$Y1E2'#>8[OVN_3FW<Z.)D)^@YRPU%6C<X)/:\K?+#U+Z0$
M<-Q# "L_,<8OQ@TBV*SZWQ&KIZNE)#=B/%8:0[.2''VEC$"ZS5!ZJ08[U_Y;
M&D04-N#/&(HOWEY@JNTAG*[($N2I4$HRLN>WE%90302BSA;.?.,%%&NV9JHA
M@L73LRTP80LT63%DSEZ<F%.\U.6-WSD)P O.=M&Q]<@N]BMF?2?I$\C%3E5$
M\J1ARB#*'XRM4M<=;]"KJ B@F0=W8LQ?OOK*AM]/6F:HAD/Q2O87N6K 2PJJ
MT2H"JK>3\2@YS%XXWG;R03Z:0R'/D1P0(D?T-Q3E_!)*!9*!%6AT3)*:/* _
M]R6_-B%;$?!WH;?A( +_"5<H"XEY"L"U2 JZR&F[H9A2N466QOME%2%[^:CF
M8'_V[9LT<.HT BG(Q,)PXW%$4<=,):/XIN=*?=,'ZZ*3L]>'K]>T*D6;32O^
M/9DBF(%U$\K-"V,3E9NP!+'D3I%GICR!QX4&)B4KA;$9VN;0L;:R#/1(G82+
M*G74P#M>52LA<'>SN;:&;&G66[(/JJEM[);:;%R32R-H%_\+K@71CMUY,V>N
M'=N/[EJWA$]RQ&(WL9G \ &^QDN*+L4V&]=+BMNW3&+717% #I(_L0LG?NH:
M9UCW-+2:F+"TH#8K8<6#-LMP0,IQ".8_UQ9)LN]\(<PZLT5K-,R[+9KYCB/E
M=X#N;J;>O_1_IE=3PE4]+3]$&ZLAQE:E24P;/2K"26O$*\BOOK'\RQ8&02VS
MPX&KR=>M4;R%G/K89)[%7MRY_HUL:%T0&UKM"%\UD#\@M0M-Y#=N9,"Q.E_X
MC+.ALOQHJC9K! N!3](6;.RS'"\I7(6$PI[[P_6N=^&$'OS*," NW(U^&<\0
M5Q:1(,RM5F:R7OJLTATQHIN0IY):>L>J#\IOIO4NM]S$KXR-78&Y^'0YT<I9
M[58,_/F.<1]6YE&; 9=<65B/0[%!"2_'*.6-[-<BCDY&Z++HWS\<L;JFCS.T
M=:O$TET%I5SOI!Z-^+A/EO=E?FA92$3)+FB#Q<8RL.;L10]74M_X)[RA&C"^
M-^ZBE*+)OW=MANFZ>!=H;\,YDZLP)9Q[0I,]Q@?YIC7'6RQI*A0'8<Y^#I1L
MF[@^M;[@=!<E0F'5]V-E89B:MAPUD$CMP?'@YO96K4V7)V_^<VFGV_/S?UQ\
M86R4/W/#K++"S.JL10'0C7OG90:6T<9*&2(:F09G4V5C_NQ:,T;%X$6=#M\M
MQ' I_X'Y5C_]@'AWE6[N1'Q2^E93=>"[]H5R:++@J;)+=GR$K1$BUZ+>#:W#
M<+@WLEB5D]*ZVWMB^U48*"2J6^?TA[JQY+JMBR:SSYA"T9[( >2[ *)YX?K0
MVGS_=1.)?WW4Z,$2 9Y]FJ_>2&ZHQ#K[-DU7K1VL-DQY2@H<1*)7AH6SF5.O
M?[PF^&_YAS>Q'RM3^2,D;L]XL#4B T=.DFAGSC+:)-]ZKB>FFB;]^;.(QG)=
M4XUYF>S/.$";D,S8)$A]W<FX",(^E)8UK^+K>+$,AHG%Q1N#RGK%JIX*K%)U
M%7N!]PURL]-7RI7%&,K,S==/]'6Z9FR1[<I+J3Z>O8/Z.J4_S2^2X/M$8]G@
M+SUIEQ3=6Q??VF9OWY6[I$ 9D%XO/+OV+"Q0Y!'E^]Y@;: ,^>?3_J[X]_>,
MA$E2U9AHF)9$:R>VA"SM"F8Q_I'_5*PH_.>MN+-WG0;E5<8@Q3UEL/CB]K'_
MS,5^V6D%?*15T&^Q$"S>.F<]N%B9VMC_&]!ZK@KC.TDG*A!NH>RE.@@9$626
MBT*  BS^23M>*;84OU[M5"4<BQ 72#6.ERSYPC;W_<V;^BG)C? 1AI]ES;K(
M05X!HL9Y8$C?N,XJ_;^7%"SPI^<F\/OHL(7_O'";@]OL)<7=HRJI*?E9+4R?
M\IT\W'&8R/PHD'H1YM/3^&'/AH[>_/X:$'U)\7Z3J;OS[I^OEQ36G7P=#U%B
MU>IN[TG^*@.4_Z($-;)BZVB-;ZA]\86XI/I.NM1UZGW$U3>WY>NM?>IY*+#/
M_0VI=X_6$>";<KH-L,"DPNO$ PIRO!6!T55YZPIK*DWNY+E>W-OIQQGNWF:E
M5-,;!@"T^*=G52J#Q0H&2D976O89_IB@'@MSBC[8C=20Q!FPMNM.-VG$'IQQ
MC&K&9@2:ECN"QK_$1! XS(4J"\4:ZFGS.RBY.(^5%_TFM7]>4M0!][KP0R=5
MXTX(/&D$6\U3J'ZR'%;M*@N<"S!NFMI E\(^9Q]T8WQ3V4![>P@ZL6<>"F!5
MFX^?4P_K+BI"P>I1ZG754?+@ D94$ [" TOU >$/L5E1M+*P^MZL<7GOGYY_
MHY)?3$C.K4:;SD+&,=9%%=P/W3G#YT%_^;*!>"/@O_GW+O+@/B4A2YT4>Y)P
MOC*W$*')4B+*"7OJ4[HMX_Y.PPE"X-1G\5Q)A+)[%:M DOB1-R=[ #SM>JWC
M+5$?A5J O\2?$ SW9 ACN,Z]:D+H,X#,K&]>X'S7,IUOH1J;-5M8E:=.=A^/
MK.BTK.]C3CU]LR5,+V#R._@O9_ZFO>J;Y+7.1I_;"FMIT]& U]OO3/HJ)0T=
M:V2BU6HA-->W=2L]5;MS^36'TC+=Q89.D%A@M'*)+LEM2,8R5SB2J":P[9K+
M<%']S%;[_:I_3+=#32Y=U,B.EE&F4?88EP9'Y!BX_!=)2D^/E\ LYK39#27O
M7F0[7]2'".]D(WOV,;+GW4 Z  \L'#5K#8D*N4:$O+"")@KOR?;@P8 '!*&O
MR17]Y8(%.;1XNY^I"VK#&UKC7U]4_3Y1+:##; &$B="O5@9>*VT$H5I<L)W@
M083<'$QJKA+^V,WH6FVKG;\U6FJW^)(B*[Y=X5-*2W4[YIE75^9*1<^!VII2
MV:'0ZV_69HF?&!X\-TMB$OA^Q]YBR:] 1,2%2  S$QHXW6&L>_+-3WE-6[Y_
M^FYMYUZR:,%0F9EYUI$FI3XC7O12II[F1%F+,4]"7\TT[Z6!.OV_(\7AU3'I
MQ?:6<<W!X)G2@0'#.S53T[:F3@8RI3<TOU4'# *'N?U[C,><+7XY6VG?66.O
M'(K&'[^#1]^BE;**'*KYE,GW"PO6;=M9]5$A8I(R:1B2A[TM*T-DOPLQ]5CD
M.E 9DZJ)(H9[/)<4-[2(:X3W#@$=?"&CV:$D<77Z6&_)ZH)"C#N ];#*K*X6
M%8JSL^C#G,8\A E-U,7H?5;I;&3;S<)V<I'G.FFE&R#,VT J-7U".'8_]@T>
MTB--]]2]<8M0CVTL+ 7.V<*R#%T:X^U;"&P1"#V[QU_CUL>L.I*?@7?TL,&N
MDJA.,G706S510NO).E&I>C>Y]\RPCYX%_)=>C'VCM:&%4!HG5>*8& L8<_7$
M>5Z#OM;=FT[GYW;NU +(D;@G0A[#):] 5J/GKX\;66CBV$;2IRM$8=PYM=\>
M+YS8T)@+\^G-OK%")T]_]X.F/^M,M GZ#Z3A="+5G^; $BXHX6=E9U[,B2 \
M(GG)OLW6E:F*Z!-C[&[N7;H#LWR6(91V$G)A%F):<,S&0BA10NVSP(+HLUP>
MM17>^]DFC;US9TB.EM8IKN(BMB>7)7ID)OA8I<RAWMV4F*72LP$;IGNSM2Y6
M<.()#= U(DWA^_OI$T+I0D&=[_-O7;19Z.,1G9'R8S$JABA(0C8S&]T*)*YE
M.=[#=Y%>K[UIYM^P68T"@TG'J="&RNK=RN-6<)[NP'&02*7Y8Y?]Z1!&8J-A
M_'*#_Q['N?56=H+%,@V9"_8J9.R2@N:8':>C':<=[3!U;,A$1+Y0[.J8*[4C
MIKW*7L*L,]R;:C ;W__:=^ID>)NX0W _/,DAWL#GG.@2CJ,2U-V ;/!W$QU4
M)#OTL;[*4K!%EPG13/JXW0FGE>RRR3D"-\.."'$ETX.SP30>._ZL'Q;U:%X
M$\?A8$+:B?"46BA>HZ>#LI,X=ZX,9R$(Y93H$8!= '9D> ^ =H($*2Q@_F5#
M3-- >V$@N_NUVVF8;0NEE.]Y-TM+EQ1SRK<:UWD>GC8EZ+LK^?(#.2)+K:-D
M%<24]9AH7:<AVC0)K[+4L.&6(//<4VDV _F=:=N#\HX^N SMAD"_:=*M:"*X
MYZ6]WL>W[1+AU'&H-;A"WEM36"N-A2*.3&>Y\)CV)A-'[Z=\*&VI^)#SQ_Y;
MGU[[<*/84$V6W8^XOP.^G-/:$U&HT#K(KD, 5IU*&[>C=X5'F%4P6T4%H( O
MJJ_X\TZ@X,AZ!><O>PZ)9<-/QU92\)_6,H7%<:AU=X81OCW)!K0':V-YJ@=(
M#9FA6V3^(UE@\%\VQXUW?1%:Z <!"8-4TL2M2XKKR03I<(6Q\"4%XAO:E@PD
MJB &4]EQET"9D^-327QVXMC!,457\2)DV+EFTN.86Z5F\9N:B;+;:*C#S($J
ME7."A(_^>C\=\@.SPM%!Y"^.<(^EXG1#*2RMKG^!E,*/<]MZU=*/^ VZUZOA
M75ASO2Q<C9DW$6XNS1 W+&S"8\-,1NBVGK"[/IW*4&'H-M$M5EQ3'O5B#!VV
MEW^;KQ1->D<(YXKO6X=N>QNR]<<\/-52IPSO<CB "RE)=AG>HI78>O9H\*!G
M91M;L:K>X-[2%%A[(I;'_JR(U:XA*>L0E& TG<_<W"3VQ"I\R)MS-</*JVJ.
ME<+&%T13S_JAI\YS:012.@8)EI^8[_>1-S>IK[%<2W6J&S^F'&;R3*0>D/DY
M-#HU;V,XX5FUVAY@,]PV+613<6KL<F_A_C7%<(%3QVOEM1\HKX6K$<R.]>ML
M>IW+^F@] ]P9]U^[ 9D*M>\[4H7]ODM%RP+_\=)C*..ZDWD>M7*?3)F_BD5:
M.NA@U"!#);7A3?7-W+7Z]&V3];KXK"XEW6*8EFQZV7E*)=HH0Z_[=L-6;[.X
MJ.8W@>JAVS[>^@.:61\T64@?9&_6-S6:PCZ24@:\?>N&XYI.C7T1((ZGMU/O
MB_SS*0[E^7;'IVQS8LFF?:<2#8H/N'\X?!=%^TR;JA(MF#<D9#"=:OIZ^#Q<
M0?&O<=2RT>0NXD&\5%$%74/7&\6_8UY"[SZ\;)UP"0HHS7QA1>H]^*ME][!?
M^M54"1H*%A=LC-JQFMK%2 )<9,H#Q,4DIX^'?]^*6II^$_OGPS4A:*+CC2),
MV['[9*GHE(G1JVI.:(!IL3$O1N85ZN#9@9F86(VODCW::,U 5N?8J-"X/!*@
M+6KZ1:SA^RK[T*^!9HN-[#7?LA:Y1'_?T_NJ'6Y(;KZYD6J;5;X][8M"NDHE
M,(XO<N!>_:>2,/T.2KMZT521(HU[RC(O*B?P:@/,4>+G;R\I!M@:+BEJK^PK
MWYF1_\N+7$G^>F+7^:N>U-A%TE-\!S@^^>'@+)LLD4UN^(]5W>CJ_:>8&$:%
M[@=QH7NH2PH!^TER_Q7AAFYI+H;49I2)?7J6L=!1E0',UC6XI#!!V1\D.+&>
M(YASVANF2/6*:Q!Y[[ID9+_UA+?Y6:]=H:B!D=W7WQAS_7RS_T_#JB$R_27%
M![KDBZ"KB)]OGX6O9)&&E__>N*180 2/^E]2/,@U+.&[I# 6*6!+#_W9?S7:
MN_.HUV1)Y&L<B7CN&/7_2*LTG^I<G>A<CK^DT+"NAUR-P8?.LG<>W?A,3S?;
MZ:H>#;A'S HBF&,5YOF8P)Q^GTJ(<9+BYF!)N9X4MT"7UL+-=^"'$O10\2US
M7OXI7!2-WKPJS0"@R[M\;IMIR_I-9FX\N7_YUFKX<TX=0G0T5)W.&L;8CR+?
M'X>;!3M7@U@+Z$-XP:&W&X*";#9TQGN#5]09=E1XF[+N&K1D82:-G.--ZVK:
M$20R,8L0CV,C/58W(QI""4$]2[Q$Z&?20R(ECH^>R#BVNH_JC&Q1V(@AZ5>2
M#/1?=Z(*F(FAQ@3M/LIJ'AJMFK8)-?ZRK:RW_=RO/F7J?42&P&'B)T/$8X=S
M%7?R/6+ N26Q?S4Z'JYS?@,.)0X1,E&O"+?"VDR^D4>6V=I8JC?/0E&))B\)
MMZ*/N&SV*<=POSNGCUR(H;CY*JUUD^+$D$',HL0^[UOZ3284L!;9!:%>@OG9
M\<[W>F\!>).[WUW-+6DHKMW@$!6XCEP!THRM+%,12WLR+20%^ZIQC^E1D]K@
M&T>SL70CBU%IE4",W8ZU0=XW&_?-SKK0[L=,+VO1]Y$$P>.23R!\CGXM>9K
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M:PA6TF&?BLS+NVC=.8/FY2,#@D-]UC%\>P&K]7C_D_>$:2S1"K=H@]7N&J.
MVT\H=%(!W35^K._@Z*/5=+[KX"\I>NH53HJAD$J8!-%O:=^R$]D:9[-\!U:
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M\O30H0< ^!$KHSQVVTG68^^;609MQR./O\*H"=Q+7M=,B^*([NFR3(<*G/A
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M'DM3SS?NF %\?]WP.:JZM"V(!"74:1?P0IS1:3!M!0$@(8G#(K,"6*3J*GS
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MM6T[$A/D$.Y$%'G?+0H&^U/F4?E17UA.0Y_3Q<AW+=-YMRZ!OF*E*H*?#A$
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MRU;<283<*G&5ES?X]!;L:@_@IL@,5;'&=P[ 1E78<+M&R3>>A?EMF#YX@'Q
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MS_Z<U8T^3H* (O9X1?*M/T1ICG/Z98#\_.6#(;[_B!@=WW,RF;ZI9I AHWA
M3%#XQIN%_WQ/0#9+1!_::5H]6)8-'%'/Y?OBY] K91;SU*K(JDIZJ@DIMGGB
M?U6*<-?^;:2Q:R&?\\R*>ON+E 9R-F_9TO=<49F1D+."V_1?D#UBXB7"*<_W
ML<G!7*E*2Z[+:PMX)]!WDT0Q;$W&LALFF5:A^'ELW]LE:<_XH#TQM5 NS9BC
M(ZZ#[4'9/XJ8W+G*;V/#C\.;5+?D6DF/_+HXE]Q!M[[:-B?Z>;,Y<X:W6 7P
MI&C1I7^4\O9ZG0."WLUH61[53CM0^F,@]Y:8Q\M:;W$^W%6$YWF5Y70ON&E3
MQ-*KUUT.K_+L%2),[XE8395E8+T56\&LXV2J9KII^V/K?<F1,M5DJRH;#8D)
MR4HQ"3JI;,NF;$9[!R/Y5-[Q,@E/ONE0$3.E5(V.EC8I2U]Y>6G7*3-I2PM
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M!"1=77159CF787@.Y;8#98'PR:<"![O!P ]M4]6EPM[14](H'1%.C@WI](S
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M"]^DQ.W8-:K^S/LSC3GS.N+!,GW:79\BMG^(W0]5+X];?E?^ >SXQ?%/T&C
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MZE5<)4M)#_L39@Z2D]J59O\?<WQW4,_> *5]9#Q75(*/:V>#G;:]_E<40!H
MN\G^#K PF3P0$LPUM.VO[L/=QM)']R D,N\TH1O&/0>.5=\38\DSKZ9)7X6Y
M'J1NS^?8.0L0P.":E#\#YNT-8-8<K,;Y'ZKF1["1_>NF21U__5A_KE6[&9CC
M_[V6//]M#W(3"T3BN*+"?%PWV_T_/(#R8;\TCRN(=)"&9SEJ.$+G-"A"-]K(
M_3= :WC2Z#5>BI%>;B2@B.4;6N,!!?PJ@)W[PM>/ECWR$JN?&$_7$5;?*?D#
M+$0?]0W^-J$HVS["K,-@DK8C"F*LZ%K_V@Z<@ *@"R"XA8/ W'I@!W>B>\E
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MOTUI4GU'.^>$T+ND(QG"#>W]_;1:[>DUG_HP)]CR9.Q3R:BFA]<?BYV\ (%
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M!-/&@LEIU^5'"67SI%SMRA9_G>MU_S 3L-[32>Z*%&+2V)I9G+^6U(*$,Y/
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MKIMA4 VV=60B9&]:MP\.S!I[]*HRI;6?@[B:]U",J9=H")KF7NJ*(#O+*H5
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MOPD8]7C:IXA!>)N+E"%SL-'1E>5[&YE_;0+>^\*>;('695:;9$@4.='FXYL
MZ";@,]%\$Y 6A&G "IK7-P%3P^)#A$W /*G6-\Z<4JZQ*D5<+IF?7U_[).G8
M<DM=>KI5FP#<%K!LVTW ?@1#8V$34(+Y[H+;!+32S/^%'Y1BJ<'M3]K8Q5[C
MK(1&1GS#>'_'_%+-&-RRMFT+L\S3_XY=XW_1-FG&KUGR;"IB:KVFSFS:O/R1
MN4C:=A8SOD7-)V6K*?D7Y$EB)^CA+9 ;89N [>1-@,290W2P7JKPW 1<0=$7
M)= M'37Z*S56=^.7S1>VJ/V_74SN&F0+V'O:\---@.Z6BK+3@[(;.QS7<"LK
MD1']/^O^%7CNOXF,FKKE\#]O-V8I8(_DK\((YOKZ%K-YV+\A[_YWD1<_GI6P
MVS&_=*B\NK8M%1G_R9#_9,A_,N0_&?+_,4.,PH\(:)\\0TF7]AA#)YOA2\9!
M?9?,VF4_D*JO"5RC17\<9=HEY#M5V@>YCSG[5TM9G=:\=+MD)^-(Z,^_I=A,
M%A1_'#L\V?VH,(YXEN)S-#B'@TU(71GLR9;:=_WZ+8$H]S2Y2B%E 3Q$&*/L
M/YM3V?D^)^[LCLW^_P)02P,$%     @ 3XQ^7#6BS,Y5)0( <SD" !    !D
M;3$Y.7!R;V9I;&4N:G!GI+AG5%-;%"X:*QVD=Z(@H+2($&I(CJ @77HG(B)-
M1 0D:$B.TOL1*5(D!Q$B)82.(A @ 50$I LH)$% FNRHX%9">)QW[[CWS_MQ
MQ[MKCS7&'F.MO=;^YIKSF]]<^Q_WZ9 35N:6YI!#APY!KAX\D'T&1.,2)O@&
M!&)K"U&#0"#<!V/:D,,';[P'7>:@0RSN! 3<B@P*CX+LST',_OOV_ZK]M\C_
M[1J']KLAPMR'/ X;'SFD"#DL?.B(\*%]&@0*@1PZ]C\F0/YG.W3XR-%CQ[FX
M>7CY#B:TG( </G3DR.&C1XX=.WKT8#3N8!QR5/B8R"GM"\=%'?RX%"/$SC]X
M5,:M9-K0(^XX"IS6N7;G(0^OA*24M(RRBNJ9LVJZ<#U] T,CLXN7S"TN6UHY
M.;NXNKE[>/I?#[@1&!0<$AD5?3<&$WLO/B$Q*3DE-2WG<6Y>?L&3PJ)GY<\K
M*HDOJJH;FYI;6MM>OFKOI=+Z^@?>O'TW-CXQ.37]<6:6P5S\LK2\\G5UC?7]
MQ\_MG5_@[S__X3H$.?*_H/]_XA(^P'7XZ-$C1[G^PW7H<,Q_$X2/'CNE?5SD
M@@.77X2HXOD'W&*FC\H:>GB4=!P!\6MW1GDE3NLRE%G_0?M_D?V? 7OX_PO9
M_P+VOW'-0OB/'#HXO"/"$!2$PSGS+ T"EB]F;_X"1'=P8.X^A*<C$DJSWH=(
M4QDU]I+>[J!.M]%(NE\+L/<EYV)1(JW]2L[%),G4Q,%8Y:N?I>Y^5E2_J[</
M:0W?V*W"C<R?W*N,@DI14I'BH.=Q_ G?H**PS_VOGW\>,'G:/&N[#TG^)C'M
MT#CY;PYGM*+Q=9;$=Y6L9;V<^<M+^-2Z#DO&".\^I.<:UKH:)*)'$885Y(U
M.57'Z6UK 85N&VPP8^8B^N9$8%N;R!._HBNE-WZ(.7;I*3T"OC7I%3"A\13
M?426;7S?.OM!ERJ+\H .F'#2JJ")VVB1X#^U(XMQ9G^=..V:TQ,-YQ1&*$\^
MZ] _]VEF4(XDG"(T=X=SB,&F"CWJ&1T")FOH&%7M_F61?H=2+GE.X\I+&X)T
M/N/%X"&NA+ZQBM12?1Z':PW>$\#+E EJ"S08.J#=$5%*;Y!^G^=-%+;*,LZX
MPY8X;N!9WT_?ATQ^*A M8D3*77+)*NKS"W&A#G"E)4_63U6E4MNCQ[$Y>^T3
M^Y";E+_OV6_,!>RZ^8"5BQSQX^4!@=&!+RX1.]HG?KG-%HX^&Y4T]T PZBRJ
M-5K=C"+?D,,U.WORI@P*UZUI"RTCW?;'L"< RB;7(E3.$^//F,Y$P)]A:J@B
MH<)P2DHT"463N-LV&]9:S'A^?JUMMGAN_J_QCQX]$9KU6N.Y6?H18#1+9T<!
M?,08>>"+*OWAW?QX1P]([B&A=_+ 2'I>UP^X+#Z3<P;T?Q9,+OL\UYST!1-(
M;<]HWTJ-^OH\L"&'"30_LHW#:[3B?K-J&/@>BO#!.:HBI;"VK/YX1J<UT^TA
MQ1_*'XSGWXZ[!\0U615X BL)*I.RU%F?H5GWD9JW.\9.\NR[^C(5N7Y3P\S/
MJD\NVS_ *+N\19*+EPNSH/!%J27QBH):W?6KC>R[\JZ#C6LLDLSMI- D+&46
M?-(^<9M5!?-+(AMIB9[J+[FVN@)U?]?XJ:O+H]=>MT+N/LTT2P<:7U=U0SI1
MVK%D18,LK!"^4:O;F1?R_>'.QZ(K+RHICIR3N*E]R*$N2;82@.X?D0&'H@A'
ML>;U'\+97&TV$^'8"\P1T#+J(SQ.<? BL)37_*=EN0Q)B!2GM;Z]*5!=XMUL
MXZRGE;@;QGE?>A*$,V'9KA0QW1K[9%]A2IALGWX1J;6L,M23*P4QD005#/&5
M>=V2[9WN\SK??6S0SEI:Y?6GD>,@XRF3/<MJS0MCPOY& S9H638"K &2S< V
M8(%*$"H']!,X:B%N+%!V0&:.?0Z8N#>0N+5-DEBX$D_E*-:GG;G>XF-Y[<F0
MD1G$>J&IEB >JB \Q5$'RW>^3"-/8]&@-MUK$):);BIMJ !?6V1[M.^5ML"R
MC"0*JM4Q"LL[IR<"<XZ$FRSGD3!)WXY9;@\:#YG^F9^:^G-!8<8MB0W/ZK7"
ME-P*3:I)>J^F$7#Q4[4%GZ!&!76TA_%].\^YQF>R9RI)S["%WTXQ-\*!G, 9
M?@%L=Y8:$E*\S>)IO098!;<48DJW$\;JSE*&@@H6YH3,U^HR7/Z'>,FQS[%4
MQ,/G)E+A>?U861KGPT.:PPHG"16X#YD=H(=OPA6Z"#P='GK$:M"%9)_2 2<%
MS9*3.NR?>Z$?SD;O3:62/&=]Y?6ON/@'XWFMPT[)\J>?XHZ+'^# QW!R&/4^
M!<1T6$MHIVROI^;.ZZK9KT8W__0WF902^.P1GC?R0CF/\)@WS\U"A4;4&6XD
MG#CF&/8^2W]G!_R -,$,,)*3KA)V3K'TDSCG,#5TU=06=1@OV^1#=)B9;;P]
MX0J87&LM)]&E55^_Z]IYO")&H#JH]<3?#7M%JOGAL^0'2 4@)A$GR#8"5J@'
MS.J#-0/L'C'BC :IOO NEC@E_1;6NL(\(VS;$&L6,A1:S1,OGA4DE//HV04I
MOA,.+&\?JH>;(+/>Y?9VA L 5DO;Z56B-R54=(,6;X^3?1^.5#'J?ZI-WGD^
M+V&M$5^50+86*W<4[K2O9_@JOO^QH:>5KY@OD:4DX*7;,R#_!OA>X\65DB@#
MKW@T07,C6Q5E.C=8+NLXLYQ#&"55[RR=?JLS5MAB*SLW0<+B10":^',KPY:L
MO+M:],\$4@S,ZA^D_HJ8\_%IQBF]OOWVV2&!O!Z5/;^>S$:(J_IV6_<^)!-Y
M?*\,*0W>9TY3TS/-UWLXJG&>)FIQ7G8%5I2[H]'%>[R@O;\.XI_-"=VYBHPF
MZ/F3.1E<ARFZJ.NW48R[!\SAD77<@C9S^_9Y%/,2B^O[R/H0+N: WU+ T%UC
M?(\AS@2T[YLWJ6=M9>!#>;IDU_K8 776# R"JQHSP.27Y$B-8Y5W:,!>?F&,
M2JK\)K#+WR:3R"FKMH_393*Y-W$#LMT(_<Q2_Z1WQ"=+!B4:H&>I".;]19T0
M]^K?*SPW.NP],P/L!0JL!6P1FOS*B(NX^M5J%[5V<9]HN^RW])<K*;=O=U_3
M,0CX70D5%52N2LN22/C>_C+$$"8>X&UHWB*),/>3N_BE(;I!ITSY@NU$(MRS
MZ-F*VY]"LCHXPWK<@V[:AU"A8E@?,!59'D;?XJ(21VJ'GJ]^#REZJ$*L<0]J
MI00VI"[&SI!;9%UNR]\U'SEE8(8>T4^["C)8!0/05GT:E4G@QT@R8;VH6<<?
MO;X\X&N6T$[Q)$=D=1]RF&W"(/E*=6@S7@L=]?;2CP_O,&&F\\5N?H/!8[YW
MV,?LE"^]9[+(*$<\G>B$]L;W&"%UO$/N> Q5V3/"DYU"1(/'-?L)FC^[C 'K
MSV_]C1(]-N;O/B)5NO"=/B8'D>+]O0H<A\)&7NIK]"\WLYI_L-?5!R.-I% !
M5EV\!@./IVHVU/J[-.U*@-_520I=BEDRE)8RQ^?UZD(($T_.3X.U+I02\],@
M5[YSK[W2.QV- 2URVD[+F6OSXC<FJJHGEBQX&8Y2&0WO.F7$(W3C\H),#09\
MQ5>O['%]P%I48AY3C6#I40.%/\/NFXYW6! M=34%J*M%E01!8M#W[H$H)W@M
MJZEWX([A&;M+L93N\&RH$"7H0'BT4D2[I+W7"G#BKZ?@0X+2+9GGPQ1_+H#W
MKQ383+C4$@,?7?-ZX6UVRB#O'!T2^EW(:>SG2 :J!=T#3=B'2++]F61^M@:@
MOR'-"$_U/=(XB@TC8U'U!0/XF3\!741F>>W7/W4%_'_(R;I]^<N';H\58S1F
M@_,V3G8D<G1!/'-!X2.G%]] H&;S??YL32>G+[3\RD:HLXZ2,UJ$DEMQY\87
M68BFKUT"TQWX<MHOG-PHPE_W5^.:V]T&B4(-\3S^"",HFH>1)"G^M_>KI^XW
M#&IOV#N6$$U/=-,;.ZA<?09KCW8FU<>S_+,P-Y,DDO4.9_+;5"0]]?CQK@6J
M+LPT5Q7*N.41;7CUW$?$E+@2[UBIOG3AU09O[8>5>PEGACUP?.N&2_;X GG7
M+AEU4=[;7S+5%B8#(E BR).82(;]WQT^+-6^L<\]C.RC04;)J?"9VC#?/]]-
M=&P>U&F5S@Z?)T>>RQ1\X_+@;O=1-Z;KH[IU?!.Y&SHG2T6)([Q'L4;A\J L
M%2^($\&-+#3?Q*' *J# G=7R?L>(0$VG*&#RQ^*<NHWN$C4K<H%]2+C93G&8
MFL_MF8NWGKQ%I7Q43<-RD? ]YEV\%L^\,4=Z6E$-686+AX#2:696 RO4\D.'
M&Y)0:191FWG?;6_I0/!XF;@N+](DIH0'@G[I<YM]]NKQ/XW%0/G+?5M5GO\(
M0',E]E^-*UEUH)I*9QTGW9+/@CN0Y'H[K3#O3QND"_%27'N7#;C=B&<Z>OHK
M>";7^S'I:KKU'[)<OS)9[C:!S437.L7(05;S:N (SV;0X"%S\7,OJPL%%:,X
M#:G=_D33B*+NLTYD7O0'W ,6NE=!&;2HQ(:-K5#"#X?,'TYGVCZE39TWJX+R
MVY;M0WHO/K:LS#]?L;(3/GSSE^0/2I14:2CS0(C@>YSQUV'0D'GI\6LL6 9;
M.7A1G5$!!M(XQH $A4'@"OGSZ)5>:$ XLY!1;&'IN0%ON)_^Y&I:0%1I4*NA
M[V-ZW%+%%EO4K?NQQV<OGS[HQH/0F]]G1\1IP1&A0 7]U8-YE6@/TDHFHU31
MC*J&N*/6_@]*]1IKNE=['W+4&"#_S;8@@_8.K&]-?M6KG.- ^%SSID7?=_"=
M?9;GYE2Q5L&_U--_:&ZW5X<BC#\K5]\<7[D>C'C]9LP'<S_^/"+NYKA 1F^@
M056=\2#&C =!$;?+LZ$(/-%8+#Y/&RL](BZ'GIA'FT<'ZR<0U6Z1UAW'' :1
M3/;*$6L-FI^VA[F,"+UD((T5,7 @F8E9-+J"PV"!WQI5/CE?_!J'XBJVIIQ6
MHE+EF6=M,/C'_:CP/W>$3F8EW!M%)WJBJ6'^3(O-)4"2@>[#BX"<=T)"G)Y]
MB #;81$F&(34GF(;A]=A%GMGNQX=^]R6:EX<+=:VH^016[?-IWW:G+,V-N%C
MJ]SA>$%_B"",4_8)WH<T%+#%9.T+!@I<D9IM>QW;83IF306T\5G,0W45L//?
M>15"^5SGQKV'L_**TU?:)5K/G#**[OPRCYYY5EA0P,<@3*LO@3>1L3(MK.SD
M"A>J9LE7OZ\1$J%.ZM3I3)>,3LR'J.IK:IQON?+Z5FK/<K^L_F1VF&.L#-B7
ML'GCY?%9V*JJ9>W,D.WO<HWY ;X951WR+XS66HS$*+&N(2&U3_6E+CES"I7S
MSRCFQ'[)DO++7"H*]O%/.U/N^-WR=);IZ:"_FUZ?J/ZWZ<0A^)<%88X!VP#T
M![*]P472>G -V^!#5$K+V^T1'BF$K3BGT.2]WC^?OFY5?K(,KQHX/?ZL?,Z[
M^:;^.>Q9<F_X;*@5"]8'RUIH1E-?^4UWG<4\VX<P"KI'A-@\10.+X@5_(W0
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M@78=#[UGG](ECU'M)HAT'1NI @]X9FE@TZR:[<IJZU?__=,ZT]\:[*D 96F
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MBO4-/X6!09$<M6BHY-:VB=N.'5A6'7JW=]!C A^8+8M>FWHRMV-K]X/12HS
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M\4'@'[S#XUONQOUI>)?'C\.%V!)S'?# .HS0CL->"4<*5.I'"R*X@.0>CAR
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MFPF84UB1)_&/#:DM]I.A,7KF/EV@(+X+RD:U@'X,$"L+D/L&%T>29P_KE>_
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MS)VU#3,B=6[GD6@XY]%_@']/USFS?S#(<Z]W?%@Q_?D@U[_LB^WMK"^E&JQ
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M^';?A.=SIS='?#[Y/O]5D' H.O(<Q*UG@0=%KRK2:]B]SOF$;E(=0/%^/0A
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M=KNPG%GGC2$+"PF?*[DW+:GS'D/Y!B-F?A24-&@+G)OCB HH:,#5AL*QH(
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MPYT_M&(1LU,\TY)G1KVQUEA*'6<N\^TI8;C^!_G- EC=TEJV%L,?N+0WXYC
MK"8(S=$S$05)C-?D^BWAEH!D+*7WS_!/Z. H'77*4L?LMW(6MQ>0UCTY2HSP
M@W'F*=V!6:US/MB+F=T"G4&7ZY$:02(5AH?5=G=.:[53N' ;VQE-;W;ZS*E+
MK;#X<:O2MS]#?]VK&O?>'BZU:U6+]1MK7L*3Y]*ADL&J<_)0'.RX'Z]Z9]V>
M&X._FI[#3%95YI\&B]LG+;*5F&4ZJIYV7+&JHDJ*.]>F; GKVD'S!B1'JM'F
MB7X!=[O']8O75K\9O46-\@;0WS.C@HT#WLYR&B>V#7'"";2W,/9M5T^?3M8B
M]./\2^;=7<94-#=KRJ-5LLPTLN83[KWW#*K1?V@;6LF5"ZOG6TO58@0 ,G<Y
MQF#]/_.PI&?]Y&9M4L!^!.O]#^BV=@]'!"R%<AC!\MR$B6)1Y(EY*E_[9F2V
M*M@W/\N-#M011/.PCI3/PR9<.L<;(UMXX[-H1!OP%>#-AMP8D*D%"%/H^%G]
M6@3?BGI[MY8_J44<V)_0#RF9YI%.U S997%'SS?AF(4Z.FCE^4/0$\&(?4MT
M^1S\(UD"W4UE5=)\YT2Z<K@\L$>T!<O!J5;$<=)ASPK,UQ8A@"N,(4ET=SH]
MKHVB:JH0/%M3TS?CNJ-W4$*Z%2MU5D531LQCG$'M!?TV:SN\68-WF8>WAU@;
MCA#<*D=J^@P*FX<WU][ENWL_WGR\4?/;:X/@?38@)BAP'EV(?W->S^HT#<O'
MAKAO@C+U;9[BZ^H4+)[C%Z\-[UP+;QJI8 CG?D,_F+W7$&&G4=P<JS=8,;9Q
MQ^59_-^9=YSQ<3Z/=>MJ+.2;2T8QR8MLB/1B&-/Y$^QG8!(;0NGGJ(_>_C2L
M&PJ\H!]:^T&!A.!(:TU=&I0BLL[<OX\9XF@LF2&&[:&Q^NP38"N-C* MA9VE
M!4M)M7P89NA3"%:' !S^$: <?6L0B5$"QG&J1NLZ4]:#9RW _#8$8$*>3* 0
M_YPB,>\66VK?C,7(T&36?E=@6__1EJ?I4_37EO;UT%B.KN^T +K7K^_?!LNI
MY/99*1!&%6#<!OC".:*P"IF:+87K8/&/:/L6F#0&1#^24ZI5%%LRPD[Y[OMC
M/H41N_L/',,.KW,D]QF.S&B"/53>4V[YBU-T4YRB(YSD$57&<4=CDN7(GSE_
MM $#W7]]3V>2:R_!&"1&#PC?5V1@F"^UO?;5@X- V#[48^;RL!\;,I$_G]"*
ME6+U-2JOR\YM2C+T0/@\-(8S"WG[UP5=J1]:+C&>C <?ILQ*VH$9'>E%1#>:
MB==5A]2E?T:5AUG\XK!3Z"##^FQL;K#DOC9F<&]\788*C\?RMXB#7&V"Z&$6
M=Q(%^T*L)6E.66 Y'1>A?9TV!(_"J-%04=H'*(4MGHK>*-YEM>?TK&,Z,HU#
M:WY>!O/*$C$]/SIW?)@DF MMG"/._M5'@4S2'K8?K\*:P5;^7-W_!SS(AAQ$
MP7X?K;'U=E'&'<!C7MMM;A4I[R3@"-CUM=1ICF>XI,:&#"]1CS?LBW$$H"X!
MZTK$8:N%=]N)T:P+P$8*&W*H![0$>%J=Q#DA,0C6!C7G$@YAAB8#7C!N4^ Q
M!ONWP-#9SG3K.)W3X.VX&1$$UVV*$2R*Q:MFM;=0TP*M;1IQ&\F9V<9^@]'3
M:D!C#I/^ IJ[7VS[C[=<Y]Q2@_R04\&4E \T;,31U1QA'2%6/X)?^_ \G,_)
M\4+1_<''?CG"Z%CCJMHQ?P.O;4]PH[!E>&.Q-B80MW* V<R&N.2.T\- +$<_
MU),989SU(W\SXV$_*3I0[)P_APJG1RN*5=/:4Q_Q#1^.QJ9<8D-L-0)8N-_*
M+,G_)+ZEB1G9<O4&<O^^$8V+_N@]N$I!Q6 D.*+:RP[M\G$2WM4G2"'&HS@&
MUDTYX@G:DVH=@Q$#J;VVPU.MLT(Z(N@R><XT6:=74Z%_(UEG1K9!?%JLRJIM
MRZ12\&5F,LQK.J"37(F-QB@@6RZ/,60!0=91'EH:=1SG#$[1Y"GU\3K7&-K,
M5/_^B=A.[''2023-LXLE,+IS78;JED %WQ!7+TU^=]]C0_#!!L6@B"707!RE
MK5_J^+,QN8Y<A 5F<RJ)3 GU]L&=%A+T:]=K+(I3:%^>8-VQ.)($MGMGTRGG
MU[R=0I)6D*MH_O;'![,+=Q"KRL>Q@S<2L93Q W]JOX^;#7%6GKSSYXQ>I#.@
M%M<XD\O)U-<Q3K/J18MP%/[M)'I@"S-WD;:MHQ;TJB3*VB:MS5L9VM9_FO;/
M4[_=]_MW+HU/0>MFVY3CM.J[4-_*Z1D@#-A:G5<=7ZNF"5*S=N-T^'ZR9 !<
M.,F:FG.$X00ZEH!_;SH!3L4T+GN@/U1)VWANBE8\VUD AG7,2"68#RG[1RG4
MVFR&JXT[<?0#WT%F'!?C.[R]GW&<D_<?1W4Y.SS,C,4A)N4IW_9FG1*8[\MM
M_WY.[[D:$$)(G8>R*")[_>W8[7L_L."SC]A?-WX/ [IT.6:17TXLMFJWJU\,
MS:,'%(QC 5/$E R]"ZR?L\>*H5VL&T#%.50\HIJO(R'<Z0#0-TI/"[F00-T4
M;&GPIR!)EM 7WO[K<OW6-*GR *^2%3$O?%>I#!DS3*[,Z4)-=M,IH-L\'D'5
M[T"]P$+(;M!_,9?J0<]YY?#)I78_6@(>HQ'L/T:FB(,92&P1NJD=HQ7$QPNZ
M4: 1?@0!GO+-X]]Z2AS!5=M8PQ&I(_X:KGOV+"G^_9,'P_;U@K6@]ON#>TR<
M4 X Y'PK)S)44.V9SYDMN]"<;SX6'WRCG":./V5>(?G.HGX_@:[">+&#NJ\X
M/7Z*D^<^K@781^P$'_T+\U4M=$*^TP (LV$6;.=\BY^G3S%?D^0I??)41)LQ
ME(KJ4)ZHGL?%8$3!\3E$5P)?_SQ, %3^J.9T'F@FMO_YUL9K0$Y4L#Y%T<MO
M:I5@W;X7THFO;4GRV?E!YB5[*NK3D_Z\Y8@9=I(%#U+L[7..,A29!2Q!S #'
M38DP;@*X"18WK)MX@G&&IAP9;(X,H!+@[<^Q"=O$8[K D-?5;AI:B[IO]V&L
M]EP)VOK.^/;"-.)N#G@1M69"@D["*)]T<E#-K%0A'.LH=%_P0-+^G6 -"';D
MYBX;\E(N[1CMW!3N5_UR\OPL:S66Z4Y)(?,_-&*M_.8T"A5HRFRU\EK*/H+5
M-8#IQ)[*9^9XZVB@\REN:PO[)APO*,3B!:]R A%RKDN*OP$LW+_53BO^Z'3]
M#^*0>3X>AL[H=M"^E\#P#5IS+3'VS+C?JK$UG%0U[)\VK%SS8YOOFR_]+V8N
MS"TA;K:R.(81D@M:.4(I]6NQ^_=!3RHFE])_ FFMA0AM4<(,8VM-8O=OV3!4
M@-'D(?M5L7X<0Z9XI7$V0C%8OQA9Z5YM#SX8NVLGO9/RGGF<X\*C,1W8[:<(
M7HX.<@[BB.8_$9#9YX\GUZ2U8QFGG-B0K</6>\2.?F_)?@1SZ"H?RTUD;[B=
M!W/N$Q;83&-#?MUXP6GKW: D[1S],3,<ZP9_,2M28P\_SM ' RF.G@8TO6CG
M\N7TG>PL_X!YA. *_:7]RJ1JYTQ:H.BPJKSL0=OO!D+V7PZ5=_PDHZT[R0 -
M\0W'BH=3R"RN6>S682[64?G]$YS]Y+0[[XPHDW__5<ZTH.;L7:AF0QA7'\$8
M7Z"K\&/80?V7'%[.*K,ABV'K<O+4?$XYBS)QG'*VIKSO9M[Z\\$,3MF+,W'Z
MC._U[2@&7PNL%U[&AEA\(*RW:]]D0S9BWV!_7<(2'#B+W+[ Z0>X.#(;DLY7
M^Y,8P\<0\J5+2&*1J,C\52PG[9_W=LB1V%KHVBXM5=)JGA+023R"GKDN<.?L
M:"0NY/POY+I?Q=BZKS=PVT?"_+&SQ(QI1)8AMSJ^-OY<)#J!2\\F#L&WA';0
MU@Q<I5ZI"#EZ:3$Q+K!LM+V+?S')%/^#>"&Q"2E& 6-Q-'\779[L']_2AQ=_
MY..^ )9EO2F:1JE96EN9#0\R4I*JC)OY@O,:$* Q0Y8C27MAC%@VI.LGQUC.
MMN5L2W"B](G,\";UESU@0WZ*\W/*R .[)9._4Z',/$3A9-T?QC+J"UFRO/V4
M#&2 YJRP5.QO$<YT&.28$'($[*>F&QOR"@M.0RTZV9 !M7.<9'-$YP_=51O$
M'C='A,VM8!EIZ?M?RV(6L!1UH)C)I<#A#">$XODL0>Q1[,#3?C;D+!M":]0I
MY>SL[6-]%C>G_W["C;TG;POB.$.;L]QO9=7=+$OASVQ(&XH"WSMNR[D#@J6N
MS[C $N)\9B&'=9L-F?<+,>?L[)]O"0Q!<\ZF^ C.V)\R' T;QEEOR\ES4ZM,
M/N6_<"?\5UCVBI19+RJAX(5BSJ:@=FT<2"90-H2+L]X/TOB,OX6U_'_C_C^C
MLG,7P3SX  88PUFW=&HC.)O+A+&.<U;K"2225DK>6?\7:-A_Q63E-7GO[P[L
M7'H.(RK$DX>S-0TL0Q+.AB3^0@2.FCH0_PLR]O\,R.AE[#9O%"=HJK#?)_;&
M1%BA3]@04"OGCP9O^57V?^5!PO]!@S/_/V5!>EB7E&A#NH;B3A"R*"547^+!
MHT<NWPZ(_'/%)O/P/=NH>W>6/;62RX:0EL5F&<\+S03"D-[C5ZSK7Q7(#94'
MF!1J1=MM",:MAUC^MJ\=*]O/Z<&N2\$9*NK=V7!&*C;F>C^33VP=W04O9?0%
MJ:]S^"/#1UMB]<(ZH4P3U<DMO,S=YK$=1W7]82^E'5Y=2W+-<,7CQV<\,U9[
MFZ:BU@GKCPG#B]DK@0]M"!0GUY177(J(MC?)#M6/VR[')A>^IN;EI7POH*D*
M&,C73549]N5TVX:BKG:5%/V@@<F)QG4S9Y'G4Z:\?B8:9^F'Z4#1.=W6>U[9
M^,?O[5:>KQ='GAGW5T_L;P?08?=J/S0-^V7TF?<F\GBNZ\DC;R<+"%_]<%"N
M*2OD[_XYM::@0N0NL+KG3!KUZX=,?UOF]<2D)92A-SNM9T2DH%E9MYX@P)#M
M9G/3T4+?'^*>HGGA;Y[(?R/!#Q>W]PG7!'D:-2O>'R)L[T^%H-H:B]OAPI[I
M(1&[4]MOM!$4+TMQHQ&2(Z7OGN(N+CB PFNX;VX.32K[N85,G!9E('745J >
MR/29GRA2@JE];""UGH0SO0*V&2@3%B^3DZXXH*>L1@A'K$^.]WC?5/%Y@="5
M.&[YKT_^Z\8DXD7XY >+9\6:Y_-[UC+"Z +67I\+W$P_\VH],2M?A1].O9^)
M=/F^9'<OI\8GPS1\0?C45I :=52DW-O<O!1=NT8M-$.<8' U#9 T">B7:++)
M:/Z?YW!6 *Y]_:KA4*U]%H(:P#CWU!@:S3!^^^ULS9C.R<&'D7<*1HG#GQNS
M+H3.*AX+#]X[]?+(@QNBAR1"^6[R/?'<OMK>N)%;XIX^O111-/[8GPNP[,)=
MR <XU-YE:= BDR@\(1<H7B112F2M-5#<MGE8X1IG8IT?71I3)CF7=RKE^Y3>
M*&YN[X1USAYC2:!QU/H80K H!:D2&V(U;SQ:BX YC,"JMC,<K]T<7AS9N9;1
MQ*FHN1N\M7C2\,G+EZ9$>R"/ZKL71ES,#QQKB<NLC/&C&&866D]:^LN6E#18
MEII/:H[2/3(B5(_ZY$L%&\.1T>61KFE#ED].]/[LZS]9:"+T=L%TI+S_L+"4
M1W7IUR735O,G1;DF*@\*HW)J.D;G>C2=X CSG\BG(?!%SY],=;H9V/ .77T'
MP.'F@/HH;XZ#DPSJFCDY5@,5G/28$:%9X2FEA^LJ3X81)FZK6&L1"M=>?3,H
M<M#U])%<>]7^Y+2U+9^JU_[U8%L2L-E.%)@ 73>\6N3 ,"=@-K3FYY+EF*KX
M+&_'ULJX]4E?!5,;I-4R+\7KYLKR6?QCY4<?;$Z']3U(-7_3Z?EO9[FO\IP%
MLE9;Y?I8W@A1X1'_[:X5A&U^K[^9R%RV:?I%,@CO\AY[_1RO5AP15FV*G$%_
M/^_B^4O;^+C]O@VB_3^(!DA\<YO'T56*!CML2(R4$(@>@_]E?YOJ">6?T2FI
M/E>3.)'%<W=$0+5>3L#TZ8,'0[+_?!1T2D#N*S <&FG6<0PI>O:I87_X7R#N
M#A!9[5,!UNL/J63DB'C2\W9U@;KH4D3O(;NNIG+[C<3/71,!&OI*M'^Y/[4P
M,SE6;H:73,O.S5L>LYI\EE(&AFZVUVMMI$'Q+D 7C@##^2<(\W&_^5HJ@U/I
M\]!44%95T8L7/9=X,_(04I\8T5NY72R7\O3[[3LW53,I9JEG3]1R-UHV%!I:
M+$%=S*>SB@@J\^?7!B@IBRIEAH2[^8).*:I1_K(C^=$1UYP+USP;/L>5CB2\
M+]\P&<:7Z;^:^7K!.H$E8 ^JMVGQQ:O H[*%P3#*=$"'77^$V6:[U>1.OLVJ
MEE1&P<IXZJZ/9^I)@1./:YM$SZ%-!])<%5_^0PM0,'SQ(?$)I.=\(@1R+-%
M _(4_E=++*G^ XF91CJ,1!X:MPZ U?!UH D$K[S$H(QH>/MLY"W]0_SRO0KA
M!\/QHO$:PMV@W$\0VH:1!M\<NJP>JZ@Z+?+1Z8#G!P'W;9B@YYA6%[$4?&]_
M-YY8 KK\,_#NZ\M'-U/3%XL+9[R0B@-\]M\&Z2,+PA)*DLYG8O\<^!!"MG-+
MZ)TU7<HL5C]5JG'CZU92G&;:E8?C;6:E,?EB]VSLA)_8!%LZ(9!V*GG O0[J
M]9S:4MF1E(;F+,U1$_/DTTO"TM)PEM 2GO V$GNBAX(])/XZ+YM'61+=W3XC
M,E90GW721@G:GC;>W6'UWD%O69I4WVA9X]NQK*) TVJRAAWU_PO.L)X]0NOA
MC/I7^4QL V@]B:A&, 3'NV!2#%&J<K2._+B2MO+)2M< G[ERYB-956-$EQBC
MPE5KHU9ZN)F*Q@0&Y#:[)>Z:IEHUU?&A3@0EQ&FC@/J.V>,DKQ+&=1KF7Y4$
M(60:[9LQ\DK7_<S^T_%#],_+-V(VC9O-JNV<VNQD<Q^'2CJ*2'BCHCX#:(7/
M1-[%R[V^4JXO.JF7D^=62Y:Y35*TY=%N3NKE-[.LG]<T[YF5'FG(CKQZMOS%
MQ[E*,#-?$LZ5 %_Y$/.M9*:0T,NQO#;[,E8P4J'8*Y/":Y\SRVYKGJAO"[E5
M<K";? 3L9HS@H=FSTR7VE L%WSA%M4LYU85=+'"?F5T;KW# ?(:*K-<V)?#6
MAZT7CBON9$SS[.OPO)9.])P2CPT*?!CI%?OX\4.12]_M9WJU[\$?V]WR^O13
MXQ/K</#=U,DA-$L2'5TX<L%]364'8.5-XM<,'NS%SMI-$MY<1?9XBC<YG3M5
M57 L3D!)N8N2'@?:7XHU2S;+LNN=C0U-QGY/(XMH%/-%:W:JENFK;+TQ?Y9M
M_+JU;KS9K&PWCR*JSQRGQF8*)G0^JVFR7K"G_%VFQQ7/XL\VZ&<HX,5?^K)Z
M=DHRYC;>^;(APK-M.K._S%2\)]@0MQ;/]T!W*]\IL-Z -+I-D#&,5JSE];Q3
M,^QO?+/7:*RV#]&>'FQ'C%(A<!F2+G]?4=]3#:?_0GP\I&/>+URFDA:ON.*E
M/@?MF+;SY#&"0SSU]LU&*_QBO;2\Q/8XNO3JO9H/Y%"6_;/JZ>.)=<_J1<P]
MCM\RM>]R:\7MIHSJ=T@\MRB$1] LSUG-]'35(LMR>),=GC369=K%;UR)2_1!
MDE*M1<N\14VT3,L)ZF*UYXLQ^ODV;L^&C14G$Q.--1J>& .>-AK=\2W\QQO8
MD-BD? Z^^!%%P-[N/!O2Z0]$;7/L4%+>?#W'-1E.T6#M""&TFLH'&C0"M=W+
MO</#5.JU^C#LEF P0E296*IO,E8W33Q4UVR9./DTX>#[5(ULFZV8CA#G?6E,
MA]CN^KD+N53%!TAM*#!O$K\QIGR"D&SNM/J<VK%\.#O64Z?C0\W[#Y=[RV8J
M3US4=>&I[26GK+HZG7>SC736E_OXA%3N4F;;%4XS+YHWUKOB[_&Y\*)>BK"X
MP6AFOKBAFM=G.;O[3_G6M4.TF[A37.1</#Q*2-95"Z$Q2:5FEI<&\5J&2AL%
MF2Z/*J9\%L%*UE'/BCL("<;9I5,<W"GY!Z:8F9;/P#/$AQS</D#4CR=8BJM[
M,5<.'9.R"A-K.0@VS>DG*),.SWLI32M17=1>E=MU-QG2CJ><CU"L=;SRR.'U
M#XJWU\/./OS'H*"(PZ8_!FFPM5&:?MLN_S\L/ITSOP[%*LR<B(?S=[KZ"J\]
M]YSP@#ZH_56QP9I5L'I5\#YJP\T_?@SYC=KH0J6'1);'O 6-]Q^W^.3'%:P\
MD-96-5 _U57A;/SAUY;A4+V\T1NUBAG!3Q2QU^E7/E\];'U8%2YL;)5<?--K
M0J_ )=Q;_4EB;&VZ<=%P+.;4[,'@FP:<4IRE\'.QRJPX4KQC;X07D.EXB/VT
M#H0#/FR(B/+M^5^(!:?. @8$+"=X].9-!%^EG9VM*V;&KP;E.2S3 0_$ [&$
M"27O3>?0L1EXI4K N;X4BVX%!>Y?^=,)*""(*CD[P>H#YCNOQA*4ENSJ+Z,]
M35\:%TST'6X>RQ>U-Q,;F@DJ=R]\+1DMW=>8](;*-P[O-CF;ER_=YK.PF.PB
M&_)L*$7=V$1V2_Y#P["9-<F!FI7Y*K;GHD;15L7GH>2W.;7E%6^72SNQE9LB
M&K+2U8GV'[*M93["!-5\YK'A$O,LCT>Q4] U2S?P(#53 CU,.;#\"<S(<R,6
MS?[J"U)-:$5$[<4MBF-Q3N?_DB\A*+V3!I@,JU0!@]*>_+01);OQWNI(23WQ
M6.3"Z[(.>GT0>7XR)'$%<0AS&EDWGL:Q2Q$K=O$91=^^KVAE%^<OISU/S2BR
MG?048^%4]B+63K;<KL&B@*XJ 3U?P5;W7PJO;:V4]A!WG"X6-5#:- *$14W6
M7=)-\0V%0[2$R><EJT'2!6S(?<J"%&J-U-.=TH+R@D7*.ADQ8RDQUD_MY-5#
M^"FH?1V00%[T!6]PQI\?'(.A+.6PFJV2Z($T7REM5R!,:E:P!GYC)6RHA<Q,
MQS[B$V(-.:DF_#- ,#<"NEX##FARY[!=^<3/]&#\*]XJM='F,92IH]_^X<</
M5?MZ];T$K_I!:Q%K253EB?S.!Z)Y6KOM3&^D?5NVXLF2%G?319V$B@(/E^HQ
MKQ,_WMU2'^"KF1(X--BY8;JGZT.Z$N@&S'T_5)7NGRIE4V\NW--7X/#;TM)T
M,&Z\*L4?ZB(V9-' S/-QY*=<[)5+]:O*#.H]8VN:*K_JF6)(7S+=(U[+%V5M
M6(Z$));OMV"P?J MV0U^2O#5/#1L*6F<^@S7A9U3=>2T5ZAHYGP7E*N;TXUZ
MX -D,)OC#ZW'!C!]K*OIU]5L"P&G'*E"B@J-G%'F&=HV"P?6QNVD4PACQ?ZJ
M_];6)6YL=HBYDDYT7^^2LM49 !3N=@*L+S#A"Q].]E'L[9^=F#8Z_^O[1X4\
MM>RK=8#$2YU< >.'W@7CWNLS,T>6 AJ&"AS-).D=@LVP@B7)MN^9PO^FY!46
M7.6>U)DW<:A%R-6D9!)&/>;E?5N$"NB?K^K[92R\6W@XXN^AH998T[CLK_C=
M3D<;-4'LZKB/[IYC0UB2O!S['\V0J\;TZ6AH'NR<Y?J5309J5)2=R,]:WM"P
M;7PGT=*U!JI>D._(YVIYZ3J<?GGE,WVI_>5*U[7 \\-ZA.L1!<:!!YKJXM$Q
M2CUN$1;OLT\FC6%=V9 )^X[9FN*X<<-AQ<A7<]-2-A=H";$/Z_3"C&N>?6_$
M9$L<(HTKO[+U4A1Z==2;U#"!$E6<"-VS\MF0N92?ZOQ!_6)I0H<%W>_]YBHM
ML_!9H4Q?5)R+B412\DI/V9-P-UD#/24C;1BW<Z7-BJV71/7E;#72B.S WF1<
M1I,)/./OO-+VU*=95J,:>@+)!<GV.@=1$TG=#_G_?,-&*QOBPH;PZ-]D0ZCZ
MOU5Y6%^DM$^_^O/Z1G<Q(D;K>! -WWP<:\CD8I:P(:Y004YH+K'Z1DZ+S8;Z
MOW%+:F4I&UG<J17WD\XP&3WW3X_SNPF]?QKJ%!<<]70F'O;SW'GYM!&UUDOC
M,P^:3M41KPWM^N(!#PPLRYMR0.+S092#HV'W6EU @$BJHC-U^E!LE.+$K=T6
M(^?<Y.)<\V4WJAZ?9'3ORA,]D\K76C'99Q,N.,N8F)DEGU^0L)8OME)9,$NQ
ME#$I$-$^3QV6(Q\VS8WKN.^QH%G@8V/;E?7<2$0T2/W\=ZC*$V\EX3.B)EFW
M98Z^-+F7A,\ G3E@^J,>PY.HJ' 1 2F!\R"!$F4[5561ECAE?P$>6!S-]4S2
M\Q,)"[1WLR''E @*)%]*^?HQCR?-7_$E@6//L\.(=AT4Z4:.G8S:#B+H_C/N
M17UDF>TH;]9T<NA2S ]=-1=HL1JL.@&_8TO2=#VD(V#/A@C5\!8CS4&<2:Q5
M?!N]WYP\O!.T+L.'_3NE9,)]=_=D/3=*NUQ@*J,I"%%O^YMQ.SO,\V1Y*8./
MAO^BSCI(*ZK0OE9ZX_'0S 3:ODLD1E%;G<;7=G/QE/3[L1IC,R.;S<D9\1O$
MGV8>6E+E0O1?_WBU=+]@I?WNDH=]WF)=I=R]X)C\"/W91OCUG)12UEU%NW<Y
MB@;F'1;E1T>6RUYFV>@G>B@&?;:"?^T$GHE94$L'NN?DQ]*JVJTZ1B,<5 TW
M3F1>' UK-RT55D*7CN&MUX1&%@P)#7R]^C(^/^@;(8<M'SS;@?GM[JH.K,Q
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MXN<XN'/,M>9+%J'*%E*5W2,]7W73O(=,<J<LWB:['I\PO8**LE[YTH;++"C
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MR*$M]TOLGHSJ/JC8P8.7*%D$UP7-QOI#9CJW@=.+$MN?%_]LV7+B%.R#EE(
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M7RE(X4 X5J(&;2F:M T^NB+NX7/A)-X:VZ5M(<$=1PAB3KA;,S.O<$JW(4)
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M\T)2(^XQ3X%*D )@27A9S(EI[C"48<<1[>HPSZ1-/<YTX. -2 ])8K4&>,I
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M2/&UXH/<-*<93_5QF?8MR%'IV5RC+!1Y0U3/"U(U_;2ML5!F $:]I\+)F'I
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MMFJ2"XKX0'$LD/_0Y\8?GZXC(!\".J?*2)L2L#ACF+9NTV^_TF^+M%Q:&T"
MPG+D[9!R)H&Y)L"2!D?@KCP^H4YRJM?@.-8C< 9&EV0#XAR_Q8ZQ.!@WD:RO
M,(G8R\Y,FWBR00)3CX+B[RG0?(&12,];N,+"$39U;Y,EFIPVPA=.MW1-[,PF
M/^+IJHOP#]%[;^&9EE''X@RDFM*SJ9J;-X0VPPXLH:<D.)XR@D@H<._"!5KH
M@N8$](DW9:W#EES'QVC8/8: 6#@V=^(N4;=6D$].]+]KZWPW\^$.6?2CH(D[
MW;WCL+[C,DGBQ7Y)\NZV.*3:GMCAB%B/JDN :I.B+3V==93HN:2[ 1T&%"M!
M$,,$-]([?K*6=76ROPM)2K]JBL;/[SAO"SF[?9N=F^NE?&0#?(O.#=]8*A&$
MNA!7&AFO:06L?7]'4^HN8?63_FD,%3$>MX7R]^LX#G<3V11RN^HJ9)RPLX$5
M6;=6RLW >CU<79?))3>8-XLXU7%IKUS(]0L9K#'1N?BQ0[2O]>-0C]IE<UXZ
M>FWD&S 7'"B,K[1!:*PQV0#ZELCU=/!F&OV;G])IFYY#\!FY T50[R\9 :<Q
MVP#KW+MMKRHM;8(K3QE:K_[0O8%BAC("27<8-SEZN*+O\YF'6NAY]/@6&0%3
MQ&+U_,L)#Z><B&>4)$Q2[V!?8>;B_ES&4C<-M=65K*_ JKO^9JH7DL"]19J]
M^=5^;9VCDRLM-:BREI!^07C579FL^5H5Y5K0"GE:PS@B)* YW-95<=33_<3'
M-.Q@04N:@4]D*#A#QS'!EIRPEZD>F$+L$F-XJ4 OAR&\BOFI:CH+B)HYWQD'
M%-GJN+<;3\'81D^!TD+FB=\;"U<Y[";5M *RB/2?\](S^K*'];I&E!C-OK:G
M(B6)K O@(V.@1[!FJ'E(DFARAU.9=UMZ?D(I _G!:RVH[%IV#[_;1L'RU$OF
M[8C@J2[Q0$XUP1NF_J@AC<)5!]*FY0."S9=@7=5L>P]D&NK"5.70\UQ-8?.<
M%;@KI6J06T887ZTKJ"Z'.*T_]:&$YVM\DC+XG2/L>.0U]*K(_=7^@0\A]D].
M_E 4TYY*"4#H0+Y(D>>J#E2^KBOHKL_<GW0TU,G]AS@+]'<-#8D,4#?!V2PK
MEM@Z<]_8,K6R&+0PZ> 5#6L-_>>SU$/D>)<&U+J)(4<M&00+8+@$V8 ^AUB.
M"<HD<B)T&HYI[>+WT=!Q>6RQ5OHQZ1Y^JYQPM8.H[HWZ>1FG%NU["'2.Q$V4
MPM*:<&O51\07[4D4AQM#IP\,6+@%D</W:F+B!X;XS9W#V.^,8<O VPTT27UI
M? VZ[B1CKP][#MP?*T!S;WY=[@WCT14@Z\%ZK2))F;P_Z'2C^]2?&-)A,+EG
MF,L-)P>ET#,/B_3EF'<9==19\O8_^K*NC,<&"3-F1;J7SR](.\]N/3$GCK_\
MBSI?E)\2JG+<S0U")AZG<J?PD\4+J]>&2*EKB\!\R\Z[M22#)>\IYUC']E_'
MMJH4QE@"W"(MO75GW*!WT!8JR6UYF;Z5$&*_N$$C"/*!/*-.4$(]PDR&H?3'
M<!>N9%SWA:_S>3\B>F_"DX&?M8)A/HF* Q2Z7V/FL]G5M46!VEG?9H%[KWWI
MR6+!YYOG&Z^+VNMON5P>A\7R8+HT)K=GAEH".E\&8SJG;RX^+4(M;$7@5Z*7
M8X-81' 3=C PI40(S2W(U,E30(G,?NKZ-SM^@2EG5-8RSJTN@3/1!BE8:AZC
MA1Q01$I7U6RB;4VE0T_Z,86)FF>S9@8_H-('MF1 !)X#>B7%( ,D1B]!^'0I
M'Q;DVQ.81@@&"'^O::)+9K1" U-C>I'NT B2.'_AD81[;F"M9*[]Y8:3(:_N
M:\;%3D;!MK!DBUDQT27!<L?>@KUN5.R4&[&#/X+$];<2/]F_E%CGAP&?\UU0
M)/X,:PT(,U/:4>(VP\E,(/!*>=&IAT9]S<(=+P\5Q2Z:B&-$JB!1UZLY=<(:
MW'#G+RH6!A6]7PX+S7%.MQ\%FC_+*54&Y580T\U]"\HJA^3P'RCRKW.WO&5;
M@S'1&,EWH?EMN"QJ$6S)E'F^S@DO4[Q-UL_7QX; H;>I8\A(!&.O>\:M(7II
M40!22,I D.JX?T25L0%<Y1-HO2=WJ LOR6)7^Q8N?YP(* 1-72*&I5\(K08+
M>&M$G5^0."PV6"KUKV!P6-!D^JSJF?J,Z HHX".&NIW(DO>:</&]QN V_(J6
M$)<:J& =2[)OK2>F=5TB8-(Y^H0*4,ADJ1=GHC^Z=^ ++79$?0,9<G;ZZM3C
M]>O[CQG\]VF#_=GD0G_/.PQ8M<\^]PM%IJL8LJ?0TKX&ZE@FV;Q?TLM8)01@
ME)28MRM[R2/)2KM*JJ*R,U[[5L]%,IGG.5B",CV0KAM>'\!_J2=EA&*3?W_1
M%_?^)=D\%3)* @O-<QWK!RT?J4E5L65Z23SZC7JTJ.AYUM=VFA+ZY[[/WG"G
M%R[;7E5HY,)XWFEY!*'*K"K(V[2H3=4.-Y6'OGHR]^ZL /"<.6W0]6/UT'Q,
M0N3-EI%M&86UGT,82/%%[-\&2Y51FKU%_#VQ(HQ9TJCJ:L^",$.OS/O7@PWQ
M<X6.!!&)A&:=B+X--4+8^#%7[U<&B?K2WCPN#)^?^S-W:"J)&.?O[V;0AC*'
M+R:R;5)-<8^)'AFK#S(M\)3)GY?3KR12["SN.MXOEH4K7;2VA$AG:5&D>(7E
M^=Z+3'SH\ .J0A ".EH^T,:<.L,7<N9 G],NOS*:B!>'MV9LBFH*+)IS!<SI
M16:N4@=#K3-3F+KFC)F K,Z%F@\I"J\(P0+G$KJ?GD40+@K>O_V0^[&)B>\O
ML#5#^R"\%DL]Z!5)ZEN\X++&NL& D_6NDE?3T"IBTXM>X;#3+T06D_$#^F)X
M1R,J"T$=<2"HU#"EEK94>O;M5U]*)EFU3KG-Q%Q><#XB;,3'MXYG >X[O=0Z
M7:7ZI8\J<$LRZQ: #ZBPBC(BLUHHU0>+9YA_X=6V!>:F7>:\V]B ?G^_.96>
MP%-NSI_I>\WA0L0$97U)1IW56ZE$&#?#QA.GEOI#$DUS3-XI_(9M#(B^%E:%
M"],KTKEAJ1PY%9?C'=V4YOYEQMI[:/AZA&VE,(@OYW&:KXGJLLT[\G;9P\W5
M&F=+J?!.0B$^3QFXIC$^*G.8!0OPH'(DZ/.L@T69!NY((VH2J>6%7PWS-NW<
M1K_###*EZZ(KX]R!?6O+1)C8%:XG3IV98"H113O.*+!\5%MB.KFS_?="OP J
MO\0M_SWKRV*+:V+#DUJ)M+;8EQ6B)4D@Y$LD7M=18) I'7N5.O;OXMU1CDXN
M/_)8P'G,EF9?[(6O^@H6GG#7P?.@8 ;<?.*]A5UC<[0$?+N+?ZWKU.%[-L!3
MXL+Z_D(393RY8(3Y=$*=#9" %-_Q-_2]N7C2V_%E*2/B+F8:#KG90W694<MK
M.Q?OSUVXW*W1%%.S>"M_DCY85R_SZT+MS'0NI,HA@R^HDM,^_^#BE7?S3K8E
M_7*M \ 7[J/6<D/JD-OSPD9<)Y<C[+6T^F/IEM.&JLY2'JTS/IHIT1HUXR,2
MB8M__WO^K[A8"<EX,9VEVTU1&.6@*+9-]=WT17G,6E%7FJ@+Y-4>Z_4- <R+
MX U-O!O(>T&^DSKP7&\(KW:S,RATI.BT:&##>I3*>@0.*P0C4?7%)Z <%"L1
M"(64ETLZ\BH#2ORDKI>!!NE(7#9XHC;,(%D5DNUH1]-__F%NO/)'K ##D\QE
M=4^';\--\$@1ZG943JV)7XYQ\_WF'^/8#Z;:9G*9DF$SMMW8LQU"<*8%C>.3
M 1]3'U?S$ ?URV^"E/3&RA"VT0:"C)F88[U1ILD=H-#Q8^M1[J.$-M-$-14^
MW_W%I.T=/<][^)7,^Z=:4D9^@WX#RT_G:@I)15TO-2GI='@!"GXQJ3FB:R^+
MLC6W]-U<';:I2T"*FG0@8UVE5[45#!T:@X*):M_GZ\+S?YL<Y39HQU7'OA*&
MG%!W"<![L2F\]"BG2MK]V*4+-3\*7<_5+7)I F/I90PK($'MIIXMB*:15 7)
MOO.U<#"OP*$4!?$T;DHR;7R.41CG 54?9D "_#\D];,!5&LVX-B/O"X1 M.
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MJ"FML-= H".,-D5NKH.=%;]"9/I&EV97I#_^M>!<9'BF\KLSEP91=F=41VL
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MK1NGW.S'IEA$*B:N&FZ'\ _QI&C\=A$\=>/SDAHX'GRV0^^X8)O!"T5%U%8
MZ">15Q^N&S[%7>[JM275..\V=HG#HK.M24[P,_/E&[\YWOSOH0QG6J;;)-B.
M9I74821=Y$XI22I6%A?3OUE@I]D&3H$"=:V"/KAB4WZZ?/"*2LQ6,_"*$;_9
M#N$3C=&8(<^HH0IAB8MB"'WU).M)J-=4 3)9;5MC?:H_O+G  5DND2(854K0
MU5,$[;3E92LE/7=PEKN4,M([D>J>?4]#YUV/PDM=;<]<6MAE,&_WM[9?2"M^
M127S;T[ 3BV<O<P(U.3DC?<TVU(SW O1PDRLC;Q/@@XKY(N\8XZ/_6=?0LX3
M^XEW/UKMXI)N8M8?D=?:\(AS=_M;U;?-I"L'D 3!Q9,LH1D?'0=4X%*1H)+1
MG<9Z/+K]^5D4W4+OAOG'KS6/'A1[Q%E=-6G[B&,.4?*<_$HV?YM)>@N;TPW.
MZO-Y5;J3?+FY( $]UI7=%#T#,[-P']/[7R?5#F*"1\6_KYN(22N4X:] G#<=
M'%H4RJM,_0VF%S^IJR3!A-5<P6 B5+E8BI#6-MCO+,JE<)^14'%$E5T@P-7N
M6%$T59)G,*+VGF*M,Q@S*<YUVT'/8^:'7O_D/#I"Z>8<X^:22HH.1Q_W.49\
M_XP;2C_=TYVF>:LYWX&XB1&SN(/;'=D^Y:MS>IXS;-YGW>+",D[=XL%2O"UA
MM:GM]?%V_Z?\'%:BEN2U1_#NVOCBZ]:5+UGC-J6G(2G?Y.V#Y*L^X=/@-CFS
MU<J!020^5)2U_26*F_[">0?CS=G:4GFL0Z=L3PV55N06EI3B8_?]S_SAE+$<
M\GA9YTLF/U4_>HJJ\("AOALVL>EG0!)V!9V8>H\+19G_[M.)C+>RO.5#3WU4
MN;C@D]="7./J[YCBLQ3KJ7#M%(7*,H)!_>/Q.^[^&H-W\4JG;TL^OLG%8>\:
M8M+\VL;8.0>/>7H04^W*66:V$+[@0 [+7BECV%/0-/OF?#;@5!J7>LE@]7:J
M%<WSP.(N=PPI\F%7@0KWFPXV@&$F9 ^IO4P=0D-.YN5=/WP_GSQY5=R)? ;&
M S&P9=P@!8KXQ&KDL0+/_2BH2U%;H9F4UKJZ,O(HY"O*LPH*=3Q&[F2C,&]O
M;\1Z6]A'VED=8+R"FW'9M\^+WIW?J]_9=N,K;45[(%%V%,W$!"=2+,J<U[X>
MO4:2T?DF6$ZFA7E46Z]T3Z;+-\'E#-7=K3B?E!KR%U^51IP: .8\_7$@:R*/
M$#9)S;VG5X9':8?@.SEE@7;?R4C9P]9'5$]2>$%_C:X ?%:[$Q=V'$+\/L2U
M\CPR&@:W]+\Z=V.F2'75NM-7K=D+GJCP5LE>?Z19(']@W[-G)*C"9Y&GI*?-
M!Y(W"*3.TTO)KC93=Y/LFR9V.<.V;E@(";7DO;[YS4=)&1'P2G5.LK!LR!@
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ML$?]ASFP ;5MF:Q\"]?S;,"Z.QL0A,T-:6$#?JFL+^Y.61^-=,W7W* ?P0:
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MXI;BU\>S8:D'%/"\GL@>"*% YT:3_<[8A4BP<] M"&7VSY'9]"1 &I:Z=5B
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ML(4N5RIZM -3U5*H^1CLGU5:(K8KKF)&'_E5<.N_QA8)L3BHJ:.Q$HVU=2W
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M_?H]N,ZQ%VPPMM14M^5&+3D,F)Q=\8MO%\ L(#RFM+F4=LI*O1U7Z97DW>M
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M6-GBL34)!8(WFI4[GGBHLZ/W^$,'G'SZ;)HV^.53*2GI/1MS13?0QR6Z"33
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M*PRJ<A;LR7+TOG1121-D2VQ0V_$D?*V.<Y*S+.>30W%-+U^S*7O3^OXY[!]
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M@7GEW_*;]7O1PZ3A<>+/V7[RA)6YBC9+T-N>".369_O[K$3=HE*CRBZYVJ+
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M+(H+WP['Q"@CU;#[PX0O3KQAL",M>;(PC1[7X=<WPMOGQ$A)"SLM)O(+&E-
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MUW)8J68O>9^Q,_;WQNJ,T6&C QA]6O;VV<<9R).AW\ENM'IGNE,IA-!IV1G
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MS#4+E=5V9,R6SK091@WYWP48B$@=G"@$EGFI:V[^\1<PZ ]9 '5N"X: &C.
MG(G.-H@6?AN/ PHH;O[O%\"-"3+>! -B>0(E<3S2R]]!<NI^775##:RP-B/P
M>B6T9CK?0?%J_,,3C+>?,PQ>2I8<WJQ:X\_)5JKC_S'.;U\^?PH0Q$6&77/G
M=]F=U#_H5VR?O)<F?+/^?1=6N;:#:._)C978;/6QTD_%ESQ>(\@CF/!NN[V\
M6=I0;T/%XE4L7%I:TBS2,+5P52\C)6MYJSAX<&DRS3OM<7%7)&RT8*,$+8F(
M4_2-\UUT')[H>F:6JM_'"_W8<Z/@!=99_^0USE5&L0-B'>?=)(<DE$.-2-L=
MWG&L-,FFX>V-VF0@%4QBB" 8!W10ECXZ%\*"0C<//B+Q2-9N_)>\NIK*8?B>
M!T]#[8CW@L?!EN<IX ER(A/,W=8^G_[2,S*I8O(@]\!!9&/9>#0AS2L]PS;.
M1</93A\]:3-Q]Q%\<T,I9NI>5=2<?@ZA"PHA,L9N:<'FY]@050M@?BCUAD;0
MVMC8':L/W>B9GAL93Y(V2MN,LM4F9XSX3!<-%'4'%1TB0\NE?[;(1EXRUK*Z
M;N$QB(;$+V.8A\J:RX B/CX-)?U]XFCN29@VF^/[9_L2;>5JM]O*KIG)M/5W
MF<;'NQL8J'()\1O;6?IVMPB%#<R=#V-?YX_"$?OPV$@J>YE[P\U4?+_>\;]5
MP>JR-=H<S$:A<@\0U.57,IO7*VL NE>\%;^E3&L-/[V[H61JZ"]F9N(OII$"
M$Y/HZ346?9)5.%5E(%H1:RN@)Q]7XY1?.R0A6H'5+<):73'5_;<M3OS3F?]E
MG1.YFI#Z742$CV]+X<+WS3<>1.:#$U)M5,'Q_6FRQX+7^S AJAQ9_Y,M8@Z?
MQ;]9-8O=9*IH%VK>*E@P,G;@)LB\&,:WE&CQ6T?K<$Y\]\=X7^GW7M"&ZG_
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M6SA&RW,=+QOV$U2;WOV%&DK<Q6]W89+/(PX&"*!$JC>1TNY #+J7,1!=.\
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M6ZN']Q%^'=7UX4+.[9.I8]%<NUHW=PZ& K-U\GD3N#3\\";-:F86(^+=%U?
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M*^$=MMW@VLA-GE/ O^L#:-TIAX*]Z!\NIP"E@X=UJW'KWI08.BCH\<VCQS>
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MK(9Z;HXD9H-@'E(.O_9R.=T:ZJ/]IP1"P;KC2NO]4I;#6P6V\&UIN4_!'IA
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M[\5;J!-L.SFC)B_[R8>/^G-Y2:TEP?I&V<:/JR_*YYP%FNC,,3J6J_K3['Q
M3,M9P$PGA:S=\];,CI'6O);/TD<KE4::>\GN8W\PAH5P\9JCE!0S@Q57''U.
MC2K%F>[1BLJ^\@HFM13\&K46$7D[/!*4<3RE,[#E&L^ ;5D'-[,40[>![4<7
MTT5&PISRGJL*ZWLM_+)BT=PX<- 4]2W*A*Q/[4O5F^^#?N)T<?,?#H*XNKMR
MXWDF]^>B_3[XL4UD+GC'^-'+##FW%:+?H:W:QM^2BB<O?R8])(;5.Q?_]@B
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M%;0+E_[T<06]G_#9M"2_[ERM6*5'[] :,:-HQOQ[K:ZD[[<=&=!SN=/1C%0
M+7-+7V0/>ZO<[8@^TKM,4R(\=>Z^ UPNFZI2"D:>ZT6@WL!C%Q80CL%OL0Y.
M,P_3'J:A@.2\W#-MN\LTI]+C@C E4':&N,H]W[S$=6I-MZ#0R4O@<M%=MR2
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M+<H%FE&W4^R[LQU6,JW1?8<9,942S[!-&40CDTJ]Q7 @)06AX$^=F7XSY7J
MU5-2BG#AS]:1MA+4FU0J:N$QDY0;O9;15;$B/_=Q8_BM#/UW_2N!E7UN-?3.
ME0N8KB\P\+CF7/_JWB]?0#(GE)DC*\RA?J1.9<GWT<.BZGK@(GBN\Z5%MX/"
MLO:@COU>3D<?OA_)XPI36\UT&#</5=^&Z@F"FRG#18W;!_6A45S9R70;DMQ'
M[T#+ TW(8Y%7NH@7LMM*1_!#7S/L$SA/+(/"?5!1RQ2H(Z>JMLB5X,?!A?CI
M4DM!;&,;&/;KEKD"?Q@S?P4K2U0DLZFFY;U$@Q+OB!T"9D()F'"S#!"^#"X<
M="%@' 1"<@!O&"H/UB#,7H.A^);J7H9&-F;*J;W<DS_ Q)76W_DN' 7M"V;7
MR-%BU8:W1+.!P$P93L98MGMVFX^\V4;<N-\^L)UMF>"?F=M+KZ-L)Z0WQKF=
M'.9.1QSJ+G7OO3=1@<<D%+_$@L?A<T)M5 7=Q_<[NH)9)D"R>(/WTE0?& <W
MC.T3Z*Q&ZT/W:]<&TA13><-))J8#*\87G/JR>BXS@?YG0:T^=E<77O_U5X":
M 4A9#\%AE8X"Z9%B!:)^/P/V%JP4^NW"VZ]YT'S<4(^6EX&6H7F$%3^6><B=
M73MR?T;M4*^.?C51HW#8NTK1R/>1.R\MR]+BUONV3@960H,#O2+#0P(T.R4R
MS57K,13BK>)2%<-U["$:%CK#DT4GQ><K!U;:K%N",UAD<2O/4V"<5!I-E2R[
M<"W7[C2> CR] O<1&1K0"%7"01#.HT$(BRUI54[-97[CW%V$.LY:T%_="\L3
M$Q?0TMY.-/(0>C=VM-$G[UT?PRH'.Z4247 ^>:=&99I(?3I?IBAI5$E8#QKP
M*7(@MR%B7U^IR'0"!L$AM?J(ICG3_2D!^+M*4=J'ZEB8I >](]/G)L,2HGIT
MWJ2-8TE>ID%^QHEPGR-_[8(/?N=P*W7+:"6L>55)VHVN58N$/_+QRV& (?B2
M84N_"5M6>?),.S#+U.Z_JVB?%L -?WF#_JXZW,CEB$5"_<-)KFUW]PTE/E>B
M 3)\*38J)EUMJ\"3 ]L)_NCOX6M08H-T-)NKQI3KZ#Z2P'R"#N13P]^@"5EJ
M [1 EEP5>;$"I+>=M:JZN$5CY SNAW/#X7'X\-*'C+:TET&"LPU(??!:1EMR
MW-NIM9CZW)E@IV-Y=VE>JZY'WC'6[V5X9 ;G#5OPYL\Z#SQQ\;SQKCV%-XJW
M\E=@/)0E?;%8#R)N2W:\V+LB4&4)1P(P%KQ1.RY'UO\-A=R#>LJ+*WGJB%%>
M9L6&^E94K0(X0=*Q]MF;\89S8P?(D''D3H*6L)4.QDU %8E.?7I%H%ZXT:PI
M$!,=/-$AAR$8<(*Q0)E8XX-8,Y[-MA[%K3G-1$!(6V: +X2$AHS_4ZB71B69
MOO\[TV+F0IM:FMJF+8I.!3A?-RHS,T(KRP54ILP4$1G+!16ET7(=M7+"TDDJ
M132W+)%"A!34:<Q,0%!<P6EQ01\FTR<7_#'O_^?\7SQOKW.=^[H^VW/?'S^5
MW( YN:9_N=X?TAT\FL8B#68*2RUZF;)&>IJEGMJ8WHZV(S^3"3&0[$\LB<:(
MG['L&%.'!=$4N%I?B"*-YR)-NI4JJS/2N.9O(KC%7N]>5FZ!83\UHO%'!E^E
M J 4UTJPX-)K68U=%(GKSAST(94/X0(B%^30CB<Q^'(\IQKZ*)V<C@$8?[C!
M7O;.,%CWH$:+ S9_1AI S1GT^6X05KJSEW*)$*,T[W;TD^T#_I0GD:F^F>U.
M";_+CG]@]0'!LHQK;.R<^F2H4&Y34CGQLB1.%&?>P>:_RI*/;-=Q6>IP0JH(
M8]!P96HSD/J^IT-?"<DQY;R_S:!XJGVRN($,.6COHTOY.2"VP!!O&@+O?0R(
MALFLU%WNH:1U[14/R[L3B,G4:)ASQ-ZFSW!<%A\X7YV<<KWG%'@4N'%1HA&/
MARJZ,?].+IWY0.OQ:5"7\[8%^WT@:Y;\:9,SWUSTPH]B&35FC4RACUYOE'T-
MW )9_VJ%LZRO*R0O(TJWJ,.T:IN]K =4=_12,&)8]X6O)W.0OTL7BD)T&GCB
MC'OW!M[663_)WY<LY3?%N'8\80;V8U'QL/\NE-:M77G Q=CYMHT<X:N-9ZH9
M^.*ZPHJ(1>N/,T^>&5*#>UV<%<FV!_;L\TI0IG@*B\TB_G6Y.R%8.N9>A9N0
M-27E,1ZL-\UU\?VO4B/0%AFR!0A_D^<I=!>D[F27G)+ 5G6V=?[BXIE,NARC
MQ&T14%P2")5>C"_/.'\@0M82][CZ7. 6BP8U6P]L$:%R)_S;^>P_F\PD]\BV
M"C2-P91/'A48A%BT2&KL'Q%=7$T>DA1+V6X_X?TY*Y)[P6!Z<+'K%4'K'5/Q
M--=2%B_NN:$D)\6OO';;,! \@L?T?6JX7#_861F,!5,[?0J#I/5V*FZH@K\N
MX+DX5K0PG\!IJE*NZAAUX\.HQ*AUC*4SLOW3"6D;?]6,CKZ,ZZ"O,(WXRJ(F
MS5\2>!"U#:*\>/_J<]&R5WW=7=CU .9 '*''D.S87FK=E#$]*&]_2DX^SY60
M[ *P'K_^\%%>_SMUK'PKMB<A%!@?6VDJTQ[ZZ,1S.TQC\=4%?YP1%[]25D'P
MPZMM;&LC/=3#[/3REP4^K\33<]465[!>WZ 7IKR;)5 .SB02R8[_38L6><]-
M[M$Q!Q,PM-VL)P-[]H.+/[2[EG^+Z_QTV5QD[B>&+74Y9)G,QTP6]W1 4<&O
M4OR(>O?GT <;FZN;_RDYQA>G\!4+*E\@7>F9#]7L_.*VAU72+I/R["2Q*B?]
M:NP_'#'%6ND\:S1\]BOFC(H0$R_=.HGXU6<3F_,\'Q]53UIK3_B[T6IP5.'V
M1*GR$5CNZJ7@QKJ"82"W4XFF>DCV?F!5QM9G)XQ"7-;$*;HJI_^2JE+M/!B1
M(_N ^^UWR7N?BZ-K2>7YY($WNK:)REGP0##C6^.B9[IF!SFM\X+6)H9<>B%U
ML>1M3X%M3L KG0E549J?";._L/%KR&ERU4?99_'VB1 S.HI&/+.D-5,@2^DP
M6(<$3TY3;,=FUP=]6?1/<[, FSM']GY([2V;7"P2&N[O+-7OTTZ=;HA_ <K\
M[Y#/4#=BP6:49,Z\(;$ZLJEC>V//YM,+J8&JR_\]!DA]YXLF7J5<KA$\"TKY
M$Y'M>(MR M[EWQ?%=:@$@QU@#Z:O\MC4'7*RN&U6<>[#W2J?ZM;+NUF2O:\;
M,QV\M16R4[L7.-;SK 3J>/#F1I7C^;ZZ6"*VE9,SA0]E#I(+_;YV5]!MGORH
M%7D*M(H\Z'-D^!3;;=,]<<!0[E'W3;J/OEC:_G>+-ASA7^I6V*I=3V]&;43,
M %ZSI@^&6EK;0,-M)"31"L=UQ;[*]NEB:,=])7]Z&"+4Z)M5L"K)S-,TJ/\9
MF0L\>8>H0((TG$EUF.),[F^W/<B%)U9I>D;UKZIMZ(KJUSX9,%P.>Y$IW,"E
M6MTFC1 ZL;DPL_UW;8-'T(9I$2KK[JX#Q=Y'?5=>N:W!)]$:F*C:2!%*,3A\
MK3/X-@SJN^3=VGA)4A?M8'X:P2<&.R[M%Z3"9!BE.JK.U!-(928:/OI[)&+\
MW&QLC]RVM=0>H I7=;8N(W6#Z8KTT<%(O](]KRS7B6;MIXEN_==PFP@?4N[)
M3D:X_[4XV KEQG3,-* >W+IIM6,B=>T*F\\:O*"V;%8&L/26'=00@6:G.'9V
M^P@.I'KV+3L[9BS;CEEMBF2;D;)A>8>F+JA',QHMW#O819I#P&QV%(QD3*Y8
M'$$?Z1^$S<K)$,6JCBHJ3AO,"/+HLA0%U.$T0,_Y!?15].3AME"(:LN^9735
M),9]0L;?K 3XN5'1\)]W1WS[?D%\OD4=\U)<(18?;P:FK]?=97"T=G?;]4!R
MSB>?M%3;)@XP>WO6Q<?M?HH2NM5'8B83%'>VHAT[\F(,APXL4C!A]$X?_:E2
M2\?3;,M#HNFX@T1B[0Z5"2ZL3QM01K=-K!F_]6+Y2%K*T;%A"2)/Z4PRFWCQ
MQ>GC=))=J75?K!=N6O\9GK.2GYVL.$ZX;/3PF0VSGEPG$SSO-GE2,;EG%\19
MS;N_1)C@[0;F7RJ6Z!O!M'&-<4AA#=@F\VCA-X))J4? :,+P#[%("-G?7Q9%
MN4BQ4)*YURCAU0+'[%WW",B,>(Y[L'W]LS<+ 7+= NK8TX3SF%6=-D^@6F'R
M,"&&,9'@8'07'U>%#033IA2,1ZK/F:3H6<VAB9-X!'_+X+DTJND =B3+Q=68
M5F2:.<M"9;,(T04"JZ9'JSI9<\BL(CY03CE/JB=O;4-NYGISUH8<!(;4PVB
M+BP]!/CDQ6JC[<,:!<"=&K?:$.D4GOF1P^*E1+<%P"\3PC<&N9LZ_F?JUS#(
MNKY]C1,\8S#=W^0&ICW4C5X;.&1^BP58_J:&M!<5WV]AY UW%##!&\=DRCO#
MW=LZSV'-)VJ?_-7(YN@PJ\D]\ZLZZ4(.C:UPN%6ZK1"M]L_AZEG0,L<-HZ6?
MT0#S9LW5%V)*X,$F$3>,Z)KY.TG1!R=M+L^V9S!Z3#/MYI)S42C5&;W.L&=@
M[OP*D8H2-5+UE_78O?O &&">Z",LXGCF.,SX*KV?U)*]D5FBUB?N:GUT4ZZ
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M>N6DY=MGJ3*-7EJG((F7K5@A!&J=KV+X:'N26[WU_.W0RRF/)Q="]-+:--(
MEL7)/XJM3"+9^A:B@>Y=@.GOTI&#(NT*O4>=6N%I#*?,\ILK6$4YL*K&V>Q2
M"(AG=%5_69#2Y+4+!3"?3"?9+8>ZC]A ZG/=G%#U<I6BV0+M-^Z;*TBZ/U00
M9MQ>N6NG=6<V=8R15!/3/TRV&BNX]4NFQKA]6,-^;"W+9IE_>Z5VN/D)+"S#
M)T4SQE5NHSY8I,%4*DP<VX+!D^KV<8"KG#S&\R(AYJ3)6AJ5/9\[-IOA5'X$
MW"\L=01\TBB7GX+IJ.*N\[D>ZOHL.!:7QDE(7_90YI[6V&![4BK)8=8@JY*
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M='F'HMO_7)IM"=JI[=,!$FEN,/=!V:N&WKG<@[W[+M'$*'%MN:%AW@N/]72
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MG3+&HAK@G)K0";/_=\B#K [\'U!+ P04    " !/C'Y<1.Q_$:H2  !'\P
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METRT]9")WG&@]Q&><NXS%!";T!?>.[51EC9J$.(]*<0\MA_%<JW[3.Z.XWN
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M/K2OQ*(ZH(#*V+9AT1U20(=/26)AN5MJ!4Y?F&X<Z2VP.E2E^W=ZJZH:BD$
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M]TE-R9A8JUP-ANE_DY"=9_$9WVQ-E"F:]DCEV6K73[*L#-,[LJ#LK:&A:N:
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MS6>I^2RU=YFE!CC=$5KDFIP!CWR$YK<1HTV@ *&M;<0;H+B?8P-T\^L\H+.
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M-W)"LUA"OUY/MRF J]*#-WQ#YU<TS,3MDDU%A*VD3Y;;GQ4Y#C:&](EW>@_
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M_#=VBEWEO FI=\.\'_SD[/)]--^^6;Z_GFE9Y::TGK11SA<'290RI']S-KE
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MFS<VN\9EB?&VE]\UIF=(^8A?JU,*ZG<!C\E]I,E@PY.[YBX.?=;M;L@00%\
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M*XYM@-/80'B)I5WQ'<1W5Y %+DNZO5%VB24C^48^,@OG$TSN6G%UP:*25</
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M<(5V*Y@A'M<8M(Z5'PGMJ87ED2&\J=P]<S%/VJ6>XAPOT@I.A='J6CI3:"I
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MZ'Y_3:LERJ&URI9+2&Z!.RPK+C-Q)E9VRE]]VD,T!>: <)QN%=K#^7P=]T>
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MI[M$P%&6(1I4<Z0(S])J,R]P=$:20VM"]&<--=B=QOE;W0$\I6<X8UPU[H\
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M8 20$06- +;_Z](878D*L;RII=^B(H70ZFL(N(;H$8$N$H[35$!'\_FR'XX
MZYR]%K#7< BT4!$#&S!J2<P,1)I&'G-A**DQ"XO"Z<M@\HMHH':VR^&$_M);
M#B'KY;.8XZ_!YBU8)(N]LQP6(3\0>2(Y.O'/FXA]?HZT+<WC^M 3)C56X\P7
MSNF:Q5O [:G/02,&V_NA/TY9HD2N@ F"YWA-RK2ZK9:XF)<EKN33<,6?6DL3
M/ 81+E/P&!<[R8)&:S3)S6\ 3R7[=H"=!I,%Q^CG/[UFS*@6#S1-L/%N5A]#
M-DJQ\6M8;\$&MZP'.*(OP\:F;:UJ<\#=5<[B.!II;&]L9_1M;3 ?PQ1LC6.:
M]EH: D)Y]'KF)<G2A%?AEGIID_E$V^LIGMJ]U[,#>W(O9E)$)SJ4],9J]^GS
MLKI=?"XQ._QOGZH((LVO\HO7> F=!B])<9GF\'+!U&9;I6,CX$/C^3295!NN
M\S!"9E.A*/Y'G18X076>X (M&"IP=F: 39@FH<9;1:S3W_$9?-<^W0G<_(/C
M#,[?O?E\A&SU E:-W;*$O4X24&M -'Z*8.\3PPQ!I.D4T$5Q5^!UE";#.0ZR
MGUES3>Q/'\XML8^''9>$]MI,W!$-T&VE Y911.!6#W5%1MTMWOP4 KX:]%$,
M$=31B7&15_1PNDPS?%/W%'T?&J)Q3AQ.Y>.(.(2I>CJ8XZQQ,'"@"* B&;0=
M' G";2<R=''*KA<K7#Q3H_+7@GRMEA ,'^6'AKKD:&TF[IW5>?%LSA8M;,2!
MHP9Z(!89IB]1))ICR_B13C]@$'?_;& 'PS0^S5^ IVOUZN%J8NR.8^O0PMW;
M83)&"J=J[&$59=EI7=(+Y%%CGY%1VFIK;S9/ZHK!1"W00%JJGXQ$DC9N^6")
MLVSL%.L;I,\%G<G\V6!=J'I6F!G>^G88@QOXF.UE ")''<>'ZE6^@!*.X.V]
MIL)S5>'5T+O/T'"#0[=O6F\O0!W@Z N 1PR^7W^]-)&)*N7\,5!?\QR9H788
MQTL+G'ZF"=#01HJN8EX)VI:FP-'MXAY'V459115N6^L)_'YCPW6KF0BF]>7G
M$\'7*EUB;2TZ9<DAD9DL$(!''#Z26XRK>B5C#$-4*>?4A+RKG[(TOLQ(=!A-
M-#A&VX#LS.7/?NP U3,?C;#6MQXY6"2!N#/CL6_OB11IG/N=BS,J,L^D$%]]
M>D<9>9^WLWFZ 3.8J 4:T)5[3,8C;ZZ -D[YH$E[NL=K4D#DV@-5H[VA8S+#
MM3FC?UI_^JT?OIZJL[46?:W7YM]M44 RZW'&_2,\0U2)YU0>?B-9G5=1P052
M+ B"<=H2<#"?/]8_ *S'\\;8ZS/[%C2268 S)A?Q Y$FDU.V_D^<9?\S)U_S
M!QR5!,*FRK(>>',>&:_-YH)Y_;&[  $]MK>V&GWV!Q1.?@<<4(L$DEF2,T$8
MXQRB3$ CP<!QTC@UXF0G&/0??Y]_C8KD<?5\GI;QM<!W.CI.41"$\SF/$06@
MZ#%=@34 D#-2UG1\.(_I.&F)-+T<<\BG?)T"=%&$O-18 TXYFM,KMWRZN;OJ
ML SZ$BHF7H[,1(EV :,FVQYZ$OGO\I]:BYX\!A$N@O(8%[M=(+76:!)).5_Q
M3I!%Z$1Z!<:2Z@?I)-E>3D&?Y652)#WEH<<'&JKFW82N140,644@;.*O\^!P
M=+A TE*:8,A=^0)HA#U6>OBCYTP1$<VMLP[G51%E5WF"7_\G%KMM!>/TW7/[
M\WERW390$0.+*-Q0_BL!-8DTB1RIORLN-H]%! 7-6+9?BLN[@@S>9Q2^TE",
M$K.[9I\&!=3@@%HD6+X"8(*3\%<?E5T@FJ1UJHON\3/K-997-]&J+VQD:)BV
M)MJ?SI_;:!^NGK?(%'=])]$.,AI'WYD>%; "D:61:RV:=$5JGI UM>L%]J3T
M-R8:5#3W5/1G@Y*4S>9EF5HUS>ROU>5I,<IOAV>%''6=GA3G9!6EN?"$V/^S
M]LG I_%DFG[AT/S'#/:2C(S1P='V7N/G*.-0YZ]IWUNI8(3&)A_,Y'J?&3C4
M[C9 ]+_7(N(1"8HX%>AYDE#2E<U_P/C\()3N@;':HMXSIR>Y;T#.VA\0NT+<
MYJ%,JB'J$B62^0L?3OYW75:L7\,CH?BD$,\<97=1FESE9]$ZK:*,5>QF3X'L
M01!*>D Q+5'E0QM3ZH8A&X#V%JIL@*-6.+-7FNAX('<(HHJ@'8H(<$1ICAHL
M9[P8/G]03V:H115)T,95=+0-7B<N-LO1]>R&Y/=UAC]\__33AWE!+=I57HFN
M9:-C-:YCPCE]./N%P%5O6Q97H2%P%/H)@$< _^0#HAA P2:>DHR+59I' 2]7
MXUQ#E(CHP_:"1F^WQ2/Y*KY7"4>:VEV[&7U;7:SS'J&W=0H[K,750]4^>TM$
M*D>Z4EI16M>2X52D'?T84#E.5S'*:47G*E&.WX<=MB,C#3G>HW-V +0)S_OV
MNXJ8/K"?=8Q->E@^C$^U.5_NJ!D>9?]ONA:T QX?;&H,[$WJVQ[@P!&%'J85
MKP1Y^ZR" 9KY8!K(J<&WQ5U!7M(\'F4;P7!3QCF8UC?K,/!@2[8(A&4>$9'[
MV&>0<GYNX<.'[?A@\WNXYR-7#-WP)N[[X!VZB@<^?"78IO\B[N8(%@O#IZK(
MP#HO;Q>/10)F[T!BP/A@#6$03^I:&#Y1W5.D]-!EX*%P1/MTWN6DH#D"$A0G
M:F3T]CCR*2I^QQ7$3S_@N"[2*L5E7UD>Z?&:SQK">=VS5PL8[2 'J= C3V*B
M3#>W0<+R#8W5/M(/'P[8U%@."\U,?ZOK,LCW[VG</(F^S8K\1?2(Z^B4;\XU
M>BJ<;J[RI$\-CPW3.-G[IG,M(STG.+TA/6T@\CY]29.:'O<A5/ H>8DLS3RF
M^;W@YCD5&M\]5?,\V1T*%_^HH5CD]FB@?SS#!?0Q:9? ZNCODBW'>C*Y!J>=
M3N@&+?>1KUN\(0H ,&>!H!VKA"/?-4[>P8AF 3MCF"WA_23R9KTQ"_'- 8[L
MJ :)A\WJB60])E/OWS6LH[UY?"EY#LV[&=!/,S)*"&^:^R%>XJ3.\.WBKB!)
M'8]51E7^3E.7CL[OFG%NH@K4%[WI-^TM69L\CDNWCBITYZ0L &EPK*PJU)1,
MR]^#7M[D-X=H4]Q5<#6!AM1+DHO;PXB&Z(17'TSEXUIV"%/U$F:.L\:5BP%%
M#&JH]C#";2<R=/&G4'=1@^?TG,^?>?,R?IEC?[Q=@TB5%Z^XB-,2)R(-JSV1
MKLI5!NC<,&T#3ZE2C?EMG]_G4;VF/U=+C'"#"PPI6=0JX4C*W_[#44-#$!G\
MD].(PF/M 7!>\G.GZX=^VJ#NN+MHPQ\Z()%_AAJ\9ZC%G%G]34/ *5/-I/;(
M%EXPKY %N2;V".U-'S+38>Q"WS](4X_M3^8KW6 ?JH[LF.*M]2Q:4>EG@,/$
M]0LVGLA191J'^CV]\A=I3%42&\:T[ VN;A>7I%C@%*X1HA0>:_.Z./)EX$_
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M]GW1+P#\"5F<U/0?[*'0_,)OO"0;CK'[=F$4#5[A?@(W?1$C"2_Z@Z3TE_&
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M(S5X4QX>K)U(WC>I^Y3R0S8,>QD>(2U1HU>(@_>,![QR:T!82G?\4%:;Q_S
MEH/G]7EJL,RRO)48;.D:0:S[QDR#6'LS&RS*/2&C69%U^XT?G4T)=ER4Q\><
MY-DQ\*6E@Z0'@J_(10E4].J8V%SA+WR%.7Z&@ 0U<=V9=M%T%M1L&;WPI"1Y
MJ**B4EO4:=/\,X*4L><TAQY_;>--:*XYL15>Y(J;UED?AI %V95Y,GF&-,*
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MDZ/.^]"O!2GENAN)/K+2UNAP<M=\)8>%>9,C\W5I%QH_?L^<05V]*:Q)KQ'
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M8GE?M"2!:I]OG\G+=PE.N1#0'W:\3__Q]ZMX4<QKB@(IYE5%)92=B9=9]'S
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M7V<F1AF>LGBYNLFB^JQEYGK] !5T=IT#6)LBP3%"2?T4R8:99O.]T@R=N4G
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M21_S=$[[T5^C)JF-/9VTQ%D:,Q^SI FF-+9)LZP'@<%4TVJJ[85Y#Y\XVSV
MUOTND=(  Q!^3OD6KQ"B._X:YVC]M_T0;#?-LGT],XG;;82"E'OV ?W;CDGI
M7_[X&KVDBVK1"FKG[_JI2G,^56V_:Z?JECG^6K9RZV]FJ.E$J.57LR6^J51+
MTJPJT^>]U+OS%Q;;0 E+JV W!:MR?87M/"(Y/2U8F+"Y2[AJ'X#SKH^!+SJ
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MB$]@7YQ/(C91U>%]<4:!\)&R%'WEG.-U6(+%2G!5MBIL?6QH&Z[+#Y/BB6+
M;E!2;:^N_U6N9!V6W$&,NBD!E 3GI%;GY/3^ZVQ.=W/7*^C\1@,0<+:6)7>,
M$;[E*<^A)VI['/[0NY**HED=F2IF54GW5)YPEP_480#"[I_0AY_>?YY1?>2A
M*B[SF *0/B-V%;6;.'"GH0C\\/Z<RC:\8LM#M:<J1LV?X-1*CV#VUN#WB"2"
MPE^M;<;K5QW_#"QYAAL^1FA/0G!+WPG;&RZAECY3.4OW6[,#N:3S&YOUMD:L
MY$&-X375E6;S^I%GR@443JZ?&][14N&WFK23U6D6%5S/-Z"'V1DPA>(DHI8)
MJW6#**:-U4/A?6S.\9/5KLU-5(O^6HCN)&F>,,'/UH6_AAH_Y5/,0 .]E-/6
MED;S+A+3VN#A5NG^9F=7/10I-;W(:D](<#0 8?L0SY&14R&J$Z(ZGD=UVFT&
M;/)D\P5*L?#%ZDJ?-R !9"^6/M!\"8%(L1#$]O$E(@("!N+5](93Y/81QS7D
M"R+"DPSHYO!ERW3B(>L]!@/B>'%3/B"P* 08"\>?K.9C(>F]!X/B^,O5 % 4
M@P2^R!3@J3-<HH;C(D56FPWI&NVP*/G@;&1J?&Q2&QZ8K<LN8VT-8MEL#>%
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MYI*&N+3XLTF@87_JG(VPA^D9K"NCL9=K@0LB[F+6G(I(3G=P<8-(_28A;!K
M7F;K540I87G9Z"N*F">"2=R&+MB<I/N;O>&_6%+Z&$TS0E7P)2ZB;#:_POGC
M%;71DCKC'"@4^@QEIZH!<%Z"YD9IOT(41G1%60D!EP70P^@,OD;D3U0R+>L.
MQ15)RW1#5\<$Q!V,TG^-ON]I* 3G](]QD^\D(Q94AS$ZUS<T"!0W0>OQ46ZI
M:A6W&#%WJTCTM/I6@LQ&D>H;*K9PZ/U6H-G\O"C3!26GB];V1OXXJX<SHK'(
M;Z OM]K9<A] 03KVK/.C+O71R?3'\)XE;_+'=N="I.]A>9^>+]  YHM5O#=C
MWSYR^*@$+7RY-"G'00I*LB^7*>6 XJFWOERGE!0^\C$*7VY6R@$%]4.!T?G%
M)W3 010P/'_U"1[%*  8K%]] JM_) &,VV>?< .[^N%JI%=ZMK1[%(Z3/_HV
M-!4'CHU7FK92Z@,<*Z^4;5CD% Z.5WJW5*X#'".O5.Y^05*S^<#UFW$?)T6U
M6$1D-<%S842AMB5D'\;K\063C^?U)C/D#VO-'VZ+@/5=.%&:ZC",83_-8T9.
MGUB-F\M\OT6:QRG=6+P[0H.,:3;$'3^AI,K0;#ZE)"5I5K&K.SO_Q_E+G%5T
ME[*G79EF5)7K)U_?GF["*+^V#UG"ZRU=)U&1QLSP8%-;OW@+!T5IM) ,P7T
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MNS&JK]1GK-*@FD$F',>D-08D)IAB=DPQX?* [##@(AM21O=*=9ZA(B;I4O3
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MB\O\F:J<==RYPY\"'\#2#*]1R>B[(?@YI3OS9/6-"O_+?"MYUZGNZ4&\2WZ
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M^Q5Y=/H6@)]VUK,@17_P*VCU*S3'7GWS;E-(KO[+MSPMBSM4EAGJ3-Q5'V
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M5,5!ZPTS]5<51'Y37WAJ6*A:';1@J!RO9CXL5*V>8&^X"F[XJ+D??.$IPWE
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MA9*,WN1/#U+4<$@K;NQY-T>=3-T>=< "]__89QU2R >'LM7CB&&^/E\P&%[
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MYBF5TQ$+PJYIXEX)E^IK=%:7.64@M#O:V%?9>=5=.P#0PX49<._0@?J8+C2
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M!65)8;@JT7:-+G.Z2C$JBELJ1>D9]$29Z@P]HPPOV2P[4@M4A[$[U[V-?HW
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M",#=Z0N#6+Z_[CBWA/OK@T4EP?X42"QR_0O[OX>H0/1?_C]02P,$%     @
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M?J6,][K#_H&5=\;NX?$81$_,A_CXVHN_?P7=( *%P1]W>CV!N5V7T36H'F$
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MBX;L>AC!MVV\"5B.'/4NC=A.72^1X_I99\.YTXLZ^+XPZF14/?/MOCJR?ZY
M:ZW8MP?B4[M386&>FZXS56J9.R#CO%@!N,3J':9G@U*S.%S#CTFG:<\G7RK\
MY(11)'1*- K3*$(W:HB,=>>%:>R/%5^5??5G>4M5_IUYP4TR3$[QZ\=Z3":/
M'50\]C012:XFY(40CC!>SFR5%4\:?$-B1+LK48XZ(3EC05SZX]B+9;(\FI9W
MHMZU\53#<T\$,<M7=)G")8HSZ*^;G*CEK9&8^O?_VM]M[[W_X(@H-AVP$1S$
M=\B]>ASRN#5W#SMTV[O-1JMY4F_!%JI.1,.;&0]02506VV9)X#;GLP.QL\5A
MO1<QG/'C!9NN)/'@:9M7NZG7,.2'N1YVOP^+AZL[Y/P*3BV:OH/N0N7IP+PD
M2C^*P5;Q:?.14[J'8A[>")H\<D":\,8$J0^'$&QCW#\D^OTP)EW4]@7JH1Y<
M DG J6%X0^FG[N$EEH\1MCB$C]HD'?X[#82UT^12?6L3'Z9;NM)]@J&X&7,:
MAC%M=Z -G#:D4@L<-;!)&+@*H^"/E"OT*!&!-1N>&=*14U>L8WOD)7"O3%9!
MW0^E&T(-U"@L\[\DAY]1W 2N,W^^W\CQ>@Y9"W0ZCW_^=G,RR>Y7I)R=^:&=
M@)T' X6K>7WH,$B'=3=,ZJYP/&"+#4O^ PRZ^M[&T?N]QCO%]VI<1Q;PG __
M6,7"Y]ELWR&6@14"-FL?$,_LUY U@+&(NTJ7"!=B8HD4P%NV1)2H5Q+ S0#L
M.)7O,DW(!@,&UZO6?/*JG5^<;1SM[=3>O6O7]IK[$XO'5"W=/V'VX55<VL<S
MV$XNC[]]/;VXI3+@R^NKR^L.XFY]_)=U?7IV>GUZ<7RZEGE65R"=K//S<QU=
M9M <ZUJ;I6?P&@LQDHS20QA#3C9[ ;,@\OVF%-3D@DA4R;*#8M%4Y>!1&6?&
M+>0%6XRJ,$767D7AP]C2N(_DQ$"#$7>3&O(G,'XCE*)"$ ?#C&C7#$#BH[;&
M1\2](+LXR)(XR 6"WT63UDPK08-<NR\,T -\P$,;B),U++N72(T&7RL/#!.B
M!KZDSB=/'0*H,2(A%[F=%H+&-PO\;PY8@XL'_YN;UQF=PT_V.A?@)%?/;5SF
M Y[S AK+:.)PED!S3F.E^9P]L_ H5O+,>7S.>=BRRPN+X/T8BN\5,++.SF^.
M83C_.NU<6Z<7)W#RGYP>GW[]>'IM8'FMZ5+<=CY^.44HIN/+BUM4@18\TY7/
M@0&CQW7]3*26!$J?\?2[GWM\_S4*:F!U@IS8!Z-#0E0<<G#!]_#,07VS+W[9
MQOM+BV.>GF"P?$0O#8W_Q0##FSQ'HWYWL]W<!0&S\P[^9V]ORT#'@WN03K]N
MM#>>0X/Y900==[XAP%OG^E_6Q>7M*0CO3YWKD_.+3RB\_PG_K'^YO/R,?Q-<
M\5>6)4_.;E@H)]-VST^O-8,9'UG"O3U:O>5?PO.+DV\WM[" ".7\M7/]^?36
M.NG<=E9HF=H_ODPKL].N.J 4G:_0HNR\_-Y9BH4X3\30:C5^8B7>S7F$*M?O
M;3#+M!V\1,S2669NN?;B[]:9[21AM$H<TWZWUO+EXS*SS+< FYOX&"B_2>Q>
MCSRA&()?(?[9.UAKD7.\S/QS/.Z*2&87C=\(SRR_S&DO,\M<1>$(1R!62L;\
MQ!FU_#)F9YGYY8OHVS[&"!U!1;!OA6V67\SL+C/;? 7#R;JQ>R(96R=>C)E%
M:?3F9<Z2.D-6R1NR]WYA>QH+M!:YH?>6=D/K2L#WA4R7^GO>[9Q<AYDC)0BA
M$C&-&XK6X [J_<H@4IQ 8GW%XHR(TT(8Q<>Z2B-G8,>"<L/X62.!Y#F48ER^
ME>38Y5=>]I>6:>'-_^^UB$4$YO7_MT(2;G]_G;66@V7FEZ^3]6"HO*2<FX;"
MJ6-40)SIZI?C,'"Y$!#O :9+?2Z_N1P)#M7&1EA^1=APK?TZ!TOM2OZ_L:K%
MPZJZ.T$L!3_XZF]#G;8ZW3!-5&X[.J!7B,$.=M=9SKU;9O[*)-=-5O6%?':3
MCD8^_6U'8\+;6B6&VEMGB?5^F1GJF!*Y8^N<3T 0478_$I*Q_HE)X!TN5;:I
M+C50?U*3 '@@8\A,NJT0Y[U?:Y7M_5*?E:![80$^RR_R4[HKYFGZ&>Y9 ;FU
MU!'82ZJ8/<]J;-X(WZR U%GJR&MV3*''RXX('_0LC 0,QOIOHZ^<K*:_BL0=
M%E>=!UBT11?>"*>MFB]\E9SA[]<ZCMYJ+K<$0 "-,(IKUJG&L+BDYFK2D7VL
M*CJM3PA;@1KN2BFU:^T :BUUYFG&4<<&K,H;89X5D$Q+G>*C^KU8E_<!R**!
M-T)7]#$,RO8"ZZ,(! @IM+7Y.LFJS/,M7=A38W1OA E70((M==Z08C?B)%1W
M@0WC'&_=(GPBPV/$->DVXB,5M&17C!!D\>V<F"L@])8ZX>A*M[K-/(W6F9!0
M$S<BNL.NMV^$F5;,YOI]E99EK7,*6\N;@T1:\<#K>C)451+#LFZ<@7!3?[7V
M^5KG-K>6.C\HPU^Z28=P995J*%K-MU!4?7/^Z:)S^^WZ=*6JW9O3"JG7#LW_
M6;A*7@6I- =(I8R690OPDVAD[;V98&2(Z;(P<+!5@@;*P[AX1[>(3F<SF%Y4
M@O^'0)9@+L>P;FPW]\+HWH[<NA^&WV5_@!P\,R+]2; \A,0;"CM0P'P2O;M]
MT%& >=\"C[TY!"^8[\LJFSKN$(BJ/:36!C5I-,D7M4X??5%9F\C)-^*@C;Z-
M^,;8[@EK8$==!*6.A"T17!FK6N$:-I!2UC",<G"(V)="6+]L>T>R.QG0^1@X
M$BYA]M)%F!2"<T30+Y*@6>930[^BM0ZLUHFQ586$>->8B+4,4C)&VN?)=N+9
M7P6"2M=,6GA'M$0%"LM>&H4;\S?=B]G7PS0J7(?US=^2QL57I(&/R,$,4D^X
MKU:(X?M[+]8=(6,Y3YRBGA3B 4?V2 !K.)BCY#2(&]&2 &Z,/=<#BN*CV#85
MF)<!)9%9X3MQZ'LNL2405+]2#:UU@$.+\S>6P^)?9_3/+\WD<N0 8@M4P)UN
M ?U*P9BG]:,G%E\#WOZGL+ 1-=X5IL#G@=%+(8EL5R!F-MN',;M\"$4[KLG.
M!R0B4X*_EZ$Y/^R'#>LF](4_EOU;@CL1>+A0A$%<?"_]27#"$^M81%]%^8SY
MN=DF:AWLTB+BB^2Z[KYKTT\Q-;V'D7;31#6_U0P3PWM\[D339:Y,(FS @ (V
M&*L&$=3M5C8?#=&WC\Q,KYHQAWL/F!Y?C)U/4$Y(P=Q+?=ANB<*:Y38F]FCD
MPY<05,ZW[XD^7F21?A@S8',"U(15<D-ZIX*#A?=A^QP8H.O%(Y^QOVGS2DQZ
M+^-SWE*SAHS=6[#)#K4FR-S+1.\:?@2^&48Q^P2P2^L(=Z>.A*2(L%OCO@3Y
M(2QZFZQHDRW/JQILS6ZP5:*FE_?<^OL?:9A\*' 5__CCW;?D*A-^X(\!RZTD
M'&?><9#IRTI*SU"_M4J-0LL5L1-Y(]UO%YX%T8K^!:MG.PFC;,_0S\O5\DGU
M^2KR[O (,M3H+_"?/F-]@[J P]/Z]/N];)3<<05N*FE@Y7#/9Y#;F&AF2USP
M2>4[\F(I6M- &ATT!/J(P\<-]J'P[O!DM*D)%IV=JH4#2%JN;J(&0E3R5#-4
M'T?51-6PHQEEO<F#&142[BY!1\7 QB*7!*@W2OC<]+"VU.N-9Q$9;001#;T
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ME3Y^;E^#*D9E+C":CY];US2R\4C&VL- )06K2 U8$P.=H1=[2<IN\RVL+[+
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ML>*,A)>80Q(4! ES 2&=PQ8Y^(?I;67#-U^YI3*:]#S"8G)V+8-0R-(9=!B
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MIKLBP,4[$$F8,861!MU>/BN%YR.4#@ZSUW$&0U:C. 5:U[4,)[I6@"9#GTB
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M%0\3":/B<D(56OT9"HZ!J)EW/)3[';5VJOV*&*SB<&M&Z6DN-* &#%TW/V0
MWQIBI\KW#E%8IQYG5(]R(#2R Q1MVX4W':UB*^^KV,H2I^+,.7#:(<F824 )
MIV>[=_"0;"^I2Y='A<Q#\A9[,E&6G-6Z*QM>XD;E@K&BD[#.;84G&ZA3YV4=
M\#9<NS9HOR*B\X*3-6)X)[<%EV&,?#][ZJ891K9O)I%@P]<X!FF$&3+3OU*3
M+<RPPZ+CAWR4)5XW=!4,%?GS)>J@*K^30.7ZD@&_S4#@=R%W9>-@@(B4A23]
M DQ:\RPFV%IJ<VN&<B96!=.5"Y30AP;FPM2>F =##5^PGR3-$WLRPM&W9VU>
MG9SN;>4R;$2CWT $31_L+KOG^5OJK$/:? _D6LZ@,/N *,$"Q7^.$JN<\D(Q
M/;7L"KW>[ !3.*=ECUC3D43]BD.9UDHIXL:1:W875>U+N;6H4GBT_TV#D5%&
MU2CT$34U Z&N&8CM%.A!KM;)]J@&D*.-^IWK6,"$]I8WF3)U32E>.I/7G(14
M?G@<UN;OIY_.MC(D?,5*Z/GSXB@=)9,?5ME!TL/H&F@G)MPV:TQ24<J6A:05
M;MG$7()\_:)L1*B:"K3UMJF9WD/A,6HH$ >;,^*^GGP-SB]['NE)&P-VPW?=
M9!GOF^@<BP^R:JE"MB7] A:M'\T",BKT9I/=HHHMVLR?-731.@635+4MGFZY
MQ@6%O,I\\KJNHAE%'GHU&"JL85WA038('=EPC/.94-@;5;,J;*VV0^%#FUT0
M*Y1=B7EQY* NW %F]+OFW@>KM=.TAL/?^EN9Z<!S4=7SUZ<GW_XGJXA3Q?3'
MM\W=5GMGO[6SQ2<]]4(%><)5+N6 UM;F\>>3K5J>1N91ER?0M+%OWGS$%LF)
MY8+@>;\W 94RG^/C1\M!9RK@D\,SU>A':T++"NGU&_8:.W\K+Q4%K1OS"'_=
MV-&CY'G5NV&2A,/#&,CN6JW1@U;:"U\:>J[K"UE9VFXU]O_VTF6<D\&)8BDB
M<Z;B4^ LZY:8\YH#X(?61[4)@%_^M_;I3-9H_J6$LGEZ$"F8*%&_N]FL6?C_
MMCY8/[@ /_<12?R,51JMOREK3)JIV:NZH(E]7_SB ,DMZ:Y#.0._*$E3MA!S
M($JKL;<*1-E=+%$>(XFZ*ET;RTBQO>D46\1^7BA+Y1$]Z+2SCBDCBH]K)>'F
MP#JYF2^=A*D?- XD&[P]25)OM1O["YO]2HF,>KO=:)629KUEPQ5<]5-4C<&*
M +KHFI';^JV(DZTW)R":C6:K]1:% TR\N5O)A1*J[+PMD7"1#KO<3NG*\!N\
M.4&P>_ 6I<#.0F3?2HF UM[/0C2]\)@*R2YSB54\X_O_^YR1A^.\GY$+@GS?
M<L)!&$D!LL)Y,6!"(B#BVX2N*FT_M8885G)BF,]=Q/JAWJ'VR',Q]2E+CE+U
M7%T$!9B *[(Y=BI#XKFJ(Q4XPJ;4G=A2]3=<#*!36KGA86P$FA"?'UO-4:H.
M!Y(9;FC,K3)2F9PE&G*98FPVC% VE,W G8PX?_\^U$!5B>B'F-9S2*B?A#LD
MAF$4#>P^-U*E-AW43JN$-E0*A@$X,R;&!0&R.G',I(!?'#],K$W5<7=+1=#M
MD@_JDB22)?A^RN6BB+00+H4 *6_>1!(JD/::&H_(!"GJI"67F(56S;*'V)LY
ME U=L>E?C4/F6!-@8PE9#FABLR0AE&HKQ!WAT\O78RXA!OFH+DVG[-M)@F4#
MF[?G'8QF>'97))B,0.]T0(!0,#W$TDNO;T<B@4T7#[%( V9J<PBEYW4CSU=%
M6-3&VZ'<9F(&E:8;=D4,_ZYRHA:9$]5J5DE1*Y(4];,'Q5?*QT>@OAXG0LAT
M^(C0^RA= +MH&YVH02K45%<D1#8V)1<="?JD, 48'0>18%P.0V+K-_\98@&7
M"6_BA)'(7U=@AX0@J.M*]<F5#6'3^+<.J>(]!WM_PRF];_Z-Q"^FF,L2,>Z6
M'A$#4H*K^O!(!&!(1C;BOT4>I;A0R]\D)-",B'/C]>VRLZ_YJO+)-*Q_,OS_
MT M2DIY,T2P8C#9"^7%;0AI9FQ?+LG#.2\5B#3]U0EFJ&#Z,^R*0V2:9#D!D
MQ(IK$?7'5(XE:W%!4/?[F"]E%GPC)?N1[5)G@YJ%,7Q9>V*DB038J"B0I>>,
MQ4@$MT?A* EC3Q9+3Q"9Y@+G2'@OJ!R.NZ$C#I-UYU'\V6PBR5T3[JA!,YXD
M(I?82TD^\,X )JMC^_2JT*$STU6UV5.IVK"^!?#!).4*B)HL8)-C]:AC0Y^Z
M/ZH:$%?X]ECK.ZJ23VI1.;0^7@6<(*5C(_&F4([T*BSML/H(,D5U-\]CCDVL
M;HF<A-$ U:=Z?HJF: K<G(ZL38$E?)P4%]_+!IPRGQNGJ"H0':"HQUVN916)
MK-N7R0FAL>L-2$ZF!VY:A8J5@Q2P=5J5&GHNUXI5PEAVD%%*C]&#5%9FAH;*
M)M4H3-Q Q2C*EVHJ=LYP(DC[ZT>H>6@]6 X;:9)#>:PI!%2]GC!:I3.AFJIH
M#!H7B&54GN00N><UJHAC&D,-I:]PL"(H!/X>$M8"[R,)N P$&TBES?40+ "I
MAO)"ZTRN%]O8GSI11?3P>J;;=E<,;%#H(EHP_@!O/1^T16XT!.(A4:2@:B(\
M$;A$%K,R:ZI-=S#.&II$XH_4H^(LW=(:\RB]1 -#&\VN]3@9PPU+$> % QZR
M*B3C[@[9J!!YS4M2N?S8L)H./" NLMQO2D#()EPLO_47[SU8ZGN"I_#X,WJ3
M9^(\@-LM1$R27<OE]'F0*NV5R\&DG:00S\($CT8,.'!*C,DJ;H;GP>*)K"?"
M#>$Z-E6UM8:%2N4UG[!AU\6LGBCU_&<8^:YR(UQBA4W&_@I&N(@(W6YDF-"R
M1]@]ON8>LR +I7UD%[(0/FB\TX]1C1RY,@J:&6SNB3%^:]PTK&,R!=AR5+X>
MA7](_? 8QH\LP^.38U2*<J-^I^I*><"JI!1?7:Q&U!,W!O_NX&\S!UWLB:SM
MY@P#FV9MDYPR=*246&XH62Y EF/\&>K>IP3.IDH.EZWL=8&2;.!GOE'*.-7(
MK\9][]$AR+A!C&+H)015@P6G)NQ<)GBX(K:]*Z4 [_T,Y0>_2',9#T$A&BXT
MJ75!TN"+-Y3BG4X7"=F7E24R,Y9ZY)9%7LP#JX^/">I9Z06(=*'RL*G. +U*
M]6X:&TB?,3EA!J#!=D-_C/BGC."ID4_S.*EFU6?I=@,1X2>(%87YJ,E5IP9K
M@ .(A6JA_DF@Q@)*R1:UI]?OAIT VV>?2RCWFW6V7%@MA$V!;J/-\]^Q<,+
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M/3([Z^@_ER%T,H_D'TQ5&'F.1(E-J.6D/1J@;2RH#=>]F4U;#L^KT>:MS6B
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MJKZC?+T7 "&,R\)"L[FR!^U\^3G-\NQ#*KMW=I45:<]U7 C!V!8*Y+YG([H
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MBR.C;G;MX!8A\=,;GI4P9>3^,. $3:,RGM],HY(K<!').]0WE8X/W$F@#1>
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M$5"Y^1/JFQ62#24*R1"!YQ86TFV @#1SSW,T1TCR2Y$)H<(6<&!->6GP]M'
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MUL)#-II>R1 #DL$SN4.JS<&.$VR-4-$QZ$(L>DRH91:U6% 1/W06=L6HC'9
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M@-R^#!)H]7*/]/:/;1>T%"T#O954]C T3$;\E?K3Q/<(]>T^E!W1EY )\GO
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M(,_^C")#/4SC8/'C#T;H+90#J;8A=S([M>ORKA\KS1@G:-J)N],B*J6MQ ?
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MMHX?S/U?-]%XR:A[LQ,8=$CQ<+Q6T9=+@J\%O1PZCL'I)(S&QZKW?8!XK]:
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M6WM()EET_ BG\,SA=1W:4TNE25 )W=HTF*+5[LIN-=S5<-^9'QZ1-,VK):Y
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M^X[VG*'<+[Q+CH\IFXC>W/.Y/[2=7#3IN?R%!9YVP+%%%X[,TC[!PWKG) 6
M#>,IXJ%A90(8GC ^/G7[BLH(5?#H_1BUQ[<4]UATL3N';X?AC8*GN.^@9 P]
M^P6T=([$<@^U+&LJCJ0&\T,30#[+ V\Z!(8BZ%W)XY+X=2TQ8N7KDNXKGH'7
M2-;&E,<]_W.6A/MXAJYV+/?XH1=_?A:WL$17F.GHZ 7P?(VPZ7;F;IQ>2OPB
M_51)EM2$+KT9?L))6N.E852KK^%:F/THCW/Y61H3.+F521J\C:E<QCU9?>'N
M2$J%;B1 I!>:^?/++-"6K!>)BU9([MJNWM^1V<CQU<*[1)NB@EDNP#;=1=.P
ME\])Q_9+ 4XTN.8Z+(8XM.?C!_<RFA.3_[#'?'(Z&..-$T,4[:XCFWC<JIMK
M:B)"W[#=C?QMGG?1T^&>NRRT/L$WAF6C:[K/5;K;[3:O?;J3/C"I=I(#6-@O
M9,8U:[TE/2G9^6J'J%E:F&"C1C)@@_#"KI>$CV0#=0%SEG(L<D%;/1#YG,6R
M.(5]BV>Z.?NJ>2TD]>O'%-EXHX^.Y2VHT&!N*]2YR'+^CR&ACDGDT]2(<.?$
MH74#LZ\7<_'2]$NF9Y-!SKA<K"JZ&IFMQ6. I 1;5I;8=]%7UZDUP=\K?/%]
M<G52!,/FR55$D)^<E0G1C"AS%R8]XH+ L?&R._&QHO$>;8AL*:[\F')7."9+
M ]0]\LPXVD<2_4]S0C#K?!W(8K2\^=]CC^GN3[[^X;\_C3NM;GMR1[(6P4FZ
MB*1(7>>KDSPLE0=W7<5MF'TW7ENGRM]']N43'TBB!9'/'%HR!I:K>#GXY')'
MR5VZ'UGLVZIG2SWD_DZ3/\G(?2SH.FD6[>%C\4T@U>O#9!=XM1;7\R _.C:6
M=<171RIX^(7#%6Z 8HE%;9>L>1'CEQBZEH2OCF=Y>2=2?KDH:C3TZCI7OLAN
M\N&SE0Y..>OT\'13H9BVC2LYZ!QGIBZ4SKABZ3J+!W4R5$IGNH:/AEWHG18/
M'4<::"3HDW0X=2TS/:)%+Q,:7-ED0VAFDCRAK8.]^">;/U=MG9X19T]FF@BH
M3,N7^N;ZWFD/4(.$Q(+\-3A3?Y9EZ 3O'.8;45_4'V/L%C;/ZK**SNLIT8;X
MOSZ-:W?U/]7N)4%D4',:A\ ?^6EL^AO*-9[NAGM=P4T@:2P29J1.<CGNI6A%
MT:W86,]RN?'_\U>X)LFZ?X-D4O31%8OUFV*Q_GW%8CT2+-;#,;=KUOF(B0_C
MQ:A)^$UHDT?S8R(#@"AP[!F_Q-B0#F$S%<:SND >67G?7.2'(9<D%@DG.3F%
M^+8QM<BTL/.+Z\SY"EU_DSNB,AX?R-*T@,VII-)HE0RUUW6"9[7!MVV#T_0
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M/249OLQ$ZK/YFXR_D_%-I"!U9E6:ZZG>$EP]=%QZ9IU:+GG\A7%/O:I>3'1
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MR:-CNFN[E_@T]@H--]RCSCOZ:?S YSB[KC3 #<8S:NYQ Z>C *A#W&>!TK1
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M&>8O($GP** VH2'GMKENA7.'593"C*QD>=+J0W=<1#%E5DSO,VXEVFP&Y;F
M:4B8!!]S^0!KDMK./0E(*93TE ;VRL$=HB64:F48KC_3;X.7Z[:M;U5@]=54
M#VW7MJ2=)_O^)_]<BL5PS^>^S/-O,G*FMZ!?Z0+OVBKI FRZ-IY= [/*9LC(
MJKG2[T'!@%BB.#S0K>\0RL) =79;AV=FR.P2) 6>77QN8N&P98LO4IZ*-\$#
M'4OA5*"P A.XO(VB'='8?S\>E6#$'_VTT!4I$UN6J-0[B2%F>AQ]Z%OC)R:6
M@-^:A&3'DK7C/(OH/6]^3HHJ*G$SMB*H/C-)*$%GYVS"]#\NY30,'*)_(^B0
MPHEB!C),<AE9/DYEO*_UXG)F_6;I$O=EF\&4V]Q7$$1SW=7N>1&]E'!*S+*!
M@:M=U>W&(Q^;?:%C5TK7DLMMEX,_>1,]6N,D>F4@3J@FDY!P^C2S=^CG9>![
M(<0QDI0D0K7MJKU4#L$\1,%4=>17?#/&A3)*HH?N'4 NDBN+%E<M14Y=F#R'
M_W96492HGB.P='CQ?_<VXA-O3H\]?$@#I4 :@0/_8N8D0*FC+\0%$HUG;-$'
M.W.^@Z%A",<=QCI/*AQ#MSNV+6Q%;@2/,V?FG/,,N8BG<-[+#YP[HAJW@A^;
MUZ(<UZ;6)<IB"I>XO<:.V_X2&QW$J2UD'MF?Q,KBB>HN!$\4W]TQWAOSZM9!
M./"-;,AFS%OLIX%<)D)\S5&%A\J-=8<CM_$=ZRLI2DGJS3632?!I1 *=K??H
M%2=;L%T*9&#BHF, V$\'DO,N@*OWSU\ "Q]!O!"%FA@_<! 0MYK2;;6=9S_B
M-R^QDZC'3@+<-,2DYRR_GZR )/T)#AJRO]"U>6OPC^% $%BKA;^>]F!J+UU'
MKXUKOG1.$2F0P+CW8[.G>6%G0/<G.JAHQ(-&%QM?K"@#8THM7/4P]J%W,?NH
M2 \]!^EC=\%)->QN6JJQ@)V;B)V02MS9U9U\N5Q'?O[BF'M6<XLF1<[B2C:,
M795"VDK )0-+A[Z$*Q6.)/_Y,]BMF3V![3X;N$Y: #FG\= ZCG(>FB'.1=%%
M35KP*3>#V.0!=U<DK@*#Z+>'8O)R'$U<V7%-*=FGDVSWW\%"Y1P7DS=>]2XT
M!4L:,] ZR<N<P]L=9HKU9'(G/5E^75GKG9TP'_S)\/S@VS<9H9\8KDD6N& Q
MR5L@7.PM;*K29N8Y$*$*/!+#K^A'(Y-R*3=]M719GUZ@\">R#8E,RHQ:Z1%B
M<!><^<*"5A02C?R$DT"+E2SXZ?<DISHJUD%$+WV5/+@<2-5RA6*0&I,\:N'?
MF+GIBE2?"]Y*AO=)X5&\9=E^\5P1\;M;=]$L;L=/@!.5TDB"3Y/>=\K6)J3%
M$R+S>_S@O2)-0L(NI9(\!X2;E8 2YR875UP$ZK]]N+"TS-I86 "RR+.^,K3]
M=EBD+U<LTON'17KW38QI.S73>*%J51)H,9'GO[N72H0U64.5VZAHA4Q"W!O6
MH8W13]5(U3QU7[N H)5U3^P2@Y>IR\&8V8G"7I^.E3UQ7 S,TYK4FN)3@2:T
M31(%3F<%)I^*B,PYI\HN5"^1UBV_A>JVJC$2T*!E&.U0;N_)QLD?4CC:'JN=
MFY@N<@G5'5<6*AP,;_#.F1]["*26&Z/4AAXN/8PJ&1$Y7\SER^:E"F@A\5%%
M&EHV+\1*10!( ]]6+.^>6IA[*;'#/K+#!M2JM/:%7;=L4B*(9^R'#S]!?\XG
M);HHR,EB=GQDKECA0#2R82TX$7%KNZV%/S85Q;8(G7=AAB/C ,#"AL2N1J=J
M1F=D/3!42'S;!ID9!X8<L^  874*:N@:6YEPX*:HCAZMF/^,ZYO%Q+-M/#T
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M0P5J(HRM9X)TK13\=:2M++]1E[P;#I /,XVO%&W5X9KB'8!)XBZAZ"9>'_6
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M5:BB-V:W892J-M&8K/K^*4&#"*$AR@33 $L5'!]UKQ.C)?/PKSKFTSV3TYB
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MQA++M,^I""8TP-H(1[%I!:."$U8.H+0$;5B)"I^LD2RK=)F;Y2$F!WI[Z1
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MC?)^CLF6W&,GV61[3\ASVXP.,D) J.F>3ZV81YV[*RRJ2<4P;],R)$9WYVZ
M*F8@FQ#'C9%HB 9"M@9.(-$4/VQ\Q=;IX;<2X">B?F$"^"%S'9>$1*!V"Y-!
MD#$A8.%;AY$0LT> ]AB1#%(&=<X68/BAKO- N$NFG C*-T@_C[[H5'PQ S,<
M[.,.>A(@38>KR4S(IN49.$&R!$&P!"Q,W*OF0F,2GTH6P6I'?/6P;KCAJ95!
M]XB[=/ U7[M#[8=X0F$A3XQI\+@#R@E@MY"\D/0^83'8B:Y[X<Q,F_.#.1I(
M:;?PI%49/\'@II3!M"VX3/^-Q-J0S\"14C0H(2425%<WRRXC5LQPD^ =]F\A
M$,$U0J9=&@3VL]WA7N[*59#3K"_N"FE?M)#VY*Z0]CLII+V0B4HT"P=5C(L9
MJ+W%*0G+3>).-;1^$+&F3]Z'%O\Z^RL6,%+.$-Q0?P5Q.75V=HD:E8C;4?[.
M.I?& .A'V;(BC'U(4V#&:T:8$1_BI-_%JM[@<<@ML/B@,%WIJS(VY;2"0<Q5
M;T ;?A &-DD2RXYI8(V821L[:IG;Y,K0E+HUNJR:I>;#8[@:;X^6W8ZSUP8W
MVH>3<P<A27)+_1@M3&KT >1\OP08M:L&Z"#NS>2V5B)6[FF*! V>YI?SV WF
M1-F$<[6*GJ"\[N,T9L<R>UB>/O<CL6$NA2%Y>+F(%,-?&EX;B"Y\,SKU86(W
MR!"R2)U%DF^6).+&YZ6YO=-V<8*KAQ-S)#VM77I2O31-N)+46KF-A2P*<7GE
M/#<MMV9Z9/1?1+\2 ;?V'TK.$\'4OT\6[[4E-B!(,JW!.KU<>T?2=Y6U,4.H
MN/IWXX-4UM_B=--H'Z< -L[';*7%F!K^K@0VR,,6 _Y5V0%4'DNFLJ/>,,OG
M']4!@F!G%3X*UL:MWC6X3#V&+.,^=V5R:C:I9PLI@D'H2JOM;<Y%7PB70S ,
M(O>Q^J5L!E ,)TF@#;>Y%"\8*\*ZQK=Q5PARF]K%"_JYX[E_86.69VCK?(:G
M;R)]-@IO\Z/;"\(,B*O^"7!L"IO0\HBTH=_X _3=Y/LW3EUWV1O/A/?7C;M2
M=E:L*\BEOM":RVW(V6A6"Y'SPJ[-;1G38DVG5#BC(,'BSE?MNS3>EUN>V5-=
M"K&4M$YI48VIWPAI_:V:(DEJ>OJ!E=3=.(68Y,S_G?&U_+WDBI;=G14RI:I_
M8^J ?5FL:!O8&R8K#_MDBIR^9BP)9_1:P]8W_3R-I8 T!3^)\'+()T-29+O;
MALK+V61B@>%,$)CNJF?L/IAD+-N*F:C:<!X%<EY$)N8*T$#+JKPL/8*#Y4$H
MXWGL,#ZU>]4EC'RE!@R<J1M)F/,EL:V10$RX? OGHK@U[]Y7: 8[3$^ ]Y$;
M;A7W;VCIAG_HFD1 *+/X0910=#1WT5-[N$,FNMJPG6 Z#]I,S#41.WT)\ F(
M$:*613JPD$'9H#G;T>F"^VN:$>,N#__2X0'?M>T@<!"#@2V"-ONR92NBPU6E
MS5'R4.A'0OC!L/'(=_="N.-)UXMM5SF3QFQT=GXKNWU$&3MMG9<,YK6B6F[-
MAC5>PW (XKX/^K+IX6F0WI$K8 "#-T-2<P(]3,O8F?4@/HI2+2&+UZ<FTC$0
M%]_F8Y<Y6 ,?S#;M15$S:U.2,"88O #GH.7<+!T,K>SI0YE9@?-&@/<DUC/G
M_C17_8(#>];[F+PNV\MJ6G81%B4P*]!2[3[3[F5>$JR7@ F*W29R;:CMB/R=
M]%3MFVX]U+ZCX"^K]V#FZY(<&Z-I#.D3'1S#'0FWDXTY0W&CX)?+!<8IT*0%
MY\Y10TK&GD7@MMCE4U3<&'1.=_81:KM12D&+3S/FQI"FH#P<[E8Y"TIG 0;7
M&B>Y61X8#*+ X_(UZ^.PU=DY&3.,HQ M"WCX<DJT[ ].\NS^O?L/<Z'O?O P
M VPDH8,# )RGO+W_./V9(GGMK^."64AZA=PV**V3)8.G.F)41<@#MTFWI=2.
M2#=282LE_RKE*)Z4[4JMB?6#B:#!.UQYI(<D7^DG>(&'!=P^06W-Y#6ZS1IK
M/UAG9SD0=0GWTM-J"*WH_M')S?EK 2#$"<K/&+.Q;M;4T+]_P0-([%]4"OB/
MK^Y]E4&*?0W[7%_HS]VZF,K/08T%JP4?<72_^OZ/?_CC'_[P73]I9MOOO^M;
M]S/\.(LN^SAXT'X6?PS2C7"$. G?-^MO@V_BQS_;\CUY],T36C^XS7Z/M^N9
M?JV^\PG;Y39RE,F; H"_QT\KU@;-0P^(UBB"]/["X#7=?V'3_NC^2WOX9Y2@
M.U&Z':)DM)?WYJ3OV:@Y2<WY_F)T.RH$%GBS@'E*[*4FK'B]694MZ#Z]>%<Y
M2WHG9;\O*5/*!U\/RYEK?>(G$G3%LB0VV<+]94.L$$SWRJP.PY&,T(#LU)ZS
M[IC-NA.LWY5@6=U3 9'/9>2)84+(<D_GF?/VA .19I_;]+LGZO7%C6:)$;VX
MLN)6<AZ>1Q<<?X3DW=A RS,Z^UFX@3/"Y@3]9^,!BW<_$Z9880$Q#K/-"OS.
MJAK@FSVG:.-L)ROZJ0OW^8.O.>H\D_#T-@3RE")YMP@:>'XY4;PP]8!:@%9=
MDX#&L<*+JKS$SB5&6!,[,CC$)J<203 O:,ZPHN/,E^"O&+GV82X1P7.;VU,&
MD5ZK_=KSJRY4$>P+<*\O3#G%<E4BEX[<9;(%N.Z)C5H!C-+GFG/-).=9..-\
MBVEO95A%2D:B26FYH<X7M6UV=KX1P#27UM]AOS5DNT$0AX\$&==@:89K8A /
ML5":MH\YMR=JA2CGUZ6.YKNLP9VO]'%.N!,>2J21#C5:3,.S$GY53+?LD,_+
M?OLQP=H="OA+H( ?WKM# ?_V4,!W.O+FZTCEJUZ6X@9BAZC,0(1R&_?6(7""
M,F0?E<^Z,]=WHKC/$R'\IE#RX*L"I[AWF)*@+B?&0+![J81\$O!DRP(@.?7%
MG73>2>>G3[QU_9'6!S!G@]5:BQ/#P44Z< @8I>^$\4X8/Y/5'DC>TKG6-8$&
M>I@CA?G<5=DOFIF?C]IM</9WN\^7[B3W3G(_A^2&6E132MK 9\MD5GX%K"(<
M@.P'?&P9[$Y4[T1U/XL/3#D7):=MJ]4$$+<T):595M09- \:AHBQ),K!ZO1U
MHDGP0^,D2\H=B#3;(I$6QJYZR<J+KXNH:WG"R9; L70)!7B%#XW W>AIW>>Z
MZFBDY\GPK04O]+NH_/' 8,\0Y[L  \$86^PX)[ZC9(, .:R8''$Y!54AFW9E
MA^*6,*XCZ"28NO&%72]<T,$ZK=98<..,?:0V)1&O?8A(-=A1J'5K2C< 8HQV
M@*#_/GKT+1A!V2;@;]VS]&-J&[ETM^32T23GO]&F/Q8CS+/LE"1J_./;D3KB
M6JKX;)Y%S ]#C0Z\4R2+TCE\"SK&'O7$(I,@;P'A"/@K7V"K24NB3S\ E;(4
ME_CZ4F.2-I59AM]9+XM=;0 OK2 SY<T%$P(7?:"'_-*U8\LV7 [?@U' &$4S
M"3>4#'/2L9^=AQ+0@"!:$EM)D&/E=L+6:X&@6\<+P%_=+6KIZ:"91L204J?P
MU$ 1<[V209IA&)G$W+V6YMC4YR9;WAC:!:(2;CN9]T0Z9%-7P+F976?UMER2
M2]BY%*?+M]E"V,U$2!+?Q,EP.-S22]CU#X)L=GWOQX4#Q8U^39YV\.V6N&9.
M&>D-;1JY_]JLG%:>GYOKE-BO%717E=.F;J#%!1MMBG;&V&;GO!++ ^S%K-T8
MYH.K12GC@3NPCZ3+H0'<K5"+9 .HU8LU4LC:V(Q9NEMD)Q#.))A+!D1.*N&>
M%%3?!F8""D?01YBDWDQ/3"P>D[<E\.3((&&-#(-U,;YLO.SQ+%0_7X:+V+0*
M,&8&=O6 9HA.&Z;<4S;"&7!6]I5[Y^Z0UEW;J>85SC[5/,P6N^@B;+\Y#FV)
M8L]C=Q#[!*?4?*);,Y^([Q&TJCMX6Z5IKPAD/%U@TQ_\_@*&C &O8VR'Y4N7
MS7*S0HR\.Y5X8:(* %4(]%3'V6MY20(D<4<!3^3>ST*Y;]'D2B\@O"FSQ%&!
M07-F=VFV34B"@" Q'D:#;//=S9_^]VH'AV;.:91/@-8)H!#8'4H-MLTHZ6S
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M(5->;R";M2$ %[ O29X.[]!N+A+Y.*V\^-SB!K*"X@RY;XA>!O&*>O@]=@B
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ME=M0B-5NXMGR<,-!XJDKM;FT(:]2_Q@&HZ-Y;$[=R (."TB:'_C?WNO%98<
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M_.8TVM&M.I+^,0VLR25*^XZ^SRT'M816WD2G@3&!E1S$>(KA3K>2<&@G]1_
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M94W2NS/@O(.V5^JB%9"W;=;BS@:<[E9YZ,2)*&##._(L<0CY+/% ]#K9@7
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M1IYK4V0<&$'%U0QL$ZD&8,03!01&TW#32#M 95-J;KV%38-!J7,[*@8-<"*
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MXI)D&JJ@@'ZENYXPNW,N$4<E.,QH"GMYX8=;"KGIFI6(WW)VV\^=]NX1Z'F
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M#3XX4^&XU$HS]A$0/2T J._ND#OH3) !Z\:(F]&ER[;NX6Q_;NX>O(S-3&H
M_FGGGD;^4V5+E7KD?"ILUQ*%0U:'1.[Y;F!&F66C5&%.>QOJTP_OL3*GK#]9
MVC\,3'^?&@T523BO..NZR NMB]RLZR)O2%WDW[HG?WG_23T7B^JB CMS1EX"
M^.:;ZA.^\JFUY?FD<9902KC5S^U"3^Y"UBW=X7[JDW-)^3% &GT8AC-1J>*Q
M3-Z=UL13'7Q0\M*794]LG[N5X*NH!Y<+HM3S9=LXV0V+; E>9USGMM:YK:N6
M-?("8?3&^45U<MB<D\-*\V^K-\TZ\[$F[M<1MU5MZJXS-#<VUIQ'-^Q'.0/
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MX[1I"(OCW*)]<9?WXG&TUM4^Y&5+_*>RK6>\70+"Q'%!EN-9*5M)JL5,?U.
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M?_Q;R,"7=A_F"5(9M<"711O6,-?,:)A!\I+4;%IQ9EGVD/[9@"%BV6_L'#7
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MEH& Z,;&BP*P-AB+,KQO@:<Y/8&7:%,%"UJB5$UTM3O@.Y-)%/J<MY>M0&=
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MKNA[/:^^6+KZN?G;$X34S"T.OHG$\0+A7CA1X 6WL4$VYTPUL\DE*X:=@Y\
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MA#WJ"&8]1CU&Y<:HD(38!.ODM^[)=3H:^0*34QW?<D%#^6&<1EP41A7+LKR
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M)E$;K]UZ_A]X0JVK"F3PV@UX@@DI*] #"_5^$/K^HQ7> QJRXK0;>ZX'KT2
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M%AWZ=R!R/CJ>C]80B3CZ+/]M5/>\0V3HHZ$*)PE&A_,8ERY#<I*LL$DN/P]
M0 _>P+X"$/0]A_UGV8XPK6G^1>_+D 6?=)B,@4Z%PS)8J,"#0!H'N>;WI2F]
MOTA[QGOXE8"-*T[>+DODXTUYVD1)EDCAV4%_)PKOQS_L 9*PGD\_>7'&23.?
ML+'"^2?3;^/-U[._O.!'><I*[A^*P"ER*1!/>3KV&+5.F5DH2:NX1I-XBY-Y
M$\L<35DPLM(HDU[ S)GAF(ZD,6?(-I0Q9MQ "FB*CULRX9!UBG9A%2Q]?!%J
M0'R +?#QH$,I+,!G2.*Q*S\_IJVL1#4'&7V0ZT.M%* X1^Q)F9,JP@ J#>%,
M(&_P*B6M%UL2HB@LU?> (]$@4#,CL1LC]3VU1M+%^3?)F1GZ+$NWQT!#RO@U
MTXLK[QPZI7T^!ZT.9DQDM9L*-2D@#=HKI19J '5BAH$_ER?9-O=FK0OT3;!O
M\<*)L%YE?-H#DY#CH.<"[;NL8NK^2QIN&153#UJ[X_?1P*8 DQ&S"SQRO9)Q
M@%$/6E2 OI<&H ))V!AALMC+5+Y?>JL<;"]'&_;4=LVI*0K?3/H+!GOM)K6?
MW",V#K']+?J?U,UZZ87G8':^ <]3:Y_';88)_32^JJF4]-.8<6-:1[O-B1M#
M:(U]3$5D301!&5$8Z"&GI]XGR4Y@O7AHG8.E "A/()XUI:846AC.!7'+@@Z?
M[@O\'68 X!  0=:S&$[I/?H!PD<',:;^7(>.9=@8AD0@BFX)+=F4 0/3)V-1
M5_C)>  !:RP$!V-ICD3YV?+ED@V_S]B288GWIBU5"(236R.+RW.4D0-8,IIL
M&I2F36<_)>YWK:=%'?E2NN1]1.*V2^K=Z:P*6CY ZS1ZEM /YU@K[31PK]%W
M>".BX:6.M,](W2=[1[OC'5D54=MDWU*T5N93/;'&HY>ND1*5_L4#R'RM61>Q
MMSM>0RI;!.$ S!Q#KZ&(8IEM1\?*$&7"FEIE]72G.C=JCR>'NZ!A9EW:_E-"
M9]5QQU="=JKE>@R,V\M*M@Q 1'0Q=H!JE)PBPC7R7#S9?)#BE'R2&3,"G_O)
M #UX&L(H)S)E(,!;)9KNI^3^8LQ'0C7#>@/R 8Z_'8;L"W1J<0 %'5]QSD,A
M(Z99:(1D!>)QD%VA#G*3Z)2I#/ ?^VPP^Y'2&D$J>@Q^M2"D&!(ZVM ;/0IC
M3@K#*@^P!T"I(465M80R@Q045_%"E/XK3S:&JC7W&7U<.3UK)BHY.JJA/#:X
ML]I!1_E5IO[) (SRL*-+1;K'I,F24U#D"C9U4OX-^=P\<RAEA4W.PL)\IW$X
MH+\7VS)\%GKP.@Z5PSP?56!*6D8NOB>74A6#@#*!"]&:=.2_6/W)$$4YH,#P
M'2K5#$T4L[B ID',6LT6>B*3@<'H9*8!DYL,KV-PS]Q_XACN$-W#C!V\H4R&
M##.KNR]#3?)<&2H11;$1;E%."QZ BB]D'G_Y0GRWX37%EZM<R5(S/7N!N>?C
M7D,B-[G^@@>5';Z9F[?@3-5!PV/Z465*75THURHYZK6_6*<\J>FK.9G3EX&&
MF!_FY!!>KUPK3;$LQ)EYO.4>XI[F1!L'F;0YGN%%I,T@EEF;['OE=-4)*8EX
MFK$%7.U[*O9[GW.D,JW+W7U.=J.@);D"U$JHLS 2SC!+<E0 WK8HT8*Y#&3S
MN#BF,)WCQ2:XXNCJ74@)K+OKDH^N(5%V7&#9(T?"VJ^ ?7MEJ>FMYN)2T]LO
M3DV_3H?P$H*.QK*L;%V66ECVYH4IW=<?57:U#6B55O)8/*##3N.@U=D_:APV
M#O8.VHLX+%T9XX@/SCNA2V*$%\T) \^L_ 4!4EO_/WO?VMPV<JS]^>RO0"G9
MQ*X"M21X]_JHBKK8\;NVI9+E39U/*8@8BHA)@ $(R<RO?[M[9G A 8JB>!F0
MDTIBB2(PM[Y/]]/IFM]G59W,1^+15P(-P5 !#VM*(T3*4G*!BVNZS%@,\Z*N
MRK-%7>:*55V]T2@CM^D.2Q9C49YC^K[NWA[Q^SY^(X]6.QNAPK7%Y5;FW/<H
M,5]9K?,A\OI<IUR0FNK/\IFNUK"L1K?6[32Z5K6!B$;[X+IDMD*K]F>'PG+9
MFPX':-\.T#[@QN+"LC&(Y>(M_X27J?+JO-@12QE(^#EEOXR(F].4;F;RH!(+
M 7_%^6+>4\9TRIB?0Y;,!L8!3Q+31_K"?!0&+K$]O)=R"J19&3\&?,23CKCE
M1'9W7BMUD904HA$E XG4=SU5@ D<;G 8C,3)7=PVO]^/R 3$I EQ&\\-,=O
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MB86K2FYJGYN0F7.'R*FM[S]X=#-HBT &5IB?&JDH-)D*R:,"]B$5&4'U;KO
M/Z8,#L6WS',)'WY@Y*ZFU$KW,YP"X^V8BY(NK6:SW6I5Z\UJI]EJ[RDIFL_P
M$#3J/U/= 'B.#+ #]@1@4NW9A/S!D*ACM+T$X'^,:5>VO%YBU @2(WR\ U:<
M)R!>@9AT/OJ7=IC*'4CP+?%NG>+?\I$8+AC(@)*B$2V%X!>PE?TIF*TY;XN3
M"G *],5"&8T_T_:@?<M?)+[&.U?$[0#XW^)6$O$S><LQQ9UB*+HA5F!T.Z,R
M4"V*AHDIO#4^Q%QFT=R?R1''AD\8(7XCS/3;Z^_"&G\KA":EO,X]FDG&\R1\
M7)%^S9\=C"1&2-72TLE1DSF$CJ=S3I>!\N_+:BK^'G),\B:9CBG'0W"@D7CZ
M<6H\?R0!TPLX3$=L/M#?>7"[>"'+MRI.*!&B/;Y7B*]/O92,GIN0M 13B^:S
MX;\[/N.WRP(>6R@6Q*.8&J)Q'#9H2;RZD=W_0?IO#A[(YK%] 3@4=X9)[LQ3
MV421)S&N!'QJJ@\=OX/.5+3))Z7)*T*"O' P/E0>S$_NFRL\'Y,2NJ2A%F?K
MB:)#N5+"ENU36E5<S,R9GX,5QC:T /SDJA1F>^\'@?]$@$#QQ5KQ.8MH0IBP
M,L8M'V7CTCD&QSN_B20V$CZ$+,,EI6QK0,_\GCI=;DM0N70F+9([W;ZX"")#
MB><6(-*XCP<R2]H6I%%MV$\\F9!QB2)?\-R43HW/:5$V9YU0R6'6<^$UAWGD
M6G;]UDM=P)&NNI^!B)*M[(CT@1#BVUG![I7$R"6SC.K@ ]GP2YX4MW4SL1VQ
M=6/?B7-(L<9]\=.XGH9J;U/Y=*(A09QRF'D(N$J"%XS(5)KKML"E,%[?AES[
MI54)/A57."0*F4::$UPQ!C[?( 1<FK*D!I<Z@]@C0C+%JX%8#A1,!<P%N@5^
M^3Z8@D]$@$PZ'2)I%VQ'K)CR\,H^)!C?)\$ 93:";P747<]S+A-,KRO.RYFR
MAV:GWFS4JM5:M=6IM?>$,G);A,Q'1LXAV,B%*XQ1>G*SZ!#T-\XM07D=\(8H
MP2.RC-#YV)TP-A:7-B/Y/85B*%J-B'>E_Y2>7B*7LKUKZ&!^QX9 J-D-+PK(
M;$K>1C=X]CU64B! HF@9>VK<_LT>3WZ_Y"_@R2H2S CMX/D>L[]GMR#3<&6Q
M W*FN^YB%Q8QV7A:KC _YIKRBL:/J8A3=B31\8;VC%;!.\;[HMFB$42\5(7>
M0YVS9'0I 08@.2A@XTBC4G+AU*7FA''B'O=:6#^2D<7Y5@ (M4C#B[$()A (
MP@>!-N*SR[0L B./ SK=@UDWH+(WVG5T_2GUNG(OHIYC)$LN7@6)IH']YL8H
MO8K'$@1JCE8,$LJ/6O2<0XN(FV R4$<&X# :8X.B>9A#Q/%D =YI\,!.]@NI
MEC[X35LTT"9#^]^(\HD@MF1Q\!K#$,4$SWE#)T7"!CW#^AADA>_'"R$\B"E1
M930IF%' X@LD,F$RI#B5F).&_1 PT8GJ2DJS.2(6RY>(GGD[%&?<BVJ=3.V2
MS0N(P3GP*8T@:?"$$?:XNAE>S9LT);T2?6Z38?)_SAK-U=HW"<'!.W/)X "=
M S^3N5Y=<ZO%#> +%9CF0YYA;:=%&$M56PJ_,6G;CL:/.\+Z H,:-/Z7\3 )
MG">"G6!>&BAMWE5D!J0S)D(5@0=IUE/>X=@-0XDG*A]9.)"X5ZV(0J2SP B#
M;\HI7^+D^J(CDNC^*]V^)VD*"P3=J9]N;!2G(^&%26K#R.L7O>'2*=*)-2?%
MF8FA502-$<DF,4:SC/3@FW,Q4^>_E>J^)C58FF.3#EX)/I;$BT;K-O*$)1HF
M]FT^M5W<7G.26NCW)@0 >7Q\=I*JJ>Y,;J+)72_1*QDE [E=H<_I*1Z5)8R8
M9!8*+B(6R0@DVNV<&?-4]AG_.\R=+F;F9S[?J5B,PL6,"$_+SI,4W(E%73K<
MS3V2J1W^X.(@86$!.I8S/006X((B:U6(067[:>KM]4BP/915.R=]S*SAD5$
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M$21U;14<&1OE)<J^O!)@SQ&-;KMMUJW]!0[78Z/5,P5+BA0(\^AQM%;8G)O
M]_Q(-+H5V/CYT(&=MM5JUJI@)%2K5EX.T&Y:BN)]'351]B=4;!BO!*$N4TLY
M!$3!3UZ2Z 'G6>>8T!]ZW\XE>E_OVW?CJW]*?ZU4NZ;Q:4S=2S@<_M0W$M1-
MX](-^R,_)%1XV1\>GQ?/RC[QIT;J0PZ+-^5M(Q 5C[\^#9[II%Z;=#21C=28
M-T2,42?U-0Q9I9ZGKKX(QNIA7SN.P>9BLSM3E(V$]L,#(J!+=#;Q[!M,YGO+
MNR4B%[A>1+F",9"KF0/Q:;P1W5K>TLLSF*#8C=2D-,'TDNYGQH YV-[#Y*#
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M@P>:>>WI5]+6&^>!LM50*:2+#[Z&)?Y?K9,J:%G,*CEP7?TL]]>!^QT_PG#
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M =Z#CV]VO4<?.=?$1,D1YG6B<6 _V,#_,!/7PW3,:>3,?IL$/N9TQD\8,+^
MX6I@[&@"3_5AY!&C%\ (L4S@W ^//[KPU5-#DA4MG?*8W(%+37.,/K<?\-7
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M80,5<XNP8G.3T)@00Z6$WRNLV:UMIM *?B ^PN_53N3A=Y8:K0L(;IQ?2\^
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MVDC0!6T+ZAW=MF!'%O'A><-[;UN@(EAVNA^!L4N\=4T&*I/!S@#4=1L*W5!
M]88"O;$?(6J'0BT%--V4@&YN6-!GFG TX6B!H^GF6 7.\5WFR&A!T]IS\QML
M'&[<4X=P?;WS3&2ZN_M"D*+6\8V\2I#UKF.4;!U?M\QV72F0_[<'&>C(T9X;
MINI]+TV+J7V*J;Q2D/4NQI044U;#;-24ZJ6CQ51YEJ:0V:NS'/48>@P]AAY#
MCU&B,132H,>0!1RG),E$I"0U*=!0-VIY7GEUQFOGZV83KPHR%7NRR^,W2169
MY*W7^EH-LUNK*>]J:3K?*2).X\5UJ3=1P.;I?)5LPU6INV*M3-[6R5FM>;J_
M1-V<;?Y5'2([?)HNE-V;J"152G;7S59K?]V/M.Q64W;GE10M)7,MNU>2W0IY
M18</<9;RBB:!_^@"U8%C9'N.,4)@O?2ENO:1%-.S>65;&_*1\M$56;A>.5=&
MDS:4DCI:DRJ@25\,][ZN)GV6K%^@0NN@0FNG2KGTVOU102QO O5]!V(YDPA@
MMFM=E2A9B^7]B^5F'MSX5AR<8Q'+"GDVQW#?(_!%>48PD6&H_1=U%&5S<TG
M"XIR'EH69<ZE"S2 ?51=E!BO4YAM];/F-#GO5EN^&#9\76VY,FV_3&M63Y4*
M<6M?1@&:W@3:]TXE]%FMKA(1JT9:AT_)A<9&WDW[5IR9[8CGQ/2HJN7<O%71
MNSF&>YNO\!W[)R%#^0%\QW.8$P$YX <NUHP<-,2-'D./H<?08^@Q=+;Z(>KW
MW(:L0SM@E7L[9(@A,L8$.+(X=5!3'8\Y+_=Q0S'-KVD33^0_$DF<(T5<I CB
MPE^W-OBL66NJY%VH1FF'3]B%#O2+$=37=:#7I/,UW>G::4LE@G^KXYX*2/&-
M J+O08I;;1T&56<XE:1X7JK=5L*@NY;B.BBJ@Z*%3I/AAF%D>WT&Q!_J+!"E
M)%)>NN2J'I,SMOOOEB66X>%_$F>/<N;5F9*UALZ35&(X=:S%5EZ>Y,J>$9'P
M2DF2Q;3\TD0/I5Q\[? H((5;>;EXJWH\NY?"ZD-K:@+>K0Q^,5+COF6P4OZ*
MBN[*<=[Q7$^'+-#^B4*:<8M(1'DQ$B* 5X,-J21<M'Y40#_N#&CH>9I^@::L
MD*I4JF#\N-V5[>UL#J,44_,6$89>+),'[D_F5/[+ G^><O_VEXY5LWY7B7I5
MHZGC%<@[0P\Z&H&LD.]R^%<M)V<70]M[@'>[GO%HCR*B-</&YM#H'&L71AU1
MLT6<($X$G[Q+-F!!P!SX0B\,V33\4Y)$3U+$FJD,'=/J*A4K48W0#I^N"UWS
MG>$&K4/F:V8R6,U3I7)W=$*:"B)\BYA"VQ?A+;-65XJF52.TPZ?K(A'>WAG&
MT&Y%N%(6BY+9:#N[WME^H=3>N@NOW,?WN*:RM^/0=*#45#0=:#K0=*#IX"7'
MH9"%= Q!Y%Y_&F51YO?3NGV!-NK/L.I.3/=YYH%)&8X?(<++'/<HU5!Y]6D7
M>84;18;,MHI9MZ).H913)8A5A3FL3&?JA416GWMAZ&2+@)-Y7<H/"K>L@'QW
M%NQ6@GVTOI&LM%&<R]?KF\;)65VA' LEB%6%.1RWOMDB@J;6-\+O_ 7^O?>=
M&<X4H1W/?I%K^!J-8;#^V2^_Y+MJ?Y^;Z=]_3V9%D\JX8\(;$\Y8-E ^*1QC
M;H@7C] +C>F0&7Y\QH8_H$\0#L#V9@:6:D\"YOACUX.7C&9(<9B[QASX'KC(
M#T/#G89&TK/,1E150L."Y\W,RX9VB"_#KSCT!]G$S*"M-:(0#H0_,=\8.OXF
MS"^7';KMU8">_A63>2^:#OW G<Z^ C_T?KIAA4:U;]DC\R+6>V!>?_:%C>\Q
M,4_9EH$+'/7KZ3*"V3!1PMCL9W\4.>SLO>,^&OV1'<+,;CZ>_W$RS\[5ZJ]Y
M?"@^(7E+'YT BV7>]>'N-GY96D3W@=!8\+N1&F#NV>&@$OA/BQ_VV6ADW'S\
M^OW+TA?G!U"D.)KGO9.S;N/];S 0BHCT/[^\'\:AJYO>QZO*^>U5[X]*[\/=
MU>T[PQX]V;-0J@,,RW@LLZ;?C2'CFV.!B#)$0.HO5?I/7JQ*_.GDM_F-_,=E
M_D;B::R]C7?7%Y]=[T="&#D[P/_Y_^U=>6_;2);_>_=3%-*8A3V0%9&ZTQD#
MCH^,.X<]MC.]B\5B4*)*%CL4J6:1=C2??M^K*AZ2*%EV2)F4:H#I6!*/.M[[
MO?N5(-6(7!:()]O9M42M&^)\1@([SC%-O(N#*01>[\:(GGB$XQ0P##$1-A?0
M$4!LJ*+>B&SP#L190,>1AR%O_FZ[+)P(L\WLUWGTN[7&;!@Z[&JT%,G'$X1L
M.@ ,#&S&[Q#D[^#I'QS/^OXF5F, N!F@WQ2IT@\9TIF4!Y(E_O8&4Q* U)3$
MCC_S*;7BSY(H1[8KWA*3N5*R@#,<.N5 )M%?"RRVGM6?H7G,51 VA$X!2@3J
M-U*+"/S46/_.*,[HS;8<VY4.ZF>^ [83R #TR\[32+X5-7YE.&6K/OVL-9CW
M\[\?')\Q2V@WI&G4WK\='&^C/?FS0SZ:60I@%E,SRW.9!>5?J9A$4TTUJ*95
M*JHI431]2_F&D9[7!37O52/K9RF-'W1]U(_)@9.HQX?O]/D@^AWZ'9N_HT1@
MMONI0?.6K=&;JB./CL!RMP/J$,<#3./$HKYO \J-//^1^L/=+CO-2NY?%XDU
MS-)4,'47:O7LC?-XEMP\*D3DWG\&$CB%_9^IS7]A6[GC5J/6-$K5!;YL%4.:
MB"41]S.(>*/D@(*)&!,&S)K9*E'20(FEY[YUEE/2\X9Q1GUK3*@[!.)Y8(XW
MG6!\0*3<#NT@])ENC5TBN.DU<I.9E^ZU[UF,\X@(3MSA64("+^W-8'3+"S@E
M(*7]I5PC-T&YAY1;(E&YIX;F-0W@(Q>2TM,=64L&+N9SQ:+H[[R$+( KH(0'
M,[79@"LO[KT*^G>K4V+ENP3TL[_DVGRN+"R<7-OH\R@QN99( .ZIK:B/FJT
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MAI4/LT7L$6><PH?KB 1N) 7<>:=R_Z_%]B\=>9H!:\NO6WS9Z9BZ]^S2/9D
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M)_+HA<XP/15;/$7T(,^< +PEF< !Y3AX&"[S)W@'4+3MXE/<:/@X^H/[P]3
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M5M5AJZ=A:U&5:A25.5XL;,6VATP>-+H:MU9&V#1N51VW^AJWEDS O-6M9[O
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M[FX6OAN/CGSO<?E+K.@D3^M-SU>5FO.:QH+> 7\HO7,<3)SC_P=02P,$%
M  @ 3XQ^7$CMG;X]5P$ ]FT! !4   !E87)L>61E;&EV97)Y;6]R="YJ<&>D
MNFE0DTL;+1J<4 $1D7G(I\@\J<P8R!8W("!$""3,$1"91$!  H9$F6>VRJ H
ML!D"A!#"/ E$2( M*/.,"$F4&4D4\-T0PN$[Y]2Y?^Z/6_?T6UW55=UO5ZWN
MYWG66E5].'VX"#IO:69A!N+AX0'=._I AW20FBG:[P$(9&T-4@&!0*>/YJZ!
MCAV-SAYUR:,.,G_L[?THU#<H#'0X![KUWW__K]I_-_F_W8/G\ -(Z#3/@V,6
MQWDN@XX)\1P7XCFD@< @$,_)_[4 ]+\;S['C)TZ>XCU]YBS?T8+&\Z!C/,>/
M'SMQ_.3)$R>.9J./YD$GA$Y>N'3MYBEA6P_>RR$7KS]_471:SJ2V2\1NA'5%
MR_-QS)FSHF+B$I+R"HI*RBK:.KIZ^@:&M_XT-3._;6$)MW= (!V=G+WN>S_P
M\?7S#PT+?Q*!CHR*C8M/2$Q*3GGY*BL[)_?UF[SBDE)\67D%H;*NOJ&QJ;FE
MM:V;2NOI[?OG8__HV/C$Y-3TS"R=P?SV?6EY976-_?/7]L[N;^#?O?_BX@$=
M_S_0_U]Q"1WA.G;BQ/$3O/_%Q7,LXK\+A$Z<O'3MU(6;MKP>(<*7KS\_?='D
M15%MUQDY+3N6B.?CD;.B5[3I\NS_0ON?R/Z_ 8OY_X7L_P#[?W#-@OB/\QQ=
MWG$A$!3$Y2H54RYBKZ(+F3XT'* DUK/P?$]O,X"1.3/W05804*639?VN.Y(3
MOHTP)[T;6-MBME\4WAL7I 9JK45(9L^I?WO)_?[!/JZ^9QNC0ZUG0,P\++Q8
MK8'2]:JDMYZUCFWZLRS'*/%W"J*V\=(4OK0>^\HU+^66WHM76KUT9^LH0^QS
M.%EPT?-*EOZ[[FJO-[;]K.F'ZJXR9]IV:H"J/[T-6S;,Q 1LWGG$5[PK=S;^
ME6*%F-H,%P%*]HT.05V6[3?IN.E#D!E V?_#+XI,V[09VHUI 4[RID+.E,VX
M6#/Y;GG($LJ!7O7KVDW-X^Y2#_(&?<.>.BZ/?TL9*6G6J__2NO>6!FW&]^9J
M4LF\*POU/KVX\YC'0'8I4-(S&_&A[! 4YV+"+DS@\- _!]T=#>2@F$\[7!P3
M;[.^&7)TP8&C85,M[]_[Y.X;TXO>"ZEQRZ#43I4/7B'Z!O?\D!E@<.8 MQ4F
M$8^/)<+5RE6 V1%B*C$A6TU#-L[!&7CG #%2@_C8Z"?;$>S.8Q_Q9J)]9&*I
M#&8ZP91QU5$Z8D+%(T3GFCW]]7BZM(P$O'N49E*M*N1ND\UO+(F/>IUL4EJS
M1C(,?8<S42(_QQ^"8I(X8N#ZSG3V[M2?[([-H23C_YBRGEH %N=R'Q@KN'+N
MOZ1OPJBQ95*_//,:3 687Z);28/O6+#S+W\L?>UVRTR$-D-CP@&LCA]%M)V/
M"7LF:P#PT'W;P]E27>XW#(W+0P5C'H7]JIA%OZ*V]25L-0IHT70?%Z6,WB:Y
MWWC=R$>\X9 !#[^8O@R+;2G(EW:(_#;=TL>;0HBEW?H-$Y+<#M''R*!\XAQD
M53HD'=O=Q03@PB;I=[15&;YVV=Z&-7;;EWK:#>RJ)=.T,&KX5.HM,9. V6BW
M86(B.;5TS3-?)Z$$42;&ETR#4Z>(,"%#_:@).8O>K"]8>C'%J/,,=J&)(H;Q
M8ZU39YLWV.SW='*\L=;TVFQAUR$H659^5'O>O+M3K7ZT2._F3J2VZOL9S)6]
M_/)<W;]FDUOJ.\5$$VZ,"'PO_?7OU(;5OAGP"P[H[",QMP$" 5AFO,)H'/QM
MK.3;=BZ]:!7,>H&N@YWS/>]WW()5'K\=J,L7&?3C2DM^<5V,&8]WJT_!$I^]
M3VIE\W$?P%77RT4B$9](RAWO)T0CYT9I#CTPW5[&S[UKU(ENFTZ1P01-7I1@
M"MZN7668)&%+.(D0CHOT99>9I]#N*=%5QVEV??!/:P<^TQ-%, %^\IFX/H?L
M*,>*N[0*1#?3%TFUCY<8(YN%$,^T/8[#[^6;8I19J;M?4#(<)"R&(L3EQ5@
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M#VWDA-XDKB(+FJBFXV8RV]O73:R@!MZ3'#G9?BUU]<^8TZGFX0)?YU[L%'Y
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ML,>!&W3%C5^,S$1=0[V,H# GB#43*@,4+-!TFZ^NBCH[? )8.UG..]0Y?[W
M$X\"U5-ZZ]8NW/3>YS$-L6-^08!Y4@98;W1A\7CXOF?!,7N$Q^<L>BA'@_?D
M6X_@6D(&X2R;1J^Y>(_HE:/2H3Q.<RBWM2EU,^YO%TP@9W0SV0:=@<E$V+Y"
MF:%.P:F9,D4Y&O/:&W=%816T2FB1FK&<#,(.'X/V_^\K$>6QX')Y^+\3B;MW
M#TK$N&<"6,S%]Q@%MCY07LH=^<@4L.J"LM6Y4_6L:;9B<M @09-SQ_CC+N[R
MCYE.J[*'G]+3WX3\5LS$@CBF['+.122"/0;X.#8 < 9X>HQV"#KSH_,_?ZJ[
M6->S]9+"K58RWL5N0OWUAIV^')!N-@M)EUV!ZBZ,^ZN6BS$00:G$]"J64[3*
MZ]DO2'>[<FFK70?]IC(7N/@J@7&%%)>#-%]+\4<L$S8/FM\/) A3VXE\5KRF
M7M=V_!976!VG*U]2N3^E5?DQ5PM&NN-DV%;72#O-YUQ^PG>-^T>7N('<4]R^
M3G46XBUK:C&"!IV.9<!HFK( DG&_CP85#==,YUYB36WLB\47L^6YQ'+T+Y.&
MT?:;N!.S387E7WHDT5&:?#.N[N+W<R+-\+A0'[$:[,PAZ#A6#FAF+-/ %S"7
M#UYQKZ*E=I-P0H G+JZPH?G#0I+AH\)%LM@J^\NJ%:Z2XYX0C325!5,:1S?+
M:_+%+#L[WA<HI0]6[I[]'+D_8AHQU/-NJ2P4=H/XC#I.,RM0MR^"C"4MQY!<
M9-*HS&L8P&#Y.E7MW&5'_S!5;Y7<W>@[6M_RQ>P*9!O/G4:[9<$_+K^"]TZ5
M)X9?[1QLN/XE1KS?OL;1$KBCJ*$A<2=$4"HQXW+XZH.7E>QMMK*-3K;!%-[E
M.V7VN-7!WSX'+SE^I1CU\3S4K!Q7I" _H'PM3[VG.C\T@C$=V-##UN;*MK;Y
MJC\,5UWQFC2+U?KX2'UKN0[]O?G%A3\Y]0<%7!#'$=R8N!'-=D8]H\AR+I6@
M]3X4&(]PKP*'("8N4S -8TI"_[)EZ99[1U99_0_VWO.KJ?0-_V7&@H 0D0Y"
M5$0Z46D"(?G:0$"(]"9D%!4" B(@ 4(R2F\R(R(C"!FDA!8BTJ0E0@*,,O0F
M("6)BC39>]2PAQ1.YKP[Y\7Y \[ZO4C62E[LO?+<UWW=GVMGYTEP$F?KT$+(
MG.S7MGA>DES(]?&/4_3W(R<S@Y4R"G8E"'JTTK?X>;7'MWP;O-,&7ZW6SUDU
M&]XHZG.EJ?O2O=T-J.?J+4[FJD,$<^O'K%_T;N"\*E-9PU2?<^\JN5N?!9HI
MP]%(VAE6$ C$7WO5\>3N6W;M6,&U.E/*LS'J4 9SFGI>/&;.C@YX,3W*Q2:9
M:^!>E&OC!"AX"PMW)4*D=B66BTDMD;VJ=!7\8TRFUEEA>2Q,&8_IU>8CUQ)F
MTDWHQP7HJ7R?9G@$'SV[OZ1J307S>>1(E8U^3M1?5\YCPB>14OSSHA%2Z],R
M<*D'^Q/!&:0QT>KH8.P>@67I$M-O.K7":9FDA0]D]B:$SD.U*][M:9H(YM:N
MQ(&I^NVBVG^__+:X\#9,<VJ8S+/)>[]F.%7#";P5\/D4ZY.OE[9,$2>ZR\Y&
MRC(OU7K0IOPW][I+'F6YE8$E2/.((V]NZ#F6^$Q&QY9YQ>H/V:%NH>5>[<!^
M<I=]]MF'X.)[0:?\8=^E7VH]7OSCU_YAU?,N-:7F?#1K;*3Q?<):3*7SA??#
MSX^YR;D+UG<E'@8*]*%"()(7D-W#4"9H)RV35>&96K;3$6:VYYUPE4[&?J(Y
MSOAGJ_#;I?K&*S]C=+;3[J:V;AH,?48WQ6T4AL?S,<0/I>80"&CW[FRG":)
M)Z=INDH8^1!!FQVI,+]6= '#B:Y>")&M/5<S@COXPMG"Z3?MEF]/G;"G3/N]
M$-,&AF]9(#T,J]DWFVH=<^J/1Z>B\&_9P5F51BHFN-0AOS=#WKS?W.I2<]42
M<=/=4L.(Q5"GR;*>]EM'X-++H1[4K++>4">I(U=.37F9%ANQ;F5R?_F2:'5V
MG/6N.2E'WZ_Y&"+U+&.E%3ZKS4TKY&N3>BX1U4(8DK%)AI[0,_ZE*@:0WVL=
MVY!W2ZM]N3-2*\32*ZYC7PGUPWVO#N?6O!O;RKQ=B2^+SL\-%;W8D_\S)"0
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M2C  7D'IK/LHW0F"/4DM)F.@PO?]W/ #ML7.3=-K29EBK2Q WJ "&]Z+R$R
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MF2LX,T8*_D*WA )'V/ <@L>BSCCA$DFV9#$?R.X;Q=,N/Y:]D5@7@'5VH)_
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M)%8"BUM<%(44SIXE:E >Y ]8W\Q+8C<B$Q[E+Q?_T>4:SPF*EQU^  \"OO$
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M;[@L2LEOW9OQ2H6)GIOGF*'5Q'ZC1 J>[P.#^1'H?0(=X#G]4$M62 O5#GL
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MU';5D73;@H>F"R*',O78#BOW , #INL^K]=B^>2C;[2P[!@Q-*?(5H0,&9'
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M17\[>VZGN3:F@WI\.BM4'E>\N+N8\7"[9J7QU7ZR-<''PKJA!^Z[\*TI0=J
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M>93-^7P 0!L= #I+_OMM4./#Q$S<S']['ESG>P!0LVXVA$[_P@:_7;5W2CH
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MQRO-A9'N-W5G5"96B U6M?0VS"_2,R+9 MX#I#2G%\^!3[*(IJD6C.'*Y@.
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M_[:V;MSE_(2R3# B+ 3%EC?*5AHN677*>>WW2[>8JB"6-D-H]@"PND6;,NK
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M\OA]TT&5WWY2R?".CH&^:&I088^3>_/[M+>N7E):&,,&_^6X'0<4'\._U=Q
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MT!+^7M98G:V_>+AB,;,J3 &#<$K9"+D3T@'9PPO\K.=L>\92%_F^,RE:W[,
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MAGNZD@(*$5.R/U".3!,; $=7WLSUMQP=0J9U2%<75TQY-Z#?U^D:Q>247O/
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MEBO.A,2T4$\RC29&FF4)HVML*ZHP'Q)"-TDP%'1;<%-)-KAW6Y'I'X\G"!C
M_AJJ6@[B7+ B9NZT7Y@G-_U=,ZS($66F/",*,(4M:_NY)Y"0-O3E@8?!:A8/
M>LR9*;%:&#'X2&AG[!N6G/,(R;FFJ:Y^J)(]AOX:?LPTV'_VZZ_NG'$UCVGH
M/G@(>:2T!'FA+?1),<W"K-V)*9'O09V4']AQ&]XH-1G8=/59G?I^>=/"W ))
M#Q-86E!JJ$'V5\TDEK_Z&MMQ=\':NBK*?O'WU\\7:6_!JM8-:7!\J)F9:J^Q
M1+K7Q3J<)7%V0BWLDI.3XI.BZO$:!_B"O,/RX./^(BP?0Y*VB>UJB:USTXSI
M"K]P*WF!T!1V,^_G>#6VLC@IIE2Q]H..(Q9.V!&J<%=OHN1)!V4%O7?^IE ;
M^W?S'J#=B%F_(K#CN)@MNA0']])I=94/P ..G89'B3H-F*A@ZJ,?\&:-?H*!
M\6HK<>AB0VU5)=E^>Q4A,)Z1?+7%T;OA8#2UQ_2LOD'!@JY@XFA6=F*=LT:.
M5S'9O,SG0M-(?KAB;:+FU:VL41O3P*=!?WM]SIV"3_YZX/&[KUWXSV48.8M,
MFC:&,EXQY93-TO/?Z ;-'.H1YK/4@)>9+/TT[W);F1G,P&G85?Y9"_I5DB=N
M9F9A@6MV^(Q]7U$^TE.U$3)?^%_Y"M]?_YZWKVB"TL(BWKJ4V%4__\JJVLG3
M-OW5$*W&E(\^3U[Z9-HZF0>6NJ9G+=?_,-$SAP?,?/TUH?#X87BC%8VT_&87
MM/_!\"[H/B:&W-*^%@MCW+(:%VL?&7738WK%;^1 ^);0>P>(XB7P[4G 5V,
MMA<H;6W6&?0:*1C,K]L%1<4ZUC0,GMV<O#T!(Q7>/GWV-&L[?JUM%CDA+@V@
MM#WYC[_IQ[FEE_57\*>]*U>U*!]:=,FP+ZNL+.Y=4_+T"_WI+#YG675;QR;=
M2SHP<?&J=9()GU;N95+(H2:_84+MY"[HTB#K%J<^Z"U6:!?4:H4^XZKJ\;6.
MN;8\N*,-E/.!W&T6?<7:Y(\,><+63 4W"=_^4C_Y)U*3K;H+BBCQ)CUYL^..
M[G:[D&QH(WP<_7?>><;RJ.J%6@T(6VGG6L\Q#;9_'L5,^5.W\^]X#K@ O^,H
MNM9KHI&[U6R;>687M#+O?AJ2G8J^S[',,GM=O L*_%0/F!&RIM'R*#F AY '
MB( ',X$5/8PV9.\'3N^8LJ4,E0<* :\"U$D@C=H2[:;P8>!N?V7>G!W@X4M'
MA/'NE>CJWE/#* .F28>;W&@A,]2M+@.?=+S^S:9<*5M\WS0D>O74P"X(#CG
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MW6VC_\K#KINBC7D'W^T"#+"[@+_*\X3ZYO_G;:+27.FF>?_V%'+UI\3*TO0
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M?'U.<%=H4'*5_#CTZ+*ZEIM.V,7>GAZN@;%20F);M!;0I2-78O38J)&JQ6K
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MM:CQ>>3+2XL?]4''OU&YQSNX)P5TAKUU:/:]5:/CR""HR3^)/[3@0P8":2S
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M_L(4]SWY)?3\<YS<DVYPW \R8:74R]\$7(\T !I(?!6NO OY7@KB1N6:G/J
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M"9A;=F6.5<IH*70>[P9*> *JZ7&=Z=FZ_K-V7:..RRMV731VT?*DKX(-M+]
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MF9)>:#;^1GB:?KRHA_\C/+EN"*=CSA5;XUCY1U-XD<JOK&X3CB!>"O.2$K:
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M*<OZLM-#Y&56J0*^[-^.Y>TJGG=(S_<$+EUX31HP2Q!H\?4X P38T^BU1O/
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MMYS=;T((MW-'9!A".4QE#,7Q(Q5CG ")PSN46%^]YQ5\4ROD[\%=./BM9.H
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MZ 3[!L3N_\E87&FG$>(@KQAUZ?G?M=5_7#D3-=O]. ?OD1X1L?8;4GZXQO?
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M*Z!$\7Y;]H4O/OTQY5M=R3,3Q1-BK\T,FW>Z3T^%9=(/K6.ZN$E!&E!_"8G
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M$MALH'>48[;QC!P#?$/R:<Y@#*]?(9#$6OUSXR%%EQPYTI,B#7QZB13?A3X
MLJGJ_$T83T,SGY&\O'B^UW$X0-3&G;"JIEL*@I2#B*?.U5F''B5']G !=X8^
MI(_A'^K2Q,A+==#[R3LYD)EHUTI!?ZH. &IFH@^1R1 !R.M&*P\NUBL;O<IO
MQ5/T!J*I:72\>/&6\Q+R+OW*E4A1']QO]"AQ>1$U23&@MF/(VJ"'Y%(KB.C!
M\8\.S?<P=DKM 91$?9S&=@;&'9JA4:% $4<JWJIR''TJOU_DT?A0K(?&:1$
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M[3Y!VCBE>11G6X*9^[-F,-/V,\.Z/&]@\M($OZEHN;9T_2 ID&,XOPE381N
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MZM7J\_?B2[=F*!RZ8H7;<RQ];-H>V:6I5&L7=PT7"CIN/*?BL_1D XLU9!V
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M_L]S[QCG&?>\NN,^+]:+M=8O:\[?7#-S?KYCK+5^GIH=7R_$5$Y?\> /U(F
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MZ$A2E@];:ZZ;HLM\6.)YG?FMW>-='1L\B,"+7>VE3\YW&E@.05&E-SDQ?:-
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M@=F<:GL/!4Z?C3S;*+@GHX3VLOCAOF_)V[(<TC72.)1C ZO8FPH:<+R"*ZD
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MY4V=KX??WVEO>16'9EMXO,K\"8L4NHD8$_L!WUQ]DY?Y;9T^46$S/8\^'>S
M*?6TLM83 % '?!EBWQ7;%07T=Y,!;YM3R0 G1>"E-Q+1_G\[ "#(4PK'H2>C
MQRJ 1*W/Y".%K5M7R\@@ VCP@W1SNQ].3@^<OL?P2K9IRJRW8!FI-G1J(L@
M/J=)"('M+, /KTZ@\5Z#IIE2"G!?\+HL$30.V?209X B"RG5C0P8D2<@T3%F
M:(*7%^G99Q4R8 D!VOM!:L%D9D*OKKU %V%MTA"0:?O9LT6MDRGGQ0."S[WB
M%T.^B#3<-J6W5_L;L;-T^:S72[_7:>'_#;@\!QK5W-(9]_A4>TX& #$\.F2
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M=-I.H^,&_HJF<7*XISY--ORU0T#W/9HY0L_:/'9CT>P")]U]K*&JMCZ7C2N
M@RJ);<+.[)Q_,0';%CPG!CX)JUC'),6$EI.=(B.:S;YESWUAC49T,&.ZQ\H(
MAA_=.)T^D1_*"UUF]+6019O-*W4^)6"@$@F-%3D9F,NOPA'= YV+K/!.C05F
M-C&+PCK]S*\_$<;_]*]:SBW_U9CM?R]8?MJ/$E XE@X.2V>C\0B]SV>NE:9\
MJA['0O6+\6D>SD.A.BH]53)?-2$S5B<2<)[=YYI?64I+V]LCA%_URB72S<<<
M7D.'_3P,GS^PE[ES\G4L8NF>L,XI]I)4P*,?3QXTVI_X7-GD>>]KWHM3MMGB
MTKD?O]8KE)M@&E,/GAV:&[Q!E-9E+O:.=K4]&T6=Z"I"9P[0C9SK38Q>%"U>
M#] ;6W2;?/?4NR[1"=@@<6S/!ZW]_BLV.*K :("3\./E^-AGG]]X,>Q0@4:?
M<I_!#OPJ8%]7/O%?CAOC?8I7?77E-V:(:@SH:V>#>M)8<%MK+>4"XTOSB[D\
M_X3/O=?(-;RWE5Q\DM8:7CC 6#RPX SW<#['T_RZ9_3PW[5]M3M>VC9C="-$
MB<LE8=ZPL72TATG<V<&*Y8]%W$.M[]V5'GSP<OMNNU!PE*E;<9A8MO P8"!P
MV/EQU)(R\P3)(,__M*W9.>9/.90M(YD=1+O"[.M1CMALV/3%]0>K:/^^0$@9
M#T]^,R'D):=+LOLJX25XU-KR^O.B,TQZK"_'VZ'V=FZMI,G1AY-QP<%8,^CA
M\_J:[?84S:-)#":=H[@$C,1' R3;HQK7G^L9! RD2[WM<,K*C(_22+_I_KAL
MY6'72I#5!I%;T115&I![HT"A/WAM^XI]8=%<I%0D_Z\J3ZN>6-@*.US=>N!N
M[LD?9X^^,_I]LN!*KH67*?$&5S?-]"8G38TAAOF;RQ-Y.S]:\.R>$M=LB)"P
M.D-!_[.9FYAHL-Y0,V1H9U;.*].^;-T_.?@I_-0U#^G?CEVUK7(T$_LFCHAL
M $RJOH8;F<+NYW!A50$2]Q>:!]T,*VOZ';9092]O9X1M>Y@'[^]HE_SGO2?6
M,P!CD^N5;D%WON_A/E]]]E*0Z7O5A$$*H^!0[D0Z(%%]M:T)HG=;_X]J%-TT
MLL#>\0N:<)&N;K@=GT[W!@I^V3BU>_O9"OBW_!I-=@Y&.$YT-R+CJU\R?/\H
MN%_N<R[7DI>M&YNQL>:@.DL4)Y=1SJ_*-"V9#BBH[$=MLB<1K7\#S.),2&TZ
M S];.4^%&Y[RKC:DL4-$@A*O<[U('VB87.<$@[#&S/-K94G/[$K_*RP2$7J$
MXBSN0L96ITL><8^S8=*82]STIBEA&.>(P8XF(^?3![L*P7M:FYL-P]&8W/S6
MXJ4F_W+,?S^E"DU[=:S"KE+QL NMW/AAGD;OX5&+D'=SS"UL$H<J;A4B%FCR
M.T!57^J1)*<SV#Z>Z%F:C59PE.]\D_J/S;.$'$WV</O[:=&FNKO/GKGFGG,Y
MN_@Z+FOG@GRHEY=K.N>U"A8C+3K[\CSCX><ZK6$Y86_59;O+'W4V[.H'PV>J
M-WUVG-M@)T'OY_<G@I6YQ@D/TT]WS:(5/!+C'[R,/IX@O<_S>OFI1:@#7B7Z
MY,<;-[!%EI+>SB)/7B\._2Q+(9Z"+VZVZ8ZU@3/:Y:;A;VO%=O+5]A;%/48!
ML;CS:THH-ENJ?]P5C#.OS/3OYP29NJ"RLZM:QT>]WO@F(99^YIL:N\6F]=16
M]88\\ LR%>]85'8TUSJJ[, X+48Z]?3SW()-];.V9Y=(/[MH+$&=>V$QK9<[
MH@S*%K5AOU">%J)9 4IN/0<^.VLH6R:[^J!'GE])_^QZ:1SN![_UQ]2+4-W5
ML:S6A555.,>%)VC5X8XAP3?T/KN/-/9$Z/4!@\46NM_#D/2\0^\B22V;.7K_
M34&&=LS8SO)^(Y.ZTK21#2/7(MHM7.VYI5@TP^>%27BI-Q=]S]/MP9,'>JEE
M[ _LQ<$4^N3-0K?R.Z6-NQ !]!A[\QA N7"7IV@Q]7 I6']A_2$KR&00^%5Z
M;*@TYJC]RMG$ZE*[BCNO5:PF9M-L7F I_SM+]1LP_T5B4']%0"7AB],=NY"M
M%/_UG]0J$5Z>\6/J4M@>Q.Q"RA6YT:V:_U_>1;7_#/]Q763[V2YD$'/IS\9%
MOJ7D+J0+N0NQ+8GU1,[6[4(.*:="QQ8W&.=[><A>A=?;>>MF1]?/[T6C7<AE
MMUT(# ^J"UVBAH2,'=F$*Y#1,;N0WJWM#1*3K(TW0KTJ+\]&KC"NP4VX^S&O
ML/LFASOWFGP>B'.;PT4A 4M%/*@JLH06"$DXAUM <([MF)&^($&ELV.[D(/T
M'7PBD:8NP/<8W<'F.__.$<=]LB+@OL_J[W5V=';E@CC%*@OVQ\F#SU,1):7B
M@I"C5AR1)3:;^BB3=Q: )L 4P=[IR&458'4CMM\@Y"0ZYQJ0'N<;RCU@P7VQ
M4U\36Q&0:]\:&7 H;3:AW&'F;=^ZNM37GS^OW*NH4$HX"OM*4@:K /,] N]L
MPDK;3B\*;F^"9MS0#IP<3^B>(6KGC OO;^!F29WO&R1+4.:V;'%\*X5:JK5E
MMYKG'=%O^9N^+.2+,1^"ZV ,]X;1&GQ4@1T:QD'*^8?P8B"J@W6REC4RW!7=
M];AV-;FYOK4$8[D+>6+9Z\(5P"_5Y8 8F)0;3Z6?YQA6()$^3(==Z,=@OWFX
MH9-GS1LJ,S@()29\BHB4PL1NP_E#HY0F-DF()P+F <';[:IC;*<L#EX6C-E(
M R0+RKDH*R"5UD41!U. +OMOJP8I.SJ_OOICHJ;LS.D%$DV-@S^^01Z#-#3\
MNO=.$E9@A!<TA+TX[\-12.0@1-$],&5T3H>; 'U5SA\IB$%PQ>#'&N($TGC6
MP+0U4XMG6 [&K^FJRJ6D6?;'Q+2TV&I;+C!C%J_HB/= ^4=?;>M,MD^_)YNC
MN%:=CN!FNYL(S;8'T;D+D>;%<GI0--9QTPM<8:Q& .4@@*TI7S2.SDDD&U N
M)(^Y-E8W-$7IR'[].FK=4]YL_K?"B8I=2/O?%'T<S9[GOI/[T70?0&1_+?O?
MSEGNYM023I9GQ57JH&B!O;"T*339PGMZ-3%'"B=B"$^$70#BOY9O[.@L=HQ:
MI=[B]KR@I'P(S(FP/E1./X'9A;!)H#II67UJ];O5E%\7*RD"5X-X"M-&[T+:
MX.(P318Z@&PWG:]/]](#(X%9>Y-'61UP8;(B6SAR;QD\2>"[& K:X3PC&L#P
M*=NP_G!MG.LVK.C^/1PB!'Y;Y)$;L3-?;;J@11I/MN8@1-![7CF<@-'F()-@
M9X?Y,J![ERSK<19[+ZJPA'BPH7!;DHA_]-="]G6S)UWV]8\9=RB#NG]5)Z]L
M</RX/GNKHW#GV7#'J'3<O;7>Y.B[B>S>8SQG,+;8H@3C S[R"Q>@Z:;^9")/
M\711<^N$.CAM+&7LO*&\)DT5634WW.&J9?I^12WYFL@+BA*NW86B#>*<N5W)
MIC* 2-MH;SL^'GM@)XVBCOE[R-2<*^+23_E+;2^TH]1Y<!]4$>C^3R7 +"I<
MF#P-S&PFW;N:XY9>7A20T#_Y\Y+D>.\IS;55&G+,=IK(0*12)>X".6WXHTC^
M9^H1O@[/"I2?UGUZ#G,E$0'6%8-Y[,3$'X/D2],/INSL.P8L!WF2L-830$]Z
MQKO%2*Q.>(;A:I59INV]@JS2_VTW^[8ZTZ"B9,4H-EZ\/HEKWK8+@5#DP68)
M;E>23\$J#5ICP4R) @I&^^=#GHS&?LV")ZXQAW2#9"^F1?F\"+=J=/TAW/<=
MVP&OJ<CA]M[8>:-EH"LQ"M:X<BU+IR=L.P!PE?$ H]4"QI>##W6/+BK ">SG
MT6_1EB'2"VX'+W?^=LJS?_:YWPY]6WK ^F$;] RVC0 XK$KQ1Y"B1=_J0A[G
M3(H#QFE8N06J).P4>MBJCZ]F]&HO!?DE37WC %"Z)ZX3=A"@/C&$G@ILMELF
M)1LLKB;DKB;S-#8>!)H$#+IM_-<";CZF3KV!URK+PFFL(Q@88)P(T\#\#;9N
M7^:S%([UKU!T0/XF;129$!8RTG!M:+WUI%$IFW#$RP-1Q"AVSQ.,50^+"I>J
MKV^HYP\:B]EBJ.]8$+B/R.,]ZK)LB?S(T\[B&!83>$J;!>+ ;!SO$M>J2T$5
MC)T2$42"Z;.,R +HWH.=CVLCT!5O\*>N)<LD3]AX.8)995XRZND^_U^0NSX-
M6DE86I[:0;5M\1/9JZ*72C&F7$)7+Q1]VY6')$U8!7$0HV[,E5Y.:\\7?2^#
MR/JMC]+#@L6NXV5C<UJ?M]S^_N\=!'.!Z[ZQL?..Y[[]%Y^V"ZF-7%IFPQ,4
MY+@"RS+<+#;N7W(XF_"T.:'J_?S6G4E-9KCN\4D09T$=,&B:"5+=1/:'W"+0
M@^[E5N2_$T1UFYEPN#,-R/.@R'8,OQ\F 7*G=R%'>(Y]&#.NR!0AA3I50JU-
M7*IY TZN,D+=P-]L.DP6Z&E(XD'9Y0(=LKBXI;5R\S:OD_7](4$LAR'#19)X
MX+G%%G+C@+WJXEJ.PTX<U2_(=B,8@"]]&-5-7L)*8@R9:[KB:.%:PBDP[RJ7
M&$^V9I-.>**)YL.U^%.N+ 9',]81P=35\4W^X:5W]NI&M69;Q(UFY)+:]L4
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M>9P]L#,>N2D;E/C44-CLWOKAG&?@\#86.T0X /?'@V?"\V?CL2?075.D)1(
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M7Q@*3?3-SWBW$P#&[GW8=6=/_#X3%^V X:7\;12HSUGMF-#W&#(,,F83EZT
MQKUUZM'Y3O4?E?T\/2ZT/7/1>7/3.73"2V5 V+A=%B,=^3#PLTJ <HU"VG3^
M14Y7QW]+')"Q?1[CV[>TLC9QD58SCM$"!@DG34\4]X9?:&P<-+3#M3FRT)G\
MSI\KUC]C[@+D:RXC[3\7!4-C[FLOX^2*<M#Y[->:WO?/G_=[?5&=R6!^KOJN
M\:?3UEG2R6#^<[T\^X'XUW/10SZ6>.:"[TMRF;A7JM+E"KC,L>LENQ#+3^B!
MTPP.^^4/C*WSZ:^M^28(R7BZE2[C)O%H=Y;(TX[IN5[=GM+^< U;$5O]=I_W
MUU_/.J1I/'SMI_NCVW5/FC;8H>8;];8*+]ZPRM>_&#&/[$* 9ZYV!CFG9;2F
M?I'64'*AIMEOC9YJ?UG)O+M_P#IWF2>Y-XZH'6+=Q.7)7GJ#FW3\/651PZ6R
MXV7A,;[*/0=/X#4=$__NGWE^!:AKXX\DQ*"5)S.N1)3AKHPV+-MM&X&1G3D*
M)[AX!DL81-#CG/K?[5G,!XLR_]P?UP3U@H)".9ZRVQ9U>;2Y7Z<9PI0&J;P/
M=D?QR\0EN%^"F:<<AQ6?1Y>]F\AF"?%<P*+W@0+7^SA#L!,8)2Z>3CH6\,M:
MI<S%6B IC"#(F-HQ7#_SY)SG2$5YB-^^*Q-ODD:G/O4A&!Y;K=;?:&B?K!N,
MSAOL,[8R]/"YSY]A_;;"YD_/.+=&U\RD*AAG99K6J5GJ!/'CD.F-%(,+'[BM
MIPR-99 R"'5VLTN.;*6--I/T+_W6S-*;NMQVHSQRD8.U"H!?^M]_RC>!(L#I
M!QR"U%6^*;<^[YR62?&?OI#RL.T,"?'V4-\#GBZ7#MYK4![M.IP7<G_U9$WK
M4-W= @CNLJG%M+:QS2!&#]@VKZ[B&M/3;O>C0OX/WMX[JJGM[1J-QZ,<18Q2
MI>98 )&F2)$:E0.(" @H5<A11$J$B(!$#(E*[QX54%JD@Y0()" 0$DDH!Q'I
M($$@"4HO.]*V)"0WWG_N]_[N'?=[QQWW^S+&_B,98^UD/6NN^<RY]LJS]F'D
M@3F92:VAVXG*TA&4YQE9T<<M@&2G=A^-/+5A%$JW15RT:](#OT1JS-/V!*R6
M6KB^F+]'JIZBK3Y0ZZSH#]?II>BD#IC$\?><U?:I0Q]5AMS"4/MXAL!(33[:
ME[8=T]([%K2,XOF6VYA4/#SK.:>1D> =MNT+R&^> E6YIA;5"-"HTV68'#Z]
M-Q:AR'/DV';DEO/.<W+J/XJ/B-D[1UVN)0T2;8V4;2)A-(K"X#I"=&ZDIAU5
M,K>Y4-10_IB)->; Y!^W@U%I>1[/F#Z7JV5.T&[F9]X\V65AE'[:T$[J:K&Y
MK+O9QU35TVV.:/*5DS1TSAVC_B*J+!LGKI-3@B9;(A(JVGC6"8[%+F<ZID]Y
MKR<%Y2!GPE15@-" RU57S#R>?*/UORR6TWWW3[D*9H>KB?UL1*4A1!<8 DC[
M<D0G&]XQ%3\23SU,FJHU5XW533GZNI0((IA5^NAD9_YOP,]G]%JV ;XM?%Z%
M\/9U$3(L+AY<$PXE?><QU1^Q+)J6A*BETE+L/8;N,M]EME..]#E]4-)I(-7?
M CI+P>Q6Z)L%]T=J&@=&:CN-*W3(R4=&%T1X1]WM>9M"74SMP_W0A $Q_O U
MX<_A"R 7!)!_23NF3UMONQYH$'W) G0S=N^[K.O'6K@:XU=67%F\+)FS8,L=
M/G7Y1\[XR^R[_ #"J^"#QW4(V=TZ;8.?@O5,BV_8'KA^P]2FXB1-*RE.V2@X
M^:9=3N ?%\\D.E_BVU ,<:W5"*',3E)N',+Y3J5192@BD[VA:U8%Z%KZ);"+
MN:A^$];E7=KZ,(S9*]O6<_KK%H.00AK]R[MV./'Q5 I<GLK\2@#5<#0'K7Q@
M$AY-)7JE*81O.1K0>^6H<1CK0)1?"/) G@P8Y\U*:K&Z/G3\9T$-\/USH\+]
M*%'/,U]Z^<E"*OFO/2;B:%)% D@O4@#A[@BY_-AH6C(K5;K#LU(!J(M88_F<
M0H:N%ZL:G7&/S J>V*A#N&2@8SH-41H^KQP^J5E.-7]2H]7Y^ZW&EY2QBR:S
M/I-)UEOVO%B^-D]\IP)^I[NB IZ&KYOM@$?W>DOJ3$ZBNS]@_WS7'^C]_MR3
M6<Z!!YE*L/@KZ 2$DPOV_!7.K_  UC!A'Y_^/8#?] "Y;%.1*T"A7\,B4-&>
M1>HIR86\SUCWZF7:.GF07]_57-*#ZZ_8GIJ9_C=/]E/&5<3#S(PN%#^^*8Z^
M>G!A4\<_@BQ6,7\_W3^TQUT1[C18[&/HG$';[GAD+6M_RDOZU$-',2P*@Q62
M[HE?RUIP?X]<<V<PG:N&WCO:+E>=KT\H0X^SAEQP^\C(R I;6?ME19LVJI@J
M4%]<T2T[?LH#*3XUOZP13!RY'\/ 2L !NG;/Z8'"F$^^EXM\]W^)2%<;*G2.
MB7!R*G;4>[=V/T@GL2G9OP'9<2]3(W][KR>;]RW=9%J9Z/Z]W.3@,:GYSYK*
MYVQ$$ZXA3@P/%7#.-@ULU2&Z2W^5JOS] ^<T)XVG#1M#MIWU,]/(<R7U'K=O
M]+#1=)S9X'4'FE^)-%Q532!=FL@R7G1%Z?;<VGV@*4=_P$:KXN&/&W#BZ/)K
MH%JZGW+F5YE.(+<^6_)!H6>4G?Z+KS]U1/:LWM7M/3S?X&? S!:#V9-T*I]:
M/G=<FAIMB,8Q7WB= *'%[G,XH;(/2$LPTP2THMYXSO.50#>NM3L:V4'U:7%Y
MT%>U3DCVD@"FXDQ\657R]/[:\?FK"U@%#F^S[W4;]>[#OY%PTQ'JG5X&X6+P
MWG*NOK^2SO#Q8;D.^@WP(0?1&D&)"Y%J$T6A*KP(;<:(W8O_>'@PW#NTE;8N
MI_JM:E4?K[<B!9_(N]][3@!1I0]]"(;O&9SV,WR+9SSTN5O=HC$J<600P3"<
M@L[*P@[YH"M[QSHJE5_??.>FKWWX9(=K^:V:L 7VPLYGD130Y2R-=3J=\]-.
M>]^3HG>@@H&X8T_MTK1J:\> 6Y!]NZ%6X(L[+^_W^NU\VJLND]5?*+,$U-!9
M<_WY-C_=B#NE\+OP^ P #&=V+O69R&@R,\;T'C7[KSJ.V+SJ=_XK*U*=MMEO
M_,<'L0H&@M'U/=HO]P$ITIBK)X27@8G-6W2+F0GV"_]TPRBI&UJWZ.!OM%*J
MF!=3?*S(Y<&=[;5K^IO2IR\><&@]\>S+W /'@B2+(94LXV[M.?R5G1=P_QTK
MCX9W_7P1C E@]SQ#9DL'G=8)E];]ECJYO<(>V9;7A%\"'[%ZI:=69?8N!U67
MZL])_1UKJ%*_3P'NR3LK1#D.[6*7-^@)KDZK\0V0#"QAIR[?3QSM;0X0Z-!]
M=IF'O;Y8E* =3VX$>K>MS1O$^]8.87!LG 1]SX!%V=RVV9,'\J;7SF*-/I=U
M:K'XXO1[>Z7#O!TI_J]-WMKO\31*XIJ?9%7&'6?Q"F0KU;HTS.!G:+-GZ<,O
MW][,DR:KW9KN>LV9.O#MR]T;.@MCH<XJ,3?TKFB+58[*9,^<,TH\Z.;EVZ%@
MGNWK5J236.O@FJSDD=AM2CIG%,9**CSURI^7!L W_0:QFO/6D=,"R $S/!!$
M&[R8^2'+E3Q,M$5UN.<F6N%\V!Z+\KXU1EXQK'*&;O]?0-5F"Z$]I+KWP"$&
MPW2T$CGU#D9K^:N(895 ]B[\.O[OC_FINY$R;=)-MVLM^ZTUWU 'CP\5I!<\
M,-=UKW32R:TZNI=J)X (71I:*0R$[('8!$&N0TX]UKPG=7[7>8CPM<OJOR:5
M2*S+!Q.)3)^7][=_!GQ:+'<F)/6<J<FI,Z'+)I2?^E+II2UK5Z0^5.%.+'9H
MO/8B*7SFY<]2;1KG:UC'JQQ:O<&^UT/=)ZTOYLEKTNS@8Z")GF2^98R&WN7[
MA7X73G[$=AFE;EU6>)?&GDH5NG5[:3_*H<:^]4AYAU'2Q+$C+^A&G].*>R)]
M*VV*B"YR/CU+<IA, _=3G@^1-Q_N^2)Q(DGW'7&D5V&V4YN_!RRE;</B>)?S
M]HP2M:7'YOU-IZ*U=;MCAH*6Y3X>?<MPMRZE/_(-TR-6*4Z0D69=JW?YGU2L
MKW\CS,'XAZI4^8\0 LC4'/RG= Y%;% FIG'HFM(E-Y:L&=EC_\\E5#1//3[=
MFG6F,6_?QZ!K^2>OMCL49-MVG,E1&\FRF8C*._IY)"3=VLN1:R*3@D%=3*)/
ME_DTIIQZ%>%Z]TK1(FOQEG\_9CUG=M_G9!^YU.N:!XSB3/ GU"J4>9^0VX24
M)8PU,_<R>^97J31Q5SU_$ZLWZ#B:S&$OL&B"X:%X8#ZBOG /L<EUT%?')ERQ
MWHNE^M=K^\SO!A;!;%O]A?Y2Y+\VIB,9XOKW3.(EKM?>VW5\U^N7-L82C_?2
MVKV_X@IV4"Q<M(F-M_YKMJ:IWK(12\ZPDH36T)/W/QRO424U_+(B]D_I#[\_
MTT$37I-_/5_?VLDBWU1N6V3UH&B9!A?:?H#&'H%*>P]F']'*U*Q:23IT_,5W
M_S*W!%^-MJR?!P9I"A;ZW]-GSET),T:,39\<;G6Q3[?*. B5NHC87Q?R)O<;
MP^[KE%4&FOJTZHCYN8]GSIU*.,>]L2?@W$>M'TTO6==O(BV[FL=&(TZD9SGP
M[YL8YOL+(+ P^3&^/-C@!AQ@A+=Q>T&;RN*!I?&VU6#6LA>+;,'ZS>4J\I'N
M<*[C]I1#U/*BRHO[_2V%\LA7R/4&UBKM=M:Y:K'FD_ZP!P/_/K;0?<9\\CCX
M7<;7@W8A?2[OP5+^/@?6A+BMKRMXG*,D% \CI.PJN--0%3FXU"U M'+165/R
MT$)67#SFK&^A9WNP?VE'C?M'7?7%AN=_8+CTS&?![M E.A?GQR UQ-XENS''
M8:*,K]W[P:S9:\#DN[J_)N].!69I>M"R\(DJJ0^_$"ONC[H\_O>!9>(^6-X=
M)?G@.^*5-Q6JJ\(<VM58#]4' NNKOU_H';/<[AJY5BCS8#Q- [^ [-#(UOO@
M5*SP(U<UMG#_*<.70AAUI!^QS#W2(75K?BC]E$NQ3%S.=T<UP[5K=OQ'7'OT
M(ETX=E@E?^>SKL@LH1-.U>N&B=&+092MIY4[F92'=EYA?/RSKWU7D__1IX^Z
MNYA/!VWY0V3K#*2>V':K4"C 70"75JBH?]-RX3PCHS"X"GSN:735.= ,>A@I
MDU65GC.'&_YJX1."FNTP^U8\Q/OP9!:WG^H]H4IGM,>E8K70!8OLAK1 I<F%
M+YX>2=I_^#5<O8,,+O7[-- R]46KI#FC[_-(UOF,:Y0H^@.C:.M[5#^712_Y
M>P<-8A?99Y,9UUBI;3>5#J:*O]PI?5?H6'5JH]@]..A@Y>S%Y)M_&)ZTU+F?
MJ=MX$S2(5PB,8>_7U?FTN]PK1L&IG1T\?(U=(Y5O%UHV2!\L*W34]:<5.\\Z
MGDZW_MP?[:WD_]+! DO&NO]O+'N]@V,6]J>!*/CXKAH!1&^Z\W;.]E3JV(II
MQ<YO%;].C7N:LEL $6-QO;B\<,X8C] )NBPI25AE&_2$VO/%!1 3+QBP@KW)
MOM:H\Y4T7_WW"'6#3?#FU@M;ZAW M9X10&X?%D"N?49T\\4C<5+;*,1K'&"Y
M F>^1M0>$D#>^JKRBQ@;V"R7M7!)7)=-&VS3N >^8=3([84V?Y.57WWI0UAM
M==@/=F\.[!3PC_(_;\M\L >O3XH!X2ED!*=S\S6(XIJY^O.-.7OK6&D'_:G
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M4I1#ILO[^D3^RHH\ HI4DAN^/:B7:]EKSQ7=?+?30%'#?L814:VKL4YH498
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MPZ+*\@?LN<?1]P40_N%>\:-#9O!.=H]-*Y09$JB2T:#_+T5E0$_,F"\N^JH
M^'E(-+]<WNUX.BEOMZ)ML9-(8M3SZ(+2BY4W"J];#[Y$287I[7M/"E/>IP<T
M>Q_HW.5@/=C!4BE4Z[ [DNCX/5UUCZ,.<:+8=JBD)*\F)#&],9U?2&CF_X[K
MTA_ +6X)-?=@U3#V*$9TARJ W($RK-AQ"?Q#&"6.2S+9?AHF,@'VVH_Z-H*V
M'./S0*A1''T9C?9MKY?.@X^2U4M!;4?* *EV1*77?F1%2RO+L(B4ZL=*S]S<
M8EKQ7@2J\JEA^!VC"9=),"R.$,N^8F%B(4<\A?-F*W<YBY>:N=UZIY^I,?!
M^!KYQ-MJJ[2$2='/1;P/6*^1%$#J3W,V7P9<K#0LC.E8L\HZZ##CXN+21"E]
MUV\AQ7T"JOUT84_]-(8FXC<X+-R.!3%B#?_EJ9O+I@]PN;+V5)H<!K?K^A<(
M_-?BM +DH,B)//5^LM 8JM[D./$I)D(W7E:?YH7D'A) NNK0ZOQ.^S2A/1J
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M-WM)"8;_(,<+]N,;D"F<0V3[PPS%1S;]FD&^ $BDB@5C%F]E,F'YH2XTF(0
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M/KNIZL@I2A>!O2_#4JY3 RNT?867X)SJGN_=5<'XYX,H_^R@JXLL?Y,BGF[
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MQT3;B>H/.EKJK[5GED]IXF.)82"9IT:]7!(8;J[&ROK6@5* !#+&L'';8'I
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M$(;V,H(I*PEHWM(]TG9:&VH-<1>TU^?F38#3?ML-N\D*E1\PALIV[2D *U,
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MOL:/DI@QU_'6/3RI1N2TR7^Y^L?.@:JIC G'<X'^^8FT,I[.\[CKY3GB1\*
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MYNH/V1)3""=1N R:=S!J&+#J_E^GT6']1BT$S0#I(Z=6!GBOD'=N6)D_95;
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M2$UT&N\R.Z$LGT(8EK>L"=6A#(,3*=\+E0 6M*A$GU?[Q7X*$,!: V6$+V&
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MN3N?.Q4?@J?W-Q\_&GYO^WN;\-WX$.TP*_4O!W<I;.1_\M,=&%'B*A;MBF>
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MP:X=#P8G8IBK\\46D/ZAE@X+ "E)UMQEQIS6=79B__S1$Z<UQ@$WHHET5,8
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MR,TNS#\L]?KDVO!?94L)="9$HUG"6X==9B68!*M;(+FRB-=8PYVRF2PQ735
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M"Z+R*3=H3<:E -JG3F;2/!NKV-=:]GZ]D\SJO(+'#R9L&U,JXMGY!]!!PNL
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M;IF;)IB^@W[/X=C.VT8L M*DK (J["Y)?^1+K:PCWW:HJ&C"^I9UJ;5&K<0
MX_D4;B0_BH#R$%W!MI;+?/LN=ZYS+U/M<' F#FL> ="SEQ"B\EYE11.V$P-G
MN$UL+2!";/#G!"0NO""SA.C22;D1\ MQ0!PSFV1NXBI4BH%-#(O(7X";RF<&
M3[N]KF KK@B!/QS]@I<R.JA?09%\>[)_@&B'$G-\M'L83@O(&+*60"+SJ2P
MP@?LN\P-#!5\^YY Q6ZK>(*IV\7D$9VLVZN9.,DTY'+G_MJ^F:FCN?<_WQ%&
M?ZMZ*$PO;I; !O0Q59;AK=S5TXW6SUB/IK:(B(3+TOR^N%G2]E<UQ);ISZFN
M,ON^!_JN,N,QG#1_;\)0]\ '672V6>:*I<FQ:9-?H<(<-BA*J898?;';_'^1
M[Y>"DR3=YA&XZCJO2&7DU*C;)Q*O^Q;C+'6V0?2P".T^5'("7FXK;NXQG_ZY
MI1VJ3^Q><NLYR)2![P^-^C5RMG,"^TD(L3YAIWP=<!LO1@^46SU<,%%K%H"+
M_#/.5?B4WL9:+I$MGH78A@_!MDP<'QPP=\I/E<'$?[O7Y+4V4K<9[@%7OZ9'
MR^TDHH'0E0N"X->*G4 0$KH'")'<F<?[-9X (A=$:L#L1:FB4B56;DNVL9.A
MVISO8I61C5P8?7C+H=;OX&!O&54E3J]O.IR9/1LC]UZYBGPU=*A26GN67X>,
M#!(/GK;O"5%KUQP]RV>4$'8!C5R?OCK$2ZQ(:V9V3\\7J;FAE@ ?O*J"[NF>
M]>SQBY7 S>\C+-]MF%HV_E;;:*CL;_>CT1\3VW%BY-V'2]:/TDLGE@]5EH[7
M)'V&"6L\XBQ@VXBXQ@QVNDRCHX5WH9,P8Z%L#&,LZ^:T5W_VZ9Q=%M.G,E3-
M+!6F.$C5;'PP3V^<HB$'OP)0?:X(5]BZR>T3PH.%#TE0^C!5KRHK1**IL.D)
M5G>6 DP;2("@ZMB $&WRY9/(/]OX-L5_W1)SQW>93&N$.GW]Y:3A!FE:O+22
M>Q$H<7DC, WIR>B8=&/('/+2,YKI<4?E*H94240]U !ZB<4GU/DH3BBISP#7
M_4^$24LYWC?L>G&1LCP69V1E46$YL'OFD#A=RZIP,M-/0E4AQG$K<=8=N>!H
M^1G),7%1<#VFV3HK+3& Y%$ A+W+Z%)TLO52@(11#SXSTNBW[INU+S;,&R;(
MOU#BUT!2%WV<R?J3,#_1AJ$3WACTI(=;@,_N- 4$/*!$(*3A$PGXC?+)9#DS
MO3GC11I4R]NM8=L$/@^[N"S(+3HSLO*<IN_(C+.7*>6^\6_2CI+\"8J*_,3K
M26'?(X4I:KSFJ8^)M'Z2>)T+-1+8H%^3S&3K>DWK/*X3(O( 2\DW.W[(_Y@^
M_WQ>L_7B35_>FE6'7__C6KKB954!^TM6T1_'/[(_O/Y'9-TU:WGN']G'Y&RO
M[;'99_5C[B-I?ZE,.?4?V?(].C;6IN^/YNH__,_0O,<QL_R1/?NZW<N.;/O/
MP&T3O#S^=MQ!F["H;4N752Q<.MUOQ^6DUU_J>8"EOW/23JOM7?4/C:Z4[K;O
MC#.[5F.Y("/.[$<Y?T/>'MZ5%8LN_N%]>%XJWOV1/O^/+LD_UDN 98[GBJQI
M5NF=:[[&VN4*IGVX(QYV?M$%]M>YHC_9DQ^\O_U.XLGFS'VZWBQQO%=M3/E6
MKZC8_?#RJ_!-9K,?VV9]/WK=+.R^V+U;QX_?ZN_2LS%_<%?LUJU7KQTNVZA<
MNZ=V6?]+K-^IUZ[;[E^LT?^=OZZYLG3MG9K,+1^GS7Q0WQZ5>W=I>X^=R*LZ
MR8_MW<''XECW737EYSE:_LAL^N$P.:D/H?,[2O(E8E]=-P1V^@6^KHT_LGW;
MMEVE\WH?EGT48'_U5O2Y/;?"QT,5_F_G"ZJ4?C3;_(A?-/OL4D_5*6<?U@I'
M?E1;7O\PG\/VW&R5:^;;Y<0^G+GEUUZ[(NJLCM2TA:GE]<(Y.T/E>AU810*'
M));_?Q, 4$L#!!0    ( $^,?ES&?)?39@(  &L'   -    97A?.3,Q-S8X
M+FAT;=5576_:,!1]7G_%%0_K*A%("!\II$@4 D*%%$'0GIW$$&N.'=GN!_OU
MNP1H1==-DZ8^5)'B>WV.?7Q/K%P_,SGO^QDE:?_BBV^8X;3OUP_CQ1=\_/H!
M]&.9[G H0)L=IS>5C13&VI"<\5TW8CG5$-(G6,J<B%Z):?:3=AV[,(?TD2A&
MA.D*J7+">X8^&XMPMA5=Q;:9Z>5$;9GH[OF5OA_W@^>,Q<Q PZTY?CW&4Q7]
MBS_H7[XYP.6_G.!,\*N(=='[F\;_U9A08:@ZUQS>AZL@C.!^#--P%"P"?&&Z
M#";3510L@Q$LUK>SZ1 &P^'].HRFX03&T^7\$SIQIO"=0D85C7>02*'1&# 2
M3$:!B42J0BIBF!2 N*(;)(ID#Y6,)=TR;8Z$E2&&YKA> V9C5(*5Y<*W,>,4
M0ED#UW6M1MNVV^WJ(>ZX=ML[QI[=:39/\;73NCYQ/*?9!B+2$]1J-J[*_*C@
MO2CHHT3#\QK.<;GK=)S.,6Z[K:9[BML=[T7BNN/8KQ(H;GM7(#<P8F1.4Y80
MB- A4M 'PQ(-4Y'4]K!\4&@)&F0@Q=)3F!.59.#:56C8#2Q248[6B.W)T+V_
MDK,#><,$$0DC'+_IR;@J/&4,MR!%08G2!YN9/I3JV-8=;*0JM]HA#E2DN-&(
M)C2/J0+7*85;M<]^(^NZ#K?D!Y84,<YWL%Y5839;?/:RYDP(2@J\ ?BART1+
M0SY4\>Q"?MSO])V6<69GRAXAX43KF\ILL(JLQ6 26+?+8'!7Z9^AB\DX6KZ9
MRS:6DD^_3R:4<UA,PO7\50T9R'MOP%/4RYZ)'73?9'\!4$L#!!0    ( $^,
M?EQ:$@+0A0<  %(Q   -    97A?.3,Q-S8Y+FAT;>U;[T\;N1;]O/TK+%9M
M04H@@=?N4Y(BI33MHMT"@E1Z[Z,SX\E8>,93VY.0_>OW7'OR@Q @='=;LDHK
M-1W[VKZVS_&YUY-T4I>IXTXJ>'S\XJ>.DTZ)X\Y!^'SQ$_YV#D)E9Z#C";-N
MHL2[G:@T5IL6XZ73[1U4%M.:1.>NGO!,JDFK+S-AV9D8LTN=\;SMZZS\0[2:
MC<*%QQ$WDN>NE6N3<=5VXL;5N9+#O&7D,'7MC)NAS%MDOW/<&1SW;E(YD(X=
M-?>;G8,!?"V.7]PS_NLE!UZOX\&M 5_E UNT'QKCK\TQ$KD3YLXD3WJ7_=./
MIR?=_NGY&;OX<GGUI7O69_US=M4[\65'C</=[AX[_\CZO_8>6X=_Q,>K[N7[
M[EGOJG[^O]][_V?=DSYY<]AH'&[HMMP:X;3&+F5TS2YXJ6R-1<(XF4R82[EK
M?<>Y.3Y0@@VTB85YM]/8@2-*%3R.93Z</=N"1]/GRJ6QC%W:8LU&XV6;^;V4
M>8Q];+%&<4.$!;/!=C.U']'\(JZJ+6=.%]Z*C.*E3H_>>C]]Y6P-JBDPF@-;
M  ]3(D')XA*Q5U]+[=I+"Q4*:\P7UY@51B95.[]XK!F6I[GOEX8&/W#Q/2Y.
MCZ4?X^(I2_E(,"-&4HQ%#-!(RWB>EURAL-#&,9VSC]A[M*C_QG3"/DC^6<38
M =9/A>&%*+$=EIWFT7Y[>;[X-,?^8/;HV$+Q1^WSX?.'XGMN 4"@+9NPZUR/
ME8B'HA8064$QUN@XUXY%:,UE#J1.6)D[4PJXRYW(L%F$4<XR/ $MBB4\0I%A
M.H,2.QWL[ACD(A+6<C,ADXQ?"XR[T*=%60QG,*0BJ:<QR""2)BHSF.5H#D^
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M@(%&+$WUL81_OI-=4!:*:TG1\4E9]>2<$5]*"??]F5+FD;]>WMM>0&V\QF[
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MCYLFL)EJOK:RZO[8.-XV44,A6^D;?LL:[M]'+]I(9[U_M0@61]@Y@.TG;S'
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M$]0&IWP^"UXV"B_,2PN^&2L(':)\><AKKMQN?IH>ESSX7:]7[R$08G4)Z/+
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M@,-[+8["S>HJ<8EQE0XQB3"867'Y'-W/7N/&:#A<(:R!-\C?B>KO54AK_IB
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M3+T]XW;ZQ2??Z6Q[K1#+U?S73S.9!$&[,;N4^AWUH;U=+V"<GDGLVDWIUFE
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M;9RA0DGK5N=4A;I$1MY35TFG]3PJQ6E%=_V7ZW8?(G_)M]KZJRW9.NI O?4
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M!*]'O(I-B,G&F*&5@"8FP@Z(8"!F%:V 7.:HU>@V7%H$A&*NSLD!;TM>G9U
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M4 U(#%U("WCF]^STKSC7#7GFKST*3L%4HGH6+##-&8J+Z2[R["/ILO0YF>6
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M;6Y]<0S1M?I596U?,=4>;'YAQO'Y:Z=2N^!1*-S4EL68QSW9*-CJY8).D>0
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M'3 ES["F5[B@.W.!.WOF6' ##\OYTRN>QK_Z7U@X3D.WE<=XDI_/[;H)AC(
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MRS_UO]N%]IQI^,G13US0<;1.^,&EY9B"O?7-AC43<B?YM&$O7,9S@!9_Q1G
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MGJ:#UP85'-@2O2XXQ#^KUPQ(F_\-[H4!*LD;@@QX.A=T&J,"2/2*H\^.DG2
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M !L+I^D<Z*E0 !^86U=%>N446E[B[Z4.>K:['@.W%I-4SE74#H1X.MO7QO?
M^H.%QW,CZ]GLVK'CNDC=JTF_:FI>]!V\;O74RM'!*@GK+T+RDX271=;\)-"P
MC(<U->+&4^YAC,<ED"UHX[,P!71/LYHQ%YZ4-PCL1?LZ#VH.+;XN0+><Y4S6
M^]F@UO3-SE5F<ZAQ4Z,&Y='WV%9)'F<G+CP+G]I'2TX=]A39:FN&%0_1]I^=
M/OU,==K"Q8I6.4I$^&6&9F3IB1LGF/CVN8?5=<L?D3?9S)1[NHLYJ"M4,_?\
MZ<O\BC/Q75<X#6K;AY"%W*WXX.5BZ;$D^>[1JLJLQ*V\XKMF3K]@)P9EOI%W
M\N^/XU0\$ ID&6Y8K!GL+F/EUE7J[F\A"=).MGN1=NVZEVT3[&VT?AG=@;-(
M"H+H+#O9LEN$F.EMG,_).#PL'EY!;9^;E;FOMH[_@HOGA<3":S2:H5+>_615
MD56O]Z"9*P-I?)FKD,VT#1@!%&S;\Z.*6 X]96Q[FX* +,>QU\PD)UV8?4-]
MUJ@LD,;WY2SP6L4O%E%*"$">2YSI+&'Q+-9QVI.NY4T#:_C-7!96@7^9X6HP
M*V-560N+'_D3Z/5U#&[L1'$E[GOJXYK8VWR/_T+/.CG_);< 7GS=>REQ09^H
MY?B 8!5@IMWR/4Q'UUE3U?:@<./F=*U:JYV/G5^-Y&BU19S(\([-A;<4#1+\
M)FMJ.E)K;?5GOPS9.L;#ACL_PS*.5J1;7,BR.H^O7'1>RR&T+<.W814Q1MS9
MI3?*4<M)HK7C<XIC+FX-3]V&/=&9+;30JB!?Y+XWGWF\?J^&PPUO/O7F53QM
MS9HK'@*J: )D,>GI-+ ,.DQB(V)^+LH4!/>#;.H?H#$BW.L+M(=(7*1V7<VK
MQ<G_CFAO]%X/UM\<ZV;G(QXE?0'*R$)\N%GOH:/9-U,<2+7WO>\TO1@ZLOO0
M7^_7335C=N1C+*E+/2JN7A@X]^##9C4]91TIM03&?1[[W.*H\27O8/KPFY*G
MYC]2=\ADK#MUX5YKUHKJ5!PWW J9Z1/,]S[Q90SA$'S[^9>MVK&L:P2WF.UD
MD\83)2TF3==?_69P!GVT;+:\-N[:[) =$?E\2UZ,Z?K$]I[C71S<)8)R%8<?
M?^(-^UW($;GWE06*T5WE<IJSAZB/'!QK\\I^Y:4N+H'BZT%GT,_.(E$HT_"5
M7#6A^]3O++">KOQ8-:+=P1]^EV*)50UI"\8C2%T6JX!2S%LM2W94&G4D#*4=
M)GP@&*G&ZX-E$)^9#WX#BF#Z;""U6HP%,JM:RL9P&:S9ZMR4U0H)5*Z$1,Y1
M$$NG?BXM#0F#O5#._230/(OVB5]9F*/[/^)4R+M'V<!1_@>ZLH$Z3;'9Q+B)
M<E]-@9\2,FX*EQ.M-<K=@H<--:P?5[)017>=X5/U$Y=.B%P+T?-2Q?4JI6HJ
M[@6>N);MK-"^<SCWB*BQ%,H3+)ZZ-.*]'!@OLD&-$'F%WV8Q&B',2/UH!%-?
M"8UM:8?*8%5=11;<V;):+GC@;OP1YESL#HPZQU#<$W? !J?(-V["JGT3N9<$
M+&_ST/;D=UT<T*],@K8H/#7_:DL5R4D@[29Y_--?];=C-/A!OG<5FTHW,L-2
M&JXQ4,K3)AM;4M3Y?5.\YVK'.:63C]R2,ZPJ&'R+;6BE/>_KR1)(W)6Q@[5I
M;M[R;0]>H]A_))#=I*4%+RP<VS@G3+=$S\VL3-#E10[\/1PB4S\9<Q2SBPFR
M&EKC%%?F,>;83R]:66K1M)/]#P_W-L1;":2UF;91YP")U-@]<-A&]6Y&N@O^
M>CZJ*62T'BR2:W\I+ZX ZB!R=ZZ>IN'-@ +I#JB\U8?QE8-)2S6@MPB=7>95
MUU/<W<E-"T#EJ/]DOPVXJ'69!#(U15A"KGTWYRLP)JV(&:M@AH7K?Q4;^5G
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M#*+L.BY0-4C)?VQ5'.H_Y$KM<M3UT9;O8E$=+$.KYX]V'#NM<4<^CM@Y-[S
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M0B_U71T@E)-J(AOUYI'&#@,S>9$U>4=/A=Q^5_K4>HHZ@Q">Q"B(\RC^Q&1
MEZ_"/= "ES,[EB?:QI=GS+I[<$J[V\;PU\HZ)G#);@FLRUU!"&3UDH[^S!^:
MIG.KL?T)#:SV<6P'?=<B3@8:8W84OZ&R-ACIZU!7QW_QAI_=09;G4[@44"E;
MQ<?:!1TQ9F$3,!G^S5TV'YUH92F^1OC2,7]G"[/& 4.7Q:+@E45/D\]_=IW9
M8FL27"[OWY>6?OSKM_2!VGP?WY!\2G FP;ETT]=@_Z]YDR\S&[*"*NJ=*BK@
M0U/3P6EGMO88N3 7;KAX+^R[LJ!Y]U&<L2S9>G>T9=>1G9"!,,6,C ?[Z^I(
MU:Y3R4,[@LPNQ97=W&>)DDU]=M[LC:RJU@O5AU5VTEAC= IOH[BXBK[YMVR
M>B7V-1.FRJ+%Y)<%9+57<3<R#3/2[C*EC5V_!5JH3@MVY90HEO]6M-C:Y\T]
MB]1,3T06P:<?V/0<'^TV)Q)<@':<VBRPCZ_M4,LOW5_*$3;AMS7(,Z>JN-!6
MZ&,+O4&,S6NT[TG.9!(E-G!1%SLT9=U;)2.#&/+:3RTQN^Q?[#6-U43)=F^M
MK$;J]JM"B6R[1MQ:>,L?H(&,C9WVE+.WF1I9@.?2#[N!9=0B6P)I8J&,/J]>
M$ELFX_7A'RT078597B,2B-WH [#.TX<DD/Z9[_6(**@4D?+S:=0M,&6/C"R1
M;."XCE*R>-A2SH%.S,@B9Y<Z2B#ZNZL;+6:K&QL=,]VQ:RSE+H.ISQ#\M;0T
MS7,'G:*N\\E_]T=4QWG]V5H)9-^A.:!#9KT$POJCS&J20!H9%+987ZRW?R=E
MV<-:'%XD@;PYUF&V0P+9NQ0KO@VZ])/R0U3-_V&B*!<)'.MO(A'H3-Z;I*Q?
MM3"OP8R]T"6!7+A._* ]@?L/;<>SQ5.@0?-2!UZF+IW8R#FBOL2#"D[___0$
ML/651S_\LQ*E?#?D]7_W;*Z+ZG\\2TS,F-]=49/ZU#)9*F_L[-?>&I?1Y_EK
M*H&S&'-N-ZD-1I-AT)OD^?*<8Q]S5?G^3(J\S40V;)-?'25IL78)ON;[CR8"
M.NPB]R3_P!N^(FQ(I#'ACHA,.FUKVA$4H.Q4E>_A?U1C.C0S- B@>'SA\:@[
M.E"&/YZ<TNE$!%Y75-17O<5&K<EUN;KCXF>-Q]T&]BB?!<VDHRU<*N]:G^&N
M'3P2]R:)R6[T_K@\!N7?YR:T1\C<!_:A*;S7G-@X/:3(NQB.,*I32^&(T!V7
MQ8D-\"(_I[NW&NOXX6)26=2#43/+HE0FHM'[2ATGY88X]<T^;ON=VU$QFWI^
M043^?J]D7D#]4E:4*3XIPA/F!R001V@;94'$9M7]E]4A_L/J0-E65%OJ$K6@
M">=YFF)F!DWA!Z30QN\"%>-[V-$G.!M(:<E;@ZBY$3<@MMA8ZE1L;(4$(GU9
MZ+&\!EB#OXAK6ULZE?O<[(;@AG-Q&B*E -A<-HJ5 M0HX4W/ZZ_Y$D8*2<!B
M",49U6'W91KCTQ-'WND-Q#1>3)1--CM6LH-*<HA:8;FIR\Y;[.(O%&DTY1Z"
MY$H@W#V4'HM8_.5VF2H9I;5@)39N4;L-BZ_2B_ &M)+@*_,;!W2]^,E0YAAZ
M>1>4(<5U9K^BWT-_;)I+#N_!;#D>2F<KQF7C.BW3<&RI9HH^S'Q1?_5*I_,F
MW/=LI65<R?!DHV'C,LQ6OV@67F$MRD[YUQ,E-VP8SL"K+!FBX6P5\W^VP\!V
MZ4CD[64))/9W'39K[A>H&?#,E; EV&M+^0EZ)32AJB>6#L$>YPM;=K0@F?"U
M(G5^YH2,C(?'1[W25U2S8^.-"+>^F[55ODF!I4S*!U)X:<[@@22W_5=W/G%'
M/65-(I!())N$V"6.P!#9(S#+=R8]VS G.=08L+H1_PY8&&LK%9UL&)S!&*HJ
M^XB[7RZ;J*4;5>!V_<I?)^-->%_^P)IDT\G,X [F5YUWW3?,I;?@:23&UAPB
MYFY-8SW7O)B5J\M/*:,/&S\R',GN\C1E!&:/(XW;$KDL'JF\\:>BFF:O3V5?
M!GS6M81H.=F64V)_T9N_UID+G=6>R-[UUT0KKK*0$!)T394J0+816F3^]G>N
M\_E%S.LI\/KA F<Y#SD/]7<2IA5#RV'2S;:!^_VOHJ>NI&/<&;7<I!F\K$'/
M!I'W4.5P98H\7P)I!@QJARQ47:;#3'C$B233%B@GR^-4.-/<CLD(;H3;]C:8
M%KK3_)=M":SJ",U*Y:,N[C):<R?&,7_"IS8ZHNUPU[)N(J\4>#U[^XWW\D2V
M%;\PC1>4(\XQSDOW/[U)^&G^SICI)R_GUC+YZ1KK-?="Y-Y7A?^D5,]_;[.G
MS=H6G8>^?S/TKF.QW#=$?JF@=&;=<WU=1MVC]RT[RS1<O?>%K,LOTGAKII9^
MDZ(N@=SL2817'@+Z*5(6.]'TB6W<Y7LB9\X<<U#\->[NN(PT.I#99<\YA($"
M3;65@P;GI9N2CX?,GM9.0$0_/='RL:TU]2_Z>_G!E(_7C\Y<?/^\0-Y-]M&;
MUP>_:MD=>1DU65^Q8DKX1M?]<KNV>OO.+ZJ$0_*:Q]LO/R08L<BN7OJ.[_S-
M]:H\=X+LVD8IQ.>/B'BSWI1 ?'*.?$-#YK\N@+* 4!%2C%6PF-6-6NZE0"E8
ML@]8F^K8P\'5H_7#7B"WO-69Z\?B=1?I(2S"ZF6'4!;25"];OPFS/(U%8:O[
M47J"Y87-0 A&%\2= +4]_.&0*(9XJV :3M.>0&=,+YQ[7U_SY$#27/JZM![D
MON[R*WL#[\A"+-><7"LX1&083U ?8XWU9P\(+[6,S]'6,M5;)! 9=Z"7HK"[
MG$.(^?G8CV=J..^;L;XN][P9>WCX3]DY;:4LZR,=RIC\177I^41L4 [S_7"H
M\LYW _.T0<*FP7S+0PCY1X\*"5[V#P,<=Y=DI]GRD%@4,]3[0=<=U5VWL%H,
M+1N#?#M#1^6EEX6<FMJ#Q[\](JBT'TU#WAG3.N%9+(&<P[UW>D'PQU429M>@
M"ED\DUO;,3OXLCI/_'FAO"-FA':ZZI//7'?K[08%\G*?/GN\>_M5;LV!!S@_
MZ$BL535<'9W)R$E),I-F9C?BSG\SL+75P9@SUPTN4K:C<^=IN*TN?"==!.A3
MLIO4E&JJDNGM6<B,HK=H@OVW[4,"4^WBN0-,"G_/3<)$XQEFYJP'&<J/9:K'
M9;VT6,^7Y9F'M>TS(OAX[Z_@8J3W[H\/(PG7A<EVA^W<MH_N5U]S]/S>G4/0
M0?PF7-,IG"]*%AVST$*;Y55P1F8XGJ._W3I2%%L4LO3CD3,-K@<>^"*WXV30
M^%9G050/C_GW>+^9,P'MZ]10GKHD9:,T>ZO*NIQ30]GX^&.0'O)A6V_2%BNU
MACU.SWPWIS[*57LT0["M.6^X;TZ!^D6@)]WZK?UV.RRN>0B=:.YA4'"A(OI"
M8)#C='&-8Z*OPIO2N7V+=7W4%>CJ?;QY&%@];/-G^@=2'#'-$Z5@ARN?6XH;
M<8/)^&.5!KPYRX_.DE7A)/37,92LAW_=4!(&^;JZGL,C\MR+,DZLK\0>!CM)
M$UW@[*M+;M1OT=7NB+"<Q-^/B?8>1YOAPO.Z=18P9QNY#6YA<2@S%5^+_#*:
MOYO:0T)'@6U!DP^".!*0P:%[CGSN=P<>NF&'\!\F>WA:)'XW9]*J/*K8E;7?
MTXOV+:K8.O[KQ.7P[L^G#=YZDP:#NQZ1!VS3"Q:5R9F&.6U?W H2/*Z>$=X$
MNDHCW[IU<35:,I0#,\B*(,S.BF#^KW]XH>L=N!8O"*[NW3I[?ZEDNZ=LGKXS
M/4]W'1YF56>:A"PNXWP&KKT@!]TJ)9UA4;JBH,1O?+H3>&B)&!_.:![;0DN,
MKU3?RD=<@JW/@7H.8.R9_)E%/-_%0J-WT78S2L%8M/MY_VQE<:2PF+)=2J&Q
MEI2C4S*SN_YIN)O.+ K8?)F[@7H9^%K+WU-"<__.RMW./09'!_2WD?='P:RS
M.VBX:$/V9+7:]A@;F S"Q)')SVRBRJCSR!6,E8QY[<C(>O /7K&D3V/S#G,-
M3#*BBS'7^(YE-%:8@EMR?B'<X]1;FF58'OKA.1/+OI$>?QU%YU#R@2BERC,!
M%3]L2EK6LJZ[%QO[&0=2$+CA#UH,4C]Y']K:I>$)W\OTL8'X#"RN4J@N'S!$
MT\L,P1F]-HRNE*71QTXIY!?$T=W[$Q/DLL[5HDM_PJF9,%;H+@FD#/#&W8#2
M-KJ)"RQVV')WP#D7R>L&=!M\F"F;<3X&68E#)-Z8>LT#;628+?[*^_Y 0O_2
MN4"%<_N,9F71DRZ!>AJ.3\267IM00EMLC\TX OZXB.O>Y.2UMG8@I%M!778T
M0*O0W[\8#;](&3([5? %Y5WU]*L$8M5G4&KM0/Y0%R/U6$>'4'<D7*N!3TV4
M0,9?4RID[IM=-HX.H2C!S+^8E+THZ'SGEW'&LU<#Z!L$=OF=YC%!DYS+GLD8
MRDII4]_<$;1^X/#TG9&N\$@":WDHR+TG%)L5/$]!2B"VBB%4PC2/Q.:KW[;W
MTBP&^J!_&6S@O!_"'N(?LX,I\QW8'1:*-36#X^[F[DV\2U+9^.UG,,=\-SQ)
M/7QD; R&DF^]7SK[A?0W5\^2. L7&H_Y&5L<>#BA?Q_W?N:+37B44?FN\LJL
MR)P[G[7=B]W3XWFTE3F,(=%%_ #A-V?)R[Q[8XCY>Y\>].M8CLXB'6E(#1R"
M%HOI>%;1HJ;\_"*^FCA3L.F:?@<N]I,WJ?]/65C I&6B<EJ UMJ L\T;GG_;
MI>&(=# _,]/GE\K*>D3[[&+I>YM+:<57RWS$K1==YAHW@P=!EOD;,2;?;W;@
M+7T:V"OK3U:JP2F="H\L^.Y/*^F?JZ^I[-?)=J2B% 8-D)N;?WWUA%TA(:)/
M2B#$3R")"1:KNUC3VK\V06_AA[N ';8J'YWH.PS<Y[:Q37@41GI\K_Z^RGY#
MHC1KJ*XPWZ=D+/M&=7\BCSI4].8'*#PWAO0*C.I"VEI[/Q?=6> UBY_?,K1I
M5%B8"+OW:E#'T%;?DER)]+1QG:[K+B'1HI)^Q*F<09EE873??MV?JM!AYQ<B
MQ:O^4$/*O3*'8L^Y 46"):@G;AR</)FBQ1SY*8J,A;;H!+_"NS@ )RVZEL?O
M@'U;"J_4=5BPK#$VXM6].=QR>^B7P^,*:\W&5F,%:N@OA/:G?>=+]0X\GB.>
MSJ-SQ@+&LMUANX?8?RB>F<2</\( ^7]'.\$TV5),@OZ,]@1IAS%.$9NW>+I
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MU=#@7$RU_.GAN3_SSYTO[P*,[.15:Q(.%:[\R5GQ=K#K;"/(%P]:9/+\E)^
M8W:3,INZ':'.(5B8)5W;F^Z;&%!<*%)3?A(?<B[#KXV5?:-8#G$(PE;6HD&#
MM+G&XW^K<VCT-::IG Y>0I,$4HW;%"XO](&O;==;X6D.[V<Q1O,_-.XTU=>D
M"?4(K)>;YUIJ4";\>MH0;.0S;TPL@5C,Y,5K3PHQU5A$V=R2^W>!D%P70'8/
MZ1<,FP8XYR+@"EAE_MU+]7U5<RK\L',#MURWS_=?&KA:G36<L_WL#IU$LM?/
M5"6;J]M:UE']<>_\ZZYK3RM')SU.NQT[2PKE/7"R?UJ>':?A?-7DGIW)R\VB
M'#Y1Z,P?:9- _L+JGW^-1GR41<]=Y#\L0)M:]@66A-BZ067]E)-)XO1W'XN0
M1)9Q1L3< ]J.$"9*=A\U:W?,IG9\WH].W9=W,51%[[NW*F(7+O9K$I_UMOF@
MMP1Z&V8S@HZ_U S8J:.@L9VSW/Q+*9C35V02W-]VH<#/GO!U3"W?OX/ZZ7V-
M3J#_@Z9?<N45^4FMC/<!+LJ+;ZD%9G;[D]01PA_[]>2?R14$R$:?N(+?ZWCM
M'>ZMEPH7M-FB:T$A" 9N.\MDMNV95E"80G;8KB[W%NWG$T_ME4P=?\@[1#RQ
M#F"S%ZQYH>**AE-<[7;Z5LP))DH&K=VR#=UER8\+(;K0-%S9Y.TUG'2!M/R2
M]B#7B%3HP0I+C2INH5+W'K_'=<(;A!W]?7G,WTU^F658.EJPJ'W7)P05'CCY
M (8P"-M6Z^#XH&N'R1&'OZ_N''\@8\CVZ?VR)_I-Q44K*?FDY5&W8>QV\D:I
M@Y_#"E]'MTY4'/KVE-"E_#1#+^_E0&&ZH>9.#I-<PK[@8G(\ZWA85]<6SPAT
M?._3Q"LKQ0XMU_P_S]?')_T]W]Z;EF87V"9G[RFFE%$'V?U3_#*4%QOX:XF"
MTCU-R9!)A',NR(P06Z$JY./\KJ9<=3%^";X)+03=:[)9.*-X]NX$-!X#+;5(
M84:=@],LW_T>HF\T9$=*_5[C1XB1O@[LO7+4[HP\?!H;O\P/BZO(E6MW_')4
MY\KMY^^^^S,.7<G98J%ILJ/8JI+1&4=PDFWXW9]Y-.7H^>'IN06198L25'Z\
MR&?EEP*Z1%?U;- 5QA9+S#%'AEW!P1Z\M-,SVJ52QSOG:^H+^P)TL8:X)AWH
M]13:,9XC-Z4#+X>)>,_W+>C@[@#EV0"ZQ15CSATJGXCI>:@OBHI\YS%-52;>
M%VW7.4OAI ];^DHW*+;#]C(F,W2LB,N3F3/1'!E;3A+AP:($LM:_6OFBVZ]2
MIJX=LYG683=D9O\.X835?#^@9^9:XL]S(@&[PV^)7$M/5L O+MOOXZZ$;;Z^
M3GS,\O:OX3)3TR]!KF4^3H;<[[34XKA2Y>"W[7>3CE]VN/*[.>>XV[;X"]OB
M,:109,Z*G>.#SJ,S>HX9?<&'CQ\T<0EP*'*HB#8^<<5_H%3+,>W.RZJ7V<[5
MG1H+V'Y@D[UP]XCEF]/ CL% J@V):K#2W9JKDE25H^[Y_EME9W#.I6'T]?Y;
M1@H6*KVEB[/6%Y1O4I1=B;20R ]?8.<G4O@'%#\2X]PP0VHF7.-V_1TJ79Y[
M6Z[4#V*P>IJ#BW,REF6G&&QIJR^_6ZR?2O^EBYWQ^W"F\%18(4RZ:JG@B]N]
MFOH:X7S\0CT.-'Q>U>8:X_"=N"8SBZT($X47UQB>WNVY4M1@FYZ8-#_R_O*A
MMDD@$\6AMPHL:GUX+H&S7B-"JU\]L+KR9,"O4('J'#0MC3)U?ZQ6M2S:<9D7
M-&"HTNWDGA(72DM^36#Q2%2:<]+DM[FY*A49^3,3UY@V8AO+_DJQ]26N*EDK
MV?.ZME!8_WP1D3U['F.,S#OSUJ/MP.]=<FU4P?R(8*XL2P0G $WP"@#/"56_
MW][22L5*)3"CZ&U#3R?<8W8%X)0"4,>';F8MV_67(-MSRH;'IDV\*@@MWEM,
M8EZ\"W"J2.-U>C#1*& 357@<;>/(R2U]14/3OL(W=C'"%X4WN2'=W04S9)EJ
MONN&V/UEF48?NG'[CF+4.,C9UD+T9'UCRN7<L&MO/\4M>\H128MU&($@[#W<
M68PEB2PB\++\.6#3BM ,8]5+5D%'MBFH':KIM5! ;[S"1S!&I.#;2K,]^3"G
MQY9A!$3$2Z.UK@.ZD]IR)).( ">:19%F8]%0Y:BMKNY3O>#5Y\*A/N<K=QF?
M;.24E49M2&>D***]QAA+*BH:^RR.<"U>,-G=7@L7^H)S3%O":+ST8I:"QNF!
MLL432='Q/[XW&!^&PW4[Z /V8C\Q5 HS^Q[!$NM#'4FCU(6A96!3G%!K6DWA
M/:> &FM8I+,HOCGED?S[QV]=L\RLG)C\0O9O 297!;>U;>/CV2H;RFR0_^N1
MB_V'<YL1FRXF'7B-\14_POGVI'@=@BF)3GU;<A\-A98W?V@))W3=-.A"[J6>
MJ>WMMQVLS'%JW@6]TC]SRWO 2PI=]1<O];P/[D8[RG@F_B!0%^Z_ -1MH/SK
M)FRA.IZ'X]@2A^?L!JJZ[[1<X1/\F3+;$&%U8+%[?)W[P:B2%CV4$T9P_T3M
M]YMOG/#7,LQIS[0HU)_;7=,;?,UPL*TTV_VBQ^JX22 WW4<U+O9524/;:"5U
MODDI*91JP]([+1Z#<U7#(NU7:-/+0DQ=>URDKV99Q1NTM[4Q4THE\DU#M;%)
MU&C"N6G<R8/Y50W5LV+<^8!=N/$(_V7V<JX41X,7Q \3FKBBNV#\X)#O,PU!
MS'",ZSM: "U14<$HXEDU*Y"5[Y^A8'+S14'3H==9\^=N)0%%Z'FO:2IU&3DE
M$Y$7;PPTZE&D'632E@!*UY]3\+W "'[^=!EHZF[_U_-QQ?_V ,C@_^WYN.3_
M\6A'F4T3=%[?!4?]F[*XQA.)?0$;3WF] K*:_-60U9Y2"6= L$K/!)ZUP6\X
MMP/_WA1D+/P*FF:H^(3&]!V9\>M0]@QN\9&<O26F=^X_OBL1;=P^1MXI0.!Z
MSA'#B1OX(]06=5O4"DN>?0,W;] L@?S B:U*PFLIHH1R]>6-$@BLSVQO_$'B
MMY2XU6=-38C_9+L3_X$ &<<3 "OH\E^94\?8\_K+6N! X 6VQXS=%BCE2Z@*
ME?0:H)LRK_R5-L:;L>6Y8O(1OJ'2!:.?H@JE$*^04YFW+J_=486U!+Z0S?E-
MX=Q,!JQY+AY>L2%%:(XQYX>AF$AU!CYN!E!BT0(PSM3Q;WIO8NU[=5%+79W8
M]?Y.)NLR4WO&DXXN,+<6%T_[AR.1S%)H\Y!"!0)?"NS9GK/68]L/PS<=U@.M
MQGZD+[P/XGB<'L/YXHV!%Z\QYXH)'^C;7[D=_;'SD\A%G%ZUQ,<+;=%;Z8Z<
MS%F--W31P81VYTRR)I_.->9E<SON86#,2/%V3RU]"RF6U_&^RKFMY+C]*9&:
MDQV/R?O.,,3>-H@7F&-O^-@YUVIR'6F5$LFKY/P+1MOMVP;_UVW;3W$+.T3N
M0-7B**93>!;W:5"H$R*!I*U>T[N"<6?/KCX-TB"!=%$Y$.)7"41F.S0 3YM*
M)G)D<D7HM>YFWD_^AJ@=-__ZMWJ>_ J=P9! E"X+/:Z":\#NA>\Z(8$\6NN^
M6S@?,9Z:F'O$J] 6D$!LB+7.D4L/L3E&H175-%6E:'*Q,:'#]K=@P8HF'EJQ
M()#"IH^Q?G#O\Z=VAXR+UP?!9;]:J*&7(>K\/-'EM.3S0!-ERKQBA'AWJ/Y4
MISDY-CEJS7BRE=U6FQO.2MR=]SD+';5?<0PIKM<=:QC(=2L6\=A&<^T9D$^V
MXAB1 JQZ)I9PCP3GS2%#/"GC9,"K7VB ZZS!]D@@O+-D.0ED>M,K:C4U#NB&
MS@?"(4?Z 3E\,U%\RD"9]UG$+N7]J1_5M\@.F4XI98O]024'XJ(Q7*$7KI.
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M "N[X6HW6 QQHM5FR_SZZ#]7JX=094GU%^X/:LI.ZURY_R3&TLE'I;Q)2NR
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M5F?6?A\'P\VM.%<M07(*1Z)\S4&!T/3TB=^5L= )TM?!-B'QV-G[*AL T ;
M?9!"@_7^WD2V#(;ALWL6";Q=C5 .(U!H/G994I40(:4'P=<)9'Q$@U9&J,L,
MSO]-!8N\)O22P32:IU"U >A_4S87RV?\ISO?M3< 02UH:M0&H.APF,-YX4X;
M45BB^-4SR:ADF''^*\71_[B4L0C\AZ-?#Q+%UF^@ZXD;@.+!Q'^7QQF74)3
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MKG_8H#R]5>R6L]R] 5A,VP#L,/UD\5.2KS-TQ8H\J/"0^5Y)W-F5+AGTAQL
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M^8YMDF3*@5S:R_/^D;C7S':+LXTHBWIUP!G$+<26\%.N+:L[6CC5U32>PD6
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M]7SRI(CFEL]:Z&]FV<%#HLE^C&O<(Y_1$?23!"Z0%",T>U1A$2=4U&_I#M\
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M7_U"M\'455F7E EL4^:]&E\;5E%+P\%Y):-ZXF"]+S/>G-5_;-7.5X4"+JX
MWO(^U#"PB%O7,4KY8^KG=?+[Q#-0L(W6M/ADJ%Z*6U0+@KNYB2"8G.3E%,&,
M/3MB#?9BD;,89]M>),;,0,=Z()Q<*BISY%I$33V?^UCG (PW:*[2_G!O3?UT
M3J7R7*?:@#.:4Z%N$[EF.\"*G&A7_ZNNVMW9:C#4I'Q&4%E9RSU!22PM6'LA
M-/4#[CL84C=DT(JO3PN!QWVI"$99>%H\#1 ?^LAU,P?\C13IK36K1$2^1Y(4
M3$8@J%TCS.Z<B/L)RA05AK$[MAD:Q9GWCH7H/24AP'G%/H7\S6_XY]?AXN]0
M%5.+,):%;.B%/J&9ET>).ZQPI",X+8YI9CT[%T"[-;!&,0RDE0&[7Q[#S"2-
MU7ZL(?OY,7&#NN5^GK''S!YK)&ALK0 .FYY2;H-&Q;/VONV=[FA7^8-]VO1J
MYR-C,*U!T.7/^WAQV1U3]962-!^2I-"Y#W&6BO8@#9-:&_=SL"]629$@7][S
M\2P%_5W\N^WV-Z#7"F&GX,'.T6FC]NJEZ<J/#;&Y,.+I,88=,M!X)#.H* 16
M%.N@<5'T(GP+V(V?^[,U8T^X)D+.KJ0 .T29;>J7),OU$B_^9AWQ8G&E2V3G
M.D!G P> LR/5_GU#+H59N][$/":>T[B ;F;SC:_$FNN$GM7=><KMRO-VL<II
M2YFVWLIGMA[B?H9*=W"7E]+J];6+X.(S:JDVK1L U?I-S!$P[ '^F"FBF.'&
M=G)25^>C".*3W"WSO+?O9R$',[[K&MG5!L3"'JSH=,&?!&KA3ON<!KGB*AL^
M>RZKF?".BS(-PBPNDU?04>09Z0^SP5$Q!N!Y_79U(_)JUA'(($)=L &X1<:7
M.<JWE0Z/]3PZP??6ZSL8.35%&3M$R';)D'8<6F0^,#;_E.=H$>.DH<!?9"G'
MX^NR5%N-&9%X6Q8_Z0,$%>C.&8QLR/5Q:CS<AW.JS*#,J>F#"*04%T+.=:-+
MM"SAZ:>>KN*1#< VI)UTETCC/+^H'),3A36UY?D:?59Y035RRE#*RYUI-,17
MN^H=BH1O **>\..L4]K[]O7+Z-$$^S!^R"T/G.&<-5X9WX9KU!H V<L99$0[
M;0"</^$26X@JI,A5-1U'KF["AWQ4G2L9V:#$GI3*R66?Y&]NIZ0%II^B&=0F
M1JR"+;3N@9\\LKDF2@S?S'X:AY7EOSWCE3_#/"$^'&I%QJ1UV=1RQGXX)<WP
MU(\1R'>K!^YS B,LF >K$KH?".V5HW#%IN>W%LA\M)[V=QS&,@,C0SWR42,M
M!./OF>6P\$.?N ;/H/*S&6UXT4JM<CS.!'PD"D(:5+;O72%SE=M!W0D1'^+U
MK\1!* MXB^JW^U(_F_'^=Y=L_S^X9#>&_Q=02P,$%     @ 3XQ^7(SFKP_]
MC $ ')4! !0   !P;&%C96YT86QD:7-E87-E+FIP9Z299U!3T1OFHZB B$AO
M0E1ZE]XB41$0$)#>B4@G0D1:P$!4I#>E*E6D]QIJ .D"4D,-4I((2),$(40(
ML/QW=W;WPW[8<NZ\,W?FG'OF/O.>][V_9^[9W-D*X(:>MJXVX,*%"X!GYQ?@
M# >0U()[N ( !@8 <0  0'<^)PNX>'YW]3QXS@.@\\K%Q=O7'>8'.%L :/[G
MV?^O\9]-_G_WN'#V#<!,=T'JP@'-A3N B\P7:)@OG/4"@ # A<O_;0'@OX\+
M%VDN7;Y"2T=_E>%\ >H&X.(%&IJ+EV@N7[YTZ7PVY'P><(GY,LMMV0=76(T=
M:>_XL,F]_9A')_"PMHO=9((H*/_\U3OZJQR<7-P\0L(BHF+B"HI*RBJJ:IJ/
MM+1U'NOJF9J96UA:6=LX.;NXNKE[>/KZ^0<$PH."P]Z'1T1&1<<D):>DIJ5_
M^ISQ-;^@L*BXI+2LKKX!U=C4W-+:W=/;US_P?7!H$C,U/3,[-X_%X0F_5M?6
M?V]LDO;^[A^0#RG_COZCZP* YG](_]_J8C[7=?'2)9I+M/_1=>%BX'\6,%^Z
M?%OV"LL#8UI'']8[<F_IV!Y^S*OMHA>0-R&R/W\U<95#4 $G1/J/M/^J[/],
MV+O_)V7_0]C_U(4%7*.Y<)X\&F8 &'!ZTN3__;=JORZ9Z]MH2+W!W^MRG"(8
MP=!"GY.0,I%4<^XHE7A=P4  W]P@S2RWRMBE-[K5;R21*T7@.M1A;QLXDN-H
M-^Y1<'HO_2G;!H1%&D2+5T>^MZGNA7L+UB%I/<X -YSK>>[--,P2!YVCXLF6
MV:#O?W)^5&("GNW]&+@;'[12 Z\P>UEJUHN^QVGNB!/%7JW P4W7DI+M1DU2
M*_FRT3\=8.G/A!YRH;UYF4":GN\EILW6(:E5@7JY@L6*E]MB]>W]ZL$/E'/_
M' XL;0UXJQTCH_*#"!*SQ>"Q!/")W5\'@Y6Q>.0UC3OP<CS3.S0O?@=L3[+L
M;K<T&J<BOV(+\79PF/G4_OZT9$65<\X2KVUQVI!5@1O&M>,=I^.ER0%1,8=(
M:)F5PY7FVM:&]J8$U[=_I*2_-H>[/$1,RSV<E/X=@9A2<7:L3;F9L58:V6=<
M*FJ19Y&5XF[F4TEOXA/N7LSO !?9E;:N<A,14N\?3I4J=:J9SAO19WY8O2NB
MJY?ZV-S0[!=!6<.ZF"T+HICTJ[[CQ[1<.+= \TW?P0/"VP3=;;' G*U$P^#3
MW/5_Q!GD#2IS$%Z,*N2%'V/\2?G*R(XV4H[<.:B4\W(%,E;N;:P[9!K&_/K9
MEW_2TI?DR?*HL<Z^O#LIJ6#6 %9J:V];.5VYB%IL*'.0B(7&OHX2!,KAN9,T
M;Q:TLO\SDKZ)I'DNHL]J*!=O8YC]")_2GE7Q;RID24?XW]?,Y-EEBU4]\DU9
M>'#.@=K$^;M.9DN[JT R3@_1:8,%4T$09=-'3^C[KX06-YD>WO]V-)ZD?G!?
MM0M[_(:_!:O1O'*J2$*^Z82-S</P;OV\N6]SF"@1_D#>V!VD+D8X_0'I<GHX
MPJ@2;O8=8? 5KMG/F?'"@9^D5)U/)YST9UBGL\4U0B3MRN<GKX^KKY[.G $
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M,0?*V_(MBV0[FP%B(,XK>Z?  4C)\Q**V>39C46;,FP=>75_0JD_PE3 G-G
M'L>)3!X8!">E';_+Y@'A!/D MPN/U5"[VW])%AA\4R3: "^,1DW*(''B)YD:
M8A35"BDDSM4S&#TKT*M?;. 3<NG#,L/7"?N35'#)/TF%K7RV0XZ =!/QQS6&
M7E)5.5RN]Y,6%D96Y>F*Z;K]HM_Z&WUZ5'E-?%XA6UA74BBM>S"GSWI_38F\
M=Q+V2CNO86\B*&#>BCGU*S.BQ$Z\-/UYC\\:D/$FD[2MQ=TO),.F^KXN29U9
MH8?F3GHR=*OOBM6F,-7;=B[#%GIQ);]S4%2-ON<B,9D_IM:CCEH+@>5G@#9Q
M%F^F)YKF-N\5S%53*G=% L96#\E-C5-HK6/#T'&:\Y)-4("]YVD_ [P_I;$/
M'<U8[F6B1SPC(7N9KGO4N[=Z_9B@7HG\QI.E)$^9-235Y!J11E)F6B,*2W\.
MOSQ\61C=^K&S&':YJ*2#@UA,GOZ1?M0-]]4T,"2_5L]6@XX\\"OW"0F4"I^S
MC>7V]HZKR]0/_[L3V]X^.I_\K-.WV"-Y^/+(2&K*B.?0S*SE#9MAH681J ++
MCX3QO(<3D=H6XG;@49K&%&10@E+6S7<7_M7(T=NE7KTB^_:#ODP&5\T_ZAD@
M6B#GV2LTZ*X1[<T.^?B32E7C=;.[*3P]#Q52@V6S[E95NL^6V^;X"V,209E'
MTC=QZ4D$>= 34BRW)/0KQF]+/&?5\T! ?-3?G@-W4T>23^WEKZ>M:ZM:/YH.
MD<:G;-Y=7=^HOM3(?]1ZVQ_=OTI41V63'E^JVI:Y37\I\I:HG;Q<;LJ=GSIW
M(K5,*KC3C&1M[I1]:?E[ _U,@J^ X_([],?(> ;+85]]G1'#T47>I25HYT<R
MHT;:OTZCOWM4OLIU@5MNF"RWV9*C2>]M5=B3P]TQ0_':U/N#7)*]TH^?&CVY
MN&!>I^DT[+8B]ONG3%9FC/BOJI/EUV^^Y'Y*_?Y=O,M,/M7?WR(N4FQ4'^\W
MV9BP:]^)VWF]6?E3L6U!QVLV_=_)DDTY-^S/&8#0'?<?14^YIP.(I2UD,5<[
M==9PN@?JL6$IYL-*#U?DFK58UE]*9'_QIO'I$N=R2=7+37D7(/\L239\Q,1[
ML$73OK)8:['-\W 6\\7Z'W(%DE%?JV%T:+0&[D^6.EFFPLU=TE^M#S%T$__>
MZE%[QQPC7[72*[;WH\QW3_Z&F>@'E@=1;^@O-/&AKWUX12-Q#?$M[AK[M<DP
M+KM%&<[U$<Z_D[/VH8ZN3:M-D"#P>&W:Z>XI2'3PSUW:#F2JI7P_@PO<[H;V
M2\W;CG_O6G4)W@6J/O'ZN?FCA,8OBS@ ^/.4_@7+PYVK#'S'5L(/SX' ST?F
M.U Q=554L&G_H/.WQ/+CAH4)Z"Q)A.EC&U"F*H2$2=C'&SGFM)/VM[:.S(WE
M6M^$W4X<FGO.%2"P2INC%OY/L_F')W>JM(K0-\CG-T(?&$L"TMTN?7T7J%:U
MYG/C9Y>S,/NGP?[Q%/SZ(._O/ZM\XLJKJ+2T32%A3("%4>I62+#7UL+NW'^3
M(?9 ==5G]X/G!16!]R+5W#2,?U\NU+X+.%ERMGLKZ-XK]B)=-!_J=4VOA'><
M19=F]9KY)[=7U4/*<CLW/XC_K,A%=^A#TJH=L+);,X/^@<'2QQPE9:3O-%Z.
M#;7J]""5RRW<@%_2RE5R\<TW2RQ?LVD5565ZS!\/IVZMPK;6[JFI5^&TV,P!
MQEIL_VM<<-"Z /%1OT]SJZ[IQWU>O0_??I%J_BS&=RHB%9>N49J.'_QVN!C;
M!:8]58,@!#$OT,SG3N3=2;[B\ +3)8K$P%%U--J6*$'N;L*@F0I/Z@=X0ILX
MTG%MQOA%0[Y7RT\25/WYI!]A*F$*+1Q2A@-'%B^YC4PQ?^JOK:Q?*KT4=\#'
MY6+XX$Z+%94)1[=7BH-=[V>L0CT[5K@G1F,%3SKPE[DQ5Y,PPEQQL/. X]"Z
M:6'5LTDOG>>=W??,1 <&7J.KQ3PI^<;#Z>D9LBE.:CY9'BANK6*8AW!J$BQU
M0<M;CQ)D#DWSIH<-BPG/1/]5K$B>+UK<G:XG!B%7OB Y%2%8>;)/X_BIX.B1
M3L*I2.CP&>#*J2!5O!W3P4!!=AEOG@&XD6[V8/QZ;#XQ(#TDI"1TO$-QFM!*
M$HE$ZQ=0'S3P\U)\<<? 1LH3CU#!G&6;Z8)_''_)(Y2UV!4D-@9#V(T,E4;
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MG8L&[N@2W$$A*XE, S@@P^ER[;ENM &>Z>WAT7KWB2GY%>E*TQ?JK5D0)W%
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M\C:&B7ZANI%V:CEW/*%JB?HG?@/^#>^T?:")U1L7N*%)=VL3N][$*J?@-](
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MNT2]I0B =S04.+SGKB+U@ .L*'HX&:]+]XUK%:$C6L]XTVG\B"#;.M*(EM4
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M77=5@,7;33O./0U >\,C=?(9^QA++6+:E,Y!8B4#IC@71S60^MYS,VYT;$>
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M/O8)"E@'AV)+]Q/9J@G4G<YRA*4,!=9.-WY;U.'(<I\-?3[NINAAL=NY#RN
M^ER(+7_0,GB]Y;K4$@M+8_6=MX5*IPR\B\^1&M]>$3YC^TR==>RI[N#5]408
M3:,?3+TCK&+ 5+V6RWOTH5,:".T/.>DV+]V69I#'HUS_V$!CZ5"5DWY_$L+5
M"P_P/*$3U<AVLV5]L @L) =+#&_ <5QKM=Q+]I>IK+CK,U3ZX\X(QODDK*-T
MC<EVC9-H$50WMFCK?>@+@-%R,TH*Y7PFJ?0.4LCUFS+Z(O(O*2\6?7%=0KNC
M503\BFZXM,6/TITIHO'0!$BI9M^TQEB1KYW"]&]-[^HG<>?-.<>U'E1E*OJZ
M[X3-NY(ISV>'B'"CW0THG9&44ZB(;?RS@.O,"BY!3QZ#4BFF7,:P7"H^^OD6
M_Q\1[AC-DD0WC3X72';U:EUWJ&=9KU8DSO-,H9>2$\%RFI$9Q-'XM](D\'Y8
MX/UGIS*^K*W-D7.MWG" #!7'ZDDC(AEVMN;##JNSKJM'=__8V?D_17WS[R T
MP2#[1 O7'1?C/^BH?[83.C=WH%_>Y_\E4@2.01>M0<>@.8MO^)W9ZME6'^@V
M5]TQ"/<8GXQC/RK _V1; A_*AP@QLG8)^Y:RC.LSF%V*T+;FJ<+_O6PU7>#^
M=@Q2^+_K9HR-,ZX%CR5@9@F8%AU&E,#3Z1_ [%%8Z6$JYH^_$R<#,]!!!U,E
MC\+24'N2+CA7'W'W84MB"?FE&>BTV<5[]U)31T]=Y$M\F7YA[8OZ]7#C:TJG
M-Q_=_AJW'0EJ5%?7N>)M;VPOHQU0S\?\NE[HRUO0Z)VWU[K.SN(7Q%U7F)UZ
M/>IU**K^Q7>1O=U0#KH=Z1C$Z@)P+6YO+2,H+&3HQE"[/-7]2T_?W341ZZC\
M&;4B&)'_8@W/2)E%127@22K)NM="X^PL)BN6H2[)O/M@)"8EK3>9U$.P)##<
M-&O7]U<#9DFCX*_-V5=*PX>O;&>737[X551.*B^5"$E_B(6KRL&""AH6DCZ>
M&/$0P)/Z+$S?G(9N"0I<YGS&IQ,%$0-NFN%IF#X$CS&K2<LD2KY@4'FZ.I7O
MDQG=!#=6@'3_GKK7X2O Z2$#'(/V^H"D@CO'(%]K$BX<#&K7/!SI;#@THEN]
MOCWK=]F1Y2&& ZEC]PTE6SJRLAFL7 BD8O^I1GMA-.0P/)V*R.&].6#8BRS.
MOB=40]W?&*8N]TU:!I+!A+&]*+W.ED-S5%"'7(T9>8&I9__ '4O&< +HE?\F
M5R&2M"D]--ZP/B,(PGM21%YK>M1V8=Y;SS<QV/8/8?3SAY@!<")AL?#P!F#L
M/-TP%I\AH4 32O(PSGWT!2PT!^3G>5!_V+9_5"DTT$ ^M-"\W9C_Y'LL7O]K
M\RSWN<G>)6+]!X=B<5W;%U83/HV3&[.>!X-O#+A(\6+R@_I]O4()E2RV-EA=
M)<,=O[3[YC8=.X[8KUF(][[C1P0?#^KMED!#H^<4\-[0T<MVBXKZSAM_;+2*
MWV;=_E,PHY^@N!?9-N6<:_*?B05[N6M.LOGR%T3Y#I30.Y"EZ1@$%H!PCH21
MUO,Y7@_B3QE<#Z!)FC8VO)-GC'=0)5H\/P+??$CBTD'4B+&DZAL:!B_@O AH
M?]0&]AC$+$85BD.+ 6?))A11FD8?9QDP?'/<X"&>DR%$^*.=Y9 843UWL]+'
M)7 _40MF:;5U>ZKZ^7!VL.JF ?0^2[S&L#2V/I65<S*LX?#&#QB4:HX(/] 9
M0'R/<FZ<I'.3//A7<R6 '*H^.:@/)TC_#\ LYTCVVW1F>E< WD8T[NA'4\_!
MXCXN$]]]_=WH$#SU:)J1#:D@9*27W^EK=&2XBR:)*58$ZJ83S(S<?"><X.[S
MLI,TDXXLP*:K)37Q+/?+THA*K2$VTMVR9FO3<C?HH^J-60,O<8'I]T>I2,G!
MW'- )JG2^L1LT!SCEE4Y%LWWQF$B+.1%5Z/@4XI!);X\R>*+R55S5[>W=N#N
MA%Z[R2).P6*8]Y4[\U4>V:+!^@[1S!(7'%XQ\Q9#[K7ML_SX@DR8N4E/0?=Z
M4!V36-#C:,/QZOK/.[BYS+U\FH'>$Q?#C=;XUMFN/((AZ8$D$+ \?&\F:+E/
MQ\N]MS<DLDR:%A51Q,%@I;GG_QPC=5@?W*>>I;"0DJ(EF#MI#B5Q%3Z=*M]V
MOZ,XR8@(IR08-.ZY:DR0(KL/@S>%'$QY@MM9N*\"WT6<0X[.[ U>FVV7#N:.
M5MZL_W48V/G^P,HI:_RKC[%-;>K$066'MM5P.9U$#GKS_G<4LH^FJ6C_9=W(
M0%LU>6C$+,#8UM\O-=9]/4VJL/!%ZXL=:P%?0GR=RTFMW"^'D>$OIC=7IIEO
M_U!]TZZ9Q.&2%.-WJ241YAS(QGRBI@S^B=+(U5VW9^0)\F^K[.NU,]5P/4NP
MR>1S3O5AXW%*YV#)ZK=WV'N\8_HUP5(9:^2US36S+<36[Y:W"[ZMD?D&LX3(
M\N" T+*['AZ6RO/+@'5ODYYRPV)AY5VC"B2NSZZW EGH&#<6&KSI&>55G5D\
MHM610P8\>VFCA$<1;*^M$C+<+)Q;:QIG47:5UF'3>7YGQ4) 7*>37R=:!67*
M@E*<K^/<UW1<B1;K=4W68S7_V%RV&(9^T/7XO(-3.'?JU6-0++37G6"8? SZ
M#,*X;(OB@=WF8U"U.N;/F8[0KF/0MBR 8'3M00^D89^_YDQK368?@TX::P=Y
MY?67_]6+=)MCIG4S@=Z:7 Q_IB[*P<7%*M"W?@SBI/.1\_B0X %W2>I,4A50
M22IFM%2@(+-;52EA3MT'23$&T#"2Y8O]&^UOZQN=])JB O6/)([&&W_<<1MC
MO\AENBF'4_91>?BS^%%UT4R221TE?Z.^J&H"5N>1AWF_77,4#7U8N,S-B;KF
M,7<,(L6CM:E!T8&J@DCOOG&D[X2ADQE-!;N<$$"VW&SA6'VE7<30IT%/((JS
MG_!#U-"[3X\R$MWHYFF;^/OR[-[IH_BJHIJ4R3T$8.>K23Q]<K<Y'P090O6Q
MHZH@8 ;*>YT,/2=Z4D+_RS1IJZ-EQM4/6_C<#RC\PY"=K0\3W] <<3F8P7R2
MJTZJ(MO"YF?J'(,J=4H6O+Y'&*?X5#QUI/"W/9\O@#RBZ6S #I6!D887-(\N
M7.3B);WM&UD]ZQ"1FBD[6T$B1S6#PS6[O\T,M?>:Y$ 9?$E^=&F)^E<YI^V&
MS5W];H^:P8T.ZEJ8^N]N#Z83F4+_-CT1[J1V>>\ ']*\F1]W9*>\;X8+L<_M
MW %LK'ZH?#57:WKCXA3=S+M<M"S0[>9(1[-Q<Y:/U(%[K&V?4UJP>,BH=D-'
MT40#%B[=\,JF*&=*$F-MO6WR6[OI1 P+CM[L!@(^1?-T9JK5ZR5H9*XR+2EA
M"7#[^"?++:_WA%J020/N;$DD^BQ:=_Q7;6OS[+UO!CH(F!<I6Z"SOF8"#B^8
M6&Y*O>DPD4G40GSOW7.:-8EW<@*XJ3-'D(NK#+D)^J,ZI.\8Y'(-K32V7E4,
M*"#>5CCE-=U^GX3@ -(7515<PV#7)[78G2\U-R3,KA(4<A5Y_R&BJ_X)%(:D
MC'MD6X:NX2I\7MRP]Y$AE+)W[+@<@WIWMZ;^&0_O73A*UJ0PV5$[,C?VJ0/$
M:S,,"5\BFQ96197+M;BZCCKH1BO>[[/TZ"+T%"KZ=DK@:9WE%4!&J/+U3?LU
ME^I2F1>^0N6&2<+H42BH72V8!EU^D7=H"$CVX_FT,*> +]SG9;))'3+0\W23
M3ZU4[002UJ*[KJ-/U?/YH@IU++Q=?JG%=H_M4MND9H)(KXV.X(S-DX.LPK33
M\5:LYYX)ORSB^?S@YGUKXW^N"J;GK,](*+2[+?@V9M<?@X*UD/@8:&B%R_Y"
MPD3)LI_IGXX%P00X;O<7.@PE<90&O9\4E\=!9Z=9]T#K,+WZ&$ZZ[4E(_]Z8
MA/^F[GY(T>G9&S?0J4 B>O3JV35G:G\ (<-FWS2U<[V:IY0WGNMSGK.\$:9J
ME635N'L,NH >(M8V%I;C^D[*@B 0$%J%]!XD$ >.08 9;D=39P]MT%Y')<W2
M/0."147C*G-N3'9UGL]T#E^GZ 72._F^J6S6_ZO63##$MO_=NSB_Y*J:B*][
MN.A0GU=7.@@5_I,K].EL0"\UDUR:3JLDZ=Z]_+%V0A,LO@!<'GIPM-!"A8\4
M^F7)\AP-7?ZE%A_9;1#XV2!0 ;1A]?.B6-0-IG.XN+Y)K*X"$/4Y?X/BB%K\
M8A8:\U=[,G'_SZ%P3X*N;6:+A)<63N%%$(6Z@5_*@Z#'P.S01__;QN+9X2"X
MSOL-&ORX4PB8.D#TN1(%@#.+!!BWQ,TREV""3'WK2-7D4:E%DF7[6R!DE#U]
M\GDV;&YYXLD36]>RE7UEI]X#JX[[@47KK>@\[*I.C3!"$^O2,V\SZ5=P$9?N
M[X5,G1\1G+@>LRPW'WWQXW_68Y:F31M\M,M;?=KCHICOF<MGXZ3;:5YOC440
M&WFTP@&1=W_;71]J1^]@Y@[)^]$-YU&N?A59)CUC,2Z5R-RYY_^[Z<$^,#4.
MG:A$2GO+;?N1CE=C";[-?3VE2O1)[-KM ;=TJ\ P7'V$D^YPCNSHFOEJ457V
MLX[)25=*8. CF.C59LUZER+L_IS[,0CS"^6%17=!ZS36G!8O4\^^T<*_9"AV
M])J1$7.# YU*P 7T=L#A\(@DZ1>V$&GM\NQ.XP*F-Z2>5PV"4@\/R#P&G8/M
M?05>S#.$T-,N0OUN,HM2B6,]F ;5G@ZP WY[,KR0G-1MUBF\5O[4Z>?ABXZE
M,:$?"?F_+")U<9_:;Y)'N'L%E3&XM8PLKW)]SQ3RC5KSKK]B5R+^/DP5>Y,@
M<GW_O8/ .Q1N&4SP<_)YTLY=<B;)/T$+[BM[9\Z_/CN45<S4F"REL5"O]N;L
MU].&7T7[S'5L_;-]*JT4"H,LC$(U=\?EC8]!(W60N,M+]/WHD@SGS.D<87,5
MY&J 7<^-F78O=X\V>&"X;<[6L.!]/$7QT!BE]Q=#"F0,NBM/[1PZ.+302C>&
ME\<XZ$_&I25/6[087")?90BB;C>\?*A6/TD'DRV:N_4YUD6_:&KB #F/#5RU
M598AKB]:T_J"J8T0:;]/6?8.8+-,-#RX+A31*?\=J6^+3[[+OU!L5#:PT1SQ
M\T$L48%N#M3/M&IMQ:.5D,<@JQ.ICGQR-B>H"FCSF&A7([EIO5"S^4V\NWI@
M#U5(7:FJO5LGO!?S?A;Z/H\7NG3B1JF6%NRA8^>0O7MQ5)V^0^&50T-BI&8>
M"Y"ZS!4AZ0DKTO8AA7GW.D5JL11G$7Q^&=LGC:K55&\(NL6/2%*NM%BI=TA1
M1 "D?8Y>1I->&F_JZW#"I,_<<^*.,]+&1*FD.(NFS?: 7&A[1[M@]>KH6#KY
MXK+SLXV?GT:4">D-1RLT,$47:^QB*-LC:>7,_\YO=_6ALF8P^<[E!H^Z5O6E
M0I/ BU(5-1S=ULEK1#&&S%I^%%W*XCX/AZ.A^L#HI.]23N>3Y!^+\I2TG NO
M%&YZWV>$[)S(BCR"SMM[B\^,ND]&#.:]>H-_KSS6P\V*>DHUB?BO*H _$P*:
MVE$50('3> ,4S*A'#^_,#:6HETLY:.$!Y;,;TTOK.3+$7G ].IE&[K7)AB\T
M)4&]$1)T31I7DF^+[0$ND2%D;* ;Y*\!3]2 4]4WO1W_JGANQ]<:$2'<8PKS
MWTDPNV<3FK^-RAM_P"^X6 Y0")ORRA)9A:O;I=TM4IY*WASWU,RSS)%KRK\T
M'T[C'-I=]V+-W.]^"A]WEMR/NDUSBM52[[6AR32\Z/LK,(I%?^EZR\9C<;G@
M=/]_%BLK#"K[2UA.ZN]+I?#A%-1PS&R0,,=-*YNF,P]%KTE%<O;=J@7W<"+V
MFFE$"I-L//HRTFX9&J-I'9[+3@V*0]E5T/4!PWR/=O8SZ:0.\[]6$II &TFT
MC3O^0#L*5F;BC:A82T:I4['%M58N/G";FQ;_*,%4=G+IP!A!OQ?/A%*N -9)
M+]XO]QXU+.4E'(,DVCUHF $7?%+]\E*;JL3U4IGWG(D1)(KLP'DDPA9!X>:8
MER0^;LW("_(N1\8@1-3<3P_5*016V@P,LF7<B%\0\%#KOQ%;Z2BO.26OL"OV
MZ&CA8FZ3^6^*@7[\TI/1#ZL/=RL>^$YV37R5CARJ%4E?&SSW:]KY@:1[<*"!
M@?RAKEX*>ES.?,U5X^"WS[U$>9ET4B3!H#Z3^VD,ATWY4(IS!N*2D)^%8%B9
M^NB75^_TNQC:5.6M^!V*D#5M\-560PSG?F;A=V1O;Q"A?=$RI]?BY^H,H;UI
MFSE>L[;6M=6$UW3CT/,!5.A_XTH2_*K:@$<ULCWTT)+^C.;7H!]<Y^:R,+<J
MP1'YZ$;V1:I5L6ITQMJ5M?YJ+4-'BZ9[E1UW*SG!<Q8,MK/<&PN'5DCV9>X(
MR$5 =4#$)(K8+_-KL&_QU-0.0N"Z1!W)$&&2\!SN:3:S^43RWU:Z*OOW*G5G
MP\^1<L5JR=668OAUO]S[%FI[:6O]))HPV[>^I75+RV>*,\A;_]V7=]95X*OU
M*5G\1_OE=.Z'XOO9H0 .CF6EN@L4:G BM^C+?N/LWJ%1S=]6&8H<:\T+1JWT
MIH:-]T=G?T"_3(#,P:V]HOSW0<.\YS=5Z^^W7(0/773DW] (;X%D>\E"NOES
MU5),;Y^Q>LJ&>T\WH_XE+R1\;J;"Z2'_#4E>"8/VJP\RO1[XZU4>17HU_S/S
M^S$H\+6\W&(0>8R'05@4^/8P:[9'@I-6\%_*D-9>*DLB%N<RR.%S)7@GU&)!
M>W%).,93NC%/:>7Z99D/19;[PEF:"N.IO0\R->_]*'/*FUX;7'"R";#Z\!N>
M3@F]R] GT?$\UGR1^>Y1;3%EY!K[M4F<\- 7!06;?"L'^6Z=JA76.?=M2%_Z
M@MGVSV1V"6T+.29F\!)*E0D(7UY_=<N#!QD^Z%\_$VCQ[ V)=^V%/5-;SR_3
M/8E7!!U[*7TXZ!/=N?FH*M#Z/+<J&4?Q(1-?<6Q;,S>*>'=5OIDH>"R#]+M<
M1[.L=SK_A38FUGCX,U'78#BTZ/%@6L#O7"F@YE#MW<_VCF-0>#O=9F*3WX]/
M>7?AP_F-2]09GC_*PCR?AG@CYZ8J>5[_?1>/BQ5Y0_TG ^E@JR]W#/]MUV;I
M8I'Q 1<(,Y-= '?^O*K"-)'KW1=LI/#I;D,Y>?6!M/"PU<.I3]MI]>M5#@W6
MKF@& ?60UOC!P>EVP[2G34)60I6ZKFVQZ=\JSO8O4?JH%2>F<LFLH=JI3G:/
M.9B+21R:!=#;LJ)!^[$:RYG1\)WU4.<GNTGQ+D:;$66/\7P-XMI'7T;(E:)X
MCL="P^C9C\H#4:6?]ZK&F3R^'C519FF*)$0?G@D)6_*F!)!4Y[>,:9&E8:7#
MU/G^3H$I%-]RA]ZL55VF0]N4$N.RQ^J!8Y( ?N^)^I?6Q%*,\H?3@C"LMJB-
M 951A^3;(P!\RYBHQES=CFF4)0EV6*XEKM4ILIY[?K882 TE*TO AJUY_DB(
M4G<<!P;[EV_@/S77SJ"<BWQQ)Q7N6J1,=G^NTC=EM^*DKD(G?>3G>PQL7.^#
MHI^K-K@;SXMM)NLRI1^/VI<43!>1I(?V4GQ_3]&@D0SQ^[7-O[X/]DY?X8O]
M]55]XU;YJ-B^3<)=34$A(9%T79G5BN^!(D0!'>G-O (/SF.0=Q(@>U0^>9+X
MK"A6X"9IZ![-+WLYE%-EO^?\O(&$ZD0]9T!/B%7I8\++7-:21FI3].X6A[,/
M]:Y1Z3&H1[5B3432)Z%(4VW^7U1TN\ZA"*#<@)BKVWMTE&K 1SL&D=')I+P8
M*'<#,;+S7,-K*R" .MF+N4!Y+NH130 /(N((!6L042#H([+)G)H41=G%G3%G
MR "9Y:L0B?$=(B?*8$J) K\8]UL9A*Q;'HCCCM92%79&RI)D2MJ4#02H3F29
M5#).'*@@//%K! H/;R+!=IWC='$?.0=+$])^EZ6YN,D77I>U$X,>^.[6 2K/
M&*6+Q[S)@N20\B(:"=XG\'7.AUDFAV1];G7&!1H!=WSDJ8_QO'[.)U-'Q]8O
MSW9:I7^@IF*L=<L6W]:B_.N@@8:L$G-0"G09YD\)].DIN3SEEA+OVYC^H[._
M8WA^T4R#V@Q8<.S.#%"G%D45XW6I#1H*;VT'M)3=Y ;B?\@[:Q;;FE4N8+4.
MIM#]'G6RL5)4?"Q#\L1NGT5 +ON(;$ ,6J?J%\XO$.[033N:J1!<E2_!N#04
M5NJK]T:>C#N%A)ZDG-:PJ8HWGMH9@177'K8-AZH*0N?L]KB!=2K1@EH%9NED
M19D#;DM),42>76ONU0P7KN1RI&LOF+=!50#6F">0_ZWH39PK6Z"U@"5NE:$]
ML=-D*>O8:7G3<FI#15#-$SQZ#!+ ^$"CH3Q+M4<?VA4KH:_H=LN<VL,N0 LM
MJ&?<C=-S::RKP_;7EEFVTS?LPT0:!:V&<DP9<Z!F=H?J^QL0# 0[%8#LH'L'
M0:^5JK2VOFV];M7IP;.A]*B9KQC<<W]"3'JWSOQI1%^@SKS*#Y]IE4DN[1?'
M-N8IF&Z[*Y$>\*[ARK:F5'$/FSNGJOT0TJTMS;_24=;*>A-]TPX*4!_S%"QT
M82(.[ABR8 X?<MES:9,^@16-K\W>:E\4'",5661O1#B32A-+N>'AY8Z" 0D&
M#E*KEG([=[&!/B5)J0QA="^F1C6<(86"-TP:L"TEB: <:8,)2A -NA&"G_"'
M@(_=$04+TDW!O&BP3X;C7H8V-VGKU&.& >#M78&4O)5X)?)OUPS&)^/?CCX;
M_"@=^H![[E(@/FI1RF-NG_1R%B(P?]V;NF\C(5KWMUW>!T96#NK/<"0\N<=J
MD /MZY2C:>-*E?OLQ/7V^T+6O[\[@RN+RU4D]90?=>!]7VWS'8,X=@\EK^@_
MW<"0E([*MOOQ,WK);[A,+6-$[M6>1O^PV[_&U.RYFFCR*_A@F@Q[4"A]X0'L
M"[5W!+WG:I6@:_$(&R2[_:(S=E'YZO5R]&9LZ04Y62M*B[NB^Z/%]96?J/ZS
M&\Z'"O-(?Y2D4!<F,JJ7AWYQ"@+J_CA,RM;=:;,.;ZTNEVDI0ZG5U&>C7D"X
M6F>\]-((EJ4I20$"[U4$>T;NMP4<2J"_.K6B7Q<14=Q 0)D/6K@%P ;EKQY$
M158AL$^\@94SA7#:Z_,_BF("SO:]:W E K>J-F="#='.DLU3\-^M30VYW,5R
M51F*O%C?W?2<Z0HSY_4753N(]PO8S:TVK3U^!,9;=*MI-ZSQ^S\GLZ.H8]##
M$QP* $QN 6S47]Q<"TB]9=+1KP\'EQ?8CT%GW8 OJM%!+ER%@<'*_7OYWO[+
M[Q[0[$>" I7[6J=L%MLI4C;\^5AT-[[F&!1]#XB#5S+&,!Q;R@PE((-;&'4S
M8H<E$<H')"ZN.W>(Y/P)1V9=\-LR,"$K8MV5#:L^SE0;W*P>KAA\01@HW,NK
M?EQ4<_7-O,.ZNRMC+X32L5(]O FN*3X&0<J/04L\QR!)5=/Q^I&SUI\F-&'L
MRHJF$T^P.R.*%I/8^W4UD\_GKSYHK)W<@,,GKBH_J<+>"Y^9F&"=8(<]OA3.
M;UJ0(&0;J\CN.]\&7VB<GX</UTY:UCM.$ /#DUO!^0S[^O]WT7:)QN__WV7>
M[D+_/_\=><QD'"OW\?3_72_^:>EJTEBL[=P!]#.W+@UW<&B]+W,,^D:NYM\9
MQ'W1XZA#5; 9G&J.3^VZ8%C9>M)@W>/_&HBJT0><"YIB>'YF!?\P83YO7/PK
M-UA8P/12@HO9#VJR8HTD/+19NR/\V0N+H#GXRGB0P;E/Z;=N>0JW-"ZU\+;E
M;+2$KNWLOH#<.RI!RP.O>[(049U"=!V\'J8_+TZQPN5/Z\93DZ=$3CI+0=R=
M]D":E:M%\HKX35.]Q#P2GLEE<>"3!W ,<ALOSA7-432;N8P;4ES'L"+_5:&D
M27&F7@ G%=<GU @1&5])#Q37(2/Z,-PPN\Z6Y6,0_]TO,AX"WY&(?MK:V5LM
MTS^GG/J(YY=FVX.PU:7*F5$E%X@-LQ1V\AT#(1S*G(HNELFFI>[] ')(27.3
M>][W6S;I+-02,RT+*#?0V",:E6+A@]*G[JE&0\$-BB7L_"<Y#HF#E>G/.[MH
M=B1%M*L5 )*]$'&J=R2<)2_*0+; IU-B'"OT6['XSUY,:5_Q^[<_[HX)-!%4
M_$HO_]K<#I8(%LY9WL[5'O/2V=5S$',SD7[<=O6&MJVUQ:*/WZ[3^((^!@8$
M]=A?-8E\RIA08TP.VCG4"(C95<I_>9I2M#!_N]#R3Z;RPN;[VOV;%+1%V[^Z
M2VU<7Y>&Q-M8WYV^6Z-FD/R5)HA0,D-HRHB/<NCLB:"QI6MZQG6E<[X')^+T
M8U5O)K5\?C"L=%W$B]+>2,A-+R,LL.6WUW34YYH^:GS<9QO#ZD6,NI#UTV[P
M<59Q153;MY^,2=.Y<<&U >&'(L6%]2.\-U3J)Y5ND/_TP\5_:KM^&(CTS?Z/
M=B:*K"\*M^LE-"1B[VL*[MO\<+X[^+22I4=I/#A<G8)X.CXFHLFG8,918R;V
MRG0$[17T?!>NOWA 7]S<6YO;2PEP_* Z$JB\,._XXE?=BQ=UL[N0L*-W$#8"
MG0_P/K&R+T08=66 _C4@B<9T"T!JA?[#J1I(4XG]PY[52-?N/9U,57^%U=SS
M<7?;)NL+)<F*K,IO;L]+-Z40^Z,H9K3UO0I:4RS]/E5C>6Q %8PRJ@<\:1I]
MK6(20K,K]5D3W.>!T#M3!E"?8%C)*L'K4^@J? *\T4QV2A#Y@RUB_?H0L67<
MCW5RF%U*O$/?S;S5@H]B-F-MGB ECI?<ULT-M3!6X'G'GR0Z8 S-0!"BEG*3
M2$F  C=%:-EU+C'=$\[=BXC.%9M^(/B=VA2'5O@S Z] [DWH5[E:5@#</8P+
MP/ME*$=8X7 X5,1G4:(YK6+^4^KWSU>VU 8G>LS*AGE3'*12?_JG!,K,U\&-
M*0L,/9SYA16Q3.XLSQI-2<<2B?!*X[AXUQQG<[7>?GU#+^V42==*H@4]G>JZ
MY]]*Q;_18L?'$;X2. [05;>R+*-BGG.SK3)8IL\/*F_&+*M&A_QTHG4OM^G.
M*&8 H=3)GKSSJ #2?%$S@M^(I&PD68OX,[G'>X(&KU%NK4!,*5#:B^=ZKDH(
MN V(4BO<F,A:F:\[55T(J  :HL?51TM<E^ZJDDX+($7U4+C)JK%T\< R8W@@
MGF.]%1S]9(=BX4(]^JD7D908F.HQ3(QLO[FL&M]ZHM\&'MH)E3X2%V["\ND:
MWU2,5K_1^:A;EJFV[>,[RC*_5O]SLLJ#"85LUJ\JC\4:./N7PT(6^G_5E(\]
M)?J@N_)XJB'<: +XU.[L]D F%KE&))7&*SUBU\HH)G''F*($*KXO5E8:3I?#
M'2<8IJ7!IYIK(J\YV%\\TE<=^71'+\V'=&7'A^3I:%]H8.E;UT>^J\PV]>S-
MM(B-G>5D>'AJPX>D]A'4I5&#&]3%:HT89*J0V$.J $U8J3I1E)M#PD/.:.A^
M4;'%_)0#7[R#CP/<<L[Y\8F:]N[!CLH8Y] S1.Y?0 +5KN_ONK;>HQI_$E$$
M\'"?**6.]:E&HM7KKLTR.(',I1&CB]-T,-F5=2YO0Z=&6)5BL2;B-GV4]O:'
MV8[06O 8,W<:!<473XH%L7)T-]T[-;9D]1XFNS%&D]TS.*I"R>I]3^*G^V4S
MV#(//5;'+[F"8W(YK?G7&?Q'F0R9]1?C_+'[@Q@.Q!.#2Z1#,-\81U;.[TB4
M4_F?@_3U;I]2,\3A[N7T(&/I6(./&=TO_&7&)9-?WC5F?C)_318JIW6@)5\^
M6>JL^JPH['O;HO(V;O$%'/]LS+7RQS%(J>Y#8XE#EN<GL$C7@\K[ON;6SJW/
M5NP<0UWM4YW:)@M*@XY!$DW@W0'K(] L#@G^WP<L)Z3R76+P&/0?-IB32 _Y
M@9F] -UA<N]8POSCH^L<@^Z%@H]X&WX]\MC>HGO07T4ZTUWR-"H*8A5'##_^
M[S_Y_]]18JK^AH.IFWDYO.B\\?4+S*?564>O&LKOS(BF)3Y]RJ6WE.O[,-72
MS,U/-M0'_YZ*BQ9&*1]U&K!5*VKAHZ"^'N&02X!_N9(-F1T7BP<U*.*B(>>R
MUBS;1(Y!]H#/,CCVZ;_BPA17!*M+EZ#-Z6@TR5M4RM$N_HINMUW3ZVGSE]>9
M!46=U?M 5]!R1QT[AR.22V&9 R,*HI78T#T/('5)E: ^H2B :+ F$4_Y8F$T
M]QY5U><)$N54F!L0<T]Y8"7%-<TYZ-*7L)O5P%:O!)BZ@9;NF%8>30J$L2SF
M^'LK? TTW:3,_!H[U#ICM'[WOWLP.T'@EI^+HVF&.:'R5[%5I8^56H2\E466
M <T_9*TZS<6Q=6ZN1-C7H9(\(\1YH^1R0Q#8TSA-;$5>7\4^!=YBJ+>9X,'O
MXW(V^KEXP'6:5V)F%>#I-H'823K_^&"Z [N75/G')2>A/Q%;LM88%*>5/OH>
M4_K#&HYAZ8,C A%*GVY)L(E<^@=;4HTG'(,V\)5)<P6<*. W*1%79E'$&,KC
M;UAOZ[AQ:%%74Y=MVWGT'G6_?(UE4^MDS(.-&K)M 'G<FE"J-4V5U)D3F#_D
M7XF<[&J:=5?<@<9 A0*/06!+K0I]'W=1)R*\:* [BP:2&JJP..^5UBSZJ,;Q
MS@._*Z-,3F1K.K_GWM\3O;(VGH*<>MS)7PL,T9SZM?7<"\G6K/.^^R(/,9QT
MJ&>Y,RP+$;L5B+TP:?\-(OU]T84  [-G6X+G0V2C*9I@WI$5%Y.2.1CRIH"Y
MV-3/-&IK:T*+0EIQ727KX7::9)M3PD1=0S7FQM.D5RTEGN:1ERN*HT<JGI%7
MO?C2#..*K8EI:@[_RB=M/CA).:DG::P\JR#*[Y=2I _=Z)<! 1]P'.:Q1^R>
MGC3C8XI9X:J.QE@%LM#MP4@M-Q?@=$M(+^U;RQQWGL]]1,F@5$U1YF,+=;0#
M@&.P*_K@D'N]2V,;QZ!#'=0-6E#_EF"!*U*UMU//YJ-ODY/.WH.M6S.!8);'
MPY7(2"A7-U-U*0924PZ$+!JJH:<#RK[?&1'_]_?0F@V)&(#( U'^2Z%>S2<B
MGDAWHP9%T[U)8W%$X4!EQ;[&8Q!KNQ9I07#.@WS+@ZM!&>HV"1%'CEG3))WI
M^B?>B U>U8!A0UE.>?3ASU$N4B4J2?IRC,JC%+P7\0VFIC0*=3VH>%VDM ^7
MZ,$C"$N*Q]0[):I(3:$O([?L.]\N>!C=+_<5$MK/!5._ZM1I+93$J_I5^U5#
MAL/(%@FV5,'$E4R;_->5\5_]I^5FG.[<DA#,RG&AEH,#A/12;",,#/ALY[/6
M1E?O'!V#WM3=:M+,$%(BY4HDWA?CC>"8%(_'.9U*/TF)UP>C["SA/7+V _8%
M)+E#9T]E'>\OJ8YT:6#+F^9I!R0MXV.A3=;QZ#.,\5QM(+C(-XN2U,4=C9?P
MG&@76O+8P*NO_;U!_=V->=/ZP\5K$<L,6S$BM1'YI%=Z>Q.\=H5>I%C/$M\0
M3[ $OF#2M<@S [GPA_A)=F..I,H#>%^?W8%YG*:?%\G E_J(++[W*7?.CJ[>
MT?6T^+[4'JZ?T=F6WD_=SC7;0V3^-=DK.<H,' O/.[VK-86Z3PUPI)I$T3V>
MH*"8?+I\DCDPL@QW[1=I^/DV+YJAFQ+Z?E-B8&;S8&W'U=WB3*F_#TQZY)/_
M.=Q:T,;DH<L<ZA$ 7AKCF?_A:E*]*A)8&F'@7?)?34^6=2S*\#ZL>%')L8QO
M8Z8US<9UC?!@H&90.H'D$(QZ[](9Z*_BGU1-1<8/J_>V&T)N:8D(MR+->0O2
M6XHYE/44;'VDOV)UIM?0_^*I8U&U&SB6=S\-]).GRV/ZKCX2CEE:>3=])\E;
MI*(@4=>AW(K/*L 734C3M0_.:M,3S?M^XY <MH+=IP0<VJ&L@'5/A((5ZNQ'
MPBJ4G2$1]T8_D2+:2S,SJ,DXIS,_5O+E2VR0[%=%"N84H+@$[N$\/=\+YF0(
MH:#4W(0'/:;W)MMU2\)*@J<Y8 &8BA_= 15K0OUF=J'!P8:S7_TOY[U#E6-H
MMDLI+(,C^ZZ_[B=_"#^=;I-[1EAW4UC"1#F IDZ)4_^AMCH>O?7]I?]Z2JFX
M_ZRHS0#Y4_MV?DR?0FJ<@\)AR.2'5(OLW*)?*U+TQ5R3S-BEK):QNH,C)8.R
M23.[WLD>TI_;;YZ[_P)SFZ>S#BD7;_S#P9H>>F*Z[8]!/M_1HHP1$;\(TJO"
M>21^@'B^79_[33%<TK3E9,0B 4?YP*.;?5F6$;L)"_$BC>F/T;U%"V-PO=6L
MA*.2PGL9!PD1;SXY'V5T<@/Z-UN!T$,3)'X9T>]!D!P4<F?^U P$G)@HD;6%
MU4Z6<0.'@FNJ'KTN_$%"CF]A0MI;,MEEOD&JAM]M D1Q!!?72#K'28ZGT(,A
M4.!?*< 3*)AJ!3B0WFG.& =^7Y2A05.QZU9GG/^CW=%.\+Z<]B)JZ)W0!3F\
MPS&H6_>D)^Q8NRY"9K>;DPVQ#"D,:5J::7Z ]5^B6)%RMZP3OF1X?0MT?:^2
M#5-+LIRF6*?S$FJ'EZ>^SJB"%1K\N?!2GN?4*AU&-4O/?"CZN';UK]'<WZN-
M555CN&& 3ZZ+NM:SHM8U,3B-<SIT/@EG:6S?_=^L/?P*#K?W*M*E1;]\D!8>
MTI4OEY4Z!A4% 6V^_*<4XL\'O!W9KN32^"#TZ-';^-._KS)=;H-&Y?%A&SPN
M^(@\&VK^<=16QH$)NO]L<,M;ETGRU:3X-E1N?E"G%-H>**R4GQ;U_?JYT5/?
MWWQ M7TGI?W^33!\O02.K_X--)'N/,Q4E-V;_6*%WDPHTP&I#8E>7UU#"FS>
MDWWBQKQB-5EI21@=O4NK.^%UBY ?]*T$@#?MZDU(Q<=_^1F>6\/P#!&XBCTE
M3&)MX^AE!^V&)/A=//V5L0.;5$44#^C%)I-R&JOZ2KI] TK_\#JRR2)O( O>
MGQE3]40+T P55Q^%N[K39L/A!A<J%MS=?CPFC*8N=_!.VE%_95;ZJO]0='O,
MD/O46C>C]&12H_]<0Q4CO1K(,.U[]_:TKEV]MFC V^Z'+&QVX6SBUR3?JOWE
M[H.KFM%,IQZU=M*X,@/*?-1]7*I:S]2IY$BT%?=S5'+E85T^-V7HI?DK#HG7
MSSK6NKE61<IM"FK4=E9J5=K:BT28![T1K86K)"&B7)UWUK9@>5\6):CU<LLD
ME^>EFPVLI0(;4U[2:%^7&R'Z^B4,%SP&T*^.PX&(W-%F)!P/,LJ.-I:HQ<W/
M//Y$AOI]EM* V]#?__:D&EOZ2O/HYJ&"N#D,F#A5[AN4E?#UD^N07).EI74/
M\93L7UP@. +,IM,KMF_KJP/E;&</T"HPXAM2_N[S_[#VGD%-=E'?;Q05I8CT
M3I0B':07D=R"= 'I3<B-2 L"@I0 @2A(;P(2%(1([R"]!2*$(B @74)-(B#5
MA!HAA,/]S)R9<V;.>3^\\WZX/EYE[UE[K?6[]MKK?\!B\(:].'SGSG-SY;K;
MP*@(+MA#!]-H)YJ$']<_QV)FZKR3Q.X^S]N0$75_T9@^)J\QZ[^+\-QU,JAY
MGO8KN%SI')#X[N=&]O1H^4O7B1W%</LM<ZWAIL:M</6UL .1S#0C;%%9U7 3
M5Z4"H$U ZA7*AY4)8EO1:)_HHT@RH3,0V6W5J5QV:P[GM#A>:.E)XG!.K38O
M <=D0QL)9BN?UWE@!P<6F6K-F?.H0I%%(_<]40R]; )5F"A)D<W ^:9T"6PL
M*1 5J5?(8964.V>?-#F\LJT;BL@5#I*5P%2J&GF<T.G&V^$U_+.W2X+$^48&
M^*C%47Z7@)E%A([T-G=WH<\^@YS10)@!\6Y..9D3#WHSBU\M.D%2I,Z$^JS;
MUU,T;U$G$5N!_"/5LWVJE%?.H,2#Q!SBL0F5MFY*:2Q&@+%U+Z-'V3XXT[VB
M^R^.Z+ZRW&O BZM-H&C70)UVCY;VNR/N35*%-P5DR87!))N>BQR*)ZBTD*(R
M3@')5'71U#4TC]^)ZFG/'30(J#9]G+ZW=_I/YY2C(/RGHPKAVE^[D4&K\#[=
MHY\)]2&>/&V:;M\%7$2=>Z%T@H]#N(,"/TX7JK/+<64[]3=6.E=*["?;2S>)
M;GN!L[-]]:Z?IF]=JT'.^ 5'MUG=O(LAW00RO3G!8Z9[9@OU;IATV8&9Z%4G
M^IQ7=Z9UALTKDPWZ<^%>:FKWQ8K)CGC?:Z:GTE[^Y+&>"'[R^CG@2@]YSFV\
M:;02IXK2)E4>L9"+-6C"YKRLTU3B DWI-HYWT,?FI8G.=2W9:F[U;V[+:Y\T
MG"I>>#RM""'R)&9)BJBR<XG(LOX5W9@:N4)<RL65.:.\@2O!_2.^_<K!*DN<
M,P=P;LADU K\QL/\N4W0+4V1)=.CG?L]X)N*QG"SAK94*R-3QK$#V51-%<]L
M%4PJU_(F=BFSH+]+8,I;.O"!C6XKB2/'LVKS"[^D5MXZIGE&_=/)E*@M:I(0
MKOAS4S8$I?W+B)?+8?\8-X:YR,:HTZ%C?? 8)%O 'QXP18C\D8B=?8H.-\5$
M\$_$1NW  LM*XR@ZQ1&CYP .U"42D\E$X!G3 )JWL7(YWKZD#DY$F]5-*2;R
MW\<==138>_+<S?WLB7R5Y>?&>\]_&%K*&=-?$?!R^.H'O)B)'4IT1[!"RS;!
MA*TNX*]C&Z3F>56A6(<"24!S149H^,N4@@S@&\0UD36NVN@^!B=786?T&0>U
M_HHCI5GD.\FC_GJ:>!L\X#FVV:[%(&GGR/<QP6:#>"Y4(-Z78TNEZQXY@R2P
MM'1]K!<NL'GOH7.9UY>'/K/W-O*X)UY4;</N$/<QGAI?H-HX:B+N#U.WQB2F
M;,'IQ"FU>O.$?0]BSW]P$GC8=L>MX4/-A%992SK74ZP!GS/K<]9K8@PUXQV#
M;: T-#MU\!S0E$5AG>]31W3BD'' 1LYDM/NS1\U +K1;6%D@B(O,,1_ZP;3/
M]TU[-7GR<.N^T05/U2B>;H4KZK"->-?8=?05MOP$T<!72M"\BCOWO$#$+)CP
M64<7Y\87[L,S;9PVO*?ZK 3%[GQ+T@^.'WOC))AH-*5TR87-5WIU+/8@V=10
MG"\]E0VE4YJ8H?3-CQR:61?06>.,,"['*'4_M/K\>0>B)-;=_A/LUIBEI*87
M'#Q;*S0,#6;.G/QV)^[K2MV!AT2@:K!Z[)1?X);-)+,-H\0(3BZP8M2XY;!/
MK5R$!^QZ#C  7=:\9SMP^B\E? ;F%\B?V]]$E#VR'3\'-!;&%;]KG419G#X&
M-D(8!YM.#=J8LVBWZ^XQ#"7TZY\#S'9\JW?Q*?@9VY+( ":&.OWZ ?FT3.B"
M"^Q%J02&MYXNLE2)@HL80?)&\%/'-1^0<TFO<$X-?E5DD -9Y_0!%J-TEMF?
M6;'1WOP1C\;*,+K\,W,P_'/"B]]%OUV0_C>_ZYLT?%M]>UO+Q[O 0B"CIJP7
MG*DFOT7 IQK7QO2G\>.-H&:[&[)^1?K;UC<T^J]6_PJH>^=[9;XC\<-?.26U
M"N?YMW_#HZ\/%:3V#<:N9DYEIQ\3Z+MT?'7'NA7&Z"2>_78+R=.YH<T<\]WO
M0,(U68NNZ-[/+$/-X<Q!+8ADMID_Q,PFI1U9(O)-]>NHO/S/L1\K40-J8SA#
M7F& ZI^,;R<WSP'%_DYL))]H@K'@LNV/FHD][).'6K"VZM)_KC3/WE)E<1CA
MY4\7SK_W<[Z3VZZ]6,+AM7]U2AN5Q1]#D_*:^9T!WXE[P!$573N@36P_D.."
M3-\C9[\JM,[4NS'Y_BE$U\PK6TF0>B5W>FG+;;"L(.'Z_^B,_#\/F;S6#/O_
M/T2BA+L )LH;#9IS@*NLUCE@TJG#::/H'/!-?8S:64#5?:WH49  $*\]-OW[
MQZ3H 1,:B&3SG/7IBO1LG @*&C]R_P3]$7'T _AW_=XY8*" G92U$XAW6*1?
MT4M0-.;9V889D$R?$)>[X8R+_ZSZO%@GYY8STCI,5<=U[Q^ K\![[/  7.$]
M?C'0AP_[+J<*_>X*]D?W1;JW(B?$+%(4&LM4"<&/4YK^KI]:C)V5DXR.W(FO
M5K#89<I3<D[X-7^>=4P7QT07\'?#K7L*5P=ZS_0Q=X2UE>5X.6[FO5\K=ZVN
M%A$S\#@,-O(Z[ @5FEEY7,^-YEQ5M>M3]^O7ZM0?ME*'!JHW"1Z-GRJUC-@U
MG@,^@9*7V0+0\4BBO>]K= ,U15" \>R__AI@GJTC=>..*$]7PA\!J.'L*Z[7
M^L>>3E>1W2>6$O.K+7=W. =UTQ5.PJ3*KYCZJ<WS_3,HG$)SC<X2$<BU7RH5
M89Z0OTQW*P,\!-QN.=7!DG.H]*DD5KQF'9QGX[]B3QE**-FW:&%,L$K$MV#J
M@.DR-C8M[<D"D,XCU+%,Q"IOYUD\C?Q__=!9L'I^2JB4>H[&]X-L$#NA?;K<
MO.<OK@?_4_F*B>%UOKO8,^SRV-RA@?7W.J7)=2L)V>>-]<6\>IGV,].0XSE'
MY&)(#>?FV)5/?+*Q3X*FQ8<S1VJ\90=]D,)FZF&0-S$-;+Z0]0![RV&V+Q(L
MPG:!<J#=/S[3 !=?_X(>J0%Z^X757+D7N](4G<N+GCWTTG!=[Z-3UJ$4AQO^
M",;;5EHPM6H['[\K.)/<E\YV^3'4^6_(#^1)$B]FF8'*#VWHBQ":>:'X@%.;
M>/@G#F94L;PL\E9=[^V+HAA^%YOTWR$XF:*$;0\J;UUWV]3AUN^ 8>AZYG-F
M2AUQZ^@-60Y_#N#J7C&-1C8JOR'=']C!@04H;N,[4DKPFYM9-NTLD)GTARNI
MLCJ3+Q3]\C<T>5J;)_,G?&>6':ACDSN'^T+G +>F;R2^DO3TXB+'>>-.CC/O
MDZTUSZQ5I3JR!/G;*!OQP)==?!AAD6XOZ>G1@DJ?V)T'OO3$CD8'R31=:6^<
MW"7L[03J="$>:'K=:"2H*^7EBZR_NS%9Y%E@Q_:]9,Z?EW6^:'DDMA^= F>,
MD/NO*2'(PPO-,%Q*^8<<0ES_"K\N"[,++-!O+T;&PZ2);H[:/6B>T82 #8?3
MB$DMHF_?&/>6+/O;K'M>'!$,TRS3Z_J%3(>S% [.(Q/2<=\Y()9'I2_UC1^Y
M3L.WJ+O:E/3JT015<%- @-@2%\%*#NNV'X@KF6[RI7NZ92T G&Y:I".8)O0L
M$70:$BVGL\S"0>9V"UAC3CP3A16D.U4%>T5 )C1SE&"7,4X\=3\4&<..G:50
MVGCZ^7 M_"B]4=EJ"M'QM_J+NLVKD]MF&Y-G,7O N_O?0 :8Z?PW?4\&+%.;
M+!=J#:0=);IV;&6#;%[%Q+<.9W84OVJ0Q:F23)@X8S#/5AE\!)F3Q?K?5Z@K
M$1NL7AY*%+W/Y9I]*ZK"42QVMW9^ YSB))^H]5_]/W>QG?VF*8Y1F\J\E?,[
M/DKG0U_I'(0G<#G6.47V[C'FN-WQ,*4X?Q.Q>Y0UHQ)=;:3K@@ SDWE+(3S'
M V.1]N%Q+N6;:!XJQ_S\=83^SR5C0O75K"'&U$-;F7]@9>;;=.7L&UC?_M0W
M<#:8&0$9LSR'%4CV6CGM-!SK/M$MKR3'&DUZPT N87=043C1/GX:75+T:"S.
MBSZUT8BV!YBPQ$B"QZ#47%_6KH!Y?_,8WDWU/ !NYQ,10_"DHRYIL@)\Q=A]
M 'U5*I I23D+R:PIJI*(XL0Y@.C.,A5W7ID14S&RL>I!I83$/SN=1H;-Q+&8
M&@V7E4K0+7+\MN*<>Q,]G ^<O^*?K9JH@69]6_O6V(2].*Z0P5)L*OO5VR_3
MSB;^U2;&?65ZMD43<\@O$Z2@%(ON5A20^>5,<.S(/5O(3\.M2U%YLC2)O18)
MD0@@YW6K0CJ6\NNFV=7Z5B6_#H+JSL2A)VN@1)MS0+WH=A8NQ,*2Y'MA560Q
M=#+:"\GK\%/#OR4*[6XZ!\+[E/M5D)>M]^:*)AK'V,A_,)J<Q-38FG4HI_V,
MK(QS7<*&=$U"Q-FW-3OAM->+PNE#?5#>O*?R^\<O'SISCS&B7]+0XI _.X[N
M$@>V*XO)6?VAQ_%*R 1T8W!?QP,!WR0X%\6N=*/=I-CO9MZL>DPN<?8KE6/\
M>[LLQC>:>FM:R5C_=Q?MN/"]L;*NTNHMF_:2NI?'Z>$#LVJ#?Q,OFY@$5?QZ
M=XW0^.\GAE]$R0/(O6AUQ7(MI_&>&VU-7I62B_8CU2Q=,];!/\X!=U2SY.VZ
M C^LW4O"':+<[A;F^^)J7VS/)]>JZ@X%MW<M&L["25M^YX"GS\\!/QA#C]^<
M WZ9$I?/WFS##PQGWRU>1+7J@3._C'/ /TI;2[3G@#00!GY$6W<.&)=T"KI(
MCF3. 1>3^$T@XO]KB^#S^I>Q%D/Q&U_')O_^N,SQ[XVYC(VTL;_G ,WO[G=,
MA[1=[OLKI"A$3:H.<DO(7S.,>A?=^J_![>,3 53:FZVG[LDHSR*RD%;G3).>
ML /^?IAM F_.?,M AON+M[@:5S=>[8@=UH")>\E\5V6L..8AXD[&#CJSX9IG
M0)?'=P6ZU#LU-#D^;3Z3M$SFL;Q=*ZJ>GO3L3 UIXP6VK)F]3PIV)!K'OCD\
M PZ\ZROS$)"<4))EV.2A3Y5W##:9V5Z;##16=(C5@XI.[I8ZE"R4\[=EC8CU
MF9OV&*&Q45_! +CK'T9HQE$^N;P8JJ)/OMR^OGU<"29'VAF/%N)EH[)GBE>J
M!28QV2+I3I E(9)I(@Q83/;M.YI1U\E=R@_SK'T(ESVYU8Z0#3TK/0= 0)<H
M\L2U3E(M83992D,$)RUYQC'MN+3F)A/I **_>$.RT[XCZ=KG2\QVMMJ:^0]Z
M'O0MW,/^LZ]-V:#XD'G_ZTZH17FX N:'!30VG7U4.C/%LU$E?U" E?/#^'!_
M*K_]\07>7)714%CY0[]AL75K$\X6N,RP 6^HC4<9G^6[7#D17"*C>WF:BG@X
M4F$6';(I/)T:C_TLZS)?'N3S&7^A-&Y9ENVN&K*4<_($+(C<#!F5+FHKF#OC
MQ<!HP&]%,!]+Y)L%4F3E^TQI$BOCDES??C5E-S#,$I4/E&/-EU P-C?*MF+)
M0$M::=Z!=[NB/9>QB0-R%(%S0"04QB# ;NQC5';!A8E 3NGJ0"!;]=L77XSQ
M\[XWA/>@>E^S1=X^/JZ'= FVD<1;[CQ7A\\3;NFL:XI?W.P*4R*[$S%X=/]R
M$IJ7>H?B=I8OI2&.9XJSR9.?*HUDNCH';9^YT33BF85I853.QP][/]OE;K3S
M16E7)G\!\VXYWNW1J4NB1E&4R,'$EB,HL9=*3S;#;7G3C>H]K/'R5H?D"9,<
M1SXPBQS':1C7[39)5^&-5)^=:F:4]A!.E;'7IQP&]\9V"*2[A$=GB C9):FY
M#(N)@&JZ92:>AK'J"[=:)S?0_GA'[JS8^<V,I#]SGJOW/&%?(4+,\B4T <K'
MP2DQ/*W>N+[]6^)#Q9=,3?"R2^ZZN$I8O[1.YW3:619&D^??>HHUKV*_"RFD
M^+&(H>K0A^SI4@;%S^\E'TY]U7J2VE R$?"7\$"EJV7S'/ ,S :9A3,<H!.P
M+?W>%OB;Q7C@S=IH]Q]5SHDZXQ3.(^E'$)ZU++P8/MU8KP]X2W3*)8%@01*-
M]]G=O5MG9!#@X3*9:Z?Y>1H6_$H<-MIW+"\?X_;R&[N0C91VB(-CUT/1]+5_
M'!D2TE/7Z(^,SHHU_(B%>&'E" $BM0F/9H"F>#G(\D.U#?30=E)6;YG),1/*
M+EZEF_:":G).2P;NC-.IR")>'-O1OD-$"47WK%63!?JPI'DBT&B,&V*67NF%
M^] W=?T;$*;"LYT^OV%TY]+#E(DM,U>Y;ZF\99>H8/$^/<6B3Y*S 1NB8]9-
M]N_%)4)?Z4X[Y.H7A^ERQBS4@4Q3P&GJD^6(E4^>5M4[+Z?DMQD\V]1$N)MT
MZ=CPI:(^P<.BX:X=&F-4NC!2R<1_R,^HR3=<)N$(L6\N).20DTX3;'\?K>M,
M9#]Z-4,P0W5!7>DJ5>O3,F]^![X#.:,30*P4(1)D\<#T"GGR*1E,T/<^D.5=
M\,R^5OJJ=&.$7NT'RG8V_2%_9.[-$->$3?W5?=<)F5V"^S4QG5?_:;%"SE[U
M.UVPPML6#/R:)I")@U]YS+B9Y!Z_+0USKMC .K[)V;:N6_ J/O!^D.^YFC4X
M<<#U2X5EZ,_]>$TP+8FV#Y@:H>*8)T]NJI&.%SX'./\V[T*6S,>L%"DC!KU*
M>P!W #'CA69)0I>>?DA@LY9@AQ!6[=F*N76YI!3+.W1*AVV8G<P38Q 92=)>
M'7RM57_B(NH8D)<R7)QU/Q5L35BJ>3Z!C4-*!!O7#:--7'T\)BNA?7N+DLAQ
MSGBJ*N4^,3]30X?@2^\IR_US?)D<96SPX?73G2:#I8VO .9F_J\L=A:>8U%;
MH!;9K[EW]6Q1X+O-O^FE[&_&5FT:2,K:4G\T?^EEV^/1<;=ZW'R="Q3]_:N"
M? &M2(.0H$9R9Z*"PE"]RL<[&/TA2S6^*]:29AJ?;AD(^2S+R@SIAEPU8O_U
MG/E-2F&QK\6#[HECL97R5\)_*YZMVC>&@K,52PWYFCLG$C?#@4>!(3VW>M=8
MCR9*=R0LNG_D:RD&&&.R_7O;E%H4A0\CW#^33Y^0[^!->:$=_5VR9"2)QG*:
M8H-_ .ZU^?&[BXE(??]EN,*I<VA^W9;DO9W,Q]QHG6 _#AHGT*7U!&TOD?5(
M&2MZ/;+\'A%*1$LX>U,JLT<M#.$'H<H2^W-+-V^4SQMXAGG"75UPB:5A]S^X
MIA6_D7TM4Y?;)W0=QK;!(ZC8D"MJE.HGM9=S/VCA._WM=(/,0>E(@X6*MZXI
M/_1GD7JMXS-SNP?WJ_EE"*RVP^$%1B5Z_@D?TW9*VAJB?5@$'\I")LL38=&9
MD0.B45H!Q,.ENWDVT4GYP"J3 ''+LG(3\\35K/N5](-AXU$0Z[#JL;@4N[S)
M 8M<V+ T!E?J5)4K)@6>K;R;7LXN9I(KWCK1$?RVH.CHQYDXDDHG6[F:OHR+
M_CR@ANQG^>9O] D1]>AAZY]+K5BK)_^Z*!WX;H>=0LF)_<#&8 R:Z2E,<V+[
M]I1I LW" -YH^*,@!Y5]5L:RRK2XO[;ML]7M^M=5^FKL?QF)E;C85$UE\K(!
M^15Q63L+3+*N=TVGMVYU"//R"@N\MG=JWA:T5RTM%566BQ6WL]='L*<M7#JY
M0XP]TB"?GMZC3H!I*3HD(8RR+R[9',SA8 =MP*BG'JW%LN]#M<&F=<L+.E?D
MY[[MU46*VXM+Y^G(_1V^KW<%:?6>0(YEE[!MMY7(?/FEIES]/9%-+7R >SH=
MPC>JN%&Y*%K17!OAI%J-:87%J@Y+$E9->>.'_10P3\H3*TTL$O-E/18@EF2D
M_KQ-W6DR 8A%['47#<1XK\X-]M<*LK[K346:!G(MIL _LN_]201YMU9IC(,B
M:VVOOE-KGKTC)4^'B!LLJ?ACVBFP7>[*S?CC+[QWT63?-#B&BCT:\G2Q*TS9
MPSH8W(W18608[PYZ]YCT_:V&O["QP(1*._]G"CN)OI>.YT6;>?#-&T_Y%RJ^
MT'%_'93D#O_,LD#C- K2J#8V]I]<,]BO:!2_+RFYKYW.:CBX;Z?BU=@$ JPL
M 3'3V7X5! ["]KI)I[O(78*G\5!AHH/RYXR@C?S#:\C3()@ZT28VX!S 5!M#
M"1?X6)SX33!O-2#99$\D;]-K$/%/BS4#L7^O+G$HYNY70'I1PBK%]-07QDF.
MPC$QDVVA6>;$W/7X@-GQY%TTKMI5&M>(3KLS=6U'1#8I?:RD<\%,XIN075'2
MD#WS;=#[+K49+!Y7N+3]O>^&]'&:PTL&OXP?E_UOT-)&>HWP::OJM,6(3_,9
MLCR_F2C!5_@9]+)$%:@R$C,&L/ENI%EJ-YK[5.!RH[V?_Y-<<>'M6FZ=2@.?
M8K<:N/FOM@<058C5AHM<0]6"VU]W+<N[LT)-MM9)M<:M6 .EP%<G#XFU.])$
MEUY);Z_/,!UB58GPA=%95#K,/:[T93/B<C#6WLXR6KU^)%'=+HHHNEX(DC]M
MSB+0A[UGF8-8'YOI7TD8-Q2Q^38H9\ E=^MKU/'K ^$5X*K1]Y1_-/H,V*Z8
MK5_G$GN:L3\*>&);^7*XQ0-0IUJ#QBPIDX)CA.U@LG@TL\=-=&=R0*X]=89%
MZS7O=KP0UH@[Z.?CYIT;YESWAC*W,&X?':$]\CTV!3N%^4[R 6W2P<.J2][8
M#97@>O=.J0Z!G'(^-QY4_M!?/ULH!JMK[-\>Z&SOU^$[U\3SM#H\RPLXM59<
M;@_-T>TD[K8QM(0ZE?.9/97BS K*"AIA(SVU7_X)40^8F3WQ*2Q9Q/B6;<P>
M66""7<*\KDZCQD=8U/>!#5=W8J->1 B!/4]F.JJ[&D@V_0@P=NG.]&W4E.@$
MY4&EL8]T@8.8U+:WN>^M)7*L+8K#/O"3/:(T/+!\47<VQLZ5\M^O? QILD?V
M\B9/3!;!09]!]-O,]DCGKVA=6[WRWV.7@0J\UG;;NX4T81W7'*L/T5_'YF-Q
M)KD%<V07IXFF<\"E#C!D]H]FZ:MSP V!O-F3I<J0RDU6HVK/M'@&?[#3@KQ!
M2$GWD<=':YOKR?(;1HQ1?9;Y8)J$4K.N8'75FJ>*"X@A$\B38$^8\N)\VY@#
M4T)I9*^S7$AXX,Y3"7,$3TZO\QU#B8E/^<8]?KEV30+6N0BLQSG@,_(FS#+O
M;C+BL/"=F..W/BX^%3'"NA6?MW'O->[1&^P$-#O<!?AS^2A_"C<5(4CA)^XB
M"<,=98AAO#NF(R<U!GSKQ2$]0M]YBK>7RJG\;'=75*Y^R0O1GJUE:7S/59=V
M'4A+,?Q!,7"Y5HZKO;6!G4'ZM7Q#3=8Z=S2_2VLM,*499%4%AJB$).A]KVR<
M_:_U[7=31@]L5P?<[[+=[U#7HW+_6?.K3:!_&[R0#:.66?.*.*E?^IFEGG=M
M/Z<8%.G4VL>X?GS>Y&*>#-/E\7/:*]344?7 ^OA8;DEZ%(NK5O.DS%(&U(C[
MHG@ZBV@- 59>\V(<3Z:'-M:Y3L%0+B/A254QMRIZO=[3M)P448E#\D?T9;\]
M"=X&GCZ&"O4Q$4>'@"S08PRH4: 0+M-$D*8+@7OXWH(6?NVZ1^S*+?1<$IEL
M\HT]R4OCRR!']=GK18)P[&W3!T:G9X;=&F:E=YN.?;>[+]##DEC:"^>%FJYD
M[9@2AZW/TJD/R,LZ$X&I@(?XW,<0Y#6J[,;2[9;(+;VI+BZ*WD?L0G,38X]R
MEGO%XJ!OL,(YP,V!'$.PD-MH@(40@QVG(C0WNP2)?Q*:PI;)>E09&(C$!N;X
M16I.Q/WN$H1V8-H1.:\*EZ""OK<\E$\^86O?:G)0_IEJ7&8F<V*HLM,P$![]
M]AS0.<EI.'NPJ#5CK'+_Z"79;F49NW]D1?ZOY\KA69'06YC>V0>47?5OX$T-
MR+-S0$+A5\3L;$L#F6E DQ-E';/F*&LZ->&M\F22PW3[S!VCHNZ-^+QSE$A?
M*5O40S*Q0L[&,"E^U4J6TA'3XN[E$W=Y^3/!WZ1HLTQLHMIPUMN0L2G"Z0^)
MSS02Y=+=9NV>[:P0"EUPX^0%LY]]Y'EU4B)TR;I$I,<\VLZP2+)-ZYX5*X1O
MR&16GYH#XR14A^%VZ[,1F4)B0;9*WA*_WC9W)2QDIO/F!/\[[OB5*\1&G"_5
M5_#]=4&[_(R#Q&X!I7'4JT),M<>DC_F5X*#Z^K.2GM\R&]N[E@!S?8/3D<SG
M$M\& N'B<*(A$]8++]J7&KW,#'<'8^GVC%*Q-D?*I$J8,#DJ),S??0KEC'.P
MD]FFT!,,5MV8RHU$NC(#"R#J#4+*)8IG0-NVH+:9/ .06P00>FI)AM=B*N84
M'GSJLK0?_5 45UMUS)RIC:)/='TV\UU;C3MZ,2HV=>S[O4S_JI[FRPWM!2N%
M9I)5CR Z)KFV&\31G/5)DU@"Q:'[IZ;Z8&&OG8Y2]*CG9$T=VSJGZ;P5IHGN
M@^'X^&CQ5*%6H:G1_<:QJ3]RK7\?7EG)_:EV\F]&?]A1:?DS$UU:W_WE"T(9
M(;_JY0F./T@&V4^XL_Y<=HC'!P+D=]7N#>5\+,CF8&2(FQ/[C:O;\_F->7Z\
MWE)":W9X,' . (NXA\-KR=YPW-CJR?N*\4K[3%L3=G$3R\V)[-5,[IXA@[Y3
M;./Q?.=N[+@.VZW_XX*EY@)($[B,IX<H /DP6X5F!/9,X4'9QH=?W0>".MT#
M,):;]]\D[0^LE>[(!<R@&T4Q1EFW&>\?!9"GR[36A:6&">> F/1%$$TDR^@-
M&\".B!XQ$FX$<Y-3^KRU]U@]% 6EPL(.:D>6L4X_3$G[*PM\8M/4ZY2P\?@7
M+$_)M2O;.9S"U_YM, SZ!#",P6NG5)EG#!50)](=01VN^^A?X;%O*6F$[;;!
MHGQ3EI6\Q.7"N/;= ]"0(\JHQHX\Y,O[^R2W/Q/O(,MU\3"#&6F1/=_&Y5L.
M7A-;V1&%#&V+1Y6.#Z5WHWJ$;;'W'%^G)<##P0T7QL=&_;'<0-LMFQS\1256
MPX7$BUM+K8:0I)XD2Q^V7>U+*2[O\PQF2YCAR:3FG?1EMMX:.7)H?<0@*.^(
MH0R= [IE0"NYV:([XJ12?' B5=$S8QG&1J8G&.OU9*=&_TJW%2)'D^B6+=%>
MOO3+3QW:AS04"C:.-LK(]?2>+@CJ&N'Q!-:VH#/=DHJJVMY6-%;'&(T?;#V0
M-9JLV@D843"<K*[>;CQ3>5P7+5T5<*8YRC5!?]_A?L MAVZZ*K.[0;I5H^"_
MYP"%\AN63Y+"?X\6"52?)MBT_'UP#F ]S8KW@X:F1%\7&VI4<]VQVKFRT6?(
M",[R:=Z==2#[=)ZJDR7QP6]W-)1.'V+<265*AX@6/*^QV^BZ+C$V3D.O])JC
MBOD41=RY?(3_L":.?S2Z&!***"WQV!T+=(5D[?JDCIR@MX6(DBMC?<LQX$;T
M-HFXWK-,1[$B[IO-*)X#XO(XB8?-E;ZX,2!%@F03^^< Q.WYX[<U,YC>5,!C
MIH7DM<35\:6YV='?B'='R#P)X\<P RZXG5=LF-&]=,D5C+M^[=*=+WWUJK0)
MCCN\PG4AD1XB!O@P/R$COG$?<4&IL*02%3>$2+8:JM3]V?R-^76=(6:_*$_%
MZ=K BA:'/U-_VZ$5![_2RT6Y9=W%1"$^\N,MU[&<7CLB@6$E$0H1/\\!S9P]
MQBJ84/3V,<$WD<KTHX2<MG)]M+(::M,G[!6T=&NV<:8Q?<@HAY=?'^IE<Z]I
ML:CYPBL'9\W /1)&&=554,U11%:"^PXK$=T-8LI9 6^W>?HZXQ+),M(4.WRK
M,SIIN2_0T]>][&YN>+EB:%Y^!>3H:*@=T3S$PJ_1B?AXA8'#8A+>;8MB/U4F
M<QXUDZRS3C4@)YU'=4$GS96D9?WV['. ^3A*B91A,2L;* U^_"/0V%QU#96^
MNT22.1R1UAPO_FT_E3%G-_IFM:&!\EWXMDNF<?[@R\V.C[JN?[])W[;H_YV&
M2[Q2]._GP.-[[]7$M8I\OV]C.V:.QF6R]F8=I<-!SH-RE?29_2F\C S2L,<L
ME0DE.V9]13E6L@%5M<\G6K27SP&N3+$\ZWW+6*\58 ^:4:;XK)RPG+#$2.S0
M?)<V#'<NV Q-DH,BS9*+[/(??2%BM^R+9Y'KMGU7J_:_L7#MOH4OQ6Y7GUZ'
M\9_E=,F0C7J C!GV)-%81<=@#)+E'. %C.N2ZVK*/OJ#40[]"VI8CW0W,I+T
MIM>;\-&4^JE#,'8P2.@9+"0&1\,,*LF)UD9&<4)ME()S0.1=:@_M13#U NY,
MDC)Z.$^0_:"$;._::+B;:;3O96V\JJ(L_PC'Q_P%VXU9^AQ?;HIS9E558SFW
ME882<<IIJSVZ-TB]N4$Y]RR*PDH6HL4@8]JSHF&.?EYX,"_L4>N4AC8)V8OP
M>HF@WB;%M#A[%R]A/1K*$];F>Y88QW<:T=?)MSY*KW[Y 0.5;((]4ZU;T6A0
MV<L\.QD/O*CQW<,U.#NRM[:RP6&KI1*]OYR\)#(S*,^@JQ?5;Y@+FY"/EGI
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MB=PY_\SZ-'H*.(H^)CGEJ#]=WCA"S/:,V7X,V*@Y&-[JU)S=X0FXQZTU>.I
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M[,/0[2A1+-MM\;A?L<<3)5UZZN$>CU1SAPI3I*L5#&$M]WLHF&\^;&1/)V_
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MK7\7)V,Q8*YIY9377HG]L)3:;? EEKU[1MU2&6N/,$/[[5:1#J /L&7VW9D
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M##S+!S<[K?@-%64^2B!P%)AX490>5 AM-&QV (GE;[:!'?[N'31XT82OFCN
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MV4DNR.C[' $*</<XEBR[ED#(6'+(.E8<96X)!'0.B**O?-V B:!Z**EABDW
M'D\/1AH0H4%%II?TH_/P:4JH$.80]NP^_XJ!!4 1=5^;B3-[//+]I9AAO"A)
M9=E(I7- 9/'!$H%)5JB;*JI"M<'!&!9"!&SK-(.0WHZ@?7E362$PNU%'*L0!
M=*6V*LHUCH04P4?7(N$BZY5=1CV9D78B1%B+, Z8H'+UW@ZIHZVJ41),D7_7
M(J''0 \Y#^,.>5KA%M48V0%!)&WC6GKK1K-FX>;=9H?=ZE]8 J.O^PZ%:C5
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MH/H0S'0-P8P8)YTK88H2<_A2^<Y5Q-X[/MMU?NML3Q9G5*!,2SA\B(691@[
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M7&MA[Z9[0/ZFB?N)I-^E#^XM K:IA.8[+YKZ:ZL=Y:Y\K'U:XM[3Y:C^*$.
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MN(KJB@^M?.!YF]__*F^ULU5\I(BPC;J09#"6)6!<'C>AA.2( _+K?YMU=^P
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ML=N* 3H\DZ&#- $DS]$G3H$V_V=Y@[+O%(1&Z-D7S%^:1>"I6 @')>M@YLA
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MH6:>DUC9,2>#NS&)Y3/";U&4,;5$3 29VKF0E-3NCGQW&%+C>80A,V< 9RJ
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MG _OE_6L=ZW?N];Z/>O]/>O#FM#@T6L]_27(7+43[=PE9!>60QQ&A67#MCC
M>1E]*XGKW-0RG9_L# ](G9>%LEY\4FXZ"7+K)N9"\V)="&VX3:V-Z#<;3.F5
MX8]#R.FC#_<_$>1=G%CKYI.*Z+GM++X-V0&7LZ(8J.8PL2^*#QZ4;R/*,Z*3
MM(>9'7JM4.(2EY1MG,I$_'WWD9-Z]U\H7AMU(M,=.4!,.68("7X_I]8E7DVY
M4EI$S.\X#>V.;X-/W0OB/N/(ZYBB[NM ??MN4G' K#&]2.X,9*6]_3:,;(/^
M7O%KG]7"8'WEY/D5W^(HG(E%&CDUPB+6A_+!-M6L@):[PX.JMPL39'U=D12
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M9R4#/L7-7KQ8EA1NP!VPD" H,<6#KMJ[4]O7!=*)Y-A5TF8^E"[* 0P2^3@
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M1Y#TYU*Z+[#Q'$F]A=:'I(,,75F.RYA!L2[#A6-@M\X/C/;0BG@BJ?VU]=Z
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M3.[7A]?XBZ$]GHLL%O!GF:YP6^[%E8/]0O7< ";[OJZ -5O=C5O'1,]7;L,
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M\!K**;8A&'O83!]ULAR .NF)MM?T <OW,ZNMG[YS\/E\/7[N8^ZH4]5Z],[
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M@'"VXY8<]"D;3$=0M4^$GJ3.L5ZB8<.I6%E20!423O6.-)F&=:"I8!E P0;
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MU/^(M \KCE)G":V.U_J<&=4OQ"NA],91L72Q_<[<(IRN53YKT9,5-_8\VL_
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M\5_=E<WCO[IOW?OWEM&-O&BY :]\F$[UVMFW^X_]BN:[=9-FMG:K06YM?Z:
MZ9FZG?C(7C>PQG=I::WY&/$W3H]^0HZ[*(?5F486\M;M8WF%85VS=1=D'K^#
M%*+3?7H<OCY]V,_NH=RGN4G__M,=&,EONJ_*S,K84080Z9TU:1G1XH32'<6
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MI?W,I9[.CE"+ZABY _I2+^X1HYWSL+*MWVX:*T\<]/[ZRB8]8?J[V8ZJ VY
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MR@A#810IQ,K@KCIG"LIK((LZS!+KD9E0WZ7K1(&E:%9QH0<\DP^.%6UY3&=
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M')W8>=1[OO]"]Q_*4[)"'EC/?'RT/'HK'7%[OKQ5I3G,*ZTM3WNAP"S3*;,
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M/JB#R,6^0^./SS_*>E9(7\Z[98YLT9DU8G&: [;7C=$Y S]KC>D*.\L=G--
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M=7P#8]0H.@X;"^!.H5NE[.:_N!N VT-09PW/4C2_U;S34FZ26,HJAUSYJF%
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M&H^<;.Y4VA^\;[EG:AM/PG?,#<*2?774ZY%25%@7WQ-$D;KZI[]3SWG,1/>
MPG+_=V>V_UU$ ;(H4U7VKZ8SW%OW0X )- K'=E Q_MPT25%[Z2+>D:C?IK<6
M2:R*9:C1Q"D\-<".)1NWG1E#,@]DEU(=L*<'>++C:"A+MAT!;6<8#A$5)BWZ
MM;*1L492&A & S))+L\WK^CSV<DIPW4E3NZ&=>^!WDNRWU_XYWS&4=6_TE&6
M90ZS*FTW3EQ\^\[L7X)R2$)L[G5ODR?55C^[EG_2-K7<[,5FK+EUR >#4&R3
MFV'V"E)6,ZZLW/SMI8FUFKM+P5AR#" [U5OOP3*.RZON)!8O2>;%5*!DOQ]D
MR93#*^$.H83_SCV-,G1WWT1&E7Y8V&;4LP1=!.++"M-O#F,L64=RF3XQ<!<:
M*;/>V!N]TY9EWH$\"#1_EERN']G625B7-J<TI?>^U;RZ^&PDJ[C95(N1IS71
M,E,A^>J$@^^EC%[6T->8-=\+"9!Z>?;:5/U+GN02686#?6L<Q[6:SCL;#T$*
M []9?'%J7 \6/D? LKF5O!]E(S3'\<-1713L8?9$;WF911':A"*)37Q?L:7N
MY_A,1Z^YN\QR26MAQUFQ&F_Y(UU^]7K(4"1"K<9N:>9998AUFJO\7<<G>,YF
M#7$TO':B1:]P>BGY>S83\6,!%\BJBAU<TD!'6'+<:ZIP_KXGX4;G.*+1L1@(
MJYG@OLH;I9RT+)STVZY*1.6'!S"ART>BNK[0:H<_UJ9LZI/"A+YK,,5RLV0S
M6<FQ3UW1$)-AKAHS/GD%*3C>5H3VZ;@/O)SL:#J[+=H:F4HQNE#'N>1^X0V\
MWEUA0 N_M$]M+=)B8;Y_-\6MK60IT9QY3][G;RS&*7ZYM&[QE""NDI$Y7I*T
M+0/>;DD-#-R]E;Y6N<T8#5L)QLG/8];8\$T8V_'S1+#C*%>.)23I5^\R&:4I
M*P"ELII7Q!TFD4P\!"*MOJEB)GBB"U*O!//[IZO0](/@0:OG<N2WI9 B[34^
MTF*60SJ!KIU#@(5BJTI)_W3+)97"#F]D=Y^X'1@/*9NIMXPQT:S6,Q-9.?RN
ML\#LKUW1.=8U^P!4<0QUJ-R=<#NMU%:Q<,!4J7.D->]V,H3O5I*;=8[R:0^3
ML6%4V2]JUQ@8_ >=ISZQXM^BYJ] EN!J/:7R9-#GXY4*J]EU\;/J.E]/MG[_
MD_Q5QC%MZ=+-1ZDS!@<YI2O#4[+1=/GEC>FP><SU E^Z43%S31KM2<UXI@WS
M*EQDR [Q1(%MWN'A6KA#Q)V6QD&N:2$0]F!P0P(A8C>H6B'IIOYKXC+<81=4
MU;,' I2\9HM+L9_W0%)5ZVGJBV+TP/!<+3E+' P=UM%DU]F3E_J$3-?Q/$;-
M]N63<;_^P<D5<M<F[GU>PW+&Z^'QWCT0VWYE"R.4T#'*XITMALC&/RG/GIJW
M4DPO66@G^IW]FJE9I=K<HFF<*AOA?J1E!"/'S%X3]I/LBIYF3T9RY=_[2JI%
MD#RKG,T?3;<WB?):6.&VV_R(E<H--;$?4!,<HLAMH<8);6X!1YS@@YUK2H&:
M 1)3 @0PJT)/)\;H(J!YLQQ=-[ACR4E.6M52(,CO2/<0653"C_EMKX$XUJ+O
M0S;CG5=<OSD^'BEO2[SI(X?.>[$6) W^S!.G;4Q*+X[0#^]ORD"TMZ".\V#E
M&NK!2R<O&E'PZ==?78AMI^^ND(4F_3N:@.>C7,<,=,$+,F<W"BN!-MH#=6F'
M)N6PH&><OP,F%J1]^QI=R=4O\.7)#VMFH]]JNND[CFRT[).O5DE>D:])1P0T
M7#M<QLUL==P*KF2)[_MTUY\K,82/"0I9;!LB;"!_A$F5%/O8[Z">O0ME,!R,
M!X]/+H:8'W-(DG'*<G)!NW#RG>7<:QF7X^Z7QA7:[WQ,J*P2RR)_R2O!?>IZ
M3CK/6AN/GF+DE/KRC@U< A38<RSQ%;DR7V.A0#BS&2J*N2F^!SI:*W32TA,>
M&'RF*:4?2%(ZHZ8FYCL]I'9;\K'.ZQ]WC#'[]H_'7S.526*+=X#I/DX?DZ21
MFRF<8#IWWUSPQZW9[7]X^0?:CHG]4/ +'K\4!I88HT,!'J-SUL*H4ZM!+NJ*
M?T>5VH)TN*K,B70M 9<)S5][(+6E![AL4D@VK0>(%K?-MCX3JHN15K@91K"Q
M>;=8I= ;" ZW:]DNDV]\R'=#.GJN&;?!G3=XEWMG_HY-\F=5A2OK*RDWIE(;
M#BD7@9Q$545C#SR5.O2<?YAJ\5OWMR4XZ6D.3YKP>Z<%'.]@,V-=Y+BKGQ5M
M[Y]<_&TBT&P08U6P2);BG,B!$=!AKC4--")!Q"9*/T?-D;::9H+R*!MK>E-9
M4;DR^F\S,4U38_R+7/6-]W>05,D;\:=/F1ZZ=OLCY7!3>-915J+PF7-Q#.&/
M-Y'PXU=52-<Z/1-M/!,]3UV*!*[/3WRZ^_&S:DS1ST?^JL4W#\2]?I'ROOS0
M@72/%-#7.H&3%O<_BUXZ^2!2?O;L(]'+:?1DQ?0[FA.FU@X/UI1T; ?\%VJS
M0W6\PM,+Q\Q.:"1<[+'-K"Z_SK!/$R7ZNW!7)UER(9/4Y&AM8S'2 98L:%&<
M!H,1Y")[2O"G3S%R]!WVS:ZAISDIH]TG3M#L*%'%J&=M>>[U>1+1><I&X%O-
MS?GHBQ*'_!?2/4:E+/Z=?N;H'Y#337LZ<UT>5'7N'Q,%T(',+X<2NH;3O/YM
M,WV<P)[5/291<H0,3<JW)HM+WZJ4$K$ IX[?KS(U^S0'/3[NON0R"?</O>ZO
M+Y+JK7NVB\_]?@=3::!C@'!8(DQR75&QUD_W"]TA?8@UW!+*\W3%]AC7B?:6
M:K^53^;QWV3B,^'!PPBNOB9B$_RI+F]N#,#M7/VOP4]5RB]81E8+.;?&A=+X
M<510[;N1^$<@;$>)*\TV?TE$GIRP*/'-6&/NGGI$6]4"BP,['?3(;]N$V3PF
MDG^> _7C71HAPIO+*U5J5?C )+B*_N/?KN,NYD:%@MF3<2ZCB6J5M4(O)/U?
ML[:(39E6HU@E.%(?(\U._WFO.]C+*Z#XWZQ2:K*HRYWCZFC'-AV+(F=7!2+'
M)]E /R FV6*J+S+4_-6&U![H]*)D9^,T.#:T+D\ULP(#YIB//>+<%DNM(64Y
M1CY6)A!J90^@'7IO"Y=&8J1+8:&('P$W=6+\,3>?R8W* 3)B;%HT("_ZQKM1
MZ[BUDA140/')]LAYAS0/I-_'(3DY&4N6=JK5+U@-;4VWM&/U_/0[56B:-^Y^
MFU?0M9-5MKIZJA$Y*#F+T0ZE>AW)8#_^7\6UM@8ZT]#.OK&+5'<1#E];:[++
MY@M4(;!%B3#CU%,(3T?F'(8TQZUNT95B,<:L!^PLO]?S1N<&9;_")&G..KDR
M0\HCLR->31$KHG\VRG!M\CP!C$7<-$LGPAC11P_=8:)V8)*O7!Q2I\%\0#<X
MB481;X4/K!.,788-] VYT.];D9YQTG[T);L,1].AK#V0?E1O#1L\#:8(O&*_
M,_Y4%<53I@AVEA"FE\Z1Y>*[''7J^171J1#GBY*YJ16IQQTUQEV_(/^F]87Q
M:YA>22&S=E.,!-'=S,U(CIH=$)$/RQ5*9>7%!NT^%8JD(W[H-/F\>HRHA2Y_
M(8^J-$&^)R+=Y"1WE2TL;7S\5]N\4H:-%;Z@HV-U)^,YU\$B3R)%,V<X'90E
M.\KTU=:Q#_S6B8H-7]^E77L#ZUVPBT@?#_7-YB6US9V9/ QHG]D#'>=:?'MR
MAC1RQL)2+3_^Z^]C$CE^-<5FQ- S_&8MKLVBDIJP(?L'GK::0^<5ZF6#I]5
M/!KT8_#R8=E$G,^N@&-JVW9G7N4>J-V"<W</1,U")J):A8%ZJKO&@+*!>1F0
MU\'3'L3HBT=OM#R;HS159I?Y9629?AT'?,"--2]'S:J)S<\9&#Z/?6M8LUN$
M<KM,Z]@#?6Q=,2^>AQXR<"LWY8#;R<> _$(_G@1'/'J9%/@P<SL4ZF<#P%WR
M.IY=O-<8B_ 8K@AR<YA87E'3TE=;B?=J11+(FO^UR=D#/=J5[V0HL#,I>2_V
M^=X8QIF2?LH;[<!>!%#L/HK>'NA%$/(4[.GX]\6 >=YESCV[G@J_NN"KL$U9
M.$US8<2!]MC1:EB50$ \DGV(I>R!ZN>6)W;LN@.GJJ*SH$F\LUQ+*^$Y*@UC
M".#?FQ0 V>[LX=R"(($J8;3_YI?56K#(?)W+-Z%BAE$Z)E,RB*.IHZW=G_YL
MQSR*:7V.ZH'VJ]/@-UE$*0ZT[]XEN&A-W/U!'HP2(Y[YX*<!WQI)?1KZ?0L(
MOKIM@[Z>Z8-5F@)P4C'=Z!0G _"I:=U4U3;O@8Y>1?)%_KB>C[I-Z=<>* X6
MNY1^K%(\_??"@P"'8K',J/U9,&J=>D.^MIO)N]C#F9SNZM2'QAN+3;&M\]ES
M[<_(DH.]Z4R< #JX0Z]Q%/4O<D.@V=(0VM%$9!3\KLM1&2Y)/YQ([%D^-?[C
M3QWTT:[ID)$:1FX05<MFX#GFS-Y,EL11IW5#DTZ>9,V(=/TAE*179ZGTXINB
M"]>#/W](^K?1Z%$8=VZSGAW=:1PC6V/>B3O"Z^/)&9T"NEEJ!Q<E<<]1G##5
M3*TZ_*5-!BJ'7'/R=Y#2A,_=E[]O#:+F$RP+%G4V@W^6/[_*TS. [)P#6)96
MR'ND/=#+I]@!$RB;434U-ZH5E@/MR#W'P1;B%V7.I<QU;$=.?+,H<T9/4O3^
M.V?@4PY80X#7[RS"<<5?@CW+DY;7=#*CSSQ6!?_S4_1:0\BDJ)V(2W%H[9RM
MNDVZ[M<<1:+?0]%R>05=N6\5RQ69(+;6_@(&YG'FXK%7IGZ=7<U0$L@8;/,H
MFSDCZQF=7<*,CSSNKW38?!'J5*Z(\&@A0&'';Q<5BDN =_*2[LR89B@(.T']
MOQ1Z7$*2SZNKJ_M/2)G9<Z>.*U94_E*4'EKD_M<M$LR5VWUO=!3;2Z]ZQ3-R
M79*\"\>=(EE6<"4!'U;B8^"_VH]C6%&#DU\\F&JGH(:S11F95[]]6C0QW7'[
M$:JL\29^O*5]81-7]CGBG:CN,6L)R(&F\,')1&S\/]X#O4^_J1KVYXK5J1XK
M]A-]7!J%+YAY%PS^\&E,::F 9\ 1BORT>GS:_2*SHM2P&R@\F.:M]03]> ]T
M0&F*,^D0D#)C4ZXEY',WL-"9EL9<>9#FI4M'E@%(7FO'=.MF9";O]0$(3X\3
M%3ME+.#'4^%<\!N<WY:4Z_GE&WJDD=7R@*JU+G:#[FLD\VD(A9\5_F'*2_;T
M?#IPV?^EYK/>A3ZN#@LGDK<=XR34M>S)-0VUZQR\(Q6\79/@"7]R0DKQQHFC
M"HWVQD]_==Z<>!UUK?T,GJB*#%Y-2<R>KVHM?<MBXB8NTEU_-$\T<*%/C;5P
MCXUC6VNZ7O"NHO5DD_)J$KLZQG781V: UR5=^4M;=-5HEK$X'3@Q?8?,MAA2
MP9A7TA?$C>1ESL7M/B:>P>@CPO!+[F>UF\:MZULOH)L[\M@6"$<7=G3B>P#)
MFKAH,Z!FYSS@R1:B(*7GH[O8$.#9EMFP\@9>6IM^F6.41#[T@",>XT&.$Q\R
M4&)9$*7=Y^SC.^@;"7N@1I?65P8*+ 56(X<ORL"PRM5$@$XUJBY8H!=W:*=8
M;L:J>&3Q&"Q?)CPR":=XW?;<?-))3<M<!/8D1L&2."3"C*84M23?^S1@NV$@
MRBPBN<E:A772:E$-5M>\)-U2_?32,NK.D[L>;R?.I3[&!^AFYBY9.33#X=NN
MJRVT\(N%ST)E$U,P-OM@NP_/,FMD]@1.;8Q25I0H]#2C,VXW#?A9X6*_<$)H
M?\.+3ASYV/,C!DHHU6K/8D"&8QY-0H:A#//B:R'QB>XC0H9:XTL+.['8:[BV
M:P;76%87Z+)C/ A8!"@:1V=M#]*FAF=:>+&>QA'^*-E#B]L;%:DW);\#7)BM
M+^-0_8 PS]"'.A)\F=4')O=K38#O[=J#7T+Y6"T-PW9,,.7VT"HQ1ZE#)S0.
MS=?^I<P-WB3\XW(LX8=;249-3X5O]<1$97K9U[7 TMT/:\O)QUPU/8]U;?H#
M_*5]E7U>;"2S-@"(!P_4YCA:9[>'FH[$7LYDSALX(HI@=2Z'AXNV9=(]D4))
M)!]RWUU:Q4I)-I4LU]@<MSH-&7K4J$H(6]C%O>E[P1/%3LA^%&^SE.KC0_/9
M<Z*BD=-@">X-(/Z2.;,O";EJ8([W2RP'XJF\*\]O%EMWF?2O!5&FK-KI=,$+
MO[HL!A#349UBK= "LBB/L0>JV:).QK@+ UY,@B>4R(E.6C. >#!SQ%WZU6HG
M3%9RC[*+D^,QEJ7PD9K\/$I6;I[_-K7L)4\KCK5$<2DFUO[J!@FM-LDN+["5
M*%;E1I'L8&;QJZRNF"J2<_E7\G'V\N $$'^?-C/HCW+,F+;*<EJ->FU 5ZF.
MNL.J&2@)5Z5?6?\QYFCCP2YE5F96C:'Q]P#4E*$&5=)W2!S,D8Y^A3&&5SI5
M5D:B[&N&IV@/APB%0P<4PD1;OEFB2U%C:2D?W(*AHUR]'>JWUB(NB33*"!4]
M;7//&[6^!_+YU/3FT9GWZ1$!R>EU";^_R.>O=V'YYG2H*O2M3L&G;9/?W/B8
M:J^X!TK&]Z6D2U]7<LR:6(WBN[/W,"I3,5E6K=<_9=S9K/6'KPMU?'I3&_O/
M7P9_'CY/ KQ_G_D5BC@C7VD-ZM)BGW\^R>MW5\UPV /9<8RG>OZ).9XJ%L%V
M=.4H6^\:3S.6[N?>Z5)J+/*L75&QQ3642J=CK$XSMLU&!TIJR55]EAITYIA9
MKL:U#BM]IGKYZ#XO2E*9Z:;?4H&%!^^\!HIHSXS>-@VNKQGZK][X:X(A\"#A
MV]1#S3BZW*NO2T$JH]_&9,>&C_QL^W,8^X#KPSG4-$KMBXUB6:A:9U>:,K^K
M5!8EKP2,P38'8 N>_@^%;_*E8I!(FV'O)(7*$@V]MR?Z1L\4F#749?J[R=E)
M_G.0'W).KPZ<AIMPOKZQ (V1)-1F932R"*;4UO$J TCECR^X:__<2;' ^QVQ
M^)XIEQ_GZ[AR4L8GH5P.W VU>=7>7D,05;W3IFHE6K3>DHD$/&>?-*:5/92Y
M@,P9&W9L*1]"I:7!%O SL*7B*H2F.O>F<EW&YDAPN3#% Z[X2;GD0;.&5(9P
M-_^Q7ST!IRS-7I6<57!*>)^/O 06FM\';#]'**)[(6-4F#@:H]ESX4[E^@YP
MX??QK;JLD-^VC)U[22QXK=NUE97*%>[.T8ZX?]1#S?+?+TD6A-P*'[@[T/=X
MNP@+7P07N5$NC3RE"JTJ5Q1?. !'GK;35$*J^A]9#6F.KV8N-4A!B322L5@!
MQ]GE7TP)L:%14//9LSSZ_7^%30)^_AF9HH^SP'IBN]\=D5T-M,M=3 W%C8!K
M@?G7S0AG;XO,E!2-JJAZ#2^G3)J2H[=*7W(]4KQ=U2(_>VW,VWV[V@_7_AQF
M>K?%;S"KW!9?BL>'8KGN<0HZX2@&\%#\7C^"+/V=%6Y@.+&97.XV,:']K_.H
M7:KUCO)'N9%T3<)F;.WP/S^<J#"#UW3W>[:Z/[<]F6>32S&WV4,B;?[G.6>W
M&#)#09M)0C4'REWZ?KI\>-/_(T0'[X6#Z0O/_CH49E&087;SM] +S:5LI87#
MQ9WO$9J&9I9.SG(_-C=3-)^.CX]+Q9!F,KZY:F>-O-:M:TKZ<MOA"=_CL*A4
MK:] =-N6P).J "1K7YK_, DY>5YJF3Y<U*VI#CKTI/%VT O+D".FD9A_OWAL
M"QT9[)S^Y >%E%YYT-YC6[38?C^UB."=-HA #,CV&ND,?WW:>Y5JD"EB?K*Z
MOS2ART3 03%Z],.(;6I"H;R07P&Q-&B-D#R0%Y<K.DAL/>;;CTXZLZI95B44
MB;&XI+!IW\BN2E[):W.9^>$72?[ZNB^L$/U23+!)JD=1*M)IQBG!9?(@UP:_
ME/M7_QZ(*=<@;J3.]B[]@#'F5,S%RG/ +[1\^OTW)&Z HCB"1$)>S"7O!XBL
M_O,!M8ZP::NS\%Q)CGM"?OJ&]$6G^N>1#QU6SJ?,MC\ !6R&?9].$75E/C2A
M8(C3K4?7W)$R&-?$:X*M<15&IS#V<:?IMOMR$WLHC[+-,14D5=23CT:M+O[=
M+#C]U9YQZ\;(DR19V;L!V%GY+=%SE03M] ^&AEJ3V&:LEW5MC:H4U8PX['I9
MP>$]'3EVDW7%U,YZU'TPXT+%ATOTNXGZ$+LEH1@9R7VVYXI7 9Y=U[IT7J&R
M#R"J3(U* _,OC9C=\89J.-0V?R15@[6OW,R2P@?\/M!Z*((3O"+/IDV9=X#C
M/P&6U%:9#:%(L@YG[?/XA #52'A@O#V#GH1GUU#T,A-7UZ$B;:Q$',6E+I\]
M4"N([.!IO%O:EFEAXO-.=WD%E\:^\Q4*]-PLJ6)6"6)NL!-X9_;IIP2=1W'I
M?5>GUQ>],:Z$,+<80J11+D*@L*V[_=:YCZ^T7Y\.>'[S\91.KVRM^;(=VW,S
M>WA]Q9'UCJ?;( F-W-?LL&)?F4M6(G?"X.-CR)4J?Y51Z^;&UH::EJL3N$=0
M]Q]HL'U*W[T6CF,TJC$H1]W22$%.0M?M<NZ';258\Z=%PI)78'?I98(-83#E
M Q&/$!VR'R;/%;I)<#*:][T;8_=U91!!K_?W]$A^*0E[;'A] 6K/P;T@JDC=
MIXW>8;M'G*@/8?:$*JT)^4GZ)^0*5M-&:([$X2#G=8&EO!-NYBH)8D\AJ_/&
MU4++1*90K.Q?1 %9.A0:X<;V+F:U2@!*E$R&!H *:CUI8#+5&N,NRP$G;1C:
M,M<]0EAHKE* )W,/) BG&[;T1U D57/RXWTU(3UG)O+<Z_<%CROOWU/H;BM.
MA;O B+@]C7AE0PGBO%%CE!)[N"NR*FA7>_Q.\Z>L4;.!H/BUX]G9@A=O66D/
M7N>:L^)##M2,S%9;[3O)EUZ\KZWL2I(QFPP^#D2!^='N2RRYV<1CZ#A+*]MA
MWN5) +O6D;^1H]?;9=.4X412*?AN4N;J:E2Q*99B4KXH650?[*A^*\V]QRA+
MGV>VP&"$865GD]\:F.P<Q%)=$+MS\0:6.W?A?45^VU'QA5U(EFR\C-B(,F%#
M[2Q0>'^8?-K71:%1&-*&1)8N,J3[#02+5=([MNNRIR;YX$_ JOB211=&,5_<
M'L@C><QB!1RU 1T7Z,@*SZ1""";W(NZU<O9 %$B9@6<YT-1%=0F.\'\DXB2
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MSY[G>L'JV[G@EV@O0Q<:\N_9?@'U*5X9WVKZS0QQ*(!__EBY,9@\"1Y_X6Y
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MM_Z=\>-;5N%*58]^14(^9??XM:'[[Z9^,HU8+*;'_FU8%#4V\<C9"G:+K?^
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M4,&IZ3<RJ%6A<W_VUO\@),;C? X!M8MKY#+6?W3I]FSI%!"7+/,36=*Y5EJ
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M(;$HL;N9]C8J5R?\N1)Y<RJM&W0:Z74(F$CK1@JR+[%DAQ!R3(\V-I!FF53
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MPPPHV]3F+I@AYN0H-X2S_H#5%F&_O>18'=5/ (J H)+;L/E8+2.HDQ_@L_(
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MHDL3AB_%W"<DIL'/0,)4_8 KO4H3@[YG1%%S2I)B@NB)W<]TR6MKS]\$?P,
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ML4JE^=7#^:2K+R'MBU='O$[X-M8$>'9;;A-UP@+E'#*,VZ3/2_^G]GWGTXK
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M\, Y&<5[:F/W&P<W+;1^_FD-)5<MT>:(Q=V9:8]-BB>6,FV6BH,-JEL+%*K
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M]4'J_3E]5$X^%SG*O=BDPYTZZ_MX62:II=Y4L;2HGE>T7<4*"N?)LE;OQE"
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MKT]JXG^B7+%SX1%4E%KW30&,FP3_N9Z=LN(>=!U:-BS(SNOU09X?V7S7)L*
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MS"+XX !Z%TF3(%TK] 8MZAH"XSC^<>P#Q6SGYK&K,-'=,GH).I4"!,!U"=X
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ML4?=7<=KK"9"A'82I9.N,%7P&/Y9X$ 2X-:YYI)*O^P>,<2@U(O3 J.H1X*
M!H9V@"QHV?5W4_&-M[W%G-H3.&6(SK"L"L O8#2&7D!E:VBC4%P<MPWM#FZG
M3&B>DLLAR(A*:,K$?DD7*[0'X"Q$4@U-5[@-N%]J5MP5H/RAR?!FF+L>S@#?
MP#"R T\V^^97OPC5^W0SE&8!>K35-F9X76U\,^9OKE+;>.!#UQ]!@L3IV4K"
M>VV!KB(^0-@Z250A>$O.B32-[EW#=I/R2[4D'7VA(!RJZ^>0NU6,S^;XM4 Y
MG/="%\&QA<*UC+R?*WX)]I]QW>@PLA]H\C;B/M(IX<6.>\\JJ#_\-:7^%,1+
M9L@095N*MT )G/%_T4U=A+, )>DG41<*YES! IZ2BB+;PC"$L[^NB)JKJ_!F
M[F!)"^\2/)-'V/<\],$YWP>5Y2[/E0Q/B/L&?ZWIY^2XQ1L7GI><\Q%QA]UG
M^N)<6!3 Y(RG(NHQ_-1U6,-;B?=H$[T2FA!U?]@-2?P^IS:A>RT*\N/^S-OQ
M"I1F% UEVS2#: 96 R4I:^KSA:>^ZZUF-AE*8T:C^S&C$EHLDR06 '"E?LQA
M?UV'\72JA"B@L!<C]8DX<4OB#5K]!(XN+/J,-W\:J,A@X#9#J]V^<;F$0*Y;
MF^41T9/?(JLC(#4S)G&_F8-3CY%FPP>"FVD:+H:YX5E5J3QHF=GJ\")138 D
M_H/=0 I"WYZ0G#6Z/5&G5]*O[:OT"5V[FL+.&<IC&A#"7T N;A,U7I@WDM+
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M!V6/F)S8*^5P> CVR[X MA8U\<;LTHV/KSTV%ZE6?:G0.N3S>O:]JW]$4]A
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MJ?$<_7:E5XG$%UE>MMB>EIHIY+V_37)?WR7_/7+)/H9T":.JW!UU&2'6.[3
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MTU ];^]#_=8W":V4XT$;3YX^D3P"67R"LM^U?O $=/NU6SNY]-<Q*>B#<&_
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M575%L0-/RSN3/]G]9CV\KZ[R]IZEM4M 5;)JCNR?.[8UP<:?\2(X5L80[BK
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MJM_/4]"YB>5K MDWF.=R4A10RB3WOU%#$T':O-V#4P)]!T5U)0D,$2##QE'
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M[9N1UV2/&Q_'D*&Q>0+4^;C =][3CA7]R<,-W_8\N@R5AZN^OGUB\/YQ+&0
MK_N(HM$'F0KKT0B>/U';0L4^4_Y6,PUWOVQDZFIW5W'!H?1RJ:2RD7:4?<=(
MA<=P1O1,Z-?[I3YN01.VZ'XQBRQA[_W13%-/E(>1:5DA-F"CGJ['6T,SH[ 1
MX0GYF8'HD[]2]^+2K^V-6_8\W=*F_32U.=,G+RH7+WL<>@-]M9#BW@U]AI<(
M]+E#;.C"\WDU*]5\8XU0%T^>P[^PE/K7GYOZ^42-P@6"@H31K.V$M!B]@2:E
MZN-&3N4"XKJ:.VOB=5L013'W0#SBGO_(^+&!E6<#Y'6#[&$;890"^]&-VC")
M\"?WG;[!N53\G+W%V7WE3K\V\OUT3=9=K$-3KV,U^;&3^ 4A-_$7-J8WO(*=
MUBR&?F;.S2?+AS]&#KAUWD,.\DE:\%SJLA"?OWQWLSRT$(N6"\2Z=!AO7#TT
M.=\.J%0:1WW1UNT+TJ:XL@3K+FP9@!#"NNR'#Q!X*R *OC#X'"5516F+7OWY
M9Q</9'__L,[R_.MOZX+>ZW:BYS1E/+'#BMX>;M?6;RO&.+_JS"UT/=G1_I@O
M+?W8 *_S5DDW9'*9N-P-Y8<!979->.W,GXLS7/V"['RZ[R;;,WHU^W0/N2A
MN=2TIR'^,'"N+EPI\!'!<3[79Y%TQ4GN6[8^YQ7&J-_]KT+9-77E?ZR:?]9_
MG<8[-O_"XA\=EDXH4E;#6@X;\TU<ZH=<0\XUI5G?/OOO8ESF/CA; O?0B-.6
MU$ 3U&"<TG$_]$,-A<+[\.S()ZD+!2O2 L,T/9?\7RC!!))!2 GTJGZ%U/>K
M4^4"MV),FI+^E ?%:H(FQC#B$+=!?@1;K[Y(&V!*S(4YQGZIJ"P):C%U,:W
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M;YP Q;<>=XGJ'@4/5/0&BR#RNXC8A%TZ_R+B%6S5)A1;BN2A1^&=X=%'(,$
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MXE1_M9I7&G@6K5*4L[% R35MXT0U0JGB=WT.FAO@<_@O4A;PHTXL;,9#B)<
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MV?EK[ _3+G4LTUV2GDT\:ZU:::BP_[BM[&C!?L$R[K:V26&65%"L4NV"9/"
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MP>]T%Q-/K=^W+;]2G7)[7#TP+T3)6D!HU%K:(V6*VV_6NSKE4NWS+AP1%^S
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MG[/3LMSC\E#M\?K106G@R)?DOY\\U:OJPYWSK(ELGNF;_V7/H0VS.LW7?5A
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M\''()0QP\.XEN &5HF(6OV !L8:H!;&. G%<>P.H%K<HRF7[4$1C$#D_=CV
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M0%;J2#&"RA)ZRI6+B1W,U:3P7W9Q]2A*J":(K@9RA=KDZ2[Y.I0^K UJC]T
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MG,^ WJ8&:RZ/T]+-(7701(4YY@#5")JGA=[#A)]L"Y1N5"]T75Y^HC.,F6^
MQEWS\Q]DF#QPTPP\=,/*_L[VQ@T)L6VDTGT5AE83&*UU B!HU^+$\F6\.K3
MV&# QJ;C-]RC<_>!I*ZBCKRN6-.#SF/&?8&A^MGG3]^HW!$R?"S\I/ZMFU^]
M?$FGT\X"5YV$D8/+;)])(<@.VH:R48H^H]]VJX]V<7SSXXW#6FQ,*?(]D=B*
MD6;]UY-Z&HZZM_#-'G?_P,NOE-JK\@CDXQ3VFV=?5PH+[ 9VA/1C'C //X]Q
M)=7?^G3JCH]-HIGJ@4O#;R:YP6=#> NP.CC!L<_D] SK<H39R1I<_%"; *B7
M'[Y*9ENDVS7DV6H$L'ZLKVM^5_=X=*0C-(;3I&=YX8NN>FH*W=EQ^#OJ##EA
MS%;(*GOD0PF2("J9($%XX\)6?RM'9WNG3]N/<&R8&F\?C8Y.VAOU3WMQ?H3=
M"9_8VP I'U*9R#I3=^T&X@-\5Z+?AOQZHXOTQ2A5VZ!XF_#^>AQZRF(/C(".
MD9<4IJ.C5TJ'JFV6AII+UX0X?>Y4;AZV4IVYB\BOWNCHML-O%[2P?[#%%8SA
M:)+N'Z>65X2,J3?5]?]\<'[GK.W\=*;ARW6.Q\Z)W-G3MD8 ; !">:HYYF!W
M6^ ^D96XDD3V8_0G$4 ^+:VP>4+GQ2DW![L=_I*P_'PLA$IJ46?7($[Q>_R5
M[0>+,3DYRFLO7(J0W>:K8&I><>7\%LV6\NG=].5#/UA"?)])M=9LB/9"(>&[
MR*\.2/\^?TT!0'?#D?CI"YQ&O@B&R&LHXJM%,%!S6)HB#91R%0!?ZX&KB0?P
M,4*UK#G()4OF=2:\5L@B?PV384R/C #HH_*\!$"KB9!LY@R(S"LJ0C.\G1/)
MQ&],@A&1I90K +I#4.PRVWT"P'$9\A4 0!V-[^LN_O&8=Q<-["_4%@!%5U=K
MHV-]_ 6 R4,!D'070JRHSW1@>:)"OKMXP0%Y^LC_:?I_FOZ/:BH+_ 96,-OL
MQ+\8<6?^PPCBO\YWH8Y/8YDU(1Y;U"QX_T*RCRBVZ9E%O$-5X5/^?4Z*\"<[
M#H#ZPJ0:7[0Y@?$70EO$2C"3^&/IZ7+<#RKUF0#P-6M:@F_LYF8X'>(K].L
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M"'PS_SL)^)O<UDSX5226(:YA]7VNY/^#.OTO$93@TW\!4$L! A0#%     @
M3XQ^7'&:>JB:T0  SMD  !(              ( !     &%I<W1R96%T;65N
M=&]P+FIP9U!+ 0(4 Q0    ( $^,?ESROY"[T_L! ,,+ @ (
M  "  <K1  !B:W(R+FIP9U!+ 0(4 Q0    ( $^,?EQ0 6D);EX! #MM 0 2
M              "  </- @!D979E;'!M96YT<&EP92YJ<&=02P$"% ,4
M" !/C'Y<IA[M8B@Y @!>3P( "0              @ %A+ 0 9&TQ.3DN:G!G
M4$L! A0#%     @ 3XQ^7#2Z*LE/8 ( @7$" !,              ( !L&4&
M &1M,3DY8V]L;&%T8VER8RYJ<&=02P$"% ,4    " !/C'Y<-:+,SE4E @!S
M.0( $               @ $PQ@@ 9&TQ.3EP<F]F:6QE+FIP9U!+ 0(4 Q0
M   ( $^,?EQ$['\1JA(  $?S   1              "  ;/K"@!D;6%C+3(P
M,C4Q,C,Q+GAS9%!+ 0(4 Q0    ( $^,?EP#(881)0X  ([=   5
M      "  8S^"@!D;6%C+3(P,C4Q,C,Q7V-A;"YX;6Q02P$"% ,4    " !/
MC'Y<&"< MDA+  #ZE@8 %0              @ 'D# L 9&UA8RTR,#(U,3(S
M,5]D968N>&UL4$L! A0#%     @ 3XQ^7)]>EA5@8P  @Y@% !4
M     ( !7U@+ &1M86,M,C R-3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( $^,
M?EPCRN/+]%   % \!P 5              "  ?*["P!D;6%C+3(P,C4Q,C,Q
M7W!R92YX;6Q02P$"% ,4    " !/C'Y<C1B(B=CF @#W1AH %
M    @ $9#0P 9&UT<#(P,C4Q,C,Q7S$P:RYH=&U02P$"% ,4    " !/C'Y<
M2.V=OCU7 0#V;0$ %0              @ $C] X 96%R;'ED96QI=F5R>6UO
M<G0N:G!G4$L! A0#%     @ 3XQ^7"D+SN//Q0$ _.8!  @
M ( !DTL0 &5D:&8N:G!G4$L! A0#%     @ 3XQ^7,9\E]-F @  :P<   T
M             ( !B!$2 &5X7SDS,3<V."YH=&U02P$"% ,4    " !/C'Y<
M6A("T(4'  !2,0  #0              @ $9%!( 97A?.3,Q-S8Y+FAT;5!+
M 0(4 Q0    ( $^,?EP)3L9JB0<  &(Q   -              "  <D;$@!E
M>%\Y,S$W-S N:'1M4$L! A0#%     @ 3XQ^7+D"8HLP!   HA0   T
M         ( !?2,2 &5X7SDS,3<W,2YH=&U02P$"% ,4    " !/C'Y<])Q_
M(B@$  #4$P  #0              @ '8)Q( 97A?.3,Q-S<R+FAT;5!+ 0(4
M Q0    ( $^,?EPOMOY?O?4  ,P$ 0 ,              "  2LL$@!K;&LQ
M;'9L<RYJ<&=02P$"% ,4    " !/C'Y<C.:O#_V, 0 <E0$ %
M    @ $2(A, <&QA8V5N=&%L9&ES96%S92YJ<&=02P$"% ,4    " !/C'Y<
M\$ !3-MH 0 ?<0$ "P              @ %!KQ0 <W1A9V4P,BYJ<&=02P$"
M% ,4    " !/C'Y<"A=U('[>  "L[   %               @ %%&!8 <W1R
G;VME<F5C=7)R96YC92YJ<&=02P4&     !< %P"0!0  ]?86

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>dmtp20251231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:dmac="http://www.diamedica.com/20251231"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dmac-20251231.xsd" xlink:type="simple"/>
    <context id="d_2025-01-01_2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-10-01_2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_TaxCreditCarryforwardAxis-TaxCreditsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dmac:TaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dmac:NoncapitalIncomeTaxLossesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dmac:NoncapitalIncomeTaxLossesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToPriorPeriodsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dmac:TaxPositionsRelatedToPriorPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToPriorPeriodsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dmac:TaxPositionsRelatedToPriorPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToCurrentPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dmac:TaxPositionsRelatedToCurrentPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToCurrentPeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">dmac:TaxPositionsRelatedToCurrentPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-DeferredShareUnitPlanMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_AwardTypeAxis-DeferredShareUnitPlanMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_PlanNameAxis-NonemployeeDirectorCompensationProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:NonemployeeDirectorCompensationProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_PlanNameAxis-The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_PlanNameAxis-The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PlanNameAxis-The2012DSUPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2012DSUPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PlanNameAxis-StockOptionPriorPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:StockOptionPriorPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-07-31_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="d_2021-12-03_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-03</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PlanNameAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-05-22_PlanNameAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-22</instant>
        </period>
    </context>
    <context id="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:NonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_AwardTypeAxis-The2021EmploymentInducementIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:The2021EmploymentInducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_AwardTypeAxis-The2019OmnibusIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:The2019OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_AwardTypeAxis-DeferredShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_AwardTypeAxis-StockOptionsOutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:StockOptionsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-25</instant>
        </period>
    </context>
    <context id="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-25</startDate>
            <endDate>2024-06-25</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-08-12_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-12</instant>
        </period>
    </context>
    <context id="i_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-21</instant>
        </period>
    </context>
    <context id="d_2025-07-21_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-21</startDate>
            <endDate>2025-07-21</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dmac:IndemnificationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dmac:IndemnificationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dmac:ResearchAndDevelopmentContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2022-06-30_LeaseContractualTermAxis-MinneapolisMNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">dmac:MinneapolisMNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">dmac:CommercialPaperAndCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-CommonStockDeferredStockUnitsSettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:CommonStockDeferredStockUnitsSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-CommonStockDeferredStockUnitsSettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:CommonStockDeferredStockUnitsSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:ATMOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2026-03-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2026-03-27</instant>
        </period>
    </context>
    <context id="i_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001401040</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2025-01-01_2025-12-31" id="ixv-11047">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2025-01-01_2025-12-31" id="ixv-11048">2025</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="d_2025-01-01_2025-12-31" id="ixv-11049">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="d_2025-01-01_2025-12-31" id="ixv-11050">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d_2025-01-01_2025-12-31" id="ixv-11051">0001401040</dei:EntityCentralIndexKey>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2025-10-01_2025-12-31" id="c1122">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2025-10-01_2025-12-31" id="c1121">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2025-10-01_2025-12-31" id="c1120">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2025-10-01_2025-12-31" id="c1119">false</ecd:Rule10b51ArrAdoptedFlag>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c866"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"
      decimals="-3"
      id="c735"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"
      decimals="-3"
      id="c734"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-12-31_AwardTypeAxis-DeferredShareUnitPlanMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"
      decimals="-3"
      id="c733"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2025-12-31_AwardTypeAxis-DeferredShareUnitPlanMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"
      decimals="-3"
      id="c732"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"
      id="c727">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      id="c605">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-NonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      id="c604">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MaximumMember"
      id="c603">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember_RangeAxis-MinimumMember"
      id="c602">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2022-05-18_2022-05-18_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      id="c601">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ContractualObligation
      contextRef="i_2024-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember"
      decimals="-3"
      id="c560"
      unitRef="USD">0</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="i_2025-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember"
      decimals="-3"
      id="c559"
      unitRef="USD">0</us-gaap:ContractualObligation>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c434"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c432"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c430"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c428"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c426"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c424"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c419"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c417"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c415"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c413"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c411"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c409"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      id="c327">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MaximumMember"
      id="c326">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MinimumMember"
      id="c325">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c324"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CommonStockValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c117"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c116"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="d_2024-01-01_2024-12-31" id="c111">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="d_2025-01-01_2025-12-31" id="c110">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockNoParValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c109"
      unitRef="USDPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c108"
      unitRef="USDPerShare">0</us-gaap:CommonStockNoParValue>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="d_2025-01-01_2025-12-31" id="c53">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="d_2025-01-01_2025-12-31" id="c51">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="d_2025-01-01_2025-12-31" id="c47">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="d_2025-01-01_2025-12-31" id="c40">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="d_2025-01-01_2025-12-31" id="c39">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="d_2025-01-01_2025-12-31" id="c37">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <dei:DocumentType contextRef="d_2025-01-01_2025-12-31" id="c3">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2025-01-01_2025-12-31" id="c4">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2025-01-01_2025-12-31" id="c5">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2025-01-01_2025-12-31" id="c6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2025-01-01_2025-12-31" id="c7">001-36291</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="d_2025-01-01_2025-12-31" id="c8">DIAMEDICA THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2025-01-01_2025-12-31" id="c9">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="d_2025-01-01_2025-12-31" id="c10">301 Carlson Parkway, Suite 210</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2025-01-01_2025-12-31" id="c11">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2025-01-01_2025-12-31" id="c12">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2025-01-01_2025-12-31" id="c13">55305</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2025-01-01_2025-12-31" id="c14">763</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2025-01-01_2025-12-31" id="c15">496-5454</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2025-01-01_2025-12-31" id="c16">Voting Common Shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2025-01-01_2025-12-31" id="c17">DMAC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2025-01-01_2025-12-31" id="c18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2025-01-01_2025-12-31" id="c19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2025-01-01_2025-12-31" id="c20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2025-01-01_2025-12-31" id="c21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2025-01-01_2025-12-31" id="c22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2025-01-01_2025-12-31" id="c23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2025-01-01_2025-12-31" id="c24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2025-01-01_2025-12-31" id="c25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2025-01-01_2025-12-31" id="c26">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="d_2025-01-01_2025-12-31" id="c27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="d_2025-01-01_2025-12-31" id="c28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i_2025-06-30"
      decimals="-5"
      id="c29"
      unitRef="USD">95800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2026-03-27"
      decimals="INF"
      id="c30"
      unitRef="Share">53882506</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c34">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We recognize the importance of identifying, assessing, and managing material risks associated with cybersecurity threats, which risks include, among other things, operational risks, intellectual property theft, fraud, extortion, harm to employees or participants in our clinical trials, and violation of data privacy or security laws. In the ordinary course of our business, we collect and store certain confidential information such as information about our employees, contractors, vendors, suppliers, and clinical data. We augment the capabilities of our people, processes, and technologies in order to address our cybersecurity risks. Our cybersecurity risks, and the controls designed to mitigate those risks, are integrated into our overall risk management governance and are reviewed regularly by our Audit Committee.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;b&gt;&lt;i&gt;Risk Management and Strategy&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:c37"&gt;Identifying, assessing, and managing cybersecurity risk is integrated into our overall enterprise risk management systems and processes. Our cybersecurity risk management program has been developed based upon prevailing security standards and the National Institute of Standards and Technology (NIST) framework for evaluating and responding to potential cybersecurity risks, and addressing cybersecurity threats and incidents to the extent they arise. We have designed our business applications to minimize the impact that cybersecurity incidents could have on our business and have identified back-up systems where appropriate. Security events and data incidents are evaluated, ranked by severity, and prioritized for response and remediation when or if they occur. Incidents are evaluated to determine materiality, as well as operational, business and privacy impact. An important component of this program is employee awareness of and vigilance regarding cybersecurity risks. Our employees receive ongoing cybersecurity awareness trainings, including specific topics related to social engineering, phishing and email fraud.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Recognizing the complexity and evolving nature of cybersecurity threats, incidents and risks, we &lt;span style="-sec-ix-hidden:c39"&gt;engage third-party experts&lt;/span&gt;, including managed information technology (IT) service providers and cybersecurity consultants, to evaluate and support our risk management systems, &lt;span style="-sec-ix-hidden:c40"&gt;monitor potential vulnerabilities&lt;/span&gt;, periodically test our cybersecurity controls and procedures, and respond to cybersecurity incidents affecting us, including prompt escalation and communication of major security incidents to legal counsel, senior management and the Audit Committee of our Board of Directors. We utilize advanced technologies for continuous cybersecurity monitoring across our IT environment which are designed to prevent, detect and minimize cybersecurity attacks, as well as alert management of such attacks.&lt;/p&gt;
</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="d_2025-01-01_2025-12-31" id="c38">Identifying, assessing, and managing cybersecurity risk is integrated into our overall enterprise risk management systems and processes. Our cybersecurity risk management program has been developed based upon prevailing security standards and the National Institute of Standards and Technology (NIST) framework for evaluating and responding to potential cybersecurity risks, and addressing cybersecurity threats and incidents to the extent they arise. We have designed our business applications to minimize the impact that cybersecurity incidents could have on our business and have identified back-up systems where appropriate. Security events and data incidents are evaluated, ranked by severity, and prioritized for response and remediation when or if they occur. Incidents are evaluated to determine materiality, as well as operational, business and privacy impact. An important component of this program is employee awareness of and vigilance regarding cybersecurity risks. Our employees receive ongoing cybersecurity awareness trainings, including specific topics related to social engineering, phishing and email fraud</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="d_2025-01-01_2025-12-31" id="c41">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;b&gt;&lt;i&gt;Governance&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Audit Committee of our Board of Directors is responsible for overseeing our cyber security risk management and strategy, including overseeing management&#x2019;s responsibility to assess, manage and mitigate risks associated with our business and operational activities, to administer our various compliance programs, in each case including cybersecurity concerns, and to oversee our IT systems, processes and data. Our Chief Financial Officer and cybersecurity consultants regularly meet with and provides periodic briefings to our Audit Committee regarding our cybersecurity risks and activities, including any recent cybersecurity incidents, if any, and related responses, and cybersecurity systems testing.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Management has implemented risk management policies and procedures, and management is responsible for the day-to-day cybersecurity risk management. Our Chief Financial Officer is responsible for the day-to-day assessment and management of our cybersecurity risks.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;b&gt;&lt;i&gt;Cybersecurity Threat Disclosure&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of the date of this annual report on Form 10-K, risks from cybersecurity threats including as a result of any previous cybersecurity incidents, have not materially affected, and we do not believe they are reasonably likely to materially affect, us, our business strategy, results of operations, or financial condition. However, cybersecurity threats are constantly evolving, becoming more frequent and more sophisticated and are being made by groups of individuals with a wide range of expertise and motives, which increases the difficulty of detecting and successfully defending against them. While we have implemented measures to safeguard our operational and technology systems, the evolving nature of cybersecurity attacks and vulnerabilities means that these protections may not always be effective.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For further discussion of cybersecurity risks, please see Item 1A, "Risk Factors".&lt;/p&gt;
</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="d_2025-01-01_2025-12-31" id="c44">The Audit Committee of our Board of Directors is responsible for overseeing our cyber security risk management and strategy, including overseeing management&#x2019;s responsibility to assess, manage and mitigate risks associated with our business and operational activities, to administer our various compliance programs, in each case including cybersecurity concerns, and to oversee our IT systems, processes and data. Our Chief Financial Officer and cybersecurity consultants regularly meet with and provides periodic briefings to our Audit Committee regarding our cybersecurity risks and activities, including any recent cybersecurity incidents, if any, and related responses, and cybersecurity systems testing.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="d_2025-01-01_2025-12-31" id="c45">The Audit Committee of our Board of Directors is responsible for overseeing our cyber security risk management and strategy, including overseeing management&#x2019;s responsibility to assess, manage and mitigate risks associated with our business and operational activities, to administer our various compliance programs, in each case including cybersecurity concerns, and to oversee our IT systems, processes and data. Our Chief Financial Officer and cybersecurity consultants regularly meet with and provides periodic briefings to our Audit Committee regarding our cybersecurity risks and activities, including any recent cybersecurity incidents, if any, and related responses, and cybersecurity systems testing.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="d_2025-01-01_2025-12-31" id="c46">The Audit Committee of our Board of Directors is responsible for overseeing our cyber security risk management and strategy, including overseeing management&#x2019;s responsibility to assess, manage and mitigate risks associated with our business and operational activities, to administer our various compliance programs, in each case including cybersecurity concerns, and to oversee our IT systems, processes and data. Our Chief Financial Officer and cybersecurity consultants regularly meet with and provides periodic briefings to our Audit Committee regarding our cybersecurity risks and activities, including any recent cybersecurity incidents, if any, and related responses, and cybersecurity systems testing.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="d_2025-01-01_2025-12-31" id="c48">Management has implemented risk management policies and procedures, and management is responsible for the day-to-day cybersecurity risk management. Our Chief Financial Officer is responsible for the day-to-day assessment and management of our cybersecurity risks.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="d_2025-01-01_2025-12-31" id="c49">Management has implemented risk management policies and procedures, and management is responsible for the day-to-day cybersecurity risk management. Our Chief Financial Officer is responsible for the day-to-day assessment and management of our cybersecurity risks.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="d_2025-01-01_2025-12-31" id="c50">Management has implemented risk management policies and procedures, and management is responsible for the day-to-day cybersecurity risk management. Our Chief Financial Officer is responsible for the day-to-day assessment and management of our cybersecurity risks.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="d_2025-01-01_2025-12-31" id="c52">As of the date of this annual report on Form 10-K, risks from cybersecurity threats including as a result of any previous cybersecurity incidents, have not materially affected, and we do not believe they are reasonably likely to materially affect, us, our business strategy, results of operations, or financial condition. However, cybersecurity threats are constantly evolving, becoming more frequent and more sophisticated and are being made by groups of individuals with a wide range of expertise and motives, which increases the difficulty of detecting and successfully defending against them. While we have implemented measures to safeguard our operational and technology systems, the evolving nature of cybersecurity attacks and vulnerabilities means that these protections may not always be effective.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <dei:AuditorFirmId contextRef="d_2025-01-01_2025-12-31" id="c57">23</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2025-01-01_2025-12-31" id="c58">Baker Tilly US, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2025-01-01_2025-12-31" id="c59">Minneapolis, Minnesota</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c64"
      unitRef="USD">15647000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c65"
      unitRef="USD">3025000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c66"
      unitRef="USD">44243000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c67"
      unitRef="USD">41122000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c68"
      unitRef="USD">481000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c69"
      unitRef="USD">227000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c70"
      unitRef="USD">258000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c71"
      unitRef="USD">236000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c72"
      unitRef="USD">60629000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c73"
      unitRef="USD">44610000</us-gaap:AssetsCurrent>
    <us-gaap:DeferredCosts
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c75"
      unitRef="USD">400000</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c76"
      unitRef="USD">0</us-gaap:DeferredCosts>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c77"
      unitRef="USD">197000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c78"
      unitRef="USD">279000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c79"
      unitRef="USD">145000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c80"
      unitRef="USD">148000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c81"
      unitRef="USD">0</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c82"
      unitRef="USD">1308000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c83"
      unitRef="USD">742000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c84"
      unitRef="USD">1735000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c85"
      unitRef="USD">61371000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c86"
      unitRef="USD">46345000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c88"
      unitRef="USD">1475000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c89"
      unitRef="USD">940000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c90"
      unitRef="USD">3545000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c91"
      unitRef="USD">4347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c92"
      unitRef="USD">101000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c93"
      unitRef="USD">90000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c94"
      unitRef="USD">11000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c95"
      unitRef="USD">13000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c96"
      unitRef="USD">5132000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c97"
      unitRef="USD">5390000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c99"
      unitRef="USD">124000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c100"
      unitRef="USD">225000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c101"
      unitRef="USD">4000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c102"
      unitRef="USD">12000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c103"
      unitRef="USD">128000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c104"
      unitRef="USD">237000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2025-12-31"
      id="c105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2025-12-31"
      id="c106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c112"
      unitRef="Share">53742370</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c113"
      unitRef="Share">53742370</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c114"
      unitRef="Share">42818660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c115"
      unitRef="Share">42818660</us-gaap:CommonStockSharesIssued>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c118"
      unitRef="USD">228829000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c119"
      unitRef="USD">180697000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2025-12-31"
      decimals="-4"
      id="c120"
      unitRef="USD">50000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c121"
      unitRef="USD">23000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c122"
      unitRef="USD">-172768000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c123"
      unitRef="USD">-140002000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c124"
      unitRef="USD">56111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c125"
      unitRef="USD">40718000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c126"
      unitRef="USD">61371000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c127"
      unitRef="USD">46345000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c132"
      unitRef="USD">24614000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c133"
      unitRef="USD">19057000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c134"
      unitRef="USD">9783000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c135"
      unitRef="USD">7624000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c136"
      unitRef="USD">34397000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c137"
      unitRef="USD">26681000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c138"
      unitRef="USD">-34397000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c139"
      unitRef="USD">-26681000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c140"
      unitRef="USD">1659000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c141"
      unitRef="USD">2267000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c142"
      unitRef="USD">1659000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c143"
      unitRef="USD">2267000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c144"
      unitRef="USD">-32738000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c145"
      unitRef="USD">-24414000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c146"
      unitRef="USD">28000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c147"
      unitRef="USD">30000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c148"
      unitRef="USD">-32766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c149"
      unitRef="USD">-24444000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c151"
      unitRef="USD">27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c152"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c153"
      unitRef="USD">-32739000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c154"
      unitRef="USD">-24427000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c155"
      unitRef="USDPerShare">-0.7</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c156"
      unitRef="USDPerShare">-0.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c157"
      unitRef="Share">46980777</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c158"
      unitRef="Share">40404681</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c162"
      unitRef="Share">37958000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c163"
      unitRef="USD">166609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c164"
      unitRef="USD">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c165"
      unitRef="USD">-115558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c166"
      unitRef="USD">51057000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c167"
      unitRef="USD">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c168"
      unitRef="Share">4720000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c169"
      unitRef="USD">11747000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c170"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c171"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c172"
      unitRef="USD">11747000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c173"
      unitRef="Share">117000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c174"
      unitRef="USD">256000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c175"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c176"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c177"
      unitRef="USD">256000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c178"
      unitRef="Share">23660</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c179"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c180"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c181"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c182"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c184"
      unitRef="USD">2085000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c185"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c186"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c187"
      unitRef="USD">2085000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c189"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c190"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c191"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c192"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c194"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c195"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c196"
      unitRef="USD">-24444000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c197"
      unitRef="USD">-24444000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c198"
      unitRef="Share">42818660</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c199"
      unitRef="USD">180697000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c200"
      unitRef="USD">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c201"
      unitRef="USD">-140002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c202"
      unitRef="USD">40718000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c203"
      unitRef="USD">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c204"
      unitRef="Share">8606425</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c205"
      unitRef="USD">29967000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c206"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c207"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-3"
      id="c208"
      unitRef="USD">29967000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-5"
      id="c209"
      unitRef="USD">400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="INF"
      id="c210"
      unitRef="Share">1724472</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c211"
      unitRef="USD">13315000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c212"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c213"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-3"
      id="c214"
      unitRef="USD">13315000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c215"
      unitRef="Share">415253</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c216"
      unitRef="USD">1004000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c217"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c218"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c219"
      unitRef="USD">1004000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c220"
      unitRef="Share">142345</dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c225"
      unitRef="Share">35215</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c226"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c227"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c228"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c229"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c231"
      unitRef="USD">3846000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c232"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c233"
      unitRef="USD">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c234"
      unitRef="USD">3846000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c236"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c237"
      unitRef="USD">27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c238"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c239"
      unitRef="USD">27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c241"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c242"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c243"
      unitRef="USD">-32766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c244"
      unitRef="USD">-32766000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c245"
      unitRef="Share">53742370</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c246"
      unitRef="USD">228829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-4"
      id="c247"
      unitRef="USD">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c248"
      unitRef="USD">-172768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c249"
      unitRef="USD">56111000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c254"
      unitRef="USD">-32766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c255"
      unitRef="USD">-24444000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c257"
      unitRef="USD">3846000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c258"
      unitRef="USD">2085000</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c259"
      unitRef="USD">942000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c260"
      unitRef="USD">1343000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <dmac:NoncashLeaseExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c261"
      unitRef="USD">82000</dmac:NoncashLeaseExpense>
    <dmac:NoncashLeaseExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c262"
      unitRef="USD">75000</dmac:NoncashLeaseExpense>
    <us-gaap:Depreciation
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c263"
      unitRef="USD">43000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c264"
      unitRef="USD">39000</us-gaap:Depreciation>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c266"
      unitRef="USD">254000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c267"
      unitRef="USD">-184000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c268"
      unitRef="USD">22000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c269"
      unitRef="USD">-133000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c270"
      unitRef="USD">-1308000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c271"
      unitRef="USD">1308000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c272"
      unitRef="USD">535000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c273"
      unitRef="USD">14000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c274"
      unitRef="USD">-892000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c275"
      unitRef="USD">2489000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c276"
      unitRef="USD">-29062000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c277"
      unitRef="USD">-22076000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c279"
      unitRef="USD">59278000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c280"
      unitRef="USD">50411000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c281"
      unitRef="USD">57126000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-6"
      id="c282"
      unitRef="USD">59000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c283"
      unitRef="USD">40000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c284"
      unitRef="USD">25000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c285"
      unitRef="USD">-2192000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c286"
      unitRef="USD">8564000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c288"
      unitRef="USD">43282000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c289"
      unitRef="USD">11747000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c290"
      unitRef="USD">1004000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c291"
      unitRef="USD">256000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c292"
      unitRef="USD">10000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c293"
      unitRef="USD">9000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-5"
      id="c294"
      unitRef="USD">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c295"
      unitRef="USD">-0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c296"
      unitRef="USD">43876000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c297"
      unitRef="USD">11994000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c298"
      unitRef="USD">12622000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c299"
      unitRef="USD">-1518000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c300"
      unitRef="USD">3025000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c301"
      unitRef="USD">4543000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c302"
      unitRef="USD">15647000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c303"
      unitRef="USD">3025000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaid
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c305"
      unitRef="USD">28000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c306"
      unitRef="USD">26000</us-gaap:IncomeTaxesPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c307"
      unitRef="USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c308"
      unitRef="USD">30000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="d_2025-01-01_2025-12-31" id="c309">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;1.&lt;/b&gt;&#160; &#160; &#160; &#160; &#160; &#160;&lt;b&gt;Business&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;DiaMedica Therapeutics Inc. and its wholly owned subsidiaries, DiaMedica USA Inc. and DiaMedica Australia Pty Ltd. (collectively, we, us, our, DiaMedica and the Company), is a clinical stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS). DiaMedica&#x2019;s lead product candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein, an established therapeutic modality in Asia for the treatment of preeclampsia, acute ischemic stroke and other vascular diseases. Our common shares are publicly traded on The Nasdaq Capital Market under the symbol &#x201c;DMAC.&#x201d;&lt;/p&gt;
</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dmac:RisksAndUncertaintiesTextBlock contextRef="d_2025-01-01_2025-12-31" id="c312">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;2.&lt;/b&gt;&#160; &#160; &#160; &#160; &#160; &#160;&lt;b&gt;Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the United States Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union, and comparable agencies in other countries. We are in the clinical stage of development of our lead product candidate, DM199, for the treatment of PE and AIS. We have not completed the development of any product candidate and do not generate any revenues from the commercial sale of any product candidate. Our lead product candidate, DM199, requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for at least three to four years, if at all.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;With respect to our PE clinical program, a Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 for the treatment of PE is currently being conducted at the Tygerberg Hospital in Cape Town, South Africa. This Phase 2 study consists of three studies in PE (Part 1a, dose-escalation; Part 1b, dose-expansion; and Part 2, expectant management) and a fourth study in fetal growth restriction (FGR, Part 3, expectant management). Part 1a topline study results are intended to identify a suitable dose for Parts 1b, 2, and 3. Up to 90 women with PE and potentially an additional 30 subjects with fetal growth restriction may be evaluated. The first subject in Part 1a was enrolled in the fourth quarter of 2024 and interim results from Part 1a of the study were released in July 2025. The interim results (N=28 subjects) demonstrated that DM199 appears safe and well-tolerated with clinically-relevant pharmacodynamic activity with no evidence of placental transfer. Additionally, subjects exhibited rapid, statistically significant reductions in blood pressure with duration of effect that was sustained up to 24 hours post-infusion compared to pre-treatment baseline. Preparations are underway to initiate Part 1b where up to 30 subjects with PE and expected delivery within 72 hours will be treated with a dose regimen identified from Part 1a.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;With respect to our AIS clinical program, we are currently conducting a Phase 2/3, adaptive design, randomized, double-blind, placebo-controlled trial of DM199 for the treatment of AIS, (the ReMEDy2 trial). Our ReMEDy2 trial is intended to enroll approximately 300 participants at up to 100 sites globally. The adaptive design component includes an interim analysis by our independent data safety monitoring board to be conducted after the first 200 participants have completed the trial. Based on the results of the interim analysis, the study may then be stopped for futility or the final sample size will be determined, ranging between 300 and 728 patients, according to a pre-determined statistical plan. We have experienced and continue to experience slower than expected site activations and enrollment in our ReMEDy2 trial. We believe these conditions may be due to hospital and medical facility staffing shortages; inclusion/exclusion criteria in the study protocol; concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; concerns regarding the prior clinically significant hypotension events and circumstances surrounding the previous clinical hold; use of artificial intelligence and telemedicine which have enabled smaller hospitals to retain AIS patients not eligible for mechanical thrombectomy instead of sending these patients to the larger stroke centers which are more likely to be sites in our trial; and competition for research staff and trial subjects due to other pending stroke and neurological trials. We continue to reach out to current and potential study sites to understand the specific issues at each study site. In an effort to mitigate the impact of these factors, we have significantly expanded our internal clinical team and have brought in-house certain trial activities, including site identification, qualification and activation, clinical site monitoring, supporting vendor management and overall program management. We are currently conducting our ReMEDy2 trial in the United States and in the countries of Canada and Georgia. We are in the process of preparing regulatory filings and identifying and engaging study sites in an additional seven European countries and, on August 28, 2025, received approval for the conduct of this study in the United Kingdom. We continue to work closely with our contract research organizations and other advisors to develop procedures to support both U.S. and global study sites and potential participants as needed. We intend to continue to monitor the results of these efforts and, if necessary, implement additional actions to enhance site activations and enrollment in our ReMEDy2 trial; however, no assurances can be provided as to the success of these actions and if or when these issues will resolve. Failure to resolve these issues may result in further delays in our ReMEDy2 trial and increase the difficulty in forecasting enrollment. We currently estimate that the interim analysis will be completed in the second half of 2026.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our future success is dependent upon the success of our development efforts, our ability to demonstrate clinical progress for our DM199 product candidate in the United States or other markets, our ability, or the ability of any future partner, to obtain required governmental approvals of our product candidate, our ability to license or market and sell our DM199 product candidate and our ability to obtain additional financing to fund these efforts.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of December 31, 2025, we have incurred losses of $172.8 million since our inception in 2000. For the year ended December 31, 2025, we incurred a net loss of $32.8 million and negative cash flows from operating activities of $29.1 million. We expect to continue to incur substantial operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical study of, and to seek regulatory approval for, our DM199 product candidate. As of December 31, 2025, we had combined cash, cash equivalents and marketable securities of $59.9 million, working capital of $55.5 million, and shareholders&#x2019; equity of $56.1 million.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our principal source of cash has been net proceeds from the issuance of equity securities. Although we have previously been successful in obtaining financing through equity securities offerings, there is no assurance that we will be able to do so in the future. This is particularly true if our clinical data are not positive or if economic and market conditions deteriorate.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We expect that we will need substantial additional capital to further our research and development activities and complete the required clinical studies, regulatory activities and manufacturing development for our product candidate, DM199, or any future product candidates, to a point where they may be licensed or commercially sold. We expect our current cash, cash equivalents and marketable securities to be sufficient to fund our planned operations for at least the next 12 months from the date of issuance of these consolidated financial statements. The amount and timing of our future funding requirements will depend on many factors, including timing and results of our ongoing development efforts, including our current ReMEDy2 trial and the rate of site activation and participant enrollment in the study; the Phase 2 PE trial; the potential expansion of our current development programs; the effects of ongoing site staffing shortages; and other factors on our clinical trials and our operating expenses. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable.&lt;/p&gt;
</dmac:RisksAndUncertaintiesTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c315"
      unitRef="USD">-172800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-5"
      id="c316"
      unitRef="USD">-32800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-5"
      id="c317"
      unitRef="USD">-29100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c318"
      unitRef="USD">59900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <dmac:WorkingCapital
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c319"
      unitRef="USD">55500000</dmac:WorkingCapital>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c320"
      unitRef="USD">56100000</us-gaap:StockholdersEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2025-01-01_2025-12-31" id="c321">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;3.&lt;/b&gt;&#160; &#160; &#160; &#160; &#160; &#160;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Basis of consolidation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements include the assets, liabilities and expenses of DiaMedica Therapeutics Inc., and our wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Functional currency&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The United States dollar is our functional currency as it represents the economic effects of the underlying transactions, events and conditions and various other factors, including the currency of historical and future expenditures and the currency in which funds from financing activities are mostly generated by the Company. A change in the functional currency occurs only when there is a material change in the underlying transactions, events and condition. A change in functional currency could result in material differences in the amounts recorded in the consolidated statements of operations and comprehensive loss for foreign exchange gains and losses. All amounts in the accompanying consolidated financial statements are in U.S. dollars unless otherwise indicated.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company operates in a &lt;span style="-sec-ix-hidden:c324"&gt;single&lt;/span&gt; segment focusing on developing potentially transformative treatments for severe ischemic diseases. Consistent with the Company&#x2019;s operational structure, its chief operating decision maker manages and allocates resources for the Company at a consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting. Substantially all assets of the Company are held in the United States.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Use of estimates&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of the Company&#x2019;s cash equivalents approximates fair value due to the short maturity of the investments.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Marketable securities&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company&#x2019;s marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third-party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive income or loss, which is a separate component of shareholders&#x2019; equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no material other-than-temporary unrealized losses as of December 31, 2025 or 2024.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Concentration of credit risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with two financial institutions. These balances generally exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Fair value measurements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The hierarchy is broken down into three levels defined as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"&gt;&lt;i&gt;Level 1 Inputs&lt;/i&gt; &#x2014; quoted prices in active markets for identical assets and liabilities&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"&gt;&lt;i&gt;Level 2 Inputs&lt;/i&gt; &#x2014; observable inputs other than quoted prices in active markets for identical assets and liabilities&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"&gt;&lt;i&gt;Level 3 Inputs&lt;/i&gt; &#x2014; unobservable inputs&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of December 31, 2025, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled &#x201c;&lt;i&gt;Marketable Securities&lt;/i&gt;&#x201d; for additional information.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Long-lived assets&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment are stated at purchased cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of &lt;span style="-sec-ix-hidden:c325"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c326"&gt;ten&lt;/span&gt; years for office equipment and &lt;span style="-sec-ix-hidden:c327"&gt;four&lt;/span&gt; years for computer equipment. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss. Repairs and maintenance are expensed as incurred.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets may not be recoverable. If the expected future undiscounted cash flows are less than the carrying amount of the asset, an impairment loss is recognized at that time. Measurement of impairment may be based upon appraisal, market value of similar assets or discounted cash flows.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We determine if an arrangement is a lease at inception. We have made a policy election to not separate lease and non-lease components for our real estate leases to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. Our facility lease includes variable non-lease components, such as common-area maintenance costs. Our operating lease is included in operating lease right-of-use (&#x201c;ROU&#x201d;) asset and operating lease obligations on our consolidated balance sheets. Our operating lease ROU asset represents our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. The operating lease ROU asset and operating lease obligation are recognized based on the present value of lease payments over the lease term. The lease does not provide an implicit rate and, due to the lack of a commercially salable product, we are generally considered unable to obtain commercial credit. Therefore, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases, we estimated our incremental borrowing rate. The operating lease ROU asset excludes lease incentives. Our lease includes an option to extend or terminate the lease; lease terms are only adjusted for these options when it is reasonably certain that we will exercise such options to extend or terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Assumptions made by us at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Research and development costs&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development expenses consist primarily of fees paid to external service providers such as contract research organizations; clinical support services; clinical development including clinical site costs; outside nursing services; and laboratory testing. R&amp;amp;D costs also include non-clinical testing; fees paid to our contract manufacturing and development organizations and outside laboratories for development of DM199 and related manufacturing processes; costs for production runs of DM199; consulting resources with specialized expertise related to the execution of our development plan for DM199; and personnel costs, including salaries, benefits, non-cash share-based compensation expense; and other personnel costs.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We charge research and development costs to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from various contract research organizations. Upfront costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials are recorded or accrued based on actual invoices received and estimates of work completed to date by clinical trial sites, contract research organizations and outside vendors that assist with management and performance of the trials, and those that manufacture the investigational product. While we utilize electronic data capture systems to facilitate the transmission and capture of clinical trial activity, such information is often incomplete or delayed. Therefore, we are required to estimate the levels of performance under each significant contract, including, among other things, the extent of participant enrollment, the extent of supporting services performed and other activities through communications with the clinical trial sites, CROs and supporting vendors and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual work performed at each clinical trial site and by each CRO or supporting vendor. Additionally, actual costs may be charged to us and are recognized as the tasks are completed by the clinical trial site. Accrued R&amp;amp;D costs may be subject to revisions as clinical trials, non-clinical research and DM199 development programs progress and any revisions are recorded in the period in which the facts that give rise to the revisions become known.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Patent costs&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Costs associated with applying for, prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, the resulting probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in general and administrative costs and were $377,000 and $251,000 for the years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Share-based compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The fair value of option awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our share price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon United States Government bond rates appropriate for the expected term of each award. Expected volatility rates are based on the historical volatility over a period equal to the expected term of the option. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Income taxes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted rates for each of the jurisdictions in which the Company operates, and expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of December 31, 2025 and 2024. See Note 16, titled &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d; for additional information. The Company&#x2019;s policy is to classify interest and penalties related to income taxes as income tax expense.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Net loss per share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to the exclusion of common share equivalents as their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(32,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,444&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted average shares outstanding&#x2014;basic and diluted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,980,777&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,404,681&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.70&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.60&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Employee and non-employee stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,864,854&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,692,438&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares issuable upon settlement of deferred stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;174,515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;284,886&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,039,369&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,977,324&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;



&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Recently adopted accounting pronouncements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;). ASU 2023-09 is intended to improve income tax disclosures primarily through enhanced disclosure of income tax rate reconciliation items, and disaggregation of income (loss) from continuing operations, income tax expense (benefit) and income taxes paid, net disclosures by federal, state and foreign jurisdictions, among others. ASU 2023-09 is effective for annual reporting periods beginning after December&#160;15, 2024, and early adoption is permitted. Adoption of ASU 2023-09 did not have a material effect on the Company's consolidated financial statements and disclosures.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Recently issued accounting pronouncements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03), which is intended to improve disclosures about a public business entity&#x2019;s expenses by requiring disaggregated disclosure, in the notes to the consolidated financial statements, of certain categories of expenses included in the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 on its consolidated financial statement disclosures.&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c840724690807573">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Basis of consolidation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements include the assets, liabilities and expenses of DiaMedica Therapeutics Inc., and our wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;
</us-gaap:ConsolidationPolicyTextBlock>
    <dmac:FunctionalCurrencyPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1422491984920406">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Functional currency&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The United States dollar is our functional currency as it represents the economic effects of the underlying transactions, events and conditions and various other factors, including the currency of historical and future expenditures and the currency in which funds from financing activities are mostly generated by the Company. A change in the functional currency occurs only when there is a material change in the underlying transactions, events and condition. A change in functional currency could result in material differences in the amounts recorded in the consolidated statements of operations and comprehensive loss for foreign exchange gains and losses. All amounts in the accompanying consolidated financial statements are in U.S. dollars unless otherwise indicated.&lt;/p&gt;
</dmac:FunctionalCurrencyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c8868404978462">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company operates in a &lt;span style="-sec-ix-hidden:c324"&gt;single&lt;/span&gt; segment focusing on developing potentially transformative treatments for severe ischemic diseases. Consistent with the Company&#x2019;s operational structure, its chief operating decision maker manages and allocates resources for the Company at a consolidated level. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting. Substantially all assets of the Company are held in the United States.&lt;/p&gt;
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2025-01-01_2025-12-31" id="c280241568477491">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Use of estimates&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1115645225243019">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company considers all bank deposits, including money market funds and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of the Company&#x2019;s cash equivalents approximates fair value due to the short maturity of the investments.&lt;/p&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="d_2025-01-01_2025-12-31" id="c1571481191849694">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Marketable securities&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company&#x2019;s marketable securities may consist of obligations of the United States government and its agencies, bank certificates of deposit and investment grade corporate obligations, which are classified as available-for-sale. Marketable securities which mature within 12 months from their purchase date are included in current assets. Securities are generally valued based on market prices for similar assets using third-party certified pricing sources and are carried at fair value. The amortized cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method. Interest income is included in other income in the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We conduct periodic reviews to identify and evaluate each available-for-sale debt security that is in an unrealized loss position in order to determine whether an other-than-temporary impairment exists. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Declines in fair value considered to be temporary and caused by noncredit-related factors of the issuer, are recorded in accumulated other comprehensive income or loss, which is a separate component of shareholders&#x2019; equity. Declines in fair value that are other than temporary or caused by credit-related factors of the issuer, are recorded within earnings as an impairment loss. There were no material other-than-temporary unrealized losses as of December 31, 2025 or 2024.&lt;/p&gt;
</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2025-01-01_2025-12-31" id="c1550197030631463">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Concentration of credit risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with two financial institutions. These balances generally exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.&lt;/p&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c940050838047353">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Fair value measurements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The hierarchy is broken down into three levels defined as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"&gt;&lt;i&gt;Level 1 Inputs&lt;/i&gt; &#x2014; quoted prices in active markets for identical assets and liabilities&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"&gt;&lt;i&gt;Level 2 Inputs&lt;/i&gt; &#x2014; observable inputs other than quoted prices in active markets for identical assets and liabilities&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 90pt;text-indent:-81pt;"&gt;&lt;i&gt;Level 3 Inputs&lt;/i&gt; &#x2014; unobservable inputs&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of December 31, 2025, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled &#x201c;&lt;i&gt;Marketable Securities&lt;/i&gt;&#x201d; for additional information.&lt;/p&gt;
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c629656696643157">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Long-lived assets&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment are stated at purchased cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of &lt;span style="-sec-ix-hidden:c325"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c326"&gt;ten&lt;/span&gt; years for office equipment and &lt;span style="-sec-ix-hidden:c327"&gt;four&lt;/span&gt; years for computer equipment. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss. Repairs and maintenance are expensed as incurred.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets may not be recoverable. If the expected future undiscounted cash flows are less than the carrying amount of the asset, an impairment loss is recognized at that time. Measurement of impairment may be based upon appraisal, market value of similar assets or discounted cash flows.&lt;/p&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1255766035085671">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We determine if an arrangement is a lease at inception. We have made a policy election to not separate lease and non-lease components for our real estate leases to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease expense. Our facility lease includes variable non-lease components, such as common-area maintenance costs. Our operating lease is included in operating lease right-of-use (&#x201c;ROU&#x201d;) asset and operating lease obligations on our consolidated balance sheets. Our operating lease ROU asset represents our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. The operating lease ROU asset and operating lease obligation are recognized based on the present value of lease payments over the lease term. The lease does not provide an implicit rate and, due to the lack of a commercially salable product, we are generally considered unable to obtain commercial credit. Therefore, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases, we estimated our incremental borrowing rate. The operating lease ROU asset excludes lease incentives. Our lease includes an option to extend or terminate the lease; lease terms are only adjusted for these options when it is reasonably certain that we will exercise such options to extend or terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Assumptions made by us at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/p&gt;
</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2025-01-01_2025-12-31" id="c583541001068176">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Research and development costs&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development expenses consist primarily of fees paid to external service providers such as contract research organizations; clinical support services; clinical development including clinical site costs; outside nursing services; and laboratory testing. R&amp;amp;D costs also include non-clinical testing; fees paid to our contract manufacturing and development organizations and outside laboratories for development of DM199 and related manufacturing processes; costs for production runs of DM199; consulting resources with specialized expertise related to the execution of our development plan for DM199; and personnel costs, including salaries, benefits, non-cash share-based compensation expense; and other personnel costs.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We charge research and development costs to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from various contract research organizations. Upfront costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials are recorded or accrued based on actual invoices received and estimates of work completed to date by clinical trial sites, contract research organizations and outside vendors that assist with management and performance of the trials, and those that manufacture the investigational product. While we utilize electronic data capture systems to facilitate the transmission and capture of clinical trial activity, such information is often incomplete or delayed. Therefore, we are required to estimate the levels of performance under each significant contract, including, among other things, the extent of participant enrollment, the extent of supporting services performed and other activities through communications with the clinical trial sites, CROs and supporting vendors and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual work performed at each clinical trial site and by each CRO or supporting vendor. Additionally, actual costs may be charged to us and are recognized as the tasks are completed by the clinical trial site. Accrued R&amp;amp;D costs may be subject to revisions as clinical trials, non-clinical research and DM199 development programs progress and any revisions are recorded in the period in which the facts that give rise to the revisions become known.&lt;/p&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <dmac:PatentCostsPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1271729201649828">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Patent costs&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Costs associated with applying for, prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, the resulting probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in general and administrative costs and were $377,000 and $251,000 for the years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;
</dmac:PatentCostsPolicyTextBlock>
    <dmac:PatentExpense
      contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="c328"
      unitRef="USD">377000</dmac:PatentExpense>
    <dmac:PatentExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="c329"
      unitRef="USD">251000</dmac:PatentExpense>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c365378272781826">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Share-based compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The fair value of option awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our share price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon United States Government bond rates appropriate for the expected term of each award. Expected volatility rates are based on the historical volatility over a period equal to the expected term of the option. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.&lt;/p&gt;
</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1589218084476396">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Income taxes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted rates for each of the jurisdictions in which the Company operates, and expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of December 31, 2025 and 2024. See Note 16, titled &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;&#x201d; for additional information. The Company&#x2019;s policy is to classify interest and penalties related to income taxes as income tax expense.&lt;/p&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1151118916321710">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Net loss per share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to the exclusion of common share equivalents as their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(32,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,444&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted average shares outstanding&#x2014;basic and diluted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,980,777&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,404,681&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.70&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.60&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Employee and non-employee stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,864,854&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,692,438&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares issuable upon settlement of deferred stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;174,515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;284,886&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,039,369&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,977,324&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c358">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(32,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,444&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Weighted average shares outstanding&#x2014;basic and diluted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;46,980,777&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,404,681&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Basic and diluted net loss per share&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.70&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.60&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c361"
      unitRef="USD">-32766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c362"
      unitRef="USD">-24444000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c363"
      unitRef="Share">46980777</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c364"
      unitRef="Share">40404681</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c365"
      unitRef="USDPerShare">-0.7</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c366"
      unitRef="USDPerShare">-0.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2025-01-01_2025-12-31" id="c367">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Employee and non-employee stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,864,854&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,692,438&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares issuable upon settlement of deferred stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;174,515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;284,886&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,039,369&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,977,324&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"
      decimals="INF"
      id="c370"
      unitRef="Share">6864854</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeAndNonemployeeStockOptionsMember"
      decimals="INF"
      id="c371"
      unitRef="Share">4692438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-CommonStockDeferredStockUnitsSettlementMember"
      decimals="INF"
      id="c372"
      unitRef="Share">174515</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-CommonStockDeferredStockUnitsSettlementMember"
      decimals="INF"
      id="c373"
      unitRef="Share">284886</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c374"
      unitRef="Share">7039369</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c375"
      unitRef="Share">4977324</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c872651020400267">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Recently adopted accounting pronouncements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (&#x201c;ASU 2023-09&#x201d;). ASU 2023-09 is intended to improve income tax disclosures primarily through enhanced disclosure of income tax rate reconciliation items, and disaggregation of income (loss) from continuing operations, income tax expense (benefit) and income taxes paid, net disclosures by federal, state and foreign jurisdictions, among others. ASU 2023-09 is effective for annual reporting periods beginning after December&#160;15, 2024, and early adoption is permitted. Adoption of ASU 2023-09 did not have a material effect on the Company's consolidated financial statements and disclosures.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Recently issued accounting pronouncements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03), which is intended to improve disclosures about a public business entity&#x2019;s expenses by requiring disaggregated disclosure, in the notes to the consolidated financial statements, of certain categories of expenses included in the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. ASU 2024-03 may be applied either on a prospective or retrospective basis, and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of ASU 2024-03 on its consolidated financial statement disclosures.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c376">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;4.&lt;/b&gt;&#160; &#160; &#160; &#160; &#160; &#160;&lt;b&gt;Marketable Securities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements as of &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025 &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Using Inputs Considered as&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper and corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,822&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c409"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,822&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c411"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Government securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;39,421&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c413"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;39,421&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c415"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total marketable securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;44,243&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c417"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;44,243&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c419"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements as of &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Using Inputs Considered as&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper and corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c424"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c426"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Government securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,831&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c428"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,831&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c430"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total marketable securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,122&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c432"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,122&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c434"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accrued interest receivable on available-for-sale securities was $250,000 and $235,000 for the years ended December 31, 2025 and 2024, respectively, and is included in amounts receivable.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the year ended December 31, 2025.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the terms of the Company&#x2019;s investment policy, purchases of marketable securities are limited to investment grade governmental and corporate obligations and bank certificates of deposit with a primary objective of principal preservation. Maturities of individual securities are less than one year, and the amortized cost of all securities approximated fair value as of December 31, 2025 and 2024.&lt;/p&gt;
</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock
      contextRef="d_2025-01-01_2025-12-31"
      id="A69AF074-EB91-46DA-A17A-3836E16F290C">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements as of &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025 &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Using Inputs Considered as&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper and corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,822&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c409"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,822&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c411"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Government securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;39,421&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c413"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;39,421&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c415"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total marketable securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;44,243&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c417"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;44,243&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c419"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value Measurements as of &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Using Inputs Considered as&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper and corporate bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c424"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c426"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Government securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,831&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c428"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,831&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c430"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total marketable securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,122&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c432"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,122&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c434"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</dmac:FairValueMarketableSecuritiesMeasuredOnARecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c408"
      unitRef="USD">4822000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c410"
      unitRef="USD">4822000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c412"
      unitRef="USD">39421000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c414"
      unitRef="USD">39421000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c416"
      unitRef="USD">44243000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c418"
      unitRef="USD">44243000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c423"
      unitRef="USD">28291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperAndCorporateBondsMember"
      decimals="-3"
      id="c425"
      unitRef="USD">28291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c427"
      unitRef="USD">12831000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c429"
      unitRef="USD">12831000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c431"
      unitRef="USD">41122000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c433"
      unitRef="USD">41122000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="i_2025-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember"
      decimals="0"
      id="c403"
      unitRef="USD">250000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i_2024-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-AccruedInterestReceivableOnAvailableForSaleSecuritiesMember"
      decimals="0"
      id="c404"
      unitRef="USD">235000</us-gaap:InterestReceivable>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c435">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;5.&lt;/b&gt;&#160; &#160; &#160; &#160; &#160; &#160;&lt;b&gt;Amounts Receivable&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Amounts receivable consisted of the following (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued interest receivable on marketable securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;235&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total amounts receivable&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;258&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;236&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c444">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued interest receivable on marketable securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;250&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;235&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total amounts receivable&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;258&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;236&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
      contextRef="i_2025-12-31"
      decimals="-4"
      id="c447"
      unitRef="USD">250000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c448"
      unitRef="USD">235000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c449"
      unitRef="USD">8000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c450"
      unitRef="USD">1000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c451"
      unitRef="USD">258000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c452"
      unitRef="USD">236000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c453">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;6.&lt;/b&gt;&#160; &#160; &#160; &#160; &#160; &#160;&lt;b&gt;Prepaid Expenses and Other Assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Prepaid expenses and other assets consist primarily of insurance premiums, yearly subscriptions for services and deposits expected to be recovered during the next twelve months.&lt;/p&gt;
</us-gaap:OtherAssetsDisclosureTextBlock>
    <dmac:DepositAssetsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c456">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;7.&lt;/b&gt;&#160; &#160; &#160; &#160; &#160; &#160;&lt;b&gt;Deposits&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We periodically advance funds to vendors engaged to support the performance of our clinical trials and related supporting activities. The funds advanced are held, interest free, for varying periods of time and may be recovered by the Company through partial reductions of ongoing invoices, application against final study/project invoices or refunded upon completion of services to be provided. Deposits are classified as current or non-current based upon their expected recovery time.&lt;/p&gt;
</dmac:DepositAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c459">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;8.&lt;/b&gt;&#160; &#160; &#160; &#160; &#160; &#160;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment consisted of the following (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;151&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;118&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;295&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;262&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less accumulated depreciation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(150&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(114&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Property and equipment, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;145&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;148&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Depreciation expense was $43,000 and $39,000 for the years ended December 31, 2025 and 2024, respectively. During 2025 and 2024, we disposed of $7,000 and $25,000 of equipment, respectively, all of which was fully depreciated.&lt;/p&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2025-01-01_2025-12-31" id="c478">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;151&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;118&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Leasehold improvements&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;295&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;262&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less accumulated depreciation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(150&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(114&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Property and equipment, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;145&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;148&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="-3"
      id="c481"
      unitRef="USD">151000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="-3"
      id="c482"
      unitRef="USD">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c483"
      unitRef="USD">128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c484"
      unitRef="USD">128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c485"
      unitRef="USD">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c486"
      unitRef="USD">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c487"
      unitRef="USD">295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c488"
      unitRef="USD">262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2025-12-31"
      decimals="-4"
      id="c489"
      unitRef="USD">150000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c490"
      unitRef="USD">114000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c491"
      unitRef="USD">145000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c492"
      unitRef="USD">148000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c474"
      unitRef="USD">43000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c475"
      unitRef="USD">39000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c476"
      unitRef="USD">7000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c477"
      unitRef="USD">25000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c493">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;9.&#160; &#160; &#160; &#160; &#160; &#160;&lt;b&gt;Accrued Liabilities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,380&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,060&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Clinical trial costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,277&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development services&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;749&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;888&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Professional services fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;120&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;112&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total accrued liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,545&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,347&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c508">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,380&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,060&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Clinical trial costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,277&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development services&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;749&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;888&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Professional services fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;120&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;112&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total accrued liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,545&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,347&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="-4"
      id="c511"
      unitRef="USD">1380000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c512"
      unitRef="USD">1060000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <dmac:AccruedClinicalStudyCostsCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c513"
      unitRef="USD">1291000</dmac:AccruedClinicalStudyCostsCurrent>
    <dmac:AccruedClinicalStudyCostsCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c514"
      unitRef="USD">2277000</dmac:AccruedClinicalStudyCostsCurrent>
    <dmac:AccruedResearchAndProfessionalFeesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c515"
      unitRef="USD">749000</dmac:AccruedResearchAndProfessionalFeesCurrent>
    <dmac:AccruedResearchAndProfessionalFeesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c516"
      unitRef="USD">888000</dmac:AccruedResearchAndProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2025-12-31"
      decimals="-4"
      id="c517"
      unitRef="USD">120000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c518"
      unitRef="USD">112000</us-gaap:AccruedProfessionalFeesCurrent>
    <dmac:AccruedTaxesAndOtherLiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c519"
      unitRef="USD">5000</dmac:AccruedTaxesAndOtherLiabilitiesCurrent>
    <dmac:AccruedTaxesAndOtherLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c520"
      unitRef="USD">10000</dmac:AccruedTaxesAndOtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c521"
      unitRef="USD">3545000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c522"
      unitRef="USD">4347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="d_2025-01-01_2025-12-31" id="c523">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;10.&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Operating Lease&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In June 2022, we entered into an agreement to lease approximately 6,000 square feet of office space in Minneapolis, Minnesota. The lease commencement date was September 1, 2022, has a term of 65 months expiring on January 31, 2028, and included an incentive of five months of full rent abatement. This incentive is subject to repayment if we default in performance of any material obligations under the lease prior to the 48&lt;sup style="vertical-align:top;line-height:120%;"&gt;th&lt;/sup&gt; month of the lease and the landlord terminates the lease. Upon lease commencement, the Company recognized an operating lease right-of-use asset and a corresponding operating lease obligation of $446,000, respectively.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our operating lease costs were $104,000 for each of the years ended December 31, 2025 and 2024, respectively. Our variable lease costs were $91,000 and $89,000 for the years ended December 31, 2025 and 2024, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Maturities of our operating lease obligation are as follows as of December 31, 2025 (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;116&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Total lease payments&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;245&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Less interest portion&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(20&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Present value of lease obligation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;225&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Less current portion of operating lease&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(101&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Operating lease obligation, non-current&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;124&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2022-06-30_LeaseContractualTermAxis-MinneapolisMNMember"
      decimals="INF"
      id="c526"
      unitRef="SquareFoot">6000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2022-06-30_LeaseContractualTermAxis-MinneapolisMNMember"
      id="c527">P65M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2022-06-30_LeaseContractualTermAxis-MinneapolisMNMember"
      decimals="0"
      id="c528"
      unitRef="USD">446000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2022-06-30_LeaseContractualTermAxis-MinneapolisMNMember"
      decimals="0"
      id="c529"
      unitRef="USD">446000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c530"
      unitRef="USD">104000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c531"
      unitRef="USD">104000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c532"
      unitRef="USD">91000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c533"
      unitRef="USD">89000</us-gaap:VariableLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c542">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;116&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Total lease payments&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;245&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Less interest portion&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(20&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Present value of lease obligation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;225&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Less current portion of operating lease&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(101&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Operating lease obligation, non-current&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;124&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c545"
      unitRef="USD">116000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c546"
      unitRef="USD">119000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2025-12-31"
      decimals="-4"
      id="c547"
      unitRef="USD">10000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c548"
      unitRef="USD">245000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2025-12-31"
      decimals="-4"
      id="c549"
      unitRef="USD">20000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c550"
      unitRef="USD">225000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c551"
      unitRef="USD">101000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c552"
      unitRef="USD">124000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c553">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Clinical trials and product development&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In the normal course of business, we incur obligations to make future payments as we execute our business plan. These obligations may relate to preclinical or clinical studies, manufacturing or manufacturing process development and other related or supporting activities. Currently, these obligations include costs to be incurred with contract research organizations, central laboratory and pharmacy services, clinical study sites, home nursing services, various other vendors supporting the performance of our clinical trials and contract manufacturing and development organizations. The contracts we enter into with these vendors and the commitments within these contracts are subject to significant variability based upon the actual activities/services performed by each vendor. As a result, the ultimate amounts due may be materially different as these obligations are affected by, among other factors, the number and pace of clinical study sites activated, the number of countries in which clinical sites are activated, the number of participants enrolled, the amount of time to complete trial enrollment and the time required to finalize, analyze and report our clinical trial results. Clinical research agreements, including supporting vendors, are generally cancelable upon 60-90 days&#x2019; notice, with our obligation limited to costs incurred up to that date, including any non-cancelable costs. Cancelation terms for product manufacturing and process development contracts vary and are generally dependent upon timelines for sourcing research materials and reserving laboratory time. As of December 31, 2025, we estimate that our outstanding commitments, including such cancellable contracts, are approximately $24.7 million of which $19.3 million become due over the next 12 months and approximately $5.4 million become due in the next 12 months thereafter.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Technology license&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We have entered into an exclusive license agreement with Catalent Pharma Solutions, LLC (Catalent) whereby we have licensed certain gene expression technology and we contract with Catalent for the manufacture of DM199. Under the terms of this license, certain milestone and royalty payments may become due under this agreement and are dependent upon, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain. As of December 31, 2025, one milestone payment obligation remains which is due upon our first regulatory approval of DM199 for commercial sale. Following the launch of our first product, we will also incur a royalty obligation of less than 1% of net sales. The royalty term is indefinite, but the license agreement may be canceled by us on 90 days&#x2019; prior written notice. The license may not be terminated by Catalent unless we fail to make required milestone and royalty payments.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Indemnification of directors and officers&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company, as permitted under laws of the BCBCA and in accordance with the Company&#x2019;s Articles and indemnification agreements, will indemnify and advance expenses to its directors and officers to the fullest extent permitted by law and may choose to indemnify other employees or agents from time to time. The Company has secured insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to the Company. As of December 31, 2025, there was no pending litigation or proceeding involving any director or officer of the Company as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. Insofar as indemnification for liabilities arising under the United States Securities Act of 1933, as amended (Securities Act) may be permitted to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the United States Securities and Exchange Commission (SEC), such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company had &lt;span style="-sec-ix-hidden:c559"&gt;&lt;span style="-sec-ix-hidden:c560"&gt;not&lt;/span&gt;&lt;/span&gt; recorded any liabilities for these obligations as of December 31, 2025 or 2024.&lt;/p&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="i_2025-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember"
      decimals="-5"
      id="c556"
      unitRef="USD">24700000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="i_2025-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember"
      decimals="-5"
      id="c557"
      unitRef="USD">19300000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="i_2025-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember"
      decimals="-5"
      id="c558"
      unitRef="USD">5400000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c561">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;12.&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Shareholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Authorized capital stock&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;DiaMedica has authorized share capital of an unlimited number of common voting shares, and the shares do not have a stated par value. Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company&#x2019;s annual general meeting and any extraordinary or special general meeting.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Equity issued during the year ended December 31, 2025&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On July 21, 2025, we entered into securities purchase agreements with accredited investors, pursuant to which we agreed to issue and sell an aggregate 8,606,425 common shares at a purchase price of $3.50 per share in a private placement. As a result of the offering, which closed on July 23, 2025, we received gross proceeds of $30.1 million, which resulted in net proceeds to us of approximately $30.0 million, after deducting the offering expenses.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In connection with the July 2025 private placement, we entered into a registration rights agreement (2025 Registration Rights Agreement) with the investors pursuant to which we agreed to file with the SEC a registration statement registering the resale of the shares sold in the July 2025 private placement (2025 Resale Registration Statement). The 2025 Resale Registration Statement was filed with the SEC on August 1, 2025 and declared effective by the SEC on August 8, 2025. Under the terms of the 2025 Registration Rights Agreement, we agreed to keep the 2025 Resale Registration Statement effective at all times until the shares are no longer considered &#x201c;Registrable Securities&#x201d; under the 2025 Registration Rights Agreement and if we fail to keep the 2025 Resale Registration Statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the 2025 Resale Registration Statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the 2025 Registration Rights Agreement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On August 12, 2025, we entered into a Sales Agreement (the 2025 Sales Agreement) with TD Securities (USA) LLC (TD Cowen) under which the Company may, from time to time, sell common shares having an aggregate offering price of up to $100&#160;million, through an &#x201c;at-the-market&#x201d; offering program (ATM Offering). TD Cowen receives a customary commission from the Company for any common shares sold under the 2025 Sales Agreement. Any shares offered and sold in the ATM Offering are to be issued pursuant to the Company&#x2019;s shelf registration statement on Form S-3 424(b)(2), the prospectus contained therein, and one or more prospectus supplements. As of December 31, 2025, the remaining availability under this ATM was $86.2 million.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During the year ended December 31, 2025, 142,345 common shares were issued upon settlement of deferred share units, 35,215 common shares were issued upon the vesting and settlement of restricted stock units, 415,253 common shares were issued upon the exercise of stock options for gross proceeds of $1.0 million and 1,724,472 common shares were issued and sold under our ATM Offering program for aggregate gross proceeds of $13.8 million.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Equity issued during the year ended December 31, 2024&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On June 25, 2024, we entered into securities purchase agreements with accredited investors, pursuant to which we issued and sold an aggregate 4,720,000 common shares at a purchase price of $2.50 per share in a private placement. As a result of the offering, which closed on June 28, 2024, we received gross proceeds of $11.8 million, which resulted in net proceeds to us of approximately $11.7 million, after deducting the offering expenses.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In connection with the June 2024 private placement, we entered into a registration rights agreement (2024 Registration Rights Agreement) with the investors pursuant to which we agreed to file with the SEC a registration statement registering the resale of the shares sold in the June 2024 private placement. This registration statement was filed with the SEC on July 10, 2024 and declared effective by the SEC on July 18, 2024. Under the terms of the 2024 Registration Rights Agreement, we agreed to keep the registration statement effective at all times until the shares are no longer considered &#x201c;Registrable Securities&#x201d; under the 2024 Registration Rights Agreement and if we fail to keep the registration statement effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the investors in an amount of up to 10% of the invested capital, excluding interest. We also agreed, among other things, to indemnify the selling holders under the registration statement from certain liabilities and to pay all fees and expenses incident to our performance of or compliance with the 2024 Registration Rights Agreement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During the year ended December 31, 2024, 23,660 common shares were issued upon the vesting and settlement of restricted stock units and 117,000 common shares were issued upon the exercise of stock options for gross proceeds of $256,000.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Shares reserved&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Common shares reserved for future issuance are as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Employee and non-employee stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,864,854&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares issuable upon settlement of deferred stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;174,515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;948,666&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Shares available for grant under the 2021 Employment Inducement Incentive Plan&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;653,125&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,641,160&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-07-21_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c564"
      unitRef="Share">8606425</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c565"
      unitRef="USDPerShare">3.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-07-21_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c566"
      unitRef="USD">30100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <dmac:ProceedsFromIssuanceOfCommonStockNet
      contextRef="d_2025-07-21_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-7"
      id="c567"
      unitRef="USD">30000000</dmac:ProceedsFromIssuanceOfCommonStockNet>
    <dmac:LiquidatedDamagePercentageOfInvestedCapitalMaximum
      contextRef="i_2025-07-21_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="1"
      id="c568"
      unitRef="Pure">0.10</dmac:LiquidatedDamagePercentageOfInvestedCapitalMaximum>
    <dmac:EquityIssuanceMaximumAggregateOfferingPrice
      contextRef="i_2025-08-12_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-8"
      id="c569"
      unitRef="USD">100000000</dmac:EquityIssuanceMaximumAggregateOfferingPrice>
    <dmac:EquityIssuanceRemainingAvailableOfferingPrice
      contextRef="i_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-5"
      id="c570"
      unitRef="USD">86200000</dmac:EquityIssuanceRemainingAvailableOfferingPrice>
    <dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c571"
      unitRef="Share">142345</dmac:StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c572"
      unitRef="Share">35215</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c573"
      unitRef="Share">415253</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-6"
      id="c574"
      unitRef="USD">1000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="INF"
      id="c575"
      unitRef="Share">1724472</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-ATMOfferingMember"
      decimals="-5"
      id="c576"
      unitRef="USD">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c577"
      unitRef="Share">4720000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c578"
      unitRef="USDPerShare">2.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c579"
      unitRef="USD">11800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <dmac:ProceedsFromIssuanceOfCommonStockNet
      contextRef="d_2024-06-25_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c580"
      unitRef="USD">11700000</dmac:ProceedsFromIssuanceOfCommonStockNet>
    <dmac:LiquidatedDamagePercentageOfInvestedCapitalMaximum
      contextRef="i_2024-06-25_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="1"
      id="c581"
      unitRef="Pure">0.10</dmac:LiquidatedDamagePercentageOfInvestedCapitalMaximum>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c582"
      unitRef="Share">23660</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c583"
      unitRef="Share">117000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c584"
      unitRef="USD">256000</us-gaap:ProceedsFromStockOptionsExercised>
    <dmac:CommonStockReservedForFutureIssuanceTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c590">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Employee and non-employee stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,864,854&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common shares issuable upon settlement of deferred stock units&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;174,515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;948,666&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Shares available for grant under the 2021 Employment Inducement Incentive Plan&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;653,125&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,641,160&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</dmac:CommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-12-31_AwardTypeAxis-StockOptionsOutstandingMember"
      decimals="INF"
      id="c593"
      unitRef="Share">6864854</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-12-31_AwardTypeAxis-DeferredShareUnitsMember"
      decimals="INF"
      id="c594"
      unitRef="Share">174515</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-12-31_AwardTypeAxis-The2019OmnibusIncentivePlanMember"
      decimals="INF"
      id="c595"
      unitRef="Share">948666</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-12-31_AwardTypeAxis-The2021EmploymentInducementIncentivePlanMember"
      decimals="INF"
      id="c596"
      unitRef="Share">653125</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c597"
      unitRef="Share">8641160</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c598">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;13.&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Amended and Restated 2019 Omnibus Incentive Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan (as amended from time to time, the 2019 Plan) was adopted by the Board of Directors (Board) on March 14, 2019 and approved by our shareholders at our 2019 Annual General Meeting of Shareholders held on May 22, 2019. Subsequent amendments to the plan, comprised principally of increasing the authorized shares under the plan, were approved by our shareholders at our 2022 and 2024 Annual General Meetings of Shareholders.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The 2019 Plan permits the Board, or a committee or subcommittee thereof, to grant to the Company&#x2019;s eligible employees, non-employee directors and certain consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units (RSUs), deferred stock units (DSUs), performance awards, non-employee director awards and other share-based awards. We grant options to purchase common shares under the 2019 Plan at no less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of &lt;span style="-sec-ix-hidden:c601"&gt;ten&lt;/span&gt; years and generally vest over &lt;span style="-sec-ix-hidden:c602"&gt;one&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c603"&gt;four&lt;/span&gt; years. Options granted to non-employees have a maximum term of &lt;span style="-sec-ix-hidden:c604"&gt;five&lt;/span&gt; years and generally vest over &lt;span style="-sec-ix-hidden:c605"&gt;one&lt;/span&gt; year. Subject to adjustment as provided in the 2019 Plan, the maximum number of the Company&#x2019;s common shares authorized for issuance under the 2019 Plan is 7,000,000 shares. As of December 31, 2025, options to purchase an aggregate of 5,402,444 common shares were outstanding and 164,770 common shares were reserved for issuance upon settlement of DSUs under the 2019 Plan.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;2021 Employment Inducement Incentive Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On December 3, 2021, the Board adopted the DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan (Inducement Plan) to facilitate the granting of equity awards as an inducement material to new employees joining the Company. The Inducement Plan was adopted without shareholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and is administered by the Compensation Committee of the Board of Directors. The Board reserved 1,000,000 common shares of the Company for issuance under the Inducement Plan, which permits the grant of non-statutory options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other share-based awards, to eligible recipients. The only persons eligible to receive awards under the Inducement Plan are individuals who are new employees and satisfy the standards for inducement grants under Nasdaq Listing Rule 5635(c)(4) or 5635(c)(3), as applicable. Also, on December 3, 2021, the Compensation Committee adopted a form of notice of option grant and option award agreement for use under the Inducement Plan, which contains terms substantially identical to the form of notice of option grant and option award agreement for use under the shareholder-approved 2019 Plan. The Inducement Plan has a term of 10 years. The share reserve under the Inducement Plan may be increased at the discretion of and approval by the Board and, on July 31, 2025, the Board increased the number of common shares reserved for issuance under the plan to 2,000,000. As of December 31, 2025, options to purchase an aggregate of 1,100,000 common shares were outstanding under the Inducement Plan.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Prior stock option plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our Board of Directors ceased granting awards under the DiaMedica Therapeutics Inc. Stock Option Plan, Amended and Restated November 6, 2018 (Prior Plan) upon receipt of the shareholder approval of the 2019 Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the 2019 Plan. As of December 31, 2025, options to purchase an aggregate of 362,410 common shares were outstanding under the Prior Plan.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Prior deferred stock unit plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our Board of Directors ended participation in the DiaMedica Therapeutics Inc. Amended and Restated Deferred Stock Unit Plan (Prior DSU Plan) upon receipt of the shareholder approval of the 2019 Plan. Awards outstanding under the Prior DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of December 31, 2025, there were 9,745 common shares reserved for issuance upon settlement of DSUs outstanding under the Prior DSU Plan.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Stock options&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Share-based compensation expense for each of the periods presented is as follows (in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,526&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,464&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,320&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;621&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,846&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,085&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We recognize share-based compensation for options awards based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those options that actually vest.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;A summary of option activity is as follows (in thousands except share and per share amounts):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Underlying&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average Exercise&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price Per Share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balances as of December 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,871,013&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.61&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;832&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,864,775&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.03&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(531,350&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.96&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Expired/cancelled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(395,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.08&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(117,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2.19&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balances as of December 31, 2024&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,692,438&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.33&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,243&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,433,416&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.88&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(830,747&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.80&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(415,253&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.43&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Expired/cancelled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(15,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5.02&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balances as of December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,864,854&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.11&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;26,479&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;A summary of the status of our unvested shares underlying options during the year ended and as of December 31, 2025 is as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Underlying&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Grant Date Fair &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Value Per Share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested as of December 31, 2024&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,371,983&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.18&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,433,416&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Vested&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,143,530&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(801,372&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2.57&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested as of December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,860,497&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.06&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Information about stock options outstanding, vested and expected to vest as of December 31, 2025, is as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 2%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Outstanding, Vested and Expected to Vest&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options Vested and Exercisable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td colspan="3" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Per Share &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Contractual &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average Exercise &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Contractual Life &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$1.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$1.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;51,443&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.64&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;42,989&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.66&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$2.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$2.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,278,895&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.73&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,515,350&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.70&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$3.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$3.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;311,893&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.56&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;247,519&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.66&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$4.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$4.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,917,069&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.32&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;808,626&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.51&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$5.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$5.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;549,287&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;256,787&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.03&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$6.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$16.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;756,267&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8.5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7.14&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;133,086&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7.97&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 2%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,864,854&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7.3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.11&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,004,357&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.68&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The cumulative grant date fair value of employee options vested during the years ended December 31, 2025 and 2024 was $2.6 million and $1.5 million, respectively. A total of 415,253 and 117,000 options were exercised during the years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of December 31, 2025, total compensation expense related to unvested employee stock options not yet recognized was $10.6 million, which is expected to be allocated to expenses over a weighted-average period of 3.1 years.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended December 31, 2025 and 2024:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024 &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common share fair value&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$4.07&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$8.67&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$2.40&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$5.38&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free interest rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.7&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.4%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.8&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.5%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected dividend yield&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;0%&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;0%&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected option life (years)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.0&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected stock price volatility&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;75.7&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;83.3%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;83.0&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;124.1%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Deferred stock units and restricted stock units&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under our non-employee director compensation program, non-employee directors may elect to receive RSUs or DSUs in lieu of all or a portion of the annual cash retainers payable to such director. Each RSU or DSU represents the right to receive one common share. These recipients receive a number of RSUs or DSUs equal to the amount of the elected portion of the annual cash retainers divided by the 10-trading day average closing sale price of our common shares as determined on the third business day prior to the anticipated grant date of the award. These annual RSU and DSU grants vest quarterly over &lt;span style="-sec-ix-hidden:c727"&gt;one&lt;/span&gt; year, conditioned on continuous service. The cost of the RSUs and DSUs is measured and recognized based on the fair market value of our common shares on the date of grant. RSUs will be settled immediately upon vesting and DSU awards will be settled following a separation from service by such director.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;There were 174,515 and 284,886 vested DSUs outstanding under our share-based compensation plans as of December 31, 2025 and 2024, respectively. During 2025, 35,215 common shares were issued upon the vesting and settlement of RSUs. During 2024, 23,660 common shares were issued upon the vesting and settlement of RSUs. There were &lt;span style="-sec-ix-hidden:c732"&gt;&lt;span style="-sec-ix-hidden:c733"&gt;&lt;span style="-sec-ix-hidden:c734"&gt;&lt;span style="-sec-ix-hidden:c735"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; unvested DSUs or RSUs as of December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2024-05-22_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      decimals="INF"
      id="c606"
      unitRef="Share">7000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-12-31_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      decimals="INF"
      id="c607"
      unitRef="Share">5402444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-12-31_PlanNameAxis-The2019OmnibusIncentivePlanMember"
      decimals="INF"
      id="c608"
      unitRef="Share">164770</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"
      decimals="INF"
      id="c609"
      unitRef="Share">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2021-12-03_2021-12-03_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"
      id="c610">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-07-31_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"
      decimals="INF"
      id="c611"
      unitRef="Share">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-12-31_PlanNameAxis-The2021EmploymentInducementIncentivePlanMember"
      decimals="INF"
      id="c612"
      unitRef="Share">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-12-31_PlanNameAxis-StockOptionPriorPlanMember"
      decimals="INF"
      id="c613"
      unitRef="Share">362410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2025-12-31_PlanNameAxis-The2012DSUPlanMember"
      decimals="INF"
      id="c614"
      unitRef="Share">9745</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c736">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,526&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,464&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,320&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;621&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Total share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,846&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,085&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c739"
      unitRef="USD">2526000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c740"
      unitRef="USD">1464000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-4"
      id="c741"
      unitRef="USD">1320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c742"
      unitRef="USD">621000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c743"
      unitRef="USD">3846000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c744"
      unitRef="USD">2085000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="d_2025-01-01_2025-12-31"
      id="c2C30E968-81B0-4781-A879-0209D2007EEF">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Underlying&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average Exercise&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price Per Share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Intrinsic Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balances as of December 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,871,013&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.61&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;832&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,864,775&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.03&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(531,350&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.96&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Expired/cancelled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(395,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.08&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(117,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2.19&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balances as of December 31, 2024&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,692,438&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.33&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,243&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,433,416&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.88&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(830,747&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.80&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(415,253&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.43&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"&gt;Expired/cancelled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(15,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5.02&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balances as of December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,864,854&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.11&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;26,479&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Underlying&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Grant Date Fair &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Value Per Share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested as of December 31, 2024&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,371,983&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.18&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,433,416&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Vested&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,143,530&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(801,372&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2.57&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested as of December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,860,497&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.06&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c748"
      unitRef="Share">3871013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c749"
      unitRef="USDPerShare">3.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c750"
      unitRef="USD">832000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c751"
      unitRef="Share">1864775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c752"
      unitRef="USDPerShare">3.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c753"
      unitRef="Share">531350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c754"
      unitRef="USDPerShare">2.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c755"
      unitRef="Share">395000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c756"
      unitRef="USDPerShare">5.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c757"
      unitRef="Share">117000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c758"
      unitRef="USDPerShare">2.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c759"
      unitRef="Share">4692438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c760"
      unitRef="USDPerShare">3.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c761"
      unitRef="USD">10243000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c762"
      unitRef="Share">3433416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c763"
      unitRef="USDPerShare">4.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c764"
      unitRef="Share">830747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c765"
      unitRef="USDPerShare">3.8</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c766"
      unitRef="Share">415253</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c767"
      unitRef="USDPerShare">2.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c768"
      unitRef="Share">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c769"
      unitRef="USDPerShare">5.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c770"
      unitRef="Share">6864854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c771"
      unitRef="USDPerShare">4.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c772"
      unitRef="USD">26479000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c776"
      unitRef="Share">2371983</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c777"
      unitRef="USDPerShare">2.18</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c778"
      unitRef="Share">3433416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c779"
      unitRef="USDPerShare">3.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c780"
      unitRef="Share">1143530</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c781"
      unitRef="USDPerShare">2.28</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c782"
      unitRef="Share">801372</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c783"
      unitRef="USDPerShare">2.57</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c784"
      unitRef="Share">3860497</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c785"
      unitRef="USDPerShare">3.06</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="d_2025-01-01_2025-12-31" id="c786">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 2%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Outstanding, Vested and Expected to Vest&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options Vested and Exercisable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td colspan="3" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Per Share &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Contractual &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average Exercise &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Average &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Contractual Life &lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$1.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$1.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;51,443&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.64&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;42,989&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1.66&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$2.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$2.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,278,895&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.73&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,515,350&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.70&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$3.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$3.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;311,893&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.56&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;247,519&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.66&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$4.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$4.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,917,069&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.32&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;808,626&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.51&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$5.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$5.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;549,287&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.16&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;256,787&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.03&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$6.00&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$16.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;756,267&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8.5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7.14&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;133,086&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7.97&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 2%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,864,854&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7.3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4.11&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,004,357&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3.68&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c789"
      unitRef="USDPerShare">1</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c790"
      unitRef="USDPerShare">1.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c791"
      unitRef="Share">51443</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      id="c792">P7Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c793"
      unitRef="USDPerShare">1.64</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c794"
      unitRef="Share">42989</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      id="c795">P1Y7M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c796"
      unitRef="USDPerShare">2</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c797"
      unitRef="USDPerShare">2.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c798"
      unitRef="Share">2278895</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      id="c799">P6Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c800"
      unitRef="USDPerShare">2.73</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c801"
      unitRef="Share">1515350</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      id="c802">P2Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c803"
      unitRef="USDPerShare">3</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c804"
      unitRef="USDPerShare">3.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c805"
      unitRef="Share">311893</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      id="c806">P4Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c807"
      unitRef="USDPerShare">3.56</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c808"
      unitRef="Share">247519</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      id="c809">P3Y7M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c810"
      unitRef="USDPerShare">4</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c811"
      unitRef="USDPerShare">4.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c812"
      unitRef="Share">2917069</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      id="c813">P7Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c814"
      unitRef="USDPerShare">4.32</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c815"
      unitRef="Share">808626</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      id="c816">P4Y6M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c817"
      unitRef="USDPerShare">5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c818"
      unitRef="USDPerShare">5.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c819"
      unitRef="Share">549287</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      id="c820">P7Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c821"
      unitRef="USDPerShare">5.16</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c822"
      unitRef="Share">256787</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      id="c823">P5Y10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      decimals="INF"
      id="c824"
      unitRef="USDPerShare">6</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      decimals="INF"
      id="c825"
      unitRef="USDPerShare">16</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      decimals="INF"
      id="c826"
      unitRef="Share">756267</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      id="c827">P8Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      decimals="INF"
      id="c828"
      unitRef="USDPerShare">7.14</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      decimals="INF"
      id="c829"
      unitRef="Share">133086</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2025-01-01_2025-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      id="c830">P7Y11M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c831"
      unitRef="Share">6864854</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2025-01-01_2025-12-31" id="c832">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c833"
      unitRef="USDPerShare">4.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c834"
      unitRef="Share">3004357</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2025-01-01_2025-12-31" id="c835">P3Y8M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2025-01-01_2025-12-31_PlanNameAxis-The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember"
      decimals="-5"
      id="c703"
      unitRef="USD">2600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember"
      decimals="-5"
      id="c704"
      unitRef="USD">1500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c705"
      unitRef="Share">415253</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c706"
      unitRef="Share">117000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c707"
      unitRef="USD">10600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2025-01-01_2025-12-31" id="c708">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c836">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 7%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024 &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common share fair value&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$4.07&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$8.67&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$2.40&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$5.38&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free interest rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.7&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.4%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.8&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.5%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected dividend yield&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;0%&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;0%&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected option life (years)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.0&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.7&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 72%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected stock price volatility&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;75.7&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;83.3%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;83.0&lt;/td&gt;
			&lt;td style="width: 2%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&#x2013;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;124.1%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i_2025-12-31_RangeAxis-MinimumMember"
      decimals="INF"
      id="c839"
      unitRef="USDPerShare">4.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i_2025-12-31_RangeAxis-MaximumMember"
      decimals="INF"
      id="c840"
      unitRef="USDPerShare">8.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i_2024-12-31_RangeAxis-MinimumMember"
      decimals="INF"
      id="c841"
      unitRef="USDPerShare">2.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i_2024-12-31_RangeAxis-MaximumMember"
      decimals="INF"
      id="c842"
      unitRef="USDPerShare">5.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2025-01-01_2025-12-31_RangeAxis-MinimumMember"
      decimals="3"
      id="c843"
      unitRef="Pure">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2025-01-01_2025-12-31_RangeAxis-MaximumMember"
      decimals="3"
      id="c844"
      unitRef="Pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember"
      decimals="3"
      id="c845"
      unitRef="Pure">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember"
      decimals="3"
      id="c846"
      unitRef="Pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c847"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c848"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2025-01-01_2025-12-31_RangeAxis-MinimumMember"
      id="c849">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2025-01-01_2025-12-31_RangeAxis-MaximumMember"
      id="c850">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember"
      id="c851">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember"
      id="c852">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2025-01-01_2025-12-31_RangeAxis-MinimumMember"
      decimals="3"
      id="c853"
      unitRef="Pure">0.757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2025-01-01_2025-12-31_RangeAxis-MaximumMember"
      decimals="3"
      id="c854"
      unitRef="Pure">0.833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MinimumMember"
      decimals="2"
      id="c855"
      unitRef="Pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2024-01-01_2024-12-31_RangeAxis-MaximumMember"
      decimals="3"
      id="c856"
      unitRef="Pure">1.241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"
      decimals="INF"
      id="c728"
      unitRef="Share">174515</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-DeferredShareUnitsMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"
      decimals="INF"
      id="c729"
      unitRef="Share">284886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"
      decimals="INF"
      id="c730"
      unitRef="Share">35215</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-NonemployeeDirectorCompensationProgramMember"
      decimals="INF"
      id="c731"
      unitRef="Share">23660</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="d_2025-01-01_2025-12-31" id="c857">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;14. &lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We maintain an employee 401(k) retirement savings plan (401(k) Plan). The 401(k) Plan provides eligible employees with an opportunity to make tax-deferred contributions into a long-term investment and savings program. All employees over the age of 21 may elect to participate in the 401(k) Plan beginning on their hire date. The 401(k) Plan allows eligible employees to contribute a portion of their annual compensation, subject only to maximum limits required by law. We contribute an amount up to 4% of each employees&#x2019; compensation under the safe harbor provisions provided by the Internal Revenue Service rules governing 401(k) plans. Employee and employer safe harbor contributions vest immediately.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We have recorded contribution expenses of $234,000 and $166,000 under the 401(k) Plan for the years ended December&#160;31, 2025 and 2024, respectively.&lt;/p&gt;
</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="d_2025-01-01_2025-12-31"
      decimals="2"
      id="c860"
      unitRef="Pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c861"
      unitRef="USD">234000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c862"
      unitRef="USD">166000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c863">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;15.&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Segment Information&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;An operating segment is identified as a component of an enterprise that engages in business activities about which separate discrete financial information and operating results is regularly reviewed by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. The Company's CODM is the Chief Executive Officer. The Company operates in a &lt;span style="-sec-ix-hidden:c866"&gt;single&lt;/span&gt; operating segment focused on the development of its drug product candidate DM199 for the treatment of severe ischemic disease. The CODM manages and allocates resources to the operations of the Company on a total company basis. Further, the CODM reviews and utilizes functional expenses (i.e., research, development and general and administrative) at the consolidated level to manage the Company's operations. Other segment items included in consolidated net loss are revenues, share-based compensation, interest income, other expense, net, and income tax expense, which are reflected in the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table presents financial information, including significant segment expenses, which are regularly provided to the CODM and included within segment and consolidated net loss:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating expenses, excluding share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23,294&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,436&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,257&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,160&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Total operating expenses, excluding share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;30,551&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;24,596&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,320&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;621&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,526&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,464&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Total share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,846&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,085&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(34,397&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(26,681&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Interest income&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,669&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,301&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Other expense, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(34&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Segment and consolidated net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(32,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(24,444&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="d_2025-01-01_2025-12-31" id="c889">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating expenses, excluding share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23,294&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,436&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,257&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,160&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Total operating expenses, excluding share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;30,551&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;24,596&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,320&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;621&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,526&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,464&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Total share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,846&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,085&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Operating loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(34,397&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(26,681&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Interest income&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,669&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,301&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Other expense, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(34&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Segment and consolidated net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(32,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(24,444&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c892"
      unitRef="USD">23294000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c893"
      unitRef="USD">18436000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c894"
      unitRef="USD">7257000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-4"
      id="c895"
      unitRef="USD">6160000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c896"
      unitRef="USD">30551000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <dmac:OperatingExpensesExcludingSharebasedCompensation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c897"
      unitRef="USD">24596000</dmac:OperatingExpensesExcludingSharebasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-4"
      id="c898"
      unitRef="USD">1320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c899"
      unitRef="USD">621000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c900"
      unitRef="USD">2526000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c901"
      unitRef="USD">1464000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c902"
      unitRef="USD">3846000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c903"
      unitRef="USD">2085000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c904"
      unitRef="USD">-34397000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c905"
      unitRef="USD">-26681000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c906"
      unitRef="USD">1669000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c907"
      unitRef="USD">2301000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c908"
      unitRef="USD">10000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c909"
      unitRef="USD">34000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c910"
      unitRef="USD">28000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c911"
      unitRef="USD">30000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c912"
      unitRef="USD">-32766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c913"
      unitRef="USD">-24444000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c914">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;16.&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The domestic and foreign components of gain (loss) from continuing operations before provision for income taxes are as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Domestic (Canada)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(33,119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,452&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;381&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss before income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(32,738&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(24,414&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has computed its provision for income taxes based on the actual effective tax rate for the year as the Company believes this is the best estimate for the annual effective tax rate. The Company is subject to income taxes in Canada, the United States and Australia.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Significant judgment is required in evaluating the Company&#x2019;s uncertain tax positions and determining the provision for income taxes. The Company recognizes benefits from uncertain tax positions based on the cumulative probability method whereby the largest benefit with a cumulative probability of greater than 50% is recorded. An uncertain tax position is not recognized if it has less than a 50% likelihood of being sustained.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The provision for income taxes consists of:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Current&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Federal&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;24&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;State&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Foreign&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total current&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Federal&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;State&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Foreign&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table reconciles the expected Canadian statutory federal income tax to the actual income tax expense:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Percent&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Percent&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss before income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(32,738&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,414&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Canadian federal statutory rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,911&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,662&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Canadian provincial and local income tax rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,640&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,719&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign tax effects&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(74&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Nontaxable or nondeductible items&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1.6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;273&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Share issuance costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(149&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(8&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Changes in valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(25.3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,133&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(25.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Actual income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As the operations of the Company are predominantly conducted through its Canadian parent company, the Company has prepared the tax rate table using the Canadian federal tax rate of 15%.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The principal component of deferred taxes are as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets (liabilities):&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Non-capital losses carried forward&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,316&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;32,240&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Research and development expenditures&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;817&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;817&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Patents and other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;460&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;400&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;419&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;284&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Share issue costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;379&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;275&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Accruals&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;92&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;256&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Property and equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(71&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(89&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax asset, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;42,412&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;34,183&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(42,412&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(34,183&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax asset&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table presents a reconciliation of the valuation allowance:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at beginning of the year&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;34,183&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,039&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Increase based on tax positions related to current period&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,229&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,144&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Increase based on tax positions related to prior periods&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at end of the year&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;42,412&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;34,183&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company assesses available positive and negative evidence to estimate if it is more likely than not to use certain jurisdiction-based deferred tax assets including net operating loss carryovers. On the basis of this assessment, the Company continues to maintain a valuation allowance on its net deferred tax assets for the year ended December 31, 2025.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Pursuant to Internal Revenue Code (&#x201c;IRC&#x201d;) Sections 382 and 383, annual use of the Company&#x2019;s net operating loss (&#x201c;NOL&#x201d;) and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company&#x2019;s NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period). Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net operating losses and tax credit carryforwards as of December 31, 2025, are as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 19.2%; border-bottom: 1px solid black;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiration Years&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 65.8%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-capital income tax losses, net &#x2013; domestic&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;145,679&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Beginning 2027&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-capital income tax losses, net &#x2013; foreign&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expense carry forwards&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,027&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Indefinitely&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tax credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;473&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Beginning 2026&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1008">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Domestic (Canada)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(33,119&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,452&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;381&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss before income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(32,738&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(24,414&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1011"
      unitRef="USD">-33119000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1012"
      unitRef="USD">-24452000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1013"
      unitRef="USD">381000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1014"
      unitRef="USD">38000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1015"
      unitRef="USD">-32738000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1016"
      unitRef="USD">-24414000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1017">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Current&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Federal&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;24&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;State&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Foreign&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total current&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Federal&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;State&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Foreign&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1020"
      unitRef="USD">24000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1021"
      unitRef="USD">28000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1022"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1023"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1024"
      unitRef="USD">4000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1025"
      unitRef="USD">2000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1026"
      unitRef="USD">28000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c1027"
      unitRef="USD">30000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1028"
      unitRef="USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1029"
      unitRef="USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1030"
      unitRef="USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1031"
      unitRef="USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1032"
      unitRef="USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1033"
      unitRef="USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1034"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1035"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1036"
      unitRef="USD">28000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c1037"
      unitRef="USD">30000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1038">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Percent&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Percent&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Loss before income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(32,738&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(24,414&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Canadian federal statutory rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4,911&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,662&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Canadian provincial and local income tax rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(3,640&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,719&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Foreign tax effects&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(74&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;13&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(0.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Nontaxable or nondeductible items&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;515&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1.6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;273&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Share issuance costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(149&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(8&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(4&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Changes in valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(25.3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,133&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(25.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Actual income tax expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;30&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1041"
      unitRef="USD">-32738000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1042"
      unitRef="USD">-24414000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1043"
      unitRef="USD">-4911000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="2"
      id="c1044"
      unitRef="Pure">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1045"
      unitRef="USD">-3662000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="2"
      id="c1046"
      unitRef="Pure">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-4"
      id="c1047"
      unitRef="USD">-3640000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c1048"
      unitRef="Pure">0.111</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1049"
      unitRef="USD">-2719000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c1050"
      unitRef="Pure">0.111</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1051"
      unitRef="USD">-74000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c1052"
      unitRef="Pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1053"
      unitRef="USD">13000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c1054"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1055"
      unitRef="USD">515000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c1056"
      unitRef="Pure">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1057"
      unitRef="USD">273000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c1058"
      unitRef="Pure">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <dmac:IncomeTaxRateReconciliationShareIssuanceCosts
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1059"
      unitRef="USD">-149000</dmac:IncomeTaxRateReconciliationShareIssuanceCosts>
    <dmac:EffectiveIncomeTaxRateReconciliationShareIssuanceCosts
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c1060"
      unitRef="Pure">0.005</dmac:EffectiveIncomeTaxRateReconciliationShareIssuanceCosts>
    <dmac:IncomeTaxRateReconciliationShareIssuanceCosts
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1061"
      unitRef="USD">-8000</dmac:IncomeTaxRateReconciliationShareIssuanceCosts>
    <dmac:EffectiveIncomeTaxRateReconciliationShareIssuanceCosts
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c1062"
      unitRef="Pure">0.001</dmac:EffectiveIncomeTaxRateReconciliationShareIssuanceCosts>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1063"
      unitRef="USD">-4000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1064"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1065"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1066"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1067"
      unitRef="USD">8291000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c1068"
      unitRef="Pure">-0.253</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c1069"
      unitRef="USD">6133000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c1070"
      unitRef="Pure">-0.251</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c1071"
      unitRef="USD">28000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c1072"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-4"
      id="c1073"
      unitRef="USD">30000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c1074"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2025-01-01_2025-12-31_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember"
      decimals="2"
      id="c975"
      unitRef="Pure">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1075">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets (liabilities):&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Non-capital losses carried forward&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,316&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;32,240&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Research and development expenditures&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;817&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;817&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Patents and other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;460&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;400&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;419&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;284&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Share issue costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;379&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;275&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Accruals&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;92&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;256&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Property and equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(71&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(89&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax asset, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;42,412&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;34,183&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;"&gt;Valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(42,412&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(34,183&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax asset&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1078"
      unitRef="USD">40316000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2024-12-31"
      decimals="-4"
      id="c1079"
      unitRef="USD">32240000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1080"
      unitRef="USD">817000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1081"
      unitRef="USD">817000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <dmac:DeferredTaxAssetsPropertyPatentsAndOther
      contextRef="i_2025-12-31"
      decimals="-4"
      id="c1082"
      unitRef="USD">460000</dmac:DeferredTaxAssetsPropertyPatentsAndOther>
    <dmac:DeferredTaxAssetsPropertyPatentsAndOther
      contextRef="i_2024-12-31"
      decimals="-5"
      id="c1083"
      unitRef="USD">400000</dmac:DeferredTaxAssetsPropertyPatentsAndOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1084"
      unitRef="USD">419000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1085"
      unitRef="USD">284000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <dmac:DeferredTaxAssetsPropertyShareIssueCosts
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1086"
      unitRef="USD">379000</dmac:DeferredTaxAssetsPropertyShareIssueCosts>
    <dmac:DeferredTaxAssetsPropertyShareIssueCosts
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1087"
      unitRef="USD">275000</dmac:DeferredTaxAssetsPropertyShareIssueCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1088"
      unitRef="USD">92000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1089"
      unitRef="USD">256000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1090"
      unitRef="USD">71000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1091"
      unitRef="USD">89000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <dmac:DeferredTaxAssetsLiabilitiesGross
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1092"
      unitRef="USD">42412000</dmac:DeferredTaxAssetsLiabilitiesGross>
    <dmac:DeferredTaxAssetsLiabilitiesGross
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1093"
      unitRef="USD">34183000</dmac:DeferredTaxAssetsLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1094"
      unitRef="USD">42412000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1095"
      unitRef="USD">34183000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1096"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1097"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1098">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at beginning of the year&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;34,183&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,039&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Increase based on tax positions related to current period&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,229&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,144&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"&gt;Increase based on tax positions related to prior periods&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at end of the year&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;42,412&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;34,183&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1101"
      unitRef="USD">34183000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c1102"
      unitRef="USD">28039000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2025-01-01_2025-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToCurrentPeriodMember"
      decimals="-3"
      id="c1103"
      unitRef="USD">8229000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2024-01-01_2024-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToCurrentPeriodMember"
      decimals="-3"
      id="c1104"
      unitRef="USD">6144000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2025-01-01_2025-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToPriorPeriodsMember"
      decimals="-3"
      id="c1105"
      unitRef="USD">0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2024-01-01_2024-12-31_ValuationAllowanceByDeferredTaxAssetAxis-TaxPositionsRelatedToPriorPeriodsMember"
      decimals="-3"
      id="c1106"
      unitRef="USD">0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c1107"
      unitRef="USD">42412000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c1108"
      unitRef="USD">34183000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1109">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 19.2%; border-bottom: 1px solid black;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiration Years&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 65.8%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-capital income tax losses, net &#x2013; domestic&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;145,679&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Beginning 2027&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-capital income tax losses, net &#x2013; foreign&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expense carry forwards&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,027&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Indefinitely&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tax credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;473&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Beginning 2026&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember"
      decimals="-3"
      id="c1112"
      unitRef="USD">145679000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember"
      decimals="-3"
      id="c1113"
      unitRef="USD">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2025-12-31_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-3"
      id="c1114"
      unitRef="USD">3027000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2025-12-31_TaxCreditCarryforwardAxis-TaxCreditsMember"
      decimals="-3"
      id="c1115"
      unitRef="USD">473000</us-gaap:TaxCreditCarryforwardAmount>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1116">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Item 9B.&lt;/b&gt;&#160; &#160; &#160; &#160; &#160; &#160; &#160;&lt;b&gt;Other Information&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"&gt;&lt;i&gt;Rule 10b5-1 Plan and Non-Rule 10b5-1 Trading Arrangement Adoptions, Terminations, and &lt;/i&gt;&lt;i&gt;Modifications&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During the three months ended December 31, 2025, &lt;span style="-sec-ix-hidden:c1119"&gt;&lt;span style="-sec-ix-hidden:c1120"&gt;&lt;span style="-sec-ix-hidden:c1121"&gt;&lt;span style="-sec-ix-hidden:c1122"&gt;none&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; of our directors or &#x201c;officers&#x201d; (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a &#x201c;Rule 10b5-1 trading arrangement&#x201d; or &#x201c;non-Rule 10b5-1 trading arrangement,&#x201d; as each term is defined in Item 408(a) and 408(c) respectively of SEC Regulation S-K.&lt;/p&gt;
</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="d_2025-01-01_2025-12-31" id="c1126">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1127">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Item 11.&lt;/b&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;b&gt;Executive Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The information required by this Item is incorporated herein by reference to the information under the headings &#x201c;Director Compensation,&#x201d; &#x201c;Executive Compensation,&#x201d; &#x201c;Corporate Governance &#x2013; Compensation Committee&#x201d; appearing in the Annual Proxy Statement.&lt;/p&gt;
</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="d_2025-01-01_2025-12-31" id="c1130">false</ecd:AwardTmgMnpiCnsdrdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
